PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Gomis, RR; Cid, E; Garcia-Rocha, M; Ferrer, JC; Guinovart, JJ				Gomis, RR; Cid, E; Garcia-Rocha, M; Ferrer, JC; Guinovart, JJ			Liver glycogen synthase but not the muscle isoform differentiates between glucose 6-phosphate produced by glucokinase or hexokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN; HEPATOCYTES; EXPRESSION; CELLS; GLUCOSE-6-PHOSPHATE; OVEREXPRESSION; ADENOVIRUS; QUANTITIES; STORAGE; BINDING	Using adenovirus-mediated gene transfer into FTO-2B cells, a rat hepatoma cell line, we have overexpressed hexokinase I (HK I), glucokinase (GK), liver glycogen synthase (LGS), muscle glycogen synthase (MGS), and combinations of each of the two glucose-phosphorylating enzymes with each one of the GS isoforms. FTO-2B cells do not synthesize glycogen even when incubated with high doses of glucose. Adenovirus-induced overexpression of HK I and/or LGS, two enzymes endogenously expressed by these cells, did not produce a significant increase in the levels of active GS and the total glycogen content. In contrast, GK overexpression led to the glucose-dependent activation of endogenous or overexpressed LGS and to the accumulation of glycogen. Similarly overexpressed MGS was efficiently activated by the glucose-6-phosphate (GIc-6-P) produced by either endogenous or overexpressed HK I and by overexpressed GK. These results indicate the existence of at least two pools of Glc-6-P in the cell, one of them is accessible to both isoforms of GS and is replenished by the action of GK, whereas LGS is excluded from the cellular compartment where the Gle-6-P produced by HK I is directed. These findings are interpreted in terms of the metabolic role that the two pairs of enzymes, HK I-MGS in the muscle and GK-LGS in the hepatocyte, perform in their respective tissues.	Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Barcelona, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain	University of Barcelona; University of Barcelona	Guinovart, JJ (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Marti Franques 1, E-08028 Barcelona, Spain.	guinovart@pcb.ub.es	Cid, Emili/F-7207-2016; Gomis, Roger R/E-9788-2016; Ferrer, Joan C./AAP-2145-2021	Cid, Emili/0000-0002-5025-352X; Gomis, Roger R/0000-0001-6473-2858; Garcia-Rocha, Mar/0000-0003-2467-2090; Ferrer, Joan C./0000-0003-1212-5161				Azpiazu I, 2000, AM J PHYSIOL-ENDOC M, V278, pE234, DOI 10.1152/ajpendo.2000.278.2.E234; BAI G, 1990, J BIOL CHEM, V265, P7843; Baque S, 1998, DIABETES, V47, P1392, DOI 10.2337/diabetes.47.9.1392; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BELL GI, 1993, J BIOL CHEM, V268, P19161; Bollen M, 1998, BIOCHEM J, V336, P19, DOI 10.1042/bj3360019; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cardenas ML, 1998, BBA-MOL CELL RES, V1401, P242, DOI 10.1016/S0167-4889(97)00150-X; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; Cid E, 2000, J BIOL CHEM, V275, P33614, DOI 10.1074/jbc.M005358200; de la Iglesia N, 1999, FEBS LETT, V456, P332, DOI 10.1016/S0014-5793(99)00971-0; FernandezNovell JM, 1997, BIOCHEM J, V321, P227, DOI 10.1042/bj3210227; Ferrer JC, 1997, FEBS LETT, V415, P249, DOI 10.1016/S0014-5793(97)01136-8; Garcia-Bellido J, 2000, J HIGH ENERGY PHYS; Gomis RR, 2000, BIOCHEM J, V351, P811, DOI 10.1042/0264-6021:3510811; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; LANG G, 1974, METHOD ENZYMAT AN, V3, P1238; Mukhtar M, 1999, FEBS LETT, V462, P453, DOI 10.1016/S0014-5793(99)01580-X; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; POLAKIS PG, 1985, ARCH BIOCHEM BIOPHYS, V236, P328, DOI 10.1016/0003-9861(85)90633-2; Roach Peter J., 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P139; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; Seoane J, 1999, J BIOL CHEM, V274, P31833, DOI 10.1074/jbc.274.45.31833; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TOBWIN H, 1992, BIOTECHNOLOGY, V24, P145; VALERA A, 1994, EUR J BIOCHEM, V222, P533, DOI 10.1111/j.1432-1033.1994.tb18895.x; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078; Wilson JE, 1998, DIABETES, V47, P1544, DOI 10.2337/diabetes.47.10.1544; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; Zvibel I, 1998, DIFFERENTIATION, V63, P215, DOI 10.1111/j.1432-0436.1998.00215.x	32	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23246	23252		10.1074/jbc.M111208200	http://dx.doi.org/10.1074/jbc.M111208200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11882651	hybrid			2022-12-25	WOS:000176475700021
J	Jardine, H; MacNee, W; Donaldson, K; Rahman, I				Jardine, H; MacNee, W; Donaldson, K; Rahman, I			Molecular mechanism of transforming growth factor (TGF)-beta(1)-induced glutathione depletion in alveolar epithelial cells - Involvement of AP-1/ARE and Fra-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; ANTIOXIDANT RESPONSE ELEMENT; IDIOPATHIC PULMONARY FIBROSIS; NAPHTHOFLAVONE-INDUCED EXPRESSION; HEAVY SUBUNIT GENE; FACTOR-KAPPA-B; FACTOR-BETA; OXIDATIVE STRESS; ENDOTHELIAL-CELLS; C-JUN	Glutathione (GSH) is a ubiquitous antioxidant in lung epithelial cells and lung lining fluid. Transforming growth factor beta(1) (TGF-beta(1)) is a pleiotropic cytokine involved in cellular proliferation and differentiation. The level of TGF-beta(1), is elevated in many chronic inflammatory lung disorders associated with oxidant/antioxidant imbalance. In this study, we show that TGF-beta(1), depletes GSH by down-regulating expression of the enzyme responsible for its formation, gamma-glutamylcysteine synthetase (gamma-GCS) and induces reactive oxygen species production in type II alveolar epithelial cells (A549). To investigate the molecular mechanisms of inhibition of glutathione synthesis, we employed reporters containing fragments from the promoter region of the gamma-GCS heavy subunit (h), the gene that encodes the catalytic subunit of gamma-GCS. We found that TGF-beta(1), reduced the expression of the long gamma-GCSh construct (-3802/GCSh5'-Luc), suggesting that an antioxidant response element (ARE) may be responsible for mediating the TGF-beta(1) effect. Interestingly, the electrophoretic mobility shift assay revealed that the DNA binding activity of both activator protein-1 (A-P-1) and ARE was increased in TGF-beta(1)-treated epithelial cells. The gamma-GCSh ARE contains a perfect AP-1 site embedded within it, and mutation of this internal AP-1 sequence, but not the surrounding ARE, prevented DNA binding. Further studies revealed that c-Jun and Fra-1 dimers, members of the AP-1 family previously shown to exert a negative effect on phase II gene expression, bound to the ARE sequence. We propose a novel mechanism of gamma-GCSh down-regulation by TGF-beta(1), that involves the binding of c-Jun and Fra-1 dimers to the distal promoter. The findings of this study provide important information, which may e used for the modulation of glutathione biosynthesis in inflammation.	Univ Edinburgh, Sch Med, Ctr Inflammat Res, Resp Med Unit,MRC,ELEGI,Colt Res Labs, Edinburgh EH8 9AG, Midlothian, Scotland; Napier Univ, Biomed Res Grp, Edinburgh EH10 5DT, Midlothian, Scotland	University of Edinburgh; Edinburgh Napier University	Rahman, I (corresponding author), Univ Edinburgh, Sch Med, Ctr Inflammat Res, Resp Med Unit,MRC,ELEGI,Colt Res Labs, Wilkie Bldg,Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.			MacNee, William/0000-0002-3692-1448				Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Arsalane K, 1997, AM J RESP CELL MOL, V17, P599, DOI 10.1165/ajrcmb.17.5.2833; BUNNELL E, 1993, AM REV RESPIR DIS, V148, P1174, DOI 10.1164/ajrccm/148.5.1174; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152, DOI 10.1152/jappl.1987.63.1.152; CANTIN AM, 1989, AM REV RESPIR DIS, V139, P370, DOI 10.1164/ajrccm/139.2.370; Chen YH, 1999, BIOCHEM BIOPH RES CO, V265, P18, DOI 10.1006/bbrc.1999.1609; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dahl EL, 2001, TOXICOL SCI, V61, P265, DOI 10.1093/toxsci/61.2.265; de Boer WI, 1998, AM J RESP CRIT CARE, V158, P1951, DOI 10.1164/ajrccm.158.6.9803053; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; FAVREAU LV, 1995, J BIOL CHEM, V270, P24468, DOI 10.1074/jbc.270.41.24468; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; GIPP JJ, 1992, BIOCHEM BIOPH RES CO, V185, P29, DOI 10.1016/S0006-291X(05)80950-7; GIRI SN, 1993, THORAX, V48, P959, DOI 10.1136/thx.48.10.959; Hagiwara S, 2000, AM J RESP CRIT CARE, V162, P225, DOI 10.1164/ajrccm.162.1.9903129; Hong YH, 1997, J IMMUNOL, V159, P2418; Huang Y, 2000, J BIOL CHEM, V275, P18234, DOI 10.1074/jbc.M909431199; Jeyapaul J, 2000, BIOCHEM PHARMACOL, V59, P1433, DOI 10.1016/S0006-2952(00)00256-2; Junn E, 2000, J IMMUNOL, V165, P2190, DOI 10.4049/jimmunol.165.4.2190; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; KHALIL N, 1991, AM J RESP CELL MOL, V5, P155, DOI 10.1165/ajrcmb/5.2.155; MACNEE W, 1995, THORAX, V50, pS53, DOI 10.1136/thx.50.Suppl_1.S53; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; MULCAHY RT, 1995, CANCER RES, V55, P4771; Pittet JF, 2001, J CLIN INVEST, V107, P1537, DOI 10.1172/JCI11963; Rahman I, 1999, FREE RADICAL BIO MED, V27, P60, DOI 10.1016/S0891-5849(99)00035-0; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Rahman I, 1998, FEBS LETT, V427, P129, DOI 10.1016/S0014-5793(98)00410-4; Rahman I, 1999, AM J PHYSIOL-LUNG C, V277, pL1067, DOI 10.1152/ajplung.1999.277.6.L1067; Rahman I, 1996, BIOCHEM BIOPH RES CO, V229, P832, DOI 10.1006/bbrc.1996.1888; Rahman I, 1999, J BIOL CHEM, V274, P5088, DOI 10.1074/jbc.274.8.5088; ROUM JH, 1993, J APPL PHYSIOL, V75, P2419, DOI 10.1152/jappl.1993.75.6.2419; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; SCHMIDT KN, 1995, J BIOL CHEM, V270, P27136, DOI 10.1074/jbc.270.45.27136; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; Sekhar KR, 1997, BIOCHEM BIOPH RES CO, V234, P588, DOI 10.1006/bbrc.1997.6697; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Takizawa H, 2001, AM J RESP CRIT CARE, V163, P1476, DOI 10.1164/ajrccm.163.6.9908135; THANNICKAL VJ, 1993, AM J PHYSIOL, V265, pL622, DOI 10.1152/ajplung.1993.265.6.L622; Thannickal VJ, 1998, J BIOL CHEM, V273, P23611, DOI 10.1074/jbc.273.36.23611; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; VANDEPUTTE C, 1994, CELL BIOL TOXICOL, V10, P415, DOI 10.1007/BF00755791; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wang QJ, 1999, THORAX, V54, P805, DOI 10.1136/thx.54.9.805; WHITE AC, 1992, AM J RESP CELL MOL, V6, P364, DOI 10.1165/ajrcmb/6.4.364; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wild AC, 1998, BIOCHEM J, V332, P373, DOI 10.1042/bj3320373; Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200	58	87	95	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21158	21166		10.1074/jbc.M112145200	http://dx.doi.org/10.1074/jbc.M112145200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11912197	hybrid			2022-12-25	WOS:000176286000008
J	Abreu, MT; Arnold, ET; Thomas, LS; Gonsky, R; Zhou, YH; Hu, B; Arditi, M				Abreu, MT; Arnold, ET; Thomas, LS; Gonsky, R; Zhou, YH; Hu, B; Arditi, M			TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; NF-KAPPA-B; DERMAL ENDOTHELIAL-CELLS; BACTERIAL LIPOPOLYSACCHARIDE; INFLAMMATORY CYTOKINES; ESCHERICHIA-COLI; STAT3 ACTIVATION; CUTTING EDGE; TNF-ALPHA; INDUCTION	The normal intestinal epithelium is not inflamed despite contact with a high density of commensal bacteria. Intestinal epithelial cells (IEC) express low levels of TLR4 and MD-2 and are lipopolysaccharide (LPS)-unresponsive. We hypothesized that immune-mediated signals regulate the expression of TLR4 and MD-2 in IEC. Expression of TLR4 and MD-2 was examined in normal colonic epithelial cells or intestinal epithelial cell lines. The effect of the cytokines interferon (IFN)-gamma, IFN-alpha, and tumor necrosis factor-alpha (TNF-alpha) on TLR4 and MD-2 expression was examined by reverse transcription-PCR and Western blot. NF-kappaB transcriptional activation and interleukin-8 secretion were used as measures of LPS responsiveness. Native colonic epithelial cells and IEC lines express a low level of TLR4 and MD-2 mRNA. IFN-gamma regulates MD-2 expression in both IEC lines, whereas IFN-gamma and TNF-a regulate TLR4 mRNA expression in IEC lines. Pre-incubation with IFN-gamma and/or TNF-alpha sensitizes IEC to LPS-dependent interleukin-8 secretion. To examine MD-2 transcriptional regulation, we cloned a 1-kb sequence proximal to the MD-2 gene translational start site. This promoter directed expression of a reporter gene in endothelial cells and IEC. IFN-gamma positively regulated MD-2 promoter activity in IEC. Co-expression of a STAT inhibitor, SOCS3, blocked IFN-gamma-mediated MD-2 promoter activation. T cell-derived cytokines lead to increased expression of TLR4 and MD-2 and LPS-dependent pro-inflammatory cytokine secretion in IEC. IFN-gamma regulates expression of the critical TLR4 co-receptor MD-2 through the Janus tyrosine kinase-STAT pathway. Th1 cytokines may initiate or perpetuate intestinal inflammation by altering toll-like receptor expression and bacterial reactivity.	Cedars Sinai Med Ctr, Ctr Inflammatory Bowel Dis, Div Gastroenterol, Dept Med, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Div Pediat Infect Dis, Dept Pediat,Burns & Allen Res Inst, Steven Spielberg Pediat Res Ctr, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Dept Pathol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Abreu, MT (corresponding author), Cedars Sinai Med Ctr, Ctr Inflammatory Bowel Dis, Div Gastroenterol, Dept Med, 8631 W 3rd St,Suite 245E, Los Angeles, CA 90048 USA.	maria.abreu@cshs.org	Eckhardt, Erik/G-1567-2010	Abreu, Maria T./0000-0002-7294-0574	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002635] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66436] Funding Source: Medline; NIAID NIH HHS [AI40275] Funding Source: Medline; NIDDK NIH HHS [DK02635] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; Abreu MT, 2000, GASTROENTEROLOGY, V119, P1524, DOI 10.1053/gast.2000.20232; Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Backhed F, 2001, CELL MICROBIOL, V3, P153, DOI 10.1046/j.1462-5822.2001.00101.x; Blumberg RS, 2000, CURR OPIN IMMUNOL, V12, P226, DOI 10.1016/S0952-7915(99)00079-5; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508, DOI 10.1002/jlb.67.4.508; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Casola A, 1998, GASTROENTEROLOGY, V114, P947, DOI 10.1016/S0016-5085(98)70314-2; Chackerian AA, 2001, INFECT IMMUN, V69, P2666, DOI 10.1128/IAI.69.4.2666-2674.2001; Cong YZ, 2000, J IMMUNOL, V165, P2173, DOI 10.4049/jimmunol.165.4.2173; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; Dohi T, 2000, GASTROENTEROLOGY, V119, P724, DOI 10.1053/gast.2000.16500; Doughty LA, 2001, J IMMUNOL, V166, P2658, DOI 10.4049/jimmunol.166.4.2658; Dunne C, 2001, INFLAMM BOWEL DIS, V7, P136, DOI 10.1097/00054725-200105000-00010; ECKMANN L, 1993, INFECT IMMUN, V61, P4569, DOI 10.1128/IAI.61.11.4569-4574.1993; Elewaut D, 1999, J IMMUNOL, V163, P1457; Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058; Faure E, 2001, J IMMUNOL, V166, P2018, DOI 10.4049/jimmunol.166.3.2018; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; French N, 2000, GUT, V47, P162, DOI 10.1136/gut.47.2.162; Hecht G, 1999, AM J PHYSIOL-CELL PH, V277, pC351, DOI 10.1152/ajpcell.1999.277.3.C351; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; HOGAN MM, 1988, J IMMUNOL, V140, P513; HOGAN MM, 1987, J IMMUNOL, V139, P3697; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Jiang QQ, 2000, J IMMUNOL, V165, P3541, DOI 10.4049/jimmunol.165.7.3541; JUNG HC, 1995, J CLIN INVEST, V95, P55, DOI 10.1172/JCI117676; Kim JM, 1998, J CLIN INVEST, V102, P1815, DOI 10.1172/JCI2466; MacDonald TT, 2000, INFLAMM BOWEL DIS, V6, P116, DOI 10.1097/00054725-200005000-00008; MADARA JL, 1985, J CELL BIOL, V101, P2124, DOI 10.1083/jcb.101.6.2124; Matsuguchi T, 2000, J IMMUNOL, V165, P5767, DOI 10.4049/jimmunol.165.10.5767; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MCINTIRE FC, 1967, BIOCHEMISTRY-US, V6, P2363, DOI 10.1021/bi00860a011; Means TK, 1999, J IMMUNOL, V163, P3920; Mita Y, 2001, BRIT J HAEMATOL, V112, P1041, DOI 10.1046/j.1365-2141.2001.02658.x; Naidu AS, 1999, CRIT REV FOOD SCI, V39, P13, DOI 10.1080/10408699991279187; Naik S, 2001, J PEDIATR GASTR NUTR, V32, P449, DOI 10.1097/00005176-200104000-00011; Novak U, 1999, GROWTH FACTORS, V16, P305, DOI 10.3109/08977199909069148; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Papadakis KA, 2000, GASTROENTEROLOGY, V119, P1148, DOI 10.1053/gast.2000.18160; Plevy SE, 1997, J IMMUNOL, V159, P6276; Qureshi N, 1995, Prog Clin Biol Res, V392, P151; Rath HC, 1999, INFECT IMMUN, V67, P2969, DOI 10.1128/IAI.67.6.2969-2974.1999; Rath HC, 1999, GASTROENTEROLOGY, V116, P310, DOI 10.1016/S0016-5085(99)70127-7; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Riffault S, 2001, VET RES, V32, P71, DOI 10.1051/vetres:2001111; Rollo EE, 1999, J IMMUNOL, V163, P4442; Sansonetti PJ, 1999, SEMIN IMMUNOL, V11, P193, DOI 10.1006/smim.1999.0175; Savkovic SD, 1997, AM J PHYSIOL-CELL PH, V273, pC1160, DOI 10.1152/ajpcell.1997.273.4.C1160; Schultz M, 2000, AM J GASTROENTEROL, V95, pS19, DOI 10.1016/S0002-9270(99)00812-6; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Svanborg C, 2001, J INFECT DIS, V183, pS61, DOI 10.1086/318858; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Veltkamp C, 2001, GASTROENTEROLOGY, V120, P900, DOI 10.1053/gast.2001.22547; Wang TY, 2000, J IMMUNOL, V165, P6308, DOI 10.4049/jimmunol.165.11.6308; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	65	300	330	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20431	20437		10.1074/jbc.M110333200	http://dx.doi.org/10.1074/jbc.M110333200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923281	hybrid			2022-12-25	WOS:000176204500043
J	Lin, TH; Chia, CM; Hsiao, JC; Chang, W; Ku, CC; Hung, SC; Tzou, DLM				Lin, TH; Chia, CM; Hsiao, JC; Chang, W; Ku, CC; Hung, SC; Tzou, DLM			Structural analysis of the extracellular domain of vaccinia virus envelope protein, A27L, by NAM and CD spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							14-KILODALTON FUSION PROTEIN; CHEMICAL-SHIFTS; GUANIDINE-HYDROCHLORIDE; HEPARAN-SULFATE; BINDING-SITES; AMINO-ACIDS; NMR; IDENTIFICATION; FORMS; C-13	This study presents the molecular structure of the extracellular domain of vaccinia virus envelope protein, A27L, determined by NMR and CD spectroscopy. A recombinant protein, eA27L-aa, containing this domain in which cysteines 71 and 72 were replaced with alanine, was constructed to prevent self-assembly due to intermolecular disulfide bonds between these two cysteines. The soluble eA27L-aa protein forms an oligomer resembling that of A27L on vaccinia virions. Heteronuclear correlation NMR spectroscopy was carried out on eA27L-aa in the presence or absence of urea to determine backbone resonance assignments. Chemical shift index (CSI) propensity analysis showed that eA27L-aa has two distinct structural domains, a relatively flexible 22-amino acid random coil in the N-terminal region and a fairly rigid a-helix structure in the remainder of the structure. Binding interaction studies using isothermal titration calorimetry suggest that a 12-amino acid lysine/arginine-rich segment in the N-terminal region is responsible for glycosaminoglycan binding. The rigid a-helix portion of eA27L-aa is probably involved in the intrinsic self-assembly, and CSI propensity analysis suggests that region N37-E49, with a residual a-helix tendency, is probably the self-assembly core. Self-assembly was ascribed to three hydrophobic leucine residues (Leu(41), Leu(45), and LeU(48)) in this segment. The folding mechanism of eA27L-aa was analyzed by CD spectroscopy, which revealed a two-step transition with a Gibbs free energy of 2.5 kcal/mol in the absence of urea. Based on these NMR and CD studies, a residue-specific molecular model of the extracellular domain of A27L is proposed. These studies on the molecular structure of eA27L-aa will help in understanding how vaccinia virus enters cells.	Acad Sinica, Inst Chem, Taipei 11529, Taiwan; Natl Yang Ming Univ, Inst Biochem, Taipei 11221, Taiwan; Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan; Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Academia Sinica - Taiwan	Tzou, DLM (corresponding author), Acad Sinica, Inst Chem, 128 Yen Chiu Yuan Rd,Sec 2, Taipei 11529, Taiwan.	tzou@ccvax.sinica.edu.tw	Chang, Wen/AAA-5076-2021; Tzou, Der-Lii M/E-9499-2015	Chang, Wen/0000-0003-3369-083X; Tzou, Der-Lii M/0000-0002-3755-8230				Alexandrescu AT, 1998, J BIOMOL NMR, V11, P461, DOI 10.1023/A:1008283925446; Alexandrescu AT, 2000, J MOL BIOL, V295, P239, DOI 10.1006/jmbi.1999.3354; BAX A, 1994, METHOD ENZYMOL, V239, P79; BENTZ J, 1993, VIRAL FUSION MECH; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chung CS, 1998, J VIROL, V72, P1577, DOI 10.1128/JVI.72.2.1577-1585.1998; Eliezer D, 1997, FEBS LETT, V417, P92, DOI 10.1016/S0014-5793(97)01256-8; FINN BE, 1992, PROTEIN ENG PRACTICA, P167; Fromm JR, 1997, ARCH BIOCHEM BIOPHYS, V346, P252, DOI 10.1006/abbi.1997.0299; Fromm JR, 1997, ARCH BIOCHEM BIOPHYS, V343, P92, DOI 10.1006/abbi.1997.0147; Fry EE, 1999, EMBO J, V18, P543, DOI 10.1093/emboj/18.3.543; HAYWOOD AM, 1994, J VIROL, V68, P1; Hileman RE, 1998, BIOCHEMISTRY-US, V37, P15231, DOI 10.1021/bi980212x; Hsiao JC, 1998, J VIROL, V72, P8374, DOI 10.1128/JVI.72.10.8374-8379.1998; Kay LE, 1997, BIOCHEM CELL BIOL, V75, P1, DOI 10.1139/o97-023; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; LOGAN TM, 1994, J MOL BIOL, V236, P637, DOI 10.1006/jmbi.1994.1173; MEYER H, 1994, VIROLOGY, V200, P778, DOI 10.1006/viro.1994.1241; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; Radhakrishnan I, 1998, FEBS LETT, V430, P317, DOI 10.1016/S0014-5793(98)00680-2; RODRIGUEZ D, 1993, J VIROL, V67, P3435, DOI 10.1128/JVI.67.6.3435-3440.1993; RODRIGUEZ D, 1995, J VIROL, V69, P4640; RODRIGUEZ JF, 1987, J VIROL, V61, P3550, DOI 10.1128/JVI.61.11.3550-3554.1987; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; SCHLEUCHER J, 1993, ANGEW CHEM INT EDIT, V32, P1489, DOI 10.1002/anie.199314891; SCHULMAN BA, 1997, NAT STRUCT, V6, P24; Shirley B A, 1995, Methods Mol Biol, V40, P177; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; TAKAHASHI T, 1994, VIROLOGY, V202, P844, DOI 10.1006/viro.1994.1406; Vazquez MI, 1998, J VIROL, V72, P10126; Wang Y, 1996, PROTEIN SCI, V5, P1898, DOI 10.1002/pro.5560050916; WIMMR E, 1994, CELLULAR RECEPTORS A; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; [No title captured]	37	13	13	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20949	20959		10.1074/jbc.M110403200	http://dx.doi.org/10.1074/jbc.M110403200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11901147	hybrid			2022-12-25	WOS:000176204500109
J	Pullar, JM; Hampton, MB				Pullar, JM; Hampton, MB			Diphenyleneiodonium triggers the efflux of glutathione from cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-MEDIATED APOPTOSIS; NEUTROPHIL NADPH OXIDASE; ISOLATED RAT HEPATOCYTES; REDUCED GLUTATHIONE; HYDROGEN-PEROXIDE; GSH EXTRUSION; REDOX STATE; ANTI-FAS; INHIBITION; BCL-2	Diphenyleneiodonium (DPI) is a broad-spectrum flavoprotein inhibitor commonly used to inhibit oxidant production by the NADPH oxidase of phagocytic and nonphagocytic cells. A previous study has shown that DPI can sensitize T24 bladder carcinoma cells to Fas-mediated apoptosis. We observed DPI to deplete intracellular reduced glutathione (GSH) in T24 cells and a range of other primary and transformed cell types. The effect was immediate, with 50% loss of intracellular GSH within 2 h of treatment with DPI. The glutathione was quantitatively recovered in the extracellular medium, indicating that efflux was occurring. The loss of GSH was blocked with bromosulfophthalein, an inhibitor of the canalicular GSH transporters. We conclude that DPI induces a dramatic efflux of cellular GSH from T24 cells via a specific transport channel. This provides a potential mechanism for its proapoptotic effect, and it also has important implications for the regulation of glutathione homeostasis in cells.	Christchurch Sch Med & Hlth Sci, Free Rad Res Grp, Dept Pathol, Christchurch, New Zealand	University of Otago	Pullar, JM (corresponding author), Christchurch Sch Med & Hlth Sci, Free Rad Res Grp, Dept Pathol, POB 4345, Christchurch, New Zealand.	juliet.pullar@chmeds.ac.nz	Hampton, Mark B/A-8490-2008	Hampton, Mark B/0000-0002-7349-3729				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AW TY, 1986, AM J PHYSIOL, V251, pG354, DOI 10.1152/ajpgi.1986.251.3.G354; AW TY, 1984, J BIOL CHEM, V259, P9355; BALLATORI N, 1994, J BIOL CHEM, V269, P19731; BALLATORI N, 1985, AM J PHYSIOL, V248, pG238, DOI 10.1152/ajpgi.1985.248.2.G238; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; DOUSSIERE J, 1992, EUR J BIOCHEM, V208, P61, DOI 10.1111/j.1432-1033.1992.tb17159.x; Doussiere J, 1999, BIOCHEMISTRY-US, V38, P3694, DOI 10.1021/bi9823481; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; FERNANDEZ A, 1995, J IMMUNOL, V155, P5133; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; HAMPTON MB, 1995, FREE RADICAL BIO MED, V18, P633, DOI 10.1016/0891-5849(94)00181-I; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jenkins M, 1999, J IMMUNOL, V163, P1195; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Krammer PH, 1997, CELL DEATH DIFFER, V4, P362, DOI 10.1038/sj.cdd.4400252; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Lu SC, 1996, J CLIN INVEST, V97, P1488, DOI 10.1172/JCI118571; LU SC, 1995, INVEST OPHTH VIS SCI, V36, P2523; Macho A, 1997, J IMMUNOL, V158, P4612; MARTIN J, 1991, J CHROMATOGR-BIOMED, V568, P219, DOI 10.1016/0378-4347(91)80356-H; MEISTER A, 1994, CANCER RES, V54, pS1969; Meredith MJ, 1998, BIOCHEM BIOPH RES CO, V248, P458, DOI 10.1006/bbrc.1998.8998; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Midis GP, 1996, CANCER RES, V56, P3870; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; Mittur AV, 1998, AM J PHYSIOL-GASTR L, V274, pG923, DOI 10.1152/ajpgi.1998.274.5.G923; Mittur AV, 2000, BBA-BIOMEMBRANES, V1464, P207, DOI 10.1016/S0005-2736(00)00152-8; Mori S, 1996, CANCER RES, V56, P1874; NATOLI G, 1995, ONCOGENE, V11, P1157; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; O'Flaherty E, 2000, IMMUNOLOGY, V100, P289, DOI 10.1046/j.1365-2567.2000.00048.x; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Poulaki V, 2001, CANCER RES, V61, P4864; Pullar JM, 1999, AM J PHYSIOL-HEART C, V277, pH1505, DOI 10.1152/ajpheart.1999.277.4.H1505; RAGAN CI, 1977, BIOCHEM J, V163, P605, DOI 10.1042/bj1630605; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SHIMA Y, 1995, BLOOD, V85, P757, DOI 10.1182/blood.V85.3.757.bloodjournal853757; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; SZATROWSKI TP, 1991, CANCER RES, V51, P794; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Vile GF, 2000, ARCH BIOCHEM BIOPHYS, V377, P122, DOI 10.1006/abbi.2000.1706; Voehringer DW, 1999, FREE RADICAL BIO MED, V27, P945, DOI 10.1016/S0891-5849(99)00174-4; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; Willems F, 2000, BLOOD, V95, P3478, DOI 10.1182/blood.V95.11.3478.011k10_3478_3482	60	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19402	19407		10.1074/jbc.M111053200	http://dx.doi.org/10.1074/jbc.M111053200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11904296	hybrid			2022-12-25	WOS:000175894800023
J	Paulsson, KM; Kleijmeer, MJ; Griffith, J; Jevon, M; Chen, SW; Anderson, PO; Sjogren, HO; Li, SL; Wang, P				Paulsson, KM; Kleijmeer, MJ; Griffith, J; Jevon, M; Chen, SW; Anderson, PO; Sjogren, HO; Li, SL; Wang, P			Association of tapasin and COPI provides a mechanism for the retrograde transport of major histocompatibility complex (MHC) class I molecules from the Golgi complex to the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN PRESENTATION; PEPTIDE REPERTOIRE; LOADING COMPLEX; MUTANT MICE; TAP; PROTEINS; RETENTION; BINDING; GLYCOPROTEIN; SUBUNIT	Tapasin is a subunit of the transporter associated with antigen processing (TAP). It associates with the major histocompatibility complex (MHC) class I. We show that tapasin interacts with beta- and gamma-subunits of COPI coatomer. COPI retrieves membrane proteins from the Golgi network back to the endoplasmic reticulum (ER). The COPI subunit-associated tapasin also interacts with MHC class I molecules suggesting that tapasin acts as the cargo receptor for packing MHC class I molecules as cargo proteins into COPI-coated vesicles. In tapasin mutant cells, neither TAP nor MHC class I are detected in association with the COPI coatomer. Interestingly, tapasin-associated MHC class I molecules are antigenic peptide-receptive and detected in both the ER and the Golgi. Our data suggest that tapasin is required for the COPI vesicle-mediated retrograde transport of immature MHC class I molecules from the Golgi network to the ER.	Lund Univ, Inst Tumor Immunol, S-22362 Lund, Sweden; Univ Med Ctr, Inst Biomembranes, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Brunel Univ, Dept Biol Sci, Uxbridge UB8 3PH, Middx, England; Barts & London Sch Med & Dent, Dept Gastroenterol, Immunol Grp, London EC1A 7ED, England	Lund University; Utrecht University; Utrecht University Medical Center; Brunel University; University of London; Queen Mary University London	Li, SL (corresponding author), Lund Univ, Inst Tumor Immunol, Solvegatan 21, S-22362 Lund, Sweden.			Anderson, Per/0000-0002-0958-7990; Wang, Ping/0000-0001-8992-1233				Androlewicz MJ, 1999, IMMUNOL RES, V20, P79, DOI 10.1007/BF02786464; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; Bangia N, 1999, EUR J IMMUNOL, V29, P1858, DOI 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C; Barnden MJ, 2000, J IMMUNOL, V165, P322, DOI 10.4049/jimmunol.165.1.322; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; DAY PM, 1995, IMMUNITY, V2, P137, DOI 10.1016/S1074-7613(95)80014-X; Garbi N, 2000, NAT IMMUNOL, V1, P234, DOI 10.1038/79775; Grandea AG, 1997, IMMUNOGENETICS, V46, P477, DOI 10.1007/s002510050308; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; Grandea AG, 2000, IMMUNITY, V13, P213, DOI 10.1016/S1074-7613(00)00021-2; Harter C, 2000, Subcell Biochem, V34, P1; Harter C, 1996, P NATL ACAD SCI USA, V93, P1902, DOI 10.1073/pnas.93.5.1902; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KNIPE DM, 1977, J VIROL, V21, P1128, DOI 10.1128/JVI.21.3.1128-1139.1977; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Lewis JW, 1998, EUR J IMMUNOL, V28, P3214, DOI 10.1002/(SICI)1521-4141(199810)28:10<3214::AID-IMMU3214>3.3.CO;2-3; Lewis JW, 1996, CURR BIOL, V6, P873, DOI 10.1016/S0960-9822(02)00611-5; Li SL, 1997, P NATL ACAD SCI USA, V94, P8708, DOI 10.1073/pnas.94.16.8708; Li SL, 2000, J BIOL CHEM, V275, P1581, DOI 10.1074/jbc.275.3.1581; Marguet D, 1999, IMMUNITY, V11, P231, DOI 10.1016/S1074-7613(00)80098-9; Neisig A, 1996, J IMMUNOL, V156, P3196; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Paulk M. C., 2000, Cutter IT Journal, V13, P23; PeaceBrewer AL, 1996, IMMUNITY, V4, P505, DOI 10.1016/S1074-7613(00)80416-1; Peh CA, 1998, IMMUNITY, V8, P531, DOI 10.1016/S1074-7613(00)80558-0; Purcell AW, 2001, J IMMUNOL, V166, P1016, DOI 10.4049/jimmunol.166.2.1016; RAPOSO G, 1997, WEIRS HDB EXPT IMMUN, P208; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schoenhals GJ, 1999, EMBO J, V18, P743, DOI 10.1093/emboj/18.3.743; Sijts AJAM, 1997, J EXP MED, V185, P1403, DOI 10.1084/jem.185.8.1403; Solheim JC, 1999, IMMUNOL REV, V172, P11, DOI 10.1111/j.1600-065X.1999.tb01352.x; Spiliotis ET, 2000, IMMUNITY, V13, P841, DOI 10.1016/S1074-7613(00)00081-9; SRIVASTAVA SP, 1991, J BIOL CHEM, V266, P20337; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; Wang P, 1996, J IMMUNOL, V157, P213; Wang P, 1996, J BIOL CHEM, V271, P24830, DOI 10.1074/jbc.271.40.24830; Williams AP, 2000, IMMUNOGENETICS, V52, P9, DOI 10.1007/s002510000244	47	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18266	18271		10.1074/jbc.M201388200	http://dx.doi.org/10.1074/jbc.M201388200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11884415	hybrid			2022-12-25	WOS:000175975800005
J	Clemens, S; Bloss, T; Vess, C; Neumann, D; Nies, DH; zur Nieden, U				Clemens, S; Bloss, T; Vess, C; Neumann, D; Nies, DH; zur Nieden, U			A transporter in the endoplasmic reticulum of Schizosaccharomyces pombe cells mediates zinc storage and differentially affects transition metal tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PHYTOCHELATIN SYNTHASE; CAENORHABDITIS-ELEGANS; CONFERS RESISTANCE; GENE; CADMIUM; YEAST; FAMILY; PEPTIDES; COBALT	The cation diffusion facilitator (CDF) family represents a class of ubiquitous metal transporters. Inactivation of a CDF in Schizosaccharomyces pombe, Zhf, causes drastically different effects on the tolerance toward various metals. A deletion mutant is Zn2+/Co2+-hypersensitive yet displays significantly enhanced Cd2+ and Ni2+ tolerance. Accumulation of zinc, cobalt, and cadmium is reduced in mutant cells. Non-vacuolar zinc content, as measured by analytical electron microscopy, is lower in zhf(-) cells compared with wild-type cells in the presence of elevated Zn2+ concentrations. The protective effect against cadmium toxicity is independent of the phytochelatin detoxification pathway. Phytochelatin synthase-deficient cells show extremely enhanced (about 200-fold) cadmium tolerance when zhf is disrupted. Immunogold labeling indicates endoplasmic reticulum (ER) localization of Zhf. Electron spectroscopic imaging shows that accumulation of zinc coincides with Zhf localization, demonstrating a major role of the ER for metal storage and the involvement of Zhf in cellular zinc homeostasis. Also, these observations indicate that Cd2+ ions exert their toxic effects on cellular metabolism in the ER rather than in the cytosol.	Leibniz Inst Pflanzenbiochem, D-06120 Halle Saale, Germany; Univ Halle Wittenberg, Inst Mikrobiol, D-06120 Halle Saale, Germany	Leibniz Institut fur Pflanzenbiochemie; Martin Luther University Halle Wittenberg	Clemens, S (corresponding author), Leibniz Inst Pflanzenbiochem, Weinberg 3, D-06120 Halle Saale, Germany.		Nies, Dietrich H/H-4143-2011; Clemens, Stephan/A-5107-2009	Clemens, Stephan/0000-0003-0570-1060				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anton A, 1999, J BACTERIOL, V181, P6876, DOI 10.1128/JB.181.22.6876-6881.1999; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bloss T, 2002, PLANTA, V214, P783, DOI 10.1007/s00425-001-0677-1; Clemens S, 2001, PLANTA, V212, P475, DOI 10.1007/s004250000458; Clemens S, 2001, EUR J BIOCHEM, V268, P3640, DOI 10.1046/j.1432-1327.2001.02293.x; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; Cobbett CS, 2000, CURR OPIN PLANT BIOL, V3, P211, DOI 10.1016/S1369-5266(00)00066-2; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; GRILL E, 1989, P NATL ACAD SCI USA, V86, P6838, DOI 10.1073/pnas.86.18.6838; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; Korshunova YO, 1999, PLANT MOL BIOL, V40, P37, DOI 10.1023/A:1026438615520; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Li LT, 2001, J BIOL CHEM, V276, P5036, DOI 10.1074/jbc.M008969200; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; NIES DH, 1995, J BACTERIOL, V177, P2707, DOI 10.1128/jb.177.10.2707-2712.1995; NIES DH, 1992, PLASMID, V27, P17, DOI 10.1016/0147-619X(92)90003-S; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; Pence NS, 2000, P NATL ACAD SCI USA, V97, P4956, DOI 10.1073/pnas.97.9.4956; Persans MW, 2001, P NATL ACAD SCI USA, V98, P9995, DOI 10.1073/pnas.171039798; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; RAUSER WE, 1995, PLANT PHYSIOL, V109, P1141, DOI 10.1104/pp.109.4.1141; Sneller FEC, 2000, J AGR FOOD CHEM, V48, P4014, DOI 10.1021/jf9903105; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; van der Zaal BJ, 1999, PLANT PHYSIOL, V119, P1047, DOI 10.1104/pp.119.3.1047; Vatamaniuk OK, 2001, J BIOL CHEM, V276, P20817, DOI 10.1074/jbc.C100152200; Vatamaniuk OK, 2000, J BIOL CHEM, V275, P31451, DOI 10.1074/jbc.M002997200; [No title captured]	37	75	82	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18215	18221		10.1074/jbc.M201031200	http://dx.doi.org/10.1074/jbc.M201031200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11886869	hybrid			2022-12-25	WOS:000175685100104
J	Hellauer, K; Akache, B; MacPherson, S; Sirard, E; Turcotte, B				Hellauer, K; Akache, B; MacPherson, S; Sirard, E; Turcotte, B			Zinc cluster protein Rdr1p is a transcriptional repressor of the PDR5 gene encoding a multidrug transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEIOTROPIC DRUG-RESISTANCE; SACCHAROMYCES-CEREVISIAE; COMPLETE INVENTORY; YEAST; EXPRESSION; DNA; ACTIVATION; BIOSYNTHESIS; STRAINS; FAMILY	The yeast PDR5 gene encodes an efflux pump that confers multidrug resistance. Expression of PDR5 is positively regulated by the transcription factors Pdr1p and Pdr3p that recognize the same pleiotropic drug resistance elements (PDREs) in the PDR5 promoter. Pdr1p and Pdr3p belong to the Gal4p family of zinc cluster proteins. The function of RDR1 (YOR380W), which also encodes a member of this family, is unknown. To identify target genes for Rdr1p, we have performed whole-genome analysis of gene expression with DNA microarrays. Our results show that Rdr1p is a transcriptional repressor of five genes, including PDR5. A Deltardr1 strain has increased resistance to cycloheximide, as expected from the overexpression of PDR5. In addition, the activity of a PDR5-lacZ reporter is increased in a Deltardr1 strain. All (but one) genes affected by removal of Rdr1p contain PDREs in their promoters. We tested if the effect of Rdr1p is mediated through PDREs by inserting this DNA element in front of a minimal promoter. Activity of this reporter was increased in a Deltardr1 strain. Moreover, mutations known to reduce binding of Pdr1/Pdr3p abolished the induction observed in the Deltardr1 strain. Thus, we have identified a transcriptional repressor involved in the control of multidrug resistance.	McGill Univ, Royal Victoria Hosp, Ctr Hlth, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Ctr Hlth, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Ctr Hlth, Dept Microbiol & Immunol, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital	Turcotte, B (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Dept Med, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	turcotte@lan1.molone.megill.ca		Akache, Bassel/0000-0002-5377-7193				Akache B, 2001, NUCLEIC ACIDS RES, V29, P2181, DOI 10.1093/nar/29.10.2181; Alarco AM, 1997, J BIOL CHEM, V272, P19304, DOI 10.1074/jbc.272.31.19304; Angus-Hill ML, 2001, MOL CELL, V7, P741, DOI 10.1016/S1097-2765(01)00219-2; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; Carvajal E, 1997, MOL GEN GENET, V256, P406, DOI 10.1007/s004380050584; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Devauz F, 2001, EMBO REP, V2, P493, DOI 10.1093/embo-reports/kve114; FORSBURG SL, 1988, MOL CELL BIOL, V8, P647, DOI 10.1128/MCB.8.2.647; Goffeau A, 1997, YEAST, V13, P43, DOI 10.1002/(SICI)1097-0061(199701)13:1<43::AID-YEA56>3.0.CO;2-J; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hallstrom TC, 2001, J BIOL CHEM, V276, P23674, DOI 10.1074/jbc.M101568200; Hallstrom TC, 1998, J BIOL CHEM, V273, P2098, DOI 10.1074/jbc.273.4.2098; Hampsey M, 1997, YEAST, V13, P1099, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1099::AID-YEA177>3.3.CO;2-Z; Hellauer K, 1996, MOL CELL BIOL, V16, P6096; Hellauer K, 2001, J BIOL CHEM, V276, P13587, DOI 10.1074/jbc.M011196200; Hemming SA, 2000, J BIOL CHEM, V275, P35506, DOI 10.1074/jbc.M004721200; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; Kolaczkowska A, 1999, DRUG RESIST UPDATE, V2, P403, DOI 10.1054/drup.1999.0113; LEPPERT G, 1990, GENETICS, V125, P13; Lussier M, 1997, GENETICS, V147, P435; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; Martens JA, 1996, J BIOL CHEM, V271, P15884, DOI 10.1074/jbc.271.27.15884; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Noel J, 1998, J BIOL CHEM, V273, P17463, DOI 10.1074/jbc.273.28.17463; Nourani A, 1997, MOL GEN GENET, V256, P397, DOI 10.1007/s004380050583; Nourani A, 1997, MOL CELL BIOL, V17, P5453, DOI 10.1128/MCB.17.9.5453; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; Schwabe JWR, 1997, NAT STRUCT BIOL, V4, P680, DOI 10.1038/nsb0997-680; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Todd RB, 1997, FUNGAL GENET BIOL, V21, P388, DOI 10.1006/fgbi.1997.0993; Traven A, 2001, J BIOL CHEM, V276, P4020, DOI 10.1074/jbc.M006807200; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Wolfger H, 1997, FEBS LETT, V418, P269, DOI 10.1016/S0014-5793(97)01382-3	46	41	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17671	17676		10.1074/jbc.M201637200	http://dx.doi.org/10.1074/jbc.M201637200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882665	hybrid			2022-12-25	WOS:000175685100037
J	Javanbakht, H; Cen, S; Musier-Forsyth, K; Kleiman, L				Javanbakht, H; Cen, S; Musier-Forsyth, K; Kleiman, L			Correlation between tRNA(Lys3) aminoacylation and its incorporation into HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TRANSFER-RNA-SYNTHETASE; REVERSE-TRANSCRIPTASE; IDENTITY DETERMINANTS; TRANSFER RNA(SER); TRANSFER RNA(LYS); ANTICODON DOMAIN; WILD-TYPE; PR160GAG-POL; PARTICLES	During human immunodeficiency virus type 1 (HIV-1) assembly, tRNA(Lys) is selectively packaged into the virus, where tRNA(Lys3) serves as the primer for reverse transcription. Lysyl-tRNA synthetase is also selectively incorporated into HIV-1 and is therefore a strong candidate for being the signal by which viral proteins interact with tRNA(Lys) isoacceptors. Previously, mutations in the tRNA(Lys3) anticodon have been shown to strongly inhibit the charging of tRNA(Lys3) by lysyl-tRNA synthetase in vitro, and we show here that in vivo aminoacylation is also inhibited by anticodon changes. The order of decreasing in vivo aminoacylation for tRNA(Lys3) anticodon mutants is: wild-type SUU (where S=mcm(5)S(2)U) 100%) -->SGU(49%)-->CGU(40%)-->SGA (0%) and CGA (0%). We found that the ability of these tRNA(Lys3) anticodon variants to be aminoacylated in vivo is directly correlated with their ability to be packaged into HIV-1. These data showed that the anticodon is a major determinant for tRNA(Lys3) packaging and support the conclusion that its productive interaction with lysyl-tRNA synthetase is important for tRNA(Lys3) incorporation into HIV-1.	Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; Jewish Gen Hosp, McGill AIDS Ctr, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Immunol, Montreal, PQ H3T 1E2, Canada; Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University; McGill University; University of Minnesota System; University of Minnesota Twin Cities	Kleiman, L (corresponding author), Jewish Gen Hosp, Lady Davis Inst Med Res, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.							ACHSEL T, 1993, EMBO J, V12, P3333, DOI 10.1002/j.1460-2075.1993.tb06003.x; Arts EJ, 1998, J BIOL CHEM, V273, P14523, DOI 10.1074/jbc.273.23.14523; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cen S, 1999, J VIROL, V73, P4485, DOI 10.1128/JVI.73.5.4485-4488.1999; Cen S, 2001, J VIROL, V75, P5043, DOI 10.1128/JVI.75.11.5043-5048.2001; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Francin M, 2002, J BIOL CHEM, V277, P1762, DOI 10.1074/jbc.M109759200; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; HASEGAWA T, 1992, BIOCHEM BIOPH RES CO, V184, P478, DOI 10.1016/0006-291X(92)91219-G; HO YS, 1987, P NATL ACAD SCI USA, V84, P2185, DOI 10.1073/pnas.84.8.2185; Huang Y, 1996, J VIROL, V70, P4700, DOI 10.1128/JVI.70.7.4700-4706.1996; HUANG Y, 1994, J VIROL, V68, P7676, DOI 10.1128/JVI.68.12.7676-7683.1994; JIANG M, 1993, J VIROL, V67, P3246, DOI 10.1128/JVI.67.6.3246-3253.1993; Khorchid A, 2000, J MOL BIOL, V299, P17, DOI 10.1006/jmbi.2000.3709; Ko YG, 2000, J CELL BIOL, V149, P567, DOI 10.1083/jcb.149.3.567; Mak J, 1997, J MOL BIOL, V265, P419, DOI 10.1006/jmbi.1996.0742; MAK J, 1994, J VIROL, V68, P2065, DOI 10.1128/JVI.68.4.2065-2072.1994; Mak J, 1997, J VIROL, V71, P8087, DOI 10.1128/JVI.71.11.8087-8095.1997; PARK J, 1992, J VIROL, V66, P6304, DOI 10.1128/JVI.66.11.6304-6313.1992; SARIHCOTTIN L, 1992, J MOL BIOL, V226, P1, DOI 10.1016/0022-2836(92)90117-3; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; Shiba K, 1997, J BIOL CHEM, V272, P22809, DOI 10.1074/jbc.272.36.22809; SMITH AJ, 1993, J VIROL, V67, P2266, DOI 10.1128/JVI.67.4.2266-2275.1993; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; Stello T, 1999, NUCLEIC ACIDS RES, V27, P4823, DOI 10.1093/nar/27.24.4823; Swanstrom R., 1997, P263; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P2335, DOI 10.1093/nar/20.9.2335; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; WOHRL BM, 1993, J BIOL CHEM, V268, P13617; WU XQ, 1993, NUCLEIC ACIDS RES, V21, P5589, DOI 10.1093/nar/21.24.5589	31	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17389	17396		10.1074/jbc.M112479200	http://dx.doi.org/10.1074/jbc.M112479200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884398	hybrid			2022-12-25	WOS:000175685100004
J	Riihimaa, P; Nissi, R; Page, AP; Winter, AD; Keskiaho, K; Kivirikko, KI; Myllyharju, J				Riihimaa, P; Nissi, R; Page, AP; Winter, AD; Keskiaho, K; Kivirikko, KI; Myllyharju, J			Egg shell collagen formation in Caenorhabditis elegans involves a novel prolyl 4-hydroxylase expressed in spermatheca and embryos and possessing many unique properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE-ISOMERASE SUBUNIT; ALPHA-SUBUNIT; BACULOVIRUS EXPRESSION; IV COLLAGEN; LYSYL HYDROXYLASE; ENZYME TETRAMER; C-ELEGANS; PROTEIN; CLONING; GENE	The collagen prolyl 4-hydroxylases (EC 1.14.11.2) play a critical role in the synthesis of all collagens. The enzymes from all vertebrate species studied are alpha(2)beta(2) tetramers, in which the beta subunit is identical to protein disulfide isomerase (PDI). Two isoforms of the catalytic a subunit, PHY-1 and PHY-2, have previously been characterized from Caenorhabditis elegans. We report here on the cloning and characterization of a third C. elegans a subunit isoform, PHY-3. It is much shorter than the previously characterized vertebrate and C. elegans a subunits and shows 23-30% amino acid sequence identity to PHY-1 and PHY-2 within the catalytic C-terminal region. Recombinant PHY-3 coexpressed in insect cells with a C. elegans PDI isoform that does not associate with PHY-1 was found to be an active prolyl 4-hydroxylase. The phy-3 gene consists of five exons, and its expression pattern differs distinctly from the hypodermally expressed phy-1 and phy-2 in that it is expressed in embryos, late larval stages, and adult nematodes, expression in the latter being restricted to the spermatheca. Nematodes homozygous for a phy-3 deletion are phenotypically of the wild type and fertile, but the 4-hydroxyproline content of phy-3(-/-) early embryos was reduced by about 90%. PHY-3 is thus likely to be involved in the synthesis of collagens in early embryos, probably of those in the egg shell.	Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem, FIN-90014 Oulu, Finland; Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, Glasgow G11 6NU, Lanark, Scotland	University of Oulu; University of Oulu; University of Glasgow	Myllyharju, J (corresponding author), Univ Oulu, Bioctr Oulu, Collagen Res Unit, POB 5000, FIN-90014 Oulu, Finland.	johanna.myllyharju@oulu.fi						Ackley BD, 2001, J CELL BIOL, V152, P1219, DOI 10.1083/jcb.152.6.1219; Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; Annunen P, 1999, J BIOL CHEM, V274, P6790, DOI 10.1074/jbc.274.10.6790; Annunen P, 1998, J BIOL CHEM, V273, P5989, DOI 10.1074/jbc.273.11.5989; Bird, 1991, STRUCTURE NEMATODES, P7; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Eriksson M, 1999, J BIOL CHEM, V274, P22131, DOI 10.1074/jbc.274.32.22131; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Friedman L, 2000, P NATL ACAD SCI USA, V97, P4736, DOI 10.1073/pnas.97.9.4736; Graham PL, 1997, J CELL BIOL, V137, P1171, DOI 10.1083/jcb.137.5.1171; Gupta MC, 1997, J CELL BIOL, V137, P1185, DOI 10.1083/jcb.137.5.1185; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; Hill KL, 2000, GENETICS, V155, P1139; Johnstone IL, 2000, TRENDS GENET, V16, P21, DOI 10.1016/S0168-9525(99)01857-0; JOHNSTONE IL, 1992, EMBO J, V11, P3857, DOI 10.1002/j.1460-2075.1992.tb05478.x; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nissi R, 2001, J HISTOCHEM CYTOCHEM, V49, P1143, DOI 10.1177/002215540104900908; Norman KR, 2000, DEV BIOL, V227, P690, DOI 10.1006/dbio.2000.9897; Page AP, 1997, DNA CELL BIOL, V16, P1335, DOI 10.1089/dna.1997.16.1335; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; ROGALSKI TM, 1993, GENE DEV, V7, P1471, DOI 10.1101/gad.7.8.1471; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SUZUKI H, 1988, ANAL BIOCHEM, V172, P259, DOI 10.1016/0003-2697(88)90440-X; Veijola J, 1996, BIOCHEM J, V317, P721, DOI 10.1042/bj3170721; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; Winter AD, 2000, MOL CELL BIOL, V20, P4084, DOI 10.1128/MCB.20.11.4084-4093.2000; Wood W. B., 1988, NEMATODE C ELEGANS, P215	39	24	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18238	18243		10.1074/jbc.M200895200	http://dx.doi.org/10.1074/jbc.M200895200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11891226	hybrid			2022-12-25	WOS:000175685100107
J	Eriksson, M; Leppa, S				Eriksson, M; Leppa, S			Mitogen-activated protein kinases and activator protein 1 are required for proliferation and cardiomyocyte differentiation of P19 embryonal carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR MEF2C; SKELETAL-MUSCLE DIFFERENTIATION; SIGNAL-REGULATED KINASE; HEART TUBE FORMATION; C-JUN EXPRESSION; VENTRAL MORPHOGENESIS; CARDIAC MYOCYTES; STRESS-RESPONSE; MAP KINASES; P38	Mitogen-activated protein kinases (MAPKs) have been implicated as regulators of differentiation. The biological effect of MAPK signaling in the nucleus is achieved by signal-responsive transcription factors. Here we have investigated MAPK signaling and activation of AP-1 transcription factors in P19 embryonal carcinoma cells undergoing cardiomyocyte differentiation. We show that aggregation and Me,SO treatment, which trigger the differentiation response, result in sustained activation of JNK1, p38, and ERK1/2 MAPKs and acquisition of AP-1 DNA binding activity. The induced AP-1 activity consists of c-Jun, JunD, and Fra-2 proteins and is accompanied with the increased expression of these proteins. JNK is involved in c-Jun phoshorylation, whereas ERK and p38 activities are essential for maximal c-Jun and Fra-2 expression, and AP-1 DNA binding activity. While the inhibition of ERK can partially prevent the formation of beating cardiomyocytes, the activity of p38 is absolutely required for the differentiation. Expression of dominant negative c-Jun(bZIP) in P19 cells can also inhibit the differentiation response. Surprisingly, however, expression of dominant negative SEK or JNK causes an inhibition of P19 cell proliferation. Taken together, the results show that ERK, JNK, p38, and AP-1 are activated in a coordinated and sustained manner, and contribute to proliferation and cardiomyocyte differentiation of P19 cells.	Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Res Program, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Oncol, FIN-00029 Huch, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Leppa, S (corresponding author), Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Res Program, POB 63, FIN-00014 Helsinki, Finland.			Leppa, Sirpa/0000-0002-8265-511X				Alonso G, 2000, J BIOL CHEM, V275, P40641, DOI 10.1074/jbc.M007835200; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Davidson SM, 2000, DEV BIOL, V218, P146, DOI 10.1006/dbio.1999.9596; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; Fritz G, 1999, MOL CELL BIOL, V19, P1768; Grepin C, 1997, DEVELOPMENT, V124, P2387; GRUDA MC, 1994, ONCOGENE, V9, P2537; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN TH, 1995, MOL CELL BIOL, V15, P2907; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; KovacicMilivojevic B, 1996, ENDOCRINOLOGY, V137, P1108, DOI 10.1210/en.137.3.1108; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Leppa S, 2001, MOL CELL BIOL, V21, P4369, DOI 10.1128/MCB.21.13.4369-4378.2001; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Monzen K, 2001, J CELL BIOL, V153, P687, DOI 10.1083/jcb.153.4.687; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Nicol RL, 2001, EMBO J, V20, P2757, DOI 10.1093/emboj/20.11.2757; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Skerjanc IS, 1998, J BIOL CHEM, V273, P34904, DOI 10.1074/jbc.273.52.34904; SZABO E, 1994, CELL GROWTH DIFFER, V5, P439; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Treinies I, 1999, MOL CELL BIOL, V19, P321; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	65	66	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15992	16001		10.1074/jbc.M107340200	http://dx.doi.org/10.1074/jbc.M107340200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11884386	hybrid			2022-12-25	WOS:000175510400104
J	Guerini, D; Guidi, F; Carafoli, E				Guerini, D; Guidi, F; Carafoli, E			Differential membrane targeting of the SERCA and PMCA calcium pumps: experiments with recombinant chimeras	FASEB JOURNAL			English	Article						plasma membrane Ca2+ pump; chimeric proteins; ER/SR Ca2+ pump	PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; CA2+ PUMP; SARCOPLASMIC-RETICULUM; GOLGI RETENTION; TRANSMEMBRANE SEGMENT; CA-2+ PUMP; PROTEINS; EXPRESSION; DOMAIN	Structural features underlying retention of the SERCA pump in intracellular compartments and the sorting of the PMCA pump to the plasma membrane are not known. The biochemical properties of the two pumps suggest that their differential localization may respond to specific functional demands. The two pumps may control Ca2+ gradients of different magnitude and dynamic properties. For instance, it has recently become clear that the Ca2+ gradient across the endoplasmic reticulum (ER) membrane is smaller than that across the plasma membrane. Previous experiments with chimerical constructs of the SERCA and PMCA pumps had suggested a role for the amino-terminal domain in the ER retention of the SERCA pump. Experiments aimed at narrowing down the region responsible for the retention now indicate that the first 28 amino acids of the SERCA pump may play a role in membrane localization. Results also suggest that the formation of oligomers (possibly through the first 28 amino acids) might be critical to the retention mechanism.	Univ Padua, Dept Biochem, I-35121 Padua, Italy; Univ Padua, Venetian Inst Mol Med, I-35121 Padua, Italy; Novartis Pharma AG, CH-4002 Basel, Switzerland; Swiss Fed Inst Technol, Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland	University of Padua; University of Padua; Veneto Institute Molecular Medicine; Novartis; ETH Zurich	Carafoli, E (corresponding author), Univ Padua, Dept Biochem, Viale G Colombo 3, I-35121 Padua, Italy.	carafoli@civ.bio.unipd.it	Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				ADAMO HP, 1992, J BIOL CHEM, V267, P14244; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; Carafoli E, 1996, EXPERIENTIA, V52, P1091, DOI 10.1007/BF01952107; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; FOLETTI D, 1995, FASEB J, V9, P670, DOI 10.1096/fasebj.9.8.7768360; Grimaldi ME, 1996, J BIOL CHEM, V271, P26995, DOI 10.1074/jbc.271.43.26995; Guerini D, 1998, ACTA PHYSIOL SCAND, V163, P265; Guerini D, 2000, J BIOL CHEM, V275, P31361, DOI 10.1074/jbc.M003474200; HEIM R, 1992, J BIOL CHEM, V267, P24476; HOFMANN F, 1993, J BIOL CHEM, V268, P10252; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; Preiano BS, 1996, BIOCHEMISTRY-US, V35, P7946; Robert V, 1998, J BIOL CHEM, V273, P30372, DOI 10.1074/jbc.273.46.30372; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VERMA AK, 1988, J BIOL CHEM, V263, P14152; ZVARITCH E, 1995, J BIOL CHEM, V270, P2679, DOI 10.1074/jbc.270.6.2679; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	37	8	8	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					519	528		10.1096/fj.01-0362com	http://dx.doi.org/10.1096/fj.01-0362com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11919154				2022-12-25	WOS:000175425900005
J	Singh, J; Murata, K; Itahana, Y; Desprez, PY				Singh, J; Murata, K; Itahana, Y; Desprez, PY			Constitutive expression of the Id-1 promoter in human metastatic breast cancer cells is linked with the loss of NF-1/Rb/HDAC-1 transcription repressor complex	ONCOGENE			English	Article						helix-loop-helix protein; proliferation; invasion; metastasis; transcription	LOOP-HELIX PROTEINS; HISTONE DEACETYLASE; DNA-BINDING; GENE; DIFFERENTIATION; ID1; REGULATOR; CARCINOMA; ROLES	The helix-loop-helix protein Id-1 is a dominant negative regulator of basic helix -loop- helix transcription factors, and plays a key role in the control of breast epithelial cell growth, invasion and differentiation. Previous investigations in our laboratory have shown that Id-1 mRNA was constitutively expressed in highly aggressive and invasive human breast cancer cells in comparison to non-transformed or non-aggressive cancerous cells, and that this loss of regulation is mediated by a 2.2-kb region of the human Id-1 promoter. Here we show that a 31 bp sequence within this 2.2-kb promoter, located 200 bp upstream of the initiation of transcription, is responsible for the constitutive expression of Id-1 in metastatic human breast cancer cells. Using gel shift experiments, we identified a high molecular weight complex present only in non-aggressive breast cancer cells cultured in serum-free medium and which appear to be necessary for proper Id-1 repression. In contrast, nuclear extracts from highly aggressive and metastatic cell lines do not contain this large molecular weight complex. Using DNA affinity precipitation assays (DAPA), we show that this complex contains SP-1, NF-1, Rb and HDAC-1 proteins. On the basis of these findings, we propose a mechanism for the loss of regulation of Id-1 promoter in invasive and metastatic human breast cancer cells.	Calif Pacific Med Ctr, Geraldine Brush Canc Res Inst, San Francisco, CA 94115 USA	California Pacific Medical Center	Desprez, PY (corresponding author), Calif Pacific Med Ctr, Geraldine Brush Canc Res Inst, 2330 Clay St,Stern Bldg, San Francisco, CA 94115 USA.	pdesprez@cooper.cpmc.org			NCI NIH HHS [R01 CA82548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; CHEN HC, 1994, ONCOGENE, V9, P2905; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; GERADTS J, 1994, INT J CANCER, V58, P161, DOI 10.1002/ijc.2910580203; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hu YC, 2001, CLIN CANCER RES, V7, P2213; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; Kaluz S, 1999, BIOTECHNIQUES, V26, P446, DOI 10.2144/99263bm18; Kebebew E, 2000, SURGERY, V128, P952, DOI 10.1067/msy.2000.111082; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Langlands K, 2000, CANCER RES, V60, P5929; Lin CQ, 2000, CANCER RES, V60, P1332; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Nayak BK, 1999, MOL BIOL REP, V26, P223, DOI 10.1023/A:1007006011253; Nehlin JO, 1997, BIOCHEM BIOPH RES CO, V231, P628, DOI 10.1006/bbrc.1997.6152; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Ouyang XS, 2001, CARCINOGENESIS, V22, P965, DOI 10.1093/carcin/22.6.965; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Polsky D, 2001, CANCER RES, V61, P6008; Schindl M, 2001, CANCER RES, V61, P5703; Singh J, 2001, J BIOL CHEM, V276, P11852, DOI 10.1074/jbc.M006931200; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Takai N, 2001, CANCER LETT, V165, P185, DOI 10.1016/S0304-3835(01)00433-5; TAMURA G, 1994, PATHOL INT, V44, P34, DOI 10.1111/j.1440-1827.1994.tb02583.x; Tournay O, 1996, MOL CELL BIOL, V16, P2418; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	45	61	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1812	1822		10.1038/sj.onc.1205252	http://dx.doi.org/10.1038/sj.onc.1205252			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896613				2022-12-25	WOS:000174284500003
J	Paterson, IC; Davies, M; Stone, A; Huntley, S; Smith, E; Pring, M; Eveson, JW; Robinson, CM; Parkinson, EK; Prime, SS				Paterson, IC; Davies, M; Stone, A; Huntley, S; Smith, E; Pring, M; Eveson, JW; Robinson, CM; Parkinson, EK; Prime, SS			TGF-beta 1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest	ONCOGENE			English	Article						TGF-beta 1; keratinocytcs; Smad 4; tumor suppression	GROWTH-FACTOR-BETA; SQUAMOUS-CELL CARCINOMAS; TRANSFORMING GROWTH-FACTOR-BETA-1; FUNCTIONAL-CHARACTERIZATION; DOWN-REGULATION; GENE-MUTATIONS; RECEPTOR GENE; II RECEPTOR; SKIN TUMORS; HIGH-RISK	This study examined the role of TGF-beta1 in human keratinocyte malignancy. Two carcinoma-derived human oral keratinocyte cell lines, BICR 31 and H314, were selected on the basis of their known resistance to TGF-beta1-induced G(1) arrest, the presence of wild type TGF-beta cell surface receptors and normal Ras. Smad 4 protein was undetectable in both cell lines, but Smad 2 and Smad 3 were expressed at levels comparable with a fully TGF-beta responsive cell line, and treatment of the cells with TGF-beta1 resulted in the phosphorylation of Smad 2. Treatment with exogenous TGF-beta1 resulted in a failure to induce transcription from an artificial Smad-dependent promoter and a failure to down-regulate c-myc, but resulted in an up-regulation of AP-1 associated genes (Fra-1, JunB and fibronectin). Transient transfection of Smad 4 into BICR 31 restored TGF-beta1-induced growth inhibition and Smad-dependent transcriptional activation. Protracted treatment of cells with exogenous TGF-beta1 resulted in the attenuation of cell growth in vitro. To over-express TGF-beta1, both cell lines were transfected with latent TGF-beta1 cDNA; neutralization studies of conditioned media demonstrated that whilst the majority of the peptide was in the latent form, a small proportion was present as the active peptide. Cells that overexpressed endogenous TGF-beta1 grew more slowly in vitro compared to both the vector-only controls and cells that did not over-express the peptide. Orthotopic transplantation of cells that over-expressed endogenous TGF-beta1 to the floor of the mouth in athymic mice resulted in marked inhibition of primary tumor formation compared to controls. Expression of a dominant-negative TGF-beta1 type II receptor in cells that over-expressed endogenous TGF-beta1 resulted in enhanced cell growth in vitro and diminished the tumor suppressor effect of the ligand in vivo, indicating that the endogenous TGF-beta1 was acting in an autocrine capacity. The results demonstrate that over-expression of endogenous TGF-beta1 in human malignant oral keratinocytes leads to growth inhibition in vivo and tumor suppression in vitro by mechanisms that are independent of Small 4 expression and TGF-beta1-induced G(1) arrest.	Univ Bristol, Dept Oral & Dent Sci, Bristol BS1 2LY, Avon, England; CRC, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	University of Bristol; Beatson Institute	Paterson, IC (corresponding author), Bristol Dent Hosp & Sch, Div Oral Med Pathol & Microbiol, Lower Maudlin St, Bristol BS1 2LY, Avon, England.	ian.paterson@bristol.ac.uk	Paterson, Ian/G-8688-2011; Robinson, Max/R-5280-2018	Paterson, Ian/0000-0001-9156-401X; Robinson, Max/0000-0003-4491-6865; Pring, Miranda/0000-0003-4658-5772				Amendt C, 1998, ONCOGENE, V17, P25, DOI 10.1038/sj.onc.1202161; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen TP, 2001, INT J CANCER, V93, P653, DOI 10.1002/ijc.1381; CLARK LJ, 1993, BRIT J CANCER, V68, P617, DOI 10.1038/bjc.1993.396; CUI W, 1994, CANCER RES, V54, P5831; Davies M, 1997, INT J CANCER, V73, P68, DOI 10.1002/(SICI)1097-0215(19970926)73:1<68::AID-IJC12>3.3.CO;2-D; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Fink SP, 2001, CANCER RES, V61, P256; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Howell M, 1999, DEV BIOL, V214, P354, DOI 10.1006/dbio.1999.9430; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kim SK, 1996, CANCER RES, V56, P2519; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Korchynskyi O, 1999, INT J CANCER, V82, P197, DOI 10.1002/(SICI)1097-0215(19990719)82:2<197::AID-IJC8>3.0.CO;2-V; LEDAI J, 1999, MOL CARCINOG, V26, P37; Malliri A, 1996, CELL GROWTH DIFFER, V7, P1291; Masuyama N, 1999, J BIOL CHEM, V274, P12163, DOI 10.1074/jbc.274.17.12163; PATERSON IC, 1995, BRIT J CANCER, V72, P922, DOI 10.1038/bjc.1995.434; Paterson IC, 2001, J PATHOL, V193, P458, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH822>3.0.CO;2-V; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; PRIME SS, 1994, INT J CANCER, V56, P406, DOI 10.1002/ijc.2910560320; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Riggins GJ, 1997, CANCER RES, V57, P2578; Schutte M, 1996, CANCER RES, V56, P2527; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Wang D, 1997, CARCINOGENESIS, V18, P2285, DOI 10.1093/carcin/18.11.2285; Wilentz RE, 2000, AM J PATHOL, V156, P37, DOI 10.1016/S0002-9440(10)64703-7; Wilentz RE, 2000, CANCER RES, V60, P2002; Wong C, 1999, MOL CELL BIOL, V19, P1821; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yan W, 2000, ONCOL RES, V12, P157; YEUDALL WA, 1995, ORAL ONCOL, V31B, P136, DOI 10.1016/0964-1955(94)00030-8; YEUDALL WA, 1993, ORAL ONCOL, V29B, P63, DOI 10.1016/0964-1955(93)90012-4; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	45	25	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1616	1624		10.1038/sj.onc.1205217	http://dx.doi.org/10.1038/sj.onc.1205217			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896591				2022-12-25	WOS:000173956800018
J	Fukiage, C; Nakajima, E; Ma, H; Azuma, M; Shearer, TR				Fukiage, C; Nakajima, E; Ma, H; Azuma, M; Shearer, TR			Characterization and regulation of lens-specific calpain Lp82	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC CALPAIN; RAT LENS; MOLECULAR-CLONING; MESSENGER-RNA; IN-VIVO; CALPASTATIN; EXPRESSION; CALCIUM; P94; IDENTIFICATION	Eye tissues contain splice variants of muscle-preferred p94 (calpain 3), such as lens-specific Lp82 and Lp85, retina-specific Rt88, and cornea-specific Cn94. The purpose of the present experiment was to analyze the activation and regulation of the best characterized p94 splice variant, Lp82. Recombinant rat Lp82 (rLp82) was expressed using the baculovirus system, purified with Ni-NTA affinity and DEAE-ion exchange chromatographies, and characterized by SDS-PAGE, casein zymography, and immunoblotting. After incubation with calcium, rLp82 autolyzed into two major fragments at similar to60 and 22 kDa. Sequencing of the autolytic fragments showed loss of three amino acids from the N terminus and cleavage near the IS2 region. Also, Lp82 and calpain 2 were found to hydrolyze each other. Calpastatin inhibited calpain 2 activity, but not Lp82. Homology modeling suggested that the lack of inhibition of Lp82 by calpastatin was due to molecular clashes at the unique AX1 region of Lp82. Lp82 also hydrolyzed calpastatin. These results suggested that Lp82 might regulate other calpain activities and cause hydrolysis of substrates such as crystallins during lens cataract formation.	Senju Pharmaceut Corp Ltd, Senju Lab Ocular Sci, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Dept Oral Mol Biol & Ophthalmol, Portland, OR 97201 USA	Senju Pharmaceutical Co. Ltd.; Oregon Health & Science University	Fukiage, C (corresponding author), Oregon Hlth & Sci Univ, Senju Lab Ocular Sci, W Campus 505 NW 185th Ave, Beaverton, OR 97006 USA.	fukiagec@ohsu.edu			NEI NIH HHS [EY05786] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Azuma M, 2000, CURR EYE RES, V21, P710, DOI 10.1076/0271-3683(200009)21:3;1-R;FT710; EMORI Y, 1988, J BIOL CHEM, V263, P2364; GRAHAMSIEGENTHALER K, 1994, J BIOL CHEM, V269, P30457; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Kinbara K, 1998, BIOCHEM J, V335, P589, DOI 10.1042/bj3350589; Lee HJ, 1998, BIOL CHEM, V379, P175, DOI 10.1515/bchm.1998.379.2.175; Ma H, 2000, CURR EYE RES, V20, P183, DOI 10.1076/0271-3683(200003)20:3;1-9;FT183; Ma H, 1998, EXP EYE RES, V67, P221, DOI 10.1006/exer.1998.0515; Ma H, 1998, INVEST OPHTH VIS SCI, V39, P454; Ma H, 2000, INVEST OPHTH VIS SCI, V41, P4232; MAKI M, 1989, J BIOL CHEM, V264, P18866; Murachi T, 1980, Adv Enzyme Regul, V19, P407; MURACHI T, 1989, BIOCHEM INT, V18, P263; Nakajima T, 2001, BBA-GENE STRUCT EXPR, V1519, P55, DOI 10.1016/S0167-4781(01)00212-3; Nakamura Y, 1999, EXP EYE RES, V69, P155, DOI 10.1006/exer.1998.0686; Nakamura Y, 2000, INVEST OPHTH VIS SCI, V41, P1460; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Shearer TR, 1998, CURR EYE RES, V17, P1037, DOI 10.1076/ceyr.17.11.1037.5232; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; TAKANO E, 1995, FEBS LETT, V362, P93, DOI 10.1016/0014-5793(95)00219-Y; TAKEMOTO LJ, 1995, CURR EYE RES, V14, P837, DOI 10.3109/02713689508995806; Ueda Y, 2001, EXP EYE RES, V73, P625, DOI 10.1006/exer.2001.1071	26	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20678	20685		10.1074/jbc.M200697200	http://dx.doi.org/10.1074/jbc.M200697200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11904300	hybrid			2022-12-25	WOS:000176204500075
J	Shen, GZ; Antonkine, ML; van der Est, A; Vassiliev, IR; Brettel, K; Bittl, R; Zech, SG; Zhao, JD; Stehlik, D; Bryant, DA; Golbeck, JH				Shen, GZ; Antonkine, ML; van der Est, A; Vassiliev, IR; Brettel, K; Bittl, R; Zech, SG; Zhao, JD; Stehlik, D; Bryant, DA; Golbeck, JH			Assembly of photosystem III. Rubredoxin is required for the in vivo assembly of F-x in Synechococcus sp PCC 7002 as shown by optical and EPR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; IRON-SULFUR CENTERS; RADICAL PAIRS; P-700(CENTER DOT+); A(1)(CENTER DOT-); TRANSFER KINETICS; TRANSIENT EPR; ACCEPTOR A(1); PULSED EPR; PCC 7002	The rubA gene was insertionally inactivated in Synechococcus sp. PCC 7002, and the properties of photosystem I complexes were characterized spectroscopically. X-band EPR spectroscopy at low temperature shows that the three terminal iron-sulfur clusters, F-X, F-A, and F-B, are missing in whole cells, thylakoids, and photosystein (PS) I complexes of the rubA mutant. The flashinduced decay kinetics of both P700(+) in the visible and A(1)(-) in the near-UV show that charge recombination occurs between P700degrees and A(1)(-) in both thylakoids and PS I complexes. The spin-polarized EPR signal at room temperature from PS I complexes also indicates that forward electron transfer does not occur beyond A, In agreement, the spin-polarized X-band EPR spectrum of P700(+) A(1)(-) at low temperature shows that an electron cycle between A(1)(-) and P700degrees occurs in a much larger fraction of PS I complexes than in the wild-type, wherein a relatively large fraction of the electrons promoted are irreversibly transferred to [F-A/F-B]. The electron spin polarization pattern shows that the orientation of phylloquinone in the PS I complexes is identical to that of the wild type, and out-of-phase, spin-echo modulation spectroscopy shows the same P700degrees to A(1)(-) center-to-center distance in photosystem I complexes of wild type and the rubA mutant. In contrast to the loss of F-X, F-B, and F-A, the Rieske iron-sulfur protein and the non-heme iron in photosystem 11 are intact. It is proposed that rubredoxin is specifically required for the assembly of the Fx iron-sulfur cluster but that Fx is not required for the biosynthesis of trimeric P700-A(1) cores. Since the PsaC protein requires the presence of Fx for binding, the absence of F-A and F-B, may be an indirect result of the absence of F-X.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Brock Univ, Dept Chem, St Catharines, ON L2S 3A1, Canada; CEA, Serv Bioenerget, F-91191 Gif Sur Yvette, France; CEA Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; Free Univ Berlin, Inst Phys Expt, D-14195 Berlin, Germany; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Brock University; CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); Free University of Berlin; Peking University	Golbeck, JH (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, S-310 Frear Bldg, University Pk, PA 16802 USA.	jhg5@psu.edu	Bittl, Robert/I-8149-2013	Bittl, Robert/0000-0003-4103-3768				Bittl R, 1997, J PHYS CHEM B, V101, P1429, DOI 10.1021/jp962256q; BOCK CH, 1989, FEBS LETT, V247, P91, DOI 10.1016/0014-5793(89)81247-5; Boudreaux B, 2001, J BIOL CHEM, V276, P37299, DOI 10.1074/jbc.M102327200; BRETTEL K, 1988, FEBS LETT, V239, P93, DOI 10.1016/0014-5793(88)80552-0; Brettel K, 1997, BBA-BIOENERGETICS, V1318, P322, DOI 10.1016/S0005-2728(96)00112-0; Brettel K, 1995, PHOTOSYNTH RES, V45, P183, DOI 10.1007/BF00015559; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; da Costa PN, 2001, MOL MICROBIOL, V41, P217, DOI 10.1046/j.1365-2958.2001.02509.x; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; Dzuba SA, 1997, CHEM PHYS LETT, V264, P238, DOI 10.1016/S0009-2614(96)01302-4; Golbeck J. H., 1995, CRC HDB ORGANIC PHOT, P1407; Golbeck JH, 1999, PHOTOSYNTH RES, V61, P107, DOI 10.1023/A:1006281802710; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; GOLBECK JH, 1994, MOL BIOL CYANOBACTER, P179; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; MILLER AF, 1991, BIOCHIM BIOPHYS ACTA, V1056, P1, DOI 10.1016/S0005-2728(05)80067-2; Muhiuddin IP, 2001, FEBS LETT, V503, P56, DOI 10.1016/S0014-5793(01)02696-5; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; PARRETT KG, 1989, BIOCHIM BIOPHYS ACTA, V973, P324, DOI 10.1016/S0005-2728(89)80439-6; SALIKHOV JM, 1992, APPL MAGN RESON, V15, P199; Schluchter WM, 1996, PHOTOCHEM PHOTOBIOL, V64, P53, DOI 10.1111/j.1751-1097.1996.tb02421.x; Shen GZ, 2002, J BIOL CHEM, V277, P20343, DOI 10.1074/jbc.M201103200; Shen GZ, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P3147; SIECKMAN I, 1991, FEBS LETT, V284, P98, DOI 10.1016/0014-5793(91)80771-T; VANDEREST A, 1994, BIOCHEMISTRY-US, V33, P11789, DOI 10.1021/bi00205a015; Vassiliev IR, 1997, BIOPHYS J, V72, P301, DOI 10.1016/S0006-3495(97)78669-7; Vassiliev IR, 2001, BBA-BIOENERGETICS, V1507, P139, DOI 10.1016/S0005-2728(01)00197-9; WARREN PV, 1990, BIOCHEMISTRY-US, V29, P6545, DOI 10.1021/bi00480a001; WARREN PV, 1993, BIOCHEMISTRY-US, V32, P849, DOI 10.1021/bi00054a016; Wastl J, 2000, J BIOL CHEM, V275, P30058, DOI 10.1074/jbc.M004629200; Wastl J, 2000, FEBS LETT, V471, P191, DOI 10.1016/S0014-5793(00)01399-5; XU Q, 1994, J BIOL CHEM, V269, P21512; Yang F, 1998, J PHYS CHEM B, V102, P8288, DOI 10.1021/jp981952i; YU JP, 1995, PLANT MOL BIOL, V29, P331, DOI 10.1007/BF00043656; Zech SG, 1996, BER BUNSEN PHYS CHEM, V100, P2041, DOI 10.1002/bbpc.19961001220; Zech SG, 1997, BIOCHEMISTRY-US, V36, P9774, DOI 10.1021/bi970754z; ZHAO J, 1993, MOL MICROBIOL, V9, P183, DOI 10.1111/j.1365-2958.1993.tb01680.x; Zybailov B, 2000, J BIOL CHEM, V275, P8531, DOI 10.1074/jbc.275.12.8531	39	71	86	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20355	20366		10.1074/jbc.M201104200	http://dx.doi.org/10.1074/jbc.M201104200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11914374	hybrid			2022-12-25	WOS:000176204500034
J	Galasinski, SC; Resing, KA; Goodrich, JA; Ahn, NG				Galasinski, SC; Resing, KA; Goodrich, JA; Ahn, NG			Phosphatase inhibition leads to histone deacetylases 1 and 2 phosphorylation and disruption of corepressor interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; COMPLEX; GENE; PROTEIN; BINDING; IDENTIFICATION; CHROMATIN; COMPONENT; FAMILY; YEAST	The regulation of histone deacetylases (HDACs) by phosphorylation was examined by elevating intracellular phosphorylation in cultured cells with the protein phosphatase inhibitor okadaic acid. After fractionation of extracts from treated versus untreated cells, HDAC 1 and 2 eluted in several peaks of deacetylase activity, assayed using mixed acetylated histones or acetylated histone H4 peptide. Stimulation of cells with okadaic acid led to hyperphosphorylation of HDAC I and 2 as well as changes in column elution of both enzymes. Hyperphosphorylated HDAC2 was also observed in cells synchronized with nocodazole or taxol, demonstrating regulation of HDAC phosphorylation during mitosis. Phosphorylated HDAC1 and 2 showed a gel mobility retardation that correlated with a small but significant increase in activity, both of which were reversed upon phosphatase treatment in vitro. However, the most pronounced effect of HDAC phosphorylation was to disrupt protein complex formation between HDAC1 and 2 as well as complex formation between HDAC1 and corepressors mSin3A and YY1 In contrast, interactions between HDAC1/2 and RbAp46/48 were unaffected by okadaic acid. These results establish a novel link between HDAC phosphorylation and the control of protein-protein interactions and suggest a mechanism for relief of deacetylase-catalyzed transcriptional repression by phosphorylation-dependent signaling.	Univ Colorado, Dept Chem & Biochem, Howard Hughes Med Inst, Boulder, CO 80309 USA; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	Ahn, NG (corresponding author), Univ Colorado, Dept Chem & Biochem, Howard Hughes Med Inst, Campus Box 215, Boulder, CO 80309 USA.	Natalie.Ahn@colorado.edu						Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; Cai R, 2001, BIOCHEM BIOPH RES CO, V283, P445, DOI 10.1006/bbrc.2001.4786; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Galasinski SC, 2002, J BIOL CHEM, V277, P2579, DOI 10.1074/jbc.M107894200; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HENDZEL MJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P307, DOI 10.1016/0167-4781(92)90443-4; Huang EY, 2000, GENE DEV, V14, P45; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; JOHNS EW, 1967, BIOCHEM J, V105, P611, DOI 10.1042/bj1050611; Johnson CA, 1999, SEMIN CELL DEV BIOL, V10, P179, DOI 10.1006/scdb.1999.0299; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Laj A, 1999, MOL CELL BIOL, V19, P6632; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nicol R, 1998, J BIOL CHEM, V273, P3588, DOI 10.1074/jbc.273.6.3588; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Pflum MKH, 2001, J BIOL CHEM, V276, P47733, DOI 10.1074/jbc.M105590200; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zeng YY, 1998, J BIOL CHEM, V273, P28921, DOI 10.1074/jbc.273.44.28921; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	45	126	131	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19618	19626		10.1074/jbc.M201174200	http://dx.doi.org/10.1074/jbc.M201174200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11919195	hybrid			2022-12-25	WOS:000175894800051
J	Pfeiffer, M; Koch, T; Schroder, H; Laugsch, M; Hollt, V; Schulz, S				Pfeiffer, M; Koch, T; Schroder, H; Laugsch, M; Hollt, V; Schulz, S			Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL GABA(B) RECEPTOR; PROTEIN; ACTIVATION; RAT; OLIGOMERIZATION; DIMERIZATION; ASSEMBLE; SUBTYPES; RESENSITIZATION; IDENTIFICATION	Heterodimerization has been shown to modulate the ligand binding, signaling, and trafficking properties of G protein-coupled receptors. However, to what extent heterodimerization may alter agonist-induced phosphorylation and desensitization of these receptors has not been documented. We have recently shown that heterodimerization of sst(2A) and sst(3) somatostatin receptors results in inactivation of sst(3) receptor function (Pfeiffer, M., Koch, T., Schroder, H., Klutzny, M., Kirscht, S., Kreienkamp, H. J., Hollt, V., and Schulz, S. (2001) J. Biol. Chem. 276,14027-14036). Here we examine dimerization of the sst(2A) somatostatin receptor and the mu-opioid receptor, members of closely related G protein-coupled receptor families. In coimmunoprecipitation studies using differentially epitope-tagged receptors, we provide direct evidence for heterodimerization of sst(2A) and MOR1 in human embryonic kidney 293 cells. Unlike heteromeric assembly of sst(2A) and sst(3), sst(2A)-MOR1 heterodimerization did not substantially alter the ligand binding or coupling properties of these receptors. However, exposure of the sst(2A)-MOR1 heterodimer to the sst(2A)-selective ligand L-779,976 induced phosphorylation, internalization, and desensitization of sst(2A) as well as MOR1. Similarly, exposure of the sst(2A)-MOR1 heterodimer to the mu-selective ligand [D-Ala(2),Me-Phe(4),Gly(5)-ol]enkephalin induced phosphorylation and desensitization of both MOR1 and sst(2A) but not internalization of sst(2A). Cross-phosphorylation and cross-desensitization of the sst(2A)-MOR1 heterodimer were selective; they were neither observed with the sst(2A)-sst(3) heterodimer nor with the endogenously expressed lysophosphatidic acid receptor. Heterodimerization may thus represent a novel regulatory mechanism that could either restrict or enhance phosphorylation and desensitization of G protein-coupled receptors.	Univ Magdeburg, Dept Pharmacol & Toxicol, D-39120 Magdeburg, Germany	Otto von Guericke University	Schulz, S (corresponding author), Univ Magdeburg, Dept Pharmacol & Toxicol, Leipziger Str 44, D-39120 Magdeburg, Germany.		Laugsch, Magdalena/AAH-8170-2021; Schulz, Stefan/A-6928-2017	Schulz, Stefan/0000-0002-5997-8885				AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Bell JR, 1999, MED J AUSTRALIA, V171, P26, DOI 10.5694/j.1326-5377.1999.tb123493.x; Bereiter DA, 1997, NEUROSCIENCE, V77, P863, DOI 10.1016/S0306-4522(96)00541-6; BETOIN F, 1994, J PHARMACOL EXP THER, V269, P7; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Ciruela F, 2001, J BIOL CHEM, V276, P18345, DOI 10.1074/jbc.M006960200; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; Gomes I, 2001, J MOL MED, V79, P226, DOI 10.1007/s001090100219; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hipkin RW, 2000, J BIOL CHEM, V275, P5591, DOI 10.1074/jbc.275.8.5591; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Koch T, 2000, MOL PHARMACOL, V58, P328, DOI 10.1124/mol.58.2.328; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Rohrer SP, 1998, SCIENCE, V282, P737, DOI 10.1126/science.282.5389.737; Schulz S, 1998, EUR J NEUROSCI, V10, P3700, DOI 10.1046/j.1460-9568.1998.00386.x; Schulz S, 1998, NEUROSCIENCE, V82, P613; Tallent M, 1998, NEUROSCIENCE, V85, P873, DOI 10.1016/S0306-4522(97)00675-1; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449	34	213	227	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19762	19772		10.1074/jbc.M110373200	http://dx.doi.org/10.1074/jbc.M110373200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11896051	hybrid			2022-12-25	WOS:000175894800069
J	Gorzalczany, Y; Alloul, N; Sigal, N; Weinbaum, C; Pick, E				Gorzalczany, Y; Alloul, N; Sigal, N; Weinbaum, C; Pick, E			A prenylated p67(phox)-Rac1 chimera elicits NADPH-dependent superoxide production by phagocyte membranes in the absence of an activator and of p47(phox) - Conversion of a pagan NADPH oxidase to monotheism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CELL-FREE SYSTEM; SODIUM DODECYL-SULFATE; SRC HOMOLOGY-3 DOMAINS; BINDING; FLAVOCYTOCHROME; PROTEIN; RAC1; MECHANISM; COMPONENT	Activation of the superoxide-generating NADPH oxidase of phagocytes is the result of the assembly of a membrane-localized flavocytochrome (cytochrome b(559)) with the cytosolic components p47(phox), p67(phox), and the small GTPase Rac. Activation can be reproduced in an in vitro system in which cytochrome b(559)-containing membranes are mixed with cytosolic components in the presence of an anionic amphiphile. We proposed that the essential event in activation is the interaction between p67(phox) and cytochrome b(559) and that Rac and p47(phox) serve as carriers for p67(phox) to the membrane. When prenylated, Rac can fulfill the carrier function by itself, supporting oxidase activation by p67(phox) in the absence of p47(phox) and amphiphile. We now show that a single chimeric protein, consisting of residues 1-212 of p67(phox) and full-length Rac1 (residues 1-192), prenylated in vitro and exchanged to GTP, becomes a potent oxidase activator in the absence of any other component or stimulus. Oxidase activation by prenylated chimera P67(phox) (1-212)-Rac1 (1-192) is accompanied by its spontaneous association with membranes. Prenylated chimeras p67(phox) (1-212)-Rac1 (178-192) and p67(phox) (1-212)-Rac1 (189-192), containing specific C-terminal regions of Rac1, are inactive; the activity of the first but not of the second chimera can be rescued by supplementation with exogenous nonprenylated Rac1-GTP. An analysis of prenylated p67(phox)-Rac1 chimeras suggests that the basic requirements for oxidase activation are: (i) a "two signals" membrane-localizing motif present in Rac, comprising the prenyl group and a C-terminal polybasic sequence and (ii) an intrachimeric or extrachimeric protein-protein interaction between p67(phox) and Rac1, causing a conformational change in the "activation domain" in p67(phox).	Tel Aviv Univ, Sackler Sch Med, Julius Friedrich Cohnheim Minerva Ctr Phagocyte R, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Ela Kodesz Inst Host Def Infect Dis, IL-69978 Tel Aviv, Israel; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Duke University	Pick, E (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel.		Pick, Edgar/B-1795-2008	Pick, Edgar/0000-0003-4625-3233				Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Alloul N, 2001, BIOCHEMISTRY-US, V40, P14557, DOI 10.1021/bi0117347; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; Cross AR, 1999, J BIOL CHEM, V274, P15519, DOI 10.1074/jbc.274.22.15519; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; Di-Poi N, 2001, BIOCHEMISTRY-US, V40, P10014, DOI 10.1021/bi010289c; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; Grizot S, 2001, J BIOL CHEM, V276, P21627, DOI 10.1074/jbc.M100893200; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; Lambeth JD, 2000, J BIOCHEM MOL BIOL, V33, P427; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; Leto TL., 1999, INFLAMMATION BASIC P, P769; Mineo C, 1997, J BIOL CHEM, V272, P10345; Miyano K, 2001, BIOCHEMISTRY-US, V40, P14089, DOI 10.1021/bi010882u; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993; ZHANG FL, 1994, J BIOL CHEM, V269, P23465	35	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18605	18610		10.1074/jbc.M202114200	http://dx.doi.org/10.1074/jbc.M202114200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11896062	hybrid			2022-12-25	WOS:000175975800049
J	Pedersen, LC; Petrotchenko, E; Shevtsov, S; Negishi, M				Pedersen, LC; Petrotchenko, E; Shevtsov, S; Negishi, M			Crystal structure of the human estrogen sulfotransferase-PAPS complex - Evidence for catalytic role of Ser(137) in the sulfuryl transfer reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; BINDING; DOMAIN	Estrogen sulfotransferase (EST) transfers the sulfate group from T-phosphoadenosine 5'-phosphosulfate (PAPS) to estrogenic steroids. Here we report the crystal structure of human EST (hEST) in the context of the V269E mutant-PAPS complex, which is the first structure containing the active sulfate donor for any sulfotransferase. Superimposing this structure with the crystal structure of hEST in complex with the donor product 3'-phosphoadenosine 5'-phosphate (PAP) and the acceptor substrate 17beta-estradiol, the ternary structure with the PAPS and estradiol molecule, is modeled. These structures have now provided a more complete view of the S(N)2-like in-line displacement reaction catalyzed by sulfotransferases. In the PAPS-bound structure, the side chain nitrogen of the catalytic Lys(47) interacts with the side chain hydroxyl of Ser(137) and not with the bridging oxygen between the 5'-phosphate and sulfate groups of the PAPS molecule as is seen in the PAP-bound structures. This conformational change of the side chain nitrogen indicates that the interaction of Lys(47) with Ser(137) may regulate PAPS hydrolysis in the absences of an acceptor substrate. Supporting the structural data, the mutations of Ser(137) to cysteine and alanine decrease gradually k(cat) for PAPS hydrolysis and transfer activity. Thus, Ser(137) appears to play an important role in regulating the side chain interaction of Lys(47) with the bridging oxygen between the 5'-phosphate and the sulfate of PAPS.	NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Negishi, M (corresponding author), NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA.	negishi@niehs.nih.gov	Negishi, Masahiko/F-7805-2019; Pedersen, Lars/C-6173-2019	Negishi, Masahiko/0000-0002-2076-8928; Pedersen, Lars/0000-0002-4488-4077	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071005] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bidwell LM, 1999, J MOL BIOL, V293, P521, DOI 10.1006/jmbi.1999.3153; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dajani R, 1999, J BIOL CHEM, V274, P37862, DOI 10.1074/jbc.274.53.37862; Duffel MW, 1997, COMPREHENSIVE TOXICO, V3, P365; Falany CN, 1997, FASEB J, V11, P1; Homma H, 1996, BBA-PROTEIN STRUCT M, V1296, P159, DOI 10.1016/0167-4838(96)00065-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kakuta Y, 1998, J BIOL CHEM, V273, P27325, DOI 10.1074/jbc.273.42.27325; Kakuta Y, 1998, BIOCHEM PHARMACOL, V55, P313, DOI 10.1016/S0006-2952(97)00465-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; Marsolais F, 1997, EUR J BIOCHEM, V247, P1056, DOI 10.1111/j.1432-1033.1997.01056.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ong E, 1999, J BIOL CHEM, V274, P25608, DOI 10.1074/jbc.274.36.25608; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen LC, 2000, FEBS LETT, V475, P61, DOI 10.1016/S0014-5793(00)01479-4; Petrotchenko EV, 2001, FEBS LETT, V490, P39, DOI 10.1016/S0014-5793(01)02129-9; Sueyoshi T, 1998, FEBS LETT, V433, P211, DOI 10.1016/S0014-5793(98)00913-2	24	91	97	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17928	17932		10.1074/jbc.M111651200	http://dx.doi.org/10.1074/jbc.M111651200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884392	hybrid			2022-12-25	WOS:000175685100069
J	Scheibner, KA; De Angelis, J; Burley, SK; Cole, PA				Scheibner, KA; De Angelis, J; Burley, SK; Cole, PA			Investigation of the roles of catalytic residues in serotonin N-acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELATONIN RHYTHM ENZYME; ACTIVE-SITE; HISTONE ACETYLTRANSFERASES; MECHANISM; PROTEIN; NMR; ISOMERASE; BINDING; ANALOGS; SUBUNIT	Serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase (AANAT)) is a critical enzyme in the light-mediated regulation of melatonin production and circadian rhythm. It is a member of the GNAT (GCN-5-related N-acetyltransferase) superfamily of enzymes, which catalyze a diverse array of biologically important acetyl transfer reactions from antibiotic resistance to chromatin remodeling. In this study, we probed the functional properties of two histidines (His-120 and His-122) and a tyrosine (Tyr-168) postulated to be important in the mechanism of AANAT based on prior x-ray structural and biochemical studies. Using a combination of steady-state kinetic measurements of microviscosity effects and pH dependence on the H122Q, H120Q, and H120Q/H122Q AANAT mutants, we show that His-122 (with an apparent pK(a) of 7.3) contributes similar to6-fold to the acetyltransferase chemical step as either a remote catalytic base or hydrogen bond donor. Furthermore, His-120 and His-122 appear to contribute redundantly to this function. By analysis of the Y168F AANAT mutant, it was demonstrated that Tyr-168 contributes similar to150-fold to the acetyltransferase chemical step and is responsible for the basic limb of the pH-rate profile with an apparent (subnormal) pK(a) of 8.5. Paradoxically, Y168F AANAT showed 10-fold enhanced apparent affinity for acetylCoA despite the loss of a hydrogen bond between the Tyr phenol and the CoA sulfur atom. The X-ray crystal structure of Y168F AANAT bound to a bisubstrate analog inhibitor showed no significant structural perturbation of the enzyme compared with the wild-type complex, but revealed the loss of dual inhibitor conformations present in the wild-type complex. Taken together with kinetic measurements, these crystallographic studies allow us to propose the relevant structural conformations related to the distinct alkyltransferase and acetyltransferase reactions catalyzed by AANAT. These findings have significant implications for understanding GNAT catalysis and the design of potent and selective inhibitors.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Biophys, New York, NY 10021 USA	Johns Hopkins University; Howard Hughes Medical Institute; Rockefeller University	Cole, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.	pcole@jhmi.edu		Burley, Stephen K./0000-0002-2487-9713				Arendt J., 1995, MELATONIN MAMMALIAN; Berg J M, 2001, Science, V291, P203; BLACKLOW SC, 1988, BIOCHEMISTRY-US, V27, P1158, DOI 10.1021/bi00404a013; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COLE PA, 1994, J BIOL CHEM, V269, P30880; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; Dyda F, 2000, ANNU REV BIOPH BIOM, V29, P81, DOI 10.1146/annurev.biophys.29.1.81; Gastel JA, 1998, SCIENCE, V279, P1358, DOI 10.1126/science.279.5355.1358; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; Ibarra C, 2001, BIOCHEMISTRY-US, V40, P10614, DOI 10.1021/bi010672h; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P463; Khalil EM, 1998, J BIOL CHEM, V273, P30321, DOI 10.1074/jbc.273.46.30321; Khalil EM, 1998, J AM CHEM SOC, V120, P6195, DOI 10.1021/ja981365a; Khalil EM, 1999, P NATL ACAD SCI USA, V96, P12418, DOI 10.1073/pnas.96.22.12418; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; KULIOPULOS A, 1989, BIOCHEMISTRY-US, V28, P149, DOI 10.1021/bi00427a022; Langer MR, 2001, J BIOL CHEM, V276, P31321, DOI 10.1074/jbc.M103839200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEWENDON A, 1994, BIOCHEMISTRY-US, V33, P1944, DOI 10.1021/bi00173a043; Marmorstein R, 2001, J MOL BIOL, V311, P433, DOI 10.1006/jmbi.2001.4859; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERONA JJ, 1994, BIOCHEMISTRY-US, V33, P3252, DOI 10.1021/bi00177a016; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Schafer SL, 1996, BIOCHEMISTRY-US, V35, P5662, DOI 10.1021/bi960174m; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Thompson J, 2001, P NATL ACAD SCI USA, V98, P9002, DOI 10.1073/pnas.151257098; Warshel A, 1998, J BIOL CHEM, V273, P27035, DOI 10.1074/jbc.273.42.27035; Wei YM, 2001, BIOCHEMISTRY-US, V40, P11279, DOI 10.1021/bi011085z; Wilmouth RC, 2001, NAT STRUCT BIOL, V8, P689, DOI 10.1038/90401; Wolf E, 2002, J MOL BIOL, V317, P215, DOI 10.1006/jmbi.2001.5371; Zheng WP, 2001, CHEM BIOL, V8, P379, DOI 10.1016/S1074-5521(01)00020-5	35	56	58	5	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18118	18126		10.1074/jbc.M200595200	http://dx.doi.org/10.1074/jbc.M200595200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884405	hybrid			2022-12-25	WOS:000175685100093
J	Kawaguchi, M; Onuchic, LF; Huang, SK				Kawaguchi, M; Onuchic, LF; Huang, SK			Activation of extracellular signal-regulated kinase (ERK)1/2, but not p38 and c-Jun N-terminal kinase, is involved in signaling of a novel cytokine, ML-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHIAL EPITHELIAL-CELLS; PROTEIN-KINASE; ENDOTHELIAL-CELLS; INDUCED EXPRESSION; MAP KINASE; IN-VITRO; RANTES; IDENTIFICATION; INTERLEUKIN-8; INHIBITOR	A novel cytokine, ML-1, was recently discovered, which shares a similar sequence homology with, but is functionally distinct from, IL-17 (Kawaguchi, M Onuchic, L., Li, X. D., Essayan, D. M., Schroeder, J., Xiao H. Q., Liu, M. C., Krishnaswamy, G., Germino, G., Q Huang, S. K. (2001) J. Immunol. 167, 4430-4435). To determine the signaling mechanisms of ML-1, we investigated activation of mitogen-activated protein (MAP) kinases induced by ML-1. Results show that ML-1 induces in a time-dependent fashion the expression of IL-6 and IL-8 in both primary bronchial epithelial cells (PBECs) and human umbilical vein endothelial cells (HUVECs). ML-1 activated a MAP kinase and an extracellular signal-regulated kinase (ERK)1/2 but not p38 or the c-Juu N-terminal kinase (JNK) in both cell types. Selective MAP kinase kinase (MEK)1/2 inhibitors, PD98059 and U0126, inhibited, in a dose-dependent manner, ML-1-induced expression of IL-6 and IL-8. These findings suggest that ML-1-induced IL-6 and IL-8 production is mediated through the activation of ERK1/2 in both cell types.	Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Dept Med, Div Nephrol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21224 USA; Univ Sao Paulo, Sch Med, Div Nephrol, BR-01246903 Sao Paulo, Brazil	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Universidade de Sao Paulo	Huang, SK (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, 5501 Bayview Circle, Baltimore, MD 21224 USA.	skhuang@mail.jhmi.edu	Huang, Shau-Ku/F-5509-2010; Onuchic, Luiz Fernando/H-1589-2012	Onuchic, Luiz Fernando/0000-0002-4053-5419	NIAID NIH HHS [AI-34002, AI-40274] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040274, R29AI034002] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Chayama K, 2001, P NATL ACAD SCI USA, V98, P4599, DOI 10.1073/pnas.081021898; Chen CC, 1996, CYTOKINE, V8, P58, DOI 10.1006/cyto.1995.0008; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Goebeler M, 1999, BLOOD, V93, P857, DOI 10.1182/blood.V93.3.857.403k03_857_865; Griego SD, 2000, J IMMUNOL, V165, P5211, DOI 10.4049/jimmunol.165.9.5211; Hashimoto S, 2000, CLIN EXP ALLERGY, V30, P48; Hashimoto S, 2000, AM J RESP CRIT CARE, V161, P280, DOI 10.1164/ajrccm.161.1.9904110; Hymowitz SG, 2001, EMBO J, V20, P5332, DOI 10.1093/emboj/20.19.5332; Kampen GT, 2000, BLOOD, V95, P1911, DOI 10.1182/blood.V95.6.1911; Kawaguchi M, 2001, J ALLERGY CLIN IMMUN, V108, P804, DOI 10.1067/mai.2001.119027; Kawaguchi M, 2001, J IMMUNOL, V167, P4430, DOI 10.4049/jimmunol.167.8.4430; Kujime K, 2000, J IMMUNOL, V164, P3222, DOI 10.4049/jimmunol.164.6.3222; KWON OJ, 1994, AM J PHYSIOL-LUNG C, V267, pL398, DOI 10.1152/ajplung.1994.267.4.L398; Lee J, 2001, J BIOL CHEM, V276, P1660, DOI 10.1074/jbc.M008289200; Li HZ, 2000, P NATL ACAD SCI USA, V97, P773, DOI 10.1073/pnas.97.2.773; Matsukura S, 1996, J ALLERGY CLIN IMMUN, V98, P1080, DOI 10.1016/S0091-6749(96)80195-3; May MJ, 1998, AM J PHYSIOL-CELL PH, V274, pC789, DOI 10.1152/ajpcell.1998.274.3.C789; Reibman J, 2000, J IMMUNOL, V165, P1618, DOI 10.4049/jimmunol.165.3.1618; Shi YG, 2000, J BIOL CHEM, V275, P19167, DOI 10.1074/jbc.M910228199; Starnes T, 2001, J IMMUNOL, V167, P4137, DOI 10.4049/jimmunol.167.8.4137; Steerenberg PA, 1998, EXP LUNG RES, V24, P85, DOI 10.3109/01902149809046056; Surapisitchat J, 2001, P NATL ACAD SCI USA, V98, P6476, DOI 10.1073/pnas.101134098; YOO ZB, 1995, J IMMUNOL, V155, P5483	24	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15229	15232		10.1074/jbc.C100641200	http://dx.doi.org/10.1074/jbc.C100641200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11891214	hybrid			2022-12-25	WOS:000175510400003
J	Finkeltov, I; Kuhn, S; Glaser, T; Idelman, G; Wright, JJ; Roberts, CT; Werner, H				Finkeltov, I; Kuhn, S; Glaser, T; Idelman, G; Wright, JJ; Roberts, CT; Werner, H			Transcriptional regulation of IGF-I receptor gene expression by novel isoforms of the EWS-WT1 fusion protein	ONCOGENE			English	Article						DSRCT; IGF-I receptor; EWS; WT1; translocation	ROUND-CELL TUMOR; HUMAN MYXOID CHONDROSARCOMA; WILMS-TUMOR; EWS GENE; EWINGS-SARCOMA; CHROMOSOME-TRANSLOCATION; PROMOTER ACTIVITY; MALIGNANT-MELANOMA; GENOMIC STRUCTURE; SUPPRESSOR WT1	The EWS family of genes is involved in numerous chromosomal translocations that are characteristic of a variety of sarcomas. A recently described member of this group is desmoplastic small round cell tumor (DSRCT), which is characterized by a recurrent t(11;22)(p13;q12) translocation that fuses the 5' exons of the EWS gene to the 3' exons of the WT1 gene. The originally described chimera comprises exons 1 - 7 of EWS and exons 8 - 10 of WT1. We have previously reported that the WT1 protein represses the expression of the IGF-I receptor gene, whereas the EWS(1 - 7)-WT 1(8 - 10) fusion protein activates IGF-I receptor gene expression. It has recently become apparent that EWS-WT1 chimeras produced in DSCRT are heterogeneous as a result of fusions of different regions of the EWS gene to the WT1 gene. We have recently characterized additional EWS-WT1 translocations that involve the juxtaposition of EWS exons 7 or 8 to WT1 exon 8, and an EWS-WT1 chimera that lacks EWS exon 6. The chimeric transcription factors encoded by these various translocations differ in their DNA-binding characteristics and their ability to transactivate the IGF-I receptor promoter. These data suggest that the molecular pathology of DSRCT is more complex than previously appreciated, and that this diversity may provide the foundation for predictive genotype-phenotype correlations in the future.	Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Ramat Aviv, Israel; NCI, Med Branch, Div Clin Sci, NIH, Bethesda, MD 20889 USA; Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Oregon Health & Science University	Werner, H (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Ramat Aviv, Israel.	hwerner@post.tau.ac.il	Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772	NIDDK NIH HHS [DK50810] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050810] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonescu CR, 1998, DIAGN MOL PATHOL, V7, P24, DOI 10.1097/00019606-199802000-00005; BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; Bosilevac JM, 1999, J BIOL CHEM, V274, P34811, DOI 10.1074/jbc.274.49.34811; BRODIE SG, 1995, HUM PATHOL, V26, P1370, DOI 10.1016/0046-8177(95)90303-8; Chan AS, 1999, PEDIATR DEVEL PATHOL, V2, P188, DOI 10.1007/s100249900108; Clark J, 1996, ONCOGENE, V12, P229; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; GANSLER T, 1989, AM J PATHOL, V135, P961; GERALD WL, 1991, AM J SURG PATHOL, V15, P499, DOI 10.1097/00000478-199106000-00001; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GILL S, 1995, GENE CHROMOSOME CANC, V12, P307, DOI 10.1002/gcc.2870120412; GONZALEZCRUSSI F, 1990, AM J SURG PATHOL, V14, P633, DOI 10.1097/00000478-199007000-00004; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; JEON IS, 1995, ONCOGENE, V10, P1229; Karnieli E, 1996, J BIOL CHEM, V271, P19304, DOI 10.1074/jbc.271.32.19304; Kim J, 1998, ONCOGENE, V16, P1973, DOI 10.1038/sj.onc.1201716; KURODA M, 1995, AM J PATHOL, V147, P1221; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; LADANYI M, 1994, CANCER RES, V54, P2837; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Liu J, 2000, CLIN CANCER RES, V6, P3522; Maor SB, 2000, MOL GENET METAB, V69, P130, DOI 10.1006/mgme.1999.2958; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; OHNO T, 1994, ONCOGENE, V9, P3087; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAUSCHER FJ, 1994, COLD SPRING HARB SYM, V59, P137, DOI 10.1101/SQB.1994.059.01.017; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; RESNICOFF M, 1995, CANCER RES, V55, P3739; SAWYER JR, 1992, AM J SURG PATHOL, V16, P411, DOI 10.1097/00000478-199204000-00010; Shimizu Y, 1998, CANCER GENET CYTOGEN, V106, P156, DOI 10.1016/S0165-4608(98)00062-4; Tajinda K, 1999, ENDOCRINOLOGY, V140, P4713, DOI 10.1210/en.140.10.4713; WERNER H, 1994, VITAM HORM, V48, P1, DOI 10.1016/S0083-6729(08)60495-1; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1992, MOL ENDOCRINOL, V6, P1545, DOI 10.1210/me.6.10.1545; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Werner H, 1996, J MOL NEUROSCI, V7, P111, DOI 10.1007/BF02736791; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402	48	27	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1890	1898		10.1038/sj.onc.1205042	http://dx.doi.org/10.1038/sj.onc.1205042			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896622				2022-12-25	WOS:000174284500012
J	Howlett, CJ; Robbins, SM				Howlett, CJ; Robbins, SM			Membrane-anchored Cbl suppresses Hck protein-tyrosine kinase mediated cellular transformation	ONCOGENE			English	Article						Src family kinases; Cbl; ubiquitination; transformation	C-CBL; GENE HCK; NEGATIVE REGULATOR; CSF-1 RECEPTOR; SRC; GROWTH; PHOSPHORYLATION; DEGRADATION; UBIQUITINATION; ASSOCIATION	The mammalian proto-oncogene CbI and its cellular homologues in Caenorhabtlitis elegans (Sli-1) and Drosophila (D-Cbl) are negative regulators of some growth factor receptor signaling pathways. Herein we show that CbI can negatively regulate another signaling molecule, namely the Src-family kinase Hck by targeting it for degradation. Hck-mediated cellular transformation of murine fibroblasts is reverted by ectopic expression of a membrane-anchored allele of CbI as assessed by the cellular morphology, suppression of anchorage independent growth, and an overall reduction in the total tyrosine phosphorylation levels within the cells. The expression of CbI at the plasma membrane targets both Hck and itself for ubiquitination and degradation, requiring an intact RING finger. Pharmacological inhibition of the proteasome prevents the degradation of Hck correlating with an increase in the phosphotyrosine levels within the cells. Activated Hck and membrane-anchored CbI are present in similar subcellular localizations and co-immunoprecipitate, suggesting that their interaction is required for subsequent ubiquitination and degradation. Interestingly, both constitutively active and kinase-inactive Hck interact with and are targeted for degradation by Cbl. This work illustrates alternate means to regulate Src-family kinases, and suggests that CbI may be able to suppress many signaling pathways that are activated in various proliferative syndromes including cancer.	Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Robbins, SM (corresponding author), Univ Calgary, Dept Oncol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	srobbins@ucalgary.ca		Robbins, Stephen/0000-0001-7475-1665				Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; Howlett CJ, 1999, BIOCHEM BIOPH RES CO, V257, P129, DOI 10.1006/bbrc.1999.0427; Joazeiro CAP, 2000, SCIENCE, V289, P2061, DOI 10.1126/science.289.5487.2061; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Johnson TM, 2000, J BIOL CHEM, V275, P33353, DOI 10.1074/jbc.M002022200; LAW DA, 1992, MOL IMMUNOL, V29, P917, DOI 10.1016/0161-5890(92)90130-P; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LICHTENBERG U, 1992, ONCOGENE, V7, P849; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Oda H, 1999, P NATL ACAD SCI USA, V96, P9557, DOI 10.1073/pnas.96.17.9557; Okamura-Oho Y, 1997, FEBS LETT, V419, P231, DOI 10.1016/S0014-5793(97)01461-0; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Pawson T, 1997, NATURE, V385, P582, DOI 10.1038/385582b0; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Scholz G, 2000, J BIOL CHEM, V275, P14615, DOI 10.1074/jbc.275.19.14615; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	42	20	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1707	1716		10.1038/sj.onc.1205228	http://dx.doi.org/10.1038/sj.onc.1205228			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896602				2022-12-25	WOS:000174214200009
J	Tomer, G; Buermeyer, AB; Nguyen, MM; Liskay, RM				Tomer, G; Buermeyer, AB; Nguyen, MM; Liskay, RM			Contribution of human M1h1 and Pms2 ATPase activities to DNA mismatch repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; MUTL; PCNA; HETERODIMER; EXONUCLEASE; HYDROLYSIS; MECHANISM; INTERACTS; PROTEINS; GENE	MutLalpha, a heterodimer composed of Mlh1 and Pms2, is the major MutL activity in mammalian DNA mismatch repair. Highly conserved motifs in the N termini of both subunits predict that the protein is an ATPase. To study the significance of these motifs to mismatch repair, we have expressed in insect cells wild type human MutLa and forms altered in conserved glutamic acid residues, predicted to catalyze ATP hydrolysis of Mlh1, Pms2, or both. Using an in vitro assay, we showed that MutLa proteins altered in either glutamic acid residue were each partially defective in mismatch repair, whereas the double mutant showed no detectable mismatch repair. Neither strand specificity nor directionality of repair was affected in the single mutant proteins. Limited proteolysis studies of MutLa demonstrated that both Mlh1 and Pms2 N-terminal domains undergo ATP-induced conformational changes, but the extent of the conformational change for Mlh1 was more apparent than for Pms2. Furthermore, Mlh1 was protected at lower ATP concentrations than Pms2, suggesting Mlh1 binds ATP with higher affinity. These findings imply that ATP hydrolysis is required for MutLa activity in mismatch repair and that this activity is associated with differential conformational changes in Mlh1 and Pms2.	Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA	Oregon Health & Science University; Oregon State University	Liskay, RM (corresponding author), Oregon Hlth & Sci Univ, Dept Mol & Med Genet, L103,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	liskaym@ohsu.edu	Buermeyer, Andrew/AAW-4099-2020	Buermeyer, Andrew/0000-0003-4502-4666	NIGMS NIH HHS [GM45413, GM 7R01, R37 GM32741] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032741, R01GM045413] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aronshtam A, 1996, NUCLEIC ACIDS RES, V24, P2498, DOI 10.1093/nar/24.13.2498; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Brino L, 2000, J BIOL CHEM, V275, P9468, DOI 10.1074/jbc.275.13.9468; Buermeyer AB, 1999, CANCER RES, V59, P538; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Burdett V, 2001, P NATL ACAD SCI USA, V98, P6765, DOI 10.1073/pnas.121183298; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; COOPER DL, 1993, J BIOL CHEM, V268, P11823; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; FANG WH, 1993, J BIOL CHEM, V268, P11838; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Guarne A, 2001, EMBO J, V20, P5521, DOI 10.1093/emboj/20.19.5521; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Hall MC, 2002, J BIOL CHEM, V277, P3673, DOI 10.1074/jbc.M106120200; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; Kampranis SC, 1998, J BIOL CHEM, V273, P26305, DOI 10.1074/jbc.273.41.26305; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Marra G, 2001, CANCER RES, V61, P7719; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; Nicolaides NC, 1998, MOL CELL BIOL, V18, P1635, DOI 10.1128/MCB.18.3.1635; Peltomaki P, 2001, MUTAT RES-REV MUTAT, V488, P77, DOI 10.1016/S1383-5742(00)00058-2; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; RAHMATULLAH M, 1994, J BIOL CHEM, V269, P3574; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; Schmutte C, 1998, CANCER RES, V58, P4537; Schmutte C, 2001, J BIOL CHEM, V276, P33011, DOI 10.1074/jbc.M102670200; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Spampinato C, 2000, J BIOL CHEM, V275, P9863, DOI 10.1074/jbc.275.13.9863; SU SS, 1988, J BIOL CHEM, V263, P6829; Thomas David C., 1995, Methods (Orlando), V7, P187, DOI 10.1006/meth.1995.1024; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tran PT, 2000, MOL CELL BIOL, V20, P6390, DOI 10.1128/MCB.20.17.6390-6398.2000; Tran PT, 2001, P NATL ACAD SCI USA, V98, P9760, DOI 10.1073/pnas.161175998; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Williams NL, 2001, J MOL BIOL, V306, P969, DOI 10.1006/jmbi.2001.4468; Yang W, 2000, MUTAT RES-DNA REPAIR, V460, P245, DOI 10.1016/S0921-8777(00)00030-6	54	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21801	21809		10.1074/jbc.M111342200	http://dx.doi.org/10.1074/jbc.M111342200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11897781	hybrid			2022-12-25	WOS:000176286000089
J	Hoeprich, S; Guo, PX				Hoeprich, S; Guo, PX			Computer modeling of three-dimensional structure of DNA-packaging RNA (pRNA) monomer, dimer, and hexamer of Phi29 DNA packaging motor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL-VIRUS PHI29; BACTERIOPHAGE-PHI-29 PROHEAD RNA; PHOTOAFFINITY CROSS-LINKING; PERMUTED TRANSFER-RNAS; BICOID MESSENGER-RNA; RIBONUCLEASE-P RNA; PHAGE PHI-29; CHEMICAL MODIFICATION; IN-VITRO; MODIFICATION INTERFERENCE	A striking common feature in the maturation of all linear double-stranded DNA viruses is that their lengthy genome is translocated with remarkable velocity into the limited space within a preformed protein shell and packaged into near crystalline density. A DNA-translocating motor, powered by ATP hydrolysis, accomplishes this task, which would otherwise be energetically unfavorable. DNA-packaging RNA, pRNA, forms a hexameric complex to serve as a vital component of the DNA translocating motor of bacterial virus Phi29. The sequential action of six pRNA ensures continual function in the DNA translocation process. The Phi29 motor has been assembled with purified components synthesized by chemical or biotechnological approaches and is able to pump the viral DNA into the protein shell in vitro. pRNA dimers are the building blocks of the hexamer. The computer models of the three-dimensional structure of the motor was constructed based on experimental data derived from photoaffinity cross-linking by psoralen, phenphi (cis-Rh (1,10-phenanthroline) (9,10-phenanthrenequinone diimine)Cl-2(+)), and azidophenacyl; chemical modification and chemical modification interference with dimethyl sulfate, 1-cyclohexyl-3-(2-morpholinoethy)carbodiimide metho-p-toluene sulfonate, and kethoxal; complementary modification; and nuclease probing by single- and double-stranded specific RNases. The shapes of these computer models are very similar to the published pRNA images of cryo-atomic force microscopy. pRNA hexamer docking with the connector crystal structure reveals a very impressive match with the available biochemical, genetic, and physical data.	Purdue Univ, Purdue Canc Res Ctr, W Lafayette, IN 47907 USA; Purdue Univ, Dept Pathobiol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Guo, PX (corresponding author), Purdue Univ, Purdue Canc Res Ctr, B-36 Hansen Life Sci Res Bldg, W Lafayette, IN 47907 USA.	guop@purdue.edu	Guo, Peixuan/I-7184-2015; Guo, Peixuan/AAE-2573-2022	Guo, Peixuan/0000-0001-5706-2833	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060529, R01GM059944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60529, GM59944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson Dwight, 1993, P859; BAILEY S, 1990, J BIOL CHEM, V265, P22365; BAZINET C, 1985, ANNU REV MICROBIOL, V39, P109; Black LW, 1988, BACTERIOPHAGES, P321; CARAZO JM, 1986, J MOL BIOL, V192, P853, DOI 10.1016/0022-2836(86)90033-1; Chen CP, 1997, J VIROL, V71, P3864, DOI 10.1128/JVI.71.5.3864-3871.1997; Chen CP, 2000, J BIOL CHEM, V275, P17510, DOI 10.1074/jbc.M909662199; Chen CP, 1999, RNA, V5, P805, DOI 10.1017/S1355838299990350; Chen CP, 1997, J VIROL, V71, P495, DOI 10.1128/JVI.71.1.495-500.1997; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; Clever JL, 1996, J VIROL, V70, P5902, DOI 10.1128/JVI.70.9.5902-5908.1996; CONWAY L, 1987, EMBO J, V6, P4177, DOI 10.1002/j.1460-2075.1987.tb02764.x; Davenport RJ, 2001, SCIENCE, V291, P807, DOI 10.1126/science.291.5511.2071; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; Ferrandon D, 1997, EMBO J, V16, P1751, DOI 10.1093/emboj/16.7.1751; Garver K, 1997, RNA, V3, P1068; Garver K, 2000, J BIOL CHEM, V275, P2817, DOI 10.1074/jbc.275.4.2817; Greatorex JS, 1996, NUCLEIC ACIDS RES, V24, P2919, DOI 10.1093/nar/24.15.2919; GRIMES S, 1990, J MOL BIOL, V215, P559, DOI 10.1016/S0022-2836(05)80168-8; GUO PX, 1994, SEMIN VIROL, V5, P27, DOI 10.1006/smvy.1994.1004; GUO PX, 1994, SEMIN VIROL, V5, P1, DOI 10.1006/smvy.1994.1001; GUO PX, 1987, NUCLEIC ACIDS RES, V15, P7081, DOI 10.1093/nar/15.17.7081; GUO PX, 1987, SCIENCE, V236, P690, DOI 10.1126/science.3107124; Guo PX, 1998, MOL CELL, V2, P149, DOI 10.1016/S1097-2765(00)80124-0; Guo PX, 2002, PROG NUCLEIC ACID RE, V72, P415, DOI 10.1016/S0079-6603(02)72076-X; HAASNOOT CAG, 1986, J BIOMOL STRUCT DYN, V3, P843, DOI 10.1080/07391102.1986.10508468; HARRIS ME, 1994, EMBO J, V13, P3953, DOI 10.1002/j.1460-2075.1994.tb06711.x; Hendrix RW, 1998, CELL, V94, P147, DOI 10.1016/S0092-8674(00)81413-0; HUI CF, 1985, P NATL ACAD SCI USA, V82, P1381, DOI 10.1073/pnas.82.5.1381; JIMENEZ J, 1986, SCIENCE, V232, P1113, DOI 10.1126/science.3754654; Laughrea M, 1996, BIOCHEMISTRY-US, V35, P1589, DOI 10.1021/bi951838f; Massire C, 1998, J MOL GRAPH MODEL, V16, P197, DOI 10.1016/S1093-3263(98)80004-1; Mat-Arip Y, 2001, J BIOL CHEM, V276, P32575, DOI 10.1074/jbc.M100045200; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; Mohammad T, 1999, BIOORG MED CHEM LETT, V9, P1703, DOI 10.1016/S0960-894X(99)00265-6; Morais MC, 2001, J STRUCT BIOL, V135, P38, DOI 10.1006/jsbi.2001.4379; Muriaux D, 1996, J BIOL CHEM, V271, P33686, DOI 10.1074/jbc.271.52.33686; NOLAN JM, 1993, SCIENCE, V261, P762, DOI 10.1126/science.7688143; PAN T, 1991, SCIENCE, V254, P1361, DOI 10.1126/science.1720569; Pecenkova T, 1997, GENE, V199, P157; REID RJD, 1994, J BIOL CHEM, V269, P18656; REID RJD, 1994, J BIOL CHEM, V269, P9084; REID RJD, 1994, J BIOL CHEM, V269, P5157; RYMOND BC, 1988, GENE DEV, V2, P428, DOI 10.1101/gad.2.4.428; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; Simpson AA, 2000, NATURE, V408, P745, DOI 10.1038/35047129; Simpson AA, 2001, ACTA CRYSTALLOGR D, V57, P1260, DOI 10.1107/S0907444901010435; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; Smith DE, 2001, NATURE, V413, P748, DOI 10.1038/35099581; Trottier M, 2000, RNA, V6, P1257, DOI 10.1017/S1355838200992501; Trottier M, 1997, J VIROL, V71, P487, DOI 10.1128/JVI.71.1.487-494.1997; Trottier M, 1996, J VIROL, V70, P55, DOI 10.1128/JVI.70.1.55-61.1996; Trottier M, 1997, NUCL ACIDS S SER, V36, P187; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; TYC K, 1992, NUCLEIC ACIDS RES, V20, P5375, DOI 10.1093/nar/20.20.5375; Wagner C, 2001, J MOL BIOL, V313, P511, DOI 10.1006/jmbi.2001.5057; WASSARMAN DA, 1993, MOL BIOL REP, V17, P143, DOI 10.1007/BF00996222; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; Zhang CL, 1995, RNA, V1, P1041; ZHANG CL, 1995, VIROLOGY, V207, P442, DOI 10.1006/viro.1995.1103; ZHANG CL, 1994, VIROLOGY, V201, P77, DOI 10.1006/viro.1994.1267; ZHANG CL, 1995, VIROLOGY, V211, P568, DOI 10.1006/viro.1995.1439; Zhang CL, 1997, RNA, V3, P315; Zhang CL, 2001, VIROLOGY, V281, P281, DOI 10.1006/viro.2000.0771; Zhang F, 1998, MOL CELL, V2, P141, DOI 10.1016/S1097-2765(00)80123-9; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	67	63	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20794	20803		10.1074/jbc.M112061200	http://dx.doi.org/10.1074/jbc.M112061200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11886855	hybrid			2022-12-25	WOS:000176204500089
J	Huang, KJ; Zemelman, BV; Lehman, IR				Huang, KJ; Zemelman, BV; Lehman, IR			Endonuclease G, a candidate human enzyme for the initiation of genomic inversion in herpes simplex type 1 virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL-DNA REPLICATION; A-SEQUENCES; STRUCTURAL FEATURES; RECOMBINATION; MITOCHONDRIA; SEGMENT; SITE; AMPLIFICATION; SPECIFICITY; COMPONENTS	The herpes simplex virus type 1 (HSV-1) a sequence is present as a direct repeat at the two termini of the 152-kilobase viral genome and as an inverted repeat at the junction of the two unique components L and S. During replication, the HSV-1 genome undergoes inversion of L and S, producing an equimolar mixture of the four possible isomers. Isomerization is believed to result from recombination triggered by breakage at the a sequence, a recombinational hot spot. We have identified an enzyme in HeLa cell extracts that preferentially cleaves the a sequence and have purified it to near homogeneity. Microsequencing showed it to be human endonuclease G, an enzyme with a strong preference for G+C-rich sequences. Endonuclease G appears to be the only cellular enzyme that can specifically cleave the a sequence. Endonuclease G also showed the predicted recombination properties in an in vitro recombination assay. Based on these findings, we propose that endonuclease G initiates the a sequence-mediated inversion of the L and S components during HSV-1 DNA replication.	Stanford Univ, Dept Biochem, Beckman Ctr, Stanford, CA 94305 USA	Stanford University	Lehman, IR (corresponding author), Stanford Univ, Dept Biochem, Beckman Ctr, Stanford, CA 94305 USA.			Zemelman, Boris/0000-0003-2463-4887	NIAID NIH HHS [AI20538] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bataille D, 1997, J VIROL, V71, P7736, DOI 10.1128/JVI.71.10.7736-7743.1997; BRUCKNER RC, 1992, P NATL ACAD SCI USA, V89, P10950, DOI 10.1073/pnas.89.22.10950; COTE J, 1993, SCIENCE, V261, P765, DOI 10.1126/science.7688144; COTE J, 1989, J BIOL CHEM, V264, P3301; DAVISON AJ, 1981, J GEN VIROL, V55, P315, DOI 10.1099/0022-1317-55-2-315; DEISS LP, 1986, J VIROL, V59, P605, DOI 10.1128/JVI.59.3.605-618.1986; DELIUS H, 1976, Journal of General Virology, V33, P125, DOI 10.1099/0022-1317-33-1-125; DUTCH RE, 1992, J VIROL, V66, P277, DOI 10.1128/JVI.66.1.277-285.1992; DUTCH RE, 1994, J VIROL, V68, P3733, DOI 10.1128/JVI.68.6.3733-3741.1994; DUTCH RE, 1995, J VIROL, V69, P3084, DOI 10.1128/JVI.69.5.3084-3089.1995; GERSCHENSON M, 1995, NUCLEIC ACIDS RES, V23, P88, DOI 10.1093/nar/23.1.88; GOTTLIEB J, 1990, J BIOL CHEM, V265, P10842; HARLOW E, 1999, USING ANTIBODIES LAB, P311; HAYWARD GS, 1975, P NATL ACAD SCI USA, V72, P4243, DOI 10.1073/pnas.72.11.4243; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ikeda S, 1997, ACTA MED OKAYAMA, V51, P55; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Martin DW, 1996, J VIROL, V70, P8801, DOI 10.1128/JVI.70.12.8801-8812.1996; Martinez R, 1996, J VIROL, V70, P2075, DOI 10.1128/JVI.70.4.2075-2085.1996; MOCARSKI ES, 1982, P NATL ACAD SCI-BIOL, V79, P5626, DOI 10.1073/pnas.79.18.5626; MOCARSKI ES, 1981, P NATL ACAD SCI-BIOL, V78, P7047, DOI 10.1073/pnas.78.11.7047; MOCARSKI ES, 1985, J VIROL, V55, P140, DOI 10.1128/JVI.55.1.140-146.1985; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; ROIZMAN B, 2001, FIELDS VIROLOGY, V2, P2399; RUIZCARRILLO A, 1987, EMBO J, V6, P401, DOI 10.1002/j.1460-2075.1987.tb04769.x; Sambrook J., 2002, MOL CLONING LAB MANU; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Umene K, 1999, REV MED VIROL, V9, P171, DOI 10.1002/(SICI)1099-1654(199907/09)9:3&lt;171::AID-RMV243&gt;3.0.CO;2-A; UMENE K, 1991, J VIROL, V65, P5410, DOI 10.1128/JVI.65.10.5410-5416.1991; WEBER PC, 1988, CELL, V54, P369, DOI 10.1016/0092-8674(88)90200-0; Widlak P, 2001, J BIOL CHEM, V276, P48404, DOI 10.1074/jbc.M108461200; WOHLRAB F, 1991, P NATL ACAD SCI USA, V88, P6432, DOI 10.1073/pnas.88.15.6432; WOHLRAB F, 1987, J BIOL CHEM, V262, P6407; ZEMELMAN BV, 1997, THESIS STANFORD U; ZHANG X, 1994, VIROLOGY, V202, P530, DOI 10.1006/viro.1994.1375	36	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					21071	21079		10.1074/jbc.M201785200	http://dx.doi.org/10.1074/jbc.M201785200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11912214	hybrid			2022-12-25	WOS:000176204500122
J	Liu, SC; Kiosses, WB; Rose, DM; Slepak, M; Salgia, R; Griffin, JD; Turner, CE; Schwartz, MA; Ginsberg, MH				Liu, SC; Kiosses, WB; Rose, DM; Slepak, M; Salgia, R; Griffin, JD; Turner, CE; Schwartz, MA; Ginsberg, MH			A fragment of paxillin binds the alpha(4) integrin cytoplasmic domain (tail) and selectively inhibits alpha(4)-mediated cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION PROTEIN; CYTOSKELETAL LINKAGES; LD MOTIFS; ASSOCIATION; KINASE; LOCALIZATION; MODULATION; PEST; SRC	The alpha(4) integrins play important roles in embryogenesis, hematopoiesis, cardiac development, and the immune responses. The alpha(4) integrin subunit is indispensable for these biological processes, possibly because the alpha(4) subunit regulates cellular functions differently from other integrin a subunits. We have previously reported that the alpha(4) cytoplasmic domain directly and tightly binds paxillin, an intracellular signaling adaptor molecule, and this interaction accounts for some of the unusual functional responses to alpha(4) integrin-mediated cell adhesion. We also have identified a conserved 9-amino acid region (Glu(983)-Tyr(991)) in the alpha(4) cytoplasmic domain that is sufficient for paxillin binding, and an alanine substitution at either Glu(983) or Tyr(991) within this regrion disrupted the alpha(4)-paxillin interaction and reversed the effects of the alpha(4) cytoplasmic domain on cell spreading and migration. In the current study, we have mapped the alpha(4)-binding site within paxillin using mutational analysis, and examined its effects on the alpha(4) tail-mediated functional responses. Here we report that sequences between residues Ala(176) and Asp(275) of paxillin are sufficient for binding to the alpha(4) tail. We found that the alpha(4) tail, paxillin, and FAT, the focal adhesion targeting domain of pp125(FAK), could form a ternary complex and that the alpha(4)-binding paxillin fragment, P(Ala(176)-Asp(275)), specifically blocked paxillin binding to the alpha(4) tail more efficiently than it blocked binding to FAT. Furthermore, when expressed in cells, this alpha(4)-binding paxillin fragment specifically inhibited the alpha(4) tail-stimulated cell migration. Thus, paxillin binding to the alpha(4) tail leads to enhanced cell migration and inhibition of the alpha(4)-paxillin interaction selectively blocks the alpha(4)-dependent cellular responses.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	Scripps Research Institute; Scripps Research Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Liu, SC (corresponding author), Millennium Pharmaceut Inc, Cardiovasc Res, 256 E Grand Ave, San Francisco, CA 94080 USA.	shouchun.liu@mpi.com		schwartz, martin/0000-0002-2071-1243	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, P01HL031950] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027214, R37AR027214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047607, R29GM047607] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48728, HL31950] Funding Source: Medline; NIAMS NIH HHS [AR27214] Funding Source: Medline; NIGMS NIH HHS [GM47607, R01 GM047607] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Brown MC, 1998, NAT STRUCT BIOL, V5, P677, DOI 10.1038/1370; Cary LA, 1996, J CELL SCI, V109, P1787; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; Han JW, 2001, J BIOL CHEM, V276, P40903, DOI 10.1074/jbc.M102665200; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hemler M E, 1995, Curr Opin Hematol, V2, P61; HEMLER ME, 1992, COLD SPRING HARB SYM, V57, P213, DOI 10.1101/SQB.1992.057.01.026; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ILLC D, 1995, NATURE, V377, P539; KASSNER PD, 1995, MOL BIOL CELL, V6, P661, DOI 10.1091/mbc.6.6.661; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Liu S, 2000, TRENDS CARDIOVAS MED, V10, P253, DOI 10.1016/S1050-1738(00)00073-6; Liu SC, 2001, J BIOL CHEM, V276, P37086, DOI 10.1074/jbc.M105114200; Liu SC, 2000, J BIOL CHEM, V275, P22736, DOI 10.1074/jbc.M000388200; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Shimizu Y, 1999, ADV IMMUNOL, V72, P325, DOI 10.1016/S0065-2776(08)60024-3; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Tong X, 1997, J BIOL CHEM, V272, P33373, DOI 10.1074/jbc.272.52.33373; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; WENG ZG, 1993, J BIOL CHEM, V268, P14956	33	45	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20887	20894		10.1074/jbc.M110928200	http://dx.doi.org/10.1074/jbc.M110928200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11919182	hybrid			2022-12-25	WOS:000176204500101
J	Kageyama, K; Ihara, Y; Goto, S; Urata, Y; Toda, G; Yano, K; Kondo, T				Kageyama, K; Ihara, Y; Goto, S; Urata, Y; Toda, G; Yano, K; Kondo, T			Overexpression of calreticulin modulates protein kinase B/Akt signaling to promote apoptosis during cardiac differentiation of cardiomyoblast H9c2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; RETINOIC ACID; PHOSPHATIDYLINOSITOL 3-KINASE; CATALYTIC SUBUNIT; GENE-EXPRESSION; PHOSPHATASE 2A; IN-VITRO; MOLECULAR CHAPERONE; CANCER-CELLS; CA2+ INFLUX	Calreticulin is a Ca2+-binding molecular chaperone of the lumen of the endoplasmic reticulum. Calreticulin has been shown to be essential for cardiac and neural development in mice, but the mechanism by which it functions in cell differentiation is not fully understood. To examine the role of calreticulin in cardiac differentiation, the calreticulin gene was introduced into rat cardiomyoblast H9c2 cells, and the effect of calreticulin overexpression on cardiac differentiation was examined. Upon culture in a differentiation medium containing fetal calf serum (1%) and retinoic acid (10 nM), cells transfected with the calreticulin gene were highly susceptible to apoptosis compared with controls. In the gene-transfected cells, protein kinase B/Akt signaling was significantly suppressed during differentiation. Furthermore, protein phosphatase 2A, a Ser/Thr protein phosphatase, was significantly up-regulated, implying suppression of Akt signaling due to dephosphorylation of Akt by the up-regulated protein phosphatase 2A via regulation of Ca2+ homeostasis. Thus, overexpression of calreticulin promotes differentiation-dependent apoptosis in H9c2 cells by suppressing the Akt signaling pathway. These findings indicate a novel mechanism by which cytoplasmic Akt signaling is modulated to cause apoptosis by a resident protein of the endoplasmic reticulum, calreticulin.	Atom Bomb Dis Inst, Dept Biochem & Mol Biol Dis, Nagasaki 8528523, Japan; Nagasaki Univ, Sch Med, Dept Internal Med 3, Nagasaki 8528523, Japan	Nagasaki University	Ihara, Y (corresponding author), Atom Bomb Dis Inst, Dept Biochem & Mol Biol Dis, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.							Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Chen D, 1999, MOL CELL BIOL, V19, P4684; CHEN Q, 1994, J CELL PHYSIOL, V161, P293, DOI 10.1002/jcp.1041610214; Coffer PJ, 1998, BIOCHEM J, V335, P1; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; DE LUCA LM, 1991, FASEB J, V5, P2924; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; Desai D, 1996, J BIOL CHEM, V271, P15153, DOI 10.1074/jbc.271.25.15153; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Fadel MP, 2001, J BIOL CHEM, V276, P27083, DOI 10.1074/jbc.M101676200; Fasolato C, 1998, MOL BIOL CELL, V9, P1513, DOI 10.1091/mbc.9.6.1513; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guo L, 2001, J BIOL CHEM, V276, P2797, DOI 10.1074/jbc.C000822200; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HESCHELER J, 1991, CIRC RES, V69, P1476, DOI 10.1161/01.RES.69.6.1476; Holaska JM, 2001, J CELL BIOL, V152, P127, DOI 10.1083/jcb.152.1.127; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; Ihara Y, 1997, J BIOL CHEM, V272, P9629; ImanakaYoshida K, 1996, J MOL CELL CARDIOL, V28, P553, DOI 10.1006/jmcc.1996.0051; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; Johnson S, 2001, TRENDS CELL BIOL, V11, P122, DOI 10.1016/S0962-8924(01)01926-2; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KHEWGOODALL Y, 1991, BIOCHEMISTRY-US, V30, P89, DOI 10.1021/bi00215a014; Kim JM, 1999, ARCH BIOCHEM BIOPHYS, V367, P67, DOI 10.1006/abbi.1999.1232; KIMES BW, 1976, EXP CELL RES, V98, P367, DOI 10.1016/0014-4827(76)90447-X; KITAGAWA Y, 1991, BIOCHIM BIOPHYS ACTA, V1089, P339, DOI 10.1016/0167-4781(91)90174-K; KITAGAWA Y, 1988, BIOCHIM BIOPHYS ACTA, V951, P123, DOI 10.1016/0167-4781(88)90032-2; KITAMURA K, 1991, J BIOCHEM-TOKYO, V109, P307; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Menard C, 1999, J BIOL CHEM, V274, P29063, DOI 10.1074/jbc.274.41.29063; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Nakamura K, 2001, J CLIN INVEST, V107, P1245, DOI 10.1172/JCI12412; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NISHIKAWA M, 1994, CANCER RES, V54, P4879; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; RAMACHANDRAN C, 1987, J BIOL CHEM, V262, P3210; Rauch F, 2000, EXP CELL RES, V256, P105, DOI 10.1006/excr.2000.4818; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; SAMBROOK J, 1989, MOL CLONING LAB MANU, P7; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Shago M, 1997, EXP CELL RES, V230, P50, DOI 10.1006/excr.1996.3408; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; WINROW CJ, 1995, MOL CELL ENDOCRINOL, V111, P175, DOI 10.1016/0303-7207(95)03563-M; Xu W, 2000, J BIOL CHEM, V275, P36676, DOI 10.1074/jbc.M002041200; Zhu N, 1999, CANCER RES, V59, P1896	68	74	81	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19255	19264		10.1074/jbc.M112377200	http://dx.doi.org/10.1074/jbc.M112377200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11907032	hybrid			2022-12-25	WOS:000175894800004
J	Wierzbicka-Patynowski, I; Schwarzbauer, JE				Wierzbicka-Patynowski, I; Schwarzbauer, JE			Regulatory role for Src and phosphatidylinositol 3-kinase in initiation of fibronectin matrix assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; CELL-CYCLE PROGRESSION; PHOSPHOINOSITIDE 3-OH KINASE; EXTRACELLULAR-MATRIX; FAMILY KINASES; PROTEIN-KINASE; GROWTH-FACTOR; INTEGRIN; ACTIVATION; BINDING	Fibronectin (FN) matrix assembly is a tightly regulated stepwise process that is initiated by interactions between FN and cell surface integrin receptors. These interactions activate many intracellular signaling pathways that regulate processes such as cell adhesion, migration, and survival. Here we demonstrate that cells lacking Src family kinases showed reduced ability to assemble FN fibrils as detected by immunofluorescence and by analysis of detergent extracts. The amount of FN matrix was further reduced by treatment with the phosphatidylinositol 3 (PI 3-kinase) inhibitor, wortmannin. CHOalpha5 cells, which are dependent on exogenous FN to initiate fibril formation, also showed significant reductions in matrix when treated with inhibitors of Src and PI 3-kinase. Combination of both inhibitors showed an additive inhibitory effect on assembly, which was concomitant with a loss of focal adhesion kinase phosphorylation. Decreased binding of the 70-kDa amino-terminal FN fragment at matrix assembly sites further supports a role for these kinases early during the process. We propose that these two signaling molecules, which lie downstream of integrins and focal adhesion kinase, are essential for efficient initiation of FN matrix assembly.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Schwarzbauer, JE (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.			Schwarzbauer, Jean/0000-0003-1012-7593	NATIONAL CANCER INSTITUTE [T32CA009528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059383] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09528-16] Funding Source: Medline; NIGMS NIH HHS [R01 GM59383] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; DZAMBA BJ, 1994, J BIOL CHEM, V269, P19646; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hocking DC, 1996, J CELL BIOL, V133, P431, DOI 10.1083/jcb.133.2.431; Hynes RO, 1990, FIBRONECTINS; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; KWON HJ, 1992, CANCER RES, V52, P6926; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Mercurius KO, 1998, CIRC RES, V82, P548, DOI 10.1161/01.RES.82.5.548; Mercurius KO, 2001, BMC CELL BIOL, V2, part. no., DOI 10.1186/1471-2121-2-18; Mosher DF, 1989, FIBRONECTIN; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; Sechler JL, 1998, J BIOL CHEM, V273, P25533, DOI 10.1074/jbc.273.40.25533; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shen TL, 2001, FEBS LETT, V499, P176, DOI 10.1016/S0014-5793(01)02545-5; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SOMERS CE, 1993, J BIOL CHEM, V268, P22277; SOTTILE J, 1994, J BIOL CHEM, V269, P17192; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WENNSTROM S, 1994, ONCOGENE, V9, P651; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021; Zhao J H, 2000, Prog Mol Subcell Biol, V25, P37	51	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19703	19708		10.1074/jbc.M200270200	http://dx.doi.org/10.1074/jbc.M200270200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11912200	hybrid			2022-12-25	WOS:000175894800062
J	Aikawa, R; Huggins, GS; Snyder, RO				Aikawa, R; Huggins, GS; Snyder, RO			Cardiomyocyte-specific gene expression following recombinant adeno-associated viral vector transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOASSOCIATED VIRUS VECTORS; HEAVY-CHAIN GENE; SARCOPLASMIC-RETICULUM CA2+-ATPASE; REPLICATION-DEFECTIVE ADENOVIRUS; LEFT-VENTRICULAR FUNCTION; COAGULATION-FACTOR-IX; IMMUNE-RESPONSE; IN-VIVO; GROWTH-HORMONE; DILATED CARDIOMYOPATHY	Recombinant adeno-associated viral (rAAV) vectors hold promise for delivering genes for heart diseases, but cardiac-specific expression by the use of rAAV has not been demonstrated. To achieve this goal rAAV vectors were generated expressing marker or potentially therapeutic genes under the control of the cardiac muscle-specific alpha myosin heavy chain (MHC) gene promoter. The rAAV-MHC vectors expressed in primary cardiomyocytes with similar kinetics to rAAV-CMV; however, expression by the rAAV-MHC vectors was restricted to cardiomyocytes. rAAV vectors have low cytotoxicity, and it is demonstrated here that rAAV fails to induce apoptosis in cardiomyocytes compared with a recombinant adenoviral vector. rAAV-MHC or rAAV-CMV vectors were administered to mice to determine the specificity of expression in vivo. The rAAV-MHC vectors expressed specifically in cardiomyocytes, whereas the control rAAV-CMV vector expressed in heart, skeletal muscle, and brain. rAAV-MHC transduction resulted in long term (16 weeks) expression of human growth hormone following intracardiac, yet not intramuscular, injection. Finally, we defined the minimal MHC enhancer/promoter sequences required for specific and robust in vivo expression in the context of a rAAV vector. For the first time we describe a panel of rAAV vectors capable of long term cardiac specific expression of intracellular and secreted proteins.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA; Massachusetts Gen Hosp, Cardiac Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Huggins, GS (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 677 Huntington Ave, Boston, MA 02115 USA.				NHLBI NIH HHS [R01 HL054592, R01 HL54592-06] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054592] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; ATCHISON RW, 1965, SCIENCE, V149, P754, DOI 10.1126/science.149.3685.754; BARR E, 1994, GENE THER, V1, P51; Chan SY, 1999, NAT MED, V5, P1143, DOI 10.1038/13467; Cordier L, 2000, MOL THER, V1, P119, DOI 10.1006/mthe.1999.0019; DOUD SK, 1995, J MOL CELL CARDIOL, V27, P2359; Fazio S, 1996, NEW ENGL J MED, V334, P809, DOI 10.1056/NEJM199603283341301; Flannery JG, 1997, P NATL ACAD SCI USA, V94, P6916, DOI 10.1073/pnas.94.13.6916; Flotte T, 1996, HUM GENE THER, V7, P1145, DOI 10.1089/hum.1996.7.9-1145; Franz WM, 1997, CARDIOVASC RES, V35, P560, DOI 10.1016/S0008-6363(97)00154-5; FRENCH BA, 1994, CIRCULATION, V90, P2414, DOI 10.1161/01.CIR.90.5.2414; Genth-Zotz S, 1999, CIRCULATION, V99, P18, DOI 10.1161/01.CIR.99.1.18; GILGENKRANTZ H, 1995, HUM GENE THER, V6, P1265, DOI 10.1089/hum.1995.6.10-1265; Giordano FJ, 1997, CIRCULATION, V96, P400; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Greelish JP, 1999, NAT MED, V5, P439, DOI 10.1038/7439; GULICK J, 1991, J BIOL CHEM, V266, P9180; Gupta M, 1998, MOL CELL BIOL, V18, P7243, DOI 10.1128/MCB.18.12.7243; GUZMAN RJ, 1993, CIRC RES, V73, P1202, DOI 10.1161/01.RES.73.6.1202; Hagstrom JN, 2000, BLOOD, V95, P2536; Hajjar RJ, 1997, CIRC RES, V81, P145, DOI 10.1161/01.RES.81.2.145; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; Hongo M, 2000, BASIC RES CARDIOL, V95, P431, DOI 10.1007/s003950070018; Jiang S, 2001, CANCER GENE THER, V8, P469, DOI 10.1038/sj.cgt.7700327; Jooss K, 1998, J VIROL, V72, P4212, DOI 10.1128/JVI.72.5.4212-4223.1998; Kaplitt MG, 1996, ANN THORAC SURG, V62, P1669, DOI 10.1016/S0003-4975(96)00946-0; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; Klein RL, 1998, EXP NEUROL, V150, P183, DOI 10.1006/exnr.1997.6736; Li J, 1999, GENE THER, V6, P74, DOI 10.1038/sj.gt.3300830; Mandel RJ, 1997, P NATL ACAD SCI USA, V94, P14083, DOI 10.1073/pnas.94.25.14083; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Mathews LC, 2002, METHOD ENZYMOL, V346, P393; Miao CH, 2000, J VIROL, V74, P3793, DOI 10.1128/JVI.74.8.3793-3803.2000; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; Molkentin JD, 1996, J MOL CELL CARDIOL, V28, P1211, DOI 10.1006/jmcc.1996.0112; Morkin E, 2000, MICROSC RES TECHNIQ, V50, P522, DOI 10.1002/1097-0029(20000915)50:6<522::AID-JEMT9>3.0.CO;2-U; Morral N, 1999, P NATL ACAD SCI USA, V96, P12816, DOI 10.1073/pnas.96.22.12816; NABEL EG, 1995, CIRCULATION, V91, P541, DOI 10.1161/01.CIR.91.2.541; Nuss HB, 1996, GENE THER, V3, P900; Phaneuf D, 2000, MOL MED, V6, P96, DOI 10.1007/BF03401777; Quinones MJ, 1996, CIRCULATION, V94, P1394, DOI 10.1161/01.CIR.94.6.1394; Rendahl KG, 1998, NAT BIOTECHNOL, V16, P757, DOI 10.1038/nbt0898-757; Schroder G, 2000, TRANSPLANTATION, V70, P191; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; Snyder RO, 1997, HUM GENE THER, V8, P1891, DOI 10.1089/hum.1997.8.16-1891; Song S, 1998, P NATL ACAD SCI USA, V95, P14384, DOI 10.1073/pnas.95.24.14384; Su H, 1997, P NATL ACAD SCI USA, V94, P13891, DOI 10.1073/pnas.94.25.13891; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Svensson EC, 1999, CIRCULATION, V99, P201, DOI 10.1161/01.CIR.99.2.201; Vincent-Lacaze N, 1999, J VIROL, V73, P1949, DOI 10.1128/JVI.73.3.1949-1955.1999; WALSH CE, 1994, J CLIN INVEST, V94, P1440, DOI 10.1172/JCI117481; Wu P, 2000, J VIROL, V74, P8635, DOI 10.1128/JVI.74.18.8635-8647.2000; Xiao X, 2000, J VIROL, V74, P1436, DOI 10.1128/JVI.74.3.1436-1442.2000; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996; Yap J, 1997, CARDIOVASC RES, V35, P529, DOI 10.1016/S0008-6363(97)00165-X; Zou LL, 2000, MOL THER, V2, P105, DOI 10.1006/mthe.2000.0104	58	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18979	18985		10.1074/jbc.M201257200	http://dx.doi.org/10.1074/jbc.M201257200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889137	hybrid			2022-12-25	WOS:000175975800096
J	Elble, RC; Ji, GJ; Nehrke, K; DeBiasio, J; Kingsley, PD; Kotlikoff, MI; Pauli, BU				Elble, RC; Ji, GJ; Nehrke, K; DeBiasio, J; Kingsley, PD; Kotlikoff, MI; Pauli, BU			Molecular and functional characterization of a murine calcium-activated chloride channel expressed in smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ANOCOCCYGEUS MUSCLE; RABBIT PORTAL-VEIN; ENDOTHELIAL-CELLS; INWARD CURRENTS; BREAST-CANCER; NORADRENALINE; CLONING; LUNG; MEMBRANE; TRACHEA	To identify the gene products responsible for the calcium-activated chloride current in smooth muscle, reverse transcription-PCR with degenerate primers was performed on mouse intestine and other organs. A new member of the CLCA gene family was identified, mCLCA4, that is expressed preferentially in organs containing a high percentage of smooth muscle cells, including intestine, stomach, uterus, bladder, and aorta. Reverse transcription-PCR using template RNA prepared from mouse bladder and stomach smooth muscle layers dissected free of mucosa yielded mCLCA4-specific bands. In situ hybridization with an mCLCA4-specific probe confirmed prominent expression in smooth muscle of major vessels of the heart but not cardiac muscle. High expression was also detected in the gastrointestinal tract, in bronchioles, and in aortic and lung endothelial cells. Transient expression of mCLCA4 in 293T cells resulted in the appearance of a prominent calcium-activated chloride current. Whole-cell currents activated by ionomycin or methacholine were anion-selective and showed minimal rectification or voltage-dependent gating. Similar to endogenous currents in smooth muscle cells, methacholine-induced currents were transient, and spontaneous transient inward currents were occasionally observed at resting membrane potentials. These results link calcium-activated chloride channels in smooth muscle with a gene family whose members have been implicated in cystic fibrosis, cancer, and asthma.	Cornell Univ, Coll Vet Med, Canc Biol Labs, Ithaca, NY 14853 USA; Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Coll Vet Med, Dept Biomed Sci, Ithaca, NY 14853 USA; Univ Rochester, Aab Inst Biomed Res, Ctr Oral Biol, Rochester, NY 14642 USA; Univ Rochester, Aab Inst Biomed Res, Ctr Human Genet & Mol Pediat Dis, Rochester, NY 14642 USA	Cornell University; Cornell University; Cornell University; University of Rochester; University of Rochester	Elble, RC (corresponding author), Cornell Univ, Coll Vet Med, Canc Biol Labs, Ithaca, NY 14853 USA.			Nehrke, Keith/0000-0001-9697-726X; Ji, Guangju/0000-0001-8626-3490	NCI NIH HHS [CA47668] Funding Source: Medline; NHLBI NIH HHS [HL41084, HL45239] Funding Source: Medline; NIDCR NIH HHS [DE09692] Funding Source: Medline; NIDDK NIH HHS [DK58795] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047668] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041084, R01HL045239, R01HL041084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058795] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdel-Ghany M, 2001, J BIOL CHEM, V276, P25438, DOI 10.1074/jbc.M100478200; Agnel M, 1999, FEBS LETT, V455, P295, DOI 10.1016/S0014-5793(99)00891-1; AMEDEE T, 1990, J PHYSIOL-LONDON, V428, P501, DOI 10.1113/jphysiol.1990.sp018224; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; Arreola J, 1996, J GEN PHYSIOL, V108, P35, DOI 10.1085/jgp.108.1.35; BYRNE NG, 1987, BRIT J PHARMACOL, V92, P371, DOI 10.1111/j.1476-5381.1987.tb11333.x; BYRNE NG, 1985, BRIT J PHARMACOL, V86, P711, DOI 10.1111/j.1476-5381.1985.tb08950.x; BYRNE NG, 1988, J PHYSIOL-LONDON, V404, P557, DOI 10.1113/jphysiol.1988.sp017306; BYRNE NG, 1987, J PHYSIOL-LONDON, V389, P513, DOI 10.1113/jphysiol.1987.sp016669; CLANCY JP, 1990, AM J PHYSIOL, V258, pL25, DOI 10.1152/ajplung.1990.258.2.L25; Criddle DN, 1996, BRIT J PHARMACOL, V118, P1065, DOI 10.1111/j.1476-5381.1996.tb15507.x; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; Dong QG, 1997, ARTERIOSCL THROM VAS, V17, P1599, DOI 10.1161/01.ATV.17.8.1599; Elble RC, 1997, J BIOL CHEM, V272, P27853, DOI 10.1074/jbc.272.44.27853; Elble RC, 2001, J BIOL CHEM, V276, P40510, DOI 10.1074/jbc.M104821200; EVANS MG, 1986, J PHYSIOL-LONDON, V378, P437, DOI 10.1113/jphysiol.1986.sp016229; FLEISCHMANN BK, 1994, P NATL ACAD SCI USA, V91, P11914, DOI 10.1073/pnas.91.25.11914; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; Gruber A. D., 2000, Current Genomics, V1, P201, DOI 10.2174/1389202003351526; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 1998, HISTOCHEM CELL BIOL, V110, P43, DOI 10.1007/s004180050263; Gruber AD, 1999, CANCER RES, V59, P5488; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; HARVEY RD, 1989, SCIENCE, V244, P983, DOI 10.1126/science.2543073; HIRST GDS, 1980, J PHYSIOL-LONDON, V303, P43, DOI 10.1113/jphysiol.1980.sp013269; Janssen LJ, 1998, AM J PHYSIOL-LUNG C, V275, pL516, DOI 10.1152/ajplung.1998.275.3.L516; JANSSEN LJ, 1994, PFLUG ARCH EUR J PHY, V427, P473, DOI 10.1007/BF00374263; JANSSEN LJ, 1992, J PHYSIOL-LONDON, V453, P197, DOI 10.1113/jphysiol.1992.sp019224; Komiya T, 1999, BIOCHEM BIOPH RES CO, V255, P347, DOI 10.1006/bbrc.1999.0168; Large WA, 1996, AM J PHYSIOL-CELL PH, V271, pC435; LEVERKOEHNE I, 2002, IN PRESS J HISTOCHEM; MAYER ML, 1985, J PHYSIOL-LONDON, V364, P217, DOI 10.1113/jphysiol.1985.sp015740; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; MORRIS AP, 1993, AM J PHYSIOL, V264, pC977, DOI 10.1152/ajpcell.1993.264.4.C977; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; Nelson MT, 1997, J PHYSIOL-LONDON, V502, P259, DOI 10.1111/j.1469-7793.1997.259bk.x; Nilius B, 1997, J PHYSIOL-LONDON, V498, P381, DOI 10.1113/jphysiol.1997.sp021865; O'Brien CD, 2001, FASEB J, V15, P1257, DOI 10.1096/fj.00-0467fje; OWEN DG, 1984, NATURE, V311, P567, DOI 10.1038/311567a0; SMITH PM, 1992, J PHYSIOL-LONDON, V449, P109, DOI 10.1113/jphysiol.1992.sp019077; Takano H, 2000, JPN J PHYSIOL, V50, P597, DOI 10.2170/jjphysiol.50.597; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; VANHELDEN DF, 1991, J PHYSIOL-LONDON, V437, P511, DOI 10.1113/jphysiol.1991.sp018609; WANG Q, 1992, J PHYSIOL-LONDON, V451, P525, DOI 10.1113/jphysiol.1992.sp019177; Wang YX, 1997, P NATL ACAD SCI USA, V94, P14918, DOI 10.1073/pnas.94.26.14918; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; ZYGMUNT AC, 1991, CIRC RES, V68, P424, DOI 10.1161/01.RES.68.2.424	47	60	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18586	18591		10.1074/jbc.M200829200	http://dx.doi.org/10.1074/jbc.M200829200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11896056	hybrid			2022-12-25	WOS:000175975800046
J	Hockin, MF; Jones, KC; Everse, SJ; Mann, KG				Hockin, MF; Jones, KC; Everse, SJ; Mann, KG			A model for the stoichiometric regulation of blood coagulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR PATHWAY; EXTRINSIC XASE COMPLEX; BOVINE FACTOR-V; FACTOR-VIIA; THROMBIN GENERATION; ANTITHROMBIN-III; PROTEIN-C; FACTOR-X; HEMOPHILIA-A; MATHEMATICAL SIMULATION	We have developed a model of the extrinsic blood coagulation system that includes the stoichiometric anticoagulants. The model accounts for the formation, expression, and propagation of the vitamin K-dependent procoagulant complexes and extends our previous model by including: (a) the tissue factor pathway inhibitor (TFPI)-mediated inactivation of tissue factor (TF)-VIIa and its product complexes; (b) the antithrombin-III (AT-III)-mediated inactivation of Ha, m-Ha, factor VIIa, factor IXa, and factor Xa; (e) the initial activation of factor V and factor VIII by thrombin generated by factor Xa-membrane; (d) factor VIIIa dissociation/activity loss; (e) the binding competition and kinetic activation steps that exist between TF and factors VII and VIIa; and (f) the activation of factor VII by Ha, factor Xa, and factor IXa. These additions to our earlier model generate a model consisting of 34 differential equations with 42 rate constants that together describe the 27 independent equilibrium expressions, which describe the fates of 34 species. Simulations are initiated by "exposing" picomolar concentrations of TF to an electronic milieu consisting of factors II, IX X, VII, VIIa, V, and VIIII, and the anticoagulants TFPI and AT-III at concentrations found in normal plasma or associated with coagulation pathology. The reaction followed in terms of thrombin generation, proceeds through phases that can be operationally defined as initiation, propagation, and termination. The generation of thrombin displays a nonlinear dependence upon TF, AT-III, and TFPI and the combination of these latter inhibitors displays kinetic thresholds. At subthreshold TF, thrombin production/ expression is suppressed by the combination of TFPI and AT-M; for concentrations above the TF threshold, the bolus of thrombin produced is quantitatively equivalent. A comparison of the model with empirical laboratory data illustrates that most experimentally observable parameters are captured, and the pathology that results in enhanced or deficient thrombin generation is accurately described.	Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA	University of Vermont	Mann, KG (corresponding author), Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.				NHLBI NIH HHS [P0-1 HL 46703, HL 34575] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034575, R01HL034575, P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; Baugh RJ, 1998, J BIOL CHEM, V273, P4378, DOI 10.1074/jbc.273.8.4378; Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; BELTRAMI E, 1995, P NATL ACAD SCI USA, V92, P8744, DOI 10.1073/pnas.92.19.8744; BERESFORD CH, 1988, BLOOD REV, V2, P239, DOI 10.1016/0268-960X(88)90013-6; Bergum PW, 2001, J BIOL CHEM, V276, P10063, DOI 10.1074/jbc.M009116200; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BoltonMaggs PHB, 1996, BAILLIERE CLIN HAEM, V9, P355, DOI 10.1016/S0950-3536(96)80068-0; BOM VJJ, 1991, THROMB HAEMOSTASIS, V66, P283; BROZE GJ, 1995, THROMB HAEMOSTASIS, V74, P90; Brummel KE, 1999, J BIOL CHEM, V274, P22862, DOI 10.1074/jbc.274.32.22862; Butenas S, 1999, BLOOD, V94, P2169, DOI 10.1182/blood.V94.7.2169.419k22_2169_2178; Butenas S, 1997, J BIOL CHEM, V272, P21527, DOI 10.1074/jbc.272.34.21527; Butenas S, 1996, BIOCHEMISTRY-US, V35, P1904, DOI 10.1021/bi951768c; BUTENAS S, 1994, BIOCHEMISTRY-US, V33, P3449, DOI 10.1021/bi00177a039; Cawthern KM, 1998, BLOOD, V91, P4581, DOI 10.1182/blood.V91.12.4581.412k12_4581_4592; CHIN HCH, 1983, J CLIN INVEST, V72, P493; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; De Moerloose P, 1998, SEMIN THROMB HEMOST, V24, P321, DOI 10.1055/s-2007-996020; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; ESMON CT, 1989, J BIOL CHEM, V264, P4743; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; FOSTER WB, 1983, J BIOL CHEM, V258, P5608; GENTRY R, 1995, BIOPHYS J, V69, P356, DOI 10.1016/S0006-3495(95)79907-6; GRIFFIN JH, 1987, PROG HEMATOL, V15, P39; Hockin MF, 1999, BIOCHEMISTRY-US, V38, P6918, DOI 10.1021/bi981966e; HOYER LW, 1994, NEW ENGL J MED, V330, P38, DOI 10.1056/NEJM199401063300108; JONES KC, 1994, J BIOL CHEM, V269, P23367; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KESSELS H, 1994, COMPUT BIOL MED, V24, P277, DOI 10.1016/0010-4825(94)90024-8; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAWSON JH, 1993, METHOD ENZYMOL, V222, P177; LAWSON JH, 1993, J BIOL CHEM, V268, P767; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; Mann K., 1995, WILLIAMS HEMATOLOGY, P1206; Mannucci PM, 2001, NEW ENGL J MED, V344, P1773, DOI 10.1056/NEJM200106073442307; Mounts WM, 1997, INT J BIOL MACROMOL, V20, P265, DOI 10.1016/S0141-8130(97)00026-3; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; OBRIEN DP, 1994, BIOCHEMISTRY-US, V33, P14162, DOI 10.1021/bi00251a027; OZSOYLU S, 1973, ACTA HAEMATOL-BASEL, V50, P305; POORT SR, 1994, THROMB HAEMOSTASIS, V72, P819; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; Reitsma PH, 1997, THROMB HAEMOSTASIS, V78, P344; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; Shobe J, 1999, J BIOL CHEM, V274, P24171, DOI 10.1074/jbc.274.34.24171; TRACY PB, 1979, J BIOL CHEM, V254, P354; van't Veer C, 2000, BLOOD, V95, P1330, DOI 10.1182/blood.V95.4.1330.004k28_1330_1335; vantVeer C, 1997, J BIOL CHEM, V272, P4367, DOI 10.1074/jbc.272.7.4367; vantVeer C, 1997, J BIOL CHEM, V272, P7983, DOI 10.1074/jbc.272.12.7983; Zoller B, 1999, HAEMATOLOGICA, V84, P59	60	285	294	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18322	18333		10.1074/jbc.M201173200	http://dx.doi.org/10.1074/jbc.M201173200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893748	hybrid			2022-12-25	WOS:000175975800011
J	Ikeda, K; Wang, LH; Torres, R; Zhao, H; Olaso, E; Eng, FJ; Labrador, P; Klein, R; Lovett, D; Yancopoulos, GD; Friedman, SL; Lin, HC				Ikeda, K; Wang, LH; Torres, R; Zhao, H; Olaso, E; Eng, FJ; Labrador, P; Klein, R; Lovett, D; Yancopoulos, GD; Friedman, SL; Lin, HC			Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASES; SIGNAL-TRANSDUCTION; MATRIX METALLOPROTEINASE-2; FAMILY KINASES; CELL-ADHESION; GROWTH-FACTOR; PROTEIN; INTEGRIN; PROLIFERATION; EXPRESSION	Discoidin domain receptor 2 (DDR2) is an unusual receptor tyrosine kinase in that its ligand is fibrillar collagen rather than a growth factor-like peptide. We examined signal transduction pathways of DDR2. Here we show that DDR2 is also unusual in that it requires Src activity to be maximally tyrosine-phosphorylated, and that Src activity also promotes association of DDR2 with Shc. The interaction with Shc involves a portion of She not previously implicated in interaction with receptor tyrosine kinases. These results identify Src kinase and the adaptor protein Shc as key signaling intermediates in DDR2 signal transduction. Furthermore, Src is required for DDR2-mediated transactivation of the matrix metalloproteinase-2 promoter. The data support a model in which Src and the DDR2 receptor cooperate in a regulated fashion to direct the phosphorylation of both the receptor and its targets.	Mt Sinai Sch Med, Dept Med, Div Liver Dis, New York, NY 10029 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; European Mol Biol Lab, Dev Biol Program, D-69117 Heidelberg, Germany; Univ Calif San Francisco, Dept Med, Vet Affairs Med Ctr, San Francisco, CA 94121 USA	Icahn School of Medicine at Mount Sinai; Regeneron; European Molecular Biology Laboratory (EMBL); University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Friedman, SL (corresponding author), Mt Sinai Sch Med, Dept Med, Div Liver Dis, Box 1123,1425 Madison Ave,Rm 1170F, New York, NY 10029 USA.		Klein, Ruediger/C-6147-2008; Olaso, Elvira/AAA-4497-2019; Labrador, Juan Pablo/C-3018-2014	Klein, Ruediger/0000-0002-3109-0163; Olaso, Elvira/0000-0001-6597-3530; Labrador, Juan Pablo/0000-0003-3671-848X	PHS HHS [R01 56621] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALVES F, 1995, ONCOGENE, V10, P609; Ankoma-Sey V, 1998, ONCOGENE, V17, P115, DOI 10.1038/sj.onc.1201912; Aplin AE, 1998, PHARMACOL REV, V50, P197; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Ellerbroek SM, 1999, CANCER RES, V59, P1635; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Keegan K, 1996, ONCOGENE, V12, P1537; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Labrador JP, 2001, EMBO REP, V2, P446, DOI 10.1093/embo-reports/kve094; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Olaso E, 2002, J BIOL CHEM, V277, P3606, DOI 10.1074/jbc.M107571200; Olaso E, 2001, J CLIN INVEST, V108, P1369, DOI 10.1172/JCI12373; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; Schmandt R, 1999, ONCOGENE, V18, P1867, DOI 10.1038/sj.onc.1202507; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Sternberg PW, 1998, CELL, V95, P447, DOI 10.1016/S0092-8674(00)81612-8; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Vogel S, 2000, J LIPID RES, V41, P882; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel W, 1999, FASEB J, V13, pS77, DOI 10.1096/fasebj.13.9001.s77	29	106	114	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19206	19212		10.1074/jbc.M201078200	http://dx.doi.org/10.1074/jbc.M201078200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11884411	hybrid			2022-12-25	WOS:000175975800124
J	Sundararajan, S; MacKenzie, RE				Sundararajan, S; MacKenzie, RE			Residues involved in the mechanism of the bifunctional methylenetetrahydrofolate dehydrogenase-cyclohydrolase - The roles of glutamine 100 and aspartate 125	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; SITE-DIRECTED MUTAGENESIS; METHENYLTETRAHYDROFOLATE-CYCLOHYDROLASE; ESCHERICHIA-COLI; FORMYLTETRAHYDROFOLATE SYNTHETASE; ANGSTROM RESOLUTION; PORCINE LIVER; ACTIVE-SITE; DEHYDROGENASE/CYCLOHYDROLASE; BINDING	The human bifunctional dehydrogenase-cyclohydrolase domain catalyzes the interconversion of 5,10-methylene-H(4)folate and 10-formyl-H(4)folate. Although previous structure and mutagenesis studies indicated the importance of lysine 56 in cyclohydrolase catalysis, the role of several surrounding residues had not been explored. In addition to further defining the role of lysine 56, the work presented in this study explores the functions of glutamine 100 and aspartate 125 through the use of site-directed mutagenesis and chemical modification. Mutants at position 100 are inactive with respect to cyclohydrolase activity while preserving significant dehydrogenase levels. We succeeded in producing a K56Q/ Q100K double mutant, which has no cyclohydrolase yet retains more than two-thirds of wild type dehydrogenase activity. Neither activity is detectable in aspartate 125 mutants with the exception of D125E. The results indicate that the function of glutamine 100 is to activate lysine 56 for cyclohydrolase catalysis and that aspartate 125 is involved in the binding of the H(4)folate substrates. In highlighting the importance of these residues, catalytic mechanisms are proposed for both activities as well as an explanation for the differences in channeling efficiency in the forward and reverse directions.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	MacKenzie, RE (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg, Montreal, PQ H3G 1Y6, Canada.	remack@med.mcgill.ca						a'Bhaird NN, 1998, BIOCHEM J, V330, P1029, DOI 10.1042/bj3301029; Allaire M, 1998, STRUCTURE, V6, P173, DOI 10.1016/S0969-2126(98)00019-7; ALMASSY RJ, 1992, P NATL ACAD SCI USA, V89, P6114, DOI 10.1073/pnas.89.13.6114; Anderson B M, 1980, Methods Enzymol, V66, P81; BOND MD, 1981, BIOCHEM BIOPH RES CO, V102, P243, DOI 10.1016/0006-291X(81)91513-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chiericatti G, 1998, BIOCHEMISTRY-US, V37, P9038, DOI 10.1021/bi9802770; CORMACK B, 1997, CURRENT PROTOCOLS MO, V1; DAWSON RMC, 1989, DATA BIOCH RES, P1; DRURY EJ, 1975, ARCH BIOCHEM BIOPHYS, V169, P662, DOI 10.1016/0003-9861(75)90210-6; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HUM DW, 1991, PROTEIN ENG, V4, P493, DOI 10.1093/protein/4.4.493; INGLESE J, 1990, BIOCHEMISTRY-US, V29, P6678, DOI 10.1021/bi00480a018; JACOB F, 1990, BIOCHEM J, V271, P399, DOI 10.1042/bj2710399; KAN CC, 1992, J PROTEIN CHEM, V11, P467, DOI 10.1007/BF01025023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacKenzie R E, 1984, FOLATES PTERINS CHEM, V1, P255; Pawelek PD, 2000, BBA-PROTEIN STRUCT M, V1479, P59, DOI 10.1016/S0167-4838(00)00058-3; Pawelek PD, 1998, BIOCHEMISTRY-US, V37, P1109, DOI 10.1021/bi971906t; PELLETIER JN, 1995, BIOCHEMISTRY-US, V34, P12673, DOI 10.1021/bi00039a025; PELLETIER JN, 1994, BIOCHEMISTRY-US, V33, P1900, DOI 10.1021/bi00173a037; Schmidt A, 2000, BIOCHEMISTRY-US, V39, P6325, DOI 10.1021/bi992734y; SMITH DDS, 1985, BIOCHEM BIOPH RES CO, V128, P148, DOI 10.1016/0006-291X(85)91657-2; SMITH DDS, 1983, CAN J BIOCHEM CELL B, V61, P1166, DOI 10.1139/o83-150; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; TAN LUL, 1977, BIOCHIM BIOPHYS ACTA, V485, P52, DOI 10.1016/0005-2744(77)90192-9; Trimmer EE, 2001, BIOCHEMISTRY-US, V40, P6216, DOI 10.1021/bi002790v; VILLAR E, 1985, J BIOL CHEM, V260, P2245; WINDHOLZ M, 1976, MERCK INDEX ENCY CHE; YANG XM, 1992, PROTEIN EXPRES PURIF, V3, P256, DOI 10.1016/1046-5928(92)90022-O	30	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18703	18709		10.1074/jbc.M200127200	http://dx.doi.org/10.1074/jbc.M200127200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11904299	hybrid			2022-12-25	WOS:000175975800062
J	Eto, K; Huet, C; Tarui, T; Kupriyanov, S; Liu, HZ; Puzon-McLaughlin, W; Zhang, XP; Sheppard, D; Engvall, E; Takada, Y				Eto, K; Huet, C; Tarui, T; Kupriyanov, S; Liu, HZ; Puzon-McLaughlin, W; Zhang, XP; Sheppard, D; Engvall, E; Takada, Y			Functional classification of ADAMs based on a conserved motif for binding to integrin alpha(9)beta(1) - Implications for sperm-egg binding and other cell interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC INTERACTION; ALPHA-SECRETASE CLEAVAGE; DISINTEGRIN DOMAIN; FERTILIN BETA; METALLOPROTEASE-DISINTEGRIN; SWISS-MODEL; MURINE EGGS; ADHESION; PROTEIN; SUBUNIT	ADAMs (a disintegrin and metalloproteases) are members of the metzincin superfamily of metalloproteases. Among integrins binding to disintegrin domains of ADAMs are alpha(9)beta(1) and alpha(v)beta(3), and they bind in an RGD-independent and an RGD-dependent manner, respectively. Human ADAM15 is the only ADAM with the RGD motif in the disintegrin domain. Thus, both integrin alpha(9)beta(1) and alpha(v)beta(3) recognize the ADAM15 disintegrin domain. We determined how these integrins recognize the ADAM15 disintegrin domain by mutational analysis. We found that the Arg(481) and the Asp-Leu-Pro-Glu-Phe residues (residues 488-492) were critical for alpha(9)beta(1) binding, but the RGD motif (residues 484-486) was not. In contrast, the RGD motif was critical for alpha(v)beta(3) binding, but the other residues flanking the RGD motif were not. As the RX6DLPEF alpha(9)beta(1) recognition motif (residues 481-492) is conserved among ADAMs, except for ADAM10 and 17 we hypothesized that alpha(9)beta(1) may recognize disintegrin domains in all ADAMs except ADAM10 and 17. Indeed we found that alpha(9)beta(1) bound avidly to the disintegrin domains of ADAM1, 2, 3, and 9 but not to the disintegrin domains of ADAM10 and 17. As several ADAMs have been implicated in sperm-oocyte interaction, we tested whether the functional classification of ADAMs, based on specificity for integrin alpha(9)beta(1), applies to sperm-egg binding. We found that the ADAM2 and 15 disintegrin domains bound to oocytes, but the ADAM17 disintegrin domain did not. Furthermore, the ADAM2 and 15 disintegrin domains effectively blocked binding of sperm to oocytes, but the ADAM17 disintegrin domain did not. These results suggest that oocytes and alpha(9)beta(1) have similar binding specificities for ADAMs and that alpha(9)beta(1), or a receptor with similar specificity, may be involved in sperm-egg interaction during fertilization. As alpha(9)beta(1) is a receptor for many ADAM disintegrins and alpha(9)beta(1) and ADAMs are widely expressed, alpha(9)beta(1)-ADAM interaction may be of a broad biological importance.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Burnham Inst, La Jolla, CA 92037 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Environm & Occupat Hlth, Lung Biol Ctr, Cardiovasc Res Inst, San Francisco, CA 94143 USA	Scripps Research Institute; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Takada, Y (corresponding author), Scripps Res Inst, Dept Cell Biol, VB-6,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	takada@scripps.edu	Tarui, Takehiko/L-4778-2019	Tarui, Takehiko/0000-0002-2519-7052; takada, yoshikazu/0000-0001-5481-9589	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045446] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45446] Funding Source: Medline; NIGMS NIH HHS [GM49899] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Bigler D, 2000, J BIOL CHEM, V275, P11576, DOI 10.1074/jbc.275.16.11576; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Bridges LC, 2002, J BIOL CHEM, V277, P3784, DOI 10.1074/jbc.M109538200; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; Evans JD, 2001, BIOESSAYS, V23, P62, DOI 10.1002/1521-1878(200101)23:1&lt;62::AID-BIES1008&gt;3.0.CO;2-7; Evans JP, 1997, DEV BIOL, V187, P79, DOI 10.1006/dbio.1997.8611; EVANS JP, 1995, J CELL SCI, V108, P3267; EVANS JP, 1999, FRONT BIOSCI, V4, P114; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; McLane MA, 1998, P SOC EXP BIOL MED, V219, P109, DOI 10.3181/00379727-219-44322; Miller BJ, 2000, J CELL BIOL, V149, P1289, DOI 10.1083/jcb.149.6.1289; Nath D, 2000, J CELL SCI, V113, P2319; Nath D, 1999, J CELL SCI, V112, P579; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Takahashi Y, 2001, MOL BIOL CELL, V12, P809, DOI 10.1091/mbc.12.4.809; Taooka Y, 1999, J CELL BIOL, V145, P413, DOI 10.1083/jcb.145.2.413; WANG A, 1995, DEV DYNAM, V204, P421, DOI 10.1002/aja.1002040408; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; WESKAMP G, 1994, P NATL ACAD SCI USA, V91, P2748, DOI 10.1073/pnas.91.7.2748; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345; Zhu XL, 2000, J BIOL CHEM, V275, P7677, DOI 10.1074/jbc.275.11.7677	38	146	164	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17804	17810		10.1074/jbc.M200086200	http://dx.doi.org/10.1074/jbc.M200086200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882657	hybrid			2022-12-25	WOS:000175685100054
J	Kim, JH; Wilder, PJ; Hou, JW; Nowling, T; Rizzino, A				Kim, JH; Wilder, PJ; Hou, JW; Nowling, T; Rizzino, A			Activation of the murine type II transforming growth factor-beta receptor gene - Up-regulation and function of the transcription factor Elf-3/Ert/Esx/Ese-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; UBIQUITIN-MEDIATED PROTEOLYSIS; GASTRIC-CANCER CELLS; TGF-BETA; DNA-BINDING; ETS FAMILY; MICROSATELLITE INSTABILITY; DIFFERENTIAL EXPRESSION; PROMOTER SEQUENCES; AUTO-INHIBITION	Previous studies demonstrated that differentiation of mouse embryonal carcinoma cells leads to transcriptional up-regulation of the mouse type II transforming growth factor-beta receptor (mTbetaR-II) gene. To elucidate the molecular mechanisms regulating transcription of this gene, we isolated the 5'-flanking region of the mTbetaR-II gene and characterized its expression in F9-differentiated cells. Analysis of mTbetaR-II promoter/reporter gene constructs demonstrates that two conserved Ets-binding sites play an important role in the activity of the mTbetaR-II promoter. Importantly, we present evidence that mElf-3, a member of the Ets family, plays a key role in the activation of the mTbetaR-II promoter. Northern blot analysis reveals that the steady-state levels of mTbetaR-II mRNA increase in parallel with those of mElf-3 mRNA during the differentiation of F9 embryonal carcinoma cells. We also demonstrate that mElf-3 contains one or more domains that influence its binding to DNA. Finally, we report that a single amino acid substitution in the transactivation domain of mElf-3 reduces its ability to transactivate and elevates its steady-state levels of expression. In conclusion, our data argue that mElf-3 plays a key role in the regulation of the mTbetaR-II gene, and Elf-3 itself is regulated at multiple levels.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Rizzino, A (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 600 S 42nd St, Omaha, NE 68198 USA.				NCI NIH HHS [CA 36727, CA 00476, CA 79491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727, R01CA079491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Bojovic BB, 2001, J BIOL CHEM, V276, P4509, DOI 10.1074/jbc.M005509200; Chang CH, 1999, ONCOGENE, V18, P3682, DOI 10.1038/sj.onc.1202674; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chang J, 1997, CANCER RES, V57, P2856; Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Cowley DO, 2000, GENE DEV, V14, P366; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Graves BJ, 1998, COLD SPRING HARB SYM, V63, P621, DOI 10.1101/sqb.1998.63.621; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; Hodge DR, 1996, ONCOGENE, V12, P11; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; Jackson RJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P290, DOI 10.1006/abbi.1999.1459; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; KELLY D, 1992, DEV BIOL, V153, P172, DOI 10.1016/0012-1606(92)90102-M; Kelly D, 1998, J BIOL CHEM, V273, P21115, DOI 10.1074/jbc.273.33.21115; Kelly DL, 1999, ANTICANCER RES, V19, P4791; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Laget MP, 1996, ONCOGENE, V12, P1325; Lazzereschi D, 1997, CANCER RES, V57, P2071; Liu Y, 2000, J BIOL CHEM, V275, P12231, DOI 10.1074/jbc.275.16.12231; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MA YG, 1992, DEV BIOL, V154, P45, DOI 10.1016/0012-1606(92)90046-J; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; MunozAntonia T, 1996, CANCER RES, V56, P4831; Neve R, 1998, FASEB J, V12, P1541, DOI 10.1096/fasebj.12.14.1541; Norgaard P, 1996, BRIT J CANCER, V73, P1037, DOI 10.1038/bjc.1996.201; Nowling TK, 2000, J BIOL CHEM, V275, P3810, DOI 10.1074/jbc.275.6.3810; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; PANKOV R, 1994, MOL CELL BIOL, V14, P7744, DOI 10.1128/MCB.14.12.7744; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; REEVES R, 1990, J BIOL CHEM, V265, P8573; RIZZINO A, 1987, CANCER RES, V47, P4386; Rizzino Angie, 1998, P115; ROSFJORD E, 1994, IN VITRO CELL DEV-AN, V30A, P477; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; SAMBROOK J, 1989, MOL CLONING LAB MANU, P269; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SETH A, 1993, ONCOGENE, V8, P1783; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; SUN LZ, 1994, J BIOL CHEM, V269, P26449; SUZUKI A, 1994, FEBS LETT, V355, P19, DOI 10.1016/0014-5793(94)01156-7; Tansey WP, 2001, GENE DEV, V15, P1045, DOI 10.1101/gad.896501; Thomas RS, 2000, ADV EXP MED BIOL, V480, P123; TOMODA T, 1994, BIOCHEM BIOPH RES CO, V198, P1054, DOI 10.1006/bbrc.1994.1150; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; Wiebe MS, 2000, GENE, V246, P383, DOI 10.1016/S0378-1119(00)00086-X; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yoshida N, 2000, MECH DEVELOP, V97, P27, DOI 10.1016/S0925-4773(00)00419-6; Zhang T, 1997, CANCER RES, V57, P1638	72	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17520	17530		10.1074/jbc.M110434200	http://dx.doi.org/10.1074/jbc.M110434200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11893733	hybrid			2022-12-25	WOS:000175685100018
J	Gu, YC; Gorelik, J; Spohr, HA; Shevchuk, A; Lab, MJ; Harding, SE; Vodyanoy, I; Klenerman, D; Korchev, YE				Gu, YC; Gorelik, J; Spohr, HA; Shevchuk, A; Lab, MJ; Harding, SE; Vodyanoy, I; Klenerman, D; Korchev, YE			High-resolution scanning patch-clamp: new insights into cell function	FASEB JOURNAL			English	Article						calcium channels; chloride channels; potassium channels; cardiomyocyte; neuron; sperm; patch-clamp; scanning probe microscopy	ION CONDUCTANCE MICROSCOPY; RAT VENTRICULAR MYOCYTES; CHLORIDE CHANNELS; CARDIAC MYOCYTES; CA2+ CHANNELS; POTASSIUM CHANNELS; SKELETAL-MUSCLE; SODIUM-CHANNELS; LIVING CELLS; CL CHANNELS	Cell specialization is often governed by the spatial distribution of ion channels and receptors on the cell surface. So far, little is known about functional ion channel localization. This is due to a lack of satisfactory methods for investigating ion channels in an intact cell and simultaneously determining the channels' positions accurately. We have developed a novel high-resolution scanning patch-clamp technique that enables the study of ion channels, not only in small cells, such as sperm, but in submicrometer cellular structures, such as epithelial microvilli, fine neuronal dendrites, and, particularly, T-tubule openings of cardiac myocytes. In cardiac myocytes, as in most excitable cells, action potential propagation depends essentially on the properties of ion channels that are functionally and spatially coupled. We found that the L-type calcium and chloride channels are distributed and colocalized in the region of T-tubule openings, but not in other regions of the myocyte. In addition, chloride channels were found in narrowly defined regions of Z-grooves. This finding suggests a new synergism between these types of channels that may be relevant for action potential propagation along the T-tubule system and excitation-contraction coupling.	Univ London Imperial Coll Sci Technol & Med, Div Med, MRC Clin Sci Ctr, Fac Med, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; Off Naval Res, Arlington, VA 22217 USA; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	Imperial College London; Imperial College London; United States Department of Defense; United States Navy; University of Cambridge	Korchev, YE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Med, MRC Clin Sci Ctr, Fac Med, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	y.korchev@ic.ac.uk	Korchev, Yuri/D-2498-2009; Harding, Sophie/HCH-8711-2022	Korchev, Yuri/0000-0002-4872-8696; Gorelik, Julia/0000-0003-1148-9158; Klenerman, David/0000-0001-7116-6954; gu, yuchun/0000-0002-7558-0447				Abrami L, 1997, EUR J CELL BIOL, V73, P215; Ahmed N, 2000, BIOCHEM J, V352, P789, DOI 10.1042/0264-6021:3520789; Alkondon M, 1996, J PHARMACOL EXP THER, V279, P1491; ALMERS W, 1983, J PHYSIOL-LONDON, V336, P261, DOI 10.1113/jphysiol.1983.sp014580; Alonso G, 1997, NEUROSCIENCE, V77, P617; ANGELIDES KJ, 1986, NATURE, V321, P63, DOI 10.1038/321063a0; Banke TG, 1997, J NEUROSCI RES, V49, P176, DOI 10.1002/(SICI)1097-4547(19970715)49:2<176::AID-JNR6>3.0.CO;2-6; Britton FC, 2000, AM J PHYSIOL-HEART C, V279, pH2225, DOI 10.1152/ajpheart.2000.279.5.H2225; CHENG H, 1994, PFLUG ARCH EUR J PHY, V428, P415, DOI 10.1007/BF00724526; COHEN MW, 1991, J NEUROSCI, V11, P1032; Curtis Michael J., 1994, Journal of Basic and Clinical Physiology and Pharmacology, V5, P19; Duan D, 2000, CIRC RES, V86, pE63, DOI 10.1161/01.RES.86.4.e63; Duan D, 1997, CIRC RES, V80, P103, DOI 10.1161/01.RES.80.1.103; EHARA T, 1990, NATURE, V347, P284, DOI 10.1038/347284a0; FROSCH MP, 1992, NEUROSCI LETT, V138, P59, DOI 10.1016/0304-3940(92)90472-J; Gathercole DV, 2000, J MOL CELL CARDIOL, V32, P1981, DOI 10.1006/jmcc.2000.1230; Grabner M, 1998, P NATL ACAD SCI USA, V95, P1903, DOI 10.1073/pnas.95.4.1903; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANSMA PK, 1989, SCIENCE, V243, P641, DOI 10.1126/science.2464851; HARDING SE, 1988, J MOL CELL CARDIOL, V20, P635, DOI 10.1016/S0022-2828(88)80121-4; HAUSSLER U, 1994, PFLUG ARCH EUR J PHY, V428, P323, DOI 10.1007/BF00724514; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; JOE EH, 1992, NATURE, V356, P333, DOI 10.1038/356333a0; KARPEN JW, 1992, J PHYSIOL-LONDON, V448, P257, DOI 10.1113/jphysiol.1992.sp019040; KINNAMON SC, 1988, P NATL ACAD SCI USA, V85, P7023, DOI 10.1073/pnas.85.18.7023; Korchev YE, 2000, NAT CELL BIOL, V2, P616, DOI 10.1038/35023563; Korchev YE, 1997, BIOPHYS J, V73, P653, DOI 10.1016/S0006-3495(97)78100-1; Korchev YE, 2000, BIOPHYS J, V78, P451, DOI 10.1016/S0006-3495(00)76607-0; Lopatin AN, 1998, TRENDS PHARMACOL SCI, V19, P395, DOI 10.1016/S0165-6147(98)01238-3; Maduke M, 2000, ANNU REV BIOPH BIOM, V29, P411, DOI 10.1146/annurev.biophys.29.1.411; Marrion NV, 1998, NATURE, V395, P900, DOI 10.1038/27674; Pascarel C, 1999, EXP PHYSIOL, V84, P1043, DOI 10.1111/j.1469-445X.1999.01876.x; Premkumar LS, 1999, MOL PHARMACOL, V56, P1138, DOI 10.1124/mol.56.6.1138; Reinhardt J, 1998, P NATL ACAD SCI USA, V95, P5378, DOI 10.1073/pnas.95.9.5378; SARIBANSOHRABY S, 1984, J BIOL CHEM, V259, P1221; Saviane C, 1999, J GEN PHYSIOL, V113, P457, DOI 10.1085/jgp.113.3.457; Scriven DRL, 2000, BIOPHYS J, V79, P2682, DOI 10.1016/S0006-3495(00)76506-4; Sorota S, 1999, CARDIOVASC RES, V42, P361, DOI 10.1016/S0008-6363(99)00039-5; Spencer CI, 2000, BRIT J PHARMACOL, V129, P235, DOI 10.1038/sj.bjp.0703074; SUN XH, 1995, J CELL BIOL, V129, P659, DOI 10.1083/jcb.129.3.659; TOUSSON A, 1989, J CELL SCI, V93, P349	41	65	68	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					748	+		10.1096/fj.01-1024fje	http://dx.doi.org/10.1096/fj.01-1024fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923226				2022-12-25	WOS:000174755900002
J	Schliess, F; Gorg, B; Fischer, R; Desjardins, P; Bidmon, HJ; Herrmann, A; Butterworth, RF; Zilles, K; Haussinger, D				Schliess, F; Gorg, B; Fischer, R; Desjardins, P; Bidmon, HJ; Herrmann, A; Butterworth, RF; Zilles, K; Haussinger, D			Ammonia induces MK-801-sensitive nitration and phosphorylation of protein tyrosine residues in rat astrocytes	FASEB JOURNAL			English	Article						MAP kinases; calcium; hepatic; encephalopathy; nitric oxide; NMDA receptor; glutamine synthetase; liver	NITRIC-OXIDE SYNTHASE; D-ASPARTATE RECEPTORS; BRAIN IN-VIVO; HEPATIC-ENCEPHALOPATHY; PORTACAVAL ANASTOMOSIS; GLUTAMINE-SYNTHETASE; CULTURED ASTROCYTES; HYPO-OSMOLARITY; CEREBRAL EDEMA; NMDA RECEPTORS	Astrocytes play a key role in the pathogenesis of ammonia-induced neurotoxicity and hepatic encephalopathy. As shown here, ammonia induces protein tyrosine nitration in cultured rat astrocytes, which is sensitive to the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801. A similar pattern of nitrated proteins is produced by NMDA. Ammonia-induced tyrosine nitration depends on a rise in [Ca2+](i), IkappaB degradation, and NO synthase (iNOS) induction, which are prevented by MK-801 and the intracellular Ca2+ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA-AM). Moreover, the increase in tyrosine nitration is blunted by L-NMMA, 1400W, uric acid, Cu, Zn-superoxide dismutase/catalase treatment, and methionine-sulfoximine, which indicate the involvement of reactive nitrogen intermediates and intracellular glutamine accumulation. Such reactive nitrogen intermediates additionally mediate ammonia-induced phosphorylation of the MAP-kinases Erk-1/Erk-2 and p38(MAPK). Among the proteins, which are tyrosine-nitrated by ammonia, glyceraldehyde-3-phosphate dehydrogenase, the peripheral-type benzodiazepine receptor, Erk-1, and glutamine synthetase are identified. Ammonia-induced nitration of glutamine synthetase is associated with a loss of enzymatic activity. Astroglial protein tyrosine nitration is found in brains from rats after acute ammonia-intoxication or after portacaval anastomosis, indicating the in vivo relevance of the present findings. The production of reactive nitrogen intermediates and protein tyrosine nitration may alter astrocyte function and contribute to ammonia neurotoxicity.	Univ Dusseldorf, Med Einrichtungen, Klin Gastroenterol Hepatol & Infektiol, D-40225 Dusseldorf, Germany; Univ Montreal, Hop St Luc, Neurosci Res Unit, Montreal, PQ H3C 3J7, Canada; Univ Dusseldorf, C&O Vogt Inst Brain Res, D-40225 Dusseldorf, Germany; Cardion AG, Erkrath, Germany; Res Ctr Julich, Inst Internal Med, Julich, Germany	Heinrich Heine University Dusseldorf; Universite de Montreal; Heinrich Heine University Dusseldorf; Helmholtz Association; Research Center Julich	Haussinger, D (corresponding author), Univ Dusseldorf, Med Einrichtungen, Klin Gastroenterol Hepatol & Infektiol, Moorenstr 5, D-40225 Dusseldorf, Germany.	Haeussin@uni-duesseldorf.de	Zilles, Karl/Y-3784-2019; Zilles, Karl/J-9704-2013	Zilles, Karl/0000-0002-4705-4175; Zilles, Karl/0000-0001-9296-9959; Gorg, Boris/0000-0002-4630-9420				Allert N, 1998, BRAIN RES, V782, P261, DOI 10.1016/S0006-8993(97)01288-2; Araque A, 2000, J NEUROSCI, V20, P666, DOI 10.1523/JNEUROSCI.20-02-00666.2000; Bidmon HJ, 2001, EXP NEUROL, V168, P1, DOI 10.1006/exnr.2000.7456; Blei AT, 1999, J HEPATOL, V31, P771, DOI 10.1016/S0168-8278(99)80361-4; Braissant O, 1999, NEUROSCI LETT, V266, P89, DOI 10.1016/S0304-3940(99)00274-8; Brunelli L, 2001, FREE RADICAL BIO MED, V30, P709, DOI 10.1016/S0891-5849(00)00512-8; Buchczyk DP, 2000, BIOL CHEM, V381, P121, DOI 10.1515/BC.2000.017; BUTTERWORTH RF, 1987, NEUROCHEM PATHOL, V6, P1, DOI 10.1007/BF02833598; BUTTERWORTH RF, 1988, J NEUROCHEM, V51, P486, DOI 10.1111/j.1471-4159.1988.tb01064.x; Chamuleau RAFM, 1996, SEMIN LIVER DIS, V16, P265, DOI 10.1055/s-2007-1007239; Desjardins P, 1999, METAB BRAIN DIS, V14, P273, DOI 10.1023/A:1020741226752; Fischer R, 1997, GLIA, V20, P51; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; GIGUERE JF, 1992, BRAIN RES, V585, P295, DOI 10.1016/0006-8993(92)91222-Z; HAUSSINGER D, 1994, GASTROENTEROLOGY, V107, P1475; Haussinger D, 2000, J HEPATOL, V32, P1035, DOI 10.1016/S0168-8278(00)80110-5; Hazell AS, 1999, P SOC EXP BIOL MED, V222, P99, DOI 10.1046/j.1525-1373.1999.d01-120.x; Hazell AS, 1998, NEUROCHEM RES, V23, P869, DOI 10.1023/A:1022411012512; Hermenegildo C, 2000, HEPATOLOGY, V31, P709, DOI 10.1002/hep.510310322; HIDAKA H, 1983, METHOD ENZYMOL, P94; Hooper DC, 1998, P NATL ACAD SCI USA, V95, P675, DOI 10.1073/pnas.95.2.675; Isaacks RE, 1999, NEUROCHEM RES, V24, P51, DOI 10.1023/A:1020928029845; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Klotz LO, 2000, BIOCHEM J, V352, P219, DOI 10.1042/0264-6021:3520219; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Kosenko E, 1999, FREE RADICAL BIO MED, V26, P1369, DOI 10.1016/S0891-5849(98)00339-6; Kosenko E, 2000, BRAIN RES, V880, P139, DOI 10.1016/S0006-8993(00)02785-2; Kosenko E, 1998, METAB BRAIN DIS, V13, P29, DOI 10.1023/A:1020626928259; Larsen FS, 2001, J HEPATOL, V34, P548, DOI 10.1016/S0168-8278(00)00069-6; Lin KI, 1998, CELL DEATH DIFFER, V5, P577, DOI 10.1038/sj.cdd.4400384; MARTINEZHERNANDEZ A, 1977, SCIENCE, V195, P1356, DOI 10.1126/science.14400; Master S, 1999, HEPATOLOGY, V30, P876, DOI 10.1002/hep.510300428; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; NORENBERG MD, 1991, NEUROCHEM RES, V16, P833, DOI 10.1007/BF00965694; Norenberg MD, 1998, METAB BRAIN DIS, V13, P319, DOI 10.1023/A:1020688925901; OCONNOR ER, 1993, J NEUROSCI, V13, P2638, DOI 10.1523/JNEUROSCI.13-06-02638.1993; Peng TI, 1998, MOL PHARMACOL, V53, P974; Schliess F, 2001, J HEPATOL, V34, P610, DOI 10.1016/S0168-8278(01)00051-4; Schliess F, 1996, BIOCHEM J, V320, P167, DOI 10.1042/bj3200167; Stewart VC, 2000, J NEUROCHEM, V75, P694, DOI 10.1046/j.1471-4159.2000.0750694.x; Vogels BAPM, 1997, HEPATOLOGY, V25, P820, DOI 10.1002/hep.510250406; WARD HK, 1979, J NEUROCHEM, V33, P339, DOI 10.1111/j.1471-4159.1979.tb11737.x; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104	44	238	244	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3					739	+		10.1096/fj.01-0862fje	http://dx.doi.org/10.1096/fj.01-0862fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923223				2022-12-25	WOS:000174755900012
J	Amanullah, A; Liebermann, DA; Hoffman, B				Amanullah, A; Liebermann, DA; Hoffman, B			Deregulated c-Myc prematurely recruits both Type I and IICD95/Fas apoptotic pathways associated with terminal myeloid differentiation	ONCOGENE			English	Article						myeloid; c-myc; differentiation; apoptosis; CD95; Fas	DNA-REPLICATION ORIGIN; FAS-LIGAND; LEUKEMIA CELLS; DEATH DOMAIN; T-CELLS; GROWTH; EXPRESSION; GENE; PROTEASE; MICE	Previously we have reported that deregulated expression of c-myc in normal and leukemic myeloid cells blocked differentiation and, concomitantly, induced p53-independent apoptosis. Here, we show that this morbidity was due to premature recruitment of the Fas/CD95 cell death pathway which normally operates to induce apoptosis at the end of the terminal myeloid differentiation program. Analysis of the regulated components of this pathway revealed that IL6-mediated induction of differentiation resulted in rapid cell surface expression of CD95 receptor. Deregulated c-myc prevented the downregulation of CD95 ligand by maintaining its transcription, but caused premature downregulation of c-FLIP. First, the Type II (mitochondria-dependent, bcl-2-sensitive) and, then, the Type I (mitochondria-independent, bcl-2-insensitive) pathway were activated. Stable exogenous c-FLIP expression completely rescued the apoptotic phenotype. Furthermore, when the deregulated c-myc transgene was stably transduced into bone marrow cells from Fas(lpr/lpr) (CD95 receptor mutant) and Fas(gld/gld) (CD95 ligand mutant) mice, cell death was significantly suppressed relative to c-myc-transduced wild type bone marrow cells upon induction of differentiation. These data indicate that c-myc-mediated apoptosis associated with blocks in myeloid differentiation is dependent on the Fas/CD95 pathway. Our findings offer important new insights into understanding how deregulated c-myc alters normal blood cell homeostasis, and how additional mutations might promote leukemogenesis.	Temple Univ, Sch Med, Fels Inst Canc Res, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res, 3307 N Broad St, Philadelphia, PA 19140 USA.	lieberma@unix.temple.edu; hoffman@unix.temple.edu			NCI NIH HHS [R01CA81168] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081168] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amanullah A, 2000, ONCOGENE, V19, P2967, DOI 10.1038/sj.onc.1203638; ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brunner T, 2000, J BIOL CHEM, V275, P9767, DOI 10.1074/jbc.275.13.9767; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Eilers M, 1999, MOL CELLS, V9, P1; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Fecho K, 1998, CELL IMMUNOL, V188, P19, DOI 10.1006/cimm.1998.1339; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Genestier L, 1999, J EXP MED, V189, P231, DOI 10.1084/jem.189.2.231; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; Harwood FG, 2000, J BIOL CHEM, V275, P10023, DOI 10.1074/jbc.275.14.10023; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kasibhatla S, 2000, CURR BIOL, V10, P1205, DOI 10.1016/S0960-9822(00)00727-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELLICER A, 1978, CELL, V14, P133, DOI 10.1016/0092-8674(78)90308-2; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; TAIRA T, 1994, MOL CELL BIOL, V14, P6386, DOI 10.1128/MCB.14.9.6386; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	47	25	25	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1600	1610		10.1038/sj.onc.1205231	http://dx.doi.org/10.1038/sj.onc.1205231			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896589				2022-12-25	WOS:000173956800016
J	Ogawara, Y; Kishishita, S; Obata, T; Isazawa, Y; Suzuki, T; Tanaka, K; Masuyama, N; Gotoh, Y				Ogawara, Y; Kishishita, S; Obata, T; Isazawa, Y; Suzuki, T; Tanaka, K; Masuyama, N; Gotoh, Y			Akt enhances Mdm2-mediated ubiquitination and degradation of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; SERINE-THREONINE KINASE; NUCLEAR RECEPTOR NUR77; TUMOR-SUPPRESSOR P53; RING-FINGER DOMAIN; NF-KAPPA-B; PROTEIN-KINASE; CELL-SURVIVAL; MOLECULAR-CLONING; GENE-EXPRESSION	p53 plays a key role in DNA damage-induced apoptosis. Recent studies have reported that the phosphatidylinositol 3-OH-kinase-A-kt pathway inhibits p53-mediated transcription and apoptosis, although the underlying mechanisms have yet to be determined. Mdm2, a ubiquitin ligase for p53, plays a central role in regulation of the stability of p53 and serves as a good substrate for Akt. In this study, we find that expression of Akt reduces the protein levels of p53, at least in part by enhancing the degradation of p53. Both Akt expression and serum treatment induced phosphorylation of Mdm2 at Ser(186). Akt-mediated phosphorylation of Mdm2 at Ser(186) had little effect on the subcellular localization of Mdm2. However, both Akt expression and serum treatment increased Mdm2 ubiquitination of p53. The serum-induced increase in p53 ubiquitination was blocked by LY294002, a phosphatidylinositol 3-OH-kinase inhibitor. Moreover, when Ser(186) was replaced by Ala, Mdm2 became resistant to Akt enhancement of p53 ubiquitination and degradation. Collectively, these results suggest that Akt enhances the ubiquitination-promoting function of Mdm2 by phosphorylation of Ser(186), which results in reduction of p53 protein. This study may shed light on the mechanisms by which Akt promotes survival, proliferation, and tumorigenesis.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138613, Japan; Japan Sci & Technol Corp, PRESTO Res Project, Osaka 5600082, Japan	University of Tokyo; Tokushima University; Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST)	Gotoh, Y (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.			Suzuki, Toshiaki/0000-0002-0650-6251				BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hay TJ, 2000, FEBS LETT, V478, P183, DOI 10.1016/S0014-5793(00)01850-0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 1997, CANCER RES, V57, P5013; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ozes ON, 1999, NATURE, V401, P82; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Yamaguchi A, 2001, J BIOL CHEM, V276, P5256, DOI 10.1074/jbc.M008552200; Zhang TT, 2001, J BIOL CHEM, V276, P29702, DOI 10.1074/jbc.M011326200; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	60	450	476	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21843	21850		10.1074/jbc.M109745200	http://dx.doi.org/10.1074/jbc.M109745200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11923280	hybrid			2022-12-25	WOS:000176286000094
J	Christian, M; Zhang, XH; Schneider-Merck, T; Unterman, TG; Gellersen, B; White, JO; Brosens, JJ				Christian, M; Zhang, XH; Schneider-Merck, T; Unterman, TG; Gellersen, B; White, JO; Brosens, JJ			Cyclic AMP-induced forkhead transcription factor, FKHR, cooperates with CCAAT/enhancer-binding protein beta in differentiating human endometrial stromal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RESPONSE SEQUENCE; PAX3-FKHR FUSION PROTEIN; HUMAN PROLACTIN GENE; KINASE-A; PHOSPHOENOLPYRUVATE CARBOXYKINASE; ALVEOLAR RHABDOMYOSARCOMA; C/EBP-BETA; PROMOTER; EXPRESSION; FAMILY	Decidual transformation of human endometrial stromal (ES) cells requires sustained activation of the protein kinase A (PKA) pathway. In a search for novel transcriptional mediators of this process, we used differential display PCR analysis of undifferentiated primary ES cells and cells stimulated with 8-bromo-cAMP (8-Br-cAMP). We now report on the role of forkhead homologue in rhabdomyosarcoma (FKHR), a recently described member of the forkhead/winged-helix transcription factor family, as a mediator of endometrial differentiation. Sustained 8-Br-cAMP stimulation resulted in the induction and nuclear accumulation of FKHR in differentiating ES cells. Immunohistochemical studies revealed that endometrial stromal expression of FKHR in vivo is confined to decidualizing cells during the late secretory phase of the cycle and coincides with the expression of CCAAT/enhancer-binding protein 13 (C/EBPbeta). Reporter gene studies showed that FKHR potently enhances PKA-dependent activation of the tissue-specific decidual prolactin (dPRL) promoter, a major differentiation marker in human ES cells. Transcriptional augmentation by FKHR was effected through functional cooperation with C/EBPbeta and binding to a composite FKHR-C/EBPbeta response unit in the proximal promoter region. Furthermore, FKHR and C/EBPbeta were shown to interact directly in a glutathione S-transferase pull-down assay. These results provide the first evidence of regulated expression of FKHR and demonstrate that FKHR has an integral role in PKA-dependent endometrial differentiation through its ability to bind and functionally cooperate with C/EBPbeta.	Univ London Imperial Coll Sci Technol & Med, Wolfson & Weston Res Ctr Family Hlth, Hammersmith Hosp, Fac Med,Inst Reprod & Dev Biol, London W12 0NN, England; Univ Illinois, Coll Med, Chicago, IL 60612 USA; Chicago Area Vet Healthcare Syst, W Side Div, Chicago, IL 60612 USA; Univ Hamburg, Inst Hormone & Fertil Res, D-22529 Hamburg, Germany	Imperial College London; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Hamburg	Brosens, JJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Wolfson & Weston Res Ctr Family Hlth, Hammersmith Hosp, Fac Med,Inst Reprod & Dev Biol, London W12 0NN, England.			Christian, Mark/0000-0002-1616-4179; Brosens, Jan/0000-0003-0116-9329	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041430, R01DK041430] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41430] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; BERWAER M, 1994, MOL ENDOCRINOL, V8, P635, DOI 10.1210/me.8.5.635; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brar AK, 1997, ENDOCRINE, V6, P301, DOI 10.1007/BF02820507; Brosens JJ, 1999, ENDOCRINOLOGY, V140, P4809, DOI 10.1210/en.140.10.4809; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Christian M, 2002, MOL ENDOCRINOL, V16, P141, DOI 10.1210/me.16.1.141; DAVIS RJ, 1994, CANCER RES, V54, P2869; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GELLERSEN B, 1994, MOL ENDOCRINOL, V8, P356, DOI 10.1210/me.8.3.356; Ghosh AK, 2001, J BIOL CHEM, V276, P8507, DOI 10.1074/jbc.M008541200; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; Lee YM, 1996, MOL CELL BIOL, V16, P4257; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; Miau LH, 1997, MOL CELL BIOL, V17, P230, DOI 10.1128/MCB.17.1.230; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Pohnke Y, 1999, J BIOL CHEM, V274, P24808, DOI 10.1074/jbc.274.35.24808; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; RITTENHOUSE J, 1984, ANAL BIOCHEM, V138, P442, DOI 10.1016/0003-2697(84)90836-4; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Steiger Johann Anselm, 1993, KERYGMA DOGMA, V39, P64; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Telgmann R, 1997, ENDOCRINOLOGY, V138, P929, DOI 10.1210/en.138.3.929; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; Yeagley D, 2001, J BIOL CHEM, V276, P33705, DOI 10.1074/jbc.M101215200; Zhao HH, 2001, J BIOL CHEM, V276, P27907, DOI 10.1074/jbc.M104278200	41	139	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20825	20832		10.1074/jbc.M201018200	http://dx.doi.org/10.1074/jbc.M201018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11893744	hybrid			2022-12-25	WOS:000176204500093
J	Czuwara-Ladykowska, J; Sementchenko, VI; Watson, DK; Trojanowska, M				Czuwara-Ladykowska, J; Sementchenko, VI; Watson, DK; Trojanowska, M			Ets1 is an effector of the transforming growth factor beta (TGF-beta) signaling pathway and an antagonist of the profibrotic effects of TGF-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P300/CBP TRANSCRIPTIONAL COACTIVATORS; COLLAGEN GENE-EXPRESSION; HUMAN DERMAL FIBROBLASTS; HUMAN SKIN FIBROBLASTS; NECROSIS-FACTOR-ALPHA; RHEUMATOID-ARTHRITIS; EXTRACELLULAR-MATRIX; BREAST-CANCER; DIFFERENTIAL REGULATION; STROMELYSIN PROMOTER	Extracellular matrix (ECM) production and turnover are tightly controlled under normal physiological conditions. Ets factors regulate matrix turnover by activating transcription of several metalloproteinases (MMPs) and are frequently overexpressed in aggressive tumors and arthritis. Because of the prominent role of transforming growth factor beta (TGF-beta) in ECM synthesis, this study was undertaken to determine the possible interactions between Ets1 and the TGF-beta pathway. Experiments using adenoviral delivery of Ets1 in human fibroblasts have established that Ets1 strongly suppresses TGF-beta induction of collagen type I and other matrix-related genes and reverses TGF-beta-dependent inhibition of MMP-1. Subsequent experiments utilizing COLIA2 promoter demonstrated that Ets1 in the presence of TGF-beta signaling interferes with the stimulatory role of p300. To gain further insight into the mechanism of Ets1 inhibition of the TGF-beta signaling, the protein levels and post-translational modifications of Ets1 after TGF-beta treatment were analyzed. The level of total Ets1 protein was not affected after 24 h of TGF-beta stimulation. Moreover, TGF-beta did not affect either serine or threonine phosphorylation levels of Ets1. However, TGF-beta induced rapid and prolonged lysine acetylation of Ets1. In addition, analyses of endogenous p300-Ets1 complexes revealed that acetylated Ets1 is preferentially associated with the p3oo/CBP complexes. TGF-beta treatment leads to dissociation of Ets1 from the CBP/p300 complexes. Together, these findings suggest that elevated expression of Ets1 in fibroblasts fundamentally alters their responses to TGF-beta in favor of matrix degradation and away from matrix deposition as exemplified by arthritis and cancer.	Med Univ S Carolina, Div Rheumatol & Immunol, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Lab Canc Genom, Hollings Canc Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Trojanowska, M (corresponding author), Med Univ S Carolina, Div Rheumatol & Immunol, Dept Med, 96 Jonathan Lucas St,Suite 912, Charleston, SC 29425 USA.	trojanme@musc.edu	Czuwara, Joanna/AAK-4504-2020	Trojanowska, Maria/0000-0001-9550-7178	NCI NIH HHS [P01-CA78582] Funding Source: Medline; NIAMS NIH HHS [AR 44883, AR 42334] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044883, R01AR042334] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; BOLON I, 1995, AM J PATHOL, V147, P1298; BONIFACINO JS, 2000, CURRENT PROTOCOLS CE; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Buttice G, 1996, ONCOGENE, V13, P2297; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; COFFER P, 1994, ONCOGENE, V9, P911; Cowley DO, 2000, GENE DEV, V14, P366; Czuwara-Ladykowska J, 2001, J BIOL CHEM, V276, P20839, DOI 10.1074/jbc.M010133200; DALAL BI, 1993, AM J PATHOL, V143, P381; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Gilles F, 1996, EXP CELL RES, V222, P370, DOI 10.1006/excr.1996.0046; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GORSCH SM, 1992, CANCER RES, V52, P6949; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hen BG, 2001, J BIOL CHEM, V276, P7937, DOI 10.1074/jbc.M007470200; Ichiki Y, 1997, J RHEUMATOL, V24, P90; ISHIKAWA O, 1990, BIOCHEM BIOPH RES CO, V169, P232, DOI 10.1016/0006-291X(90)91458-5; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KOIZUMI S, 1990, ONCOGENE, V5, P675; LAFYATIS R, 1989, J IMMUNOL, V143, P1142; Le Gallic L, 1999, MOL CELL BIOL, V19, P4121; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Lindemann RK, 2001, J BIOL CHEM, V276, P46661, DOI 10.1074/jbc.M105816200; LUBINUS M, 1994, J BIOL CHEM, V269, P9822; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; MullerLadner U, 1996, AM J PATHOL, V149, P1607; Naito S, 2000, PATHOL RES PRACT, V196, P103, DOI 10.1016/S0344-0338(00)80041-2; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; Poncelet AC, 1999, KIDNEY INT, V56, P1354, DOI 10.1046/j.1523-1755.1999.00680.x; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; Redlich K, 2001, ARTHRITIS RHEUM, V44, P266, DOI 10.1002/1529-0131(200102)44:2<266::AID-ANR43>3.3.CO;2-7; Reiss M, 1997, BREAST CANCER RES TR, V45, P81, DOI 10.1023/A:1005865812918; Rutter JL, 1998, CANCER RES, V58, P5321; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Santala M, 1998, BRIT J CANCER, V77, P1825, DOI 10.1038/bjc.1998.303; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Verrecchia F, 2001, ONCOGENE, V20, P2205, DOI 10.1038/sj.onc.1204347; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; WATSON DK, 1990, ADV AP BIOT, V6, P221; Wernert N, 1997, VIRCHOWS ARCH, V430, P433, DOI 10.1007/s004280050053; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Yuan WH, 2001, J BIOL CHEM, V276, P38502, DOI 10.1074/jbc.M107081200; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200	67	101	102	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20399	20408		10.1074/jbc.M200206200	http://dx.doi.org/10.1074/jbc.M200206200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11919190	hybrid			2022-12-25	WOS:000176204500039
J	Pizzi, M; Goffi, F; Boroni, F; Benarese, M; Perkins, SE; Liou, HC; Spano, P				Pizzi, M; Goffi, F; Boroni, F; Benarese, M; Perkins, SE; Liou, HC; Spano, P			Opposing roles for NF-kappa B/Rel factors p65 and c-Rel in the modulation of neuron survival elicited by glutamate and interleukin-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; B ACTIVATION; NUCLEAR TRANSLOCATION; HIPPOCAMPAL-NEURONS; GENE-EXPRESSION; CELLS; ALPHA; INDUCTION	The nuclear transcription factors NF-kappaB/Rel have been shown to function as key regulators of either cell death or survival in neuronal cells. Here, we investigated whether selective activation of diverse NF-kappaB/Rel family members might lead to distinct effects on neuron viability. In both cultured rat cerebellar granule cells and mouse hippocampal slices, we examined NF-kappaB/Rel activation induced by two opposing modulators of cell viability: 1) interleukin-1beta (IL-1beta), which promotes neuron survival and 2) glutamate, which can elicit toxicity. IL-1beta produced a prolonged stimulation of NF-kappaB/Rel factors by inducing both IkappaBbeta and IkappaBbeta degradation. Glutamate produced a delayed and transient activation of NF-kappaB/Rel, which was associated with a brief loss of IkappaBalpha. Moreover, IL-1beta activated the p50, p65, and c-Rel subunits of NF-kappaB/Rel, whereas glutamate activated only the p50 and p65 proteins. The inhibition of NF-kappaB/Rel protein expression by antisense oligonucleotides in cerebellar granule cells showed that p65 was involved in glutamate-mediated cell death, whereas c-Rel was essential for IL-1beta-preserved cell survival. Furthermore, the depletion of c-Rel in cultured neurons as well as in the hippocampus from the c-Rel(-/-) mouse converted the IL-1beta effect into toxicity. These findings suggest that, within a single neuron, the balance between cell death and survival in response to external stimuli may rely on the activation of distinct NF-kappaB/Rel proteins.	Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Div Pharmacol & Expt Therapeut, I-25123 Brescia, Italy; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Lab Anim Facil, New York, NY 10021 USA	University of Brescia; Cornell University; Cornell University	Pizzi, M (corresponding author), Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Div Pharmacol & Expt Therapeut, Via Valsabbina 19, I-25123 Brescia, Italy.	pizzi@med.unibs.it	Pizzi, Marina/C-1452-2011; Spano, Pier Franco F/J-9944-2016; Spano, Pier Franco A/E-7621-2010; Pizzi, Marina/K-2064-2016	Spano, Pier Franco F/0000-0002-9906-0964; Pizzi, Marina/0000-0002-4857-5204				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bernard D, 2001, CANCER RES, V61, P2656; Bethea JR, 1998, J NEUROSCI, V18, P3251; Brooks PJ, 1996, J NEUROSCI, V16, P939; Chapman NR, 2000, J BIOL CHEM, V275, P4719, DOI 10.1074/jbc.275.7.4719; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Clemens JA, 1997, STROKE, V28, P1073, DOI 10.1161/01.STR.28.5.1073; Darville MI, 2000, ENDOCRINOLOGY, V141, P153, DOI 10.1210/en.141.1.153; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grilli M, 1996, J BIOL CHEM, V271, P15002, DOI 10.1074/jbc.271.25.15002; Grilli M, 1999, CELL DEATH DIFFER, V6, P22, DOI 10.1038/sj.cdd.4400463; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; KALTSCHMIDT B, 1993, MOL ASPECTS MED, V14, P171, DOI 10.1016/0098-2997(93)90004-W; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; Koulich E, 2001, J NEUROCHEM, V76, P1188, DOI 10.1046/j.1471-4159.2001.00134.x; Lezoualc'h F, 1998, J NEUROSCI, V18, P3224; Lin SC, 1998, MOL CELL BIOL, V18, P5523, DOI 10.1128/MCB.18.9.5523; Liou HC, 1999, INT IMMUNOL, V11, P361, DOI 10.1093/intimm/11.3.361; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Middleton G, 2000, J CELL BIOL, V148, P325, DOI 10.1083/jcb.148.2.325; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Owyang AM, 2001, J IMMUNOL, V167, P4948, DOI 10.4049/jimmunol.167.9.4948; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; Phelps CB, 2000, J BIOL CHEM, V275, P29840, DOI 10.1074/jbc.M004899200; Pizzi M, 1996, EUR J NEUROSCI, V8, P1516, DOI 10.1111/j.1460-9568.1996.tb01614.x; Pizzi M, 1996, MOL PHARMACOL, V49, P586; Qin ZH, 1999, J NEUROSCI, V19, P4023; Qin ZH, 2000, MOL BRAIN RES, V80, P111, DOI 10.1016/S0169-328X(00)00147-9; Qiu JX, 2001, J NEUROSCI RES, V64, P223, DOI 10.1002/jnr.1070; Roshak AK, 1996, J BIOL CHEM, V271, P31496, DOI 10.1074/jbc.271.49.31496; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; STRIJBOS PJLM, 1995, J NEUROSCI, V15, P3468; Tam WF, 2001, J BIOL CHEM, V276, P7701, DOI 10.1074/jbc.C000916200; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Terai K, 1996, BRAIN RES, V739, P343, DOI 10.1016/S0006-8993(96)01073-6; Terai K, 1996, BRAIN RES, V735, P159; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	50	133	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20717	20723		10.1074/jbc.M201014200	http://dx.doi.org/10.1074/jbc.M201014200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11912207	hybrid			2022-12-25	WOS:000176204500080
J	Ahn, JY; Li, XH; Davis, HL; Canman, CE				Ahn, JY; Li, XH; Davis, HL; Canman, CE			Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; LI-FRAUMENI-SYNDROME; FHA DOMAIN; IONIZING-RADIATION; IN-VIVO; MUTATION; P53; ACTIVATION; CANCER; CDS1	Phosphorylation of Thr-68 by the ataxia telangiectasia-mutated is necessary for efficient activation of Chk2 when cells are exposed to ionizing radiation. By an unknown mechanism, this initial event promotes additional autophosphorylation events including modifications of Thr-383 and Thr-387, two amino acid residues located within the activation loop segment within the Chk2 catalytic domain. Chk2 and related kinases possess one or more Forkhead-associated (FHA) domains that are phosphopeptide-binding modules believed to be crucial for their checkpoint control activities. We show that the Chk2 FHA domain is dispensable for Thr-68 phosphorylation but necessary for efficient autophosphorylation in response to ionizing radiation. Phosphorylation of Thr-68 promotes oligomerization of Chk2 by serving as a specific ligand for the FHA domain of another Chk2 molecule. In addition, Chk2 phosphorylates its own FHA domain, and this modification reduces its affinity for Thr-68-phosphorylated Chk2. Thus, activation of Chk2 in irradiated cells may occur through oligomerization of Chk2 via binding of the Thr-68-phosphorylated region of one Chk2 to the FHA domain of another. Oligomerization of Chk2 may therefore increase the efficiency of trans-autophosphorylation resulting in the release of active Chk2 monomers that proceed to enforce checkpoint control in irradiated cells.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Canman, CE (corresponding author), Pfizer Global Res & Dev, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.	Christine.Canman@Pfizer.com		, Christine/0000-0001-8892-7430	NATIONAL CANCER INSTITUTE [R01CA086861] Funding Source: NIH RePORTER; NCI NIH HHS [CA86861, R01 CA086861] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn JY, 2000, CANCER RES, V60, P5934; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Haruki N, 2000, CANCER RES, V60, P4689; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hofmann WK, 2001, LEUKEMIA RES, V25, P333, DOI 10.1016/S0145-2126(00)00130-2; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lee SB, 2001, CANCER RES, V61, P8062; Li J, 1999, P NATL ACAD SCI USA, V96, P7821, DOI 10.1073/pnas.96.14.7821; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Miller CW, 2002, GENE CHROMOSOME CANC, V33, P17, DOI 10.1002/gcc.1207; Shieh SY, 2000, GENE DEV, V14, P289; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Tomlinson GE, 1998, CANCER RES, V58, P3237; Vahteristo P, 2001, CANCER RES, V61, P5718; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	31	154	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19389	19395		10.1074/jbc.M200822200	http://dx.doi.org/10.1074/jbc.M200822200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11901158	hybrid			2022-12-25	WOS:000175894800021
J	Braem, CV; Kas, K; Meyen, E; Debiec-Rychter, M; Van de Ven, WJM; Voz, ML				Braem, CV; Kas, K; Meyen, E; Debiec-Rychter, M; Van de Ven, WJM; Voz, ML			Identification of a karyopherin alpha 2 recognition site in PLAG1, which functions as a nuclear localization signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; PLEOMORPHIC ADENOMAS; GENE-EXPRESSION; SALIVARY-GLANDS; IMPORTIN-ALPHA; SEQUENCE; BETA; ACTIVATION; REGION; CELLS	The activation of the pleomorphic adenoma gene I (PLAG1) is the most frequent gain-of-function mutation found in pleomorphic adenomas of the salivary glands. To gain more insight into the regulation of PLAG1 function, we searched for PLAG1-interacting proteins. Using the yeast two-hybrid system, we identified karyopherin alpha2 as a PLAG1-interacting protein. Physical interaction between PLAG1 and karyopherin alpha2 was confirmed by an in vitro glutathione S-transferase pull-down assay. Karyopherin alpha2 escorts proteins into the nucleus via interaction with a nuclear localization sequence (NLS) composed of short stretches of basic amino acids. Two putative NLSs were identified in PLAG1. The predicted NLS1 (KRKR) was essential for physical interaction with karyopherin alpha2 in glutathione S-transferase pull-down assay, and its mutation resulted in decreased nuclear import of PLAG1. Moreover, NLS1 was able to drive the nuclear import of the cytoplasmic protein beta-galactosidase. In contrast, predicted NLS2 of PLAG1 (KPRK) was not involved in karyopherin a2 binding nor in its nuclear import. The residual nuclear import of PLAG1 after mutation of the NLS1 was assigned to the zinc finger domain of PLAG1. These observations indicate that the nuclear import of PLAG1 is governed by its zinc finger domain and by NLS1, a karyopherin a2 recognition site.	Catholic Univ Louvain, Dept Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium	Universite Catholique Louvain	Van de Ven, WJM (corresponding author), Catholic Univ Louvain, Dept Human Genet, Mol Oncol Lab, Herestr 49, B-3000 Louvain, Belgium.	wim.vandeven@med.kuleuven.ac.be						Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Astrom AK, 1999, CANCER RES, V59, P918; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Debiec-Rychter M, 2001, LAB INVEST, V81, P1289, DOI 10.1038/labinvest.3780342; Furukawa T, 2001, ONCOGENE, V20, P4718, DOI 10.1038/sj.onc.1204647; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, GENOMICS, V43, P349, DOI 10.1006/geno.1997.4819; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kovac CR, 2000, J BIOL CHEM, V275, P16752, DOI 10.1074/jbc.M001551200; Mirski SEL, 1999, EXP CELL RES, V251, P329, DOI 10.1006/excr.1999.4587; Mo YY, 2000, J BIOL CHEM, V275, P41107, DOI 10.1074/jbc.M003135200; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; Nakai A, 2000, J BIOL CHEM, V275, P34665, DOI 10.1074/jbc.M005302200; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Schwamborn K, 1998, EXP CELL RES, V244, P206, DOI 10.1006/excr.1998.4177; Sorg G, 1999, BIOTECHNIQUES, V26, P858, DOI 10.2144/99265bm12; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; Voz ML, 2000, CANCER RES, V60, P106; Voz ML, 1998, ONCOGENE, V16, P1409, DOI 10.1038/sj.onc.1201660; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x	25	25	28	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19673	19678		10.1074/jbc.M112112200	http://dx.doi.org/10.1074/jbc.M112112200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11882654	hybrid, Green Submitted			2022-12-25	WOS:000175894800058
J	Fong, AM; Alam, SM; Imai, T; Haribabu, B; Patel, DD				Fong, AM; Alam, SM; Imai, T; Haribabu, B; Patel, DD			CX(3)CR1 tyrosine sulfation enhances fractalkine-induced cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CX3C CHEMOKINE DOMAIN; P-SELECTIN; GLYCOPROTEIN LIGAND-1; RECEPTOR CX(3)CR1; IDENTIFICATION; BINDING; RECOGNITION; ACTIVATION; CONTRIBUTE; CONSENSUS	Fractalkine is a unique CX3C chemokine/mucin hybrid molecule that functions like selectins in inducing the capture of receptor-expressing cells. Because of the importance of tyrosine sulfation for ligand binding of the selectin ligand PSGLl, we tested the role of tyrosine sulfation for CX(3)CR1 function in cell adhesion. Tyrosine residues 14 and 22 in the N terminus of CX(3)CR1 were mutated to phenylalanine and stably expressed on K562 cells. Cells expressing CX(3)CR1-Y14F were competent in signal transduction but defective in capture by and firm adhesion to immobilized fractalkine under physiologic flow conditions. In static binding assays, CX(3)CR1-Y14F mutants had a 2-4-fold decreased affinity to fractalkine compared with wild type CX(3)CR1. By surface plasmon resonance measurements of fractalkine binding to biosensor chip-immobilized cell membranes, CX(3)CR1-Y14F mutants had a 100-fold decreased affinity to fractalkine. CX(3)CR1-expressing cell membranes treated with arylsulfatase to desulfate tyrosine residues also showed a 100-fold decreased affinity for fractalkine. Finally, synthesized, sulfated N-terminal CX(3)CR1 peptides immobilized on biosensor chips showed a higher affinity for fractalkine than non-sulfated peptides. Thus, we conclude that sulfation of tyrosine 14 enhances the function of CX(3)CR1 in cell capture and firm adhesion. Further, tyrosine sulfation may represent a general mechanism utilized by molecules that function in the rapid capture of circulating leukocytes.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Kinki Univ, Sch Med, Dept Microbiol, Osaka 5898511, Japan	Duke University; Kindai University (Kinki University)	Patel, DD (corresponding author), Duke Univ, Med Ctr, Dept Med, 223 Med Sci Res Bldg,Box 2632, Durham, NC 27710 USA.	patel003@mc.duke.edu	Alam, S. Munir/AAC-6711-2019; Bodduluri, Haribabu/A-2584-2010	Bodduluri, Haribabu/0000-0002-8261-3294	NIAMS NIH HHS [AR39162] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039162] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALI H, 1994, J BIOL CHEM, V269, P24557; ASA D, 1995, J BIOL CHEM, V270, P11662, DOI 10.1074/jbc.270.19.11662; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 2001, J EXP MED, V193, P1059, DOI 10.1084/jem.193.9.1059; Faure S, 2000, SCIENCE, V287, P2274, DOI 10.1126/science.287.5461.2274; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Fong AM, 2000, J BIOL CHEM, V275, P3781, DOI 10.1074/jbc.275.6.3781; Goda S, 2000, J IMMUNOL, V164, P4313, DOI 10.4049/jimmunol.164.8.4313; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Harrison JK, 2001, J BIOL CHEM, V276, P21632, DOI 10.1074/jbc.M010261200; Haskell CA, 2001, J CLIN INVEST, V108, P679, DOI 10.1172/JCI12976; Haskell CA, 1999, J BIOL CHEM, V274, P10053, DOI 10.1074/jbc.274.15.10053; HOFSTEENGE J, 1990, EUR J BIOCHEM, V188, P55, DOI 10.1111/j.1432-1033.1990.tb15370.x; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; LEYTE A, 1991, J BIOL CHEM, V266, P740; Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078; Mizoue LS, 1999, BIOCHEMISTRY-US, V38, P1402, DOI 10.1021/bi9820614; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Preobrazhensky AA, 2000, J IMMUNOL, V165, P5295, DOI 10.4049/jimmunol.165.9.5295; Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771; Robinson LA, 2000, J IMMUNOL, V165, P6067, DOI 10.4049/jimmunol.165.11.6067; Snapp KR, 1998, BLOOD, V91, P154, DOI 10.1182/blood.V91.1.154.154_154_164; Sykulev Y, 1998, IMMUNITY, V9, P475, DOI 10.1016/S1074-7613(00)80631-7; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Yoneda O, 2000, J IMMUNOL, V164, P4055, DOI 10.4049/jimmunol.164.8.4055	31	80	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19418	19423		10.1074/jbc.M201396200	http://dx.doi.org/10.1074/jbc.M201396200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11909868	hybrid			2022-12-25	WOS:000175894800025
J	Garda, HA; Arrese, EL; Soulages, JL				Garda, HA; Arrese, EL; Soulages, JL			Structure of apolipophorin-III in discoidal lipoproteins - Interhelical distances in the lipid-bound state and conformational change upon binding to lipid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; ALPHA-HELICES; EXCHANGEABLE APOLIPOPROTEINS; ENERGY-TRANSFER; APOA-I; FLUORESCENCE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; TRANSPORT; MODEL	The structure of apolipophorin III in the lipid-bound state and the extent of the conformational change that takes place when the five-helix bundle apolipoprotein binds to a lipoprotein lipid surface were investigated by fluorescence resonance energy transfer in discoidal lipoproteins. Four intramolecular interhelical distances between helix pairs 1-4, 2-4, 3-4, and 5-4 were estimated by fluorescence resonance energy transfer in both the lipid-free and the lipid-bound states. Depending on the helices pairs, the intramolecular interhelical distances increased between 15 and greater than or equal to 20 Angstrom upon binding of the apolipoprotein to lipid, demonstrating for the first time that binding to lipid is accompanied by a major change in interhelical distances. Using discoidal lipoproteins made with a combination of apolipophorin III molecules containing donor and acceptor groups and apolipophorin III molecules containing neither donor nor acceptor groups, it was possible to obtain information about intermolecular interhelical distances between the helix 4 of one apolipoprotein and the helices 1, 2, 3, and 5 of a second apolipoprotein residing in the same discoidal lipoprotein. Altogether, the estimated intermolecular and intramolecular interhelical distances suggest a model in which the apolipoprotein arranges in pairs of antiparallel and fully extended polypeptide chains surrounding the periphery of the bilayer disc.	Oklahoma State Univ, Dept Biochem & Mol Biol, Noble Res Ctr 355, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Soulages, JL (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Noble Res Ctr 355, Stillwater, OK 74078 USA.	jose@biochem.okstate.edu			NIGMS NIH HHS [GM55622] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055622, R29GM055622] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; CHEUNG H, 1991, TOPICS FLUORESCENCE, V2, P55; DALE RE, 1976, P NATL ACAD SCI USA, V73, P271, DOI 10.1073/pnas.73.2.271; Dettloff M, 2001, BIOCHEMISTRY-US, V40, P3150, DOI 10.1021/bi0013804; Fielding P. E., 1996, BIOCH LIPIDS LIPOPRO, P495; GRIEP MA, 1990, J BIOL CHEM, V265, P20356; HAAS E, 1978, BIOCHEMISTRY-US, V17, P5064, DOI 10.1021/bi00616a032; HAUGLAND RP, 1996, HDB FLUORESCENT PROB, P23; Jonas A, 2000, BBA-MOL CELL BIOL L, V1529, P245, DOI 10.1016/S1388-1981(00)00153-0; JONAS A, 1989, J BIOL CHEM, V264, P4818; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P374; Li HH, 2000, J BIOL CHEM, V275, P37048, DOI 10.1074/jbc.M005336200; McGuire KA, 1996, J LIPID RES, V37, P1519; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; RAUSSENS V, 1995, J BIOL CHEM, V270, P12542, DOI 10.1074/jbc.270.21.12542; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; Ryan RO, 2000, ANNU REV ENTOMOL, V45, P233, DOI 10.1146/annurev.ento.45.1.233; RYAN RO, 1995, J LIPID RES, V36, P1066; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; SEGREST JP, 1992, J LIPID RES, V33, P141; SMITH AF, 1994, J LIPID RES, V35, P1976; Soulages JL, 2000, BIOCHEMISTRY-US, V39, P10574, DOI 10.1021/bi0007223; Soulages JL, 2000, J BIOL CHEM, V275, P17501, DOI 10.1074/jbc.M909661199; Soulages JL, 1998, BIOCHEM BIOPH RES CO, V243, P372, DOI 10.1006/bbrc.1998.8099; SOULAGES JL, 1994, ADV PROTEIN CHEM, V45, P371; Soulages JL, 2001, BIOCHEMISTRY-US, V40, P14279, DOI 10.1021/bi010949d; Soulages JL, 2001, J BIOL CHEM, V276, P34162, DOI 10.1074/jbc.M105836200; Tricerri MA, 2001, BIOCHEMISTRY-US, V40, P5065, DOI 10.1021/bi002815q; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WIENTZEK M, 1994, J BIOL CHEM, V269, P4605; Xu SZ, 1997, J LIPID RES, V38, P1289	35	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19773	19782		10.1074/jbc.M110089200	http://dx.doi.org/10.1074/jbc.M110089200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11896049	hybrid			2022-12-25	WOS:000175894800070
J	Hama, J; Suri, C; Haremaki, T; Weinstein, DC				Hama, J; Suri, C; Haremaki, T; Weinstein, DC			The molecular basis of Src kinase specificity during vertebrate mesoderm formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; XENOPUS; INDUCTION; PROTEIN; INHIBITION; ACTIVATION; EXPRESSION; XWNT-8; LALOO	Members of the Src family of non-receptor tyrosine kinases play a critical role in mesoderm formation in the frog, Xenopus laevis, acting as required mediators downstream of the fibroblast growth factor receptor. At least four members of this gene family, Sre, Fyn, Yes, and Laloo, are expressed during early embryonic development. Ectopic expression of Laloo and Fyn, but not Src, induce mesoderm in ectodermal explants, indicating that these factors are non-redundant during early vertebrate development. Here we investigate the basis for the differential activity of the Src and Laloo kinases during mesoderm formation. We demonstrate that although both Src and Laloo physically interact with the substrate protein SNT-1/FRS2alpha only Laloo phosphorylates SNT-1, an event previously shown to be required for the activity of the latter and for mesoderm induction in vivo. We show that Src is enzymatically capable of stimulating mesoderm formation, as an activated Sre construct both phosphorylates SNT-1 and induces mesoderm in explant cultures. However, a chimeric Laloo construct containing a Src C-terminal tail is inactive, suggesting that the early embryo contains a specific Laloo-activating, or Src-inactivating, factor. Finally, through further chimeric analysis, we provide evidence to suggest that differences in Laloo and Sre activity are also mediated by the SH2, SH3, and kinase domains of these molecules.	CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Weinstein, DC (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, 1 Gustave L Levy Pl,Box 1215, New York, NY 10029 USA.	weinsd01@doc.mssm.edu		Weinstein, Daniel/0000-0001-7832-9285	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061671] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM61671] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BASSEZ T, 1990, DEVELOPMENT, V110, P955; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hama J, 2001, MECH DEVELOP, V109, P195, DOI 10.1016/S0925-4773(01)00524-X; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; KLEIN PS, 1994, ENDOCR REV, V15, P326, DOI 10.1210/er.15.3.326; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; Kusakabe M, 2001, EMBO REP, V2, P727, DOI 10.1093/embo-reports/kve152; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; Song Y, 2001, ONCOGENE, V20, P5210, DOI 10.1038/sj.onc.1204672; STEELE RE, 1985, NUCLEIC ACIDS RES, V13, P1747, DOI 10.1093/nar/13.5.1747; STEELE RE, 1989, ONCOGENE RES, V4, P223; SUPERTIFURGA G, 1995, FEBS LETT, V369, P62, DOI 10.1016/0014-5793(95)00636-N; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Weinstein DC, 1997, DEVELOPMENT, V124, P4235; Weinstein DC, 1998, NATURE, V394, P904, DOI 10.1038/29808; Weinstein DC, 2001, DEV DYNAM, V220, P163, DOI 10.1002/1097-0177(2000)9999:9999<1::AID-DVDY1098>3.0.CO;2-5; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; Xu H, 2001, J BIOL CHEM, V276, P13049, DOI 10.1074/jbc.M009925200	24	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19806	19810		10.1074/jbc.M110637200	http://dx.doi.org/10.1074/jbc.M110637200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11912191	hybrid			2022-12-25	WOS:000175894800074
J	Munster, AK; Weinhold, B; Gotza, B; Muhlenhoff, M; Frosch, M; Gerardy-Schahn, R				Munster, AK; Weinhold, B; Gotza, B; Muhlenhoff, M; Frosch, M; Gerardy-Schahn, R			Nuclear localization signal of murine CMP-Neu5Ac synthetase includes residues required for both nuclear targeting and enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLNEURAMINIC ACID; CELL-ADHESION MOLECULE; ESCHERICHIA-COLI K1; POLYSIALIC ACID; SIALIC-ACID; SEQUENCE REQUIREMENTS; NEURAL DEVELOPMENT; PROTEIN-TRANSPORT; SERUM RESISTANCE; LARGE-T	5-N-Acetylneuraminic acid (Neu5Ac) is the major sialic acid derivative found in animal cells. As a component of cell surface glycoconjugates, Neu5Ac is pivotal to numerous cellular recognition and communication processes including host-parasite interactions. A prerequisite for the synthesis of sialylated glycoconjugates is the activation of Neu5Ac to cytidine-monophosphate N-acetylneuraminic acid (CMP-Neu5Ac). The reaction is catalyzed by CMP-Neu5Ac-synthetase (syn), which, for unknown reasons, resides in the nucleus. Sequence analysis of the cloned murine CMP-Neu5Ac synthetase identified three clusters of basic amino acids (BC1-BC3) that might function as nuclear localization signals (NLS). In the present study chimeric protein and mutagenesis strategies were used to show that BC1 and BC2 are active NLS sequences when attached to the green fluorescent protein (enhanced GFP), but only BC2 is necessary and sufficient to mediate the nuclear import of CMP-Neu5Ac synthetase. Site-directed mutations identified the residues (KRXR)-R-198 to be essential for nuclear transport and Arg(202) to be necessary to complete the transport process. Cytoplasmic forms of CMP-Neu5Ac synthetase generated by single site mutations in BC2 demonstrated that (i) enzyme activity is independent of nuclear localization, and (ii) Arg(199) and Arg(202) are involved in both nuclear transport and synthetase activity. Comparison of all known and predicted CMPsialic acid synthetases reveals Arg(202) and Gln(203) as highly conserved in evolution and critically important for optimal synthetase activity but not for nuclear localization. Combined, the data demonstrate that nuclear transport and enzyme activity are independent functions that share some common amino acid requirements in CMP-Neu5Ac synthetase.	Hannover Med Sch, Inst Physiol Chem Prot Struktur, D-30625 Hannover, Germany; Univ Wurzburg, Inst Hyg & Mikrobiol, D-97080 Wurzburg, Germany	Hannover Medical School; University of Wurzburg	Gerardy-Schahn, R (corresponding author), Hannover Med Sch, Inst Physiol Chem Prot Struktur, Carl Neuberg Str 1, D-30625 Hannover, Germany.	gerardy-schahn.rita@mh-hannover.de						Bliss JM, 1996, MOL MICROBIOL, V21, P221, DOI 10.1046/j.1365-2958.1996.6461357.x; BRATOSIN D, 1995, GLYCOCONJUGATE J, V12, P258, DOI 10.1007/BF00731328; Bruses JL, 2001, BIOCHIMIE, V83, P635, DOI 10.1016/S0300-9084(01)01293-7; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Cremer H, 2000, INT J DEV NEUROSCI, V18, P213, DOI 10.1016/S0736-5748(99)00090-8; Daniel L, 2000, CANCER RES, V60, P80; Dell A, 1999, BBA-GEN SUBJECTS, V1473, P196, DOI 10.1016/S0304-4165(99)00179-8; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; EDWARDS U, 1992, FEMS MICROBIOL LETT, V96, P161; EMIG S, 1995, J BIOL CHEM, V270, P13787, DOI 10.1074/jbc.270.23.13787; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GERARDYSCHAHN R, 1995, MOL MICROBIOL, V16, P441, DOI 10.1111/j.1365-2958.1995.tb02409.x; Gluer S, 1998, BRIT J CANCER, V78, P106, DOI 10.1038/bjc.1998.450; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Guerry P, 1996, MOL MICROBIOL, V19, P369, DOI 10.1046/j.1365-2958.1996.369895.x; Guo N, 2000, J CELL SCI, V113, P3085; Haft RF, 1996, MOL MICROBIOL, V19, P555, DOI 10.1046/j.1365-2958.1996.395931.x; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; Hood DW, 1999, MOL MICROBIOL, V33, P679, DOI 10.1046/j.1365-2958.1999.01509.x; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; Horton P., 1996, P INT SYST MOL BIOL, V4, P109; Inoue S, 2001, J BIOL CHEM, V276, P31863, DOI 10.1074/jbc.M103336200; JANN B, 1990, CURR TOP MICROBIOL, V150, P19; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Jimbo T, 2001, INT J CANCER, V94, P192, DOI 10.1002/ijc.1458; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KEAN E L, 1991, Glycobiology, V1, P441, DOI 10.1093/glycob/1.5.441; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luneberg E, 2000, INT J MED MICROBIOL, V290, P37; Malykh YN, 2001, EUR J CELL BIOL, V80, P48, DOI 10.1078/0171-9335-00139; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Moran AP, 1996, FEMS IMMUNOL MED MIC, V16, P105, DOI 10.1111/j.1574-695X.1996.tb00127.x; MORELAND RB, 1985, P NATL ACAD SCI USA, V82, P6561, DOI 10.1073/pnas.82.19.6561; Mosimann SC, 2001, J BIOL CHEM, V276, P8190, DOI 10.1074/jbc.M007235200; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; Munday J, 1999, J LEUKOCYTE BIOL, V66, P705, DOI 10.1002/jlb.66.5.705; Munster AK, 1998, P NATL ACAD SCI USA, V95, P9140, DOI 10.1073/pnas.95.16.9140; Nakata D, 2001, GLYCOBIOLOGY, V11, P685, DOI 10.1093/glycob/11.8.685; Potvin B, 1995, J BIOL CHEM, V270, P30415, DOI 10.1074/jbc.270.51.30415; RICHARD M, 1975, BIOCHEM BIOPH RES CO, V64, P108, DOI 10.1016/0006-291X(75)90225-9; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; RIJCKEN WRP, 1993, BIOCHEM J, V293, P207, DOI 10.1042/bj2930207; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Schauer R, 2000, GLYCOCONJUGATE J, V17, P485, DOI 10.1023/A:1011062223612; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHAW L, 1988, BIOL CHEM H-S, V369, P477, DOI 10.1515/bchm3.1988.369.1.477; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Tullius MV, 1996, J BIOL CHEM, V271, P15373, DOI 10.1074/jbc.271.26.15373; VIMR ER, 1985, J BACTERIOL, V164, P854, DOI 10.1128/JB.164.2.854-860.1985; VIMR ER, 1989, J BACTERIOL, V171, P1106, DOI 10.1128/jb.171.2.1106-1117.1989; Vionnet J, 1999, GLYCOBIOLOGY, V9, P481, DOI 10.1093/glycob/9.5.481; Vogel U, 1999, INFECT IMMUN, V67, P954, DOI 10.1128/IAI.67.2.954-957.1999; Yoneda Y, 1999, CELL STRUCT FUNCT, V24, P425, DOI 10.1247/csf.24.425; ZAPATA G, 1989, J BIOL CHEM, V264, P14769	58	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19688	19696		10.1074/jbc.M201093200	http://dx.doi.org/10.1074/jbc.M201093200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11893746	hybrid			2022-12-25	WOS:000175894800060
J	Soeth, E; Thurber, DB; Smith, CL				Soeth, E; Thurber, DB; Smith, CL			The viral transactivator E1A regulates the mouse mammary tumor virus promoter in an isoform- and chromatin-specific manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; ADENOVIRUS E1A; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; CELLULAR PROTEINS; BINDING PROTEIN; MMTV PROMOTER; ZINC-FINGER; ACTIVATION	Proteins encoded by the adenovirus E1A gene regulate both cellular and viral genes to mediate effects on cell cycle, differentiation, and cell growth control. We have identified the mouse mammary tumor virus (MMTV) promoter as a target of E1A action and investigated the role nucleoprotein structure plays in its response to E1A. Both 12 and 13 S forms target the MMTV promoter when it has a disorganized and accessible chromatin configuration. However, whereas the 13 S form is stimulatory, the 12 S form is repressive. When the MMTV promoter adopts an organized and repressed chromatin structure, it is targeted only by the 13 S form, which stimulates it. Although evidence indicates that E1A interacts with the SWI/SNF remodeling complex, E1A had no effect on chromatin remodeling at the MMTV promoter in organized chromatin. Analysis of E1A mutants showed that stimulation of the MMTV promoter is mediated solely through conserved region 3 and does not require interaction with Rb, p300/CBP-associated factor, or CBP/p300. Imaging analysis showed that E1A colocalizes with MMTV sequences in vivo, suggesting that it functions directly at the promoter. These results indicate that E1A stimulates the MMTV promoter in a fashion independent of chromatin conformation and through a direct mechanism involving interaction with the basal transcription machinery.	NCI, Signal Transduct Grp, Lab Receptor Biol & Gene Express, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Smith, CL (corresponding author), NCI, Signal Transduct Grp, Lab Receptor Biol & Gene Express, Ctr Canc Res,NIH, Bldg 41,Rm B608,41 Lib Dr MSC 5055, Bethesda, MD 20892 USA.							ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; BROCKMANN D, 1995, CURR TOP MICROBIOL, V199, P81; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DORSMAN JC, 1995, J VIROL, V69, P2962, DOI 10.1128/JVI.69.5.2962-2967.1995; Fletcher TM, 2000, MOL CELL BIOL, V20, P6466, DOI 10.1128/MCB.20.17.6466-6475.2000; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; FOLKERS GE, 1995, MOL CELL BIOL, V15, P5868; Fragoso G, 1998, MOL CELL BIOL, V18, P3633, DOI 10.1128/MCB.18.6.3633; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klemm DJ, 1996, J BIOL CHEM, V271, P8082, DOI 10.1074/jbc.271.14.8082; Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; Mazzarelli JM, 1997, J VIROL, V71, P7978, DOI 10.1128/JVI.71.10.7978-7983.1997; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; MILLER ME, 1995, ONCOGENE, V11, P1623; Miller ME, 1996, MOL CELL BIOL, V16, P5737; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Muller WG, 2001, J CELL BIOL, V154, P33, DOI 10.1083/jcb.200011069; Mymryk JS, 1997, BIOCHEM CELL BIOL, V75, P95, DOI 10.1139/bcb-75-2-95; O'Connor MJ, 1999, J VIROL, V73, P3574; PENNIE WD, 1995, MOL CELL BIOL, V15, P2125; Perissi V, 1999, P NATL ACAD SCI USA, V96, P3652, DOI 10.1073/pnas.96.7.3652; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; Sanchez TA, 2000, AM J RESP CELL MOL, V23, P670, DOI 10.1165/ajrcmb.23.5.3675; Sang NL, 1997, J CELL PHYSIOL, V170, P182, DOI 10.1002/(SICI)1097-4652(199702)170:2<182::AID-JCP10>3.0.CO;2-K; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Smith CL, 1997, J BIOL CHEM, V272, P14227, DOI 10.1074/jbc.272.22.14227; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P11202, DOI 10.1073/pnas.90.23.11202; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Wahlstrom GM, 1999, MOL ENDOCRINOL, V13, P1119, DOI 10.1210/me.13.7.1119; WANG HGH, 1995, J VIROL, V69, P7917, DOI 10.1128/JVI.69.12.7917-7924.1995; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Xu Y, 2000, MOL CELL BIOL, V20, P2138, DOI 10.1128/MCB.20.6.2138-2146.2000; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	52	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19847	19854		10.1074/jbc.M200629200	http://dx.doi.org/10.1074/jbc.M200629200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11909860	hybrid			2022-12-25	WOS:000175894800080
J	Trent, JT; Hargrove, MS				Trent, JT; Hargrove, MS			A ubiquitously expressed human hexacoordinate hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; SULFHEME PROTEINS; FACILITATED DIFFUSION; ESCHERICHIA-COLI; LIGAND-BINDING; PLANT; LEGHEMOGLOBIN; OXYGEN; GENE; MYOGLOBIN	We have identified a new human hemoglobin that we call histoglobin because it is expressed in a wide array of tissues. Histoglobin shares less than 30% identity with the other human hemoglobins, and the gene contains an intron in an unprecedented location. Spectroscopic and kinetic experiments with recombinant human histoglobin indicate that it is a hexacoordinate hemoglobin with significantly different ligand binding characteristics than the other human hexacoordinate hemoglobin, neuroglobin. In contrast to the very high oxygen affinities displayed by most hexacoordinate hemoglobins, the biophysical characteristics of histoglobin indicate that it could facilitate oxygen transport. The discovery of histoglobin demonstrates that humans, like plants, differentially express multiple hexacoordinate hemoglobins.	Iowa State Univ Sci & Technol, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Hargrove, MS (corresponding author), Iowa State Univ Sci & Technol, Dept Biochem Biophys & Mol Biol, 4114 Mol Biol Bldg, Ames, IA 50011 USA.	msh@iastate.edu						APPLEBY CA, 1984, ANNU REV PLANT PHYS, V35, P443, DOI 10.1146/annurev.pp.35.060184.002303; Arredondo-Peter R, 1998, PLANT PHYSIOL, V118, P1121, DOI 10.1104/pp.118.4.1121; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; Ascoli F, 1981, Methods Enzymol, V76, P72; Awenius C, 2001, BIOCHEM BIOPH RES CO, V287, P418, DOI 10.1006/bbrc.2001.5614; BABIOR BM, 1999, REACTIVE OXYGEN SPEC; BERTIN A, 1992, J MED MICROBIOL, V37, P141, DOI 10.1099/00222615-37-2-141; BERZOFSKY JA, 1972, J BIOL CHEM, V247, P3783; BERZOFSKY JA, 1971, J BIOL CHEM, V246, P7366; BERZOFSKY JA, 1972, J BIOL CHEM, V247, P3774; BERZOFSKY JA, 1971, J BIOL CHEM, V246, P3367; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P21, DOI 10.1016/S0968-0004(00)01698-4; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; *COMP BIOL INF LAB, 2001, ALLGENE VERS 2 2; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; Couture M, 2000, EUR J BIOCHEM, V267, P4770, DOI 10.1046/j.1432-1327.2000.01531.x; Delledonne M, 1998, NATURE, V394, P585, DOI 10.1038/29087; Delledonne M, 2001, P NATL ACAD SCI USA, V98, P13454, DOI 10.1073/pnas.231178298; Doherty DH, 1998, NAT BIOTECHNOL, V16, P672, DOI 10.1038/nbt0798-672; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; Dunford B.H., 1999, HEME PEROXIDASES; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Fukuto JM, 1999, MET IONS BIOL SYST, V36, P547; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Goodman MD, 2001, J BIOL CHEM, V276, P6834, DOI 10.1074/jbc.M009254200; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; Hargrove MS, 2000, BIOPHYS J, V79, P2733, DOI 10.1016/S0006-3495(00)76512-X; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Helleboid S, 2000, J EXP BOT, V51, P1189, DOI 10.1093/jexbot/51.348.1189; Herbers K, 1996, FEBS LETT, V397, P239, DOI 10.1016/S0014-5793(96)01183-0; Hunt PW, 2001, PLANT MOL BIOL, V47, P677, DOI 10.1023/A:1012440926982; Hvitved AN, 2001, J BIOL CHEM, V276, P34714, DOI 10.1074/jbc.M105175200; HYLDIGNIELSEN JJ, 1982, NUCLEIC ACIDS RES, V10, P689, DOI 10.1093/nar/10.2.689; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kawada N, 2001, J BIOL CHEM, V276, P25318, DOI 10.1074/jbc.M102630200; LORBERTH R, 1992, PLANT J, V2, P477; Masuhara M, 2000, BIOCHEM BIOPH RES CO, V268, P697, DOI 10.1006/bbrc.2000.2223; Membrillo-Hernandez J, 1999, J BIOL CHEM, V274, P748, DOI 10.1074/jbc.274.2.748; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; MURRAY JD, 1971, J BIOL CHEM, V246, P5903; OCARRA P, 1976, PORPHYRINS METALLOPO; Ohuchi J, 2001, MOL REPROD DEV, V59, P350, DOI 10.1002/mrd.1041; Olson J S, 1981, Methods Enzymol, V76, P631; PUPPO A, 1980, BIOCHIM BIOPHYS ACTA, V614, P303, DOI 10.1016/0005-2744(80)90220-X; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; Scott NL, 2000, PROTEIN SCI, V9, P587; SIEVERS G, 1978, BIOCHIM BIOPHYS ACTA, V533, P293, DOI 10.1016/0005-2795(78)90376-8; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; TAYLOR ER, 1994, PLANT MOL BIOL, V24, P853, DOI 10.1007/BF00014440; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Trent JT, 2001, BIOCHEMISTRY-US, V40, P6155, DOI 10.1021/bi0100790; Trevaskis B, 1997, P NATL ACAD SCI USA, V94, P12230, DOI 10.1073/pnas.94.22.12230; Weber RE, 2001, PHYSIOL REV, V81, P569, DOI 10.1152/physrev.2001.81.2.569; WHITAKER TL, 1995, BIOCHEMISTRY-US, V34, P8221, DOI 10.1021/bi00026a002; WITTENBE.JB, 1966, J BIOL CHEM, V241, P104; WITTENBERG JB, 1972, J BIOL CHEM, V247, P527; WYMAN J, 1966, J BIOL CHEM, V241, P115	60	296	304	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19538	19545		10.1074/jbc.M201934200	http://dx.doi.org/10.1074/jbc.M201934200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11893755	hybrid			2022-12-25	WOS:000175894800041
J	Terraz, C; Brideau, G; Ronco, P; Rossert, J				Terraz, C; Brideau, G; Ronco, P; Rossert, J			A combination of cis-acting elements is required to activate the pro-alpha 1(I) collagen promoter in tendon fibroblasts of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL; COL1A1 PROMOTER; EXPRESSION; IDENTIFICATION; TRANSCRIPTION; MUTATIONS; SEQUENCE; DISEASES; REGION; GENES	The genes encoding the two type I collagen chains are selectively activated in few cell types, including fibroblasts and osteoblasts. By generating transgenic mice, we have previously shown that the activity of the mouse pro-alpha1(I) promoter was controlled by separate cell-specific cis-acting elements. In particular, a sequence located between -3.2 and -2.3 kb was needed to induce expression of the reporter gene at high levels in tendon fibroblasts. In the present work, by using the same transgenic approach, we have identified two short elements in this sequence, named tendon-specific element (TSE) 1 and TSE2, that were necessary to direct reporter gene expression selectively in tendon fibroblasts. Gel shift assays showed that TSE1 and TSE2 bound proteins specifically present in nuclear extracts from tendon fibroblasts and that the sequence of TSE2 binding a tendon-specific protein corresponded to an E-box. Analysis of transgenic mice further indicated that TSE1 and TSE2 needed to cooperate not only with each other but also with other cis-acting elements of the proximal promoter to activate reporter gene expression in tendon fibroblasts. Similarly, it pointed out that the so-called osteoblast-specific element had to interact with downstream sequences to drive reporter gene expression in osteoblasts of transgenic mice. Thus, expression of the mouse pro-alpha1(I) collagen gene in tendon fibroblasts appears to be the result of a unique combination of different cis-acting elements, including TSE1 and TSE2.	Hop Tenon, INSERM, U489, F-75020 Paris, France; Univ Paris 06, F-75020 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite	Rossert, J (corresponding author), Hop Tenon, INSERM, U489, 4 Rue Chine, F-75020 Paris, France.	jerome.rossert@tnn.ap-hop-paris.fr	Ronco, Pierre/AAC-8390-2022					Ambrosetti DC, 2000, J BIOL CHEM, V275, P23387, DOI 10.1074/jbc.M000932200; BEDALOV A, 1995, J BONE MINER RES, V10, P1443; BOGDANOVIC Z, 1994, J BONE MINER RES, V9, P285; Byers PH, 1997, AM J MED GENET, V72, P94, DOI 10.1002/(SICI)1096-8628(19971003)72:1<94::AID-AJMG20>3.0.CO;2-O; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dodig M, 1996, J BIOL CHEM, V271, P16422, DOI 10.1074/jbc.271.27.16422; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; HOGAN B, 1986, MANIPULATING MOUSE E; HOUGLUM K, 1995, J CLIN INVEST, V96, P2269, DOI 10.1172/JCI118282; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9; LISKA DJ, 1994, J CELL BIOL, V125, P695, DOI 10.1083/jcb.125.3.695; Niederreither K, 1995, MATRIX BIOL, V14, P705, DOI 10.1016/S0945-053X(05)80013-7; PRIE D, 1991, J CELL BIOL, V113, P951, DOI 10.1083/jcb.113.4.951; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; Rossert J., 2002, PRINCIPLES BONE BIOL; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; Schweitzer R, 2001, DEVELOPMENT, V128, P3855; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; SLACK JL, 1991, MOL CELL BIOL, V11, P2066, DOI 10.1128/MCB.11.4.2066; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; WASSARMAN PM, 1993, GUIDES TECHNIQUES MO	24	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19019	19026		10.1074/jbc.M200125200	http://dx.doi.org/10.1074/jbc.M200125200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11882659	hybrid			2022-12-25	WOS:000175975800101
J	Wei, WL; Wang, XT; Kusiak, JW				Wei, WL; Wang, XT; Kusiak, JW			Signaling events in amyloid beta-peptide-induced neuronal death and insulin-like growth factor I protection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; C-JUN; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; KAPPA-B; HIPPOCAMPAL-NEURONS; COUPLED RECEPTORS; INDUCED APOPTOSIS; CORTICAL-NEURONS	Amyloid beta-peptide (Abeta) is implicated as the toxic agent in Alzheimer's disease and is the major component of brain amyloid plaques. In vitro, Abeta causes cell death, but the molecular mechanisms are unclear. We analyzed the early signaling mechanisms involved in Abeta toxicity using the SH-SY5Y neuroblastoma cell line. Abeta caused cell death and induced a 2- to 3-fold activation of JNK JNK activation and cell death were inhibited by overexpression of a dominant-negative SEK1 (SEK1-AL) construct. Butyrolactone I, a cdk5 inhibitor, had an additional protective effect against Abeta toxicity in these SEK1-AL-expressing cells suggesting that cdk5 and JNK activation independently contributed to this toxicity. Abeta also weakly activated ERK and Akt but had no effect on p38 kinase. Inhibitors of ERK and phosphoinositide 3-kinase (PI3K) pathways did not affect Abeta-induced cell death, suggesting that these pathways were not important in Abeta toxicity. Insulin-like growth factor I protected against Abeta toxicity by strongly activating ERK and Akt and blocking JNK activation in a PI3K-dependent manner. Pertussis toxin also blocked Abeta-induced cell death and JNK activation suggesting that G(i/o) proteins were upstream activators of JNK. The results suggest that activation of the JNK pathway and cdk5 may be initial signaling cascades in Abeta-induced cell death.	NIA, Mol Neurobiol Unit, Cellular & Mol Biol Lab, Intramural Res Program,Gerontol Res Ctr,NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Wei, WL (corresponding author), NIA, Mol Neurobiol Unit, Cellular & Mol Biol Lab, Intramural Res Program,Gerontol Res Ctr,NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	weiwa@grc.nia.nih.gov; jk133r@nih.gov			NATIONAL INSTITUTE ON AGING [Z01AG000500] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abe K, 2000, NEUROSCI LETT, V292, P1, DOI 10.1016/S0304-3940(00)01415-4; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; Alvarez A, 2001, EXP CELL RES, V264, P266, DOI 10.1006/excr.2001.5152; Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; ANDERSON AJ, 1995, J NEUROCHEM, V65, P1487; BEHL C, 1994, BRAIN RES, V645, P253, DOI 10.1016/0006-8993(94)91659-4; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cheng HL, 1998, J BIOL CHEM, V273, P14560, DOI 10.1074/jbc.273.23.14560; Combs CK, 2001, J NEUROSCI, V21, P1179; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CREWS FT, 1992, J NEUROCHEM, V58, P1205, DOI 10.1111/j.1471-4159.1992.tb11330.x; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; Dore S, 1997, NEUROSCIENCE, V80, P1033, DOI 10.1016/S0306-4522(97)00154-1; Dore S, 1997, P NATL ACAD SCI USA, V94, P4772, DOI 10.1073/pnas.94.9.4772; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ekinci FJ, 1999, J BIOL CHEM, V274, P30322, DOI 10.1074/jbc.274.42.30322; Ferreira A, 1997, MOL CELL NEUROSCI, V9, P220, DOI 10.1006/mcne.1997.0615; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Gudermann T, 2000, N-S ARCH PHARMACOL, V361, P345, DOI 10.1007/s002109900208; Hara F, 2001, J ORTHOPAED RES, V19, P126, DOI 10.1016/S0736-0266(00)00011-5; Hashimoto Y, 2000, J BIOL CHEM, V275, P34541, DOI 10.1074/jbc.M005332200; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; Ikeuchi T, 1998, Hum Cell, V11, P125; IVERSEN LL, 1995, BIOCHEM J, V311, P1; Kajkowski EM, 2001, J BIOL CHEM, V276, P18748, DOI 10.1074/jbc.M011161200; Kihiko ME, 1999, J NEUROCHEM, V73, P2609, DOI 10.1046/j.1471-4159.1999.0732609.x; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Kuner P, 1998, J NEUROSCI RES, V54, P798, DOI 10.1002/(SICI)1097-4547(19981215)54:6<798::AID-JNR7>3.3.CO;2-K; Lackey BR, 2000, GROWTH HORM IGF RES, V10, P1, DOI 10.1054/ghir.1999.0129; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Levresse V, 2000, J NEUROSCI RES, V62, P799; Lorenzo A, 2000, NAT NEUROSCI, V3, P460, DOI 10.1038/74833; Marcus DL, 1998, NEUROBIOL AGING, V19, P393, DOI 10.1016/S0197-4580(98)00077-3; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; McDonald DR, 1998, J NEUROSCI, V18, P4451; Mograbi B, 2001, J BIOL CHEM, V276, P45307, DOI 10.1074/jbc.M101220200; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; Niikura T, 2001, J NEUROSCI, V21, P1902, DOI 10.1523/JNEUROSCI.21-06-01902.2001; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Rapoport M, 2000, J NEUROCHEM, V74, P125, DOI 10.1046/j.1471-4159.2000.0740125.x; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rymer DL, 2001, J BIOL CHEM, V276, P2523, DOI 10.1074/jbc.M005800200; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shoji M, 2000, MOL BRAIN RES, V85, P221, DOI 10.1016/S0169-328X(00)00245-X; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.00218.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wylie PG, 1999, BIOCHEM J, V338, P619, DOI 10.1042/0264-6021:3380619; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yaar M, 2002, J BIOL CHEM, V277, P7720, DOI 10.1074/jbc.M110929200; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; YAN MH, 1994, NATURE, V372, P798; ZHENG WH, 2000, J NEURAL TRANSM-SUPP, V60, pS261; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x	69	164	180	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17649	17656		10.1074/jbc.M111704200	http://dx.doi.org/10.1074/jbc.M111704200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882652	hybrid			2022-12-25	WOS:000175685100034
J	Ishida, N; Hara, T; Kamura, T; Yoshida, M; Nakayama, K; Nakayama, KI				Ishida, N; Hara, T; Kamura, T; Yoshida, M; Nakayama, K; Nakayama, KI			Phosphorylation of p27(Kip1) on serine 10 is required for its binding to CRM1 and nuclear export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT-KINASE INHIBITOR; CELL-CYCLE; CDK INHIBITORS; MICE LACKING; P27; DEGRADATION; HYPERPLASIA; CANCER; SKP2; CKS1	Phosphorylation of the cyclin-dependent kinase inhibitor p27(Kip1) has been thought to regulate its stability. Ser(10) is the major phosphorylation site of p27(Kip1), and phosphorylation of this residue affects protein stability. Phosphorylation of p27(Kip1) on Ser(10) has now been shown to be required for the binding of CRM1, a carrier protein for nuclear export. The p27(Kip1) protein was translocated from the nucleus to the cytoplasm at the Go-G, transition of the cell cycle, and this export was inhibited by leptomycin B, a specific inhibitor of CRM1-dependent nuclear export. The nuclear export and subsequent degradation of p27(Kip1) at the Go-G, transition were observed in cells lacking Skp2, the F-box protein component of an SCF ubiquitin ligase complex, indicating that these early events are independent of Skp2-mediated proteolysis. Substitution of Ser(10) with Ala (S10A) markedly reduced the extent of p27(Kip1) export, whereas substitution of Ser(10) with Asp (S10D) or Glu (S10E) promoted export. Co-immunoprecipitation analysis showed that CRM1 preferentially interacted with S10D and S10E but not with S10A, suggesting that the phosphorylation of p27(Kip1) on Ser(10) is required for its binding to CRM1 and for its subsequent nuclear export.	Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol Genet, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan	Kyushu University; Kyushu University; Japan Science & Technology Agency (JST); University of Tokyo	Nakayama, KI (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.		Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674				Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsihlias J, 1999, ANNU REV MED, V50, P401; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x	31	223	235	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14355	14358		10.1074/jbc.C100762200	http://dx.doi.org/10.1074/jbc.C100762200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11889117	hybrid			2022-12-25	WOS:000175203000002
J	Platt, G; Carbone, A; Mittnacht, S				Platt, G; Carbone, A; Mittnacht, S			P16INK4a loss and sensitivity in KSHV associated primary effusion lymphoma	ONCOGENE			English	Article						p16INK4a; retinoblastoma (Rb); Kaposi's sarcoma associated herpes virus (KSHV); human herpesvirus 8 (HHV8); primary effusion lymphoma (PEL)	KAPOSIS-SARCOMA; T-CELL; HOMOZYGOUS DELETIONS; DNA-SEQUENCES; RETINOBLASTOMA-PROTEIN; NUCLEAR ANTIGEN; B-CELL; CYCLIN; EXPRESSION; GENES	The Kaposi's Sarcoma associated Herpes virus (KSHV) encodes two genes with the potential to affect the activity of the retinoblastoma protein (Rb). Open reading frame (orf) 72 encodes a D type cyclin (kcyc) that can elicit p16INK4a resistant cdk activity and orf73 encodes the latency associated nuclear antigen (LNA) that can bind Rb and neutralize E2F regulation. This indicates that, like papilloma and adenovirus associated malignancies, those associated with KSHV are defective with respect to their Rb pathway. To address this we investigated whether KSHV associated primary effusion lymphoma (PEL) derived cell lines are resistant to growth inhibition by p16INK4a. We provide evidence that ectopic expression of p16INK4a in these cells causes an Rb dependent G1 cell cycle block. Importantly, endogenous p16INK4a expression is not detected in six PEL derived cell lines and four primary PEL samples and examination of the p16INK4a locus shows deletion in two out of six and hypermethylation in four out of six PEL lines. Treatment of the latter with the demethylating agent 5'-aza-2' deoxycytidine leads to re-expression of p16INK4a protein. Taken together these results suggest that p16INK4a loss may be a cellular change frequently associated with PEL. They furthermore argue that despite the presence of KSHV DNA and expression of a latent gene program Rb function is intact in PEL.	Inst Canc Res, Chester Beatty Labs, Ctr Mol & Cell Biol, London SW3 6JB, England; Natl Canc Inst, IRCCS, Ctr Riferimento Oncol, Div Pathol, Aviano, Italy	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; IRCCS Aviano (CRO)	Mittnacht, S (corresponding author), Inst Canc Res, Chester Beatty Labs, Ctr Mol & Cell Biol, 237 Fulham Rd, London SW3 6JB, England.	sibylle@icr.ac.uk	Carbone, Antonino/AAA-2217-2019	Carbone, Antonino/0000-0003-2211-639X				Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Baur AS, 1999, BLOOD, V94, P1773, DOI 10.1182/blood.V94.5.1773.417a12_1773_1781; Boshoff C, 1998, BLOOD, V91, P1671, DOI 10.1182/blood.V91.5.1671.1671_1671_1679; Carbone A, 2000, AM J PATHOL, V156, P1209, DOI 10.1016/S0002-9440(10)64991-7; Carbone A, 2000, LEUKEMIA, V14, P1301, DOI 10.1038/sj.leu.2401802; Carbone A, 2000, BRIT J HAEMATOL, V111, P247, DOI 10.1046/j.1365-2141.2000.02329.x; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Child ES, 2001, ONCOGENE, V20, P3311, DOI 10.1038/sj.onc.1204447; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Drexler HG, 1998, LEUKEMIA, V12, P1507, DOI 10.1038/sj.leu.2401160; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Gaidano G, 1999, GENE CHROMOSOME CANC, V24, P16, DOI 10.1002/(SICI)1098-2264(199901)24:1<16::AID-GCC3>3.0.CO;2-F; Gessain A, 1997, LEUKEMIA, V11, P266, DOI 10.1038/sj.leu.2400549; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; Hangaishi A, 1996, BLOOD, V87, P4949, DOI 10.1182/blood.V87.12.4949.bloodjournal87124949; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kellam P, 1997, J Hum Virol, V1, P19; KELLEY MJ, 1995, INT J CANCER, V63, P226, DOI 10.1002/ijc.2910630214; Klaes R, 2001, INT J CANCER, V92, P276, DOI 10.1002/ijc.1174; Klangby U, 1998, BLOOD, V91, P1680, DOI 10.1182/blood.V91.5.1680.1680_1680_1687; LIU Y, 1995, BLOOD, V86, P1911, DOI 10.1182/blood.V86.5.1911.bloodjournal8651911; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Oksenhendler E, 1998, NEW ENGL J MED, V338, P1585, DOI 10.1056/NEJM199805283382204; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Pinyol M, 1998, BLOOD, V91, P2977, DOI 10.1182/blood.V91.8.2977.2977_2977_2984; Platt GM, 2000, VIROLOGY, V272, P257, DOI 10.1006/viro.2000.0343; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SILL H, 1995, BLOOD, V85, P2013, DOI 10.1182/blood.V85.8.2013.bloodjournal8582013; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; Villuendas R, 1998, AM J PATHOL, V153, P887, DOI 10.1016/S0002-9440(10)65630-1; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; Yamada Y, 1997, J CLIN ONCOL, V15, P1778, DOI 10.1200/JCO.1997.15.5.1778	46	36	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1823	1831		10.1038/sj.onc.1205360	http://dx.doi.org/10.1038/sj.onc.1205360			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896614				2022-12-25	WOS:000174284500004
J	Dhanalakshmi, S; Singh, RP; Agarwal, C; Agarwal, R				Dhanalakshmi, S; Singh, RP; Agarwal, C; Agarwal, R			Silibinin inhibits constitutive and TNF alpha-induced activation of NF-alpha B and sensitizes human prostate carcinoma DU145 cells to TNF alpha-induced apoptosis	ONCOGENE			English	Article						prostate cancer; NF-kappa B; apoptosis; silibinin	I-KAPPA-B; TUMOR-NECROSIS-FACTOR; FLAVONOID ANTIOXIDANT SILYMARIN; CANCER-CELLS; MEDIATED APOPTOSIS; CYCLOOXYGENASE 2; DNA-SYNTHESIS; KINASE; EXPRESSION; GROWTH	Prostate cancer (PCA) is one of the most common invasive malignancies of men in the US, however, there have been Limited successes so far in its therapy. Even most potent agents (e.g. TNFalpha) are ineffective in killing human PCA cells possibly due to constitutive activation of NF-kappaB that subsequently activates a large number of anti-apoptotic genes. In such a scenario, strong apoptotic agent TNFalpha, further induces NF-kappaB activation rather than inducing apoptosis. In several recent studies, we have demonstrated both cancer preventive and anti-cancer efficacy of silymarin and its constituent silibinin in a variety of experimental tumor models and cell culture systems. Here we examined whether silibinin is effective in inhibiting constitutive NF-kappaB activation in human PCA cells, which would help in overcoming TNFY-insensitivity. Our studies reveal that silibinin effectively inhibits constitutive activation of NF-kappaB in advanced human prostate carcinoma DU145 cells. Consistent with this, nuclear levels of p65 and p50 sub-units of NF-kappaB were also reduced. In the studies assessing molecular mechanism of this effect, silibinin treatment resulted in a significant increase in the level of IkappaBalpha with a concomitant decrease in phospho-IkappaBalpha. Kinase assays revealed that silibinin dose-dependently decreases IKKalpha kinase activity. The effect of silibinin on IKKalpha seemed to be direct as evidenced by the in vitro kinase assay, where immunoprecipitated IKKalpha was incubated with silibinin. This shows that silibinin does not necessarily need an upstream event to bring about its inhibitory effect on IKKalpha and downstream effectors. Additional studies showed that silibinin also inhibits TNFalpha-induced activation of NF-kappaB via IkappaBalpha pathway and subsequently sensitizes DU145 cells to TNFa-induced apoptosis. These results indicate that silibinin could be used to enhance the effectiveness of TNFalpha-based chemotherapy in advanced PCA.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Agarwal, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th Ave,Box C238, Denver, CO 80262 USA.	Rajesh.Agarwal@uchsc.edu		Singh, Rana Pratap/0000-0003-4261-7044	NCI NIH HHS [CA64514, CA83741] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064514, R01CA064514, R01CA083741] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad N, 1998, BIOCHEM BIOPH RES CO, V247, P294, DOI 10.1006/bbrc.1998.8748; BACUERLE PA, 1996, CELL, V87, P13; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bhatia N, 1999, CANCER LETT, V147, P77, DOI 10.1016/S0304-3835(99)00276-1; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Davis JN, 1999, NUTR CANCER, V35, P167, DOI 10.1207/S15327914NC352_11; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dong G, 1999, CANCER RES, V59, P3495; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; JONES S, 1997, WORKING PAPERS LIT, V1, P17; Lahiri-Chatterjee M, 1999, CANCER RES, V59, P622; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LETTERON P, 1990, BIOCHEM PHARMACOL, V39, P2027, DOI 10.1016/0006-2952(90)90625-U; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Manna SK, 1999, J IMMUNOL, V163, P6800; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Muenchen HJ, 2000, CLIN CANCER RES, V6, P1969; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; NAKAJIMA Y, 1995, UROL RES, V23, P205, DOI 10.1007/BF00393299; Nomura M, 2000, CARCINOGENESIS, V21, P1885, DOI 10.1093/carcin/21.10.1885; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Ripple MO, 1999, JNCI-J NATL CANCER I, V91, P1227, DOI 10.1093/jnci/91.14.1227; Rokhlin OW, 1997, CANCER RES, V57, P1758; Sharma Y, 2001, MOL CARCINOGEN, V30, P224, DOI 10.1002/mc.1032; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; SINHA BK, 1995, BBA-MOL BASIS DIS, V1270, P12, DOI 10.1016/0925-4439(94)00065-X; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Sumitomo M, 1999, J UROLOGY, V161, P674, DOI 10.1016/S0022-5347(01)61993-1; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Waddick KG, 1999, BIOCHEM PHARMACOL, V57, P9, DOI 10.1016/S0006-2952(98)00224-X; WAGNER H, 1974, ARZNEIMITTEL-FORSCH, V24, P466; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wattenberg LW, 1997, P SOC EXP BIOL MED, V216, P133; Wellington K, 2001, BIODRUGS, V15, P465, DOI 10.2165/00063030-200115070-00005; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Yu R, 2000, CANCER RES, V60, P2384; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhao JF, 1999, MOL CARCINOGEN, V26, P321, DOI 10.1002/(SICI)1098-2744(199912)26:4<321::AID-MC11>3.3.CO;2-0; Zi XL, 2000, CANCER RES, V60, P5617; Zi XL, 1998, CANCER RES, V58, P1920; Zi XL, 1998, CLIN CANCER RES, V4, P1055; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	59	140	144	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1759	1767		10.1038/sj.onc.1205240	http://dx.doi.org/10.1038/sj.onc.1205240			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896607				2022-12-25	WOS:000174214200014
J	Fisher, MC; Zeisel, SH; Mar, MH; Sadler, TW				Fisher, MC; Zeisel, SH; Mar, MH; Sadler, TW			Perturbations in choline metabolism cause neural tube defects in mouse embryos in vitro	FASEB JOURNAL			English	Article						neurulation; dimethylaminoethanol; ET-18-OCH3; embryo culture	HUMAN LEUKEMIC-CELLS; PROTEIN-KINASE-C; LIQUID-CHROMATOGRAPHY; PARENTERAL-NUTRITION; HEPATIC STEATOSIS; CHICK-EMBRYO; FOLIC-ACID; RAT-LIVER; APOPTOSIS; CERAMIDE	A role for choline during early stages of mammalian embryogenesis has not been established, although recent studies show that inhibitors of choline uptake and metabolism, 2-dimethylaminoethanol (DMAE), and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3), produce neural tube defects in mouse embryos grown in vitro. To determine potential mechanisms responsible for these abnormalities, choline metabolism in the presence or absence of these inhibitors was evaluated in cultured, neurulating mouse embryos by using chromatographic techniques. Results showed that 90%-95% of C-14-choline was incorporated into phosphocholine and phosphatidylcholine (PtdCho), which was metabolized to sphingomyelin. Choline was oxidized to betaine, and betaine homocysteine methyltransferase was expressed. Acetylcholine was synthesized in yolk sacs, but 70 kDa choline acetyltransferase was undetectable by immunoblot. DMAE reduced embryonic choline uptake and inhibited phosphocholine, PtdCho, phosphatidylethanolamine (PtdEtn), and sphingomyelin synthesis. ET-18-OCH3 also inhibited PtdCho synthesis. In embryos and yolk sacs incubated with H-3-ethanolamine, 95% of recovered label was PtdEtn, but PtdEtn was not converted to PtdCho, which suggested that phosphatidylethanolamine methyltransferase (PeMT) activity was absent. In ET-18-OCH3 treated yolk sacs, PtdEtn was increased, but PtdCho was still not generated through PeMT. Results suggest that endogenous PtdCho synthesis is important during neurulation and that perturbed choline metabolism contributes to neural tube defects produced by DMAE and ET-18-OCH3.	Univ N Carolina, Dept Cell Biol & Anat, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Sadler, TW (corresponding author), Univ N Carolina, Dept Cell Biol & Anat, Sch Med, CB 7090, Chapel Hill, NC 27599 USA.	tsadler@med.unc.edu						Albright CD, 1999, DEV BRAIN RES, V113, P13, DOI 10.1016/S0165-3806(98)00183-7; Arthur G, 1998, BBA-LIPID LIPID MET, V1390, P85, DOI 10.1016/S0005-2760(97)00163-X; AUGUSTINSSON KB, 1949, J CELL COMPAR PHYSL, V34, P311, DOI 10.1002/jcp.1030340208; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boggs K, 1998, BBA-LIPID LIPID MET, V1389, P1, DOI 10.1016/S0005-2760(97)00145-8; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; BUCHMAN AL, 1995, HEPATOLOGY, V22, P1399, DOI 10.1002/hep.1840220510; BUCHMAN AL, 1992, GASTROENTEROLOGY, V102, P1363; Buznikov GA, 1996, CELL MOL NEUROBIOL, V16, P533, DOI 10.1007/BF02152056; CHANDAR N, 1988, CARCINOGENESIS, V9, P259, DOI 10.1093/carcin/9.2.259; COPELAND DH, 1946, AM J PATHOL, V22, P1059; Cui Z, 1997, BBA-LIPID LIPID MET, V1346, P10, DOI 10.1016/S0005-2760(97)00012-X; CZEIZEL AE, 1995, J PEDIATR GASTR NUTR, V20, P4, DOI 10.1097/00005176-199501000-00003; DACOSTA KA, 1993, J BIOL CHEM, V268, P2100; DANIEL LW, 1993, CANCER CHEMOTHERAPY, P146; DEAN W, 1990, SMART DRUGS NUTR IMP, P99; DIOMEDE L, 1993, INT J CANCER, V53, P124, DOI 10.1002/ijc.2910530123; Eskes TKAB, 1998, EUR J PEDIATR, V157, pS139, DOI 10.1007/PL00014299; ESSIEN FB, 1992, TERATOLOGY, V45, P205, DOI 10.1002/tera.1420450214; FALUGI C, 1993, EUR J HISTOCHEM, V37, P287; Fisher MC, 2001, TERATOLOGY, V64, P114, DOI 10.1002/tera.1053; GROSMAN DD, 1995, J NEUROCHEM, V65, P484; GUSTAFSON T, 1970, EXP CELL RES, V62, P102, DOI 10.1016/0014-4827(79)90512-3; GWEE MCE, 1978, CLIN EXP PHARMACOL P, V5, P649, DOI 10.1111/j.1440-1681.1978.tb00721.x; HAUBRICH DR, 1981, BIOCHEM PHARMACOL, V30, P2993, DOI 10.1016/0006-2952(81)90265-3; HAUBRICH DR, 1975, LIFE SCI, V17, P975, DOI 10.1016/0024-3205(75)90451-8; HAUBRICH DR, 1981, J NEUROCHEM, V37, P476, DOI 10.1111/j.1471-4159.1981.tb00480.x; HolmesMcNary MQ, 1997, DEV BRAIN RES, V101, P9, DOI 10.1016/S0165-3806(97)00044-8; HUEMER RP, 1999, J ADV MED, V12, P119; Johnston R B Jr, 1997, Adv Pediatr, V44, P231; Klein NW, 1997, INT J DEV BIOL, V41, P267; LAASBERG T, 1987, COMP BIOCHEM PHYS C, V86, P313, DOI 10.1016/0742-8413(87)90085-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLOYD JB, 1990, TERATOLOGY, V41, P383, DOI 10.1002/tera.1420410404; LOCKER J, 1986, CARCINOGENESIS, V7, P1309, DOI 10.1093/carcin/7.8.1309; LOHR J, 1990, J PHARMACOL EXP THER, V252, P154; LORENZI MV, 1992, DNA CELL BIOL, V11, P593, DOI 10.1089/dna.1992.11.593; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCAS M, 1995, GEN PHARMACOL, V26, P881, DOI 10.1016/0306-3623(94)00295-X; Meck WH, 1997, NEUROREPORT, V8, P3045, DOI 10.1097/00001756-199709290-00009; Meck WH, 1999, DEV BRAIN RES, V118, P51, DOI 10.1016/S0165-3806(99)00105-4; MISAWA H, 1992, J BIOL CHEM, V267, P20392; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; MODOLELL M, 1979, CANCER RES, V39, P4681; MOLLINEDO F, 1993, BIOCHEM BIOPH RES CO, V192, P603, DOI 10.1006/bbrc.1993.1458; Moon EA, 1997, J REPROD FERTIL, V110, P213, DOI 10.1530/jrf.0.1100213; *NAT AC SCI I MED, 1998, DIET REF INT THIAM R, P255; National Toxicology Program, 1999, NIH PUBL; NOSEL PG, 1992, TERATOLOGY, V46, P499, DOI 10.1002/tera.1420460514; Oakley GP, 1996, J NUTR, V126, pS751, DOI 10.1093/jn/126.suppl_3.751S; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; PELECH SL, 1983, CAN J BIOCHEM CELL B, V61, P1147, DOI 10.1139/o83-147; PFEIFFER CC, 1957, SCIENCE, V126, P610, DOI 10.1126/science.126.3274.610; POMFRET EA, 1989, ANAL BIOCHEM, V180, P85, DOI 10.1016/0003-2697(89)90091-2; PRATT HPM, 1980, J REPROD FERTIL, V58, P237, DOI 10.1530/jrf.0.0580237; Previati M, 1996, ANAL BIOCHEM, V233, P108, DOI 10.1006/abio.1996.0014; SADLER TW, 1979, J EMBRYOL EXP MORPH, V49, P17; Shaw GM, 1997, TERATOLOGY, V56, P295, DOI 10.1002/(SICI)1096-9926(199711)56:5<295::AID-TERA1>3.0.CO;2-X; STEELE CE, 1974, J EMBRYOL EXP MORPH, V31, P707; Stott WT, 2000, TOXICOL LETT, V114, P67, DOI 10.1016/S0378-4274(99)00197-6; SWEIRY JH, 1985, J PHYSIOL-LONDON, V366, P251, DOI 10.1113/jphysiol.1985.sp015795; Tooyama I, 2000, J CHEM NEUROANAT, V17, P217, DOI 10.1016/S0891-0618(99)00043-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALINSKY JE, 1984, CELL DIFFER DEV, V14, P287, DOI 10.1016/0045-6039(84)90017-4; Vrablic AS, 2001, FASEB J, V15, P1739, DOI 10.1096/fj.00-0300com; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; WELLS IC, 1954, J BIOL CHEM, V207, P575; Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135; Yen CLE, 2001, FASEB J, V15, P1704, DOI 10.1096/fj.00-0800com; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; ZEISEL SH, 1993, FASEB J, V7, P551, DOI 10.1096/fasebj.7.6.8472893; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; ZEISEL SH, 1995, J NUTR, V125, P3049; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061; ZEISEL SH, 1981, ANNU REV NUTR, V1, P95, DOI 10.1146/annurev.nu.01.070181.000523	76	91	95	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					619	+		10.1096/fj.01-0564fje	http://dx.doi.org/10.1096/fj.01-0564fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919173				2022-12-25	WOS:000174203700001
J	Song, GJ; Harding, SE; Duchen, MR; Tunwell, R; O'Gara, P; Hawkins, TE; Moss, SE				Song, GJ; Harding, SE; Duchen, MR; Tunwell, R; O'Gara, P; Hawkins, TE; Moss, SE			Altered mechanical properties and intracellular calcium signaling in cardiomyocytes from annexin 6 null-mutant mice	FASEB JOURNAL			English	Article						heart failure; homeostasis; knockout; stimulus-response coupling	SARCOPLASMIC-RETICULUM; CARDIAC-MUSCLE; VI; HEART; RAT; IDENTIFICATION; MYOCYTES; NEURONS	Annexin 6 is one of a widely expressed family of calcium-binding proteins found in most mammalian tissues, including the heart. Several studies have implicated annexin 6 in the regulation of intracellular Ca(2+) signaling, and it has been shown in vitro to act as a modulator of the sarcoplasmic reticulum Ca(2+)-release channel, cardiac L-type calcium channel, and Na(+)/Ca(2+) exchanger. To investigate the role of annexin 6 in intact cardiomyocytes, we used mice containing a targeted disruption of the annexin 6 gene. Compared with controls, the myocytes of annexin 6 null-mutant mice demonstrated a significant increase in the rates of shortening and relengthening. Intracellular Ca(2+) transients in fura-2-loaded cardiomyocytes induced by caffeine showed a normal baseline and amplitude, whereas the rate of decay was doubled in annexin 6(-/-) myocytes compared with control mice. These results show that annexin 6 knockout in the mouse leads to an increase in myocyte contractility and faster diastolic Ca(2+) removal from the cytoplasm. In light of published findings showing annexin 6 to be down-regulated in end-stage heart failure, these results are consistent with a role for annexin 6 as a negative inotropic factor in the regulation of cardiomyocyte mechanics.	UCL, Inst Ophthalmol, Div Cell Biol, London EC1V 9EL, England; Natl Heart & Lung Inst, Imperial Coll Sch Med, London SW3 6LY, England; UCL, Dept Physiol, London WC1E 6BT, England	University of London; University College London; Imperial College London; University of London; University College London	Moss, SE (corresponding author), UCL, Inst Ophthalmol, Div Cell Biol, 11-43 Bath St, London EC1V 9EL, England.	s.moss@ucl.ac.uk	duchen, michael/A-2116-2009	duchen, michael/0000-0003-2548-4294; Harding, Sian/0000-0002-3651-6354				Benz J, 1996, J MOL BIOL, V260, P638, DOI 10.1006/jmbi.1996.0426; DIAZMUNOZ M, 1990, J BIOL CHEM, V265, P15894; DOUBELL AF, 1993, CARDIOVASC RES, V27, P1359, DOI 10.1093/cvr/27.7.1359; DOUBELL AF, 1991, HYPERTENSION, V18, P648, DOI 10.1161/01.HYP.18.5.648; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; GunteskiHamblin AM, 1996, AM J PHYSIOL-HEART C, V270, pH1091, DOI 10.1152/ajpheart.1996.270.3.H1091; HARDING SE, 1988, J MOL CELL CARDIOL, V20, P635, DOI 10.1016/S0022-2828(88)80121-4; Hawkins TE, 2000, CELL BIOCHEM BIOPHYS, V33, P275, DOI 10.1385/CBB:33:3:275; Hawkins TE, 1999, MOL CELL BIOL, V19, P8028; HAZARIKA P, 1991, J CELL BIOCHEM, V46, P78, DOI 10.1002/jcb.240460112; HAZARIKA P, 1991, J CELL BIOCHEM, V46, P86, DOI 10.1002/jcb.240460113; Heubach JF, 1999, CARDIOVASC RES, V42, P173, DOI 10.1016/S0008-6363(98)00262-4; IWASAKI A, 1989, J BIOCHEM-TOKYO, V106, P43, DOI 10.1093/oxfordjournals.jbchem.a122816; LIN HC, 1992, CELL, V70, P283, DOI 10.1016/0092-8674(92)90102-I; Naciff JM, 1996, AM J PHYSIOL-CELL PH, V271, pC2004; Nowicky AV, 1998, J PHYSIOL-LONDON, V507, P131, DOI 10.1111/j.1469-7793.1998.131bu.x; Ortega D, 1998, J CELL SCI, V111, P261; PULA G, 1990, FEBS LETT, V277, P53, DOI 10.1016/0014-5793(90)80808-V; SHIBATA S, 1992, J BIOCHEM-TOKYO, V112, P552, DOI 10.1093/oxfordjournals.jbchem.a123937; SMYTHE E, 1994, J CELL BIOL, V124, P301, DOI 10.1083/jcb.124.3.301; SOBOTA A, 1990, BIOCHEM BIOPH RES CO, V172, P1067, DOI 10.1016/0006-291X(90)91555-7; SONG G, 1995, CIRCULATION S, V92, P697; Song GJ, 1998, J MOL CELL CARDIOL, V30, P443, DOI 10.1006/jmcc.1997.0608; Tunwell REA, 1996, BIOCHEM J, V318, P477, DOI 10.1042/bj3180477; TUNWELL REA, 1991, BIOCHEM J, V279, P203, DOI 10.1042/bj2790203	25	41	42	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					622	+		10.1096/fj.01-0892fje	http://dx.doi.org/10.1096/fj.01-0892fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919174				2022-12-25	WOS:000174203700009
J	Khachigian, LM; Fahmy, RG; Zhang, GS; Bobryshev, YV; Kaniaros, A				Khachigian, LM; Fahmy, RG; Zhang, GS; Bobryshev, YV; Kaniaros, A			c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury - Inhibition by a novel DNA enzyme targeting c-Jun	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NH2-TERMINAL KINASE; ANTISENSE OLIGODEOXYNUCLEOTIDES; TRANSCRIPTIONAL ACTIVITY; GENE-EXPRESSION; FACTOR-BETA; IN-VITRO; OLIGONUCLEOTIDES; FOS; RNA; PHOSPHORYLATION	Neointima formation is a characteristic feature of common vascular pathologies, such as atherosclerosis and post-angioplasty restenosis, and involves smooth muscle cell proliferation. Determination of whether the bZIP transcription factor c-Jun plays a direct regulatory role in arterial lesion formation, or indeed in other disease, has been hampered by the lack of a potent and specific pharmacological inhibitor. c-Jun is poorly expressed in the uninjured artery wall and transiently induced following arterial injury in animal models. Here we generated a gene-specific DNAzyme-targeting c-Jun. We show that c-Jun protein is expressed in human atherosclerotic lesions. Dz13, a catalytically active c-Jun DNAzyme, cleaved c-Jun RNA and inhibited inducible c-Jun protein expression in vascular smooth muscle cells. Dz13 blocked vascular smooth muscle cell proliferation with potency exceeding its exact non-catalytic antisense oligodeoxynucleotide equivalent. Moreover, Dz13 abrogated smooth muscle cell repair following scraping injury in vitro and intimal thickening in injured rat carotid arteries in vivo. These studies demonstrate the positive influence on neointima formation by c-Jun and the therapeutic potential of a DNAzyme controlling its expression.	Univ New S Wales, Dept Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia; Prince Wales Hosp, Dept Haematol, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Khachigian, LM (corresponding author), Univ New S Wales, Dept Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia.		Bobryshev, Yuri/J-2838-2013; Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				AUTIERI MV, 1995, BIOCHEM BIOPH RES CO, V213, P827, DOI 10.1006/bbrc.1995.2204; BAUTERS C, 1994, CIRCULATION, V89, P2327, DOI 10.1161/01.CIR.89.5.2327; BENNETT MR, 1994, J CLIN INVEST, V93, P820, DOI 10.1172/JCI117036; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; CHEN B, 1992, J CLIN INVEST, V90, P1778, DOI 10.1172/JCI116052; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; GILLARDON F, 1995, BRIT J OPHTHALMOL, V79, P277, DOI 10.1136/bjo.79.3.277; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Izumi Y, 2001, CIRC RES, V88, P1120, DOI 10.1161/hh1101.091267; Kanatani Y, 1996, CELL GROWTH DIFFER, V7, P187; Khachigian LM, 1999, CIRC RES, V84, P1258, DOI 10.1161/01.RES.84.11.1258; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kondo T, 2000, HISTOCHEM J, V32, P509, DOI 10.1023/A:1004164905041; Kuwabara T, 1997, NUCLEIC ACIDS RES, V25, P3074, DOI 10.1093/nar/25.15.3074; Lowe HC, 2001, CIRC RES, V89, P670, DOI 10.1161/hh2001.097867; Metzler B, 2000, AM J PATHOL, V156, P1875, DOI 10.1016/S0002-9440(10)65061-4; MIANO JM, 1990, AM J PATHOL, V137, P761; MIANO JM, 1993, ARTERIOSCLER THROMB, V13, P211, DOI 10.1161/01.ATV.13.2.211; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; Nishio H, 2001, HISTOCHEM J, V33, P167, DOI 10.1023/A:1017952310800; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; Pessah M, 2001, P NATL ACAD SCI USA, V98, P6198, DOI 10.1073/pnas.101579798; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215; Santiago FS, 2001, J BIOL CHEM, V276, P41143, DOI 10.1074/jbc.M104913200; Santiago FS, 1999, AM J PATHOL, V155, P897, DOI 10.1016/S0002-9440(10)65189-9; Santoro SW, 1998, BIOCHEMISTRY-US, V37, P13330, DOI 10.1021/bi9812221; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197; Silverman ES, 1999, AM J PATHOL, V155, P1311, DOI 10.1016/S0002-9440(10)65233-9; SIMONS M, 1994, J CLIN INVEST, V93, P2351, DOI 10.1172/JCI117240; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Wagner EF, 2001, ONCOGENE, V20, P2334, DOI 10.1038/sj.onc.1204416; Wakisaka S, 1998, ANN RHEUM DIS, V57, P487, DOI 10.1136/ard.57.8.487; Wang NP, 2001, ARTERIOSCL THROM VAS, V21, P1414, DOI 10.1161/hq0901.095549; Watson L, 2000, EUR J CLIN INVEST, V30, P11; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	40	94	98	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22985	22991		10.1074/jbc.M200977200	http://dx.doi.org/10.1074/jbc.M200977200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11891228	hybrid			2022-12-25	WOS:000176313600113
J	Toompuu, M; Yasukawa, T; Suzuki, T; Hakkinen, T; Spelbrink, JN; Watanabe, K; Jacobs, HT				Toompuu, M; Yasukawa, T; Suzuki, T; Hakkinen, T; Spelbrink, JN; Watanabe, K; Jacobs, HT			The 7472insC mitochondrial DNA mutation impairs the synthesis and extent of aminoacylation of tRNA(Ser(UCN)) but not its structure or rate of turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICODON WOBBLE NUCLEOTIDE; OSTEOSARCOMA CELL CYBRIDS; TRANSFER-RNA SYNTHETASE; INHERITED HEARING-LOSS; POINT MUTATION; PALMOPLANTAR KERATODERMA; MOLECULAR PHENOTYPE; MODIFICATION DEFECT; MYOCLONUS EPILEPSY; RIBONUCLEIC-ACID	The 7472insC mitochondrial DNA mutation in the tRNA(Scr(UCN)) gene is associated with sensorineural deafness combined, in some patients,,with a wider neurological syndrome. In cultured cybrid cells it causes a 70% decrease in tRNA(Src(UCN)) abundance and mild respiratory impairment, previously suggested to be due to decreased tRNA stability. When mitochondrial transcription was blocked by ethidium bromide treatment, the half-life of the mutant tRNA was not significantly different from that of wild-type tRNA(Ser(UCN)). Over-expression of mitochondrial translational elongation factor EF-Tu also had no effect on the mutant phenotype. However, during recovery from prolonged ethidium bromide treatment, the synthesis of the mutant tRNA(Ser(UCN)) was specifically impaired, without polarity effects on downstream tRNAs of the light strand transcription unit. We infer that the mutation acts posttranscriptionally to decrease tRNA(Ser(UCN)) abundance by affecting its synthesis rather than its stability. The extent of aminoacylation of the mutant tRNA was also decreased by similar to25%. In contrast, the mutation had no detectable effect on tRNA(Ser(UCN)) base modification or structure other than the insertion of an extra guanosine templated by the mutation, which was structurally protected from nuclease digestion like the surrounding nucleotides. These findings indicate a common molecular process underlying sensorineural deafness caused by mitochondrial tRNA(Ser(UCN)) mutations.	Univ Tampere, Inst Med Technol, FIN-33014 Tampere, Finland; Tampere Univ Hosp, FIN-33014 Tampere, Finland; NICPB, EE-12618 Tallinn, Estonia; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Tokyo 1138656, Japan; Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Tokyo 1138656, Japan; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	Tampere University; Tampere University; Tampere University Hospital; National Institute of Chemical Physics & Biophysics (NICPB); University of Tokyo; University of Tokyo; University of Glasgow	Jacobs, HT (corresponding author), Univ Tampere, Inst Med Technol, FIN-33014 Tampere, Finland.	howy.jacobs@uta.fi	Suzuki, Tsutomu/J-1776-2015; Yasukawa, Takehiro/AAP-1335-2020; Jacobs, Howard T/G-2434-2011; Spelbrink, Johannes N/L-4661-2015	Suzuki, Tsutomu/0000-0002-9731-1731; Spelbrink, Johannes N/0000-0002-9756-2602; Jacobs, Howard/0000-0003-1895-6003; Yasukawa, Takehiro/0000-0001-9531-8780				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Asahara H, 1993, NUCL ACIDS S SER, V29, P207; BINDOFF LA, 1993, J BIOL CHEM, V268, P19559; Borner GV, 2000, HUM MOL GENET, V9, P467, DOI 10.1093/hmg/9.4.467; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai YC, 2000, J BIOL CHEM, V275, P20308, DOI 10.1074/jbc.M001899200; CARRARA G, 1989, CELL, V58, P37, DOI 10.1016/0092-8674(89)90400-5; Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199; DiMauro S, 2000, BRAIN PATHOL, V10, P431; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123; El Meziane A, 1998, NAT GENET, V18, P350; El Meziane A, 1998, HUM MOL GENET, V7, P2141, DOI 10.1093/hmg/7.13.2141; ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47; Enriquez JA, 1996, P NATL ACAD SCI USA, V93, P8300, DOI 10.1073/pnas.93.16.8300; Francisci S, 1998, CURR GENET, V33, P110, DOI 10.1007/s002940050315; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; Guan MX, 1998, MOL CELL BIOL, V18, P5868, DOI 10.1128/MCB.18.10.5868; Helm M, 1999, NUCLEIC ACIDS RES, V27, P756, DOI 10.1093/nar/27.3.756; Hutchin TP, 2000, J MED GENET, V37, P692, DOI 10.1136/jmg.37.9.692; Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409; Kaufmann P, 1996, ANN NEUROL, V40, P172, DOI 10.1002/ana.410400208; Kelley SO, 2000, NAT STRUCT BIOL, V7, P862, DOI 10.1038/79612; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KNIGHT E, 1969, BIOCHEMISTRY-US, V8, P5089, DOI 10.1021/bi00840a062; KRUPP JL, 1988, NUCLEIC ACIDS RES, V16, P770, DOI 10.1093/nar/16.2.770; KUCHINO Y, 1987, METHOD ENZYMOL, V155, P379; Levinger L, 2001, NUCLEIC ACIDS RES, V29, P4334, DOI 10.1093/nar/29.21.4334; Lynn S, 1998, DIABETES, V47, P1800, DOI 10.2337/diabetes.47.11.1800; Mansergh FC, 1999, AM J HUM GENET, V64, P971, DOI 10.1086/302344; Martin L, 2000, BRIT J DERMATOL, V143, P876, DOI 10.1046/j.1365-2133.2000.03797.x; MASUCCI JP, 1995, MOL CELL BIOL, V15, P2872; Mohan A, 2000, J MOL BIOL, V303, P605, DOI 10.1006/jmbi.2000.4162; NAKAMURA M, 1995, BIOCHEM BIOPH RES CO, V214, P86, DOI 10.1006/bbrc.1995.2260; Nashimoto M, 1999, J MOL BIOL, V287, P727, DOI 10.1006/jmbi.1999.2639; OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0; Puranam RS, 2001, MOL CELL BIOL, V21, P548, DOI 10.1128/MCB.21.2.548-561.2001; Reid FM, 1997, HUM MOL GENET, V6, P443, DOI 10.1093/hmg/6.3.443; Rinaldi T, 1997, CURR GENET, V31, P494, DOI 10.1007/s002940050235; ROSSMANITH W, 1995, J BIOL CHEM, V270, P12885, DOI 10.1074/jbc.270.21.12885; Rossmanith W, 1998, FEBS LETT, V433, P269, DOI 10.1016/S0014-5793(98)00928-4; Sevior KB, 1998, AM J MED GENET, V75, P179, DOI 10.1002/(SICI)1096-8628(19980113)75:2<179::AID-AJMG11>3.3.CO;2-1; Shah Z H, 2001, Hum Mutat, V17, P433, DOI 10.1002/humu.1123; Shimada N, 2001, J BIOL CHEM, V276, P46770, DOI 10.1074/jbc.M105150200; Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905; TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421; Toompuu M, 1999, HUM MOL GENET, V8, P2275, DOI 10.1093/hmg/8.12.2275; Verhoeven K, 1999, EUR J HUM GENET, V7, P45, DOI 10.1038/sj.ejhg.5200247; WAKITA K, 1994, NUCLEIC ACIDS RES, V22, P347, DOI 10.1093/nar/22.3.347; WELLS J, 1995, FEBS LETT, V358, P119, DOI 10.1016/0014-5793(94)01403-N; WU XQ, 1993, NUCLEIC ACIDS RES, V21, P5589, DOI 10.1093/nar/21.24.5589; Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251; Yasukawa T, 2000, FEBS LETT, V467, P175, DOI 10.1016/S0014-5793(00)01145-5; Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794; YOKAGAWA T, 1991, NUCLEIC ACIDS RES, V19, P6101; ZYLBER E, 1969, J MOL BIOL, V46, P201, DOI 10.1016/0022-2836(69)90067-9	58	42	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22240	22250		10.1074/jbc.M200338200	http://dx.doi.org/10.1074/jbc.M200338200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11919191	hybrid			2022-12-25	WOS:000176313600019
J	Zurovec, M; Sehnal, F				Zurovec, M; Sehnal, F			Unique molecular architecture of silk fibroin in the waxmoth, Galleria mellonella	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBYX-MORI; MESSENGER-RNA; SPIDER SILKS; CODON USAGE; GENE; PROTEIN; IDENTIFICATION; EVOLUTION; SEQUENCE; CHAIN	Proteins of silk fibers are characterized by reiterations of amino acid repeats. Physical properties of the fiber are determined by the amino acid composition, the complexity of repetitive units, and arrangement of these units into higher order arrays. Except for very short motifs of 6-10 residues, the length of repetitive units and the number of these units concatenated in higher order assemblies vary in all spider and lepidopteran silks analyzed so far. This paper describes an exceptional silk protein represented by the 500-kDa heavy chain fibroin (H-fibroin) of the waxmoth, Galleria mellonella. Its non-repetitive N-terminal (175 residues) and C-terminal (60 residues) parts, the overall gene organization, and the nucleotide sequence around the TATA box show that it is homologous to the H-fibroins of other Lepidoptera. However, over 95% of the protein consists of highly ordered repetitive structures that are unmatched in other species. The repetitive region includes 11 assemblies AB(1)AB(1)AB(1)AB(2)(AB(2))AB(2) of remarkably conserved polypeptide repeats A (63 amino acid residues), B-1 (43 residues), and B-2 (18 residues). The repeats contain a high proportion of Gly (31.6%), Ala (23.8%), Ser (18.1%), and of residues with long hydrophobic side chains (16% for Leu, Ile, and Val combined). The presence of the GLGGLG and SSAASAA(AA) motifs suggests formation of pleated beta-sheets and their stacking into crystallites. Conspicuous conservation of the apolar sequence VIVI followed by DD or ED is interpreted as indicating the importance of hydrophobicity and electrostatic charge in H-fibroin cross-linking. The environment of G. mellonella larvae within bee cultures requires continuous production of silk that must be both strong and elastic. The spectacular arrangement of the repetitive H-fibroin region apparently evolved to meet these requirements.	Acad Sci Czech Republ, Inst Entomol, CR-37005 Ceske Budejovice, Czech Republic; Univ S Bohemia, Fac Biol Sci, Ceske Budejovice 37005, Czech Republic	Czech Academy of Sciences; Biology Centre of the Czech Academy of Sciences; Czech Academy of Sciences; University of South Bohemia Ceske Budejovice	Sehnal, F (corresponding author), Acad Sci Czech Republ, Inst Entomol, Branisovska 31, CR-37005 Ceske Budejovice, Czech Republic.	sehnal@entu.cas.cz	Zurovec, Michal/AAE-8185-2021; Zurovec, Michal/H-2562-2014	Zurovec, Michal/0000-0002-0913-166X; Zurovec, Michal/0000-0002-0913-166X				ARMOUR JAL, 1993, GENOME ANAL, V7, P43; Beckwitt R, 1998, INSECT BIOCHEM MOLEC, V28, P121, DOI 10.1016/S0965-1748(97)00083-0; BONNOT G, 1970, Annales de Zoologie Ecologie Animale, V2, P595; CHERBAS L, 1993, INSECT BIOCHEM MOLEC, V23, P81, DOI 10.1016/0965-1748(93)90085-7; Datta A, 2001, INSECT BIOCHEM MOLEC, V31, P1013, DOI 10.1016/S0965-1748(01)00049-2; Denny M.W., 1980, Symposia of the Society for Experimental Biology, P247; DOVER G, 1982, NATURE, V299, P111, DOI 10.1038/299111a0; GAREL JP, 1970, FEBS LETT, V7, P327, DOI 10.1016/0014-5793(70)80196-X; Gatesy J, 2001, SCIENCE, V291, P2603, DOI 10.1126/science.1057561; Gosline JM, 1999, J EXP BIOL, V202, P3295; Hayashi CY, 2000, SCIENCE, V287, P1477, DOI 10.1126/science.287.5457.1477; Hayashi CY, 1998, J MOL BIOL, V275, P773, DOI 10.1006/jmbi.1997.1478; HEPBURN HR, 1979, INSECT BIOCHEM, V9, P69, DOI 10.1016/0020-1790(79)90028-3; Inoue S, 2000, J BIOL CHEM, V275, P40517, DOI 10.1074/jbc.M006897200; KUSUDA J, 1986, MOL GEN GENET, V203, P359, DOI 10.1007/BF00422057; Lucas F., 1968, Comprehensive Biochem, V26, P475; LUCAS F, 1960, J MOL BIOL, V2, P339, DOI 10.1016/S0022-2836(60)80045-9; MANNING RF, 1980, J BIOL CHEM, V255, P9451; MARSH RE, 1955, ACTA CRYSTALLOGR, V8, P710, DOI 10.1107/S0365110X5500217X; MARSH RE, 1955, BIOCHIM BIOPHYS ACTA, V16, P1, DOI 10.1016/0006-3002(55)90178-5; Meeds T, 2001, J MOL EVOL, V53, P180, DOI 10.1007/s002390010208; MICHALIK J, 1984, ACTA BIOCHIM POL, V31, P139; MITA K, 1988, J MOL BIOL, V203, P917, DOI 10.1016/0022-2836(88)90117-9; NAKAMURA T, 1991, FEBS LETT, V289, P123, DOI 10.1016/0014-5793(91)80923-Q; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nirmala X., 2001, EUR J BIOCHEM, V268, P1; OHSHIMA Y, 1977, P NATL ACAD SCI USA, V74, P5363, DOI 10.1073/pnas.74.12.5363; PAULING L, 1953, P NATL ACAD SCI USA, V39, P253, DOI 10.1073/pnas.39.4.253; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; SEHNAL F, 1990, INT J INSECT MORPHOL, V19, P79, DOI 10.1016/0020-7322(90)90022-H; SEHNAL F, 1966, Z WISS ZOOL ABT A, V174, P53; Sezutsu H, 2000, J MOL EVOL, V51, P329, DOI 10.1007/s002390010095; SMITH GP, 1976, SCIENCE, V191, P528, DOI 10.1126/science.1251186; SUZUKI Y, 1972, J MOL BIOL, V63, P409, DOI 10.1016/0022-2836(72)90437-8; TAMURA T, 1987, MOL GEN GENET, V207, P189, DOI 10.1007/BF00331577; TAMURA T, 1989, WILD SILKMOTHS, V88, P67; TANAKA K, 1993, J BIOCHEM-TOKYO, V114, P1; Tanaka K, 1999, BBA-PROTEIN STRUCT M, V1432, P92, DOI 10.1016/S0167-4838(99)00088-6; TANAKA K, 2001, INSECT BIOCHEM MOLEC, V31, P685; TERMONIA Y, 1994, MACROMOLECULES, V27, P7378, DOI 10.1021/ma00103a018; TSUJIMOTO Y, 1979, CELL, V18, P591, DOI 10.1016/0092-8674(79)90075-8; WARWICKER JO, 1960, J MOL BIOL, V2, P350, DOI 10.1016/S0022-2836(60)80046-0; Yang CS, 1998, GENE, V209, P157, DOI 10.1016/S0378-1119(98)00029-8; Zhou CZ, 2000, NUCLEIC ACIDS RES, V28, P2413, DOI 10.1093/nar/28.12.2413; ZHOU CZ, 2001, PROTEIN-STRUCT FUNCT, V448, P119; Zurovec M, 1998, J BIOL CHEM, V273, P15423, DOI 10.1074/jbc.273.25.15423; ZUROVEC M, 1995, MOL GEN GENET, V247, P1, DOI 10.1007/BF00425815; ZUROVEC M, 1992, INSECT BIOCHEM MOLEC, V22, P55, DOI 10.1016/0965-1748(92)90100-S; Zurovec M, 1998, MOL GEN GENET, V257, P264, DOI 10.1007/s004380050647	49	42	47	2	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22639	22647		10.1074/jbc.M201622200	http://dx.doi.org/10.1074/jbc.M201622200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11886872	hybrid			2022-12-25	WOS:000176313600070
J	Liu, T; Krieger, M; Kan, HY; Zannis, VI				Liu, T; Krieger, M; Kan, HY; Zannis, VI			The effects of mutations in helices 4 and 6 of ApoA-I on scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux suggest that formation of a productive complex between reconstituted high density lipoprotein and SR-BI is required for efficient lipid transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; TOCOPHEROL TRANSFER PROTEIN; ONE-STEP PURIFICATION; HDL RECEPTOR; SELECTIVE UPTAKE; TANGIER-DISEASE; PHOSPHOLIPID-COMPOSITION; RECOMBINANT PROTEINS; 6XHIS TAG; BINDING	We have studied the effects of mutations in apoA-I on reconstituted high density lipoprotein (HDL) particle (rHDL(apoA-I)) binding to and cholesterol efflux from wild-type (WT) and mutant forms of the HDL receptor SR-BI expressed by ldlA-7 cells. Mutations in helix 4 or helix 6 of the apoA-I reduced efflux by 79 and 51%, respectively, without substantially altering receptor binding (apparent K-d values of 1.1-4.4 mug of protein/ml). SR-BI with an M158R mutation bound poorly to rHDL with WT and helix 4 mutant apoA-I; the helix 6 mutant restored tight binding to SR-BI(M158R) (Kd values of 48, 60, and 7 mug of protein/ml, respectively). SR-BI(M158R)mediated cholesterol efflux rates, normalized for binding, were high for all three rHDLs (71-111% of control). In contrast, absolute (12-19%) and binding-corrected (24-47%) efflux rates for all three rHDLs mediated by SR-BI with Q402R/Q418R mutations were very low. We propose that formation of a productive complex between apoA-I in rHDL and SR-BI, in which the lipoprotein and the receptor must either be precisely aligned or have the capacity to undergo appropriate conformational changes, is required for efficient SR-BI-mediated cholesterol efflux. Some mutations in apoA-I and/or SR-BI can result in high affinity, but non-productive, binding that does not permit efficient cholesterol efflux.	Boston Univ, Sch Med, Dept Med & Biochem, Whitaker Cardiovasc Inst,Sect Mol Genet, Boston, MA 02118 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Boston University; Massachusetts Institute of Technology (MIT)	Zannis, VI (corresponding author), Boston Univ, Sch Med, Dept Med & Biochem, Whitaker Cardiovasc Inst,Sect Mol Genet, Boston, MA 02118 USA.	vzannis@bu.edu	Eckhardt, Erik/G-1567-2010; Krieger, Marco/AAE-8611-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048739, R01HL052212, P01HL066105] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52212, HL48739, HL66105] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Anderson D., 1995, FOCUS, V17, P53; Arai T, 1999, P NATL ACAD SCI USA, V96, P12050, DOI 10.1073/pnas.96.21.12050; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BRENNER AJ, 1995, ANAL BIOCHEM, V226, P80, DOI 10.1006/abio.1995.1194; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; Crowe J, 1995, MOL BIOTECHNOL, V4, P247, DOI 10.1007/BF02779018; Crowe J, 1996, Methods Mol Biol, V58, P491; de Beer MC, 2001, J BIOL CHEM, V276, P15832, DOI 10.1074/jbc.M100228200; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; Fidge NH, 1999, J LIPID RES, V40, P187; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FIELDING CJ, 1990, ADV CHOLESTEROL RES, P271; FORTE TM, 1993, J LIPID RES, V34, P317; FORTE TM, 1995, J LIPID RES, V36, P148; Goti D, 2001, J NEUROCHEM, V76, P498, DOI 10.1046/j.1471-4159.2001.00100.x; Greene DJ, 2001, J BIOL CHEM, V276, P4804, DOI 10.1074/jbc.M008725200; Gu XJ, 2000, J BIOL CHEM, V275, P9120, DOI 10.1074/jbc.275.13.9120; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; HARA H, 1991, J BIOL CHEM, V266, P3080; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jishage K, 2001, J BIOL CHEM, V276, P1669, DOI 10.1074/jbc.C000676200; KARATHANASIS SK, 1985, BIOCH BIOL PLASMA PR, V2, P475; Kolleck I, 1999, FREE RADICAL BIO MED, V27, P882, DOI 10.1016/S0891-5849(99)00139-2; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; Mardones P, 2002, J NUTR, V132, P443, DOI 10.1093/jn/132.3.443; MATZ CE, 1982, J BIOL CHEM, V257, P4535; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; Phillips JC, 1997, BIOPHYS J, V73, P2337, DOI 10.1016/S0006-3495(97)78264-X; Pilon A, 2000, ARTERIOSCL THROM VAS, V20, P1074, DOI 10.1161/01.ATV.20.4.1074; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rinninger F, 1998, BBA-LIPID LIPID MET, V1393, P277, DOI 10.1016/S0005-2760(98)00082-4; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SEGE RD, 1986, MOL CELL BIOL, V6, P3268, DOI 10.1128/MCB.6.9.3268; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; Segrest JP, 2000, CURR OPIN LIPIDOL, V11, P105, DOI 10.1097/00041433-200004000-00002; SorciThomas MG, 1996, J LIPID RES, V37, P673; SOUTAR AK, 1975, BIOCHEMISTRY-US, V14, P3057, DOI 10.1021/bi00685a003; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; Terasawa Y, 2000, P NATL ACAD SCI USA, V97, P13830, DOI 10.1073/pnas.240462697; Thuahnai ST, 2001, J BIOL CHEM, V276, P43801, DOI 10.1074/jbc.M106695200; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Ueda Y, 2000, J BIOL CHEM, V275, P20368, DOI 10.1074/jbc.M000730200; Urban S, 2000, J BIOL CHEM, V275, P33409, DOI 10.1074/jbc.M004031200; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; Xu SZ, 1997, J LIPID RES, V38, P1289; Yancey PG, 2000, J BIOL CHEM, V275, P36596, DOI 10.1074/jbc.M006924200; ZANNIS VI, 1985, ADV HUM GENET, V14, P125; ZANNIS VI, 1993, ADV HUM GENET, V21, P145	64	83	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21576	21584		10.1074/jbc.M112103200	http://dx.doi.org/10.1074/jbc.M112103200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11882653	hybrid			2022-12-25	WOS:000176286000061
J	Rao, RV; Castro-Obregon, S; Frankowski, H; Schuler, M; Stoka, V; del Rio, G; Bredesen, DE; Ellerby, HM				Rao, RV; Castro-Obregon, S; Frankowski, H; Schuler, M; Stoka, V; del Rio, G; Bredesen, DE; Ellerby, HM			Coupling endoplasmic reticulum stress to the cell death program - An Apaf-1-independent intrinsic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-DEPENDENT ACTIVATION; CYTOCHROME-C; CASPASE ACTIVATION; POLY(ADP-RIBOSE) POLYMERASE; EPITHELIAL-CELLS; APOPTOSIS; PROTEIN; MITOCHONDRIAL; MECHANISM; INDUCTION	Accumulation of misfolded proteins and alterations in Ca2+ homeostasis in the endoplasmic reticulum (ER) causes ER stress and leads to cell death. However, the signal-transducing events that connect ER stress to cell death pathways are incompletely understood. To discern the pathway by which ER stress-induced cell death proceeds, we performed studies on Apaf-1(-/-) (null) fibroblasts that are known to be relatively resistant to apoptotic insults that induce the intrinsic apoptotic pathway. While these cells were resistant to cell death initiated by proapoptotic stimuli such as tamoxifen, they were susceptible to apoptosis induced by thapsigargin and brefeldin-A, both of which induce ER stress. This pathway was inhibited by catalytic mutants of caspase-12 and caspase-9 and by a peptide inhibitor of caspase-9 but not by caspase-8 inhibitors. Cleavage of caspases and poly(ADP-ribose) polymerase was observed in cell-free extracts lacking cytochrome c that were isolated from thapsigargin or brefeldin-treated cells. To define the molecular requirements for this Apaf-1 and cytochrome c-independent apoptosis pathway further, we developed a cell-free system of ER stress-induced apoptosis; the addition of microsomes prepared from ER stress-induced cells to a normal cell extract lacking mitochondria or cytochrome c resulted in processing of caspases. Immunodepletion experiments suggested that caspase-12 was one of the microsomal components required to activate downstream caspases. Thus, ER stress-induced programmed cell death defines a novel, mitochondrial and Apaf-1-independent, intrinsic apoptotic pathway.	Buck Inst Age Res, Novato, CA 94945 USA; Johannes Gutenberg Univ Mainz, Dept Med 3, D-55101 Mainz, Germany	Buck Institute for Research on Aging; Johannes Gutenberg University of Mainz	Bredesen, DE (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	dbredesen@buckinstitute.org; mellerby@buckinstitute.org	Stoka, Veronika/AAM-2283-2021; Castro-Obregon, Susana/AAE-5105-2020	Castro-Obregon, Susana/0000-0003-0549-5690	NCI NIH HHS [R01 CA84262] Funding Source: Medline; NIA NIH HHS [AG12282] Funding Source: Medline; NINDS NIH HHS [NS35155, NS33376] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035155, R01NS033376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bitko V, 2001, J CELL BIOCHEM, V80, P441, DOI 10.1002/1097-4644(20010301)80:3<441::AID-JCB170>3.0.CO;2-C; Brewster JL, 2000, GENESIS, V26, P271, DOI 10.1002/(SICI)1526-968X(200004)26:4<271::AID-GENE90>3.0.CO;2-E; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Burgess DH, 1999, CELL DEATH DIFFER, V6, P256, DOI 10.1038/sj.cdd.4400489; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Finkel E, 2001, SCIENCE, V292, P624, DOI 10.1126/science.292.5517.624; Forcet C, 2001, P NATL ACAD SCI USA, V98, P3416, DOI 10.1073/pnas.051378298; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Hong NA, 2000, DEV BIOL, V220, P76, DOI 10.1006/dbio.2000.9615; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Ozawa K, 1999, J BIOL CHEM, V274, P6397, DOI 10.1074/jbc.274.10.6397; Paschen W, 2001, CELL CALCIUM, V29, P1, DOI 10.1054/ceca.2000.0162; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Song ZW, 1999, TRENDS CELL BIOL, V9, pM49, DOI 10.1016/S0968-0004(99)01485-1; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Tanaka S, 2000, J BIOL CHEM, V275, P10388, DOI 10.1074/jbc.275.14.10388; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	49	404	423	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21836	21842		10.1074/jbc.M202726200	http://dx.doi.org/10.1074/jbc.M202726200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11919205	hybrid			2022-12-25	WOS:000176286000093
J	Bontems, S; Di Valentin, E; Baudoux, L; Rentier, B; Sadzot-Delvaux, C; Piette, J				Bontems, S; Di Valentin, E; Baudoux, L; Rentier, B; Sadzot-Delvaux, C; Piette, J			Phosphorylation of varicella-zoster virus IE63 protein by casein kinases influences its cellular localization and gene regulation activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY PROTEIN; TERMINAL PEST DOMAIN; KAPPA-B-ALPHA; VZV TRANSCRIPTION; HUMAN GANGLIA; NUCLEAR-LOCALIZATION; CDNA LIBRARY; EXPRESSION; LATENCY; ORF47	During the early phase of varicella-zoster virus (VZV) infection, Immediate Early protein 63 (IE63) is expressed rapidly and abundantly in the nucleus, while during latency, this protein is confined mostly to the cytoplasm. Because phosphorylation is known to regulate many cellular events, we investigated the importance of this modification on the cellular localization of IE63 and on its regulatory properties. We demonstrate here that cellular casein kinases I and II are implicated in the in vitro and in vivo phosphorylation of IE63. A mutational approach also indicated that phosphorylation of the protein is important for its correct cellular localization in a cell type-dependent fashion. Using an activity test, we demonstrated that IE63 was able to repress the gene expression driven by two VZV promoters and that phosphorylation of the protein was required for its full repressive properties. Finally, we showed that IE63 was capable of exerting its repressive activity in the cytoplasm, as well as in the nucleus, suggesting a regulation at the transcriptional and/or posttranscriptional level.	Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium	University of Liege	Piette, J (corresponding author), Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium.	jpiette@ulg.ac.be						Advani SJ, 2000, P NATL ACAD SCI USA, V97, P10996, DOI 10.1073/pnas.200375297; BAUDOUX L, 1995, NUCLEIC ACIDS RES, V23, P1341, DOI 10.1093/nar/23.8.1341; Blanquet PR, 2000, PROG NEUROBIOL, V60, P211, DOI 10.1016/S0301-0082(99)00026-X; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Blom N, 1998, NUCLEIC ACIDS RES, V26, P382, DOI 10.1093/nar/26.1.382; Briggs LJ, 2001, BIOCHEM J, V353, P69, DOI 10.1042/bj3530069; CAELLES C, 1995, MOL CELL BIOL, V15, P6694; Calkhoven CF, 1996, BIOCHEM J, V317, P329, DOI 10.1042/bj3170329; Cohrs RJ, 1996, J VIROL, V70, P2789, DOI 10.1128/JVI.70.5.2789-2796.1996; COHRS RJ, 1995, J VIROL, V69, P2674, DOI 10.1128/JVI.69.4.2674-2678.1995; COHRS RJ, 1994, J VIROL, V68, P7900, DOI 10.1128/JVI.68.12.7900-7908.1994; CROEN KD, 1988, P NATL ACAD SCI USA, V85, P9773, DOI 10.1073/pnas.85.24.9773; DEBRUS S, 1995, J VIROL, V69, P3240, DOI 10.1128/JVI.69.5.3240-3245.1995; DEFECHEREUX P, 1993, J VIROL, V67, P4379, DOI 10.1128/JVI.67.7.4379-4385.1993; DEWIND N, 1992, J VIROL, V66, P5200, DOI 10.1128/JVI.66.9.5200-5209.1992; ElHodiri HM, 1997, J BIOL CHEM, V272, P20463, DOI 10.1074/jbc.272.33.20463; Flisser A, 1999, Contrib Microbiol, V3, P76; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; HASHIMOTO N, 1994, FEBS LETT, V352, P236, DOI 10.1016/0014-5793(94)00964-3; HEINEMAN TC, 1995, J VIROL, V69, P7367, DOI 10.1128/JVI.69.11.7367-7370.1995; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; HONESS RW, 1974, J VIROL, V14, P8, DOI 10.1128/JVI.14.1.8-19.1974; INCHAUSPE G, 1989, VIROLOGY, V173, P700, DOI 10.1016/0042-6822(89)90583-7; JACKERS P, 1992, J VIROL, V66, P3899, DOI 10.1128/JVI.66.6.3899-3903.1992; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kennedy PGE, 1999, VIROLOGY, V258, P451, DOI 10.1006/viro.1999.9745; Kennedy PGE, 2001, VIROLOGY, V289, P218, DOI 10.1006/viro.2001.1173; Kenyon TK, 2001, J VIROL, V75, P8854, DOI 10.1128/JVI.75.18.8854-8858.2001; KINCHINGTON PR, 1992, J VIROL, V66, P359, DOI 10.1128/JVI.66.1.359-366.1992; Kinchington PR, 2001, J VIROL, V75, P9106, DOI 10.1128/JVI.75.19.9106-9113.2001; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOST RG, 1995, VIROLOGY, V209, P218, DOI 10.1006/viro.1995.1246; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Lungu O, 1999, Contrib Microbiol, V3, P61; Lungu O, 1998, P NATL ACAD SCI USA, V95, P7080, DOI 10.1073/pnas.95.12.7080; Mahalingam R, 1996, P NATL ACAD SCI USA, V93, P2122, DOI 10.1073/pnas.93.5.2122; MEGGIO F, 1990, EUR J BIOCHEM, V187, P89, DOI 10.1111/j.1432-1033.1990.tb15280.x; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MEIER JL, 1993, VIROLOGY, V193, P193, DOI 10.1006/viro.1993.1115; Moffat JF, 1998, P NATL ACAD SCI USA, V95, P11969, DOI 10.1073/pnas.95.20.11969; MORIUCHI H, 1993, J VIROL, V67, P2739, DOI 10.1128/JVI.67.5.2739-2746.1993; NG TI, 1992, VIROLOGY, V191, P9, DOI 10.1016/0042-6822(92)90161-H; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; OVERTON H, 1994, VIROLOGY, V202, P97, DOI 10.1006/viro.1994.1326; PERERA LP, 1992, J VIROL, V66, P5298, DOI 10.1128/JVI.66.9.5298-5304.1992; PERERA LP, 1992, VIROLOGY, V191, P346, DOI 10.1016/0042-6822(92)90197-W; PURVES FC, 1993, P NATL ACAD SCI USA, V90, P6701, DOI 10.1073/pnas.90.14.6701; Rahaus M, 1999, Contrib Microbiol, V3, P1; Sakanaka C, 2000, RECENT PROG HORM RES, V55, P225; Sanford JR, 2001, P NATL ACAD SCI USA, V98, P10184, DOI 10.1073/pnas.181340498; Schoonbroodt S, 1996, J MED VIROL, V49, P264, DOI 10.1002/(SICI)1096-9071(199608)49:4<264::AID-JMV2>3.0.CO;2-1; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; Sommer MH, 2001, J VIROL, V75, P8224, DOI 10.1128/JVI.75.17.8224-8239.2001; Spengler M, 2001, ARCH VIR S, V17, P71; Stevenson D, 1996, J VIROL, V70, P658, DOI 10.1128/JVI.70.1.658-662.1996; VAFAI A, 1988, P NATL ACAD SCI USA, V85, P2767, DOI 10.1073/pnas.85.8.2767; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737	61	45	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					21050	21060		10.1074/jbc.M111872200	http://dx.doi.org/10.1074/jbc.M111872200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11912195	hybrid, Green Submitted			2022-12-25	WOS:000176204500120
J	Gong, QG; Guo, Q; Tong, KL; Zhu, GA; Wong, JTF; Xue, H				Gong, QG; Guo, Q; Tong, KL; Zhu, GA; Wong, JTF; Xue, H			NMR analysis of bovine tRNA(Trp) - Conformation dependence of Mg2+ binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE TRANSFER-RNA; NUCLEAR-MAGNETIC-RESONANCE; MAGNESIUM-ION BINDING; IMINO PROTON SIGNALS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; TRANSFER RNA(TRP); METAL-BINDING; SYNTHETASE; ASSIGNMENT	NMR was used to study the solution structure of bovine tRNA(TrP) hyperexpressed in Escherichia coli. With the use of N-15 labeling and site-directed mutagenesis to assign overlapping resonances through the base pair replacement of U(71)A(2) by G(2)C(71), U(27)A(43) by G(27)C(43), and G(12)C(23) by U(12)A(23), the resonances of all 26 observable imino protons in the helical regions and in the tertiary interactions were assigned unambiguously by means of two-dimensional nuclear Overhauser effect spectroscopy and heteronuclear single quantum coherence methods. When the discriminator base A(73) and the G(12)C(23) base pair on the D stem, two identity elements on bovine tRNA(Trp) that are important for effective recognition by tryptophanyl-tRNA synthetase, were mutated to the ineffective forms of G(73) and U(12)A(23), respectively, NMR analysis revealed an important conformational change in the U(12)A(23) mutant but not in the G(73) mutant molecule. Thus A(73) appears to be directly recognized by tryptophanyl-tRNA synthetase, and G(12)C(23) represents an important structural determinant. Mg2+ effects on the assigned resonances of imino protons allowed the identification of strong, medium, and weak Mg2+ binding sites in tRNA(Trp). Strong Mg2+ binding modes were associated with the residues G(7), s(4)U(8) (where s(4)U(8) is 4-thiouridine), G(12), and U-12. The observations that G(42) was associated with strong Mg2+ binding in only the U(12)A(23) mutant tRNA(Trp) but not the wild type or G(73) mutant tRNA(Trp) and that the G(7), s(4)U(8), G(24), and G(12) imino protons are associated with a two-site Mg2+ binding mode in wild type and G(73) mutant but only a one-site mode in the U(12)A(21) mutant established the occurrence of conformational change in the U(12)A(21) mutant tRNA(Trp). These observations also established the dependence of Mg2+ binding on tRNA conformation and the usefulness of Mg2+ binding sites as conformational probes. The thermal titration of tRNATrP in the presence and absence of 10 mM Mg2+ indicated that overall tRNA(Trp) structure stability was increased by more than 15 degreesC by the presence of Mg2+.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Xue, H (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.	hxue@ust.hk		Wong, J. Tze-Fei/0000-0001-8539-8537; Xue, Hong/0000-0002-8133-9828				BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRADBURY EM, 1986, NMR LIFE SCI, P93; Colmenarejo G, 1999, J MOL BIOL, V290, P119, DOI 10.1006/jmbi.1999.2867; Gonzalez RL, 1999, J MOL BIOL, V289, P1267, DOI 10.1006/jmbi.1999.2841; Guo Q, 2002, J BIOL CHEM, V277, P14343, DOI 10.1074/jbc.M111745200; HALL KB, 1989, BIOCHEMISTRY-US, V28, P5794, DOI 10.1021/bi00440a014; HARE DR, 1985, BIOCHEMISTRY-US, V24, P4300, DOI 10.1021/bi00337a008; HARE DR, 1982, BIOCHEMISTRY-US, V21, P1835, DOI 10.1021/bi00537a020; Hayashi I, 1997, J BIOCHEM-TOKYO, V121, P1115, DOI 10.1093/oxfordjournals.jbchem.a021703; Hayashi I, 1998, J MOL BIOL, V284, P57, DOI 10.1006/jmbi.1998.2151; HYDE EI, 1986, EUR J BIOCHEM, V155, P57, DOI 10.1111/j.1432-1033.1986.tb09458.x; HYDE EI, 1985, BIOCHEMISTRY-US, V24, P4307, DOI 10.1021/bi00337a009; JACK A, 1977, J MOL BIOL, V111, P315, DOI 10.1016/S0022-2836(77)80054-5; Jovine L, 2000, J MOL BIOL, V301, P401, DOI 10.1006/jmbi.2000.3950; KEARNS DR, 1971, J MOL BIOL, V61, P265, DOI 10.1016/0022-2836(71)90224-5; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; Maderia M, 2000, BIOCHEMISTRY-US, V39, P12113, DOI 10.1021/bi001249w; Misra VK, 2000, J MOL BIOL, V299, P813, DOI 10.1006/jmbi.2000.3769; MOORE PB, 1995, ACCOUNTS CHEM RES, V28, P251, DOI 10.1021/ar00054a002; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; NIIMI T, 1993, BIOCHIMIE, V75, P1109, DOI 10.1016/0300-9084(93)90010-P; QUIGLEY GJ, 1978, P NATL ACAD SCI USA, V75, P64, DOI 10.1073/pnas.75.1.64; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; Roberts G. C. K., 1993, NMR MACROMOLECULES P, P217; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROY S, 1982, BIOCHEMISTRY-US, V21, P6081, DOI 10.1021/bi00267a009; Rudisser S, 2000, J MOL BIOL, V295, P1211, DOI 10.1006/jmbi.1999.3421; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SCHIMMEL PR, 1980, ANNU REV BIOPHYS BIO, V9, P181, DOI 10.1146/annurev.bb.09.060180.001145; WALLIS NG, 1995, BIOCHEMISTRY-US, V34, P7668, DOI 10.1021/bi00023a013; WESTHOF E, 1986, BIOCHEMISTRY-US, V25, P4868, DOI 10.1021/bi00365a022; XUE H, 1993, J CHROMATOGR-BIOMED, V613, P247, DOI 10.1016/0378-4347(93)80139-U; XUE H, 1993, J BIOL CHEM, V268, P9316; Yan XZ, 2000, J BIOL CHEM, V275, P6712, DOI 10.1074/jbc.275.10.6712; YUE DX, 1994, BIOCHEMISTRY-US, V33, P8905, DOI 10.1021/bi00196a007	36	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20694	20701		10.1074/jbc.M202299200	http://dx.doi.org/10.1074/jbc.M202299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11919203	hybrid			2022-12-25	WOS:000176204500077
J	Akgoz, M; Azpiazu, I; Kalyanaraman, V; Gautam, N				Akgoz, M; Azpiazu, I; Kalyanaraman, V; Gautam, N			Role of the G protein gamma subunit in beta gamma complex modulation of phospholipase C beta function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; CRYSTAL-STRUCTURE; ACTIVATION; INTERACTS; ADENYLYL-CYCLASE-2; STIMULATION; RESOLUTION; EFFECTORS; REGULATOR; PHOSDUCIN	The G protein betagamma complex regulates a wide range of effectors, including the phospholipase C isozymes (PLCbetas). Different domains on the beta subunit are known to contact phospholipase Cbeta and affect its regulation. In contrast, the role of the gamma subunit in Gbetagamma modulation of PLCbeta function is not known. Results here show that the gamma subunit C-terminal domain is involved in mediating Gbetagamma interactions with phospholipase Cbeta. Mutations were introduced to alter the position of the post-translational prenyl modification at the C terminus of the gamma subunit with reference to the beta subunit. These mutants were appropriately post-translationally modified with the geranylgeranyl moiety. A deletion that shortened the C-terminal domain, insertions that extended this domain, and a point mutation, F59A, that disrupted the interaction of this domain with the beta subunit were all affected in their ability to activate PLCbeta to varying degrees. All mutants, however, interacted equally effectively with the G(o)alpha subunit. The results indicate that the G protein gamma subunit plays a direct role in the modulation of effector function by the betagamma complex.	Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Gautam, N (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, Box 8054, St Louis, MO 63110 USA.	gautam@morpheus.wustl.edu	Akgoz, Muslum/A-6234-2015; Akgoz, Muslum/AAG-4598-2019	Akgoz, Muslum/0000-0001-5065-8087; Akgoz, Muslum/0000-0001-5065-8087	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046963] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046963, GM46963] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azpiazu I, 2001, J BIOL CHEM, V276, P41742, DOI 10.1074/jbc.M104034200; Buck E, 2001, J BIOL CHEM, V276, P36014, DOI 10.1074/jbc.M103228200; CASEY PJ, 1991, METHOD ENZYMOL, V195, P315; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Dietrich A, 1996, BIOCHEMISTRY-US, V35, P15174, DOI 10.1021/bi960305j; Fogg VC, 2001, J BIOL CHEM, V276, P41797, DOI 10.1074/jbc.M107661200; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LINDER ME, 1995, METHOD ENZYMOL, V250, P314; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; Myung CS, 2000, P NATL ACAD SCI USA, V97, P9311, DOI 10.1073/pnas.97.16.9311; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; PRONIN AN, 1994, METHOD ENZYMOL, V237, P482; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Romoser V, 1996, J BIOL CHEM, V271, P25071, DOI 10.1074/jbc.271.41.25071; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Weng GZ, 1996, J BIOL CHEM, V271, P26445, DOI 10.1074/jbc.271.43.26445; Yan K, 1997, J BIOL CHEM, V272, P2056; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597; YI F, 1991, J BIOL CHEM, V266, P3900; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhang SY, 1996, J BIOL CHEM, V271, P20208, DOI 10.1074/jbc.271.33.20208	31	29	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19573	19578		10.1074/jbc.M201546200	http://dx.doi.org/10.1074/jbc.M201546200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11914377	hybrid			2022-12-25	WOS:000175894800045
J	Boucher, N; Wu, Y; Dumas, C; Dube, M; Sereno, D; Breton, M; Papadopoulou, B				Boucher, N; Wu, Y; Dumas, C; Dube, M; Sereno, D; Breton, M; Papadopoulou, B			A common mechanism of stage-regulated gene expression in Leishmania mediated by a conserved 3 '-untranslated region element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEINASE GENES; PROCYCLIN MESSENGER-RNAS; 3' UNTRANSLATED REGION; TRYPANOSOMA-BRUCEI; TRANSLATIONAL REGULATION; DEVELOPMENTAL REGULATION; DIFFERENTIAL EXPRESSION; CAENORHABDITIS-ELEGANS; DONOVANI AMASTIGOTES; AXENIC AMASTIGOTES	Developmental regulation of mRNA levels in trypanosomatid protozoa is determined post-transcriptionally and often involves sequences located in the 3'-untranslated regions (3'-UTR) of the mRNAs. We have previously identified a developmentally regulated gene family in Leishmania encoding the amastin surface proteins and showed that stage-specific accumulation of the amastin mRNA is mediated by sequences within the 3'-UTR. Here we identified a 450-nt region within the amastin 3'-UTR that can confer amastigote-specific gene expression by a novel mechanism that increases mRNA translation without an increase in mRNA stability. Remarkably, this 450-nt 3'-UTR element is highly conserved among a large number of Leishmania mRNAs in several Leishmania species. Here we show that several of these mRNAs are differentially expressed in the intracellular amastigote stage of the parasite and that the 450-nt conserved element in their 3'-UTRs is responsible for stage-specific gene regulation. We propose that the 450-nt conserved element, which is unlike any other regulatory element identified thus far, is part of a common mechanism of stage-regulated gene expression in Leishmania that regulates mRNA translation in response to intracellular stresses.	CHU Laval, Ctr Rech Infectiol, Ctr Rech, Laval, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Biol Med, Laval, PQ G1V 4G2, Canada	Laval University; Laval University	Papadopoulou, B (corresponding author), CHU Laval, Ctr Rech Infectiol, Ctr Rech, Laval, PQ G1V 4G2, Canada.		denis, Sereno/I-7242-2019	denis, Sereno/0000-0002-0034-9291				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; ALY R, 1994, NUCLEIC ACIDS RES, V22, P2922, DOI 10.1093/nar/22.15.2922; ARGAMAN M, 1994, MOL BIOCHEM PARASIT, V64, P95, DOI 10.1016/0166-6851(94)90138-4; ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; Beetham JK, 1997, J BIOL CHEM, V272, P17360, DOI 10.1074/jbc.272.28.17360; BERBEROF M, 1995, EMBO J, V14, P2925, DOI 10.1002/j.1460-2075.1995.tb07292.x; Bergsten SE, 1999, DEVELOPMENT, V126, P659; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BRODIN TN, 1992, MOL BIOCHEM PARASIT, V52, P241, DOI 10.1016/0166-6851(92)90056-P; Brooks DR, 2001, J BIOL CHEM, V276, P47061, DOI 10.1074/jbc.M108498200; Burchmore RJS, 1998, J BIOL CHEM, V273, P29118, DOI 10.1074/jbc.273.44.29118; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; CHAREST H, 1994, MOL CELL BIOL, V14, P2975, DOI 10.1128/MCB.14.5.2975; Coughlin BC, 2000, J BIOL CHEM, V275, P12051, DOI 10.1074/jbc.275.16.12051; Coulson RMR, 1996, MOL BIOCHEM PARASIT, V82, P227, DOI 10.1016/0166-6851(96)02739-9; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; de Moor CH, 2001, INT REV CYTOL, V203, P567; Denison SH, 2000, FUNGAL GENET BIOL, V29, P61, DOI 10.1006/fgbi.2000.1188; Di Noia JM, 2000, J BIOL CHEM, V275, P10218, DOI 10.1074/jbc.275.14.10218; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; Dyall SD, 2000, MOL BIOCHEM PARASIT, V109, P73, DOI 10.1016/S0166-6851(00)00235-8; ELFAKHRY Y, 2002, IN PRESS PROTEOMICS, V9; FLINN HM, 1992, NUCLEIC ACIDS RES, V20, P755, DOI 10.1093/nar/20.4.755; Foster JW, 1999, CURR OPIN MICROBIOL, V2, P170, DOI 10.1016/S1369-5274(99)80030-7; Furger A, 1997, MOL CELL BIOL, V17, P4372, DOI 10.1128/MCB.17.8.4372; Garlapati S, 1999, MOL BIOCHEM PARASIT, V100, P95, DOI 10.1016/S0166-6851(99)00037-7; Ghosh M, 2000, MOL BIOCHEM PARASIT, V108, P93, DOI 10.1016/S0166-6851(00)00208-5; GLASER TA, 1991, MOL BIOCHEM PARASIT, V45, P337, DOI 10.1016/0166-6851(91)90102-C; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Gunkel N, 1998, GENE DEV, V12, P1652, DOI 10.1101/gad.12.11.1652; HEHL A, 1994, P NATL ACAD SCI USA, V91, P370, DOI 10.1073/pnas.91.1.370; Hotz HR, 1997, NUCLEIC ACIDS RES, V25, P3017, DOI 10.1093/nar/25.15.3017; Hubel A, 1997, MOL CELL BIOL, V17, P5987; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Krobitsch S, 1998, J BIOL CHEM, V273, P6488, DOI 10.1074/jbc.273.11.6488; Lamontagne J, 1999, J BIOL CHEM, V274, P6602, DOI 10.1074/jbc.274.10.6602; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; Lipshitz HD, 2000, CURR OPIN GENET DEV, V10, P476, DOI 10.1016/S0959-437X(00)00116-7; Liu KY, 2000, PARASITOL RES, V86, P140, DOI 10.1007/s004360050023; Macdonald P, 2001, CURR OPIN CELL BIOL, V13, P326, DOI 10.1016/S0955-0674(00)00215-5; MACFARLANE J, 1990, EUR J BIOCHEM, V190, P377, DOI 10.1111/j.1432-1033.1990.tb15586.x; MATTHEWS KR, 1994, GENE DEV, V8, P491, DOI 10.1101/gad.8.4.491; McKean PG, 1997, MOL BIOCHEM PARASIT, V85, P221, DOI 10.1016/S0166-6851(97)02829-6; MEADE JC, 1989, MOL BIOCHEM PARASIT, V33, P81, DOI 10.1016/0166-6851(89)90045-5; Mottram JC, 1997, J BIOL CHEM, V272, P14285, DOI 10.1074/jbc.272.22.14285; Muyombwe A, 1998, J INFECT DIS, V177, P188, DOI 10.1086/513821; Myler PJ, 1999, P NATL ACAD SCI USA, V96, P2902, DOI 10.1073/pnas.96.6.2902; Noll TM, 1997, MOL BIOCHEM PARASIT, V84, P215, DOI 10.1016/S0166-6851(96)02801-0; Nourbakhsh F, 1996, MOL BIOCHEM PARASIT, V76, P201, DOI 10.1016/0166-6851(95)02559-6; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; PAPADOPOULOU B, 1994, MOL BIOCHEM PARASIT, V65, P39, DOI 10.1016/0166-6851(94)90113-9; Papadopoulou B, 1996, BIOCHEM BIOPH RES CO, V224, P772, DOI 10.1006/bbrc.1996.1098; Quijada L, 1997, J BIOL CHEM, V272, P4493, DOI 10.1074/jbc.272.7.4493; Quijada L, 2000, MOL BIOCHEM PARASIT, V110, P79, DOI 10.1016/S0166-6851(00)00258-9; RAMAMOORTHY R, 1995, J BIOL CHEM, V270, P12133, DOI 10.1074/jbc.270.20.12133; Richter JD, 2001, SCIENCE, V293, P60, DOI 10.1126/science.1062237; Richter JD, 1999, MICROBIOL MOL BIOL R, V63, P446, DOI 10.1128/MMBR.63.2.446-456.1999; Roy G, 2000, MOL BIOCHEM PARASIT, V110, P195, DOI 10.1016/S0166-6851(00)00270-X; Sambrook J., 2002, MOL CLONING LAB MANU; SCHURCH N, 1994, MOL CELL BIOL, V14, P3668, DOI 10.1128/MCB.14.6.3668; Sereno D, 1997, ANTIMICROB AGENTS CH, V41, P972, DOI 10.1128/AAC.41.5.972; Sereno D, 2001, ANTIMICROB AGENTS CH, V45, P1168, DOI 10.1128/AAC.45.4.1168-1173.2001; SOUZA AE, 1992, FEBS LETT, V311, P124, DOI 10.1016/0014-5793(92)81382-V; Tamar S, 2000, MOL BIOCHEM PARASIT, V111, P401, DOI 10.1016/S0166-6851(00)00337-6; TEIXEIRA SMR, 1994, J BIOL CHEM, V269, P20509; Thompson JF, 1997, J BIOL CHEM, V272, P18766, DOI 10.1074/jbc.272.30.18766; Thompson SR, 2000, MOL CELL BIOL, V20, P2129, DOI 10.1128/MCB.20.6.2129-2137.2000; TRAUBCSEKO YM, 1993, MOL BIOCHEM PARASIT, V57, P101, DOI 10.1016/0166-6851(93)90248-V; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; Uliana SRB, 1999, EXP PARASITOL, V92, P183, DOI 10.1006/expr.1999.4410; VASSELLA E, 1994, NUCLEIC ACIDS RES, V22, P1359, DOI 10.1093/nar/22.8.1359; Viviani V, 2001, BIOCHEM BIOPH RES CO, V280, P1286, DOI 10.1006/bbrc.2001.4254; Wreden C, 1997, DEVELOPMENT, V124, P3015; Wu Y, 2000, MOL BIOCHEM PARASIT, V110, P345, DOI 10.1016/S0166-6851(00)00290-5; Zhang WW, 2001, MOL MICROBIOL, V39, P935, DOI 10.1046/j.1365-2958.2001.02286.x; ZILBERSTEIN D, 1994, ANNU REV MICROBIOL, V48, P449, DOI 10.1146/annurev.mi.48.100194.002313; Zilka A, 2001, J BIOL CHEM, V276, P47922, DOI 10.1074/jbc.M108271200	78	112	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19511	19520		10.1074/jbc.M200500200	http://dx.doi.org/10.1074/jbc.M200500200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11912202	hybrid			2022-12-25	WOS:000175894800038
J	Brown, KD; Hostager, BS; Bishop, GA				Brown, KD; Hostager, BS; Bishop, GA			Regulation of TRAF2 signaling by self-induced degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-RECEPTOR; KAPPA-B ACTIVATION; LATENT MEMBRANE-PROTEIN-1; EFFECTOR FUNCTIONS; CD40; UBIQUITIN; LYMPHOCYTES; FAMILY; LIGAND; DOMAIN	Receptors belonging to the tumor necrosis factor receptor (TNF-R) family utilize cytoplasmic adapter proteins called TNF-R-associated factors (TRAFs) as key elements in their signaling pathways. However, it is not yet clear how individual TRAFs regulate signaling by this large and growing receptor family. Signaling via the TNF-R family member CD40 has recently been shown to result in recruitment of TRAF2 to plasma membrane detergent-resistant microdomains (lipid rafts) as well as to subsequently initiate TRAF2 degradation. As TRAF2 associates with most members of the TNF-R family, we wished to determine how this degradation occurs. We show here that CD40-mediated TRAF2 degradation requires the zinc-binding RING domain of TRAF2 and is preceded by TRAF2 ubiquitination, suggesting that the TRAF2 RING may promote ubiquitination although the RING itself is not a target of ubiquitination. Several approaches show that ubiquitination and proteasomal activity are integral to TRAF2 degradation, and inhibition of this process potentiates CD40 signaling.	Univ Iowa, Dept Microbiol, Coll Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Med Scientist Training Program, Grad Program Immunol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Bishop, GA (corresponding author), Univ Iowa, Dept Microbiol, Coll Med, 3-570 Bowen Sci Bldg, Iowa City, IA 52242 USA.			Bishop, Gail/0000-0002-1291-5078	NATIONAL CANCER INSTITUTE [P01CA066570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028847, R56AI028847, R29AI028847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NCI NIH HHS [CA66570] Funding Source: Medline; NIAID NIH HHS [AI28847] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Baccam M, 1999, EUR J IMMUNOL, V29, P3855, DOI 10.1002/(SICI)1521-4141(199912)29:12<3855::AID-IMMU3855>3.0.CO;2-S; Baker SJ, 1996, ONCOGENE, V12, P1; BISHOP GA, 1995, EUR J IMMUNOL, V25, P1230, DOI 10.1002/eji.1830250515; Bishop GA, 2001, IMMUNOL RES, V24, P97, DOI 10.1385/IR:24:2:097; Bishop GA, 2001, ARCH IMMUNOL THER EX, V49, P129; Brown KD, 2001, J EXP MED, V193, P943, DOI 10.1084/jem.193.8.943; Busch LK, 1999, J IMMUNOL, V162, P2555; Busch LK, 2001, J IMMUNOL, V167, P5805, DOI 10.4049/jimmunol.167.10.5805; Chan FKM, 2000, EUR J IMMUNOL, V30, P652; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; Dunn IF, 1999, MOL IMMUNOL, V36, P611, DOI 10.1016/S0161-5890(99)00075-9; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; HAMANO T, 1982, J IMMUNOL, V129, P1403; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hostager BS, 1999, J IMMUNOL, V162, P6307; Hostager BS, 1996, J IMMUNOL, V157, P1047; Hostager BS, 2000, J BIOL CHEM, V275, P15392, DOI 10.1074/jbc.M909520199; Hsing Y, 1999, J IMMUNOL, V162, P2804; Hsing Y, 1997, J IMMUNOL, V159, P4898; Jalukar SV, 2000, J IMMUNOL, V164, P623, DOI 10.4049/jimmunol.164.2.623; KULKA RG, 1988, J BIOL CHEM, V263, P15726; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; LEE SY, 1997, IMMUNITY, V7, P701; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LONG EO, 1991, HUM IMMUNOL, V31, P229, DOI 10.1016/0198-8859(91)90092-N; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lotz M, 1996, J LEUKOCYTE BIOL, V60, P1; Oda H, 1999, P NATL ACAD SCI USA, V96, P9557, DOI 10.1073/pnas.96.17.9557; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	38	84	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19433	19438		10.1074/jbc.M111522200	http://dx.doi.org/10.1074/jbc.M111522200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11909853	hybrid			2022-12-25	WOS:000175894800027
J	Legendre-Guillemin, V; Metzler, M; Charbonneau, M; Gan, L; Chopra, V; Philie, J; Hayden, MR; McPherson, PS				Legendre-Guillemin, V; Metzler, M; Charbonneau, M; Gan, L; Chopra, V; Philie, J; Hayden, MR; McPherson, PS			HIP1 and HIP12 display differential binding to F-actin, AP2, and clathrin - Identification of a novel interaction with clathrin light chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLES; TERMINAL DOMAIN; PROTEIN HIP1R; HUNTINGTIN; ENDOCYTOSIS; FAMILY; AP-2; LOCALIZATION; CYTOSKELETON; APPENDAGE	Huntingtin-interacting protein 1 (HIP1) and HIP12 are orthologues of Sla2p, a yeast protein with essential functions in endocytosis and regulation of the actin cytoskeleton. We now report that HIP1 and HIP12 are major components of the clathrin coat that interact but differ in their ability to bind clathrin and the clathrin adaptor AP2. HIP1 contains a clathrin-box and AP2 consensus-binding sites that display high affinity binding to the terminal domain of the clathrin heavy chain and the ear domain of the AP2 alpha subunit, respectively. These consensus sites are poorly conserved in HIP12 and correspondingly, HIP12 does not bind to AP2 nor does it demonstrate high affinity clathrin binding. Moreover, HIP12 co-sediments with F-actin in contrast to HIP1, which exhibits no interaction with actin in vitro. Despite these differences, both proteins efficiently stimulate clathrin assembly through their central helical domain. Interestingly, in both HIP1 and HIP12, this domain binds directly to the clathrin light chain. Our data suggest that HIP1 and HIP12 play related yet distinct functional roles in clathrin-mediated endocytosis.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Univ British Columbia, Dept Med Genet, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada	McGill University; University of British Columbia	McPherson, PS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Rue Univ, Montreal, PQ H3A 2B4, Canada.	peter.mcpherson@mcgil.ca	Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; Bennett EM, 2001, TRAFFIC, V2, P851, DOI 10.1034/j.1600-0854.2001.21114.x; Chopra VS, 2000, MAMM GENOME, V11, P1006, DOI 10.1007/s003350010195; De Camilli P, 2002, FEBS LETT, V513, P11, DOI 10.1016/S0014-5793(01)03306-3; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Drake MT, 2001, J BIOL CHEM, V276, P28700, DOI 10.1074/jbc.M104226200; Engqvist-Goldstein AEY, 2001, J CELL BIOL, V154, P1209, DOI 10.1083/jcb.200106089; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; Kay BK, 1999, PROTEIN SCI, V8, P435; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Kelly MA, 2001, MOL BIOL CELL, V12, p156A; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; Metzler M, 2001, J BIOL CHEM, V276, P39271, DOI 10.1074/jbc.C100401200; Micheva KD, 2001, J CELL BIOL, V154, P355, DOI 10.1083/jcb.200102098; Mishra SK, 2001, J BIOL CHEM, V276, P46230, DOI 10.1074/jbc.M108177200; Morgan JR, 1999, J NEUROSCI, V19, P10201; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Seki N, 1998, J HUM GENET, V43, P268, DOI 10.1007/s100380050087; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; Slepnev VI, 2000, J BIOL CHEM, V275, P17583, DOI 10.1074/jbc.M910430199; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Teo M, 2001, J BIOL CHEM, V276, P18392, DOI 10.1074/jbc.M008795200; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Tukamoto T, 1997, MOL BRAIN RES, V51, P8, DOI 10.1016/S0169-328X(97)00205-2; Velier J, 1998, EXP NEUROL, V152, P34, DOI 10.1006/exnr.1998.6832; Waelter S, 2001, HUM MOL GENET, V10, P1807, DOI 10.1093/hmg/10.17.1807; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Yang S, 1999, MOL BIOL CELL, V10, P2265, DOI 10.1091/mbc.10.7.2265; Yang WN, 2001, J BIOL CHEM, V276, P17468, DOI 10.1074/jbc.M010893200; Ybe JA, 1998, EMBO J, V17, P1297, DOI 10.1093/emboj/17.5.1297	48	81	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19897	19904		10.1074/jbc.M112310200	http://dx.doi.org/10.1074/jbc.M112310200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11889126	Green Accepted, hybrid			2022-12-25	WOS:000175894800087
J	Nunn, CM; Djordjevic, S; Hillas, PJ; Nishida, CR; de Montellano, PRO				Nunn, CM; Djordjevic, S; Hillas, PJ; Nishida, CR; de Montellano, PRO			The crystal structure of Mycobacterium tuberculosis alkylhydroperoxidase AhpD, a potential target for antibubercular drug design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISONIAZID RESISTANCE; OXIDATIVE-STRESS; SELENOMETHIONYL PROTEINS; ANTIOXIDANT DEFENSE; CATALASE PEROXIDASE; GENE; PEROXIREDOXIN; SENSITIVITY; EXPRESSION; MUTANT	The resistance of Mycobacterium tuberculosis to isoniazid is commonly linked to inactivation of a catalase-peroxidase, KatG, that converts isoniazid to its biologically active form. Loss of KatG is associated with elevated expression of the alkylhydroperoxidases AhpC and AhpD. AhpD has no sequence identity with AhpC or other proteins but has alkylhydroperoxidase activity and possibly additional physiological activities. The alkylhydroperoxidase activity, in the absence of KatG, provides an important antioxidant defense. We have determined the M. tuberculosis AhpD structure to a resolution of 1.9 Angstrom. The protein is a trimer in a symmetrical cloverleaf arrangement. Each subunit exhibits a new all-helical protein fold in which the two catalytic sulfhydryl groups, Cys-130 and Cys-133, are located near a central cavity in the trimer. The structure supports a mechanism for the alkylhydroperoxidase activity in which Cys-133 is deprotonated by a distant glutamic acid via the relay action of His-137 and a water molecule. The cysteine then reacts with the peroxide to give a sulfenic acid that subsequently forms a disulfide bond with Cys-130. The crystal structure of AhpD identifies a new protein fold relevant to members of this protein family in other organisms. The structural details constitute a potential platform for the design of inhibitors of potential utility as antitubercular agents and suggest that AhpD may have disulfide exchange properties of importance in other areas of M. tuberculosis biology.	Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of London; University College London	Djordjevic, S (corresponding author), Univ Calif San Francisco, Sch Pharm, S-926, San Francisco, CA 94143 USA.	snezana@biochemistry.ucl.ac.uk; ortiz@cgl.ucsf.edu			NIGMS NIH HHS [GM56531] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM056531] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Chen JW, 2000, J BIOL CHEM, V275, P28421, DOI 10.1074/jbc.M005073200; Cole ST, 1998, NATURE, V396, P190, DOI 10.1038/24206; Declercq JP, 2001, J MOL BIOL, V311, P751, DOI 10.1006/jmbi.2001.4853; DelVecchio VG, 2002, P NATL ACAD SCI USA, V99, P443, DOI 10.1073/pnas.221575398; DERETIC V, 1995, MOL MICROBIOL, V17, P889, DOI 10.1111/j.1365-2958.1995.mmi_17050889.x; Dhandayuthapani S, 1996, J BACTERIOL, V178, P3641, DOI 10.1128/jb.178.12.3641-3649.1996; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Hillas PJ, 2000, J BIOL CHEM, V275, P18801, DOI 10.1074/jbc.M001001200; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keshavjee S, 2000, JAMA-J AM MED ASSOC, V283, P1201, DOI 10.1001/jama.283.9.1201; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li ZM, 1998, J INFECT DIS, V177, P1030, DOI 10.1086/515254; Manca C, 1999, INFECT IMMUN, V67, P74, DOI 10.1128/IAI.67.1.74-79.1999; Menchise V, 2001, BIOCHEM J, V359, P65, DOI 10.1042/0264-6021:3590065; MITCHISON DA, 1963, J PATHOL BACTERIOL, V86, P377, DOI 10.1002/path.1700860213; MORSE WC, 1954, AM REV TUBERC PULM, V69, P464; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; Pearl FMG, 2001, NUCLEIC ACIDS RES, V29, P223, DOI 10.1093/nar/29.1.223; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Redenbach M, 1996, MOL MICROBIOL, V21, P77, DOI 10.1046/j.1365-2958.1996.6191336.x; ROUSEL A, 2000, TURBO MANUAL AFMB IF; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; Schroder E, 1998, PROTEIN SCI, V7, P2465, DOI 10.1002/pro.5560071125; Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498; SHERMAN DR, 1995, P NATL ACAD SCI USA, V92, P6625, DOI 10.1073/pnas.92.14.6625; Sherman DR, 1996, SCIENCE, V272, P1641, DOI 10.1126/science.272.5268.1641; Slayden RA, 2000, MICROBES INFECT, V2, P659, DOI 10.1016/S1286-4579(00)00359-2; Tame JRH, 2002, BIOCHEMISTRY-US, V41, P2982, DOI 10.1021/bi015717t; Wengenack NL, 2001, BIOCHEMISTRY-US, V40, P8990, DOI 10.1021/bi002614m; Wilson TM, 1996, MOL MICROBIOL, V19, P1025, DOI 10.1046/j.1365-2958.1996.449980.x; WILSON TM, 1995, MOL MICROBIOL, V15, P1009, DOI 10.1111/j.1365-2958.1995.tb02276.x; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833; Zhang Y, 1996, P NATL ACAD SCI USA, V93, P13212, DOI 10.1073/pnas.93.23.13212; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	48	36	41	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					20033	20040		10.1074/jbc.M200864200	http://dx.doi.org/10.1074/jbc.M200864200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11914371	hybrid			2022-12-25	WOS:000175894800104
J	Smirnova, JB; McFarlane, RJ				Smirnova, JB; McFarlane, RJ			The unique centromeric chromatin structure of Schizosaccharomyces pombe is maintained during meiosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTIONAL CHROMOSOME SEGREGATION; FISSION YEAST; FUNCTIONAL-ANALYSIS; DNA; PROTEIN; RECOMBINATION; MIS6; COMPLEXES; DOMAINS; NUMBER	In meiosis I sister centromeres are unified in their polarity on the spindle, and this unique behavior is known to require the function of meiosis-specific factors that set some intrinsic property of the centromeres. The fission yeast, Schizosaccharomyces pombe, possesses complex centromeres consisting of repetitive DNA elements, making it an excellent model in which to study the behavior of complex centromeres. In mitosis, during which sister centromeres mediate chromosome segregation by establishing bipolar chromosome attachments to the spindle, the central core of the S. pombe centromere chromatin has a unique irregular nucleosome pattern. Deletion of repeats flanking this core structure have no effect on mitotic chromosome segregation, but have profound effects during meiosis. While this demonstrates that the outer repeats are critical for normal meiotic sister centromere behavior, exactly how they function and how monopolarity is established remains unclear. In this study we provide the first analysis of the chromatin structure of a complex centromere during meiosis. We show that the nature and extent of the unique central core chromatin structure is maintained with no measurable expansion. This demonstrates that monopolarity of sister centromeres, and subsequent reversion to bipolarity, does not involve a global change to the centromeric chromatin structure.	Univ Wales, Sch Biol Sci, Mol & Cell Biol Grp, Bangor LL57 2UW, Gwynedd, Wales	Bangor University	McFarlane, RJ (corresponding author), Univ Wales, Sch Biol Sci, Mol & Cell Biol Grp, Mem Bldg,Deiniol Rd, Bangor LL57 2UW, Gwynedd, Wales.	ramsay@sbs.bangor.ac.uk		McFarlane, Ramsay/0000-0002-3139-3092				ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; Bernard P, 2001, NAT CELL BIOL, V3, P522, DOI 10.1038/35074598; Cervantes MD, 2000, MOL CELL, V5, P883, DOI 10.1016/S1097-2765(00)80328-7; Choo KHA, 2000, TRENDS CELL BIOL, V10, P182, DOI 10.1016/S0962-8924(00)01739-6; Choo KHA, 2001, DEV CELL, V1, P165, DOI 10.1016/S1534-5807(01)00028-4; Clarke L, 1998, CURR OPIN GENET DEV, V8, P212, DOI 10.1016/S0959-437X(98)80143-3; CLARKE L, 1990, MOL CELL BIOL, V10, P1863, DOI 10.1128/MCB.10.5.1863; CLARKE L, 1993, COLD SPRING HARB SYM, V58, P687, DOI 10.1101/SQB.1993.058.01.076; Donze D, 2001, EMBO J, V20, P520, DOI 10.1093/emboj/20.3.520; FISHEL B, 1988, MOL CELL BIOL, V8, P754, DOI 10.1128/MCB.8.2.754; Gilbert N, 2001, P NATL ACAD SCI USA, V98, P11949, DOI 10.1073/pnas.211322798; Goshima G, 1999, GENE DEV, V13, P1664, DOI 10.1101/gad.13.13.1664; HAHNENBERGER KM, 1991, MOL CELL BIOL, V11, P2206, DOI 10.1128/MCB.11.4.2206; Henikoff S, 2001, SCIENCE, V293, P1098, DOI 10.1126/science.1062939; KISHIDA M, 1994, CURR GENET, V25, P497, DOI 10.1007/BF00351668; Kitagawa K, 2001, NAT REV MOL CELL BIO, V2, P678, DOI 10.1038/35089568; Kniola B, 2001, MOL BIOL CELL, V12, P2767, DOI 10.1091/mbc.12.9.2767; Lee B, 2001, CURR OPIN CELL BIOL, V13, P770, DOI 10.1016/S0955-0674(00)00282-9; MARSCHALL LG, 1995, J CELL BIOL, V128, P445, DOI 10.1083/jcb.128.4.445; Mizuno K, 1997, GENE DEV, V11, P876, DOI 10.1101/gad.11.7.876; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Ngan VK, 1997, MOL CELL BIOL, V17, P3305, DOI 10.1128/MCB.17.6.3305; Paliulis LV, 2000, J CELL BIOL, V150, P1223, DOI 10.1083/jcb.150.6.1223; Partridge JF, 2000, GENE DEV, V14, P783; Pidoux AL, 2000, CURR OPIN CELL BIOL, V12, P308, DOI 10.1016/S0955-0674(00)00094-6; POLIZZI C, 1991, J CELL BIOL, V112, P191, DOI 10.1083/jcb.112.2.191; Saitoh S, 1997, CELL, V90, P131, DOI 10.1016/S0092-8674(00)80320-7; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; Takahashi K, 2000, SCIENCE, V288, P2215, DOI 10.1126/science.288.5474.2215; Toth A, 2000, CELL, V103, P1155, DOI 10.1016/S0092-8674(00)00217-8; Watanabe Y, 1999, NATURE, V400, P461, DOI 10.1038/22774; Watanabe Y, 2001, NATURE, V409, P359, DOI 10.1038/35053103; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Yamamoto M, 1996, TRENDS BIOCHEM SCI, V21, P18, DOI 10.1016/0968-0004(96)80880-2	34	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19817	19822		10.1074/jbc.M200765200	http://dx.doi.org/10.1074/jbc.M200765200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11909862	hybrid			2022-12-25	WOS:000175894800076
J	Asadi, A; Jorgensen, J; Jacobsson, A				Asadi, A; Jorgensen, J; Jacobsson, A			Elovl1 and p55Cdc genes are localized in a tail-to-tail array and are co-expressed in proliferating cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; DOUBLE-STRANDED-RNA; CHAIN FATTY-ACIDS; SACCHAROMYCES-CEREVISIAE; CYCLE GENE; PROTEIN; EXPRESSION; BIOSYNTHESIS; FAMILY; ELONGATION	Elovl1 is a ubiquitously expressed gene, the product of which belongs to a highly conserved family of microsomal enzymes, which are involved in the formation of very long chain fatty acids and sphingolipids in yeast to man. To elucidate the structure and regulation of the Elovl gene we have isolated a lambda phage genomic DNA clone containing the entire mouse gene and found that Elovl1 consists of eight exons that are dispersed over 5.4 kb of genomic sequence. Interestingly, sequencing of the lambda clone to completion revealed that the insert contained a segment of the cell cycle gene p55Cdc directed in the opposite orientation. The genes are very tightly linked so that the 3'-end of the long mRNA species are complementary over a short, stretch of nucleotides. Although both Elovl1 and p55Cdc are highly conserved genes, a BLAST search implies that the tail-to-tail arrangement has evolved in vertebrates. Despite the non-similar expression pattern in different tissues, mRNA analysis of the two genes disclosed simultaneous transcription during a proliferation-differentiation transition state, which suggests that the two genes may be regulated through a common bi-directional transcription mechanism under specific conditions.	Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden	Stockholm University	Jacobsson, A (corresponding author), Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden.	anders.jacobsson@wgi.su.se						ANTONSON P, 1995, EUR J BIOCHEM, V232, P397, DOI 10.1111/j.1432-1033.1995.tb20824.x; Bass BL, 2000, CELL, V101, P235, DOI 10.1016/S0092-8674(02)71133-1; Batshake B, 1996, BIOCHEM BIOPH RES CO, V227, P70, DOI 10.1006/bbrc.1996.1469; Beaudoin F, 2000, P NATL ACAD SCI USA, V97, P6421, DOI 10.1073/pnas.110140197; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Campbell HD, 1997, GENOMICS, V42, P46, DOI 10.1006/geno.1997.4709; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Domeier ME, 2000, SCIENCE, V289, P1928, DOI 10.1126/science.289.5486.1928; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; HANADA K, 1992, J BIOL CHEM, V267, P23527; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Leonard AE, 2000, BIOCHEM J, V350, P765, DOI 10.1042/0264-6021:3500765; LERNER A, 1993, J IMMUNOL, V151, P3152; Millar AA, 1999, PLANT CELL, V11, P825, DOI 10.1105/tpc.11.5.825; Millar AA, 1997, PLANT J, V12, P121, DOI 10.1046/j.1365-313X.1997.12010121.x; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; POULOS A, 1994, ANN NEUROL, V36, P741, DOI 10.1002/ana.410360509; REVARDEL E, 1995, BBA-GENE STRUCT EXPR, V1263, P261, DOI 10.1016/0167-4781(95)00124-Y; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Stewart ME, 1999, J LIPID RES, V40, P1434; Tvrdik P, 2000, J CELL BIOL, V149, P707, DOI 10.1083/jcb.149.3.707; Tvrdik P, 1999, J BIOL CHEM, V274, P26387, DOI 10.1074/jbc.274.37.26387; Tvrdik P, 1997, J BIOL CHEM, V272, P31738, DOI 10.1074/jbc.272.50.31738; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; Weinstein J, 1998, MOL GENET METAB, V64, P52, DOI 10.1006/mgme.1998.2698; WELLS GB, 1983, J BIOL CHEM, V258, P200; Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817	35	7	8	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18494	18500		10.1074/jbc.M111503200	http://dx.doi.org/10.1074/jbc.M111503200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11891222	hybrid			2022-12-25	WOS:000175975800033
J	Doray, B; Bruns, K; Ghosh, P; Kornfeld, S				Doray, B; Bruns, K; Ghosh, P; Kornfeld, S			Interaction of the cation-dependent mannose 6-phosphate receptor with GGA proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; EAR HOMOLOGY DOMAIN; CYTOPLASMIC DOMAIN; GAMMA-ADAPTIN; PHOSPHORYLATION SITE; MUTATIONAL ANALYSIS; CARBOXYL-TERMINUS; TRANS-GOLGI; VHS DOMAINS; BINDING	The GGAs (Golgi-localizing, (&gamma;) under bar -adaptin ear homology domain, ARF-binding) are a multidomain family of proteins implicated in protein trafficking between the Golgi and endosomes. Recent evidence has established that the cation-independent (Cl) and cation-dependent (CD) mannose 6-phosphate receptors (MPRs) bind specifically to the VHS domains of the GGAs through acidic cluster-dileucine motifs at the carboxyl ends of their cytoplasmic tails. However, the CD-MPR binds the VHS domains more weakly than the CI-MPR. Alignment of the C-terminal residues of the two receptors revealed a number of non-conservative differences in the acidic cluster-dileucine motifs and the flanking residues. Mutation of these residues in the CD-MPR cytoplasmic tail to the corresponding residues in the CI-MPR conferred either full binding (H63D mutant), intermediate binding (R60S), or unchanged binding (E56F/S57H) to the GGAs as determined by in vitro glutathione S-transferase pull-down assays. Furthermore, the C-terminal methionine of the CD-MPR, but not the C-terminal valine of the CI-MPR, inhibited GGA binding. Addition of four alanines to the C-terminal valine of the Cl-MPR also severely reduced GGA binding, demonstrating the importance of the spacing of the acidic cluster-dileucine motif relative to the C terminus for optimal GGA interaction. Mouse L cells stably expressing CD-MPRs with mutations that enhance GGA binding sorted cathepsin D more efficiently than wild-type CD-MPR. These studies provide an explanation for the observed differences in the relative affinities of the two MPRs for the GGA proteins. Furthermore, they indicate that the GGAs participate in lysosomal enzyme sorting mediated by the CD-MPR.	Washington Univ, Sch Med, Div Hematol, Dept Internal Med, St Louis, MO 63110 USA; Southwestern Univ, Dept Chem, Georgetown, TX 78627 USA	Washington University (WUSTL)	Kornfeld, S (corresponding author), Washington Univ, Sch Med, Div Hematol, Dept Internal Med, 660 S Euclid Ave,Campus Box 8125, St Louis, MO 63110 USA.			Doray, Balraj/0000-0003-3347-5013	NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NCI NIH HHS [CA08759] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Black MW, 2000, J CELL BIOL, V151, P587, DOI 10.1083/jcb.151.3.587; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Breuer P, 1997, MOL BIOL CELL, V8, P567, DOI 10.1091/mbc.8.4.567; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; Chen HJ, 1997, J BIOL CHEM, V272, P7003, DOI 10.1074/jbc.272.11.7003; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Denzer K, 1997, BIOCHEM J, V326, P497, DOI 10.1042/bj3260497; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Poussu A, 2000, J BIOL CHEM, V275, P7176, DOI 10.1074/jbc.275.10.7176; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Shiba T, 2002, NATURE, V415, P937, DOI 10.1038/415937a; Takatsu H, 2000, BIOCHEM BIOPH RES CO, V271, P719, DOI 10.1006/bbrc.2000.2700; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Zhdankina O, 2001, YEAST, V18, P1, DOI 10.1002/1097-0061(200101)18:1<1::AID-YEA644>3.0.CO;2-5; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	27	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18477	18482		10.1074/jbc.M201879200	http://dx.doi.org/10.1074/jbc.M201879200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886874	hybrid			2022-12-25	WOS:000175975800030
J	Dyckman, D; Fried, AG				Dyckman, D; Fried, AG			The Escherichia coli cyclic AMP receptor protein forms a 2 : 2 complex with RNA polymerase holoenzyme, in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATABOLITE ACTIVATOR PROTEIN; LARGE-SCALE PURIFICATION; CAP-DNA COMPLEX; TRANSCRIPTION ACTIVATION; DEPENDENT PROMOTERS; SIGMA(70) SUBUNIT; BINDING; CAMP; CORE; CRP	Sedimentation equilibrium studies show that the Escherichia coli cyclic AMP receptor protein (CAP) and RNA polymerase holoenzyme associate to form a 2:2 complex in vitro. No complexes of lower stoichiometry (1:1, 2:1,1:2) were detected over a wide range of CAP and RNA polymerase concentrations, suggesting that the interaction is highly cooperative. The absence of higher stoichiometry complexes, even in the limit of high [protein], suggests that the 2:2 species represents binding saturation for this system. The 2:2 pattern of complex formation is robust. A lower-limit estimate of the formation constant in our standard buffer (40 mM Tris (pH 7.9), 10 mM MgCl2, 0.1 mM dithiothreitol, 5% glycerol, 100 mM KCl) is 2 x 10(20) M-3. The qualitative pattern of association is unchanged over the temperature range 4 degreesC less than or equal to T less than or equal to 20 degreesC, by substitution of glutamate for chloride as the dominant anion, or on addition of 20 muM cAMP to the reaction mix. These results limit the possible mechanisms of CAP-polymerase association. In addition, they support the idea that CAP binding may influence the availability of the monomeric form of RNA polymerase that mediates transcription at many promoters.	Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Fried, AG (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, POB 850, Hershey, PA 17033 USA.	mfried@psu.edu						ADHYA S, 1990, J BIOL CHEM, V265, P10797; AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; ANDERSON WB, 1971, J BIOL CHEM, V246, P5929; Bailey, 1981, STAT METHODS BIOL; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BERG D, 1970, BIOCHEMISTRY-US, V9, P5055; Bevington PR., 2002, DATA REDUCTION ERROR; BLAZY B, 1980, MOL BIOL REP, V6, P39, DOI 10.1007/BF00775753; BURGESS RR, 1969, J BIOL CHEM, V244, P6160; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Burgess RR, 1976, RNA POLYMERASE, P69; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; Callaci S, 1998, BIOCHEMISTRY-US, V37, P3312, DOI 10.1021/bi972041m; Chamberlin M., 1976, RNA POLYMERASE BOOK, P17; Chamberlin M.J., 1976, RNA POLYMERASE, P159; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; FRIED M, 1982, THESIS YALE U NEW HA; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HARRIS SJ, 1995, BIOCHEMISTRY-US, V34, P8752, DOI 10.1021/bi00027a026; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; HUANG CY, 1982, METHOD ENZYMOL, V87, P509; HUDSON JM, 1993, EUR J BIOCHEM, V212, P539, DOI 10.1111/j.1432-1033.1993.tb17691.x; JIN RZ, 1995, J BIOL CHEM, V270, P19213, DOI 10.1074/jbc.270.33.19213; Johnson CM, 2000, J BACTERIOL, V182, P1995, DOI 10.1128/JB.182.7.1995-2000.2000; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; MCKAY DB, 1982, J BIOL CHEM, V257, P9518; Nasser W, 2001, J BIOL CHEM, V276, P17878, DOI 10.1074/jbc.M100632200; Niu W, 1996, CELL, V87, P1123, DOI 10.1016/S0092-8674(00)81806-1; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; Passner JM, 1997, P NATL ACAD SCI USA, V94, P2843, DOI 10.1073/pnas.94.7.2843; PILZ I, 1972, EUR J BIOCHEM, V28, P205, DOI 10.1111/j.1432-1033.1972.tb01904.x; PINKNEY M, 1988, BIOCHEM J, V250, P897, DOI 10.1042/bj2500897; RAMSEIER TM, 1995, MICROBIOL-SGM, V141, P1901, DOI 10.1099/13500872-141-8-1901; RICHARDS.JP, 1966, P NATL ACAD SCI USA, V55, P1616, DOI 10.1073/pnas.55.6.1616; Richet E, 2000, EMBO J, V19, P5222, DOI 10.1093/emboj/19.19.5222; ROE JH, 1985, BIOCHEMISTRY-US, V24, P4271; Savery N, 1996, PHILOS T ROY SOC B, V351, P543, DOI 10.1098/rstb.1996.0053; Savery NJ, 1998, EMBO J, V17, P3439, DOI 10.1093/emboj/17.12.3439; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHANER SL, 1982, BIOCHEMISTRY-US, V21, P5539, DOI 10.1021/bi00265a025; SHANER SL, 1982, COLD SPRING HARB SYM, V47, P463; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P2723, DOI 10.1021/bi00332a019; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; TANG H, 1994, GENE DEV, V8, P3058, DOI 10.1101/gad.8.24.3058; TRAVERS AA, 1982, NUCLEIC ACIDS RES, V10, P5043, DOI 10.1093/nar/10.16.5043; VONHIPPEL PH, 1992, TRANSCRIPTIONAL REGU, P179; ZOU C, 1992, MOL MICROBIOL, V6, P2599, DOI 10.1111/j.1365-2958.1992.tb01437.x	50	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19064	19070		10.1074/jbc.M110554200	http://dx.doi.org/10.1074/jbc.M110554200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11904295	hybrid			2022-12-25	WOS:000175975800107
J	Gao, ZG; Chen, A; Barak, D; Kim, SK; Muller, CE; Jacobson, KA				Gao, ZG; Chen, A; Barak, D; Kim, SK; Muller, CE; Jacobson, KA			Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A(3) adenosine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE; TRANSMEMBRANE DOMAIN; MOLECULAR-CLONING; PHOSPHOLIPASE-C; RHODOPSIN; EXPRESSION; STIMULATION; INHIBITION; HYDROLYSIS; MECHANISMS	Ligand recognition has been extensively explored in G protein-coupled A(1), A(2A), and A(2B) adenosine receptors but not in the As receptor, which is cerebroprotective and cardioprotective. We mutated several residues of the human A(3) adenosine receptor within transmembrane domains 3 and 6 and the second extracellular loop, which have been predicted by previous molecular modeling to be involved in the ligand recognition, including His(95), Trp(243), Leu(244), Ser(247), Asn(250), and Lys(152). The N250A mutant receptor lost the ability to bind both radiolabeled agonist and antagonist. The H95A mutation significantly reduced affinity of both agonists and antagonists. In contrast, the K152A (EL2), W243A (6.48), and W243F (6.48) mutations did not significantly affect the agonist binding but decreased antagonist affinity by similar to3-38-fold, suggesting that these residues were critical for the high affinity of A(3) adenosine receptor antagonists. Activation of phospholipase C by wild type (WT) and mutant receptors was measured. The As agonist 2-chloro-N-6-(3-iodobenzyl)-5'-N-methylcarbamoyladenosine stimulated phosphoinositide turnover in the WT but failed to evoke a response in cells expressing W243A and W243F mutant receptors, in which agonist binding was less sensitive to guanosine 5'-gamma-thiotriphosphate than in WT. Thus, although not important for agonist binding, Trp(243) was critical for receptor activation. The results were interpreted using a rhodopsin-based model of ligand-A(3) receptor interactions.	NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; Univ Bonn, Inst Pharmaceut, D-53115 Bonn, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Bonn	Jacobson, KA (corresponding author), NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-19, Bethesda, MD 20892 USA.	kajacobs@helix.nih.gov	Jacobson, Kenneth Alan/A-1530-2009; Müller, Christa Elisabeth/C-7748-2014	Jacobson, Kenneth Alan/0000-0001-8104-1493; Müller, Christa Elisabeth/0000-0002-0013-6624	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031115, Z01DK031117] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 DK031117-20] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abbracchio MP, 1995, MOL PHARMACOL, V48, P1038; Barbhaiya H, 1996, MOL PHARMACOL, V50, P1635; Befort K, 1996, J BIOL CHEM, V271, P10161, DOI 10.1074/jbc.271.17.10161; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Beukers MW, 2000, MOL PHARMACOL, V58, P1349, DOI 10.1124/mol.58.6.1349; BLUML K, 1994, J BIOL CHEM, V269, P18870; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen A, 2001, BIOCHEM BIOPH RES CO, V284, P596, DOI 10.1006/bbrc.2001.5027; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; Fredholm BB, 2000, N-S ARCH PHARMACOL, V362, P364, DOI 10.1007/s002100000313; Gao ZG, 2000, BIOCHEM PHARMACOL, V60, P661, DOI 10.1016/S0006-2952(00)00357-9; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; HARDEN TK, 1988, BIOCHEM J, V252, P583, DOI 10.1042/bj2520583; HIBERT MF, 1993, TRENDS PHARMACOL SCI, V14, P7, DOI 10.1016/0165-6147(93)90106-T; Jacobson KA, 1997, NEUROPHARMACOLOGY, V36, P1157, DOI 10.1016/S0028-3908(97)00104-4; Jacobson KA, 2001, J MED CHEM, V44, P4125, DOI 10.1021/jm010232o; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; Jiang QL, 1996, MOL PHARMACOL, V50, P512; Kaiser SM, 1999, DRUG DISCOV TODAY, V4, P542, DOI 10.1016/S1359-6446(99)01421-X; KIM JH, 1995, J BIOL CHEM, V270, P13987, DOI 10.1074/jbc.270.23.13987; Lee K, 2001, BIOORG MED CHEM LETT, V11, P1333, DOI 10.1016/S0960-894X(01)00213-X; Liang BT, 1998, P NATL ACAD SCI USA, V95, P6995, DOI 10.1073/pnas.95.12.6995; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Marie J, 2001, J BIOL CHEM, V276, P41100, DOI 10.1074/jbc.M104875200; Mouledous L, 2000, MOL PHARMACOL, V57, P495, DOI 10.1124/mol.57.3.495; Muller CE, 2002, BIOORG MED CHEM LETT, V12, P501, DOI 10.1016/S0960-894X(01)00785-5; NAKAYAMA TA, 1990, J BIOL CHEM, V265, P15762; OLAH ME, 1992, J BIOL CHEM, V267, P10764; Olah ME, 2000, PHARMACOL THERAPEUT, V85, P55, DOI 10.1016/S0163-7258(99)00051-0; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PARDO L, 1992, P NATL ACAD SCI USA, V89, P4009, DOI 10.1073/pnas.89.9.4009; PERLMAN JH, 1995, MOL PHARMACOL, V47, P480; PERLMAN JH, 1994, J BIOL CHEM, V269, P23383; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; Rivkees SA, 1999, J BIOL CHEM, V274, P3617, DOI 10.1074/jbc.274.6.3617; Sajjadi FG, 1996, J IMMUNOL, V156, P3435; SALVATORE CA, 1993, P NATL ACAD SCI USA, V90, P10365, DOI 10.1073/pnas.90.21.10365; Salvatore CA, 2000, J BIOL CHEM, V275, P4429, DOI 10.1074/jbc.275.6.4429; TUCKER AL, 1994, J BIOL CHEM, V269, P27900; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S; von Lubitz DKJE, 1999, ANN NY ACAD SCI, V890, P93; VONLUBITZ DKJE, 1994, EUR J PHARMACOL, V263, P59, DOI 10.1016/0014-2999(94)90523-1; YAMANO Y, 1995, J BIOL CHEM, V270, P14024, DOI 10.1074/jbc.270.23.14024; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432; ZOFFMANN S, 1993, FEBS LETT, V336, P506, DOI 10.1016/0014-5793(93)80865-R	49	140	142	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19056	19063		10.1074/jbc.M110960200	http://dx.doi.org/10.1074/jbc.M110960200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11891221	Green Accepted, hybrid			2022-12-25	WOS:000175975800106
J	Liu, CY; Wong, HN; Schauerte, JA; Kaufman, RJ				Liu, CY; Wong, HN; Schauerte, JA; Kaufman, RJ			The protein kinase/endoribonuclease IRE1 alpha that signals the unfolded protein response has a luminal N-terminal ligand-independent dimerization domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; GLUCOSE-REGULATED PROTEINS; ER STRESS; TRANSLATIONAL CONTROL; TRANSMEMBRANE PROTEIN; MAMMALIAN-CELLS; IRE1; PERK; SECRETION; IDENTIFICATION	In response to accumulation of unfolded proteins in the endoplasmic reticulum (ER), cells activate an intracellular signal transduction pathway called the unfolded protein response (UPR). IRE and PERK are the two type-I ER transmembrane protein kinase receptors that signal the UPR. The N-terminal luminal domains (NLDs) of IRE1 and PERK sense ER stress conditions by a common mechanism and transmit the signal to regulate the cytoplasmic domains of these receptors. To provide an experimental system amenable to detailed biochemical and structural analysis to elucidate the mechanism of ER-transmembrane signaling mechanism mediated by the NLD, we overexpressed the soluble luminal domain of human IRE1a in COS-1 cells by transient DNA transfection. Here we report the expression, purification, and characterization of the soluble NLD. The biological function of the NLD was confirmed by its ability to associate with itself and to interact with both the membrane-bound full-length IRE1alpha receptor and the ER chaperone BiP. Functional and spectral studies suggested that the highly conserved N-linked glycosylation site is not required for proper protein folding and self-association. Interestingly, we demonstrated that the NLD forms stable dimers linked by intermolecular disulfide bridges. Our data support that the luminal domain represents a novel ligand-independent dimerization domain.	Univ Michigan, Med Ctr, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Div Biophys Res, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Kaufman, RJ (corresponding author), Univ Michigan, Med Ctr, Sch Med, Howard Hughes Med Inst, 4570 MSRB 2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.		Longo, Kenneth A/A-5631-2010; Liu, Andrew C/B-3548-2009	Liu, Andrew C/0000-0003-1927-0900				Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Butler SA, 1999, J MOL ENDOCRINOL, V22, P185, DOI 10.1677/jme.0.0220185; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; Okamura K, 2000, BIOCHEM BIOPH RES CO, V279, P445, DOI 10.1006/bbrc.2000.3987; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Tirasophon W, 2000, GENE DEV, V14, P2725, DOI 10.1101/gad.839400; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	30	86	91	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18346	18356		10.1074/jbc.M112454200	http://dx.doi.org/10.1074/jbc.M112454200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11897784	hybrid			2022-12-25	WOS:000175975800014
J	Martins, LO; Soares, CM; Pereira, MM; Teixeira, M; Costa, T; Jones, GH; Henriques, AO				Martins, LO; Soares, CM; Pereira, MM; Teixeira, M; Costa, T; Jones, GH; Henriques, AO			Molecular and biochemical characterization of a highly stable bacterial laccase that occurs as a structural component of the Bacillus subtilis endospore coat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPHENOL OXIDASE; ASCORBATE OXIDASE; CRYSTAL-STRUCTURE; GENE; PURIFICATION; EXPRESSION; CLONING; TRANSGLUTAMINASE; BIOSYNTHESIS; PROTEINS	The Bacillus subtilis endospore coat protein CotA shows laccase activity. By using comparative modeling techniques, we were able to derive a model for CotA based on the known x-ray structures of zucchini ascorbate oxidase and Cuprinus cereneus laccase. This model of CotA contains all the structural features of a laccase, including the reactive surface-exposed copper center (T1) and two buried copper centers (T2 and T3). Single amino acid substitutions in the CotA T1 copper center (H497A, or M502L) did not prevent assembly of the mutant proteins into the coat and did not alter the pattern of extractable coat polypeptides. However, in contrast to a wild type strain, both mutants produced unpigmented colonies and spores unable to oxidize syringaldazine (SGZ) and 2'2-azino-bis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS). The CotA protein was purified to homogeneity from an overproducing Escherichia coli strain. The purified CotA shows an absorbance and a EPR spectra typical of blue multicopper oxidases. Optimal enzymatic activity was found at less than or equal topH 3.0 and at pH 7.0 for ABTS or SGZ oxidation, respectively. The apparent K-m values for ABTS and SGZ at 37 degreesC were of 106 +/- 11 and 26 +/- 2 muM, respectively, with corresponding k(cat) values of 16.8 +/- 0.8 and 3.7 +/- 0.1 s(-1). Maximal enzyme activity was observed at 75 degreesC with AETS as substrate. Remarkably, the coat-associated or the purified enzyme showed a half-life of inactivation at 80 degreesC of about 4 and 2 h, respectively, indicating that CotA is intrinsically highly thermostable.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2781901 Oeiras, Portugal; Univ Lusofona Humanidades & Tecnol, Dept Engn & Tecnol, P-1749024 Lisbon, Portugal; Emory Univ, Dept Biol, Atlanta, GA 30322 USA	Universidade Nova de Lisboa; Lusofona University; Emory University	Henriques, AO (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Av Republ, P-2781901 Oeiras, Portugal.	aoh@itqb.unl.pt	Teixeira, Miguel/A-9098-2011; Costa, Teresa/C-7247-2012; Pereira, Manuela M./B-9029-2011; Soares, Claudio M/E-2675-2012; Teixeira, Miguel/M-1509-2019; Martins, Lígia O./C-2513-2009	Teixeira, Miguel/0000-0003-4124-6237; Pereira, Manuela M./0000-0003-2033-4553; Soares, Claudio M/0000-0003-1154-556X; Teixeira, Miguel/0000-0003-4124-6237; Martins, Lígia O./0000-0003-0082-9591; Costa, Teresa/0000-0001-6724-6126; Henriques, Adriano/0000-0003-4292-4802				AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; Alexandre G, 2000, TRENDS BIOTECHNOL, V18, P41, DOI 10.1016/S0167-7799(99)01406-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breen A, 1999, CURR OPIN BIOTECH, V10, P252, DOI 10.1016/S0958-1669(99)80044-5; Chefetz B, 1998, APPL ENVIRON MICROB, V64, P3175; Dong GQ, 1997, APPL ENVIRON MICROB, V63, P3577, DOI 10.1128/AEM.63.9.3577-3584.1997; DONOVAN W, 1987, J MOL BIOL, V196, P1, DOI 10.1016/0022-2836(87)90506-7; Driks A, 1999, MICROBIOL MOL BIOL R, V63, P1; Ducros V, 1998, NAT STRUCT BIOL, V5, P310, DOI 10.1038/nsb0498-310; Edens WA, 1999, APPL ENVIRON MICROB, V65, P3071; EGGERT C, 1995, FEBS LETT, V376, P202, DOI 10.1016/0014-5793(95)01274-9; FAURE D, 1994, APPL ENVIRON MICROB, V60, P3413, DOI 10.1128/AEM.60.9.3413-3415.1994; FREEMAN JC, 1993, BIOCHEMISTRY-US, V32, P4826, DOI 10.1021/bi00069a018; GIVAUDAN A, 1993, FEMS MICROBIOL LETT, V108, P205, DOI 10.1111/j.1574-6968.1993.tb06100.x; Henriques AO, 2000, METHODS, V20, P95, DOI 10.1006/meth.1999.0909; Henriques AO, 1998, J BACTERIOL, V180, P2285, DOI 10.1128/JB.180.9.2285-2291.1998; HENRIQUES AO, 1995, J BACTERIOL, V177, P3394, DOI 10.1128/jb.177.12.3394-3406.1995; Henriques AO, 2001, J INORG BIOCHEM, V86, P259; Hullo MF, 2001, J BACTERIOL, V183, P5426, DOI 10.1128/JB.183.18.5426-5430.2001; Isticato R, 2001, J BACTERIOL, V183, P6294, DOI 10.1128/JB.183.21.6294-6301.2001; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Kobayashi K, 1996, FEMS MICROBIOL LETT, V144, P157, DOI 10.1016/0378-1097(96)00353-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; Mizuguchi K, 1998, PROTEIN SCI, V7, P2469, DOI 10.1002/pro.5560071126; Nicholls A., 1992, GRASP GRAPHICAL REPR; Ranocha P, 1999, EUR J BIOCHEM, V259, P485, DOI 10.1046/j.1432-1327.1999.00061.x; ROGOLSKY M, 1968, J BACTERIOL, V95, P2426, DOI 10.1128/JB.95.6.2426-2427.1968; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez-Amat A, 2001, BBA-PROTEIN STRUCT M, V1547, P104, DOI 10.1016/S0167-4838(01)00174-1; SanchezAmat A, 1997, BIOCHEM BIOPH RES CO, V240, P787, DOI 10.1006/bbrc.1997.7748; SANDMAN K, 1988, J MOL BIOL, V200, P461, DOI 10.1016/0022-2836(88)90536-0; Seyler RW, 1997, MOL MICROBIOL, V25, P955, DOI 10.1111/j.1365-2958.1997.mmi532.x; Solano F, 1997, APPL ENVIRON MICROB, V63, P3499, DOI 10.1128/AEM.63.9.3499-3506.1997; Solano F, 2001, FEMS MICROBIOL LETT, V204, P175, DOI 10.1111/j.1574-6968.2001.tb10882.x; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297; SULLIVAN MA, 1984, GENE, V29, P21, DOI 10.1016/0378-1119(84)90161-6; Suzuki S, 2000, BIOSCI BIOTECH BIOCH, V64, P2344, DOI 10.1271/bbb.64.2344; THURSTON CF, 1994, MICROBIOL-SGM, V140, P19, DOI 10.1099/13500872-140-1-19; Tsai HF, 1999, J BACTERIOL, V181, P6469, DOI 10.1128/JB.181.20.6469-6477.1999; Williamson PR, 1998, J BACTERIOL, V180, P1570, DOI 10.1128/JB.180.6.1570-1572.1998; Xu F, 1997, J BIOL CHEM, V272, P924, DOI 10.1074/jbc.272.2.924; Xu F, 1996, BBA-PROTEIN STRUCT M, V1292, P303, DOI 10.1016/0167-4838(95)00210-3; ZHENG LB, 1988, GENE DEV, V2, P1047, DOI 10.1101/gad.2.8.1047; ZHENG LB, 1990, J MOL BIOL, V212, P645, DOI 10.1016/0022-2836(90)90227-D	49	401	444	5	113	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18849	18859		10.1074/jbc.M200827200	http://dx.doi.org/10.1074/jbc.M200827200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11884407	hybrid			2022-12-25	WOS:000175975800079
J	Matsuzaki, T; Hanai, S; Kishi, H; Liu, ZH; Bao, YL; Kikuchi, A; Tsuchida, K; Sugino, F				Matsuzaki, T; Hanai, S; Kishi, H; Liu, ZH; Bao, YL; Kikuchi, A; Tsuchida, K; Sugino, F			Regulation of endocytosis of activin type II receptors by a novel PDZ protein through Ral/Ral-binding protein 1-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; PUTATIVE EFFECTOR PROTEIN; FSH-RELEASING PROTEIN; EH-DOMAIN; IDENTIFICATION; ACTIVATION; FAMILY; GRADIENT; SIGNAL; RAS	Using yeast two-hybrid screening, we have identified a mouse Postsynaptic density 95/Discs large/Zona occludens-1 (PDZ) protein that interacts with activin. type II receptors (ActRIIs). We named the protein activin receptor-interacting protein 2 (ARIP2). ARIP2 was found to have one PDZ domain in the NH2-terminal region and interact specifically with ActRIIs among the receptors for the transforming growth factor beta family by the PDZ domain. Interestingly, overexpression of ARIP2 enhances endocytosis of ActRIIs and reduces activin-induced transcription in Chinese hamster ovary K1 cells. In addition, immunofluorescence co-localization studies indicated the direct involvement of ARIP2 in the intracellular translocation of ActRIIs by PDZ domain-mediated interaction. Moreover, we have identified that the COOH-terminal region of ARIP2 interacts with Ral-binding protein 1 (RaIBP1). RaIBP1 is a potential effector protein of small GTP-binding protein Ral and regulates endocytosis of epidermal growth factor and insulin receptors. The studies using deletion mutants of RaIBP1 and constitutively GTP and GDP binding forms of Ral indicate that ARIP2 regulates endocytosis of ActRIIs through the Ral/RaIBP1-dependent pathway, and the GDP-GTP exchange of Ral is critical for this regulation.	Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan; Hiroshima Univ, Fac Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan	Tokushima University; Hiroshima University	Tsuchida, K (corresponding author), Univ Tokushima, Inst Enzyme Res, 3-18-15 Kuramoto, Tokushima 7708503, Japan.	tsuchida@ier.tokushima-u.ac.jp	Tsuchida, Kunihiro/A-4501-2012	Tsuchida, Kunihiro/0000-0002-3983-5756				Anders RA, 1997, MOL BIOL CELL, V8, P2133, DOI 10.1091/mbc.8.11.2133; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; Attisano L, 1996, MOL CELL BIOL, V16, P1066; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chen Y, 2001, NATURE, V411, P607, DOI 10.1038/35079121; Dore JJE, 1998, J BIOL CHEM, V273, P31770, DOI 10.1074/jbc.273.48.31770; Dubois L, 2001, CELL, V105, P613, DOI 10.1016/S0092-8674(01)00375-0; Dyson S, 1998, CELL, V93, P557, DOI 10.1016/S0092-8674(00)81185-X; Ehrlich M, 2001, J CELL SCI, V114, P1777; Entchev EV, 2000, CELL, V103, P981, DOI 10.1016/S0092-8674(00)00200-2; Ethier JF, 1997, ENDOCRINOLOGY, V138, P2425, DOI 10.1210/en.138.6.2425; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Fialka I, 1999, J BIOL CHEM, V274, P26233, DOI 10.1074/jbc.274.37.26233; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HAGE W, 1997, J CELL BIOL, V136, P811; HEMMATIBRIVANLOU A, 1992, DEV DYNAM, V194, P1, DOI 10.1002/aja.1001940102; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Iwahori Y, 1997, BRAIN RES, V760, P52, DOI 10.1016/S0006-8993(97)00275-8; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATHEWS LS, 1993, J BIOL CHEM, V268, P19013; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; Matsubara K, 1997, FEBS LETT, V410, P169, DOI 10.1016/S0014-5793(97)00633-9; McDowell N, 1997, CURR BIOL, V7, P671, DOI 10.1016/S0960-9822(06)00294-6; MOGAMI H, 1995, ENDOCRINOLOGY, V136, P2960, DOI 10.1210/en.136.7.2960; Morinaka K, 1999, ONCOGENE, V18, P5915, DOI 10.1038/sj.onc.1202974; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; OGAWA Y, 1992, J BIOL CHEM, V267, P14233; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; Parks WT, 2001, J BIOL CHEM, V276, P19332, DOI 10.1074/jbc.M100606200; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; SHIBATA H, 1993, FEBS LETT, V329, P194, DOI 10.1016/0014-5793(93)80220-O; Shoji H, 1998, BIOCHEM BIOPH RES CO, V246, P320, DOI 10.1006/bbrc.1998.8613; Shoji H, 2000, J BIOL CHEM, V275, P5485, DOI 10.1074/jbc.275.8.5485; Song JW, 1999, DEV BIOL, V213, P157, DOI 10.1006/dbio.1999.9370; TAKANO K, 1992, BIOCHEM BIOPH RES CO, V182, P1408, DOI 10.1016/0006-291X(92)91890-3; Teleman AA, 2001, CELL, V105, P559, DOI 10.1016/S0092-8674(01)00377-4; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TSUCHIDA K, 1995, ENDOCRINOLOGY, V136, P5493, DOI 10.1210/en.136.12.5493; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Willis SA, 1996, MOL ENDOCRINOL, V10, P367, DOI 10.1210/me.10.4.367; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wurthner JU, 2001, J BIOL CHEM, V276, P19495, DOI 10.1074/jbc.M006473200; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	58	71	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19008	19018		10.1074/jbc.M112472200	http://dx.doi.org/10.1074/jbc.M112472200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11882656	hybrid			2022-12-25	WOS:000175975800100
J	Shu, LM; Lee, L; Shayman, JA				Shu, LM; Lee, L; Shayman, JA			Regulation of phospholipase C-gamma activity by glycosphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSYLCERAMIDE SYNTHASE; MEMBRANE DOMAINS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PHOSPHORYLATION CASCADE; INOSITOL TRISPHOSPHATE; CHOLESTEROL DEPLETION; ENDOTHELIAL-CELLS; KIDNEY-CELLS; CAVEOLAE; KINASE	Glycosphingolipid-enriched domains are hot spots for cell signaling within plasma membranes and are characterized by the enrichment of glycosphingolipids. A role for glucosylceramide-based glycosphingolipids in phospholipase C-mediated inositol 1,4,5-trisphosphate formation has been previously documented. These earlier studies utilized a first generation glucosylceramide synthase inhibitor to deplete cells of their glycosphingolipids. Recently, more active and specific glucosylceramide synthase inhibitors, including D-threo-ethylendioxyphenyl-2-palmitoylamino-3-pyrrolidinopropanol (D-t-EtDO-P4), have been designed. D-t-EtDO-P4 has the advantage of blocking glucosylceramide synthase at low nanomolar concentrations but does not cause secondary elevations in cell ceramide levels. In the present study, D-t-EtDO-P4 depleted cellular glucosylceramide and lactosylceramide in cultured ECV304 cells at nanomolar concentrations without obvious cellular toxicity. The expression of several signaling proteins was evaluated in glycosphingolipid-depleted ECV304 cells to study the role of glycosphingolipids in phospholipase C-mediated signaling. No difference was observed in the cellular expression of phospholipase C-gamma between controls and glycolipid-depleted cells. Western blot analysis, however, revealed that depletion of endogenous glycosphingolipids in cultured ECV304 cells with D-t-EtDO-P4 induced tyrosine phosphorylation of phospholipase C-gamma in a concentration-dependent manner with maximum induction at 100 nM. The phosphorylation of phospholipase C-gamma induced by D-t-EtDO-P4 was abolished by exogenously added glucosylceramide, consistent with a specific glycosphingolipid-phospholipase C-gamma interaction. The phospholipase C-gamma phosphorylation was maximally enhanced by bradykinin when cells were exposed to 100 nM D-t-EtDO-P4. The measurement of cellular activity of phospholipase C-gamma, by myoinositol 1,4,5-trisphosphate radioreceptor assay, demonstrated that depletion of glucosylceramide-based glycosphingolipids in cultured ECV304 cells with D-t-EtDO-P4 resulted in significantly increased formation of inositol 1,4,5-trisphosphate above base line, and an increased sensitivity of phospholipase C-gamma to bradykinin stimulation. Thus, the activation of phospholipase C-gamma is negatively regulated by membrane glycosphingolipids in ECV304 cells.	Univ Michigan, Sch Med, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Shayman, JA (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, Div Nephrol, Box 0676,Rm 1560,MSRB 2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055823] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK55823] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe A, 2000, J CLIN INVEST, V105, P1563, DOI 10.1172/JCI9711; Abe A, 1996, J BIOL CHEM, V271, P14383, DOI 10.1074/jbc.271.24.14383; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; DeMali KA, 1997, J BIOL CHEM, V272, P9011; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Dobrowsky RT, 2000, METHOD ENZYMOL, V311, P184; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; Iwabuchi K, 2000, METHOD ENZYMOL, V312, P488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu YM, 1998, BIOCHEM BIOPH RES CO, V245, P684, DOI 10.1006/bbrc.1998.8329; MAHDIYOUN S, 1992, ARCH BIOCHEM BIOPHYS, V292, P506, DOI 10.1016/0003-9861(92)90023-P; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Myers SJ, 1999, ATHEROSCLEROSIS, V143, P389, DOI 10.1016/S0021-9150(98)00331-1; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; PREISS J, 1986, J BIOL CHEM, V261, P8597; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; Shayman JA, 2000, METHOD ENZYMOL, V311, P373; Shu LM, 2000, ARCH BIOCHEM BIOPHYS, V373, P83, DOI 10.1006/abbi.1999.1553; Smith RM, 1998, CELL SIGNAL, V10, P355, DOI 10.1016/S0898-6568(97)00170-8; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; Toselli M, 2001, J PHYSIOL-LONDON, V536, P361, DOI 10.1111/j.1469-7793.2001.0361c.xd; Ushio-Fukai M, 2001, J BIOL CHEM, V276, P48269, DOI 10.1074/jbc.M105901200; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P455	31	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18447	18453		10.1074/jbc.M111363200	http://dx.doi.org/10.1074/jbc.M111363200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886852	hybrid			2022-12-25	WOS:000175975800026
J	Sun, YP; Nonobe, E; Kobayashi, Y; Kuraishi, T; Aoki, F; Yamamoto, K; Sakai, S				Sun, YP; Nonobe, E; Kobayashi, Y; Kuraishi, T; Aoki, F; Yamamoto, K; Sakai, S			Characterization and expression of L-amino acid oxidase of mouse milk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIPER CALLOSELASMA-RHODOSTOMA; HYDROGEN-PEROXIDE; BOVINE MASTITIS; MAMMARY-GLAND; RECEPTOR GENE; PEPTIDES; PURIFICATION; PREVALENCE; MODULATION; MELPHALAN	L-Amino acid oxidase (LAO) was purified from mouse milk. LAO reacted with L-amino acids in an apparent order of Phe > Met, Tyr > Cys, Leu > His >> other 11 amino acids tested and produced H2O2 in a dose- and time-dependent manner. LAO in milk had a molecular mass of about 113 kDa and was converted to a 60-kDa protein by SDS-PAGE. LAO consisted of two subunits. The N- and C-terminal amino acid sequence determination followed by cDNA cloning showed that the 60-kDa protein consisted of 497 amino acids. LAO mRNA spanned about 2.0 kb, and its expression was found only in the mammary epithelial cells. Glucocorticoid was essential for LAO gene expression. Thus, the LAO gene is expressed acutely upon the onset of milk synthesis. LAO mRNA increased I day before parturition, peaked during early to mid-lactation, and decreased at the end of lactation. This is the first demonstration showing that LAO is present in milk. Mastitis is caused by an intra-mammary bacterial infection. As mouse milk produced H2O2 using endogenous free amino acids, we suggest that LAO, together with free amino acids, is responsible for killing bacteria in the mammary gland.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Anim Breeding, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Kashiwa, Chiba 2778562, Japan	University of Tokyo; University of Tokyo	Sakai, S (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Anim Breeding, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1138657, Japan.	asenkiti@mail.ecc.u-tokyo.ac.jp	Sun, Youping/AAX-7058-2021					ARMSTRONG MD, 1963, P SOC EXP BIOL MED, V113, P680, DOI 10.3181/00379727-113-28460; ATKINSON SA, 1980, AM J CLIN NUTR, V33, P811, DOI 10.1093/ajcn/33.4.811; BHUYAN KC, 1977, BIOCHIM BIOPHYS ACTA, V497, P641, DOI 10.1016/0304-4165(77)90284-7; Blanchard M, 1944, J BIOL CHEM, V155, P421; Bramley A. J., 1996, CURRENT CONCEPTS BOV, P1; BRIGHT HJ, 1975, ENZYMES, V12, P456; Chu CC, 1997, P NATL ACAD SCI USA, V94, P2507, DOI 10.1073/pnas.94.6.2507; Clare DA, 2000, J DAIRY SCI, V83, P1187, DOI 10.3168/jds.S0022-0302(00)74983-6; CURTI B, 1968, J BIOL CHEM, V243, P2306; CURTI B, 1992, CHEM BIOCH FLAVOENZY, V3, P84; DAVIS TA, 1994, BRIT J NUTR, V72, P845, DOI 10.1079/BJN19940089; De Oliveira AP, 2000, J DAIRY SCI, V83, P855, DOI 10.3168/jds.S0022-0302(00)74949-6; EKSTRAND B, 1989, FOOD BIOTECHNOL, V3, P105, DOI 10.1080/08905438909549703; Fujimura S, 1998, J VET MED SCI, V60, P937, DOI 10.1292/jvms.60.937; GROSVENOR CE, 1993, ENDOCR REV, V14, P710, DOI 10.1210/edrv-14-6-710; GROVES ML, 1971, MILK PROTEINS CHEMIS, V2, P367; JARAALMONTE M, 1972, J DAIRY SCI, V55, P1502, DOI 10.3168/jds.S0022-0302(72)85703-5; Kim Jae-Young, 1998, Animal Science and Technology, V69, P728; KLEBANOFF SJ, 1966, BIOCHIM BIOPHYS ACTA, V117, P63, DOI 10.1016/0304-4165(66)90152-8; KOLDOVSKY O, 1989, J NUTR, V119, P1543, DOI 10.1093/jn/119.11.1543; Macheroux P, 2001, EUR J BIOCHEM, V268, P1679, DOI 10.1046/j.1432-1327.2001.02042.x; MCRIPLEY RJ, 1967, J BACTERIOL, V94, P1425, DOI 10.1128/JB.94.5.1425-1430.1967; Mizoguchi Y, 1996, ENDOCR J, V43, P537, DOI 10.1507/endocrj.43.537; Mizoguchi Y, 1997, MOL CELL ENDOCRINOL, V132, P177, DOI 10.1016/S0303-7207(97)00134-2; Moynihan K, 1997, CANCER CHEMOTH PHARM, V39, P179; NIEDERMANN DM, 1990, J BIOL CHEM, V265, P17246; PONNUDURAI G, 1994, ARCH BIOCHEM BIOPHYS, V313, P373, DOI 10.1006/abbi.1994.1401; Raibekas AA, 1998, BIOCHEM BIOPH RES CO, V248, P476, DOI 10.1006/bbrc.1998.9024; RASSIN DK, 1978, EARLY HUM DEV, V2, P1, DOI 10.1016/0378-3782(78)90048-8; REITER B, 1978, J DAIRY RES, V45, P131, DOI 10.1017/S0022029900016290; RICH JN, 1995, CANCER CHEMOTH PHARM, V36, P379, DOI 10.1007/BF00686186; RICH JN, 1996, J IMMUNOL, V156, P42; SAKAI S, 1979, BIOCHIM BIOPHYS ACTA, V582, P79, DOI 10.1016/0304-4165(79)90290-3; SIKORA L, 1982, MOL GEN GENET, V186, P33, DOI 10.1007/BF00422908; SMITH KL, 1985, J DAIRY SCI, V68, P1531, DOI 10.3168/jds.S0022-0302(85)80993-0; SPINCER J, 1969, BIOCHEM J, V111, P727, DOI 10.1042/bj1110727; Stevenson EM, 1994, INT DAIRY J, V4, P205, DOI 10.1016/0958-6946(94)90013-2; STILES BG, 1991, TOXICON, V29, P1129, DOI 10.1016/0041-0101(91)90210-I; Sun Y, 2001, MOL CELL ENDOCRINOL, V172, P177, DOI 10.1016/S0303-7207(00)00370-1; TAN NH, 1991, INT J BIOCHEM, V23, P323; TAN NH, 1989, BIOCHEM INT, V19, P937; Torii S, 1997, J BIOL CHEM, V272, P9539, DOI 10.1074/jbc.272.14.9539; UEDA N, 1992, J CLIN INVEST, V90, P2593, DOI 10.1172/JCI116154; Varadi M, 1999, BIOSENS BIOELECTRON, V14, P335, DOI 10.1016/S0956-5663(98)00130-4; VINA JR, 1987, J NUTR, V117, P533, DOI 10.1093/jn/117.3.533; Wilson DJ, 1997, J DAIRY SCI, V80, P2592, DOI 10.3168/jds.S0022-0302(97)76215-5; WU GY, 1994, J NUTR, V124, P415, DOI 10.1093/jn/124.3.415; Xu RJ, 1998, FOOD REV INT, V14, P1, DOI 10.1080/87559129809541147	48	59	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19080	19086		10.1074/jbc.M200936200	http://dx.doi.org/10.1074/jbc.M200936200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11907037	hybrid			2022-12-25	WOS:000175975800109
J	Ugi, S; Sharma, PM; Ricketts, W; Imamura, T; Olefsky, JM				Ugi, S; Sharma, PM; Ricketts, W; Imamura, T; Olefsky, JM			Phosphatidylinositol 3-kinase is required for insulin-stimulated tyrosine phosphorylation of Shc in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHOTYROSINE-BINDING DOMAIN; ACTIVATED PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; FACTOR RECEPTORS; RAS ACTIVATION; MAP KINASE; IN-VIVO; INHIBITION	The interactions between the phosphatidylinositol 3-kinase (PI 3-kinase) and Ras/MAPK kinase pathways have been the subject of considerable interest. In the current studies, we find that epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) lead to rapid phosphorylation of She (maximum at 1-2 min), whereas insulin-mediated She phosphorylation is relatively delayed (maximum. at 5-10 min), suggesting that an intermediary step may be necessary for insulin stimulation of Shc phosphorylation. The Src homology-2 (SH2) domain of Shc is necessary for PDGF- and EGF-mediated Shc phosphorylation, whereas the phosphotyrosine binding (PTB) domain is critical for the actions of insulin. Because the Shc PTB domain can interact with phospholipids, we postulated that PI 3-kinase might be a necessary intermediary step facilitating insulin-stimulated phosphorylation of Shc. In support of this' we found that the PI 3-kinase inhibitors, wortmannin and LY294002, blocked insulin-stimulated but not EGF- or PDGF-stimulated Shc phosphorylation. Furthermore, overexpression of a dominant negative PI 3-kinase construct (p85N-SH2) blocked insulin, but not EGF- or PDGF-induced Shc phosphorylation. All three growth factors cause localization of Shc to the plasma membrane, but only the effect of insulin was inhibited by wortmannin, supporting the view that PI 3-kinase-generated phospholipids mediate insulin-stimulated She phosphorylation. Consistent with this, expression of a constitutively active PI 3-kinase (p110(CAAX)) increased membrane localization of Shc, and this was completely blocked by wortmannin. A mutant She with a disrupted PTB domain (Shc S154) did not localize to the membrane in p110(CAAX)-expressing cells or after insulin stimulation and was not phosphorylated by insulin. In summary, 1) PI 3-kinase is a necessary early step in insulin-stimulated Shc phosphorylation, whereas the effects of EGF and PDGF on Shc phosphorylation are independent of PI 3-kinase. 2) PI 3-kinase-stimulated generation of membrane phospholipids can localize Shc to the plasma membrane through the She PTB domain facilitating phosphorylation by the insulin receptor.	Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; San Diego Vet Affairs Hosp, Res Serv, La Jolla, CA 92161 USA; Whittier Diabet Inst, La Jolla, CA 92037 USA	University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med 0673, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NIDDK NIH HHS [DK 33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R01DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Ceresa BP, 1998, MOL CELL BIOCHEM, V182, P23, DOI 10.1023/A:1006819008507; DePaolo D, 1996, MOL CELL BIOL, V16, P1450; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; LAM K, 1994, J BIOL CHEM, V269, P20648; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIPER RC, 1991, AM J PHYSIOL, V260, P570; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; Ricketts WA, 1999, MOL ENDOCRINOL, V13, P1988, DOI 10.1210/me.13.12.1988; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sakaguchi K, 1998, MOL ENDOCRINOL, V12, P536, DOI 10.1210/me.12.4.536; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Suga J, 1997, DIABETES, V46, P735, DOI 10.2337/diabetes.46.5.735; Ugi S, 2002, MOL CELL BIOL, V22, P2375, DOI 10.1128/MCB.22.7.2375-2387.2002; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; Yang CM, 2000, MOL ENDOCRINOL, V14, P317, DOI 10.1210/me.14.2.317; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	32	7	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18592	18597		10.1074/jbc.M201019200	http://dx.doi.org/10.1074/jbc.M201019200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11897789	hybrid			2022-12-25	WOS:000175975800047
J	Weeber, EJ; Levy, M; Sampson, MJ; Anflous, K; Armstrong, DL; Brown, SE; Sweatt, JD; Craigen, WJ				Weeber, EJ; Levy, M; Sampson, MJ; Anflous, K; Armstrong, DL; Brown, SE; Sweatt, JD; Craigen, WJ			The role of mitochondrial porins and the permeability transition pore in learning and synaptic plasticity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; DEPENDENT ANION CHANNEL; PROTEIN-KINASE; MEMORY FORMATION; CYCLOSPORINE-A; CYCLOPHILIN-D; CELL-DEATH; CALCINEURIN; PHOSPHATASE; INHIBITOR	Mitochondrial outer membrane permeability is conferred by a family of porin proteins. Mitochondrial porins conduct small molecules and constitute one component of the permeability transition pore that opens in response to apoptotic signals. Because mitochondrial porins have significant roles in diverge cellular processes including regulation of mitochondrial ATP and calcium flux, we sought to determine their importance in learning and synaptic plasticity in mice. We show that fear conditioning and spatial learning are disrupted in porin-deficient mice. Electrophysiological recordings of porin-deficient hippocampal slices reveal deficits in long and short term synaptic plasticity. Inhibition of the mitochondrial permeability transition pore by cyclosporin A in wild-type hippocampal slices reproduces the electrophysiological. phenotype of porin-deficient mice. These results demonstrate a dynamic functional role for mitochondrial porins and the permeability transition pore in learning and synaptic plasticity.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Craigen, WJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.		Levy, Michael/A-3268-2011; Weeber, Edwin J/A-5396-2012	Levy, Michael/0000-0002-7969-8346; Sweatt, J. David/0000-0003-3567-485X	PHS HHS [R01 55713] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1124/jpet.112.192138; Bennett PC, 1998, FEBS LETT, V431, P386, DOI 10.1016/S0014-5793(98)00795-9; Bennett PC, 1996, BRAIN RES, V730, P107; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; CHAPMAN PF, 1995, NEURON, V14, P591, DOI 10.1016/0896-6273(95)90315-1; CONNERN CP, 1992, BIOCHEM J, V284, P381, DOI 10.1042/bj2840381; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; David G, 1998, J PHYSIOL-LONDON, V509, P59, DOI 10.1111/j.1469-7793.1998.059bo.x; Decker WK, 2000, MOL GENET METAB, V70, P69, DOI 10.1006/mgme.2000.2987; Doolette DJ, 1997, NEUROCHEM INT, V30, P211, DOI 10.1016/S0197-0186(96)00055-1; FUNAUCHI M, 1994, NEUROSCI RES, V19, P269, DOI 10.1016/0168-0102(94)90039-6; Goosens KA, 2001, LEARN MEMORY, V8, P148, DOI 10.1101/lm.37601; Hodge T, 1997, J MEMBRANE BIOL, V157, P271, DOI 10.1007/s002329900235; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; KAMIYA H, 1994, NATURE, V371, P603, DOI 10.1038/371603a0; Lemasters JJ, 1999, J BIOENERG BIOMEMBR, V31, P305, DOI 10.1023/A:1005419617371; LINDEN M, 1984, BIOCHIM BIOPHYS ACTA, V770, P93, DOI 10.1016/0005-2736(84)90077-4; Lu YF, 1996, NEUROSCI LETT, V205, P103, DOI 10.1016/0304-3940(96)12384-3; Lu YM, 2000, NEURON, V26, P197, DOI 10.1016/S0896-6273(00)81150-2; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Malleret G, 2001, CELL, V104, P675, DOI 10.1016/S0092-8674(01)00264-1; McKernan MG, 1997, NATURE, V390, P607, DOI 10.1038/37605; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Nguyen PV, 1997, J NEUROPHYSIOL, V78, P281, DOI 10.1152/jn.1997.78.1.281; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Onuma H, 1998, NEUROSCI RES, V30, P313, DOI 10.1016/S0168-0102(98)00012-1; Roberson ED, 1996, J BIOL CHEM, V271, P30436, DOI 10.1074/jbc.271.48.30436; Sampson MJ, 2001, J BIOL CHEM, V276, P39206, DOI 10.1074/jbc.M104724200; Sampson MJ, 1997, J BIOL CHEM, V272, P18966, DOI 10.1074/jbc.272.30.18966; Sampson MJ, 1998, J BIOL CHEM, V273, P30482, DOI 10.1074/jbc.273.46.30482; SANDOVAL ME, 1980, BRAIN RES, V181, P357, DOI 10.1016/0006-8993(80)90618-6; Shepherd GMG, 1998, J NEUROSCI, V18, P8300; Silva AJ, 1996, CURR BIOL, V6, P1509, DOI 10.1016/S0960-9822(96)00756-7; Tang YG, 1997, NEURON, V18, P483, DOI 10.1016/S0896-6273(00)81248-9; Vyssokikh MY, 2001, BIOCHEM J, V358, P349, DOI 10.1042/0264-6021:3580349; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang JH, 1996, LEARN MEMORY, V3, P170, DOI 10.1101/lm.3.2-3.170; Weeber EJ, 2000, J NEUROSCI, V20, P5906, DOI 10.1523/JNEUROSCI.20-16-05906.2000; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; WU LG, 1994, J NEUROSCI, V14, P645; Wu SL, 1999, BBA-MOL CELL RES, V1452, P68, DOI 10.1016/S0167-4889(99)00120-2; Zeng HK, 2001, CELL, V107, P617, DOI 10.1016/S0092-8674(01)00585-2; Zucker RS, 1999, CURR OPIN NEUROBIOL, V9, P305, DOI 10.1016/S0959-4388(99)80045-2	45	142	149	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18891	18897		10.1074/jbc.M201649200	http://dx.doi.org/10.1074/jbc.M201649200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11907043	hybrid			2022-12-25	WOS:000175975800084
J	Zhang, Y; Zhai, QW; Luo, Y; Dorf, ME				Zhang, Y; Zhai, QW; Luo, Y; Dorf, ME			RANTES-mediated chemokine transcription in astrocytes involves activation and translocation of p90 ribosomal S6 protein kinase (RSK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; KAPPA-B-ALPHA; RECEPTOR EXPRESSION; MURINE ASTROCYTES; NERVOUS-SYSTEM; T-CELLS; PHOSPHORYLATION; PROLIFERATION; GROWTH; INFLAMMATION	RANTES (regulated on activation normal T cell expressed and secreted) (greater than or equal to10 ng/ml) stimulates the induction of KC and other chemokines in astrocytes. Elements of the signal transduction pathway controlling this response were identified. RANTES induced phosphorylation of MEK, ERK1/2, p90 ribosomal S6 kinases (RSK), and cAMP-response element-binding protein (CREB) in astrocytes. U0126, a pharmacological inhibitor of MEK, blocked the phosphorylation of the downstream elements ERK, RSK, and CREB, inhibited chemokine synthesis, and reduced transcription from a KC promoter construct. Dominant negative mutants of RSK or CREB blocked the transcription driven by the KC promoter. Finally, RANTES treatment induces nuclear translocation of phosphorylated RSK in astrocytes. This novel role for RSK in signaling chemokine responses and synthesis in astrocytes may contribute to the amplification mechanisms responsible for prolonging inflammatory responses in the central nervous system.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Dorf, ME (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Armenise Bldg,D530,200 Longwood Ave, Boston, MA 02115 USA.		Zhang, Ye/D-5015-2011	Zhang, Ye/0000-0002-3494-7206	NATIONAL CANCER INSTITUTE [R01CA067416] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037284] Funding Source: NIH RePORTER; NCI NIH HHS [CA67416] Funding Source: Medline; NINDS NIH HHS [NS37284] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abromson-Leeman S, 2001, EUR J IMMUNOL, V31, P527, DOI 10.1002/1521-4141(200102)31:2<527::AID-IMMU527>3.0.CO;2-D; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Bacon KB, 2000, J NEUROIMMUNOL, V104, P92, DOI 10.1016/S0165-5728(99)00266-0; Bajetto A, 2001, J NEUROCHEM, V77, P1226, DOI 10.1046/j.1471-4159.2001.00350.x; Bakhiet M, 2001, NAT CELL BIOL, V3, P150, DOI 10.1038/35055057; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; Dorf ME, 2000, J NEUROIMMUNOL, V111, P109, DOI 10.1016/S0165-5728(00)00371-4; DORF ME, 2002, UNIVERSES DELICATE B, P257; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fischer FR, 2000, J NEUROIMMUNOL, V110, P195, DOI 10.1016/S0165-5728(00)00351-9; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Grunfeld C, 1990, Adv Intern Med, V35, P45; Han YL, 2000, GLIA, V30, P1; Han YL, 2001, J CLIN INVEST, V108, P425, DOI 10.1172/JCI12629; Huang DR, 2000, IMMUNOL REV, V177, P52, DOI 10.1034/j.1600-065X.2000.17709.x; Janabi N, 1999, J IMMUNOL, V162, P1701; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Klein RS, 1999, J IMMUNOL, V163, P1636; Kwon EM, 2000, BLOOD, V95, P2552, DOI 10.1182/blood.V95.8.2552.008k30_2552_2558; Lane TE, 1998, J IMMUNOL, V160, P970; Lazarini F, 2000, EUR J NEUROSCI, V12, P117, DOI 10.1046/j.1460-9568.2000.00894.x; Luo Y, 2000, J IMMUNOL, V165, P4015, DOI 10.4049/jimmunol.165.7.4015; Luo Y, 1999, J IMMUNOL, V163, P3985; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; McManus CM, 2000, AM J PATHOL, V156, P1441, DOI 10.1016/S0002-9440(10)65013-4; Molina-Holgado E, 2000, BRIT J PHARMACOL, V131, P152, DOI 10.1038/sj.bjp.0703557; Morgan BP, 1997, IMMUNOPHARMACOLOGY, V38, P43; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; NORENBERG MD, 1997, IMMUNOLOGY NERVOUS S, P173; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pindon A, 2000, J NEUROSCI, V20, P2543; Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1; Richards SA, 2001, MOL CELL BIOL, V21, P7470, DOI 10.1128/MCB.21.21.7470-7480.2001; Robinson S, 1998, J NEUROSCI, V18, P10457; Rottman JB, 1997, AM J PATHOL, V151, P1341; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Sayah S, 1999, J NEUROCHEM, V72, P2426, DOI 10.1046/j.1471-4159.1999.0722426.x; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Tanabe S, 1997, J NEUROSCI, V17, P6522; Wong M, 2001, J BIOL CHEM, V276, P11427, DOI 10.1074/jbc.M010750200; Wu Q, 2000, J NEUROSCI, V20, P2609; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; Zhang PS, 1996, J NEUROSCI RES, V46, P114, DOI 10.1002/(SICI)1097-4547(19961001)46:1<114::AID-JNR14>3.0.CO;2-5; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	52	26	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19042	19048		10.1074/jbc.M112442200	http://dx.doi.org/10.1074/jbc.M112442200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893739	hybrid			2022-12-25	WOS:000175975800104
J	Germain, M; Mathai, JP; Shore, GC				Germain, M; Mathai, JP; Shore, GC			BH-3-only BIK functions at the endoplasmic reticulum to stimulate cytochrome c release from mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; BCL-2 FAMILY PROTEINS; P53-DEPENDENT APOPTOSIS; BH3-ONLY PROTEINS; CELL-DEATH; P53; BAX; INTERACTS; MEMBRANE; ADENOVIRUS	Stimulation of apoptosis by p53 is accompanied by induction of the BH-3-only proapoptotic member of the BCL-2 family, BIK, and ectopic expression of BIK in p53-null cells caused the release of cytochrome c from mitochondria and activation of caspases, dependent on a functional BH-3 domain. A significant fraction of BIK, which contains a predicted transmembrane segment at its COOH terminus, was found inserted in the endoplasmic reticulum (ER) membrane, with the bulk of the protein facing the cytosol. Restriction of BIK to this membrane by replacing its transmembrane segment with the ER-selective membrane anchor of cytochrome b(5) also retained the cytochrome c release and cell death-inducing activity of BIK. Whereas induction of cell death by BIK was strongly inhibited by the caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone, the inhibitor was without effect on the ability of BIK to stimulate egress of cytochrome c from mitochondria. This benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone-insensitive pathway for stimulating cytochrome c release from mitochondria by ER BIK was successfully reconstituted in vitro and identified the requirement for components present in the light membrane (ER) and cytosol as necessary for this activity. Collectively, the results identify BIK as an initiator of cytochrome a release from mitochondria operating from a location at the ER.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Shore, GC (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg,3655 Promenade Sir William, Montreal, PQ H3G 1Y6, Canada.	gordon.shore@mcgill.ca						Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; AKAO Y, 1994, CANCER RES, V54, P2468; BOYD JM, 1995, ONCOGENE, V11, P1921; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; GOPING IS, 1995, FEBS LETT, V373, P45; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han J, 1996, MOL CELL BIOL, V16, P5857; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pedrazzini E, 2000, J CELL BIOL, V148, P899, DOI 10.1083/jcb.148.5.899; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Rudner J, 2001, J CELL SCI, V114, P4161; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	33	119	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18053	18060		10.1074/jbc.M201235200	http://dx.doi.org/10.1074/jbc.M201235200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884414	hybrid			2022-12-25	WOS:000175685100084
J	Lemeshko, VV				Lemeshko, VV			Cytochrome c sorption-desorption effects on the external NADH oxidation by mitochondria - Experimental and computational study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; PROGRAMMED CELL-DEATH; ELECTRON-TRANSPORT; OUTER-MEMBRANE; APOPTOSIS; ACTIVATION; SYSTEM; CHAIN; AGE	The rupture of the outer mitochondrial membrane is known to be critical for cell death, but the mechanism, specifically its redox-signaling aspects, still needs to be studied in more detail. In this work, the external NADH oxidation by rat liver mitochondria was studied under the outer membrane rupture induced by the mitochondria hypotonic treatment or the inner membrane permeability transition. The saturation of the oxidation rate was observed as a function of mitochondrial protein concentration. This effect was shown to result from cytochrome e binding to the mitochondrial membranes. At a relatively high concentration of mitochondria, the oxidation rate was strongly activated by 4 mm Mg2+ due to cytochrome c desorption from the membranes. A minimal kinetic model was developed to explain the main phenomena of the external NADH oxidation modulated by cytochrome e and Mg2+ in mitochondria with the ruptured outer membrane. The computational behavior of the model closely agreed with the experimental data. We suggest that the redox state of the released cytochrome c, considered by other authors to be important for apoptosis, may strongly depend on its oxidation by the fraction of mitochondria with the ruptured outer membrane and on the cytoplasmic cytochrome c reductase activity.	Univ Nacl Colombia, Fac Ciencias, Sch Phys, Dept Sci,Medellin Branch, AA-3840 Medellin, Colombia	Universidad Nacional de Colombia	Lemeshko, VV (corresponding author), Univ Nacl Colombia, Fac Ciencias, Sch Phys, Dept Sci,Medellin Branch, Calle 65,Cra 64, AA-3840 Medellin, Colombia.	vvasilie@perseus.unalmed.edu.co						BERNARDI P, 1981, J BIOL CHEM, V256, P7187; Bodrova ME, 1998, FEBS LETT, V435, P269, DOI 10.1016/S0014-5793(98)01072-2; Cai JY, 2000, FREE RADICAL BIO MED, V29, P334, DOI 10.1016/S0891-5849(00)00312-9; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Cai JY, 1999, J BIOENERG BIOMEMBR, V31, P327, DOI 10.1023/A:1005423818280; COOPER CE, 1990, BIOCHIM BIOPHYS ACTA, V1017, P187, DOI 10.1016/0005-2728(90)90184-6; Cortese JD, 1998, BIOCHEMISTRY-US, V37, P6402, DOI 10.1021/bi9730543; HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010; Hancock JT, 2001, FREE RADICAL BIO MED, V31, P697, DOI 10.1016/S0891-5849(01)00646-3; La Piana G, 1998, BIOCHEM BIOPH RES CO, V246, P556; Lemeshko V. V., 1995, Ukrainskii Biokhimicheskii Zhurnal, V67, P28; LEMESHKO VV, 1993, MECH AGEING DEV, V68, P221, DOI 10.1016/0047-6374(93)90153-I; Lemeshko VV, 2000, FEBS LETT, V472, P5, DOI 10.1016/S0014-5793(00)01419-8; Lemeshko VV, 2001, ARCH BIOCHEM BIOPHYS, V388, P60, DOI 10.1006/abbi.2000.2214; LEMESHKO VV, 1982, BIOFIZIKA+, V27, P837; LEMESHKO VV, 2001, KEYSTONE S, P107; LOFRUMENTO NE, 1991, ARCH BIOCHEM BIOPHYS, V288, P293, DOI 10.1016/0003-9861(91)90198-R; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; MARZULLI D, 1995, ARCH BIOCHEM BIOPHYS, V319, P36, DOI 10.1006/abbi.1995.1264; Marzulli D, 1999, BIOCHEM BIOPH RES CO, V259, P325, DOI 10.1006/bbrc.1999.0787; MATLIB MA, 1976, ARCH BIOCHEM BIOPHYS, V173, P27, DOI 10.1016/0003-9861(76)90230-7; Mokhova E. N., 1977, BIOCHIM BIOPHYS ACTA, V501, P415; NICHOLLS P, 1969, FEBS LETT, V3, P242, DOI 10.1016/0014-5793(69)80147-X; NICHOLLS P, 1974, BIOCHIM BIOPHYS ACTA, V346, P261, DOI 10.1016/0304-4173(74)90003-2; Pan ZH, 1999, CELL DEATH DIFFER, V6, P683, DOI 10.1038/sj.cdd.4400544; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; Skulachev VP, 2001, EXP GERONTOL, V36, P995, DOI 10.1016/S0531-5565(01)00109-7; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; SKULACHEV VP, 1969, ACCUMULATION ENERGY; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; TAYLOR DD, 1992, MITOCHONDRIA HLTH DI; WIKSTROM M, 1985, FEBS LETT, V183, P293, DOI 10.1016/0014-5793(85)80796-1; WILLIAMS JN, 1964, ARCH BIOCHEM BIOPHYS, V107, P537, DOI 10.1016/0003-9861(64)90313-3; WILLIAMS JN, 1968, BIOCHIM BIOPHYS ACTA, V162, P175, DOI 10.1016/0005-2728(68)90100-X; Wojtczak L, 1974, Rev Roum Physiol, V11, P173	36	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17751	17757		10.1074/jbc.M201002200	http://dx.doi.org/10.1074/jbc.M201002200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11886867	hybrid			2022-12-25	WOS:000175685100047
J	Nixon, AB; Grenningloh, G; Casey, PJ				Nixon, AB; Grenningloh, G; Casey, PJ			The interaction of RGSZ1 with SCG10 attenuates the ability of SCG10 to promote microtubule disassembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; HETEROTRIMERIC G-PROTEINS; IN-VITRO PHOSPHORYLATION; YEAST 2-HYBRID SYSTEM; SACCHAROMYCES-CEREVISIAE; SIGNALING PROTEINS; NEURITE OUTGROWTH; BINDING DOMAINS; AXONAL GROWTH; GENE FAMILY	RGS proteins (regulators of G protein signaling) are a diverse family of proteins that act to negatively regulate signaling by heterotrimeric G proteins. Initially characterized as GTPase-activating proteins for Galpha subunits, recent data have implied additional functions for RGS proteins. We previously identified an RGS protein (termed RGSZ1) whose expression is quite specific to neuronal tissue (Glick, J. L., Meigs, T. E., Miron, A., and Casey, P. J. (1998) J. Biol. Chem. 273, 26008-26013). In a continuing effort to understand the role of RGSZ1 in cellular signaling, the yeast two-hybrid system was employed to identify potential effector proteins of RGSZ1. The microtubule-destabilizing protein SCG10 (superior cervical ganglia, neural specific 10) was found to directly interact with RGSZ1 in the yeast system, and this interaction was further verified using direct binding assays. Treatment of PC12 cells with nerve growth factor resulted in Golgi-specific distribution of SCG10. A green fluorescent protein-tagged variant of RGSZ1 translocated to the Golgi complex upon treatment of PC 12 cells with nerve growth factor, providing evidence that RGSZ1 and SCG10 interact in cells as well as in vitro. Analysis of in vitro microtubule polymerization/depolymerization showed that binding of RGSZ1 to SCG10 effectively blocked the ability of SCG10 to induce microtubule disassembly as determined by both turbidimetric and microscopy-based assays. These results identify a novel connection between RGS proteins and the cytoskeletal network that points to a broader role than previously envisioned for RGS proteins in regulating biological processes.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Lausanne, Inst Biol Cellulaire & Morphol, CH-1005 Lausanne, Switzerland	Duke University; Duke University; University of Lausanne	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, C133 LSRC,Res Dr, Durham, NC 27710 USA.		Nixon, Andrew/AAJ-4712-2020	Nixon, Andrew/0000-0003-3971-2964; Casey, Patrick/0000-0002-7366-9309	NIGMS NIH HHS [F32 GM19663, R01 GM55717] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055717, F32GM019663] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonsson B, 1998, J BIOL CHEM, V273, P8439, DOI 10.1074/jbc.273.14.8439; Antonsson B, 1997, PROTEIN EXPRES PURIF, V9, P363, DOI 10.1006/prep.1996.0710; Bai C, 1996, METHOD ENZYMOL, V273, P331; Bai C, 1997, METHOD ENZYMOL, V283, P141; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Benzing T, 2000, J BIOL CHEM, V275, P28167; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burchett SA, 2000, J NEUROCHEM, V75, P1335, DOI 10.1046/j.1471-4159.2000.0751335.x; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Challacombe JF, 1997, J NEUROSCI, V17, P3085; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Di Paolo G, 1997, J NEUROSCI RES, V50, P1000, DOI 10.1002/(SICI)1097-4547(19971215)50:6<1000::AID-JNR10>3.0.CO;2-8; DiPaolo G, 1997, J BIOL CHEM, V272, P5175, DOI 10.1074/jbc.272.8.5175; DiTella MC, 1996, J CELL SCI, V109, P467; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; ESMAELIAZAD B, 1994, J CELL SCI, V107, P869; GASKIN F, 1974, J MOL BIOL, V89, P737, DOI 10.1016/0022-2836(74)90048-5; Gavet O, 1998, J CELL SCI, V111, P3333; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; Howell B, 1999, J CELL SCI, V112, P3713; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Lutjens R, 2000, EUR J NEUROSCI, V12, P2224, DOI 10.1046/j.1460-9568.2000.00112.x; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OKAZAKI T, 1993, GENOMICS, V18, P360, DOI 10.1006/geno.1993.1477; Ozon S, 1997, EUR J BIOCHEM, V248, P794, DOI 10.1111/j.1432-1033.1997.t01-2-00794.x; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Ponting CP, 1999, J MOL MED, V77, P695, DOI 10.1007/s001099900054; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; Rochlin MW, 1996, J NEUROSCI, V16, P3236; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; STEIN R, 1988, DEV BIOL, V127, P316, DOI 10.1016/0012-1606(88)90318-1; TANAKA E, 1995, J CELL BIOL, V128, P139, DOI 10.1083/jcb.128.1.139; Tint I, 1998, J NEUROSCI, V18, P8660; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Zhang SL, 2000, ACTA MATH SCI, V20, P1	50	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18127	18133		10.1074/jbc.M201065200	http://dx.doi.org/10.1074/jbc.M201065200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882662	hybrid			2022-12-25	WOS:000175685100094
J	Salamanca, S; Villegas, V; Vendrell, J; Li, L; Aviles, FX; Chang, JY				Salamanca, S; Villegas, V; Vendrell, J; Li, L; Aviles, FX; Chang, JY			The unfolding pathway of leech carboxypeptidase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRINOLYSIS INHIBITOR; DENATURED STATES; PROTEINS; MECHANISM; COMPLEX; UREA	The unfolding and denaturation curves of leech carboxypeptidase inhibitor (LCI) were elucidated using the technique of disulfide scrambling. In the presence of thiol initiator and denaturant, the native LCI denatures by shuffling its native disulfide bonds and transforms into a mixture of scrambled species. 9 of 104 possible scrambled isomers of LCI, amounting to 90% of total denatured LCI, can be distinguished. The denaturation curve that plots the fraction of native LCI converted into scrambled isomers upon increasing concentrations of denaturant shows that the concentration of guanidine thiocyanate and guanidine hydrochloride required to reach 50% of denaturation is 2.4 and 3.6 M, respectively. In contrast, native LCI is resistant to urea denaturation even at high concentration (8 m). The LCI unfolding pathway was defined based on the evolution of the relative concentration of scrambled isoforms of LCI upon denaturation. Two populations of scrambled species suffer variations along the unfolding pathway. One accumulates as intermediates under strong denaturing conditions and corresponds to open or relaxed structures, among which the beads-form isomer is found. The other population shows an inverse correlation between their relative abundances and the denaturing conditions and should have another kind of non-native structure that is more compact than the unfolded state. The rate constants of unfolding of LCI are low when compared with other disulfide-containing proteins. Overall, the results presented in this study show that LCI, a molecule with potential biotechnological applications, has slow kinetics of unfolding and is highly stable.	Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain; Univ Texas, Inst Mol Med, Res Ctr Prot Chem, Houston, TX 77030 USA; Univ Texas, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Autonomous University of Barcelona; Autonomous University of Barcelona; University of Texas System; University of Texas System	Aviles, FX (corresponding author), Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain.		Villegas, Sandra/D-8789-2011; Avilés, Francesc Xavier/A-2664-2015; Aviles, Francesc Xavier/F-3482-2019; Villegas, Sandra/ABF-8206-2021; Vendrell, Josep/A-6731-2010	Villegas, Sandra/0000-0001-8644-4304; Avilés, Francesc Xavier/0000-0002-1399-6789; Aviles, Francesc Xavier/0000-0002-1399-6789; Villegas, Sandra/0000-0001-8644-4304; Vendrell, Josep/0000-0002-9378-4742				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Bajzar L, 2000, ARTERIOSCL THROM VAS, V20, P2511, DOI 10.1161/01.ATV.20.12.2511; Chang JY, 1999, PROTEIN SCI, V8, P1463, DOI 10.1110/ps.8.7.1463; Chang JY, 1999, J BIOL CHEM, V274, P123, DOI 10.1074/jbc.274.1.123; Chang JY, 1997, J BIOL CHEM, V272, P69; Chang JY, 2000, J BIOL CHEM, V275, P14205, DOI 10.1074/jbc.275.19.14205; Chang JY, 1998, BIOCHEMISTRY-US, V37, P6745, DOI 10.1021/bi9714565; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; HABER E, 1962, J BIOL CHEM, V237, P1839; LIEPINSH E, 1994, J AM CHEM SOC, V116, P9670, DOI 10.1021/ja00100a036; MATOUSCHEK A, 1992, J MOL BIOL, V224, P819, DOI 10.1016/0022-2836(92)90564-Z; Pace C N, 1986, Methods Enzymol, V131, P266; PACE CN, 1990, BIOCHEMISTRY-US, V29, P2564, DOI 10.1021/bi00462a019; REES DC, 1982, J MOL BIOL, V160, P475, DOI 10.1016/0022-2836(82)90309-6; Reverter D, 1998, J BIOL CHEM, V273, P32927, DOI 10.1074/jbc.273.49.32927; Reverter D, 2000, NAT STRUCT BIOL, V7, P322, DOI 10.1038/74092; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176	19	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17538	17543		10.1074/jbc.M200040200	http://dx.doi.org/10.1074/jbc.M200040200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11893741	hybrid			2022-12-25	WOS:000175685100020
J	Guzzi, F; Zanchetta, D; Cassoni, P; Guzzi, V; Francolini, M; Parenti, M; Chini, B				Guzzi, F; Zanchetta, D; Cassoni, P; Guzzi, V; Francolini, M; Parenti, M; Chini, B			Localization of the human oxytocin receptor in caveolin-1 enriched domains turns the receptor-mediated inhibition of cell growth into a proliferative response	ONCOGENE			English	Article						cell growth; oxytocin receptor; G-protein coupled receptor; caveolin; MDCK cells	SIGNAL-TRANSDUCTION; ADENYLYL-CYCLASE; CHOLESTEROL; VASOPRESSIN; SEQUESTRATION; MECHANISMS; COMPLEXES; PROTEINS	In this study, we investigated the functional role of the localization of human OTR in caveolin-1 enriched membrane domains. Biochemical fractionation of MDCK cells stably expressing the WT OTR-GFP indicated that only minor quantities of receptor are partitioned in caveolin-1 enriched domains. However, when fused to caveolin-2, the OTR protein proved to be exclusively localized in caveolin-1 enriched fractions, where it bound the agonist with increased affinity and efficiently coupled to Galpha(q/11). Interestingly, the chimeric protein was unable to undergo agonist-induced internalization and remained confined to the plasma membrane even after prolonged agonist exposure (120 min). A striking difference in receptor stimulation was observed when the OT-induced effect on cell proliferation was analysed: stimulation of the human WT OTR inhibited cell growth, whereas the chimeric protein had a proliferative effect. These data indicate that the localization of human OTR in caveolin-1 enriched microdomains radically alters its regulatory effects on cell growth; the fraction of OTR residing in caveolar structures may therefore play a crucial role in regulating cell proliferation.	CNR, Cellular & Mol Pharmacol Ctr, I-20129 Milan, Italy; Univ Milan, Dept Expt & Environm Med, I-20052 Monza, Italy; Univ Turin, Dept Biomed Sci & Oncol, I-10126 Turin, Italy; Univ Milan, Dept Pharmacol, I-20129 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Turin; University of Milan	Chini, B (corresponding author), CNR, Cellular & Mol Pharmacol Ctr, I-20129 Milan, Italy.	B.Chini@csfic.mi.cnr.it	Cassoni, Paola/I-8544-2018	Chini, Bice/0000-0002-1686-284X; FRANCOLINI, MAURA/0000-0002-3126-1575				ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Cassoni P, 2001, ENDOCRINOLOGY, V142, P1130, DOI 10.1210/en.142.3.1130; Cassoni P, 1997, INT J CANCER, V72, P340, DOI 10.1002/(SICI)1097-0215(19970717)72:2<340::AID-IJC23>3.0.CO;2-I; Cassoni P, 1998, INT J CANCER, V77, P695, DOI 10.1002/(SICI)1097-0215(19980831)77:5<695::AID-IJC6>3.0.CO;2-Q; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; Chini B, 1996, FEBS LETT, V397, P201, DOI 10.1016/S0014-5793(96)01135-0; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dessy C, 2000, EMBO J, V19, P4272, DOI 10.1093/emboj/19.16.4272; ELANDS J, 1988, AM J PHYSIOL, V254, pE31, DOI 10.1152/ajpendo.1988.254.1.E31; Gimpl G, 2000, EUR J BIOCHEM, V267, P2483, DOI 10.1046/j.1432-1327.2000.01280.x; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hailstones D, 1998, J LIPID RES, V39, P369; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Hoare S, 1999, J BIOL CHEM, V274, P28682, DOI 10.1074/jbc.274.40.28682; KIRK CJ, 1986, BIOCHEM J, V240, P197, DOI 10.1042/bj2400197; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; OHMICHI M, 1995, ENDOCRINOLOGY, V136, P2082, DOI 10.1210/en.136.5.2082; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ostrom RS, 2000, MOL PHARMACOL, V57, P1075; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; STRAKOVA Z, 1997, AM J PHYSIOL, V272, P870; STRAKOVA Z, 1998, AM J PHYSL SE, V274, P634; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304	34	85	85	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1658	1667		10.1038/sj.onc.1205219	http://dx.doi.org/10.1038/sj.onc.1205219			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896597				2022-12-25	WOS:000174214200004
J	Faivre, J; Frank-Vaillant, M; Poulhe, R; Mouly, H; Jessus, C; Brechot, C; Sobczak-Thepot, J				Faivre, J; Frank-Vaillant, M; Poulhe, R; Mouly, H; Jessus, C; Brechot, C; Sobczak-Thepot, J			Centrosome overduplication, increased ploidy and transformation in cells expressing endoplasmic reticulum-associated cyclin A2	ONCOGENE			English	Article						cell cycle; cyclins; cytoplasm; endoplasmic reticulum	HEPATITIS-B-VIRUS; TRANSMEMBRANE ORIENTATION; MALIGNANT-TRANSFORMATION; ONCOGENIC ACTIVATION; NUCLEAR-LOCALIZATION; DEPENDENT KINASES; REQUIRES E2F; G(1) CYCLIN; IN-VITRO; PROTEIN	Cyclin A2 is predominantly, but not exclusively, localized in the nucleus from G1/S transition onwards. It is degraded when cells enter mitosis after nuclear envelope breakdown. We previously showed that a fusion protein (S2A) between the hepatitis B virus (HBV) surface antigen protein and a non-degradable fragment of human cyclin A2 (Delta152) resides in the endoplasmic reticulum membranes, escapes degradation and transforms normal rat fibroblasts. The present study investigates whether cytoplasmic cyclin A2 may play a role in oncogenesis. We show that the sequestration of non-degradable cyclin A2-Delta152 by a cellular ER targeting domain (PRL-A2) leads to cell transformation when coexpressed with activated Ha-ras. REF52 cells constitutively expressing PRL-A2 are found to have a high incidence of multinucleate giant cells, polyploidy and abnormal centrosome numbers, giving rise to the nucleation of multipolar spindles. Injection of these cells into athymic nude mice causes tumors, even in the absence of a cooperating Ha-ras oncogene. These results demonstrate that, independently of any viral context, an intracellular redistribution of non-degradable cyclin A2 is capable of deregulating the normal cell cycle to the point where it promotes aneuploidy and cancer.	Inst Pasteur, INSERM, U370, Fac Med Necker, F-75015 Paris, France; Univ Paris 06, CNRS, UMR 7622, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite	Faivre, J (corresponding author), Inst Pasteur, INSERM, U370, Fac Med Necker, 156 Rue Vaugirard, F-75015 Paris, France.	faivre@necker.fr	Sobczak, Joelle/HHZ-5610-2022	Sobczak, Joelle/0000-0001-7180-2789				Aaltomaa S, 1999, PROSTATE, V38, P175; Aaltomaa S, 1999, BRIT J CANCER, V80, P2001, DOI 10.1038/sj.bjc.6690634; Albrecht JH, 1999, AM J PHYSIOL-GASTR L, V277, pG1207, DOI 10.1152/ajpgi.1999.277.6.G1207; Allan K, 2000, ARCH PATHOL LAB MED, V124, P216; BAILLY E, 1992, J CELL SCI, V101, P529; Berasain C, 1998, ONCOGENE, V16, P1277, DOI 10.1038/sj.onc.1201893; BRECHOT C, 1993, CURR OPIN GENET DEV, V3, P11, DOI 10.1016/S0959-437X(05)80335-1; BUENDIA B, 1992, J CELL BIOL, V116, P1431, DOI 10.1083/jcb.116.6.1431; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CASTRO A, 1994, BIOCHEM BIOPH RES CO, V201, P1072, DOI 10.1006/bbrc.1994.1814; Coverley D, 2000, J CELL SCI, V113, P1929; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; EBLE BE, 1987, MOL CELL BIOL, V7, P3591, DOI 10.1128/MCB.7.10.3591; Faivre J, 2001, FEBS LETT, V506, P243, DOI 10.1016/S0014-5793(01)02920-9; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Grzanka A, 2001, NEOPLASMA, V48, P112; Gudas JM, 1999, MOL CELL BIOL, V19, P612; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HALL FL, 1991, J BIOL CHEM, V266, P17430; Handa K, 1999, INT J CANCER, V84, P225, DOI 10.1002/(SICI)1097-0215(19990621)84:3<225::AID-IJC5>3.0.CO;2-A; Hildt E, 1998, RECENT RES CANCER, V154, P315; Huuhtanen RL, 1999, CANCER RES, V59, P2885; Jacobs HW, 2001, EMBO J, V20, P2376, DOI 10.1093/emboj/20.10.2376; Kaufmann H, 2001, J BIOL CHEM, V276, P29987, DOI 10.1074/jbc.M005452200; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; LAUER U, 1992, J VIROL, V66, P5284, DOI 10.1128/JVI.66.9.5284-5289.1992; LINGAPPA VR, 1984, P NATL ACAD SCI-BIOL, V81, P456, DOI 10.1073/pnas.81.2.456; Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313; LU XP, 1992, J BIOL CHEM, V267, P2841; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; MARIDOR G, 1993, J CELL SCI, V106, P535; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; Parry DH, 2001, CURR BIOL, V11, P671, DOI 10.1016/S0960-9822(01)00204-4; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; PRANGE R, 1995, EMBO J, V14, P247, DOI 10.1002/j.1460-2075.1995.tb06998.x; SLUDER G, 1986, J CELL BIOL, V103, P1873, DOI 10.1083/jcb.103.5.1873; Sluder G, 1999, BIOL CELL, V91, P413, DOI 10.1016/S0248-4900(99)80083-5; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Sprenger F, 1997, CURR BIOL, V7, P488, DOI 10.1016/S0960-9822(06)00220-X; THOMAS L, 1992, J BIOL CHEM, V267, P6183; Verges M, 1997, BIOCHEM BIOPH RES CO, V230, P49, DOI 10.1006/bbrc.1996.5851; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Winston N, 2000, DEV BIOL, V223, P139, DOI 10.1006/dbio.2000.9721; WOLFF A, 1992, EUR J CELL BIOL, V59, P425; WOODMAN PG, 1993, MOL BIOL CELL, V4, P541, DOI 10.1091/mbc.4.5.541; YOST CS, 1983, CELL, V34, P759; Zhai YL, 1999, INT J CANCER, V84, P244, DOI 10.1002/(SICI)1097-0215(19990621)84:3<244::AID-IJC8>3.0.CO;2-2	54	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1493	1500		10.1038/sj.onc.1205215	http://dx.doi.org/10.1038/sj.onc.1205215			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896577				2022-12-25	WOS:000173956800004
J	Comerford, KM; Lawrence, DW; Synnestvedt, K; Levi, BP; Colgan, SP				Comerford, KM; Lawrence, DW; Synnestvedt, K; Levi, BP; Colgan, SP			Role of vasodilator-stimulated phosphoprotein in protein kinase A-induced changes in endothelial junctional permeability	FASEB JOURNAL			English	Article						cytoskeleton; neutrophil; adenosine; inflammation; cyclic AMP	CELL GAP FORMATION; FOCAL-ADHESION; BARRIER FUNCTION; LISTERIA-MONOCYTOGENES; HUMAN PLATELETS; SERINE-239 PHOSPHORYLATION; BINDING PROPERTIES; ENA/VASP PROTEINS; TIGHT JUNCTIONS; ACTIN-BINDING	At sites of ongoing inflammation, polymorphonuclear leukocytes (PMN, neutrophils) migrate across vascular endothelia, and such transmigration has the potential to disturb barrier properties and can result in intravascular fluid loss and edema. It was recently appreciated that endogenous pathways exist to dampen barrier disruption during such episodes and may provide an important anti-inflammatory link. For example, during transmigration, PMN-derived adenosine activates endothelial adenosine receptors and induces a cAMP-dependent resealing of endothelial barrier function. In our study reported here, we sought to understand the link between cyclic nucleotide elevation and increased endothelial barrier function. Initial studies revealed that adenosine-induced barrier function is tightly linked to activation of protein kinase A (PKA). Because PKA selectively phosphorylates serine and threonine residues, we screened zonula occludens-1 (ZO-1) immunoprecipitates for the existence of such phosphorylated proteins as targets for barrier regulation. This analysis revealed a dominantly phosphorylated band at 50 kDa. Microsequencing identified this protein as vasodilator-stimulated phosphoprotein (VASP), an actin binding protein with multiple serine/threonine phosphorylation sites. Immunofluorescent microscopy revealed that VASP localizes to endothelial junctional complexes and colocalizes with ZO-1, occludin, and junctional adhesion molecule-1 (JAM-1). To address the role of phospho-VASP in regulation of barrier function, we generated a phosphospecific VASP antibody targeting the Ser157 residue phosphorylation site, the site preferred by PKA. Immunolocalization studies with this antibody revealed that upon PKA activation, phospho-VASP appears at cell-cell junctions. Transient transfection of truncated VASP fragments revealed a parallel increase in barrier function. Taken together, these studies reveal a central role for phospho-VASP in the coordination of PKA-regulated barrier function, such as occurs during episodes of inflammation.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Colgan, SP (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Thorn Bldg 704,75 Francis St, Boston, MA 02115 USA.	colgan@zeus.bwh.harvard.edu	Colgan, Sean P./B-4573-2009	Lawrence, Donald/0000-0001-5912-6992				ADKINS WK, 1992, J APPL PHYSIOL, V72, P492, DOI 10.1152/jappl.1992.72.2.492; Ahern-Djamali SM, 1999, P NATL ACAD SCI USA, V96, P4977, DOI 10.1073/pnas.96.9.4977; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; BALUK P, 1994, AM J PHYSIOL, V266, pL461, DOI 10.1152/ajplung.1994.266.4.L461; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; BUTT E, 1994, J BIOL CHEM, V269, P14509; CASNOCHA SA, 1989, J APPL PHYSIOL, V67, P1997, DOI 10.1152/jappl.1989.67.5.1997; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; Cohen CR, 1997, EXP CELL RES, V231, P184, DOI 10.1006/excr.1996.3450; Colgan SP, 1996, J EXP MED, V184, P1003, DOI 10.1084/jem.184.3.1003; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; DANCEY JT, 1976, J CLIN INVEST, V58, P705, DOI 10.1172/JCI108517; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; DRAIJER R, 1995, CIRC RES, V77, P897, DOI 10.1161/01.RES.77.5.897; Drees B, 2000, J BIOL CHEM, V275, P22503, DOI 10.1074/jbc.M001698200; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Friedman GB, 1998, J CELL PHYSIOL, V176, P76, DOI 10.1002/(SICI)1097-4652(199807)176:1<76::AID-JCP9>3.0.CO;2-5; GARCIA JGN, 1995, J INVEST MED, V43, P117; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; HALBRUGGE M, 1992, CELL SIGNAL, V4, P189, DOI 10.1016/0898-6568(92)90082-J; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; HUANG AJ, 1988, J CELL PHYSIOL, V135, P355, DOI 10.1002/jcp.1041350302; HUBER AR, 1989, J CLIN INVEST, V83, P1122, DOI 10.1172/JCI113992; Huttelmaier S, 1999, FEBS LETT, V451, P68, DOI 10.1016/S0014-5793(99)00546-3; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Lehr HA, 2000, J PATHOL, V190, P373, DOI 10.1002/(SICI)1096-9896(200002)190:3&lt;373::AID-PATH593&gt;3.0.CO;2-3; Lennon PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/jem.188.8.1433; LEWIS RE, 1988, MICROVASC RES, V35, P27, DOI 10.1016/0026-2862(88)90048-9; LOFTON CE, 1990, BIOCHEM BIOPH RES CO, V172, P793, DOI 10.1016/0006-291X(90)90744-8; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; LUM H, 1994, AM J PHYSIOL, V267, pL223, DOI 10.1152/ajplung.1994.267.3.L223; Machesky LM, 2000, CELL, V101, P685, DOI 10.1016/S0092-8674(00)80879-X; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; MARCHESI V. T., 1960, QUART JOUR EXPTL PHYSIOL, V45, P343; MEYRICK B, 1984, TISSUE CELL, V16, P1, DOI 10.1016/0040-8166(84)90014-4; Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL203, DOI 10.1152/ajplung.1998.275.2.L203; Narravula S, 2000, J IMMUNOL, V165, P5262, DOI 10.4049/jimmunol.165.9.5262; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; NOLTE C, 1991, J BIOL CHEM, V266, P14808; Nusrat A, 2000, J CELL SCI, V113, P1771; Nusrat A, 2000, AM J PHYSIOL-GASTR L, V279, pG851, DOI 10.1152/ajpgi.2000.279.5.G851; Oelze M, 2000, CIRC RES, V87, P999, DOI 10.1161/01.RES.87.11.999; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; Price CJ, 2000, ARTERIOSCL THROM VAS, V20, P2051, DOI 10.1161/01.ATV.20.9.2051; REINECKER HC, 1995, P NATL ACAD SCI USA, V92, P8353, DOI 10.1073/pnas.92.18.8353; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; Riley MV, 1998, INVEST OPHTH VIS SCI, V39, P2076; SHASBY DM, 1982, CIRC RES, V51, P657, DOI 10.1161/01.RES.51.5.657; SHAW JO, 1982, AM J PATHOL, V108, P17; Smolenski A, 2000, J BIOL CHEM, V275, P25723, DOI 10.1074/jbc.M909632199; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Stevens T, 1999, AM J PHYSIOL-LUNG C, V277, pL119, DOI 10.1152/ajplung.1999.277.1.L119; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Zund G, 1996, P NATL ACAD SCI USA, V93, P7075, DOI 10.1073/pnas.93.14.7075	66	143	148	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					583	+		10.1096/fj.01-0739fje	http://dx.doi.org/10.1096/fj.01-0739fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919161				2022-12-25	WOS:000174203700016
J	Weiss, RG; Chatham, JC; Charron, MJ; Georgakopolous, D; Wallimann, T; Kay, L; Walzel, B; Wang, YB; Kass, DA; Gerstenblith, G; Chacko, VP				Weiss, RG; Chatham, JC; Charron, MJ; Georgakopolous, D; Wallimann, T; Kay, L; Walzel, B; Wang, YB; Kass, DA; Gerstenblith, G; Chacko, VP			An increase in the myocardial PCr/ATP ratio in GLUT4 null mice	FASEB JOURNAL			English	Article						phosphocreatine; glucose; left ventricular hypertrophy; P-31 NMR spectroscopy; magnetic resonance imaging	CORONARY-ARTERY DISEASE; LEFT-VENTRICULAR HYPERTROPHY; ACTIVATED PROTEIN-KINASE; DECREASED ENERGY RESERVE; P-31 NMR-SPECTROSCOPY; SKELETAL-MUSCLE; CREATINE-KINASE; DILATED CARDIOMYOPATHY; HEART-FAILURE; IN-VIVO	ATP and creatine phosphate (PCr) are prime myocardial high-energy phosphates. Their relative concentrations are conserved among mammalian species and across a range of physiologic cardiac workloads. The cardiac PCr/ATP ratio is decreased with several pathologic conditions, such as ischemia and heart failure, but there are no reports of an increase in the cardiac PCr/ATP ratio in any species or with interventions. We studied the in vivo energetics in transgenic mice lacking expression of the glucose transport protein GLUT4 (G4N) and observed a significant 60% increase in the myocardial PCr/ATP ratio in G4N that was confirmed in three different experimental settings including intact animals. The higher PCr/ATP in G4N is cardiac-specific and is due to higher total cardiac creatine (CR) concentrations in G4N than in wild-type (WT). However, [ATP], [ADP], and -DeltaG(similar toATP) did not differ between the strains. Expression of the creatine transport protein (CreaT) that is responsible for creatine uptake in myocytes was preserved in G4N cardiac tissue. These observations demonstrate, for the first time to our knowledge, that G4N manifest a unique increase in the cardiac PCr/ATP ratio, which suggests a novel genetic strategy for increasing myocardial creatine levels.	Johns Hopkins Univ, Sch Med, Dept Radiol, NMR Res Div, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10467 USA; ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins University; Yeshiva University; Albert Einstein College of Medicine; Swiss Federal Institutes of Technology Domain; ETH Zurich; University System of Maryland; University of Maryland Baltimore	Weiss, RG (corresponding author), Johns Hopkins Univ Hosp, Carnegie 584,600 N Wolfe St, Baltimore, MD 21287 USA.	rgweiss@rad.jhu.edu	Wallimann, Theo/C-6047-2008	Wallimann, Theo/0000-0003-4957-5836; Wang, Yibin/0000-0003-0852-0767				Abel ED, 1999, J CLIN INVEST, V104, P1703, DOI 10.1172/JCI7605; BALABAN RS, 1986, SCIENCE, V232, P1121, DOI 10.1126/science.3704638; BARKER PB, 1990, SOC MAGN RES MED, V9, P1089; BOTTOLEY PA, 1989, NMR BIOMED, V20, P284; BOTTOMLEY PA, 1991, J MAGN RESON, V95, P341, DOI 10.1016/0022-2364(91)90223-G; BOTTOMLEY PA, 1993, J MAGN RESON SER A, V103, P242, DOI 10.1006/jmra.1993.1162; Bottomley PA, 1996, MAGNET RESON MED, V35, P664, DOI 10.1002/mrm.1910350507; BROOKER HR, 1987, MAGNET RESON MED, V5, P417, DOI 10.1002/mrm.1910050503; Chacko VP, 2000, AM J PHYSIOL-HEART C, V279, pH2218, DOI 10.1152/ajpheart.2000.279.5.H2218; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; FLAHERTY JT, 1982, CIRCULATION, V65, P561, DOI 10.1161/01.CIR.65.3.561; FROM AHL, 1986, FEBS LETT, V206, P257, DOI 10.1016/0014-5793(86)80992-9; Gamcsik MP, 1996, BIOTECHNOL BIOENG, V49, P348, DOI 10.1002/bit.260490302; Georgakopoulos D, 1998, AM J PHYSIOL-HEART C, V274, pH1416, DOI 10.1152/ajpheart.1998.274.4.H1416; GIBBS C, 1985, J MOL CELL CARDIOL, V17, P727, DOI 10.1016/S0022-2828(85)80034-1; Green AL, 1996, AM J PHYSIOL-ENDOC M, V271, pE821, DOI 10.1152/ajpendo.1996.271.5.E821; Gross WL, 1996, P NATL ACAD SCI USA, V93, P5604, DOI 10.1073/pnas.93.11.5604; Guerrero-Ontiveros ML, 1998, MOL CELL BIOCHEM, V184, P427, DOI 10.1023/A:1006895414925; HARDY CJ, 1991, AM HEART J, V122, P795, DOI 10.1016/0002-8703(91)90527-O; HETHERINGTON HP, 1995, MAGNET RESON MED, V33, P427, DOI 10.1002/mrm.1910330318; Horn M, 1999, CARDIOVASC RES, V43, P117, DOI 10.1016/S0008-6363(99)00075-9; INGWALL JS, 1993, CIRCULATION, V87, P58; INGWALL JS, 1994, INOTROPIC DRUGS BASI; Jung WI, 1998, CIRCULATION, V97, P2536, DOI 10.1161/01.CIR.97.25.2536; Kass DA, 1998, CIRC RES, V82, P519, DOI 10.1161/01.RES.82.4.519; Katz Arnold M., 1998, Cardiology Clinics, V16, P633, DOI 10.1016/S0733-8651(05)70040-0; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; KINGSLEYHICKMAN PB, 1990, J BIOL CHEM, V265, P1545; Liao RL, 1996, CIRC RES, V78, P893, DOI 10.1161/01.RES.78.5.893; MCDONALD KM, 1994, J AM COLL CARDIOL, V23, P786, DOI 10.1016/0735-1097(94)90769-2; MENON RS, 1992, MAGNET RESON MED, V26, P368, DOI 10.1002/mrm.1910260216; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Nascimben L, 1996, CIRCULATION, V94, P1894, DOI 10.1161/01.CIR.94.8.1894; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; Neubauer S, 1999, CIRCULATION, V100, P1847, DOI 10.1161/01.CIR.100.18.1847; NEUBAUER S, 1992, CIRCULATION, V86, P1810, DOI 10.1161/01.CIR.86.6.1810; Neubauer S, 1997, CIRCULATION, V96, P2190; Odoom JE, 1996, MOL CELL BIOCHEM, V158, P179; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; Omerovic E, 2000, BIOCHEM BIOPH RES CO, V271, P222, DOI 10.1006/bbrc.2000.2518; Ponticos M, 1998, EMBO J, V17, P1688, DOI 10.1093/emboj/17.6.1688; POOL PE, 1967, CIRC RES, V21, P365, DOI 10.1161/01.RES.21.3.365; REN JM, 1993, AM J PHYSIOL, V264, pC146, DOI 10.1152/ajpcell.1993.264.1.C146; Russell RR, 1999, AM J PHYSIOL-HEART C, V277, pH643, DOI 10.1152/ajpheart.1999.277.2.H643; Saupe KW, 1998, CIRC RES, V82, P898; Steenge GR, 1998, AM J PHYSIOL-ENDOC M, V275, pE974, DOI 10.1152/ajpendo.1998.275.6.E974; Stenbit AE, 1996, J CLIN INVEST, V98, P629, DOI 10.1172/JCI118833; Stenbit AE, 2000, AM J PHYSIOL-HEART C, V279, pH313, DOI 10.1152/ajpheart.2000.279.1.H313; SUN DQ, 1994, CIRCULATION, V89, P793, DOI 10.1161/01.CIR.89.2.793; SWAIN JL, 1982, P NATL ACAD SCI-BIOL, V79, P655, DOI 10.1073/pnas.79.2.655; Taegtmeyer H, 1994, Curr Probl Cardiol, V19, P59; Tian R, 2001, CIRCULATION, V103, P2961, DOI 10.1161/01.CIR.103.24.2961; Tian R, 1996, J MOL CELL CARDIOL, V28, P755, DOI 10.1006/jmcc.1996.0070; Tian R, 1996, AM J PHYSIOL-HEART C, V270, pH1207, DOI 10.1152/ajpheart.1996.270.4.H1207; Tsao TS, 1997, J CLIN INVEST, V100, P671, DOI 10.1172/JCI119579; WEISS RG, 1990, NEW ENGL J MED, V323, P1593, DOI 10.1056/NEJM199012063232304; WEISS RG, 1989, J MOL CELL CARDIOL, V21, P469, DOI 10.1016/0022-2828(89)90787-6; ZHANG JY, 1993, J CLIN INVEST, V92, P993, DOI 10.1172/JCI116676; ZHANG JY, 1995, AM J PHYSIOL-HEART C, V268, pH1891, DOI 10.1152/ajpheart.1995.268.5.H1891; Zierath JR, 1998, J BIOL CHEM, V273, P20910, DOI 10.1074/jbc.273.33.20910; Zorzano A, 2000, BIOCHEM J, V349, P667, DOI 10.1042/bj3490667; Zorzano A, 1997, AM J CARDIOL, V80, pA65, DOI 10.1016/S0002-9149(97)00459-1	62	41	42	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					613	+		10.1096/fj.01-0462fje	http://dx.doi.org/10.1096/fj.01-0462fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919171				2022-12-25	WOS:000174203700006
J	Karisola, P; Alenius, H; Mikkola, J; Kalkkinen, N; Helin, J; Pentikainen, OT; Repo, S; Reunala, T; Turjanmaa, K; Johnson, MS; Palosuo, T; Kulomaa, MS				Karisola, P; Alenius, H; Mikkola, J; Kalkkinen, N; Helin, J; Pentikainen, OT; Repo, S; Reunala, T; Turjanmaa, K; Johnson, MS; Palosuo, T; Kulomaa, MS			The major conformational IgE-binding epitopes of hevein (Hev b6.02) are identified by a novel chimera-based allergen epitope mapping strategy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-RUBBER LATEX; AMARANTHUS-CAUDATUS; PROHEVEIN; PROTEINS; DER-P-2; AVIDIN; GLOVES; TOOLS	A novel approach to localize and reconstruct conformational IgE-binding epitope regions of hevein (Hev b6.02), a major natural rubber latex allergen, is described. An antimicrobial protein (AMP) from the amaranth Amaranthus caudatus was used as an immunologically non-IgE-binding adaptor molecule to which terminal or central parts of hevein were fused. Hevein and AMP share a structurally identical core region but have different N-terminal and C-terminal regions. Only 1 of 16 hevein-allergic patients showed weak IgE binding to purified native or recombinant AMP. Chimeric AMP with the hevein N terminus was recognized by IgE from 14 (88%) patients, and chimeric AMP with the hevein C terminus was recognized by IgE from 6 (38%) patients. In contrast, chimeric AMP containing the hevein core region was recognized by IgE from only two patients. When both the N-terminal and C-terminal regions of hevein were fused with the AMP core, IgE from all 16 patients bound to the chimera. This chimera was also able to significantly inhibit (>70%) IgE binding to the native hevein. On the contrary, linear synthetic peptides corresponding to hevein regions in the AMP chimeras showed no significant IgE binding capacity in either enzyme-linked immunosorbent assay or inhibition enzyme-linked immunosorbent assay. These results suggest that the IgE binding ability of hevein is essentially determined by its N-terminal and C-terminal regions and that major IgE-binding epitopes of hevein are conformational. The chimera-based epitope mapping strategy described here provides a valuable tool for defining structural epitopes and creating specific reagents for allergen immunotherapy.	Univ Jyvaskyla, Dept Biol & Environm Sci, FIN-40014 Jyvaskyla, Finland; Finnish Inst Occupat Hlth, FIN-00250 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Abo Akad Univ, Dept Biochem & Pharm, FIN-20521 Turku, Finland; Tampere Univ Hosp, Dept Clin Chem, FIN-33521 Tampere, Finland; Natl Publ Hlth Inst, FIN-00300 Helsinki, Finland	University of Jyvaskyla; Finnish Institute of Occupational Health; University of Helsinki; Abo Akademi University; Tampere University; Tampere University Hospital; Finland National Institute for Health & Welfare	Kulomaa, MS (corresponding author), Univ Jyvaskyla, Dept Biol & Environm Sci, POB 35 YAB, FIN-40014 Jyvaskyla, Finland.		Kalkkinen, Nisse EJ/B-3923-2010; Kulomaa, Markku S/C-9063-2014; Pentikäinen, Olli T/E-1980-2012	Pentikäinen, Olli T/0000-0001-7188-4016; Susanna, Repo/0000-0003-3488-4767; Alenius, Harri/0000-0003-0106-8923				Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Airenne KJ, 1999, PROTEIN EXPRES PURIF, V17, P139, DOI 10.1006/prep.1999.1123; ALENIUS H, 1995, CLIN EXP ALLERGY, V25, P659, DOI 10.1111/j.1365-2222.1995.tb01114.x; ALENIUS H, 1994, ANN ALLERGY, V73, P315; Alenius H, 1996, J IMMUNOL, V156, P1618; ANDERSEN NH, 1993, BIOCHEMISTRY-US, V32, P1407, DOI 10.1021/bi00057a004; Banerjee B, 1997, J IMMUNOL, V159, P5724; Beezhold DH, 1997, CLIN EXP IMMUNOL, V108, P114, DOI 10.1046/j.1365-2249.1997.d01-983.x; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Berman HM, 2000, NAT STRUCT BIOL, V7, P957, DOI 10.1038/80734; BROEKAERT WF, 1992, BIOCHEMISTRY-US, V31, P4308, DOI 10.1021/bi00132a023; Chen ZP, 2000, INT ARCH ALLERGY IMM, V123, P291, DOI 10.1159/000053641; Colombo P, 1998, J IMMUNOL, V160, P2780; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; Hakkaart GAJ, 1998, CLIN EXP ALLERGY, V28, P169, DOI 10.1046/j.1365-2222.1998.00205.x; Hanninen AR, 1999, J ALLERGY CLIN IMMUN, V104, P194, DOI 10.1016/S0091-6749(99)70135-1; Johnson M. S., 2000, BIOINFORMATICS SEQUE, P15; King TP, 2001, J IMMUNOL, V166, P6057, DOI 10.4049/jimmunol.166.10.6057; Martins JC, 1996, J MOL BIOL, V258, P322, DOI 10.1006/jmbi.1996.0253; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; ORR GA, 1986, METHOD ENZYMOL, V122, P83; Palosuo T, 1998, ALLERGY, V53, P59, DOI 10.1111/j.1398-9995.1998.tb03774.x; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Simon-Nobbe B, 2000, J ALLERGY CLIN IMMUN, V106, P887, DOI 10.1067/mai.2000.110799; Smith AM, 1997, CLIN EXP ALLERGY, V27, P593, DOI 10.1111/j.1365-2222.1997.tb00750.x; Tamborini E, 1997, EUR J BIOCHEM, V249, P886, DOI 10.1111/j.1432-1033.1997.00886.x; Tang B, 2000, BIOCHEM BIOPH RES CO, V270, P1128, DOI 10.1006/bbrc.2000.2546; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Van Regenmortal Marc H. V., 1996, Methods (Orlando), V9, P465, DOI 10.1006/meth.1996.0054; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Vrtala S, 2000, J IMMUNOL, V165, P6653, DOI 10.4049/jimmunol.165.11.6653; Wilson KS, 1998, J MOL BIOL, V276, P417; Ylitalo L, 2000, CLIN EXP ALLERGY, V30, P1611	33	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22656	22661		10.1074/jbc.M201076200	http://dx.doi.org/10.1074/jbc.M201076200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11909866	hybrid			2022-12-25	WOS:000176313600072
J	Beer, HD; Munding, C; Dubois, N; Mamie, C; Hohl, D; Werner, S				Beer, HD; Munding, C; Dubois, N; Mamie, C; Hohl, D; Werner, S			The estrogen-responsive B box protein - A novel regulator of keratinocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; NUCLEAR RECEPTOR; FACTOR FGF-7; FACTOR-ALPHA; BINDING; FAMILY; GENE; EXPRESSION; CELLS; COACTIVATORS	Keratinocyte growth factor (KGF) regulates proliferation, differentiation, migration, and survival of different types of epithelial cells, including keratinocytes of the skin. To gain insight into the mechanisms underlying these multiple functions, we searched for KGF-regulated genes in keratinocytes. Using the differential display reverse transcriptase-PCR technology, we identified the gene encoding the estrogen-responsive B box protein (EBBP) which has as yet not been functionally characterized. The full-length murine and human EBBP cDNAs were cloned and fully sequenced. They were shown to encode 75-kDa proteins, which are mainly localized in the cytoplasm of keratinocytes in vitro and in vivo. In vivo, EBBP was found at high levels in the KGF and epidermal growth factor-responsive basal keratinocytes of human skin, but the expression was downregulated in the hyperthickened epithelium of skin wounds. Stable overexpression of EBBP in HaCaT keratinocytes did not affect the proliferation rate of the transfected cells, but enhanced the early differentiation process. These results suggest that the presence of EBBP in basal keratinocytes is important for the differentiation capacity of these cells, and that downregulation of EBBP expression in a hyperproliferative epithelium is required to maintain the cells in a non-differentiated stage.	ETH Zurich, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland; CHU Vaudois, Hop Beaumont, Serv Dermatol, CH-1011 Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Beer, HD (corresponding author), ETH Zurich, Inst Cell Biol, Dept Biol, HPM D44, CH-8093 Zurich, Switzerland.			Werner, Sabine/0000-0001-7397-8710; Beer, Hans-Dietmar/0000-0002-8085-713X				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CARTER DM, 1987, DERMATOLOGY GENERAL, P759; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOPHERS E, 1987, DERMATOLOGY GENERAL, P461; Frank S, 1996, J BIOL CHEM, V271, P24337, DOI 10.1074/jbc.271.40.24337; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; Harvat BL, 1998, J CELL SCI, V111, P1185; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Henry J, 1998, MOL BIOL EVOL, V15, P1696, DOI 10.1093/oxfordjournals.molbev.a025896; Hines MD, 1996, J BIOL CHEM, V271, P6245, DOI 10.1074/jbc.271.11.6245; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Igarashi M, 1998, J BIOL CHEM, V273, P13230, DOI 10.1074/jbc.273.21.13230; KING LE, 1990, J INVEST DERMATOL, V95, pS10, DOI 10.1111/1523-1747.ep12505661; Liu HLC, 1998, MOL ENDOCRINOL, V12, P1733, DOI 10.1210/me.12.11.1733; Madlener H, 1997, GENE, V202, P75, DOI 10.1016/S0378-1119(97)00456-3; Marchese C, 1997, CELL GROWTH DIFFER, V8, P989; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MARCHESE C, 1990, J CELL PHYSIOL, V144, P326, DOI 10.1002/jcp.1041440219; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; TODD R, 1991, AM J PATHOL, V138, P1307; Torok M, 2001, DIFFERENTIATION, V67, P63, DOI 10.1046/j.1432-0436.2001.067003063.x; TSUBOI R, 1993, J INVEST DERMATOL, V101, P49, DOI 10.1111/1523-1747.ep12358892; Wakita N, 1999, J BIOL CHEM, V274, P37285, DOI 10.1074/jbc.274.52.37285; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Werner S, 1998, CYTOKINE GROWTH F R, V9, P153, DOI 10.1016/S1359-6101(98)00010-0; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896	35	31	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20740	20749		10.1074/jbc.M111233200	http://dx.doi.org/10.1074/jbc.M111233200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11919186	hybrid, Green Published			2022-12-25	WOS:000176204500083
J	Lee, SR; Yang, KS; Kwon, J; Lee, C; Jeong, W; Rhee, SG				Lee, SR; Yang, KS; Kwon, J; Lee, C; Jeong, W; Rhee, SG			Reversible inactivation of the tumor suppressor PTEN by H2O2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MAMMALIAN THIOREDOXIN REDUCTASE; TYROSINE-PHOSPHATASE 1B; AIRWAY SMOOTH-MUSCLE; HYDROGEN-PEROXIDE; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL ACTIVATION; PHOSPHOINOSITIDE 3-KINASE; AKT PHOSPHORYLATION; CATALYTIC DOMAIN	The tumor suppressor PTEN regulates cell migration, growth, and survival by removing the T-phosphate of phosphoinositides. Exposure of purified PTEN or of cells to H2O2 resulted in inactivation of PTEN in a time-and H2O2 concentration-dependent manner. Analysis of various cysteine mutants, including mass spectrometry of tryptic peptides, indicated that the essential Cys(124) residue in the active site of PTEN specifically forms a disulfide with Cys(71) during oxidation by H2O2. The reduction of H2O2-oxidized PTEN in cells appears to be mediated predominantly by thioredoxin. Thus, thioredoxin was more efficient than glutaredoxin, glutathione, or a 14-kDa thioredoxin-like protein with regard to the reduction of oxidized PTEN in vitro. Thioredoxin co-immunoprecipitated with PTEN from cell lysates; and incubation of cells with 2,4-dinitro-1-chlorobenzene (an inhibitor of thioredoxin reductase) delayed the reduction of oxidized PTEN, whereas incubation with buthioninesulfoximine (an inhibitor of glutathione biosynthesis) did not. These results suggest that the reversible inactivation of PTEN by H2O2 might be important for the accumulation of 3'-phosphorylated phosphoinositides and that the uncontrolled generation of H2O2 associated with certain pathological conditions might contribute to cell proliferation by inhibiting PTEN function.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rhee, SG (corresponding author), NHLBI, Lab Cell Signaling, NIH, Bldg 50,Rm 3523, Bethesda, MD 20892 USA.			Kwon, Jaeyul/0000-0002-2452-4111				Adey NB, 2000, CANCER RES, V60, P35; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Besse D, 1997, ANGEW CHEM INT EDIT, V36, P883, DOI 10.1002/anie.199708831; Brar SS, 1999, J BIOL CHEM, V274, P20017, DOI 10.1074/jbc.274.28.20017; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ishikawa A, 1999, NEUROSCI LETT, V277, P99, DOI 10.1016/S0304-3940(99)00850-2; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Kim JR, 2000, ANAL BIOCHEM, V283, P214, DOI 10.1006/abio.2000.4623; Kisseleva MV, 2000, J BIOL CHEM, V275, P20110, DOI 10.1074/jbc.M910119199; Kisseleva MV, 2002, J BIOL CHEM, V277, P6266, DOI 10.1074/jbc.M105969200; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nordberg J, 1998, J BIOL CHEM, V273, P10835, DOI 10.1074/jbc.273.18.10835; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; Page K, 2000, AM J RESP CELL MOL, V23, P436, DOI 10.1165/ajrcmb.23.4.3953; Pani G, 2000, J BIOL CHEM, V275, P38891, DOI 10.1074/jbc.M007319200; Rhee S.G., 2000, SCI STKE; Salsman S, 2001, ARCH BIOCHEM BIOPHYS, V386, P275, DOI 10.1006/abbi.2000.2202; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SZATROWSKI TP, 1991, CANCER RES, V51, P794; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Tolkacheva T, 2000, ONCOGENE, V19, P680, DOI 10.1038/sj.onc.1203331; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Van der Kaay J, 1999, J BIOL CHEM, V274, P35963, DOI 10.1074/jbc.274.50.35963; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	54	792	815	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20336	20342		10.1074/jbc.M111899200	http://dx.doi.org/10.1074/jbc.M111899200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11916965	hybrid			2022-12-25	WOS:000176204500032
J	Wiest, A; Grzegorski, D; Xu, BW; Goulard, C; Rebuffat, S; Ebbole, DJ; Bodo, B; Kenerley, C				Wiest, A; Grzegorski, D; Xu, BW; Goulard, C; Rebuffat, S; Ebbole, DJ; Bodo, B; Kenerley, C			Identification of peptaibols from Trichoderma virens and cloning of a peptaibol synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBIOTIC PEPTIDES; 11-RESIDUE PEPTAIBOL; FORMING PEPTAIBOLS; TRICHORZINS HA; HARZIANUM; SEQUENCE; GENE; BIOSYNTHESIS; MODEL; MA	The fungus Trichoderma virens is a ubiquitous soil saprophyte that has been applied as a biological control agent to protect plants from fungal pathogens. One mechanism of biocontrol is mycoparasitism, and T. virens produces antifungal compounds to assist in killing its fungal targets. Peptide synthetases produce a wide variety of peptide secondary metabolites in bacteria and fungi. Many of these are known to possess antibiotic activities. Peptaibols form a class of antibiotics known for their high a-aminoisobutyric acid content and their synthesis as a mixture of isoforms ranging from 7 to 20 amino acids in length. Here we report preliminary characterization of a 62.8-kb continuous open reading frame encoding a peptaibol synthetase from T. virens. The predicted protein structure consists of 18 peptide synthetase modules with additional modifying domains at the N- and C-termini. T. virens was shown to produce a mixture of peptaibols, with the largest peptides being 18 residues. Mutation of the gene eliminated production of all peptaibol isoforms. Identification of the gene responsible for peptaibol production will facilitate studies of the structure and function of peptaibol antibiotics and their contribution to biocontrol activity.	Texas A&M Univ, Dept Plant Pathol & Microbiol, College Stn, TX 77843 USA; Museum Natl Hist Nat, Lab Chim Subst Nat, F-75005 Paris, France	Texas A&M University System; Texas A&M University College Station; Museum National d'Histoire Naturelle (MNHN)	Kenerley, C (corresponding author), Texas A&M Univ, Dept Plant Pathol & Microbiol, College Stn, TX 77843 USA.	kenerley@ppserver.tamu.edu	Rebuffat, Sylvie/AAE-4194-2021; Rebuffat, Sylvie/AAO-2072-2020	Rebuffat, Sylvie/0000-0002-5257-5039				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AugevenBour I, 1997, J CHEM SOC PERK T 1, P1587, DOI 10.1039/a605629f; AUVINGUETTE C, 1992, J AM CHEM SOC, V114, P2170, DOI 10.1021/ja00032a035; Baek JM, 1998, FUNGAL GENET BIOL, V23, P34, DOI 10.1006/fgbi.1997.1025; BODO B, 1985, J AM CHEM SOC, V107, P6011, DOI 10.1021/ja00307a028; Challis GL, 2000, CHEM BIOL, V7, P211, DOI 10.1016/S1074-5521(00)00091-0; DUVAL D, 1998, BIOCHIM BIOPHYS ACTA, V17, P370; ELHAJJI M, 1987, INT J PEPT PROT RES, V29, P207; Engelberth J, 2000, ANGEW CHEM INT EDIT, V39, P1860, DOI 10.1002/(SICI)1521-3773(20000515)39:10<1860::AID-ANIE1860>3.0.CO;2-F; GOULARD C, 1995, J ANTIBIOT, V48, P1248, DOI 10.7164/antibiotics.48.1248; GRZEGORSKI D, 2001, THESIS TEXAS A M U; HLIMI S, 1995, J ANTIBIOT, V48, P1254, DOI 10.7164/antibiotics.48.1254; HOWELL CR, 1993, BIOCONTROL SCI TECHN, V3, P435, DOI 10.1080/09583159309355298; JEN WC, 1987, J APPL BACTERIOL, V63, P293, DOI 10.1111/j.1365-2672.1987.tb02705.x; KARLE IL, 1991, P NATL ACAD SCI USA, V88, P5307, DOI 10.1073/pnas.88.12.5307; Keller NP, 1997, FUNGAL GENET BIOL, V21, P17, DOI 10.1006/fgbi.1997.0970; Konz D, 1999, CHEM BIOL, V6, pR39, DOI 10.1016/S1074-5521(99)80002-7; Lorito M, 1996, MOL PLANT MICROBE IN, V9, P206, DOI 10.1094/MPMI-9-0206; Lorito M, 1996, J BACTERIOL, V178, P6382, DOI 10.1128/jb.178.21.6382-6385.1996; Marahiel MA, 1997, CHEM BIOL, V4, P561, DOI 10.1016/S1074-5521(97)90242-8; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; PANDEY RC, 1977, J AM CHEM SOC, V99, P8469, DOI 10.1021/ja00468a016; REBUFFAT S, 1995, J CHEM SOC PERK T 1, P1849, DOI 10.1039/p19950001849; REBUFFAT S, 1992, FEMS MICROBIOL IMMUN, V105, P151, DOI 10.1016/0378-1097(92)90086-4; REBUFFAT S, 1989, INT J PEPT PROT RES, V34, P200; Rebuffat S, 1996, J CHEM SOC PERK T 1, P2021, DOI 10.1039/p19960002021; RINEHART KL, 1981, J AM CHEM SOC, V103, P6517, DOI 10.1021/ja00411a052; SANSOM MSP, 1991, PROG BIOPHYS MOL BIO, V55, P139, DOI 10.1016/0079-6107(91)90004-C; SCHWYN B, 1987, ANAL BIOCHEM, V160, P47, DOI 10.1016/0003-2697(87)90612-9; Stachelhaus T, 1999, CHEM BIOL, V6, P493, DOI 10.1016/S1074-5521(99)80082-9; Stein T, 1996, J BIOL CHEM, V271, P15428, DOI 10.1074/jbc.271.26.15428; THOMAS MD, 1989, CURR GENET, V15, P415, DOI 10.1007/BF00376798; Weber T, 2001, STRUCTURE, V9, pR3, DOI 10.1016/S0969-2126(00)00560-8; Wilhite SE, 2001, APPL ENVIRON MICROB, V67, P5055, DOI 10.1128/AEM.67.11.5055-5062.2001; Xu BW, 1996, J FERMENT BIOENG, V81, P473, DOI 10.1016/0922-338X(96)81465-6; Yun BS, 2000, TETRAHEDRON LETT, V41, P1429, DOI 10.1016/S0040-4039(99)02308-4; Zocher R, 1997, ADV MICROB PHYSIOL, V38, P85	37	157	171	4	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20862	20868		10.1074/jbc.M201654200	http://dx.doi.org/10.1074/jbc.M201654200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11909873	hybrid			2022-12-25	WOS:000176204500098
J	Cussac, D; Schaak, S; Denis, C; Paris, H				Cussac, D; Schaak, S; Denis, C; Paris, H			alpha(2B)-adrenergic receptor activates MAPK via a pathway involving arachidonic acid metabolism, matrix metalloproteinases, and epidermal growth factor receptor transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ALPHA(2)-ADRENERGIC RECEPTORS; KINASE ACTIVATION; EPITHELIAL-CELLS; ANGIOTENSIN-II; STIMULATION; PHOSPHORYLATION; ENDOCYTOSIS; PROLIFERATION; ADRENOCEPTORS	We have investigated the mechanisms whereby a,,adrenergic receptor (alpha(2B)-AR) promotes MAPK activation in a clone of the renal tubular cell line, LLC-PK1, transfected with the rat nonglycosylated alpha(2)-AR gene. Treatment of LLC-PK1-alpha(2B) with UK14304 or dexmedetomidine caused arachidonic acid (AA) release and ERK2 phosphorylation. AA release was abolished by prior treatment of the cells with pertussis toxin, quinacrine, or methyl arachidonyl fluorophosphonate but not by the addition of the MEK inhibitor U0126. The effects of alpha(2)-agonists on MAPK phosphorylation were mimicked by cell exposure to exogenous AA. On the other hand, quinacrine abolished the effects of UK14304, but not of AA, suggesting that AA released through PLA2 is responsible for MAPK activation by alpha(2B)-AR. The effects of alpha(2)-agonists or AA were PKC-independent and were attenuated by indomethacin and nordihydroguaiaretic acid. Treatment with batimastat, CRM 197, or tyrphostin AG1478 suppressed MAPK phosphorylation promoted by alpha(2)-agonist or AA. Furthermore, conditioned culture medium from UK14304-treated LLC-PK1-alpha(2B) induced MAPK phosphorylation in wild-type LLC-PK1. Based on these data, we propose a model whereby activation of MAPK by alpha(2B)-AR is mediated through stimulation of PLA2, AA release, generation of AA derivatives, activation of matrix metalloproteinases, release of heparin-binding EGF-like growth factor, transactivation of epidermal growth factor receptor, and recruitment of She. Whether this pathway is particular to alpha(2B)-AR and LLC-PK1 or whether it can be extended to other cell types and/or other G-protein-coupled receptors remains to be established.	CHU Rangueil, Inst Louis Bugnard, INSERM Unit 388, F-31403 Toulouse 4, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Paris, H (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM Unit 388, Bat L3, F-31403 Toulouse 4, France.		Denis, Colette/K-1571-2019; Denis, Colette/U-5267-2017; Cussac, Daniel/AAP-1544-2020	Denis, Colette/0000-0002-8376-8351; Cussac, Daniel/0000-0002-7227-898X				Attiga FA, 2000, CANCER RES, V60, P4629; BOULOUMIE A, 1994, J BIOL CHEM, V269, P30254; BYLUND DB, 1994, PHARMACOL REV, V46, P121; Capodici C, 1998, J CLIN INVEST, V102, P165, DOI 10.1172/JCI592; Chen JK, 1999, J BIOL CHEM, V274, P4764, DOI 10.1074/jbc.274.8.4764; Cussac D, 2002, AM J PHYSIOL-RENAL, V282, pF943, DOI 10.1152/ajprenal.0108.2001; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dulin NO, 1998, P NATL ACAD SCI USA, V95, P8098, DOI 10.1073/pnas.95.14.8098; Dulin NO, 1998, HYPERTENSION, V32, P1089, DOI 10.1161/01.HYP.32.6.1089; ERMAN A, 1985, J BIOL CHEM, V260, P4679; FLORDELLIS CS, 1995, J BIOL CHEM, V270, P3491, DOI 10.1074/jbc.270.8.3491; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; Jiao HY, 1998, P NATL ACAD SCI USA, V95, P7417, DOI 10.1073/pnas.95.13.7417; Kable JW, 2000, J PHARMACOL EXP THER, V293, P1; Kribben A, 1997, N-S ARCH PHARMACOL, V356, P225, DOI 10.1007/PL00005045; Lin WW, 1999, BRIT J PHARMACOL, V126, P1419, DOI 10.1038/sj.bjp.0702436; Liu FM, 2001, AM J PHYSIOL-RENAL, V280, pF415, DOI 10.1152/ajprenal.2001.280.3.F415; Nally JE, 1996, PULM PHARMACOL THER, V9, P211, DOI 10.1006/pulp.1996.0026; NORD EP, 1987, J CLIN INVEST, V80, P1755, DOI 10.1172/JCI113268; Oyekan A, 1997, AM J PHYSIOL-REG I, V273, pR293, DOI 10.1152/ajpregu.1997.273.1.R293; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; RAO GN, 1994, J BIOL CHEM, V269, P32586; Sano H, 2001, J IMMUNOL, V166, P3515, DOI 10.4049/jimmunol.166.5.3515; Schaak S, 2000, GUT, V47, P242, DOI 10.1136/gut.47.2.242; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336	31	45	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19882	19888		10.1074/jbc.M110142200	http://dx.doi.org/10.1074/jbc.M110142200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11891218	hybrid			2022-12-25	WOS:000175894800085
J	Gu, JG; Fujibayashi, A; Yamada, KM; Sekiguchi, K				Gu, JG; Fujibayashi, A; Yamada, KM; Sekiguchi, K			Laminin-10/11 and fibronectin differentially prevent apoptosis induced by serum removal via phosphatidylinositol 3-kinase/Akt- and MEK1/ERK-dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; ACTIVATED PROTEIN-KINASE; PROGRAMMED CELL-DEATH; SIGNALING PATHWAYS; EPITHELIAL-CELLS; TYROSINE KINASE; CARCINOMA CELLS; GROWTH-FACTOR; MAP KINASE; SURVIVAL	Cell adhesion to the extracellular matrix inhibits apoptosis, but the molecular mechanisms underlying the signals transduced by different matrix components are not well understood. Here, we examined integrin-mediated antiapoptotic signals from laminin-10/11 in comparison with those from fibronectin, the best characterized extracellular adhesive ligand. We found that the activation of protein kinase B/Akt in cells adhering to laminin-10/11 can rescue cell apoptosis induced by serum removal. Consistent with this, wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase, or ectopic expression of a dominant-negative mutant of Akt selectively accelerated cell death upon serum removal. In contrast to laminin-10/11, fibronectin rescued cells from serum depletion-induced apoptosis mainly through the extracellular signal-regulated kinase pathway. Cell survival on fibronectin but not laminin was significantly reduced by treatment with PD98059, a specific inhibitor of mitogen- or extracellular signal-regulated kinase kinase-1 (MEK1) and by expression of a dominant-negative mutant of MEK1. Laminin-10/11 was more potent than fibronectin in preventing apoptosis induced by serum depletion. These results, taken together, demonstrate laminin-10/11 potency as a survival factor and demonstrate that different extracellular matrix components can transduce distinct survival signals through preferential activation of subsets of multiple integrin-mediated signaling pathways.	Osaka Univ, Inst Prot Res, Div Prot Chem, Suita, Osaka 5650871, Japan; NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	Osaka University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Sekiguchi, K (corresponding author), Osaka Univ, Inst Prot Res, Div Prot Chem, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	sekiguch@protein.osaka-u.ac.jp	Gu, Jianguo/ABC-9257-2020	Yamada, Kenneth/0000-0003-1512-6805	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000525, ZIADE000524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000525, Z01DE000524] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Fujiwara H, 2001, J BIOL CHEM, V276, P17550, DOI 10.1074/jbc.M010155200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gu JG, 2001, J BIOL CHEM, V276, P27090, DOI 10.1074/jbc.M102284200; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Kikkawa Y, 1998, J BIOL CHEM, V273, P15854, DOI 10.1074/jbc.273.25.15854; Kikkawa Y, 2000, J CELL SCI, V113, P869; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Matter ML, 1998, J CELL BIOL, V141, P1019, DOI 10.1083/jcb.141.4.1019; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Montanaro F, 1999, J CELL BIOL, V145, P1325, DOI 10.1083/jcb.145.6.1325; OBrien V, 1996, EXP CELL RES, V224, P208, DOI 10.1006/excr.1996.0130; Pullan S, 1996, J CELL SCI, V109, P631; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Welsh CF, 2000, BBA-REV CANCER, V1471, pM21, DOI 10.1016/S0304-419X(00)00016-0; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zugasti O, 2001, MOL CELL BIOL, V21, P6706, DOI 10.1128/MCB.21.19.6706-6717.2001	58	99	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19922	19928		10.1074/jbc.M200383200	http://dx.doi.org/10.1074/jbc.M200383200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11891225	hybrid, Green Submitted			2022-12-25	WOS:000175894800090
J	Liang, YX; Li, XY; Rebar, EJ; Li, PX; Zhou, YY; Chen, BL; Wolffe, AP; Case, CC				Liang, YX; Li, XY; Rebar, EJ; Li, PX; Zhou, YY; Chen, BL; Wolffe, AP; Case, CC			Activation of vascular endothelial growth factor A transcription in tumorigenic glioblastoma cell lines by an enhancer with cell type-specific DNase I accessibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAS DOMAIN PROTEIN-1; HYPOXIA-INDUCIBLE FACTOR-1; FACTOR GENE-TRANSCRIPTION; C6 GLIOMA-CELLS; FACTOR EXPRESSION; FACTOR VEGF; TUMOR-GROWTH; NITRIC-OXIDE; INDUCTION; ANGIOGENESIS	Unregulated expression of vascular endothelial growth factor-A (VEGF-A) plays an important role in tumor growth. We have identified a cell type-specific enhancer, HS-1100, that contributes to VEGF-A transcriptional activation in tumorigenic glioblastoma cell lines. This enhancer exhibits increased accessibility to DNase I in glioblastoma cell lines that express high levels of VEGF-A but not in several other cell lines that express much lower levels of VEGF-A. HS-1100 contains a number of sequence elements that are highly conserved among human, mouse, and rat, including the hypoxia-response element (HRE). We show that the HRE contributes significantly to the cell type-specific enhancer activity of HS-1100 in U87MG glioblastoma cells. We use chromatin immunoprecipitation assays to show that endothelial PAS domain protein 1 (EPAS1) can efficiently bind to the endogenous HRE in U87MG cells but not in HEK293 cells in which the chromosomal HS-1100 is not accessible to DNase I. A dominant negative EPAS1 significantly reduces HS-1100 enhancer activity and VEGF-A levels in U87MG cells. Our results provide insight into the molecular mechanisms of VEGF-A up-regulation during cancer development.	Sangamo Biosci Inc, Point Richmond Tech Ctr, Richmond, CA 94804 USA	Sangamo Therapeutics, Inc.	Case, CC (corresponding author), Sangamo Biosci Inc, Point Richmond Tech Ctr, 501 Canal Blvd Suite A100, Richmond, CA 94804 USA.	ccase@sangamo.com						Akeno N, 2001, ENDOCRINOLOGY, V142, P959, DOI 10.1210/en.142.2.959; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chaudhry IH, 2001, HISTOPATHOLOGY, V39, P409, DOI 10.1046/j.1365-2559.2001.01230.x; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Damert A, 1997, BIOCHEM J, V327, P419, DOI 10.1042/bj3270419; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Feldkamp MM, 1999, INT J CANCER, V81, P118, DOI 10.1002/(SICI)1097-0215(19990331)81:1<118::AID-IJC20>3.3.CO;2-X; Flamme I, 1998, AM J PATHOL, V153, P25, DOI 10.1016/S0002-9440(10)65541-1; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Hossain MA, 2000, J BIOL CHEM, V275, P27874; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; Kimura H, 2001, J BIOL CHEM, V276, P2292, DOI 10.1074/jbc.M008398200; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Machein MR, 1999, HUM GENE THER, V10, P1117, DOI 10.1089/10430349950018111; Maemura K, 1999, J BIOL CHEM, V274, P31565, DOI 10.1074/jbc.274.44.31565; Maity A, 2000, CANCER RES, V60, P5879; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Mori K, 2000, FREE RADICAL RES, V33, P157, DOI 10.1080/10715760000300711; Mueller MD, 2000, P NATL ACAD SCI USA, V97, P10972, DOI 10.1073/pnas.200377097; Pal S, 2001, J BIOL CHEM, V276, P2395, DOI 10.1074/jbc.M007818200; PLATE KH, 1995, GLIA, V15, P339, DOI 10.1002/glia.440150313; Saleh M, 1996, CANCER RES, V56, P393; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Shi Q, 2001, CANCER RES, V61, P4143; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Valter MM, 1999, INT J DEV NEUROSCI, V17, P565, DOI 10.1016/S0736-5748(99)00048-9; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Xia GB, 2001, CANCER-AM CANCER SOC, V91, P1429, DOI 10.1002/1097-0142(20010415)91:8<1429::AID-CNCR1149>3.0.CO;2-V; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765	38	26	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					20087	20094		10.1074/jbc.M201766200	http://dx.doi.org/10.1074/jbc.M201766200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11912213	hybrid			2022-12-25	WOS:000175894800110
J	Gorski, JP; Liu, FT; Artigues, A; Castagna, LF; Osdoby, P				Gorski, JP; Liu, FT; Artigues, A; Castagna, LF; Osdoby, P			New alternatively spliced form of galectin-3, a member of the beta-galactoside-binding animal lectin family, contains a predicted transmembrane-spanning domain and a leucine zipper motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE ACIDIC GLYCOPROTEIN-75; IN-GEL DIGESTION; MEMBRANE-PROTEIN; OSTEOCLAST PRECURSORS; CALCITONIN RECEPTORS; CHICKEN OSTEOCLASTS; CRYSTAL-STRUCTURE; MAC-2 ANTIGEN; EXPRESSION; CELLS	Osteoclasts or their precursors interact with the glycoprotein-enriched matrix of bone during extravasation from the vasculature, and upon attachment prior to resorption. Reverse transcriptase-PCR studies showed that two new alternatively spliced forms of chicken galectin-3, termed Gal-3TM1 and Gal-3TR1, were enriched and preferentially expressed in highly purified chicken osteoclast-like cells. Gal-3TM1 and Gal-3TR1 mRNA were also detected in chicken intestinal tissue, but not in kidney, liver, or lung. Gal-3TM1 and Gal-3TR1 messages both contain an open reading frame encoding a predicted 70-amino acid TM1 sequence inserted between the N-terminal Gly/Pro repeat domain and the carbohydrate recognition domain (exons 3 and 4). Gal-3TR1 mRNA contains an additional 241-bp sequence, which encodes a truncated open reading frame between the 4th and 5th exons, and, whose translation is expected to terminate within the carbohydrate recognition domain encompassing exons 4, 5, and 6. Immunoblotting and affinity chromatography showed that purified osteoclast preparations and intestinal homogenates contained a 36-kDa lactose-binding galectin. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analyses on chymotryptic peptides from the 36-kDa lectin confirmed its identity as Gal-3TM1. The TM1 insert contains a single transmembrane-spanning region and a leucine zipper-like stalk domain that is predicted to position the intact carbohydrate recognition domain of Gal-3TM1 on the exterior surface of the plasma membrane. Immunofluorescent staining of chicken osteoclasts confirmed the expression of Gal-3TM1 at the plasma membrane. Gal-3TM1 is the first example of a galectin superfamily member capable of being expressed as a soluble protein and as a transmembrane protein.	Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA; Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO 64110 USA; Univ Calif Davis, Sch Med, Dept Dermatol, Sacramento, CA 95817 USA; Univ Missouri, Sch Biol Sci, Mass Spectrometry Core Facil, Kansas City, MO 64110 USA; Agencia Cordoba Ciencia SE Unidad Ctr Excellence, RA-6420 Cordoba, Argentina; Washington Univ, Dept Biol, St Louis, MO 63130 USA	University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City; University of California System; University of California Davis; University of Missouri System; University of Missouri Kansas City; Washington University (WUSTL)	Gorski, JP (corresponding author), Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Rm 109B BSB,5007 Rockhill Rd, Kansas City, MO 64110 USA.		Liu, FU-TONG/A-5749-2019	Liu, FU-TONG/0000-0002-3354-1001	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE011157] Funding Source: NIH RePORTER; NIA NIH HHS [AG-1543] Funding Source: Medline; NIDCR NIH HHS [DE-11157] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; Balch SG, 1998, J BIOL CHEM, V273, P18656, DOI 10.1074/jbc.273.29.18656; BEYER EC, 1980, J BIOL CHEM, V255, P4236; CASTAGNA LF, 1994, J NEUROSCI RES, V37, P750, DOI 10.1002/jnr.490370609; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; COLLINOSDOBY P, 1991, J BONE MINER RES, V6, P1353; COLLINOSDOBY P, 1995, J BONE MINER RES, V10, P45; Colnot C, 1999, CELL MOL BIOL, V45, P1191; Colucci S., 1993, Bollettino Societa Italiana Biologia Sperimentale, V69, P295; Colucci S, 1996, J CELL SCI, V109, P1527; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; ELIAM MC, 1988, J ENDOCRINOL, V119, P243, DOI 10.1677/joe.0.1190243; Essen LO, 1998, P NATL ACAD SCI USA, V95, P11673, DOI 10.1073/pnas.95.20.11673; FRIGERI LG, 1992, J IMMUNOL, V148, P861; Gitt MA, 1998, J BIOL CHEM, V273, P2954, DOI 10.1074/jbc.273.5.2954; GORSKI JP, 1990, J BIOL CHEM, V265, P14956; Gorski JP, 2000, BONE, V27, P103, DOI 10.1016/S8756-3282(00)00295-7; GORSKI JP, 1988, J BIOL CHEM, V263, P15938; HAMANN J, 1993, J IMMUNOL, V150, P4920; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Higuchi Y, 1999, BONE, V25, P17, DOI 10.1016/S8756-3282(99)00103-9; HSU DK, 1992, J BIOL CHEM, V267, P14167; HUBERT M, 1995, EXP CELL RES, V220, P397, DOI 10.1006/excr.1995.1331; Iglesias MM, 1998, GLYCOBIOLOGY, V8, P59, DOI 10.1093/glycob/8.1.59; Kadrofske MM, 1998, ARCH BIOCHEM BIOPHYS, V349, P7, DOI 10.1006/abbi.1997.0447; Kukita T, 1998, CALCIFIED TISSUE INT, V63, P140, DOI 10.1007/s002239900504; KUKITA T, 1989, LAB INVEST, V60, P532; LAKKAKORPI P, 1989, J BONE MINER RES, V4, P817; LAKKAKORPI PT, 1991, J CELL BIOL, V115, P1179, DOI 10.1083/jcb.115.4.1179; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; Menon RP, 1999, EUR J BIOCHEM, V264, P569, DOI 10.1046/j.1432-1327.1999.00671.x; Midura RJ, 1996, GLYCOBIOLOGY, V6, P677, DOI 10.1093/glycob/6.7.677; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; NICHOLSON GC, 1987, J BONE MINER RES, V2, P53; NIIDA S, 1994, J BONE MINER RES, V9, P873; Nurminskaya M, 1996, DEV DYNAM, V206, P260, DOI 10.1002/(SICI)1097-0177(199607)206:3<260::AID-AJA4>3.0.CO;2-G; Olives B, 1996, FEBS LETT, V386, P156, DOI 10.1016/0014-5793(96)00425-5; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OSDOBY P, 1982, J EXP ZOOL, V224, P331, DOI 10.1002/jez.1402240306; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROSENBERG I, 1991, J BIOL CHEM, V266, P18731; ROSENBERG IM, 1993, J BIOL CHEM, V268, P12393; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SAKAKURA Y, 1990, J BIOL CHEM, V265, P21573; SATO M, 1992, FASEB J, V6, P2966, DOI 10.1096/fasebj.6.11.1644260; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; SHINAR DM, 1993, J BONE MINER RES, V8, P403; TAKAHASHI N, 1994, DEV BIOL, V163, P212, DOI 10.1006/dbio.1994.1137; TAKAO M, 1988, VISION RES, V28, P471, DOI 10.1016/0042-6989(88)90169-1; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; Tsurukai T, 1998, J CELL PHYSIOL, V177, P26, DOI 10.1002/(SICI)1097-4652(199810)177:1<26::AID-JCP3>3.0.CO;2-G; Vinogradov AE, 1999, J MOL EVOL, V49, P376, DOI 10.1007/PL00006561; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WOO HJ, 1990, J BIOL CHEM, V265, P7097; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yoshikawa T, 1999, MOL IMMUNOL, V36, P1223, DOI 10.1016/S0161-5890(99)00139-X; Zhang H, 2000, BBA-GENE STRUCT EXPR, V1494, P14, DOI 10.1016/S0167-4781(00)00198-6; [No title captured]	66	30	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18840	18848		10.1074/jbc.M109578200	http://dx.doi.org/10.1074/jbc.M109578200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886849	hybrid			2022-12-25	WOS:000175975800078
J	Marchenko, ND; Marchenko, GN; Strongin, AY				Marchenko, ND; Marchenko, GN; Strongin, AY			Unconventional activation mechanisms of MMP-26, a human matrix metalloproteinase with a unique PHCGXXD cysteine-switch motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY MEMBERS; EXPRESSION; SEQUENCE; CELLS; TUMOR; STROMELYSIN-1; SECRETION; INVASION; CLONING; BIOLOGY	ProMMP-26 has the unique Pro-His(81)-Cys-Gly-Xaa-Xaa-Asp cysteine-switch motif that discriminates this protease from all other matrix metalloproteinases (MMPs) known so far. The conserved, free cysteine residue of the conventional PRCXXPD sequence interacts with the zinc ion of the catalytic domain and provides the fourth coordination site for the catalytic zinc, thereby preventing latent proMMPs from becoming active. MMPs become functionally active when proteolytic cleavage releases the prodomain and the PRCXXPD sequence and exposes the zinc atom. Here, we report that the Pro-His(81)-Cys-Gly-Xaa-Xaa-Asp motif is not functional in proMMP-26 and consequently is not involved in the activation mechanisms. Organomercurial treatment failed to activate proMMP-26. The autolytic Lys-Lys-Gln(59)down arrowGln(60)-Phe-His cleavage upstream of the Pro-His(81)-Cys-Gly-Xaa-Xaa-Asp motif induced the proteolytic activity of recombinant proMMP-26 whereas any further cleavage inactivated the enzyme. The His(81) --> Arg(81) mutation restored the conventional cysteine-switch sequence in the prodomain but failed to induce the cysteine-switch activation mechanism. These data and computer modeling studies allowed us to hypothesize that the presence of His(81) significantly modified the fold of proMMP-26, abolished the functionality of the cysteine-switch motif, and stimulated an alternative intramolecular activation pathway of the proenzyme.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Strongin, AY (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016	NCI NIH HHS [CA83017, CA77470] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083017, R01CA077470] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHEN LC, 1993, BIOCHEMISTRY-US, V32, P10289, DOI 10.1021/bi00090a003; de Coignac AB, 2000, EUR J BIOCHEM, V267, P3323; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Fingleton B, 2001, NEOPLASIA, V3, P459, DOI 10.1038/sj.neo.7900190; Galazka G, 1996, BIOCHEMISTRY-US, V35, P11221, DOI 10.1021/bi960618e; Heppner KJ, 1996, AM J PATHOL, V149, P273; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; John Anitha, 2001, Pathology and Oncology Research, V7, P14; Kotra LP, 2001, J AM CHEM SOC, V123, P3108, DOI 10.1021/ja001896a; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee RT, 2001, TRENDS CARDIOVAS MED, V11, P202, DOI 10.1016/S1050-1738(01)00113-X; Marchenko GN, 2002, BIOCHEM J, V363, P253, DOI 10.1042/0264-6021:3630253; Marchenko GN, 2001, BIOCHEM J, V356, P705, DOI 10.1042/0264-6021:3560705; Marchenko GN, 2001, GENE, V265, P87, DOI 10.1016/S0378-1119(01)00360-2; Marie-Claire C, 1998, J BIOL CHEM, V273, P5697, DOI 10.1074/jbc.273.10.5697; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Opdenakker G, 2001, J LEUKOCYTE BIOL, V69, P851; Park HI, 2000, J BIOL CHEM, V275, P20540, DOI 10.1074/jbc.M002349200; Parks WC, 2001, RESP RES, V2, P10, DOI 10.1186/rr33; Pei DQ, 2000, J BIOL CHEM, V275, P33988, DOI 10.1074/jbc.M006493200; Rychlewski L, 2000, PROTEIN SCI, V9, P232, DOI 10.1110/ps.9.2.232; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Uria JA, 2000, CANCER RES, V60, P4745; VanMeter TE, 2001, J NEURO-ONCOL, V53, P213, DOI 10.1023/A:1012280925031; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Velasco G, 1999, J BIOL CHEM, V274, P4570, DOI 10.1074/jbc.274.8.4570	32	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18967	18972		10.1074/jbc.M201197200	http://dx.doi.org/10.1074/jbc.M201197200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889136	hybrid			2022-12-25	WOS:000175975800094
J	Cui, Y; Miyoshi, K; Claudio, E; Siebenlist, UK; Gonzalez, FJ; Flaws, J; Wagner, KU; Hennighausen, L				Cui, Y; Miyoshi, K; Claudio, E; Siebenlist, UK; Gonzalez, FJ; Flaws, J; Wagner, KU; Hennighausen, L			Loss of the peroxisome proliferation-activated receptor gamma (PPAR gamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; IN-VITRO; TERMINAL DIFFERENTIATION; INDUCE APOPTOSIS; RETINOIC ACID; LUTEIN CELLS; EXPRESSION; LIGAND; MICE; GENE	The peroxisome proliferation-activated receptor gamma (PPARgamma) is expressed in many cell types including mammary epithelium, ovary, macrophages, and Band T-cells. PPARgamma has an anti-proliferative effect in pre-adipocytes and mammary epithelial cells, and treatment with its ligands reduced the progression of carcinogen-induced mammary tumors in mice. Because PPARgamma-null mice die in utero it has not been possible to study its role in development and tumorigenesis in vivo. To investigate whether PPARgamma is required for the establishment and physiology of different cell types, a cell-specific deletion of the gene was carried out in mice using the Cre-loxP recombination system. We deleted the PPARgamma gene in mammary epithelium using WAP-Cre transgenic mice and in epithelial cells, B- and T-cells, and ovary cells using MMTV-Cre mice. The presence of PPARgamma was not required for functional development of the mammary gland during pregnancy and for the establishment of B- and T-cells. In addition, no increase in mammary tumors was observed. However, loss of the PPARgamma gene in oocytes and granulosa cells resulted in impaired fertility. These mice have normal populations of follicles, they ovulate and develop corpora lutea. Although progesterone levels are decreased and implantation rates are reduced, the exact cause of the impaired fertility remains to be determined.	NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA; NIAID, Immunoregulat Lab, Immune Activat Sect, NIH, Bethesda, MD 20892 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Tokushima, Sch Dent, Dept Biochem, Tokushima 7708504, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; University of Nebraska System; University of Nebraska Medical Center; Tokushima University	Hennighausen, L (corresponding author), NIDDK, Lab Genet & Physiol, NIH, Bldg 8,Rm 107,8 Ctr Dr, Bethesda, MD 20892 USA.		Wagner, Kay-Uwe/B-6044-2009	Hennighausen, Lothar/0000-0001-8319-9841; Wagner, Kay-Uwe/0000-0002-5081-0226; Miyoshi, Keiko/0000-0001-6910-4172; Flaws, Jodi/0000-0001-5579-9268	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000722, ZIAAI000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK061000, Z01DK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Binart N, 2000, ENDOCRINOLOGY, V141, P2691, DOI 10.1210/en.141.7.2691; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Chang TH, 2000, CANCER RES, V60, P1129; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364; DEOME KB, 1959, CANCER RES, V19, P515; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gasic S, 1998, ENDOCRINOLOGY, V139, P4962, DOI 10.1210/en.139.12.4962; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Keelan JA, 1999, BIOCHEM BIOPH RES CO, V262, P579, DOI 10.1006/bbrc.1999.1257; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Komar CM, 2001, ENDOCRINOLOGY, V142, P4831, DOI 10.1210/en.142.11.4831; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Kubota T, 1998, CANCER RES, V58, P3344; Lambe KG, 1996, EUR J BIOCHEM, V239, P1, DOI 10.1111/j.1432-1033.1996.0001u.x; Law RE, 2000, CIRCULATION, V101, P1311, DOI 10.1161/01.CIR.101.11.1311; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lohrke B, 1998, J ENDOCRINOL, V159, P429, DOI 10.1677/joe.0.1590429; Mehta RG, 2000, J NATL CANCER I, V92, P418, DOI 10.1093/jnci/92.5.418; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Padilla J, 2000, J IMMUNOL, V165, P6941, DOI 10.4049/jimmunol.165.12.6941; Pighetti GM, 2001, ANTICANCER RES, V21, P825; Reese J, 2000, ENDOCRINOLOGY, V141, P1872, DOI 10.1210/en.141.5.1872; Robinson GW, 2001, ONCOGENE, V20, P7115, DOI 10.1038/sj.onc.1204888; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Spiegelman B M, 1997, Eur J Med Res, V2, P457; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Sundvold H, 1997, BIOCHEM BIOPH RES CO, V239, P857, DOI 10.1006/bbrc.1997.7564; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Viergutz T, 2000, J REPROD FERTIL, V118, P153, DOI 10.1530/reprod/118.1.153; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007	43	148	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17830	17835		10.1074/jbc.M200186200	http://dx.doi.org/10.1074/jbc.M200186200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884400	hybrid			2022-12-25	WOS:000175685100057
J	Gu, CH; Limberg, BJ; Whitaker, GB; Perman, B; Leahy, DJ; Rosenbaum, JS; Ginty, DD; Kolodkin, AL				Gu, CH; Limberg, BJ; Whitaker, GB; Perman, B; Leahy, DJ; Rosenbaum, JS; Ginty, DD; Kolodkin, AL			Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE MOLECULE; NERVOUS-SYSTEM; AXON GUIDANCE; RECEPTOR; DOMAIN; TRANSMEMBRANE; VERTEBRATES; EXPRESSION; EPHRIN-B2; PROTEIN	Neuropilin-1 (Npn-1) is a receptor for both semaphorin 3A (Sema3A) and vascular endothelial growth factor 165 (VEGF(165)). To understand the role Npn-1 plays as a receptor for these structurally and functionally unrelated ligands, we set out to identify structural features of Npn-1 that confer binding to Sema3A or VEGF(165). We constructed Npn-1 variants containing deletions within the "a" and "b" domains of Npn-1. More than 16 variants were expressed in COS-1 cells and tested for alkaline phosphatase-Sema3A as well as alkaline phosphatase-VEGF(165) binding. Our results indicate that each of the two Npn-1 CUB domains and the amino-terminal coagulation factor V/VIII domain (CF V/VIII) are essential for Sema3A binding, but only the amino-terminal Npn-1 CF V/VIII domain is required for binding to VEGF(165). Guided by the structure of the bovine spermadhesin CUB domain, point mutants targeting defined surfaces of the Npn-1 a1 CUB domain were generated and tested for Sema3A and VEGF(165) binding. One Npn-1 variant, Npn-1(2ABC), exhibits complete loss of Sema3A binding while retaining normal VEGF165 binding. Moreover, co-immunoprecipitation experiments show that Npn-1(2ABC) can form a signaling complex with the VEGF(165) signaling receptor KDR/VEGFR-2. These results establish the identity of contact sites between Npn-1 and its semaphorin ligands, and they provide a foundation for understanding how Npn-1 functions as a receptor for distinct classes of ligands in vivo.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; Procter & Gamble Pharmaceut, Mason, OH 45040 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Procter & Gamble	Ginty, DD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.				NIMH NIH HHS [R01MH59199] Funding Source: Medline; NINDS NIH HHS [5F32NS11016-02] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS011016] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bagnard D, 2001, J NEUROSCI, V21, P3332, DOI 10.1523/JNEUROSCI.21-10-03332.2001; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Cheng HJ, 2001, NEURON, V32, P249, DOI 10.1016/S0896-6273(01)00478-0; EVANS SV, 1993, J MOL GRAPHICS, V11, P127; Feiner L, 2001, DEVELOPMENT, V128, P3061; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Fujisawa H, 1997, CELL TISSUE RES, V290, P465, DOI 10.1007/s004410050954; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Goodman CS, 1999, CELL, V97, P551, DOI 10.1016/S0092-8674(00)80766-7; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Nakamura F, 2000, J NEUROBIOL, V44, P219, DOI 10.1002/1097-4695(200008)44:2<219::AID-NEU11>3.0.CO;2-W; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Raper JA, 2000, CURR OPIN NEUROBIOL, V10, P88, DOI 10.1016/S0959-4388(99)00057-4; Renzi MJ, 1999, J NEUROSCI, V19, P7870; Romero A, 1997, NAT STRUCT BIOL, V4, P783, DOI 10.1038/nsb1097-783; Shimizu M, 2000, J CELL BIOL, V148, P1283, DOI 10.1083/jcb.148.6.1283; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAKAGI S, 1995, DEV BIOL, V170, P207, DOI 10.1006/dbio.1995.1208; Takahashi T, 2001, NEURON, V29, P429, DOI 10.1016/S0896-6273(01)00216-1; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Wilkinson DG, 2000, INT REV CYTOL, V196, P177	39	185	194	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18069	18076		10.1074/jbc.M201681200	http://dx.doi.org/10.1074/jbc.M201681200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11886873	hybrid			2022-12-25	WOS:000175685100086
J	Jeong, DW; Yoo, MH; Kim, TS; Kim, JH; Kim, IY				Jeong, DW; Yoo, MH; Kim, TS; Kim, JH; Kim, IY			Protection of mice from allergen-induced asthma by selenite - prevention of eosinophil infiltration by inhibition of NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; AIRWAY HYPERRESPONSIVENESS; TRANSCRIPTION FACTOR; CANCER PREVENTION; PROINFLAMMATORY CYTOKINE; GLUTATHIONE-PEROXIDASE; THIOREDOXIN REDUCTASE; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; REDOX MECHANISM	The potential anti-inflammatory effect of sodium selenite in a mouse model of asthma was investigated. Selenite was injected into the peritoneum of allergen (ovalbumin) -sensitized mice before allergen challenge. Ovalbumin challenge resulted in activation of the transcription factor NF-kappaB and an increase in the expression of cell adhesion molecules (intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and E-selectin, which are encoded by NF-kappaB-dependent genes) in lung tissue as well as in the recruitment of eosinophils to lung airways. These effects of ovalbumin challenge were all inhibited by pretreatment of mice with selenite. Selenite administration also increased the activity of selenium-dependent glutathione peroxidase in lung tissue. Furthermore, supplementation of A549 human airway epithelial cell cultures with selenite increased glutathione peroxidase activity as well as inhibited both the generation of hydrogen peroxide and the activation of NF-kappaB induced by tumor necrosis factor alpha in these cells. Selenite also reversed in vitro the activation of NF-kappaB induced by this cytokine in intact A549 cells. These results suggest that selenite regulates the activity of NF-kappaB by increasing the activity of glutathione peroxidase, thereby removing potential activators of NF-kappaB, and possibly also by direct oxidation of critical sulfhydryl groups of this transcription factor. These effects of selenite likely underlie its anti-inflammatory action in asthma.	Korea Univ, Grad Sch Biotechnol, Lab Cellular & Mol Biochem, Seoul 136701, South Korea; Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea	Korea University; Gwangju Institute of Science & Technology (GIST)	Kim, IY (corresponding author), Korea Univ, Grad Sch Biotechnol, Lab Cellular & Mol Biochem, 1 5-Ka, Seoul 136701, South Korea.		Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208				Adler V, 1996, CARCINOGENESIS, V17, P1849, DOI 10.1093/carcin/17.9.1849; Baker JC, 2000, RESP MED, V94, P925, DOI 10.1053/rmed.2000.0873; BERGAD PL, 1986, CURR EYE RES, V5, P919, DOI 10.3109/02713688608995172; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Caffrey PB, 2000, CANCER CHEMOTH PHARM, V46, P74, DOI 10.1007/s002800000127; Chen F, 1999, CLIN CHEM, V45, P7; Cheng TH, 1999, CARDIOVASC RES, V41, P654, DOI 10.1016/S0008-6363(98)00275-2; Choi JH, 2000, INFLAMMATION, V24, P385, DOI 10.1023/A:1007068010645; Christman JW, 2000, CHEST, V117, P1482, DOI 10.1378/chest.117.5.1482; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Collard CD, 1998, IMMUNOPHARMACOLOGY, V39, P39, DOI 10.1016/S0162-3109(97)00096-9; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; Feghali CA, 1997, FRONT BIOSCI, V2, P12; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gopalakrishna R, 1997, ARCH BIOCHEM BIOPHYS, V348, P37, DOI 10.1006/abbi.1997.0335; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480, DOI 10.1165/ajrcmb.21.4.3659; HANDEL ML, 1995, P NATL ACAD SCI USA, V92, P4497, DOI 10.1073/pnas.92.10.4497; Hart L, 2000, AM J RESP CRIT CARE, V161, P224, DOI 10.1164/ajrccm.161.1.9809019; Haycock JW, 2000, J BIOL CHEM, V275, P15629, DOI 10.1074/jbc.275.21.15629; Helmy MH, 2000, TOXICOLOGY, V144, P57, DOI 10.1016/S0300-483X(99)00190-0; Holben DH, 1999, J AM DIET ASSOC, V99, P836, DOI 10.1016/S0002-8223(99)00198-4; Ip C, 1998, J NUTR, V128, P1845, DOI 10.1093/jn/128.11.1845; IP C, 1985, FED PROC, V44, P2573; ISLAM F, 1991, ARCH BIOCHEM BIOPHYS, V289, P161, DOI 10.1016/0003-9861(91)90456-S; Kanehiro A, 2001, AM J RESP CRIT CARE, V163, P173, DOI 10.1164/ajrccm.163.1.2001118; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Kim IY, 1997, P NATL ACAD SCI USA, V94, P12904, DOI 10.1073/pnas.94.24.12904; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; Lewis AJ, 1999, CURR OPIN CHEM BIOL, V3, P489, DOI 10.1016/S1367-5931(99)80071-4; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Makropoulos V, 1996, ARCH TOXICOL, V70, P277, DOI 10.1007/s002040050274; Matsukura S, 1999, J IMMUNOL, V163, P6876; Oitzinger W, 2001, BLOOD, V97, P1611, DOI 10.1182/blood.V97.6.1611; Pallud S, 1997, J BIOL CHEM, V272, P18104, DOI 10.1074/jbc.272.29.18104; Park HS, 2000, J BIOL CHEM, V275, P8487, DOI 10.1074/jbc.275.12.8487; Park HS, 2000, J BIOL CHEM, V275, P2527, DOI 10.1074/jbc.275.4.2527; Picado C, 2001, ALLERGY, V56, P43, DOI 10.1034/j.1398-9995.2001.00793.x; Rao CV, 2000, CARCINOGENESIS, V21, P617, DOI 10.1093/carcin/21.4.617; Schieke SM, 1999, FEBS LETT, V448, P301, DOI 10.1016/S0014-5793(99)00372-5; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sinha R, 1997, CARCINOGENESIS, V18, P1541, DOI 10.1093/carcin/18.8.1541; Soutar A, 1997, THORAX, V52, P166, DOI 10.1136/thx.52.2.166; Stapleton SR, 1997, BBA-MOL CELL RES, V1355, P259, DOI 10.1016/S0167-4889(96)00140-1; Stewart MS, 1999, FREE RADICAL BIO MED, V26, P42, DOI 10.1016/S0891-5849(98)00147-6; TASHIMA Y, 1989, J BIOCHEM-TOKYO, V105, P358, DOI 10.1093/oxfordjournals.jbchem.a122668; Teixeira MM, 1997, J CLIN INVEST, V100, P1657, DOI 10.1172/JCI119690; Tolando R, 2000, FREE RADICAL BIO MED, V28, P979, DOI 10.1016/S0891-5849(00)00183-0; Tomkinson A, 2001, J IMMUNOL, V166, P5792, DOI 10.4049/jimmunol.166.9.5792; Webb DC, 2001, IMMUNOL CELL BIOL, V79, P165, DOI 10.1046/j.1440-1711.2001.00989.x; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739	56	78	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17871	17876		10.1074/jbc.M200808200	http://dx.doi.org/10.1074/jbc.M200808200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11897787	hybrid			2022-12-25	WOS:000175685100062
J	Smith, JD; Waelde, C; Horwitz, A; Zheng, P				Smith, JD; Waelde, C; Horwitz, A; Zheng, P			Evaluation of the role of phosphatidylserine translocase activity in ABCA1-mediated lipid efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MDR3 P-GLYCOPROTEIN; PLASMA-MEMBRANE; CHOLESTEROL EFFLUX; ABCA1 TRANSPORTER; APOPTOTIC CELLS; ENGULFMENT; BINDING; PHOSPHATIDYLCHOLINE; REDISTRIBUTION; PHOSPHOLIPIDS	The following two theories for the mechanism of ABCA1 in lipid efflux to apolipoprotein acceptors have been proposed: 1) that ABCA1 directly binds the apolipoprotein ligand and then facilitates lipid efflux and 2) that ABCA1 acts as a phosphatidylserine (PS) translocase, increasing PS levels in the plasma membrane exofacial leaflet, and that this is sufficient to facilitate apolipoprotein binding and lipid assembly. Upon induction of ABCA1 in RAW264.7 cells by cAMP analogues there was a moderate increase in cell surface PS as detected by annexin V binding, whereas apoAI binding was increased more robustly. Apoptosis induced large increases in annexin V and apoAI binding; however, apoptotic cells did not efflux lipids to apoAI. Annexin V did not act as a cholesterol acceptor, and it did not compete for the cholesterol acceptor or cell binding activity of apoAI. ApoAI binds to ABCA1-expressing cells, and with incubation at 37 degreesC apoAI is co-localized within the cells in ABCA1-containing endosomes. Fluorescent recovery after photobleaching demonstrated that apoAI bound to ABCA1-expressing cells was relatively immobile, suggesting that it was bound either directly or indirectly to an integral membrane protein. Although ABCA1 induction was associated with a small increase in cell surface PS, these results argue against the notion that this cell surface PS is sufficient to mediate cellular apoA1 binding and lipid efflux.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Smith, JD (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.		Smith, Jonathan D./H-9723-2013	Smith, Jonathan D./0000-0002-0415-386X	NHLBI NIH HHS [R01HL66082] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066082] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; Borst P, 2000, BBA-MOL CELL BIOL L, V1486, P128, DOI 10.1016/S1388-1981(00)00053-6; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Dekkers DWC, 1998, BIOCHEMISTRY-US, V37, P14833, DOI 10.1021/bi981011w; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; Marguet D, 1999, NAT CELL BIOL, V1, P454, DOI 10.1038/15690; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2001, J LIPID RES, V42, P1173; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Raggers RJ, 2001, BIOCHEM J, V357, P859, DOI 10.1042/0264-6021:3570859; Serra MV, 1996, BBA-BIOMEMBRANES, V1282, P263; SMIT JJM, 1994, LAB INVEST, V71, P638; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; Szakacs G, 2001, BIOCHEM BIOPH RES CO, V288, P1258, DOI 10.1006/bbrc.2001.5905; Takahashi Y, 2000, BBA-GENE STRUCT EXPR, V1492, P385, DOI 10.1016/S0167-4781(00)00133-0; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wu YC, 1998, CELL, V93, P951, DOI 10.1016/S0092-8674(00)81201-5; Zha XH, 2001, J BIOL CHEM, V276, P39476, DOI 10.1074/jbc.M105067200; Zheng P, 2001, BBA-MOL CELL BIOL L, V1534, P121, DOI 10.1016/S1388-1981(01)00183-4	23	98	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17797	17803		10.1074/jbc.M201594200	http://dx.doi.org/10.1074/jbc.M201594200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11893753	hybrid			2022-12-25	WOS:000175685100053
J	Christensen, MO; Barthelmes, HU; Feineis, S; Knudsen, BR; Andersen, AH; Boege, F; Mielke, C				Christensen, MO; Barthelmes, HU; Feineis, S; Knudsen, BR; Andersen, AH; Boege, F; Mielke, C			Changes in mobility account for camptothecin-induced subnuclear relocation of topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR ARCHITECTURE; PROTEIN DYNAMICS; DNA; CELLS; EXPRESSION; RNA; MECHANISM; BINDING	DNA topoisomerase I is a nucleolar protein, which relocates to the nucleoplasm in response to drugs stabilizing topoisomerase I-DNA intermediates (e.g. camptothecin). Here we demonstrate that this phenomenon is solely caused by the drug's impact on the interplay between mobility and localization of topoisomerase I in a living cell nucleus. We show by photobleaching of cells expressing biofluorescent topoisomerase I-chimera that the enzyme moves continuously between nucleoli and nucleoplasm. Complex kinetics of fluorescence recovery after photobleaching indicates that two enzyme fractions with different mobility coexist in nucleoli and nucleoplasm. However, the whole complement of topoisomerase I is in continuous flux between these compartments and nucleolar accumulation can plausibly explained by the enzyme's 2-fold lesser overall mobility in nucleoli versus nucleoplasm. Upon addition of camptothecin, topoisomerase I relocates within 30 s from the nucleoli to radial nucleoplasmic structures. At these sites, the enzyme becomes retarded in a dose-dependent manner. Inside nucleoli the mobility of topoisomerase I is much less affected by camptothecin. Thus, the enzyme's distribution equilibrium is shifted toward the nucleoplasm, which causes nucleolar delocalization. In general, topoisomerase I is an entirely mobile nuclear component, unlikely to require specific signaling for movements between nuclear compartments.	Univ Wurzburg, Med Poliklin, Dept Clin Chem, D-97070 Wurzburg, Germany; Univ Aarhus, Dept Mol & Struct Biol, DK-8200 Aarhus C, Denmark	University of Wurzburg; Aarhus University	Mielke, C (corresponding author), Univ Wurzburg, Med Poliklin, Dept Clin Chem, Klin Str 6-8, D-97070 Wurzburg, Germany.		Andersen, Anni/O-1162-2017; Boege, Fritz/H-3261-2019	Knudsen, Birgitta Ruth/0000-0002-3484-3802; Andersen, Anni/0000-0001-7194-3258				Buckwalter CA, 1996, CANCER RES, V56, P1674; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Danks MK, 1996, CANCER RES, V56, P1664; Hendzel MJ, 1999, MOL BIOL CELL, V10, P2051, DOI 10.1091/mbc.10.6.2051; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; Mielke C, 2000, GENE, V254, P1, DOI 10.1016/S0378-1119(00)00294-8; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Mo YY, 2002, J BIOL CHEM, V277, P2958, DOI 10.1074/jbc.M108263200; Mo YY, 2000, EXP CELL RES, V256, P480, DOI 10.1006/excr.2000.4864; MULLER MT, 1985, EMBO J, V4, P1237, DOI 10.1002/j.1460-2075.1985.tb03766.x; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Shopland LS, 2000, J CELL BIOL, V150, pF1, DOI 10.1083/jcb.150.1.F1; Straub T, 1997, BIOCHEMISTRY-US, V36, P10777, DOI 10.1021/bi970417q; White J, 1999, TRENDS CELL BIOL, V9, P61, DOI 10.1016/S0962-8924(98)01433-0; ZHANG H, 1988, P NATL ACAD SCI USA, V85, P1060, DOI 10.1073/pnas.85.4.1060	20	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15661	15665		10.1074/jbc.C200066200	http://dx.doi.org/10.1074/jbc.C200066200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11907023	hybrid			2022-12-25	WOS:000175510400060
J	Nguyen, QD; Faivre, S; Bruyneel, E; Rivat, C; Seto, M; Endo, T; Mareel, M; Emami, S; Gespach, C				Nguyen, QD; Faivre, S; Bruyneel, E; Rivat, C; Seto, M; Endo, T; Mareel, M; Emami, S; Gespach, C			RhoA- and RhoD-dependent regulatory switch of G alpha subunit signaling by PAR-1 receptors in cellular invasion	FASEB JOURNAL			English	Article						colon cancer progression; metastatic potential; guanylate cyclases; src; rac; myosin light chain kinase; guanylin; cGMP	NUCLEOTIDE EXCHANGE FACTOR; SMOOTH-MUSCLE CONTRACTION; COLONIC EPITHELIAL-CELLS; TUMOR-CELLS; ACTIN CYTOSKELETON; THROMBIN RECEPTOR; STRESS FIBERS; CYCLIC-GMP; ALPHA-6-BETA-4 INTEGRIN; NEOPLASTIC PROGRESSION	Thrombin and proteinase-activated receptors (PAR) specifically regulate several functions that markedly enhance the transformation phenotype such as inflammation, cell proliferation, tumor growth, and metastasis. We recently reported that thrombin inhibits cellular invasion induced by src, hepatocyte growth factor (HGF), and leptin in kidney and colonic epithelial cells via predominant activation of the pertussis toxin (PTx) -sensitive G-proteins Galphao/Galphai. We provide pharmacological and biochemical evidence that in the presence of PTx, PAR-1 induced cellular invasion through Galpha12/Galpha13- and RhoA/Rho kinase (ROCK)-dependent signaling. However, inhibition of the endogenous small GTPase RhoA by the C3 exoenzyme, dominant-negative N19-RhoA, activated G26V-RhoD, and activators of the nitric oxide/cGMP pathways conferred invasive activity to PAR-1 via a signaling cascade using Galphaq, phospholipase C (PLC), Ca2+ / calmodulin myosin light chain kinase (CaM-MLCK), and phosphorylation of MLC. We found that cellular invasion induced by the src oncogene is abrogated by inhibitors of the RhoA/ROCK pathway and is independent of PLC/CaM-MLCK signaling. Our data demonstrate that the RhoA and RhoD small GTPases are acting as a molecular switch of cellular invasion and reveal a novel critical mechanism by which PAR-1 bypass Galphao/i and RhoA inhibition via differential coupling to heterotrimeric G-proteins linked to divergent or convergent biological responses. Our data also indicate that Rho GTPases and ROCK mediate a src-dependent invasion signal in kidney and colonic cancer cells. We conclude that dynamic regulation of Rho GTPases activation and inactivation by oncogenes, growth factors, cGMP-inducing agents, and adhesion molecules can initiate convergent invasion signals controlled by the thrombin PAR-1 in cancer cells.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; State Univ Ghent Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Chiba Univ, Dept Biol, Inage Ku, Chiba 2638522, Japan; Asahi Chem Ind Co Ltd, Shizuoka 4160934, Japan	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; Chiba University	Gespach, C (corresponding author), Hop St Antoine, INSERM, U482, F-75571 Paris 12, France.	gespach@st-antoine.inserm.fr		Faivre, Sandrine/0000-0002-1590-485X				Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHASTRE E, 1993, GASTROENTEROLOGY, V105, P1776, DOI 10.1016/0016-5085(93)91076-T; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Donovan FM, 1998, J BIOL CHEM, V273, P12746, DOI 10.1074/jbc.273.21.12746; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Faivre S, 2001, MOL PHARMACOL, V60, P363, DOI 10.1124/mol.60.2.363; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; Fiorentini C, 1997, J BIOL CHEM, V272, P19532, DOI 10.1074/jbc.272.31.19532; Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0; Furman MI, 1998, P NATL ACAD SCI USA, V95, P3082, DOI 10.1073/pnas.95.6.3082; Gilchrist A, 2001, J BIOL CHEM, V276, P25672, DOI 10.1074/jbc.M100914200; Grosheva I, 2001, J CELL SCI, V114, P695; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kamath L, 2001, CANCER RES, V61, P5933; Katoh K, 2001, J CELL BIOL, V153, P569, DOI 10.1083/jcb.153.3.569; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; LAUNAY JM, 1994, AM J PHYSIOL, V35, pR526; Lucas KA, 2000, PHARMACOL REV, V52, P375; MACKIE EJ, 1988, J CELL BIOL, V107, P2757, DOI 10.1083/jcb.107.6.2757; MACKIE EJ, 1987, P NATL ACAD SCI USA, V84, P4621, DOI 10.1073/pnas.84.13.4621; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PFEIFER A, 1995, J BIOL CHEM, V270, P9052, DOI 10.1074/jbc.270.16.9052; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Ridley A, 2000, J CELL BIOL, V150, pF107, DOI 10.1083/jcb.150.4.F107; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; Sagi SA, 2001, J BIOL CHEM, V276, P15445, DOI 10.1074/jbc.M008961200; Sakurada K, 1998, AM J PHYSIOL-CELL PH, V274, pC1563, DOI 10.1152/ajpcell.1998.274.6.C1563; Santagata S, 2001, SCIENCE, V292, P2041, DOI 10.1126/science.1061233; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Sawada N, 2001, BIOCHEM BIOPH RES CO, V280, P798, DOI 10.1006/bbrc.2000.4194; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Tanaka M, 2000, INT J MOL MED, V5, P505; Tsubakimoto K, 1999, ONCOGENE, V18, P2431, DOI 10.1038/sj.onc.1202604; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wenk MB, 2000, J CELL BIOL, V150, P913, DOI 10.1083/jcb.150.4.913; Wilde C, 2000, J BIOL CHEM, V275, P16478, DOI 10.1074/jbc.M910362199; WOJTUKIEWICZ MZ, 1995, CANCER RES, V55, P698; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146	67	51	52	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					565	576		10.1096/fj.01-0525com	http://dx.doi.org/10.1096/fj.01-0525com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11919159				2022-12-25	WOS:000175425900010
J	Perez-Mancera, PA; Perez-Losada, J; Sanchez-Martin, M; Rodriguez-Garcia, MA; Flores, T; Battaner, E; Gutierrez-Adan, A; Pintado, B; Sanchez-Garcia, I				Perez-Mancera, PA; Perez-Losada, J; Sanchez-Martin, M; Rodriguez-Garcia, MA; Flores, T; Battaner, E; Gutierrez-Adan, A; Pintado, B; Sanchez-Garcia, I			Expression of the FUS domain restores liposarcoma development in CHOP transgenic mice	ONCOGENE			English	Article						chromosomal abnormality; malignant solid tumors; adipose tissue; cancer development	HUMAN MYELOID-LEUKEMIA; RNA-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; MYXOID LIPOSARCOMA; FUS/TLS-CHOP; GENE; ERG; TRANSLOCATION; C/EBP; MALIGNANCIES	Fusion proteins created by chromosomal abnormalities are key components of mesenchymal cancer development. The most common chromosomal translocation in liposarcomas, t(12;16)(q13;p11), creates the FUS-CHOP fusion gene. In the past, we generated FUS-CHOP and CHOP transgenic mice and have shown that while FUS-CHOP transgenic develop liposarcomas, mice expressing CHOP, which lacks the FUS domain, display essentially normal white adipose tissue (WAT) development, suggesting that the FUS domain of FUS-CHOP plays a specific and critical role in the pathogenesis of liposarcoma. To test the significance of FUS and CHOP domain interactions within a living mouse, we generated mice expressing the FUS domain and crossed them with CHOP-transgenic mice to generate double-transgenic FUSxCHOP animals. Here we report that expression of the FUS domain restores liposarcoma development in CHOP-transgenic mice. Our results provide genetic evidence that FUS and CHOP domains function in trans for the mutual restoration of liposarcoma. These results identify a new mechanism of tumor-associated fusion genes and might have impact beyond myxoid liposarcoma.	Univ Salamanca, CSIC, Ctr Invest Canc, IBMCC, Salamanca 37007, Spain; Univ Salamanca, Serv Anat Patol, Salamanca 37007, Spain; Univ Salamanca, Dept Bioquim & Biol Mol, Salamanca 37007, Spain; Ctr Invest & Tecnol, Area Reprod Anim, Madrid 28040, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Salamanca	Sanchez-Garcia, I (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, IBMCC, Campus Unamuno, Salamanca 37007, Spain.	isg@gugu.usal.es	Sanchez-Martin, Manuel/N-5327-2016; Gutierrez-Adan, Alfonso/A-1485-2014; SANCHEZ-GARCIA, ISIDRO/A-5631-2019; Pintado, Belen/N-3233-2014; Pérez-Losada, Jesús/A-5883-2019	Sanchez-Martin, Manuel/0000-0001-8370-1336; Gutierrez-Adan, Alfonso/0000-0001-9893-9179; Pintado, Belen/0000-0002-8485-2520; Pérez-Losada, Jesús/0000-0003-2400-624X; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905	NATIONAL CANCER INSTITUTE [R01CA079955] Funding Source: NIH RePORTER; NCI NIH HHS [1 R01 CA79955-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Castellanos A, 1997, BLOOD, V90, P2168, DOI 10.1182/blood.V90.6.2168.2168_2168_2174; CHANG HR, 1989, CANCER, V64, P1514, DOI 10.1002/1097-0142(19891001)64:7<1514::AID-CNCR2820640726>3.0.CO;2-2; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KNIGHT JC, 1995, CANCER RES, V55, P24; MACK TM, 1995, CANCER-AM CANCER SOC, V75, P211, DOI 10.1002/1097-0142(19950101)75:1+<211::AID-CNCR2820751309>3.0.CO;2-X; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Perez-Losada J, 2000, ONCOGENE, V19, P6015, DOI 10.1038/sj.onc.1204018; Perez-Losada J, 2000, ONCOGENE, V19, P2413, DOI 10.1038/sj.onc.1203572; PRASAD DDK, 1994, ONCOGENE, V9, P3717; PRICE BD, 1992, CANCER RES, V52, P3814; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sanchez-Garcia I, 1997, ANNU REV GENET, V31, P429, DOI 10.1146/annurev.genet.31.1.429; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	25	18	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1679	1684		10.1038/sj.onc.1205220	http://dx.doi.org/10.1038/sj.onc.1205220			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896599				2022-12-25	WOS:000174214200006
J	Maxwell, RA; Welch, WH; Schooley, DA				Maxwell, RA; Welch, WH; Schooley, DA			Juvenile hormone diol kinase - I. Purification, characterization, and substrate specificity of juvenile hormone-selective diol kinase from Manduca sexta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPOXIDE HYDROLASE; CYTOSOLIC SULFOTRANSFERASES; TOBACCO HORNWORM; TRICHOPLUSIA-NI; ESTERASE; ACID; STADIUM; CHROMATOGRAPHY; IDENTIFICATION; METAMORPHOSIS	Manduca sexta juvenile hormone diol kinase (JHDK) catalyzes the conversion of juvenile hormone (JH) diol to JH diol phosphate. JHDK may be the first example of a phosphotransferase directly involved in the catabolism and inactivation of a lipid-soluble hormone. JHDK is an enzyme crucial for secondary metabolism of JH and possesses high specificity and catalytic efficiency for JH diol. In this study, the purification and characterization of native JHDK are described; its enzymatic properties are examined; and its role in cellular JH metabolism is explored. Using a variety of potential substrates, we show that JHDK has a preference for ATP, but will catalyze the formation of JH diol phosphate with GTP as the phosphate donor. JHDK has a nanomolar K-m for JH I diol and a low micromolar value for MgATP. JH II and III diols also serve as phosphate acceptors with low micromolar K-m, whereas other diol derivatives of terpenoid esters structurally similar to JH metabolites are not phosphorylated. The reaction proceeds via a sequential Bi Bi mechanism. JHDK is active as a homodimer with a subunit molecular mass of 20 kDa. JHDK binds 5'-p-fluorosulfonylbenzoyladenosine and is inhibited by micromolar levels of Ca2+.	Univ Nevada, Dept Biochem, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno	Schooley, DA (corresponding author), Univ Nevada, Dept Biochem, 1664 N Virginia St, Reno, NV 89557 USA.							ABDELAAL YAI, 1985, INSECT BIOCHEM, V15, P111, DOI 10.1016/0020-1790(85)90051-4; BAKER FC, 1987, INSECT BIOCHEM, V17, P989, DOI 10.1016/0020-1790(87)90108-9; BERGOT BJ, 1981, J CHROMATOGR, V204, P231, DOI 10.1016/S0021-9673(00)81664-7; COHEN SA, 1993, ANAL BIOCHEM, V211, P279, DOI 10.1006/abio.1993.1270; DANN LG, 1978, BIOCHEM J, V169, P39, DOI 10.1042/bj1690039; DEBERNARD S, 1994, J INSECT PHYSIOL, V40, P975, DOI 10.1016/0022-1910(94)90136-8; deKort CAD, 1996, ARCH INSECT BIOCHEM, V33, P1, DOI 10.1002/(SICI)1520-6327(1996)33:1&lt;1::AID-ARCH1&gt;3.0.CO;2-2; Falany CN, 1997, FASEB J, V11, P1; Falany CN, 1997, FASEB J, V11, P206, DOI 10.1096/fasebj.11.4.9068609; Feyereisen R., 1985, P391; GRANGER NA, 1995, INSECT BIOCHEM MOLEC, V25, P427, DOI 10.1016/0965-1748(94)00076-B; GRIENEISEN ML, 1995, ARCH INSECT BIOCHEM, V30, P255, DOI 10.1002/arch.940300213; Grieneisen ML, 1997, INSECT BIOCHEM MOLEC, V27, P365, DOI 10.1016/S0965-1748(97)00008-8; HALARNKAR PP, 1993, EXPERIENTIA, V49, P988, DOI 10.1007/BF02125646; HAMMOCK B, 1975, MOL CELL ENDOCRINOL, V3, P167, DOI 10.1016/0303-7207(75)90043-X; HAMMOCK BD, 1980, LIFE SCI, V27, P1635, DOI 10.1016/0024-3205(80)90636-0; Hinton AC, 2001, INSECT BIOCHEM MOLEC, V32, P57, DOI 10.1016/S0965-1748(01)00079-0; Ismail SM, 1998, ARCH INSECT BIOCHEM, V37, P305, DOI 10.1002/(SICI)1520-6327(1998)37:4&lt;305::AID-ARCH6&gt;3.0.CO;2-P; Ismail SM, 2000, J INSECT PHYSIOL, V46, P59, DOI 10.1016/S0022-1910(99)00102-X; Kallapur VL, 1996, J INSECT PHYSIOL, V42, P181, DOI 10.1016/0022-1910(95)00057-7; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; LASSITER MT, 1994, J MED ENTOMOL, V31, P586, DOI 10.1093/jmedent/31.4.586; Maxwell RA, 2002, ANAL BIOCHEM, V305, P40, DOI 10.1006/abio.2002.5660; NAKANISHI K, 1971, J CHEM SOC CHEM COMM, P1235, DOI 10.1039/c29710001235; Rees H.H., 1989, P28; RHOADS DG, 1968, J BIOL CHEM, V243, P3963; RICARD J, 1972, EUR J BIOCHEM, V31, P14, DOI 10.1111/j.1432-1033.1972.tb02494.x; SANBURG LL, 1975, NATURE, V253, P266, DOI 10.1038/253266a0; Schooley D.A., 1984, P373; Schooley DA, 1985, COMPREHENSIVE INSECT, P363; SHARE MR, 1988, ANAL BIOCHEM, V169, P81, DOI 10.1016/0003-2697(88)90257-6; SLADE M, 1974, COMP BIOCHEM PHYSIOL, V49, P99, DOI 10.1016/0305-0491(74)90228-4; Slade M., 1972, P155; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Strydom D. J., 1993, TECHNIQUES PROTEIN C, VIV, P299; SU S, 1967, BIOCHIM BIOPHYS ACTA, V132, P370, DOI 10.1016/0005-2744(67)90156-8; Sutherland TD, 1998, P NATL ACAD SCI USA, V95, P12884, DOI 10.1073/pnas.95.22.12884; TOUHARA K, 1993, J BIOL CHEM, V268, P19604; Truman JW, 1999, NATURE, V401, P447, DOI 10.1038/46737; Vakiani E, 1998, J BIOL CHEM, V273, P35381, DOI 10.1074/jbc.273.52.35381; YAMAMOTO RT, 1969, J ECON ENTOMOL, V62, P1427, DOI 10.1093/jee/62.6.1427; ZIMOWSKA G, 1989, ARCH INSECT BIOCHEM, V12, P1, DOI 10.1002/arch.940120102	42	42	48	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21874	21881		10.1074/jbc.M201510200	http://dx.doi.org/10.1074/jbc.M201510200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11909871	hybrid			2022-12-25	WOS:000176286000098
J	Liu, J; Tian, ZG; Gao, B; Kunos, G				Liu, J; Tian, ZG; Gao, B; Kunos, G			Dose-dependent activation of antiapoptotic and proapoptotic pathways by ethanol treatment in human vascular endothelial cells - Differential involvement of adenosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; NF-KAPPA-B; MODERATE ALCOHOL-CONSUMPTION; CORONARY HEART-DISEASE; NITRIC-OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; MOLECULAR-CLONING; INDUCED APOPTOSIS	Moderate but not heavy drinking has been found to have a protective effect against cardiovascular morbidity. We investigated the effects of ethanol (EtOH) treatment on the cell survival-promoting phosphatidylinositol 3-kinase (PI3K)/Akt pathway in cultured human umbilical vein endothelial cells (HUVEC). Exposure of cells to 2-20 mm EtOH resulted in rapid (< 10 min) induction of Akt phosphorylation that could be prevented by pertussis toxin or the PI3K inhibitors wortmannin and LY294002. Among the downstream effectors of PI3K/Akt, p70S6 kinase, glycogen synthase kinase 3alpha/p, and IKB-alpha were phosphorylated, the latter resulting in 3-fold activation of NF-kappaB. EtOH also activated p44/42 mitogenactivated protein kinase in a PI3K-dependent manner. Low concentrations of EtOH increased endothelial nitric-oxide synthase activity, which could be blocked transfection of HUVEC with dominant-negative Akt, implicating the PI3K/Akt pathway in this effect. The adenosine Al receptor antagonist 1,3-dipopyleyclopentylxanthine prevented the phosphorylation of Akt observed in the presence of EtOH, adenosine, or the Al agonist N-6-cyclopentyladenosine. Incubation of HUVEC with 50100 mm EtOH resulted in mitochondrial permeability transition and caspase-3 activation followed by apoptosis, as documented by DNA fragmentation and TUNEL assays. EtOH-induced apoptosis was unaffected by DPCPX and was potentiated by wortmannin or LY294002. We conclude that treatment with low concentrations of EtOH activates the cell survival promoting PI3K/Akt pathway in endothelial cells by an adenosine receptor-dependent mechanism and activation of the proapoptotic caspase pathway by higher concentrations of EtOH via an adenosine-independent mechanism can mask or counteract such effects.	NIAAA, Lab Physiol Studies, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Kunos, G (corresponding author), NIAAA, Lab Physiol Studies, NIH, 12420 Parklawn Dr,Rm 120,MSC 8115, Bethesda, MD 20892 USA.	gkunos@mail.nih.gov	Tian, Zhigang/J-3512-2013		NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000351, Z01AA000351, Z01AA000366] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; Acevedo CG, 1997, PLACENTA, V18, P387, DOI 10.1016/S0143-4004(97)80038-0; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bottomley MJ, 1998, BBA-MOL CELL BIOL L, V1436, P165, DOI 10.1016/S0005-2760(98)00141-6; Bouma MG, 1996, AM J PHYSIOL-CELL PH, V270, pC522, DOI 10.1152/ajpcell.1996.270.2.C522; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chen CH, 1999, P NATL ACAD SCI USA, V96, P12784, DOI 10.1073/pnas.96.22.12784; Constant J, 1997, CORONARY ARTERY DIS, V8, P645, DOI 10.1097/00019501-199710000-00007; Corder R, 2001, NATURE, V414, P863, DOI 10.1038/414863a; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DAVDA RK, 1993, HYPERTENSION, V21, P939, DOI 10.1161/01.HYP.21.6.939; de la Monte SM, 2001, ALCOHOL CLIN EXP RES, V25, P898, DOI 10.1097/00000374-200106000-00016; DEL PL, 1997, SCIENCE, V278, P687; Diao LH, 1996, J PHARMACOL EXP THER, V278, P542; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Foo SY, 1999, TRENDS GENET, V15, P229; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fredholm BB, 1996, PHARMACOL TOXICOL, V79, P120, DOI 10.1111/j.1600-0773.1996.tb00254.x; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Germack R, 2000, BRIT J PHARMACOL, V130, P867, DOI 10.1038/sj.bjp.0703396; Gold MR, 1999, J IMMUNOL, V163, P1894; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffin G, 2000, J PHARMACOL EXP THER, V292, P886; Guo TL, 1998, TOXICOL APPL PHARM, V152, P397, DOI 10.1006/taap.1998.8526; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Higuchi H, 2001, HEPATOLOGY, V34, P320, DOI 10.1053/jhep.2001.26380; JARVIS MF, 1988, PHARMACOL BIOCHEM BE, V30, P707, DOI 10.1016/0091-3057(88)90088-3; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KRAUSS SW, 1993, MOL PHARMACOL, V44, P1021; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; KUNOS G, 1996, NIAAA RES MONOGR, V31, P243; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Liu J, 2000, BIOCHEM J, V346, P835, DOI 10.1042/0264-6021:3460835; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Marchetti P, 1996, J IMMUNOL, V157, P4830; NAGY LE, 1991, MOL PHARMACOL, V40, P812; NAGY LE, 1990, J BIOL CHEM, V265, P1946; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; SAPRU MK, 1994, J PHARMACOL EXP THER, V271, P542; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Takasuga S, 1999, J BIOL CHEM, V274, P19545, DOI 10.1074/jbc.274.28.19545; Tanasescu M, 2001, J AM COLL CARDIOL, V38, P1836, DOI 10.1016/S0735-1097(01)01655-2; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; van Tol A, 2001, CURR OPIN LIPIDOL, V12, P19, DOI 10.1097/00041433-200102000-00004; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	57	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20927	20933		10.1074/jbc.M110712200	http://dx.doi.org/10.1074/jbc.M110712200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11919181	hybrid			2022-12-25	WOS:000176204500106
J	Walter, L; Franklin, A; Witting, A; Moller, T; Stella, N				Walter, L; Franklin, A; Witting, A; Moller, T; Stella, N			Astrocytes in culture produce anandamide and other acylethanolamides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS CANNABINOID ANANDAMIDE; FATTY-ACID ETHANOLAMIDES; RAT-BRAIN; N-ACYLETHANOLAMINES; STRIATAL ASTROCYTES; RECEPTOR; CELLS; STIMULATION; NEURONS; DELTA(9)-TETRAHYDROCANNABINOL	Anandamide (arachidonylethanolamide) is an endocannabinoid that belongs to the acylethanolamide lipid family. It is produced by neurons in a calcium-dependent manner and acts through cannabinoid CB1 receptors. Other members of the acylethanolamide lipid family are also produced by neurons and act through G-protein-coupled receptors: homo-gamma-linolenylethanolamide (HEA) and docosatetraenylethanolamide (DEA) act through CB1 receptors, palmitylethanolamide (PEA) acts through CB2-like receptors, and oleylethanolamide (OEA) acts through receptors that have not yet been cloned. Although it is clear that anandamide and other acylethanolamides play a major role in neuronal signaling, whether astrocytes also produce these lipids is unknown. We developed a chemical ionization gas chromatography/mass spectrometry method that allows femtomole detection and quantification of anandamide and other acylethanolamides. Using this method, we unambiguously detected and quantified anandamide, HEA, DEA, PEA, and OEA in mouse astrocytes in culture. Stimulation of mouse astrocytes with ionomycin, a calcium ionophore, enhanced the production of anandamide, REA, and DEA, whereas PEA and OEA levels were unchanged. Endothelin-1, a peptide known to act on astrocytes, enhanced the production of anandamide, without affecting the levels of other acylethanolamides. These results show that astrocytes produce anandamide, REA, and DEA in a calcium-dependent manner and that anandamide biosynthesis can be selectively stimulated under physiologically relevant conditions. The relative levels of acylethanolamides in astrocytes from rat and human were different from the relative levels of acylethanolamides in mouse astrocytes, indicating that the production of these lipids differs between species. Because astrocytes are known to express CB1 receptors and inactivate endocannabinoids, our finding strongly suggests the existence of a functional endocannabinoid signaling system in these cells.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Stella, N (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.			Walter, Lisa/0000-0003-3421-2362	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD000836] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD000836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014486] Funding Source: NIH RePORTER; NICHD NIH HHS [HD000836] Funding Source: Medline; NIDA NIH HHS [DA14486] Funding Source: Medline; NIGMS NIH HHS [GM07270] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTEL J, 1997, CLIN NEUROIMMUNOLOGY; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Berdyshev EV, 2000, BIOCHEM J, V346, P369, DOI 10.1042/0264-6021:3460369; Blazquez C, 1999, J NEUROCHEM, V72, P1759, DOI 10.1046/j.1471-4159.1999.721759.x; BOUABOULA M, 1995, J BIOL CHEM, V270, P13973, DOI 10.1074/jbc.270.23.13973; Cadas H, 1997, J NEUROSCI, V17, P1226; Calignano A, 2000, NATURE, V408, P96, DOI 10.1038/35040576; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Costa B, 2000, EUR J PHARMACOL, V395, P1, DOI 10.1016/S0014-2999(00)00170-9; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; Desagher S, 1997, J NEUROCHEM, V68, P78; Deutsch DG, 2001, J BIOL CHEM, V276, P6967, DOI 10.1074/jbc.M003161200; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; DiMarzo V, 1996, BIOCHEM BIOPH RES CO, V227, P281, DOI 10.1006/bbrc.1996.1501; DiTomaso E, 1997, ADV EXP MED BIOL, V407, P335; Fedoroff Sergey, 1997, P131; Felder CC, 1996, FEBS LETT, V393, P231, DOI 10.1016/0014-5793(96)00891-5; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P7656, DOI 10.1073/pnas.90.16.7656; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; GEBICKEHAERTER PJ, 1989, J NEUROSCI, V9, P183; Gerhards P., 1999, GC MS CLIN CHEM; Giuffrida A, 1998, FEBS LETT, V422, P373, DOI 10.1016/S0014-5793(98)00046-5; Giuffrida A, 1999, NAT NEUROSCI, V2, P358, DOI 10.1038/7268; GIUFFRIDA A, 1999, LIPID 2 MESSENGERS; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Griffin G, 2000, J PHARMACOL EXP THER, V292, P886; HANUS L, 1993, J MED CHEM, V36, P3032, DOI 10.1021/jm00072a026; Magistretti PJ, 2000, BRAIN RES, V886, P108, DOI 10.1016/S0006-8993(00)02945-0; PERTWEE R, 1994, EUR J PHARMACOL, V259, P115, DOI 10.1016/0014-2999(94)90499-5; Piomelli D, 1999, P NATL ACAD SCI USA, V96, P5802, DOI 10.1073/pnas.96.10.5802; Piomelli D, 1998, NEUROBIOL DIS, V5, P462, DOI 10.1006/nbdi.1998.0221; Rezaie P, 1999, MICROSC RES TECHNIQ, V45, P359, DOI 10.1002/(SICI)1097-0029(19990615)45:6<359::AID-JEMT4>3.3.CO;2-4; Rodriguez JJ, 2001, J NEUROSCI, V21, P823, DOI 10.1523/JNEUROSCI.21-03-00823.2001; Sagan S, 1999, EUR J NEUROSCI, V11, P691, DOI 10.1046/j.1460-9568.1999.00480.x; Sanchez C, 1998, FEBS LETT, V436, P6, DOI 10.1016/S0014-5793(98)01085-0; Sanchez C, 1998, MOL PHARMACOL, V54, P834, DOI 10.1124/mol.54.5.834; SATOH JI, 1995, J NEUROSCI RES, V41, P805, DOI 10.1002/jnr.490410611; Schmid HHO, 2000, CHEM PHYS LIPIDS, V108, P71, DOI 10.1016/S0009-3084(00)00188-2; Schmid PC, 1997, P NATL ACAD SCI USA, V94, P4188, DOI 10.1073/pnas.94.8.4188; Schmid PC, 1997, CHEM PHYS LIPIDS, V87, P103, DOI 10.1016/S0009-3084(97)00032-7; Spinedi A, 1999, BIOCHEM BIOPH RES CO, V255, P456, DOI 10.1006/bbrc.1999.0230; Stella N, 2001, EUR J PHARMACOL, V425, P189, DOI 10.1016/S0014-2999(01)01182-7; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; VENANCE L, 1995, NATURE, V376, P590, DOI 10.1038/376590a0; VOGEL Z, 1993, J NEUROCHEM, V61, P352, DOI 10.1111/j.1471-4159.1993.tb03576.x; Walker JM, 1999, P NATL ACAD SCI USA, V96, P12198, DOI 10.1073/pnas.96.21.12198; Wilson RI, 2001, NATURE, V410, P588, DOI 10.1038/35069076	49	147	149	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20869	20876		10.1074/jbc.M110813200	http://dx.doi.org/10.1074/jbc.M110813200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11916961	hybrid			2022-12-25	WOS:000176204500099
J	Plohl, M; Prats, E; Martinez-Lage, A; Gonzalez-Tizon, A; Mendez, J; Cornudella, L				Plohl, M; Prats, E; Martinez-Lage, A; Gonzalez-Tizon, A; Mendez, J; Cornudella, L			Telomeric localization of the vertebrate-type hexamer repeat, (TTAGGG)(n), in the wedgeshell clam Donax trunculus and other marine invertebrate genomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-SITU HYBRIDIZATION; CHROMOSOMAL LOCATION; SATELLITE DNA; SEQUENCE; MOLLUSCA; INSECTS; NUMBER; FAMILY; GENES; ENDS	The hexamer repeat sequence (TTAGGG)(n), found at the ends of all vertebrate chromosomes, was previously identified as the main building element of one member of a HindIII satellite DNA family characterized in the genome of the bivalve mollusc Donax trunculus. It was also found in 22 perfect tandem repeats in a cloned junction region juxtaposed to the proper satellite sequence, from which the DNA tract encompassing the clustered tandem copies was excised and subeloned. Here, the chromosomal distribution of (TTAGGG)(n) sequences in the Donax was studied by the sensitivity to Bal31 exonuclease digestion, fluorescence in situ hybridization (FISH) on metaphase chromosomes and rotating-field gel electrophoresis. To verify the occurrence of the hexamer repeat in the genomes of taxonomically related molluscs and other marine invertebrates, genomic DNA from the mussel Mytilus galloprovincialis and the echinoderm. Holothuria tubulosa was also analyzed. The kinetics of Bal31 hydrolysis of high molecular mass DNA from the three marine invertebrates revealed a marked decrease over time of the hybridization with the cloned (TTAGGG)(22) sequence, concomitantly with a progressive shortening of the positively reacting DNA fragments. This revealed a marked susceptibility to exonuclease consistent with terminal positioning on the respective chromosomal DNAs. In full agreement, FISH results with the (TTAGGG)(22) probe showed that the repeat appears located in telomeric regions in all chromosomes of both bivalve molluscs. The presence of (TTAGGG)(n) repeat tracts in marine invertebrate telomeres points to its wider distribution among eukaryotic organisms and suggests an ancestry older than originally presumed from its vertebrate distinctiveness.	CSIC, Dept Mol & Cell Biol, Inst Biol Mol Barcelona, E-08034 Barcelona, Spain; Univ A Coruna, Dept Mol & Cellular Biol, E-15071 La Coruna, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Universidade da Coruna	Cornudella, L (corresponding author), CSIC, Dept Mol & Cell Biol, Inst Biol Mol Barcelona, Jordi Girona 18-26, E-08034 Barcelona, Spain.	lcmbmc@cid.csic.es	González-Tizón, Ana M./A-4409-2015; Plohl, Miroslav/AAQ-6428-2021; Prats, Eva/K-6434-2014; Martinez-Lage, Andres/A-4356-2015; Mendez, Josefina/H-7318-2016	Prats, Eva/0000-0001-7838-2027; Martinez-Lage, Andres/0000-0002-8218-7002; Mendez, Josefina/0000-0002-7567-980X				Biessmann H, 2000, CHROMOSOMA, V109, P372, DOI 10.1007/s004120000094; BIESSMANN H, 1994, CHROMOSOMA, V103, P154, DOI 10.1007/BF00368007; BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Chiurillo MA, 1999, MOL BIOCHEM PARASIT, V100, P173, DOI 10.1016/S0166-6851(99)00047-X; Collins K, 2000, CURR OPIN CELL BIOL, V12, P378, DOI 10.1016/S0955-0674(00)00103-4; CORNET M, 1990, GENETICA, V82, P93, DOI 10.1007/BF00124637; Drabent B, 1995, DNA SEQUENCE, V6, P41, DOI 10.3109/10425179509074698; Drabent B, 1999, J MOL EVOL, V49, P645, DOI 10.1007/PL00006585; Estabrooks SL, 1999, J SHELLFISH RES, V18, P401; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Garrido-Ramos MA, 1998, CYTOGENET CELL GENET, V83, P3, DOI 10.1159/000015151; GONZALEZTIZON A, 2000, GENOME, V43, P1; Guo XM, 1997, J SHELLFISH RES, V16, P87; HINEGARDNER R, 1974, COMP BIOCHEM PHYSIOL, V47, P447, DOI 10.1016/0300-9629(74)90008-5; JHA AN, 1995, CHROMOSOME RES, V3, P507, DOI 10.1007/BF00713966; Joffe BI, 1998, CHROMOSOMA, V107, P173, DOI 10.1007/s004120050294; Kazazian HH, 2000, SCIENCE, V289, P1152, DOI 10.1126/science.289.5482.1152; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; LEJNINE S, 1995, P NATL ACAD SCI USA, V92, P2393, DOI 10.1073/pnas.92.6.2393; Malik HS, 1999, MOL BIOL EVOL, V16, P793, DOI 10.1093/oxfordjournals.molbev.a026164; Martens UM, 2000, BIOCHEM SOC T, V28, P245, DOI 10.1042/bst0280245; MEYNE J, 1989, P NATL ACAD SCI USA, V86, P7049, DOI 10.1073/pnas.86.18.7049; MEYNE J, 1990, CHROMOSOMA, V99, P3, DOI 10.1007/BF01737283; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; MULLER F, 1991, CELL, V67, P815, DOI 10.1016/0092-8674(91)90076-B; Nomoto Y, 2001, ZOOL SCI, V18, P417, DOI 10.2108/zsj.18.417; OKAZAKI S, 1993, MOL CELL BIOL, V13, P1424, DOI 10.1128/MCB.13.3.1424; Plohl M, 1997, J MOL EVOL, V44, P189, DOI 10.1007/PL00006135; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; Sahara K, 1999, CHROMOSOME RES, V7, P449, DOI 10.1023/A:1009297729547; SAIGA H, 1985, EMBO J, V4, P799, DOI 10.1002/j.1460-2075.1985.tb03700.x; SAINZ J, 1990, NUCLEIC ACIDS RES, V18, P885, DOI 10.1093/nar/18.4.885; TESCHKE C, 1991, NUCLEIC ACIDS RES, V19, P2677, DOI 10.1093/nar/19.10.2677; Vermeesch JR, 1996, CYTOGENET CELL GENET, V72, P310, DOI 10.1159/000134211; Vitturi R, 2000, GENETICA, V108, P253, DOI 10.1023/A:1004151513129; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; ZHANG YJ, 1994, MOL CELL BIOL, V14, P8028, DOI 10.1128/MCB.14.12.8028; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	39	44	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19839	19846		10.1074/jbc.M201032200	http://dx.doi.org/10.1074/jbc.M201032200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11907038	hybrid, Green Accepted			2022-12-25	WOS:000175894800079
J	Tkachenko, E; Simons, M				Tkachenko, E; Simons, M			Clustering induces redistribution of syndecan-4 core protein into raft membrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; KINASE; PHOSPHORYLATION; PATHWAY	Syndecan-4 is a heparan sulfate-carrying core protein that has been directly implicated in fibroblast growth factor 2 (FGF2) signaling. Recent studies have suggested that many signaling proteins localize to the raft compartment of the plasma cell membrane. To establish whether syndecan-4 is present in the raft compartment, we have studied the distribution of the core protein and an Fc receptor (FcR)-syndecan-4 chimera prior to and following clustering with FGF2 or antibodies. Whereas unclustered syndecan-4 was present predominantly in the non-raft membrane compartment, clustering induced extensive syndecan-4 redistribution to the rafts as demonstrated by the sucrose gradient centrifugation and life confocal microscopy. Although syndecan-4 and caveolin-1 moved in tandem, syndecan-4 was not present in caveolae, a major subset of raft compartments. We conclude that syndecan-4 clustering induces its redistribution to the non-caveolae raft compartment. This process may play an important role in syndecan-4-mediation of FGF2 signaling.	Dartmouth Coll Sch Med, Dartmouth Hitchcock Med Ctr, Cardiol Sect, Dept Med, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Angiogenesis Res Ctr, Lebanon, NH 03756 USA	Dartmouth College; Dartmouth College	Simons, M (corresponding author), Dartmouth Coll Sch Med, Dartmouth Hitchcock Med Ctr, Cardiol Sect, Dept Med, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	michael.simons@dartmouth.edu	Tkachenko, Eugene/A-9779-2012; Simons, Michael/G-8553-2014	Simons, Michael/0000-0003-0348-7734; Tkachenko, Eugene/0000-0002-7964-484X				Brodsky RA, 2000, AM J CLIN PATHOL, V114, P459, DOI 10.1093/ajcp/114.3.459; Carey DJ, 1996, J BIOL CHEM, V271, P15253, DOI 10.1074/jbc.271.25.15253; Couchman JR, 2001, INT REV CYTOL, V207, P113; Fuki IV, 2000, BIOCHEM J, V351, P607, DOI 10.1042/0264-6021:3510607; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Horowitz A, 1998, J BIOL CHEM, V273, P25548, DOI 10.1074/jbc.273.40.25548; Horowitz A, 1998, J BIOL CHEM, V273, P10914, DOI 10.1074/jbc.273.18.10914; *J WIL SONS INC, 2001, CURR PROT IMM ONL; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; Rodrigueza WV, 1997, ARTERIOSCL THROM VAS, V17, P383, DOI 10.1161/01.ATV.17.2.383; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; Simons M, 2001, CELL SIGNAL, V13, P855, DOI 10.1016/S0898-6568(01)00190-5; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Volk R, 1999, J BIOL CHEM, V274, P24417, DOI 10.1074/jbc.274.34.24417; Waugh MG, 2001, BIOCHEM SOC T, V29, P509, DOI 10.1042/BST0290509; Williams K J, 2001, Methods Mol Biol, V171, P457; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4; Zimmermann P, 1999, FASEB J, V13, pS91	24	94	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19946	19951		10.1074/jbc.M200841200	http://dx.doi.org/10.1074/jbc.M200841200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11889131	hybrid			2022-12-25	WOS:000175894800093
J	Wu, JF; Li, JF; Huang, KP; Huang, FL				Wu, JF; Li, JF; Huang, KP; Huang, FL			Attenuation of protein kinase C and cAMP-dependent protein kinase signal transduction in the neurogranin knockout mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE MODIFICATION; RAT-BRAIN NEUROGRANIN; MAP KINASE; SYNAPTIC PLASTICITY; SUBSTRATE RC3; LATE-PHASE; AREA CA1; PHOSPHORYLATION; ACTIVATION; CASCADE	Neurogranin (Ng) is a brain-specific, postsynaptically located protein kinase C (PKC) substrate, highly expressed in the cortex, hippocampus, striatum, and amygdala. This protein is a Ca2+-sensitive calmodulin (CaM)-binding protein whose CaM-binding affinity is modulated by phosphorylation and oxidation. To investigate the role of Ng in neural function, a strain of Ng knockout mouse (KO) was generated. Previously we reported (Pak, J. H., Huang, F. L., Li, J., Balschun, D., Reymann, K. G., Chiang, C., Westphal, H., and Huang, K.-P. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 1123211237) that these KO mice displayed no obvious neuro-anatomical abnormality, but exhibited deficits in learning and memory and activation of Ca2+/CaM-dependent protein kinase II. In this report, we analyzed several downstream phosphorylation targets in phorbol 12-myristate 13-acetate- and forskolin-treated hippocampal slices from wild type (WT) and KO mice. Phorbol 12-myristate 13-acetate caused phosphorylation of Ng in WT mice and promoted the translocation of PKC from the cytosolic to the particulate fractions of both the WT and KO mice, albeit to a lesser extent in the latter. Phosphorylation of downstream targets, including mitogen-activated protein kinases, 90-kDa ribosomal S6 kinase, and the cAMP response element binding protein (CREB) was significantly attenuated in KO mice. Stimulation of hippocampal slices with forskolin also caused greater stimulation of protein kinase A (PKA) in the WT as compared with those of the KO mice. Again, phosphorylation of the downstream targets of PKA was attenuated in the KO mice. These results suggest that Ng plays a pivotal role in regulating both PKC- and PKA-mediated signaling pathways, and that the deficits in learning and memory of spatial tasks detected in the KO mice may be the result of defects in the signaling pathways leading to the phosphorylation of CREB.	NICHHD, Metab Regulat Sect, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Huang, FL (corresponding author), NICHHD, Metab Regulat Sect, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA.	fhuang@helix.nih.gov	Li, Junfa/H-8707-2013	Li, Junfa/0000-0002-1930-9724	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000187] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000187] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Bapat S, 2001, FEBS LETT, V499, P21, DOI 10.1016/S0014-5793(01)02511-X; Blum S, 1999, J NEUROSCI, V19, P3535; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; Crow T, 2001, J NEUROCHEM, V78, P358, DOI 10.1046/j.1471-4159.2001.00404.x; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; FEDOROV NB, 1995, EUR J NEUROSCI, V7, P819, DOI 10.1111/j.1460-9568.1995.tb00685.x; FIORE RS, 1993, J NEUROCHEM, V61, P1626, DOI 10.1111/j.1471-4159.1993.tb09796.x; Gerendasy DD, 1997, MOL NEUROBIOL, V15, P131, DOI 10.1007/BF02740632; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Giovannini MG, 2001, J NEUROSCI, V21, P7053, DOI 10.1523/JNEUROSCI.21-18-07053.2001; HUANG KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P570, DOI 10.1006/abbi.1993.1463; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; HUANG KP, 1988, J BIOL CHEM, V263, P14839; Huang YY, 2000, J NEUROSCI, V20, P6317, DOI 10.1523/JNEUROSCI.20-17-06317.2000; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KLANN E, 1992, J NEUROCHEM, V58, P1576, DOI 10.1111/j.1471-4159.1992.tb11382.x; Li JF, 1999, J BIOL CHEM, V274, P1294, DOI 10.1074/jbc.274.3.1294; Lo LW, 2001, J CELL PHYSIOL, V188, P304, DOI 10.1002/jcp.1124; Mahoney CW, 1996, J BIOL CHEM, V271, P28798, DOI 10.1074/jbc.271.46.28798; MARTZEN MR, 1995, J NEUROCHEM, V64, P92; Miao HH, 2000, BIOELECTROCHEMISTRY, V51, P163, DOI 10.1016/S0302-4598(00)00062-3; MIYASAKA T, 1990, BIOCHEM BIOPH RES CO, V168, P1237, DOI 10.1016/0006-291X(90)91161-K; NeunerJehle M, 1996, BRAIN RES, V733, P149, DOI 10.1016/0006-8993(96)00786-X; Pak JH, 2000, P NATL ACAD SCI USA, V97, P11232, DOI 10.1073/pnas.210184697; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; Prichard L, 1999, J BIOL CHEM, V274, P7689, DOI 10.1074/jbc.274.12.7689; RAMAKERS GMJ, 1995, J BIOL CHEM, V270, P13892, DOI 10.1074/jbc.270.23.13892; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; Roberson ED, 1999, J NEUROSCI, V19, P4337; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sheu FS, 1996, J BIOL CHEM, V271, P22407, DOI 10.1074/jbc.271.37.22407; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; Villacres EC, 1998, J NEUROSCI, V18, P3186; Viola HE, 2000, J NEUROSCI, V20; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; WATSON JB, 1994, MOL BRAIN RES, V27, P323, DOI 10.1016/0169-328X(94)90017-5; Wong ST, 1999, NEURON, V23, P787, DOI 10.1016/S0896-6273(01)80036-2; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zanassi P, 2001, J BIOL CHEM, V276, P11487, DOI 10.1074/jbc.M007631200; Zhang YG, 2001, J BIOL CHEM, V276, P14572, DOI 10.1074/jbc.M004615200	48	51	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19498	19505		10.1074/jbc.M109082200	http://dx.doi.org/10.1074/jbc.M109082200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11912190	hybrid			2022-12-25	WOS:000175894800036
J	Domkin, V; Thelander, L; Chabes, A				Domkin, V; Thelander, L; Chabes, A			Yeast DNA damage-inducible Rnr3 has a very low catalytic activity strongly stimulated after the formation of a cross-talking Rnr1/Rnr3 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE RIBONUCLEOTIDE REDUCTASE; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; CHECKPOINT PATHWAYS; SUBUNIT INTERACTION; ESCHERICHIA-COLI; PROTEIN; TRANSCRIPTION; KINASE; REPLICATION	The ribonucleotide reductase system in Saccharomyces cerevisiae includes four genes (RNR1 and RNR3 encoding the large subunit and RNR2 and RNR4 encoding the small subunit). RNR3 expression, nearly undetectable during normal growth, is strongly induced by DNA damage. Yet an rnr3 null mutant has no obvious phenotype even under DNA damaging conditions, and the contribution of RNR3 to ribonucleotide reduction is not clear. To investigate the role of RNR3 we expressed and characterized the Rnr3 protein. The in vitro activity of Rnr3 was less than 1% of the Rnr1 activity. However, a strong synergism between Rnr3 and Rnr1 was observed, most clearly demonstrated in experiments with the catalytically inactive Rnr1-C428A mutant, which increased the endogenous activity of Rnr3 by at least 10-fold. In vivo, the levels of Rnr3 after DNA damage never reached more than one-tenth of the Rnr1 levels. We propose that heterodimerization of Rnr3 with Rnr1 facilitates the recruitment of Rnr3 to the ribonucleotide reductase holoenzyme, which may be important when Rnr1 is limiting for dNTP production. In complex with inactive Rnr1-C428A, the activity of Rnr3 is controlled by effector binding to Rnr1-C428A. This result indicates cross-talk between the Rnr1 and Rnr3 polypeptides of the large subunit.	Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	Umea University	Chabes, A (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd,POB 100, Cold Spring Harbor, NY 11724 USA.	chabes@cshl.org		Chabes, Andrei/0000-0003-1708-8259				ABERG A, 1989, J BIOL CHEM, V264, P12249; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chabes A, 2000, P NATL ACAD SCI USA, V97, P2474, DOI 10.1073/pnas.97.6.2474; Chabes A, 1999, J BIOL CHEM, V274, P36679, DOI 10.1074/jbc.274.51.36679; DAVIS R, 1994, J BIOL CHEM, V269, P23171; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; Ho Y, 1997, P NATL ACAD SCI USA, V94, P581, DOI 10.1073/pnas.94.2.581; Huang MX, 1997, MOL CELL BIOL, V17, P6105, DOI 10.1128/MCB.17.10.6105; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Li B, 2001, J BIOL CHEM, V276, P33788, DOI 10.1074/jbc.M104220200; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9752, DOI 10.1021/bi00155a031; Paesi-Toresan SO, 1998, CURR GENET, V34, P124, DOI 10.1007/s002940050376; Reichard P, 2000, J BIOL CHEM, V275, P33021, DOI 10.1074/jbc.M005337200; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Ruiz MAD, 2000, FEBS LETT, V485, P205, DOI 10.1016/S0014-5793(00)02198-0; Wang PJ, 1997, MOL CELL BIOL, V17, P6114, DOI 10.1128/MCB.17.10.6114; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zhao XL, 2000, MOL CELL BIOL, V20, P9076, DOI 10.1128/MCB.20.23.9076-9083.2000; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; ZHOU Z, 1992, GENETICS, V131, P851; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	29	44	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18574	18578		10.1074/jbc.M201553200	http://dx.doi.org/10.1074/jbc.M201553200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893751	hybrid			2022-12-25	WOS:000175975800044
J	Gonzalez, MM; Carlberg, C				Gonzalez, MM; Carlberg, C			Cross-repression, a functional consequence of the physical interaction of non-liganded nuclear receptors and POU domain transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; THYROID-HORMONE RECEPTOR; VITAMIN-D-RECEPTOR; RESPONSE ELEMENTS; SYNERGISTIC ACTIVATION; BINDING PROTEIN; COACTIVATOR; GENE; PROMOTER; PATHWAY	Nuclear receptors (NRs) and POU domain factors form two important transcription factor families for which several levels of functional interference have been described. In this study, the adopted orphan receptors constitutive androstane receptor (CAR) and pregnane X receptor (PXR) were found to perform direct protein-protein interactions with Pit-1, a representative POU domain factor. The ligand-dependent interaction profile of Pit-1 with CAR, PXR, and the vitamin D receptor in solution was shown to be that of a corepressor. In the absence of receptor agonist Pit-1 inhibited the complex formation of NRs with the retinoid X receptor on DNA. Also in living cells, Pit-1 and Oct-1, another POU domain factor, behaved like corepressors of NR signaling, and Pit-1-mediated repression was found to involve histone deacetylases. Conversely vitamin D receptor, CAR, and PXR were shown to act as repressors of Pit-1 signaling in different cell lines (MCF-7, HaCaT, and GH4C1). This repression was found to be independent of histone deacetylases and seems to be based on a competition of NRs with coactivator and corepressor proteins for overlaying interaction interfaces on the surface of Pit-1. Taken together this study suggests that cross-repression should occur in all tissues in which POU domain factors and non-liganded NRs meet each other.	Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland	Finland National Institute for Health & Welfare; University of Eastern Finland	Carlberg, C (corresponding author), Univ Kuopio, Dept Biochem, POB 1627, FIN-70211 Kuopio, Finland.		Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				Altucci L, 2001, TRENDS ENDOCRIN MET, V12, P460, DOI 10.1016/S1043-2760(01)00502-1; Auwerx J, 1999, CELL, V97, P161; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Bourguet W, 2000, TRENDS PHARMACOL SCI, V21, P381, DOI 10.1016/S0165-6147(00)01548-0; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; Castillo AI, 1999, MOL ENDOCRINOL, V13, P1141, DOI 10.1210/me.13.7.1141; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Herdick M, 2000, MOL PHARMACOL, V57, P1206; Honkakoski P, 1996, J BIOL CHEM, V271, P9746, DOI 10.1074/jbc.271.16.9746; Honkakoski P, 2000, BIOCHEM J, V347, P321, DOI 10.1042/0264-6021:3470321; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; ONATE SA, 1995, SCIENCE, V270, P1354; Palomino T, 1998, FASEB J, V12, P1201, DOI 10.1096/fasebj.12.12.1201; Quack M, 2000, J MOL BIOL, V296, P743, DOI 10.1006/jmbi.2000.3499; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; SANCHEZPACHECO A, 1995, MOL CELL BIOL, V15, P6322; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Schaufele F, 2000, MOL ENDOCRINOL, V14, P2024, DOI 10.1210/me.14.12.2024; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; Scully KM, 2000, SCIENCE, V290, P1127, DOI 10.1126/science.290.5494.1127; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Toell A, 2002, J CELL BIOCHEM, V85, P72, DOI 10.1002/jcb.10104; Toell A, 2000, BIOCHEM J, V352, P301, DOI 10.1042/0264-6021:3520301; Tolon RM, 1998, J BIOL CHEM, V273, P26652, DOI 10.1074/jbc.273.41.26652; Tzameli I, 2001, TRENDS ENDOCRIN MET, V12, P7, DOI 10.1016/S1043-2760(00)00332-5; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719	42	28	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18501	18509		10.1074/jbc.M200205200	http://dx.doi.org/10.1074/jbc.M200205200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11891224	hybrid			2022-12-25	WOS:000175975800034
J	Haas, A; Wang, HJ; Tian, J; Xie, ZJ				Haas, A; Wang, HJ; Tian, J; Xie, ZJ			Src-mediated inter-receptor cross-talk between the Na+/K+-ATPase and the epidermal growth factor receptor relays the signal from ouabain to mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC MYOCYTES; TYROSINE KINASE; TRANSDUCING FUNCTION; RESPONSE GENES; TRANSACTIVATION; FAMILY; CELLS; NA+,K+-ATPASE; HYPERTROPHY; CASCADES	Binding of ouabain to Na+/K+-ATPase activates tyrosine phosphorylation of the epidermal growth factor receptor (EGFR), Src, and p42/44 mitogen-activated protein kinases (MAPKs) in both cardiac myocytes and A7r5 cells. Here, we explored the roles of Src and the EGFR in the ouabain-invoked pathways that lead to the activation of MAPKs. Exposure of A7r5 and LLC-PK1 cells to ouabain caused a dose-dependent inhibition of Na+/K+-ATPase activity, which correlated well with ouabain-induced activation of Src and MAPKs in these cells. Immunoprecipitation experiments showed that ouabain stimulated Src binding to Na+/K+-ATPase in a dose- and time-dependent manner and increased phosphorylation of Sre at Tyr(418) but had no effect on Tyr(529) phosphorylation. Ouabain failed to activate MAPKs in A7r5 cells that were pretreated with the Src inhibitor PP2 and in SYF cells in which Src family kinases are knocked out. Preincubation with AG1478, but not AG1295, also blocked the effects of ouabain on p42/44 MAPKs in A7r5 cells. Significantly, both herbimycin A and PP2 abrogated ouabain-induced but not epidermal growth factor-induced Sre binding to the EGFR and the subsequent EGFR tyrosine phosphorylation. Ouabain also failed to affect tyrosine phosphorylation of the EGFR in SYF cells. In addition, unlike epidermal growth factor, ouabain did not increase EGFR autophosphorylation at Tyr(1173). These findings clearly indicate that ouabain transactivates the EGFR by activation of Src and stimulation of Sre binding to the EGFR. Furthermore, we found that the transactivated EGFR was capable of recruiting and phosphorylating the adaptor protein She. This resulted in increased binding of another adaptor protein Grb2 to the Src-EGFR complex and the subsequent activation of Ras and MAPKs. Taken together, these new findings suggest that Sre mediates the inter-receptor cross-talk between Na+/K+-ATPase and the EGFR to transduce the signals from ouabain to the Ras/ MAPK cascade.	Med Coll Ohio, Dept Pharmacol, Toledo, OH 43614 USA; Med Coll Ohio, Dept Med, Toledo, OH 43614 USA		Xie, ZJ (corresponding author), Med Coll Ohio, Dept Pharmacol, 3035 Arlington Ave, Toledo, OH 43614 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573, R01HL063238] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-63238, HL-36573] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; Aydemir-Koksoy A, 2001, J BIOL CHEM, V276, P46605, DOI 10.1074/jbc.M106178200; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Haas M, 2000, J BIOL CHEM, V275, P27832; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Huang LY, 1997, J MOL CELL CARDIOL, V29, P429, DOI 10.1006/jmcc.1996.0320; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; KELLY RA, 1993, J AM COLL CARDIOL, V22, pA107, DOI 10.1016/0735-1097(93)90472-D; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu J, 2000, J BIOL CHEM, V275, P27838; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tian J, 2001, AM J PHYSIOL-HEART C, V281, pH1899, DOI 10.1152/ajpheart.2001.281.5.H1899; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Xie ZJ, 2001, CELL MOL BIOL, V47, P383; Xie ZJ, 1999, J BIOL CHEM, V274, P19323, DOI 10.1074/jbc.274.27.19323; XIE ZJ, 1989, ANAL BIOCHEM, V183, P215, DOI 10.1016/0003-2697(89)90470-3; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297	26	235	248	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18694	18702		10.1074/jbc.M111357200	http://dx.doi.org/10.1074/jbc.M111357200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11907028	hybrid			2022-12-25	WOS:000175975800061
J	Holden, JH; Czajkowski, C				Holden, JH; Czajkowski, C			Different residues in the GABA(A) receptor alpha(1)T60-alpha(1)K70 region mediate GABA and SR-95531 actions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC ACID(A) RECEPTOR; LIGAND-BINDING DOMAIN; BENZODIAZEPINE BINDING; ACETYLCHOLINE-RECEPTOR; NICOTINIC RECEPTORS; XENOPUS OOCYTES; DELTA-SUBUNIT; ALPHA-SUBUNIT; CHANNEL; SITE	Although gamma-aminobutyric acid type A receptor agonists and antagonists bind to a common site, they produce different conformational changes within the site because agonists cause channel opening and antagonists do not. We used the substituted cysteine accessibility method and two-electrode voltage clamping to identify residues within the binding pocket that are important for mediating these different actions. Each residue from alpha(1)T60 to alpha(1)K70 was mutated to cysteine and expressed with wild-type beta(2) subunits in Xenopus oocytes. Methanethiosulfonate reagents reacted with alpha(1)T60C, alpha(1)D62C, alpha(1)F64C, alpha(1)R66C, alpha(1)S6SC, and alpha(1)K70C. gamma-Aminobutyric acid (GABA) slowed methanethiosulfonate modification of alpha(1)F64C, alpha(1)R66C, and alpha(1)S68C, whereas SR-95531 slowed modification of alpha(1)D62C, alpha(1)F64C, and alpha(1)R66C, demonstrating that different residues are important for mediating GABA and SR-95531 actions. In addition, methanethiosulfonate reaction rates were fastest for alpha(1)F64C and alpha(1)R66C, indicating that these residues are located in an open, aqueous environment lining the core of the binding pocket. Positively charged methanethiosulfonate reagents derivatized alpha(1)F64C and alpha(1)R66C significantly faster than a negatively charged reagent, suggesting that a negative subsite important for interacting with the ammonium group of GABA exists within the binding pocket. Pentobarbital activation of the receptor increased the rate of methanethiosulfonate modification of alpha(1)D62C and alpha(1)S68C, demonstrating that parts of the binding site undergo structural rearrangements during channel gating.	Univ Wisconsin, MSC, Dept Physiol, Madison, WI 53706 USA; Univ Wisconsin, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Czajkowski, C (corresponding author), Univ Wisconsin, MSC, Dept Physiol, 1300 Univ Ave,Rm 197, Madison, WI 53706 USA.				NINDS NIH HHS [NS34727] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034727, R56NS034727] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; Barnard EA, 1998, PHARMACOL REV, V50, P291; Boileau AJ, 1999, J NEUROSCI, V19, P4847; Boileau AJ, 1998, MOL PHARMACOL, V53, P295, DOI 10.1124/mol.53.2.295; Boileau AJ, 2002, J BIOL CHEM, V277, P2931, DOI 10.1074/jbc.M109334200; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CAVALLA D, 1985, J NEUROCHEM, V44, P916, DOI 10.1111/j.1471-4159.1985.tb12904.x; Chang YC, 1996, J NEUROSCI, V16, P5415; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; CHOU TC, 1974, MOL PHARMACOL, V10, P235; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; Jones MV, 1998, J NEUROSCI, V18, P8590; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kucken AM, 2000, MOL PHARMACOL, V57, P932; LEVITAN ES, 1988, NEURON, V1, P773, DOI 10.1016/0896-6273(88)90125-0; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Martin M, 1996, J BIOL CHEM, V271, P13497, DOI 10.1074/jbc.271.23.13497; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; NICOLL RA, 1980, BRAIN RES, V191, P225, DOI 10.1016/0006-8993(80)90325-X; NICOLL RA, 1975, NATURE, V258, P625, DOI 10.1038/258625a0; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Robertson GA, 1996, NEUROPHARMACOLOGY, V35, P841, DOI 10.1016/0028-3908(96)00113-X; ROGNAN D, 1992, J MED CHEM, V35, P1969, DOI 10.1021/jm00089a005; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SMITH GB, 1994, J BIOL CHEM, V269, P20380; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; Wagner DA, 2001, J NEUROSCI, V21, P67, DOI 10.1523/JNEUROSCI.21-01-00067.2001; Westh-Hansen SE, 1999, NEUROREPORT, V10, P2417, DOI 10.1097/00001756-199908020-00036; WesthHansen SE, 1997, EUR J PHARMACOL, V329, P253, DOI 10.1016/S0014-2999(97)89186-8; Whiting PJ, 1999, ANN NY ACAD SCI, V868, P645, DOI 10.1111/j.1749-6632.1999.tb11341.x; Yan D, 1999, J BIOL CHEM, V274, P5537, DOI 10.1074/jbc.274.9.5537; Yang NB, 1997, BIOPHYS J, V73, P2260, DOI 10.1016/S0006-3495(97)78258-4	41	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18785	18792		10.1074/jbc.M111778200	http://dx.doi.org/10.1074/jbc.M111778200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11896052	hybrid			2022-12-25	WOS:000175975800072
J	Miyoshi, K; Tsujii, R; Yoshida, H; Maki, Y; Wada, A; Matsui, Y; Toh-e, A; Mizuta, K				Miyoshi, K; Tsujii, R; Yoshida, H; Maki, Y; Wada, A; Matsui, Y; Toh-e, A; Mizuta, K			Normal assembly of 60 S ribosomal subunits is required for the signaling in response to a secretory defect in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; TERMINAL SILENCING DOMAIN; RNA SYNTHESIS; PROTEINS L5; 5S RNA; YEAST; REPRESSION; PATHWAY; GENE; L16	A secretory defect leads to transcriptional repression of both ribosomal protein and rRNA genes in yeast. To elucidate the mechanism of the signaling, we previously isolated rrs mutants that were unable to respond to a secretory defect, and we cloned RRS1 encoding a nuclear protein that was required for ribosome biogenesis (Tsuno, A., Miyoshi, K., Tsujii, R., Miyakawa, T., and Mizuta, K (2000) Mol Cell Biol. 20, 2066-2074). We identified duplicated genes encoding ribosomal protein L11, RPL11B as a wild-type allele complementing the rrs2 mutation, and RPL11A in two-hybrid screening using RRS1 as bait. Rpl11p was copurified with Rrs1p in immunoprecipitation analysis. Ultracentrifugation analysis revealed that Rrs1p associated fairly tightly with 60 S preribosomal subunits. These results suggest that signaling in response to a secretory defect requires the normal assembly of 60 S ribosomal subunits including Rrs1p and Rpl11p.	Hiroshima Univ, Grad Sch Biosphere Sci, Dept Biol Sci, Higashihiroshima 7398528, Japan; Hiroshima Univ, Grad Sch Adv Sci Matter, Dept Mol Biotechnol, Higashihiroshima 7398528, Japan; Osaka Med Coll, Dept Phys, Osaka 5690084, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	Hiroshima University; Hiroshima University; Osaka Medical College; University of Tokyo	Mizuta, K (corresponding author), Hiroshima Univ, Grad Sch Biosphere Sci, Dept Biol Sci, Kagamiyama 1-4-4, Higashihiroshima 7398528, Japan.			Yoshida, Hideji/0000-0001-7213-4735				CHENSCHMEISSER U, 1977, FEBS LETT, V74, P287, DOI 10.1016/0014-5793(77)80866-1; Eisinger DP, 1997, MOL CELL BIOL, V17, P5136, DOI 10.1128/MCB.17.9.5136; Fath S, 2000, J CELL BIOL, V149, P575, DOI 10.1083/jcb.149.3.575; Gadal O, 2001, MOL CELL BIOL, V21, P3405, DOI 10.1128/MCB.21.10.3405-3415.2001; HORNE JR, 1972, MOL GEN GENET, V119, P337, DOI 10.1007/BF00272091; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kaiser C., 1994, METHODS YEAST GENETI; Kressler D, 1999, MOL CELL BIOL, V19, P7897; LEER RJ, 1984, FEBS LETT, V175, P371, DOI 10.1016/0014-5793(84)80771-1; Li BJ, 1996, J BIOL CHEM, V271, P16813, DOI 10.1074/jbc.271.28.16813; Li Y, 2000, MOL CELL BIOL, V20, P3843, DOI 10.1128/MCB.20.11.3843-3851.2000; Mager WH, 1997, NUCLEIC ACIDS RES, V25, P4872, DOI 10.1093/nar/25.24.4872; Milkereit P, 2001, CELL, V105, P499, DOI 10.1016/S0092-8674(01)00358-0; Miyoshi K, 2001, NUCLEIC ACIDS RES, V29, P3297, DOI 10.1093/nar/29.16.3297; Mizuta K, 1998, NUCLEIC ACIDS RES, V26, P1063, DOI 10.1093/nar/26.4.1063; MIZUTA K, 1994, MOL CELL BIOL, V14, P2493, DOI 10.1128/MCB.14.4.2493; MORITZ M, 1991, MOL CELL BIOL, V11, P5681, DOI 10.1128/MCB.11.11.5681; MORITZ M, 1990, J CELL BIOL, V111, P2261, DOI 10.1083/jcb.111.6.2261; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; Nierras CR, 1999, J BIOL CHEM, V274, P13235, DOI 10.1074/jbc.274.19.13235; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTENBERG MO, 1988, GENE DEV, V2, P160, DOI 10.1101/gad.2.2.160; SMITH N, 1978, EUR J BIOCHEM, V89, P501, DOI 10.1111/j.1432-1033.1978.tb12554.x; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; SPIERER P, 1978, BIOCHEMISTRY-US, V17, P2474, DOI 10.1021/bi00606a002; SYNETOS D, 1992, J BIOL CHEM, V267, P3008; TEEM JL, 1984, NUCLEIC ACIDS RES, V12, P8295, DOI 10.1093/nar/12.22.8295; THIERRY T, 1995, J BIOL CHEM, V270, P9961; TSAY YF, 1994, J BIOL CHEM, V269, P7579; Tsujii R, 2000, GENES CELLS, V5, P543, DOI 10.1046/j.1365-2443.2000.00346.x; Tsuno A, 2000, MOL CELL BIOL, V20, P2066, DOI 10.1128/MCB.20.6.2066-2074.2000; UDEM SA, 1972, J MOL BIOL, V65, P227, DOI 10.1016/0022-2836(72)90279-3; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Woolford Jr JL, 1991, MOL CELLULAR BIOL YE, P587	35	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18334	18339		10.1074/jbc.M201667200	http://dx.doi.org/10.1074/jbc.M201667200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893754	hybrid			2022-12-25	WOS:000175975800012
J	Tang, T; Arbiser, JL; Brandt, SJ				Tang, T; Arbiser, JL; Brandt, SJ			Phosphorylation by mitogen-activated protein kinase mediates the hypoxia-induced turnover of the TAL1/SCL transcription factor in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING MOTIF; SCL GENE-PRODUCT; IN-VIVO; CHROMOSOMAL TRANSLOCATION; HEMATOPOIETIC LINEAGES; BLOOD-VESSELS; GROWTH-FACTOR; MAP KINASES	The basic helix-loop-helix transcription factor TAL1 (or SCL), originally identified from its involvement by a chromosomal rearrangement in T-cell acute lymphoblastic leukemia, is required for hematopoietic development. TAL1 also has a critical role in embryonic vascular remodeling and is expressed in endothelial cells postnatally, although little is known about its function or regulation in this cell type. We report here that the important proangiogenic stimulus hypoxia stimulates phosphorylation, ubiquitination, and proteasomal breakdown of TAL1 in endothelial cells. Tryptic phosphopeptide mapping and chemical inhibitor studies showed that hypoxia induced the mitogen-activated protein kinase-mediated phosphorylation of a single serine residue, Ser(122), in the protein, and site-directed mutagenesis demonstrated that Ser(122) phosphorylation was necessary for hypoxic acceleration of TAL1 turnover in an immortalized murine endothelial cell line. Finally, whereas TAL1 expression was detected in endothelial cells from both large and small vessels, hypoxia-induced TAL1 turnover was observed only in microvascular endothelial cells. Besides their implications for TAL1 function in angiogenic processes, these results demonstrate that a protein kinase(s) important for mitogenic signaling is also utilized in hypoxic endothelial cells to target a transcription factor for destruction.	Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vet Affairs Tennessee Valley Hlth Care Syst, Nashville, TN 37232 USA; Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Emory University	Brandt, SJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Rm 777,Preston Res Bldg, Nashville, TN 37232 USA.	stephen.brandt@mcmail.vanderbilt.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049118] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL49118] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1991, ONCOGENE, V6, P1477; Bies J, 2000, ONCOGENE, V19, P2846, DOI 10.1038/sj.onc.1203613; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRANDT SJ, 2000, TRANSCRIPTION FACTOR, P51; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; Candal FJ, 1996, MICROVASC RES, V52, P221, DOI 10.1006/mvre.1996.0060; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CHENG JT, 1993, ONCOGENE, V8, P677; Cohen-Kaminsky S, 1998, EMBO J, V17, P5151, DOI 10.1093/emboj/17.17.5151; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; DAMORE PA, 1993, GROWTH FACTORS, V8, P61, DOI 10.3109/08977199309029135; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOYLE K, 1994, J BIOL CHEM, V269, P12099; Drake CJ, 1997, DEV BIOL, V192, P17, DOI 10.1006/dbio.1997.8751; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELLEDGE SJ, 1998, BIOCHIM BIOPHYS ACTA, V1377, P61; Elwood NJ, 1998, BLOOD, V91, P3756; Gavine PR, 1999, ONCOGENE, V18, P7552, DOI 10.1038/sj.onc.1203102; Gering M, 1998, EMBO J, V17, P4029, DOI 10.1093/emboj/17.14.4029; GOLDFARB AN, 1992, BLOOD, V80, P2858; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hofmann TJ, 1996, ONCOGENE, V13, P617; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; Huang SM, 1999, ONCOGENE, V18, P4958, DOI 10.1038/sj.onc.1202889; HWANG LY, 1993, ONCOGENE, V8, P3043; KALLIANPUR AR, 1994, BLOOD, V83, P1200; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kroon ME, 2001, J CELL SCI, V114, P825; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Matsuda N, 1998, BIOCHEM BIOPH RES CO, V249, P350, DOI 10.1006/bbrc.1998.9151; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PRASAD KSS, 1995, J BIOL CHEM, V270, P11603, DOI 10.1074/jbc.270.19.11603; Ray-Gallet D, 1999, FEBS LETT, V464, P164, DOI 10.1016/S0014-5793(99)01687-7; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; Roland I, 2000, EUR J BIOCHEM, V267, P3567, DOI 10.1046/j.1432-1327.2000.01385.x; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Seimiya H, 1999, BIOCHEM BIOPH RES CO, V260, P365, DOI 10.1006/bbrc.1999.0910; Seko Y, 1996, CIRC RES, V78, P82, DOI 10.1161/01.RES.78.1.82; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Song XD, 1999, J BIOL CHEM, V274, P1677, DOI 10.1074/jbc.274.3.1677; Tang T, 1999, BIOCHEM J, V343, P615, DOI 10.1042/0264-6021:3430615; Taylor CT, 2000, P NATL ACAD SCI USA, V97, P12091, DOI 10.1073/pnas.220211797; Thomas D, 2000, CURR BIOL, V10, pR341, DOI 10.1016/S0960-9822(00)00462-0; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Valtieri M, 1998, CANCER RES, V58, P562; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wang JJ, 2000, P NATL ACAD SCI USA, V97, P3497, DOI 10.1073/pnas.97.7.3497; Wu M, 2000, GENE DEV, V14, P301; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; ZETTER BR, 1981, DIABETES, V30, P24, DOI 10.2337/diab.30.2.S24	86	22	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18365	18372		10.1074/jbc.M109812200	http://dx.doi.org/10.1074/jbc.M109812200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11904294	hybrid			2022-12-25	WOS:000175975800016
J	Ma, ASW; Moran-Jones, K; Shan, J; Munro, TP; Snee, MJ; Hoek, KS; Smith, R				Ma, ASW; Moran-Jones, K; Shan, J; Munro, TP; Snee, MJ; Hoek, KS; Smith, R			Heterogeneous nuclear ribonucleoprotein A3, a novel RNA trafficking response element-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN MESSENGER-RNA; HNRNP A1; MOLECULAR CHARACTERIZATION; EXPORT SIGNAL; MYELIN; LOCALIZATION; TRANSPORT; EXPRESSION; GENE; OLIGODENDROCYTES	The cis-acting response element, A2RE, which is sufficient for cytoplasmic mRNA trafficking in oligodendrocytes, binds a small group of rat brain proteins. Predominant among these is heterogeneous nuclear ribonucleoprotein (hnRNP) A2, a trans-acting factor for cytoplasmic trafficking of RNAs bearing A2RE-like sequences. We have now identified the other A2RE-binding proteins as hnRNP A1/A1(B), hnRNP B1, and four isoforms of hnRNP A3. The rat and human hnRNP A3 cDNAs have been sequenced, revealing the existence of alternatively spliced mRNAs. In Western blotting, 38-, 39-, 41 -, and 41.5-kDa components were all recognized by antibodies against a peptide in the glycine-rich region of hnRNP A3, but only the 41- and 41.5-kDa bands bound antibodies to a 15-residue N-terminal peptide encoded by an alternatively spliced part of exon 1. The identities of these four proteins were verified by Edman sequencing and mass spectral analysis of tryptic fragments generated from electrophoretically separated bands. Sequence-specific binding of bacterially expressed hnRNP A3 to A2RE has been demonstrated by biosensor and UV cross-linking electrophoretic mobility shift assays. Mutational analysis and confocal microscopy data support the hypothesis that the hnRNP A3 isoforms have a role in cytoplasmic trafficking of RNA.	Univ Queensland, Dept Biochem & Mol Biol, Brisbane, Qld 4072, Australia	University of Queensland	Smith, R (corresponding author), Univ Queensland, Dept Biochem & Mol Biol, Brisbane, Qld 4072, Australia.	ross.s@mailbox.uq.edu.au	Munro, Trent/AAC-1129-2020; Munro, Trent/B-4856-2009	Munro, Trent/0000-0003-1987-2020; Snee, Mark/0000-0003-4018-816X				Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; AMURUMARJEE S, 1993, J NEUROSCI RES, V36, P99, DOI 10.1002/jnr.490360111; BARBARESE E, 1995, J CELL SCI, V108, P2781; Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; Bassell GJ, 1999, FASEB J, V13, P447, DOI 10.1096/fasebj.13.3.447; Bassell GJ, 1998, J NEUROSCI, V18, P251; BIAMONTI G, 1994, NUCLEIC ACIDS RES, V22, P1996, DOI 10.1093/nar/22.11.1996; Bogerd HP, 1999, J BIOL CHEM, V274, P9771, DOI 10.1074/jbc.274.14.9771; BUVOLI M, 1990, EMBO J, V9, P1229, DOI 10.1002/j.1460-2075.1990.tb08230.x; CAMPAGNONI AT, 1991, ANN NY ACAD SCI, V633, P178; Carson J H, 2001, Results Probl Cell Differ, V34, P69; Carson JH, 1997, CELL MOTIL CYTOSKEL, V38, P318, DOI 10.1002/(SICI)1097-0169(1997)38:4<318::AID-CM2>3.0.CO;2-#; Carson JH, 1998, CURR OPIN NEUROBIOL, V8, P607, DOI 10.1016/S0959-4388(98)80088-3; COLMAN DR, 1982, J CELL BIOL, V95, P598, DOI 10.1083/jcb.95.2.598; Dangli A, 1996, BIOCHEM J, V320, P761, DOI 10.1042/bj3200761; DAVIES RJ, 1994, TECHNIQUES PROTEIN C, V5; DING D, 1993, BIOESSAYS, V15, P651, DOI 10.1002/bies.950151004; GOOD PJ, 1993, NUCLEIC ACIDS RES, V21, P999, DOI 10.1093/nar/21.4.999; Grunert S, 1996, CURR OPIN GENET DEV, V6, P395, DOI 10.1016/S0959-437X(96)80059-1; Hamasaki M, 2001, ANTICANCER RES, V21, P979; Hoek KS, 1998, BIOCHEMISTRY-US, V37, P7021, DOI 10.1021/bi9800247; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; Jansen RP, 1999, FASEB J, V13, P455, DOI 10.1096/fasebj.13.3.455; Kamma H, 1999, EXP CELL RES, V246, P399, DOI 10.1006/excr.1998.4323; Kiebler MA, 2000, NEURON, V25, P19, DOI 10.1016/S0896-6273(00)80868-5; KOZU T, 1995, GENOMICS, V25, P365, DOI 10.1016/0888-7543(95)80035-K; Kwon S, 1999, J CELL BIOL, V147, P247, DOI 10.1083/jcb.147.2.247; Lasko P, 1999, FASEB J, V13, P421, DOI 10.1096/fasebj.13.3.421; Makeyev AV, 1999, J BIOL CHEM, V274, P24849, DOI 10.1074/jbc.274.35.24849; Matsui M, 2000, BBA-GENE STRUCT EXPR, V1493, P33, DOI 10.1016/S0167-4781(00)00154-8; MICHAEL WM, 1995, CELL, V83, P415; Mohr E, 1999, PROG NEUROBIOL, V57, P507, DOI 10.1016/S0301-0082(98)00066-5; Mowry KL, 1999, FASEB J, V13, P435, DOI 10.1096/fasebj.13.3.435; Munro TP, 1999, J BIOL CHEM, V274, P34389, DOI 10.1074/jbc.274.48.34389; Plomaritoglou A, 2000, BBA-GENE STRUCT EXPR, V1490, P54, DOI 10.1016/S0167-4781(99)00054-8; Pokrywka NJ, 1995, CURR TOP DEV BIOL, V31, P139; Schnapp BJ, 1999, CURR BIOL, V9, pR725, DOI 10.1016/S0960-9822(99)80468-0; Shan JG, 2000, J BIOL CHEM, V275, P38286, DOI 10.1074/jbc.M007642200; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Speicher K D, 2000, J Biomol Tech, V11, P74; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; Sueoka E, 1999, CANCER RES, V59, P1404; TAKIGUCHI S, 1993, CYTOGENET CELL GENET, V64, P128, DOI 10.1159/000133568; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRAPP BD, 1987, P NATL ACAD SCI USA, V84, P7773, DOI 10.1073/pnas.84.21.7773; Truant R, 1999, J BIOL CHEM, V274, P32167, DOI 10.1074/jbc.274.45.32167; VERITY AN, 1988, J NEUROSCI RES, V21, P238, DOI 10.1002/jnr.490210216; WILKINS MR, 1998, 2 D PROTEOME ANAL PR, P531; Zhang HL, 1999, J CELL BIOL, V147, P59, DOI 10.1083/jcb.147.1.59	50	86	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18010	18020		10.1074/jbc.M200050200	http://dx.doi.org/10.1074/jbc.M200050200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11886857	hybrid			2022-12-25	WOS:000175685100079
J	Nirthanan, S; Charpantier, E; Gopalakrishnakone, P; Gwee, MCE; Khoo, HE; Cheah, LS; Bertrand, D; Kini, RM				Nirthanan, S; Charpantier, E; Gopalakrishnakone, P; Gwee, MCE; Khoo, HE; Cheah, LS; Bertrand, D; Kini, RM			Candoxin, a novel toxin from Bungarus candidus, is a reversible antagonist of muscle (alpha beta gamma delta) but a poorly reversible antagonist of neuronal alpha 7 nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; 3-DIMENSIONAL SOLUTION STRUCTURE; SITE-DIRECTED MUTAGENESIS; NAJA-NIGRICOLLIS VENOM; BLACK MAMBA VENOM; X-RAY STRUCTURE; SNAKE TOXINS; COBRA VENOM; FUNCTIONAL-PROPERTIES; CURAREMIMETIC TOXINS	In contrast to most short and long chain curaremimetic neurotoxins that produce virtually irreversible neuromuscular blockade in isolated nerve-muscle preparations, candoxin, a novel three-finger toxin from the Malayan krait Bungarus candidus, produced postjunctional neuromuscular blockade that was readily and completely reversible. Nanomolar concentrations of candoxin (IC50 = similar to10 nm) also blocked acetylcholine-evoked currents in oocyte-expressed rat muscle (alphabetagammadelta) nicotinic acetylcholine receptors in a reversible manner. In contrast, it produced a poorly reversible block (IC50 = similar to50 nm) of rat neuronal alpha7 receptors, clearly showing diverse functional profiles for the two nicotinic receptor subsets. Interestingly, candoxin lacks the helix-like segment cyclized by the fifth disulfide bridge at the tip of the middle loop of long chain neurotoxins, reported to be critical for binding to alpha7 receptors. However, its solution NMR structure showed the presence of some functionally invariant residues involved in the interaction of both short and long chain neurotoxins to muscle (alphabetagammadelta) and long chain neurotoxins to alpha7 receptors. Candoxin is therefore a novel toxin that shares a common scaffold with long chain alpha-neurotoxins but possibly utilizes additional functional determinants that assist in recognizing neuronal alpha7 receptors.	Natl Univ Singapore, Fac Med, Dept Anat, Venom & Toxin Res Programme, Singapore 119260, Singapore; Ctr Med Univ Geneva, Dept Physiol, CH-1211 Geneva 4, Switzerland; Natl Univ Singapore, Fac Sci, Dept Biol Sci, Singapore 119260, Singapore; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA	National University of Singapore; University of Geneva; National University of Singapore; Virginia Commonwealth University	Gopalakrishnakone, P (corresponding author), Natl Univ Singapore, Fac Med, Dept Anat, Venom & Toxin Res Programme, 10 Kent Ridge Crescent, Singapore 119260, Singapore.	antgopal@nus.edu.sg	Kini, Manjunatha/H-8029-2012; Nirthanan, Selvanayagam/ABI-4281-2020	Kini, Manjunatha/0000-0002-6100-3251; Nirthanan, S. Niru/0000-0001-9888-8447				Aird SD, 1999, TOXICON, V37, P609, DOI 10.1016/S0041-0101(98)00199-8; ALBRAND JP, 1995, BIOCHEMISTRY-US, V34, P5923, DOI 10.1021/bi00017a022; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Antil S, 1999, J BIOL CHEM, V274, P34851, DOI 10.1074/jbc.274.49.34851; Antil-Delbeke S, 2000, J BIOL CHEM, V275, P29594, DOI 10.1074/jbc.M909746199; Arias HR, 2000, NEUROCHEM INT, V36, P595, DOI 10.1016/S0197-0186(99)00154-0; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BERTRAND D, 1992, NEUROSCI LETT, V146, P87, DOI 10.1016/0304-3940(92)90179-B; Bertrand D, 1991, METHODS NEUROSCIENCE, V4, P174; BETZEL C, 1991, J BIOL CHEM, V266, P21530; BILWES A, 1994, J MOL BIOL, V239, P122, DOI 10.1006/jmbi.1994.1357; BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763; Buisson B, 1998, J PHYSIOL-PARIS, V92, P89, DOI 10.1016/S0928-4257(98)80144-7; CARLSSON FHH, 1975, BIOCHIM BIOPHYS ACTA, V400, P310, DOI 10.1016/0005-2795(75)90186-5; Cervenansky C., 1991, P303; Chang C.C., 1979, SNAKE VENOMS, P309; CHANGEUX JP, 1990, TRENDS PHARMACOL SCI, V11, P485, DOI 10.1016/0165-6147(90)90049-E; Chiappinelli VA, 1996, TOXICON, V34, P1243, DOI 10.1016/S0041-0101(96)00110-9; Cordero-Erausquin M, 2000, TRENDS PHARMACOL SCI, V21, P211, DOI 10.1016/S0165-6147(00)01489-9; CORFIELD PWR, 1989, J BIOL CHEM, V264, P9239; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DANSE JM, 1990, NUCLEIC ACIDS RES, V18, P1045, DOI 10.1093/nar/18.4.1045; DEWEILLE JR, 1991, P NATL ACAD SCI USA, V88, P2437, DOI 10.1073/pnas.88.6.2437; DRASDO A, 1992, MOL CELL NEUROSCI, V3, P237, DOI 10.1016/1044-7431(92)90043-2; Ducancel F, 1996, J BIOL CHEM, V271, P31345, DOI 10.1074/jbc.271.49.31345; EAKER DL, 1967, JPN J MICROBIOL, V11, P353, DOI 10.1111/j.1348-0421.1967.tb00356.x; Endo T., 1991, P165; FERTUCK HC, 1975, J CELL BIOL, V66, P209, DOI 10.1083/jcb.66.1.209; FLEMING TJ, 1993, J IMMUNOL, V150, P5379; GINSBORG BL, 1960, BRIT J PHARM CHEMOTH, V15, P410, DOI 10.1111/j.1476-5381.1960.tb01264.x; Grant GA, 1998, BIOCHEMISTRY-US, V37, P12166, DOI 10.1021/bi981227y; GRANT GA, 1988, BIOCHEMISTRY-US, V27, P3794, DOI 10.1021/bi00410a041; GRANT GA, 1985, BIOCHEMISTRY-US, V24, P1532, DOI 10.1021/bi00327a036; GUMLEY TP, 1995, IMMUNOL CELL BIOL, V73, P277, DOI 10.1038/icb.1995.45; Jacobsen RB, 1999, BIOCHEMISTRY-US, V38, P13310, DOI 10.1021/bi9907476; JERUSALINSKY D, 1994, TRENDS PHARMACOL SCI, V15, P424, DOI 10.1016/0165-6147(94)90092-2; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; JOUBERT FJ, 1980, H-S Z PHYSIOL CHEM, V361, P425, DOI 10.1515/bchm2.1980.361.1.425; JOUBERT FJ, 1975, H-S Z PHYSIOL CHEM, V356, P1901; KARLSSON E, 1971, EUR J BIOCHEM, V21, P1, DOI 10.1111/j.1432-1033.1971.tb01433.x; KIM HS, 1982, BIOCHEM J, V207, P215, DOI 10.1042/bj2070215; KOSEN PA, 1988, BIOCHEMISTRY-US, V27, P2775, DOI 10.1021/bi00408a018; Kuhn P, 2000, ACTA CRYSTALLOGR D, V56, P1401, DOI 10.1107/S0907444900011501; Lim B L, 1970, Med J Malaya, V25, P128; LOW BW, 1986, EUR J BIOCHEM, V161, P579, DOI 10.1111/j.1432-1033.1986.tb10481.x; Maslennikov IV, 1999, FEBS LETT, V444, P275, DOI 10.1016/S0014-5793(99)00069-1; MCDOWELL RS, 1992, BIOCHEMISTRY-US, V31, P4766, DOI 10.1021/bi00135a004; MCINTOSH M, 1982, ARCH BIOCHEM BIOPHYS, V218, P329, DOI 10.1016/0003-9861(82)90351-4; Mebs D., 1991, SNAKE TOXINS, P425; Menez A, 1998, TOXICON, V36, P1557, DOI 10.1016/S0041-0101(98)00148-2; Miwa JM, 1999, NEURON, V23, P105, DOI 10.1016/S0896-6273(00)80757-6; Parvathy VR, 2000, CURR SCI INDIA, V79, P219; PILLET L, 1993, J BIOL CHEM, V268, P909; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; Qian YC, 1998, BIOCHEM MOL BIOL INT, V46, P821; SATO S, 1971, BIOCHEM J, V122, P453, DOI 10.1042/bj1220453; SEGUELA P, 1993, J NEUROSCI, V13, P596; Servent D, 1997, J BIOL CHEM, V272, P24279, DOI 10.1074/jbc.272.39.24279; Servent D, 1998, J PHYSIOLOGY-PARIS, V92, P107, DOI 10.1016/S0928-4257(98)80146-0; Servent D, 2000, EUR J PHARMACOL, V393, P197, DOI 10.1016/S0014-2999(00)00095-9; SHAFQAT J, 1991, FEBS LETT, V284, P70, DOI 10.1016/0014-5793(91)80764-T; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; Tsetlin V, 1999, EUR J BIOCHEM, V264, P281, DOI 10.1046/j.1432-1327.1999.00623.x; Utkin YN, 2001, J BIOL CHEM, V276, P15810, DOI 10.1074/jbc.M100788200; Utkin YN, 2001, TOXICON, V39, P921, DOI 10.1016/S0041-0101(00)00223-3; WALKINSHAW MD, 1980, P NATL ACAD SCI-BIOL, V77, P2400, DOI 10.1073/pnas.77.5.2400; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011	69	85	90	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17811	17820		10.1074/jbc.M111152200	http://dx.doi.org/10.1074/jbc.M111152200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884390	hybrid			2022-12-25	WOS:000175685100055
J	Ong, E; Suzuki, M; Belot, F; Yeh, JC; Franceschini, I; Angata, K; Hindsgaul, O; Fukuda, M				Ong, E; Suzuki, M; Belot, F; Yeh, JC; Franceschini, I; Angata, K; Hindsgaul, O; Fukuda, M			Biosynthesis of HNK-1 glycans on O-linked oligosaccharides attached to the neural cell adhesion molecule (NCAM) - The requirement for core 2 beta 1,6-N-acetylglucosaminyltransferase and the muscle-specific domain in NCAM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY-N-ACETYLLACTOSAMINE; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; MYELIN-ASSOCIATED GLYCOPROTEIN; MONOCLONAL-ANTIBODY HNK-1; SULFATED GLUCURONIC-ACID; CARBOHYDRATE EPITOPE; NERVOUS-SYSTEM; EXPRESSION CLONING; POLYSIALIC ACID; DIFFERENTIATION ANTIGEN	The HNK-1 glycan, sulfo-->3G1cAbeta1-->3Galbeta1-->4GlcNAcbeta1-->R, is highly expressed in neuronal cells and apparently plays critical roles in neuronal cell migration and axonal extension. The HNK-1 glycan synthesis is initiated by the addition of beta1,3-linked GlcA to N-acetyllactosamine followed by sulfation of the C-3 position of GlcA. The cDNAs encoding beta1,3-glucuronyltransferase (GlcAT-P) and HNK-1 sulfotransferase (HNK-1ST) have been recently cloned. Among various adhesion molecules, the neural cell adhesion molecule (NCAM) was shown to contain HNK-1 glycan on N-glycans. In the present study, we first demonstrated that NCAM also bears HNK-1 glycan attached to O-glycans when NCAM contains the O-glycan attachment scaffold, muscle-specific domain, and is synthesized in the presence of core 2 beta1,6-N-acetylglucosaminyltransferase, GlcAT-P and HNK-1ST. Structural analysis of the HNK-1 glycan revealed that the HNK-1 glycan is attached on core 2 branched O-glycans, sulfo-->3GlcAbeta1-->3Galbeta1-->4GlcNAcbeta1-->6(Galbeta1-->3)GalNAc. Using synthetic oligosaccharides as acceptors, we found that GlcAT-P and HNK-1ST almost equally act on oligosaccharides, mimicking N- and O-glycans. By contrast, HNK-1 glycan was much more efficiently added to N-glycans than O-glycans when NCAM was used as an acceptor. These results are consistent with our results showing that HNK-1 glycan is minimally attached to O-glycans of NCAM in fetal brain, heart, and the myoblast cell line, C2C12. These results combined together indicate that HNK-1 glycan can be synthesized on core 2 branched O-glycans but that the HNK-1 glycan is preferentially added on N-glycans over O-glycans of NCAM, probably because N-glycans are extended further than O-glycans attached to NCAM containing the muscle-specific domain.	Burnham Inst, Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Fukuda, M (corresponding author), Burnham Inst, Canc Res Ctr, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Angata, Kiyohiko/M-2749-2018	Angata, Kiyohiko/0000-0001-5561-1368	NATIONAL CANCER INSTITUTE [R37CA033000, P01CA071932, R01CA033895] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA71932, R01CA33895, R37CA33000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABO T, 1981, J IMMUNOL, V127, P1024; Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 2000, J BIOL CHEM, V275, P18594, DOI 10.1074/jbc.M910204199; ARIGA T, 1987, J BIOL CHEM, V262, P848; BAENZIGER J, 1974, J BIOL CHEM, V249, P7270; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; Belot F, 2000, CARBOHYD RES, V326, P88, DOI 10.1016/S0008-6215(00)00032-X; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; BRONNERFRASER M, 1986, DEV BIOL, V115, P44, DOI 10.1016/0012-1606(86)90226-5; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; CARLSSON SR, 1993, ARCH BIOCHEM BIOPHYS, V304, P65, DOI 10.1006/abbi.1993.1322; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CHOU DKH, 1993, J BIOL CHEM, V268, P330; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DICKSON G, 1987, CELL, V50, P1119, DOI 10.1016/0092-8674(87)90178-4; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; Figarella-Branger D, 1999, AM J PATHOL, V155, P1261, DOI 10.1016/S0002-9440(10)65228-5; FINNE J, 1982, J BIOL CHEM, V257, P1966; Franceschini I, 2001, GLYCOBIOLOGY, V11, P231, DOI 10.1093/glycob/11.3.231; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; Kudo M, 1996, J BIOL CHEM, V271, P32667, DOI 10.1074/jbc.271.51.32667; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Liedtke S, 2001, GLYCOBIOLOGY, V11, P373, DOI 10.1093/glycob/11.5.373; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MARGOLIS RK, 1987, BIOCHEM BIOPH RES CO, V145, P1142, DOI 10.1016/0006-291X(87)91556-7; MARTINI R, 1992, EUR J NEUROSCI, V4, P628, DOI 10.1111/j.1460-9568.1992.tb00171.x; MARTINI R, 1994, J NEUROSCI, V14, P7180; McAuliffe JC, 1999, BIOORG MED CHEM LETT, V9, P2855, DOI 10.1016/S0960-894X(99)00485-0; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; Misra AK, 2001, BIOORG MED CHEM LETT, V11, P2667, DOI 10.1016/S0960-894X(01)00550-9; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; Nakayama J, 1998, PATHOL INT, V48, P665, DOI 10.1111/j.1440-1827.1998.tb03967.x; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; OBATA K, 1988, NEUROSCI RES, V6, P131, DOI 10.1016/0168-0102(88)90015-6; Ong E, 1999, J BIOL CHEM, V274, P25608, DOI 10.1074/jbc.274.36.25608; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; Priatel JJ, 2000, IMMUNITY, V12, P273, DOI 10.1016/S1074-7613(00)80180-6; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; STANLEY P, 1975, P NATL ACAD SCI USA, V72, P3323, DOI 10.1073/pnas.72.9.3323; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; TSUZUKIDA Y, 1979, P NATL ACAD SCI USA, V76, P1104, DOI 10.1073/pnas.76.3.1104; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; Ujita M, 1999, J BIOL CHEM, V274, P16717, DOI 10.1074/jbc.274.24.16717; VIITALA J, 1988, P NATL ACAD SCI USA, V85, P3743, DOI 10.1073/pnas.85.11.3743; von der Ohe M, 2002, GLYCOBIOLOGY, V12, P47, DOI 10.1093/glycob/12.1.47; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; WALSH FS, 1989, DEVELOPMENT, V105, P803; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; Yuen CT, 1997, J BIOL CHEM, V272, P8924	61	24	24	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18182	18190		10.1074/jbc.M201312200	http://dx.doi.org/10.1074/jbc.M201312200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11891229	hybrid			2022-12-25	WOS:000175685100100
J	Sanchez-Piris, M; Posas, F; Alemany, V; Winge, I; Hidalgo, E; Bachs, O; Aligue, R				Sanchez-Piris, M; Posas, F; Alemany, V; Winge, I; Hidalgo, E; Bachs, O; Aligue, R			The serine/threonine kinase Cmk2 is required for oxidative stress response in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ATF1 TRANSCRIPTION FACTOR; CELL-CYCLE CONTROL; MAP KINASE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; 2-COMPONENT SYSTEM; SEXUAL DEVELOPMENT; HIGH OSMOLARITY	Cmk2, a fission yeast Ser/Thr protein kinase homologous to mammalian calmodulin kinases, is essential for oxidative stress response. Cells lacking cmk2 gene were specifically sensitive to oxidative stress conditions. Upon stress, Cmk2 was phosphorylated in vivo, and this phosphorylation was dependent on the stress-activated MAPK Sty1/Spc1. Co-precipitation assays demonstrated that Cmk2 binds Sty1. Furthermore, in vivo or in vitro activated Sty1 was able to phosphorylate Cmk2, and the phosphorylation occurred at the C-terminal regulatory domain at Thr-411. Cell lethality caused by overexpression of Wis1 MAPK kinase was abolished by deletion of cmk2 or by mutation of Thr-411 of Cmk2. Taken together, our data suggest that Cmk2 acts downstream of Sty1 and is an essential kinase for oxidative stress responses.	Univ Barcelona, IDIBAPS, Dept Cell Biol, E-08036 Barcelona, Spain; Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Cell Signalling Unit, E-08003 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Pompeu Fabra University	Aligue, R (corresponding author), Univ Barcelona, IDIBAPS, Dept Cell Biol, E-08036 Barcelona, Spain.	aligue@medicina.ub.es	Hidalgo, Elena/K-2919-2014; Posas, Francesc/K-1364-2013; Aligue, Rosa/AAA-2520-2019	Hidalgo, Elena/0000-0002-3768-6785; Posas, Francesc/0000-0002-4164-7076; Aligue, Rosa/0000-0002-2085-325X; Winge, Ingeborg/0000-0001-6139-5999				Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Banuett F, 1998, MICROBIOL MOL BIOL R, V62, P249, DOI 10.1128/MMBR.62.2.249-274.1998; Bilsland-Marchesan E, 2000, MOL CELL BIOL, V20, P3887, DOI 10.1128/MCB.20.11.3887-3895.2000; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Buck V, 2001, MOL BIOL CELL, V12, P407, DOI 10.1091/mbc.12.2.407; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Cottarel G, 1997, GENETICS, V147, P1043; DAHLKVIST A, 1995, MOL GEN GENET, V246, P316, DOI 10.1007/BF00288604; Degols G, 1996, MOL CELL BIOL, V16, P2870; Gaits F, 1998, GENE DEV, V12, P1464, DOI 10.1101/gad.12.10.1464; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kanoh J, 1996, GENES CELLS, V1, P391, DOI 10.1046/j.1365-2443.1996.d01-247.x; Kato T, 1996, FEBS LETT, V378, P207, DOI 10.1016/0014-5793(95)01442-X; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Melcher ML, 1996, J BIOL CHEM, V271, P29958, DOI 10.1074/jbc.271.47.29958; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NAKAGAWA CW, 1995, J BIOCHEM-TOKYO, V118, P109, DOI 10.1093/oxfordjournals.jbchem.a124864; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Nguyen AN, 2000, MOL BIOL CELL, V11, P1169, DOI 10.1091/mbc.11.4.1169; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Samejima I, 1997, EMBO J, V16, P6162, DOI 10.1093/emboj/16.20.6162; Samejima I, 1998, MOL BIOL CELL, V9, P2325, DOI 10.1091/mbc.9.8.2325; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Shieh JC, 1998, J CELL SCI, V111, P2799; Shieh JC, 1997, GENE DEV, V11, P1008, DOI 10.1101/gad.11.8.1008; Shiozaki K, 1997, MOL BIOL CELL, V8, P409, DOI 10.1091/mbc.8.3.409; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; Teige M, 2001, P NATL ACAD SCI USA, V98, P5625, DOI 10.1073/pnas.091610798; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; Toone WM, 1998, GENE DEV, V12, P1453, DOI 10.1101/gad.12.10.1453; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Wilkinson MG, 1999, EMBO J, V18, P4210, DOI 10.1093/emboj/18.15.4210; Wilkinson MG, 1998, GENE DEV, V12, P1391, DOI 10.1101/gad.12.10.1391; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289	40	46	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17722	17727		10.1074/jbc.M200104200	http://dx.doi.org/10.1074/jbc.M200104200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11886858	hybrid			2022-12-25	WOS:000175685100043
J	Sonnenburg, JL; van Halbeek, H; Varki, A				Sonnenburg, JL; van Halbeek, H; Varki, A			Characterization of the acid stability of glycosidically linked neuraminic acid - Use in detecting de-N-acetyl-gangliosides in human melanoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SIALIC ACIDS; CELL-ADHESION; LIQUID-CHROMATOGRAPHY; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; SIGNALING DOMAIN; O-ACETYL; BINDING; EXPRESSION	The glycosidic linkage of sialic acids is much more sensitive to acid hydrolysis than those of other monosaccharides in vertebrates. The commonest sialic acids in nature are neuraminic acid (Neu)-based and are typically N-acylated at the C5 position. Unsubstituted Neu is thought to occur on native gangliosides of certain tumors and cell lines, and synthetic de-N-acetyl-gangliosides have potent biological properties in vitro. However, claims for their natural existence are based upon monoclonal antibodies and pulse-chase experiments, and there have been no reports of their chemical detection. Here we report that one of these antibodies shows nonspecific cross-reactivity with a polypeptide epitope, further emphasizing the need for definitive chemical proof of unsubstituted Neu on naturally occurring gangliosides. While pursuing this, we found that alpha2-3-linked Neu on chemically de-N-acetylated G(M3) ganglioside resists acid hydrolysis under conditions where the N-acetylated form is completely labile. To ascertain the generality of this finding, we investigated the stability of glycosidically linked alpha- and beta-methyl glycosides of Neu. Using NMR spectroscopy to monitor glycosidic linkage hydrolysis, we find that only 47% of Neualpha2Me is hydrolyzed after 3 h in 10 mm HCl at 80degreesC, whereas Neu5Acalpha2Me is 95% hydrolyzed after 20 min under the same conditions. Notably, Neubeta2Me is hydrolyzed even slower than Neualpha2Me, indicating that acid resistance is a general property of glycosidically linked Neu. Taking advantage of this, we modified classical purification techniques for de-N-acetyl-ganglioside isolation using acid to first eliminate conventional gangliosides. We also introduce a phospholipase-based approach to remove contaminating phospholipids that previously hindered efforts to study de-N-acetyl-gangliosides. The partially purified sample can then be N-propionylated, allowing acid release and mass spectrometric detection of any originally existing Neu as Neu5Pr. These advances allowed us to detect covalently bound Neu in lipid extracts of a human melanoma tumor, providing the first chemical proof for naturally occurring de-N-acetyl-gangliosides.	Univ Calif San Diego, Sch Med 0687, Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Varki, A (corresponding author), Univ Calif San Diego, Sch Med 0687, Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA.	avarki@ucsd.edu			NCI NIH HHS [P01 CA58689] Funding Source: Medline; NIGMS NIH HHS [R01-GM323373] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chammas R, 1999, CANCER RES, V59, P1337; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; Collins BE, 2000, GLYCOBIOLOGY, V10, P11, DOI 10.1093/glycob/10.1.11; COLLINS PM, 1995, MONOSACCHARIDES, P73; DAVIDSON EA, 1966, METHOD ENZYMOL, V8, P52; DOHI T, 1988, CANCER RES, V48, P5680; FEATHER MS, 1965, J ORG CHEM, V30, P153, DOI 10.1021/jo01012a035; GOTTSCHALK A, 1960, HEM BIOL SIALIC ACID; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANAI N, 1988, J BIOL CHEM, V263, P6296; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HAVERKAMP J, 1982, EUR J BIOCHEM, V122, P305, DOI 10.1111/j.1432-1033.1982.tb05881.x; HIDARI KIPJ, 1993, BIOCHEM J, V296, P259, DOI 10.1042/bj2960259; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; Kazui A, 2000, BIOCHEM BIOPH RES CO, V273, P159, DOI 10.1006/bbrc.2000.2903; Khan AA, 2001, SCIENCE, V292, P1681, DOI 10.1126/science.1056594; Klein A, 1997, GLYCOBIOLOGY, V7, P421, DOI 10.1093/glycob/7.3.421; KOJIMA N, 1992, J BIOL CHEM, V267, P17264; LUTZ MS, 1994, J BIOL CHEM, V269, P29227; MAGNANI JL, 1982, METHOD ENZYMOL, V83, P235; MANZI AE, 1990, J BIOL CHEM, V265, P13091; MARKWELL MAK, 1981, P NATL ACAD SCI-BIOL, V78, P5406, DOI 10.1073/pnas.78.9.5406; Mitsuoka C, 1999, P NATL ACAD SCI USA, V96, P1597, DOI 10.1073/pnas.96.4.1597; Moggridge RCG, 1938, J CHEM SOC, P745, DOI 10.1039/jr9380000745; NAGAI Y, 1995, BEHAV BRAIN RES, V66, P99, DOI 10.1016/0166-4328(94)00130-8; NORES GA, 1988, CARBOHYD RES, V179, P393, DOI 10.1016/0008-6215(88)84135-1; NORES GA, 1989, METHOD ENZYMOL, V179, P242; NORGARDSUMNICHT KE, 1995, J BIOL CHEM, V270, P27634, DOI 10.1074/jbc.270.46.27634; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; Probstmeier R, 1999, GLYCOBIOLOGY, V9, P101, DOI 10.1093/glycob/9.2.101; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SJOBERG ER, 1995, J BIOL CHEM, V270, P2921, DOI 10.1074/jbc.270.7.2921; Srikrishna G, 2001, J IMMUNOL, V166, P624, DOI 10.4049/jimmunol.166.1.624; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; Vyas AA, 2001, BIOCHIMIE, V83, P677, DOI 10.1016/S0300-9084(01)01308-6; WALTON KM, 1988, J BIOL CHEM, V263, P2055; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; Zanetta JP, 2001, GLYCOBIOLOGY, V11, P663, DOI 10.1093/glycob/11.8.663; ZELLER CB, 1992, AM J PHYSIOL, V262, pC1341, DOI 10.1152/ajpcell.1992.262.6.C1341; ZHOU QG, 1994, J BIOL CHEM, V269, P1959; ZWALL RFA, 1974, METHOD ENZYMOL, V32, P154	48	23	25	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17502	17510		10.1074/jbc.M110867200	http://dx.doi.org/10.1074/jbc.M110867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884388	hybrid			2022-12-25	WOS:000175685100016
J	Lutsenko, EA; Carcamo, JM; Golde, DW				Lutsenko, EA; Carcamo, JM; Golde, DW			Vitamin C prevents DNA mutation induced by oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROASCORBIC ACID; ASCORBIC-ACID; DAMAGE; TRANSPORT; ACCUMULATION; ANTIOXIDANT; INHIBITION; SUPPLEMENTATION; GLYCOSYLASE; MUTAGENESIS	The precise role of vitamin C in the prevention of DNA mutations is controversial. Although ascorbic acid has strong antioxidant properties, it also has pro-oxidant effects in the presence of free transition metals. Vitamin C was recently reported to induce the decomposition of lipid hydroperoxides independent of metal interactions, suggesting that it may cause DNA damage. To directly address the role of vitamin C in maintaining genomic integrity we developed a genetic system for quantifying guanine base mutations induced in human cells under oxidative stress. The assay utilized a plasmid construct encoding the cDNA for chloramphenicol acetyl transferase modified to contain an amber stop codon, which was restored to wild type by G to T transversion induced by oxidative stress. The mutation frequency was determined from the number of plasmids containing the wild type chloramphenicol acetyl transferase gene rescued from oxidatively stressed cells. Cells were loaded with vitamin C by exposing them to dehydroascorbic acid, thereby avoiding transition metal-related pro-oxidant effects of ascorbic acid. We found that vitamin C loading resulted in substantially decreased mutations induced by H2O2. Depletion of glutathione led to cytotoxicity and an increase in H2O2-induced mutation frequency; however, mutation frequency was prominently decreased in depleted cells preloaded with vitamin C. The mutation results correlated with a decrease in total 8-oxo-guanine measured in genomic DNA of cells loaded with vitamin C and oxidatively stressed. These findings directly support the concept that high intracellular concentrations of vitamin C can prevent oxidation-induced mutations in human cells.	Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Golde, DW (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.	d-golde@ski.mskcc.org						AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BERGSTEN P, 1990, J BIOL CHEM, V265, P2584; Brennan LA, 2000, BRIT J NUTR, V84, P195, DOI 10.1017/S0007114500001422; Cai L, 2001, CHEM-BIOL INTERACT, V137, P75, DOI 10.1016/S0009-2797(01)00210-1; DIZDAROGLU M, 1985, BIOCHEMISTRY-US, V24, P4476, DOI 10.1021/bi00337a032; FRAGA CG, 1991, P NATL ACAD SCI USA, V88, P11003, DOI 10.1073/pnas.88.24.11003; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; GALLOWAY SM, 1979, MUTAT RES, V60, P321, DOI 10.1016/0027-5107(79)90022-8; Guaiquil VH, 1997, J BIOL CHEM, V272, P9915; Guaiquil VH, 2001, J BIOL CHEM, V276, P40955, DOI 10.1074/jbc.M106878200; Halliwell B, 2000, AM J CLIN NUTR, V72, P1082; Halliwell B, 1999, FREE RADICAL BIO MED, P48; Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5; KRINSKY NI, 1993, ANN NY ACAD SCI, V686, P229, DOI 10.1111/j.1749-6632.1993.tb39180.x; Lee BM, 1998, CANCER LETT, V132, P219, DOI 10.1016/S0304-3835(98)00227-4; Lee SH, 2001, SCIENCE, V292, P2083, DOI 10.1126/science.1059501; Levine M, 2001, P NATL ACAD SCI USA, V98, P9842, DOI 10.1073/pnas.171318198; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; May JM, 1999, FREE RADICAL BIO MED, V26, P1513, DOI 10.1016/S0891-5849(99)00017-9; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Podmore ID, 1998, NATURE, V392, P559, DOI 10.1038/33308; Rivas CI, 1997, J BIOL CHEM, V272, P5814, DOI 10.1074/jbc.272.9.5814; ROSIN MP, 1980, CANCER LETT, V8, P299, DOI 10.1016/0304-3835(80)90145-7; Rumsey SC, 2000, J BIOL CHEM, V275, P28246; Sambrook J., 1989, MOL CLONING, pA1; Schneider M, 2001, FREE RADICAL RES, V34, P209, DOI 10.1080/10715760100300201; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Sonntag C, 1987, CHEM BASIS RAD BIOL; SPEIT G, 1980, MUTAT RES, V78, P273, DOI 10.1016/0165-1218(80)90109-3; STICH HF, 1979, CANCER RES, V39, P4145; STICH HF, 1976, NATURE, V260, P722, DOI 10.1038/260722a0; Sweetman SF, 1997, NUTR CANCER, V27, P122, DOI 10.1080/01635589709514513; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; VERA JC, 1994, BLOOD, V84, P1628; VERA JC, 1995, J BIOL CHEM, V270, P23706, DOI 10.1074/jbc.270.40.23706; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; WAGNER JR, 1992, P NATL ACAD SCI USA, V89, P3380, DOI 10.1073/pnas.89.8.3380; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Zhu L, 1996, Methods Mol Biol, V57, P13	42	122	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16895	16899		10.1074/jbc.M201151200	http://dx.doi.org/10.1074/jbc.M201151200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11884413	hybrid			2022-12-25	WOS:000175564500074
J	Bennasser, Y; Bahraoui, E				Bennasser, Y; Bahraoui, E			HIV-1 Tat protein induces interleukin-10 in human peripheral blood monocytes: involvement of protein kinase C-beta II and -delta	FASEB JOURNAL			English	Article						IL-10; PKC isoforms; uninfected monocytes	HUMAN-IMMUNODEFICIENCY-VIRUS; SECONDARY STRUCTURES; PKC-INHIBITOR; ACTIVATION; CELLS; EXPRESSION; DIFFERENTIATION; ISOZYMES; PATHWAY; TYPE-1	In HIV-infected patients, production of interleukin-10 (IL-10), a highly immunosuppressive cytokine, is associated with the disease progression toward AIDS. We have previously shown that HIV-1 Tat induces IL-10 production by human monocytes via a protein kinase C (PKC)-dependent pathway. Here we show that PKC activation by Tat is essential for IL-10 induction. Among the eight PKC isoforms present in human monocytes, we investigated which isoform(s) plays this crucial role in Tat-mediated IL-10 production and show that 1) Tat can activate PKC-alpha, PKC-betaII, PKC-delta, and PKC-epsilon, 2) of these four potential candidates, only PKC-betaII, PKC-delta, and PKC-epsilon are activated by the active domain Tat 1-45, which is responsible for IL-10 production and depleted by long-term exposure to PMA, which abolishes Tat-mediated IL-10 production, 3) whereas selective inhibition of PKC-alpha and PKC-epsilon by specific antisense oligonucleotides has no effect on Tat-mediated IL-10 induction, inhibition of either PKC-betaII or PKC-delta partially inhibits IL-10 production; and 4) the simultaneous inhibition of PKC-betaII and PKC-delta totally inhibits Tat-mediated IL-10. Altogether, these results suggest that the induction of IL-10 by Tat is strictly dependent on the PKC-delta and -betaII isoforms.	Univ Toulouse 3, Lab Immuno Virol, EA 3038, F-31062 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Bahraoui, E (corresponding author), Univ Toulouse 3, Lab Immuno Virol, EA 3038, 118 Route Narbonne Batiment 4R3, F-31062 Toulouse, France.	bahraoui@cict.fr	Bennasser, Yamina/M-4833-2017	BAHRAOUI, ELMOSTAFA/0000-0003-1852-389X				Acs P, 1997, J BIOL CHEM, V272, P22148, DOI 10.1074/jbc.272.35.22148; AMEGLIO E, 1994, J BIOL REG HOMEOS AG, V8, P48; Badou A, 2000, J VIROL, V74, P10551, DOI 10.1128/JVI.74.22.10551-10562.2000; Borgatti P, 1998, BIOCHEM BIOPH RES CO, V242, P332, DOI 10.1006/bbrc.1997.7877; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; Chen CC, 1998, J IMMUNOL, V161, P6206; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Frankel AD, 1992, CURR OPIN GENET DEV, V2, P293, DOI 10.1016/S0959-437X(05)80287-4; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; Gallo RC, 1999, P NATL ACAD SCI USA, V96, P8324, DOI 10.1073/pnas.96.15.8324; Gonindard C, 1997, CELL BIOL TOXICOL, V13, P141, DOI 10.1023/A:1007321227010; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KELLER HU, 1993, BIOCHEM BIOPH RES CO, V194, P1111, DOI 10.1006/bbrc.1993.1936; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; MAGGI E, 1994, SCIENCE, V265, P244, DOI 10.1126/science.8023142; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Mochly-Rosen D, 2000, SEMIN IMMUNOL, V12, P55, DOI 10.1006/smim.2000.0207; Monick MM, 1998, AM J PHYSIOL-LUNG C, V275, pL389, DOI 10.1152/ajplung.1998.275.2.L389; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Perletti GP, 1998, ONCOGENE, V16, P3345, DOI 10.1038/sj.onc.1201871; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; SABATIER JM, 1991, J VIROL, V65, P961, DOI 10.1128/JVI.65.2.961-967.1991; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; ZUKER M, 1991, NUCLEIC ACIDS RES, V19, P2707, DOI 10.1093/nar/19.10.2707	40	51	55	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					546	554		10.1096/fj.01-0775com	http://dx.doi.org/10.1096/fj.01-0775com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11919157				2022-12-25	WOS:000175425900008
J	Buchwalow, IB; Podzuweit, T; Bocker, W; Samoilova, VE; Thomas, S; Wellnr, M; Baba, HA; Robenek, H; Schnekenburger, J; Lerch, MM				Buchwalow, IB; Podzuweit, T; Bocker, W; Samoilova, VE; Thomas, S; Wellnr, M; Baba, HA; Robenek, H; Schnekenburger, J; Lerch, MM			Vascular smooth muscle and nitric oxide synthase	FASEB JOURNAL			English	Article						vascular smooth muscle cells; NOS; VSMC	SKELETAL-MUSCLE; ENDOTHELIAL-CELLS; GUANYLATE-CYCLASE; OXIDATIVE STRESS; IN-SITU; EXPRESSION; NO; AMPLIFICATION; ADVENTITIA; RELAXATION	The concept of endothelium-derived relaxing factor (EDRF) put forward in 1980 by Furchgott and Zawadzki implies that nitric oxide (NO) produced by NO synthase (NOS) in the endothelium diffuses to the underlying vascular smooth muscle, where it modulates vascular tone as well as vascular smooth muscle cell (VSMC) proliferation by increasing cGMP formation with subsequent activation of cGMP-dependent protein kinase. According to this concept, VSMC do not express NOS by themselves. This attractive, simple scheme is now under considerable debate. To address this issue, we designed this study with the use of a novel supersensitive immunocytochemical technique of signal amplification with tyramide and electron microscopic immunogold labeling complemented with Western blotting, as in our recent studies demonstrating NOS in the myocardial and skeletal muscles. We provide the first evidence that, in contrast to the currently accepted view, VSMC in various blood vessels express all three NOS isoforms depending on the blood vessel type. These findings suggest an alternative mechanism by which local NOS expression may modulate vascular functions in an endothelium-independent manner.	Univ Munster, Dept Med B, D-48149 Munster, Germany; Univ Munster, Gerhard Domagk Inst Pathol, Interdisciplinary Ctr Clin Res, Cent Ultrastruct Res Unit, D-48149 Munster, Germany; Max Planck Inst Clin Res, D-61231 Bad Nauheim, Germany; Humboldt Univ, Fac Med Charite, Franz Volhard Clin, D-13125 Berlin, Germany; Univ Munster, Inst Arteriosclerosis Res, D-48149 Munster, Germany	University of Munster; University of Munster; Max Planck Society; Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munster	Buchwalow, IB (corresponding author), Univ Munster, Dept Med B, Domagkstr 17, D-48149 Munster, Germany.	buchwalo@uni-muenster.de	Lerch, Markus M./E-2206-2016	Lerch, Markus M./0000-0002-9643-8263; Schnekenburger, Juergen/0000-0002-0199-2908				ADAMS JC, 1992, J HISTOCHEM CYTOCHEM, V40, P1457, DOI 10.1177/40.10.1527370; Azevedo LCP, 2000, CARDIOVASC RES, V47, P436, DOI 10.1016/S0008-6363(00)00091-2; Banning AP, 1999, ATHEROSCLEROSIS, V145, P17, DOI 10.1016/S0021-9150(99)00010-6; BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X; Boulanger CM, 1998, CIRC RES, V83, P1271, DOI 10.1161/01.RES.83.12.1271; Brophy CM, 2000, AM J PHYSIOL-HEART C, V278, pH991, DOI 10.1152/ajpheart.2000.278.3.H991; Buchwalow IB, 1998, CIRCULATION, V98, P118; Buchwalow IB, 1997, ACTA HISTOCHEM, V99, P231, DOI 10.1016/S0065-1281(97)80046-3; Buchwalow IB, 2001, MOL CELL BIOCHEM, V217, P73, DOI 10.1023/A:1007286602865; Buchwalow TB, 2001, P ROY MICROSC SOC, V36, P57; Comini L, 1996, J MOL CELL CARDIOL, V28, P2241, DOI 10.1006/jmcc.1996.0216; Ding H, 2000, J PHARMACOL TOX MET, V44, P441, DOI 10.1016/S1056-8719(00)00127-1; Fleming I, 1999, J MOL CELL CARDIOL, V31, P5, DOI 10.1006/jmcc.1998.0839; FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538, DOI 10.1164/ajrccm.149.2.7508323; Gath I, 1999, BIOCHEM J, V340, P723, DOI 10.1042/0264-6021:3400723; Gath I, 1996, FASEB J, V10, P1614, DOI 10.1096/fasebj.10.14.9002553; GRIFFITH TM, 1989, INT J MICROCIRC, V8, P383; Harris D, 2000, EUR J PHARMACOL, V402, P119, DOI 10.1016/S0014-2999(00)00512-4; Heitzer T, 1999, KIDNEY INT, V55, P252, DOI 10.1046/j.1523-1755.1999.00229.x; Hopman AHN, 1998, J HISTOCHEM CYTOCHEM, V46, P771, DOI 10.1177/002215549804600611; IGNARRO LJ, 1990, PHARMACOL TOXICOL, V67, P1, DOI 10.1111/j.1600-0773.1990.tb00772.x; Kahn AM, 2000, AM J PHYSIOL-ENDOC M, V278, pE627, DOI 10.1152/ajpendo.2000.278.4.E627; KOBZIK L, 1995, BIOCHEM BIOPH RES CO, V211, P375, DOI 10.1006/bbrc.1995.1824; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; Kozlov AV, 2001, BBA-MOL BASIS DIS, V1536, P177, DOI 10.1016/S0925-4439(01)00047-3; Li HG, 2000, J PATHOL, V190, P244, DOI 10.1002/(SICI)1096-9896(200002)190:3<244::AID-PATH575>3.0.CO;2-8; Linas SL, 1997, AM J PHYSIOL-RENAL, V272, pF767, DOI 10.1152/ajprenal.1997.272.6.F767; Luscher TF, 1997, CLIN CARDIOL, V20, P3; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; Miura H, 1999, CIRCULATION, V99, P3132, DOI 10.1161/01.CIR.99.24.3132; Mizutani K, 2000, J HYPERTENS, V18, P1071, DOI 10.1097/00004872-200018080-00012; MOHAUPT MG, 1994, KIDNEY INT, V46, P653, DOI 10.1038/ki.1994.318; Napoli C, 2001, NITRIC OXIDE-BIOL CH, V5, P88, DOI 10.1006/niox.2001.0337; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; Ozel SK, 2001, PROSTAG LEUKOTR ESS, V64, P253, DOI 10.1054/plef.2001.0268; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Pernow J, 2001, EUR HEART J SUPPL, V3, pC22, DOI 10.1016/S1520-765X(01)90026-4; Pesic S, 1999, J VET MED A, V46, P509, DOI 10.1046/j.1439-0442.1999.00248.x; Punkt K, 2001, HISTOCHEM J, V33, P213, DOI 10.1023/A:1017994108174; Rajasekaran M, 1998, J UROLOGY, V160, P2210, DOI 10.1016/S0022-5347(01)62298-5; Roth J, 1982, TECHNIQUES IMMUNOCYT, P107; Sanderson M, 2000, KLUW S INF, V7, P235; Schwarz PM, 1999, ARTERIOSCL THROM VAS, V19, P2584, DOI 10.1161/01.ATV.19.11.2584; SHIKANO K, 1987, BRIT J PHARMACOL, V92, P483, DOI 10.1111/j.1476-5381.1987.tb11347.x; STEINHORN RH, 1994, J CLIN INVEST, V94, P1883, DOI 10.1172/JCI117538; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; Teoh H, 2000, MOL CELL BIOCHEM, V207, P65, DOI 10.1023/A:1007090113551; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; Trovati M, 1999, DIABETOLOGIA, V42, P831, DOI 10.1007/s001250051234; Van Zwieten P A, 1997, Blood Press Suppl, V2, P67; vonWasielewski R, 1997, J HISTOCHEM CYTOCHEM, V45, P1455, DOI 10.1177/002215549704501102; Walia M, 2000, EUR J PHARMACOL, V400, P249, DOI 10.1016/S0014-2999(00)00393-9; ZEHETGRUBER M, 1993, LIFE SCI, V52, P1397, DOI 10.1016/0024-3205(93)90063-9	55	127	132	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					500	508		10.1096/fj.01-0842com	http://dx.doi.org/10.1096/fj.01-0842com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11919152				2022-12-25	WOS:000175425900003
J	Carbone, R; Pearson, M; Minucci, S; Pelicci, PG				Carbone, R; Pearson, M; Minucci, S; Pelicci, PG			PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage	ONCOGENE			English	Article						promyelocytic leukaemia nuclear bodies; p53; hMre11; checkpoint; DNA repair	NIJMEGEN BREAKAGE SYNDROME; NUCLEAR-BODIES; PROTEIN COMPLEX; RETINOIC ACID; HISTONE H2AX; REPAIR; GENE; MRE11; ND10; DISRUPTION	PML nuclear bodies (PML NBs) respond to many cellular stresses including viral infection, heat shock, arsenic and oncogenes and have been implicated in the regulation of p53-dependent replicative senescence and apoptosis. Recently, the hMre11/Rad50/NBSI repair complex, involved in Double Strand Breaks (DSBs) repair, was found to colocalize within PML NBs, suggesting a role for these nuclear sub-domains in the DNA repair signalling pathway. We report here that in normal human fibroblasts, after ionizing radiation (IR), the PML NBs are modified and recognize sites of DNA breaks (ssDNA breaks and DSBs). Eight to 12 h after radiation PML NBs associate with hMre11 Ionizing Radiation-Induced Foci (IRIF), and subsequently with p53 within discrete foci. The PML, hMre11 and p53 colocalizing structures mark sites of DSBs as identified by immunolocalization with anti phosphorylated histone gamma-H2AX. Furthermore, we demonstrate that ionizing radiation induces the stable association of p53 with hMre11 and PML. These results suggest that the PML NBs are involved in the recognition and/or processing of DNA breaks and possibly in the recruitment of proteins (p53 and hMre11) required for both checkpoint and DNA-repair responses.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; FIRC Inst Mol Oncol, FIMO, I-20139 Milan, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	pgpelicci@ieo.it	Minucci, Saverio/J-9669-2012; Pelicci, Pier Giuseppe/AAL-6572-2020					Ahn JH, 2000, VIROLOGY, V274, P39, DOI 10.1006/viro.2000.0448; Andre C, 1996, EXP CELL RES, V229, P253, DOI 10.1006/excr.1996.0368; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Everett RD, 1999, J CELL SCI, V112, P3443; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; KELLY C, 1995, J GEN VIROL, V76, P2887, DOI 10.1099/0022-1317-76-11-2887; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lombard DB, 2000, CANCER RES, V60, P2331; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Muller S, 1998, BLOOD, V92, P4308, DOI 10.1182/blood.V92.11.4308.423k36_4308_4316; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Petrini JHJ, 1999, AM J HUM GENET, V64, P1264, DOI 10.1086/302391; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Wang Y, 2000, GENE DEV, V14, P927; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	46	154	157	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1633	1640		10.1038/sj.onc.1205227	http://dx.doi.org/10.1038/sj.onc.1205227			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896594				2022-12-25	WOS:000174214200001
J	Jinno, S; Yageta, M; Nagata, A; Okayama, H				Jinno, S; Yageta, M; Nagata, A; Okayama, H			Cdc6 requires anchorage for its expression	ONCOGENE			English	Article						Cdc6; anchorage; Cdk6; cyclin D3; NRK	EPIDERMAL-GROWTH-FACTOR; CYCLIN-DEPENDENT KINASES; CELL-CYCLE; RETINOBLASTOMA PROTEIN; MAMMALIAN CDC6; DNA-REPLICATION; G(1) CONTROL; NRK CELLS; S-PHASE; PHOSPHORYLATION	Fibroblasts need anchorage to extracellular matrix to transit from G(1) to S phase, but no longer after oncogenic transformation. Here we report that Cdc6 protein essential for the activation of replication origins requires anchorage or oncogenic stimulation for its execution. Upon anchorage loss, Cdc6 expression is shut off both transcriptionally and post-transcriptionally in a rat fibroblast despite enforced activation of E2F-dependent promoters. However, stimulation of this cell with oncogenic growth factors suppresses this shutoff and concurrently activates Cdk2 and Cdk6/4, thereby overriding the anchorage requirement for the G(1)-S transition and consequently enabling cells to perform anchorage-independent S phase entry. Analysis with enforced expression of Cdc6 indicates that the G(1) cyclin-dependent kinases and Cdc6 constitute major cell cycle targets for the restriction of the G(1)-S transition by anchorage loss.	Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Jinno, S (corresponding author), Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan.	jinno@m.u-tokyo.ac.jp; okayama@m.u-tokyo.ac.jp	Sakurai-Yageta, Mika/U-1842-2019	Sakurai-Yageta, Mika/0000-0001-5606-3324				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P71; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cifone M A, 1982, Cancer Metastasis Rev, V1, P335, DOI 10.1007/BF00124216; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Coverley D, 2000, J CELL SCI, V113, P1929; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Desdouets C, 1995, Prog Cell Cycle Res, V1, P115; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; Hosokawa Y, 1995, BIOCHEM MOL BIOL INT, V37, P393; INOUE S, 1991, J BIOL CHEM, V266, P13311; Jinno S, 1999, ONCOGENE, V18, P565, DOI 10.1038/sj.onc.1202347; Jinno S, 1999, P NATL ACAD SCI USA, V96, P13197, DOI 10.1073/pnas.96.23.13197; KATO J, 1993, GENE DEV, V7, P331; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kizaka-Kondoh S, 2000, FEBS LETT, V466, P160, DOI 10.1016/S0014-5793(99)01784-6; KUME K, 1992, NEW BIOL, V4, P504; Lahaye DHTP, 1999, FEBS LETT, V446, P256, DOI 10.1016/S0014-5793(99)00216-1; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; Lin J, 2001, ONCOGENE, V20, P2000, DOI 10.1038/sj.onc.1204375; Liu KY, 2000, J BIOL CHEM, V275, P31093, DOI 10.1074/jbc.M005451200; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Madine MA, 2000, J STRUCT BIOL, V129, P198, DOI 10.1006/jsbi.2000.4218; MASUDA A, 1992, NEW BIOL, V4, P489; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; OTSUKA H, 1976, J CELL PHYSIOL, V87, P213, DOI 10.1002/jcp.1040870209; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Reed SI, 1997, CANCER SURV, V29, P7; Resnitzky D, 1997, MOL CELL BIOL, V17, P5640, DOI 10.1128/MCB.17.9.5640; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yoshikawa Y, 2000, JPN J CANCER RES, V91, P459, DOI 10.1111/j.1349-7006.2000.tb00967.x; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	49	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1777	1784		10.1038/sj.onc.1205249	http://dx.doi.org/10.1038/sj.onc.1205249			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896609				2022-12-25	WOS:000174214200016
J	Rozenfeld-Granot, G; Krishnamurthy, J; Kannan, K; Toren, A; Amariglio, N; Givol, D; Rechavi, G				Rozenfeld-Granot, G; Krishnamurthy, J; Kannan, K; Toren, A; Amariglio, N; Givol, D; Rechavi, G			A positive feedback mechanism in the transcriptional activation of Apaf-1 by p53 and the coactivator Zac-1	ONCOGENE			English	Article						apoptosis; Apaf-1; p53 target; Zac-1 coactivation; promoter luciferase assay	TUMOR-SUPPRESSOR P53; BCL-2 FAMILY; APOPTOSIS; GENE; TARGET; CASPASE-9; PROTEINS; BINDING; DOMAIN; PUMA	p53 exerts its tumor suppressor effects by activating genes involved in cell growth arrest and programmed cell death. The p53 target genes inducing growth arrest are well defined whereas those inducing apoptosis are not fully characterized. Proapoptotic activity of p53 was shown to involve several genes like Bax, Noxa and Puma, which may function in the release of cytochrome c from the mitochondria. Cytochrome c associates with Apaf-1 and caspase 9 to form the apoptosome. Genetic and cellular data indicate that Apaf-1 deficiency abrogates the apoptotic effect of p53 and substitutes for p53 loss in promoting tumor formation. Here we show that Apaf-1, the mammalian homologue of C. elegans CED4, is a direct target of p53 as demonstrated by gel shift analysis of the target site sequence in the presence of p53 and by Apaf-1 promoter-luciferase assays. We also show that the p53 activation of the Apaf-1 luciferase construct can be enhanced by the putative tumor suppressor gene product, Zac-1, a transcription factor that has previously been shown to inhibit cell proliferation. Furthermore, we demonstrate that Zac-1 is a possible direct target of p53 since the sequence upstream to the first coding exon of Zac-1 contains a p53 recognition site and the luciferase construct containing this region is activated by p53. These results suggests the existence of a tightly controlled self amplifying mechanism of transcriptional activation leading to apoptosis by p53.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Chaim Sheba Med Ctr, Dept Pediat Hematooncol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	david.givol@weizmann.ac.il						Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Arima T, 2000, GENOMICS, V67, P248, DOI 10.1006/geno.2000.6266; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Huang SM, 2001, ONCOGENE, V20, P2134, DOI 10.1038/sj.onc.1204298; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Jia L, 2001, BLOOD, V98, P414, DOI 10.1182/blood.V98.2.414; Jiang XJ, 2000, J BIOL CHEM, V275, P31199, DOI 10.1074/jbc.C000405200; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MIYASHITA T, 1995, CELL, V80, P293; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Robles AI, 2001, CANCER RES, V61, P6660; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Varrault A, 2001, J BIOL CHEM, V276, P18653, DOI 10.1074/jbc.C100095200; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	35	55	56	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1469	1476		10.1038/sj.onc.1205218	http://dx.doi.org/10.1038/sj.onc.1205218			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896574				2022-12-25	WOS:000173956800001
J	Wu, YF; Renard, CA; Apiou, F; Huerre, M; Tiollais, P; Dutrillaux, B; Buendia, MA				Wu, YF; Renard, CA; Apiou, F; Huerre, M; Tiollais, P; Dutrillaux, B; Buendia, MA			Recurrent allelic deletions at mouse chromosomes 4 and 14 in Myc-induced liver tumors	ONCOGENE			English	Article						hepatocellular carcinoma; c-Myc; LOH; CGH; INK4A/ARF	BETA-CATENIN MUTATIONS; COPY NUMBER CHANGES; HEPATOCELLULAR-CARCINOMA; C-MYC; SUPPRESSOR GENE; TRANSGENIC MICE; HETEROZYGOSITY; VIRUS; FREQUENT; P53	Transgenic mice expressing the c-Myc oncogene driven by woodchuck hepatitis virus (WHV) regulatory sequences develop hepatocellular carcinoma with a high frequency. To investigate genetic lesions that cooperate with Myc in liver carcinogenesis, we conducted a genome-wide scan for loss of heterozygosity (LOH) and mutational analysis of beta-catenin in 37 hepatocellular adenomas and carcinomas from C57BL/6 x castaneus F1 transgenic mice. In a subset of these tumors, chromosome imbalances were examined by comparative genomic hybridization (CGH). Allelotyping with 99 microsatellite markers spanning all autosomes revealed allelic imbalances at one or more chromosomes in 83.8% of cases. The overall fractional allelic loss was rather low, with a mean index of 0.066. However, significant LOH rates involved chromosomes 4 (21.6% of tumors), 14, 9 and 1 (11 to 16%). Interstitial LOH on chromosome 4 was mapped at band C4-C7 that contains the INK4a/ARF and INK4b loci, and on chromosome 14 at band B - D including the RB locus. In man, the homologous chromosomal regions 9p21, 13q14 and 8p21 - 23 are frequently deleted in liver cancer. LOH at chromosomes 1 and 14, and beta-catenin mutations (12.5% of cases) were seen only in HCCs. All tumors examined were found to be aneuploid. CGH analysis of 10 representative cases revealed recurrent gains at chromosomes 16 and 19, but losses or deletions involving mostly chromosomes 4 and 14 generally prevailed over gains. Thus, Myc activation in the liver might select for inactivation of tumor suppressor genes on regions of chromosomes 4 and 14 in a context of low genomic instability. Myc transgenic mice provide a useful model for better defining crosstalks between oncogene and tumor suppressor pathways in liver tumorigenesis.	Inst Pasteur, Unite Recombinat & Express Genet, Dept Retrovirus, INSERM,U163, F-75724 Paris 15, France; Inst Pasteur, Unite Histopathol, F-75015 Paris, France; Inst Curie, CNRS, UMR 147, F-75231 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Buendia, MA (corresponding author), Inst Pasteur, Unite Recombinat & Express Genet, Dept Retrovirus, INSERM,U163, 28 Rue Dr Roux, F-75724 Paris 15, France.	mbuendia@pasteur.fr						Boige V, 1997, CANCER RES, V57, P1986; Bosch FX, 1997, LIVER CANCER, P13; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; DAVIS LM, 1994, CARCINOGENESIS, V15, P1637; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DIETRICH WF, 1994, P NATL ACAD SCI USA, V91, P9451, DOI 10.1073/pnas.91.20.9451; DURO D, 1995, ONCOGENE, V11, P21; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; ETIEMBLE J, 1994, ONCOGENE, V9, P727; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; HEGI ME, 1994, CANCER RES, V54, P6257; HERZOG CR, 1994, CANCER RES, V54, P4007; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hsu HC, 2000, AM J PATHOL, V157, P763, DOI 10.1016/S0002-9440(10)64590-7; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; Lander JK, 1997, J VIROL, V71, P3940, DOI 10.1128/JVI.71.5.3940-3952.1997; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; Liu P, 1997, HEPATOLOGY, V25, P874, DOI 10.1002/hep.510250415; Luttges J, 2001, AM J PATHOL, V158, P1677, DOI 10.1016/S0002-9440(10)64123-5; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Marchio AS, 2000, ONCOGENE, V19, P3733, DOI 10.1038/sj.onc.1203713; Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X; MURAKAMI Y, 1991, CANCER RES, V51, P5520; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Ogawa K, 1999, CARCINOGENESIS, V20, P2083, DOI 10.1093/carcin/20.11.2083; Pelengaris S, 2000, CURR OPIN GENET DEV, V10, P100, DOI 10.1016/S0959-437X(99)00046-5; QUELLE DE, 1995, CELL, V83, P993; Renard CA, 2000, ONCOGENE, V19, P2678, DOI 10.1038/sj.onc.1203617; Ritland SR, 1997, CANCER RES, V57, P3520; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; Sargent LM, 1999, AM J PATHOL, V154, P1047, DOI 10.1016/S0002-9440(10)65357-6; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Shao CS, 2001, NAT GENET, V28, P169, DOI 10.1038/88897; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sheu JC, 1999, BRIT J CANCER, V80, P468, DOI 10.1038/sj.bjc.6690380; Shi YP, 1997, GENE CHROMOSOME CANC, V19, P104, DOI 10.1002/(SICI)1098-2264(199706)19:2<104::AID-GCC6>3.3.CO;2-S; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300	48	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1518	1526		10.1038/sj.onc.1205208	http://dx.doi.org/10.1038/sj.onc.1205208			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896580				2022-12-25	WOS:000173956800007
J	Glick, M; Price, DA; Vuidepot, AL; Andersen, TB; Hutchinson, SL; Laugel, B; Sewell, AK; Boulter, JM; Dunbar, PR; Cerundolo, V; Oxenius, A; Bell, JI; Richards, WG; Jakobsen, BK				Glick, M; Price, DA; Vuidepot, AL; Andersen, TB; Hutchinson, SL; Laugel, B; Sewell, AK; Boulter, JM; Dunbar, PR; Cerundolo, V; Oxenius, A; Bell, JI; Richards, WG; Jakobsen, BK			Novel CD8(+) T cell antagonists based on beta(2)-microglobulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; DYNAMICS; COMPLEX; CTL; PEPTIDES; BINDING; ENERGY; DOMAIN	The CD8 coreceptor of cytotoxic T lymphocytes binds to a conserved region of major histocompatibility complex class I molecules during recognition of peptidemajor histocompatibility complex (AMC) class I antigens on the surface of target cells. This event is central to the activation of cytotoxic T lymphocyte (CTL) effector functions. The contribution of the AMC complex class I light chain, beta(2)-microglobulin, to CD8alphaalpha binding is relatively small and is mediated mainly through the lysine residue at position 58. Despite this, using molecular modeling, we predict that its mutation should have a dramatic effect on CD8aa binding. The predictions are confirmed using surface plasmon resonance binding studies and human CTL activation assays. Surprisingly, the charge-reversing mutation, Lys58 --> Glu, enhances beta(2)M-MHC class I heavy chain interactions. This mutation also significantly reduces CD8aa binding and is a potent antagonist of CTL activation. These results suggest a novel approach to CTL-specific therapeutic immunosuppression.	Avidex Ltd, Abingdon OX14 4RX, Oxon, England; Univ Oxford, Dept Chem, Cent Chem Lab, Oxford OX1 3QH, England; John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Jakobsen, BK (corresponding author), Avidex Ltd, 57 Milton Pk, Abingdon OX14 4RX, Oxon, England.		Sewell, Andrew/GPT-4220-2022; Oxenius, Annette/G-7794-2015; Dunbar, Rod/C-2570-2012; Price, David A/C-7876-2013	Sewell, Andrew/0000-0003-3194-3135; Dunbar, Rod/0000-0001-9626-2600; Price, David A/0000-0001-9416-2737; Cerundolo, Vincenzo/0000-0003-0040-3793				Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Broder CC, 1999, MOL BIOTECHNOL, V13, P223, DOI 10.1385/MB:13:3:223; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROOKS CL, 1989, J MOL BIOL, V208, P159, DOI 10.1016/0022-2836(89)90093-4; BRUNGER AT, 1987, BIOCHEMISTRY-US, V26, P5153; Dunbar PR, 1999, J IMMUNOL, V162, P6959; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; KOLLMAN P, 1993, CHEM REV, V93, P2395, DOI 10.1021/cr00023a004; LEHNER PJ, 1995, J EXP MED, V181, P79, DOI 10.1084/jem.181.1.79; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; MOSS PA, 1991, P NATL ACAD SCI USA, V20, P8987; O'Callaghan CA, 1999, ANAL BIOCHEM, V266, P9, DOI 10.1006/abio.1998.2930; Price DA, 1998, CURR BIOL, V8, P355, DOI 10.1016/S0960-9822(98)70138-1; Purbhoo MA, 2001, J BIOL CHEM, V276, P32786, DOI 10.1074/jbc.M102498200; ROCK KL, 1990, P NATL ACAD SCI USA, V87, P7517, DOI 10.1073/pnas.87.19.7517; Sewell AK, 1999, NAT MED, V5, P399, DOI 10.1038/7398; Shields MJ, 1998, J BIOL CHEM, V273, P28010, DOI 10.1074/jbc.273.43.28010; Tolfvenstam T, 2001, J VIROL, V75, P540, DOI 10.1128/JVI.75.1.540-543.2001; Whelan JA, 1999, J IMMUNOL, V163, P4342; Willcox BE, 1999, PROTEIN SCI, V8, P2418; Xu XN, 2001, IMMUNITY, V14, P591, DOI 10.1016/S1074-7613(01)00133-9	22	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20840	20846		10.1074/jbc.M201819200	http://dx.doi.org/10.1074/jbc.M201819200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11914379	hybrid			2022-12-25	WOS:000176204500095
J	Newby, LJ; Streets, AJ; Zhao, Y; Harris, PC; Ward, CJ; Ong, ACM				Newby, LJ; Streets, AJ; Zhao, Y; Harris, PC; Ward, CJ; Ong, ACM			Identification, characterization, and localization of a novel kidney polycystin-1-polycystin-2 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE PROTEIN; PLASMA-MEMBRANE; GENE-PRODUCT; CELL-LINES; PKD1; POLYCYSTIN-1; EXPRESSION; DISTRIBUTIONS; ANTIBODIES; INTERACTS	The functions of the two proteins defective in autosomal dominant polycystic kidney disease, polycystin-1 and polycystin-2, have not been fully clarified, but it has been hypothesized that they may heterodimerize to form a "polycystin complex" involved in cell adhesion. In this paper, we demonstrate for the first time the existence of a native polycystin complex in mouse kidney tubular cells transgenic for PKD1, non-transgenic kidney cells, and normal adult human kidney. Polycystin-1 is heavily N-glycosylated, and several glycosylated forms of polycystin-1 differing in their sensitivity to endoglycosidase H (Endo H) were found; in contrast, native polycystin-2 was fully Endo H-sensitive. Using highly specific antibodies to both proteins, we show that polycystin-2 associates selectively with two species of full-length polycystin-1, one Endo H-sensitive and the other Endo H-resistant; importantly, the latter could be further enriched in plasma membrane fractions and coimmunoprecipitated with poolycystin-2. Finally, a subpopulation of this complex co-localized to the lateral cell borders of PKD1 transgenic kidney cells. These results demonstrate that polycystin-1 and polycystin-2 interact in vivo to form a stable heterodimeric complex and suggest that disruption of this complex is likely to be of primary relevance to the pathogenesis of cyst formation in autosomal dominant polycystic kidney disease.	Univ Sheffield, Sect Med, Div Clin Sci, Sheffield Kidney Inst, Sheffield S5 7AU, S Yorkshire, England; Mayo Clin & Mayo Fdn, Div Nephrol, Dept Internal Med, Rochester, MN 55905 USA	University of Sheffield; Mayo Clinic	Ong, ACM (corresponding author), Univ Sheffield, No Gen Hosp, Med Sect, Sheffield Kidney Inst Clin Sci Ctr, Herries Rd, Sheffield S5 7AU, S Yorkshire, England.	a.ong@sheffield.ac.uk	Ong, Albert/AAN-9430-2021	Ong, Albert/0000-0002-7211-5400				ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; BESKROVNAYA OI, 2000, HUM MOL GENET, V9, P1641, DOI DOI 10.1093/HMG/9.11.1641; Boletta A, 2000, MOL CELL, V6, P1267, DOI 10.1016/S1097-2765(00)00123-4; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; Charron AJ, 2000, J CELL BIOL, V149, P111, DOI 10.1083/jcb.149.1.111; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; Foggensteiner L, 2000, J AM SOC NEPHROL, V11, P814, DOI 10.1681/ASN.V115814; Gallagher AR, 2000, P NATL ACAD SCI USA, V97, P4017, DOI 10.1073/pnas.97.8.4017; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; GREEN M, 1982, CELL, V257, P9039; Grupp C, 1998, EXP NEPHROL, V6, P542; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; IbraghimovBeskrovnaya O, 1997, P NATL ACAD SCI USA, V94, P6397, DOI 10.1073/pnas.94.12.6397; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Lehtonen S, 2000, J BIOL CHEM, V275, P32888, DOI 10.1074/jbc.M006624200; Lohning C, 1997, MAMM GENOME, V8, P307, DOI 10.1007/s003359900429; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; MAN NT, 1991, J CELL BIOL, V115, P1695; Markowitz GS, 1999, AM J PHYSIOL-RENAL, V277, pF17, DOI 10.1152/ajprenal.1999.277.1.F17; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; Obermuller N, 1999, AM J PHYSIOL-RENAL, V277, pF914, DOI 10.1152/ajprenal.1999.277.6.F914; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; Ong ACM, 1999, AM J PATHOL, V154, P1721, DOI 10.1016/S0002-9440(10)65428-4; Ong ACM, 1997, LANCET, V349, P1039, DOI 10.1016/S0140-6736(05)62286-6; Ong ACM, 2000, EXP NEPHROL, V8, P208; Ong ACM, 1999, KIDNEY INT, V56, P1324, DOI 10.1046/j.1523-1755.1999.00659.x; POLLACK L, 1983, J CELL BIOL, V97, P293, DOI 10.1083/jcb.97.2.293; Pritchard L, 2000, HUM MOL GENET, V9, P2617, DOI 10.1093/hmg/9.18.2617; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; ROTHMAN JE, 1980, P NATL ACAD SCI-BIOL, V77, P780, DOI 10.1073/pnas.77.2.780; Scheffers MS, 2000, HUM MOL GENET, V9, P2743, DOI 10.1093/hmg/9.18.2743; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; Ward CJ, 1996, P NATL ACAD SCI USA, V93, P1524, DOI 10.1073/pnas.93.4.1524; WARD CJ, 1994, CELL, V77, P881; Watnick T, 2000, NAT GENET, V25, P143, DOI 10.1038/75981; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5	44	158	164	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20763	20773		10.1074/jbc.M107788200	http://dx.doi.org/10.1074/jbc.M107788200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11901144	hybrid, Green Accepted			2022-12-25	WOS:000176204500086
J	Saydam, N; Adams, TK; Steiner, F; Schaffner, W; Freedman, JH				Saydam, N; Adams, TK; Steiner, F; Schaffner, W; Freedman, JH			Regulation of metallothionein transcription by the metal-responsive transcription factor MTF-1 - Identification of signal transduction cascades that control metal-inducible transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; I GENE; OXIDATIVE STRESS; MESSENGER-RNA; C-JUN; BINDING-ACTIVITY; HEAVY-METALS; ZINC; INDUCTION; ELEMENT	Every living organism must detoxify nonessential metals and carefully control the intracellular concentration of essential metals. Metallothioneins, which are small, eysteine-rich, metal-binding proteins, play an important role in these processes. In addition, the transcription of their cognate genes is activated in response to metal exposure. The zinc finger transcription factor MTF-1 plays a central role in the metal-inducible transcriptional activation of metallothionein and other genes involved in metal homeostasis and cellular stress response. Here we report that the phosphorylation of MTF-1 plays a critical role in its activation by zinc and cadmium. Inhibitor studies indicate that multiple kinases and signal transduction cascades, including those mediated by protein kinase C, tyrosine kinase, and casein kinase 11, are essential for zinc- and cadmium-inducible transcriptional activation. In addition, calcium signaling is also involved in regulating metal-activated transcription. In contrast, cAMP-dependent protein kinase may not be directly involved in the metal response. Contrary to what has been reported for other transcription factors, inhibition of transcriptional activation does not impair the binding of MTF-1 to DNA, suggesting that phosphorylation is not regulating DNA binding. Elevated phosphorylation of MTF-1 is observed tinder condition of protein kinase C inhibition, suggesting that specific dephosphorylation of this transcription factor contributes to its activation.	Duke Univ, Nicholas Sch Environm & Earth Sci, Durham, NC 27708 USA; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland	Duke University; University of Zurich	Freedman, JH (corresponding author), Duke Univ, Nicholas Sch Environm & Earth Sci, Durham, NC 27708 USA.	jonf@duke.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009949] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES09949] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS TK, 2000, METAL IONS BIOL MED, V6, P694; Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; ARIZONO K, 1993, LIFE SCI, V53, P1031, DOI 10.1016/0024-3205(93)90126-N; Athie-M V, 2000, EUR J IMMUNOL, V30, P1425, DOI 10.1002/(SICI)1521-4141(200005)30:5<1425::AID-IMMU1425>3.0.CO;2-Q; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Beyersmann D, 1997, TOXICOL APPL PHARM, V144, P247, DOI 10.1006/taap.1997.8125; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; Bittel DC, 2000, J BIOL CHEM, V275, P37194, DOI 10.1074/jbc.M003863200; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; Chen JP, 1998, ZOOL STUD, V37, P111; Chen XH, 1999, BIOCHEMISTRY-US, V38, P12915, DOI 10.1021/bi9913000; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; Dalton TP, 2000, COMP BIOCHEM PHYS B, V126, P325, DOI 10.1016/S0305-0491(00)00182-6; Datta PK, 1997, BIOCHEM BIOPH RES CO, V230, P159, DOI 10.1006/bbrc.1996.5655; Ding W, 2000, BIOCHEM BIOPH RES CO, V273, P718, DOI 10.1006/bbrc.2000.3009; DURNAM DM, 1984, MOL CELL BIOL, V4, P484, DOI 10.1128/MCB.4.3.484; FREEDMAN JH, 1989, BIOCHEM BIOPH RES CO, V164, P134, DOI 10.1016/0006-291X(89)91693-8; GARRETT SH, 1992, INT J BIOCHEM, V24, P1669, DOI 10.1016/0020-711X(92)90186-5; Gerber DA, 2000, J BIOL CHEM, V275, P23919, DOI 10.1074/jbc.M002697200; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; Hermesz E, 2001, COMP BIOCHEM PHYS C, V128, P457, DOI 10.1016/S1532-0456(01)00165-X; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1980, NATURE, V286, P295, DOI 10.1038/286295a0; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kelly EJ, 1997, P NATL ACAD SCI USA, V94, P10045, DOI 10.1073/pnas.94.19.10045; LaRochelle O, 2001, J BIOL CHEM, V276, P41879, DOI 10.1074/jbc.M108313200; Laychock SG, 2000, MOL CELL ENDOCRINOL, V165, P179, DOI 10.1016/S0303-7207(00)00247-1; Lichtlen P, 2001, NUCLEIC ACIDS RES, V29, P1514, DOI 10.1093/nar/29.7.1514; Masuya Y, 1998, J BIOCHEM-TOKYO, V124, P628; Maur AAD, 1999, BIOL CHEM, V380, P175, DOI 10.1515/BC.1999.026; Murphy BJ, 1999, CANCER RES, V59, P1315; NEBES VL, 1988, BIOCHEM J, V255, P741; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; Pfundt R, 2001, J PATHOL, V193, P248; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RADTKE F, 1995, NUCLEIC ACIDS RES, V23, P2277, DOI 10.1093/nar/23.12.2277; RIMOLDI D, 1992, RADIAT RES, V131, P325, DOI 10.2307/3578423; Samson SLA, 1998, PROG NUCLEIC ACID RE, V59, P257, DOI 10.1016/S0079-6603(08)61034-X; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; Saydam N, 2001, J BIOL CHEM, V276, P25487, DOI 10.1074/jbc.M009154200; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; SEARLE PF, 1990, NUCLEIC ACIDS RES, V18, P4683, DOI 10.1093/nar/18.16.4683; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; Smirnova IV, 2000, J BIOL CHEM, V275, P9377, DOI 10.1074/jbc.275.13.9377; Stohs Sidney J., 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P201; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; Viarengo A, 2000, CELL MOL BIOL, V46, P407; WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263; Winge DR, 1998, PROG NUCLEIC ACID RE, V58, P165; Yu CW, 1997, FEBS LETT, V420, P69, DOI 10.1016/S0014-5793(97)01489-0; YU CW, 1995, BBA-GENE STRUCT EXPR, V1262, P150, DOI 10.1016/0167-4781(95)00070-W; Zhang B, 2001, MOL CELL BIOL, V21, P4505, DOI 10.1128/MCB.21.14.4505-4514.2001	63	146	152	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20438	20445		10.1074/jbc.M110631200	http://dx.doi.org/10.1074/jbc.M110631200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923282	hybrid			2022-12-25	WOS:000176204500044
J	Shen, JL; Montecino, M; Lian, JB; Stein, GS; van Wijnen, AJ; Stein, JL				Shen, JL; Montecino, M; Lian, JB; Stein, GS; van Wijnen, AJ; Stein, JL			Historic acetylation in vivo at the osteocalcin locus is functionally linked to vitamin D-dependent, bone tissue-specific transcription.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DNA INTERACTIONS; CHROMATIN-STRUCTURE; PROMOTER ELEMENTS; GENE-EXPRESSION; RETINOIC ACID; UP-REGULATION; RECEPTOR; HYPERACETYLATION; ACTIVATION; HORMONE	The accessibility of regulatory elements in chromatin represents a principal rate-limiting parameter of gene transcription and is modulated by enzymatic transcriptional co-factors that alter the topology of chromatin or covalently modify histones (e.g. by acetylation). The bone-specific activation and 1,25-dihydroxyvitamin D-3 enhancement of osteocalcin (OC) gene transcription are both functionally linked to modifications in nucleosomal organization. The initiation of tissue-specific basal transcription is accompanied by the induction of two DNase I hypersensitive sites, and this chromatin remodeling event requires binding of the key osteogenic factor RUNX2/CBFA1 to the OC promoter. Here, we analyzed the acetylation status of histones H3 and H4 when the OC gene is active (in osteoblastic ROS17/2.8 cells) or inactive (in fibroblastic ROS24/1 cells) using chromatin immunoprecipitation assays. We find that acetylated histone H3 and H4 proteins are associated with the OC promoter only when the gene is transcriptionally active and that the acetylation status is relatively uniform across the OC locus under basal conditions. Acetylation of H4 at the OC gene is selectively increased following vitamin D3 enhancement of OC transcription, with the most prominent changes occurring in the region between the vitamin D3 enhancer and basal promoter. Thus, our results suggest functional linkage of H3 and H4 acetylation in specific regions of the OC promoter to chromatin remodeling that accompanies tissue-specific transcriptional activation and vitamin D enhancement of OC gene expression. These findings provide mechanistic insights into bone-specific gene activation within a native genomic context in response to steroid hormone-related regulatory cues.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Concepcion, Dept Mol Biol, Concepcion, Chile	University of Massachusetts System; University of Massachusetts Worcester; Universidad de Concepcion	Stein, JL (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	janet.stein@umassmed.edu	van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045689, R01AR039588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE012528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012528] Funding Source: NIH RePORTER; FIC NIH HHS [TW00990] Funding Source: Medline; NIAMS NIH HHS [AR39588, AR45689] Funding Source: Medline; NIDCR NIH HHS [DE12528] Funding Source: Medline; NIDDK NIH HHS [DK52320] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aalfs JD, 2000, TRENDS BIOCHEM SCI, V25, P548, DOI 10.1016/S0968-0004(00)01689-3; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<73::AID-JCB11>3.0.CO;2-L; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARAN DT, 1991, J BONE MINER RES, V6, P1269; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BREEN EC, 1994, P NATL ACAD SCI USA, V91, P12902, DOI 10.1073/pnas.91.26.12902; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; Christenson LK, 2001, J BIOL CHEM, V276, P27392, DOI 10.1074/jbc.M101650200; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DEMAY MB, 1989, J BIOL CHEM, V264, P2279; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Gilbert SL, 1999, P NATL ACAD SCI USA, V96, P13825, DOI 10.1073/pnas.96.24.13825; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gui CY, 2001, MOL CELL BIOL, V21, P1155, DOI 10.1128/MCB.21.4.1155-1163.2001; Guo B, 1997, P NATL ACAD SCI USA, V94, P121, DOI 10.1073/pnas.94.1.121; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Javed A, 1999, MOL CELL BIOL, V19, P7491; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; Lian JB, 1999, VITAM HORM, V55, P443; Lian JB, 1998, BIOCHEM SOC T, V26, P14, DOI 10.1042/bst0260014; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; MARKOSE ER, 1990, P NATL ACAD SCI USA, V87, P1701, DOI 10.1073/pnas.87.5.1701; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Montecino M, 1999, BIOCHEMISTRY-US, V38, P1338, DOI 10.1021/bi982171a; Montecino M, 1996, BIOCHEMISTRY-US, V35, P5093, DOI 10.1021/bi952489s; MONTECINO M, 1994, BIOCHEMISTRY-US, V33, P348, DOI 10.1021/bi00167a045; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; Nagata T, 1999, NAT STRUCT BIOL, V6, P615; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; OWEN TA, 1991, ENDOCRINOLOGY, V128, P1496, DOI 10.1210/endo-128-3-1496; OWEN TA, 1993, P NATL ACAD SCI USA, V90, P1503, DOI 10.1073/pnas.90.4.1503; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13615, DOI 10.1021/bi00212a029; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; RODAN SB, 1986, J BONE MINER RES, V1, P213; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Staal A, 1996, MOL ENDOCRINOL, V10, P1444, DOI 10.1210/me.10.11.1444; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Urnov FD, 2001, ONCOGENE, V20, P2991, DOI 10.1038/sj.onc.1204323; Vitolo JM, 2000, MOL CELL BIOL, V20, P2167, DOI 10.1128/MCB.20.6.2167-2175.2000; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; WOLFE SA, 1989, BIOCHIM BIOPHYS ACTA, V1007, P140, DOI 10.1016/0167-4781(89)90032-8; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217	59	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20284	20292		10.1074/jbc.M112440200	http://dx.doi.org/10.1074/jbc.M112440200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11893738	hybrid			2022-12-25	WOS:000176204500026
J	Yang, YL; Dong, B; Mittelstadt, PR; Xiao, H; Ashwell, JD				Yang, YL; Dong, B; Mittelstadt, PR; Xiao, H; Ashwell, JD			HIV tat binds Egr proteins and enhances Egr-dependent transactivation of the Fas ligand promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CD4(+) T-CELLS; UP-REGULATION; TRANSCRIPTION FACTOR; CYCLOSPORINE-A; DOWN-REGULATION; RETINOIC ACID; EXPRESSION; ACTIVATION; APOPTOSIS	HIV Tat can enhance activation-induced up-regulation of Fas ligand (Fast,), which may contribute to T cell apoptosis in human immune deficiency virus (HIV)-infected individuals. We have assessed functional and physical interactions between Tat and the Egr family of transcription factors (Egr-1, -2, and -3), the latter two of which are major participants in activation-induced Fast, up-regulation. Here we report that whereas Tat itself has no effect on the Fast, promoter, it binds to Egr-2 and -3 and synergizes with them to superinduce expression of a Fast, promoter-driven reporter. A Tat molecule containing a single amino acid substitution that results in the loss of transactivation activity for the HIV long terminal repeat still binds Egr-3 but can no longer enhance Egr-mediated transactivation of the Fast, promoter. Furthermore, the mutated Tat acts as a dominant negative inhibitor, blocking the superinduction of Fast, caused by wild type Tat. Because Tat is present in virus-infected cells and in the serum of HIV-infected individuals, these results suggest that increased expression of Fast, in these circumstances may result from the cooperative activities of activation-induced Egrs and Tat.	NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA; Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rockefeller University	Ashwell, JD (corresponding author), NCI, Lab Immune Cell Biol, NIH, Bldg 10,Rm 1B-40, Bethesda, MD 20892 USA.	jda@pop.nci.nih.gov						Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Alexander L, 1997, J VIROL, V71, P6094, DOI 10.1128/JVI.71.8.6094-6099.1997; Algeciras A, 1998, J EXP MED, V187, P711, DOI 10.1084/jem.187.5.711; Badley AD, 1996, J VIROL, V70, P199, DOI 10.1128/JVI.70.1.199-206.1996; Bartz SR, 1999, J VIROL, V73, P1956, DOI 10.1128/JVI.73.3.1956-1963.1999; Baumler CB, 1996, BLOOD, V88, P1741; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; Bohler T, 1997, BLOOD, V90, P886, DOI 10.1182/blood.V90.2.886.886_886_887; Boykins RA, 1999, J IMMUNOL, V163, P15; Brunner T, 2000, J BIOL CHEM, V275, P9767, DOI 10.1074/jbc.275.13.9767; Brunner T, 1996, INT IMMUNOL, V8, P1017, DOI 10.1093/intimm/8.7.1017; Carroll IR, 1998, MOL IMMUNOL, V35, P1171, DOI 10.1016/S0161-5890(98)00107-2; Chow WA, 2000, J IMMUNOL, V164, P3512, DOI 10.4049/jimmunol.164.7.3512; Conant K, 1998, P NATL ACAD SCI USA, V95, P3117, DOI 10.1073/pnas.95.6.3117; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DEBATIN KM, 1994, BLOOD, V83, P3101, DOI 10.1182/blood.V83.10.3101a.3101a; Dockrell DH, 1998, J CLIN INVEST, V101, P2394, DOI 10.1172/JCI1171; DU ZJ, 1995, CELL, V82, P665, DOI 10.1016/0092-8674(95)90038-1; Gandhi RT, 1998, J EXP MED, V187, P1113, DOI 10.1084/jem.187.7.1113; Genestier L, 1999, J EXP MED, V189, P231, DOI 10.1084/jem.189.2.231; Glynn JM, 1996, J IMMUNOL, V157, P2754; Gougeon ML, 1999, ANN NY ACAD SCI, V887, P199, DOI 10.1111/j.1749-6632.1999.tb07934.x; Herbein G, 1998, J VIROL, V72, P660, DOI 10.1128/JVI.72.1.660-670.1998; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Hosaka N, 1998, J INFECT DIS, V178, P1030, DOI 10.1086/515700; HOWCROFT TK, 1993, SCIENCE, V260, P1320, DOI 10.1126/science.8493575; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Ju S T, 1999, Int Rev Immunol, V18, P485, DOI 10.3109/08830189909088495; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; KATSIKIS PD, 1995, J EXP MED, V181, P2029, DOI 10.1084/jem.181.6.2029; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; Lafrenie RM, 1996, J IMMUNOL, V157, P974; Lafrenie RM, 1997, J IMMUNOL, V159, P4077; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; Li-Weber M, 2000, EUR J IMMUNOL, V30, P661, DOI 10.1002/1521-4141(200002)30:2<661::AID-IMMU661>3.3.CO;2-C; MAGES HW, 1993, INT IMMUNOL, V5, P63, DOI 10.1093/intimm/5.1.63; Matsui K, 2000, J IMMUNOL, V164, P3002, DOI 10.4049/jimmunol.164.6.3002; Matsui K, 1998, J IMMUNOL, V161, P3469; Mitra D, 1996, IMMUNOLOGY, V87, P581, DOI 10.1046/j.1365-2567.1996.510589.x; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; Mittelstadt PR, 1999, J BIOL CHEM, V274, P3222, DOI 10.1074/jbc.274.5.3222; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Noraz N, 1997, AIDS, V11, P1671, DOI 10.1097/00002030-199714000-00003; Oyaizu N, 1997, J IMMUNOL, V158, P2456; Rengarajan J, 2000, IMMUNITY, V12, P293, DOI 10.1016/S1074-7613(00)80182-X; RUSSELL JH, 1995, CURR OPIN IMMUNOL, V7, P382, DOI 10.1016/0952-7915(95)80114-6; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; Silvestris F, 1998, AIDS, V12, P1103; Sloand EM, 1997, BLOOD, V89, P1357, DOI 10.1182/blood.V89.4.1357; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; Xiao H, 2000, EMBO J, V19, P956, DOI 10.1093/emboj/19.5.956; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146; Xu XN, 1999, J EXP MED, V189, P1489, DOI 10.1084/jem.189.9.1489; Xu XN, 1997, J EXP MED, V186, P7, DOI 10.1084/jem.186.1.7; Yagi T, 1998, J ACQ IMMUN DEF SYND, V18, P307, DOI 10.1097/00042560-199808010-00001; YANG Y, 1995, J BIOL CHEM, V270, P18672, DOI 10.1074/jbc.270.31.18672; Yang Y, 2001, APOPTOSIS, V6, P139, DOI 10.1023/A:1009600901706; Yang YL, 1998, IMMUNOPHARMACOLOGY, V40, P139, DOI 10.1016/S0162-3109(98)00036-8; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673	68	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19482	19487		10.1074/jbc.M201687200	http://dx.doi.org/10.1074/jbc.M201687200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11909874	hybrid			2022-12-25	WOS:000175894800034
J	Smith, GAM; Tsui, HW; Newell, EW; Jiang, XP; Zhu, XP; Tsui, FWL; Schlichter, LC				Smith, GAM; Tsui, HW; Newell, EW; Jiang, XP; Zhu, XP; Tsui, FWL; Schlichter, LC			Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG QT SYNDROME; POTASSIUM CHANNEL; CARDIAC-ARRHYTHMIA; VOLUME REGULATION; T-LYMPHOCYTES; NEURONAL DEVELOPMENT; NEUROBLASTOMA-CELLS; MOUSE FIBROBLASTS; RAT LACTOTROPHS; LEUKEMIA-CELLS	Kv1.3 channels regulate proliferation of normal lymphocytes, but the role of voltage-gated potassium channels in transformed hematopoietic cells is not known. We examined transcripts for Kv1.3, h-erg, h-eag, and BEC1 genes in primary lymphocytes and leukemias and in several hematopoietic cell lines. Surprisingly, BEC1, formerly thought to be brain-specific, was present in all the primary leukemias examined, in resting peripheral blood lymphocytes, and in proliferating activated tonsillar cells, lymphocytes from Sjogren's patients, and Epstein-Barr virus-transformed B-cells. Only h-erg mRNA was up-regulated in the cancer cells, but this was not due to proliferation per se, because it was not elevated in any of the proliferating noncancerous lymphocyte types examined. Nor did h-erg transcript levels correlate with the B-cell subset, because it was elevated in immature neoplastic B-CLL cells (CD5(+)) and in a CD5(-) Burkitt's lymphoma cell line (Raji) but not in Sjogren's syndrome cells (enriched in CD5(+) B-cells) or Epstein-Barr virus-transformed B-cells, which are mature CD5(-) B-cells. The protein and whole cell current levels roughly corresponded with the amount of mRNA expressed in three hematopoietic cell lines: CEM (an acute lymphoblastic leukemic line), K562 (a chronic myelogenous leukemic line), and U937 (an acute promyelocytic leukemic line). The selective HERG channel blocker, E-4031, reduced proliferation of CEM, U937, and K562 cells, and this appears to be the first direct evidence of a functional role for the HERG current in cancer cells. Selective up-regulation of h-erg appears to occur in neoplastic hematopoietic cells, thus providing a marker and potential therapeutic target.	Toronto Western Res Inst, Div Cellular & Mol Biol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Schlichter, LC (corresponding author), Toronto Western Res Inst, Div Cellular & Mol Biol, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.		Newell, Evan W/F-9711-2012	Newell, Evan W/0000-0002-2889-243X				Ackerman MJ, 1997, NEW ENGL J MED, V336, P1575, DOI 10.1056/NEJM199705293362207; Arcangeli A, 1999, J NEUROBIOL, V40, P214; Arcangeli A, 1997, EUR J NEUROSCI, V9, P2596, DOI 10.1111/j.1460-9568.1997.tb01689.x; Arcangeli A, 1995, J PHYSIOL-LONDON, V489, P455, DOI 10.1113/jphysiol.1995.sp021065; Avdonin V, 1998, P NATL ACAD SCI USA, V95, P11703, DOI 10.1073/pnas.95.20.11703; Barros F, 1998, J PHYSIOL-LONDON, V511, P333, DOI 10.1111/j.1469-7793.1998.333bh.x; Bauer CK, 1999, MOL CELL ENDOCRINOL, V148, P37, DOI 10.1016/S0303-7207(98)00241-X; Beeton C, 2001, P NATL ACAD SCI USA, V98, P13942, DOI 10.1073/pnas.241497298; Bianchi L, 1998, CANCER RES, V58, P815; Bruggemann A, 1997, P NATL ACAD SCI USA, V94, P537, DOI 10.1073/pnas.94.2.537; Cabado AG, 2000, CELL SIGNAL, V12, P573, DOI 10.1016/S0898-6568(00)00101-7; Cahalan MD, 2001, J CLIN IMMUNOL, V21, P235, DOI 10.1023/A:1010958907271; CAYABYAB FS, 2002, J BIOL CHEM     0207; Cherubini A, 2000, BRIT J CANCER, V83, P1722, DOI 10.1054/bjoc.2000.1497; Chiesa N, 1997, J PHYSIOL-LONDON, V501, P313, DOI 10.1111/j.1469-7793.1997.313bn.x; Cui J, 2000, CURR BIOL, V10, P671, DOI 10.1016/S0960-9822(00)00516-9; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Decker K, 1998, N-S ARCH PHARMACOL, V357, P378, DOI 10.1007/PL00005182; DECOURSEY TE, 1999, INFLAMMATION BASIC P, P639; DEUTSCH C, 1993, P NATL ACAD SCI USA, V90, P10036, DOI 10.1073/pnas.90.21.10036; DIGHIERO G, 1991, BLOOD, V78, P581; DRAHEIM HJ, 1995, BBA-MOL CELL RES, V1269, P57, DOI 10.1016/0167-4889(95)00106-3; DUBOIS JM, 1993, PROG BIOPHYS MOL BIO, V59, P1, DOI 10.1016/0079-6107(93)90005-5; Emmi A, 2000, J NEUROSCI, V20, P3915, DOI 10.1523/JNEUROSCI.20-10-03915.2000; Ficker E, 2001, MOL PHARMACOL, V60, P1343, DOI 10.1124/mol.60.6.1343; Furutani M, 1999, CIRCULATION, V99, P2290, DOI 10.1161/01.CIR.99.17.2290; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; Hofmann G, 2001, J BIOL CHEM, V276, P4923, DOI 10.1074/jbc.M005682200; HUANG Y, 1994, J BIOL CHEM, V269, P31183; Jones LJ, 2001, J IMMUNOL METHODS, V254, P85, DOI 10.1016/S0022-1759(01)00404-5; KAPURAL L, 1995, BLOOD, V86, P1043; Khanna R, 2001, AM J PHYSIOL-CELL PH, V280, pC796, DOI 10.1152/ajpcell.2001.280.4.C796; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Kiehn J, 1999, AM J PHYSIOL-HEART C, V277, pH199, DOI 10.1152/ajpheart.1999.277.1.H199; Koo GC, 1997, J IMMUNOL, V158, P5120; Kotecha SA, 1999, J NEUROSCI, V19, P10680, DOI 10.1523/JNEUROSCI.19-24-10680.1999; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LU L, 1993, J MEMBRANE BIOL, V132, P267; Miyake A, 1999, J BIOL CHEM, V274, P25018, DOI 10.1074/jbc.274.35.25018; Nerbonne JM, 1998, J NEUROBIOL, V37, P37, DOI 10.1002/(SICI)1097-4695(199810)37:1<37::AID-NEU4>3.0.CO;2-9; NILIUS B, 1994, NEWS PHYSIOL SCI, V9, P105; NILIUS B, 1992, J PHYSIOL-LONDON, V445, P537, DOI 10.1113/jphysiol.1992.sp018938; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Pardo LA, 1998, J CELL BIOL, V143, P767, DOI 10.1083/jcb.143.3.767; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; Reed JC, 1997, SEMIN HEMATOL, V34, P9; REPP H, 1993, P NATL ACAD SCI USA, V90, P3403, DOI 10.1073/pnas.90.8.3403; Sanguinetti MC, 1997, NEUROPHARMACOLOGY, V36, P755, DOI 10.1016/S0028-3908(97)00029-4; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Schafer R, 1999, J PHYSIOL-LONDON, V518, P401, DOI 10.1111/j.1469-7793.1999.0401p.x; SCHLICHTER L, 1986, P NATL ACAD SCI USA, V83, P451, DOI 10.1073/pnas.83.2.451; Schonherr R, 1999, EUR J NEUROSCI, V11, P753, DOI 10.1046/j.1460-9568.1999.00493.x; Schwarz J R, 1999, Ross Fiziol Zh Im I M Sechenova, V85, P195; Shi WM, 1997, J NEUROSCI, V17, P9423; Skryma RN, 1997, PROSTATE, V33, P112, DOI 10.1002/(SICI)1097-0045(19971001)33:2<112::AID-PROS5>3.0.CO;2-M; Smith JS, 2001, J NEUROSCI, V21, P1096; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Spector PS, 1996, CIRC RES, V78, P499, DOI 10.1161/01.RES.78.3.499; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; TEULON J, 1992, J CELL PHYSIOL, V151, P113, DOI 10.1002/jcp.1041510116; Titus SA, 1997, J NEUROSCI, V17, P875; Voutsadakis IA, 2000, ACTA ONCOL, V39, P151, DOI 10.1080/028418600430707; Wang L, 1997, AM J PHYSIOL-CELL PH, V273, pC1657, DOI 10.1152/ajpcell.1997.273.5.C1657; Wang SM, 1997, J PHYSIOL-LONDON, V502, P45, DOI 10.1111/j.1469-7793.1997.045bl.x; Wonderlin WF, 1996, J MEMBRANE BIOL, V154, P91, DOI 10.1007/s002329900135; Wymore RS, 1997, CIRC RES, V80, P261, DOI 10.1161/01.RES.80.2.261; Xu B, 1996, AM J PHYSIOL-CELL PH, V271, pC2037, DOI 10.1152/ajpcell.1996.271.6.C2037; Xu DZ, 1999, BLOOD, V94, P139, DOI 10.1182/blood.V94.1.139.413k11_139_145; Yoshida Hideaki, 2000, Hokkaido Journal of Medical Science, V75, P375; Zhou W, 1998, J GEN PHYSIOL, V111, P781, DOI 10.1085/jgp.111.6.781; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061; Zigrino P, 1996, BIOCHEM BIOPH RES CO, V221, P51, DOI 10.1006/bbrc.1996.0543	73	165	178	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18528	18534		10.1074/jbc.M200592200	http://dx.doi.org/10.1074/jbc.M200592200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893742	hybrid			2022-12-25	WOS:000175975800038
J	Burgess, HA; Reiner, O				Burgess, HA; Reiner, O			Alternative splice variants of doublecortin-like kinase are differentially expressed and have different kinase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CALPAIN-MEDIATED PROTEOLYSIS; TRACT-BINDING-PROTEIN; RNA-BINDING; RAT HIPPOCAMPUS; GENE STRUCTURE; MESSENGER-RNA; MU-CALPAIN; AUTOINHIBITION; KIAA0369	Alternative splicing of mRNA transcripts expands the range of protein products from a single gene locus. Several splice variants of DCLK (doublecortin-like kinase) have previously been reported. Here, we report the genomic organization underlying the splice variants of DCLK and examine the expression profile of two splice variants affecting the kinase domain of DCLK and CPG16 (candidate plasticity gene 16), one containing an Arg-rich domain and the other affecting the C terminus of the protein. These splice alternatives were differentially expressed in embryonic and adult brain. Both splice variants disrupted DCLK PEST domains; however, all splice variants remained sensitive to proteolysis by calpain. The adult-specific C-terminal splice variant of DCLK had reduced autophosphorylation activity, but similar kinase activity for myelin basic protein relative to the embryonic splice variant. The splice variant adding an Arg-rich domain gained an autophosphorylation site at Ser-382. Although this protein isoform was expressed mainly in the adult brain, the phosphorylated form was strongly enriched in embryonic brain and adult olfactory bulb, suggesting a possible role in migrating neurons.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Reiner, O (corresponding author), Weizmann Inst Sci, Dept Mol Genet, Herzl 2, IL-76100 Rehovot, Israel.	Orly.Reiner@weizmann.ac.il	Reiner, Orly/E-9455-2010; Burgess, Harold/B-8474-2015	Reiner, Orly/0000-0001-7560-9599; Burgess, Harold/0000-0003-1966-7801				AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; Batzoglou S, 2000, GENOME RES, V10, P950, DOI 10.1101/gr.10.7.950; Berke JD, 1998, J NEUROSCI, V18, P5301, DOI 10.1523/JNEUROSCI.18-14-05301.1998; Burgess HA, 2001, J BIOL CHEM, V276, P36397, DOI 10.1074/jbc.M105153200; Burgess HA, 1999, J NEUROSCI RES, V58, P567, DOI 10.1002/(SICI)1097-4547(19991115)58:4<567::AID-JNR9>3.3.CO;2-K; Burgess HA, 2000, MOL CELL NEUROSCI, V16, P529, DOI 10.1006/mcne.2000.0891; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Carillo S, 1996, BIOCHEM J, V313, P245, DOI 10.1042/bj3130245; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Chou MY, 2000, MOL CELL, V5, P949, DOI 10.1016/S1097-2765(00)80260-9; Decatur AL, 2000, SCIENCE, V290, P992, DOI 10.1126/science.290.5493.992; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; Gonczy P, 2001, DEV CELL, V1, P363, DOI 10.1016/S1534-5807(01)00046-6; Groenen PJTA, 2000, HUM MOL GENET, V9, P605, DOI 10.1093/hmg/9.4.605; Hirano F, 1998, MOL CELL BIOL, V18, P2596, DOI 10.1128/MCB.18.5.2596; Jensen KB, 2000, NEURON, V25, P359, DOI 10.1016/S0896-6273(00)80900-9; Kan ZY, 2001, GENOME RES, V11, P889, DOI 10.1101/gr.155001; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lazaridis KN, 2000, P NATL ACAD SCI USA, V97, P11092, DOI 10.1073/pnas.200325297; Lin PT, 2000, J NEUROSCI, V20, P9152; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Matsumoto N, 1999, GENOMICS, V56, P179, DOI 10.1006/geno.1998.5673; Mironov AA, 1999, GENOME RES, V9, P1288, DOI 10.1101/gr.9.12.1288; Mizuguchi M, 1999, AM J PATHOL, V155, P1713, DOI 10.1016/S0002-9440(10)65486-7; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; MOLINARI M, 1995, J BIOL CHEM, V270, P14576, DOI 10.1074/jbc.270.24.14576; Omori Y, 1998, J HUM GENET, V43, P169, DOI 10.1007/s100380050063; Petersen-Mahrt SK, 1999, EMBO J, V18, P1014, DOI 10.1093/emboj/18.4.1014; Polydorides AD, 2000, P NATL ACAD SCI USA, V97, P6350, DOI 10.1073/pnas.110128397; PoteetSmith CE, 1997, J BIOL CHEM, V272, P379; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Shumway SD, 1999, J BIOL CHEM, V274, P30874, DOI 10.1074/jbc.274.43.30874; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Silverman MA, 1999, J BIOL CHEM, V274, P2631, DOI 10.1074/jbc.274.5.2631; Sossey-Alaoui K, 1999, GENOMICS, V56, P121, DOI 10.1006/geno.1998.5718; STAMM S, 1994, NUCLEIC ACIDS RES, V22, P1515, DOI 10.1093/nar/22.9.1515; Sultana T, 2000, ENDOCRINOLOGY, V141, P4413, DOI 10.1210/en.141.12.4413; Tokumitsu H, 1999, J BIOL CHEM, V274, P15803, DOI 10.1074/jbc.274.22.15803; Vreugdenhil E, 2001, MOL BRAIN RES, V94, P67, DOI 10.1016/S0169-328X(01)00213-3; Vreugdenhil E, 1999, J NEUROBIOL, V39, P41, DOI 10.1002/(SICI)1097-4695(199904)39:1<41::AID-NEU4>3.0.CO;2-X; Wakamatsu Y, 1997, DEVELOPMENT, V124, P3449; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1989, BIOCHEM CELL BIOL, V67, P703, DOI 10.1139/o89-105; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V267, P317, DOI 10.1016/0003-9861(88)90037-9; Wei N, 1997, RNA, V3, P1275; Xie HQ, 1998, J NEUROSCI RES, V53, P153, DOI 10.1002/(SICI)1097-4547(19980715)53:2<153::AID-JNR4>3.3.CO;2-5; Xie JY, 2001, NATURE, V410, P936, DOI 10.1038/35073593	49	55	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17696	17705		10.1074/jbc.M111981200	http://dx.doi.org/10.1074/jbc.M111981200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884394	hybrid			2022-12-25	WOS:000175685100040
J	Carozzi, AJ; Roy, S; Morrow, IC; Pol, A; Wyse, B; Clyde-Smith, J; Prior, IA; Nixon, SJ; Hancock, JF; Parton, RG				Carozzi, AJ; Roy, S; Morrow, IC; Pol, A; Wyse, B; Clyde-Smith, J; Prior, IA; Nixon, SJ; Hancock, JF; Parton, RG			Inhibition of lipid raft-dependent signaling by a dystrophy-associated mutant of caveolin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIRDLE MUSCULAR-DYSTROPHY; DEVELOPING T-TUBULES; PLASMA-MEMBRANE; SKELETAL-MUSCLE; H-RAS; GLYCOPROTEIN COMPLEX; FREE-CHOLESTEROL; BINDING PROTEIN; GOLGI-COMPLEX; N-RAS	Specific point mutations in caveolin-3, a predominantly muscle-specific member of the caveolin family, have been implicated in limb-girdle muscular dystrophy and in rippling muscle disease. We examined the effect of these mutations on caveolin-3 localization and function. Using two independent assay systems, Raf activation in fibroblasts and neurite extension in PC12 cells, we show that one of the caveolin-3 point mutants, caveolin-3-C71W, specifically inhibits signaling by activated H-Ras but not by K-Ras. To gain insights into the effect of the mutant protein on H-Ras signaling, we examined the localization of the mutant proteins in fibroblastic cells and in differentiating myotubes. Unlike the previously characterized caveolin-3-DGV mutant, the inhibitory caveolin-3-C71W mutant reached the plasma membrane and colocalized with wild type caveolins. In BHK cells, caveolin-3-C71W associated with caveolae and in differentiating muscle cells with the developing T-tubule system. In contrast, the caveolin-3-P104L mutant accumulated in the Golgi complex and had no effect on H-Ras-mediated Raf activation. Inhibition by caveolin-3-C71W was rescued by cholesterol addition, suggesting that the mutant protein perturbs cholesterol-rich raft domains. Thus, we have demonstrated that a naturally occurring caveolin-3 mutation can inhibit signaling involving cholesterol-sensitive raft domains.	Univ Queensland, Ctr Microscopy & Microanal, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Med, Dept Pathol, Queenslanbd Canc Fund Lab Expt Oncol, Brisbane, Qld 4006, Australia	University of Queensland; University of Queensland; University of Queensland	Parton, RG (corresponding author), Univ Queensland, Ctr Microscopy & Microanal, Inst Mol Biosci, Brisbane, Qld 4072, Australia.		Parton, Robert G/C-5673-2009; Morrow, Isabel/E-8632-2012; Pol, Albert/M-1865-2014; Clyde-Smith, Jodi/R-8910-2016; Nixon, Susan/D-4588-2017	Parton, Robert G/0000-0002-7494-5248; Pol, Albert/0000-0002-1750-1085; Clyde-Smith, Jodi/0000-0001-9798-9924; Prior, Ian/0000-0002-4055-5161; Nixon, Susan/0000-0003-0346-9683; Hancock, John/0000-0003-0542-4710				Arbuzova A, 2000, BIOCHEMISTRY-US, V39, P10330, DOI 10.1021/bi001039j; Betz RC, 2001, NAT GENET, V28, P218, DOI 10.1038/90050; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; Carbone I, 2000, NEUROLOGY, V54, P1373, DOI 10.1212/WNL.54.6.1373; Carozzi AJ, 2000, TRAFFIC, V1, P326, DOI 10.1034/j.1600-0854.2000.010406.x; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Crosbie RH, 1998, FEBS LETT, V427, P279, DOI 10.1016/S0014-5793(98)00442-6; de Paula F, 2001, AM J MED GENET, V99, P303, DOI 10.1002/1096-8628(2001)9999:9999<::AID-AJMG1168>3.0.CO;2-O; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 2001, J BIOL CHEM, V276, P21425, DOI 10.1074/jbc.M100828200; Galbiati F, 1999, J BIOL CHEM, V274, P25632, DOI 10.1074/jbc.274.36.25632; Hailstones D, 1998, J LIPID RES, V39, P369; Henderson LP, 2000, J BIOL CHEM, V275, P20179, DOI 10.1074/jbc.M001793200; Herrmann R, 2000, HUM MOL GENET, V9, P2335, DOI 10.1093/oxfordjournals.hmg.a018926; ISHIKAWA H, 1968, J CELL BIOL, V38, P51, DOI 10.1083/jcb.38.1.51; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Luetterforst R, 1999, J CELL BIOL, V145, P1443, DOI 10.1083/jcb.145.7.1443; McNally EM, 1998, HUM MOL GENET, V7, P871, DOI 10.1093/hmg/7.5.871; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; Parton RG, 2001, METHOD ENZYMOL, V333, P172; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Pol A, 1999, HEPATOLOGY, V29, P1848, DOI 10.1002/hep.510290602; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rahkila P, 2001, EXP CELL RES, V267, P61, DOI 10.1006/excr.2001.5101; Ralston E, 1999, EXP CELL RES, V246, P510, DOI 10.1006/excr.1998.4305; Razani B, 2000, J CELL SCI, V113, P2103; Rojo M, 1997, J CELL BIOL, V139, P1119, DOI 10.1083/jcb.139.5.1119; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Schlegel A, 1999, J BIOL CHEM, V274, P22660, DOI 10.1074/jbc.274.32.22660; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Sotgia F, 2000, J BIOL CHEM, V275, P38048, DOI 10.1074/jbc.M005321200; Sunada Y, 2001, HUM MOL GENET, V10, P173, DOI 10.1093/hmg/10.3.173; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Trigatti BL, 1999, BIOCHEM BIOPH RES CO, V255, P34, DOI 10.1006/bbrc.1998.0123; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7	44	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17944	17949		10.1074/jbc.M110879200	http://dx.doi.org/10.1074/jbc.M110879200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884389	hybrid			2022-12-25	WOS:000175685100071
J	Kotaja, N; Vihinen, M; Palvimo, JJ; Janne, OA				Kotaja, N; Vihinen, M; Palvimo, JJ; Janne, OA			Androgen receptor-interacting protein 3 and other PIAS proteins cooperate with glucocorticoid receptor-interacting protein 1 in steroid receptor-dependent signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-BINDING DOMAINS; NUCLEAR-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; SIGNATURE MOTIF; ACTIVATION; INHIBITOR; GRIP1; COREGULATOR; FAMILY; SRC-1	Androgen receptor (AR)-interacting protein 3 (ARIP3/PIASxalpha) is a coregulator capable of modulating transcriptional activity of various steroid receptors. We have characterized functional regions of ARIP3 and studied its interaction with the glucocorticoid receptor (GR)-interacting protein 1 (GRIP1). We find that the potential zinc-binding domain is critical for ARIP3 to function as a coactivator; the deletion of amino acids 347-418 or the mutation of the conserved cysteines 385 and 388 to serines converts ARIP3 to a transcriptional repressor from AR-dependent minimal promoters and abolishes its ability to activate GR. By contrast, mutations in the two LXXLL motifs of ARIP3 have relatively minor effects on its ability to regulate AR or GR function. ARIP3 is able to interact with different regions of GRIP1, but the strongest interaction is detected with the C-terminal region (amino acids 1122-1462) of GRIP1. The interaction of ARIP3 with the latter GRIP1 domain or full-length GRIP1 and the ability of ARIP3 to cooperate with GRIP1 in the regulation of AR- or GR-dependent transcription are dependent on the ARIP3 zinc-binding region. We also find a strong synergism between GRIP1 and two other PIAS family members, Miz1 and PLAS1. Taken together, our results suggest that PIAS proteins and GRIP1 interact functionally in transcriptional regulation.	Univ Helsinki, Inst Biomed Physiol, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Clin Chem, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Janne, OA (corresponding author), Univ Helsinki, Inst Biomed, Biomedicum Helsinki, POB 63, FIN-00014 Helsinki, Finland.			Kotaja, Noora/0000-0003-1503-9170; Palvimo, Jorma/0000-0003-2373-0578				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Baumann CT, 2001, MOL ENDOCRINOL, V15, P485, DOI 10.1210/me.15.4.485; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Junicho A, 2000, BIOCHEM BIOPH RES CO, V278, P9, DOI 10.1006/bbrc.2000.3753; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Liao JY, 2000, P NATL ACAD SCI USA, V97, P5267, DOI 10.1073/pnas.97.10.5267; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Sturm S, 2000, J MOL NEUROSCI, V14, P107, DOI 10.1385/JMN:14:1-2:107; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Valdez BC, 1997, BIOCHEM BIOPH RES CO, V234, P335, DOI 10.1006/bbrc.1997.6642; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922	41	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17781	17788		10.1074/jbc.M106354200	http://dx.doi.org/10.1074/jbc.M106354200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11893729	hybrid			2022-12-25	WOS:000175685100051
J	Kranz, JK; Lee, EK; Nairn, AC; Wand, AJ				Kranz, JK; Lee, EK; Nairn, AC; Wand, AJ			A direct test of the reductionist approach to structural studies of calmodulin activity - Relevance of peptide models of target proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; BINDING DOMAIN PEPTIDE; RESONANCE ASSIGNMENTS; MULTIDIMENSIONAL NMR; SECONDARY STRUCTURE; COMPLEX; RECOGNITION; SENSITIVITY; N-15; C-13	Ca2+-saturated calmodulin (CaM) directly associates with and activates CaM-dependent protein kinase I (CaMKI) through interactions with a short sequence in its regulatory domain. Using heteronuclear NMR C-13-N-15-H-1 correlation experiments, the backbone assignments were determined for CaM bound to a peptide (CaMKIp) corresponding to the CaM-binding sequence of CaMKI. A comparison of chemical shifts for free CaM with those of the CaM-CaMKIp complex indicate large differences throughout the CaM sequence. Using NMR techniques optimized for large proteins, backbone resonance assignments were also determined for CaM bound to the intact CaMKI enzyme. NMR spectra of CaM bound to either the CaMKI enzyme or peptide are virtually identical, indicating that calmodulin is structurally indistinguishable when complexed to the intact kinase or the peptide CaM-binding domain. Chemical shifts of CaM bound to a peptide (smMLCKp) corresponding to the calmodulin-binding domain of smooth muscle myosin light chain kinase are also compared with the CaM.CaMKI complexes. Chemical shifts can differentiate one complex from another, as well as bound versus free states of CaM. In this context, the observed similarity between CaM.CaMKI enzyme and peptide complexes is striking, indicating that the peptide is an excellent mimetic for interaction of calmodulin with the CaMKI enzyme.	Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Johnson Res Fdn, Philadelphia, PA 19104 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA	University of Pennsylvania; Rockefeller University	Wand, AJ (corresponding author), Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA.			Nairn, Angus/0000-0002-7075-0195	NIDDK NIH HHS [R01 DK039806, DK39806] Funding Source: Medline; NIGMS NIH HHS [GM50402, GM20206] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM020206, R01GM050402] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BODANSZKY M, 1993, PEPTIDE CHEM PRACTIC; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Chin D, 1997, J BIOL CHEM, V272, P31235, DOI 10.1074/jbc.272.50.31235; Chou JJ, 2001, NAT STRUCT BIOL, V8, P990, DOI 10.1038/nsb1101-990; CLUBB RT, 1992, J MAGN RESON, V97, P213, DOI 10.1016/0022-2364(92)90252-3; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; Elshorst B, 1999, BIOCHEMISTRY-US, V38, P12320, DOI 10.1021/bi9908235; FISHER PJ, 1994, NATURE, V368, P651, DOI 10.1038/368651a0; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; Gomes AV, 2000, ARCH BIOCHEM BIOPHYS, V379, P28, DOI 10.1006/abbi.2000.1827; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; IKURA M, 1991, BIOCHEMISTRY-US, V30, P9216, DOI 10.1021/bi00102a013; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; Kranz JK, 2002, BIOCHEMISTRY-US, V41, P2599, DOI 10.1021/bi011818f; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; Larsson G, 2001, PROTEIN SCI, V10, P169, DOI 10.1110/ps.28401; Lee AL, 2000, NAT STRUCT BIOL, V7, P72; Liddington RC, 2002, NATURE, V415, P373, DOI 10.1038/415373a; Matsushita M, 1998, J BIOL CHEM, V273, P21473, DOI 10.1074/jbc.273.34.21473; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Persechini A, 2000, J BIOL CHEM, V275, P4199, DOI 10.1074/jbc.275.6.4199; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; ROTH SM, 1992, BIOCHEMISTRY-US, V31, P1443, DOI 10.1021/bi00120a022; ROTH SM, 1991, BIOCHEMISTRY-US, V30, P10078, DOI 10.1021/bi00106a003; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488; VANELDIK LJ, 1998, CALMODULIN SIGNAL TR; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	44	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16351	16354		10.1074/jbc.C200139200	http://dx.doi.org/10.1074/jbc.C200139200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11904288	hybrid			2022-12-25	WOS:000175564500002
J	Katona, G; Wilmouth, RC; Wright, PA; Berglund, GI; Hajdu, J; Neutze, R; Schofield, CJ				Katona, G; Wilmouth, RC; Wright, PA; Berglund, GI; Hajdu, J; Neutze, R; Schofield, CJ			X-ray structure of a serine protease acyl-enzyme complex at 0.95-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE PANCREATIC ELASTASE; BARRIER HYDROGEN-BOND; ATOMIC-RESOLUTION; CATALYTIC TRIAD; ACTIVE-SITES; ANGSTROM; CRYSTALLOGRAPHY; INTERMEDIATE; MECHANISM; ERRORS	Kinetic analyses led to the discovery that N-acetylated tripeptides with polar residues at P-3 are inhibitors of porcine pancreatic elastase (PPE) that form unusually stable acyl-enzyme complexes. Peptides terminating in a C-terminal carboxylate were more potent than those terminating in a C-terminal amide, suggesting recognition by the oxy-anion hole is important in binding. X-ray diffraction data were recorded to 0.95-Angstrom resolution for an acyl-enzyme complex formed between PPE and N-acetyl-Asn-Pro-Ile-Co2H at similar topH 5. The accuracy of the crystallographic coordinates allows structural issues concerning the mechanism of serine proteases to be addressed. Significantly, the ester bond of the acyl-enzyme showed a high level of planarity, suggesting geometric strain of the ester link is not important during catalysis. Several hydrogen atoms could be clearly identified and were included within the model. In keeping with a recent x-ray structure of subtilisin at 0.78 Angstrom (1), limited electron density is visible consistent with the putative location of a hydrogen atom approximately equidistant between the histidine and aspartate residues of the catalytic triad. Comparison of this high resolution crystal structure of the acyl-enzyme complex with that of native elastase at 1.1 Angstrom (2) showed that binding of the N-terminal part of the substrate can be accommodated with negligible structural rearrangements. In contrast, comparison with structures obtained as part of "time-resolved" studies on the reacting acyl-enzyme complex at >pH 7 (3) indicate small but significant structural differences, consistent with the proposed synchronization of ester hydrolysis and substrate release.	Chalmers Univ Technol, Dept Mol Biotechnol, S-40530 Gothenburg, Sweden; Dyson Perrins Lab, Oxford OX1 3QY, England; Oxford Ctr Mol Sci, Oxford OX1 3QY, England; Uppsala Univ, Ctr Biomed, Dept Biochem, S-75123 Uppsala, Sweden	Chalmers University of Technology; University of Oxford; University of Oxford; Uppsala University	Neutze, R (corresponding author), Chalmers Univ Technol, Dept Mol Biotechnol, Box 462, S-40530 Gothenburg, Sweden.	neutze@molbiotech.chalmers.se; christopher.schofield@chem.ox.ac.uk	Neutze, Richard/A-7573-2010; Katona, Gergely/B-3491-2008	Neutze, Richard/0000-0003-0986-6153; Katona, Gergely/0000-0002-2031-8716; Schofield, Christopher/0000-0002-0290-6565				Ash EL, 1997, SCIENCE, V278, P1128, DOI 10.1126/science.278.5340.1128; Ash EL, 2000, P NATL ACAD SCI USA, V97, P10371, DOI 10.1073/pnas.97.19.10371; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Betzel C, 2001, BIOCHEMISTRY-US, V40, P3080, DOI 10.1021/bi002538n; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dauter Z, 1995, CURR OPIN STRUC BIOL, V5, P784, DOI 10.1016/0959-440X(95)80011-5; DEREWENDA ZS, 1994, J MOL BIOL, V241, P83, DOI 10.1006/jmbi.1994.1475; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HENDERSON R, 1970, Journal of Molecular Biology, V54, P341, DOI 10.1016/0022-2836(70)90434-1; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KLEYWEGT GJ, 1994, ESF CCP4 NEWSLETTER, V31, P9; KRAUT J, 1971, COLD SPRING HARB SYM, V36, P117, DOI 10.1101/SQB.1972.036.01.017; Kuhn P, 1998, BIOCHEMISTRY-US, V37, P13446, DOI 10.1021/bi9813983; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MATTHEWS BW, 1967, NATURE, V214, P652, DOI 10.1038/214652a0; Merritt EA, 1999, ACTA CRYSTALLOGR D, V55, P1109, DOI 10.1107/S0907444999003789; MEYER E, 1988, ACTA CRYSTALLOGR B, V44, P26, DOI 10.1107/S0108768187007559; MEYER EF, 1986, J MOL BIOL, V189, P533, DOI 10.1016/0022-2836(86)90322-0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rypniewski WR, 2001, ACTA CRYSTALLOGR D, V57, P8, DOI 10.1107/S0907444900014116; SCHELDRICK G, 1997, METHOD ENZYMOL, V277, P319; Schneider TR, 2000, ACTA CRYSTALLOGR D, V56, P714, DOI 10.1107/S0907444900003723; Topf M, 2001, THEOR CHEM ACC, V106, P146, DOI 10.1007/s002140000246; Warshel A, 1998, J BIOL CHEM, V273, P27035, DOI 10.1074/jbc.273.42.27035; WATSON H C, 1970, Nature (London), V225, P806, DOI 10.1038/225806a0; WHITING AK, 1994, BIOCHEMISTRY-US, V33, P552, DOI 10.1021/bi00168a021; Wilmouth RC, 1997, NAT STRUCT BIOL, V4, P456, DOI 10.1038/nsb0697-456; Wilmouth RC, 2001, NAT STRUCT BIOL, V8, P689, DOI 10.1038/90401; WRIGHT CS, 1969, NATURE, V221, P235, DOI 10.1038/221235a0; Wright PA, 2001, EUR J BIOCHEM, V268, P2969, DOI 10.1046/j.1432-1327.2001.02186.x; Wurtele M, 2000, ACTA CRYSTALLOGR D, V56, P520, DOI 10.1107/S0907444900000299	36	55	56	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21962	21970		10.1074/jbc.M200676200	http://dx.doi.org/10.1074/jbc.M200676200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11896054	hybrid			2022-12-25	WOS:000176286000109
J	Yart, A; Roche, S; Wetzker, R; Laffargue, M; Tonks, N; Mayeux, P; Chap, H; Raynal, P				Yart, A; Roche, S; Wetzker, R; Laffargue, M; Tonks, N; Mayeux, P; Chap, H; Raynal, P			A function for phosphoinositide 3-kinase beta lipid products in coupling beta gamma to Ras activation in response to lysophosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE ACTIVATION; PHOSPHATIDYLINOSITOL 3-KINASE; PI 3-KINASE; MAP KINASE; INDEPENDENT ACTIVATION; SIGNALING PATHWAY; TYROSINE KINASE; DOCKING PROTEIN; C-ZETA	Although Gbetagamma is thought to mediate mitogen-activated protein kinase (MAPK) activation in response to G protein-coupled receptor stimulation, the mechanisms involved in this pathway have not been clearly defined. Phosphoinositide 3-kinase (PI3K) has been proposed as an early intermediate in this process, but its role has remained elusive. We have observed that dominant negative mutants of p110beta, but not of p110gamma, inhibited MAPK stimulation in response to lysophosphatidic acid (LPA). The role of p110beta was located upstream from Ras. To determine which of the lipid or protein kinase activities of p110beta were important for Ras activation, we produced a mutant p110beta lacking the lipid but not the protein kinase activity. This protein displayed a dominant negative activity similar to a kinase-dead mutant, indicating that p110beta lipid kinase activity was essentially involved in Ras activation. In agreement, overexpression of the lipid phosphatase PTEN was found to specifically inhibit Ras stimulation induced by LPA. In addition, we have observed that the PH domain-containing adapter protein Gab 1, which is involved in p 11013 activation during LPA stimulation, is also implicated in this pathway downstream of p110beta. Indeed, both membrane redistribution and phosphorylation of Gab1 were reduced in the presence of PI3K inhibitors or dominant negative p110beta. Downstream of Gab1, the tyrosine phosphatase SHP2 was found to mediate Ras activation in response to LPA and to be recruited through PI3K and Gab1, because transfection of Gab1 mutant deficient for SHP2 binding inhibited Ras activation without interfering with PI3K activation. We conclude that LPA-induced Ras activation is mediated by a p110beta/Gab1/SHP2 pathway. Moreover, we present data indicating that p110beta is effectively the target of betagamma in this pathway, suggesting that the p110beta/Gab1/SHP2 pathway provides a novel link between betagamma and Ras by integrating two early events of LPA signaling, i.e. Gbetagamma release and tyrosine kinase receptor transactivation.	Hop Purpan, INSERM, U326, IFR 30, F-31059 Toulouse, France; CRBM, CNRS, UPR 1086, F-34293 Montpellier, France; Hop Cochin, INSERM, U363, F-75014 Paris, France; Univ Jena, Max Planck Res Unit Mol Cell Biol, D-07747 Jena, Germany; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Friedrich Schiller University of Jena; Max Planck Society; Cold Spring Harbor Laboratory	Raynal, P (corresponding author), Hop Purpan, INSERM, U326, IFR 30, F-31059 Toulouse, France.	raynal@toulouse.inserm.fr	Wetzker, Reinhard/AAD-8713-2019; Laffargue, Muriel/AAE-7849-2021; YART, Armelle/A-5656-2016; Raynal, Patrick/O-1926-2018	YART, Armelle/0000-0002-2412-9840; roche, serge/0000-0003-3413-3859; Raynal, Patrick/0000-0002-6731-3007; Laffargue, Muriel/0000-0003-1833-639X				August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Chun Jerold, 1999, Cell Biochemistry and Biophysics, V30, P213, DOI 10.1007/BF02738068; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gaits F, 1996, J BIOL CHEM, V271, P20151; Goetzl EJ, 1999, ADV EXP MED BIOL, V469, P259; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hirsch E, 2001, FASEB J, V15, P2019, DOI 10.1096/fj.00-0810fje; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Lynch KR, 1999, TRENDS PHARMACOL SCI, V20, P473, DOI 10.1016/S0165-6147(99)01401-7; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Motohashi K, 2000, FEBS LETT, V468, P189, DOI 10.1016/S0014-5793(00)01222-9; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Rubio I, 2000, CURR BIOL, V10, P1225, DOI 10.1016/S0960-9822(00)00731-4; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; TOKER A, 1994, J BIOL CHEM, V269, P32358; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	63	71	74	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21167	21178		10.1074/jbc.M110411200	http://dx.doi.org/10.1074/jbc.M110411200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11916960	hybrid			2022-12-25	WOS:000176286000009
J	Matsuo, H; Kanai, Y; Kim, JY; Chairoungdua, A; Kim, DK; Inatomi, J; Shigeta, Y; Ishimine, H; Chaekuntode, S; Tachampa, K; Choi, HW; Babu, E; Fukuda, J; Endou, H				Matsuo, H; Kanai, Y; Kim, JY; Chairoungdua, A; Kim, DK; Inatomi, J; Shigeta, Y; Ishimine, H; Chaekuntode, S; Tachampa, K; Choi, HW; Babu, E; Fukuda, J; Endou, H			Identification of a novel Na+-independent acidic amino acid transporter with structural similarity to the member of a heterodimeric amino acid transporter family associated with unknown heavy chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY 4F2; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-BIOLOGY; MEMBRANE-PROTEIN; CO-EXPRESSES; CLONING; SYSTEM; LOCALIZATION; SPECIFICITY; 4F2HC/CD98	We identified a novel Na+-independent acidic amino acid transporter designated AGT1 (aspartate/glutamate transporter 1). AGT1 exhibits the highest sequence similarity (48% identity) to the Na+-independent small neutral amino acid transporter Asc (asc-type amino acid transporter)-2 a member of the heterodimeric amino acid transporter family presumed to be associated with unknown heavy chains (Chairoungdua, A., Kanai, Y., Matsuo, H., Inatomi, J., Kim, D. K., and Endou, H. (2001) J. Biol Chem. 276, 49390-49399). The cysteine residue responsible for the disulfide bond formation between transporters (light chains) and heavy chain subunits of the heterodimeric amino acid transporter family is conserved for AGT1 Because AGT1 solely expressed or coexpressed with already known heavy chain 4F2hc ((4F2) under bar heavy chain) or rBAT related to (b) under bar (0,+)-amino acid transporter) did not induce functional activity, we generated fusion proteins in which AGT1 was connected with 4F2hc or rBAT. The fusion proteins were sorted to the plasma membrane and expressed the Na+-independent transport activity for acidic amino acids. Distinct from the Na+-independent cystine/glutamate transporter xCT structurally related to AGT1, AGT1 did not accept cystine, homocysteate, and L-alpha-aminoadipate and exhibited high affinity to aspartate as well as glutamate, suggesting that the negative charge recognition site in the side chain-binding site of AGT1 would be closer to the alpha-carbon binding site compared with that of xCT. The AGT1 message was predominantly expressed in kidney. In mouse kidney, AGT1 protein was present in the basolateral membrane of the proximal straight tubules and distal convoluted tubules. In the Western blot analysis, AGT1 was detected as a high molecular mass band in the nonreducing condition, whereas the band shifted to a 40-kDa band corresponding to the AGT1 monomer in the reducing condition, suggesting the association of AGT1 with other protein via a disulfide bond. The finding of AGT1 and Asc-2 has established a new subgroup of the heterodimeric amino acid transporter family whose members associate not with 4F2hc or rBAT but with other unknown heavy chains.	Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Tokyo 1818611, Japan; Natl Def Med Coll, Dept Physiol 1, Tokorozawa, Saitama 3598513, Japan; Chiba Univ, Sch Med, Dept Urol, Chuo Ku, Chiba 2608670, Japan; Japan Sci & Technol Corp, PRESTO, Tokyo 1818611, Japan	Kyorin University; National Defense Medical College - Japan; Chiba University; Japan Science & Technology Agency (JST)	Kanai, Y (corresponding author), Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, 6-20-2 Shinkawa,Mitaka, Tokyo 1818611, Japan.	ykanai@kyorin-u.ac.jp	Tachampa, Kittipong/AAK-3634-2020	Matsuo, Hirotaka/0000-0003-4302-8719; Tachampa, Kittipong/0000-0002-2011-3542				ALTMAN A, 1984, P NATL ACAD SCI-BIOL, V81, P2176, DOI 10.1073/pnas.81.7.2176; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Bassi MT, 2001, PFLUG ARCH EUR J PHY, V442, P286, DOI 10.1007/s004240100537; Chairoungdua A, 1999, J BIOL CHEM, V274, P28845, DOI 10.1074/jbc.274.41.28845; Chairoungdua A, 2001, J BIOL CHEM, V276, P49390, DOI 10.1074/jbc.M107517200; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; DANTZLER WH, 1988, AM J PHYSIOL, V255, pF397, DOI 10.1152/ajprenal.1988.255.3.F397; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Feliubadalo L, 1999, NAT GENET, V23, P52, DOI 10.1038/12652; Fukasawa Y, 2000, J BIOL CHEM, V275, P9690, DOI 10.1074/jbc.275.13.9690; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HEMLER ME, 1982, J IMMUNOL, V129, P623; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Isnard AD, 1996, J MOL BIOL, V262, P473, DOI 10.1006/jmbi.1996.0529; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Kanai Y, 2000, J BIOL CHEM, V275, P20787, DOI 10.1074/jbc.M000634200; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANAI Y, 1992, AM J PHYSIOL, V263, pF1087, DOI 10.1152/ajprenal.1992.263.6.F1087; Kanai Y, 2001, CURR DRUG METAB, V2, P339, DOI 10.2174/1389200013338324; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kanai Y, 1997, CURR OPIN CELL BIOL, V9, P565, DOI 10.1016/S0955-0674(97)80035-X; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; MACLEOD CL, 1994, J EXP BIOL, V196, P109; Mannion BA, 1998, J BIOL CHEM, V273, P33127, DOI 10.1074/jbc.273.50.33127; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Matsuo H, 2000, NEUROREPORT, V11, P3507, DOI 10.1097/00001756-200011090-00021; Mizoguchi K, 2001, KIDNEY INT, V59, P1821, DOI 10.1046/j.1523-1755.2001.0590051821.x; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Peghini P, 1997, EMBO J, V16, P3822, DOI 10.1093/emboj/16.13.3822; Pfeiffer R, 1999, MOL BIOL CELL, V10, P4135, DOI 10.1091/mbc.10.12.4135; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; SACKTOR B, 1981, J MEMBRANE BIOL, V60, P63, DOI 10.1007/BF01870833; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Segawa H, 1997, BIOCHEM J, V328, P657, DOI 10.1042/bj3280657; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Shayakul C, 1997, AM J PHYSIOL-RENAL, V273, pF1023, DOI 10.1152/ajprenal.1997.273.6.F1023; SILBERNAGL S, 1983, PFLUG ARCH EUR J PHY, V396, P218, DOI 10.1007/BF00587858; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; UtsunomiyaTate N, 1997, FEBS LETT, V416, P312, DOI 10.1016/S0014-5793(97)01232-5; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; Verrey F, 2000, PFLUG ARCH EUR J PHY, V440, P503, DOI 10.1007/s004240050001	48	41	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					21017	21026		10.1074/jbc.M200019200	http://dx.doi.org/10.1074/jbc.M200019200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11907033	hybrid			2022-12-25	WOS:000176204500117
J	Weidenfeld, J; Shu, WG; Zhang, LL; Millar, SE; Morrisey, EE				Weidenfeld, J; Shu, WG; Zhang, LL; Millar, SE; Morrisey, EE			The WNT7b promoter is regulated by TTF-1, GATA6, and Foxa2 in lung epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID TRANSCRIPTION FACTOR-1; SURFACTANT PROTEIN-B; HEPATOCYTE NUCLEAR FACTOR-3; GENE-EXPRESSION; ACTIVATES TRANSCRIPTION; FACTOR-I; BRANCHING MORPHOGENESIS; SONIC HEDGEHOG; C GENE; ENHANCER	In this study, we find that WNT7b is the only member of the WNT family of autocrine/paracrine signaling molecules whose expression in the lung is restricted to the airway epithelium during embryonic development. To study the transcriptional mechanisms that underlie this restricted pattern of WNT7b expression, we isolated the proximal 1.0-kb mouse WNT7b promoter and mapped the transcriptional start sites. Transfection of the lung epithelial cell line MLE-15, which expresses WNT7b, shows that the 1.0-kb mouse WNT7b promoter is highly active in lung epithelial cells. This region of the WNT7b promoter contains several DNA binding sites for the important lung-restricted transcription factors TTF-1, GATA6, and Foxa2. Electrophoretic mobility shift assays showed that TTF-1, GATA6, and Foxa2 can bind to a specific subset of their consensus DNA binding sites within the WNT7b promoter. Using cotransfection assays, we demonstrate that TTF-1, GATA6, and Foxa2 can trans-activate the WNT7b promoter in NIH-3T3 cells. Truncation of GATA6 or Foxa2 binding sites reduced the ability of these transcriptional regulators to trans-activate the WNT7b promoter. Finally, the minimal 118-bp region of the mouse WNT7b promoter containing only TTF-1 binding sites was synergistically activated by TTF-1 and GATA6, and we show that TTF-1 and GATA6 physically interact in vivo. Together, these results suggest that WNT7b gene expression in the lung epithelium is regulated in a combinatorial fashion by TTF-1, GATA6, and Foxa2.	Univ Penn, Mol Cardiol Res Ctr, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Morrisey, EE (corresponding author), Univ Penn, Mol Cardiol Res Ctr, Dept Med, 953 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.			Millar, Sarah/0000-0001-8792-6890				BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Braun H, 1998, J BIOL CHEM, V273, P9821, DOI 10.1074/jbc.273.16.9821; Bruno MD, 2000, J BIOL CHEM, V275, P1043, DOI 10.1074/jbc.275.2.1043; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Glasser SW, 2000, AM J PHYSIOL-LUNG C, V278, pL933, DOI 10.1152/ajplung.2000.278.5.L933; Ikeda K, 1996, MOL CELL BIOL, V16, P3626; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; KAESTNER KH, 1994, GENOMICS, V20, P377, DOI 10.1006/geno.1994.1191; Keijzer R, 2001, DEVELOPMENT, V128, P503; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Lako M, 1998, GENE, V219, P101, DOI 10.1016/S0378-1119(98)00393-X; Margana RK, 1997, J BIOL CHEM, V272, P3083, DOI 10.1074/jbc.272.5.3083; Mendelson CR, 2000, ANNU REV PHYSIOL, V62, P875, DOI 10.1146/annurev.physiol.62.1.875; Minoo P, 1999, DEV BIOL, V209, P60, DOI 10.1006/dbio.1999.9234; Monkley SJ, 1996, DEVELOPMENT, V122, P3343; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960-9822(98)70446-4; Reddy S, 2001, MECH DEVELOP, V107, P69, DOI 10.1016/S0925-4773(01)00452-X; SAWAYA PL, 1993, MOL CELL BIOL, V13, P3860, DOI 10.1128/MCB.13.7.3860; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Shaw-White JR, 1999, J BIOL CHEM, V274, P2658, DOI 10.1074/jbc.274.5.2658; Shu WG, 2001, J BIOL CHEM, V276, P27488, DOI 10.1074/jbc.M100636200; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; YAN C, 1995, J BIOL CHEM, V270, P24852, DOI 10.1074/jbc.270.42.24852; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	31	89	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					21061	21070		10.1074/jbc.M111702200	http://dx.doi.org/10.1074/jbc.M111702200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11914369	hybrid			2022-12-25	WOS:000176204500121
J	Cabedo, H; Luna, C; Fernandez, AM; Gallar, J; Ferrer-Montiel, A				Cabedo, H; Luna, C; Fernandez, AM; Gallar, J; Ferrer-Montiel, A			Molecular determinants of the sensory and motor neuron-derived factor insertion into plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; LIPID RAFTS; CELL-SURFACE; ASSOCIATION; NEUREGULIN; TRANSPORT; RECEPTORS; MICRODOMAINS; HEREGULIN; SYNAPSES	The sensory and motor neuron-derived factor (SMDF) is a type III neuregulin that regulates development and proliferation of Schwann cells. Although SMDF has been shown to be a type II protein, the molecular determinants of membrane biogenesis, insertion, and topology remain elusive. Here we used heterologous expression of a yellow fluorescent protein-SMDF fusion protein along with a stepwise deletion strategy to show that the apolar/uncharged segment (Ile(76)-Val(100)) acts as an internal, uncleaved membrane insertion signal that defines the topology of the protein. Unexpectedly, removal of the transmembrane segment (TM) did not eliminate completely membrane association of C-terminal fragments. TM-deleted fusion proteins, bearing the amino acid segment (Ser(283)-Glu(296)) located downstream to the epidermal growth factor-like motif, strongly interacted with plasma membrane fractions. However, synthetic peptides patterned after this segment did not insert into artificial lipid vesicles, suggesting that membrane interaction of the SMDF C terminus may be the result of a post-translational modification. Subcellular localization studies demonstrated that the 40-kDa form, but not the 83-kDa form, of SMDF was segregated into lipid rafts. Deletion of the N-terminal TM did not affect the interaction of the protein with these lipid microdomains. In contrast, association with membrane rafts was abolished completely by truncation of the protein C terminus. Collectively, these findings are consistent with a topological model for SMDF in which the protein associates with the plasma membrane through both the TM and the C-terminal end domains resembling the topology of other type III neuregulins. The TM defines its characteristic type II membrane topology, whereas the C terminus is a newly recognized anchoring motif that determines its compartmentalization into lipid rafts. The differential localization of the 40- and 83-kDa forms of the neuregulin into rafts and non-raft domains implies a central role in the protein biological activity.	Univ Miguel Hernandez, CSIC, Ctr Biol Mol & Celular, Alicante 03202, Spain; Univ Miguel Hernandez, CSIC, Inst Neurociencias, Alicante 03202, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Ferrer-Montiel, A (corresponding author), Univ Miguel Hernandez, CSIC, Ctr Biol Mol & Celular, Avenida Ferrocarrril S-N, Alicante 03202, Spain.		Gallar, Juana/B-4563-2011; Cabedo, Hugo/F-9404-2016; Ferrer-Montiel, Antonio/C-3072-2015; Carvajal, Asia Fernandez/G-8877-2015	Gallar, Juana/0000-0002-3559-3649; Cabedo, Hugo/0000-0002-1322-6290; Ferrer-Montiel, Antonio/0000-0002-2973-6607; Fernandez-Carvajal, Asia/0000-0003-2741-1427				Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Encinar JA, 1996, BIOPHYS J, V71, P1313, DOI 10.1016/S0006-3495(96)79331-1; Frenzel KE, 2001, J NEUROCHEM, V77, P1; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Ingham PW, 2001, SCIENCE, V294, P1879, DOI 10.1126/science.1064115; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Li QF, 2001, J BIOL CHEM, V276, P38068; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Muniz M, 2000, EMBO J, V19, P10, DOI 10.1093/emboj/19.1.10; Osheroff PL, 1999, GROWTH FACTORS, V16, P241, DOI 10.3109/08977199909002133; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; Schroering A, 1998, J BIOL CHEM, V273, P30643, DOI 10.1074/jbc.273.46.30643; Wang JY, 2001, J BIOL CHEM, V276, P2841, DOI 10.1074/jbc.M005700200; Wolpowitz D, 2000, NEURON, V25, P79, DOI 10.1016/S0896-6273(00)80873-9	24	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19905	19912		10.1074/jbc.M201587200	http://dx.doi.org/10.1074/jbc.M201587200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11896060	hybrid			2022-12-25	WOS:000175894800088
J	Taru, H; Iijima, K; Hase, M; Kirino, Y; Yagi, Y; Suzuki, T				Taru, H; Iijima, K; Hase, M; Kirino, Y; Yagi, Y; Suzuki, T			Interaction of Alzheimer's beta-amyloid precursor family proteins with scaffold proteins of the JNK signaling cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; DEPENDENT REGULATION; CYTOSOLIC ADAPTER; AXONAL-TRANSPORT; PHOSPHORYLATION; GENE; APPL; RECEPTOR; EXPRESSION; VIABILITY	We have isolated a novel protein based on its association with Drosophila APP-like protein (APPL), a homolog of the beta-amyloid precursor protein (APP) that is implicated in Alzheimer's disease. This novel APPL-interacting protein 1 (APLIP1) contains a Src homology 3 domain and a phosphotyrosine interaction domain and is expressed abundantly in neural tissues. The phosphotyrosine interaction domain of APLIP1 interacts with a sequence containing GYENPTY in the cytoplasmic domain of APPL. APLIP1 is highly homologous to the carboxyl-terminal halves of mammalian c-Jun NH2-terminal kinase (JNK)-interacting protein 1b (JIP1b) and 2 (JIP2), which also contain Src homology 3 and phosphotyrosine interaction domains. The similarity of APLIP1 to JIP1b and JIP2 includes interaction with component(s) of the JNK signaling pathway and with the motor protein kinesin and the formation of homo-oligomers. JIP1b interacts strongly with the cytoplasmic domain of APP (APPcyt), as APLIP1 does with APPL, but the interaction of JIP2 with APPcyt is weak. Overexpression of JIP1b slightly enhances the JNK-dependent threonine phosphorylation of APP in cultured cells, but that of JIP2 suppresses it. These observations suggest that the interactions of APP family proteins with APLIP1, JIP1b, and JIP2 are conserved and play important roles in the metabolism and/or the function of APPs including the regulation of APP phosphorylation by JNK. Analysis of APP family proteins and their associated proteins is expected to contribute to understanding the molecular process of neural degeneration in Alzheimer's disease.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Lab Neurosci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Univ Tokyo, Sch Pharmaceut Sci, Lab Neurobiophys, Bunkyo Ku, Tokyo 1130033, Japan	Hokkaido University; University of Tokyo	Suzuki, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Lab Neurosci, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tsuzuki@pharm.hokudai.ac.jp	Taru, Hidenori/B-7059-2009; Suzuki, Toshiharu/B-5342-2013					Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919; Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Ando K, 1999, J NEUROSCI, V19, P4421; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Coulson EJ, 2000, NEUROCHEM INT, V36, P175, DOI 10.1016/S0197-0186(99)00125-4; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Gunawardena S, 2001, NEURON, V32, P389, DOI 10.1016/S0896-6273(01)00496-2; Heber S, 2000, J NEUROSCI, V20, P7951; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; LUO LQ, 1992, NEURON, V9, P595, DOI 10.1016/0896-6273(92)90024-8; LUO LQ, 1990, J NEUROSCI, V10, P3849, DOI 10.1523/JNEUROSCI.10-12-03849.1990; Margolis B, 1999, KIDNEY INT, V56, P1230, DOI 10.1046/j.1523-1755.1999.00700.x; MARTINMORRIS LE, 1990, DEVELOPMENT, V110, P185; Matsuda S, 2001, J NEUROSCI, V21, P6597; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Noselli S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Perez RG, 1997, J NEUROSCI, V17, P9407; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; ROSEN DR, 1989, P NATL ACAD SCI USA, V86, P2478, DOI 10.1073/pnas.86.7.2478; SAMBROOK J, 1989, MOL CLONING LABORATO, pCH12; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Standen CL, 2001, J NEUROCHEM, V76, P316, DOI 10.1046/j.1471-4159.2001.00102.x; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Tomita S, 1998, J BIOL CHEM, V273, P19304, DOI 10.1074/jbc.273.30.19304; Torroja L, 1996, J NEUROSCI, V16, P4638; Torroja L, 1999, CURR BIOL, V9, P489, DOI 10.1016/S0960-9822(99)80215-2; Torroja L, 1999, J NEUROSCI, V19, P7793; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Watanabe T, 1999, J NEUROCHEM, V72, P549, DOI 10.1046/j.1471-4159.1999.0720549.x; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Xu X, 1999, P NATL ACAD SCI USA, V96, P7547, DOI 10.1073/pnas.96.13.7547; Yagi Y, 1997, GENES CELLS, V2, P41, DOI 10.1046/j.1365-2443.1997.d01-282.x; Yagi Yoshimasa, 2000, Molecular Cell Biology Research Communications, V4, P43, DOI 10.1006/mcbr.2000.0248; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zheng PZ, 1998, P NATL ACAD SCI USA, V95, P14745, DOI 10.1073/pnas.95.25.14745	49	107	116	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					20070	20078		10.1074/jbc.M108372200	http://dx.doi.org/10.1074/jbc.M108372200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11912189	hybrid			2022-12-25	WOS:000175894800108
J	Goel, R; Phillips-Mason, PJ; Raben, DM; Baldassare, JJ				Goel, R; Phillips-Mason, PJ; Raben, DM; Baldassare, JJ			alpha-Thrombin induces rapid and sustained Akt phosphorylation by beta-arrestin1-dependent and -independent mechanisms, and only the sustained Akt phosphorylation is essential for G(1) phase progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; COUPLED RECEPTOR ENDOCYTOSIS; BETA-ARRESTIN; PHOSPHOINOSITIDE 3-KINASE; CYCLIN D1; DNA-SYNTHESIS; PROTEOLYTIC MECHANISM; PERTUSSIS-TOXIN; GROWTH-FACTORS; CELL-GROWTH	In Chinese hamster embryonic fibroblasts (IIC9 cells) alpha-thrombin activates the MAPK(ERK) and phosphatidylinositol 3-OH-kinase (PI 3-kinase)/Akt pathways, and both are essential for progression through the G(1) phase of the cell cycle. We investigated in IIC9 cells, the role of beta-arrestin1 in alpha-thrombin signaling to these pathways. alpha-Thrombin stimulates rapid and sustained PI 3-kinase and Akt activities. Expression of a dominant negative alpha-arrestin1 (beta-arrestin1(V53D)) inhibits rapid but not sustained PI 3-kinase and Akt activities. Surprisingly, expression of beta-arrestin1(V53D) does not block activation of the MAPK(ERK pathway. PI 3-kinase and Akt activities are also inhibited by expression of beta-arrestin1 mutant, which impairs binding to c-Src (beta-arrestin1(P91G-P12E)), indicating the involvement of c-Src in the rapid stimulation of the PI 3-kinase/Akt pathway. Consistent with these results, PP1, a selective inhibitor of c-Src family kinases, prevents alpha-thrombin-stimulated Akt phosphorylation. Expression of Parrestin1(V53D) does not prevent G(1) progression, as its expression has no effect on [H-3]thymidine incorporation into DNA. In agreement with the ineffectiveness of beta-arrestin1(V53D) to block G(1) progression, cyclin D1 protein amounts and CDK4-cyclin D1 activity is unaffected by expression of beta-arrestin1(V53D). Thus in IIC9 cells, alpha-thrombin activates rapid beta-arrestin1-dependent and sustained beta-arrestin1-independent Akt activity, suggesting that two mechanisms are involved. Furthermore, although blocking the beta-arrestin1-independent PI 3-kinase/Akt pathway prevents G(1) progression, inhibition of the beta-arrestin1-dependent pathway does not, indicating different roles for the rapid and sustained activities.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Saint Louis University; Johns Hopkins University	Baldassare, JJ (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA.				NIDDK NIH HHS [R01 DK46814] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046814] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAFFY G, 1994, J BIOL CHEM, V269, P8483; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; BELLONI PN, 1992, MICROVASC RES, V43, P20, DOI 10.1016/0026-2862(92)90004-9; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V70, P184; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Galetic I, 1999, PHARMACOL THERAPEUT, V82, P409, DOI 10.1016/S0163-7258(98)00071-0; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; Kanthou C, 1996, CELL SIGNAL, V8, P59, DOI 10.1016/0898-6568(95)02018-7; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Krasilnikov MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P59; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; MCNAMARA C, 1992, J CLIN INVEST, V91, P94; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Ogino Y, 1996, EUR J PHARMACOL, V316, P105, DOI 10.1016/S0014-2999(96)00653-X; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; PHILLIPSMASON PJ, 2000, THESIS SAINT LOUIS U; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Rakhit S, 2001, MOL PHARMACOL, V60, P63, DOI 10.1124/mol.60.1.63; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Walker TR, 1998, MOL PHARMACOL, V54, P1007, DOI 10.1124/mol.54.6.1007; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061	43	81	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18640	18648		10.1074/jbc.M108995200	http://dx.doi.org/10.1074/jbc.M108995200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11901145	hybrid			2022-12-25	WOS:000175975800054
J	Lavenu-Bombled, C; Trainor, CD; Makeh, I; Romeo, PH; Max-Audit, I				Lavenu-Bombled, C; Trainor, CD; Makeh, I; Romeo, PH; Max-Audit, I			Interleukin-13 gene expression is regulated by GATA-3 in T cells - Role of a critical association of a GATA and two GATG motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-3; TRANSGENIC MICE; DNA-BINDING; EMBRYONIC LETHALITY; ENFORCED EXPRESSION; GAMMA PRODUCTION; NERVOUS-SYSTEM; CUTTING EDGE; TH1 CELLS; ELEMENTS	Using a transgenic approach, we studied the role of GATA-3 in T cells. As previously shown, enforced GATA-3 expression in transgenic mice inhibits Th1 differentiation of CD4 T cells, but unexpectedly, both type 1 (interferon gamma) and type 2 (interleukin (IL)-4 and IL-13) cytokine genes were activated in the transgenic CD8 T cells. Because IL-13 gene expression was highly enhanced in vivo by GATA-3 expression, we studied the human and the mouse IL-13 gene promoters and found an evolutionary-conserved association of a consensus GATA binding site and two GATG motifs. We showed that efficient GATA-3 binding to this regulatory sequence required these three motifs and that the affinity of the GATA zinc fingers for this association was five times higher than for the consensus GATA binding site alone. Transfections in a T cell line or transactivation by GATA-3 showed that the combination of the three sites was required for full transcriptional activity of the IL-13 gene promoter. Finally we showed that this association of binding sites causes a very high sensitivity of the IL-13 gene promoter to small variations in the level of GATA-3 protein. Altogether, these results indicate an important role of GATA-3 in CD8 cytokine gene expression and demonstrate that a critical network of GATA binding sites highly modulates GATA-3 activity.	Univ Paris 05, Matern Port Royal, Dept Hematol, Inst Cochen,CNRS,INSERM, F-75014 Paris, France; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Max-Audit, I (corresponding author), Univ Paris 05, Matern Port Royal, Dept Hematol, Inst Cochen,CNRS,INSERM, 123 Bd Port Royal, F-75014 Paris, France.		Lavenu-Bombled, Cecile/B-4812-2018; Romeo, Paul-Henri/L-5989-2017	Lavenu-Bombled, Cecile/0000-0002-4860-8395; Romeo, Paul-Henri/0000-0002-8294-0367				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Aune TM, 1997, MOL CELL BIOL, V17, P199, DOI 10.1128/MCB.17.1.199; Carter LL, 1999, J EXP MED, V189, P1355, DOI 10.1084/jem.189.8.1355; Dolganov G, 1996, BLOOD, V87, P3316, DOI 10.1182/blood.V87.8.3316.bloodjournal8783316; ERARD F, 1993, SCIENCE, V260, P1802, DOI 10.1126/science.8511588; Ferber IA, 1999, CLIN IMMUNOL, V91, P134, DOI 10.1006/clim.1999.4718; Finotto S, 2001, J EXP MED, V193, P1247, DOI 10.1084/jem.193.11.1247; FONG TAT, 1990, J IMMUNOL, V144, P1744; Fowler DH, 1996, J IMMUNOL, V157, P4811; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hattori N, 1996, J EXP MED, V184, P1137, DOI 10.1084/jem.184.3.1137; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Lee GR, 2001, IMMUNITY, V14, P447, DOI 10.1016/S1074-7613(01)00125-X; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Lee HJ, 1998, J IMMUNOL, V160, P2343; LEROYVIARD K, 1995, EMBO J, V14, P2341, DOI 10.1002/j.1460-2075.1995.tb07229.x; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; MAXAUDIT I, 1993, J BIOL CHEM, V268, P5431; MCKENZIE ANJ, 1993, J IMMUNOL, V150, P5436; Nawijn MC, 2001, J IMMUNOL, V167, P715, DOI 10.4049/jimmunol.167.2.715; Nawijn MC, 2001, J IMMUNOL, V167, P724, DOI 10.4049/jimmunol.167.2.724; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; PAGANELLI R, 1995, J EXP MED, V181, P423, DOI 10.1084/jem.181.1.423; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Pedone PV, 1997, EMBO J, V16, P2874, DOI 10.1093/emboj/16.10.2874; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; Ranganath S, 2001, MOL CELL BIOL, V21, P2716, DOI 10.1128/MCB.21.8.2716-2725.2001; RINCON M, 1997, CURR BIOL, V7, P729; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; SAD S, 1995, IMMUNITY, V2, P271, DOI 10.1016/1074-7613(95)90051-9; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Takemoto N, 2000, J IMMUNOL, V165, P6687, DOI 10.4049/jimmunol.165.12.6687; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; Trainor CD, 2000, J BIOL CHEM, V275, P28157; Vizler C, 2000, J IMMUNOL, V165, P6314, DOI 10.4049/jimmunol.165.11.6314; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yang D, 2001, MOL CELL BIOL, V21, P1581, DOI 10.1128/MCB.21.5.1581-1592.2001; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang DH, 1998, J IMMUNOL, V161, P3817; Zhang YK, 2001, J EXP MED, V194, P165, DOI 10.1084/jem.194.2.165; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	47	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18313	18321		10.1074/jbc.M110013200	http://dx.doi.org/10.1074/jbc.M110013200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893731	hybrid			2022-12-25	WOS:000175975800010
J	Pandey, A; Ibarrola, N; Kratchmarova, I; Fernandez, MM; Constantinescu, SN; Ohara, O; Sawasdikosol, S; Lodish, HF; Mann, M				Pandey, A; Ibarrola, N; Kratchmarova, I; Fernandez, MM; Constantinescu, SN; Ohara, O; Sawasdikosol, S; Lodish, HF; Mann, M			A novel Src homology 2 domain-containing molecule, Src-like adapter protein-2 (SLAP-2), which negatively regulates T cell receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAINS; TYROSINE KINASE; ANTIGEN RECEPTOR; ACTIVATION; TRANSDUCTION; MYRISTYLATION; SELECTION; CLONING; CALCIUM; ZAP-70	We have cloned a novel adapter protein containing Src homology 2 and Src homology 3 domains similar to the Src family of tyrosine kinases. This molecule lacks a catalytic tyrosine kinase domain and is related to a previously identified protein, Src-like adapter protein (SLAP), and is therefore designated SLAP-2. Northern blot analysis indicates that SLAP-2 is predominantly expressed in the immune system. Jurkat, T cells express SLAP-2 protein and overexpression of SLAP-2 in these cells negatively regulates T cell receptor signaling as assessed by interleukin-2 promoter or NF-AT promoter reporter constructs. Mutational analysis revealed that an intact SH2 domain of SLAP-2 is essential for this inhibitory effect, whereas mutation of the SH3 domain alone has no effect. This inhibitory effect is upstream of the activation of Ras and increase of intracellular calcium levels, as no inhibition was observed when the cells were activated by phorbol ester plus ionomycin. SLAP-2 interacts with Cbl in vivo in a phosphorylation independent manner and with ZAP-70 and T cell receptor chain upon T cell receptor activation. Finally, we show that the mutation of a predicted myristoylation site within the NH2-terminal of SLAP-2 is essential for its inhibitory effect. This report therefore implicates SLAP and SLAP-2 as a family of adapter proteins that negatively regulate T cell receptor signaling.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Univ So Denmark, Ctr Expt Bioinformat, DK-5230 Odense, Denmark; Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Christian de Duve Inst Cellular Pathol, B-1200 Brussels, Belgium; Kazusa DNA Res Inst, Chiba 2920812, Japan; RIKEN Res Ctr Allergy & Immunol, Chiba 2920812, Japan; NYU, Sch Med, Skirball Inst Biomed Res, New York, NY 10016 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Southern Denmark; Ludwig Institute for Cancer Research; Kazusa DNA Research Institute; RIKEN; New York University	Mann, M (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	mann@bmb.sdu.dk	Constantinescu, Stefan N/E-5277-2012; Ohara, Osamu/A-9119-2012; Mann, Matthias/A-3454-2013; Ohara, Osamu/G-5448-2015; Pandey, Akhilesh/B-4127-2009	Mann, Matthias/0000-0003-1292-4799; Ohara, Osamu/0000-0002-3328-9571; Pandey, Akhilesh/0000-0001-9943-6127; Constantinescu, Stefan N./0000-0002-8599-2699; Kratchmarova, Irina/0000-0001-6613-7315	NATIONAL CANCER INSTITUTE [K01CA075447] Funding Source: NIH RePORTER; NCI NIH HHS [KO1 CA75447] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; Hogquist KA, 2001, CURR OPIN IMMUNOL, V13, P225, DOI 10.1016/S0952-7915(00)00208-9; Holland SJ, 2001, J EXP MED, V194, P1263, DOI 10.1084/jem.194.9.1263; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Larson SM, 2000, PROTEIN SCI, V9, P2170, DOI 10.1110/ps.9.11.2170; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Leo A, 2001, CURR OPIN IMMUNOL, V13, P307, DOI 10.1016/S0952-7915(00)00220-X; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; Makarova O, 2000, BIOTECHNIQUES, V29, P970, DOI 10.2144/00295bm08; Manes G, 2000, MOL CELL BIOL, V20, P3396, DOI 10.1128/MCB.20.10.3396-3406.2000; Mayer BJ, 1998, CURR TOP MICROBIOL, V228, P1; Mayer BJ, 2001, J CELL SCI, V114, P1253; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Padlan EA, 1997, CURR BIOL, V7, pR17, DOI 10.1016/S0960-9822(06)00010-8; Pandey A, 1999, TRENDS BIOCHEM SCI, V24, P276, DOI 10.1016/S0968-0004(99)01400-0; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Sosinowski T, 2000, J EXP MED, V191, P463, DOI 10.1084/jem.191.3.463; Sosinowski T, 2001, IMMUNITY, V15, P457, DOI 10.1016/S1074-7613(01)00195-9; Tailor P, 1996, EUR J BIOCHEM, V237, P736, DOI 10.1111/j.1432-1033.1996.0736p.x; Tang J, 1999, P NATL ACAD SCI USA, V96, P9775, DOI 10.1073/pnas.96.17.9775; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Wang HY, 2001, J BIOL CHEM, V276, P26004, DOI 10.1074/jbc.M010738200; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; Wilson IA, 1997, CURR OPIN STRUC BIOL, V7, P839, DOI 10.1016/S0959-440X(97)80156-X; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	30	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19131	19138		10.1074/jbc.M110318200	http://dx.doi.org/10.1074/jbc.M110318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11891219	hybrid			2022-12-25	WOS:000175975800115
J	Pokutta, S; Drees, F; Takai, Y; Nelson, WJ; Weis, WI				Pokutta, S; Drees, F; Takai, Y; Nelson, WJ; Weis, WI			Biochemical and structural definition of the 1-afadin- and actin-binding sites of alpha-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; ADHERENS JUNCTIONS; CRYSTAL-STRUCTURE; BETA-CATENIN; CADHERIN; PROTEIN; COMPLEX; VINCULIN; AFADIN; DOMAIN	alpha-Catenin is an integral component of adherens junctions, where it links cadherins to the actin cytoskeleton. alpha-Catenin is also required for the colocalization of the nectin/afadin/ponsin adhesion system to adherens junctions, and it specifically associates with the nectin-binding protein afadin. A proteolytic fragment of alpha-catenin, residues 385-651, contains the afadin-binding site. The three-dimensional structure of this fragment comprises two side-by-side four-helix bundles, both of which are required for afadin binding. The alpha-catenin fragment 385-651 binds afadin more strongly than the full-length protein, suggesting that the full-length protein harbors a cryptic binding site for afadin. Comparison of the alpha-catenin 385-651 structure with the recently solved structure of the alpha-catenin M-fragment (Yang, J., Dokurno, P., Tonks, N. K, and Barford, D. (2001) EMBO J. 20, 3645-3656) reveals a surprising flexibility in the orientation of the two four-helix bundles. alpha-Catenin and the actin-binding protein vinculin share sequence and most likely structural similarity within their actin-binding domains. Despite this homology, actin binding requires additional sequences adjacent to this region.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Osaka Univ, Grad Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Stanford University; Stanford University; Osaka University	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Fairchild Bldg,299 Campus Dr W, Stanford, CA 94305 USA.		Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035527, R01GM056169] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35227, GM56169, R01 GM056169, R01 GM035527] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERLE H, 1994, J CELL SCI, V107, P3655; Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Koslov ER, 1997, J BIOL CHEM, V272, P27301, DOI 10.1074/jbc.272.43.27301; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; Pradhan D, 2001, J BIOL CHEM, V276, P4175, DOI 10.1074/jbc.M009259200; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Yang J, 2001, EMBO J, V20, P3645, DOI 10.1093/emboj/20.14.3645	40	177	180	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18868	18874		10.1074/jbc.M201463200	http://dx.doi.org/10.1074/jbc.M201463200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11907041	hybrid, Green Accepted			2022-12-25	WOS:000175975800081
J	Ramadan, K; Shevelev, IV; Maga, G; Hubscher, U				Ramadan, K; Shevelev, IV; Maga, G; Hubscher, U			DNA polymerase lambda from calf thymus preferentially replicates damaged DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; BETA; PROTEINS; EXONUCLEASES; FIDELITY; ENZYME	A new gene (POLL), has been identified encoding the novel DNA polymerase lambda and mapped to mouse chromosome 19 and at human chromosome 10. DNA polymerase lambda contains all the critical residues involved in DNA binding, nucleotide binding, nucleotide selection, and catalysis of DNA polymerization and has been assigned to family X based on sequence homology with polymerase beta, lambda, mu, and terminal deoxynucleotidyltransferase. Here we describe a purification of DNA polymerase lambda from calf thymus that preferentially can replicate damaged DNA. By testing polymerase activity on non-damaged and damaged DNA, DNA polymerase lambda was purified trough five chromatographic steps to near homogeneity and identified as a 67-kDa polypeptide that cross-reacted with monoclonal antibodies against DNA polymerase beta and polyclonal antibodies against DNA polymerase lambda. DNA polymerase lambda had no detectable nuclease activities and, in contrast to DNA polymerase beta, was aphidicolin-sensitive. DNA polymerase lambda was a 6-fold more accurate enzyme in an M13mp2 forward mutation assay and 5-fold more accurate in an M13mp2T90 reversion system than human recombinant DNA polymerase beta. The biochemical properties of the calf thymus DNA polymerase lambda, described here for the first time, are discussed in relationship to the proposed role for this DNA polymerase in vivo.	Univ Zurich Irchel, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland; Petersburg Nucl Phys Inst, Dept Mol & Radiat Biophys, Gatchina 188300, Russia; CNR, Ist Genet Mol, I-27100 Pavia, Italy	University of Zurich; National Research Centre - Kurchatov Institute; Petersburg Nuclear Physics Institute; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR)	Hubscher, U (corresponding author), Univ Zurich Irchel, Inst Vet Biochem & Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Maga, Giovanni/C-5409-2009	Maga, Giovanni/0000-0001-8092-1552				Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; Garcia-Diaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Shevelev IV, 2000, MUTAT RES-DNA REPAIR, V459, P237, DOI 10.1016/S0921-8777(00)00004-5; SHIMIZU K, 1993, J BIOL CHEM, V268, P27148; SPANOS A, 1981, NUCLEIC ACIDS RES, V9, P1825, DOI 10.1093/nar/9.8.1825; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WASER J, 1979, EUR J BIOCHEM, V97, P361, DOI 10.1111/j.1432-1033.1979.tb13122.x; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404	18	62	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18454	18458		10.1074/jbc.M200421200	http://dx.doi.org/10.1074/jbc.M200421200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886860	Green Accepted, hybrid			2022-12-25	WOS:000175975800027
J	Ray, K; Northup, J				Ray, K; Northup, J			Evidence for distinct cation and calcimimetic compound (NPS 568) recognition domains in the transmembrane regions of the human Ca2+ receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; PROTEIN-COUPLED RECEPTORS; CALCIUM-SENSING RECEPTOR; CELL-SURFACE EXPRESSION; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; CHIMERIC RECEPTORS; LIGAND-BINDING; IDENTIFICATION; SPECIFICITY	The Ca2+ receptor, a member of the family 3 of G protein-coupled receptors (GPCR), responds not only to its primary physiological ligand Ca2+ but also to other di- and trivalent metals (Mg2+, Gd3+) and the organic polycations spermine and poly-L-Arginine. As has been found for other family 3 GPCRs, the large amino-terminal extracellular domain (ECD) of the Ca2+ receptor is the primary Ca2+ binding domain. To examine how the signal is propagated from the ECD to the seven-transmembrane core domain (7TM) we constructed a Ca2+ receptor mutant (T903-Rhoc) lacking the entire ECD but containing the 7TM. We have found that this structure initiates signaling in human embryonic kidney (HEK) 293 cells stably expressing the construct. One or more cation recognition sites are also located within the 7TM. Not only Ca2+, but also several other Ca2+ receptor-specific agonists, Mg2+, Gd3+, spermine, and poly-L-Arginine, can activate T903-Rhoc truncated receptor-initiated phosphoinositide hydrolysis in HEK 293 cells. The phenylalkylamine compound, N-PS 568, identified as a positive allosteric modulator of the Ca2+ receptor can selectively potentiate the actions of Ca2+ and other polycationic agonists on the T903-Rhoc receptor. Similarly, organic polycations synergistically activate T903-Rhoc with di- and trivalent metals. Alanine substitution of all the acidic residues in the second extracellular loop of the T903-Rhoc receptor significantly impairs activation by metal ions and organic polycations in the presence of NPS 568 but not the synergistic activation of Ca2+ with poly-L-Arginine. These data indicate that although the ECD has been thought to be the main determinant for Ca2+ recognition, the 7TM core of the Ca2+ receptor contains activating site(s) recognizing Ca2+ and Gd3+ as well as the allosteric modulators NPS 568 and organic polycations that may play important roles in the regulation of receptor activation.	NIDCD, Lab Cellular Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Ray, K (corresponding author), NIDCD, Lab Cellular Biol, 5 Res Ct,Rm 2A-11, Rockville, MD 20850 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000047, Z01DC000047] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; CONKLIN BR, 1994, NATURE, V367, P22, DOI 10.1038/367022a0; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; Han GM, 1999, J BIOL CHEM, V274, P10008, DOI 10.1074/jbc.274.15.10008; Hauache OM, 2000, ENDOCRINOLOGY, V141, P4156, DOI 10.1210/en.141.11.4156; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Hu JX, 2000, J BIOL CHEM, V275, P16382, DOI 10.1074/jbc.M000277200; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Nemeth EF, 1999, TRENDS ENDOCRIN MET, V10, P66, DOI 10.1016/S1043-2760(98)00119-2; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Pearce SHS, 1996, J CLIN INVEST, V98, P1860, DOI 10.1172/JCI118987; Ray K, 1998, J BIOL CHEM, V273, P34558, DOI 10.1074/jbc.273.51.34558; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; RAY K, 2001, LIFEXY, P1027; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Sohma H, 1999, BIOCHEM J, V341, P203, DOI 10.1042/0264-6021:3410203; Sun YM, 2001, J BIOL CHEM, V276, P7754, DOI 10.1074/jbc.M009020200; Zhao XM, 1999, FEBS LETT, V448, P180, DOI 10.1016/S0014-5793(99)00368-3	30	88	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18908	18913		10.1074/jbc.M202113200	http://dx.doi.org/10.1074/jbc.M202113200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11880385	hybrid			2022-12-25	WOS:000175975800086
J	Torihashi, S; Fujimoto, T; Trost, C; Nakayama, S				Torihashi, S; Fujimoto, T; Trost, C; Nakayama, S			Calcium oscillation linked to pacemaking of interstitial cells of Cajal - Requirement of calcium influx and localization of TRP4 in caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE SMALL-INTESTINE; SLOW-WAVE FREQUENCY; GASTROINTESTINAL-TRACT; ELECTRICAL RHYTHMICITY; SMOOTH MUSCLES; TRISPHOSPHATE RECEPTOR; MOLECULAR-BASIS; EXPRESSION; CHANNELS; PROTEIN	Interstitial cells of Cajal (ICC) are considered to be pacemaker cells in gastrointestinal tracts. ICC generate electrical rhythmicity (dihydropyridine-insensitive) as slow waves and drive spontaneous contraction of smooth muscles. Although cytosolic Ca2+ has been assumed to play a key role in pacemaking, Ca2+ movements in ICC have not yet been examined in detail. In the present study, using cultured cell clusters isolated from mouse small intestine, we demonstrated Ca2+ oscillations in ICC. Fluo-4 was loaded to the cell cluster, the relative amount of cytosolic Ca2+ was recorded, and ICC were identified by e-Kit immunoreactivity. We specifically detected Ca2+ oscillation in ICC in the presence of dihydropyridine, which abolishes Ca2+ oscillation in smooth muscles. The oscillation was coupled to the electrical activity corresponding to slow waves, and it depended on Ca2+ influx through a non-selective cation channel, which was SK&F 96365-sensitive and store-operated. We further demonstrated the presence of transient receptor potential-like channel 4 (TRP4) in caveolae of ICC. Taken together, the results infer that the Ca2+ oscillation in ICC is intimately linked to the pacemaker function and depends on Ca2+ influx mediated by TRP4.	Nagoya Univ, Grad Sch Med, Dept Anat & Cell Biol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Cell Physiol, Nagoya, Aichi 4668550, Japan; Univ Saarland, Inst Pharmakol & Toxikol, D-66421 Homburg, Germany	Nagoya University; Nagoya University; Saarland University	Torihashi, S (corresponding author), Nagoya Univ, Grad Sch Med, Dept Anat & Cell Biol, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4668550, Japan.							Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Epperson A, 2000, AM J PHYSIOL-CELL PH, V279, pC529, DOI 10.1152/ajpcell.2000.279.2.C529; Farrugia G, 1999, ANNU REV PHYSIOL, V61, P45, DOI 10.1146/annurev.physiol.61.1.45; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Fujita A, 2001, AM J PHYSIOL-CELL PH, V281, pC1727, DOI 10.1152/ajpcell.2001.281.5.C1727; GRIFFITHS G, 1983, METHOD ENZYMOL, V96, P466; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Horowitz B, 1999, ANNU REV PHYSIOL, V61, P19, DOI 10.1146/annurev.physiol.61.1.19; Huang SM, 1999, AM J PHYSIOL-GASTR L, V276, pG518, DOI 10.1152/ajpgi.1999.276.2.G518; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; Kinoshita M, 2000, CELL CALCIUM, V28, P151, DOI 10.1054/ceca.2000.0143; Koh SD, 1998, J PHYSIOL-LONDON, V513, P203, DOI 10.1111/j.1469-7793.1998.203by.x; Lee JCF, 1999, AM J PHYSIOL-GASTR L, V277, pG409, DOI 10.1152/ajpgi.1999.277.2.G409; Lockwich T, 2001, J BIOL CHEM, V276, P42401, DOI 10.1074/jbc.M106956200; Malysz J, 2001, AM J PHYSIOL-GASTR L, V280, pG439, DOI 10.1152/ajpgi.2001.280.3.G439; McKay RR, 2000, BIOCHEM J, V351, P735, DOI 10.1042/0264-6021:3510735; Nakayama S, 1997, J PHYSIOL-LONDON, V505, P229, DOI 10.1111/j.1469-7793.1997.229bc.x; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; RUMESSEN JJ, 1994, DAN MED BULL, V41, P275; RUMESSEN JJ, 1992, GASTROENTEROLOGY, V102, P56, DOI 10.1016/0016-5085(92)91784-2; Sanders KM, 1996, GASTROENTEROLOGY, V111, P492, DOI 10.1053/gast.1996.v111.pm8690216; Stevens RJ, 2000, GASTROENTEROLOGY, V118, P892, DOI 10.1016/S0016-5085(00)70175-2; Suzuki H, 2000, J PHYSIOL-LONDON, V525, P105, DOI 10.1111/j.1469-7793.2000.00105.x; Suzuki H, 2000, JPN J PHYSIOL, V50, P289, DOI 10.2170/jjphysiol.50.289; SZURSZEWSKY JH, 1987, HDB GASTROINTESTINAL, P383; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Thomsen L, 1998, NAT MED, V4, P848, DOI 10.1038/nm0798-848; THUNEBERG L, 1982, ADV ANAT EMBRYOL CEL, V71, P1; Tokutomi N, 1995, PFLUG ARCH EUR J PHY, V431, P169, DOI 10.1007/BF00410188; TOKUYASU KT, 1989, J CELL BIOL, V108, P43, DOI 10.1083/jcb.108.1.43; TORIHASHI S, 1995, CELL TISSUE RES, V280, P97, DOI 10.1007/s004410050334; Walker RL, 2001, AM J PHYSIOL-CELL PH, V280, pC1184, DOI 10.1152/ajpcell.2001.280.5.C1184; WARD SM, 1994, J PHYSIOL-LONDON, V480, P91, DOI 10.1113/jphysiol.1994.sp020343; Ward SM, 2000, J PHYSIOL-LONDON, V525, P355, DOI 10.1111/j.1469-7793.2000.t01-1-00355.x; Yamazawa T, 2002, J PHYSIOL-LONDON, V538, P823, DOI 10.1113/jphysiol.2001.013045	38	157	173	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19191	19197		10.1074/jbc.M201728200	http://dx.doi.org/10.1074/jbc.M201728200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11897792	hybrid			2022-12-25	WOS:000175975800122
J	Chambeyron, S; Bucheton, A; Busseau, I				Chambeyron, S; Bucheton, A; Busseau, I			Tandem UAA repeats at the 3 '-end of the transcript are essential for the precise initiation of reverse transcription of the I factor in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-FREQUENCY RETROTRANSPOSITION; R HYBRID DYSGENESIS; MESSENGER-RNA; ORF1 PROTEIN; TRANSPOSABLE ELEMENTS; PROCESSED PSEUDOGENES; L1 RETROTRANSPOSITION; MAMMALIAN-CELLS; IDENTIFICATION; SEQUENCES	Non-long terminal repeat retrotransposons, widespread among eukaryotic genomes, transpose by reverse transcription of an RNA intermediate. Some of them, like L1 in the human, terminate at the T-end with a poly(dA) stretch whereas others, like the I factor in Drosophila melanogaster, have instead a short sequence repeated in tandem. This suggests different requirements for the initiation of reverse transcription. Here, we have used an RNA circularization/reverse transcription-PCR technique to analyze the 5'- and T-ends of the full-length transcripts produced by the I factor at the time of active retrotransposition. These transcripts are capped and polyadenylated similar to conventional messenger RNAs. We have analyzed the 3'-ends of transcripts and transposed copies produced by I elements mutated at the 3'-ends. Transcripts devoid of tandem UAA repeats, although capable of building the components of the retrotransposition machinery, are inefficiently used as retrotransposition intermediates. Such transcripts produce rare new integrated copies issued from the inaccurate initiation of reverse transcription near the 3'-end of the element. The tandem UAA repeats at the T-end of the transcripts of I are required for the efficient and precise initiation of reverse transcription. This strong specificity of the I factor reverse transcriptase for its own transcript has implications for the impact of I factor retrotransposition on the host genome.	CNRS, Inst Genet Humaine, F-34396 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Busseau, I (corresponding author), CNRS, Inst Genet Humaine, 141 Rue Cardonille, F-34396 Montpellier 5, France.	busseau@igh.cnrs.fr		Chambeyron, severine/0000-0003-2775-6556				ABAD P, 1989, P NATL ACAD SCI USA, V86, P8887, DOI 10.1073/pnas.86.22.8887; Akhmanova A, 1998, GENOME, V41, P396; Boeke JD, 1999, NATURE, V398, P108, DOI 10.1038/18118; BOUHIDEL K, 1994, NUCLEIC ACIDS RES, V22, P2370, DOI 10.1093/nar/22.12.2370; BUCHETON A, 1984, CELL, V38, P153, DOI 10.1016/0092-8674(84)90536-1; BUCHETON A, 2002, MOBILE DNA, V2, P796; Busseau I, 1998, GENETICS, V148, P267; Capri M, 1997, MECH DEVELOP, V68, P91, DOI 10.1016/S0925-4773(97)00130-5; CHABOISSIER MC, 1990, EMBO J, V9, P3557, DOI 10.1002/j.1460-2075.1990.tb07566.x; Chaboissier MC, 2000, NUCLEIC ACIDS RES, V28, P2467, DOI 10.1093/nar/28.13.2467; CHEN F, 1995, NUCLEIC ACIDS RES, V23, P2614, DOI 10.1093/nar/23.14.2614; Couttet P, 1997, P NATL ACAD SCI USA, V94, P5628, DOI 10.1073/pnas.94.11.5628; Dawson A, 1997, EMBO J, V16, P4448, DOI 10.1093/emboj/16.14.4448; Eickbush T, 1999, SCIENCE, V283, P1465, DOI 10.1126/science.283.5407.1465; Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184; FAWCETT DH, 1986, CELL, V47, P1007, DOI 10.1016/0092-8674(86)90815-9; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; FROMONTRACINE M, 1993, NUCLEIC ACIDS RES, V21, P1683, DOI 10.1093/nar/21.7.1683; Goodier JL, 2000, HUM MOL GENET, V9, P653, DOI 10.1093/hmg/9.4.653; Graber JH, 1999, P NATL ACAD SCI USA, V96, P14055, DOI 10.1073/pnas.96.24.14055; Hohjoh H, 1996, EMBO J, V15, P630, DOI 10.1002/j.1460-2075.1996.tb00395.x; JEFFS P, 1991, P ROY SOC B-BIOL SCI, V244, P151, DOI 10.1098/rspb.1991.0064; Kazazian HH, 2000, SCIENCE, V289, P1152, DOI 10.1126/science.289.5482.1152; Kuhn J, 2002, NUCLEIC ACIDS RES, V30, P439, DOI 10.1093/nar/30.2.439; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MANDL CW, 1991, BIOTECHNIQUES, V10, P484; MARTIN F, 1995, J MOL BIOL, V247, P49, DOI 10.1006/jmbi.1994.0121; Martin F, 1996, TRENDS BIOCHEM SCI, V21, P283, DOI 10.1016/S0968-0004(96)80130-7; Martin SL, 2001, MOL CELL BIOL, V21, P467, DOI 10.1128/MCB.21.2.467-475.2001; MCLEAN C, 1993, MOL CELL BIOL, V13, P1042, DOI 10.1128/MCB.13.2.1042; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; PICARD G, 1978, MOL GEN GENET, V164, P235, DOI 10.1007/BF00333152; PICARD G, 1976, CR ACAD SCI D NAT, V282, P1813; Pickeral OK, 2000, GENOME RES, V10, P411, DOI 10.1101/gr.10.4.411; PontKingdon G, 1997, NUCLEIC ACIDS RES, V25, P3088, DOI 10.1093/nar/25.15.3088; PRITCHARD MA, 1988, MOL GEN GENET, V214, P533, DOI 10.1007/BF00330491; Saint Andre CD, 1998, GENETICS, V148, P1875; Seleme MD, 1999, GENETICS, V151, P761; Sugahara Y, 2001, GENE, V263, P93, DOI 10.1016/S0378-1119(00)00557-6; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Yang J, 1998, MOL CELL BIOL, V18, P3455, DOI 10.1128/MCB.18.6.3455; Yang J, 1999, P NATL ACAD SCI USA, V96, P7847, DOI 10.1073/pnas.96.14.7847; YUE X, 1988, MOL BIOL EVOL, V5, P675	45	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17877	17882		10.1074/jbc.M200996200	http://dx.doi.org/10.1074/jbc.M200996200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882661	hybrid			2022-12-25	WOS:000175685100063
J	Dhe-Paganon, S; Werner, ED; Chi, YI; Shoelson, SE				Dhe-Paganon, S; Werner, ED; Chi, YI; Shoelson, SE			Structure of the globular tail of nuclear lamin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; CAUSE AUTOSOMAL-DOMINANT; DILATED CARDIOMYOPATHY; IMMUNOGLOBULIN FOLD; MISSENSE MUTATIONS; A/C GENE; PROTEIN; DOMAIN; LMNA; IDENTIFICATION	The nuclear lamins form a two-dimensional matrix that provides integrity to the cell nucleus and participates in nuclear activities. Mutations in the region of human LMNA encoding the carboxyl-terminal tail Lamin A/C are associated with forms of muscular dystrophy and familial partial lipodystrophy (FPLD). To help discriminate tissue-specific phenotypes, we have solved at 1.4-Angstrom resolution the three-dimensional crystal structure of the lamin A/C globular tail. The domain adopts a novel, all beta-mmunoglobulin-like fold. FPLD-associated mutations cluster within a small surface, whereas muscular dystrophy-associated mutations are distributed throughout the protein core and on its surface. These findings distinguish myopathy- and lipodystrophy-associated mutations and provide a structural framework for further testing hypotheses concerning lamin function.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Shoelson, SE (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.	Steven.Shoelson@joslin.harvard.edu			NIDDK NIH HHS [R01 DK43123, DK09393] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043123, F32DK009393] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; Bonne G, 2000, ANN NEUROL, V48, P170, DOI 10.1002/1531-8249(200008)48:2<170::AID-ANA6>3.0.CO;2-J; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Brodsky GL, 2000, CIRCULATION, V101, P473, DOI 10.1161/01.CIR.101.5.473; Brown CA, 2001, AM J MED GENET, V102, P359, DOI 10.1002/ajmg.1463; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burke B, 2001, TRAFFIC, V2, P675, DOI 10.1034/j.1600-0854.2001.21001.x; Cao H, 2000, HUM MOL GENET, V9, P109, DOI 10.1093/hmg/9.1.109; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Clements L, 2000, BIOCHEM BIOPH RES CO, V267, P709, DOI 10.1006/bbrc.1999.2023; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Cutler DA, 2002, BIOCHEM BIOPH RES CO, V291, P522, DOI 10.1006/bbrc.2002.6466; di Barletta MR, 2000, AM J HUM GENET, V66, P1407, DOI 10.1086/302869; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; Goldberg M, 1999, P NATL ACAD SCI USA, V96, P2852, DOI 10.1073/pnas.96.6.2852; Halaby DM, 1999, PROTEIN ENG, V12, P563, DOI 10.1093/protein/12.7.563; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LIN F, 1993, J BIOL CHEM, V268, P16321; Manilal S, 1996, HUM MOL GENET, V5, P801, DOI 10.1093/hmg/5.6.801; Muchir A, 2000, HUM MOL GENET, V9, P1453, DOI 10.1093/hmg/9.9.1453; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Shackleton S, 2000, NAT GENET, V24, P153, DOI 10.1038/72807; Speckman RA, 2000, AM J HUM GENET, V66, P1192, DOI 10.1086/302836; Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Wilson KL, 2001, CELL, V104, P647, DOI 10.1016/S0092-8674(02)01452-6; Worman HJ, 2000, J MEMBRANE BIOL, V177, P1, DOI 10.1007/s002320001096	33	211	219	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17381	17384		10.1074/jbc.C200038200	http://dx.doi.org/10.1074/jbc.C200038200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11901143	hybrid			2022-12-25	WOS:000175685100002
J	Nakagawa, J; Ishikura, S; Asami, J; Isaji, T; Usami, N; Hara, A; Sakurai, T; Tsuritani, K; Oda, K; Takahashi, M; Yoshimoto, M; Otsuka, N; Kitamura, K				Nakagawa, J; Ishikura, S; Asami, J; Isaji, T; Usami, N; Hara, A; Sakurai, T; Tsuritani, K; Oda, K; Takahashi, M; Yoshimoto, M; Otsuka, N; Kitamura, K			Molecular characterization of mammalian dicarbonyl/L-xylulose reductase and its localization in kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLATION END-PRODUCTS; D-ERYTHRULOSE REDUCTASE; ALDEHYDE REDUCTASE; CARBONYL REDUCTASE; TISSUE DISTRIBUTION; SPERM PROTEIN; PURIFICATION; DIACETYL; EXPRESSION; DEHYDROGENASE	In this report, we first cloned a cDNA for a protein that is highly expressed in mouse kidney and then isolated its counterparts in human, rat hamster, and guinea pig by polymerase chain reaction-based cloning. The cDNAs of the five species encoded polypeptides of 244 amino acids, which shared more than 85% identity with each other and showed high identity with a human sperm 34-kDa protein, P34H, as well as a murine lung-specific carbonyl reductase of the short-chain dehydrogenase/reductase superfamily. In particular, the human protein is identical to P34H, except for one amino acid substitution. The purified recombinant proteins of the five species were about 100-kDa homotetramers with NADPH-linked reductase activity for alpha-dicarbonyl compounds, catalyzed the oxidoreduction between xylitol and L-xylulose, and were inhibited competitively by n-butyric acid. Therefore, the proteins are designated as dicarbonyl/L-xylulose reductases (DCXRs). The substrate specificity and kinetic constants of DCXRs for dicarbonyl compounds and sugars are similar to those of mammalian diacetyl reductase and L-xylulose reductase, respectively, and the identity of the DCXRs with these two enzymes was demonstrated by their co-purification from hamster and guinea pig livers and by protein sequencing of the hepatic enzymes. Both DCXR and its mRNA are highly expressed in kidney and liver of human and rodent tissues, and the protein was localized primarily to the inner membranes of the proximal renal tubules in murine kidneys. The results imply that P34H and diacetyl reductase (EC 1.1.1.5) are identical to L-xylulose reductase (EC 1.1.1.10), which is involved in the uronate cycle of glucose metabolism, and the unique localization of the enzyme in kidney suggests that it has a role other than in general carbohydrate metabolism.	Taisho Pharmaceut Co Ltd, Med Res Labs, Saitama 3308530, Japan; Gifu Pharmaceut Univ, Biochem Lab, Gifu 5028585, Japan	Taisho Pharmaceutical Holdings Co Ltd; Gifu Pharmaceutical University	Nakagawa, J (corresponding author), Taisho Pharmaceut Co Ltd, Med Res Labs, 1-403 Yoshino Cho, Saitama 3308530, Japan.	junichi.nakagawa@po.rd.taisho.co.jp	Isaji, Tomoya/ABC-9285-2021	Oda, Koji/0000-0002-4322-7809				ARSENIS C, 1969, J BIOL CHEM, V244, P3895; BERNARDO A, 1984, INT J BIOCHEM, V16, P1065, DOI 10.1016/0020-711X(84)90089-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; BURG MB, 1988, KIDNEY INT, V33, P635, DOI 10.1038/ki.1988.46; DVORNIK D, 1987, ALDOSE REDUCTASE INH, P222; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; FEATHER MS, 1995, BIOCHIM BIOPHYS ACTA, V197, P373; Gaudreault C, 1999, BIOL REPROD, V61, P264, DOI 10.1095/biolreprod61.1.264; GRANT ME, 1975, EUR J BIOCHEM, V54, P531, DOI 10.1111/j.1432-1033.1975.tb04166.x; Gugliucci A, 1996, DIABETOLOGIA, V39, P149, DOI 10.1007/BF00403957; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; HARA A, 1983, EUR J BIOCHEM, V133, P207, DOI 10.1111/j.1432-1033.1983.tb07449.x; HARA A, 1985, ENZYMOLOGY CARBONYL, V2, P291; HAYWARD LD, 1977, CARBOHYD RES, V53, P13; HICKMAN J, 1959, J BIOL CHEM, V234, P758; HOLLMANN S, 1959, H-S Z PHYSIOL CHEM, V317, P193, DOI 10.1515/bchm2.1959.317.1.193; HORIUCHI S, 1986, J BIOL CHEM, V261, P4962; HSU SM, 1981, AM J CLIN PATHOL, V75, P816, DOI 10.1093/ajcp/75.6.816; Ishikura S, 2001, BIOCHEMISTRY-US, V40, P214, DOI 10.1021/bi001804u; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE AB, 1985, BIOCHEM GENET, V23, P61, DOI 10.1007/BF00499113; Legare C, 1999, ENDOCRINOLOGY, V140, P3318, DOI 10.1210/en.140.7.3318; Maeda M, 1998, J BIOCHEM-TOKYO, V123, P602; MAKITA Z, 1991, NEW ENGL J MED, V325, P836, DOI 10.1056/NEJM199109193251202; MAKITA Z, 1994, LANCET, V343, P1519, DOI 10.1016/S0140-6736(94)92935-1; Medvedev AE, 1996, BIOCHEM PHARMACOL, V52, P385, DOI 10.1016/0006-2952(96)00206-7; NAKANISHI M, 1995, EUR J BIOCHEM, V228, P381, DOI 10.1111/j.1432-1033.1995.tb20274.x; Niwa T, 1999, J CHROMATOGR B, V731, P23, DOI 10.1016/S0378-4347(99)00113-9; O'Connor T, 1999, BIOCHEM J, V343, P487, DOI 10.1042/0264-6021:3430487; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; Ortwerth BJ, 1998, BIOCHEM BIOPH RES CO, V245, P161, DOI 10.1006/bbrc.1998.8401; OTSUKA M, 1992, J CHROMATOGR-BIOMED, V577, P215, DOI 10.1016/0378-4347(92)80242-I; Otsuka M, 1996, J BIOCHEM-TOKYO, V119, P246; PROVECHO F, 1984, INT J BIOCHEM, V16, P423, DOI 10.1016/0020-711X(84)90142-3; Raj DSC, 2000, AM J KIDNEY DIS, V35, P365, DOI 10.1016/S0272-6386(00)70189-2; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO K, 1993, ARCH BIOCHEM BIOPHYS, V307, P286, DOI 10.1006/abbi.1993.1591; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449; SUEOKA T, 1985, BIOCHIM BIOPHYS ACTA, V843, P193, DOI 10.1016/0304-4165(85)90139-4; Takenaka M, 1998, KIDNEY INT, V53, P562, DOI 10.1046/j.1523-1755.1998.00808.x; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; Tanaka N, 2001, CURR ORG CHEM, V5, P89, DOI 10.2174/1385272013375751; Tanji N, 2000, J AM SOC NEPHROL, V11, P1656, DOI 10.1681/ASN.V1191656; THORNALLEY PJ, 1996, GEN PHARMACOL, V27, P567; TOUSTER O, 1956, J BIOL CHEM, V221, P697; UEHARA K, 1974, J BIOCHEM, V75, P333, DOI 10.1093/oxfordjournals.jbchem.a130400; WANG YM, 1970, NEW ENGL J MED, V282, P892, DOI 10.1056/NEJM197004162821604; Weiss MF, 2000, KIDNEY INT, V57, P2571, DOI 10.1046/j.1523-1755.2000.00117.x; WINEGRAD AI, 1967, INT S METABOLISM PHY, P258; Zabner J, 2000, P NATL ACAD SCI USA, V97, P11614, DOI 10.1073/pnas.97.21.11614	53	86	93	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17883	17891		10.1074/jbc.M110703200	http://dx.doi.org/10.1074/jbc.M110703200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882650	hybrid			2022-12-25	WOS:000175685100064
J	De Maria, R; Maggiora, P; Biolatti, B; Prat, M; Comoglio, PM; Castagnaro, M; Di Renzo, MF				De Maria, R; Maggiora, P; Biolatti, B; Prat, M; Comoglio, PM; Castagnaro, M; Di Renzo, MF			Feline STK gene expression in mammary carcinomas	ONCOGENE			English	Article						tyrosine kinase receptors; mammary carcinomas; companion animals tumours	HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE; POSTSURGICAL PROGNOSIS; IMMUNOHISTOCHEMICAL ANALYSIS; ESTROGEN-RECEPTORS; MOLECULAR-CLONING; MET ONCOGENE; RON GENE; CYCLIN-A; OVEREXPRESSION	The human RON and its mouse homologue stk are members of the MET family of tyrosine kinase receptors. We have previously shown that the RON gene is over-expressed in human breast carcinomas. As cat mammary tumours have been proposed as a suitable model for aggressive human breast cancer, we identified the feline stk gene and studied its expression in cat mammary cancer. Feline stk sequences were found highly homologous to the stk and RON gene exons that encode the juxtamembrane and transmembrane domains of the stk and RON receptors. Feline stk-specific transcript was detected by RT - PCR in cat lung and in 7/8 feline mammary carcinomas and a synchronous skin metastasis examined. Western blot and immunohistochemical analyses were carried out with an antibody that recognized both the human RON and mouse stk receptors. This antibody specifically detected a 135 Kd feline protein and stained 10/34 mammary carcinoma archival samples. These data show that the pattern of expression and distribution of the stk protein in feline mammary cancer could be superimposed on that of the RON receptor in human breast cancer and suggest that these feline tumours are a suitable model to test innovative approaches to therapy of aggressive human breast carcinomas.	Univ Turin, Sch Med, Inst Canc Res & Treatment, Canc Genet Lab, I-10060 Turin, Italy; Univ Turin, Inst Canc Res & Treatment, Comparat Oncol Ctr, I-10060 Turin, Italy; Univ Turin, IRCC, Inst Canc Res & Treatment, Div Mol Oncol, I-10060 Turin, Italy; Univ Turin, Sch Vet Med, Dept Anim Pathol, Turin, Italy; Univ Novara, Sch Med, Dept Med Sci, Novara, Italy; Univ Padua, Sch Vet Med, Dept Publ Hlth Comparat Pathol & Vet Hyg, I-35100 Padua, Italy	University of Turin; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Turin; University of Eastern Piedmont Amedeo Avogadro; University of Padua	Di Renzo, MF (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, Canc Genet Lab, SP 142,Km 3-95, I-10060 Turin, Italy.	mfdirenzo@ircc.unito.it	DI RENZO, Maria Flavia/B-6091-2012	DI RENZO, Maria Flavia/0000-0002-5093-3373; DE MARIA, RAFFAELLA/0000-0002-7028-2280; CASTAGNARO, Massimo/0000-0003-3311-7806; Comoglio, Paolo/0000-0002-7056-5328; BIOLATTI, Bartolomeo/0000-0003-3657-3954				Angeloni D, 2000, GENE CHROMOSOME CANC, V29, P147, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.3.CO;2-E; Castagnaro M, 1998, RES VET SCI, V64, P97, DOI 10.1016/S0034-5288(98)90002-9; Castagnaro M, 1998, RES VET SCI, V65, P223, DOI 10.1016/S0034-5288(98)90147-3; Castagnaro M, 1998, J COMP PATHOL, V119, P263, DOI 10.1016/S0021-9975(98)80049-2; de las Mulas JM, 2000, DOMEST ANIM ENDOCRIN, V18, P111, DOI 10.1016/S0739-7240(99)00067-3; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; HAMILTON JM, 1976, VET REC, V99, P477, DOI 10.1136/vr.99.24.477; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; JOHNSTON SD, 1984, AM J VET RES, V45, P379; Kobayashi Y, 2001, J VET MED SCI, V63, P211, DOI 10.1292/jvms.63.211; Kolibaba KS, 1997, BIOCHIM BIOPHYS ACTA, V1333, P217; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Murakami Y, 2000, J VET MED SCI, V62, P783, DOI 10.1292/jvms.62.783; Murakami Y, 2000, J VET MED SCI, V62, P743, DOI 10.1292/jvms.62.743; Olivero M, 1999, INT J CANCER, V82, P640, DOI 10.1002/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RONSIN C, 1993, ONCOGENE, V8, P1195; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Tuck AB, 1996, AM J PATHOL, V148, P225; Waltz SE, 1998, ONCOGENE, V16, P27, DOI 10.1038/sj.onc.1201508; WEIJER K, 1972, J NATL CANCER I, V49, P1697, DOI 10.1093/jnci/49.6.1697	26	25	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1785	1790		10.1038/sj.onc.1205221	http://dx.doi.org/10.1038/sj.onc.1205221			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896610				2022-12-25	WOS:000174214200017
J	Hiromura, K; Pippin, JW; Blonski, MJ; Roberts, JM; Shankland, SJ				Hiromura, K; Pippin, JW; Blonski, MJ; Roberts, JM; Shankland, SJ			The subcellular localization of cyclin dependent kinase 2 determines the fate of mesangial cells: role in apoptosis and proliferation	ONCOGENE			English	Article						apoptosis; cell cycle; cyclin dependent kinase; mesangial cell	NUCLEAR EXPORT; BCL-2 FAMILY; IN-VITRO; CDK2; ACTIVATION; INHIBITION; P27(KIP1); DEATH; ROSCOVITINE; MECHANISMS	Apoptosis is closely linked to proliferation. In this study we showed that inducing apoptosis in mouse mesangial cells with ultraviolet (UV) irradiation was associated with increased cyclin A-cyclin dependent kinase (CDK) 2 activity. Inhibiting CDK2 activity with Roscovitine or dominant negative mutant reduced apoptosis. Because apoptosis typically begins in the cytoplasm, we tested the hypothesis that the subcellular localization of CDK2 determines the proliferative or apoptotic fate of the cell. Our results showed that cyclin A-CDK2 was nuclear in proliferating cells. However, inducing apoptosis in proliferating cells with UV irradiation was associated with a decrease in nuclear cyclin A and CDK2 protein levels. This coincided with an increase in protein and kinase activity for cyclin A-CDK2 in the cytoplasm. Translocation of cyclin A-CDK2 also occurred in p53(-/-) mesangial cells. Finally, we showed that caspase-3 activity was significantly reduced by inhibiting CDK2 activity with Roscovitine. In summary, our results show that apoptosis is associated with an increase in cytoplasmic cyclin A-CDK2 activity, which is p53 independent and upstream of caspase-3. We propose that the subcellular localization of CDK2 determines the proliferative or apoptotic fate of the cell.	Univ Washington, Sch Med, Div Nephrol, Dept Med, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Dept Basic Sci, Seattle, WA 98104 USA; Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Shankland, SJ (corresponding author), Univ Washington, Sch Med, Div Nephrol, Dept Med, Box 356521, Seattle, WA 98195 USA.	stuartjs@u.washington.edu			NIDDK NIH HHS [DK51096, DK56799, DK34198, DK47659, DK52121] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034198, R01DK051096, P50DK047659, R01DK034198, R01DK056799, R01DK052121] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi S, 2001, CIRC RES, V88, P408, DOI 10.1161/01.res.88.4.408; BAKER AJ, 1994, J CLIN INVEST, V94, P2105, DOI 10.1172/JCI117565; Baptist M, 1996, J CELL PHYSIOL, V166, P256; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; Bresnahan WA, 1996, CELL GROWTH DIFFER, V7, P1283; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; DANNO K, 1982, BRIT J DERMATOL, V107, P423, DOI 10.1111/j.1365-2133.1982.tb00385.x; Dobashi Y, 1998, BIOCHEM BIOPH RES CO, V253, P609, DOI 10.1006/bbrc.1998.9825; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; MARTIN SJ, 1991, INT J RADIAT BIOL, V59, P1001, DOI 10.1080/09553009114550891; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Miller LJ, 1998, SCIENCE, V281, P1301, DOI 10.1126/science.281.5381.1301; Minn AJ, 1998, ADV IMMUNOL, V70, P245, DOI 10.1016/S0065-2776(08)60388-0; Mooney A, 1997, J IMMUNOL, V159, P3949; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; NISHIOKA WK, 1994, J EXP MED, V179, P769, DOI 10.1084/jem.179.2.769; Ophascharoensuk V, 1998, NAT MED, V4, P575, DOI 10.1038/nm0598-575; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; Pippin JW, 1997, J CLIN INVEST, V100, P2512, DOI 10.1172/JCI119793; Reed SI, 1997, CANCER SURV, V29, P7; Roussel ME, 1998, ADV CANCER RES, V74, P1, DOI 10.1016/S0065-230X(08)60763-0; Shankland SJ, 2000, AM J PHYSIOL-RENAL, V278, pF515, DOI 10.1152/ajprenal.2000.278.4.F515; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Syljuasen RG, 1999, RADIAT RES, V152, P328, DOI 10.2307/3580333; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yao SL, 1996, CANCER RES, V56, P4551; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x	44	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1750	1758		10.1038/sj.onc.1205238	http://dx.doi.org/10.1038/sj.onc.1205238			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896606				2022-12-25	WOS:000174214200013
J	Vasseur, S; Hoffmeister, A; Garcia-Montero, A; Mallo, GV; Feil, R; Kuhbandner, S; Dagorn, JC; Iovanna, JL				Vasseur, S; Hoffmeister, A; Garcia-Montero, A; Mallo, GV; Feil, R; Kuhbandner, S; Dagorn, JC; Iovanna, JL			p8-deficient fibroblasts grow more rapidly and are more resistant to adriamycin-induced apoptosis	ONCOGENE			English	Article						p8; p53; cell-cycle; apoptosis; MEF	TATA-BINDING PROTEIN; CELL-CYCLE CONTROL; WILD-TYPE; P53 BINDS; IN-VITRO; EXPRESSION; STRESS; GENE; P8; TRANSCRIPTION	p8 is a stress-induced DNA-binding protein, biochemically related to the architectural chromatin binding HMG protein family and whose function is presently unknown. We obtained fibroblast from mice lacking p8 and found that p8 is involved in cell growth regulation and in apoptosis. p8(-/-) mouse embryonic fibroblasts (MEFs) grow more rapidly than p8(+/+) MEFs. This might be explained by the higher intracellular level and activity of the Cdk2 and Cdk4 observed in p8-/- MEFs, which in turn may result, at least in part, from the concomitant decrease observed in the amount of cyclin-dependent kinase inhibitor p27. We also report that p8 mRNA expression is strongly activated in fibroblasts after cell growth arrest induced by serum deprivation or confluence. As expected, MEFs expressing pS arrest their growth more rapidly after serum deprivation than MEFs lacking p8, which strongly suggests that p8 overexpression is implicated in cell growth arrest. On the other hand, P8(+/+) MEFs are more sensitive than p8(-/-)MEFs to the apoptosis induced by adriamycin treatment. p53 might be involved, as p8 expression increases its intracellular amount and trans-activation capacity. Finally, demonstration that p53 is a negative transactivator of p8 suggests the presence of a complex autoregulatory loop. In conclusion, p8 is a cell growth inhibitor that facilitates apoptosis induced in fibroblasts by DNA damage.	INSERM, Ctr Rech, F-13009 Marseille, France; Inst Pharmakol & Toxikol, D-80802 Munich, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm)	Iovanna, JL (corresponding author), INSERM, Ctr Rech, EMI 0116,Parc Sci & Technol Luminy,163 Av Luminy, F-13009 Marseille, France.	iovanna@inserm-adr.univ-mrs.fr	Montero, Andres/HGA-9093-2022; vasseur, sophie/O-9803-2017; Garcia-Montero, Andres C/B-6558-2017; Feil, Susanne/AAF-7032-2019; Iovanna, Juan/M-9805-2017; Feil, Robert/B-8918-2014	vasseur, sophie/0000-0002-2339-8854; Garcia-Montero, Andres C/0000-0003-4360-1386; Iovanna, Juan/0000-0003-1822-2237; Feil, Robert/0000-0002-7335-4841				Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Bratland A, 2000, CANCER RES, V60, P5578; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Encinar JA, 2001, J BIOL CHEM, V276, P2742, DOI 10.1074/jbc.M008594200; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Goldschmidt-Clermont PJ, 1999, GENE EXPRESSION, V7, P255; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HARVEY M, 1993, ONCOGENE, V8, P2457; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jiang YF, 1999, BIOCHEM BIOPH RES CO, V260, P686, DOI 10.1006/bbrc.1999.0953; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kuhbandner S, 2000, GENESIS, V28, P15, DOI 10.1002/1526-968X(200009)28:1<15::AID-GENE20>3.0.CO;2-C; Mallo GV, 1997, J BIOL CHEM, V272, P32360, DOI 10.1074/jbc.272.51.32360; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Pesch J, 1996, J INTERF CYTOK RES, V16, P595, DOI 10.1089/jir.1996.16.595; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Ree AH, 1999, CANCER RES, V59, P4675; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shackelford RE, 1999, ENVIRON HEALTH PERSP, V107, P5, DOI 10.2307/3434468; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Su SB, 2001, CLIN CANCER RES, V7, P309; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Vasseur S, 1999, EUR J BIOCHEM, V259, P670, DOI 10.1046/j.1432-1327.1999.00092.x; Vasseur S, 1999, BIOCHEM J, V343, P377, DOI 10.1042/0264-6021:3430377; Wang E, 1999, J CELL BIOCHEM, P95; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhang LL, 2000, CANCER RES, V60, P3655	41	79	83	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1685	1694		10.1038/sj.onc.1205222	http://dx.doi.org/10.1038/sj.onc.1205222			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896600				2022-12-25	WOS:000174214200007
J	Bhatia, N; Herter, JR; Slaga, TJ; Fuchs, SY; Spiegelman, VS				Bhatia, N; Herter, JR; Slaga, TJ; Fuchs, SY; Spiegelman, VS			Mouse homologue of HOS (mHOS) is overexpressed in skin tumors and implicated in constitutive activation of NF-kappa B	ONCOGENE			English	Article						NF-kappa B; ubiquitin ligase; skin carcinogenesis; beta TrCP; HOS; F-box	F-BOX PROTEIN; BETA-TRCP; HA-RAS; UBIQUITIN LIGASE; DEPENDENT DEGRADATION; TRANSCRIPTION FACTORS; INCREASED EXPRESSION; ELEVATED EXPRESSION; POINT MUTATION; ALPHA	NF-kappaB transcription factor is activated upon ubiquitination and subsequent proteolysis of its inhibitor IkappaB. The phosphorylation-dependent ubiquitination is mediated by SCIF E3 ubiquitin ligase. In this study, we identified a novel murine F-box/WD40 repeat-containing protein, mHOS (a homologue of HOS/betaTrCP2). mHOS efficiently binds Skp1 protein (a 'core' component of SCIF ubiquitin ligase), and phosphorylated IkappaBalpha. We found that mHOS associates with SCF-ROC1 E3 ubiquitin ligase activity. We have also observed that mHOS is overexpressed in chemically-induced mouse skin tumors, and its overexpression (but not accelerated IkappaB phosphorylation) coincides with the accelerated degradation of IkappaB in vivo. The role of mHOS in the constitutive activation of NF-kappaB in skin carcinogenesis is discussed.	AMC Canc Res Ctr, Ctr Canc Causat & Prevent, Lakewood, CO 80214 USA; Univ Penn, Dept Biol Anim, Philadelphia, PA 19104 USA	AMC Cancer Research Center; University of Pennsylvania	Spiegelman, VS (corresponding author), AMC Canc Res Ctr, Ctr Canc Causat & Prevent, 1600 Pierce St, Lakewood, CO 80214 USA.	spiegelman@amc.org		Spiegelman, Vladimir S/0000-0003-4847-155X	NCI NIH HHS [CA 92900, CA 76262] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DIGIOVANNI J, 1993, MOL CARCINOGEN, V8, P272, DOI 10.1002/mc.2940080410; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; PELLING JC, 1988, CARCINOGENESIS, V9, P665, DOI 10.1093/carcin/9.4.665; PELLING JC, 1987, CARCINOGENESIS, V8, P1481, DOI 10.1093/carcin/8.10.1481; PELLING JC, 1986, CARCINOGENESIS, V7, P1599, DOI 10.1093/carcin/7.9.1599; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V26, P150, DOI 10.1002/(SICI)1098-2744(199911)26:3<150::AID-MC3>3.0.CO;2-P; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Speigelman VS, 2001, J BIOL CHEM, V276, P27152, DOI 10.1074/jbc.M100031200; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Suzuki H, 1999, FEBS LETT, V458, P343, DOI 10.1016/S0014-5793(99)01173-4; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zhang XY, 1997, AM J HEMATOL, V55, P205, DOI 10.1002/(SICI)1096-8652(199707)55:4<205::AID-AJH7>3.0.CO;2-W	38	30	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1501	1509		10.1038/sj.onc.1205311	http://dx.doi.org/10.1038/sj.onc.1205311			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896578				2022-12-25	WOS:000173956800005
J	Vail, ME; Chaisson, ML; Thompson, J; Fausto, N				Vail, ME; Chaisson, ML; Thompson, J; Fausto, N			Bcl-2 expression delays hepatocyte cell cycle progression during liver regeneration	ONCOGENE			English	Article						liver regeneration; cell cycle; Bcl-2; transgenic mice; hepatocyte	PROLIFERATION; FAMILY; DEATH; E2F; CARCINOGENESIS; INHIBITION; APOPTOSIS; PROTEINS; P130	Bcl-2 is the prototype of a family of genes that prevent apoptosis. However, several reports indicate that Bcl-2 may also act as a cell cycle modulator. In several human tumors, Bcl-2 expression correlates with a more favorable prognosis and lower tumor proliferative activity. We have shown that Bcl-2 expression delays liver tumor development in transgenic mice even when the gene is turned on shortly before the time of tumor development. We hypothesized that Bcl-2 may delay liver tumorigenesis by interfering with hepatocyte proliferation. To test whether Bcl-2 expression may act on hepatocyte replication we studied liver regeneration in Bcl-2 transgenic mice and wild-type littermates. DNA replication was delayed by approximately 8 h in Bcl-2 transgenic mice compared to the timing of the response in wild-type littermates. Cyclin D expression showed no alterations in the regenerating liver of Bcl-2 transgenic mice. In contrast, there was a delay in the expression of p107, cyclin E and in the activity of cyclin E/cdk 2 activity. These results show that Bcl-2 expression delays cell cycle progression in hepatocytes and suggests that it acts at a step involving cyclin E and p107.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Fausto, N (corresponding author), Univ Washington, Dept Pathol, K-078 Hlth Sci Bldg,Box 357705, Seattle, WA 98195 USA.	nfausto@u.washington.edu			NCI NIH HHS [CA 09437, CA74131] Funding Source: Medline; NIGMS NIH HHS [T32 GMO7270] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074131, T32CA009437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; de la Coste A, 1999, CANCER RES, V59, P5017; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; Kuwashima Y, 1997, ANTICANCER RES, V17, P3773; Lin HM, 2001, CELL DEATH DIFFER, V8, P44, DOI 10.1038/sj.cdd.4400770; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Nelsen CJ, 2001, ONCOGENE, V20, P1825, DOI 10.1038/sj.onc.1204248; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OReilly LA, 1997, INT IMMUNOL, V9, P1291, DOI 10.1093/intimm/9.9.1291; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Silvestrini R, 1996, J CLIN ONCOL, V14, P1604, DOI 10.1200/JCO.1996.14.5.1604; Sinicrope FA, 1995, CLIN CANCER RES, V1, P1103; Truchet I, 2000, EXP CELL RES, V254, P241, DOI 10.1006/excr.1999.4756; Tzung SP, 1997, AM J PATHOL, V150, P1985; Vail ME, 2001, CANCER RES, V61, P594; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; Vairo G, 1996, ONCOGENE, V13, P1511; WEBBER EM, 1994, AM J PATHOL, V145, P398; Winter JN, 1998, BLOOD, V91, P1391, DOI 10.1182/blood.V91.4.1391; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674	29	30	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1548	1555		10.1038/sj.onc.1205212	http://dx.doi.org/10.1038/sj.onc.1205212			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896583				2022-12-25	WOS:000173956800010
J	Dineley, KT; Xia, XF; Bui, D; Sweatt, JD; Zheng, H				Dineley, KT; Xia, XF; Bui, D; Sweatt, JD; Zheng, H			Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; CONTEXTUAL FEAR; NEUROPSYCHOLOGICAL MEASURES; HIPPOCAMPAL ATROPHY; DORSAL HIPPOCAMPUS; LONGITUDINAL MRI; KINASE CASCADE; BETA-PROTEIN; MAP KINASE	Familial Alzheimer's disease-associated mutations in presenilin 1 or 2 or amyloid precursor protein result in elevated beta-amyloid, beta-amyloid accumulation, and plaque formation in the brains of affected individuals. By crossing presenilin 1 transgenic mice carrying the A246E mutation with plaque-producing amyloid precursor protein K670N/M671L transgenic mice (Tg2576), we show that co-expression of both mutant transgenes results in acceleration of amyloid accumulation and associative learning deficits. At 5 months of age with no detectable plaque pathology, amyloid precursor protein transgenic animals are impaired in contextual fear learning following two pairings of conditioned and unconditioned stimuli but appear normal following a more robust five-pairing training. At 9 months of age when beta-amyloid deposition is evident, these mice are impaired following both two-pairing and five-pairing protocols. Mice carrying both transgenes are impaired in contextual fear conditioning at either age. All transgenic animal groups performed as well as controls in cued fear conditioning, indicating that the contextual fear learning deficits are hippocampus-specific. The associative learning impairments are coincident with elevated alpha7 nicotinic acetylcholine receptor protein in the dentate gyrus. These findings provide two robust and rapid assays for beta-amyloid-associated effects that can be performed on young animals: impaired contextual fear learning and up-regulation of alpha7 nicotinic receptors.	Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Dineley, KT (corresponding author), Baylor Coll Med, Div Neurosci, Rm S603,1 Baylor Plaza, Houston, TX 77030 USA.	kdineley@cns.bcm.tmc.edu; jsweatt@cns.bcm.tmc.edu		Sweatt, J. David/0000-0003-3567-485X				Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Blum S, 1999, J NEUROSCI, V19, P3535; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Buisson B, 2001, J NEUROSCI, V21, P1819, DOI 10.1523/JNEUROSCI.21-06-01819.2001; BUTTERS N, 1987, J CLIN EXP NEUROPSYC, V9, P479, DOI 10.1080/01688638708410764; Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Chishti MA, 2001, J BIOL CHEM, V276, P21562, DOI 10.1074/jbc.M100710200; DEWEER B, 1995, J NEUROL NEUROSUR PS, V58, P590, DOI 10.1136/jnnp.58.5.590; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; Dodart JC, 2000, REV NEUROSCIENCE, V11, P75; Fenster CP, 1999, ANN NY ACAD SCI, V868, P620, DOI 10.1111/j.1749-6632.1999.tb11335.x; Fox NC, 1996, BRAIN, V119, P2001, DOI 10.1093/brain/119.6.2001; Fox NC, 1996, ANN NY ACAD SCI, V777, P226, DOI 10.1111/j.1749-6632.1996.tb34423.x; Frautschy SA, 1998, AM J PATHOL, V152, P307; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Ke L, 1998, J PHARMACOL EXP THER, V286, P825; KIM JJ, 1993, BEHAV NEUROSCI, V107, P1093, DOI 10.1037/0735-7044.107.6.1093; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; Koistinaho M, 2001, P NATL ACAD SCI USA, V98, P14675, DOI 10.1073/pnas.261562998; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Maren S, 1997, BEHAV BRAIN RES, V88, P261, DOI 10.1016/S0166-4328(97)00088-0; MARKS MJ, 1983, J PHARMACOL EXP THER, V226, P817; McNish KA, 1997, J NEUROSCI, V17, P9353; Paylor R, 1998, LEARN MEMORY, V5, P302; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Qian S, 1998, NEURON, V20, P611, DOI 10.1016/S0896-6273(00)80999-X; Schafe GE, 1999, LEARN MEMORY, V6, P97; Selcher JC, 1999, LEARN MEMORY, V6, P478, DOI 10.1101/lm.6.5.478; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; WELSH K, 1991, ARCH NEUROL-CHICAGO, V48, P278, DOI 10.1001/archneur.1991.00530150046016; WELSH KA, 1992, ARCH NEUROL-CHICAGO, V49, P448, DOI 10.1001/archneur.1992.00530290030008; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002	36	188	206	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22768	22780		10.1074/jbc.M200164200	http://dx.doi.org/10.1074/jbc.M200164200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11912199	hybrid			2022-12-25	WOS:000176313600086
J	Bodi, I; Koch, SE; Yamaguchi, H; Szigeti, GP; Schwartz, A; Varadi, G				Bodi, I; Koch, SE; Yamaguchi, H; Szigeti, GP; Schwartz, A; Varadi, G			The role of region IVS5 of the human cardiac calcium channel in establishing inactivated channel conformation - Use-dependent block by benzothiazepines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PHENYLALKYLAMINE BLOCK; CA2+ CHANNEL; SODIUM-CHANNEL; MOLECULAR DETERMINANTS; RECEPTOR-SITE; HUMAN HEART; DIHYDROPYRIDINE ACTION; FUNCTIONAL EXPRESSION; POTASSIUM CHANNEL; ALPHA(1) SUBUNIT	The role of inactivated channel conformation and use dependence for diltiazem, a specific benzothiazepine calcium channel inhibitor, was studied in chimeric constructs and point mutants created in the IVS5 transmembrane segment of the L-type cardiac calcium channel. All mutations, chimeric or point mutations, were restricted to IVS5, while the YAI-containing segment in IVS6, i.e. the primary interaction site with benzothiazepines, remained intact. Slowed inactivation rate and incomplete steady state inactivation, a behavior of some mutants, were accompanied by a reduced or by a complete loss of use-dependent block by diltiazem. Single channel properties of mutants that lost use dependence toward diltiazem were characterized by drastically elongated mean open times and distinctly slower time constants of open time distribution. Mutation of individual residues of the IVMLF segment in IVS5 did not mimic the complete loss of use dependence as observed for the replacement of the whole stretch. These results establish evidence that amino acids that govern inactivation and the drug-binding site and other amino acids that are located distal from the putative drug-binding site contribute significantly to the function of the benzothiazepine receptor region. The data are consistent with a complex "pocket" conformation that is responsive to a specific class of L-type calcium channel inhibitors. The data allow for a concept that multiple sites within regions of the a, subunit contribute to auto-regulation of the L-type Ca2+ channel.	Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, Cardiovasc Res Ctr,Dept Surg, Cincinnati, OH 45267 USA; SUNY Buffalo, Dept Physiol & Biophys, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	University System of Ohio; University of Cincinnati; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Bodi, I (corresponding author), Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, Cardiovasc Res Ctr,Dept Surg, G-933,POB 670828,231 Albert Sabin Way, Cincinnati, OH 45267 USA.		Szigeti, Gyula/A-1248-2008; Tuluc, Petronel/C-2527-2011	Szigeti, Gyula/0000-0003-0411-9992; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619, T32HL007382] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07382, P01 HL22619] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berjukow S, 1999, J BIOL CHEM, V274, P6154, DOI 10.1074/jbc.274.10.6154; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; Bodi I, 1997, J BIOL CHEM, V272, P24952, DOI 10.1074/jbc.272.40.24952; CHAHINE M, 1994, NEURON, V12, P281, DOI 10.1016/0896-6273(94)90271-2; COLLIN T, 1994, EUR J BIOCHEM, V220, P257, DOI 10.1111/j.1432-1033.1994.tb18621.x; Degtiar VE, 1997, BIOPHYS J, V73, P157, DOI 10.1016/S0006-3495(97)78056-1; Deschenes I, 1999, CARDIOVASC RES, V42, P521, DOI 10.1016/S0008-6363(99)00064-4; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Ferrari R, 1997, EUR HEART J, V18, pA56; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; Hering S, 1997, P NATL ACAD SCI USA, V94, P13323, DOI 10.1073/pnas.94.24.13323; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; Hering S, 1998, TRENDS PHARMACOL SCI, V19, P439, DOI 10.1016/S0165-6147(98)01258-9; HESS P, 1984, NATURE, V311, P538, DOI 10.1038/311538a0; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; Hockerman GH, 1997, J BIOL CHEM, V272, P18759, DOI 10.1074/jbc.272.30.18759; Hockerman GH, 1997, P NATL ACAD SCI USA, V94, P14906, DOI 10.1073/pnas.94.26.14906; Johnson BD, 1996, MOL PHARMACOL, V50, P1388; KLAUS D, 1992, J CARDIOVASC PHARM, V20, pS5; KLOCKNER U, 1995, J BIOL CHEM, V270, P17306, DOI 10.1074/jbc.270.29.17306; Kraus RL, 1998, J BIOL CHEM, V273, P27205, DOI 10.1074/jbc.273.42.27205; Kraus RL, 1998, J BIOL CHEM, V273, P5586, DOI 10.1074/jbc.273.10.5586; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; McPhee JC, 1998, J BIOL CHEM, V273, P1121, DOI 10.1074/jbc.273.2.1121; Motoike HK, 1999, J BIOL CHEM, V274, P9409, DOI 10.1074/jbc.274.14.9409; Opie LH, 1997, EUR HEART J, V18, pA71; Peterson BZ, 1997, J BIOL CHEM, V272, P18752, DOI 10.1074/jbc.272.30.18752; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; Sinnegger MJ, 1997, J BIOL CHEM, V272, P27686, DOI 10.1074/jbc.272.44.27686; Sokolov S, 1999, J PHYSIOL-LONDON, V519, P315, DOI 10.1111/j.1469-7793.1999.0315m.x; Sokolov S, 2001, CIRC RES, V89, P700, DOI 10.1161/hh2001.098983; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; WAKAMORI M, 1993, BIOCHEM BIOPH RES CO, V196, P1170, DOI 10.1006/bbrc.1993.2374; WEIR MR, 1995, J CLIN PHARMACOL, V35, P220, DOI 10.1002/j.1552-4604.1995.tb04051.x; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; Yamaguchi H, 1999, P NATL ACAD SCI USA, V96, P1357, DOI 10.1073/pnas.96.4.1357	36	5	5	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20651	20659		10.1074/jbc.M200752200	http://dx.doi.org/10.1074/jbc.M200752200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11912204	hybrid			2022-12-25	WOS:000176204500072
J	Diwa, AA; Belasco, JG				Diwa, AA; Belasco, JG			Critical features of a conserved RNA stem-loop important for feedback regulation of RNase E synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; RIBONUCLEASE-E; STABILITY AMS; DEGRADATION; GENE; CLEAVAGE; PROTEIN; ENDORIBONUCLEASE	P,Nase E is an important regulatory enzyme that governs the principal pathway for mRNA degradation in Escherichia coli. This endonuclease controls its own synthesis via a feedback mechanism in which the longevity of rne (RNase E) mRNA is modulated by a cis-acting sensory element that responds to changes in cellular RNase E activity. Previous research has shown that this element is an RNA stem-loop (hp2) within the 5'-untranslated region of the rne transcript. Here we report studies involving mutational analysis and phylogenetic comparison that have identified the features of rne hp2 important for its function. These comprise an internal loop flanked on one side by a 2-bp stem and a hairpin loop and on the other side by a longer stem whose sequence is inconsequential. A search of bacterial genome sequences suggests that regulation by an hp2-like element may be a unique evolutionary adaptation of the rne transcript that is not shared by other mRNAs.	NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	New York University; New York University	Belasco, JG (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, 540 1St Ave, New York, NY 10016 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035769] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35769] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APIRION D, 1978, GENETICS, V90, P659; Arnold TE, 1998, RNA, V4, P319; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; Belasco J, 1993, CONTROL MESSENGER RN, P3; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; CLAVERIEMARTIN F, 1991, J BIOL CHEM, V266, P2843; Diwa A, 2000, GENE DEV, V14, P1249; DIWA A, 2001, THESIS NEW YORK U; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; Jain C, 2000, METHOD ENZYMOL, V318, P309; Jain C, 2002, MOL MICROBIOL, V43, P1053, DOI 10.1046/j.1365-2958.2002.02808.x; JAIN C, 1995, GENE DEV, V9, P84, DOI 10.1101/gad.9.1.84; KLUG G, 1991, P NATL ACAD SCI USA, V88, P1765, DOI 10.1073/pnas.88.5.1765; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; Mackie GA, 1998, NATURE, V395, P720, DOI 10.1038/27246; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; MUDD EA, 1993, MOL MICROBIOL, V9, P557, DOI 10.1111/j.1365-2958.1993.tb01716.x; NILSSON G, 1984, NATURE, V312, P75, DOI 10.1038/312075a0; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; Rauhut R, 1999, FEMS MICROBIOL REV, V23, P353, DOI 10.1016/S0168-6445(99)00012-1; RESNEKOV O, 1990, P NATL ACAD SCI USA, V87, P8355, DOI 10.1073/pnas.87.21.8355; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P851, DOI 10.1111/j.1365-2958.1991.tb00758.x	24	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20415	20422		10.1074/jbc.M202313200	http://dx.doi.org/10.1074/jbc.M202313200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11919204	hybrid			2022-12-25	WOS:000176204500041
J	Higashi, N; Fujioka, K; Denda-Nagai, K; Hashimoto, S; Nagai, S; Sato, T; Fujita, Y; Morikawa, A; Tsuiji, M; Miyata-Takeuchi, M; Sano, Y; Suzuki, N; Yamamoto, K; Matsushima, K; Irimura, T				Higashi, N; Fujioka, K; Denda-Nagai, K; Hashimoto, S; Nagai, S; Sato, T; Fujita, Y; Morikawa, A; Tsuiji, M; Miyata-Takeuchi, M; Sano, Y; Suzuki, N; Yamamoto, K; Matsushima, K; Irimura, T			The macrophage C-type lectin specific for galactose/N-acetylgalactosamine is an endocytic receptor expressed on monocyte-derived immature dendritic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; IMMORTALIZED B-CELLS; ASIALOGLYCOPROTEIN RECEPTOR; GENE-EXPRESSION; SERIAL ANALYSIS; MOLECULAR-CLONING; SENSITIZATION PHASE; DC-SIGN; TRAFFICKING; CDNA	Lectins on antigen presenting cells are potentially involved in the antigen uptake and the cellular recognition and trafficking. Serial analysis of gene expression in monocyte-derived dendritic cells (DCs), monocytes, and macrophages revealed that 7 of the 19 C-type lectin mRNA were present in immature DCs. Two of these, the macrophage mannose receptor and the macrophage lectin specific for galactose/N-acetylgalactosamine (MGL), were found only in immature DCs, as confirmed by reverse transcriptase-PCR and flow cytometric analysis. By subcloning and sequencing the amplified mRNA, we obtained nucleotide sequences encoding seven different human MGL (hMGL) subtypes, which were apparently derived from alternatively spliced mRNA. In addition, the hMGL gene locus on human chromosome 17p13 contains one gene. A single nucleotide polymorphism was identified at a position in exon 3 that corresponds to the cytoplasmic region proximal to the transmembrane domain. Of all the splicing variants, the hMGL variant 6C was expressed at the highest levels on immature DCs from all donors tested. Immature DCs could incorporate alpha-GaINAc-modified soluble acrylamide polymers, and this was significantly inhibited by pretreatment of the cells with an anti-hMGL monoclonal antibody that blocks the lectin-carbohydrate interaction. We propose that hMGL is a marker of imDCs and that it functions as an endocytic receptor for glycosylated antigens.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Sch Med, Dept Mol Prevent Med, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Irimura, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	irimura@mol.f.u-tokyo.ac.jp	Fujioka, Kouki/AAL-7517-2021; Tsuiji, Makoto/G-1411-2010	Fujioka, Kouki/0000-0002-9472-2922; Tsuiji, Makoto/0000-0002-5607-4880; Nagai, Shigenori/0000-0002-5018-5942; Denda-Nagai, Kaori/0000-0001-8325-3289				Ariizumi K, 2000, J BIOL CHEM, V275, P20157, DOI 10.1074/jbc.M909512199; Ariizumi K, 2000, J BIOL CHEM, V275, P11957, DOI 10.1074/jbc.275.16.11957; Avrameas A, 1996, EUR J IMMUNOL, V26, P394, DOI 10.1002/eji.1830260219; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BARND DL, 1989, P NATL ACAD SCI USA, V86, P7159, DOI 10.1073/pnas.86.18.7159; Bates EEM, 1999, J IMMUNOL, V163, P1973; Bider MD, 1996, J BIOL CHEM, V271, P31996, DOI 10.1074/jbc.271.50.31996; Chun KH, 2000, INT IMMUNOL, V12, P1695, DOI 10.1093/intimm/12.12.1695; Chun KH, 2000, J LEUKOCYTE BIOL, V68, P471; Colonna M, 2000, EUR J IMMUNOL, V30, P697; Feinberg H, 2000, J BIOL CHEM, V275, P21539, DOI 10.1074/jbc.M002366200; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Guo M, 2000, HUM IMMUNOL, V61, P729, DOI 10.1016/S0198-8859(00)00144-0; Hashimoto S, 2000, BLOOD, V96, P2206, DOI 10.1182/blood.V96.6.2206.h8002206_2206_2214; Hashimoto S, 1999, BLOOD, V94, P837, DOI 10.1182/blood.V94.3.837.413k02_837_844; Hashimoto S, 1999, BLOOD, V94, P845, DOI 10.1182/blood.V94.3.845.415k09_845_852; HIGASHI N, 2002, IN PRESS INT IMMUNOL; Ichii S, 1997, J LEUKOCYTE BIOL, V62, P761, DOI 10.1002/jlb.62.6.761; Ichii S, 2000, CANCER IMMUNOL IMMUN, V49, P1, DOI 10.1007/s002620050021; II M, 1990, J BIOL CHEM, V265, P11295; Iida SI, 1999, J BIOL CHEM, V274, P10697, DOI 10.1074/jbc.274.16.10697; Imai Y, 1995, IMMUNOLOGY, V86, P591; JEROME KR, 1993, J IMMUNOL, V151, P1654; JEROME KR, 1992, CANCER RES, V52, P5985; Kato M, 2000, INT IMMUNOL, V12, P1511, DOI 10.1093/intimm/12.11.1511; KAWAKAMI K, 1994, JPN J CANCER RES, V85, P744, DOI 10.1111/j.1349-7006.1994.tb02423.x; LEUNG JO, 1985, J BIOL CHEM, V260, P2523; LUNDAHL J, 1994, INFLAMMATION, V18, P67, DOI 10.1007/BF01534599; MACEY MG, 1994, EXP HEMATOL, V22, P967; Mizuochi S, 1997, GLYCOBIOLOGY, V7, P137, DOI 10.1093/glycob/7.1.137; OZAKI K, 1992, J BIOL CHEM, V267, P9229; PAIETTA E, 1992, J BIOL CHEM, V267, P11078; SAKAMAKI T, 1995, J LEUKOCYTE BIOL, V57, P407, DOI 10.1002/jlb.57.3.407; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Sato K, 1998, J IMMUNOL, V161, P6835; SATO M, 1992, J BIOCHEM-TOKYO, V111, P331, DOI 10.1093/oxfordjournals.jbchem.a123758; Soilleux EJ, 2000, J IMMUNOL, V165, P2937, DOI 10.4049/jimmunol.165.6.2937; Suzuki N, 1996, J IMMUNOL, V156, P128; Suzuki T, 2000, BLOOD, V96, P2584; TAKAHASHI T, 1994, J IMMUNOL, V153, P2102; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Valladeau J, 2000, IMMUNITY, V12, P71, DOI 10.1016/S1074-7613(00)80160-0; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; YAMAMOTO K, 1994, BIOCHEMISTRY-US, V33, P8159, DOI 10.1021/bi00192a021; Zeng FY, 1996, BIOCHEM BIOPH RES CO, V218, P325, DOI 10.1006/bbrc.1996.0057; Zeng FY, 1996, J BIOL CHEM, V271, P32454, DOI 10.1074/jbc.271.50.32454; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	51	127	132	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20686	20693		10.1074/jbc.M202104200	http://dx.doi.org/10.1074/jbc.M202104200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11919201	hybrid			2022-12-25	WOS:000176204500076
J	Huang, YZ; Roelink, H; McKnight, GS				Huang, YZ; Roelink, H; McKnight, GS			Protein kinase A deficiency causes axially localized neural tube defects in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL CLEAVAGE PRODUCT; PROGENITOR-CELL IDENTITY; SONIC-HEDGEHOG; CATALYTIC SUBUNIT; OOCYTE MATURATION; SIGNALING PATHWAY; GENE-EXPRESSION; NEURONAL FATE; SITE UPSTREAM; FLOOR PLATE	We have studied the function of protein kinase A (PKA) during embryonic development using a PKA-deficient mouse that retains only one functional catalytic subunit allele, either Calpha or Cbeta, of PKA. The reduced PKA activity results in neural tube defects that are specifically localized posterior to the forelimb buds and lead to spina bifida. The affected neural tube has closed appropriately but exhibits an enlarged lumen and abnormal neuroepithelium. Decreased PKA activity causes dorsal expansion of Sonic hedgehog signal response in the thoracic to sacral regions correlating with the regions of morphological abnormalities. Other regions of the neural tube appear normal. The regional sensitivity to changes in PKA activity indicates that downstream signaling pathways differ along the anterior-posterior axis and suggests a functional role for PKA activation in neural tube development.	Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	McKnight, GS (corresponding author), Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA.	mcknight@u.washington.edu		Roelink, Henk/0000-0002-5260-3634	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032875] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32875] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcedo J, 2000, MOL CELL, V6, P457, DOI 10.1016/S1097-2765(00)00044-7; Altaba ARI, 1998, DEVELOPMENT, V125, P2203; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BORNSLAEGER EA, 1986, DEV BIOL, V114, P453, DOI 10.1016/0012-1606(86)90209-5; Briscoe J, 1999, NATURE, V398, P622, DOI 10.1038/19315; Briscoe J, 2000, CELL, V101, P435, DOI 10.1016/S0092-8674(00)80853-3; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; Copp Andrew J., 1994, Current Opinion in Pediatrics, V6, P624, DOI 10.1097/00008480-199412000-00002; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Desseyn JL, 2000, P NATL ACAD SCI USA, V97, P6433, DOI 10.1073/pnas.97.12.6433; Epstein DJ, 1996, DEVELOPMENT, V122, P2885; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; FRANZ T, 1993, ANAT EMBRYOL, V187, P371; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Guthrie CR, 1997, J BIOL CHEM, V272, P29560, DOI 10.1074/jbc.272.47.29560; Hannaford PC, 1996, BAILLIERE CLIN OB GY, V10, P647, DOI 10.1016/S0950-3552(96)80010-1; Harris MJ, 1999, TERATOLOGY, V60, P292, DOI 10.1002/(SICI)1096-9926(199911)60:5<292::AID-TERA10>3.3.CO;2-Y; HOMANICS GE, 1995, TERATOLOGY, V51, P1, DOI 10.1002/tera.1420510102; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Juriloff DM, 2000, HUM MOL GENET, V9, P993, DOI 10.1093/hmg/9.6.993; MARTI E, 1995, DEVELOPMENT, V121, P2537; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MATTEN W, 1994, MOL CELL BIOL, V14, P4419, DOI 10.1128/MCB.14.7.4419; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; Orlov SN, 1999, CELL DEATH DIFFER, V6, P661, DOI 10.1038/sj.cdd.4400539; Parvathenani LK, 1998, J BIOL CHEM, V273, P6736, DOI 10.1074/jbc.273.12.6736; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; POUEYMIROU WT, 1989, DEV BIOL, V133, P588, DOI 10.1016/0012-1606(89)90061-4; Qi M, 1996, P NATL ACAD SCI USA, V93, P1571, DOI 10.1073/pnas.93.4.1571; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Roelink H, 1996, CURR OPIN NEUROBIOL, V6, P33, DOI 10.1016/S0959-4388(96)80006-7; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Skalhegg BS, 2002, MOL ENDOCRINOL, V16, P630, DOI 10.1210/me.16.3.630; Spector D. L., 1998, CELLS LAB MANUAL; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; Theil T, 1999, DEVELOPMENT, V126, P3561; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Ying LT, 2000, NAT NEUROSCI, V3, P979, DOI 10.1038/79916; Zimmermann B, 1999, J BIOL CHEM, V274, P5370, DOI 10.1074/jbc.274.9.5370	49	79	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19889	19896		10.1074/jbc.M111412200	http://dx.doi.org/10.1074/jbc.M111412200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11886853	hybrid			2022-12-25	WOS:000175894800086
J	Lewicki, DN; Gallagher, TM				Lewicki, DN; Gallagher, TM			Quaternary structure of coronavirus spikes in complex with carcinoembryonic antigen-related cell adhesion molecule cellular receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL MEMBRANE-FUSION; INFLUENZA-VIRUS HEMAGGLUTININ; MURINE CORONAVIRUS; ENVELOPE GLYCOPROTEIN; HIV-1 GP41; ESCHERICHIA-COLI; HEPATITIS-VIRUS; MONOCLONAL-ANTIBODIES; PROTEOLYTIC CLEAVAGE; OLIGOMERIC STRUCTURE	Oligomeric spike (S) glycoproteins extend from coronavirus membranes. These integral membrane proteins assemble within the endoplasmic reticulum of infected cells and are subsequently endoproteolyzed in the Golgis, generating noncovalently associated S1 and S2 fragments. Once on the surface of infected cells and virions, peripheral S1 fragments bind carcinoembryonic antigen-related cell adhesion molecule (CEACAM) receptors, and this triggers membrane fusion reactions mediated by integral membrane S2 fragments. We focused on the quaternary structure of S and its interaction with CEACAMs. We discovered that soluble S1 fragments were dimers and that CEACAM binding was entirely dependent on this quaternary structure. However, two differentially tagged CEACAMs could not co-precipitate with the S dimers, suggesting that binding sites were closely juxtaposed in the dimer (steric hindrance) or that a single CEACAM generated global conformational changes that precluded additional interactions (negative cooperativity). CEACAM binding did indeed alter S1 conformations, generating alternative disulfide linkages that were revealed on SDS golgis. CEACAM binding also induced separation of S1 and S2. Differentially tagged S2 fragments that were free of S1 dimers were not co-precipitated, suggesting that S1 harbored the primary oligomerization determinants. We discuss the distinctions between the S-CEACAM interaction and other virus-receptor complexes involved in receptor-triggered entry.	Loyola Univ, Med Ctr, Dept Microbiol & Immunol, Maywood, IL 60153 USA	Loyola University Chicago	Gallagher, TM (corresponding author), Loyola Univ, Med Ctr, Dept Microbiol & Immunol, 2160 S 1st Ave, Maywood, IL 60153 USA.	tgallag@lumc.edu			NIAID NIH HHS [5T32 AI07508-05] Funding Source: Medline; NINDS NIH HHS [R01 NS 31616] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031616] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beauchemin N, 1999, EXP CELL RES, V252, P243; BERNSTEIN HB, 1995, J VIROL, V69, P2745, DOI 10.1128/JVI.69.5.2745-2750.1995; Billker O, 2002, EMBO J, V21, P560, DOI 10.1093/emboj/21.4.560; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Cavanagh D, 1995, CORONAVIRIDAE, P73; Center RJ, 2001, P NATL ACAD SCI USA, V98, P14877, DOI 10.1073/pnas.261573898; Center RJ, 2000, J VIROL, V74, P4448, DOI 10.1128/JVI.74.10.4448-4455.2000; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chen J, 1995, P NATL ACAD SCI USA, V92, P12205, DOI 10.1073/pnas.92.26.12205; DELMAS B, 1990, J VIROL, V64, P5367, DOI 10.1128/JVI.64.11.5367-5375.1990; DOMS RW, 1991, ADV EXP MED BIOL, V300, P203; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; Doranz BJ, 1999, J VIROL, V73, P10346, DOI 10.1128/JVI.73.12.10346-10358.1999; Dutch RE, 1999, VIROLOGY, V254, P147; DVEKSLER GS, 1993, P NATL ACAD SCI USA, V90, P1716, DOI 10.1073/pnas.90.5.1716; DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; EARL PL, 1992, J VIROL, V66, P5610, DOI 10.1128/JVI.66.9.5610-5614.1992; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Fass D, 1997, SCIENCE, V277, P1662, DOI 10.1126/science.277.5332.1662; FELDMANN H, 1991, VIROLOGY, V182, P353, DOI 10.1016/0042-6822(91)90680-A; FLEMING JO, 1983, VIROLOGY, V131, P296, DOI 10.1016/0042-6822(83)90498-1; FRANA MF, 1985, J VIROL, V56, P912, DOI 10.1128/JVI.56.3.912-920.1985; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; Gallagher TM, 1997, J VIROL, V71, P3129, DOI 10.1128/JVI.71.4.3129-3137.1997; Gallagher TM, 1996, J VIROL, V70, P4683, DOI 10.1128/JVI.70.7.4683-4690.1996; GALLAGHER TM, 1990, J VIROL, V64, P731, DOI 10.1128/JVI.64.2.731-741.1990; Gallaher WR, 1996, CELL, V85, P477, DOI 10.1016/S0092-8674(00)81248-9; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; HOLMES KV, 1994, COLD SPRING HARBOR M, P403; Joshi SB, 1998, VIROLOGY, V248, P20, DOI 10.1006/viro.1998.9242; Kim M, 2001, J BIOL CHEM, V276, P42667, DOI 10.1074/jbc.M104166200; Krueger DK, 2001, J VIROL, V75, P2792, DOI 10.1128/JVI.75.6.2792-2802.2001; KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994; Kuo LL, 2000, J VIROL, V74, P1393, DOI 10.1128/JVI.74.3.1393-1406.2000; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lescar J, 2001, CELL, V105, P137, DOI 10.1016/S0092-8674(01)00303-8; LEUSCH HG, 1991, INFECT IMMUN, V59, P2051, DOI 10.1128/IAI.59.6.2051-2057.1991; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Luo ZL, 1998, VIROLOGY, V244, P483, DOI 10.1006/viro.1998.9121; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; Mothes W, 2000, CELL, V103, P679, DOI 10.1016/S0092-8674(00)00170-7; PARKER SE, 1989, VIROLOGY, V173, P664, DOI 10.1016/0042-6822(89)90579-5; Perlman S, 2000, EFFECTS OF MICROBES ON THE IMMUNE SYSTEM, P331; Phillips JJ, 1999, J VIROL, V73, P7752, DOI 10.1128/JVI.73.9.7752-7760.1999; Pletnev SV, 2001, CELL, V105, P127, DOI 10.1016/S0092-8674(01)00302-6; ROUTLEDGE E, 1991, J VIROL, V65, P254, DOI 10.1128/JVI.65.1.254-262.1991; Russell CJ, 2001, EMBO J, V20, P4024, DOI 10.1093/emboj/20.15.4024; Salzwedel K, 2000, P NATL ACAD SCI USA, V97, P12794, DOI 10.1073/pnas.230438497; Sanchez CM, 1999, J VIROL, V73, P7607; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; SCHMIDT I, 1987, J GEN VIROL, V68, P47, DOI 10.1099/0022-1317-68-1-47; Singh M, 1999, J MOL BIOL, V290, P1031, DOI 10.1006/jmbi.1999.2796; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STURMAN LS, 1985, J VIROL, V56, P904, DOI 10.1128/JVI.56.3.904-911.1985; STURMAN LS, 1990, J VIROL, V64, P3042, DOI 10.1128/JVI.64.6.3042-3050.1990; Suzuki H, 1996, J VIROL, V70, P2632, DOI 10.1128/JVI.70.4.2632-2636.1996; Taguchi F, 2002, J VIROL, V76, P950, DOI 10.1128/JVI.76.3.950-958.2002; TATU U, 1995, EMBO J, V14, P1340, DOI 10.1002/j.1460-2075.1995.tb07120.x; VENNEMA H, 1990, ADV EXP MED BIOL, V276, P9; Weissenhorn W, 1998, P NATL ACAD SCI USA, V95, P6032, DOI 10.1073/pnas.95.11.6032; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; Weissenhorn W, 1997, P NATL ACAD SCI USA, V94, P6065, DOI 10.1073/pnas.94.12.6065; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; YOO D, 1991, VIROLOGY, V180, P395, DOI 10.1016/0042-6822(91)90045-D; Young BD, 1984, CENTRIFUGATION PRACT, P127	73	53	56	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19727	19734		10.1074/jbc.M201837200	http://dx.doi.org/10.1074/jbc.M201837200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11912215	Green Published, hybrid			2022-12-25	WOS:000175894800065
J	Yin, LY; Zhang, YQ; Hillgartner, FB				Yin, LY; Zhang, YQ; Hillgartner, FB			Sterol regulatory element-binding protein-1 interacts with the nuclear thyroid hormone receptor to enhance acetyl-CoA carboxylase-alpha transcription in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO HEPATOCYTES; MALIC ENZYME GENE; FATTY-ACID SYNTHESIS; LEUCINE ZIPPER PROTEIN; COENZYME-A CARBOXYLASE; STIMULATES TRANSCRIPTION; ADIPOCYTE DETERMINATION; INHIBITS TRANSCRIPTION; RESPONSE ELEMENT; SYNTHASE GENE	In previous work, we characterized a 3,5,3'-triiodothyronine response element (T3RE) in acetyl-CoA carboxylase-alpha (ACCalpha) promoter 2 that mediated 3,5,3'-triiodothyronine (T3) regulation of ACCalpha transcription in chick embryo hepatocytes. Sequence comparison analysis revealed the presence of sterol regulatory element-1 (SRE-1) located 5 by downstream of the ACCalpha T3RE. Here, we investigated the role of this SRE-1 in modulating T3 regulation of ACCalpha transcription. Transfection analyses demonstrated that the SRE-1 enhanced T3-induced ACCalpha transcription by more than 2-fold in hepatocytes. The effect of the SRE-1 on T3 responsiveness required the presence of the T3RE in its native orientation. In pull-down experiments, the mature form of sterol regulatory element-binding protein-1 (SREBP-1) specifically bound the alpha-isoform of the nuclear T3 receptor (TR), and the presence of T3 enhanced this interaction. A region of TRalpha containing the DNA-binding domain plus flanking sequences (amino acids 21-157) was required for interaction with SREBP-1, and a region of SREBP-1 containing the basic helix-loop-helix-leucine zipper domain (amino acids 300-389) was required for interaction with TRa. In gel mobility shift experiments, TRa, retinoid X receptor-alpha, and mature SREBP-1 formed a tetrameric complex on a DNA probe containing the ACCalpha T3RE and SRE-1, and the presence of T3 enhanced the formation of this complex. Formation of the tetrameric complex stabilized the binding of SREBP-1 to the SRE-1. These results indicate that SREBP-1 directly interacts with TR-retinoid X receptor in an orientation-specific manner to enhance T3-induced ACCalpha transcription in hepatocytes. T3 regulation of ACCalpha transcription in nonhepatic cell cultures such as chick embryo fibroblasts is markedly reduced compared with that of chick embryo hepatocytes. Here, we also show that alterations in SREBP expression play a role in mediating cell type-dependent differences in T3 regulation of ACCalpha transcription.	W Virginia Univ, Dept Biochem & Mol Pharmacol, Morgantown, WV 26506 USA	West Virginia University	Hillgartner, FB (corresponding author), W Virginia Univ, Dept Biochem & Mol Pharmacol, POB 9142, Morgantown, WV 26506 USA.							BAILLIE RA, 1993, J NUTR BIOCHEM, V4, P431, DOI 10.1016/0955-2863(93)90074-7; Bennett MK, 1999, J BIOL CHEM, V274, P13025, DOI 10.1074/jbc.274.19.13025; BLENNEMANN B, 1995, MOL CELL ENDOCRINOL, V110, P1, DOI 10.1016/0303-7207(95)03509-6; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BURMAN KD, 1977, ENDOCRINOLOGY, V101, P1331, DOI 10.1210/endo-101-4-1331; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Fang XX, 1998, ARCH BIOCHEM BIOPHYS, V349, P138, DOI 10.1006/abbi.1997.0406; Foretz M, 1999, MOL CELL BIOL, V19, P3760; GAVIN LA, 1980, J BIOL CHEM, V255, P49; GAVIN LA, 1988, ENDOCRINOLOGY, V123, P1075, DOI 10.1210/endo-123-2-1075; Gondret F, 2001, J LIPID RES, V42, P106; GOODRIDG.AG, 1973, J BIOL CHEM, V248, P1924; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; HILLGARTNER FB, 1992, J BIOL CHEM, V267, P12299; Hillgartner FB, 1997, J LIPID RES, V38, P2548; Hillgartner FB, 1996, BIOCHEM J, V319, P263, DOI 10.1042/bj3190263; Hillgartner FB, 1997, ARCH BIOCHEM BIOPHYS, V337, P159, DOI 10.1006/abbi.1996.9776; Hodnett DW, 1996, ARCH BIOCHEM BIOPHYS, V334, P309, DOI 10.1006/abbi.1996.0460; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Huang CL, 1998, BIOCHEM BIOPH RES CO, V249, P704, DOI 10.1006/bbrc.1998.9217; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Jump DB, 2001, J BIOL CHEM, V276, P34419, DOI 10.1074/jbc.M105471200; JUMP DB, 1989, J BIOL CHEM, V264, P4698; Kim KH, 1997, ANNU REV NUTR, V17, P77, DOI 10.1146/annurev.nutr.17.1.77; Koo SH, 2001, J BIOL CHEM, V276, P9437, DOI 10.1074/jbc.M010029200; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Magana MM, 1997, J LIPID RES, V38, P1630; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; MARIASH CN, 1980, J CLIN INVEST, V65, P1126, DOI 10.1172/JCI109766; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Osborne TF, 1995, CRIT REV EUKAR GENE, V5, P317, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.50; Park EA, 1999, J BIOL CHEM, V274, P211, DOI 10.1074/jbc.274.1.211; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; SALATI LM, 1991, J BIOL CHEM, V266, P4010; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sato R, 2000, J BIOL CHEM, V275, P12497, DOI 10.1074/jbc.275.17.12497; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Wang YT, 2002, BIOCHEM J, V361, P391, DOI 10.1042/bj3610391; Wang YT, 2001, J BIOL CHEM, V276, P23838, DOI 10.1074/jbc.M102166200; Xu J, 2001, J BIOL CHEM, V276, P9800, DOI 10.1074/jbc.M008973200; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Yin LY, 2000, BBA-GENE STRUCT EXPR, V1517, P91, DOI 10.1016/S0167-4781(00)00267-0; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; Zhang YQ, 2001, J BIOL CHEM, V276, P974, DOI 10.1074/jbc.M005894200	66	63	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19554	19565		10.1074/jbc.M111771200	http://dx.doi.org/10.1074/jbc.M111771200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11907029	hybrid			2022-12-25	WOS:000175894800043
J	Mezentsev, A; Seta, F; Dunn, MW; Ono, N; Falck, JR; Laniado-Schwartzman, M				Mezentsev, A; Seta, F; Dunn, MW; Ono, N; Falck, JR; Laniado-Schwartzman, M			Eicosanoid regulation of vascular endothelial growth factor expression and angiogenesis in microvessel endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT CORNEAL EPITHELIUM; P42/P44 MAP KINASE; CONTACT-LENS MODEL; ARACHIDONIC-ACID; 12(R)-HYDROXYEICOSATRIENOIC ACID; 12-HYDROXYEICOSATRIENOIC ACID; INFLAMMATORY EICOSANOIDS; SIGNALING ANGIOGENESIS; KAPPA-B; HYPOXIA	12(R)-Hydroxy-5,8,14-eicosatrienoic acid (HETrE) is a potent inflammatory and angiogenic eicosanoid in ocular and dermal tissues. Previous studies suggested that 12(R)-HETrE activates microvessel endothelial cells via a high affinity binding site; however, the cellular mechanisms underlying 12(R)-HETrE angiogenic activity are unexplored. Because the synthesis of 12(R)-HETrE is induced in response to hypoxic injury, we examined its interactions with vascular endothelial growth factor (VEGF) in rabbit limbal microvessel endothelial cells. Addition of 12(R)-HETrE (0.1 mm) to the cells increased VEGF mRNA levels with maximum 5-fold increase at 45 min. The increase in VEGF mRNA was followed by an increase in immunoreactive VEGF protein. 12(R)-HETrE (0.1 mm) rapidly activated the extracellular signal-regulated kinases (ERKs) ERK1 and ERK2. Moreover, preincubation of cells with PD98059, a selective inhibitor of MEK-1, inhibited 12(R)-HETrE-induced VEGF mRNA. Addition of VEGF antibody to cells grown in Matrigel-coated culture plates inhibited 12(R)-HETrE-induced capillary tube-like formation, suggesting that VEGF mediates, at least in part, the angiogenic response to 12(R)HETrE. The results indicate that in microvessel endothelial cells, 12(R)-HETrE induces VEGF expression via activation of ERK1/2 and that VEGF mediates, at least in part, the angiogenic activity of 12(R)-HETrE. Given the fact that both VEGF and 12(R)-HETrE are produced in the cornea after hypoxic injury, their interaction may be an important determinant in the development of neovascularized tissues.	New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	New York Medical College; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Laniado-Schwartzman, M (corresponding author), New York Med Coll, Dept Pharmacol, Basic Sci Bldg 530, Valhalla, NY 10595 USA.		Mezentsev, Alexandre/B-2559-2008; Seta, Francesca/ABB-1566-2020	Mezentsev, Alexandre/0000-0001-7100-1068; Mezentsev, Alexandre/0000-0002-4972-9922; Seta, Francesca/0000-0001-7985-5615; Falck, John/0000-0002-9219-7845	NEI NIH HHS [EY06513] Funding Source: Medline; NIGMS NIH HHS [GM31278] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bamba H, 2000, BIOCHEM BIOPH RES CO, V273, P485, DOI 10.1006/bbrc.2000.2969; BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; Berra E, 2000, BIOCHEM PHARMACOL, V60, P1171, DOI 10.1016/S0006-2952(00)00423-8; CAMP RDR, 1988, BRIT J PHARMACOL, V94, P1043, DOI 10.1111/j.1476-5381.1988.tb11620.x; Cheng T, 1998, INVEST OPHTH VIS SCI, V39, P581; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Conners MS, 1997, INVEST OPHTH VIS SCI, V38, P1963; CONNERS MS, 1995, INVEST OPHTH VIS SCI, V36, P828; CONNERS MS, 1995, INVEST OPHTH VIS SCI, V36, P841; CONNERS MS, 1994, J INVEST DERMATOL, V104, P1; Fleming I, 2001, PFLUG ARCH EUR J PHY, V442, P511, DOI 10.1007/s004240100565; Folkman J., 1992, INFLAMMATION BASIC P, P821; FORM DM, 1983, P SOC EXP BIOL MED, V172, P214; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; HOLTZMAN MJ, 1989, J CLIN INVEST, V84, P1446, DOI 10.1172/JCI114319; KLINTWORTH GK, 1990, CORNEAL ANGIOGENESIS; LANIADOSCHWARTZMAN M, 1994, J BIOL CHEM, V269, P24321; Leahy KM, 2000, CURR MED CHEM, V7, P1163, DOI 10.2174/0929867003374336; MASFERRER JL, 1991, EXP EYE RES, V52, P417, DOI 10.1016/0014-4835(91)90037-F; Mastyugin V, 1999, J PHARMACOL EXP THER, V289, P1611; Mastyugin V, 2001, CURR EYE RES, V23, P1, DOI 10.1076/ceyr.23.1.1.5422; Mieyal PA, 2000, INVEST OPHTH VIS SCI, V41, P2170; Mieyal PA, 2001, INVEST OPHTH VIS SCI, V42, P328; Munzenmaier DH, 2000, AM J PHYSIOL-HEART C, V278, pH1163, DOI 10.1152/ajpheart.2000.278.4.H1163; Nie DT, 2000, BLOOD, V95, P2304, DOI 10.1182/blood.V95.7.2304.007k23_2304_2311; Nie DT, 2000, BIOCHEM BIOPH RES CO, V267, P245, DOI 10.1006/bbrc.1999.1840; Pages G, 2000, ANN NY ACAD SCI, V902, P187; Pai R, 2001, BIOCHEM BIOPH RES CO, V286, P923, DOI 10.1006/bbrc.2001.5494; Schwartzman ML, 1997, ADVANCES IN OCULAR TOXICOLOGY, P3; SHIN DS, 1989, TETRAHEDRON LETT, V30, P3923, DOI 10.1016/S0040-4039(00)99285-2; Stoltz RA, 1996, AM J PATHOL, V148, P129; Stoltz RA, 1997, J OCUL PHARMACOL TH, V13, P191, DOI 10.1089/jop.1997.13.191; Stoltz RA, 1996, P NATL ACAD SCI USA, V93, P2832, DOI 10.1073/pnas.93.7.2832; Vafeas C, 1998, J PHARMACOL EXP THER, V287, P903; VANWAUWE J, 1991, EICOSANOIDS, V4, P155; WAINWRIGHT S, 1990, BIOCHEMISTRY-US, V29, P10126, DOI 10.1021/bi00495a017	36	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18670	18676		10.1074/jbc.M201143200	http://dx.doi.org/10.1074/jbc.M201143200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11901160	hybrid			2022-12-25	WOS:000175975800058
J	Waditee, R; Hibino, T; Tanaka, Y; Nakamura, T; Incharoensakdi, A; Hayakawa, S; Suzuki, S; Futsuhara, Y; Kawamitsu, Y; Takabe, T; Takabe, T				Waditee, R; Hibino, T; Tanaka, Y; Nakamura, T; Incharoensakdi, A; Hayakawa, S; Suzuki, S; Futsuhara, Y; Kawamitsu, Y; Takabe, T; Takabe, T			Functional characterization of betaine/proline transporters in betaine-accumulating mangrove	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID PERMEASE; GLYCINE BETAINE; ESCHERICHIA-COLI; CORYNEBACTERIUM-GLUTAMICUM; PROLINE BETAINE; SYSTEM; CLONING; STRESS; YEAST; GENE	Betaine is an important osmoprotectant in many plants, but its transport activity has only been demonstrated using a proline transporter from tomato, a betaine-nonaccumulating plant. In this study, two full-length and one partial transporter genes were isolated from betaine-accumulating mangrove Avicennia marina. Their homologies to betaine transporters from bacteria and betaine/4-aminobutyrate transporters from mammalian cells were low but were high to proline transporters from Arabidopsis and tomato. Two full-length transporters could complement the Na+-sensitive phenotype of the Escherichia coli mutant deficient in betT, putPA, proP, and proU. Both transporters could efficiently take up betaine and proline with similar affinities (K-m, 0.32-0.43 mm) and maximum velocities (1.9-3.6 nmol/min/mg of protein). The uptakes of betaine and proline were significantly inhibited by mono- and dimethylglycine but only partially inhibited by betaine aldehyde, choline, and 4-aminobutyrate. Sodium and potassium chloride markedly enhanced betaine uptake rates with optimum concentrations at 0.5 m, whereas sucrose showed only modest activation. The change of amino acids Thr(290)-Thr-Ser(292) in a putative periplasmic loop to Arg(290)-Gly-Arg(292) yielded the active transporter independent of salts, suggesting the positive charge induced a conformational change to the active form. These data clearly indicate that the betaine-accumulating mangrove contains betaine/proline transporters whose properties are distinct from betaine transporters of bacteria and mammalian cells.	Meijo Univ, Res Inst, Tenpaku Ku, Nagoya, Aichi 4688502, Japan; Meijo Univ, Fac Sci & Technol, Tenpaku Ku, Nagoya, Aichi 4688502, Japan; Meijo Univ, Sch Agr, Tenpaku Ku, Nagoya, Aichi 4688502, Japan; Chulalongkorn Univ, Fac Sci, Dept Biochem, Bangkok 10330, Thailand; Chiba Univ, Fac Pharmaceut Sci, Chiba 2638522, Japan; Univ Ryukyus, Fac Agr, Okinawa 9030213, Japan; Nagoya Univ, Grad Sch Agr Sci, Chikusa Ku, Aichi 4648601, Japan	Meijo University; Meijo University; Meijo University; Chulalongkorn University; Chiba University; University of the Ryukyus; Nagoya University	Takabe, T (corresponding author), Meijo Univ, Res Inst, Tenpaku Ku, Nagoya, Aichi 4688502, Japan.	takabe@ccmfs.meijo-u.ac.jp						Breitkreuz KE, 1999, FEBS LETT, V450, P280, DOI 10.1016/S0014-5793(99)00516-5; Bremer E, 2000, BACTERIAL STRESS RESPONSES, P79; CULHAM DE, 1993, J MOL BIOL, V229, P268, DOI 10.1006/jmbi.1993.1030; Fischer WN, 1998, TRENDS PLANT SCI, V3, P188, DOI 10.1016/S1360-1385(98)01231-X; FROMMER WB, 1993, P NATL ACAD SCI USA, V90, P5944, DOI 10.1073/pnas.90.13.5944; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; HAARDT M, 1995, MOL GEN GENET, V246, P783, DOI 10.1007/BF00290728; Hamada A, 2001, PLANT PHYSIOL, V125, P437, DOI 10.1104/pp.125.1.437; Hibino T, 2001, PLANT MOL BIOL, V45, P353, DOI 10.1023/A:1006497113323; HOFMANN K, 1992, COMPUT APPL BIOSCI, V8, P331; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; HSU LC, 1993, P NATL ACAD SCI USA, V90, P7441, DOI 10.1073/pnas.90.16.7441; Igarashi Y, 2000, PLANT CELL PHYSIOL, V41, P750, DOI 10.1093/pcp/41.6.750; Kappes RM, 1996, J BACTERIOL, V178, P5071, DOI 10.1128/jb.178.17.5071-5079.1996; Kempf B, 1998, ARCH MICROBIOL, V170, P319, DOI 10.1007/s002030050649; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMARK T, 1991, MOL MICROBIOL, V5, P1049, DOI 10.1111/j.1365-2958.1991.tb01877.x; Makela P, 1996, PLANT SCI, V121, P221, DOI 10.1016/S0168-9452(96)04527-X; NELSON K, 1992, J BACTERIOL, V174, P6886, DOI 10.1128/JB.174.21.6886-6895.1992; Ortiz-Lopez A, 2000, BBA-BIOMEMBRANES, V1465, P275, DOI 10.1016/S0005-2736(00)00144-9; Peter H, 1998, J BIOL CHEM, V273, P2567, DOI 10.1074/jbc.273.5.2567; Peter H, 1996, J BACTERIOL, V178, P5229, DOI 10.1128/jb.178.17.5229-5234.1996; Racher KI, 1999, BIOCHEMISTRY-US, V38, P1676, DOI 10.1021/bi981279n; Rathinasabapathi B, 1997, P NATL ACAD SCI USA, V94, P3454, DOI 10.1073/pnas.94.7.3454; Rentsch D, 1996, PLANT CELL, V8, P1437, DOI 10.1105/tpc.8.8.1437; RHODES D, 1993, ANNU REV PLANT PHYS, V44, P357, DOI 10.1146/annurev.pp.44.060193.002041; Rubenhagen R, 2001, EMBO J, V20, P5412, DOI 10.1093/emboj/20.19.5412; Schwacke R, 1999, PLANT CELL, V11, P377, DOI 10.1105/tpc.11.3.377; Sleator RD, 1999, APPL ENVIRON MICROB, V65, P2078; Takabe T, 1998, STRESS RESPONSES OF PHOTOSYNTHETIC ORGANISMS, P115; van der Heide T, 2000, P NATL ACAD SCI USA, V97, P7102, DOI 10.1073/pnas.97.13.7102; Waditee R, 2001, J BIOL CHEM, V276, P36931, DOI 10.1074/jbc.M103650200; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649	34	60	63	1	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18373	18382		10.1074/jbc.M112012200	http://dx.doi.org/10.1074/jbc.M112012200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11907031	hybrid			2022-12-25	WOS:000175975800017
J	Griffith, JD; Lindsey-Boltz, LA; Sancar, A				Griffith, JD; Lindsey-Boltz, LA; Sancar, A			Structures of the human Rad17-replication factor C and checkpoint Rad 9-1-1 complexes visualized by glycerol spray/low voltage microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION-FACTOR-C; LOADER SMALL-SUBUNIT; DNA-POLYMERASE-III; SCHIZOSACCHAROMYCES-POMBE; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; ELECTRON-MICROSCOPY; PYROCOCCUS-FURIOSUS; DAMAGE CHECKPOINTS; PROTEIN COMPLEX	Human checkpoint Rad proteins are thought to function as damage sensors in the DNA damage checkpoint response pathway. The checkpoint proteins hRad9, hHus1, and hRad1 have limited homology to the replication processivity factor proliferating cell nuclear antigen (PCNA), and hRad17 has homology to replication factor C (RFC). Such observations have led to the proposal that these checkpoint Rad proteins may function similarly to their replication counterparts during checkpoint control. We purified two complexes formed by the checkpoint Rad proteins and investigated their structures using an electron microscopic preparative method in which the complexes are sprayed from a glycerol solution onto very thin carbon foils, decorated in vacuo with tungsten, and imaged at low voltage. We found that the hRad9, hHus1, and hRad1 proteins make a trimeric ring structure (checkpoint 9-1-1 complex) reminiscent of the PCNA ring. Similarly we found that hRad17 makes a heteropentameric complex with the four RFC small subunits (hRad17-RFC) with a deep groove or cleft and is similar to the RFC clamp loader. Therefore, our results demonstrate structural similarity between the checkpoint Rad complexes and the PCNA and RFC replication factors and thus provide further support for models proposing analogous functions for these complexes.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Sancar, A (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.		Lindsey-Boltz, Laura/A-3121-2010	Lindsey-Boltz, Laura/0000-0001-6493-8194	NCI NIH HHS [T32-CA09156] Funding Source: Medline; NIGMS NIH HHS [GM31809, F32-GM20830] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM020830] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Kaur R, 2001, MOL BIOL CELL, V12, P3744, DOI 10.1091/mbc.12.12.3744; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Kondo T, 1999, MOL CELL BIOL, V19, P1136; KORNBERG A, 1992, DNA REPLICATION, P116; KRISHNA TSR, 1994, J MOL BIOL, V241, P265, DOI 10.1006/jmbi.1994.1495; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Mayanagi K, 2001, J STRUCT BIOL, V134, P35, DOI 10.1006/jsbi.2001.4357; Melo JA, 2001, GENE DEV, V15, P2809; Naiki T, 2000, MOL CELL BIOL, V20, P5888, DOI 10.1128/MCB.20.16.5888-5896.2000; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; Oyama T, 2001, MOL CELL, V8, P455, DOI 10.1016/S1097-2765(01)00328-8; Shimada M, 1999, MOL BIOL CELL, V10, P3991, DOI 10.1091/mbc.10.12.3991; Shimomura T, 1998, MOL CELL BIOL, V18, P5485, DOI 10.1128/MCB.18.9.5485; Shiomi Y, 2000, P NATL ACAD SCI USA, V97, P14127, DOI 10.1073/pnas.97.26.14127; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	30	102	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15233	15236		10.1074/jbc.C200129200	http://dx.doi.org/10.1074/jbc.C200129200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11907025	hybrid			2022-12-25	WOS:000175510400004
J	Sato, S; Fujita, N; Tsuruo, T				Sato, S; Fujita, N; Tsuruo, T			Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine)	ONCOGENE			English	Article						UCN-01; PDK1; Akt; apoptosis; PKC	PROTEIN-KINASE-B; CANCER-CELLS; SELECTIVE INHIBITOR; ACTIVATION; APOPTOSIS; PHOSPHORYLATION; GROWTH; SUBSTRATE; CLEAVAGE; IDENTIFICATION	3-Phosphoinositide-dependent protein kinase-1 (PDKI) plays a central role in activating the AGC subfamily of protein kinases. In particular, PDKI plays an important role in the regulation of Akt/PKB survival pathway by phosphorylating Akt on Thr(308). Here we show that UCN-01 (7-hydroxystaurosporine), a drug now in clinical trials and with a unique fingerprint pattern, induced dephosphorylation and inactivation of Akt, resulting in the turnoff of the survival signals and the induction of apoptosis. Further analysis revealed that UCN-01-mediated Akt inactivation was caused by inhibiting upstream Akt kinase PDKI (IC50=33 nm) both in vitro and from cells, but not by suppressing Akt itself or phosphatidylinositide-3-OH kinase. UCN-01-induced PDKI inhibition was also observed in in vivo murine and human tumor xenografts. Overexpression of active form of Akt diminished the cytotoxic effects of UCN-01, suggesting that UCN-01 may in part exert its cytotoxicity by inhibiting PDKI-Akt survival pathway. Because UCN-01 has already proved to have potent anti-tumor activity in vivo, PDKI-Akt survival pathway is a new, attractive target for cancer chemotherapy.	Univ Tokyo, Inst Mol & Cellular Biosci, Lab Cell Growth & Regulat, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Cell Growth & Regulat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	ttsuruo@iam.u-tokyo.ac.jp	Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264				Abe S, 2001, JPN J CANCER RES, V92, P537, DOI 10.1111/j.1349-7006.2001.tb01127.x; AKINAGA S, 1991, CANCER RES, V51, P4888; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Ballif BA, 2001, J BIOL CHEM, V276, P12466, DOI 10.1074/jbc.M009939200; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Danley DE, 1996, J IMMUNOL, V157, P500; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; FUJITA N, 2002, IN PRESS J BIOL CHEM; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kurata N, 1999, CANCER CHEMOTH PHARM, V44, P12, DOI 10.1007/s002800050939; Matsuoka Y, 1998, J CELL BIOL, V142, P485, DOI 10.1083/jcb.142.2.485; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Nakashio A, 2000, CANCER RES, V60, P5303; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Sellers WR, 1999, J CLIN INVEST, V104, P1655, DOI 10.1172/JCI9053; SEYNAEVE CM, 1993, CANCER RES, V53, P2081; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sugiyama K, 1999, CANCER RES, V59, P4406; TAKAHASHI I, 1989, J ANTIBIOT, V42, P571, DOI 10.7164/antibiotics.42.571; TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WANG QZ, 1995, CELL GROWTH DIFFER, V6, P927; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	45	199	208	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1727	1738		10.1038/sj.onc.1205225	http://dx.doi.org/10.1038/sj.onc.1205225			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896604				2022-12-25	WOS:000174214200011
J	Carreno, S; Caron, E; Cougoule, C; Emorine, LJ; Maridonneau-Parini, I				Carreno, S; Caron, E; Cougoule, C; Emorine, LJ; Maridonneau-Parini, I			p59Hck isoform induces F-actin reorganization to form protrusions of the plasma membrane in a Cdc42- and Rac-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED PHAGOCYTOSIS; SRC-FAMILY KINASES; PROTEIN-TYROSINE KINASES; GAMMA RECEPTOR; SIGNAL-TRANSDUCTION; FUNCTIONAL ASSOCIATION; UROKINASE RECEPTOR; HUMAN NEUTROPHILS; CELL MOTILITY; RHO GTPASES	Hck is a protein kinase of the Src family specifically expressed in phagocytes as two isoforms, p59Hck and p61Hck, localized at the plasma membrane and lysosomes, respectively. Their individual involvement in functions ascribed to Hck, phagoeytosis, cell migration, and lysosome mobilization, is still unclarified. To investigate the specific role of p59Hck, a constitutively active variant in fusion with green fluorescent protein (p59Hck(ca)) was expressed in HeLa cells. p59Hck(ca) was found at focal adhesion sites and triggered reorganization of the actin cytoskeleton, leading to plasma membrane protrusions where it co-localized with F-actin. Similarly, microinjection of p59Hck(ca) cDNA in J774.A1 macrophages induced membrane protrusions. Whereas kinase activity and membrane association of p59Hck were dispensable for location at focal adhesions, p59Hck-induced membrane protrusions were dependent on kinase activity, plasma membrane association, and Src homology 2 but not Src homology 3 domain and were inhibited by dominant-negative forms of Cdc42 or Rac but not by blocking Rho activity. A dominant negative form of p59Hck inhibited the Cdc42- and Rac-dependent FcgammaRIIa-mediated phagocytosis. Expression of the Cdc42/Rac-interacting domain of p21-activated kinase in macrophages abolished the p59Hck(ca)-induced morphological changes. Therefore, p59Hck-triggered remodeling of the actin cytoskeleton depends upon the activity of Cdc42 and Rac to promote formation of membrane protrusions necessary for phagocytosis and cell migration.	CNRS, Inst Pharmacol & Biol Struct, UMR 5089, F-31077 Toulouse, France; UCL, MRC, Mol Cell Biol Lab, CRC Oncogene & Signal Transduct Grp, London WC1E 6BT, England	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of London; University College London	Maridonneau-Parini, I (corresponding author), CNRS, Inst Pharmacol & Biol Struct, UMR 5089, 205 Route Narbonne, F-31077 Toulouse, France.	maridono@ipbs.fr	Maridonneau-Parini, Isabelle/F-1985-2011; COUGOULE, Céline/ABB-4180-2021	Maridonneau-Parini, Isabelle/0000-0003-0189-0976; Carreno, Sebastien/0000-0002-5839-2102				Allen WE, 1997, J CELL SCI, V110, P707; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; Astarie-Dequeker C, 1999, INFECT IMMUN, V67, P469, DOI 10.1128/IAI.67.2.469-477.1999; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Carreno S, 2000, J BIOL CHEM, V275, P36223, DOI 10.1074/jbc.M003901200; Cassard L, 2000, IMMUNOL LETT, V75, P1, DOI 10.1016/S0165-2478(00)00286-8; Chiaradonna F, 1999, EMBO J, V18, P3013, DOI 10.1093/emboj/18.11.3013; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; Doussau F, 2000, J BIOL CHEM, V275, P7764, DOI 10.1074/jbc.275.11.7764; Downey GP, 1999, J BIOL CHEM, V274, P28436, DOI 10.1074/jbc.274.40.28436; English BK, 1997, J LEUKOCYTE BIOL, V62, P859, DOI 10.1002/jlb.62.6.859; Fan GF, 2001, J BIOL CHEM, V276, P13240, DOI 10.1074/jbc.M011578200; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Fitzer-Attas CJ, 2000, J EXP MED, V191, P669, DOI 10.1084/jem.191.4.669; GEIGER B, 1985, J CELL BIOL, V101, P1523, DOI 10.1083/jcb.101.4.1523; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; Gresham HD, 2000, J EXP MED, V191, P515, DOI 10.1084/jem.191.3.515; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hauck CR, 1998, EMBO J, V17, P443, DOI 10.1093/emboj/17.2.443; Hoffmann I, 2001, J CELL BIOL, V155, P133, DOI 10.1083/jcb.200106148; Ibarrola I, 1997, BBA-MOL CELL RES, V1357, P348, DOI 10.1016/S0167-4889(97)00034-7; Izadi KD, 1998, EXP CELL RES, V245, P330, DOI 10.1006/excr.1998.4259; KAPLAN G, 1977, SCAND J IMMUNOL, V6, P797, DOI 10.1111/j.1365-3083.1977.tb02153.x; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; Lowell CA, 1998, P NATL ACAD SCI USA, V95, P7580, DOI 10.1073/pnas.95.13.7580; Majeed M, 2001, J LEUKOCYTE BIOL, V70, P801; MARIDONNEAUPARINI I, 1986, J IMMUNOL, V137, P2925; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; MOHN H, 1995, BIOCHEM J, V309, P657; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; N'Diaye EN, 1998, J IMMUNOL, V161, P4983; Nair KS, 2001, CELL IMMUNOL, V208, P96, DOI 10.1006/cimm.2001.1772; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; Patel JC, 2002, MOL BIOL CELL, V13, P1215, DOI 10.1091/mbc.02-01-0002; Pereira S, 2001, J IMMUNOL, V166, P4115, DOI 10.4049/jimmunol.166.6.4115; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sato N, 1999, J IMMUNOL, V163, P6123; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Suen PW, 1999, J CELL SCI, V112, P4067; Suzuki T, 2000, J IMMUNOL, V165, P473, DOI 10.4049/jimmunol.165.1.473; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; Vely F, 1997, HYBRIDOMA, V16, P519, DOI 10.1089/hyb.1997.16.519; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; Welch H, 1997, J BIOL CHEM, V272, P102; Wilde C, 2001, TOXICON, V39, P1647, DOI 10.1016/S0041-0101(01)00152-0; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	58	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					21007	21016		10.1074/jbc.M201212200	http://dx.doi.org/10.1074/jbc.M201212200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11904303	hybrid			2022-12-25	WOS:000176204500116
J	Sandhoff, R; Hepbildikler, ST; Jennemann, R; Geyer, R; Gieselmann, V; Proia, RL; Wiegandt, H; Grone, HJ				Sandhoff, R; Hepbildikler, ST; Jennemann, R; Geyer, R; Gieselmann, V; Proia, RL; Wiegandt, H; Grone, HJ			Kidney sulfatides in mouse models of inherited glycosphingolipid disorders - Determination by nano-electrospray ionization tandem mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED GLYCOPROTEIN OLIGOSACCHARIDES; CAPILLARY GAS-CHROMATOGRAPHY; NORMAL HUMAN-LEUKOCYTES; LEUKEMIA HL60 CELLS; LOW PICOMOLE LEVEL; COMPLEX GANGLIOSIDES; EMBRYONIC ANTIGEN-1; NERVOUS-SYSTEM; E-SELECTIN; TAY-SACHS	Sulfatides show structural, and possibly physiological similarities to gangliosides. Kidney dysfunction might be correlated with changes in sulfatides, the major acidic glycosphingolipids in this organ. To elucidate their in vivo metabolic pathway these compounds were analyzed in mice afflicted with inherited glycosphingolipid disorders. The mice under study lacked the genes encoding either beta-hexosaminidase alpha-subunit (Hexa-/-), the beta-hexosaminidase beta-subunit (Hexb-/-), both beta-hexosaminidase a and beta-subunits (Hexa-/- and Hexb-/-), GD3 synthase (GD3S-/-), GD3 synthase and Ga1NAc transferase (GD3S-/- and GaINAcT-/-), GNU activator protein (Gm2a-/-), or arylsulfatase A (ASA-/-). Quantification of the sulfatides, (ISO3)-S-3--GalCer (SM4s), (IISO3-)-S-3. LacCer (SM3), (IISO3-)-S-3-Gg(3)Cer (SM2a), and IV3, II3-(SO3-)(2)-Gg(4)Cer (SB1a), was performed by nano-electrospray tandem mass spectrometry. We conclude for the in vivo situation in mouse kidneys that: 1) a single enzyme (GalNAc transferase) is responsible for the synthesis of SM2a and GNU from SM3 and GM3, respectively. 2) In analogy to GD1a, SB1a is degraded via SM2a. 3) SM2a is hydrolyzed to SM3 by beta-hexosaminidase S (Hex S) and Hex A, but not Hex B. Both enzymes are supported by GNU-activator protein. 4) Arylsulfatase A is required to degrade SB1a. It is probably the sole sphingolipid-sulfatase cleaving the galactosyl-3-sulfate bond. In addition, a human Tay-Sachs patient's liver was investigated, which showed accumulation of SM2a along with GNU storage. The different ceramide compositions of both compounds indicated they were probably derived from different cell types. These data demonstrate that in vivo the sulfatides of the ganglio-series follow the same metabolic pathways as the gangliosides with the replacement of sulfotransferases and sulfatases by sialyltransferases and sialidases. Furthermore, a novel neutral GSL, IV(6)GlcNAcbeta-Gb(4)Cer, was found to accumulate only in Hexa-/- and Hexb-/- mouse kidneys. From this we conclude that Hex S also efficiently cleaves terminal beta1-6-linked HexNAc residues from neutral GSLs in vivo.	Deutsch Krebsforschungszentrum, Abt Zellulare & Mol Pathol, D-69120 Heidelberg, Germany; Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany; Univ Giessen Klinikum, Inst Biochem, D-35392 Giessen, Germany; Univ Bonn, Inst Physiol Chem, D-53115 Bonn, Germany; NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	Helmholtz Association; German Cancer Research Center (DKFZ); University of Bonn; University Hospital of Giessen & Marburg; University of Bonn; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Sandhoff, R (corresponding author), Deutsch Krebsforschungszentrum, Abt Zellulare & Mol Pathol, INF 280, D-69120 Heidelberg, Germany.	r.sandhoff@dkfz-heidelberg.de	Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; Bosio A, 1996, P NATL ACAD SCI USA, V93, P13280, DOI 10.1073/pnas.93.23.13280; Brugger B, 2000, J CELL BIOL, V151, P507, DOI 10.1083/jcb.151.3.507; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; GEYER R, 1982, ANAL BIOCHEM, V121, P263, DOI 10.1016/0003-2697(82)90478-X; GEYER R, 1994, METHOD ENZYMOL, V230, P86; GEYER R, 1983, ANAL BIOCHEM, V133, P197, DOI 10.1016/0003-2697(83)90243-9; Gravel R. A., 2001, METABOLIC MOL BASES, V3, P3827; Gu M, 1997, ANAL BIOCHEM, V244, P347, DOI 10.1006/abio.1996.9915; HARZER K, 1974, H-S Z PHYSIOL CHEM, V355, P744; Hepbildikler ST, 2002, J BIOL CHEM, V277, P2562, DOI 10.1074/jbc.M105457200; Hess B, 1996, P NATL ACAD SCI USA, V93, P14821, DOI 10.1073/pnas.93.25.14821; HIRAIWA N, 1990, CANCER RES, V50, P2917; Hsu FF, 1998, BBA-LIPID LIPID MET, V1392, P202, DOI 10.1016/S0005-2760(98)00034-4; Ishizuka I, 1997, PROG LIPID RES, V36, P245, DOI 10.1016/S0163-7827(97)00011-8; ISHIZUKA I, 1985, J BIOL CHEM, V260, P1256; JENNEMANN R, 1994, J BIOCHEM-TOKYO, V116, P450, DOI 10.1093/oxfordjournals.jbchem.a124545; Kabayama K, 2001, J BIOL CHEM, V276, P26777, DOI 10.1074/jbc.M100428200; Kawai H, 2001, J BIOL CHEM, V276, P6885, DOI 10.1074/jbc.C000847200; KOBAYASHI T, 1993, BRIT J CANCER, V67, P76, DOI 10.1038/bjc.1993.12; KOBAYASHI T, 1994, INT J CANCER, V56, P281, DOI 10.1002/ijc.2910560223; Kolter T, 1999, ANGEW CHEM INT EDIT, V38, P1532, DOI 10.1002/(SICI)1521-3773(19990601)38:11<1532::AID-ANIE1532>3.0.CO;2-U; Kurita T, 2000, J LIPID RES, V41, P846; Liebisch G, 1999, J LIPID RES, V40, P1539; Liu YJ, 1997, P NATL ACAD SCI USA, V94, P8138, DOI 10.1073/pnas.94.15.8138; Marbois BN, 2000, BBA-MOL CELL BIOL L, V1484, P59, DOI 10.1016/S1388-1981(99)00201-2; Metelmann W, 2000, RAPID COMMUN MASS SP, V14, P543, DOI 10.1002/(SICI)1097-0231(20000415)14:7<543::AID-RCM908>3.0.CO;2-J; Metelmann W, 2001, J MASS SPECTROM, V36, P21, DOI 10.1002/jms.100; METZGER K, 1995, ANAL CHEM, V67, P4178, DOI 10.1021/ac00118a022; NAGAI K, 1987, J BIOCHEM-TOKYO, V101, P1115, DOI 10.1093/oxfordjournals.jbchem.a121976; NAGAI K, 1984, J BIOCHEM-TOKYO, V95, P1501, DOI 10.1093/oxfordjournals.jbchem.a134758; NILSSON O, 1982, J LIPID RES, V23, P327; Oya Y, 1998, ACTA NEUROPATHOL, V96, P29, DOI 10.1007/s004010050857; PARENTE JP, 1985, CARBOHYD RES, V141, P41, DOI 10.1016/S0008-6215(00)90753-5; Reinhold VN, 1996, METHOD ENZYMOL, V271, P377; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; Sandhoff R, 1999, J LIPID RES, V40, P126; Sango K, 1996, NAT GENET, V14, P348, DOI 10.1038/ng1196-348; SANGO K, 1995, NAT GENET, V11, P170, DOI 10.1038/ng1095-170; Sekine M, 1997, J BIOL CHEM, V272, P27246, DOI 10.1074/jbc.272.43.27246; SEKINE M, 1987, J BIOCHEM-TOKYO, V101, P563, DOI 10.1093/jb/101.3.563; Sekine M, 2001, EUR J BIOCHEM, V268, P1129, DOI 10.1046/j.1432-1327.2001.01980.x; SEKINE M, 1987, J BIOCHEM-TOKYO, V101, P553, DOI 10.1093/jb/101.3.553; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P770, DOI 10.1021/bi952461g; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P758, DOI 10.1021/bi951600r; Sullards MC, 2000, METHOD ENZYMOL, V312, P32; Suzuki K, 1997, J NEUROPATH EXP NEUR, V56, P693; Tadano-Aritomi K, 2000, J LIPID RES, V41, P1237; Takamiya K, 1996, P NATL ACAD SCI USA, V93, P10662, DOI 10.1073/pnas.93.20.10662; Takamiya K, 1998, P NATL ACAD SCI USA, V95, P12147, DOI 10.1073/pnas.95.21.12147; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; VONFIGURA K, 2001, METABOLIC MOL BASES, P3695; Whitfield PD, 2001, MOL GENET METAB, V73, P30, DOI 10.1006/mgme.2001.3165; YAMANAKA S, 1994, P NATL ACAD SCI USA, V91, P9975, DOI 10.1073/pnas.91.21.9975; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142	55	49	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20386	20398		10.1074/jbc.M110641200	http://dx.doi.org/10.1074/jbc.M110641200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11919180	hybrid			2022-12-25	WOS:000176204500038
J	Parnell, SC; Magenheimer, BS; Maser, RL; Zien, CA; Frischauf, AM; Calvet, JP				Parnell, SC; Magenheimer, BS; Maser, RL; Zien, CA; Frischauf, AM; Calvet, JP			Polycystin-1 activation of c-jun N-terminal kinase and AP-1 is mediated by heterotrimeric G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; MUSCARINIC ACETYLCHOLINE-RECEPTORS; KIDNEY-DISEASE GENE; BETA-GAMMA; IN-VITRO; COUPLED RECEPTORS; CATION CHANNEL; NH2-TERMINAL KINASE; TYROSINE KINASE; ALPHA-SUBUNIT	Functional analysis of polycystin-1, the product of the gene most frequently mutated in autosomal dominant polycystic kidney disease, has revealed that this protein is involved in the regulation of diverse signaling pathways such as the activation of the transcription factor AP-1 and modulation of Wnt signaling. However, the initial steps involved in the activation of such cascades have remained unclear. We demonstrated previously that the C-terminal cytosolic tail of polycystin-1 binds and activates heterotrimeric G proteins in vitro. To test if polycystin-1 can activate cellular signaling cascades via heterotrimeric G protein subunits, polycystin-1 C-terminal tail-mediated c-Jun N-terminal kinase (JNK) and AP-1 activities were assayed in transiently transfected 293T cells in the presence of dominant-negative, G protein inhibiting constructs, and in the presence of cotransfected Galpha subunits. The results showed that polycystin-l-mediated JNK/AP-1 activation is mediated by Galpha and Gbetagamma subunits. Polycystin-1-mediated AP-1 activity could be significantly augmented by cotransfected Galpha(i), Galpha(q), and Galpha(12/13) subunits, suggesting that polycystin-1 can couple with and activate several heterotrimeric G protein families.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Kidney Inst, Kansas City, KS 66160 USA; Salzburg Univ, Inst Genet & Allgemeine Biol, A-5020 Salzburg, Austria	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Salzburg University	Calvet, JP (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK057301, P01DK053763] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53763, DK57301] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnould T, 1999, MOL CELL BIOL, V19, P3423; Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Boletta A, 2000, MOL CELL, V6, P1267, DOI 10.1016/S1097-2765(00)00123-4; BURN TC, 1995, HUM MOL GENET, V4, P575, DOI 10.1093/hmg/4.4.575; CALVET JP, 1993, KIDNEY INT, V43, P101, DOI 10.1038/ki.1993.17; Calvet JP, 1998, J NEPHROL, V11, P24; Calvet JP, 2001, SEMIN NEPHROL, V21, P107, DOI 10.1053/snep.2001.20929; CAMPBELL V, 1995, FEBS LETT, V370, P135, DOI 10.1016/0014-5793(95)00813-O; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; Delmas P, 2002, J BIOL CHEM, V277, P11276, DOI 10.1074/jbc.M110483200; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; GRANTHAM JJ, 1997, KIDNEY INT S, V63, P93; Guay-Woodford LM, 2000, J AM SOC NEPHROL, V11, P1253, DOI 10.1681/ASN.V1171253; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Hanaoka K, 2000, J AM SOC NEPHROL, V11, P1179, DOI 10.1681/ASN.V1171179; HARRIS PC, 1995, J AM SOC NEPHROL, V6, P1125; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Ibraghimov-Beskrovnaya O, 2000, HUM MOL GENET, V9, P1641, DOI 10.1093/hmg/9.11.1641; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Kim K, 2000, P NATL ACAD SCI USA, V97, P1731, DOI 10.1073/pnas.040550097; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Levi NL, 1998, MOL ENDOCRINOL, V12, P815, DOI 10.1210/me.12.6.815; Lohning C, 1997, MAMM GENOME, V8, P307, DOI 10.1007/s003359900429; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; Martin-Blanco E, 2000, P NATL ACAD SCI USA, V97, P7888, DOI 10.1073/pnas.97.14.7888; McEwen DG, 2000, DEVELOPMENT, V127, P3607; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Meir A, 2000, BIOPHYS J, V79, P731, DOI 10.1016/S0006-3495(00)76331-4; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; Morisset S, 2000, NATURE, V408, P860, DOI 10.1038/35048583; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; Parnell SC, 1999, BIOCHEM BIOPH RES CO, V259, P539, DOI 10.1006/bbrc.1999.0810; Ponting CP, 1999, CURR BIOL, V9, pR585, DOI 10.1016/S0960-9822(99)80379-0; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Rumenapp U, 2001, J BIOL CHEM, V276, P2474, DOI 10.1074/jbc.M004957200; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Sutters M, 2001, KIDNEY INT, V60, P484, DOI 10.1046/j.1523-1755.2001.060002484.x; Torres VE, 1998, CURR OPIN NEPHROL HY, V7, P159, DOI 10.1097/00041552-199803000-00004; Vandorpe DH, 2001, J BIOL CHEM, V276, P4093, DOI 10.1074/jbc.M006252200; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; WARD CJ, 1994, CELL, V77, P881; WATSON S, 1996, TRENDS PHARMACOL SCI, V7, P1; Weber U, 2000, DEVELOPMENT, V127, P3619; Wilson PD, 2001, J AM SOC NEPHROL, V12, P834, DOI 10.1681/ASN.V124834; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Wylie PG, 1999, BIOCHEM J, V338, P619, DOI 10.1042/0264-6021:3380619; Yamaguchi T, 2000, KIDNEY INT, V57, P1460, DOI 10.1046/j.1523-1755.2000.00991.x; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yamauchi J, 1999, J BIOL CHEM, V274, P1957, DOI 10.1074/jbc.274.4.1957; Yassin M, 1996, BIOCHEM BIOPH RES CO, V220, P453, DOI 10.1006/bbrc.1996.0426	68	129	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19566	19572		10.1074/jbc.M201875200	http://dx.doi.org/10.1074/jbc.M201875200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11912216	hybrid			2022-12-25	WOS:000175894800044
J	Harikumar, KG; Pinon, DL; Wessels, WS; Prendergast, FG; Miller, LJ				Harikumar, KG; Pinon, DL; Wessels, WS; Prendergast, FG; Miller, LJ			Environment and mobility of a series of fluorescent reporters at the amino terminus of structurally related peptide agonists and antagonists bound to the cholecystokinin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; CONFORMATIONAL-CHANGES; A RECEPTOR; DIRECT IDENTIFICATION; SITE; LIGAND; RHODOPSIN; DOMAIN; ACTIVATION; PROBE	Fluorescence is a powerful biophysical tool for the analysis of the structure and dynamics of proteins. Here, we have developed two series of new fluorescent probes of the cholecystokinin (CCK) receptor, representing structurally related peptide agonists and antagonists. Each ligand had one of three distinct fluorophores (Alexa(488), nitrobenzoxadiazolyl, or acrylodan) incorporated in analogous positions at the amino terminus just outside the hormone's pharmacophore. All of the probes bound to the CCK receptor specifically and with high affinity, and intracellular calcium signaling studies showed the chemically modified peptides to be fully biologically active. Quenching by iodide and measurement of fluorescence spectra, anisotropy, and lifetimes were used to characterize the response of the fluorescence of the probe in the peptide-receptor complex for agonists and antagonists. All three fluorescence indicators provided the same insights into differences in the environment of the same indicator in the analogous position for agonist and antagonist peptides bound to the CCK receptor. Each agonist had its fluorescence quenched more easily and showed lower anisotropy (higher mobility of the probe) and shorter lifetime than the analogous antagonist. Treatment of agonist-occupied receptors with a non-hydrolyzable GTP analogue shifted the receptor into its inactive low affinity state and increased probe fluorescence lifetimes toward values observed with antagonist probes. These data are consistent with a molecular conformational change associated with receptor activation that causes the amino terminus of the ligand (situated above transmembrane segment six) to move away from its somewhat protected environment and toward the aqueous milieu.	Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA	Mayo Clinic	Miller, LJ (corresponding author), Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Mol Pharmacol & Expt Therapeut, 200 1st St SW, Rochester, MN 55905 USA.			Harikumar, Kaleeckal/0000-0003-0411-5334	NIDDK NIH HHS [DK32878] Funding Source: Medline; NIGMS NIH HHS [GM34847-16] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032878, R01DK032878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034847] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; BODANSZKY M, 1977, J MED CHEM, V20, P1047, DOI 10.1021/jm00218a011; BODANSZKY M, 1980, INT J PEPT PROT RES, V16, P402; Ding XQ, 2001, J BIOL CHEM, V276, P4236, DOI 10.1074/jbc.M003798200; Dong MQ, 1999, J BIOL CHEM, V274, P4778, DOI 10.1074/jbc.274.8.4778; DOUST TAM, 1984, BIOCHEM SOC T, V12, P630, DOI 10.1042/bst0120630; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; GAISANO HY, 1989, J CLIN INVEST, V83, P321, DOI 10.1172/JCI113877; Ganguli SC, 1998, J PHARMACOL EXP THER, V286, P593; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; GETHER U, 1995, J BIOL CHEM, V270, P28268; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GHIGGINO KP, 1981, BIOCHEMISTRY-US, V20, P5381, DOI 10.1021/bi00522a005; Gigoux V, 1999, PROTEIN SCI, V8, P2347; Gigoux V, 1999, J BIOL CHEM, V274, P20457, DOI 10.1074/jbc.274.29.20457; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hadac EM, 1999, J MED CHEM, V42, P2105, DOI 10.1021/jm980732q; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; Kennedy K, 1997, J BIOL CHEM, V272, P2920, DOI 10.1074/jbc.272.5.2920; LAKOWICZ JR, 1980, J BIOCHEM BIOPH METH, V2, P91, DOI 10.1016/0165-022X(80)90077-9; Loewen MC, 2001, P NATL ACAD SCI USA, V98, P4888, DOI 10.1073/pnas.051633098; MILLER LJ, 1981, J BIOL CHEM, V256, P2417; MOLERO X, 1991, MOL PHARMACOL, V39, P150; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PEARSON RK, 1987, BIOCHEM BIOPH RES CO, V147, P346, DOI 10.1016/S0006-291X(87)80128-6; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; Roettger BF, 1997, MOL PHARMACOL, V51, P357; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; TURCATTI G, 1995, BIOCHEMISTRY-US, V34, P3972, DOI 10.1021/bi00012a015	37	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18552	18560		10.1074/jbc.M201164200	http://dx.doi.org/10.1074/jbc.M201164200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893747	hybrid			2022-12-25	WOS:000175975800041
J	Rose, T; Di Cera, E				Rose, T; Di Cera, E			Three-dimensional modeling of thrombin-fibrinogen interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; A-ALPHA; BOVINE THROMBIN; BINDING; DYSFIBRINOGENEMIA; SPECIFICITY; RESOLUTION; RECEPTOR; RESIDUES; PEPTIDES	Three-dimensional models of thrombin complexed with large fragments of the fibrinogen Aalpha and Bbeta chains are presented. The models are consistent with the results of recent mutagenesis studies of thrombin and with the information available on naturally occurring fibrinogen mutants. Thrombin recognizes fibrinogen with an extended binding surface, key elements of which are Tyr(76) in exosite I, located about 20 Angstrom away from the active site, and the aryl binding site located in close proximity to the catalytic triad. A highly conserved aromatic-Pro-aromatic triplet motif is identified in the primed site region of fibrinogen and other natural substrates of thrombin. The role of this triplet, based on the three-dimensional models, is to correctly orient the substrate for optimal bridge binding to exosite I and the active site. The three-dimensional models suggest a possible pattern of recognition by thrombin that applies generally to other natural substrates.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, Box 8231, St Louis, MO 63110 USA.			ROSE, Thierry/0000-0001-8863-0207	NHLBI NIH HHS [HL49413, HL58141] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049413, R01HL058141, R29HL049413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arosio D, 2000, BIOCHEMISTRY-US, V39, P8095, DOI 10.1021/bi0006215; Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; BLOMBACK M, 1968, NATURE, V218, P134, DOI 10.1038/218134a0; BODE W, 1992, PROTEIN SCI, V1, P426; Brown JH, 2000, P NATL ACAD SCI USA, V97, P85, DOI 10.1073/pnas.97.1.85; Cantwell AM, 2000, J BIOL CHEM, V275, P39827, DOI 10.1074/jbc.C000751200; DENNINGER MH, 1978, THROMB RES, V13, P453, DOI 10.1016/0049-3848(78)90131-7; Everse SJ, 1998, BIOCHEMISTRY-US, V37, P8637, DOI 10.1021/bi9804129; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; Guinto ER, 1997, BIOPHYS CHEM, V64, P103, DOI 10.1016/S0301-4622(96)02211-9; HAGEMAN TC, 1974, ARCH BIOCHEM BIOPHYS, V164, P707, DOI 10.1016/0003-9861(74)90083-6; HANNA LS, 1984, BIOCHEMISTRY-US, V23, P4681, DOI 10.1021/bi00315a025; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HESSEL B, 1986, THROMB RES, V42, P21, DOI 10.1016/0049-3848(86)90193-3; HIGGINS DL, 1981, J BIOL CHEM, V256, P2013; HOGG DH, 1974, THROMB RES, V5, P685, DOI 10.1016/0049-3848(74)90057-7; KOOPMAN J, 1992, P NATL ACAD SCI USA, V89, P3478, DOI 10.1073/pnas.89.8.3478; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lord S T, 1990, Blood Coagul Fibrinolysis, V1, P461, DOI 10.1097/00001721-199010000-00017; Madrazo J, 2001, P NATL ACAD SCI USA, V98, P11967, DOI 10.1073/pnas.211439798; MARTIN PD, 1992, J BIOL CHEM, V267, P7911; Martin PD, 1996, BIOCHEMISTRY-US, V35, P13030, DOI 10.1021/bi960656y; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; Maurer MC, 1999, PROTEINS, V34, P29, DOI 10.1002/(SICI)1097-0134(19990101)34:1<29::AID-PROT4>3.0.CO;2-U; Maurer MC, 1998, BIOCHEMISTRY-US, V37, P5888, DOI 10.1021/bi972538w; MENACHE D, 1983, ANN NY ACAD SCI, V408, P121, DOI 10.1111/j.1749-6632.1983.tb23240.x; Mosesson MW, 2001, ANN NY ACAD SCI, V936, P11; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; NIWA K, 1993, BLOOD, V82, P3658; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SORIA J, 1972, THROMB DIATH HAEMOST, V27, P619, DOI 10.1055/s-0038-1649401; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; VANNISPEN JW, 1977, ARCH BIOCHEM BIOPHYS, V182, P227, DOI 10.1016/0003-9861(77)90303-4; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; Yang Z, 2000, P NATL ACAD SCI USA, V97, P14156, DOI 10.1073/pnas.97.26.14156; YOSHIDA N, 1991, BLOOD, V78, P149	42	52	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18875	18880		10.1074/jbc.M110977200	http://dx.doi.org/10.1074/jbc.M110977200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11901150	hybrid			2022-12-25	WOS:000175975800082
J	Thiagarajah, JR; Verkman, AS				Thiagarajah, JR; Verkman, AS			Aquaporin deletion in mice reduces corneal water permeability and delays restoration of transparency after swelling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIVO CONFOCAL MICROSCOPY; TRANSGENIC MICE; FLUID TRANSPORT; NULL MICE; MOLECULAR-IDENTIFICATION; KNOCKOUT MICE; ENDOTHELIUM; THICKNESS; CHANNELS; BICARBONATE	Two aquaporin (AQP)-type water channels are expressed in mammalian cornea, AQP1 in endothelial cells and AQP5 in epithelial cells. To test whether these aquaporins are involved in corneal fluid transport and transparency, we compared corneal thickness, water permeability, and response to experimental swelling in wild type mice and transgenic null mice lacking AQP1 and AQP5. Corneal thickness in fixed sections was remarkably reduced in AQP1 null mice and increased in AQP5 null mice. By z-scanning confocal microscopy, corneal thickness in vivo was (in mum, mean +/- S.E., n = 5 mice) 123 +/- 1 (wild type), 101 +/- 2 (AQP1 null), and 144 +/- 2 (AQP5 null). After exposure of the external corneal surface to hypotonic saline (100 mosM), the rate of corneal swelling (5.0 +/- 0.3 mum/min, wild type) was reduced by AQP5 deletion (2.7 +/- 0.1 mum/min). After exposure of the endothelial surface to hypotonic saline by anterior chamber perfusion, the rate of corneal swelling (7.1 +/- 1.0 mum/min, wild type) was reduced by AQP1 deletion (1.6 +/- 0.4 mum/min). Base-line corneal transparency was not impaired by AQP1 or AQP5 deletion. However, the recovery of corneal transparency and thickness after hypotonic swelling (10-min exposure of corneal surface to hypotonic saline) was remarkably delayed in AQP1 null mice with similar to75% recovery at 7 min in wild type mice compared with 5% recovery in AQP1 null mice. Our data indicate that AQP1 and AQP5 provide the principal routes for corneal water transport across the endothelial and epithelial barriers, respectively. The impaired recovery of corneal transparency in AQP1 null mice provides evidence for the involvement of. AQP1 in active extrusion of fluid from the corneal stroma across the corneal endothelium. The up-regulation of AQP1 expression and/or function in corneal endothelium may reduce corneal swelling and opacification following injury.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower,Box 0521, San Francisco, CA 94143 USA.				NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL60288] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK43840, DK35124] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198, P50HL060288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043840, R01DK035124, R37DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai CX, 1999, J CLIN INVEST, V103, P555, DOI 10.1172/JCI4138; Chang JH, 1999, CURR EYE RES, V19, P171, DOI 10.1076/ceyr.19.2.171.5326; Chew S J, 1992, Lens Eye Toxic Res, V9, P275; Chou CL, 1999, J CLIN INVEST, V103, P491, DOI 10.1172/JCI5704; Cooper GJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1481, DOI 10.1152/ajpcell.1998.275.6.C1481; FANG X, 2002, IN PRESS J PHYSL LON; FISCHBARG J, 1974, J PHYSIOL-LONDON, V241, P647, DOI 10.1113/jphysiol.1974.sp010676; Funaki H, 1998, AM J PHYSIOL-CELL PH, V275, pC1151, DOI 10.1152/ajpcell.1998.275.4.C1151; Hamann S, 1998, AM J PHYSIOL-CELL PH, V274, pC1332, DOI 10.1152/ajpcell.1998.274.5.C1332; HODSON S, 1976, J PHYSIOL-LONDON, V263, P563, DOI 10.1113/jphysiol.1976.sp011645; Jester JV, 1999, METHOD ENZYMOL, V307, P230; Jester JV, 2001, VISION RES, V41, P1283, DOI 10.1016/S0042-6989(00)00222-4; Kang FY, 1999, INVEST OPHTH VIS SCI, V40, P253; KLYCE SD, 1975, AM J PHYSIOL, V228, P1446, DOI 10.1152/ajplegacy.1975.228.5.1446; Kuang KY, 2001, AM J PHYSIOL-CELL PH, V280, pC491, DOI 10.1152/ajpcell.2001.280.3.C491; Kubota S, 1998, JPN J OPHTHALMOL, V42, P12, DOI 10.1016/S0021-5155(97)00111-1; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; Lane J, 2000, BIOPHYS J, V78, P2493, DOI 10.1016/S0006-3495(00)76794-4; Li J, 1999, INVEST OPHTH VIS SCI, V40, P1288; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; Ma TH, 2001, AM J PHYSIOL-CELL PH, V280, pC126; Ma TH, 2000, J CLIN INVEST, V105, P93, DOI 10.1172/JCI8258; Masters B R, 1992, Scanning Microsc Suppl, V6, P71; MAURICE DM, 1972, J PHYSIOL-LONDON, V221, P43, DOI 10.1113/jphysiol.1972.sp009737; Moore M, 2000, EXP EYE RES, V70, P557, DOI 10.1006/exer.1999.0814; OSHIO K, 2001, J AM SOC NEPHROL, V12, P35; Patil RV, 1997, EXP EYE RES, V64, P203, DOI 10.1006/exer.1996.0196; RILEY MV, 1994, INVEST OPHTH VIS SCI, V35, P560; RILEY MV, 1995, INVEST OPHTH VIS SCI, V36, P103; Riley MV, 1998, INVEST OPHTH VIS SCI, V39, P2076; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; Song YL, 2001, J BIOL CHEM, V276, P41288, DOI 10.1074/jbc.M107257200; Song YL, 2000, J PHYSIOL-LONDON, V525, P771, DOI 10.1111/j.1469-7793.2000.00771.x; Sun XC, 2001, INVEST OPHTH VIS SCI, V42, P417; Verkman AS, 2000, CURR OPIN NEPHROL HY, V9, P517, DOI 10.1097/00041552-200009000-00010; Yang BX, 2000, J BIOL CHEM, V275, P2686, DOI 10.1074/jbc.275.4.2686; YTTEBORG J, 1965, ARCH OPHTHALMOL-CHIC, V74, P477, DOI 10.1001/archopht.1965.00970040479008; ZHANG D, 2002, IN PRESS FASEB J	39	98	112	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19139	19144		10.1074/jbc.M202071200	http://dx.doi.org/10.1074/jbc.M202071200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11891232	hybrid			2022-12-25	WOS:000175975800116
J	Keller, SR; Davis, AC; Clairmont, KB				Keller, SR; Davis, AC; Clairmont, KB			Mice deficient in the insulin-regulated membrane aminopeptidase show substantial decreases in glucose transporter GLUT4 levels but maintain normal glucose homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL LEUCINE AMINOPEPTIDASE; RAT SKELETAL-MUSCLE; CELL-SURFACE; ADIPOSE-CELLS; STIMULATED TRANSLOCATION; MATERNAL SERUM; RECEPTOR; IDENTIFICATION; OXYTOCINASE; RESISTANCE	The insulin-regulated aminopeptidase (IRAP) is a zinc-dependent membrane aminopeptidase. It is the homologue of the human placental leucine aminopeptidase. In fat and muscle cells, IRAP colocalizes with the insulin-responsive glucose transporter GLUT4 in intracellular vesicles and redistributes to the cell surface in response to insulin, as GLUT4 does. To address the question of the physiological function of IRAP, we generated mice with a targeted disruption of the IRAP gene (IRAP-/-). Herein, we describe the characterization of these mice with regard to glucose homeostasis and regulation of GLUT4. Fed and fasted blood glucose and insulin levels in the IRAP-/- mice were normal. Whereas IRAP-/- mice responded to glucose administration like control mice, they exhibited an impaired response to insulin. Basal and insulin-stimulated glucose uptake in extensor digitorum. longus muscle, and adipocytes isolated from IRAP-/- mice were decreased by 30-60% but were normal for soleus muscle from male IRAP-/- mice. Total GLUT4 levels were diminished by 40-85% in the IRAP-/- mice in the different muscles and in adipocytes. The relative distribution of GLUT4 in subcellular fractions of basal and insulin-stimulated IRAP-/- adipocytes was the same as in control cells. We conclude that IRAP-/- mice maintain normal glucose homeostasis despite decreased glucose uptake into muscle and fat cells. The absence of IRAP does not affect the subcellular distribution of GLUT4 in adipocytes. However, it leads to substantial decreases in GLUT4 expression.	Univ Virginia, Dept Internal Med, Div Endocrinol, Charlottesville, VA 22908 USA; Bayer Corp, Div Pharmaceut, Dept Metab Disorders Res, West Haven, CT 06516 USA	University of Virginia; Bayer AG	Keller, SR (corresponding author), Univ Virginia, Dept Internal Med, Div Endocrinol, MR4 Bldg,Rm 5147,Lane Rd,POB 801405, Charlottesville, VA 22908 USA.	srk4@virginia.edu	Clairmont, Kevin/ABG-6161-2021	Clairmont, Kevin/0000-0003-4198-2437	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058051, R56DK025336, R55DK025336, R01DK025336] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58051, DK25336] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Abel ED, 1999, J CLIN INVEST, V104, P1703, DOI 10.1172/JCI7605; AHMAD S, 1990, J PHARMACOL EXP THER, V252, P643; Aledo JC, 1997, BIOCHEM J, V325, P727, DOI 10.1042/bj3250727; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; Carayannopoulos MO, 2000, P NATL ACAD SCI USA, V97, P7313, DOI 10.1073/pnas.97.13.7313; Champion HC, 1998, AM J PHYSIOL-ENDOC M, V274, pE115, DOI 10.1152/ajpendo.1998.274.1.E115; Cline GW, 1999, NEW ENGL J MED, V341, P240, DOI 10.1056/NEJM199907223410404; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; Doege H, 2001, BIOCHEM J, V359, P443, DOI 10.1042/0264-6021:3590443; Etgen GJ, 1999, BIOCHEM J, V337, P51, DOI 10.1042/bj3370051; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; FERACCI H, 1981, BIOCHIM BIOPHYS ACTA, V658, P148, DOI 10.1016/0005-2744(81)90258-8; Garvey WT, 1998, J CLIN INVEST, V101, P2377, DOI 10.1172/JCI1557; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; GORDGE MP, 1995, CLIN ENDOCRINOL, V42, P51, DOI 10.1111/j.1365-2265.1995.tb02598.x; Herbst JJ, 1997, AM J PHYSIOL-ENDOC M, V272, pE600, DOI 10.1152/ajpendo.1997.272.4.E600; Hoenack C, 1996, DIABETES, V45, pS82, DOI 10.2337/diab.45.1.S82; HOFMANN C, 1991, ENDOCRINOLOGY, V129, P1915, DOI 10.1210/endo-129-4-1915; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1985, AM J PHYSIOL, V248, pE567, DOI 10.1152/ajpendo.1985.248.5.E567; Jiang H, 2001, BIOCHEM BIOPH RES CO, V284, P519, DOI 10.1006/bbrc.2001.4994; KAHN BB, 1991, J CLIN INVEST, V87, P561, DOI 10.1172/JCI115031; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; KENNY J, 1986, TRENDS BIOCHEM SCI, V11, P40, DOI 10.1016/0968-0004(86)90231-8; Kozaki H, 2001, INT J GYNECOL OBSTET, V73, P207, DOI 10.1016/S0020-7292(01)00372-1; LALU K, 1986, BIOCHIM BIOPHYS ACTA, V873, P190, DOI 10.1016/0167-4838(86)90045-2; Laustsen PG, 2001, EUR J BIOCHEM, V268, P98, DOI 10.1046/j.1432-1327.2001.01848.x; Lee W, 1997, J BIOL CHEM, V272, P21427, DOI 10.1074/jbc.272.34.21427; Liu SCH, 1999, J BIOL CHEM, V274, P18093, DOI 10.1074/jbc.274.25.18093; Lund S, 1997, DIABETES, V46, P1965, DOI 10.2337/diabetes.46.12.1965; Malide D, 1997, FEBS LETT, V409, P461, DOI 10.1016/S0014-5793(97)00563-2; MARETTE A, 1993, DIABETES, V42, P1195, DOI 10.2337/diabetes.42.8.1195; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; Martin S, 1997, J CELL SCI, V110, P2281; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; Matsumoto H, 1998, ZOOL SCI, V15, P111, DOI 10.2108/zsj.15.111; Melvin DR, 1999, BIOCHEMISTRY-US, V38, P1456, DOI 10.1021/bi980988y; Moeller I, 1998, J HUM HYPERTENS, V12, P289, DOI 10.1038/sj.jhh.1000640; Nakamura H, 2000, ENDOCRINOLOGY, V141, P4481, DOI 10.1210/en.141.12.4481; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Rogi T, 1996, J BIOL CHEM, V271, P56, DOI 10.1074/jbc.271.1.56; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; RYDER JW, 1999, BIOCHEM J, V342, P31; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLIEKER LJ, 1992, DIABETES, V41, P187, DOI 10.2337/diabetes.41.2.187; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Stenbit AE, 1997, NAT MED, V3, P1096, DOI 10.1038/nm1097-1096; Subtil A, 2000, J BIOL CHEM, V275, P4787, DOI 10.1074/jbc.275.7.4787; Sumitani S, 1997, ENDOCRINOLOGY, V138, P1029, DOI 10.1210/en.138.3.1029; TSUJIMOTO M, 1992, ARCH BIOCHEM BIOPHYS, V292, P388, DOI 10.1016/0003-9861(92)90007-J; WARD PE, 1990, BIOCHEM PHARMACOL, V40, P1725, DOI 10.1016/0006-2952(90)90348-O; Waters SB, 1997, J BIOL CHEM, V272, P23323, DOI 10.1074/jbc.272.37.23323; Wu-Wong JR, 2000, J CARDIOVASC PHARM, V36, pS179, DOI 10.1097/00005344-200036001-00055; Wu-Wong JSR, 1999, J BIOL CHEM, V274, P8103, DOI 10.1074/jbc.274.12.8103; Yamahara N, 2000, LIFE SCI, V66, P1401, DOI 10.1016/S0024-3205(00)00451-3; Zini S, 1996, P NATL ACAD SCI USA, V93, P11968, DOI 10.1073/pnas.93.21.11968; Zisman A, 2000, NAT MED, V6, P924, DOI 10.1038/78693; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	64	96	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17677	17686		10.1074/jbc.M202037200	http://dx.doi.org/10.1074/jbc.M202037200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884418	hybrid			2022-12-25	WOS:000175685100038
J	Rockwell, NC; Fuller, RS				Rockwell, NC; Fuller, RS			Specific modulation of Kex2/furin family proteases by potassium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; PROHORMONE-PROCESSING ENZYME; KEX2 PROTEASE; SECRETORY GRANULES; SUBTILISIN BPN'; YEAST; LOCALIZATION; FURIN; CONVERTASE-2; EXCHANGER	Kex2 protease is the prototype for a family of proteases responsible for endoproteolytic cleavage at multibasic motifs in the eukaryotic secretory pathway. Here we demonstrate that potassium ion can act as a modulator of Kex2 activity with an apparent affinity of similar to20 mM. Other monovalent cations (Li+, Na+, etc.) display similar effects, but affinities are all over 20-fold lower. Potassium ion binding stimulates turnover at physiologically relevant Lys-Arg cleavage sites but reduces turnover with at least one incorrect sequence. Furthermore, the mammalian Kex2 homolog furin displays similar effects. In contrast, the neuroendocrine homolog PC2 is inhibited by potassium ion with all substrates examined. The pre-steady-state behavior of Kex2 is also altered upon binding of potassium ion, with opposite effects on acylation and deacylation rates. These biochemical data indicate that potassium ion concentration may function as a regulator of processing protease specificity and activity in the eukaryotic secretory pathway, with such enzymes potentially encountering compartments high in potassium ion caused by the action of antiporters such as yeast NHX1 (VPS44) or the mammalian NHE7.	Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA	University of Michigan System; University of Michigan; Stanford University	Fuller, RS (corresponding author), Univ Michigan, Med Ctr, Dept Biol Chem, Rm 5413,Med Sci I,1301 E Catherine, Ann Arbor, MI 48109 USA.				NIGMS NIH HHS [GM 39697, 2T32GM07599] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM039697, T32GM007599, R01GM039697] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Bevan A, 1998, P NATL ACAD SCI USA, V95, P10384, DOI 10.1073/pnas.95.18.10384; Bowers K, 2000, MOL BIOL CELL, V11, P4277, DOI 10.1091/mbc.11.12.4277; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRAXTON S, 1992, BIOCHEMISTRY-US, V31, P7796, DOI 10.1021/bi00149a008; BRENNER C, 1993, CURR BIOL, V3, P498, DOI 10.1016/0960-9822(93)90040-U; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; BRENNER C, 1994, METHOD ENZYMOL, V244, P152; Brickner JH, 1997, J CELL BIOL, V139, P23, DOI 10.1083/jcb.139.1.23; BRYAN P, 1992, BIOCHEMISTRY-US, V31, P4937, DOI 10.1021/bi00136a003; Cameron A., 2001, ENZYMES, V22, P291; Day R, 1998, J BIOL CHEM, V273, P829, DOI 10.1074/jbc.273.2.829; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; FULLER R, 1986, MICROBIOLOGY 1986, P273; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GALLAGHER T, 1993, PROTEINS, V16, P205, DOI 10.1002/prot.340160207; GRON H, 1992, BIOCHEMISTRY-US, V31, P6011, DOI 10.1021/bi00141a008; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HUTTON JC, 1983, BIOCHEM J, V210, P297, DOI 10.1042/bj2100297; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; Johanning K, 1998, J BIOL CHEM, V273, P22672, DOI 10.1074/jbc.273.35.22672; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Krysan DJ, 1999, J BIOL CHEM, V274, P23229, DOI 10.1074/jbc.274.33.23229; Lamango NS, 1996, ARCH BIOCHEM BIOPHYS, V330, P238, DOI 10.1006/abbi.1996.0249; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Molloy SS, 2002, ENZYMES, VXXII, P199; MULLER L, 1999, PROGR NUCL ACIDS RES; Nass R, 1998, J BIOL CHEM, V273, P21054, DOI 10.1074/jbc.273.33.21054; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; PHILIPP M, 1983, MOL CELL BIOCHEM, V51, P5, DOI 10.1007/BF00215583; Rockwell NC, 1997, BIOCHEMISTRY-US, V36, P1912, DOI 10.1021/bi961779l; Rockwell NC, 2000, ANAL BIOCHEM, V280, P201, DOI 10.1006/abio.2000.4541; Rockwell NC, 1998, BIOCHEMISTRY-US, V37, P3386, DOI 10.1021/bi972534r; Rockwell NC, 2001, J BIOL CHEM, V276, P38394, DOI 10.1074/jbc.M105782200; Rockwell NC, 2001, BIOCHEMISTRY-US, V40, P3657, DOI 10.1021/bi0020877; Rockwell NC, 2002, ENZYMES, V22, P259, DOI 10.1016/S1874-6047(02)80011-7; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEIDAH NG, 2001, ENZYMES, V22, P237; Steiner D. F., 2002, ENZYMES, V22, P163; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; Uehara M, 2001, CELL TISSUE RES, V304, P43, DOI 10.1007/s004410100364; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; WELLS JA, 1986, PHILOS T R SOC A, V317, P415, DOI 10.1098/rsta.1986.0051; ZIMMERMAN M, 1977, ANAL BIOCHEM, V78, P47, DOI 10.1016/0003-2697(77)90006-9	45	30	33	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17531	17537		10.1074/jbc.M111909200	http://dx.doi.org/10.1074/jbc.M111909200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11893737	hybrid			2022-12-25	WOS:000175685100019
J	Stefanovic, B; Schnabl, B; Brenner, DA				Stefanovic, B; Schnabl, B; Brenner, DA			Inhibition of collagen alpha 1(I) expression by the 5 ' stem-loop as a molecular decoy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STELLATE CELL ACTIVATION; FAT-STORING CELLS; MESSENGER-RNA; EXTRACELLULAR-MATRIX; HEPATIC LIPOCYTES; LIVER-CIRRHOSIS; SNRNA; PATTERNS; FIBROSIS; SITE	Collagen alpha1(I) mRNA is posttranscriptionally regulated in hepatic stellate cells (HSCs). Binding of protein factors to the evolutionary conserved stem-loop in the 5'-untranslated region (5' stem-loop) is required for a high level of expression in activated HSCs. The 5' stem-loop is also found in alpha2(I) and alpha1(III) mRNAs. Titration of the 5' stem-loop binding factors by a stably expressed RNA containing the 5' stem-loop (molecular decoy) may decrease the expression of these collagen mRNAs. We designed a 108-nt RNA that is transcribed from the optimized mouse U7 small nuclear RNA gene and contains the 5' stem-loop (p74WT decoy). This decoy accumulates in the nucleus and in the cytoplasm. When expressed in NTH 3T3 fibroblasts, the p74WT decoy decreased collagen alpha1(I) mRNA level by 60% and decreased collagen type I secreted into the cellular medium by 50%. We also expressed this decoy in quiescent rat HSCs by adenoviral gene transfer. Quiescent HSCs undergo activation in culture, resulting in a 60-70-fold increase in collagen alpha1(I) mRNA. The decoy decreases collagen alpha1(I) mRNA expression by 50-60% during activation of HSCs. It also decreases collagen a2(I) mRNA expression and collagen alpha1(III) mRNA expression. The cellular levels of collagen alpha1(I) propeptide and of disulfide-bonded collagen type I trimer are reduced by 70%. However, the p74WT decoy did not decrease a smooth muscle actin protein or the mRNA levels of glyceraldehyde-3-phosphate dehydrogenase and interleukin-6. The p74WT decoy was also introduced into activated human HSCs. In these cells, the decoy decreased collagen alpha1(I) propeptide and disulfide-bonded collagen trimer by 50-60%. These results indicate that the 5' stem-loop specifically regulates fibrillar collagen synthesis and represents a novel target for antifibrotic therapy. The molecular decoys provide a generalized method of assessing the functional significance of blocking the interactions of mRNA and proteins.	Univ N Carolina, Dept Med, Div Digest Dis & Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Stefanovic, B (corresponding author), Univ N Carolina, Dept Med, Div Digest Dis & Nutr, CB 7038,154 Glaxo Bldg, Chapel Hill, NC 27599 USA.	stefbra@med.unc.edu		Brenner, David/0000-0003-2573-525X				AYCOCK RS, 1989, CONNECT TISSUE RES, V23, P19, DOI 10.3109/03008208909103901; BLANCK TJJ, 1975, ARCH BIOCHEM BIOPHYS, V171, P259, DOI 10.1016/0003-9861(75)90031-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALESSIO M, 1990, J BIOL CHEM, V265, P7050; DELEEUW AM, 1984, HEPATOLOGY, V4, P392; Friedman SL, 1999, ALCOHOL CLIN EXP RES, V23, P904, DOI 10.1097/00000374-199905000-00020; FRIEDMAN SL, 1992, HEPATOLOGY, V15, P234, DOI 10.1002/hep.1840150211; FRIEDMAN SL, 1989, J BIOL CHEM, V264, P10756; Gorman L, 1998, P NATL ACAD SCI USA, V95, P4929, DOI 10.1073/pnas.95.9.4929; GRIMM C, 1993, EMBO J, V12, P1229, DOI 10.1002/j.1460-2075.1993.tb05764.x; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hellerbrand C, 1999, J HEPATOL, V30, P77, DOI 10.1016/S0168-8278(99)80010-5; HENDRIKS HFJ, 1985, EXP CELL RES, V160, P138, DOI 10.1016/0014-4827(85)90243-5; Herfarth HH, 1996, GUT, V39, P836, DOI 10.1136/gut.39.6.836; Iimuro Y, 2000, HEPATOLOGY, V32, p321A; JACOBSON MR, 1993, MOL CELL BIOL, V13, P1119, DOI 10.1128/MCB.13.2.1119; Knittel T, 1999, GASTROENTEROLOGY, V117, P1205, DOI 10.1016/S0016-5085(99)70407-5; Lindquist JN, 2000, NUCLEIC ACIDS RES, V28, P4306, DOI 10.1093/nar/28.21.4306; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MILANI S, 1990, AM J PATHOL, V137, P59; Niederreither K, 1995, MATRIX BIOL, V14, P705, DOI 10.1016/S0945-053X(05)80013-7; Raker VA, 1999, MOL CELL BIOL, V19, P6554; Salgado S, 2000, MOL THER, V2, P545, DOI 10.1006/mthe.2000.0210; SCHUPPAN D, 1990, SEMIN LIVER DIS, V10, P1, DOI 10.1055/s-2008-1040452; SMITH HO, 1991, P NATL ACAD SCI USA, V88, P9784, DOI 10.1073/pnas.88.21.9784; Stefanovic A, 2000, NUCLEIC ACIDS RES, V28, P641, DOI 10.1093/nar/28.2.641; STEFANOVIC B, 1995, NUCLEIC ACIDS RES, V23, P3152, DOI 10.1093/nar/23.16.3152; Stefanovic B, 1999, MOL CELL BIOL, V19, P4334; Stefanovic B, 1997, MOL CELL BIOL, V17, P5201, DOI 10.1128/MCB.17.9.5201; STEFANOVIC B, 1995, NUCLEIC ACIDS RES, V23, P3141, DOI 10.1093/nar/23.16.3141; SU MW, 1991, J CELL BIOL, V115, P565, DOI 10.1083/jcb.115.2.565; Ueki T, 1999, NAT MED, V5, P226, DOI 10.1038/5593; YAMADA Y, 1983, J BIOL CHEM, V258, P4914	36	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18229	18237		10.1074/jbc.M108065200	http://dx.doi.org/10.1074/jbc.M108065200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11889120	hybrid			2022-12-25	WOS:000175685100106
J	Levert, KL; Waldrop, GL; Stephens, JM				Levert, KL; Waldrop, GL; Stephens, JM			A biotin analog inhibits acetyl-CoA carboxylase activity and adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM-BASED INHIBITION; FATTY-ACID OXIDATION; ADIPOCYTE; STORAGE; ENZYME	Acetyl-CoA carboxylase catalyzes the first committed step in the synthesis of long chain fatty acids. In this study, we observed that treatment of 3T3-L1 cells with biotin chloroacetylated at the V nitrogen reduced the enzymatic activity of cytosolic acetyl-CoA carboxylase and concomitantly inhibited the differentiation of 3T3-L1 cells in a dose-dependent manner. Treatment with chloroacetylated biotin blocked the induction of PPARgamma, STAT1, and STAT5A expression that normally occurs with adipogenesis. Moreover, addition of chloroacetylated biotin inhibited lipid accumulation, as judged by Oil Red 0 staining. Our results support recent studies that indicate that acetyl-CoA carboxylase may be a suitable target for an anti-obesity therapeutic.	Louisiana State Univ, Dept Biol Sci, Div Biochem & Mol Biol, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Stephens, JM (corresponding author), Louisiana State Univ, Dept Biol Sci, Div Biochem & Mol Biol, Rm 202 Life Sci Bldg, Baton Rouge, LA 70803 USA.		Stephens, Jacqueline M/R-5217-2018		NIDDK NIH HHS [R01DK5268-02] Funding Source: Medline; NIGMS NIH HHS [GM51261] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051261] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Amspacher DR, 1999, ORG LETT, V1, P99, DOI 10.1021/ol990026z; Bull HG, 1996, J AM CHEM SOC, V118, P2359, DOI 10.1021/ja953069t; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; Khalil EM, 1999, P NATL ACAD SCI USA, V96, P12418, DOI 10.1073/pnas.96.22.12418; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levert KL, 2002, BIOCHEM BIOPH RES CO, V291, P1213, DOI 10.1006/bbrc.2002.6576; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; Rosen ED, 2000, GENE DEV, V14, P1293; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; TANABE T, 1975, EUR J BIOCHEM, V57, P15, DOI 10.1111/j.1432-1033.1975.tb02272.x; Thupari JN, 2001, BIOCHEM BIOPH RES CO, V285, P217, DOI 10.1006/bbrc.2001.5146; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	14	58	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16347	16350		10.1074/jbc.C200113200	http://dx.doi.org/10.1074/jbc.C200113200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11907024	hybrid			2022-12-25	WOS:000175564500001
J	Kawabe, T; Suganuma, M; Ando, T; Kimura, M; Hori, H; Okamoto, T				Kawabe, T; Suganuma, M; Ando, T; Kimura, M; Hori, H; Okamoto, T			Cdc25C interacts with PCNA at G2/M transition	ONCOGENE			English	Article						cell cycle; G2; M checkpoint; Cdc25C; PCNA; MPF	CELL NUCLEAR ANTIGEN; DNA-POLYMERASE-DELTA; PROTEIN-KINASE; HUMAN HOMOLOG; CHECKPOINT; REPLICATION; CYCLE; DAMAGE; BINDING; YEAST	Cdc25 activates maturation promoting factor (MPF) and promotes mitosis by removing the inhibitory phosphate from the Tyr-15 of Cdc2 in human cells. In this study, we searched the interacting protein(s) of human Cdc25C using the yeast two-hybrid screen and identified proliferating cell nuclear antigen (PCNA) as an interacting partner of Cdc25C. The interaction between Cdc25C and PCNA was confirmed in vitro and in vivo. Co-immunoprecipitation analyses using human T cell line, Jurkat, further revealed that Cdc25C interacted with PCNA transiently when cells began to enter mitosis. Immunofluorescence analysis also showed that Cdc25C and PCNA were transiently co-localized in the nucleus at the beginning of M phase. Together with the previous observations of the interaction between various cdc/cyclin and PCNA, our findings strongly suggested a potential role of PCNA at the G2 to M phase transition of cell cycle.	Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Sch Med, Dept Internal Med 1, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University; Nagoya City University	Okamoto, T (corresponding author), Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	tokamoto@med.nagoya-cu.ac.jp						ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; Gowdy PM, 1998, J CELL SCI, V111, P3401; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hindges R, 1997, BIOL CHEM, V378, P345; Kajino S, 2000, ONCOGENE, V19, P2233, DOI 10.1038/sj.onc.1203560; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LINDSAY HD, 1997, EMBO J, V16, P545; Loor G, 1997, NUCLEIC ACIDS RES, V25, P5041, DOI 10.1093/nar/25.24.5041; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Suganuma M, 1999, CANCER RES, V59, P5887; SZEPESI A, 1994, BLOOD, V84, P3413; TAN CK, 1986, J BIOL CHEM, V261, P2310; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; ZENG XR, 1994, J BIOL CHEM, V269, P24027; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	53	51	53	4	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1717	1726		10.1038/sj.onc.1205229	http://dx.doi.org/10.1038/sj.onc.1205229			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896603				2022-12-25	WOS:000174214200010
J	Suprynowicz, FA; Baege, A; Sunitha, I; Schlegel, R				Suprynowicz, FA; Baege, A; Sunitha, I; Schlegel, R			c-Src Activation by the E5 oncoprotein enables transformation independently of PDGF receptor activation	ONCOGENE			English	Article						ES oncoprotein; Src; papillomavirus; transformation	GROWTH-FACTOR RECEPTOR; FOCAL ADHESION KINASE; FACTOR-BETA RECEPTOR; PROTEIN-TYROSINE KINASE; OPEN READING FRAME; BOVINE PAPILLOMAVIRUS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; BINDING; PHOSPHORYLATION	The E5 oncoprotein of bovine papillornavirus type I is a Golgi-resident, hydrophobic polypeptide that can transform immortalized fibroblasts by activating endogenous platelet-derived growth factor receptor P (PDGF-R). However, the existence of E5 mutants that dissociate transformation from PDGF-R activation implies that there are additional mechanism(s) by which E5 can transform cells. We now show that both wt E5, and transforming E5 mutants that are defective for PDGF-R activation, constitutively activate endogenous c-Src in NIH3T3 cell lines to levels normally associated with acute growth factor stimulation. The ubiquitous Src family protein tyrosine kinase (PTK) Fyn is not activated by these E5 constructs, nor are focal adhesion kinase and endogenous receptor PTKs for insulin, epidermal growth factor, basic fibroblast growth factor and insulin-like growth factor. We further demonstrate that transforming activity of the L26A E5 mutant, which is highly defective for PDGF-R activation, depends on its ability to activate Src. L26A E5 does not transform SYF cells that are deficient for Src, Fyn and Yes, unless Src expression is reconstituted, and does not transform NIH3T3 cells in which Src PTK activity is maintained at a basal level by means of kinase-defective K295R Src overexpression.	Georgetown Univ, Med Ctr, Dept Pathol, Washington, DC 20007 USA	Georgetown University	Schlegel, R (corresponding author), Georgetown Univ, Med Ctr, Dept Pathol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	schleger@georgetown.edu			NATIONAL CANCER INSTITUTE [R01CA053371] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA53371] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Adduci AJ, 1999, J BIOL CHEM, V274, P10249, DOI 10.1074/jbc.274.15.10249; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANDRESSON T, 1995, J BIOL CHEM, V270, P6830, DOI 10.1074/jbc.270.12.6830; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHEN EY, 1982, NATURE, V299, P529, DOI 10.1038/299529a0; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHENG HC, 1992, J BIOL CHEM, V267, P9248; COHEN BD, 1993, MOL CELL BIOL, V13, P6462, DOI 10.1128/MCB.13.10.6462; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DiMaio D, 2000, CYTOKINE GROWTH F R, V11, P283, DOI 10.1016/S1359-6101(00)00012-5; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; DVORETZKY I, 1980, VIROLOGY, V103, P369, DOI 10.1016/0042-6822(80)90195-6; Gazit A, 1996, BIOORGAN MED CHEM, V4, P1203, DOI 10.1016/0968-0896(96)00107-1; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; KOVALENKO M, 1994, CANCER RES, V54, P6106; Lai CC, 1998, P NATL ACAD SCI USA, V95, P15241, DOI 10.1073/pnas.95.26.15241; LANCASTER WD, 1982, MICROBIOL REV, V46, P191, DOI 10.1128/MMBR.46.2.191-207.1982; LIN PH, 1995, ONCOGENE, V10, P401; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOWY DR, 1980, NATURE, V287, P72, DOI 10.1038/287072a0; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MEISCHKE HRC, 1979, J GEN VIROL, V43, P473, DOI 10.1099/0022-1317-43-3-473; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SOLTOFF SP, 1992, COLD SPRING HARB SYM, V57, P75, DOI 10.1101/SQB.1992.057.01.010; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPARKOWSKI J, 1995, EMBO J, V14, P3055, DOI 10.1002/j.1460-2075.1995.tb07308.x; Sparkowski J, 1996, J VIROL, V70, P2420, DOI 10.1128/JVI.70.4.2420-2430.1996; SPARKOWSKI J, 1994, J VIROL, V68, P6120, DOI 10.1128/JVI.68.9.6120-6123.1994; STOPPLER H, 1994, INTERVIROLOGY, V37, P168; Suprynowicz FA, 2000, J BIOL CHEM, V275, P5111, DOI 10.1074/jbc.275.7.5111; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; WITT JJ, 1975, ANAL BIOCHEM, V66, P253, DOI 10.1016/0003-2697(75)90743-5; YANG YC, 1985, NATURE, V318, P575, DOI 10.1038/318575a0	72	18	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1695	1706		10.1038/sj.onc.1205223	http://dx.doi.org/10.1038/sj.onc.1205223			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896601				2022-12-25	WOS:000174214200008
J	Koeduka, T; Matsui, K; Akakabe, Y; Kajiwara, T				Koeduka, T; Matsui, K; Akakabe, Y; Kajiwara, T			Catalytic properties of rice alpha-oxygenase - A comparison with mammalian prostaglandin H synthases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER OXIDATION-STATES; CHAIN FATTY-ACIDS; ENDOPEROXIDE SYNTHASE; CHIRAL LACTOLS; HIGHER-PLANTS; HEME; IDENTIFICATION; DIOXYGENASE; PEROXIDASE; MECHANISM	Long-chain fatty acids can be metabolized to Cn-1 aldehydes by alpha-oxidation in plants. The reaction mechanism of the enzyme has not been elucidated. In this study, a complete nucleotide sequence of fatty acid alpha-oxygenase gene in rice plants (Oryza sativa) was isolated. The deduced amino acid sequence showed some similarity with those of mammalian prostaglandin H synthases (PGHSs). The gene was expressed in Escherichia coli and purified to apparently homogenous state. It showed the highest activity with linoleic acid and predominantly formed 2-hydroperoxide of the fatty acid (C-n), which is then spontaneously decarboxylated to form corresponding Cn-1 aldehyde. With linoleic or linoleic acids as a substrate, rice alpha-oxygenase formed no product having a lambda(max) at approximately 234 rim, which indicated that the enzyme could not oxygenize the pentadiene system in the substrate. The spectroscopic feature of the purified enzyme in its ferrous state is similar to that of mammalian PGHS, whereas that of dithionite-reduced state showed significant difference. Site-directed mutagenesis revealed that His-158, Tyr-380, and Ser-558 were essential for the alpha-oxygenase activity. These residues are conserved in PGHS and known as a heme ligand, a source of a radical species to initiate oxygenation reaction and a residue involved in substrate binding, respectively. This finding suggested that the initial step of the oxygenation reaction in alpha-oxygenase has a high similarity with that of PGHS. The rice alpha-oxygenase activity was inhibited by imidazole but hardly inhibited by nonsteroidal anti-inflammatory drugs, such as aspirin, ibuprofen, and flurbiprofen, which are known as typical PGHS inhibitors. In addition, peroxidase activity could not be detected with alpha-oxygenase when palmitic acid 2-hydroperoxide was used as a substrate. From these findings, the catalytic resemblance between alpha-oxygenase and PGHS seems to be evident, although there still are differences in their substrate recognitions and peroxidation activities.	Yamaguchi Univ, Fac Agr, Dept Biol Chem, Yamaguchi 7538515, Japan	Yamaguchi University	Matsui, K (corresponding author), Yamaguchi Univ, Fac Agr, Dept Biol Chem, Yamaguchi 7538515, Japan.	matsui@agr.yamaguchi-u.ac.jp						Akakabe Y, 1999, TETRAHEDRON LETT, V40, P1137, DOI 10.1016/S0040-4039(98)02547-7; Benveniste I, 1998, BIOCHEM BIOPH RES CO, V243, P688, DOI 10.1006/bbrc.1998.8156; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMER J, 1984, FATTY ACID METABOLIS, P113; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; GALLIARD T, 1976, BIOCHIM BIOPHYS ACTA, V424, P26, DOI 10.1016/0005-2760(76)90046-1; Goodwin DC, 2000, BIOCHEMISTRY-US, V39, P5422, DOI 10.1021/bi992752f; Hamberg M, 1999, J BIOL CHEM, V274, P24503, DOI 10.1074/jbc.274.35.24503; HITCHCOC.C, 1966, BIOCHIM BIOPHYS ACTA, V116, P413, DOI 10.1016/0005-2760(66)90112-3; Hornsten L, 1999, J BIOL CHEM, V274, P28219, DOI 10.1074/jbc.274.40.28219; Jansen GA, 1997, NAT GENET, V17, P190, DOI 10.1038/ng1097-190; KAJIWARA T, 1991, PHYTOCHEMISTRY, V30, P193, DOI 10.1016/0031-9422(91)84122-9; Kalgutkar AS, 2000, P NATL ACAD SCI USA, V97, P925, DOI 10.1073/pnas.97.2.925; KANG MY, 1986, J BIOCHEM-TOKYO, V99, P549, DOI 10.1093/oxfordjournals.jbchem.a135511; KNOLLMULLER M, 1986, MONATSH CHEM, V117, P407, DOI 10.1007/BF00816535; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LATIES GG, 1967, PHYTOCHEMISTRY, V6, P49, DOI 10.1016/0031-9422(67)85007-6; Matsunaga I, 1996, FEBS LETT, V386, P252, DOI 10.1016/0014-5793(96)00451-6; NOE CR, 1982, CHEM BER-RECL, V115, P1591, DOI 10.1002/cber.19821150434; NOE CR, 1986, CHEM BER-RECL, V119, P729, DOI 10.1002/cber.19861190230; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; Psylinakis E, 2001, BBA-MOL CELL BIOL L, V1533, P119, DOI 10.1016/S1388-1981(01)00150-0; Saffert A, 2000, PLANT PHYSIOL, V123, P1545, DOI 10.1104/pp.123.4.1545; Sanz A, 1998, PLANT CELL, V10, P1523, DOI 10.1105/tpc.10.9.1523; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHINE WE, 1974, ARCH BIOCHEM BIOPHYS, V162, P147, DOI 10.1016/0003-9861(74)90113-1; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; TSAI AL, 1993, J BIOL CHEM, V268, P8554; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; vanderBiezen EA, 1996, MOL GEN GENET, V251, P267, DOI 10.1007/BF02172517; VANDEROUDERAA FJ, 1979, BIOCHIM BIOPHYS ACTA, V572, P29, DOI 10.1016/0005-2760(79)90197-8	33	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22648	22655		10.1074/jbc.M110420200	http://dx.doi.org/10.1074/jbc.M110420200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11909851	hybrid			2022-12-25	WOS:000176313600071
J	Vulin, AI; Stanley, FM				Vulin, AI; Stanley, FM			A Forkhead/winged helix-related transcription factor mediates insulin-increased plasminogen activator inhibitor-1 gene transcription.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; FACTOR-BINDING PROTEIN-1; HUMAN ENDOTHELIAL-CELLS; TYPE-1 PAI-1 GENE; PROLACTIN GENE; FACTOR FKHR; RESPONSE ELEMENT; TGF-BETA; IN-VIVO; ANGIOTENSIN-II	Plasminogen activator inhibitor-1 (PAI-1) is an important regulator of fibrinolysis by its inhibition of both tissue-type and urokinase plasminogen activators. PAI-1 levels are elevated in type II diabetes and this elevation correlates with macro- and microvascular complications of diabetes. Insulin increases PAI-1 production in several experimental systems, but the mechanism of insulin-activated PAI-1 transcription remains to be determined. Deletion analysis of the PAI-1 promoter revealed that the insulin response element is between -117 and -7. Mutation of the AT-rich site at -52/-45 abolished the insulin responsiveness of the PAI-1 promoter. This sequence is similar to the inhibitory sequence found in the phosphoenolpyruvate carboxylkinase/insulin-like growth factor-l-binding protein I promoters. Gel-mobility shift assays demonstrated that the forkhead bound to the PAI-1 promoter insulin response element. Expression of the DNA-binding domain of FKHR acted as a dominant negative to block insulin-increased PAI-1-CAT expression. A LexA-FKHR construct was also insulin responsive. These data suggested that a member of the Forkhead/winged helix family of transcription factors mediated the effect of insulin on PAI-1 transcription. Inhibition of phosphatidylinositol 3-kinase reduced the effect of insulin on PAI-1 gene expression, a result consistent with activation through FKHR. However, it was likely that a different member of the FKHR family (not FKHR) mediated this effect since FKHR was present in both insulin-responsive and non-responsive cell lines.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	New York University	Stanley, FM (corresponding author), NYU, Med Ctr, Dept Med, TCH 450,550 1St Ave, New York, NY 10016 USA.			Stanley, Frederick/0000-0002-3684-2168				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; AGRENIUS V, 1989, AM REV RESPIR DIS, V140, P1381, DOI 10.1164/ajrccm/140.5.1381; Arts J, 1999, ARTERIOSCL THROM VAS, V19, P39, DOI 10.1161/01.ATV.19.1.39; Banfi C, 2001, DIABETES, V50, P1522, DOI 10.2337/diabetes.50.7.1522; Brown NJ, 2000, J CLIN ENDOCR METAB, V85, P336, DOI 10.1210/jc.85.1.336; BRUZDZINSKI CJ, 1993, MOL ENDOCRINOL, V7, P1169, DOI 10.1210/me.7.9.1169; Busso N, 1997, ANN RHEUM DIS, V56, P550, DOI 10.1136/ard.56.9.550; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Carmassi F, 1999, AM J MED, V107, P344, DOI 10.1016/S0002-9343(99)00240-5; Chen YQ, 1998, J BIOL CHEM, V273, P8225, DOI 10.1074/jbc.273.14.8225; COCKELL KA, 1995, THROMB RES, V77, P119, DOI 10.1016/0049-3848(95)91618-U; Dichtl W, 1999, ARTERIOSCL THROM VAS, V19, P3025, DOI 10.1161/01.ATV.19.12.3025; Dietzmann K, 2000, PATHOL RES PRACT, V196, P15, DOI 10.1016/S0344-0338(00)80017-5; Friess H, 1998, SURGERY, V124, P79, DOI 10.1016/S0039-6060(98)70078-9; FROST SC, 1985, J BIOL CHEM, V260, P2646; Gallicchio M, 1996, J IMMUNOL, V157, P2610; Grenett HE, 1999, THROMB HAEMOSTASIS, V82, P1504; Grenett HE, 1998, ARTERIOSCL THROM VAS, V18, P1803, DOI 10.1161/01.ATV.18.11.1803; Hasenstab D, 1997, CIRC RES, V80, P490, DOI 10.1161/01.RES.80.4.490; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Jacob KK, 1998, J BIOL CHEM, V273, P4800, DOI 10.1074/jbc.273.8.4800; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; Jacob KK, 2001, J BIOL CHEM, V276, P24931, DOI 10.1074/jbc.M102826200; JACOB KK, 1994, J BIOL CHEM, V269, P25515; Kaestner KH, 2000, GENE DEV, V14, P142; Kietzmann T, 1999, BLOOD, V94, P4177, DOI 10.1182/blood.V94.12.4177.424k14_4177_4185; KNUDSEN H, 1994, EUR J BIOCHEM, V220, P63, DOI 10.1111/j.1432-1033.1994.tb18599.x; LANG IM, 1994, CIRCULATION, V89, P2715, DOI 10.1161/01.CIR.89.6.2715; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Lau HKF, 1999, CARDIOVASC RES, V43, P1049, DOI 10.1016/S0008-6363(99)00136-4; Marutsuka K, 1998, CORONARY ARTERY DIS, V9, P177, DOI 10.1097/00019501-199809040-00002; Motojima M, 2000, BIOCHEM J, V349, P435, DOI 10.1042/0264-6021:3490435; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; NORDT TK, 1994, CIRCULATION, V89, P321, DOI 10.1161/01.CIR.89.1.321; Nordt TK, 1998, J MOL CELL CARDIOL, V30, P1535, DOI 10.1006/jmcc.1998.0719; NORDT TK, 1995, CIRCULATION, V91, P764, DOI 10.1161/01.CIR.91.3.764; OBRIEN RM, 1991, P NATL ACAD SCI USA, V88, P6580, DOI 10.1073/pnas.88.15.6580; Olman MA, 1999, BLOOD, V94, P2029, DOI 10.1182/blood.V94.6.2029.418k25_2029_2038; PADRO T, 1995, ARTERIOSCL THROM VAS, V15, P893, DOI 10.1161/01.ATV.15.7.893; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; Samad F, 1996, MOL MED, V2, P568, DOI 10.1007/BF03401641; Samad F, 2000, MOL MED, V6, P680, DOI 10.1007/BF03402048; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SAWA H, 1992, ARTERIOSCLER THROMB, V12, P1507, DOI 10.1161/01.ATV.12.12.1507; SAWA H, 1993, CIRC RES, V73, P671, DOI 10.1161/01.RES.73.4.671; SHARROCKS AD, 1992, NUCLEIC ACIDS RES, V20, P1147, DOI 10.1093/nar/20.5.1147; SIMPSON AJ, 1991, J CLIN PATHOL, V44, P139, DOI 10.1136/jcp.44.2.139; Sobel BE, 1998, CIRCULATION, V97, P2213, DOI 10.1161/01.CIR.97.22.2213; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; STANLEY F, 1989, MOL ENDOCRINOL, V3, P1627, DOI 10.1210/mend-3-10-1627; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; SUWANICHKUL A, 1990, J BIOL CHEM, V265, P21185; Tamaki K, 1996, J AM SOC NEPHROL, V7, P2578; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; White LA, 2000, EXP CELL RES, V260, P127, DOI 10.1006/excr.2000.5001; Yamamoto K, 1997, AM J PATHOL, V151, P725	59	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20169	20176		10.1074/jbc.M112073200	http://dx.doi.org/10.1074/jbc.M112073200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11919188	hybrid			2022-12-25	WOS:000176204500012
J	Berkhout, B; Ooms, M; Beerens, N; Huthoff, H; Southern, E; Verhoef, K				Berkhout, B; Ooms, M; Beerens, N; Huthoff, H; Southern, E; Verhoef, K			In vitro evidence that the untranslated leader of the HIV-1 genome is an RNA checkpoint that regulates multiple functions through conformational changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DIMERIZATION INITIATION SITE; REVERSE TRANSCRIPTION; SECONDARY STRUCTURE; STRAND TRANSFER; IN-VITRO; TAR RNA; TYPE-1; HAIRPIN; BINDING	The HIV-1 RNA genome forms dimers through base pairing of a palindromic 6-mer sequence that is exposed in the loop of the dimer initiation signal (DIS) hairpin structure (loop-loop kissing). The HIV-1 leader RNA can adopt a secondary structure conformation that is not able to dimerize because the DIS hairpin is not folded. Instead, this DIS motif is base-paired in a long distance interaction (LDI) that extends the stem of the primer-binding site domain. In this study, we show that targeting of the LDI by either antisense oligonucleotides or specific mutations can induce the conformational switch to a branched multiple hairpin (BAIH) structure, and this LDI-to-BMH switch coincides with increased RNA dimerization. Another interesting finding is that the extended LDI stem can resist a certain level of destabilization, indicating that a buffer is created to prevent a premature conformational switch and early dimerization. Because the tRNA(Lys3) primer for reverse transcription anneals to multiple sequence elements of the HIV-1 leader RNA, including sequences in the LDI stem, we tested whether tRNA-annealing can destabilize the LDI stem such that RNA dimerization is triggered. Using a combination of stem-destabilizing approaches, we indeed measured a small but significant effect of tRNA-annealing on the ability of the RNA template to form dimers. This observation suggests that HIV-1 RNA can act as a checkpoint to control and coordinate different leader functions through conformational switches. This in vitro result should be verified in subsequent in vivo studies with HIV-infected cells.	Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Amsterdam; Academic Medical Center Amsterdam; University of Oxford	Berkhout, B (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.			Ooms, Marcel/0000-0002-0750-5832				Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; Beerens N, 2000, J BIOL CHEM, V275, P15474, DOI 10.1074/jbc.275.20.15474; Beerens N, 2000, NUCLEIC ACIDS RES, V28, P4130, DOI 10.1093/nar/28.21.4130; Beerens N, 2002, J VIROL, V76, P2329, DOI 10.1128/JVI.76.5.2329-2339.2002; Beerens N, 2002, RNA, V8, P357, DOI 10.1017/S1355838202028194; Beerens N, 2001, J BIOL CHEM, V276, P31247, DOI 10.1074/jbc.M102441200; BERKHOUT B, 1995, VIROLOGY, V207, P276, DOI 10.1006/viro.1995.1077; Berkhout B, 1996, PROG NUCLEIC ACID RE, V54, P1, DOI 10.1016/S0079-6603(08)60359-1; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Berkhout B, 2001, RNA, V7, P1097, DOI 10.1017/S1355838201002035; Berkhout B, 1998, VIROLOGY, V249, P211, DOI 10.1006/viro.1998.9321; Berkhout B, 1996, J VIROL, V70, P6723, DOI 10.1128/JVI.70.10.6723-6732.1996; Berkhout B, 2000, Adv Pharmacol, V48, P29; Berkhout B, 2000, RNA, V6, P282, DOI 10.1017/S1355838200991684; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; CLEVER J, 1995, J VIROL, V69, P2101, DOI 10.1128/JVI.69.4.2101-2109.1995; Das AT, 1997, J VIROL, V71, P2346, DOI 10.1128/JVI.71.3.2346-2356.1997; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881; Huthoff H, 2001, NUCLEIC ACIDS RES, V29, P2594, DOI 10.1093/nar/29.12.2594; Jossinet F, 1999, RNA, V5, P1222, DOI 10.1017/S1355838299990982; Klasens BIF, 1998, NUCLEIC ACIDS RES, V26, P1870, DOI 10.1093/nar/26.8.1870; Klasens BIF, 1999, NUCLEIC ACIDS RES, V27, P446, DOI 10.1093/nar/27.2.446; LAUGHREA M, 1994, BIOCHEMISTRY-US, V33, P13464, DOI 10.1021/bi00249a035; Lodmell JS, 2000, RNA, V6, P1267, DOI 10.1017/S1355838200000698; Mujeeb A, 1999, FEBS LETT, V458, P387, DOI 10.1016/S0014-5793(99)01183-7; Paillart JC, 1996, J VIROL, V70, P8348, DOI 10.1128/JVI.70.12.8348-8354.1996; PEDEN KWC, 1996, HIV PRACTICAL APPROA; Shen N, 2001, J VIROL, V75, P10543, DOI 10.1128/JVI.75.21.10543-10549.2001; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; Sohail M., 2000, Molecular Cell Biology Research Communications, V3, P67, DOI 10.1006/mcbr.2000.0178; Sohail M, 2001, NUCLEIC ACIDS RES, V29, P2041, DOI 10.1093/nar/29.10.2041; Takahashi KI, 2000, RNA, V6, P96, DOI 10.1017/S1355838200991635; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3	38	73	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19967	19975		10.1074/jbc.M200950200	http://dx.doi.org/10.1074/jbc.M200950200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11896057	hybrid			2022-12-25	WOS:000175894800096
J	Cemerski, S; Cantagrel, A; van Meerwijk, JPM; Romagnoli, P				Cemerski, S; Cantagrel, A; van Meerwijk, JPM; Romagnoli, P			Reactive oxygen species differentially affect T cell receptor-signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN-TYROSINE KINASES; HYDROGEN-PEROXIDE; RHEUMATOID-ARTHRITIS; OXIDATIVE STRESS; ZETA-CHAIN; DECREASED EXPRESSION; REDOX REGULATION; SYNOVIAL-FLUID	Oxidative stress plays an important role in the induction of T lymphocyte hyporesponsiveness observed in several human pathologies including cancer, rheumatoid arthritis, leprosy, and AIDS. To investigate the molecular basis of oxidative stress-induced T cell hyporesponsiveness, we have developed an in vitro system in which T lymphocytes are rendered hyporesponsive by co-culture with oxygen radical-producing activated neutrophils. We have observed a direct correlation between the level of T cell hyporesponsiveness induced and the concentration of reactive oxygen species produced. Moreover, induction of T cell hyporesponsiveness is blocked by addition of N-acetyl cysteine, Mn(III)tetrakis(4-benzoic acid)porphyrin chloride, and catalase, confirming the critical role of oxidative stress in this system. The pattern of tyrosine-phosphorylated proteins was profoundly altered in hyporesponsive as compared with normal T cells. In hyporesponsive T cells, T cell receptor (TCR) ligation no longer induced phospholipase C-gamma1 activation and caused reduced Ca2+ flux. In contrast, despite increased levels of ERK1/2 phosphorylation, TCR-dependent activation of mitogen-activated protein kinase ERK1/2 was unaltered in hyporesponsive T lymphocytes. A late TCR-signaling event such as caspase 3 activation was as well unaffected in hyporesponsive T lymphocytes. Our data indicate that TCR-signaling pathways are differentially affected by physiological levels of oxidative stress and would suggest that although "hyporesponsive" T cells have lost certain effector functions, they may have maintained or gained others.	CHU Purpan, Inst Claude Preval IFR 30, INSERM, U563 Tolerance & Autoimmun Sect, F-31024 Toulouse 3, France; Univ Toulouse 3, Fac Life Sci, UFR SVT, F-31062 Toulouse, France; Hop Rangueil, Dept Rheumatol, F-31403 Toulouse 4, France; Inst Univ France, F-75005 Paris, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Institut Universitaire de France	Romagnoli, P (corresponding author), CHU Purpan, Inst Claude Preval IFR 30, INSERM, U563 Tolerance & Autoimmun Sect, BP 3028, F-31024 Toulouse 3, France.		Romagnoli, Paola/K-2237-2014; van Meerwijk, Joost P.M./K-1345-2014	van Meerwijk, Joost P.M./0000-0001-8231-1897				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; ALLEN ME, 1995, EUR J IMMUNOL, V25, P1547, DOI 10.1002/eji.1830250612; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Angelini G, 2002, P NATL ACAD SCI USA, V99, P1491, DOI 10.1073/pnas.022630299; AOE T, 1995, J EXP MED, V181, P1881, DOI 10.1084/jem.181.5.1881; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; CAYOTA A, 1994, INT IMMUNOL, V6, P611, DOI 10.1093/intimm/6.4.611; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; DAVIS MJ, 1990, INT MED SPECIALIST, V11, P121; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; FINKE JH, 1993, CANCER RES, V53, P5613; FLESCHER E, 1994, J IMMUNOL, V153, P4880; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Griffith CE, 1998, J BIOL CHEM, V273, P10771, DOI 10.1074/jbc.273.17.10771; Gringhuis SI, 2000, J IMMUNOL, V164, P2170, DOI 10.4049/jimmunol.164.4.2170; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; Hehner SP, 2000, J IMMUNOL, V165, P4319, DOI 10.4049/jimmunol.165.8.4319; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KEISARI Y, 1983, IMMUNOBIOLOGY, V165, P78, DOI 10.1016/S0171-2985(83)80048-5; Kono K, 1996, CLIN CANCER RES, V2, P1825; Kono K, 1996, EUR J IMMUNOL, V26, P1308, DOI 10.1002/eji.1830260620; Lahdenpohja N, 1998, J IMMUNOL, V160, P1354; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Livolsi A, 2001, EUR J BIOCHEM, V268, P1508, DOI 10.1046/j.1432-1327.2001.02028.x; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Matsuda M, 1998, SCAND J IMMUNOL, V47, P254; Maurice MM, 1997, J IMMUNOL, V158, P1458; Maurice MM, 1997, J IMMUNOL, V159, P2973; MCCORD JM, 1974, SCIENCE, V185, P529, DOI 10.1126/science.185.4150.529; MIESCHER S, 1988, INT J CANCER, V42, P659, DOI 10.1002/ijc.2910420504; MIZOGUCHI H, 1992, SCIENCE, V258, P1795, DOI 10.1126/science.1465616; NAKAGOMI H, 1993, CANCER RES, V53, P5610; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NAKAMURA K, 1993, ONCOGENE, V8, P3133; NATHAN CF, 1977, J EXP MED, V146, P1648, DOI 10.1084/jem.146.6.1648; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Otsuji M, 1996, P NATL ACAD SCI USA, V93, P13119, DOI 10.1073/pnas.93.23.13119; OTTENHOFF THM, 1994, INT J LEPROSY, V62, P108; Renner C, 1996, BLOOD, V88, P236; Romagnoli P, 2001, INT IMMUNOL, V13, P305, DOI 10.1093/intimm/13.3.305; SALMON M, 1988, CLIN EXP IMMUNOL, V71, P79; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; Schmielau J, 2001, CANCER RES, V61, P4756; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; Stefanova I, 1996, J CLIN INVEST, V98, P1290, DOI 10.1172/JCI118915; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; TAUBER AI, 1979, BIOCHEMISTRY-US, V18, P5576, DOI 10.1021/bi00592a009; Thannickal VJ, 1998, J BIOL CHEM, V273, P23611, DOI 10.1074/jbc.273.36.23611; Wang XT, 2001, J BIOL CHEM, V276, P28364, DOI 10.1074/jbc.M102693200; WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263; WHISLER RL, 1994, LYMPHOKINE CYTOK RES, V13, P399; Zea AH, 1995, CLIN CANCER RES, V1, P1327; ZOSCHKE DC, 1987, CLIN IMMUNOL IMMUNOP, V42, P160, DOI 10.1016/0090-1229(87)90003-1	60	92	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19585	19593		10.1074/jbc.M111451200	http://dx.doi.org/10.1074/jbc.M111451200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11916964	hybrid			2022-12-25	WOS:000175894800047
J	Govindraj, P; West, L; Koob, TJ; Neame, P; Doege, K; Hassell, JR				Govindraj, P; West, L; Koob, TJ; Neame, P; Doege, K; Hassell, JR			Isolation and identification of the major heparan sulfate proteoglycans in the developing bovine rib growth plate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY ELECTROPHORESIS; BASEMENT-MEMBRANES; PERLECAN; CARTILAGE; AGGRECAN; CHONDROCYTES; BIOSYNTHESIS; EXPRESSION; PROTEIN; MATRIX	Heparan sulfate proteoglycans are thought to mediate the action of growth factors. The heparan sulfate-containing proteoglycans in extracts of the bovine fetal rib growth plate were detected using the monoclonal antibody 3610, which recognizes a neoepitope generated by heparitinase digestion (David, G., Bai, X. M., Van der Schueren, B., Cassiman, J. J., and Van den Berghe, H. (1992) J. Cell Biol. 119, 961-975). The heparan sulfate proteoglycans that react with this antibody were identified using antisera to known proteoglycans; purified using CsCl density gradient centrifugation, molecular sieve, and ion exchange chromatography; and then characterized. The major heparan sulfate proteoglycans in the growth plate had core proteins of 200 kDa and larger and were identified as perlecan and aggrecan. These two heparan sulfate proteoglycans could be effectively separated from each other by CsCl density gradient centrifugation alone. Perlecan contained 25% heparan sulfate and 75% chondroitin sulfate. The heparan sulfate chains on growth plate perlecan were considerably smaller than the chondroitin sulfate chains, and the heparan sulfate disaccharide content was different than that found for heparan sulfate from either kidney, tumor tissue, or growth plate aggrecan. Aggrecan contained only 0.1% heparan sulfate, which was localized to the CS-1 domain of aggrecan. These results indicate that perlecan and aggrecan would be the principal candidate proteoglycans involved in the action of heparan sulfate-binding proteins in the developing growth plate.	Shriners Hosp Children, Dept Res, Ctr Res Skeletal Dev & Pediat Orthoped, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Hassell, JR (corresponding author), Shriners Hosp Children, Dept Res, Ctr Res Skeletal Dev & Pediat Orthoped, 12502 N Pine Dr, Tampa, FL 33612 USA.							ALHAKIM A, 1991, ANAL BIOCHEM, V195, P68, DOI 10.1016/0003-2697(91)90296-6; Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; Arikawa-Hirasawa E, 2001, NAT GENET, V27, P431, DOI 10.1038/86941; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BUCKWALTER JA, 1987, CALCIFIED TISSUE INT, V41, P228, DOI 10.1007/BF02555243; CHINTALA SK, 1995, ARCH BIOCHEM BIOPHYS, V316, P227, DOI 10.1006/abbi.1995.1032; CHINTALA SK, 1994, ARCH BIOCHEM BIOPHYS, V310, P180, DOI 10.1006/abbi.1994.1155; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; DOEGE K, 1987, J BIOL CHEM, V262, P17757; Doege K, 1997, MATRIX BIOL, V16, P211, DOI 10.1016/S0945-053X(97)90010-X; Doege KJ, 1997, J BIOL CHEM, V272, P13974, DOI 10.1074/jbc.272.21.13974; Dolan M, 1997, J BIOL CHEM, V272, P4316, DOI 10.1074/jbc.272.7.4316; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P246; GROVER J, 1995, BIOCHEM J, V309, P963, DOI 10.1042/bj3090963; Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P4494, DOI 10.1073/pnas.77.8.4494; Hering TM, 1997, ARCH BIOCHEM BIOPHYS, V345, P259, DOI 10.1006/abbi.1997.0261; Horton WE, 1998, OSTEOARTHR CARTILAGE, V6, P245, DOI 10.1053/joca.1998.0117; HUNZIKER EB, 1987, J BONE JOINT SURG AM, V69A, P162, DOI 10.2106/00004623-198769020-00002; Karamanos NK, 1996, ELECTROPHORESIS, V17, P391, DOI 10.1002/elps.1150170217; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Nicole S, 2000, NAT GENET, V26, P480, DOI 10.1038/82638; Noonan KJ, 1998, J ORTHOPAED RES, V16, P500, DOI 10.1002/jor.1100160416; Olsen BR, 1999, J CELL BIOL, V147, P909, DOI 10.1083/jcb.147.5.909; PLAAS AHK, 1993, MATRIX, V13, P135, DOI 10.1016/S0934-8832(11)80072-7; POOLE AR, 1982, J CELL BIOL, V92, P249, DOI 10.1083/jcb.92.2.249; ROBINSON HC, 1978, J BIOL CHEM, V253, P6687; SUNDARRAJ N, 1995, J CELL SCI, V108, P2663; Tapanadechopone P, 1999, BIOCHEM BIOPH RES CO, V265, P680, DOI 10.1006/bbrc.1999.1714; TIAN MY, 1986, ARCH BIOCHEM BIOPHYS, V247, P221, DOI 10.1016/0003-9861(86)90551-5; YANAGISHITA M, 1987, METHOD ENZYMOL, V138, P279; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	34	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19461	19469		10.1074/jbc.M200786200	http://dx.doi.org/10.1074/jbc.M200786200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11909863	hybrid			2022-12-25	WOS:000175894800031
J	Iversen, LF; Moller, KB; Pedersen, AK; Peters, GH; Petersen, AS; Andersen, HS; Branner, S; Mortensen, SB; Moller, NPH				Iversen, LF; Moller, KB; Pedersen, AK; Peters, GH; Petersen, AS; Andersen, HS; Branner, S; Mortensen, SB; Moller, NPH			Structure determination of T cell protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; STRUCTURE-BASED DESIGN; CRYSTAL-STRUCTURE; INSULIN SENSITIVITY; SPECIFICITY; INHIBITOR; PTP-1B; ALPHA; PTP1B; ACID	Protein-tyrosine phosphatase 1B (PTP1B) has recently received much attention as a potential drug target in type 2 diabetes. This has in particular been spurred by the finding that PTP1B knockout mice show increased insulin sensitivity and resistance to diet-induced obesity. Surprisingly, the highly homologous T cell protein-tyrosine phosphatase (TC-PTP) has received much less attention, and no x-ray structure has been provided. We have previously co-crystallized PTP1B with a number of low molecular weight inhibitors that inhibit TC-PTP with similar efficiency. Unexpectedly, we were not able to co-crystallize TC-PTP with the same set of inhibitors. This seems to be due to a multimerization process where residues 130-132, the DDQ loop, from one molecule is inserted into the active site of the neighboring molecule, resulting in a continuous string of interacting TC-PTP molecules. Importantly, despite the high degree of functional and structural similarity between TC-PTP and PTP1B, we have been able to identify areas close to the active site that might be addressed to develop selective inhibitors of each enzyme.	Novo Nordisk AS, Signal Transduct, DK-2880 Bagsvaerd, Denmark; Med Chem Res 1, DK-2760 Malov, Denmark; Tech Univ Denmark, Chem Dept, MEMPHYS, DK-2800 Lyngby, Denmark; Royal Danish Sch Pharm, Dept Med Chem, DK-2100 Copenhagen, Denmark	Novo Nordisk; Technical University of Denmark; Royal Danish School of Pharmacy	Iversen, LF (corresponding author), Novo Nordisk AS, Signal Transduct, 6A1 086 Novo Alle, DK-2880 Bagsvaerd, Denmark.	lfiv@novonordisk.com; NPHM@novonordisk.com	Peters, Günther H.J./T-7100-2017	Peters, Günther H.J./0000-0001-9754-2663				Andersen HS, 2000, J BIOL CHEM, V275, P7101, DOI 10.1074/jbc.275.10.7101; Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Blanchetot C, 2000, FEBS LETT, V484, P235, DOI 10.1016/S0014-5793(00)02165-7; Blanchetot C, 2000, J BIOL CHEM, V275, P12446, DOI 10.1074/jbc.275.17.12446; Bleasdale JE, 2001, BIOCHEMISTRY-US, V40, P5642, DOI 10.1021/bi002865v; Burke TR, 1996, BIOCHEMISTRY-US, V35, P15989, DOI 10.1021/bi961256d; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; Dalgarno D C, 2000, Curr Opin Drug Discov Devel, V3, P549; Dunn D, 1996, J BIOL CHEM, V271, P168, DOI 10.1074/jbc.271.1.168; EKMAN P, 1993, ANAL BIOCHEM, V214, P138, DOI 10.1006/abio.1993.1468; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Fauman EB, 1996, J BIOL CHEM, V271, P18780, DOI 10.1074/jbc.271.31.18780; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Fukada T, 2001, J BIOL CHEM, V276, P25512, DOI 10.1074/jbc.M101354200; Groves MR, 1998, BIOCHEMISTRY-US, V37, P17773, DOI 10.1021/bi9816958; Hao LN, 1997, J BIOL CHEM, V272, P29322, DOI 10.1074/jbc.272.46.29322; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Ibarra-Sanchez MD, 2000, SEMIN IMMUNOL, V12, P379, DOI 10.1006/smim.2000.0220; Iversen LF, 2000, J BIOL CHEM, V275, P10300, DOI 10.1074/jbc.275.14.10300; Iversen LF, 2001, BIOCHEMISTRY-US, V40, P14812, DOI 10.1021/bi011389l; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Keng YF, 1999, EUR J BIOCHEM, V259, P809, DOI 10.1046/j.1432-1327.1999.00090.x; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Lam MHC, 2001, J BIOL CHEM, V276, P37700, DOI 10.1074/jbc.M105128200; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; Majeti R, 2000, CELL, V103, P1059, DOI 10.1016/S0092-8674(00)00209-9; Moller N P, 2000, Curr Opin Drug Discov Devel, V3, P527; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Peters GH, 2000, J BIOL CHEM, V275, P18201, DOI 10.1074/jbc.M910273199; Ravichandran LV, 2001, MOL ENDOCRINOL, V15, P1768, DOI 10.1210/me.15.10.1768; SHIFRIN VI, 1993, J BIOL CHEM, V268, P25376; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; YouTen KE, 1997, J EXP MED, V186, P683, DOI 10.1084/jem.186.5.683; ZANDER NF, 1993, ONCOGENE, V8, P1175; Zhang ZY, 1997, CURR TOP CELL REGUL, V35, P21, DOI 10.1016/S0070-2137(97)80002-7	53	140	146	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19982	19990		10.1074/jbc.M200567200	http://dx.doi.org/10.1074/jbc.M200567200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11907034	hybrid			2022-12-25	WOS:000175894800098
J	Kim, MC; Lee, SH; Kim, JK; Chun, HJ; Choi, MS; Chung, WS; Moon, BC; Kang, CH; Park, CY; Yoo, JH; Kang, YH; Koo, SC; Koo, YD; Jung, JC; Kim, ST; Schulze-Lefert, P; Lee, SY; Cho, MJ				Kim, MC; Lee, SH; Kim, JK; Chun, HJ; Choi, MS; Chung, WS; Moon, BC; Kang, CH; Park, CY; Yoo, JH; Kang, YH; Koo, SC; Koo, YD; Jung, JC; Kim, ST; Schulze-Lefert, P; Lee, SY; Cho, MJ			Mlo, a modulator of plant defense and cell death, is a novel calmodulin-binding protein - Isolation and characterization of a rice Mlo homologue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERSENSITIVE DISEASE RESISTANCE; NITRIC-OXIDE SYNTHASE; LIGHT-CHAIN KINASE; OXIDATIVE BURST; FUNGAL ELICITOR; POWDERY MILDEW; GLUTAMATE-DECARBOXYLASE; CYTOSOLIC CALCIUM; PLASMA-MEMBRANE; PEPTIDE COMPLEX	Transient influx of Ca2+ constitutes an early event in the signaling cascades that trigger plant defense responses. However, the downstream components of defense-associated Ca2+ signaling are largely unknown. Because Ca2+ signals are mediated by Ca2+-binding proteins, including calmodulin (CaM), identification and characterization of CaM-binding proteins elicited by pathogens should provide insights into the mechanism by which Ca2+ regulates defense responses. In this study, we isolated a gene encoding rice Mlo (Oryza sativa Mlo; OsMlo) using a protein-protein interaction-based screening of a cDNA expression library constructed from pathogen-elicited rice suspension cells. OsMlo has a molecular mass of 62 kDa and shares 65% sequence identity and scaffold topology with barley Mlo, a heptahelical transmembrane protein known to function as a negative regulator of broad spectrum disease resistance and leaf cell death. By using gel overlay assays, we showed that OsMlo produced in Escherichia coli binds to soybean CaM isoform-1 (SCaM-1) in a Ca2+-dependent manner. We located a 20-amino acid CaM-binding domain (CaMBD) in the OsMlo C-terminal cytoplasmic tail that is necessary and sufficient for Ca2+-dependent CaM complex formation. Specific binding of the conserved CaMBD to CaM was corroborated by site-directed mutagenesis, a gel mobility shift assay, and a competition assay with a Ca2+/CaM-dependent enzyme. Expression of OsMlo was strongly induced by a fungal pathogen and by plant defense signaling molecules. We propose that binding of Ca2+-loaded CaM to the C-terminal tail may be a common feature of Mlo proteins.	Gyeongsang Natl Univ, Div Appl Life Sci, Program BK21, Plant Mol Biol & Biotechnol Res Ctr, Chinju 660701, South Korea; Max Planck Inst Zuchtungsforsch, D-50829 Cologne, Germany	Gyeongsang National University; Max Planck Society	Cho, MJ (corresponding author), Gyeongsang Natl Univ, Div Appl Life Sci, Program BK21, Plant Mol Biol & Biotechnol Res Ctr, Chinju 660701, South Korea.		Schulze-Lefert, Paul/B-6707-2011; Park, Chan Young/F-5696-2010; Schulze-Lefert, Paul/A-7746-2008; Cho, Moo Je/F-1649-2010	Park, Chan Young/0000-0002-5183-3665; Kim, Sun Tae/0000-0002-3853-1419; gim, seontae/0000-0001-9705-6868; Kang, Chang Ho/0000-0003-4342-5247				ARAZI T, 1995, PLANT PHYSIOL, V108, P551, DOI 10.1104/pp.108.2.551; BACH M, 1993, PLANT PHYSIOL, V103, P407, DOI 10.1104/pp.103.2.407; BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; Blume B, 2000, PLANT CELL, V12, P1425, DOI 10.1105/tpc.12.8.1425; Bofill-Cardona E, 2000, J BIOL CHEM, V275, P32672, DOI 10.1074/jbc.M002780200; BOLWELL GP, 1995, FREE RADICAL RES, V23, P517, DOI 10.3109/10715769509065273; Buschges R, 1997, CELL, V88, P695, DOI 10.1016/S0092-8674(00)81912-1; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; Cho MJ, 1998, BIOCHEMISTRY-US, V37, P15593, DOI 10.1021/bi981497g; Chung WS, 2000, PLANT CELL, V12, P1393, DOI 10.1105/tpc.12.8.1393; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Devoto A, 1999, J BIOL CHEM, V274, P34993, DOI 10.1074/jbc.274.49.34993; DeWitt ND, 1996, PLANT PHYSIOL, V112, P833, DOI 10.1104/pp.112.2.833; Diggle TA, 1999, FEBS LETT, V457, P189, DOI 10.1016/S0014-5793(99)01034-0; Ebel J, 1998, BIOESSAYS, V20, P569, DOI 10.1002/(SICI)1521-1878(199807)20:7&lt;569::AID-BIES8&gt;3.0.CO;2-F; Elshorst B, 1999, BIOCHEMISTRY-US, V38, P12320, DOI 10.1021/bi9908235; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FELIX G, 1994, P NATL ACAD SCI USA, V91, P952, DOI 10.1073/pnas.91.3.952; Freialdenhoven A, 1996, PLANT CELL, V8, P5, DOI 10.1105/tpc.8.1.5; GAWIENOWSKI MC, 1993, PLANT MOL BIOL, V22, P215, DOI 10.1007/BF00014930; Grant M, 2000, PLANT J, V23, P441, DOI 10.1046/j.1365-313x.2000.00804.x; Harmon AC, 2000, TRENDS PLANT SCI, V5, P154, DOI 10.1016/S1360-1385(00)01577-6; Heo WD, 1999, P NATL ACAD SCI USA, V96, P766, DOI 10.1073/pnas.96.2.766; HOFTE H, 1992, PLANT CELL, V4, P995, DOI 10.1105/tpc.4.8.995; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Jabs T, 1997, P NATL ACAD SCI USA, V94, P4800, DOI 10.1073/pnas.94.9.4800; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Kim CY, 2000, MOL PLANT MICROBE IN, V13, P470, DOI 10.1094/MPMI.2000.13.4.470; Kim CY, 1998, PLANT MOL BIOL, V37, P523, DOI 10.1023/A:1005960313459; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; Kondo R, 1999, J BIOL CHEM, V274, P36213, DOI 10.1074/jbc.274.51.36213; KUROSAKI F, 1987, PHYTOCHEMISTRY, V26, P1919, DOI 10.1016/S0031-9422(00)81729-X; Lee SH, 1997, J BIOL CHEM, V272, P9252, DOI 10.1074/jbc.272.14.9252; LEE SH, 1995, J BIOL CHEM, V270, P21806, DOI 10.1074/jbc.270.37.21806; Lee SH, 2000, BIOCHEM J, V350, P299, DOI 10.1042/0264-6021:3500299; Lee SH, 1999, BBA-PROTEIN STRUCT M, V1433, P56, DOI 10.1016/S0167-4838(99)00149-1; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Liu Z., 1991, ACTA BOT SIN, V35, P363; LU YT, 1994, PLANT PHYSIOL BIOCH, V32, P413; LU YT, 1995, PLANT PHYSIOL, V108, P1197, DOI 10.1104/pp.108.3.1197; MATSUSHIMA S, 1994, BIOCHEM BIOPH RES CO, V202, P1329, DOI 10.1006/bbrc.1994.2076; Matsushita M, 1998, J BIOL CHEM, V273, P21473, DOI 10.1074/jbc.273.34.21473; McAinsh MR, 1998, TRENDS PLANT SCI, V3, P32, DOI 10.1016/S1360-1385(97)01150-3; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Minakami R, 1997, J BIOL CHEM, V272, P20291, DOI 10.1074/jbc.272.32.20291; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; Nurnberger T, 2001, TRENDS PLANT SCI, V6, P372, DOI 10.1016/S1360-1385(01)02019-2; ODonnell PJ, 1996, SCIENCE, V274, P1914, DOI 10.1126/science.274.5294.1914; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; PRICE AH, 1994, PLANT CELL, V6, P1301, DOI 10.1105/tpc.6.9.1301; Reddy ASN, 1996, PLANT J, V10, P9, DOI 10.1046/j.1365-313X.1996.10010009.x; REDDY ASN, 1993, PLANT SCI, V94, P109, DOI 10.1016/0168-9452(93)90012-O; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; Sambrook J., 2002, MOL CLONING LAB MANU; Sanders D, 1999, PLANT CELL, V11, P691, DOI 10.1105/tpc.11.4.691; Snedden WA, 1998, TRENDS PLANT SCI, V3, P299, DOI 10.1016/S1360-1385(98)01284-9; STAB MR, 1987, ARCH BIOCHEM BIOPHYS, V257, P416, DOI 10.1016/0003-9861(87)90585-6; STEPONKUS PL, 1967, PLANT PHYSIOL, V42, P1423, DOI 10.1104/pp.42.10.1423; TAKEZAWA D, 1995, PLANT MOL BIOL, V27, P693, DOI 10.1007/BF00020223; TAVERNIER E, 1995, PLANT PHYSIOL, V109, P1025, DOI 10.1104/pp.109.3.1025; TENHAKEN R, 1995, P NATL ACAD SCI USA, V92, P4158, DOI 10.1073/pnas.92.10.4158; Trewavas AJ, 1998, CURR OPIN PLANT BIOL, V1, P428, DOI 10.1016/S1369-5266(98)80268-9; Wang DX, 1999, J BIOL CHEM, V274, P22081, DOI 10.1074/jbc.274.31.22081; Wang W, 1996, PLANT MOL BIOL, V31, P683, DOI 10.1007/BF00042240; Wasternack C, 1997, TRENDS PLANT SCI, V2, P302, DOI 10.1016/S1360-1385(97)89952-9; Wojtaszek P, 1997, BIOCHEM J, V322, P681, DOI 10.1042/bj3220681; WOLTER M, 1993, MOL GEN GENET, V239, P122, DOI 10.1007/BF00281610; Xu HX, 1998, PLANT CELL, V10, P585, DOI 10.1105/tpc.10.4.585; Yang TB, 1996, MOL GEN GENET, V252, P684, DOI 10.1007/BF02173974; Yuan T, 1998, J BIOL CHEM, V273, P30328, DOI 10.1074/jbc.273.46.30328; ZHANG ZG, 1995, PLANT J, V8, P139, DOI 10.1046/j.1365-313X.1995.08010139.x; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	75	106	136	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19304	19314		10.1074/jbc.M108478200	http://dx.doi.org/10.1074/jbc.M108478200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11904292	hybrid			2022-12-25	WOS:000175894800010
J	Rabilloud, T; Heller, M; Gasnier, F; Luche, S; Rey, C; Aebersold, R; Benahmed, M; Louisot, P; Lunardi, J				Rabilloud, T; Heller, M; Gasnier, F; Luche, S; Rey, C; Aebersold, R; Benahmed, M; Louisot, P; Lunardi, J			Proteomics analysis of cellular response to oxidative stress - Evidence for in vivo overoxidation of peroxiredoxins at their active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMOBILIZED PH GRADIENTS; CYSTEINE-SULFENIC ACID; NECROSIS-FACTOR-ALPHA; 2-DIMENSIONAL ELECTROPHORESIS; SACCHAROMYCES-CEREVISIAE; THIOREDOXIN PEROXIDASE; PROTEIN; CLONING; EXPRESSION; FAMILY	The proteomics analysis reported here shows that a major cellular response to oxidative stress is the modification of several peroxiredoxins. An acidic form of the peroxiredoxins appeared to be systematically increased under oxidative stress conditions. Peroxiredoxins are enzymes catalyzing the destruction of peroxides. In doing so, a reactive cysteine in the peroxiredoxin active site is weakly oxidized (disulfide or sulfenic acid) by the destroyed peroxides. Cellular thiols (e.g. thioredoxin) are used to regenerate the peroxiredoxins to their active state. Tandem mass spectrometry was carried out to characterize the modified form of the protein produced in vivo by oxidative stress. The cysteine present in the active site was shown to be oxidized into cysteic acid, leading to an inactivated form of peroxiredoxin. This strongly suggested that peroxiredoxins behave as a dam upon oxidative stress, being both important peroxide-destroying enzymes and peroxide targets. Results obtained in a primary culture of Leydig cells challenged with tumor necrosis factor a suggested that this oxidized/native balance of peroxiredoxin 2 may play an active role in resistance or susceptibility to tumor necrosis factor a-induced apoptosis.	CEA Grenoble, BECP, DRDC, Lab Bioenerget Cellulaire & Pathol,EA UJF 294, F-38054 Grenoble 9, France; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98115 USA; Fac Med Lyon Sud, Unite INSERM, U189, F-69921 Oullins, France; Fac Med Lyon Sud, Unite INSERM, U407, F-69921 Oullins, France	CEA; University of Washington; University of Washington Seattle; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Rabilloud, T (corresponding author), CEA Grenoble, BECP, DRDC, Lab Bioenerget Cellulaire & Pathol,EA UJF 294, 17 Rue Martyrs, F-38054 Grenoble 9, France.			Heller, Manfred/0000-0002-6364-7325				ADAMSON GM, 1992, ARCH BIOCHEM BIOPHYS, V294, P223, DOI 10.1016/0003-9861(92)90161-O; Araki M, 1999, J BIOL CHEM, V274, P2271, DOI 10.1074/jbc.274.4.2271; Baier M, 1997, PLANT J, V12, P179, DOI 10.1046/j.1365-313X.1997.12010179.x; BENAHMED M, 1987, MOL CELL ENDOCRINOL, V50, P69, DOI 10.1016/0303-7207(87)90078-5; Buck M, 1996, EMBO J, V15, P1753, DOI 10.1002/j.1460-2075.1996.tb00524.x; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; FRIDOVICH I, 1986, ANNU REV PHYSIOL, V48, P693; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; GORG A, 1987, ELECTROPHORESIS, V8, P122, DOI 10.1002/elps.1150080207; ISHII T, 1993, J BIOL CHEM, V268, P18633; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Knoops B, 1999, J BIOL CHEM, V274, P30451, DOI 10.1074/jbc.274.43.30451; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; LIM YS, 1994, BIOCHEM BIOPH RES CO, V199, P199, DOI 10.1006/bbrc.1994.1214; Matsumoto A, 1999, FEBS LETT, V443, P246, DOI 10.1016/S0014-5793(98)01736-0; Mitsumoto A, 2001, FREE RADICAL BIO MED, V30, P625, DOI 10.1016/S0891-5849(00)00503-7; Peshenko IV, 2001, FREE RADICAL BIO MED, V31, P292, DOI 10.1016/S0891-5849(01)00579-2; Phelan SA, 1998, GENOMICS, V54, P132, DOI 10.1006/geno.1998.5568; POOLE LB, 1989, J BIOL CHEM, V264, P12330; RABILLOUD T, 1994, ELECTROPHORESIS, V15, P1552, DOI 10.1002/elps.11501501223; Rabilloud T, 1995, BIOCHEM J, V312, P699, DOI 10.1042/bj3120699; Rabilloud T, 2001, PROTEOMICS, V1, P699, DOI 10.1002/1615-9861(200104)1:5<699::AID-PROT699>3.3.CO;2-3; Rabilloud T, 1997, ELECTROPHORESIS, V18, P307, DOI 10.1002/elps.1150180303; RABILLOUD T, 1999, PROTEOME RES 2 DIMEN, P107; Rey C, 2000, BIOCHEM PHARMACOL, V60, P1639, DOI 10.1016/S0006-2952(00)00500-1; SHULL S, 1991, J BIOL CHEM, V266, P24398; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; Sinha P, 2001, PROTEOMICS, V1, P835, DOI 10.1002/1615-9861(200107)1:7<835::AID-PROT835>3.3.CO;2-U; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Verdoucq L, 1999, J BIOL CHEM, V274, P19714, DOI 10.1074/jbc.274.28.19714; WATABE S, 1994, J BIOCHEM, V115, P648, DOI 10.1093/oxfordjournals.jbchem.a124390; Yates JR, 1996, J AM SOC MASS SPECTR, V7, P1089, DOI 10.1016/S1044-0305(96)00079-7; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	37	331	344	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19396	19401		10.1074/jbc.M106585200	http://dx.doi.org/10.1074/jbc.M106585200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11904290	hybrid			2022-12-25	WOS:000175894800022
J	Biesiadecki, BJ; Jin, JP				Biesiadecki, BJ; Jin, JP			Exon skipping in cardiac troponin T of turkeys with inherited dilated cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NH2-TERMINAL VARIABLE REGION; METAL-BINDING CLUSTER; ROUND HEART-DISEASE; SKELETAL-MUSCLE; ADULT ISOFORMS; TROPOMYOSIN ISOFORMS; ALPHA-TROPOMYOSIN; TERMINAL REGION; MOLECULAR-BASIS; EXPRESSION	Troponin T is a central component of the thin filament-associated troponin-tropomyosin system and plays an essential role in the Ca2+ regulation of striated muscle contraction. The importance of the structure and function of troponin T is evident in the regulated isoform expression during development and the point mutations resulting in familial hypertrophic and dilated cardiomyopathies. We report here that turkeys with inherited dilated cardiomyopathy and heart failure express an unusual low molecular weight cardiac troponin T missing 11 amino acids due to the splice out of the normally conserved exon 8-encoded segment. The deletion of a 9-bp segment from intron 7 of the turkey cardiac troponin T gene may be responsible for the weakened splicing of the downstream exon 8 during mRNA processing. The exclusion of the exon S-encoded segment results in conformational changes in cardiac troponin T, an altered binding affinity for troponin I and tropomyosin, and an increased calcium sensitivity of the actomyosin ATPase. Expression of the exon 8-deleted cardiac troponin T prior to the development of cardiomyopathy in turkeys indicates a novel RNA splicing disease and provides evidence for the role of troponin T structure-function variation in myocardial pathogenesis and heart failure.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University	Jin, JP (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.	jxj12@po.cwru.edu		Jin, JP/0000-0001-9932-1063	NHLBI NIH HHS [T32-HL07887] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007887] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKELLA AB, 1995, CIRC RES, V76, P600, DOI 10.1161/01.RES.76.4.600; ANDERSON PAW, 1995, CIRC RES, V76, P681, DOI 10.1161/01.RES.76.4.681; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BRIGGS MM, 1993, DEV BIOL, V158, P503, DOI 10.1006/dbio.1993.1208; Burhop J, 2001, J BIOL CHEM, V276, P20788, DOI 10.1074/jbc.M101110200; Chandra M, 1999, J MOL CELL CARDIOL, V31, P867, DOI 10.1006/jmcc.1999.0928; COOPER TA, 1985, J BIOL CHEM, V260, P1140; CZARNECKI CM, 1984, COMP BIOCHEM PHYS A, V77, P591, DOI 10.1016/0300-9629(84)90169-5; EINZIG S, 1972, AM J VET RES, V33, P557; Elrick LL, 1998, MOL CELL BIOL, V18, P343, DOI 10.1128/MCB.18.1.343; Genao A, 1996, LAB ANIM SCI, V46, P399; GREIG A, 1994, CIRC RES, V74, P41, DOI 10.1161/01.RES.74.1.41; HAJJAR RJ, 1993, CARDIOVASC RES, V27, P2212, DOI 10.1093/cvr/27.12.2212; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; Huang QQ, 1999, J PHYSIOL-LONDON, V520, P231, DOI 10.1111/j.1469-7793.1999.00231.x; Huang QQ, 1999, J MOL EVOL, V49, P780, DOI 10.1007/PL00006600; Huang QQ, 1999, BIOPHYS J, V76, pA281; HUNSAKER WG, 1971, POULTRY SCI, V50, P1720, DOI 10.3382/ps.0501720; JANKUS EF, 1973, RES ANIMALS MED, P53; Jin JP, 2000, BIOCHEMISTRY-US, V39, P11702, DOI 10.1021/bi9927437; JIN JP, 1988, J BIOL CHEM, V263, P7309; JIN JP, 1992, J MOL BIOL, V227, P1269, DOI 10.1016/0022-2836(92)90540-Z; JIN JP, 1989, J BIOL CHEM, V264, P14471; Jin JP, 2001, J MOL EVOL, V52, P103, DOI 10.1007/s002390010139; Jin JP, 2001, BIOCHEMISTRY-US, V40, P2623, DOI 10.1021/bi002423j; Jin JP, 1996, GENE, V168, P217, DOI 10.1016/0378-1119(95)00803-9; Jin JP, 1996, BIOCHEM BIOPH RES CO, V225, P883, DOI 10.1006/bbrc.1996.1267; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7035, DOI 10.1021/bi00396a027; LIN JJC, 1985, HYBRIDOMA, V4, P223, DOI 10.1089/hyb.1985.4.223; LIU SK, 1980, YALE J BIOL MED, V53, P191; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; MesnardRouiller L, 1997, J MOL CELL CARDIOL, V29, P3043, DOI 10.1006/jmcc.1997.0519; Ogut O, 1999, AM J PHYSIOL-CELL PH, V276, pC1162, DOI 10.1152/ajpcell.1999.276.5.C1162; Ogut O, 1996, BIOCHEMISTRY-US, V35, P16581, DOI 10.1021/bi961712y; Ogut O, 2000, J BIOL CHEM, V275, P26089, DOI 10.1074/jbc.M910360199; Ogut O, 1998, J BIOL CHEM, V273, P27858, DOI 10.1074/jbc.273.43.27858; PAN BS, 1991, J BIOL CHEM, V266, P12432; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Redwood CS, 1999, CARDIOVASC RES, V44, P20, DOI 10.1016/S0008-6363(99)00213-8; REISER PJ, 1992, J PHYSIOL-LONDON, V449, P573, DOI 10.1113/jphysiol.1992.sp019102; Seidman CE, 1998, BASIC RES CARDIOL, V93, P13; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; Stanley SE, 1999, MOL BIOL EVOL, V16, P1575, DOI 10.1093/oxfordjournals.molbev.a026070; Sweeney HL, 1998, P NATL ACAD SCI USA, V95, P14406, DOI 10.1073/pnas.95.24.14406; Tardiff JC, 1998, J CLIN INVEST, V101, P2800, DOI 10.1172/JCI2389; TOBACMAN LS, 1988, J BIOL CHEM, V263, P2668; Tobacman LS, 1999, J BIOL CHEM, V274, P28363, DOI 10.1074/jbc.274.40.28363; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TOWNSEND PJ, 1995, J MOL CELL CARDIOL, V27, P2223, DOI 10.1016/S0022-2828(95)91587-7; Wang J, 1998, BIOCHEMISTRY-US, V37, P14519, DOI 10.1021/bi9812322; Wang J, 1997, GENE, V193, P105, DOI 10.1016/S0378-1119(97)00100-5; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; [No title captured]	57	43	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18459	18468		10.1074/jbc.M200788200	http://dx.doi.org/10.1074/jbc.M200788200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886865	hybrid			2022-12-25	WOS:000175975800028
J	Kjeldsen, T; Ludvigsen, S; Diers, I; Balschmidt, P; Sorensen, AR; Kaarsholm, NC				Kjeldsen, T; Ludvigsen, S; Diers, I; Balschmidt, P; Sorensen, AR; Kaarsholm, NC			Engineering-enhanced protein secretory expression in yeast with application to insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; QUALITY-CONTROL; BINDING; STABILITY; PRECURSORS; EFFICIENCY; PEPTIDE; HEXAMER; MONOMER; LEADERS	Adaptation to efficient heterologous expression is a prerequisite for recombinant proteins to fulfill their clinical and biotechnological potential. We describe a rational strategy to optimize the secretion efficiency in yeast of an insulin precursor by structure-based engineering of the folding stability. The yield of a fast-acting insulin analogue (Asp(B28)) expressed in yeast was enhanced 5-fold by engineering a specific interaction between an aromatic amino acid in the connecting peptide and a phenol binding site in the hydrophobic core of the molecule. This insulin precursor is characterized by significantly enhanced folding stability. The improved folding properties enhanced the secretion efficiency of the insulin precursor from 10 to 50%. The precursor remains fully in vitro convertible to mature fast-acting insulin.	Novo Nordisk AS, Insulin Res, DK-2880 Bagsvaerd, Denmark	Novo Nordisk	Kjeldsen, T (corresponding author), Novo Nordisk AS, Insulin Res, Novo Alle, DK-2880 Bagsvaerd, Denmark.			Kjeldsen, Thomas/0000-0003-0094-9286; LUDVIGSEN, SVEND/0000-0002-5671-4542				BLOOM CR, 1995, J MOL BIOL, V245, P324, DOI 10.1006/jmbi.1994.0027; BLUNDELL TL, 1971, NATURE, V231, P506, DOI 10.1038/231506a0; BRANGE J, 1988, NATURE, V333, P679, DOI 10.1038/333679a0; DEREWENDA U, 1989, NATURE, V338, P594, DOI 10.1038/338594a0; DEREWENDA U, 1991, J MOL BIOL, V220, P425, DOI 10.1016/0022-2836(91)90022-X; Dodson G, 1998, CURR OPIN STRUC BIOL, V8, P189, DOI 10.1016/S0959-440X(98)80037-7; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; KAARSHOLM NC, 1993, BIOCHEMISTRY-US, V32, P10773, DOI 10.1021/bi00091a031; KAARSHOLM NC, 1989, BIOCHEMISTRY-US, V28, P4427, DOI 10.1021/bi00436a046; Kjeldsen T, 1999, J BIOTECHNOL, V75, P195, DOI 10.1016/S0168-1656(99)00159-5; Kjeldsen T, 1996, GENE, V170, P107, DOI 10.1016/0378-1119(95)00822-5; Kjeldsen T, 1997, PROTEIN EXPRES PURIF, V9, P331, DOI 10.1006/prep.1996.0695; Kjeldsen T, 2000, APPL MICROBIOL BIOT, V54, P277, DOI 10.1007/s002530000402; Kjeldsen T, 2001, Biotechnol Genet Eng Rev, V18, P89; Kowalski JM, 1998, BIOCHEMISTRY-US, V37, P1264, DOI 10.1021/bi9722397; Kowalski JM, 1998, J BIOL CHEM, V273, P19453, DOI 10.1074/jbc.273.31.19453; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurtzhals P, 2000, DIABETES, V49, P999, DOI 10.2337/diabetes.49.6.999; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LUDVIGSEN S, 1994, BIOCHEMISTRY-US, V33, P7998, DOI 10.1021/bi00192a003; Ludvigsen S, 2001, BIOCHEMISTRY-US, V40, P9082, DOI 10.1021/bi010433u; MARKUSSEN J, 1985, INT J PEPT PROT RES, V26, P70; MARKUSSEN J, 1987, PEPTIDES 1986, P189, DOI DOI 10.1002/BIT.260460206; NAKAGAWA SH, 1992, BIOCHEMISTRY-US, V31, P3204, DOI 10.1021/bi00127a023; SNEL L, 1988, HORM METAB RES, V20, P476, DOI 10.1055/s-2007-1010862; Whittingham JL, 1998, BIOCHEMISTRY-US, V37, P11516, DOI 10.1021/bi980807s; Zhang BY, 2001, J CELL BIOL, V153, P1187, DOI 10.1083/jcb.153.6.1187	27	52	62	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18245	18248		10.1074/jbc.C200137200	http://dx.doi.org/10.1074/jbc.C200137200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11923277	hybrid			2022-12-25	WOS:000175975800001
J	Kuma, A; Mizushima, N; Ishihara, N; Ohsumi, Y				Kuma, A; Mizushima, N; Ishihara, N; Ohsumi, Y			Formation of the similar to 350-kDa Apg12-Apg5 center dot Apg16 multimeric complex, mediated by Apg16 oligomerization, is essential for autophagy in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CONJUGATION SYSTEM; SACCHAROMYCES-CEREVISIAE; AMINOPEPTIDASE-I; VACUOLE; DEGRADATION; CYTOPLASM; PATHWAYS; MUTANTS; TOR; MACROAUTOPHAGY	Autophagy, responsible for the delivery of cytoplasmic components to the lysosome/vacuole for degradation, is the major degradative pathway in eukaryotic cells. This process requires a ubiquitin-like protein conjugation system, in which Apg12 is covalently bound to Apg5. In the yeast Saccharomyces cerevisiae, the Apg12-Apg5 conjugate further interacts with a small coiled-coil protein, Apg16. The Apg12-Apg5 and Apg16 are localized in the cytosol and pre-autophagosomal structures and play an essential role in autophagosome formation. Here we show that the Apg12-Apg5 conjugate and Apg16 form a similar to350-kDa complex in the cytosol. Because Apg16 was suggested to form a homo-oligomer, we generated an in vivo system that allowed us to control the oligomerization state of Apg16. With this system, we demonstrated that formation of the similar to350-kDa complex and autophagic activity depended on the oligomerization state of Apg16. These results suggest that the Apg12-Apg5 conjugate and Apg16 form a multimeric complex mediated by the Apg16 homo-oligomer, and formation of the similar to350-kDa complex is required for autophagy in yeast.	Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies, Sch Life Sci, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi 3320012, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan; Japan Science & Technology Agency (JST)	Ohsumi, Y (corresponding author), Natl Inst Basic Biol, Dept Cell Biol, 38 Nishigonaka, Okazaki, Aichi 4448585, Japan.		Mizushima, Noboru/C-3635-2009; Ohsumi, Yoshinori/C-6449-2009	Mizushima, Noboru/0000-0002-6258-6444; Ohsumi, Yoshinori/0000-0003-2384-2166; Ishihara, Naotada/0000-0002-6305-7149				Amara JF, 1997, P NATL ACAD SCI USA, V94, P10618, DOI 10.1073/pnas.94.20.10618; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Berggrun A, 2001, P NATL ACAD SCI USA, V98, P2301, DOI 10.1073/pnas.041612198; Cabezon E, 2000, J BIOL CHEM, V275, P25460, DOI 10.1074/jbc.M003859200; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; Cupers P, 1997, J BIOL CHEM, V272, P33430, DOI 10.1074/jbc.272.52.33430; DAWSON AL, 1975, HISTOCHEM J, V7, P77, DOI 10.1007/BF01004834; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; George MD, 2000, MOL BIOL CELL, V11, P969, DOI 10.1091/mbc.11.3.969; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353	30	326	345	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18619	18625		10.1074/jbc.M111889200	http://dx.doi.org/10.1074/jbc.M111889200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11897782	hybrid			2022-12-25	WOS:000175975800051
J	Ma, K; Vattem, KM; Wek, RC				Ma, K; Vattem, KM; Wek, RC			Dimerization and release of molecular chaperone inhibition facilitate activation of eukaryotic initiation factor-2 kinase in response to endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; UNFOLDED PROTEIN RESPONSE; FACTOR 2-ALPHA KINASE; TRANSLATIONAL REGULATION; TRANSMEMBRANE PROTEIN; MAMMALIAN HOMOLOG; GENE-EXPRESSION; ALPHA-SUBUNIT; IN-VITRO; PKR	Phosphorylation of eukaryotic initiation factor-2 (eIF2) by pancreatic eIF2 kinase (PEK), induces a program of translational expression in response to accumulation of malfolded protein in the endoplasmic reticulum (ER). This study addresses the mechanisms activating PEK, also designated PERK or EIEF2AK3. We describe the characterization of two regions in the ER luminal portion of the transmembrane PEK that carry out distinct functions in the regulation of this eIF2 kinase. The first region mediates oligomerization between PEK polypeptides, and deletion of this portion of PEK blocked induction of eIF2 kinase activity. The second characterized region of PEK facilitates interaction with ER chaperones. In the absence of stress, PEK associates with ER chaperones GRP78 (BiP) and GRP94, and this binding is released in response to ER stress. ER luminal sequences flanking the transmembrane domain are required for GRP78 interaction, and deletion of this portion of PEK led to its activation even in the absence of ER stress. These results suggest that this ER chaperone serves as a repressor of PEK activity, and release of ER chaperones from PEK when misfolded proteins accumulate in the ER induces gene expression required to enhance the protein folding capacity of the ER.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Wek, RC (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.	rwek@iupui.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049164] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM49164, R01GM643540] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Austin RC, 1998, J BIOL CHEM, V273, P30808, DOI 10.1074/jbc.273.46.30808; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Castelnau P, 2000, EUR J PEDIATR, V159, P631, DOI 10.1007/PL00008394; Chen JJ, 2000, COLD SPRING HARBOR M, V39, P529; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Delepine M, 2000, NAT GENET, V25, P406, DOI 10.1038/78085; Donze O, 2001, EMBO J, V20, P3771, DOI 10.1093/emboj/20.14.3771; Donze O, 1999, MOL CELL BIOL, V19, P8422, DOI 10.1128/mcb.19.12.8422; Han AP, 2001, EMBO J, V20, P6909, DOI 10.1093/emboj/20.23.6909; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; KRAMER MF, 1999, CURRENT PROTOCOLS MO, V3; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; Ma YL, 2001, RAPID COMMUN MASS SP, V15, P1693, DOI 10.1002/rcm.426; MORI K, 1993, CELL, V74, P743; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Nanduri S, 2000, EMBO J, V19, P5567, DOI 10.1093/emboj/19.20.5567; Okamura K, 2000, BIOCHEM BIOPH RES CO, V279, P445, DOI 10.1006/bbrc.2000.3987; Ortega LG, 1996, VIROLOGY, V215, P31, DOI 10.1006/viro.1996.0004; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Ron D, 2000, COLD SPRING HARBOR M, V39, P547; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; Sood R, 2000, GENETICS, V154, P787; Thornton CM, 1997, PEDIATR PATHOL LAB M, V17, P487, DOI 10.1080/107710497174778; Thulasiraman V, 1998, EUR J BIOCHEM, V255, P552, DOI 10.1046/j.1432-1327.1998.2550552.x; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Uma S, 1999, MOL CELL BIOL, V19, P5861; Uma S, 1997, J BIOL CHEM, V272, P11648; Vattem KM, 2001, EUR J BIOCHEM, V268, P3674, DOI 10.1046/j.1432-1327.2001.02273.x; Vattem KM, 2001, EUR J BIOCHEM, V268, P1143, DOI 10.1046/j.1432-1327.2001.01979.x; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Zhang C, 2001, J BIOL CHEM, V276, P35867, DOI 10.1074/jbc.M100747200; Zhang F, 2001, J BIOL CHEM, V276, P24946, DOI 10.1074/jbc.M102108200; Zhu SH, 1997, J BIOL CHEM, V272, P14434, DOI 10.1074/jbc.272.22.14434; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989	54	188	203	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18728	18735		10.1074/jbc.M200903200	http://dx.doi.org/10.1074/jbc.M200903200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11907036	hybrid			2022-12-25	WOS:000175975800065
J	Stapleton, MR; Norte, VA; Read, RC; Green, J				Stapleton, MR; Norte, VA; Read, RC; Green, J			Interaction of the Salmonella typhimurium transcription and virulence factor SlyA with target DNA and identification of members of the SlyA regulon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE-ANTIBIOTIC-RESISTANCE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; GENE; REGULATOR; SURVIVAL; EXPRESSION; HEMOLYSIN; MARR; PROTEIN	The SlyA protein from Salmonella typhimurium is a transcription factor that contributes to virulence. It is shown that a slyA mutant is attenuated in the presence of murine macrophages compared with the parent strain. Moreover, after growth in minimal medium, survival of the slyA mutant was reduced. Altered levels of flagellin (fliC), PagC, IroN, and outer membrane proteins suggest that the slyA mutation affects the surface properties of Salmonella. The isolated SlyA protein is a cofactor-free homodimer that recognizes five sites within the promoter region of the slyA gene. One of these sites contained a near perfect inverted repeat TTAGCAAGCTAA. The other four sites contained related sequences. Occupation of the SlyA sites in the slyA promoter prevented open-complex formation, consistent with the pattern of slyA::lacZ expression parental and slyA mutant strains. By combining the footprinting data with potential SlyA binding sites recovered from a pool of random DNA sequences, a consensus was defined and used to probe the NIH Salmonella unfinished genomes data base. These searches revealed the presence of consensus SlyA sites upstream of omp, ispA, xseB, slyA, and a gene encoding a protein with homology to a hemagglutinin. Accordingly, transcription of an omp::lacZ fusion was reduced in a slyA mutant. Given the difficulties in obtaining a comprehensive picture of intracellular gene expression, the definition of the DNA sequence recognized by a transcription factor (SlyA) that is essential for survival in the macrophage environment should allow a complete regulon of genes with altered expression upon exposure to macrophages to be determined once the S. typhimurium genome annotation is complete.	Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst Biomol Res, Sheffield S10 2TN, S Yorkshire, England; Univ Sheffield, Sch Med, Div Genom Med, Sheffield S10 2RX, S Yorkshire, England	University of Sheffield; University of Sheffield	Green, J (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst Biomol Res, Sheffield S10 2TN, S Yorkshire, England.	jeff.green@sheffield.ac.uk		Read, Robert/0000-0002-4297-6728				AIBA H, 1981, J BIOL CHEM, V256, P1905; Alekshun MN, 2001, NAT STRUCT BIOL, V8, P710, DOI 10.1038/90429; Alekshun MN, 2000, MOL MICROBIOL, V35, P1394, DOI 10.1046/j.1365-2958.2000.01802.x; BAUMLER AJ, 1994, INFECT IMMUN, V62, P1623; Buchmeier N, 1997, INFECT IMMUN, V65, P3725, DOI 10.1128/IAI.65.9.3725-3730.1997; Daigle F, 2001, MOL MICROBIOL, V41, P1211, DOI 10.1046/j.1365-2958.2001.02593.x; Daniels JJD, 1996, INFECT IMMUN, V64, P5075, DOI 10.1128/IAI.64.12.5075-5084.1996; delCastillo FJ, 1997, MOL MICROBIOL, V25, P107, DOI 10.1046/j.1365-2958.1997.4391813.x; GERISCHER U, 1992, J BACTERIOL, V174, P426, DOI 10.1128/jb.174.2.426-433.1992; Green J, 1997, MICROBIOL-SGM, V143, P3785, DOI 10.1099/00221287-143-12-3785; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Kawakami T, 1999, MICROBIOL IMMUNOL, V43, P351, DOI 10.1111/j.1348-0421.1999.tb02415.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LIBBY SJ, 1994, P NATL ACAD SCI USA, V91, P489, DOI 10.1073/pnas.91.2.489; LODGE J, 1990, FEMS MICROBIOL LETT, V67, P221, DOI 10.1016/0378-1097(90)90199-Z; Ludwig A, 1995, MOL GEN GENET, V249, P474, DOI 10.1007/BF00290573; Ludwig A, 1999, MOL MICROBIOL, V31, P557, DOI 10.1046/j.1365-2958.1999.01196.x; MARTIN RG, 1995, P NATL ACAD SCI USA, V92, P5456, DOI 10.1073/pnas.92.12.5456; Maxam A M, 1980, Methods Enzymol, V65, P499; Miller PF, 1996, MOL MICROBIOL, V21, P441, DOI 10.1111/j.1365-2958.1996.tb02553.x; Nagel G, 2001, MOL MICROBIOL, V41, P1249, DOI 10.1046/j.1365-2958.2001.02522.x; Negm RS, 1999, CAN J MICROBIOL, V45, P658, DOI 10.1139/cjm-45-8-658; Oscarsson J, 1996, MOL MICROBIOL, V20, P191, DOI 10.1111/j.1365-2958.1996.tb02500.x; Revell PA, 2000, MOL MICROBIOL, V35, P677, DOI 10.1046/j.1365-2958.2000.01740.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Silhavy T.J., 1984, EXPT GENE FUSIONS; Wallace AJ, 2000, CELL, V100, P265, DOI 10.1016/S0092-8674(00)81564-0; WING HJ, 1995, J BACTERIOL, V177, P6704, DOI 10.1128/jb.177.23.6704-6710.1995	28	80	83	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17630	17637		10.1074/jbc.M110178200	http://dx.doi.org/10.1074/jbc.M110178200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882648	hybrid			2022-12-25	WOS:000175685100032
J	Varaklioti, A; Vassilaki, N; Georgopoulou, U; Mavromara, P				Varaklioti, A; Vassilaki, N; Georgopoulou, U; Mavromara, P			Alternate translation occurs within the core coding region of the hepatitis C viral genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	7th International Meeting on Hepatitis C and Related Viruses	DEC 03-07, 2000	GOLD COAST, AUSTRALIA				RIBOSOME ENTRY SITES; VIRUS CORE; MOLECULAR VIROLOGY; GENE-PRODUCTS; FACTOR-ALPHA; PROTEIN; SUBSTITUTIONS; LOCALIZATION; APOPTOSIS; GROWTH	The majority of hepatitis C virus (HCV) isolates contain an open reading frame (ORF) overlapping with the core coding sequences in the +1 frame, which was assumed. to be untranslated. We present evidence supporting the expression of this ORF (designated core+1 ORF) via novel translation mechanisms. First, fusion of the luciferase gene with the HCV-1 core+1 ORF followed by in vitro translation resulted in the synthesis of a chimeric protein (core+1-luciferase) that exhibited similar to54% luciferase activity relative to the positive control (core-luciferase). Second, antisera raised against two different synthetic core+ 1 peptides recognized the previously identified p16 (but not p21) core protein band expressed from HCV-1, indicating the presence of epitopes from the core+1 ORF within the p16 protein. Third, HCV-positive sera specifically recognized lysates of Escherichia coli cells expressing recombinant core+ 1 protein, suggesting the presence of anti-core+1 antibodies in HCV-infected patients. Finally, luciferase tagging experiments designed to assess for -1 frameshifting combined with site-directed mutagenesis experiments supported the presence of +1/-1 ribosomal frameshift translation mechanisms within the core coding region. In conclusion, our data provide evidence for novel translation mechanisms within the core coding region and demonstrate the expression of the core+1 ORF, at least for some HCV isolates.	Hellenic Pasteur Inst, Mol Virol Lab, Athens 11521, Greece		Varaklioti, A (corresponding author), Hellenic Pasteur Inst, Mol Virol Lab, 127 Vassilisis Sofias Ave, Athens 11521, Greece.		Varaklioti, Agoritsa/AAP-7116-2020; Georgopoulou, Urania/AAQ-3831-2020	Varaklioti, Agoritsa/0000-0002-3897-819X				Atkins JF, 1999, NAT STRUCT BIOL, V6, P206, DOI 10.1038/6642; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; CHAMORRO M, 1992, P NATL ACAD SCI USA, V89, P713, DOI 10.1073/pnas.89.2.713; Chang J, 1998, J VIROL, V72, P3060, DOI 10.1128/JVI.72.4.3060-3065.1998; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Clarke B, 1997, J GEN VIROL, V78, P2397, DOI 10.1099/0022-1317-78-10-2397; Farabaugh PJ, 1996, MICROBIOL REV, V60, P103, DOI 10.1128/MMBR.60.1.103-134.1996; Hayashi J, 2000, HEPATOLOGY, V32, P958, DOI 10.1053/jhep.2000.19343; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; Hussy P, 1996, VIROLOGY, V224, P93, DOI 10.1006/viro.1996.0510; INA Y, 1994, J MOL EVOL, V38, P50; Kunkel M, 2001, J VIROL, V75, P2119, DOI 10.1128/JVI.75.5.2119-2129.2001; Large MK, 1999, J IMMUNOL, V162, P931; Le SY, 1996, VIRUS GENES, V12, P135, DOI 10.1007/BF00572952; Lemon SM, 1997, SEMIN VIROL, V8, P274, DOI 10.1006/smvy.1997.0129; LO SY, 1994, VIROLOGY, V199, P124, DOI 10.1006/viro.1994.1104; LO SY, 1995, VIROLOGY, V213, P455, DOI 10.1006/viro.1995.0018; Major ME, 1997, HEPATOLOGY, V25, P1527, DOI 10.1002/hep.510250637; Makarova KS, 2000, TRENDS BIOCHEM SCI, V25, P50, DOI 10.1016/S0968-0004(99)01530-3; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; MATSUURA Y, 1993, SEMIN VIROL, V4, P297, DOI 10.1006/smvy.1993.1026; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; Moradpour D, 1996, VIROLOGY, V222, P51, DOI 10.1006/viro.1996.0397; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Rumenapf T, 1998, J VIROL, V72, P2544; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Smith DB, 1997, J MOL EVOL, V45, P238, DOI 10.1007/PL00006226; Suzuki R, 2001, VIROLOGY, V280, P301, DOI 10.1006/viro.2000.0785; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; Walewski JL, 2001, RNA, V7, P710, DOI 10.1017/S1355838201010111; Xu ZM, 2001, EMBO J, V20, P3840, DOI 10.1093/emboj/20.14.3840; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; Yeh CT, 2000, J GASTROEN HEPATOL, V15, P182, DOI 10.1046/j.1440-1746.2000.02066.x; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	36	123	135	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17713	17721		10.1074/jbc.M201722200	http://dx.doi.org/10.1074/jbc.M201722200			9	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884417	hybrid			2022-12-25	WOS:000175685100042
J	Holland, MJ				Holland, MJ			Transcript abundance in yeast varies over six orders of magnitude	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; EXPRESSION; BINDING; STATES	In the current era of functional genomics, it is remarkable that the intracellular range of transcript abundance is largely unknown. For the yeast Saccharomyces cerevisiae, hybridization-based complexity analysis and SAGE analysis showed that the majority of yeast mRNAs are present at one or fewer copies per cell; however, neither method provides an accurate estimate of the full range of low abundance transcripts. Here we examine the range of intracellular transcript abundance in yeast using kinetically monitored, reverse transcriptase-initiated PCR (kRT-PCR). Steady-state transcript levels encoded by all 65 genes on the left arm of chromosome III and 185 transcription factor genes are quantitated. Abundant transcripts encoded by glycolytic genes, previously quantitated by kRT-PCR, are present at a few hundred copies per cell whereas genes encoding physiologically important transcription factors are expressed at levels as low as one-thousandth transcript per cell. Of the genes assessed, only the silent mating type loci, HML and HMR, are transcriptionally silent. The results show that transcript abundance in yeast varies over six orders of magnitude. Finally, kRT-PCR, cDNA microarray, and high density oligonucleotide array assays are compared for their ability to detect and quantitate the complete yeast transcriptome.	Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	University of California System; University of California Davis	Holland, MJ (corresponding author), Univ Calif Davis, Sch Med, Dept Biol Chem, 1 Shields Ave, Davis, CA 95616 USA.				NHGRI NIH HHS [R01-HG1736] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001736] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Cunningham TS, 2000, J BACTERIOL, V182, P6584, DOI 10.1128/JB.182.23.6584-6591.2000; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HEREFORD LM, 1977, CELL, V10, P453, DOI 10.1016/0092-8674(77)90032-0; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Kang J J, 2000, Nucleic Acids Res, V28, pe2, DOI 10.1093/nar/28.2.e2; Kang JJ, 1997, METHODS, V13, P437, DOI 10.1006/meth.1997.0549; KANG JJ, 1999, PCR APPL PROTOCOLS F, P429; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; McANulty MM, 1996, BIOCHEMISTRY-US, V35, P6089, DOI 10.1021/bi952877u; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0	17	130	133	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14363	14366		10.1074/jbc.C200101200	http://dx.doi.org/10.1074/jbc.C200101200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11882647	hybrid			2022-12-25	WOS:000175203000004
J	Ogawa, A; Takayama, Y; Sakai, H; Chong, KT; Takeuchi, S; Nakagawa, A; Nada, S; Okada, M; Tsukihara, T				Ogawa, A; Takayama, Y; Sakai, H; Chong, KT; Takeuchi, S; Nakagawa, A; Nada, S; Okada, M; Tsukihara, T			Structure of the carboxyl-terminal Src kinase, Csk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ACTIVATION; DOMAINS; SUPPRESSION; MECHANISM; COMPLEX; SITE; SH2; LCK	The carboxyl-terminal Src kinase (Csk) is an indispensable negative regulator for the Src family tyrosine kinases (SFKs) that play pivotal roles in various cell signalings. To understand the molecular basis of the Csk-mediated regulation of SFKs, we elucidated the crystal structure of full-length Csk. The Csk crystal consists of six molecules classified as active or inactive states according to the coordinations of catalytic residues. Csk assembles the SH2 and SH3 domains differently from inactive SFKs, and their binding pockets are oriented outward enabling the intermolecular interaction. In active molecules, the SH2-kinase and SH2-SH3 linkers are tightly stuck to the N-lobe of the kinase domain to stabilize the active conformation, and there is a direct linkage between the SH2 and the kinase domains. In inactive molecules, the SH2 domains are rotated destroying the linkage to the kinase domain. Cross-correlation matrices for the active molecules reveal that the SH2 domain and the N-lobe of the kinase domain move as a unit. These observations suggest that Csk can be regulated through coupling of the SH2 and kinase domains and that Csk provides a novel built-in activation mechanism for cytoplasmic tyrosine kinases.	Osaka Univ, Microbial Dis Res Inst, Osaka 5650871, Japan; Osaka Univ, Inst Prot Res, Osaka 5650871, Japan	Osaka University; Osaka University	Okada, M (corresponding author), Osaka Univ, Microbial Dis Res Inst, 3-1 Yamadaoka, Osaka 5650871, Japan.	atsushi@protein.osaka-u.ac.jp; okadam@biken.osaka-u.ac.jp	Takayama, Yoshiharu/E-3662-2010; Nakagawa, Atsushi/D-4329-2009; Takayama, Yoshiharu/M-8826-2019; Nakagawa, Atsushi/M-5731-2019	Takayama, Yoshiharu/0000-0003-4532-7114; Nakagawa, Atsushi/0000-0002-1700-7861; Takayama, Yoshiharu/0000-0003-4532-7114; Nakagawa, Atsushi/0000-0002-1700-7861				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BORCHERT TV, 1994, FEBS LETT, V341, P79, DOI 10.1016/0014-5793(94)80244-0; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CLOUTIER JF, 1995, MOL CELL BIOL, V15, P5937; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Gonfloni S, 2000, NAT STRUCT BIOL, V7, P281; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Lamers MBAC, 1999, J MOL BIOL, V285, P713, DOI 10.1006/jmbi.1998.2369; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Shekhtman A, 2001, J MOL BIOL, V314, P129, DOI 10.1006/jmbi.2001.5126; Sheldrick GM, 1997, METHOD ENZYMOL, V276, P628, DOI 10.1016/S0076-6879(97)76083-X; Sondhi D, 1999, BIOCHEMISTRY-US, V38, P11147, DOI 10.1021/bi990827+; Sun GQ, 1999, ARCH BIOCHEM BIOPHYS, V367, P167, DOI 10.1006/abbi.1999.1253; Sun GQ, 2002, ARCH BIOCHEM BIOPHYS, V397, P11, DOI 10.1006/abbi.2001.2627; Takeuchi S, 2000, J BIOL CHEM, V275, P29183, DOI 10.1074/jbc.C000326200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4; Zhu XT, 1999, STRUCTURE, V7, P651, DOI 10.1016/S0969-2126(99)80086-0	30	116	119	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14351	14354		10.1074/jbc.C200086200	http://dx.doi.org/10.1074/jbc.C200086200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11884384	hybrid, Green Published			2022-12-25	WOS:000175203000001
J	Teitz, T; Wei, T; Liu, D; Valentine, V; Valentine, M; Grenet, J; Lahti, JM; Kidd, VJ				Teitz, T; Wei, T; Liu, D; Valentine, V; Valentine, M; Grenet, J; Lahti, JM; Kidd, VJ			Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN	ONCOGENE			English	Article						tumor suppressors; apoptosis; caspases; neuroblastoma; MYCN; Apaf-1; cytochrome c	CYTOCHROME-C RELEASE; INDUCED APOPTOSIS; BCL-2 FAMILY; P53-DEPENDENT APOPTOSIS; MEDIATED APOPTOSIS; ANTICANCER AGENTS; ALLELIC LOSS; ACTIVATION; MITOCHONDRIA; NECROSIS	Important roles have been suggested for caspase-8, caspase-9 and Apaf-1 in controlling tumor development and their sensitivity to chemotherapeutic agents. Methylation and deletion of Apaf-1 and CASP8 results in the loss of their expression in melanoma and neuroblastoma, respectively, while CASP9 localization to 1p36.1 suggests it is a good candidate tumor suppressor. The status of CASP9 and Apaf-1 expression in numerous neuroblastoma cell lines with/without amplified MYCN and chromosome 1p36 loss-of-heterozygosity (LOH) was therefore examined to test the hypothesis that one or both of these genes are tumor suppressors in neuroblastoma. Although CASP9 is included in the region encompassing 1p36 LOH in all neuroblastoma cell lines examined, the remaining CASP9 allele(s) express a functional caspase-9 enzyme. Apaf-1 is also expressed in all neuroblastoma tumor cell lines examined. Thus, the CASP9 or Apaf-1 genes do not appear to function as tumor suppressors in MYCN amplified neuroblastomas. However, similar to20% of the neuroblastoma cell lines with methylated CASP8 alleles are also highly resistant to staurosporine (STS)- and radiation-induced cell death, presumably because cytochrome c is not released from mitochondria. This suggests that a second, smaller subgroup of MYCN amplified neuroblastoma tumors exists with defect(s) in apoptotic signaling components upstream of caspase-9 and Apaf-l. Since no consistent differences in Bcl-2, BCI-x(L) or Bax expression were seen in the STS- and radiation-resistant neuroblastomas, it suggests that a unique mitochondrial signaling factor(s) is responsible for the defect in cytochrome c release in this sub-group of tumors.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Kidd, VJ (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38105 USA.	vincent.kidd@stjude.org			NATIONAL CANCER INSTITUTE [R01CA067938, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [5 PO1 CA21765, 5 R01 CA67938] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asselin E, 2001, CANCER RES, V61, P1862; Bala S, 2000, GENE CHROMOSOME CANC, V28, P258, DOI 10.1002/1098-2264(200007)28:3<258::AID-GCC3>3.0.CO;2-R; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BRODEUR GM, 1992, CANCER-AM CANCER SOC, V70, P1685, DOI 10.1002/1097-0142(19920915)70:4+<1685::AID-CNCR2820701607>3.0.CO;2-H; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eggert A, 2001, CANCER RES, V61, P1314; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Ferreira CG, 2000, CANCER RES, V60, P7133; Gastman BR, 2000, CANCER RES, V60, P6811; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KNUDSON AG, 1980, NEW ENGL J MED, V302, P1254, DOI 10.1056/NEJM198005293022210; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LaBonne C, 1999, ANNU REV CELL DEV BI, V15, P81, DOI 10.1146/annurev.cellbio.15.1.81; Lacour S, 2001, CANCER RES, V61, P1645; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Stegh AH, 2000, MOL CELL BIOL, V20, P5665, DOI 10.1128/MCB.20.15.5665-5679.2000; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Takita J, 2001, ONCOGENE, V20, P4424, DOI 10.1038/sj.onc.1204521; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tweddle DA, 2001, CANCER RES, V61, P8; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	45	42	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1848	1858		10.1038/sj.onc.1205180	http://dx.doi.org/10.1038/sj.onc.1205180			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896617				2022-12-25	WOS:000174284500007
J	Chung, JY; Chavez, PRG; Russell, RM; Wang, XD				Chung, JY; Chavez, PRG; Russell, RM; Wang, XD			Retinoic acid inhibits hepatic Jun N-terminal kinase-dependent signaling pathway in ethanol-fed rats	ONCOGENE			English	Article						alcohol; hepatocyte proliferation and apoptosis; retinoids; mitogen-activated protein kinases	MITOGEN-ACTIVATED PROTEIN; C-JUN; CELL-PROLIFERATION; AP-1; PHOSPHORYLATION; METABOLISM; EXPRESSION; APOPTOSIS; GROWTH; TRANSDUCTION	Retinoic acid (RA) supplementation suppresses ethanol-enhanced hepatocyte hyperproliferation in rats; however, little is known about the mechanism(s). Here, we investigated whether RA affects the protein kinase signaling pathways in the liver tissues of rats fed with a high dose of ethanol for a prolonged period of time (6 months). Results show that there were greater levels of phosphorylated Jun N-terminal kinase (JNK) and phosphorylated c-Jun protein, but not total JNK protein, in livers of ethanol-fed rats vs those of controls. Moreover, ethanol feeding to rats increased the levels of phosphorylated mitogen-activated protein kinase kinase-4 (MKK-4) and decreased the levels of mitogen-activated kinase phosphatase-1 (MKP-1) in liver tissue. However, hepatic levels of phosphorylated-p38 protein and total-p38 protein were not altered by the ethanol treatment. In contrast, all-trans-RA supplementation at two doses in ethanol-fed rats greatly attenuated the ethanol-induced hepatic phosphorylation of MKK-4, phosphorylated-JNK and c-Jun proteins. The level of MKP-1 was increased in ethanol-fed rats supplemented with all-trans-RA. Further, ethanol-induced hepatocyte hyperproliferation, measured by immunostaining for proliferating cell nuclear antigen, were markedly decreased by all-trans-RA supplementation. Interestingly, hepatic apoptosis in the liver of ethanol-fed rats after 6 months of treatment decreased significantly. This decrease of hepatic apoptosis in ethanol-fed rats was prevented by all-trans-RA supplementation in a dose-dependent manner. The results from these studies indicate that restoration of RA homeostasis is critical for the regulation of JNK-dependent signaling pathway and apoptosis in the liver of ethanol-fed rats.	Tufts Univ, USDA, Jean Mayer Human Nutr Res Ctr, Gastrointestinal Nutr Lab,Mol Carcinogenesis Sect, Boston, MA 02111 USA	Tufts University; United States Department of Agriculture (USDA)	Wang, XD (corresponding author), Tufts Univ, USDA, Jean Mayer Human Nutr Res Ctr, Gastrointestinal Nutr Lab,Mol Carcinogenesis Sect, 711 Washington St, Boston, MA 02111 USA.	XWang@hnrc.tufts.edu			NCI NIH HHS [R01CA49195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BARONI GS, 1994, J HEPATOL, V20, P508, DOI 10.1016/S0168-8278(05)80498-2; Boylan JM, 1996, CELL GROWTH DIFFER, V7, P1261; CASINI A, 1991, HEPATOLOGY, V13, P758, DOI 10.1016/0270-9139(91)92576-T; CASINI A, 1994, ALCOHOL ALCOHOLISM, V29, P303; Cebers G, 1996, NEUROREPORT, V8, P217, DOI 10.1097/00001756-199612200-00044; Chen JP, 1998, BIOCHEM J, V334, P669, DOI 10.1042/bj3340669; CHEN N, 2001, CANCER RES, V15, P3908; Chung JG, 2001, CARCINOGENESIS, V22, P1213, DOI 10.1093/carcin/22.8.1213; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIEHL AM, 1988, HEPATOLOGY, V8, P237, DOI 10.1002/hep.1840080208; Ding WQ, 1996, NEUROREPORT, V7, P2191, DOI 10.1097/00001756-199609020-00027; Finch A, 2001, BIOCHEM J, V353, P275, DOI 10.1042/0264-6021:3530275; Fisher GJ, 1999, PHOTOCHEM PHOTOBIOL, V69, P154, DOI 10.1111/j.1751-1097.1999.tb03268.x; Fortunato F, 2000, PANCREAS, V21, P174, DOI 10.1097/00006676-200008000-00011; Fuchs SY, 1996, ONCOGENE, V13, P1531; Gouillon Z.-Q., 1999, Frontiers in Bioscience, V4, pa16, DOI 10.2741/gouillon; Halsted CH, 1996, HEPATOLOGY, V23, P497, DOI 10.1002/hep.510230314; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HOEK JB, 1992, FASEB J, V6, P2386, DOI 10.1096/fasebj.6.7.1563591; Jarvis WD, 1997, FEBS LETT, V412, P9, DOI 10.1016/S0014-5793(97)00705-9; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHARBANDA S, 1993, BIOCHEM PHARMACOL, V45, P675, DOI 10.1016/0006-2952(93)90142-J; Kurie Jonathan M., 1999, Current Opinion in Oncology, V11, P497, DOI 10.1097/00001622-199911000-00011; Lee HY, 1999, MOL CELL BIOL, V19, P1973; Lippman SC, 2000, J NUTR, V130, p479S, DOI 10.1093/jn/130.2.479S; Liu C, 2001, GASTROENTEROLOGY, V120, P179, DOI 10.1053/gast.2001.20877; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Pandey SC, 1996, ALCOHOL CLIN EXP RES, V20, pA67, DOI 10.1111/j.1530-0277.1996.tb01749.x; Pfahl M, 1996, ANNU REV NUTR, V16, P257, DOI 10.1146/annurev.nu.16.070196.001353; Radominska-Pandya A, 2000, J BIOL CHEM, V275, P22324, DOI 10.1074/jbc.M907722199; RESNICOFF M, 1993, J BIOL CHEM, V268, P21777; Seitz HK, 2001, ALCOHOL CLIN EXP RES, V25, p137S, DOI 10.1097/00000374-200105051-00024; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; TAKADA A, 1986, HEPATOLOGY, V6, P65, DOI 10.1002/hep.1840060113; THURSTON AW, 1992, BIOCHEM BIOPH RES CO, V185, P1062, DOI 10.1016/0006-291X(92)91734-8; Uto H, 2001, CANCER RES, V61, P4779; WANDS JR, 1979, GASTROENTEROLOGY, V77, P528; Wang XD, 1998, HEPATOLOGY, V28, P744, DOI 10.1002/hep.510280321; Wang XD, 2001, ALCOHOL IN HEALTH AND DISEASE, P427; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	46	48	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1539	1547		10.1038/sj.onc.1205023	http://dx.doi.org/10.1038/sj.onc.1205023			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896582				2022-12-25	WOS:000173956800009
J	Mancini, A; Koch, A; Wilms, R; Tamura, T				Mancini, A; Koch, A; Wilms, R; Tamura, T			The SH2-containing inositol 5-phosphatase (SHIP)-1 is implicated in the control of cell-cell junction and induces dissociation and dispersion of MDCK cells	ONCOGENE			English	Article						SHIP-1; cell-cell-junctions; cell dispersion; c-Met tyrosine kinase; actin rearrangement	HEPATOCYTE GROWTH-FACTOR; MULTIFUNCTIONAL DOCKING SITE; SCATTER FACTOR; FACTOR-RECEPTOR; C-MET; IDENTIFICATION; PHOSPHATASE; 3-KINASE; SHIP; INDUCTION	Hepatocyte growth factor (HGF) induces the breakdown of cell junction and the dispersion of colonies of epithelial cells, providing a model system for the investigation of the molecular mechanisms of one of the important aspects of tumorogenesis. We have previously reported that the SH2-domain-containing inositol 5' phosphatase (SHIP)-1 binds to c-Met, and potentiated HGF-mediated branching tubulogenesis. In this study, we describe the establishment of MDCK cell lines which express MycHis-tagged SHIP-1 at different levels. Expression of SHIP-1 in MDCK cells at a high level resulted in cell morphology characteristic of an epithelial-mesenchymal like transition; cells lost cortical actin, developed actin stress fibers and gained spontaneous motility without treatment of HGF. When the level of MycHis-tagged SHIP-expression was relatively low, transfectants partially lost cortical actin and phalloidin stained puncta appeared at cell-cell junctions even in the absence of HGF. The treatment of MAP kinase inhibitor, PD98059, did not influence SHIP-1 mediated alteration of adherens-junction of MDCK cells, while, phosphatidylinositol 3 (PI 3)-kinase inhibitor, LY294002, drastically reduced SHIP-1 mediated phenotype. Furthermore, expression of a mutant SHIP-l lacking catalytic activity in MDCK cells did not alter the cortical actin distribution and HGF-mediated MAP and Akt kinase-phosphorylation, but suppressed HGF induced cell dispersion, suggesting that phosphatase activity is important for cytoskeleton rearrangement and cell dispersion.	Med Hochschule Hannover, Inst Biochem, D-30623 Hannover, Germany	Hannover Medical School	Tamura, T (corresponding author), Med Hochschule Hannover, Inst Biochem, OE 4310,Carl Neuberg Str 1, D-30623 Hannover, Germany.	Tamura.Teruko@MH-Hannover.de						Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; Giuriato S, 1997, J BIOL CHEM, V272, P26857, DOI 10.1074/jbc.272.43.26857; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Khoury H, 2001, ONCOGENE, V20, P788, DOI 10.1038/sj.onc.1204166; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PELICCI G, 1995, ONCOGENE, V10, P1631; Phee H, 2000, J BIOL CHEM, V275, P19090, DOI 10.1074/jbc.M001093200; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Rohrschneider LR, 2000, GENE DEV, V14, P505; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stefan M, 2001, J BIOL CHEM, V276, P3017, DOI 10.1074/jbc.M009333200; STOKER M, 1985, J CELL SCI, V77, P209; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vollenweider P, 1999, MOL CELL BIOL, V19, P1081; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0	30	11	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1477	1484		10.1038/sj.onc.1205224	http://dx.doi.org/10.1038/sj.onc.1205224			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896575				2022-12-25	WOS:000173956800002
J	Kakimura, J; Kitamura, Y; Takata, K; Umeki, M; Suzuki, S; Shibagaki, K; Taniguchi, T; Nomura, Y; Gebicke-Haerter, PJ; Smith, MA; Perry, G; Shimohama, S				Kakimura, J; Kitamura, Y; Takata, K; Umeki, M; Suzuki, S; Shibagaki, K; Taniguchi, T; Nomura, Y; Gebicke-Haerter, PJ; Smith, MA; Perry, G; Shimohama, S			Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins	FASEB JOURNAL			English	Article						microglia; neuroprotection; cytokines; Toll-like receptor 4; Alzheimer's disease	CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; HEME OXYGENASE-1; SCAVENGER RECEPTOR; MESSENGER-RNA; CUTTING EDGE; GLIAL-CELLS; MOUSE MODEL; BCL-X	Alzheimer's disease (AD) is characterized by the accumulation of fibrillar amyloid-beta (Abeta) peptides to form amyloid plaques. Understanding the balance of production and clearance of Abeta peptides is the key to elucidating amyloid plaque homeostasis. Microglia in the brain, associated with senile plaques, are likely to play a major role in maintaining this balance. Here, we show that heat-shock proteins (HSPs), such as HSP90, HSP70, and HSP32, induce the production of interleukin 6 and tumor necrosis factor alpha and increase the phagocytosis and clearance of Abeta peptides. This suggests that microglial interaction with Abeta peptides is highly regulated by HSPs. The mechanism of microglial activation by exogenous HSPs involves the nuclear factor kappaB and p38 mitogen-activated protein kinase pathways mediated by Toll-like receptor 4 activation. In AD brains, levels of HSP90 were increased in both the cytosolic and membranous fractions, and HSP90 was colocalized with amyloid plaques. These observations suggest that HSP-induced microglial activation may serve a neuroprotective role by facilitating Abeta clearance and cytokine production.	Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Pharmaceut Univ, Dept Neurobiol, Kyoto 6078412, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sapporo, Hokkaido 0600812, Japan; Cent Inst Mental Hlth, Dept Psychopharmacol, D-68159 Mannheim, Germany; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Kyoto University; Kyoto Pharmaceutical University; Hokkaido University; Central Institute of Mental Health; Case Western Reserve University	Shimohama, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	i53367@sakura.kudpc.kyoto-u.ac	Smith, Mark A/A-9053-2009; Perry, George/A-8611-2009	Perry, George/0000-0002-6547-0172				Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Christie RH, 1996, AM J PATHOL, V148, P399; CRAS P, 1990, AM J PATHOL, V137, P241; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; DUFF GW, 1982, J IMMUNOL METHODS, V52, P333, DOI 10.1016/0022-1759(82)90005-9; ElKhoury J, 1996, NATURE, V382, P716; FILLIT H, 1991, NEUROSCI LETT, V129, P318, DOI 10.1016/0304-3940(91)90490-K; GEBICKEHAERTER PJ, 1989, J NEUROSCI, V9, P183; Hamazaki H, 1996, FEBS LETT, V396, P139, DOI 10.1016/0014-5793(96)01087-3; HAMOS JE, 1991, NEUROLOGY, V41, P345, DOI 10.1212/WNL.41.3.345; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hoshino K, 1999, J IMMUNOL, V162, P3749; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kaneko I, 1997, J NEUROCHEM, V68, P438; Kitamura Y, 1998, GLIA, V22, P138; Kitamura Y, 1999, JPN J PHARMACOL, V79, P1, DOI 10.1254/jjp.79.1; Kitamura Y, 2000, J NEUROIMMUNOL, V106, P95, DOI 10.1016/S0165-5728(00)00239-3; Kitamura Y, 1998, BRAIN RES, V780, P260, DOI 10.1016/S0006-8993(97)01202-X; Kol A, 1998, CIRCULATION, V98, P300, DOI 10.1161/01.CIR.98.4.300; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MINOTA S, 1988, J EXP MED, V168, P1475, DOI 10.1084/jem.168.4.1475; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Panahian N, 1999, J NEUROCHEM, V72, P1187; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; PEREZ N, 1991, MOL BRAIN RES, V11, P249, DOI 10.1016/0169-328X(91)90033-T; Plumier JCL, 1997, CELL STRESS CHAPERON, V2, P162, DOI 10.1379/1466-1268(1997)002<0162:TMETHI>2.3.CO;2; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PREMKUMAR DRD, 1995, J NEUROCHEM, V65, P1399; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; SAWADA M, 1995, INT J DEV NEUROSCI, V13, P253, DOI 10.1016/0736-5748(94)00076-F; Schermer CR, 1999, J GASTROINTEST SURG, V3, P173, DOI 10.1016/S1091-255X(99)80029-8; SCHIPPER HM, 1995, ANN NEUROL, V37, P758, DOI 10.1002/ana.410370609; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sharp FR, 1999, TRENDS NEUROSCI, V22, P97, DOI 10.1016/S0166-2236(98)01392-7; SHIBAHARA S, 1988, SEMIN HEMATOL, V25, P370; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; SMITH MA, 1995, TRENDS NEUROSCI, V18, P172, DOI 10.1016/0166-2236(95)93897-7; SMITH MA, 1994, AM J PATHOL, V145, P42; Stalder M, 1999, AM J PATHOL, V154, P1673, DOI 10.1016/S0002-9440(10)65423-5; STRAUSS S, 1992, LAB INVEST, V66, P223; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; WEGIEL J, 1990, ACTA NEUROPATHOL, V81, P116, DOI 10.1007/BF00334499; Weninger SC, 2001, NAT MED, V7, P527, DOI 10.1038/87839; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yenari MA, 1998, ANN NEUROL, V44, P584, DOI 10.1002/ana.410440403; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	64	250	275	0	26	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					601	+		10.1096/fj.01-0530fje	http://dx.doi.org/10.1096/fj.01-0530fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919167				2022-12-25	WOS:000174203700002
J	Boukhvalova, MS; Dahlquist, FW; Stewart, RC				Boukhvalova, MS; Dahlquist, FW; Stewart, RC			CheW binding interactions with CheA and Tar - Importance for chemotaxis signaling in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; BACTERIAL CHEMOTAXIS; CHEMORECEPTOR COMPLEX; TRANSDUCTION PATHWAY; KINASE ACTIVATION; RECEPTOR; PHOSPHORYLATION; METHYLESTERASE; SYSTEM; ADAPTATION	The initial signaling events underlying the chemotactic response of Escherichia coli to aspartic acid occur within a ternary complex that includes Tar (an aspartate receptor), CheA (a protein kinase), and CheW. Because CheW can bind to CheA and to Tar, it is thought to serve as an adapter protein in this complex. The functional importance of CheW binding interactions, however, has not been investigated. To better define the role of CheW and its binding interactions, we performed biochemical characterization of six mutant variants of CheW. We examined the ability of the purified mutant CheW proteins to bind to CheA and Tar, to promote formation of active ternary complexes, and to support chemotaxis in vivo. Our results indicate that mutations which eliminate CheW binding to Tar (V36M) or to CheA (G57D) result in a complete inability to form active ternary complexes in vitro and render the CheW protein incapable of mediating chemotaxis in vivo. The in vivo signaling pathway can, however, tolerate moderate changes in CheW-Tar and CheW-CheA affinities observed with several of the mutants (G133E, G41D, and 154ocr). One mutant (R62H) provided surprising results that may indicate a role for CheW in addition to binding CheA/receptors and promoting ternary complex formation.	Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA; Univ Oregon, Dept Chem, Eugene, OR 97403 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University System of Maryland; University of Maryland College Park; University of Oregon; University of Oregon	Stewart, RC (corresponding author), Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA.				NIGMS NIH HHS [GM59544, GM52853] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052853, R01GM059544, R56GM059544] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; AMES P, 1994, J BACTERIOL, V176, P6340, DOI 10.1128/jb.176.20.6340-6348.1994; ARMSTRONG JB, 1967, J BACTERIOL, V93, P390, DOI 10.1128/JB.93.1.390-398.1967; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; BERG HC, 1972, NATURE, V239, P500, DOI 10.1038/239500a0; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1993, J BACTERIOL, V175, P2097, DOI 10.1128/JB.175.7.2097-2101.1993; Bren A, 2000, J BACTERIOL, V182, P6865, DOI 10.1128/JB.182.24.6865-6873.2000; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P454; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Griswold IJ, 2002, NAT STRUCT BIOL, V9, P121, DOI 10.1038/nsb753; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; JARVIS TC, 1990, J BIOL CHEM, V265, P15160; Levit MN, 1998, MOL MICROBIOL, V30, P459, DOI 10.1046/j.1365-2958.1998.01066.x; Levit MN, 1999, BIOCHEMISTRY-US, V38, P6651, DOI 10.1021/bi982839l; Li GY, 2000, CELL, V100, P357, DOI 10.1016/S0092-8674(00)80671-6; LIU JD, 1991, J BACTERIOL, V173, P4941, DOI 10.1128/jb.173.16.4941-4951.1991; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; LUPAS A, 1989, J BIOL CHEM, V264, P17337; Lybarger SR, 1999, J BACTERIOL, V181, P5527, DOI 10.1128/JB.181.17.5527-5529.1999; MADDOCK JR, 1993, SCIENCE, V259, P1717; Manson MD, 1998, J BACTERIOL, V180, P1009, DOI 10.1128/JB.180.5.1009-1022.1998; MCNALLY DF, 1991, P NATL ACAD SCI USA, V88, P6269, DOI 10.1073/pnas.88.14.6269; MINTON AP, 1981, BIOPOLYMERS, V20, P2093, DOI 10.1002/bip.1981.360201006; MINTON AP, 1983, MOL CELL BIOCHEM, V55, P119, DOI 10.1007/BF00673707; MUTOH N, 1986, J BACTERIOL, V167, P992, DOI 10.1128/jb.167.3.992-998.1986; NINFA EG, 1991, J BIOL CHEM, V266, P9764; NORBY JG, 1988, METHOD ENZYMOL, V156, P116; Osborn M J, 1974, Methods Enzymol, V31, P642; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; RUSSELL CB, 1987, THESIS U OREGON EUGE; SANDERS DA, 1989, J BACTERIOL, V171, P6271, DOI 10.1128/jb.171.11.6271-6278.1989; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SMITH RA, 1980, P NATL ACAD SCI-BIOL, V77, P5370, DOI 10.1073/pnas.77.9.5370; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; Stewart RC, 1997, BIOCHEMISTRY-US, V36, P2030, DOI 10.1021/bi962261k; STEWART RC, 1990, J BACTERIOL, V172, P3388, DOI 10.1128/jb.172.6.3388-3399.1990; STOCK AM, 1988, COLD SPRING HARB SYM, V53, P49, DOI 10.1101/SQB.1988.053.01.009; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; WEBER G, 1953, ADV PROTEIN CHEM, V8, P415, DOI 10.1016/S0065-3233(08)60096-0; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; WOLFE AJ, 1993, P NATL ACAD SCI USA, V90, P1518, DOI 10.1073/pnas.90.4.1518; WOLFE AJ, 1989, P NATL ACAD SCI USA, V86, P6973, DOI 10.1073/pnas.86.18.6973; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6; Yi TM, 2000, P NATL ACAD SCI USA, V97, P4649, DOI 10.1073/pnas.97.9.4649	55	73	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22251	22259		10.1074/jbc.M110908200	http://dx.doi.org/10.1074/jbc.M110908200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11923283	hybrid			2022-12-25	WOS:000176313600020
J	Lee, S; Fan, CY; Younger, JM; Ren, HY; Cyr, DM				Lee, S; Fan, CY; Younger, JM; Ren, HY; Cyr, DM			Identification of essential residues in the Type II Hsp40 Sis1 that function in polypeptide binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNAJ MOLECULAR CHAPERONE; ESCHERICHIA-COLI DNAJ; FINGER-LIKE DOMAIN; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; SECONDARY STRUCTURE; ALPHA-LACTALBUMIN; ATP HYDROLYSIS; PROTEIN	Sis1 is an essential yeast Type II Hsp40 protein that assists cytosolic Hsp70 Ssa1 in the facilitation of processes that include translation initiation, the prevention of protein aggregation, and proteasomal protein degradation. An essential function of Sis1 and other Hsp40 proteins is the binding and delivery of non-native polypeptides to Hsp70. How Hsp40s function as molecular chaperones is unknown. The crystal structure of a Sis1 fragment that retains peptide-binding activity suggests that Type II Hsp40s utilize hydrophobic residues located in a solvent-exposed patch on carboxyl-terminal domain I to bind non-native polypeptides. To test this model, amino acid residues Val-184, Leu-186, Lys-199, Phe-201, Ile-203, and Phe-251, which form a depression in carboxyl-terminal domain 1, were mutated, and the ability of Sis1 mutants to support cell viability and function as molecular chaperones was examined. We report that Lys-199, Phe-201, and Phe-251 are essential for cell viability and required for Sis1 polypeptide binding activity. Sis1 I203T could support normal cell growth, but when purified it exhibited severe defects in chaperone function. These data identify essential residues in Sis1 that function in polypeptide binding and help define the nature of the polypeptide-binding site in Type II Hsp40 proteins.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Cyr, DM (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, Rm 524 Taylor Hall, Chapel Hill, NC 27599 USA.				NIDDK NIH HHS [R01 DK56203] Funding Source: Medline; NIGMS NIH HHS [R01GM56981] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056981] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Chen LL, 1999, CELL, V99, P757, DOI 10.1016/S0092-8674(00)81673-6; CREIGHTON TE, 1994, BIOCHEMISTRY-US, V33, P1534, DOI 10.1021/bi00172a033; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; CYR DM, 1997, GUIDEBOOK MOL CHAPER, P89; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3694, DOI 10.1021/bi00065a023; Gall WE, 2000, CURR BIOL, V10, P1349, DOI 10.1016/S0960-9822(00)00771-5; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; GEORGOPOULOS CP, 1980, MOL GEN GENET, V178, P583, DOI 10.1007/BF00337864; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HILL RB, 1995, BIOCHEMISTRY-US, V34, P5587, DOI 10.1021/bi00016a033; Horton LE, 2001, J BIOL CHEM, V276, P14426, DOI 10.1074/jbc.M100266200; Johnson JL, 2001, J CELL BIOL, V152, P851, DOI 10.1083/jcb.152.4.851; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Qian YQ, 1996, J MOL BIOL, V260, P224, DOI 10.1006/jmbi.1996.0394; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; Saibil H, 2000, CURR OPIN STRUC BIOL, V10, P251, DOI 10.1016/S0959-440X(00)00074-9; Sha BD, 2000, STRUCTURE, V8, P799, DOI 10.1016/S0969-2126(00)00170-2; Siegert R, 2000, CELL, V103, P621, DOI 10.1016/S0092-8674(00)00165-3; SIKORSKI RS, 1989, GENETICS, V122, P19; Sondheimer N, 2001, EMBO J, V20, P2435, DOI 10.1093/emboj/20.10.2435; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; Terada K, 1997, J CELL BIOL, V139, P1089, DOI 10.1083/jcb.139.5.1089; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; Yan W, 1999, MOL CELL BIOL, V19, P7751; Zhong T, 1996, J BIOL CHEM, V271, P1349, DOI 10.1074/jbc.271.3.1349; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	49	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21675	21682		10.1074/jbc.M111075200	http://dx.doi.org/10.1074/jbc.M111075200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11919183	hybrid, Green Published			2022-12-25	WOS:000176286000075
J	Niu, SL; Mitchell, DC; Litman, BJ				Niu, SL; Mitchell, DC; Litman, BJ			Manipulation of cholesterol levels in rod disk membranes by methyl-beta-cyclodextrin. Effects on receptor activation.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN PHOSPHATIDYLCHOLINE VESICLES; PROTEIN-COUPLED RECEPTOR; OUTER SEGMENT MEMBRANES; HIGHER-ORDER ANALYSIS; LIPID-COMPOSITION; METARHODOPSIN-II; ANISOTROPY DECAY; MOLECULAR ORDER; RHODOPSIN; EQUILIBRIUM	The effect of cholesterol on rod outer segment disk membrane structure and rhodopsin activation was investigated. Disk membranes with varying cholesterol concentrations were prepared using methyl-beta-cyclodextrin as a cholesterol donor or acceptor. Cholesterol exchange followed a simple equilibrium partitioning model with a partition coefficient of 5.2 +/- 0.8 in favor of the disk membrane. Reduced cholesterol in disk membranes resulted in a higher proportion of photolyzed rhodopsin being converted to the G protein-activating metarhodopsin II (MII) conformation, whereas enrichment of cholesterol reduced the extent of MII formation. Time-resolved fluorescence anisotropy measurements using 1,6-diphenyl-1,3,5-hexatriene showed that increasing cholesterol reduced membrane acyl chain packing free volume as characterized by the parameter f(v).. The level of MII formed showed a positive linear correlation with f(v) over the range of 4 to 38 mol % cholesterol. In addition, the thermal stability of rhodopsin increased with mol % of cholesterol in disk membranes. No evidence was observed for the direct interaction of cholesterol with rhodopsin in either its agonist- or antagonist-bound form. These results indicate that cholesterol mediates the function of the G protein-coupled receptor, rhodopsin, by influencing membrane lipid properties, i.e. reducing acyl chain packing free volume, rather than interacting specifically with rhodopsin.	NIAAA, Lab Membrane Biochem & Biophys, Sect Fluorescences Studies, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Litman, BJ (corresponding author), 12420 Parklawn Dr,Rm 158, Rockville, MD 20852 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000080, Z01AA000072, ZIAAA000080] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Albert AD, 1996, BBA-PROTEIN STRUCT M, V1297, P77, DOI 10.1016/0167-4838(96)00102-1; ALLAIN CC, 1974, CLIN CHEM, V20, P470; ATTWOOD PV, 1980, FEBS LETT, V119, P323, DOI 10.1016/0014-5793(80)80281-X; BARTLETT GR, 1959, J BIOL CHEM, V234, P587; Bastiaanse EML, 1997, CARDIOVASC RES, V33, P272, DOI 10.1016/S0008-6363(96)00193-9; BOESZEBATTAGLIA K, 1989, J BIOL CHEM, V264, P8151; BOESZEBATTAGLIA K, 1990, J BIOL CHEM, V265, P20727; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; Hargrave PA, 2001, INVEST OPHTH VIS SCI, V42, P3; JACKSON ML, 1985, BIOCHIM BIOPHYS ACTA, V812, P369, DOI 10.1016/0005-2736(85)90311-6; JOHNSON BL, 1992, J EXPO ANAL ENV EPID, V1, P1; LAMOLA AA, 1974, BIOCHEMISTRY-US, V13, P738, DOI 10.1021/bi00701a016; LEWIS JW, 1992, J BIOENERG BIOMEMBR, V24, P201, DOI 10.1007/BF00762678; LITMAN BJ, 1996, LIPIDS S, V31, P193; LITMAN BJ, 1996, BIOMEMBRANE, P1; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER JL, 1986, BIOCHEMISTRY-US, V25, P4983, DOI 10.1021/bi00366a002; Mitchell DC, 1998, BIOPHYS J, V74, P879, DOI 10.1016/S0006-3495(98)74011-1; Mitchell DC, 1998, BIOPHYS J, V75, P896, DOI 10.1016/S0006-3495(98)77578-2; MITCHELL DC, 1992, BIOCHEMISTRY-US, V31, P662, DOI 10.1021/bi00118a005; MITCHELL DC, 1990, BIOCHEMISTRY-US, V29, P9143, DOI 10.1021/bi00491a007; Mitchell DC, 2001, J BIOL CHEM, V276, P42801, DOI 10.1074/jbc.M105772200; Niu SL, 2001, J BIOL CHEM, V276, P42807, DOI 10.1074/jbc.M105778200; NUNEZ MT, 1982, BIOCHEMISTRY-US, V21, P4139, DOI 10.1021/bi00260a034; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PANT L, 1999, BIOCHEMISTRY-US, V38, P12003; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Polozova A, 2000, BIOPHYS J, V79, P2632, DOI 10.1016/S0006-3495(00)76502-7; Seno K, 2001, J BIOL CHEM, V276, P20813, DOI 10.1074/jbc.C100032200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMITH HG, 1982, METHOD ENZYMOL, V81, P57; Sooksawate T, 2001, NEUROPHARMACOLOGY, V40, P178, DOI 10.1016/S0028-3908(00)00159-3; STINSON AM, 1991, EXP EYE RES, V52, P213, DOI 10.1016/0014-4835(91)90261-C; STRAUME M, 1987, BIOCHEMISTRY-US, V26, P5121, DOI 10.1021/bi00390a034; STRAUME M, 1990, BIOCHEMISTRY-US, V29, P9135, DOI 10.1021/bi00491a006; STRAUME M, 1987, BIOCHEMISTRY-US, V26, P5113, DOI 10.1021/bi00390a033; YOSHIZAWA T, 1984, VISION RES, V24, P1455, DOI 10.1016/0042-6989(84)90306-7; Yuan C, 1998, COMP BIOCHEM PHYS B, V120, P785, DOI 10.1016/S0305-0491(98)10079-2	39	115	118	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20139	20145		10.1074/jbc.M200594200	http://dx.doi.org/10.1074/jbc.M200594200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11889130	Green Submitted, hybrid			2022-12-25	WOS:000176204500008
J	Ahrens, T; Pertz, O; Haussinger, D; Fauser, C; Schulthess, T; Engel, J				Ahrens, T; Pertz, O; Haussinger, D; Fauser, C; Schulthess, T; Engel, J			Analysis of heterophilic and homophilic interactions of cadherins using the c-jun/c-fos dimerization domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; CRYSTAL-STRUCTURE; CLASSIC CADHERINS; CALCIUM-BINDING; LEUCINE ZIPPERS; STREP-TAG; PROTEINS; PURIFICATION; ULTRASTRUCTURE; SPECIFICITIES	Cadherin-mediated cell-cell adhesion is initiated by cis dimerization of cadherin ectodomains at the cell surface followed by an antiparallel trans interaction of dimers on opposing cells. To resolve open questions concerning the molecular details and specificity of cis and trans interactions, ectodomains of E- and P-cadherin were analyzed by chemical cross-linking and by electron microscopy. At the high intrinsic concentration created by artificial oligomerization the N-terminal cadherin (CAD)-domain of P-cadherin are forming ring-like cis dimers. At 2 mm Ca2+-associated rings involving two cis dimers indicate trans contacts in electron micrographs. cis and trans interactions were further analyzed by heterodimerization of the ectodomains of E-cadherin (ECAD) and P-cadherin (PCAD) through the leucine zipper domains of c-Jun and c-Fos. ECADJun/ECADFos dimers predominantly form ring-like cis dimers at 1 mm Ca2+ and double-ringed trans contacts above 2 mm Ca2+. The Ca2+-dependent tetrameric trans contacts of ECADJun/ECADFos dimers are also detectable after chemical cross-linking. Only cis contacts but no trans interactions are observed for heterodimers of ECADFos and the Trp-2 to Ala mutant ECADW2AJun arguing for a decisive role of Trp-2 in trans but not cis interaction. Neither cis nor trans interaction was found for heterodimers of ECADJun and PCADFos suggesting that specificity for homophilic interactions already exists at the level of cis dimerization.	Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland; Univ Basel, Biozentrum, Dept Biol Struct, CH-4056 Basel, Switzerland; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of Basel; University of Basel; Scripps Research Institute	Engel, J (corresponding author), Univ Basel, Biozentrum, Dept Biophys Chem, Klingelbergstr 70, CH-4056 Basel, Switzerland.		Häussinger, Daniel/C-6617-2016	Häussinger, Daniel/0000-0002-4798-0072; pertz, olivier/0000-0001-8579-4919				Angst BD, 2001, J CELL SCI, V114, P629; Baumgartner W, 2000, P NATL ACAD SCI USA, V97, P4005, DOI 10.1073/pnas.070052697; BECKER JW, 1989, P NATL ACAD SCI USA, V86, P1088, DOI 10.1073/pnas.86.3.1088; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; Chappuis-Flament S, 2001, J CELL BIOL, V154, P231, DOI 10.1083/jcb.200103143; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; ENGEL J, 1994, METHOD ENZYMOL, V245, P469; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; INUZUKA H, 1991, NEURON, V7, P69, DOI 10.1016/0896-6273(91)90075-B; Jun CD, 2001, J BIOL CHEM, V276, P29019, DOI 10.1074/jbc.M103394200; Kalandadze A, 1996, J BIOL CHEM, V271, P20156, DOI 10.1074/jbc.271.33.20156; Klingelhofer J, 2000, J CELL SCI, V113, P2829; Koch AW, 1999, CURR OPIN STRUC BIOL, V9, P275, DOI 10.1016/S0959-440X(99)80038-4; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; KOSTELNY SA, 1992, J IMMUNOL, V148, P1547; Leckband D, 2000, CURR OPIN CELL BIOL, V12, P587, DOI 10.1016/S0955-0674(00)00136-8; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; Miyaguchi K, 2000, J STRUCT BIOL, V132, P169, DOI 10.1006/jsbi.2000.4244; MURPHYERDOSH C, 1995, J CELL BIOL, V129, P1379, DOI 10.1083/jcb.129.5.1379; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; NOSE A, 1987, EMBO J, V6, P3655, DOI 10.1002/j.1460-2075.1987.tb02698.x; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; SCHMIDT TGM, 1994, J CHROMATOGR A, V676, P337, DOI 10.1016/0021-9673(94)80434-6; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schurmann G, 2001, MOL BIOL CELL, V12, P1765, DOI 10.1091/mbc.12.6.1765; Shan WS, 2000, J CELL BIOL, V148, P579, DOI 10.1083/jcb.148.3.579; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Shapiro L, 1998, CURR OPIN NEUROBIOL, V8, P593, DOI 10.1016/S0959-4388(98)80086-X; Sivasankar S, 1999, P NATL ACAD SCI USA, V96, P11820, DOI 10.1073/pnas.96.21.11820; Skerra A, 2000, METHOD ENZYMOL, V326, P271; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VOLK T, 1987, CELL, V50, P987, DOI 10.1016/0092-8674(87)90525-3	44	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19455	19460		10.1074/jbc.M200606200	http://dx.doi.org/10.1074/jbc.M200606200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11909859	hybrid			2022-12-25	WOS:000175894800030
J	Chen, H; Gu, DN; Burton-Wurster, N; MacLeod, JN				Chen, H; Gu, DN; Burton-Wurster, N; MacLeod, JN			Absence of the I-10 protein segment mediates restricted dimerization of the cartilage-specific fibronectin isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; PANCREATIC TRYPSIN-INHIBITOR; EXTRACELLULAR-MATRIX; PLASMA FIBRONECTIN; ARTICULAR-CARTILAGE; OVERLAP EXTENSION; BINDING DOMAIN; CELL-SURFACE; I MODULES; ISOMERASE	The cartilage-specific (V + C)(-) fibronectin isoform does not efficiently heterodimerize with other V-region splice variants of fibronectin. To understand better the structural elements that determine this restricted dimerization profile, a series of truncated fibronectin expression constructs with various internal deletions in the V, III-15, or I-10 segments were constructed and co-transfected into COS-7 cells with either the V+C+ or the (V + C)(-) isoform. SDS-PAGE and immunoblot analyses of the resulting conditioned media suggest that the I-10 segment must either be present in both monomeric subunits of fibronectin or absent from both subunits for efficient dimerization to occur. Further studies suggest that the I-10 segment specifically, not simply a balanced number of type I repeats at the carboxyl terminus of each monomeric subunit, plays an important role in determining different fibronectin dimerization patterns. Neither I-11 nor I-12 could be substituted for segment I-10 without significantly reducing the formation of heterodimers. Therefore, absence of segment I-10 explains why (V + C)- fibronectin is not found in heterodimeric configurations with other native V-region splice variants in cartilage. The unique dimerization pattern of (V + C)(-) fibronectin does not prevent matrix formation yet is consistent with this isoform having specialized properties in situ that are important for either the structural organization and biomechanical properties of cartilage or the regulation of a chondrocytic phenotype.	Cornell Univ, Coll Vet Med, James A Baker Inst Anim Hlth, Dept Biomed Sci, Ithaca, NY 14853 USA; Cornell Univ, Coll Vet Med, James A Baker Inst Anim Hlth, Dept Microbiol & Immunol, Ithaca, NY 14853 USA	Cornell University; Cornell University	MacLeod, JN (corresponding author), Cornell Univ, Coll Vet Med, James A Baker Inst Anim Hlth, Dept Biomed Sci, Ithaca, NY 14853 USA.				NIAMS NIH HHS [AR44340] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044340] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALEXANDER SS, 1979, J BIOL CHEM, V254, P1501; AN SSA, 1992, BIOCHEMISTRY-US, V31, P9927, DOI 10.1021/bi00156a010; Bultmann H, 1998, J BIOL CHEM, V273, P2601, DOI 10.1074/jbc.273.5.2601; Burton-Wurster N, 1999, BIOCHEM J, V341, P555, DOI 10.1042/0264-6021:3410555; BUSHUEV VN, 1985, FEBS LETT, V189, P276, DOI 10.1016/0014-5793(85)81039-5; CASTLE AM, 1995, J CELL SCI, V108, P3827; CHOI MG, 1979, J BIOL CHEM, V254, P2050; CREIGHTON TE, 1995, TRENDS BIOTECHNOL, V13, P18, DOI 10.1016/S0167-7799(00)88896-4; CREIGHTON TE, 1993, J MOL BIOL, V232, P1176, DOI 10.1006/jmbi.1993.1470; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; DARBY NJ, 1994, BIOCHEMISTRY-US, V33, P7937, DOI 10.1021/bi00191a022; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P3576, DOI 10.1021/bi00011a012; ENGAVALL E, 1977, INT J CANCER, V20, P1; ERICKSON HP, 1983, J BIOL CHEM, V258, P4539; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GENDELMAN R, 2001, P 47 ANN M SAN FRANC, V26, P385; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUAN JL, 1990, J CELL BIOL, V110, P833, DOI 10.1083/jcb.110.3.833; HALLIDAY NL, 1995, EXP CELL RES, V217, P109, DOI 10.1006/excr.1995.1069; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOMANDBERG GA, 1987, BIOPOLYMERS, V26, P2087, DOI 10.1002/bip.360261208; HOMANDBERG GA, 1986, BIOCHEMISTRY-US, V25, P6917, DOI 10.1021/bi00370a027; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hynes RO, 1999, P NATL ACAD SCI USA, V96, P2588, DOI 10.1073/pnas.96.6.2588; HYNES RO, 1990, FIBRONECTINS, P200; ICHIHARATANAKA K, 1995, J CELL SCI, V108, P907; KAR L, 1993, J BIOL CHEM, V268, P8580; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langenbach KJ, 1999, J BIOL CHEM, V274, P7032, DOI 10.1074/jbc.274.11.7032; MacLeod JN, 1996, J BIOL CHEM, V271, P18954, DOI 10.1074/jbc.271.31.18954; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCKEOWNLONGO PJ, 1989, FIBRONECTIN, P163; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; O'Reilly D., 1994, BACULOVIRUS EXPRESSI, P124; Poulouin L, 1999, PROTEIN EXPRES PURIF, V17, P146, DOI 10.1006/prep.1999.1103; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; ROCCO M, 1987, EMBO J, V6, P2343, DOI 10.1002/j.1460-2075.1987.tb02510.x; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; SCHWARZBAUER JE, 1991, BIOESSAYS, V13, P527, DOI 10.1002/bies.950131006; SCHWARZBAUER JE, 1989, J CELL BIOL, V109, P3445, DOI 10.1083/jcb.109.6.3445; SCHWARZBAUER JE, 1987, P NATL ACAD SCI USA, V84, P754, DOI 10.1073/pnas.84.3.754; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sechler JL, 1998, ANN NY ACAD SCI, V857, P143, DOI 10.1111/j.1749-6632.1998.tb10114.x; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; SOTTILE J, 1993, BIOCHEMISTRY-US, V32, P1641, DOI 10.1021/bi00057a031; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UGAROVA TP, 1995, BIOCHEMISTRY-US, V34, P4457, DOI 10.1021/bi00013a039; WILLIAMS MJ, 1994, J MOL BIOL, V235, P1302, DOI 10.1006/jmbi.1994.1083; WOODS A, 1988, EXP CELL RES, V177, P272, DOI 10.1016/0014-4827(88)90461-2; WU CY, 1993, J BIOL CHEM, V268, P21883; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; WURSTER NB, 1982, BIOCHEM BIOPH RES CO, V109, P1094, DOI 10.1016/0006-291X(82)91889-7; YAMADA KM, 1977, BIOCHEMISTRY-US, V16, P5552, DOI 10.1021/bi00644a025; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; Zheng MZ, 2000, ARCH BIOCHEM BIOPHYS, V374, P93, DOI 10.1006/abbi.1999.1613; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	61	5	5	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					20095	20103		10.1074/jbc.M201238200	http://dx.doi.org/10.1074/jbc.M201238200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11914376	hybrid			2022-12-25	WOS:000175894800111
J	Hang, J; Dasso, M				Hang, J; Dasso, M			Association of the human SUMO-1 protease SENP2 with the nuclear pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; AXIN-BINDING PROTEIN; NUCLEOPORIN NUP153; COMPLEX PROTEIN; UBIQUITIN; IMPORT; RANGAP1; EXPORT; YEAST; LOCALIZATION	SUMO-1 is a small ubiquitin-like protein that can be covalently conjugated to other proteins. A family of proteases catalyzes deconjugation of SUMO-1-containing species. Members of this family also process newly synthesized SUMO-1 into its conjugatable form. To understand these enzymes better, we have examined the localization and behavior of the human SUMO-1 protease SENP2. Here we have shown that SENP2 associates with the nuclear face of nuclear pores and that this association requires protein sequences near the N terminus of SENP2. We have also shown that SENP2 binds to Nup153, a nucleoporin that is localized to the nucleoplasmic face of the pore. Nup153 binding requires the same domain of SENP2 that mediates its targeting in vivo. Removal of the Nup153-interacting region of SENP2 results in a significant change in the spectrum of SUMO-1 conjugates within the cell. Our results suggest that association with the pore plays an important negative role in the regulation of SENP2, perhaps by restricting its activity to a subset of the conjugated proteins within the nucleus.	NICHHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dasso, M (corresponding author), NICHHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA.			Dasso, Mary/0000-0002-5410-1371	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001902] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001902] Funding Source: NIH RePORTER; NICHD NIH HHS [Z01 HD 01902-05] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Azuma Y, 2001, FASEB J, V15, P1825, DOI 10.1096/fj.00-0818fje; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Kadoya T, 2000, J BIOL CHEM, V275, P37030, DOI 10.1074/jbc.M005984200; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Love DC, 1998, P NATL ACAD SCI USA, V95, P10608, DOI 10.1073/pnas.95.18.10608; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; MEIER E, 1995, J CELL BIOL, V129, P1459, DOI 10.1083/jcb.129.6.1459; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Nishida T, 2001, J BIOL CHEM, V276, P39060, DOI 10.1074/jbc.M103955200; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Strunnikov AV, 2001, GENETICS, V158, P95; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; Takahashi Y, 2000, J BIOCHEM-TOKYO, V128, P723, DOI 10.1093/oxfordjournals.jbchem.a022807; Ullman KS, 1999, MOL BIOL CELL, V10, P649, DOI 10.1091/mbc.10.3.649; Vasu SK, 2001, CURR OPIN CELL BIOL, V13, P363, DOI 10.1016/S0955-0674(00)00221-0; Walther TC, 2001, EMBO J, V20, P5703, DOI 10.1093/emboj/20.20.5703; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	28	189	200	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19961	19966		10.1074/jbc.M201799200	http://dx.doi.org/10.1074/jbc.M201799200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11896061	hybrid			2022-12-25	WOS:000175894800095
J	Loeb, DM; Korz, D; Katsnelson, M; Burwell, EA; Friedman, AD; Sukumar, S				Loeb, DM; Korz, D; Katsnelson, M; Burwell, EA; Friedman, AD; Sukumar, S			Cyclin E is a target of WT1 transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSOR GENE; DNA-BINDING SPECIFICITY; WILMS; LEUKEMIA; DIFFERENTIATION; EXPRESSION; ACTIVATION; PROTEINS; CELLS; P21	WT1 was originally identified as a Wilms' tumor suppressor gene, but it may have oncogenic potential in leukemia and in some solid tumors. WT1 is a transcription factor that has been implicated in the regulation of target genes related to apoptosis, genitourinary differentiation, and cell cycle progression. Because induction of WT1 leads indirectly to increased p21 expression in osteosarcoma cells, we investigated the possibility that other genes involved in the G(1)/S phase transition might also be WT1 targets. Cyclin E plays a crucial role in the cell cycle by activating cyclin-dependent kinase 2, which phosphorylates Rb, leading to progression from G(1) into S phase. We identified several WT1 binding sites in the cyclin E promoter. We demonstrate that WT1 binds to these sites and that in transient transfection assays WT1 represses the cyclin E promoter. This activity is dependent on the presence of a binding site located downstream of the transcription start site. In intact cells, induction of WT1 expression down-regulates cyclin E protein levels. These results provide the first demonstration that WT1 can directly modulate the expression of a gene involved in cell cycle progression.	Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Loeb, DM (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.				NATIONAL CANCER INSTITUTE [R01CA048943] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA48943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ball K L, 1997, Prog Cell Cycle Res, V3, P125; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Englert C, 1997, CANCER RES, V57, P1429; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Hossain A, 2001, J BIOL CHEM, V276, P16817, DOI 10.1074/jbc.M009056200; Iida H, 1997, BLOOD, V90, P3707, DOI 10.1182/blood.V90.9.3707; Inoue K, 1998, BLOOD, V91, P2969, DOI 10.1182/blood.V91.8.2969.2969_2969_2976; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; Kim J, 1999, MOL CELL BIOL, V19, P2289; King-Underwood L, 1998, BLOOD, V91, P2961, DOI 10.1182/blood.V91.8.2961.2961_2961_2968; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Loeb DM, 2001, CANCER RES, V61, P921; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; WANG ZY, 1995, ONCOGENE, V10, P415	26	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19627	19632		10.1074/jbc.M201336200	http://dx.doi.org/10.1074/jbc.M201336200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11919196	hybrid			2022-12-25	WOS:000175894800052
J	Yin, XY; Grove, L; Rogulski, K; Prochownik, EV				Yin, XY; Grove, L; Rogulski, K; Prochownik, EV			Myc target in myeloid cells-1, a novel c-Myc target, recapitulates multiple c-Myc phenotypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; ORNITHINE-DECARBOXYLASE; DNA-BINDING; PROTEIN; GENE; GROWTH; EXPRESSION; MAX; IDENTIFICATION; APOPTOSIS	Using cDNA microarrays, we recently identified a large number of transcripts that are regulated differentially by the c-Myc oncoprotein in myeloid cells. Here, we characterize one of these, termed MT-MC1 (Myc Target in Myeloid Cells-1). MT-MC1 is a widely expressed nuclear protein whose overexpression, unlike that of c-Myc targets reported previously, recapitulates multiple c-Myc phenotypes. These include promotion of apoptosis, alteration of morphology, enhancement of anchorage-independent growth, tumorigenic conversion, promotion of genomic instability, and inhibition of hematopoietic differentiation. The MT-MC1 promoter is a direct c-Myc target; it contains two consensus E-box elements, both of which bind c-Myc(.)Max heterodimers. Mutation of either site abrogates DNA binding by c-Myc-Max and renders the promoter c-Myc unresponsive. Finally, MT-MC1 regulates the expression of several other c-Myc target genes. MT-MC1 represents a proximal and direct c-Myc target that recapitulates many of the properties typically associated with Myc oneoprotein overexpression.	Childrens Hosp Pittsburgh, Sect Hematol Oncol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Mol Genet & Biochem, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Canc Inst, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Sect Hematol Oncol, 3705 5th Ave, Pittsburgh, PA 15213 USA.	edward_prochownik@poplar.chp.edu			NCI NIH HHS [CA78257] Funding Source: Medline; NHLBI NIH HHS [HL33741] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078257] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Ben-Porath I, 1999, MOL CELL BIOL, V19, P3529; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; Brandvold KA, 2000, ONCOGENE, V19, P2780, DOI 10.1038/sj.onc.1203589; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Dang CV, 1999, MOL CELL BIOL, V19, P1; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; Guo QM, 2000, CANCER RES, V60, P5922; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Kamita SG, 1997, GENE, V190, P173, DOI 10.1016/S0378-1119(96)00671-3; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; Landay M, 2000, CELL DEATH DIFFER, V7, P697, DOI 10.1038/sj.cdd.4400701; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; Lewis BC, 2000, CANCER RES, V60, P6178; Li Q, 1999, MOL CELL BIOL, V19, P5339; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MAEDA S, 1991, VIROLOGY, V180, P807, DOI 10.1016/0042-6822(91)90096-T; Nagamura-Inoue T, 2001, Int Rev Immunol, V20, P83, DOI 10.3109/08830180109056724; Nakayama H, 2000, EXP HEMATOL, V28, P1232, DOI 10.1016/S0301-472X(00)00530-0; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; Nesbit CE, 1998, BLOOD, V92, P1003; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PONCZ M, 1987, BLOOD, V69, P219; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Shivdasani RA, 1997, HEMATOL ONCOL CLIN N, V11, P1199, DOI 10.1016/S0889-8588(05)70489-5; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; WAX SD, 1994, J BIOL CHEM, V269, P13041; Wood LJ, 2000, MOL CELL BIOL, V20, P5490, DOI 10.1128/MCB.20.15.5490-5502.2000; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Yin XY, 2001, CANCER RES, V61, P6487; Yin XY, 1999, ONCOGENE, V18, P6621, DOI 10.1038/sj.onc.1203097; Yin XY, 2001, ONCOGENE, V20, P2908, DOI 10.1038/sj.onc.1204417; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	57	28	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19998	20010		10.1074/jbc.M200860200	http://dx.doi.org/10.1074/jbc.M200860200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11909865	hybrid			2022-12-25	WOS:000175894800100
J	Chiarini, A; Whitfield, JF; Armato, U; Dal Pra, I				Chiarini, A; Whitfield, JF; Armato, U; Dal Pra, I			Protein kinase C-beta(II) is an apoptotic lamin kinase in polyomavirus-transformed, etoposide-treated pyF111 rat fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-II INHIBITORS; LEUKEMIA HL60 CELLS; C-DELTA HOLOENZYME; NUCLEAR LAMINS; SUBCELLULAR-LOCALIZATION; CASPASE ACTIVATION; B PHOSPHORYLATION; CALPHOSTIN-C; CDC2 KINASE; IN-VITRO	The role of protein kinase C-beta(II) (PKC-beta(II)) in etoposide (VP-16)-induced apoptosis was studied using polyomavirus-transformed pyF111 rat fibroblasts in which PKC-beta(II), specific activity in the nuclear membrane (NM) doubled and the enzyme was cleaved into catalytic fragments. No PKC-beta(II) complexes with lamin B1 and/or active caspases were immunoprecipitable from the NM of proliferating untreated cells, but large complexes of PKC-beta(II) holoprotein and its catalytic fragments with lamin B1, active caspase-3 and -6, and inactive phospho-CDK-1, but not PKC-beta(I), or PKC-delta, could be immunoprecipitated from the NM of VP-16-treated cells, suggesting that PKC-beta(II) is an apoptotic lamin kinase. By 30 min after normal nuclei were mixed with cytoplasms from VP-16-treated, but not untreated, cells, PKC-beta(II),1 holoprotein had moved from the apoptotic cytoplasm to the normal NM, and lamin B1 was phosphorylated before cleavage by caspase-6. Lamin B1 phosphorylation was partly reduced, but its cleavage was completely prevented, despite the presence of active caspase-6, by adding a selective PKC-betas inhibitor, hispidin, to the apoptotic cytoplasms. Thus, a PKC-beta(II), response to VP-16 seems necessary for lamin B1 cleavage by caspase-6 and nuclear lamina dissolution in apoptosing pyF111 fibroblasts. The possibility of PKC-beta(II) being an apoptotic lamin kinase in these cells was further suggested by lamin B1-bound PKC-delta being inactive or only slightly active and by PKC-alpha not combining with the lamin.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Univ Verona, Sch Med, Dept Biomed & Surg Sci, Histol & Embryol Unit, I-37134 Verona, Italy	National Research Council Canada; University of Verona	Whitfield, JF (corresponding author), Natl Res Council Canada, Inst Biol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.		Chiarini, Anna/F-4097-2011; Dal Prà, Ilaria Pierpaola/R-3534-2017; DAL PRÀ, Ilaria Pierpaola/AAR-4216-2021; Armato, Ubaldo/N-2255-2019	Chiarini, Anna/0000-0002-6974-7685; Dal Prà, Ilaria Pierpaola/0000-0001-5523-4910; DAL PRÀ, Ilaria Pierpaola/0000-0001-5523-4910; Armato, Ubaldo/0000-0002-7804-6143				Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Collas P, 1997, J BIOL CHEM, V272, P21274, DOI 10.1074/jbc.272.34.21274; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Dal Pra I, 2000, EXP CELL RES, V255, P171, DOI 10.1006/excr.1999.4789; Dal Pra I, 1999, EXP CELL RES, V249, P147, DOI 10.1006/excr.1999.4441; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Emoto Y, 1996, BLOOD, V87, P1990; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; Finkel E, 2001, SCIENCE, V292, P624, DOI 10.1126/science.292.5517.624; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GJERTSEN BT, 1995, BBA-MOL CELL RES, V1269, P187, DOI 10.1016/0167-4889(95)00117-B; Gokmen-Polar Y, 1998, J BIOL CHEM, V273, P20261, DOI 10.1074/jbc.273.32.20261; Goldberg M, 1999, CRIT REV EUKAR GENE, V9, P285, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.130; Goldfine H, 2000, INFECT IMMUN, V68, P5735, DOI 10.1128/IAI.68.10.5735-5741.2000; Gonindard C, 1997, CELL BIOL TOXICOL, V13, P141, DOI 10.1023/A:1007321227010; GOSS VL, 1994, J BIOL CHEM, V269, P19074; Gruenbaum Y, 2000, J STRUCT BIOL, V129, P313, DOI 10.1006/jsbi.2000.4216; Hacker G, 2000, CELL TISSUE RES, V301, P5, DOI 10.1007/s004410000193; Harada K, 1999, J NEUROCHEM, V72, P2556, DOI 10.1046/j.1471-4159.1999.0722556.x; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; IWATA M, 1994, INT IMMUNOL, V6, P431, DOI 10.1093/intimm/6.3.431; Kajstura J, 1997, J MOL CELL CARDIOL, V29, P859, DOI 10.1006/jmcc.1996.0333; KAUFMANN SH, 1989, CANCER RES, V49, P5870; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; Kawahara A, 1998, GENES CELLS, V3, P297, DOI 10.1046/j.1365-2443.1998.00189.x; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KNOX KA, 1993, EXP CELL RES, V207, P68, DOI 10.1006/excr.1993.1164; LOCK RB, 1992, CANCER RES, V52, P1817; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; Mayne GC, 1998, J BIOL CHEM, V273, P24115, DOI 10.1074/jbc.273.37.24115; MCINTOSH CHS, 1976, J NEUROCHEM, V27, P449; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Moir RD, 1995, INT REV CYTOL, V162B, P141; MOIR RD, 1994, J CELL BIOL, V125, P1201, DOI 10.1083/jcb.125.6.1201; Moir RD, 2001, CELL MOL LIFE SCI, V58, P1748, DOI 10.1007/PL00000814; MURRAY A, 1993, CELL CYCLE; MURRAY NR, 1994, J BIOL CHEM, V269, P21385; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Murray NR, 1998, J BIOL CHEM, V273, P11514, DOI 10.1074/jbc.273.19.11514; Musashi M, 2000, INT J HEMATOL, V72, P12; NORBURY C, 1994, BIOCHEM BIOPH RES CO, V202, P1400, DOI 10.1006/bbrc.1994.2086; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; Ohmori T, 1998, CELL GROWTH DIFFER, V9, P345; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; PELLICCIARI C, 1993, EUR J HISTOCHEM, V37, P381; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; ROGUE P, 1990, J BIOL CHEM, V265, P4161; ROSENBERGER U, 1995, BIOCHEM J, V305, P269, DOI 10.1042/bj3050269; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Shimizu T, 1998, J BIOL CHEM, V273, P8669, DOI 10.1074/jbc.273.15.8669; SHIMIZU T, 1995, CANCER RES, V55, P228; Shimizu T, 1997, LEUKEMIA, V11, P1238, DOI 10.1038/sj.leu.2400734; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; SNAPPER CM, 1988, P NATL ACAD SCI USA, V85, P6107, DOI 10.1073/pnas.85.16.6107; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200; Spector D.I., 1998, CELL LAB MANUAL, V1; Stuurman N, 1997, FEBS LETT, V401, P171, DOI 10.1016/S0014-5793(96)01464-0; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Tanabe F, 1998, BIOCHEM BIOPH RES CO, V242, P129, DOI 10.1006/bbrc.1997.7934; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; Varghese J, 2001, EUR J IMMUNOL, V31, P2035, DOI 10.1002/1521-4141(200107)31:7<2035::AID-IMMU2035>3.0.CO;2-Y; Ventura C, 2001, CRIT REV EUKAR GENE, V11, P243; Vlcek S, 2001, CELL MOL LIFE SCI, V58, P1758, DOI 10.1007/PL00000815; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WHITFIELD JF, 2002, CALCIUM GRAND MASTER; WHITFIELD JF, 1997, CALCIUM CELL CYCLE D; Yuan SY, 2000, CIRC RES, V87, P412; Zhao Y, 2001, CELL MOL LIFE SCI, V58, P298, DOI 10.1007/PL00000857	80	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18827	18839		10.1074/jbc.M111921200	http://dx.doi.org/10.1074/jbc.M111921200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11901153	hybrid			2022-12-25	WOS:000175975800077
J	Karmakar, P; Piotrowski, J; Brosh, RM; Sommers, JA; Miller, SPL; Cheng, WH; Snowden, CM; Ramsden, DA; Bohr, VA				Karmakar, P; Piotrowski, J; Brosh, RM; Sommers, JA; Miller, SPL; Cheng, WH; Snowden, CM; Ramsden, DA; Bohr, VA			Werner protein is a target of DNA-dependent protein kinase in vivo and in vitro, and its catalytic activities are regulated by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICASE ACTIVITY; SYNDROME CELLS; STRANDED-DNA; WRN PROTEIN; KU; BINDING; SUBUNIT; DAMAGE; INHIBITION; PHENOTYPE	Human Werner Syndrome is characterized by early onset of aging, elevated chromosomal instability, and a high incidence of cancer. Werner protein (WRN) is a member of the recQ gene family, but unlike other members of the recQ family, it contains a unique 3'-->5' exonuclease activity. We have reported previously that human Ku heterodimer interacts physically with WRN and functionally stimulates WRN exonuclease activity. Because Ku and DNA-PKcs, the catalytic subunit of DNA-dependent protein kinase (DNA-PK), form a complex at DNA ends, we have now explored the possibility of functional modulation of WRN exonuclease activity by DNA-PK. We find that although DNA-PKcs alone does not affect the WRN exonuclease activity, the additional presence of Ku mediates a marked inhibition of it. The inhibition of WRN exonuclease by DNA-PKcs requires the kinase activity of DNA-PKcs. WRN is a target for DNA-PKcs phosphorylation, and this phosphorylation requires the presence of Ku. We also find that treatment of recombinant WRN with a Ser/Thr phosphatase enhances WRN exonuclease and helicase activities and that WRN catalytic activity can be inhibited by rephosphorylation of WRN with DNA-PK. Thus, the level of phosphorylation of WRN appears to regulate its catalytic activities. WRN forms a complex, both in vitro and in vivo, with DNA-PKC. WRN is phosphorylated in vivo after treatment of cells with DNA-damaging agents in a pathway that requires DNA-PKcs. Thus, WRN protein is a target for DNA-PK phosphorylation in vitro and in vivo, and this phosphorylation may be a way of regulating its different catalytic activities, possibly in the repair of DNA dsb.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 1N4, Canada; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Calgary; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, Box 1,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	vbohr@nih.gov	Bohr, Vilhelm/AAP-5931-2020	Ramsden, Dale/0000-0003-1575-4748; Lees-Miller, Susan/0000-0001-5809-2516	NCI NIH HHS [CA84442-01, R01 CA084442] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000726, Z01AG000741] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Anderson CW, 2000, RADIAT RES, V154, P473, DOI 10.1667/0033-7587(2000)154[0473:HTFTMG]2.0.CO;2; Balajee AS, 1999, MOL BIOL CELL, V10, P2655, DOI 10.1091/mbc.10.8.2655; Barbaro BA, 2000, J VIROL, V74, P8601, DOI 10.1128/JVI.74.18.8601-8613.2000; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bohr VA, 2000, EXP GERONTOL, V35, P695, DOI 10.1016/S0531-5565(00)00145-5; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; Chan DW, 1996, BIOCHEM CELL BIOL, V74, P67, DOI 10.1139/o96-007; Chan DW, 1998, INT J RADIAT BIOL, V74, P217, DOI 10.1080/095530098141591; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Cooper MP, 2000, GENE DEV, V14, P907; Douglas P, 2001, J BIOL CHEM, V276, P18992, DOI 10.1074/jbc.M011703200; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Grigorova M, 2000, MUTAGENESIS, V15, P303, DOI 10.1093/mutage/15.4.303; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Ishimi Y, 2000, J BIOL CHEM, V275, P16235, DOI 10.1074/jbc.M909040199; Izzard RA, 1999, CANCER RES, V59, P2581; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li BM, 2000, J BIOL CHEM, V275, P39800; Machwe A, 2000, NUCLEIC ACIDS RES, V28, P2762, DOI 10.1093/nar/28.14.2762; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; MARTIN GM, 1970, LAB INVEST, V23, P86; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Nuesch JPF, 1998, J VIROL, V72, P9966; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; STEFANINI M, 1989, MUTAT RES, V219, P179, DOI 10.1016/0921-8734(89)90013-1; Ting NSY, 1998, J BIOL CHEM, V273, P2136, DOI 10.1074/jbc.273.4.2136; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; VOIT R, 1995, NUCLEIC ACIDS RES, V23, P2593, DOI 10.1093/nar/23.14.2593; Yannone SM, 2001, J BIOL CHEM, V276, P38242; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	52	127	132	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18291	18302		10.1074/jbc.M111523200	http://dx.doi.org/10.1074/jbc.M111523200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889123	hybrid, Green Published			2022-12-25	WOS:000175975800008
J	Karthikeyan, S; Leung, TL; Ladias, JAA				Karthikeyan, S; Leung, TL; Ladias, JAA			Structural determinants of the Na+/H+ exchanger regulatory factor interaction with the beta(2) adrenergic and platelet-derived growth factor receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; PDZ-DOMAIN; CRYSTAL-STRUCTURE; BETA(2)-ADRENERGIC RECEPTOR; LIGAND INTERACTIONS; NHE-RF; PROTEIN; RECOGNITION; PEPTIDE; PROGRAM	The Na+/H+ exchanger regulatory factor (NHERF) binds through its PDZ1 domain to the carboxyl-terminal sequences NDSLL and EDSFL of the beta(2) adrenergic receptor (beta(2)AR) and platelet-derived growth factor receptor, respectively, and plays a critical role in the membrane localization and physiological regulation of these receptors. The crystal structures of the human NHERF PDZ1 domain bound to the sequences NDSLL and EDSFL have been determined at 1.9- and 2.2-Angstrom resolution, respectively. The beta(2)AR and platelet-derived growth factor receptor ligands insert into the PDZ1 binding pocket by a beta-sheet augmentation process and are stabilized by largely similar networks of hydrogen bonds and hydrophobic contacts. In the PDZ1-beta(2)AR complex, the side chain of asparagine at position -4 in the beta(2)AR peptide forms two additional hydrogen bonds with Gly(30) of PDZ1, which contribute to the higher affinity of this interaction. Remarkably, both complexes are further stabilized by hydrophobic interactions involving the side chains of the penultimate amino acids of the peptide ligands, whereas the PDZ1 residues Asn(22) and Glu(43) undergo conformational changes to accommodate these side chains. These results provide structural insights into the mechanisms by which different side chains at the position -1 of peptide ligands interact with PDZ domains and contribute to the affinity of the PDZ-ligand interaction.	Harvard Univ, Sch Med, Inst Med, Div Expt Med,Mol Med Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Inst Med, Div Expt Med,Macromol Crystallog Unit, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Ladias, JAA (corresponding author), Harvard Univ, Sch Med, Inst Med, Div Expt Med,Mol Med Lab, Rm 354,4 Blackfan Circle, Boston, MA 02115 USA.		Karthikeyan, Subramanian/F-8808-2010					Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Ediger TR, 1999, ENDOCRINOLOGY, V140, P2976, DOI 10.1210/en.140.7.2976; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fuh G, 2000, J BIOL CHEM, V275, P21486, DOI 10.1074/jbc.275.28.21486; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Harris BZ, 2001, J CELL SCI, V114, P3219; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; Kimple ME, 2001, EMBO J, V20, P4414, DOI 10.1093/emboj/20.16.4414; Kozlov G, 2000, BIOCHEMISTRY-US, V39, P2572, DOI 10.1021/bi991913c; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stemmer-Rachamimov AO, 2001, AM J PATHOL, V158, P57, DOI 10.1016/S0002-9440(10)63944-2; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903	38	67	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18973	18978		10.1074/jbc.M201507200	http://dx.doi.org/10.1074/jbc.M201507200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11882663	hybrid			2022-12-25	WOS:000175975800095
J	Petroulakis, E; Wang, E				Petroulakis, E; Wang, E			Nerve growth factor specifically stimulates translation of eukaryotic elongation factor 1A-1 (eEF1A-1) mRNA by recruitment to polyribosomes in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE S6 KINASE; NEUROTROPHIC FACTOR; NEURITE REGENERATION; BINDING-PROTEIN; FACTOR 1-ALPHA; GEL SYSTEM; RAPAMYCIN; EXPRESSION; FACTOR-1-ALPHA; BRAIN	During postnatal brain development the level of peptide elongation factor-1A (eEF1A-1) expression declines and that of the highly homologous isoform, eEF1A-2, increases in neurons. eEF1A-1 is implicated in cytoskeletal interactions, tumorigenesis, differentiation, and the absence of eEF1A-2 is implicated in neurodegeneration in the mouse mutant, wasted. The translation of eEF1A-1 mRNA is up-regulated via mitogenic stimulation. However, it is not known if eEF1A-1 mRNA translation is regulated by neurotrophins or if its synthesis is differentially regulated than that of the neuronal isoform, eEF1A-2. Regulated translation of these factors by neurotrophin, particularly by the Trk class of neurotrophin receptors, would implicate them in differentiation, survival, and neuronal plasticity. In this study, we investigated the effect of nerve growth factor (NGF) stimulation on the synthesis of eEF1A-1 and eEF1A-2. We found that NGF stimulation causes a preferential synthesis of eEF1A-1 over eEF1A-2 in PC12 cells. We analyzed the co-sedimentation of eEF1A-1 mRNA with polyribosome fractions in sucrose gradients, and found that NGF stimulation enriched the presence of eEF1A-1 mRNA in polyribosomes, indicating that the translation of eEF1A-1 mRNA is regulated by NGF. Inhibitors of phosphatidylinositol 3-kinase (LY 294002), mammalian target of rapamycin (rapamycin), and the NGF receptor, TrkA (K-252a), but not of mitogen-activated protein kinase (PD 98059), prevented the recruitment of eEF1A-1 mRNA to polyribosomes. The mobilization of eEF1A-1 mRNA to polyribosomes was rapamycin-sensitive in both proliferating and differentiated PC12 cells, indicating the importance of this pathway during differentiation. Our data shows that after growth factor withdrawal, an NGF-signaling pathway Stimulates eEF1A-1 mRNA translation in proliferating and differentiated PC12 cells. Therefore, eEF1A-1 mRNA is a specific translational target of TrkA signaling.	Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3T 1E2, Canada; McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada	University of Louisville; McGill University; Lady Davis Institute; McGill University	Wang, E (corresponding author), Univ Louisville, Sch Med, Dept Biochem & Mol Biol, 570 S Preston St,Rm 304, Louisville, KY 40292 USA.	eugenia.wang@louisville.edu			NIA NIH HHS [AG10461] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANN DK, 1991, J BIOL CHEM, V266, P10429; Barker PA, 1998, CELL DEATH DIFFER, V5, P346, DOI 10.1038/sj.cdd.4400375; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Bischoff C, 2000, GENOMICS, V68, P63, DOI 10.1006/geno.2000.6271; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; Chambers DM, 1998, P NATL ACAD SCI USA, V95, P4463, DOI 10.1073/pnas.95.8.4463; Crosio C, 2000, NUCLEIC ACIDS RES, V28, P2927, DOI 10.1093/nar/28.15.2927; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; DOUCET JP, 1988, ANAL BIOCHEM, V168, P265, DOI 10.1016/0003-2697(88)90317-X; Edmonds BT, 1996, J CELL SCI, V109, P2705; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; Gangwani L, 1998, J CELL BIOL, V143, P1471, DOI 10.1083/jcb.143.6.1471; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Kahns S, 1998, NUCLEIC ACIDS RES, V26, P1884, DOI 10.1093/nar/26.8.1884; Khalyfa A, 1999, DEV DYNAM, V216, P267, DOI 10.1002/(SICI)1097-0177(199911)216:3<267::AID-DVDY5>3.0.CO;2-V; Khalyfa A, 2001, J BIOL CHEM, V276, P22915, DOI 10.1074/jbc.M101011200; Kleijn M, 1998, J BIOL CHEM, V273, P5536, DOI 10.1074/jbc.273.10.5536; Kleijn M, 2000, BIOCHEM J, V347, P399, DOI 10.1042/0264-6021:3470399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE S, 1995, EXP CELL RES, V219, P589, DOI 10.1006/excr.1995.1268; LEE S, 1993, J HISTOCHEM CYTOCHEM, V41, P1093, DOI 10.1177/41.7.8515051; LEE S, 1993, J BIOL CHEM, V268, P24453; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; MATSUDA Y, 1986, J NEUROCHEM, V47, P1728, DOI 10.1111/j.1471-4159.1986.tb13081.x; MATSUDA Y, 1987, J BIOL CHEM, V262, P2832; Meyuhas O, 2000, COLD SPRING HARBOR M, V39, P671; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Miller FD, 1998, CELL DEATH DIFFER, V5, P343, DOI 10.1038/sj.cdd.4400385; Moore DD, 1995, GLOB MOB SURV; MUTOH T, 1988, J BIOL CHEM, V263, P15853; Negrutskii BS, 1998, PROG NUCLEIC ACID RE, V60, P47, DOI 10.1016/S0079-6603(08)60889-2; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; Pedersen S, 1997, EUR J BIOCHEM, V247, P449, DOI 10.1111/j.1432-1033.1997.00449.x; Pellizzoni L, 1997, J MOL BIOL, V267, P264, DOI 10.1006/jmbi.1996.0888; Proud Christopher, 2000, V39, P719; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Snyder SH, 1998, NEURON, V21, P283, DOI 10.1016/S0896-6273(00)80538-3; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Sonenberg N, 2000, TRANSLATIONAL CONTRO; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; Takei N, 2001, J BIOL CHEM, V276, P42818, DOI 10.1074/jbc.M103237200; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; TAPLEY P, 1992, ONCOGENE, V7, P371; TWISS JL, 1995, J NEUROCHEM, V64, P550; Twiss JL, 2000, NEUROBIOL DIS, V7, P416, DOI 10.1006/nbdi.2000.0293; Zhu JF, 2001, BBA-GENE STRUCT EXPR, V1521, P19, DOI 10.1016/S0167-4781(01)00277-9	54	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18718	18727		10.1074/jbc.M111782200	http://dx.doi.org/10.1074/jbc.M111782200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11907030	hybrid			2022-12-25	WOS:000175975800064
J	Potamitou, A; Holmgren, A; Vlamis-Gardikas, A				Potamitou, A; Holmgren, A; Vlamis-Gardikas, A			Protein levels of Escherichia coli thioredoxins and glutaredoxins and their relation to null mutants, growth phase, and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; OXYR TRANSCRIPTION FACTOR; SENSITIVE SANDWICH ELISA; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; IN-VIVO; RIBONUCLEOTIDE REDUCTASE; GENE-EXPRESSION; HUMAN SERUM; GLUTATHIONE	Levels of Escherichia coli thioredoxin 1 (Trx1), Trx2, glutaredoxin 1 (Grx1), Grx2, and Grx3 have been determined by novel sensitive sandwich enzyme-linked immunosorbent assay. In a wild type strain, levels of Trx1 increased from the exponential to the stationary phase of growth (1.5-fold to 3400 ng/mg), as did levels of Grx2 (from similar to2500 to similar to8000 ng/mg). Grx3 and Trx2 levels were quite stable during growth (similar to4500 and similar to200 ng/mg, respectively). Grx1 levels decreased from similar to600 ng/mg at the exponential phase to similar to285 ng/mg at the stationary phase. A large elevation of Grx1 (20-30-fold), was observed in null mutants for the thioredoxin system whereas levels of the other redoxins in all combinations of examined null mutants barely exceeded a 2-3-fold increase. Measurements of thymidine incorporation in newly synthesized DNA suggested that mainly Grx1 and, to a lesser extent, Trx1 contribute to the reduction of ribonucleotides. All glutaredoxin species were elevated in catalase-deficient strains, implying an antioxidant role for the glutaredoxins. Trx1, Trx2, and Grx1 levels increased after exposure to hydrogen peroxide and decreased after exposure to mercaptoethanol. The levels of Grx2 and Grx3 behaved exactly the opposite, suggesting that the transcription factor OxyR does not regulate their expression.	Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden	Karolinska Institutet	Holmgren, A (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden.		Vlamis, Alexios/AAF-5152-2020; Fernandes, Aristi/D-2507-2015	Vlamis, Alexios/0000-0001-5068-6459; 				Arnold CN, 2001, J BACTERIOL, V183, P2178, DOI 10.1128/JB.183.7.2178-2186.2001; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; BECKERHAPAK M, 1995, FEMS MICROBIOL LETT, V134, P39, DOI 10.1111/j.1574-6968.1995.tb07911.x; Bjornberg O, 1991, Protein Expr Purif, V2, P287, DOI 10.1016/1046-5928(91)90085-W; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLIN A, 1995, J BACTERIOL, V177, P981, DOI 10.1128/jb.177.4.981-986.1995; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; Das KC, 1998, J IMMUNOL METHODS, V211, P9, DOI 10.1016/S0022-1759(97)00163-4; Davis R., 1980, ADV BACTERIAL GENETI; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; DYSON HJ, 1989, BIOCHEMISTRY-US, V28, P7074, DOI 10.1021/bi00443a044; FISHER MT, 1992, J BIOL CHEM, V267, P1872; Gallardo-Madueno R, 1998, J BIOL CHEM, V273, P18382, DOI 10.1074/jbc.273.29.18382; Hengge-Aronis R., 1996, ESCHERICHIA COLI SAL, V5, P1497; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; LIU JY, 1995, BIOCHEMISTRY-US, V34, P13472, DOI 10.1021/bi00041a026; Miranda-Vizuete A, 1997, J BIOL CHEM, V272, P30841, DOI 10.1074/jbc.272.49.30841; MirandaVizuete A, 1996, J BIOL CHEM, V271, P19099, DOI 10.1074/jbc.271.32.19099; Monje-Casas F, 2001, J BIOL CHEM, V276, P18031, DOI 10.1074/jbc.M011728200; NOE G, 1992, BRIT J HAEMATOL, V80, P285; Prieto-Alamo MJ, 2000, J BIOL CHEM, V275, P13398, DOI 10.1074/jbc.275.18.13398; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; Ritz D, 2000, J BIOL CHEM, V275, P2505, DOI 10.1074/jbc.275.4.2505; RUSSEL M, 1988, P NATL ACAD SCI USA, V85, P990, DOI 10.1073/pnas.85.4.990; Shi J, 1999, J BIOL CHEM, V274, P36039, DOI 10.1074/jbc.274.51.36039; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; Takemoto T, 1998, FREE RADICAL BIO MED, V24, P556, DOI 10.1016/S0891-5849(97)00287-6; Tao K, 1997, J BACTERIOL, V179, P5967, DOI 10.1128/jb.179.18.5967-5970.1997; Vlamis-Gardikas A, 2002, J BIOL CHEM, V277, P10861, DOI 10.1074/jbc.M111024200; Vlamis-Gardikas A, 2002, METHOD ENZYMOL, V347, P286; VlamisGardikas A, 1997, J BIOL CHEM, V272, P11236; Xia B, 2001, J MOL BIOL, V310, P907, DOI 10.1006/jmbi.2001.4721; YONEI S, 1987, BIOCHEM BIOPH RES CO, V143, P638, DOI 10.1016/0006-291X(87)91401-X; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	40	53	59	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18561	18567		10.1074/jbc.M201225200	http://dx.doi.org/10.1074/jbc.M201225200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893749	hybrid			2022-12-25	WOS:000175975800042
J	Tseng, Y; An, KM; Wirtz, D				Tseng, Y; An, KM; Wirtz, D			Microheterogeneity controls the rate of gelation of actin filament networks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFUSING WAVE SPECTROSCOPY; PARTICLE-TRACKING MICRORHEOLOGY; DYNAMIC CROSS-LINKING; ALPHA-ACTININ; MECHANICAL-PROPERTIES; F-ACTIN; ARP2/3 COMPLEX; VISCOELASTICITY; POLYMERIZATION; POLYMERS	Rapid sol-gel transitions of the actin cytoskeleton are required for many key cellular processes, including cell spreading and cell locomotion. Actin monomers assemble into semiflexible polymers that rapidly intertwine into a network, a process that in vitro takes similar to1 min for an actin concentration of 1 mg/ml. The same actin filament network, however, takes similar to1 h to exhibit a steadystate elasticity. We hypothesize that the slow gelation of F-actin is due to the slow establishment of a homogeneous meshwork. Using a novel method, time-resolved multiple particle tracking, which monitors the range of thermally excited displacements of microspheres imbedded in the network, we show that the increase in elasticity in a polymerizing solution of actin parallels the progressive decline of the network microheterogeneity. The rates of gelation and network homogenization slightly decrease with actin concentration and in the presence of the F-actin cross-linking proteins alpha-actinin and fascin, whereas the rate of actin polymerization increases dramatically with actin concentration. Our measurements show that the slow spatial homogenization of the actin filament network, not actin polymerization or the formation of polymer overlaps, is the rate-limiting step in the establishment of an elastic actin network and suggest that a new activity of F-actin binding proteins may be required for the rapid formation of a homogeneous stiff gel.	Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Program Mol Biophys, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Wirtz, D (corresponding author), Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA.		Wirtz, Denis/A-3257-2010					Amblard F, 1996, PHYS REV LETT, V77, P4470, DOI 10.1103/PhysRevLett.77.4470; Andrianantoandro E, 2001, J MOL BIOL, V312, P721, DOI 10.1006/jmbi.2001.5005; Apgar J, 2000, BIOPHYS J, V79, P1095, DOI 10.1016/S0006-3495(00)76363-6; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; Bray D, 2001, CELL MOVEMENTS MOL M; CASELLA JF, 1995, CELL MOTIL CYTOSKEL, V30, P164, DOI 10.1002/cm.970300208; CONDEELIS J, 1992, CELL MOTIL CYTOSKEL, V22, P1, DOI 10.1002/cm.970220102; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Coulombe PA, 2000, TRENDS CELL BIOL, V10, P420, DOI 10.1016/S0962-8924(00)01828-6; CRAIG SW, 1982, METHOD ENZYMOL, V85, P316; de Gennes P. G., 1991, SCALING CONCEPTS POL; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Gittes F, 1998, PHYS REV E, V58, pR1241, DOI 10.1103/PhysRevE.58.R1241; Haber C, 2000, P NATL ACAD SCI USA, V97, P10792, DOI 10.1073/pnas.190320097; Hinner B, 1998, PHYS REV LETT, V81, P2614, DOI 10.1103/PhysRevLett.81.2614; Isambert H, 1996, MACROMOLECULES, V29, P1036, DOI 10.1021/ma946418x; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LeDuc P, 1999, NATURE, V399, P564, DOI 10.1038/21148; Liverpool TB, 2001, PHYS REV LETT, V86, P4171, DOI 10.1103/PhysRevLett.86.4171; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; Mason TG, 1997, PHYS REV LETT, V79, P3282, DOI 10.1103/PhysRevLett.79.3282; McGrath JL, 2000, BIOPHYS J, V79, P3258, DOI 10.1016/S0006-3495(00)76558-1; Morse DC, 1998, MACROMOLECULES, V31, P7030, DOI 10.1021/ma9803032; Mullins RD, 1998, MOL BIOL CELL, V9, P841, DOI 10.1091/mbc.9.4.841; Palmer A, 1998, RHEOL ACTA, V37, P97, DOI 10.1007/s003970050095; Palmer A, 1999, BIOPHYS J, V76, P1063, DOI 10.1016/S0006-3495(99)77271-1; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POLLARD TD, 1992, J BIOL CHEM, V267, P20339; Sept D, 1999, BIOPHYS J, V77, P2911, DOI 10.1016/S0006-3495(99)77124-9; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Tang JX, 1999, BIOPHYS J, V76, P2208, DOI 10.1016/S0006-3495(99)77376-5; Tseng Y, 2001, BIOPHYS J, V81, P1643, DOI 10.1016/S0006-3495(01)75818-3; Tseng Y, 2001, J MOL BIOL, V310, P351, DOI 10.1006/jmbi.2001.4716; VERKHOVSKY AB, 1995, J CELL BIOL, V131, P989, DOI 10.1083/jcb.131.4.989; WACHSSTOCK DH, 1994, BIOPHYS J, V66, P801, DOI 10.1016/S0006-3495(94)80856-2; Xu JY, 1998, BIOPHYS J, V74, P2731, DOI 10.1016/S0006-3495(98)77979-2; Xu JY, 2002, BIOMACROMOLECULES, V3, P92, DOI 10.1021/bm015586b; Xu JY, 1998, MACROMOLECULES, V31, P6486, DOI 10.1021/ma9717754; Xu JY, 1998, RHEOL ACTA, V37, P387, DOI 10.1007/s003970050125; Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570; Xu JY, 2000, J BIOL CHEM, V275, P35886, DOI 10.1074/jbc.M002377200; Yamada S, 2000, BIOPHYS J, V78, P1736, DOI 10.1016/S0006-3495(00)76725-7	44	53	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18143	18150		10.1074/jbc.M110868200	http://dx.doi.org/10.1074/jbc.M110868200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11889122	hybrid			2022-12-25	WOS:000175685100096
J	Ching, YP; Pang, ASH; Lam, WH; Qi, RZ; Wang, JH				Ching, YP; Pang, ASH; Lam, WH; Qi, RZ; Wang, JH			Identification of a neuronal Cdk5 activator-binding protein as Cdk5 inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; BRAIN-SPECIFIC ACTIVATOR; CDC2-LIKE KINASE; INK4 INHIBITORS; BOVINE BRAIN; DOMAIN	Neuronal Cdc2-like kinase (Nclk) plays an important role in a variety of cellular processes, including neuronal cell differentiation, apoptosis, neuron migration, and formation of neuromuscular junction. The active kinase consists of a catalytic subunit, Cdk5, and an essential regulatory subunit, neuronal Cdk5 activator (p35(nck5a) or p25(nck5a)), which is expressed primarily in neurons of central nervous tissue. In our previous study using the yeast two-hybrid screening method, three novel p35(nck5a)-associated proteins were isolated. Here we show that one of these proteins, called C42, specifically inhibits the activation of Cdk5 by Nck5a. Co-immunoprecipitation data suggested that C42 and p35(nck5a) could form a complex within cultured mammalian cells. Deletion analysis has mapped the inhibitory domain of C42 to a region of 135 amino acids, which is conserved in Pho81, a yeast protein that inhibits the yeast cyclin-dependent protein kinase Pho85. The Pho85.Pho80 kinase complex has been shown to be the yeast functional homologue of the mammalian Cdk5/p35(nck5a) kinase.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Univ Calgary, Fac Med, Dept Biochem Med, Calgary, AB T2N 1N4, Canada	Hong Kong University of Science & Technology; University of Calgary	Wang, JH (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.		Ching, Yick Pang/C-4244-2009	CHING, Yick Pang/0000-0002-6461-8358; Qi, Robert Zhong/0000-0001-5596-8172				Ching YP, 2000, GENE, V242, P285, DOI 10.1016/S0378-1119(99)00499-0; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Grant P, 2001, EUR J BIOCHEM, V268, P1534, DOI 10.1046/j.1432-1033.2001.02025.x; Huang DQ, 1999, P NATL ACAD SCI USA, V96, P14445, DOI 10.1073/pnas.96.25.14445; Huang SD, 2001, MOL CELL BIOL, V21, P6695, DOI 10.1128/MCB.21.19.6695-6705.2001; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Qi Z, 1998, J BIOL CHEM, V273, P2329, DOI 10.1074/jbc.273.4.2329; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0	17	55	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15237	15240		10.1074/jbc.C200032200	http://dx.doi.org/10.1074/jbc.C200032200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11882646	hybrid			2022-12-25	WOS:000175510400005
J	Saucier, C; Papavasiliou, V; Palazzo, A; Naujokas, MA; Kremer, R; Park, M				Saucier, C; Papavasiliou, V; Palazzo, A; Naujokas, MA; Kremer, R; Park, M			Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis	ONCOGENE			English	Article						receptor tyrosine kinase; transformation; tumorigenesis; metastasis; Grb2; She	GROWTH-FACTOR RECEPTOR; TPR-MET ONCOPROTEIN; PHOSPHOLIPASE C-GAMMA; BINDING-SITE; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL MORPHOGENESIS; CARBOXY-TERMINUS; BETA-SUBUNIT; ACTIVATION; REQUIRES	Many human cancers have been associated with the deregulation of receptor tyrosine kinases (RTK). However, the individual contribution of receptor-associated signaling proteins in cellular transformation and metastasis is poorly understood. To examine the role of RTK activated signal transduction pathways to processes involved in cell transformation, we have exploited the oncogenic derivative of the Met RTK (Tpr-Met). Unlike other RTKs, twin tyrosine residues in the carboxy-terminal tail of the Met oncoprotein and receptor are required for all biological and transforming activities, and a mutant lacking these tyrosines is catalytically active but non transforming. Using this mutant we have inserted oligonucleotide cassettes, each encoding a binding site for a specific signaling protein derived from other RTKs. We have generated variant forms of the Tpr-Met oncoprotein with the ability to bind individually to the p85 subunit of P13'K, PLCgamma, or to the Grb2 or Shc adaptor proteins. Variants that recruit the Shc or Grb2 adaptor proteins generated foci of morphologically transformed fibroblast cells and induced anchorage-independent growth, scattering of epithelial cells and experimental metastasis. In contrast, variants that bind and activate P13'K or PLCgamma failed to generate readily detectable foci. Although cell lines expressing the P13'K variant grew in soft-agar, these cells were non metastatic. Using this unique RTK oncoprotein model, we have established that Grb2 or Shc dependent signaling pathways are sufficient for cell transformation and metastatic spread.	McGill Univ, Ctr Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hosp, Calcium Res Lab, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hosp, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hosp, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hosp, Dept Oncol, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Ctr Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada.	morag@molonc.mcgill.ca	Palazzo, Alexander/B-1270-2013; Saucier, Caroline/Q-9250-2019	Palazzo, Alexander/0000-0002-9700-1995; Saucier, Caroline/0000-0001-7678-9886; Kremer, Richard/0000-0002-7053-2139				Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Chang JS, 1997, CANCER RES, V57, P5465; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DeMali KA, 1997, J BIOL CHEM, V272, P9011; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sakaguchi K, 1998, MOL ENDOCRINOL, V12, P536, DOI 10.1210/me.12.4.536; SALCINI AE, 1994, ONCOGENE, V9, P2827; Smith MR, 1998, CARCINOGENESIS, V19, P177, DOI 10.1093/carcin/19.1.177; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU H, 1994, J BIOL CHEM, V269, P29943	51	57	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1800	1811		10.1038/sj.onc.1205261	http://dx.doi.org/10.1038/sj.onc.1205261			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896612	Bronze			2022-12-25	WOS:000174284500002
J	Baldassarre, G; Bruni, P; Boccia, A; Salvatore, G; Melillo, RM; Motti, ML; Napolitano, M; Belletti, B; Fusco, A; Santoro, M; Viglietto, G				Baldassarre, G; Bruni, P; Boccia, A; Salvatore, G; Melillo, RM; Motti, ML; Napolitano, M; Belletti, B; Fusco, A; Santoro, M; Viglietto, G			Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27(kip1)	ONCOGENE			English	Article						GDNF; RET; p27; embryonal carcinoma	EMBRYONAL CARCINOMA-CELLS; NEURONAL DIFFERENTIATION; RETINOIC ACID; TYROSINE KINASE; NTERA-2 CELLS; GROWTH-FACTOR; PC12 CELLS; ACTIVATION; RECEPTOR; SURVIVAL	Growth factors of the glial cell line-derived neurotrophic factor (GDNF) family control the differentiation of neuronal cells of the central and peripheral nervous systems. Intracellular signalling of these growth factors is, at least in part, mediated by activation of the RET receptor tyrosine kinase. Here, we demonstrate that GDNF triggering inhibits the proliferation of the embryonal carcinoma cell line NT2/Dl. This antiproliferative effect is accompanied by down-regulation of the SSEA-3 antigen, a marker typical of undifferentiated NT2/D1 cells. We show that these effects are mediated by activation of RET signalling. The block of RET by a kinase-deficient dominant negative mutant impairs GDNF-dependent growth inhibition, whereas the adoptive expression of a constitutively active RET, the RET-MEN2A oncogene, promotes effects similar to those exerted by GDNF. We show that RET signalling increases the expression of the cyclin-dependent kinase inhibitor P27(kip1) in NT2/Dl cells. Both DNA synthesis inhibition and SSEA-3 down-regulation are prevented if p27(kip1) expression is blocked by an antisense construct, which demonstrates that RET-triggered effects are mediated by p27(kip1).	Univ Naples Federico II, CNR, Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Ist Nazl Tumori, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, BIOGEM, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Naples Federico II	Viglietto, G (corresponding author), Univ Naples Federico II, CNR, Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.	gvigliet@tin.it	Belletti, Barbara/J-2028-2018; Baldassarre, Gustavo/K-1350-2016; Viglietto, Giuseppe/AAC-2852-2019; melillo, rosa marina/O-5255-2015; napolitano, maria/K-1615-2016	Belletti, Barbara/0000-0003-2249-0285; Baldassarre, Gustavo/0000-0002-9750-8825; Viglietto, Giuseppe/0000-0003-2327-7515; Fusco, Alfredo/0000-0003-3332-5197; MELILLO, Rosa Marina/0000-0002-9233-5275; napolitano, maria/0000-0002-8996-3297				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Baldassarre G, 1997, ONCOGENE, V15, P927, DOI 10.1038/sj.onc.1201260; Billon N, 1996, ONCOGENE, V13, P2047; Borriello A, 2000, ONCOGENE, V19, P51, DOI 10.1038/sj.onc.1203231; CALIFANO D, 1995, ONCOGENE, V11, P107; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CHEN C, 1989, BIOCHEMISTRY-US, V28, P2229, DOI 10.1021/bi00431a039; De Vita G, 2000, CANCER RES, V60, P3916; Durand B, 1998, CURR BIOL, V8, P431, DOI 10.1016/S0960-9822(98)70177-0; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; Erhardt JA, 1998, ONCOGENE, V16, P443, DOI 10.1038/sj.onc.1201577; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LEE VMY, 1986, J NEUROSCI, V6, P514; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miyazono M, 1996, J COMP NEUROL, V376, P603, DOI 10.1002/(SICI)1096-9861(19961223)376:4<603::AID-CNE8>3.0.CO;2-5; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Qu ZC, 1998, J CELL BIOL, V142, P1075, DOI 10.1083/jcb.142.4.1075; Rose GM, 1999, AGE, V22, P1, DOI 10.1007/s11357-999-0001-8; SAMBROOK J, 1989, MOL CLONINB LAB MANU; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; van Weering DHJ, 1998, RECENT RES CANCER, V154, P271; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; vanPuijenbroek AAFL, 1997, ONCOGENE, V14, P1147, DOI 10.1038/sj.onc.1200911; YAN GZ, 1995, J NEUROSCI, V15, P6200	38	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1739	1749		10.1038/sj.onc.1205226	http://dx.doi.org/10.1038/sj.onc.1205226			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896605				2022-12-25	WOS:000174214200012
J	Gobin, AS; West, JL				Gobin, AS; West, JL			Cell migration through defined, synthetic extracellular matrix analogues	FASEB JOURNAL			English	Article						PEG; hydrogel; RGD; proteolysis	SMOOTH-MUSCLE-CELLS; ADHESION PEPTIDES; DEGRADATION; HYDROGELS; COLLAGEN; GELS; PROTEOLYSIS; FIBROBLAST; SURFACES; MOTILITY	We have developed synthetic hydrogel extracellular matrix (ECM) analogues that can be used to study mechanisms involved in cell migration, such as receptor-ligand interactions and proteolysis. The biomimetic hydrogels consist of bioinert polyethylene glycol diacrylate derivatives with proteolytically degradable peptide sequences included in the backbone of the polymer and adhesive peptide sequences grafted to the network. Hydrogels have been developed that degrade as cells secrete proteolytic enzymes. Adhesive peptide sequences grafted to the hydrogel provide ligands that can interact with receptors on the cell surface to mediate adhesion and spreading. In this study, we have characterized the effects of adhesive ligand density on fibroblast migration through collagenase-degradable and plasmin-degradable hydrogels and on smooth muscle cell migration through elastase-degradable hydrogels. In all three cases, we found that cell migration has a biphasic dependence on adhesion ligand concentration, with optimal migration at intermediate ligand levels. Furthermore, both adhesive and proteolytically degradable sequences were required for cell migration to occur. These synthetic ECM analogues may be useful for 3-D mechanistic studies of many aspects of cell migration.	Rice Univ, Dept Bioengn, Houston, TX 77005 USA	Rice University	West, JL (corresponding author), Rice Univ, Dept Bioengn, 6100 Main St,MS 142, Houston, TX 77005 USA.	jwest@rice.edu	West, Jennifer L/A-4582-2008	West, Jennifer L/0000-0001-8550-2875				Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Burgess BT, 2000, ANN BIOMED ENG, V28, P110, DOI 10.1114/1.259; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; Elbert DL, 2001, BIOMACROMOLECULES, V2, P430, DOI 10.1021/bm0056299; Friedl P, 1998, MICROSC RES TECHNIQ, V43, P369, DOI 10.1002/(SICI)1097-0029(19981201)43:5<369::AID-JEMT3>3.0.CO;2-6; Friedl P, 2000, CELL MOL LIFE SCI, V57, P41, DOI 10.1007/s000180050498; Heino J, 1996, INT J CANCER, V65, P717, DOI 10.1002/(SICI)1097-0215(19960315)65:6<717::AID-IJC1>3.3.CO;2-P; Hern DL, 1998, J BIOMED MATER RES, V39, P266, DOI 10.1002/(SICI)1097-4636(199802)39:2<266::AID-JBM14>3.0.CO;2-B; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Kuntz RM, 1997, BIOPHYS J, V72, P1472, DOI 10.1016/S0006-3495(97)78793-9; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Mann BK, 2001, BIOMATERIALS, V22, P3045, DOI 10.1016/S0142-9612(01)00051-5; Mann BK, 2002, J BIOMED MATER RES, V60, P86, DOI 10.1002/jbm.10042; Mann BK, 2001, BIOMATERIALS, V22, P439, DOI 10.1016/S0142-9612(00)00196-4; MASSIA SP, 1990, ANAL BIOCHEM, V187, P292, DOI 10.1016/0003-2697(90)90459-M; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; Olbrich KC, 1996, BIOMATERIALS, V17, P759, DOI 10.1016/0142-9612(96)81412-8; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Price JT, 1999, METH MOL B, V129, P231; Schense JC, 2000, NAT BIOTECHNOL, V18, P415, DOI 10.1038/74473; SCOTTBURDEN T, 1989, HYPERTENSION, V13, P295, DOI 10.1161/01.HYP.13.4.295; Sperinde JJ, 1997, MACROMOLECULES, V30, P5255, DOI 10.1021/ma970345a; Tan J, 1999, J BIOMED MATER RES, V46, P465, DOI 10.1002/(SICI)1097-4636(19990915)46:4<465::AID-JBM4>3.0.CO;2-N; West JL, 1999, MACROMOLECULES, V32, P241, DOI 10.1021/ma981296k	25	189	195	0	45	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					751	+		10.1096/fj.01-0759fje	http://dx.doi.org/10.1096/fj.01-0759fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923220				2022-12-25	WOS:000174755900001
J	She, QB; Ma, WY; Dong, ZG				She, QB; Ma, WY; Dong, ZG			Role of MAP kinases in UVB-induced phosphorylation of p53 at serine 20	ONCOGENE			English	Article						JNKs; MAPKAPK-2; p53; phosphorylation; UV radiation	ACTIVATED PROTEIN-KINASE; RADIATION-INDUCED APOPTOSIS; N-TERMINAL KINASE; DNA-DAMAGE; AP-1 TRANSACTIVATION; ULTRAVIOLET-RADIATION; GAMMA-RADIATION; JNK ACTIVATION; IN-VITRO; T-CELLS	Phosphorylation of the p53 tumor suppressor protein is one of the key regulatory steps in its activation process. Serine 20 phosphorylation of p53 has been shown to be required for the activation of p53 following UV radiation, but the signaling pathway mediating UV-induced phosphorylation is unknown. Here, we determined the role of MAP kinases in UVB-induced phosphorylation and found that JNKs are directly involved in the phosphorylation of p53 at serine 20. In a mouse JB6 epidermal cell line, dominant negative JNK1 abrogated UVB-induced phosphorylation of p53 at serine 20, whereas dominant negative p38 kinase or its inhibitor, SB202190, partially attenuated the phosphorylation. In contrast, dominant negative ERK2 or the MEK1 inhibitor, PD98059, had no effect on p53 phosphorylation at serine 20. Importantly, UVB-activated or active recombinant JNK1/2, or the p38 kinase downstream target, MAPKAPK-2, but not ERKs or p38 kinase, phosphorylated p53 at serine 20 in vitro. Furthermore, phosphorylation of p53 at serine 20 by UVB-activated JNKs and UVB-induced p53-dependent transcriptional activity were suppressed in Jnk1 or Jnk2 knockout (Jnk1(-/-) or Jnk2(-/-)) cells. Additionally, Jnk1(-/-), Jnk2(-/-), and p53-deficient (p53(-/-)) cells, as well as re-introduction of a p53 mutant with substitution of serine 20 to alanine into p53(-/-) cells, were defective for UVB-induced apoptosis. These findings strongly suggest that JNKs are the major direct signaling mediators of UVB-induced p53 phosphorylation at serine 20.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu		She, Qing-Bai/0000-0002-7207-0599	NCI NIH HHS [CA 77646] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077646] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FRITSCHE M, 1993, ONCOGENE, V8, P307; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, P NATL ACAD SCI USA, V94, P11957, DOI 10.1073/pnas.94.22.11957; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1991, CANCER RES, V51, P4279; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOO D, 1994, CELL BIOL LAB HDB, P45; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MERRITT AJ, 1994, CANCER RES, V54, P614; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nomura M, 2001, J BIOL CHEM, V276, P25558, DOI 10.1074/jbc.M101164200; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Prives C, 1999, J PATHOL, V187, P112; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SOUSSI T, 1990, ONCOGENE, V5, P945; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Zhang YG, 2001, J BIOL CHEM, V276, P14572, DOI 10.1074/jbc.M004615200	58	55	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1580	1589		10.1038/sj.onc.1205239	http://dx.doi.org/10.1038/sj.onc.1205239			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896587	Bronze			2022-12-25	WOS:000173956800014
J	Laussmann, T; Janosi, RA; Fingas, CD; Schlieper, GR; Schlack, W; Schrader, J; Decking, UKM				Laussmann, T; Janosi, RA; Fingas, CD; Schlieper, GR; Schlack, W; Schrader, J; Decking, UKM			Myocardial proteome analysis reveals reduced NOS inhibition and enhanced glycolytic capacity in areas of low local blood flow	FASEB JOURNAL			English	Article						myocardial blood flow; heterogeneity; energy metabolism; nitric oxide; proteome; protein expression; heart	SPATIAL HETEROGENEITY; NITRIC-OXIDE; DOG HEART; CORONARY RESERVE; ENZYME-ACTIVITY; LEFT-VENTRICLE; GLUCOSE-UPTAKE; AWAKE DOGS; MICROSPHERES; PERFUSION	In the heart, in situ local myocardial blood flow (MBF) varies greater than 10-fold between individual areas and displays a spatially heterogeneous pattern. To analyze its molecular basis, we analyzed protein expression of low and high flow samples (300 mg, <50% or >150% of mean MBF, each n=30) of six beagle dogs by 2-D polyacrylamide gel electrophoresis (380+/-78 spots/gel). In low flow samples, dimethylarginine dimethylaminohydrolase (DDAH1) was increased greatly (+377%, compared with high flow samples). This increase resulted in a 75% reduction of asymmetric dimethylarginine (ADMA), the potent endogenous inhibitor of NO synthase, whereas eNOS showed no difference. Low flow samples exhibited enhanced expression of GAPDH (+89%) and phosphoglycerate kinase (+100%), whereas hydroxyacyl-CoA dehydrogenase, electron transfer flavoprotein, myoglobin, and desmin were decreased. Assessing local MBF on different days within 2 weeks revealed a high degree of MBF stability (r(2) > 0.79). Thus, stable differences in local MBF are associated with significant differences in local gene and protein expression. In low flow areas, the increased DDAH1 reduces ADMA concentration and NOS inhibition, which strongly suggests enhanced NO formation. Low flow areas are also characterized by a higher glycolytic and a lower fatty acid oxidation capacity. Both the shift in substrate utilization and the rise in NO may contribute to the known lower oxygen consumption in these areas.	Univ Dusseldorf, Dept Physiol, D-40001 Dusseldorf, Germany; Univ Dusseldorf, Dept Anesthesiol, D-40001 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Decking, UKM (corresponding author), Univ Dusseldorf, Dept Physiol, POB 10 10 07, D-40001 Dusseldorf, Germany.	decking@uni-duesseldorf.de	Janosi, Rolf Alexander/J-7810-2019	Janosi, Rolf Alexander/0000-0002-9966-6886; Laussmann, Tim/0000-0002-0180-3513				AUSTIN RE, 1990, CIRC RES, V67, P319, DOI 10.1161/01.RES.67.2.319; Balaban RS, 2001, CIRC RES, V88, P265, DOI 10.1161/01.RES.88.3.265; BASSINGTHWAIGHTE JB, 1989, CIRC RES, V65, P578, DOI 10.1161/01.RES.65.3.578; BASSINGTHWAIGHTE JB, 1990, CIRC RES, V66, P1328, DOI 10.1161/01.RES.66.5.1328; Bauer WR, 2001, CIRC RES, V88, P340, DOI 10.1161/01.RES.88.3.340; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BUSSEMAKER J, 1994, J MOL CELL CARDIOL, V26, P1017, DOI 10.1006/jmcc.1994.1122; CALDWELL JH, 1994, AM J PHYSIOL, V267, pH654, DOI 10.1152/ajpheart.1994.267.2.H654; Decking UKM, 2001, PFLUG ARCH EUR J PHY, V441, P663, DOI 10.1007/s004240000464; Deussen A, 1998, BASIC RES CARDIOL, V93, P430, DOI 10.1007/s003950050112; Deussen A, 1997, PFLUG ARCH EUR J PHY, V433, P488, DOI 10.1007/s004240050304; Deussen A, 1996, PFLUG ARCH EUR J PHY, V432, P451, DOI 10.1007/s004240050157; Dunn MJ, 1997, ELECTROPHORESIS, V18, P2795, DOI 10.1002/elps.1150181514; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Ghaleh B, 1996, CIRCULATION, V94, P2210, DOI 10.1161/01.CIR.94.9.2210; GLENNY RW, 1993, J APPL PHYSIOL, V74, P2585, DOI 10.1152/jappl.1993.74.5.2585; Gorg A, 2000, ELECTROPHORESIS, V21, P1037, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V; GRANGER BL, 1979, CELL, V18, P1053, DOI 10.1016/0092-8674(79)90218-6; Griffith OW, 1996, METHOD ENZYMOL, V268, P375; GROENEVELD ABJ, 1993, BASIC RES CARDIOL, V88, P223; Kay L, 1997, BBA-BIOENERGETICS, V1322, P41, DOI 10.1016/S0005-2728(97)00071-6; KING RB, 1989, PFLUG ARCH EUR J PHY, V413, P336, DOI 10.1007/BF00584480; KING RB, 1985, CIRC RES, V57, P285, DOI 10.1161/01.RES.57.2.285; Leiper J, 1999, CARDIOVASC RES, V43, P542, DOI 10.1016/S0008-6363(99)00162-5; Loncar R, 1998, CIRCULATION, V98, P262, DOI 10.1161/01.CIR.98.3.262; MARCUS ML, 1977, AM HEART J, V94, P748, DOI 10.1016/S0002-8703(77)80216-0; MERX MW, 2001, FASEB J; Milner DJ, 2000, J CELL BIOL, V150, P1283, DOI 10.1083/jcb.150.6.1283; Mullenheim J, 2000, ANESTH ANALG, V91, P787; OGAWA T, 1989, J BIOL CHEM, V264, P10205; Pettersson A, 1997, J CHROMATOGR B, V692, P257, DOI 10.1016/S0378-4347(96)00525-7; Ramagli LS, 1999, METH MOL B, V112, P99; Recchia FA, 1998, CIRC RES, V83, P969, DOI 10.1161/01.RES.83.10.969; ROSE CP, 1976, CIRC RES, V39, P541, DOI 10.1161/01.RES.39.4.541; SONNTAG M, 1992, PFLUG ARCH EUR J PHY, V420, P194, DOI 10.1007/BF00374990; Sonntag M, 1996, PFLUG ARCH EUR J PHY, V432, P439, DOI 10.1007/s004240050156; Trochu JN, 2000, CIRC RES, V87, P1108, DOI 10.1161/01.RES.87.12.1108; Van Oosterhout MFM, 1998, AM J PHYSIOL-HEART C, V275, pH110, DOI 10.1152/ajpheart.1998.275.1.H110; YIPINTSOI T, 1973, CIRC RES, V33, P573, DOI 10.1161/01.RES.33.5.573	40	37	38	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					628	+		10.1096/fj.01-0574fje	http://dx.doi.org/10.1096/fj.01-0574fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919176				2022-12-25	WOS:000174203700014
J	Baskakov, IV; Legname, G; Baldwin, MA; Prusiner, SB; Cohen, FE				Baskakov, IV; Legname, G; Baldwin, MA; Prusiner, SB; Cohen, FE			Pathway complexity of prion protein assembly into amyloid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSIBLE MINK ENCEPHALOPATHY; TRANSGENIC MICE; 106 RESIDUES; IN-VITRO; SCRAPIE; CONFORMATIONS; PRP; STABILITY; STRAINS; DISEASE	In vivo under pathological conditions, the normal cellular form of the prion protein, PrPC (residues 23-231), misfolds to the pathogenic isoform PrPSc, a beta-rich aggregated pathogenic multimer. Proteinase K digestion of PrPSc leads to a proteolytically resistant core, PrP 27-30 (residues 90-231), that can form amyloid fibrils. To study the kinetic pathways of amyloid formation in vitro, we used unglycosylated recombinant PrP corresponding to the proteinase K-resistant core of PrPSc and found that it can adopt two non-native abnormal isoforms, a beta-oligomer and an amyloid fibril. Several lines of kinetic data suggest that the beta-oligomer is not on the pathway to amyloid formation. The preferences for forming either a beta-oligomer or amyloid can be dictated by experimental conditions, with acidic pH similar to that seen in endocytic vesicles favoring the beta-oligomer and neutral pH favoring amyloid. Although both abnormal isoforms have high beta-sheet content and bind 1-anilinonaphthalene-8-sulfonate, they are dissimilar structurally. Multiple pathways of misfolding and the formation of distinct beta-sheet-rich abnormal isoforms may explain the difficulties in refolding PrPSc in vitro, the need for a PrPSc template, and the significant variation in disease presentation and neuropathology.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Neurodegenerat Dis, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Cohen, FE (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, Box 0450, San Francisco, CA 94143 USA.		Legname, Giuseppe/C-1723-2012	Legname, Giuseppe/0000-0003-0716-4393				Baskakov IV, 1998, BIOCHEMISTRY-US, V37, P18010, DOI 10.1021/bi981849j; Baskakov IV, 2000, BIOCHEMISTRY-US, V39, P2792, DOI 10.1021/bi9923353; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Kayed R, 1999, J MOL BIOL, V287, P781, DOI 10.1006/jmbi.1999.2646; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Konno T, 1999, FEBS LETT, V454, P122, DOI 10.1016/S0014-5793(99)00789-9; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Litvinovich SV, 1998, J MOL BIOL, V280, P245, DOI 10.1006/jmbi.1998.1863; Lu BY, 2001, EUR J BIOCHEM, V268, P3767, DOI 10.1046/j.1432-1327.2001.02283.x; Lu BY, 2001, BIOCHEMISTRY-US, V40, P13390, DOI 10.1021/bi011111t; Maiti NR, 2001, J BIOL CHEM, V276, P2427, DOI 10.1074/jbc.M007862200; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; Morillas M, 2001, BIOCHEMISTRY-US, V40, P6982, DOI 10.1021/bi010232q; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; Peretz D, 2001, PROTEIN SCI, V10, P854, DOI 10.1110/ps.39201; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Rochet JC, 2000, BIOCHEMISTRY-US, V39, P10619, DOI 10.1021/bi001315u; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; SAFAR J, 1994, BIOCHEMISTRY-US, V33, P8375, DOI 10.1021/bi00193a027; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Scott MR, 1997, J VIROL, V71, P9032, DOI 10.1128/JVI.71.12.9032-9044.1997; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Somerville RA, 1999, J GEN VIROL, V80, P1865, DOI 10.1099/0022-1317-80-7-1865; Supattapone S, 1999, CELL, V96, P869, DOI 10.1016/S0092-8674(00)80596-6; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; Wille H, 1996, J MOL BIOL, V259, P608, DOI 10.1006/jmbi.1996.0343	46	367	376	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21140	21148		10.1074/jbc.M111402200	http://dx.doi.org/10.1074/jbc.M111402200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11912192	hybrid			2022-12-25	WOS:000176286000006
J	Huang, CF; Handlogten, ME; Miller, RT				Huang, CF; Handlogten, ME; Miller, RT			Parallel activation of phosphatidylinositol 4-kinase and phospholipase C by the extracellular calcium-sensing receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; CA2+-SENSING RECEPTOR; POTASSIUM CHANNELS; RAT-KIDNEY; KINASE; IDENTIFICATION; PROTEIN; PHOSPHOINOSITIDES; DIFFERENTIATION; EXPRESSION	The calcium-sensing receptor (Call) is a G protein-coupled receptor that regulates physiological processes including Ca2+ metabolism, Na+, Cl-, K+, and H2O balance, and the growth of some epithelial cells through diverse signaling pathways. Although many effects of CaR are mediated by the heterotrimeric G proteins Galpha(q) and Galpha(i), not all signaling pathways regulated by CaR have been identified. We used human embryonic kidney (HEK)-293 cells that stably express human CaR to study the regulation of inositol lipid metabolism by CaR. The nonfunctional mutant CaRR796W was used as a negative control. We found that CaR regulates phosphatidylinositol (PI) 4-kinase, the first step in inositol lipid biosynthesis. In cells pretreated with U73122 to inhibit phospholipase C activation and to block the degradation of PI 4,5-bisphosphate to form [H-3]inositol trisphosphate (IP3), CaR stimulated the accumulation of [3H]PI monophosphate (PIP). Additionally, wortmannin, an inhibitor of both PI 3-kinase and type III PI 4-kinase, blocked Call-stimulated accumulation of [H-3]PIP and inhibited [H-3]IP3 production. CaR-stimulated inositol lipid synthesis was attributable to PI 4-kinase and not PI 3-kinase because CaR did not activate Akt, a downstream target of PI 3-kinase. CaR associates with PI 4-kinase based on the findings that CaR and the 110-kDa PI 4-kinase 13 can be co-immunoprecipitated with antibodies against either CaR or PI 4-kinase. The PI-4 kinase in co-immunoprecipitates with anti-Call antibody was activated in Ca2+-stimulated HEK-293 cells, which stably express the wild type CaR. Pertussis toxin did not affect the formation of [H-3]IP3 or the rise in intracellular Ca2+ (Handlogten, M. E., Huang, C. F., Shiraishi, N., Awata, H., and Miller, R. T. (2001) J. Biol. Chem. 276, 1394113948). RGS4, an accelerator of GTPase activity of members of the Gai and Gaq families, attenuated the CaR-stimulated PLC activation and IP3 accumulation, which is mediated by Gaq, but did not inhibit CaR-stimulated [H-3]PIP formation. In HEK-293 cells, which express wild type Call, Rho was enriched in immune complexes co-immunoprecipitated with the anti-Call antibody. C-3 toxin, an inhibitor of Rho, also inhibited the CaR-stimulated [H-3]IP3 production but did not lead to CaR-stimulated [H-3]PIP formation, reflecting inhibition of PI 4-kinase. Taken together, our data demonstrate that CaR stimulates PI 4-kinase, the first step in inositol lipid biosynthesis conversion of PI to PI 4-P by Rho-dependent and Galpha(q)- and Galpha(i)-independent pathways.	Case Western Reserve Univ, Louis Stokes Vet Affairs Med Ctr, Dept Med, Div Nephrol, Cleveland, OH 44106 USA; Univ Florida, Coll Med, Dept Med, Gainesville, FL 32106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; State University System of Florida; University of Florida	Huang, CF (corresponding author), Case Western Reserve Univ, Louis Stokes Vet Affairs Med Ctr, Dept Med, Div Nephrol, 10701 E Blvd,151W, Cleveland, OH 44106 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041726, R29DK041726] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-41726] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; BROWN EM, 1995, CELL, V83, P679, DOI 10.1016/0092-8674(95)90180-9; Bruce JIE, 1999, J BIOL CHEM, V274, P20561, DOI 10.1074/jbc.274.29.20561; BURAS RR, 1995, CELL PROLIFERAT, V28, P245, DOI 10.1111/j.1365-2184.1995.tb00067.x; Chattopadhyay N, 1997, DEV BRAIN RES, V100, P13, DOI 10.1016/S0165-3806(97)00009-6; Chattopadhyay N, 1998, AM J PHYSIOL-GASTR L, V274, pG122, DOI 10.1152/ajpgi.1998.274.1.G122; Cheng I, 1998, J CLIN ENDOCR METAB, V83, P703, DOI 10.1210/jc.83.2.703; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Ferreira MCD, 1998, J BIOL CHEM, V273, P15192, DOI 10.1074/jbc.273.24.15192; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gasman S, 1998, J BIOL CHEM, V273, P16913, DOI 10.1074/jbc.273.27.16913; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Godwin SL, 1997, J BIOL CHEM, V272, P11307; Handlogten ME, 2001, J BIOL CHEM, V276, P13941, DOI 10.1074/jbc.M007306200; Handlogten ME, 2000, AM J PHYSIOL-RENAL, V279, pF1083, DOI 10.1152/ajprenal.2000.279.6.F1083; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Hofer AM, 2000, NAT CELL BIOL, V2, P392, DOI 10.1038/35017020; HUANG CF, 1992, J BIOL CHEM, V267, P16859; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KAUFFMANNZEH A, 1994, J BIOL CHEM, V269, P31243; Kifor O, 1997, J BONE MINER RES, V12, P715, DOI 10.1359/jbmr.1997.12.5.715; Kifor O, 2001, AM J PHYSIOL-RENAL, V280, pF291, DOI 10.1152/ajprenal.2001.280.2.F291; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li M, 2000, MOL PHARMACOL, V57, P446, DOI 10.1124/mol.57.3.446; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Lin KI, 1998, BIOCHEM BIOPH RES CO, V249, P325, DOI 10.1006/bbrc.1998.9124; Mayer A, 2000, MOL BIOL CELL, V11, P807, DOI 10.1091/mbc.11.3.807; McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114; Mejillano M, 2001, J BIOL CHEM, V276, P1865, DOI 10.1074/jbc.M007271200; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Oda Y, 1998, J BIOL CHEM, V273, P23344, DOI 10.1074/jbc.273.36.23344; Osborne SL, 2001, NEURON, V32, P9, DOI 10.1016/S0896-6273(01)00455-X; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; Rosado JA, 2000, J BIOL CHEM, V275, P9110, DOI 10.1074/jbc.275.13.9110; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Sorensen SD, 1998, MOL PHARMACOL, V53, P827; TANG W, 1988, J INVEST DERMATOL, V90, P37, DOI 10.1111/1523-1747.ep12462536; Wang WH, 1996, AM J PHYSIOL-CELL PH, V271, pC103, DOI 10.1152/ajpcell.1996.271.1.C103; Weernink PAO, 2000, EUR J BIOCHEM, V267, P5237, DOI 10.1046/j.1432-1327.2000.01599.x; Weernink PAO, 2000, J BIOL CHEM, V275, P10168, DOI 10.1074/jbc.275.14.10168; Weisz OA, 2000, J BIOL CHEM, V275, P24341, DOI 10.1074/jbc.M000671200; Yang TX, 1997, AM J PHYSIOL-RENAL, V272, pF751, DOI 10.1152/ajprenal.1997.272.6.F751; Zhao XH, 2000, J BIOL CHEM, V275, P14642, DOI 10.1074/jbc.275.19.14642; Zubenko GS, 1999, BIOL PSYCHIAT, V45, P731, DOI 10.1016/S0006-3223(98)00073-0	55	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20293	20300		10.1074/jbc.M200831200	http://dx.doi.org/10.1074/jbc.M200831200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11907035	hybrid			2022-12-25	WOS:000176204500027
J	Kimura, T; Tabuchi, Y; Takeguchi, N; Asano, S				Kimura, T; Tabuchi, Y; Takeguchi, N; Asano, S			Mutational study on the roles of disulfide bonds in the beta-subunit of gastric H+,K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; FUNCTIONAL EXPRESSION; ALPHA-SUBUNIT; CDNA CLONING; BINDING-SITES; PROTON PUMP; H,K-ATPASE; ATPASE; IDENTIFICATION; NA,K-ATPASE	The gastric proton pump, H+,K+-1ATPase, consists of the catalytic a-subunit and the non-catalytic beta-subunit. Correct assembly between the alpha- and beta-subunits is essential for the functional expression of H+,K+-ATPase. The beta-subunit contains nine conserved cysteine residues; two are in the cytoplasmic domain, one in the transmembrane domain, and six in the ectodomain. The six cysteine residues in the ectodomain form three disulfide bonds. In this study, we replaced each of the cysteine residues of the beta-subunit with serine individually and in several combinations. The mutant beta-subunits were co-expressed with the alpha-subunit in human embryonic kidney 293 cells, and the role of each cysteine residue or disulfide bond in the alpha/beta assembly, stability, and cell surface delivery of the alpha- and beta-subunits and H+K+-ATPase activity was studied. Mutant beta-subunits with a replacement of the cytoplasmic and transmembrane cysteines preserved H+,K+-ATPase activity. All the mutant beta-subunits with replacement(s) of the extracellular cysteines did not assemble with the a-subunit, resulting in loss of H+,K+-ATPase activity. These mutants did not permit delivery of the alpha-subunit to the cell surface. Therefore, each of these disulfide bonds of the beta-subunit is essential for assembly with the a-subunit and expression of H+,K+-ATPase activity as well as for cell surface delivery of the alpha-subunit.	Toyama Med & Pharmaceut Univ, Mol Genet Res Ctr, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Toyama 9300194, Japan	University of Toyama; University of Toyama	Asano, S (corresponding author), Toyama Med & Pharmaceut Univ, Mol Genet Res Ctr, 2630 Sugitani, Toyama 9300194, Japan.			Tabuchi, Yoshiaki/0000-0002-6007-6176; Asano, Shinji/0000-0003-1443-8970				Asano S, 2000, J BIOCHEM, V127, P993, DOI 10.1093/oxfordjournals.jbchem.a022716; ASANO S, 1994, BIOCHEM J, V299, P59, DOI 10.1042/bj2990059; Asano S, 2000, J BIOL CHEM, V275, P8324, DOI 10.1074/jbc.275.12.8324; Asano S, 1999, J BIOL CHEM, V274, P22257, DOI 10.1074/jbc.274.32.22257; Asano S, 1997, J BIOL CHEM, V272, P17668, DOI 10.1074/jbc.272.28.17668; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; ASANO S, 1989, J BIOCHEM-TOKYO, V106, P1074, DOI 10.1093/oxfordjournals.jbchem.a122967; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; Beggah AT, 1997, J BIOL CHEM, V272, P10318; Besancon M, 1997, J BIOL CHEM, V272, P22438, DOI 10.1074/jbc.272.36.22438; Bonifacino JS, 1996, NATURE, V384, P405, DOI 10.1038/384405a0; CANFIELD VA, 1990, J BIOL CHEM, V265, P19878; CHOW DC, 1992, AM J PHYSIOL, V263, pC39, DOI 10.1152/ajpcell.1992.263.1.C39; FARLEY RA, 1985, J BIOL CHEM, V260, P3899; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; Hermsen HPH, 2000, BIOCHEMISTRY-US, V39, P1330, DOI 10.1021/bi991396y; Hermsen HPH, 1998, BIOCHEM J, V331, P465, DOI 10.1042/bj3310465; KAWAMURA M, 1984, BIOCHIM BIOPHYS ACTA, V774, P188, DOI 10.1016/0005-2736(84)90290-6; KIRLEY TL, 1990, J BIOL CHEM, V265, P4227; KLAASSEN CHW, 1993, FEBS LETT, V329, P277, DOI 10.1016/0014-5793(93)80237-O; Kowalski JM, 1998, BIOCHEMISTRY-US, V37, P1264, DOI 10.1021/bi9722397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambrecht N, 1998, J BIOL CHEM, V273, P13719, DOI 10.1074/jbc.273.22.13719; Lambrecht N, 2000, J BIOL CHEM, V275, P4041, DOI 10.1074/jbc.275.6.4041; MA JY, 1991, BIOCHEM BIOPH RES CO, V180, P39; MATHEWS PM, 1995, AM J PHYSIOL-CELL PH, V268, pC1207, DOI 10.1152/ajpcell.1995.268.5.C1207; MORII M, 1995, BIOCHEM PHARMACOL, V49, P1729, DOI 10.1016/0006-2952(95)00090-M; Morii M, 1996, J BIOL CHEM, V271, P4068; NOGUCHI S, 1994, FEBS LETT, V341, P233, DOI 10.1016/0014-5793(94)80463-X; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; SEGAL MS, 1992, J CELL BIOL, V118, P227, DOI 10.1083/jcb.118.2.227; SHULL GE, 1990, J BIOL CHEM, V265, P12123; SHULL GE, 1986, J BIOL CHEM, V261, P6788; Sone M, 1997, J BIOL CHEM, V272, P6174, DOI 10.1074/jbc.272.10.6174; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; TOH BH, 1990, P NATL ACAD SCI USA, V87, P6418, DOI 10.1073/pnas.87.16.6418; Tyagarajan K, 1997, BIOCHEMISTRY-US, V36, P10200, DOI 10.1021/bi9706125; TYAGARAJAN K, 1995, BBA-BIOMEMBRANES, V1236, P105, DOI 10.1016/0005-2736(95)00044-4; WALDERHAUG MO, 1985, J BIOL CHEM, V260, P3852	40	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20671	20677		10.1074/jbc.M200523200	http://dx.doi.org/10.1074/jbc.M200523200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11909858	hybrid			2022-12-25	WOS:000176204500074
J	Allen-Jennings, AE; Hartman, MG; Kociba, GJ; Hai, TW				Allen-Jennings, AE; Hartman, MG; Kociba, GJ; Hai, TW			The roles of ATF3 in liver dysfunction and the regulation of phosphoenolpyruvate carboxykinase gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING TRANSCRIPTION FACTOR-3; TRANSGENIC MICE; MOLECULAR-BIOLOGY; CHOROID-PLEXUS; C/EBP-ALPHA; IDENTIFICATION; HEPATOCYTE; PROTEIN; REGENERATION; HOMEOSTASIS	Activating transcription factor 3 (ATF3), a member of the ATF/cAMP-responsive element-binding protein family of transcription factors, is a transcriptional repressor, and the expression of its corresponding gene, ATF3, is induced by many stress signals. In this report, we demonstrate that transgenic mice expressing ATF3 in the liver had symptoms of liver dysfunction such as high levels of serum bilirubin, alkaline phosphatase, alanine transaminase, aspartate transaminase, and bile acids. In addition, these mice had physiological responses consistent with hypoglycemia including a low insulin:glucagon ratio in the serum and reduced adipose tissue mass. Electrophoretic mobility shift assays indicated that ATF3 bound to the ATF/cAMP-responsvie element site derived from the promoter of the gene encoding the gluconeogenic enzyme phosphoenolpyruvate carboxykinase (PEPCK). Furthermore, transient transfection assays indicated that ATF3 repressed the activity of the PEPCK promoter. Taken together, our results are consistent with the model that the expression of ATF3 in the liver results in defects in glucose homeostasis by repressing gluconeogenesis. Because ATF3 is a stress-inducible gene, these mice may provide a model to investigate the molecular mechanisms of some stress-associated liver diseases.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA; Ohio State Univ, Mol Cellular & Dev Biol Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Hai, TW (corresponding author), Rm 148 Rightmire Hall 1060 Carmack Rd, Columbus, OH 43210 USA.	hai.2@osu.edu	Hai, Tsonwin/H-4480-2011; Hai, Tsonwin/E-3185-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064938] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK064938] Funding Source: Medline; PHS HHS [08690] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allen-Jennings AE, 2001, J BIOL CHEM, V276, P29507, DOI 10.1074/jbc.M100986200; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BALLARD FJ, 1967, BIOCHEM J, V104, P866, DOI 10.1042/bj1040866; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; Croniger CM, 2001, J BIOL CHEM, V276, P629, DOI 10.1074/jbc.M007576200; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; Drysdale BE, 1996, MOL IMMUNOL, V33, P989, DOI 10.1016/S0161-5890(96)00043-0; FARBER JM, 1992, MOL CELL BIOL, V12, P1535, DOI 10.1128/MCB.12.4.1535; Fausto N., 1994, LIVER BIOL PATHOBIOL; GIRARD J, 1992, PHYSIOL REV, V72, P507, DOI 10.1152/physrev.1992.72.2.507; GIRARD JR, 1973, J CLIN INVEST, V52, P3190, DOI 10.1172/JCI107519; GRANNER D, 1991, RECENT PROG HORM RES, V47, P319; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; Ishiguro T, 1996, CANCER RES, V56, P875; JACOBSSON B, 1989, J HISTOCHEM CYTOCHEM, V37, P31, DOI 10.1177/37.1.2642294; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; MCGRANE MM, 1992, TRENDS BIOCHEM SCI, V17, P40, DOI 10.1016/0968-0004(92)90426-A; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; Nizielski SE, 1996, J NUTR, V126, P2697; Okamoto Y, 2001, AM J PATHOL, V159, P639, DOI 10.1016/S0002-9440(10)61735-X; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; SASSONECORSI P, 1994, EMBO J, V13, P4717, DOI 10.1002/j.1460-2075.1994.tb06797.x; She P, 2000, MOL CELL BIOL, V20, P6508, DOI 10.1128/MCB.20.17.6508-6517.2000; SHORT JM, 1986, J BIOL CHEM, V261, P9721; STRYER L, 1995, BIOCHEMISTRY-US, P569; Sutherland C, 1997, DIABETES, V46, P17, DOI 10.2337/diabetes.46.1.17; Tsujino H, 2000, MOL CELL NEUROSCI, V15, P170, DOI 10.1006/mcne.1999.0814; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WEIR E, 1994, HEPATOLOGY, V20, P955, DOI 10.1002/hep.1840200426; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; Ye HG, 1999, MOL CELL BIOL, V19, P8570	41	56	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					20020	20025		10.1074/jbc.M200727200	http://dx.doi.org/10.1074/jbc.M200727200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11916968	hybrid			2022-12-25	WOS:000175894800102
J	Fiermonte, G; Palmieri, L; Todisco, S; Agrimi, G; Palmieri, F; Walker, JE				Fiermonte, G; Palmieri, L; Todisco, S; Agrimi, G; Palmieri, F; Walker, JE			Identification of the mitochondrial glutamate transporter - Bacterial expression, reconstitution, functional characterization, and tissue distribution of two human isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; BOVINE MITOCHONDRIA; CARRIER PROTEINS; YEAST; GENES; CDNA; SEQUENCE; SUBUNIT; TRANSLOCASE; CLONING	The mitochondrial carriers are a family of transport proteins in the inner membranes of mitochondria. They shuttle substrates, metabolites, and cofactors through this membrane and connect cytoplasm functions with others in the matrix. Glutamate is co-transported with H+ (or exchanged for OH-), but no protein has ever been associated with this activity. Two human expressed sequence tags encode proteins of 323 and 315 amino acids with 63% identity that are related to the aspartate-glutamate carrier, a member of the carrier family. They have been overexpressed in Escherichia coli and reconstituted into phospholipid vesicles. Their transport properties demonstrate that the two proteins are isoforms of the glutamate/H+ symporter described in the past in whole mitochondria. Isoform 1 is expressed at higher levels than isoform 2 in all the tissues except in brain, where the two isoforms are expressed at comparable levels. The differences in expression levels and kinetic parameters of the two isoforms suggest that isoform 2 matches the basic requirement of all tissues especially with respect to amino acid degradation, and isoform 1 becomes operative to accommodate higher demands associated with specific metabolic functions such as ureogenesis.	Univ Bari, Dept Pharmaco Biol, Biochem & Mol Biol Lab, I-70125 Bari, Italy; MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	Universita degli Studi di Bari Aldo Moro; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Palmieri, F (corresponding author), Univ Bari, Dept Pharmaco Biol, Biochem & Mol Biol Lab, Via E Orabona 4, I-70125 Bari, Italy.		Todisco, Simona/AAU-2091-2021; Agrimi, Gennaro/D-4001-2018; agrimi, gennaro/C-6020-2009; Fiermonte, Giuseppe/D-3680-2018	Agrimi, Gennaro/0000-0002-5219-4412; Fiermonte, Giuseppe/0000-0002-6764-9395; Walker, John/0000-0001-7929-2162				AZZI A, 1967, BIOCHEM BIOPH RES CO, V29, P148, DOI 10.1016/0006-291X(67)90556-6; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BRADFORD NM, 1973, BIOCHEM J, V134, P1023, DOI 10.1042/bj1341023; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998; Fiermonte G, 1998, J BIOL CHEM, V273, P22782, DOI 10.1074/jbc.273.35.22782; Fiermonte G, 2001, J BIOL CHEM, V276, P8225, DOI 10.1074/jbc.M009607200; Fiermonte G, 1998, J BIOL CHEM, V273, P24754, DOI 10.1074/jbc.273.38.24754; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; GAY NJ, 1985, EMBO J, V4, P3519, DOI 10.1002/j.1460-2075.1985.tb04111.x; HOEK JB, 1983, J BIOL CHEM, V258, P54; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; Indiveri C, 1997, BIOCHEM J, V321, P713, DOI 10.1042/bj3210713; KING MJ, 1972, ARCH BIOCHEM BIOPHYS, V152, P670, DOI 10.1016/0003-9861(72)90263-9; Krumer R., 1992, MOL MECHANISMS BIOEN, P359, DOI DOI 10.1016/50167-7306(08)60184-2; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; LANOUE KF, 1984, BIOENERGETICS, P221; LONG C, 1961, BIOCH HDB, P682; MATSUDA C, 1993, J BIOL CHEM, V268, P24950; MCGIVAN JD, 1992, MAMMALIAN AMINO ACID TRANSPORT, P101; MCGIVAN JD, 1973, BIOCHEM J, V134, P209, DOI 10.1042/bj1340209; MEIJER AJ, 1972, BIOCHIM BIOPHYS ACTA, V283, P421, DOI 10.1016/0005-2728(72)90259-9; MEIJER AJ, 1981, MITOCHONDRIA MUSCULA, P97; MEYER J, 1973, BIOCHIM BIOPHYS ACTA, V325, P375, DOI 10.1016/0005-2728(73)90198-9; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Palmieri Ferdinando, 1999, P489; Palmieri L, 1999, J BIOL CHEM, V274, P22184, DOI 10.1074/jbc.274.32.22184; Palmieri L, 1997, FEBS LETT, V417, P114, DOI 10.1016/S0014-5793(97)01269-6; Palmieri L, 1996, FEBS LETT, V399, P299, DOI 10.1016/S0014-5793(96)01350-6; Palmieri L, 1997, FEBS LETT, V410, P447, DOI 10.1016/S0014-5793(97)00630-3; Palmieri L, 2001, EMBO J, V20, P5049, DOI 10.1093/emboj/20.18.5049; Palmieri L, 2001, J BIOL CHEM, V276, P1916, DOI 10.1074/jbc.M004332200; Palmieri L, 2001, EMBO J, V20, P5060, DOI 10.1093/emboj/20.18.5060; POWELL SJ, 1989, BIOCHEMISTRY-US, V28, P866, DOI 10.1021/bi00428a069; SCHLERF A, 1988, EMBO J, V7, P2387, DOI 10.1002/j.1460-2075.1988.tb03083.x; SCHOOLWERTH AC, 1983, J BIOL CHEM, V258, P1735; SEELAN RS, 1991, J BIOL CHEM, V266, P19752; TARVER H, 1963, LIVER, V1, P474; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H	41	156	162	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19289	19294		10.1074/jbc.M201572200	http://dx.doi.org/10.1074/jbc.M201572200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11897791	hybrid			2022-12-25	WOS:000175894800008
J	Gilboa, R; Zharkov, DO; Golan, G; Fernandes, AS; Gerchman, SE; Matz, E; Kycia, JH; Grollman, AP; Shoham, G				Gilboa, R; Zharkov, DO; Golan, G; Fernandes, AS; Gerchman, SE; Matz, E; Kycia, JH; Grollman, AP; Shoham, G			Structure of formamidopyrimidine-DNA glycosylase covalently complexed to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; OXIDATIVELY DAMAGED DNA; ALDEHYDIC ABASIC SITES; COLI FPG PROTEIN; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURE; BETA-ELIMINATION; MOLECULAR-REPLACEMENT; ENDONUCLEASE-VIII	Formamidopyrimidine-DNA glycosylase (Fpg) is a DNA repair enzyme that excises oxidized purines from damaged DNA. The Schiff base intermediate formed during this reaction between Escherichia coli Fpg and DNA was trapped by reduction with sodium borohydride, and the structure of the resulting covalently cross-linked complex was determined at a 2.1-Angstrom resolution. Fpg is a bilobal protein with a wide, positively charged DNA-binding groove. It possesses a conserved zinc finger and a helix-two turn-helix motif that participate in DNA binding. The absolutely conserved residues Lys-56, His-70, Asn-168, and Arg-258 form hydrogen bonds to the phosphodiester backbone of DNA, which is sharply kinked at the lesion site. Residues Met-73, Arg-109, and Phe-110 are inserted into the DNA helix, filling the void created by nucleotide eversion. A deep hydrophobic pocket in the active site is positioned to accommodate an everted base. Structural analysis of the Fpg-DNA complex reveals essential features of damage recognition and the catalytic mechanism of Fpg.	SUNY Stony Brook, Dept Pharmacol Sci, Biol Chem Lab, Stony Brook, NY 11794 USA; Hebrew Univ Jerusalem, Dept Inorgan Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Lab Struct Chem & Biol, IL-91904 Jerusalem, Israel; Russian Acad Sci, Siberian Div, Novosibirsk Inst Bioorgan Chem, Novosibirsk 630090, Russia; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences; United States Department of Energy (DOE); Brookhaven National Laboratory	Grollman, AP (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Biol Chem Lab, Stony Brook, NY 11794 USA.		Zharkov, Dmitry/K-2158-2012	Zharkov, Dmitry/0000-0001-5013-0194	NATIONAL CANCER INSTITUTE [R01CA017395, P01CA047995, R37CA017395] Funding Source: NIH RePORTER; NCI NIH HHS [CA47995, CA17395] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Bhagwat M, 1996, BIOCHEMISTRY-US, V35, P659, DOI 10.1021/bi9522662; BODEPUDI V, 1992, CHEM RES TOXICOL, V5, P608, DOI 10.1021/tx00029a004; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Burrows CJ, 1998, CHEM REV, V98, P1109, DOI 10.1021/cr960421s; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GERCHMAN SE, 1994, PROTEIN EXPRES PURIF, V5, P242, DOI 10.1006/prep.1994.1037; Hollis T, 2000, EMBO J, V19, P758, DOI 10.1093/emboj/19.4.758; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; Jiang DY, 1997, J BIOL CHEM, V272, P32230, DOI 10.1074/jbc.272.51.32230; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; KRAULIS P, 1991, J APPL CRYSTALLOGR, V4, P946; Kuznetsov SV, 1998, EUR J BIOCHEM, V253, P413, DOI 10.1046/j.1432-1327.1998.2530413.x; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Lavrukhin OV, 2000, BIOCHEMISTRY-US, V39, P15266, DOI 10.1021/bi001587x; LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745; LU XJ, 1997, J MOL BIOL, V300, P505; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8029, DOI 10.1021/ja00202a062; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Norman DPG, 2001, J AM CHEM SOC, V123, P359, DOI 10.1021/ja003144m; OCONNOR TR, 1993, J BIOL CHEM, V268, P9063; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Rabow LE, 1997, BIOCHEMISTRY-US, V36, P5084, DOI 10.1021/bi963005a; Rieger RA, 2000, J AM SOC MASS SPECTR, V11, P505, DOI 10.1016/S1044-0305(00)00117-3; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Sidorkina OM, 1998, NUCLEIC ACIDS RES, V26, P5351, DOI 10.1093/nar/26.23.5351; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Sugahara M, 2000, EMBO J, V19, P3857, DOI 10.1093/emboj/19.15.3857; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; TCHOU J, 1994, J BIOL CHEM, V269, P15318; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TCHOU J, 1993, J BIOL CHEM, V268, P26738; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; TONG L, 1993, J APPL CRYSTALLOGR, V26, P748, DOI 10.1107/S0021889893005631; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; van Aalten DMF, 1999, P NATL ACAD SCI USA, V96, P11809, DOI 10.1073/pnas.96.21.11809; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Werner RM, 2000, BIOCHEMISTRY-US, V39, P12585, DOI 10.1021/bi001532v; Zharkov DO, 2000, J BIOL CHEM, V275, P28607, DOI 10.1074/jbc.M002441200; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335; Zharkov DO, 2002, EMBO J, V21, P789, DOI 10.1093/emboj/21.4.789; Zharkov DO, 2002, FREE RADICAL BIO MED, V32, P1254, DOI 10.1016/S0891-5849(02)00828-6	62	210	221	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19811	19816		10.1074/jbc.M202058200	http://dx.doi.org/10.1074/jbc.M202058200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11912217	hybrid			2022-12-25	WOS:000175894800075
J	Mould, AP; Askari, JA; Barton, S; Kline, AD; McEwan, PA; Craig, SE; Humphries, MJ				Mould, AP; Askari, JA; Barton, S; Kline, AD; McEwan, PA; Craig, SE; Humphries, MJ			Integrin activation involves a conformational change in the alpha 1 helix of the beta subunit A-domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SITES; I-DOMAIN; ALPHA-5-BETA-1-FIBRONECTIN INTERACTIONS; INHIBITORY ANTI-ALPHA-5; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; MOLECULAR-BASIS; ALPHA(5)BETA(1); IDENTIFICATION; RECOGNITION	The ligand-binding region of integrin beta subunits contains a von Willebrand factor type A-domain: an alpha/beta "Rossmann" fold containing a metal ion-dependent adhesion site (MIDAS) on its top face. Although there is evidence to suggest that the betaA-domain undergoes changes in tertiary structure during receptor activation, the identity of the secondary structure elements that change position is unknown. The mAb 12G10 recognizes a unique cation-regulated epitope on the beta(1) A-domain, induction of which parallels the activation state of the integrin (i.e. competency for ligand recognition). The ability of Mn2+ and Mg2+ to stimulate 12G10 binding is abrogated by mutation of the MIDAS motif, demonstrating that the MIDAS is a Mn2+/Mg2+ binding site and that occupancy of this site induces conformational changes in the A-domain. The cation-regulated region of the 12G10 epitope maps to Arg(154)/Arg(155) in the alpha1 helix. Our results demonstrate that the al helix undergoes conformational alterations during integrin activation and suggest that Mn2+ acts as a potent activator of beta(1) integrins because it can promote a shift in the position of this helix. The mechanism of beta subunit A-domain activation appears to be distinct from that of the A-domains found in some integrin alpha subunits.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Mould, AP (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.			Humphries, Martin/0000-0002-4331-6967; mcewan, paul/0000-0001-6097-1528; Mould, Paul/0000-0003-0076-6228				BAJT ML, 1992, J BIOL CHEM, V267, P22211; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; Burrows L, 1999, BIOCHEM J, V344, P527, DOI 10.1042/0264-6021:3440527; Chen LL, 2001, J BIOL CHEM, V276, P36520, DOI 10.1074/jbc.M106216200; Coe APF, 2001, J BIOL CHEM, V276, P35854, DOI 10.1074/jbc.M103639200; Curley GP, 1999, CELL MOL LIFE SCI, V56, P427, DOI 10.1007/s000180050443; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; Humphries JD, 2000, J BIOL CHEM, V275, P20337, DOI 10.1074/jbc.M000568200; Humphries MJ, 2001, SCIENCE, V294, P316, DOI 10.1126/science.1066240; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; KLINE AD, 2001, THESIS U MANCHESTER; Lee C, 2001, IBM SYST J, V40, P592, DOI 10.1147/sj.402.0592; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; LEVITT M, 1983, J MOL BIOL, V170, P723, DOI 10.1016/S0022-2836(83)80129-6; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Lu CF, 2001, J BIOL CHEM, V276, P14642, DOI 10.1074/jbc.M100600200; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Mastrangelo AM, 1999, J CELL SCI, V112, P217; Mould AP, 2000, J BIOL CHEM, V275, P20324, DOI 10.1074/jbc.M000572200; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; Mould AP, 1996, J CELL SCI, V109, P2613; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; Sheppard D, 2000, MATRIX BIOL, V19, P203, DOI 10.1016/S0945-053X(00)00065-2; SHI DT, 1997, J CELL SCI, V110, P2619; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2000, J BIOL CHEM, V275, P38762, DOI 10.1074/jbc.C000563200; Xiong YM, 2001, J BIOL CHEM, V276, P19340, DOI 10.1074/jbc.M008903200; Zang Q, 2000, J BIOL CHEM, V275, P22202, DOI 10.1074/jbc.M002883200	45	108	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19800	19805		10.1074/jbc.M201571200	http://dx.doi.org/10.1074/jbc.M201571200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11893752	hybrid			2022-12-25	WOS:000175894800073
J	Szweras, M; Liu, DM; Partridge, EA; Pawling, J; Sukhu, B; Clokie, C; Jahnen-Dechent, W; Tenenbaum, HC; Swallow, CJ; Grynpas, MD; Dennis, JW				Szweras, M; Liu, DM; Partridge, EA; Pawling, J; Sukhu, B; Clokie, C; Jahnen-Dechent, W; Tenenbaum, HC; Swallow, CJ; Grynpas, MD; Dennis, JW			alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOPOROSIS-LIKE PHENOTYPE; FACTOR-BETA; TGF-BETA; TARGETED DISRUPTION; GROWTH-FACTOR-BETA-1 GENE; MATRIX PROTEINS; MICE LACKING; MOUSE; OSTEOGENESIS; TGF-BETA-1	Soluble transforming growth factor-beta (TGF-beta)/bone morphogenetic protein (BMP)-binding proteins are widely distributed in mammalian tissues and control cytokine access to membrane signaling receptors. The serum and bone-resident glycoprotein alpha2-HS-glycoprotein/fetuin (ASHG) binds to TGF-beta/BMP cytokines and blocks TGF-beta1 binding to cell surface receptors. Therefore, we examined bone growth and remodeling phenotypes in ASHG-deficient mice. The skeletal structure of Ahsg(-/-) mice appeared normal at birth, but abnormalities were observed in adult Ahsg(-/-) mice. Maturation of growth plate chondrocytes was impaired, and femurs lengthened more slowly between 3 and 18 months of age in Ahsg(-/-) mice. However, bone formation was increased in Ahsg(-/-) mice as indicated by greater cortical thickness, accelerated trabecular bone remodeling, and increased osteoblast numbers on bone surfaces. The normal age-related increase in cortical thickness and bone mineral density was accelerated in Ahsg(-/-) mice and was associated with increased energy required to fracture. Bone formation in response to implanted BMP cytokine extended further from the implant in Ahsg(-/-) compared with Ahsg(+/+) mice, confirming the interaction between ASHG and TGF-beta/BMP cytokines in vivo. Our results demonstrate that ASHG blocks TGF-beta-dependent signaling in osteoblastic cells, and mice lacking ASHG display growth plate defects, increased bone formation with age, and enhanced cytokine-dependent osteogenesis.	Mt Sinai Hosp, Samuel Lauenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Lab Med & Pathol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Dent, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Klinkum RWTH Aachen, IZKF, BIOMAT, D-52057 Aachen, Germany	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University of Toronto; University of Toronto; RWTH Aachen University; RWTH Aachen University Hospital	Dennis, JW (corresponding author), Mt Sinai Hosp, Samuel Lauenfeld Res Inst, Toronto, ON M5G 1X5, Canada.		Grynpas, Marc/ABG-7096-2020; Grynpas, Marc/E-4576-2013; Dennis, James/E-7268-2013; Jahnen-Dechent, Willi/A-7608-2011	Jahnen-Dechent, Willi/0000-0003-1315-4407				AKHOUNDI C, 1994, J BIOL CHEM, V269, P15925; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; ASHTON BA, 1980, CLIN SCI, V58, P435, DOI 10.1042/cs0580435; Bailon-Plaza A, 1999, BONE, V24, P211, DOI 10.1016/S8756-3282(98)00171-9; BALLOCK RT, 1993, DEV BIOL, V158, P414, DOI 10.1006/dbio.1993.1200; Barkai N, 1998, NATURE, V396, P422, DOI 10.1038/24760; Binkert C, 1999, J BIOL CHEM, V274, P28514, DOI 10.1074/jbc.274.40.28514; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; CENTRELLA M, 1991, J BONE JOINT SURG AM, V73A, P1418, DOI 10.2106/00004623-199173090-00022; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810; Demetriou M, 1996, J BIOL CHEM, V271, P12755, DOI 10.1074/jbc.271.22.12755; DICKSON IR, 1975, NATURE, V256, P430, DOI 10.1038/256430a0; DICKSON IR, 1983, CALCIFIED TISSUE INT, V35, P16, DOI 10.1007/BF02405000; Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903; Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195; Filvaroff E, 1999, DEVELOPMENT, V126, P4267; Gazit D, 1998, J CELL BIOCHEM, V70, P478, DOI 10.1002/(SICI)1097-4644(19980915)70:4<478::AID-JCB5>3.0.CO;2-G; Geiser AG, 1998, BONE, V23, P87, DOI 10.1016/S8756-3282(98)00078-7; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Huiskes R, 2000, NATURE, V405, P704, DOI 10.1038/35015116; JahnenDechent W, 1997, J BIOL CHEM, V272, P31496, DOI 10.1074/jbc.272.50.31496; Ji XH, 2000, J BONE MINER METAB, V18, P132, DOI 10.1007/s007740050103; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; Jones CM, 1998, DEV BIOL, V194, P12, DOI 10.1006/dbio.1997.8752; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KELLERMANN J, 1989, J BIOL CHEM, V264, P14121; LEBRETON JP, 1979, J CLIN INVEST, V64, P118; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; MIZUTANI H, 1982, CLIN ORTHOP RELAT R, P213; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; PARFITT AM, 2000, J BONE MINER RES, V2, P597; Pedersen KO, 1944, NATURE, V154, P575, DOI 10.1038/154575a0; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; Pfeilschifter J, 1998, J BONE MINER RES, V13, P716, DOI 10.1359/jbmr.1998.13.4.716; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; PINERO GJ, 1995, ARCH ORAL BIOL, V40, P145, DOI 10.1016/0003-9969(94)00144-Z; Saito T, 2001, J BIOL CHEM, V276, P11469, DOI 10.1074/jbc.C000859200; Schinke T, 1996, J BIOL CHEM, V271, P20789, DOI 10.1074/jbc.271.34.20789; SCHNEYER AL, 1994, ENDOCRINOLOGY, V135, P667, DOI 10.1210/en.135.2.667; SEBETAN IM, 1988, Z RECHTSMED, V101, P205; SHAH M, 1995, J CELL SCI, V108, P985; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; VILLANUEVA AR, 1988, J HISTOTECHNOL, V11, P249, DOI 10.1179/his.1988.11.4.249; Webb DJ, 1996, J BIOL CHEM, V271, P24982, DOI 10.1074/jbc.271.40.24982; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; Yamada Y, 1998, J BONE MINER RES, V13, P1569, DOI 10.1359/jbmr.1998.13.10.1569; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Zmuda JM, 1998, CALCIFIED TISSUE INT, V63, P5, DOI 10.1007/s002239900481	55	181	186	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19991	19997		10.1074/jbc.M112234200	http://dx.doi.org/10.1074/jbc.M112234200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11901155	hybrid			2022-12-25	WOS:000175894800099
J	Wang, WJ; Russo, SJ; Mulugeta, S; Beers, MF				Wang, WJ; Russo, SJ; Mulugeta, S; Beers, MF			Biosynthesis of surfactant protein C (SP-C) - Sorting of SP-C proprotein involves homomeric association via a signal anchor domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID FIBRIL FORMATION; DISULFIDE-BONDED LOOP; TRANS-GOLGI NETWORK; PULMONARY SURFACTANT; CHROMOGRANIN-B; MEMBRANE-PROTEIN; II CELLS; RAT; EXPRESSION; CONTAINS	Rat surfactant protein C (SP-C) is synthesized as a 194-amino acid propeptide (SP-C-(1-194)) that is directed to the distal secretory pathway and proteolytically processed as an integral membrane protein to yield its mature form. We had shown previously that trafficking of proSP-C is mediated both by a signal anchor domain contained within the mature SP-C sequence and by a targeting domain in the NH2-flanking propeptide. Based on evidence from other integral membrane proteins, we hypothesized that proSP-C targeting is effected by oligomerization of proSP-C monomers. To evaluate this in vitro, cDNA constructs encoding for either wild type proSP-C (peDNA3/SP-C(1-194)) or heterologous fusion proteins containing green fluorescent protein (EGFP) linked to SP-C-(1-194) (EGFP/SP-C-(1-194)), to mutant proSP-C lacking the NH2 targeting domain (EGFP/SP-C-(24-194)), or to mature SP-C alone (EGFP/SP-C-(24-58)) were produced. In transfected A549 cells, fluorescence microscopy revealed that peDNA3/SP-C-(1-194) and EGFP/SP-C-(1-194) were each expressed in CD63 (+), EEA1 (-) cytoplasmic vesicles. Expression of EGFP/SP-C-(24194) or EGFP/SP-C-(24-58) resulted in translocation but retention in early compartments. When cotransfected with pcDNA3/SP-C-(1-194), both EGFP/SPC-(24-194) and EGFP/SP-C-(24-58) were directed to CD63 (+) vesicles that also contained SP-C-(1-194). In contrast, trafficking of a folding mutant that forms juxtanuclear aggregates, EGFP/SP-C-C122/186G, was not corrected by cotransfection with pcDNA3/SP-C-(1-194). Chemical cross-linking studies of transfected cell lysates with bismaleimidohexane produced multimeric forms of both EGFP/SP-C-(1-194) and EGFP/SP-C-(24-58). These results indicate that sorting involves oligomeric association of proSP-C monomers mediated by the mature SP-C domain. Heteromeric assembly allows wild type proSP-C to facilitate trafficking of SP-C mutants with intact transmembrane domains but lacking targeting signals. We speculate that heterotypic oligomerization of wild type with SP-C folding mutants produces a dominant negative thus contributing to the pathology of chronic lung disease associated with patients heterozygous for mutant SP-C alleles.	Univ Penn, Sch Med, Div Pulm & Crit Care, Lung Epithelial Cell Biol Labs,Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Beers, MF (corresponding author), Univ Penn, Sch Med, Div Pulm & Crit Care, Lung Epithelial Cell Biol Labs,Dept Med, 807 BRB 2-3 Bldg,421 Curie Blvd, Philadelphia, PA 19104 USA.	mfbeers@mail.med.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019737, P50HL056401] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL19737, P50-HL56401] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; Ausbel F.M., 1995, CURRENT PROTOCOLS MO; Beers M. F., 1998, MED INTELL UNIT, P93; Beers MF, 1998, J BIOL CHEM, V273, P15287, DOI 10.1074/jbc.273.24.15287; BEERS MF, 1994, J BIOL CHEM, V269, P20318; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; Conkright JJ, 2002, AM J RESP CELL MOL, V26, P85, DOI 10.1165/ajrcmb.26.1.4686; Conkright JJ, 2001, J BIOL CHEM, V276, P14658, DOI 10.1074/jbc.M011770200; Cowley DJ, 2000, J BIOL CHEM, V275, P7743, DOI 10.1074/jbc.275.11.7743; CREUWELS LAJM, 1995, BBA-LIPID LIPID MET, V1254, P326, DOI 10.1016/0005-2760(94)00195-5; FISHER JH, 1989, BIOCHIM BIOPHYS ACTA, V995, P225, DOI 10.1016/0167-4838(89)90040-X; Glasser SW, 2001, P NATL ACAD SCI USA, V98, P6366, DOI 10.1073/pnas.101500298; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; Gobran LI, 2001, AM J PHYSIOL-LUNG C, V281, pL1413, DOI 10.1152/ajplung.2001.281.6.L1413; Gow A, 1996, NAT GENET, V13, P422, DOI 10.1038/ng0896-422; Gustafsson M, 1999, FEBS LETT, V464, P138, DOI 10.1016/S0014-5793(99)01692-0; Johansson J, 1997, EUR J BIOCHEM, V244, P675, DOI 10.1111/j.1432-1033.1997.00675.x; Johansson J, 2001, BIOCHEM SOC T, V29, P601, DOI 10.1042/BST0290601; JOHANSSON J, 1994, BIOCHEMISTRY-US, V33, P6015, DOI 10.1021/bi00185a042; Johnson AL, 2001, AM J RESP CELL MOL, V24, P253, DOI 10.1165/ajrcmb.24.3.4312; Kabore AF, 2001, J CELL SCI, V114, P293; KELLER A, 1992, AM J RESP CELL MOL, V6, P601, DOI 10.1165/ajrcmb/6.6.601; KELLER A, 1991, BIOCHEM J, V277, P493, DOI 10.1042/bj2770493; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Kromer A, 1998, J CELL BIOL, V140, P1331, DOI 10.1083/jcb.140.6.1331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATHIALAGAN N, 1990, BIOCHIM BIOPHYS ACTA, V1045, P121, DOI 10.1016/0005-2760(90)90140-S; Millar DG, 1996, J BIOL CHEM, V271, P25823, DOI 10.1074/jbc.271.42.25823; MILLAR DG, 1994, J BIOL CHEM, V269, P12229; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Nogee LM, 2001, NEW ENGL J MED, V344, P573, DOI 10.1056/NEJM200102223440805; Notterpek L, 1999, NEUROBIOL DIS, V6, P450, DOI 10.1006/nbdi.1999.0274; Russo SJ, 1999, AM J PHYSIOL-LUNG C, V277, pL1034, DOI 10.1152/ajplung.1999.277.5.L1034; Solarin KO, 2001, PEDIATR PATHOL MOL M, V20, P471; Solarin KO, 1997, PEDIATR RES, V42, P356, DOI 10.1203/00006450-199709000-00017; Tobler AR, 1999, J NEUROSCI, V19, P2027; VANDENBUSSCHE G, 1992, EUR J BIOCHEM, V203, P201, DOI 10.1111/j.1432-1033.1992.tb19848.x; VOORHOUT WF, 1992, AM J PHYSIOL, V263, pL479, DOI 10.1152/ajplung.1992.263.4.L479; VOORHOUT WF, 1993, MICROSC RES TECHNIQ, V26, P366, DOI 10.1002/jemt.1070260504; Vorbroker DK, 1995, AM J PHYSIOL-LUNG C, V269, pL727, DOI 10.1152/ajplung.1995.269.6.L727; Weaver TE, 2001, ANNU REV PHYSIOL, V63, P555, DOI 10.1146/annurev.physiol.63.1.555; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8816, DOI 10.1021/bi00085a012	43	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19929	19937		10.1074/jbc.M201537200	http://dx.doi.org/10.1074/jbc.M201537200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11907042	hybrid			2022-12-25	WOS:000175894800091
J	Anderson, RM; Bitterman, KJ; Wood, JG; Medvedik, O; Cohen, H; Lin, SS; Manchester, JK; Gordon, JI; Sinclair, DA				Anderson, RM; Bitterman, KJ; Wood, JG; Medvedik, O; Cohen, H; Lin, SS; Manchester, JK; Gordon, JI; Sinclair, DA			Manipulation of a nuclear NAD(+) salvage pathway delays aging without altering steady-state NAD(+) levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC-ACID PHOSPHORIBOSYLTRANSFERASE; SILENCING PROTEIN SIR2; RNA-POLYMERASE-I; SACCHAROMYCES-CEREVISIAE; LIFE-SPAN; CALORIC RESTRICTION; RIBOSOMAL DNA; NMN ADENYLYLTRANSFERASE; SALMONELLA-TYPHIMURIUM; CAENORHABDITIS-ELEGANS	Yeast deprived of nutrients exhibit a marked life span extension that requires the activity of the NAD(+)-dependent histone deacetylase, Sir2p. Here we show that increased dosage of NPT1, encoding a nicotinate phosphoribosyltransferase critical for the NAD+ salvage pathway, increases Sir2-dependent silencing, stabilizes the rDNA locus, and extends yeast replicative life span by up to 60%. Both NPT1 and SIR2 provide resistance against heat shock, demonstrating that these genes act in a more general manner to promote cell survival. We show that Npt1 and a previously uncharacterized salvage pathway enzyme, Nma2, are both concentrated in the nucleus, indicating that a significant amount of NAD(+) is regenerated in this organelle. Additional copies of the salvage pathway genes, PNC1, NMA1, and NMA2, increase telomeric and rDNA silencing, implying that multiple steps affect the rate of the pathway. Although SIR2-dependent processes are enhanced by additional NPT1, steady-state NAD(+) levels and NAD(+)/NADH ratios remain unaltered. This finding suggests that yeast life span extension may be facilitated by an increase in the availability of NAD(+) to Sir2, although not through a simple increase in steady-state levels. We propose a model in which increased flux through the NAD(+) salvage pathway is responsible for the Sir2-dependent extension of life span.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Harvard University; Harvard Medical School; Washington University (WUSTL)	Sinclair, DA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Cohen, Haim Y./0000-0002-6613-8710; Sinclair, David/0000-0002-9936-436X				Afshar G, 1999, GENE, V234, P161, DOI 10.1016/S0378-1119(99)00162-6; Ashrafi K, 2000, GENE DEV, V14, P1872; BARTON AA, 1950, J GEN MICROBIOL, V4, P84, DOI 10.1099/00221287-4-1-84; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; Bedalov A, 2001, P NATL ACAD SCI USA, V98, P15113, DOI 10.1073/pnas.261574398; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Campisi J, 2000, SCIENCE, V289, P2062, DOI 10.1126/science.289.5487.2062; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; D'Angelo I, 2000, STRUCTURE, V8, P993, DOI 10.1016/S0969-2126(00)00190-8; De Antoni A, 2000, GENE, V246, P179, DOI 10.1016/S0378-1119(00)00083-4; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; Emanuelli M, 1999, FEBS LETT, V455, P13, DOI 10.1016/S0014-5793(99)00852-2; FELL D, 1997, FRONTIERS METABOLISM, P18; FOSTER JW, 1979, J BACTERIOL, V137, P1165, DOI 10.1128/JB.137.3.1165-1175.1979; Ghislain M, 2002, YEAST, V19, P215, DOI 10.1002/yea.810; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grubmeyer CT, 1999, METHOD ENZYMOL, V308, P28; Guarente L, 2000, GENE DEV, V14, P1021; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HOGEBOOM G, 1950, J BIOL CHEM, V197, P611; HUGHES KT, 1988, J BACTERIOL, V170, P2113, DOI 10.1128/jb.170.5.2113-2120.1988; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; IMSANDE J, 1964, BIOCHIM BIOPHYS ACTA, V85, P255, DOI 10.1016/0926-6569(64)90246-9; Jazwinski SM, 2001, MECH AGEING DEV, V122, P865, DOI 10.1016/S0047-6374(01)00244-5; Jiang JC, 2000, FASEB J, V14, P2135; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; KEIL RL, 1993, GENETICS, V135, P711; Kennedy BK, 1996, TRENDS GENET, V12, P355, DOI 10.1016/0168-9525(96)10039-1; KENNEDY BK, 1994, J CELL BIOL, V127, P1985, DOI 10.1083/jcb.127.6.1985; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; Kim S, 1996, BIOCHEM BIOPH RES CO, V219, P370, DOI 10.1006/bbrc.1996.0240; KIRKWOOD TBL, 1991, PHILOS T R SOC B, V332, P15, DOI 10.1098/rstb.1991.0028; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; Landry J, 2000, BIOCHEM BIOPH RES CO, V278, P685, DOI 10.1006/bbrc.2000.3854; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SS, 2001, J BIOL CHEM, V276, P36000, DOI 10.1074/jbc.M103509200; Longo VD, 1999, NEUROBIOL AGING, V20, P479, DOI 10.1016/S0197-4580(99)00089-5; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; Olland AM, 2002, J BIOL CHEM, V277, P3698, DOI 10.1074/jbc.M109670200; Park PU, 1999, MOL CELL BIOL, V19, P3848; Perrod S, 2001, EMBO J, V20, P197, DOI 10.1093/emboj/20.1.197; Rajavel M, 1998, BIOCHEMISTRY-US, V37, P4181, DOI 10.1021/bi9720134; Saridakis V, 2001, J BIOL CHEM, V276, P7225, DOI 10.1074/jbc.M008810200; Shore D, 2000, P NATL ACAD SCI USA, V97, P14030, DOI 10.1073/pnas.011506198; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Shou WY, 2001, MOL CELL, V8, P45, DOI 10.1016/S1097-2765(01)00291-X; SIKORSKI RS, 1989, GENETICS, V122, P19; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Smith JS, 1999, MOL CELL BIOL, V19, P3184; Straight AF, 1999, CELL, V97, P245, DOI 10.1016/S0092-8674(00)80734-5; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Vanfleteren JR, 1999, NEUROBIOL AGING, V20, P487, DOI 10.1016/S0197-4580(99)00087-1; VINITSKY A, 1991, J BACTERIOL, V173, P536, DOI 10.1128/jb.173.2.536-540.1991; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; WUBBOLTS MG, 1990, J BIOL CHEM, V265, P17665; Zainal TA, 2000, FASEB J, V14, P1825, DOI 10.1096/fj.99-0881com	68	236	254	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18881	18890		10.1074/jbc.M111773200	http://dx.doi.org/10.1074/jbc.M111773200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11884393	Green Published, hybrid			2022-12-25	WOS:000175975800083
J	Massant, J; Verstreken, P; Durbecq, V; Kholti, A; Legrain, C; Beeckmans, S; Cornelis, P; Glansdorff, N				Massant, J; Verstreken, P; Durbecq, V; Kholti, A; Legrain, C; Beeckmans, S; Cornelis, P; Glansdorff, N			Metabolic channeling of carbamoyl phosphate, a thermolabile intermediate - Evidence for physical interaction between carbamate kinase-like carbamoyl-phosphate synthetase and ornithine carbamoyltransferase from the hyperthermophile Pyrococcus furiosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIMIDINE PATHWAY ENZYMES; CITRIC-ACID CYCLE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; ASPARTATE-TRANSCARBAMYLASE; MALATE-DEHYDROGENASE; EXTREME ENVIRONMENTS; HIGH-TEMPERATURES; ESCHERICHIA-COLI; STABILITY	Two different approaches provided evidence for a physical interaction between the carbamate kinase-like carbamoyl-phosphate synthetase (CKase) and ornithine carbamoyltransferase (OTCase) from the hyperthermophilic archaeon Pyrococcus furiosus. Affinity electrophoresis indicated that CKase and OTCase associate into a multienzyme cluster. Further evidence for a biologically significant interaction between CKase and OTCase was obtained by co-immunoprecipitation combined with formaldehyde cross-linking experiments. These experiments support the hypothesis that CKase and OTCase form an efficient channeling cluster for carbamoyl phosphate, an extremely thermolabile and potentially toxic metabolic intermediate. Therefore, by physically interacting with each other, CKase and OTCase prevent the thermodenaturation of carbamoyl. phosphate in the aqueous cytoplasmic environment.	Free Univ Brussels VIB, Dept Microbiol, B-1070 Brussels, Belgium; Inst Rech JM Wiame, B-1070 Brussels, Belgium; Free Univ Brussels, Microbiol Lab, B-1070 Brussels, Belgium; Free Univ Brussels VIB, Dept Immunol Parasitol & Ultrastruct, Lab Microbial Interact, B-1640 Rhode St Genese, Belgium; Free Univ Brussels, Prot Chem Lab, B-1640 Rhode St Genese, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Massant, J (corresponding author), Free Univ Brussels VIB, Dept Microbiol, 808 Route Lennik, B-1070 Brussels, Belgium.	jan.massant@vub.ac.be; nglansdo@vub.ac.be	Hu, Ruogu/B-2203-2008; Cornelis, Pierre/H-3058-2019; Verstreken, Patrik/AAC-7591-2022	Verstreken, Patrik/0000-0002-5073-5393				ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; ALLEN CM, 1964, BIOCHEMISTRY-US, V3, P1238, DOI 10.1021/bi00897a010; Anderson KS, 1999, METHOD ENZYMOL, V308, P111; BEECKMANS S, 1981, EUR J BIOCHEM, V117, P527; BEECKMANS S, 1989, EUR J BIOCHEM, V183, P449, DOI 10.1111/j.1432-1033.1989.tb14948.x; Beeckmans S, 1999, METHODS, V19, P278, DOI 10.1006/meth.1999.0857; BEECKMANS S, 1993, J MOL RECOGNIT, V6, P195, DOI 10.1002/jmr.300060408; BELKAID M, 1988, ARCH BIOCHEM BIOPHYS, V262, P171, DOI 10.1016/0003-9861(88)90179-8; Bera AK, 2000, J BIOL CHEM, V275, P7975, DOI 10.1074/jbc.275.11.7975; BUCKLE PE, 1993, BIOSENS BIOELECTRON, V8, P355, DOI 10.1016/0956-5663(93)80074-Y; BURNS VW, 1964, SCIENCE, V146, P1056, DOI 10.1126/science.146.3647.1056; Caspary F, 1999, EMBO J, V18, P3463, DOI 10.1093/emboj/18.12.3463; CHRISTOPHERSON RI, 1980, J BIOL CHEM, V255, P1381; Clantin B, 2001, EUR J BIOCHEM, V268, P3937, DOI 10.1046/j.1432-1327.2001.02302.x; COHEN NS, 1992, BIOCHEM J, V282, P173, DOI 10.1042/bj2820173; CONSALVI V, 1991, EUR J BIOCHEM, V202, P1189, DOI 10.1111/j.1432-1033.1991.tb16489.x; CULLIN C, 1994, YEAST, V10, P105, DOI 10.1002/yea.320100110; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P347, DOI 10.1016/0956-5663(93)80073-X; Daniel RM, 2000, CELL MOL LIFE SCI, V57, P250, DOI 10.1007/PL00000688; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; Durbecq V, 1997, P NATL ACAD SCI USA, V94, P12803, DOI 10.1073/pnas.94.24.12803; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; HARLOW E, 1999, USING ANTIBODIES LAB, P221; Holden HM, 1998, CURR OPIN STRUC BIOL, V8, P679, DOI 10.1016/S0959-440X(98)80086-9; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; Irvine HS, 1997, EUR J BIOCHEM, V247, P1063, DOI 10.1111/j.1432-1033.1997.01063.x; JAENICKE R, 1991, EUR J BIOCHEM, V202, P715, DOI 10.1111/j.1432-1033.1991.tb16426.x; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; LEGRAIN C, 1976, EUR J BIOCHEM, V63, P289, DOI 10.1111/j.1432-1033.1976.tb10230.x; Legrain C, 2001, METHOD ENZYMOL, V331, P227; Legrain C, 1997, EUR J BIOCHEM, V247, P1046, DOI 10.1111/j.1432-1033.1997.01046.x; LEGRAIN C, 1995, MICROBIOL-SGM, V141, P1093, DOI 10.1099/13500872-141-5-1093; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; MESSENGUY F, 1976, J BACTERIOL, V128, P49, DOI 10.1128/JB.128.1.49-55.1976; OVADI J, 1991, J THEOR BIOL, V152, P1, DOI 10.1016/S0022-5193(05)80500-4; PENVERNE B, 1994, ARCH BIOCHEM BIOPHYS, V309, P85, DOI 10.1006/abbi.1994.1089; PRESCOTT LM, 1969, ANAL BIOCHEM, V32, P408, DOI 10.1016/S0003-2697(69)80008-4; PROSSNITZ E, 1988, J BIOL CHEM, V263, P17917; Purcarea C, 1996, EUR J BIOCHEM, V236, P189, DOI 10.1111/j.1432-1033.1996.00189.x; Purcarea C, 1999, J BIOL CHEM, V274, P6122, DOI 10.1074/jbc.274.10.6122; Purcarea C, 2001, EXTREMOPHILES, V5, P229, DOI 10.1007/s007920100201; Ramon-Maiques S, 2000, J MOL BIOL, V299, P463, DOI 10.1006/jmbi.2000.3779; Roovers M, 1997, EUR J BIOCHEM, V247, P1038, DOI 10.1111/j.1432-1033.1997.01038.x; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; SRIVASTAVA DK, 1987, ANNU REV BIOPHYS BIO, V16, P175; SRIVASTAVA DK, 1986, SCIENCE, V234, P1081, DOI 10.1126/science.3775377; STALON V, 1972, EUR J BIOCHEM, V29, P25, DOI 10.1111/j.1432-1033.1972.tb01953.x; Uriarte M, 1999, J BIOL CHEM, V274, P16295, DOI 10.1074/jbc.274.23.16295; Uriarte M, 2001, METHOD ENZYMOL, V331, P236; VandeCasteele M, 1997, COMP BIOCHEM PHYS A, V118, P463, DOI 10.1016/S0300-9629(97)00007-8; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; VILLERET V, 1995, P NATL ACAD SCI USA, V92, P10762, DOI 10.1073/pnas.92.23.10762; Villeret V, 1998, P NATL ACAD SCI USA, V95, P2801, DOI 10.1073/pnas.95.6.2801; WANDERS RJA, 1984, EUR J BIOCHEM, V142, P247, DOI 10.1111/j.1432-1033.1984.tb08278.x; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; WILLIAMS LG, 1970, BIOCHEMISTRY-US, V9, P4329, DOI 10.1021/bi00824a013; WILLIAMS LG, 1971, J BIOL CHEM, V246, P973; Zierenberg RA, 2000, P NATL ACAD SCI USA, V97, P12961, DOI 10.1073/pnas.210395997	59	18	19	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18517	18522		10.1074/jbc.M111481200	http://dx.doi.org/10.1074/jbc.M111481200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893735	Green Published, hybrid			2022-12-25	WOS:000175975800036
J	Watanabe, A; Yoshimura, T; Mikami, B; Hayashi, H; Kagamiyama, H; Esaki, N				Watanabe, A; Yoshimura, T; Mikami, B; Hayashi, H; Kagamiyama, H; Esaki, N			Reaction mechanism of alanine racemase from Bacillus stearothermophilus - X-ray crystallographic studies of the enzyme bound with N-(5 '-phosphopyridoxyl)alanine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-265	The crystal structures of alanine racemase bound with reaction intermediate analogs, N-(5'-phosphopyridoxyl)-L-alanine (PLP-L-Ala) and N-(5'-phosphopyridoxyl)-D-alanine (PLP-D-Ala), were determined at 2.0-Angstrom resolution with the crystallographic R factor of 17.2 for PLP-L-Ala and 16.9 for PLP-D-Ala complexes. They were quite similar not only to each other but also to the structure of the native pyridoxal 5'-phosphate (PLP)-form enzyme; root mean square deviations at Calpha among the three structures were less than 0.28 Angstrom. The side chains of the amino acid residues around the PLP-L-Ala and PLP-D-Ala were virtually superimposable on each other as well as on those around PLP of the native holoenzyme. The alpha-hydrogen of the alanine moiety of PLP-L-Ala was located near the OH of Tyr(265'), whereas that of PLP-D-Ala was near the NZ of Lys(39). These support the previous findings that Tyr(265)' and Lys(39) are the catalytic bases removing alpha-hydrogen from L- and D-alanine, respectively. The prerequisite for this two-base mechanism is that the alpha-proton abstracted from the substrate is transferred (directly or indirectly) between the NZ of Lys(39) and the OH of Tyr(265'); otherwise the enzyme reaction stops after a single turnover. Only the carboxylate oxygen atom of either PLP-Ala enantiomer occurred at a reasonable position that can mediate the proton transfer, neither the amino acid side chains nor the water molecules were located in the vicinity. Therefore, we propose a mechanism of alanine racemase reaction in which the substrate carboxyl group directly participates in the catalysis by mediating the proton transfer between the two catalytic bases, Lys(39) and Tyr(265'). The results of molecular orbital calculation also support this mechanism.	Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan; Kyoto Univ, Grad Sch Agr, Dept Agron & Hort Sci, Kyoto 6110011, Japan; Osaka Med Coll, Dept Biochem, Takatsuki, Osaka 5698686, Japan	Kyoto University; Kyoto University; Osaka Medical College	Esaki, N (corresponding author), Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan.							AHRENS H., 1970, Methods in Enzymology, V18A, P489, DOI 10.1016/0076-6879(71)18349-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1996, XPLOR VERSION 3 851; FARACI WS, 1988, BIOCHEMISTRY-US, V27, P3267, DOI 10.1021/bi00409a022; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; IKAWA M, 1967, ARCH BIOCHEM BIOPHYS, V118, P497, DOI 10.1016/0003-9861(67)90378-5; KLEYWEGT GJ, 1995, ESF CCP4 NEWSLETT, V31, P45; Kurokawa Y, 1998, J BIOCHEM-TOKYO, V124, P1163, DOI 10.1093/oxfordjournals.jbchem.a022234; Morollo AA, 1999, BIOCHEMISTRY-US, V38, P3293, DOI 10.1021/bi9822729; Peisach D, 1998, BIOCHEMISTRY-US, V37, P4958, DOI 10.1021/bi972884d; Shaw JP, 1997, BIOCHEMISTRY-US, V36, P1329, DOI 10.1021/bi961856c; Stamper CGF, 1998, BIOCHEMISTRY-US, V37, P10438, DOI 10.1021/bi980692s; Sun SX, 1999, BIOCHEMISTRY-US, V38, P4058, DOI 10.1021/bi982924t; WALSH CT, 1989, J BIOL CHEM, V264, P2393; Watababe A, 1999, J BIOL CHEM, V274, P4189, DOI 10.1074/jbc.274.7.4189; Watanabe A, 1999, J BIOCHEM-TOKYO, V125, P987, DOI 10.1093/oxfordjournals.jbchem.a022406; Watanabe A, 1999, J BIOCHEM-TOKYO, V126, P781, DOI 10.1093/oxfordjournals.jbchem.a022517	18	114	123	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19166	19172		10.1074/jbc.M201615200	http://dx.doi.org/10.1074/jbc.M201615200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886871	hybrid			2022-12-25	WOS:000175975800119
J	Talley, EM; Bayliss, DA				Talley, EM; Bayliss, DA			Modulation of TASK-1 (Kcnk3) and TASK-3 (Kcnk9) potassium channels - Volatile anesthetics and neurotransmitters share a molecular site of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACKGROUND K+ CHANNEL; INHALATION ANESTHETICS; FUNCTIONAL EXPRESSION; PHOSPHOLIPASE-C; PROTEIN-KINASE; DOMAIN; FAMILY; PORE; INHIBITION; ACID	TASK-1 and TASK-3, members of the two-pore-domain channel family, are widely expressed leak potassium channels responsible for maintenance of cell membrane potential and input resistance. They are sites of action for a variety of modulatory agents, including volatile anesthetics and neurotransmitters/hormones, the latter acting via mechanisms that have remained elusive. To clarify these mechanisms, we generated mutant channels and found that alterations disrupting anesthetic (halothane) activation of these channels also disrupted transmitter (thyrotropin-releasing hormone, TRH) inhibition and did so to a similar degree. For both TASK-1 and TASK-3, mutations (substitutions with corresponding residues from TREK-1) in a six-residue sequence at the beginning of the cytoplasmic C terminus virtually abolished both anesthetic activation and transmitter inhibition. The only sequence motif identified with a classical signaling mechanism in this region is a potential phosphorylation site; however, mutation of this site failed to disrupt modulation. TASK-1 and TASK-3 differed insofar as a large portion of the C terminus was necessary for the full effects of halothane and TRH on TASK-3 but not on TASK-1. Finally, tandem-linked TASK-1/TA.SK-3 heterodimeric channels were fully modulated by anesthetic and transmitter, and introduction of the identified mutations either into the TASK-1 or the TASK-3 portion of the channel was sufficient to disrupt both effects. Thus, both anesthetic activation and transmitter inhibition of these channels require a region at the interface between the final transmembrane domain and the cytoplasmic C terminus that has not been associated previously with receptor signal transduction. Our results also indicate a close molecular relationship between these two forms of modulation, one endogenous and the other clinically applied.	Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia	Talley, EM (corresponding author), Univ Virginia Hlth Syst, Dept Pharmacol, POB 800735, Charlottesville, VA 22908 USA.	emt3m@virginia.edu			NIGMS NIH HHS [R01 GM066181] Funding Source: Medline; NINDS NIH HHS [NS33583] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033583, R29NS033583] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashmole I, 2001, PFLUG ARCH EUR J PHY, V442, P828, DOI 10.1007/s004240100620; Bayliss DA, 2001, RESP PHYSIOL, V129, P159, DOI 10.1016/S0034-5687(01)00288-2; Boyd DF, 2000, J PHYSIOL-LONDON, V529, P321, DOI 10.1111/j.1469-7793.2000.00321.x; Buckler KJ, 2000, J PHYSIOL-LONDON, V525, P135, DOI 10.1111/j.1469-7793.2000.00135.x; Czirjak G, 2002, J BIOL CHEM, V277, P5426, DOI 10.1074/jbc.M107138200; Czirjak G, 2000, MOL ENDOCRINOL, V14, P863, DOI 10.1210/me.14.6.863; Czirjak G, 2001, AM J PHYSIOL-CELL PH, V281, pC700, DOI 10.1152/ajpcell.2001.281.2.C700; Decher N, 2001, FEBS LETT, V492, P84, DOI 10.1016/S0014-5793(01)02222-0; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Flynn GE, 2001, NAT REV NEUROSCI, V2, P643, DOI 10.1038/35090015; Girard C, 2001, BIOCHEM BIOPH RES CO, V282, P249, DOI 10.1006/bbrc.2001.4562; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; Hilgemann D W, 2001, Sci STKE, V2001, pre19, DOI 10.1126/stke.2001.111.re19; Karschin C, 2001, MOL CELL NEUROSCI, V18, P632, DOI 10.1006/mcne.2001.1045; Kim D, 2001, BIOCHEM BIOPH RES CO, V284, P923, DOI 10.1006/bbrc.2001.5064; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; KIM GD, 1994, J BIOL CHEM, V269, P19933; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Koh SD, 2001, J BIOL CHEM, V276, P44338, DOI 10.1074/jbc.M108125200; Lei WB, 2001, J BIOL CHEM, V276, P16720, DOI 10.1074/jbc.M100207200; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; Lopes CMB, 2001, J BIOL CHEM, V276, P24449, DOI 10.1074/jbc.C100184200; Lopes CMB, 2000, J BIOL CHEM, V275, P16969, DOI 10.1074/jbc.M001948200; Maejima T, 2001, NEURON, V31, P463, DOI 10.1016/S0896-6273(01)00375-0; Maingret F, 2001, EMBO J, V20, P47, DOI 10.1093/emboj/20.1.47; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; Meadows HJ, 2001, NEUROPHARMACOLOGY, V40, P551, DOI 10.1016/S0028-3908(00)00189-1; Millar JA, 2000, P NATL ACAD SCI USA, V97, P3614, DOI 10.1073/pnas.050012597; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Patel AJ, 2001, TRENDS NEUROSCI, V24, P339, DOI 10.1016/S0166-2236(00)01810-5; Rajan S, 2000, J BIOL CHEM, V275, P16650, DOI 10.1074/jbc.M000030200; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; Sambrook J, 2001, MOL CLONING LAB MANU; Sirois JE, 1998, J PHYSIOL-LONDON, V512, P851, DOI 10.1111/j.1469-7793.1998.851bd.x; Talley EM, 2001, J NEUROSCI, V21, P7491, DOI 10.1523/JNEUROSCI.21-19-07491.2001; Talley EM, 2000, NEURON, V25, P399, DOI 10.1016/S0896-6273(00)80903-4; Vega-Saenz de Miera E, 2001, J NEUROPHYSIOL, V86, P130, DOI 10.1152/jn.2001.86.1.130; Washburn CP, 2002, J NEUROSCI, V22, P1256, DOI 10.1523/JNEUROSCI.22-04-01256.2002; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166	45	164	169	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17733	17742		10.1074/jbc.M200502200	http://dx.doi.org/10.1074/jbc.M200502200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11886861	hybrid			2022-12-25	WOS:000175685100045
J	Burakov, D; Crofts, LA; Chang, CPB; Freedman, LP				Burakov, D; Crofts, LA; Chang, CPB; Freedman, LP			Reciprocal recruitment of DRIP/mediator and p160 coactivator complexes in vivo by estrogen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; BINDING PROTEIN; LIVING CELLS; TRANSCRIPTION; ALPHA; ACTIVATION; INITIATION; INTERACTS; EXCHANGE; DYNAMICS	Two functionally distinct classes of coactivators are recruited by liganded estrogen receptor, the DRIP/Mediator complex and p160 proteins, although the relative dynamics of recruitment is unclear. Previously, we have shown a direct, estradiol-dependent interaction between the DRIP205 subunit of the DRIP complex and the estrogen receptor (ER) AF2 domain. Here we demonstrate the in vivo recruitment of other endogenous DRIP subunits to ER in response to estradiol treatment in MCF-7 cells. To explore the relationship between DRIP and p160 coactivators, we examined the kinetics of coactivator recruitment to the ER target promoter, pS2, by chromatin immunoprecipitation. We observed a cyclic association and dissociation of coactivators with the promoter, with recruitment of p160s and DRIPS occurring in opposite phases, suggesting an exchange between these coactivator complexes at the target promoter.	Cornell Univ, Joan & Sanford I Weill Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Cell Biol Program, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Freedman, LP (corresponding author), Merck Res Labs, Dept Bone Biol, WP26A-1000, W Point, PA 19486 USA.				NIDDK NIH HHS [DK45460] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045460, R01DK045460] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Burakov D, 2000, J BIOL CHEM, V275, P20928, DOI 10.1074/jbc.M002013200; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chiba N, 2000, J BIOL CHEM, V275, P10719, DOI 10.1074/jbc.275.15.10719; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Gamble MJ, 2002, TRENDS BIOCHEM SCI, V27, P165, DOI 10.1016/S0968-0004(02)02076-5; Glass CK, 2000, GENE DEV, V14, P121; JELTSCH JM, 1987, NUCLEIC ACIDS RES, V15, P1401, DOI 10.1093/nar/15.4.1401; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; Llopis J, 2000, P NATL ACAD SCI USA, V97, P4363, DOI 10.1073/pnas.97.8.4363; Mak HY, 2001, MOL CELL BIOL, V21, P4379, DOI 10.1128/MCB.21.13.4379-4390.2001; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Margeat E, 2001, J MOL BIOL, V306, P433, DOI 10.1006/jmbi.2000.4418; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Stenoien DL, 2001, MOL CELL BIOL, V21, P4404, DOI 10.1128/MCB.21.13.4404-4412.2001; Warnmark A, 2001, J BIOL CHEM, V276, P23397, DOI 10.1074/jbc.M011651200; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	26	109	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14359	14362		10.1074/jbc.C200099200	http://dx.doi.org/10.1074/jbc.C200099200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11893728	hybrid			2022-12-25	WOS:000175203000003
J	Chaudhry, MA; Chodosh, LA; McKenna, WG; Muschel, RJ				Chaudhry, MA; Chodosh, LA; McKenna, WG; Muschel, RJ			Gene expression profiling of HeLa cells in G1 or G2 phases	ONCOGENE			English	Article						microarray; genechip; cell cycle	B1 MESSENGER-RNA; CYCLIN B1; CLUSTER-ANALYSIS; IDENTIFICATION; TARGETS	The cell division cycle is regulated through both transcriptional and post-transcriptional mechanisms. The altered expression of a number of genes at the mRNA level is known to be essential for progression through the cell cycle, however, a comprehensive gene expression profile of human cells remains to be completed. Here we sought to monitor the differential gene expression of genes after the transition of G2 cells into G1 prior to the restriction point. GeneChip containing microarrays of oligonucleotides corresponding to over 12 000 human genes were employed to profile differential gene expression in G1 and G2. After three independent experiments the resultant data was filtered and a set of genes was compiled based on at least threefold-altered expression, no background noise in determining expression and observation in all experiments. Our analysis identified 154 genes that were elevated in G2 phase of cells as compared to early G1 phase including 15 novel genes. This number included mRNAs whose upregulation is known to occur in G2 phase. Surprisingly only 19 genes were upregulated in G1 phase, among these six genes were novel. Some of these genes are candidates for transition through early G1. This gene inventory for G1 and G2 phases of cell cycle will provide the basis for understanding of cell cycle delay as a result of DNA damage.	Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Abramson Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Muschel, RJ (corresponding author), Childrens Hosp, Dept Pathol & Lab Med, 269 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	muschel@mail.med.upenn.edu			NATIONAL CANCER INSTITUTE [P01CA075138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047439] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA75138] Funding Source: Medline; NIGMS NIH HHS [R01 GM47439] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1994, MOL BIOL CELL, P369; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Claverie JM, 2001, SCIENCE, V291, P1255, DOI 10.1126/science.1058969; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ghosh S, 1998, EXP CELL RES, V242, P1, DOI 10.1006/excr.1998.4115; HEINTZ N, 1993, TRENDS BIOCHEM SCI, V18, P157, DOI 10.1016/0968-0004(93)90103-T; Hitomi M, 2001, FEBS LETT, V490, P123, DOI 10.1016/S0014-5793(01)02115-9; KATO J, 1999, FRONT BIOSCI, V1, P787; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Kong M, 2000, EMBO J, V19, P1378, DOI 10.1093/emboj/19.6.1378; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Murray AW, 2001, NATURE, V409, P844, DOI 10.1038/35057033; Nakanishi M, 2000, GENES CELLS, V5, P839, DOI 10.1046/j.1365-2443.2000.00367.x; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; Sakai N, 1999, EXP CELL RES, V251, P224, DOI 10.1006/excr.1999.4552; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Werner T, 2001, PHARMACOGENOMICS, V2, P25, DOI 10.1517/14622416.2.1.25; Yang J, 1999, TRENDS CELL BIOL, V9, P207, DOI 10.1016/S0962-8924(99)01577-9	30	26	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1934	1942		10.1038/sj.onc.1205264	http://dx.doi.org/10.1038/sj.onc.1205264			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896627				2022-12-25	WOS:000174284500017
J	Ekman, S; Kallin, A; Engstrom, U; Heldin, CH; Ronnstrand, L				Ekman, S; Kallin, A; Engstrom, U; Heldin, CH; Ronnstrand, L			SHP-2 is involved in heterodimer specific loss of phosphorylation of Tyr771 in the PDGF beta-receptor	ONCOGENE			English	Article						platelet-derived growth factor; receptor tyrosine kinase; SHP-2; heterodimer; dephosphorylation	FACTOR-ALPHA-RECEPTOR; PHOSPHOLIPASE-C-GAMMA; PHOSPHOTYROSINE PHOSPHATASE; AUTOPHOSPHORYLATION SITES; SIGNAL-TRANSDUCTION; TYROSINE KINASE; DNA-SYNTHESIS; CDNA CLONING; GROWTH; IDENTIFICATION	We have previously shown that the binding site for GTPase activating protein of Ras (RasGAP) in the PDGF beta-receptor, Tyr771, is phosphorylated to a much lower extent in the heterodimeric configuration of PDGF alpha- and beta-receptors, compared to the PDGF beta-receptor homodimer. The decreased recruitment of the RasGAP to the receptor leads to prolonged activation of the Ras/MAP kinase pathway, which could explain the increase in mitogenicity seen upon induction of heterodimers. The molecular mechanism underlying these differences was investigated. We could show that the loss of phosphorylation of Tyr771 was dependent on presence of intact binding sites for the protein tyrosine phosphatase SHP-2 on the PDGF beta-receptor. Thus, in PDGF receptor mutants in which binding of SHP-2 was lost, a higher degree of phosphorylation of Tyr771 was seen, while other phosphorylation sites in the receptor remained virtually unaffected. Thus, SHP-2 appears to play an important role in modulating phosphorylation of Y771, thereby controlling RasGAP recruitment and Ras/MAP kinase signaling in the heterodimeric configuration of the PDGF receptors.	Ludwig Inst Canc Res, Ctr Biomed, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Ronnstrand, L (corresponding author), Ludwig Inst Canc Res, Ctr Biomed, Box 595, S-75124 Uppsala, Sweden.		Ronnstrand, Lars/A-2429-2011; Ekman, Simon/AAB-9387-2021	Ronnstrand, Lars/0000-0003-1275-5809; 				ANDREWS DM, 1991, INT J PEPT PROT RES, V38, P469; BAZENET CE, 1994, ONCOGENE, V9, P517; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Ekman S, 1999, ONCOGENE, V18, P2481, DOI 10.1038/sj.onc.1202606; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Pawson T, 2000, GENE DEV, V14, P1027; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Ronnstrand L, 1999, ONCOGENE, V18, P3696, DOI 10.1038/sj.onc.1202705; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; RUPP E, 1994, EUR J BIOCHEM, V225, P29, DOI 10.1111/j.1432-1033.1994.00029.x; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; XIAO S, 1994, J BIOL CHEM, V269, P21244; Yokote K, 1996, J BIOL CHEM, V271, P5101; Yokote K, 1998, ONCOGENE, V16, P1229, DOI 10.1038/sj.onc.1201641	29	34	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1870	1875		10.1038/sj.onc.1205210	http://dx.doi.org/10.1038/sj.onc.1205210			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896619				2022-12-25	WOS:000174284500009
J	Pazirandeh, A; Xue, YT; Prestegaard, T; Jondal, M; Okret, S				Pazirandeh, A; Xue, YT; Prestegaard, T; Jondal, M; Okret, S			Effects of altered glucocorticoid sensitivity in the T-cell lineage on thymocyte and T-cell homeostasis	FASEB JOURNAL			English	Article						immune system; thymus; spleen; glucocorticoid receptor; apoptosis	PITUITARY-ADRENAL AXIS; NF-KAPPA-B; MOLECULAR MECHANISMS; RECEPTOR EXPRESSION; SIGNALING PATHWAYS; RAPID METHOD; APOPTOSIS; THYMUS; SELECTION; LYMPHOCYTES	The homeostatic regulation that controls total thymocyte and peripheral T-cell numbers is not clearly understood. We describe here a direct hormonal influence of endogenous levels of glucocorticoids (GCs) on thymocyte and peripheral T-cell homeostasis independent of indirect systemic effects of GCs. The results were obtained by generating transgenic mice with an altered GC sensitivity targeted to thymocytes and peripheral T cells by increasing or decreasing glucocorticoid receptor (GR) expression specifically in thymocytes and peripheral T cells. A twofold increase in GC sensitivity resulted in a major decrease in thymocyte number, affecting all subpopulations, although single-positive CD8(+) cells were less influenced. In the thymus, this was due to increased apoptosis in the organ, whereas proliferation of thymocyte populations was unaffected. In the periphery, a pronounced reduction in T-cell number was seen, demonstrating an effect of endogenous GCs also on T-cell homeostasis. The effects were confirmed in transgenic mice with reduced GR expression, which showed increased thymocyte and T-cell numbers. Thus, our data demonstrate that physiological GC levels are directly involved in controlling the size of both thymocyte and T-cell pools.	Huddinge Univ Hosp, Karolinska Inst, Dept Med Nutr, Novum, SE-14186 Huddinge, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Okret, S (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Dept Med Nutr, Novum, SE-14186 Huddinge, Sweden.	Sam.Okret@mednut.ki.se						Almeida ARM, 2001, J EXP MED, V194, P591, DOI 10.1084/jem.194.5.591; Ashwell JD, 1996, STEM CELLS, V14, P490, DOI 10.1002/stem.140490; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; Ashwell JD, 2000, IMMUNOL TODAY, V21, P644, DOI 10.1016/S0167-5699(00)01758-8; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; Bender J, 1999, J EXP MED, V190, P367, DOI 10.1084/jem.190.3.367; Berzins SP, 1998, J EXP MED, V187, P1839, DOI 10.1084/jem.187.11.1839; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Buckland J, 2000, EUR J IMMUNOL, V30, P8, DOI 10.1002/1521-4141(200001)30:1<8::AID-IMMU8>3.3.CO;2-#; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CARLSTEDTDUKE J, 1995, ENDOCRINOL METAB, P169; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Delaunay F, 1997, J CLIN INVEST, V100, P2094, DOI 10.1172/JCI119743; DONG Y, 1989, J BIOL CHEM, V264, P13679; Ferreira V, 1999, J IMMUNOL, V162, P6442; Godfrey DI, 2000, IMMUNOL TODAY, V21, P606, DOI 10.1016/S0167-5699(00)01741-2; Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950; Jaffe HL, 1924, J EXP MED, V40, P325, DOI 10.1084/jem.40.3.325; Jamieson CAM, 2000, P NATL ACAD SCI USA, V97, P7319, DOI 10.1073/pnas.97.13.7319; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KIEFFER JD, 1971, TRANSPLANTATION, V11, P45, DOI 10.1097/00007890-197101000-00006; KING LB, 1995, IMMUNITY, V3, P647, DOI 10.1016/1074-7613(95)90135-3; Lechner O, 2000, EUR J IMMUNOL, V30, P337; Lu FWM, 2000, IMMUNITY, V12, P183, DOI 10.1016/S1074-7613(00)80171-5; Mann CL, 2000, ENDOCRINOLOGY, V141, P528, DOI 10.1210/en.141.2.528; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marrack P, 2000, NAT IMMUNOL, V1, P107, DOI 10.1038/77778; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MORALE MC, 1995, ENDOCRINOLOGY, V136, P3949, DOI 10.1210/en.136.9.3949; Newton R, 2000, THORAX, V55, P603, DOI 10.1136/thorax.55.7.603; NIETO MA, 1992, CLIN EXP IMMUNOL, V88, P341; Nyirenda MJ, 1998, J CLIN INVEST, V101, P2174, DOI 10.1172/JCI1567; OKRET S, 1984, P NATL ACAD SCI-BIOL, V81, P1609, DOI 10.1073/pnas.81.6.1609; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; Palm S, 1996, CHRONOBIOL INT, V13, P423, DOI 10.3109/07420529609020913; Pazirandeh A, 1999, FASEB J, V13, P893, DOI 10.1096/fasebj.13.8.893; PLAUT M, 1987, ANNU REV IMMUNOL, V5, P621, DOI 10.1146/annurev.iy.05.040187.003201; Purton JF, 2000, IMMUNITY, V13, P179, DOI 10.1016/S1074-7613(00)00018-2; Reichardt HM, 2000, MOL CELL BIOL, V20, P9009, DOI 10.1128/MCB.20.23.9009-9017.2000; Sacedon R, 1999, BLOOD, V94, P2819, DOI 10.1182/blood.V94.8.2819.420k12_2819_2826; Samuelsson MKR, 1999, MOL ENDOCRINOL, V13, P1811, DOI 10.1210/me.13.11.1811; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; Sprent J, 2001, SCIENCE, V293, P245, DOI 10.1126/science.1062416; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Tanchot C, 1997, Semin Immunol, V9, P331, DOI 10.1006/smim.1997.0090; Thompson EB, 1999, TRENDS ENDOCRIN MET, V10, P353, DOI 10.1016/S1043-2760(99)00187-3; Tolosa E, 1998, IMMUNITY, V8, P67, DOI 10.1016/S1074-7613(00)80459-8; Tonko M, 2001, FASEB J, V15, P693, DOI 10.1096/fj.00-0327com; Vacchio MS, 1998, ANN NY ACAD SCI, V840, P317, DOI 10.1111/j.1749-6632.1998.tb09571.x; VACCHIO MS, 1994, J EXP MED, V179, P1835, DOI 10.1084/jem.179.6.1835; Van Laethem F, 2001, J EXP MED, V193, P803, DOI 10.1084/jem.193.7.803; Van Parijs L, 1998, SCIENCE, V280, P243; VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; VONBOEHMER H, 1993, J EXP MED, V177, P891, DOI 10.1084/jem.177.4.891; Wang W, 1999, J IMMUNOL, V162, P314; WICK G, 1993, ENDOCR REV, V14, P539, DOI 10.1210/edrv-14-5-539; Wiest DL, 1999, SEMIN IMMUNOL, V11, P251, DOI 10.1006/smim.1999.0181; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	61	81	85	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					727	+		10.1096/fj.01-0891fje	http://dx.doi.org/10.1096/fj.01-0891fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923224				2022-12-25	WOS:000174755900007
J	Martino, S; Emiliani, C; Tancini, B; Severini, GM; Chigorno, V; Bordignon, C; Sonnino, S; Orlacchio, A				Martino, S; Emiliani, C; Tancini, B; Severini, GM; Chigorno, V; Bordignon, C; Sonnino, S; Orlacchio, A			Absence of metabolic cross-correction in Tay-Sachs cells. Implications for gene therapy.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-N-ACETYLHEXOSAMINIDASE; LYSOSOMAL STORAGE DISEASES; ALPHA-SUBUNIT; HEXOSAMINIDASE-A; CHAIN; DIMETHYLSULFOXIDE; OLIGOSACCHARIDE; FIBROBLASTS; EXPRESSION; TRANSPORT	We have investigated the ability of a receptor-mediated gene transfer strategy (cross-correction) to restore ganglioside metabolism in fibroblasts from Tay-Sachs (TS) patients in vitro. TS disease is a GM2 gangliosidosis attributed to the deficiency of the lysosomal enzyme beta-hexosaminidase A (HexA) (beta-N-acetylhexosaminidase, EC 3.2.1.52). The hypothesis is that transduced cells overexpressing and secreting large amounts of the enzyme would lead to a measurable activity in defective cells via a secretion-recapture mechanism. We transduced NIH3T3 murine fibroblasts with the LalphaHexTN retroviral vector carrying the cDNA encoding for the human Hex a-subunit. The Hex activity in the medium from transduced cells was approximately 10-fold higher (up to 75 milliunits) than observed in non-transduced cells. TS cells were cultured for 72 h in the presence of the cell medium derived from the transduced NIH3T3 cells, and they were analyzed for the presence and catalytic activity of the enzyme. Although TS cells were able to efficiently uptake a large amount of the soluble enzyme, the enzyme failed to reach the lysosomes in a sufficient quantity to hydrolyze the GM2 ganglioside to GM3 ganglioside. Thus, our results showed that delivery of the therapeutic HexA was not sufficient to correct the phenotype of TS cells.	Univ Perugia, Dipartimento Sci Biochim & Biotecnol Mol, I-06126 Perugia, Italy; Hosp San Raffaele, San Raffaele Telethon Inst Gene Therapy, I-20132 Milan, Italy; Childrens Hosp Burlo Garofolo, I-34100 Trieste, Italy; Univ Milan, Study Ctr Biochem & Biotechnol Glycolipids, Ctr Excellence Neurodegenerat Dis, Dept Med Chem & Biochem, I-20090 Segrate, Italy	University of Perugia; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS Burlo Garofolo; University of Milan	Orlacchio, A (corresponding author), Univ Perugia, Dipartimento Sci Biochim & Biotecnol Mol, Via Giochetto, I-06126 Perugia, Italy.	martino.sabata@hsr.it	Emiliani, Carla/G-3738-2010; Tancini, Brunella/F-6467-2014; Sonnino, Sandro/R-4154-2017; Martino, Sabata/F-2309-2014	Emiliani, Carla/0000-0002-6368-1515; Tancini, Brunella/0000-0001-9070-5765; Sonnino, Sandro/0000-0001-8180-5908; Martino, Sabata/0000-0002-3942-237X	Telethon [TGT00B02, TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		ACQUOTTI D, 1990, J AM CHEM SOC, V112, P7772, DOI 10.1021/ja00177a043; Akli S, 1996, GENE THER, V3, P769; BANERJEE P, 1994, J BIOL CHEM, V269, P4819; Barranger JA, 1999, NEUROCHEM RES, V24, P601, DOI 10.1023/A:1022548232735; BECCARI T, 1987, BIOCHEM J, V244, P801, DOI 10.1042/bj2440801; BEUTLER E, 1997, CURR OPIN HEMATOL, V1, P19; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brady RO, 2000, JAMA-J AM MED ASSOC, V284, P2771, DOI 10.1001/jama.284.21.2771; BROCCA P, 1993, GLYCOCONJUGATE J, V10, P441, DOI 10.1007/BF00737964; Chen CS, 1999, LANCET, V354, P901, DOI 10.1016/S0140-6736(98)10034-X; Chen CS, 1998, P NATL ACAD SCI USA, V95, P6373, DOI 10.1073/pnas.95.11.6373; Chigorno V, 1985, GLYCOCONJUGATE J, VV2, P279; Consiglio A, 2001, NAT MED, V7, P310, DOI 10.1038/85454; EMILIANI C, 1990, BIOCHEM J, V267, P111, DOI 10.1042/bj2670111; EMILIANI C, 1992, INT J BIOCHEM, V24, P539, DOI 10.1016/0020-711X(92)90324-T; EMILIANI C, 1990, BIOCHEM J, V272, P211, DOI 10.1042/bj2720211; Eto Y, 2000, J INHERIT METAB DIS, V23, P293, DOI 10.1023/A:1005692215317; GRAVEL RA, 2001, METABOLIC MOL BASES, V3, P30827; Guidotti JE, 1999, HUM MOL GENET, V8, P831, DOI 10.1093/hmg/8.5.831; Guidotti JE, 1998, HUM MOL GENET, V7, P831, DOI 10.1093/hmg/7.5.831; HASILIK A, 1982, EUR J BIOCHEM, V125, P317, DOI 10.1111/j.1432-1033.1982.tb06685.x; Hepbildikler ST, 2002, J BIOL CHEM, V277, P2562, DOI 10.1074/jbc.M105457200; Hou YM, 1996, BIOCHEMISTRY-US, V35, P3963, DOI 10.1021/bi9524575; IKONNE JU, 1975, AM J HUM GENET, V27, P639; Ioannou YA, 2000, J AM SOC NEPHROL, V11, P1542, DOI 10.1681/ASN.V1181542; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kolter T, 1999, BIOCHEM SOC T, V27, P409, DOI 10.1042/bst0270409; KORNELUK RG, 1986, J BIOL CHEM, V261, P8407; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Lacorazza HD, 1996, NAT MED, V2, P424, DOI 10.1038/nm0496-424; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; MAHURAN D, 1985, ISOZYMES-CURR T BIOL, V12, P229; Mahuran DJ, 1999, BBA-MOL BASIS DIS, V1455, P105, DOI 10.1016/S0925-4439(99)00074-5; MARTINO S, 1995, BBA-GEN SUBJECTS, V1243, P489, DOI 10.1016/0304-4165(94)00179-2; Martino S, 1997, BBA-GEN SUBJECTS, V1335, P5, DOI 10.1016/S0304-4165(96)00116-X; MEIER EM, 1991, J BIOL CHEM, V266, P1879; MunierLehmann H, 1996, BIOCHEM SOC T, V24, P133, DOI 10.1042/bst0240133; MYEROWITZ R, 1985, P NATL ACAD SCI USA, V82, P7830, DOI 10.1073/pnas.82.23.7830; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; Pagano RE, 2000, TRAFFIC, V1, P807, DOI 10.1034/j.1600-0854.2000.011101.x; Poenaru L, 1996, GENE THER, V3, P1039; PROIA RL, 1984, J BIOL CHEM, V259, P3350; Schmid JA, 1999, J BIOL CHEM, V274, P19063, DOI 10.1074/jbc.274.27.19063; Sena-Esteves M, 2000, HUM GENE THER, V11, P715, DOI 10.1089/10430340050015617; Sonnino S, 2000, METHOD ENZYMOL, V311, P639; Sonnino S, 1996, GLYCOBIOLOGY, V6, P479, DOI 10.1093/glycob/6.5.479-e; Tancini B, 2000, BBA-GEN SUBJECTS, V1475, P184, DOI 10.1016/S0304-4165(00)00057-X; TETTAMAN.G, 1973, BIOCHIM BIOPHYS ACTA, V296, P160, DOI 10.1016/0005-2760(73)90055-6; Wada R, 2000, P NATL ACAD SCI USA, V97, P10954, DOI 10.1073/pnas.97.20.10954; WEITZ G, 1992, J BIOL CHEM, V267, P10039; Winchester B, 2000, BIOCHEM SOC T, V28, P150, DOI 10.1042/bst0280150	52	31	33	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20177	20184		10.1074/jbc.M106164200	http://dx.doi.org/10.1074/jbc.M106164200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923278	hybrid			2022-12-25	WOS:000176204500013
J	Yamagishi, S; Inagaki, Y; Okamoto, T; Amano, S; Koga, K; Takeuchi, M; Makita, Z				Yamagishi, S; Inagaki, Y; Okamoto, T; Amano, S; Koga, K; Takeuchi, M; Makita, Z			Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL SUPEROXIDE-PRODUCTION; PROSTACYCLIN-PRODUCING ABILITY; DIABETIC-NEPHROPATHY; FACTOR-BETA; RECEPTOR; BAX; PROLIFERATION; BIOCHEMISTRY; EXPRESSION; INHIBITOR	Advanced glycation end products (AGE) have been implicated in the pathogenesis of glomerulosclerosis in diabetes. However, their involvement in the development of the early phase of diabetic nephropathy has not been fully elucidated. We investigated the effects of AGE on growth and on vascular endothelial growth factor (VEGF) and monocyte chemoattractant protein-1 (MCP-1) expression in human cultured mesangial cells. We prepared three immunochemically distinct AGE by incubating bovine serum albumin (BSA) with glucose, glyceraldehyde, or glycolaldehyde. When human mesangial cells were cultured with various types of AGE-BSA, viable cell numbers as well as DNA syntheses were significantly decreased. All of the AGE-BSA were found to significantly increase p53 and Bax protein accumulations and subsequently induce apoptotic cell death in mesangial cells. An antioxidant, N-acetylcysteine, significantly prevented the AGE-induced apoptotic cell death in mesangial cells. Human mesangial cells stimulated prostacyclin production by co-cultured glomerular endothelial cells. Furthermore, various types of AGE-BSA were found to up-regulate the levels of mRNAs for VEGF and stimulate the secretion of VEGF and MCP-1 proteins in mesangial cells. The results suggest that AGE disturbed glomerular homeostasis by inducing apoptotic cell death in mesangial cells and elicited hyperfiltration and microalbuminuria by stimulating the secretion of VEGF and MCP-1 proteins, thereby being involved in the pathogenesis of the early phase of diabetic nephropathy.	Kurume Univ, Sch Med, Dept Med, Div Endocrinol & Metab, Kurume, Fukuoka 8300011, Japan; Hokuriku Univ, Fac Pharmaceut Sci, Dept Biochem, Kanazawa, Ishikawa 9201181, Japan	Kurume University; Hokuriku University	Yamagishi, S (corresponding author), Kurume Univ, Sch Med, Dept Med, Div Endocrinol & Metab, Kurume, Fukuoka 8300011, Japan.	shoichi@med.kurume-u.ac.jp						ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Banba N, 2000, KIDNEY INT, V58, P684, DOI 10.1046/j.1523-1755.2000.00214.x; BERN MM, 1978, DIABETES, V27, P342, DOI 10.2337/diab.27.3.342; BROWNLEE M, 1981, ANNU REV BIOCHEM, V50, P385, DOI 10.1146/annurev.bi.50.070181.002125; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; BUCALA R, 1994, P NATL ACAD SCI USA, V91, P9441, DOI 10.1073/pnas.91.20.9441; Cha DR, 2000, KIDNEY INT, V58, pS104, DOI 10.1046/j.1523-1755.2000.07717.x; Choudhuri T, 2002, FEBS LETT, V512, P334, DOI 10.1016/S0014-5793(02)02292-5; De Vriese A, 2001, J AM SOC NEPHROL, V12, P993, DOI 10.1681/ASN.V125993; DONADIO JV, 1988, MAYO CLIN PROC, V63, P3, DOI 10.1016/S0025-6196(12)62658-5; DWORKIN LD, 1983, AM J PHYSIOL, V244, pF95, DOI 10.1152/ajprenal.1983.244.2.F95; FRIEDMAN EA, 1990, ELLENBERG RIFKINS DI, P684; Giustina A, 1998, DIABETES, V47, P423, DOI 10.2337/diabetes.47.3.423; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; KREISBERG J, 1985, AM J PHYSIOL, V249, pF457, DOI 10.1152/ajprenal.1985.249.4.F457; KROLEWSKI AS, 1991, AM J MED S2A, V90, P56; MAKINO H, 1995, KIDNEY INT, V48, P517, DOI 10.1038/ki.1995.322; MAKITA Z, 1991, NEW ENGL J MED, V325, P836, DOI 10.1056/NEJM199109193251202; MAKITA Z, 1992, SCIENCE, V258, P651, DOI 10.1126/science.1411574; MONCADA S, 1978, PHARMACOL REV, V30, P293; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; NOMURA M, 1995, J BIOL CHEM, V270, P28316; Ono Y, 1998, J DIABETES COMPLICAT, V12, P252, DOI 10.1016/S1056-8727(97)00091-3; Podesta F, 2000, AM J PATHOL, V156, P1025, DOI 10.1016/S0002-9440(10)64970-X; Pugliese G, 1997, DIABETES, V46, P1881, DOI 10.2337/diabetes.46.11.1881; Raj DSC, 2000, AM J KIDNEY DIS, V35, P365, DOI 10.1016/S0272-6386(00)70189-2; Sandau K, 1997, KIDNEY INT, V52, P378, DOI 10.1038/ki.1997.344; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SHARMA K, 1995, DIABETES, V44, P1139, DOI 10.2337/diabetes.44.10.1139; Takeuchi M, 1999, MOL MED, V5, P393, DOI 10.1007/BF03402128; Takeuchi M, 2000, J NEUROPATH EXP NEUR, V59, P1094, DOI 10.1093/jnen/59.12.1094; Tsuchida K, 1999, DIABETOLOGIA, V42, P579, DOI 10.1007/s001250051198; Wenzel UO, 1995, AM J KIDNEY DIS, V26, P982, DOI 10.1016/0272-6386(95)90065-9; Yamagishi S, 1999, LAB INVEST, V79, P501; Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723; Yamagishi S, 1998, DIABETOLOGIA, V41, P1435, DOI 10.1007/s001250051089; Yamagishi S, 1996, FEBS LETT, V384, P103, DOI 10.1016/0014-5793(96)00279-7; Yamagishi S, 1999, MICROVASC RES, V57, P329, DOI 10.1006/mvre.1999.2145; YAMAGISHI S, 1993, BIOCHEM BIOPH RES CO, V191, P840, DOI 10.1006/bbrc.1993.1293; Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V290, P973, DOI 10.1006/bbrc.2001.6312; Yamagishi S, 1999, BIOCHEM BIOPH RES CO, V258, P353, DOI 10.1006/bbrc.1999.0625; Yamagishi S, 2001, DIABETES, V50, P1491, DOI 10.2337/diabetes.50.6.1491; YAMAGISHI S, 1993, BIOCHEM BIOPH RES CO, V190, P418, DOI 10.1006/bbrc.1993.1064; YAMAGISHI SI, 1995, BIOCHEM BIOPH RES CO, V213, P681, DOI 10.1006/bbrc.1995.2185; Yamagishi SI, 2001, J BIOL CHEM, V276, P25096, DOI 10.1074/jbc.M007383200; Yamamoto Y, 2001, J CLIN INVEST, V108, P261, DOI 10.1172/JCI11771; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	52	291	311	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20309	20315		10.1074/jbc.M202634200	http://dx.doi.org/10.1074/jbc.M202634200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11912219	hybrid			2022-12-25	WOS:000176204500029
J	Chen, HL; Demiralp, B; Schneider, A; Koh, AJ; Silve, C; Wang, CY; McCauley, LK				Chen, HL; Demiralp, B; Schneider, A; Koh, AJ; Silve, C; Wang, CY; McCauley, LK			Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; FIBROBLAST-GROWTH-FACTOR; PTH/PTHRP RECEPTOR; OSTEOBLASTIC CELLS; PEPTIDE RECEPTOR; OSTEOGENIC DIFFERENTIATION; COLLAGENASE-3 PROMOTER; TRANSCRIPTION FACTOR; PLASMA-MEMBRANE; FOS PROMOTER	During bone formation, multipotential mesenchymal cells proliferate and differentiate into osteoblasts, and subsequently many die because of apoptosis. Evidence suggests that the receptor for parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP), the PTH-1 receptor (PTH-1R), plays an important role in this process. Multipotential mesenchymal cells (C3H10T1/2) transfected with normal or mutant PTH-1Rs and MC3T3-E1 osteoblastic cells were used to explore the roles of PTH, PTHrP, and the PTH-1R in cell viability relative to osteoblastic differentiation. Overexpression of wild-type PTH-1R increased cell numbers and promoted osteocalcin gene expression versus inactivated mutant receptors. Furthermore, the effects of PTH and PTHrP on apoptosis were dramatically dependent on cell status. In preconfluent C3H10T1/2 and MC3T3-E1 cells, PTH and PTHrP protected against dexamethasone-induced reduction in cell viability, which was dependent on CAMP activation. Conversely, PTH and PTHrP resulted in reduced cell viability in postconfluent cells, which was also dependent on LAMP activation. Further, the proapoptotic-like effects were associated with an inhibition of Akt phosphorylation. These data suggest that parathyroid hormones accelerate turnover of osteoblasts by promoting cell viability early and promoting cell departure from the differentiation program later in their developmental scheme. Both of these actions occur at least in part via the protein kinase A pathway.	Univ Michigan, Dept Periodont Prevent & Geriatr, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Hacettepe Univ, Dept Periodontol, Fac Dent, TR-06100 Ankara, Turkey; INSERM, U426, Fac Med Xavier Bichat, F-75870 Paris, France	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Hacettepe University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	McCauley, LK (corresponding author), Univ Michigan, Dept Periodont Prevent & Geriatr, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.	mccauley@umich.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053904] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE13788] Funding Source: Medline; NIDDK NIH HHS [DK53904] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; BROWN PH, 1994, ONCOGENE, V9, P791; Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; D'Alonzo RC, 2002, J BIOL CHEM, V277, P816, DOI 10.1074/jbc.M107082200; DEBARTOLO TF, 1982, CALCIFIED TISSUE INT, V34, P495, DOI 10.1007/BF02411291; Divieti P, 1998, J BONE MINER RES, V13, P1835, DOI 10.1359/jbmr.1998.13.12.1835; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; Gerstenfeld LC, 2002, J BONE MINER RES, V17, P221, DOI 10.1359/jbmr.2002.17.2.221; HABENER JF, 1984, PHYSIOL REV, V64, P985, DOI 10.1152/physrev.1984.64.3.985; HERRMANNERLEE MPM, 1976, ENDOCR RES COMMUN, V3, P21, DOI 10.3109/07435807609057738; HOCK JM, 1989, ENDOCRINOLOGY, V125, P2022, DOI 10.1210/endo-125-4-2022; INOMATA N, 1995, ENDOCRINOLOGY, V136, P4732, DOI 10.1210/en.136.11.4732; Jacobs-Helber SM, 1998, MOL CELL BIOL, V18, P3699, DOI 10.1128/MCB.18.7.3699; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Jobert AS, 1998, J CLIN INVEST, V102, P34, DOI 10.1172/JCI2918; Johnson AC, 2000, MOL MED, V6, P17, DOI 10.1007/BF03401931; Ju WJ, 2000, J BONE MINER RES, V15, P1889, DOI 10.1359/jbmr.2000.15.10.1889; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1988, J BIOL CHEM, V263, P8557; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; Lanske B, 1999, J CLIN INVEST, V104, P399, DOI 10.1172/JCI6629; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Machwate M, 1998, MOL PHARMACOL, V54, P70, DOI 10.1124/mol.54.1.70; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MARTIN TJ, 1991, CRIT REV BIOCHEM MOL, V26, P377, DOI 10.3109/10409239109114073; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MCCAULEY LK, 1992, ENDOCRINOLOGY, V130, P300, DOI 10.1210/en.130.1.300; McCauley LK, 2001, ENDOCRINOLOGY, V142, P1975, DOI 10.1210/en.142.5.1975; MCCAULEY LK, 1994, MOL CELL ENDOCRINOL, V101, P331, DOI 10.1016/0303-7207(94)90250-X; McCauley LK, 1996, J CELL BIOCHEM, V61, P638, DOI 10.1002/(SICI)1097-4644(19960616)61:4<638::AID-JCB18>3.0.CO;2-B; MOSELEY JM, 1995, CRIT REV CL LAB SCI, V32, P299, DOI 10.3109/10408369509084687; Nakamura T, 1997, BIOCHEM BIOPH RES CO, V237, P465, DOI 10.1006/bbrc.1997.7156; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; OFIR R, 1991, GENE EXPRESSION, V1, P55; Parfitt AM., 1990, BONE TREATISE, VI, P351; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; PITARU S, 1993, J BONE MINER RES, V8, P919; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Sabatini M, 1996, BONE, V18, P59, DOI 10.1016/8756-3282(95)00427-0; Schipani E, 1999, J CLIN ENDOCR METAB, V84, P3052, DOI 10.1210/jc.84.9.3052; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Schipani E, 1996, NEW ENGL J MED, V335, P708, DOI 10.1056/NEJM199609053351004; Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037; Spinella-Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756-3282(01)00580-4; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; Turner PR, 2000, MOL ENDOCRINOL, V14, P241, DOI 10.1210/me.14.2.241; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Watson PH, 2000, BONE, V26, P221, DOI 10.1016/S8756-3282(99)00264-1; WILSON JM, 1989, SCIENCE, V244, P1344, DOI 10.1126/science.2734614; ZAJAC JD, 1992, MOL CELL ENDOCRINOL, V87, P69, DOI 10.1016/0303-7207(92)90234-W; Zerega B, 1999, J BONE MINER RES, V14, P1281, DOI 10.1359/jbmr.1999.14.8.1281; Zhang P, 1998, J CLIN ENDOCR METAB, V83, P3365, DOI 10.1210/jc.83.9.3373; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	71	125	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19374	19381		10.1074/jbc.M108913200	http://dx.doi.org/10.1074/jbc.M108913200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11897779	hybrid			2022-12-25	WOS:000175894800019
J	Kunzelmann-Marche, C; Freyssinet, JM; Martinez, MC				Kunzelmann-Marche, C; Freyssinet, JM; Martinez, MC			Loss of plasma membrane phospholipid asymmetry requires raft integrity - Role of transient receptor potential channels and ERK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CALCIUM-ENTRY; OPERATED CA2+ ENTRY; HUMAN PLATELETS; T-LYMPHOCYTES; LIPID RAFTS; TRANSBILAYER REDISTRIBUTION; PHOSPHATIDYLSERINE EXPOSURE; SIGNALING PATHWAYS; ACTIN CYTOSKELETON; STIMULATED CELLS	Cholesterol-rich membrane microdomains, also termed lipid rafts, are implicated in the recruitment of essential proteins for intracellular signal transduction. In nonstimulated cells, phosphatidylserine, an anionic aminophospholipid essential for the hemostatic response, is mostly sequestered in the inner leaflet of the plasma membrane. Cell stimulation by Ca2+-mobilizing or apoptogenic agents induces the migration of phosphatidylserine to the exoplasmic leaflet, allowing the assembly and activation of several key enzyme complexes of the coagulation cascade and phagocyte recognition of stimulated or senescent cells. We have recently proposed that store-operated Ca2+ entry regulates externalization of phosphatidylserine at the cell surface (Kunzelmann-Marche, C., Freyssinet, J.-M., and Martinez, M. C. (2001) J. Biol. Chem. 276, 5134-5139). Here, we show that store-operated Ca2+ entry and phosphatidylserine exposure are dramatically reduced after raft disruption by methyl-beta-cyclodextrin. In addition, transient receptor potential channel 1-specific antibody was able to significantly decrease Ca2+-induced redistribution of phosphatidylserine. Furthermore, store-operated Ca2+ entry and phosphatidylserine exposure were dependent in part on the extracellular signal-regulated kinase pathway associated with rafts. Hence, raft integrity and store-operated Ca2+ entry involving transient receptor potential channel 1 channels are essential for completion of the phosphatidylserine transmembrane redistribution process.	Univ Strasbourg 1, Inst Hematol & Immunol, Fac Med, F-67085 Strasbourg, France; Hop Bicetre, INSERM Unite 143, F-94275 Le Kremlin Bicetre, France	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Martinez, MC (corresponding author), Univ Strasbourg 1, Inst Hematol & Immunol, Fac Med, 4 Rue Kirschleger, F-67085 Strasbourg, France.		Freyssinet, Jean-Marie/G-2719-2013					Aman MJ, 2000, CURR BIOL, V10, P393, DOI 10.1016/S0960-9822(00)00415-2; ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; Atherfold PA, 1999, MOL IMMUNOL, V36, P543, DOI 10.1016/S0161-5890(99)00076-0; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; Barabe F, 2002, J BIOL CHEM, V277, P13473, DOI 10.1074/jbc.M112149200; Berg LP, 1997, FEBS LETT, V403, P83, DOI 10.1016/S0014-5793(97)00019-7; Berridge MJ, 2000, SCIENCE, V287, P1604, DOI 10.1126/science.287.5458.1604; Bishara NB, 2002, BRIT J PHARMACOL, V135, P119, DOI 10.1038/sj.bjp.0704465; Catani L, 1998, HAEMATOLOGICA, V83, P385; Christian AE, 1997, J LIPID RES, V38, P2264; CONNOR J, 1989, BIOCHEMISTRY-US, V28, P9680, DOI 10.1021/bi00451a021; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Dillon SR, 2000, J IMMUNOL, V164, P1322, DOI 10.4049/jimmunol.164.3.1322; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fasolato C, 1998, PFLUG ARCH EUR J PHY, V436, P69, DOI 10.1007/s004240050605; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hart KC, 2000, EXP CELL RES, V257, P89, DOI 10.1006/excr.2000.4874; Henson PM, 2001, NAT REV MOL CELL BIO, V2, P627, DOI 10.1038/35085094; Kabouridis PS, 2000, EUR J IMMUNOL, V30, P954, DOI 10.1002/1521-4141(200003)30:3<954::AID-IMMU954>3.3.CO;2-P; Kukkonen JP, 2001, BRIT J PHARMACOL, V132, P1477, DOI 10.1038/sj.bjp.0703964; Kunzelmann-Marche C, 2001, J BIOL CHEM, V276, P5134, DOI 10.1074/jbc.M007924200; Lepage A, 1999, BLOOD, V94, P3366, DOI 10.1182/blood.V94.10.3366.422k35_3366_3380; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Martin S, 2000, BIOCHEM BIOPH RES CO, V279, P639, DOI 10.1006/bbrc.2000.3980; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Martinez MC, 1999, BIOCHEMISTRY-US, V38, P10092, DOI 10.1021/bi990129p; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Ohvo H, 1996, BIOCHEMISTRY-US, V35, P8018, DOI 10.1021/bi9528816; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; Parton RG, 2001, SCIENCE, V293, P2404, DOI 10.1126/science.1065677; Pasquet JM, 1996, EUR J BIOCHEM, V239, P647, DOI 10.1111/j.1432-1033.1996.0647u.x; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; Rizzo MA, 2001, J BIOL CHEM, V276, P34928, DOI 10.1074/jbc.M105918200; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rosado JA, 2001, J BIOL CHEM, V276, P15659, DOI 10.1074/jbc.M009218200; Rosado JA, 2000, TRENDS CARDIOVAS MED, V10, P327, DOI 10.1016/S1050-1738(01)00073-1; Rosado JA, 2001, BIOCHEM J, V356, P191, DOI 10.1042/0264-6021:3560191; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; Wu H, 2002, J PHARMACOL EXP THER, V300, P339, DOI 10.1124/jpet.300.1.339; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	50	72	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19876	19881		10.1074/jbc.M200324200	http://dx.doi.org/10.1074/jbc.M200324200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11909856	hybrid			2022-12-25	WOS:000175894800084
J	DiCamillo, SJ; Carreras, I; Panchenko, MV; Stone, PJ; Nugent, MA; Foster, JA; Panchenko, MP				DiCamillo, SJ; Carreras, I; Panchenko, MV; Stone, PJ; Nugent, MA; Foster, JA; Panchenko, MP			Elastase-released epidermal growth factor recruits epidermal growth factor receptor and extracellular signal-regulated kinases to down-regulate tropoelastin mRNA in lung fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SMOOTH-MUSCLE CELLS; HEPARAN-SULFATE PROTEOGLYCANS; HUMAN-LEUKOCYTE ELASTASE; EGF RECEPTOR; FACTOR-ALPHA; NEUTROPHIL ELASTASE; TYROSINE PHOSPHORYLATION; MAP KINASE; CARCINOMA-CELLS	Elastase/anti-elastase imbalance is a hallmark of emphysema, a chronic obstructive pulmonary disease associated with the rupture and inefficient repair of interstitial elastin. We report that neutrophil elastase (NE) at low physiologic concentrations, ranging from 35 nM to 1 mum, invokes transient, peaking at 15 min, activation of extracellular signal-regulated kinases 1 and 2 (ERK) in elastogenic lung fibroblasts. ERK activation is preceded by the release of soluble 25-26-kDa forms of epidermal growth factor (EGF) and transactivation of EGF receptor (EGFR) in NE-exposed cells. The stimulatory effect of NE on ERK is abrogated in the presence of anti-EGF-neutralizing antibodies, EGFR tyrosine kinase inhibitor (AG1478), and ERK kinase inhibitor (PD98059), as well as abolished in both EGFR-desensitized and endocytosis-arrested fibroblasts. Nuclear accumulation of activated ERK is associated with transient, peaking at 30 min, induction of c-Fos and sustained, observed at 24-48 h, decrease of tropoelastin mRNA levels in NE-challenged cells. Pretreatment of fibroblasts with AG1478 or PD98059 abrogates the NE-initiated tropoelastin mRNA suppression. We conclude that proteolytically released EGF signals directly via EGFR and ERK to down-regulate tropoelastin mRNA in NE-challenged lung fibroblasts.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Boston University; Boston University	Panchenko, MP (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	panchenko@biochem.bumc.bu.edu		Stone, Phillip/0000-0001-6220-690X; Panchenko, Maria/0000-0001-6247-6598; carreras, isabel/0000-0002-7120-6749; Nugent, Matthew/0000-0002-8630-4712	NHLBI NIH HHS [P01HL013262, HL-07035, P01HL046902] Funding Source: Medline; NIA NIH HHS [AG-00115] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262, P01HL046902, T32HL007035] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barnes Peter J., 2001, Current Opinion in Pharmacology, V1, P217, DOI 10.1016/S1471-4892(01)00039-X; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Belaaouaj AA, 2000, SCIENCE, V289, P1185, DOI 10.1126/science.289.5482.1185; Belmokhtar CA, 2000, EXP CELL RES, V254, P99, DOI 10.1006/excr.1999.4737; BIETH JG, 1986, BIOL EXTRACELLULAR M, V1, P217; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Buczek-Thomas JA, 1999, J BIOL CHEM, V274, P25167, DOI 10.1074/jbc.274.35.25167; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Cai TQ, 1996, J EXP MED, V184, P1213, DOI 10.1084/jem.184.4.1213; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Carreras I, 2001, AM J PHYSIOL-LUNG C, V281, pL766, DOI 10.1152/ajplung.2001.281.4.L766; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; COFFER PJ, 1995, ONCOGENE, V11, P561; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DAVIDSON JM, 1993, J CELL PHYSIOL, V155, P149, DOI 10.1002/jcp.1041550119; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; DUNLAP RP, 1987, BIOCHEM BIOPH RES CO, V145, P509, DOI 10.1016/0006-291X(87)91350-7; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; GATES RE, 1985, BIOCHEMISTRY-US, V24, P5209, DOI 10.1021/bi00340a038; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Goldkorn T, 1997, BBA-MOL CELL RES, V1358, P289, DOI 10.1016/S0167-4889(97)00063-3; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Hardie WD, 1997, AM J PATHOL, V151, P1075; Hardie WD, 1996, AM J RESP CELL MOL, V15, P499, DOI 10.1165/ajrcmb.15.4.8879184; Hardie WD, 2001, AM J PHYSIOL-LUNG C, V281, pL1088, DOI 10.1152/ajplung.2001.281.5.L1088; Hashimoto S, 1999, LIFE SCI, V64, P1465, DOI 10.1016/S0024-3205(99)00080-6; HOIDAL JR, 1983, CHEST, V83, P679, DOI 10.1378/chest.83.4.679; ICHIRO T, 1990, BIOCHEM BIOPH RES CO, V168, P850, DOI 10.1016/0006-291X(90)92399-K; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; JANOFF A, 1988, INFLAMMATION BASIC P, P803; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; KING CR, 1989, ONCOGENE, V4, P13; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Kucich U, 1997, AM J RESP CELL MOL, V17, P10, DOI 10.1165/ajrcmb.17.1.2816; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li J, 2000, J BIOL CHEM, V275, P2951, DOI 10.1074/jbc.275.4.2951; Li Y, 2000, J BIOL CHEM, V275, P37443, DOI 10.1074/jbc.M004373200; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lucey EC, 1998, AM J RESP CRIT CARE, V158, P555, DOI 10.1164/ajrccm.158.2.9705021; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; McGowan SE, 1997, AM J RESP CELL MOL, V17, P25, DOI 10.1165/ajrcmb.17.1.2686; Miettinen PJ, 1997, DEV BIOL, V186, P224, DOI 10.1006/dbio.1997.8593; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; MROCZKOWSKI B, 1989, MOL CELL BIOL, V9, P2771, DOI 10.1128/MCB.9.7.2771; MUELLER SG, 1990, MOL CELL BIOL, V10, P4596, DOI 10.1128/MCB.10.9.4596; NOGUCHI A, 1989, EXP LUNG RES, V15, P537, DOI 10.3109/01902148909069617; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; Parks WC, 1997, AM J RESP CELL MOL, V17, P1; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; PORTEU F, 1991, J BIOL CHEM, V266, P18846; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rich CB, 1996, J BIOL CHEM, V271, P23043, DOI 10.1074/jbc.271.38.23043; RICH CB, 1989, ARCH BIOCHEM BIOPHYS, V268, P551, DOI 10.1016/0003-9861(89)90322-6; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Shapiro SD, 2000, CLIN CHEST MED, V21, P621, DOI 10.1016/S0272-5231(05)70172-6; Si-Tahar M, 1997, J BIOL CHEM, V272, P11636; Skold CM, 1999, AM J RESP CRIT CARE, V159, P1138; SNIDER GL, 1991, ANN NY ACAD SCI, V624, P45, DOI 10.1111/j.1749-6632.1991.tb17005.x; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Thompson K, 1996, J CELL PHYSIOL, V166, P495, DOI 10.1002/(SICI)1097-4652(199603)166:3<495::AID-JCP4>3.0.CO;2-K; Towbin H, 1992, Biotechnology, V24, P145; Trevani AS, 1996, LAB INVEST, V74, P711; TWUMASI DY, 1977, J BIOL CHEM, V252, P1917; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; WARBURTON D, 1992, DEV BIOL, V149, P123, DOI 10.1016/0012-1606(92)90269-M; Wendel DP, 2000, AM J RESP CELL MOL, V23, P320, DOI 10.1165/ajrcmb.23.3.3906; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yang JJ, 1996, AM J PATHOL, V149, P1617; ZORBAS MA, 1993, EXP CELL RES, V206, P49, DOI 10.1006/excr.1993.1119; [No title captured]	85	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18938	18946		10.1074/jbc.M200243200	http://dx.doi.org/10.1074/jbc.M200243200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889128	hybrid			2022-12-25	WOS:000175975800090
J	Kristensen, C; Andersen, AS; Ostergaard, S; Hansen, PH; Brandt, J				Kristensen, C; Andersen, AS; Ostergaard, S; Hansen, PH; Brandt, J			Functional reconstitution of insulin receptor binding site from non-binding receptor fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ALANINE-SCANNING MUTAGENESIS; ALPHA-SUBUNIT; LIGAND SPECIFICITY; DOMAIN; REGION; IDENTIFICATION; DETERMINANTS; ECTODOMAIN; AFFINITY	We have previously shown that a minimized insulin receptor (IR) consisting of the first 468 amino acids of the insulin receptor fused to 16 amino acids from the C terminus of the a-subunit (CT domain) bound insulin with nanomolar affinity (Kristensen, C., Wiberg, F. C., Schaffer, L., and Andersen, A. S. (1998) J. Biol. Chem 273, 17780-17786). In the present study, we show that a smaller construct that has the first 308 residues fused to the CT domain also binds insulin. Insulin receptor fragments consisting of the first 468 or 308 residues did not bind insulin. However, when these fragments were mixed with a synthetic peptide corresponding to the CT domain, insulin binding was detectable. At concentrations of 10 muM CT peptide, insulin binding was fully reconstituted yielding apparent affinities of 9-11 nM. To further investigate the minimum requirement for the length of the N terminus of IR, we tested smaller receptor fragments for insulin binding in the presence of the CT peptide and found that a fragment consisting of the first 255 amino acids of IR was able to fully reconstitute the insulin binding site, yielding an apparent affinity of 11 +/- 4 nM for insulin.	Novo Nordisk AS, Dept Insulin Res, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Dept Prot Express, DK-2880 Bagsvaerd, Denmark	Novo Nordisk; Novo Nordisk	Brandt, J (corresponding author), Novo Nordisk AS, Dept Insulin Res, Novo Alle 6B1-90, DK-2880 Bagsvaerd, Denmark.		Kristensen, Claus/O-8047-2015; Ostergaard, Soren/B-8123-2019	Ostergaard, Soren/0000-0002-9415-3352; Kristensen, Claus/0000-0002-2594-7722				Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; Brandt J, 2001, J BIOL CHEM, V276, P12378, DOI 10.1074/jbc.M009402200; DEMEYTS P, 1994, DIABETOLOGIA, V37, P135; FABRY M, 1992, BIOL CHEM H-S, V373, P915, DOI 10.1515/bchm3.1992.373.2.915; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; Hoyne PA, 2000, FEBS LETT, V469, P57, DOI 10.1016/S0014-5793(00)01237-0; Hulme E. C., 1992, RECEPTOR LIGAND INTE, P63; Kristensen C, 1998, J BIOL CHEM, V273, P17780, DOI 10.1074/jbc.273.28.17780; Kristensen C, 1999, J BIOL CHEM, V274, P37351, DOI 10.1074/jbc.274.52.37351; KUROSE T, 1994, J BIOL CHEM, V269, P29190; Luo RZT, 1999, SCIENCE, V285, P1077, DOI 10.1126/science.285.5430.1077; Marino-Buslje C, 1999, BIOCHEM SOC T, V27, P715, DOI 10.1042/bst0270715; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; PASHMFOROUSH M, 1994, J BIOL CHEM, V269, P32639; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; ROACH P, 1994, DIABETES, V43, P1096, DOI 10.2337/diabetes.43.9.1096; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SCHAFFER L, 1993, EXP CLIN ENDOCRINOL, V101, P7; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; Sparrow LG, 1997, J BIOL CHEM, V272, P29460, DOI 10.1074/jbc.272.47.29460; SURINYA KH, 2002, IN PRESS J BIOL CHEM, V277; Tulloch PA, 1999, J STRUCT BIOL, V125, P11, DOI 10.1006/jsbi.1998.4066; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WARD CW, 1995, PROTEINS, V22, P141, DOI 10.1002/prot.340220207; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P2722, DOI 10.1021/bi00432a053; Whittaker J, 2001, J BIOL CHEM, V276, P43980, DOI 10.1074/jbc.M102863200	29	31	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18340	18345		10.1074/jbc.M112249200	http://dx.doi.org/10.1074/jbc.M112249200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11901156	hybrid			2022-12-25	WOS:000175975800013
J	Zimmermann, K; Ahrens, K; Matthes, S; Buerstedde, JM; Stratling, WH; Loc, PV				Zimmermann, K; Ahrens, K; Matthes, S; Buerstedde, JM; Stratling, WH; Loc, PV			Targeted disruption of the GAS41 gene encoding a putative transcription factor indicates that GAS41 is essential for cell viability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN LYSOZYME GENE; RNA-POLYMERASE-II; DNA-BINDING PROTEINS; NUCLEAR MATRIX; DISTINCT PHENOTYPES; MAMMALIAN-CELLS; ACUTE-LEUKEMIA; EXPRESSION; FUSION; GLIOMA	The glioma-amplified sequence (GAS) 41 protein has been proposed to be a transcription factor. To investigate its functional role in vivo, we attempted to knock out the GAS41 gene by targeted disruption in the chicken pre-lymphoid cell line DT40. Heterozygous GAS41+/- cell lines generated by the first round of homologous recombination express approximately half the normal level of GAS41 mRNA. However, a homozygous GAS41-/- cell line with both GAS41 alleles disrupted was not obtained following the second round of transfection, indicating that the GAS41 gene is essential for cell viability. Indeed, homozygous GAS41-/- cell lines with two disrupted GAS41 alleles can be generated following substitution of the endogenous gene by stable integration of GAS41 cDNA controlled by a tetracycline-regulated CMV promoter. Inactivation of this promoter by tetracycline withdrawal results in rapid depletion of GAS41, causing a significant decrease in RNA synthesis and subsequently cell death. Thus, our results indicate that GAS41 is required for RNA transcription.	Inst Tierzucht & Tierverhalten, D-20223 Celle, Germany; Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Hamburg, Klinikum Eppendorf, Inst Med Biochem & Mol Biol, D-20246 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Zimmermann, K (corresponding author), Inst Tierzucht & Tierverhalten, Dornbergstr 25-27, D-20223 Celle, Germany.							BABA TW, 1985, VIROLOGY, V144, P139, DOI 10.1016/0042-6822(85)90312-5; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; DWORETZKY SI, 1992, P NATL ACAD SCI USA, V89, P4178, DOI 10.1073/pnas.89.9.4178; Fischer U, 1997, HUM MOL GENET, V6, P1817, DOI 10.1093/hmg/6.11.1817; Fischer U, 1996, HUM GENET, V98, P625, DOI 10.1007/s004390050271; Goethe R, 1997, J LEUKOCYTE BIOL, V61, P367, DOI 10.1002/jlb.61.3.367; Goethe R, 1998, J IMMUNOL, V160, P4970; Harborth J, 2000, J BIOL CHEM, V275, P31979, DOI 10.1074/jbc.M000994200; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HENRY NL, 1992, J BIOL CHEM, V267, P23388; JACKSON DA, 1985, EMBO J, V4, P919, DOI 10.1002/j.1460-2075.1985.tb03719.x; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; LANGLOIS AJ, 1974, CANCER RES, V34, P1457; LUDERUS MEE, 1994, MOL CELL BIOL, V14, P6297, DOI 10.1128/MCB.14.9.6297; LYDERSEN BK, 1980, CELL, V22, P489, DOI 10.1016/0092-8674(80)90359-1; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Munnia A, 2001, ONCOGENE, V20, P4853, DOI 10.1038/sj.onc.1204650; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; Phi-van L, 1998, J BIOL CHEM, V273, P18300, DOI 10.1074/jbc.273.29.18300; Phi-Van L, 1999, NUCLEIC ACIDS RES, V27, P3009, DOI 10.1093/nar/27.15.3009; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; Regenhard P, 2001, J LEUKOCYTE BIOL, V69, P651; RUBNITZ JE, 1994, BLOOD, V84, P1747; Sambrook J., 2002, MOL CLONING LAB MANU; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; Yao F, 1998, HUM GENE THER, V9, P1939, DOI 10.1089/hum.1998.9.13-1939	38	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18626	18631		10.1074/jbc.M200572200	http://dx.doi.org/10.1074/jbc.M200572200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11901157	hybrid			2022-12-25	WOS:000175975800052
J	Pelletier, I; Sato, S				Pelletier, I; Sato, S			Specific recognition and cleavage of galectin-3 by Leishmania major through species-specific polygalactose epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGE-BINDING-PROTEIN; SURFACE EXPRESSION; MATRIX METALLOPROTEINASES; MONOCLONAL-ANTIBODIES; ENDOGENOUS LECTIN; CRYSTAL-STRUCTURE; LIPOPHOSPHOGLYCAN; PROMASTIGOTES; MACROPHAGES; MAC-2	Lipophosphoglycan is a major surface molecule of Leishmania, protozoa parasites, which are the causative agents of leishmaniasis, a disease that annually afflicts millions of people worldwide. The oligosaccharide structures of lipophosphoglycan varies among species, and epitopes of these species-specific oligosaccharides are suggested to be implicated in the interaction of Leishmania with macrophages as well as species-specific tissue tropism observed in leishmaniasis. The recognition of the species-specific variation of oligosaccharides is likely to be mediated by host carbohydrate-binding proteins, lectins, but the identities of the lectins remain elusive. Galectin-3 is a mammalian soluble beta-galactoside-binding lectin and is expressed in macrophages, dendritic cells, and keratinocytes, as well as fibroblasts, all of which are present in the site of Leishmania infection. In this paper, we found that galectin-3 binds to lipophosphoglycan of Leishmania major but not to those of Leishmania donovani through L. major-specific polygalactose epitopes. Association of galectin-3 with L. major led to the cleavage of galectin-3, resulting in truncated galectin-3 containing the C-terminal lectin domain but lacking the N-terminal domain implicated in lectin oligomerization. This cleavage was inhibited by the galectin-3 antagonist lactose, as well as 1,10-orthophenanthroline, suggesting that galectin-3 is cleaved by zinc metalloproteases after its binding to lipophosphoglycans. The modulation of various innate immunity reactions by galectin-3 is affected by its oligomerization; therefore, we propose the L. major-specific truncation of galectin-3 may contribute to the species-specific immune responses induced by Leishmania.	Univ Laval, Med Ctr, Ctr Hosp Univ Quebec, Res Ctr Infect Dis,Glycobiol Lab, Quebec City, PQ G1V 4G2, Canada	Laval University	Sato, S (corresponding author), CHU Laval, Ctr Rech Infectiol, Glycobiol Lab, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	sachiko.sato@crchul.ulaval.ca						AHMED H, 1990, BIOCHEMISTRY-US, V29, P5315, DOI 10.1021/bi00474a015; Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684; Bogdan C, 1996, CURR OPIN IMMUNOL, V8, P517, DOI 10.1016/S0952-7915(96)80040-9; BOUVIER J, 1990, BIOCHEMISTRY-US, V29, P10113, DOI 10.1021/bi00495a015; BOUVIER J, 1995, METHOD ENZYMOL, V248, P614; BRUN R, 1979, ACTA TROP, V36, P289; Butcher BA, 1996, J BIOL CHEM, V271, P20573, DOI 10.1074/jbc.271.34.20573; BUTTON LL, 1988, J EXP MED, V167, P724, DOI 10.1084/jem.167.2.724; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; Descoteaux A, 1999, BBA-MOL BASIS DIS, V1455, P341, DOI 10.1016/S0925-4439(99)00065-4; ETGES R, 1986, J BIOL CHEM, V261, P9098; FLOTTE TJ, 1983, AM J PATHOL, V111, P112; FRIGERI LG, 1992, J IMMUNOL, V148, P861; Funk VA, 1997, MOL BIOCHEM PARASIT, V84, P33, DOI 10.1016/S0166-6851(96)02780-6; HANDMAN E, 1985, EMBO J, V4, P329, DOI 10.1002/j.1460-2075.1985.tb03633.x; HSU DK, 1992, J BIOL CHEM, V267, P14167; Hughes RC, 1997, BIOCHEM SOC T, V25, P1194, DOI 10.1042/bst0251194; ILG T, 1992, J BIOL CHEM, V267, P6834; Kane MM, 2000, CURR OPIN HEMATOL, V7, P26, DOI 10.1097/00062752-200001000-00006; KELLEHER M, 1994, MOL BIOCHEM PARASIT, V66, P187, DOI 10.1016/0166-6851(94)90146-5; KELLEHER M, 1992, P NATL ACAD SCI USA, V89, P6, DOI 10.1073/pnas.89.1.6; Kuwabara I, 1996, J IMMUNOL, V156, P3939; Liu FT, 2000, CLIN IMMUNOL, V97, P79, DOI 10.1006/clim.2000.4912; Lowe JB, 2001, CELL, V104, P809, DOI 10.1016/S0092-8674(01)00277-X; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCMASTER WR, 1994, PARASITOLOGY, V108, pS29, DOI 10.1017/S0031182000075697; MOODY SF, 1993, J BIOL CHEM, V268, P18457; MOODY SF, 1993, ACTA TROP, V53, P185, DOI 10.1016/0001-706X(93)90029-B; NG K, 1994, GLYCOBIOLOGY, V4, P845, DOI 10.1093/glycob/4.6.845; Ng K, 1996, BIOCHEM J, V317, P247, DOI 10.1042/bj3170247; Ochieng J, 1998, BBA-GEN SUBJECTS, V1379, P97, DOI 10.1016/S0304-4165(97)00086-X; OCHIENG J, 1994, BIOCHEMISTRY-US, V33, P14109, DOI 10.1021/bi00251a020; PIMENTA PFP, 1992, SCIENCE, V256, P1812, DOI 10.1126/science.1615326; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Sacchettini JC, 2001, BIOCHEMISTRY-US, V40, P3009, DOI 10.1021/bi002544j; Sakanari JA, 1997, EXP PARASITOL, V85, P63, DOI 10.1006/expr.1996.4116; Sato S, 2002, J IMMUNOL, V168, P1813, DOI 10.4049/jimmunol.168.4.1813; SATO S, 1992, J BIOL CHEM, V267, P6983; SATO S, 1994, EUR J IMMUNOL, V24, P216, DOI 10.1002/eji.1830240134; SATO S, 1994, J BIOL CHEM, V269, P4424; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; Schlagenhauf E, 1998, STRUCTURE, V6, P1035, DOI 10.1016/S0969-2126(98)00104-X; SCHNEIDER P, 1993, MOL BIOCHEM PARASIT, V62, P223, DOI 10.1016/0166-6851(93)90111-A; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; Selzer PM, 1999, P NATL ACAD SCI USA, V96, P11015, DOI 10.1073/pnas.96.20.11015; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; THOMAS JR, 1992, J BIOL CHEM, V267, P6829; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; Warfield PR, 1997, INVAS METAST, V17, P101; WEBB JR, 1991, MOL BIOCHEM PARASIT, V48, P173, DOI 10.1016/0166-6851(91)90113-K; WOLLENBERG A, 1993, J EXP MED, V178, P777, DOI 10.1084/jem.178.3.777; WOO HJ, 1990, J BIOL CHEM, V265, P7097	56	93	96	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17663	17670		10.1074/jbc.M201562200	http://dx.doi.org/10.1074/jbc.M201562200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882664	hybrid			2022-12-25	WOS:000175685100036
J	Wu, ZLL; Zhang, LJ; Beeler, DL; Kuberan, B; Rosenberg, RD				Wu, ZLL; Zhang, LJ; Beeler, DL; Kuberan, B; Rosenberg, RD			A new strategy for defining critical functional groups on heparan sulfate	FASEB JOURNAL			English	Article						heparin; gel mobility shift assay; in vitro modification; antithrombin III; sulfotransferase	D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; ANTITHROMBIN-III; CDNA CLONING; EXPRESSION; BIOSYNTHESIS; MICE; BINDING; GENE	Heparan sulfate (HS) is a sulfated polysaccharide present on cell surfaces and in the extracellular matrix. Accumulating evidence shows that HS plays key roles in many biological systems by interacting with various proteins in a structural-specific manner. Due to technical difficulties, however, the understanding of critical functional groups on HS for protein interaction is vague. We report a rapid, convenient, sensitive, and inexpensive strategy using in vitro modification with pure enzymes and gel mobility shift assay to study the subject. We demonstrated the requirements of 3-O, 6-O sulfates and the minimal length of oligosaccharide for antithrombin III (AT-III) binding. We regenerated the binding sites for AT-III on completely desulfated N-resulfated heparin and revealed the critical modification enzymes. This new strategy could be used to identify critical functional groups on HS and to generate HS library and biologically active HS, providing information applicable to the design of HS drugs, such as anticoagulant reagents and viral infection blockers. The binding assay with fibroblast growth factors and receptors confirmed the general usefulness of this approach.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Rosenberg, RD (corresponding author), MIT, Dept Biol, Bldg 68-480,77 Massachusetts Ave, Cambridge, MA 02139 USA.	rdrrosen@mit.edu						Arikawa-Hirasawa E, 2001, NAT GENET, V27, P431, DOI 10.1038/86941; ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Binari RC, 1997, DEVELOPMENT, V124, P2623; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; Damus P S, 1976, Methods Enzymol, V45, P653; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Fan GP, 2000, FEBS LETT, V467, P7, DOI 10.1016/S0014-5793(00)01111-X; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; Li JP, 1997, J BIOL CHEM, V272, P28158, DOI 10.1074/jbc.272.44.28158; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; MacRae IJ, 1998, J BIOL CHEM, V273, P28583, DOI 10.1074/jbc.273.44.28583; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; PETITOU M, 1988, EUR J BIOCHEM, V176, P637, DOI 10.1111/j.1432-1033.1988.tb14324.x; Reizes O, 2001, CELL, V106, P105, DOI 10.1016/S0092-8674(01)00415-9; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; TURNBULL J, 1999, CELL SURFACE PROTEOG, V6, P13; Turnbull JE, 1999, P NATL ACAD SCI USA, V96, P2698, DOI 10.1073/pnas.96.6.2698; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537; Zhang LJ, 2001, J BIOL CHEM, V276, P28806, DOI 10.1074/jbc.M100204200; Zhang LJ, 2001, J BIOL CHEM, V276, P42311, DOI 10.1074/jbc.M101441200	41	48	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					539	545		10.1096/fj.01-0807com	http://dx.doi.org/10.1096/fj.01-0807com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11919156				2022-12-25	WOS:000175425900007
J	Grinstein, E; Jundt, F; Weinert, I; Wernet, P; Royer, HD				Grinstein, E; Jundt, F; Weinert, I; Wernet, P; Royer, HD			Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells	ONCOGENE			English	Article						cell cycle; transcription factor Sp1; G1 phase	PROTEASOME-DEPENDENT DEGRADATION; DNA-BINDING ACTIVITY; GROWTH-FACTOR; GENE-EXPRESSION; RECEPTOR; ACTIVATION; TRANSACTIVATION; D1; PHOSPHORYLATION; INHIBITION	Sp1 binding sites have been identified in enhancer/promoter regions of several growth and cell cycle regulated genes, and it has been shown that Sp1 is increasingly phosphorylated in G1 phase of the cell cycle. Interactions of Sp1 with proteins involved in control of cell cycle and tumor formation have been reported. Here we show that expression of Sp1 protein predominates in the G1 phase of the cell cycle in epithelial cells. This is achieved by proteasome-dependent degradation. Inhibition of endogeneous Sp1 activity by a dominant-negative Sp1 mutant was associated with a cell cycle arrest in G1 phase, a strongly reduced expression of cyclin D1, the EGF-receptor and increased levels of p27Kip1. We have thus identified Sp1 as an important regulator of the cell cycle in G1 phase.	Univ Dusseldorf, Inst Transplantat Diagnost & Zelltherapeut, D-40225 Dusseldorf, Germany; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Humboldt Univ, Fak Med, Robert Rossle Klin, D-13122 Berlin, Germany	Heinrich Heine University Dusseldorf; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin	Grinstein, E (corresponding author), Univ Dusseldorf, Inst Transplantat Diagnost & Zelltherapeut, Moorenstr 5, D-40225 Dusseldorf, Germany.	Edgar.Grinstein@itz.uni-duesseldorf.de	Jundt, Franziska/E-9748-2014; Royer, Hans-dieter/AAH-6293-2019	Jundt, Franziska/0000-0002-8661-7110; 				Adnane J, 1999, ONCOGENE, V18, P239, DOI 10.1038/sj.onc.1202297; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Ben-Bassat H, 1999, J PHARMACOL EXP THER, V290, P1442; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Chang YC, 2001, MOL CELL BIOL, V21, P1121, DOI 10.1128/MCB.21.4.1121-1131.2001; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grinstein E, 1996, J BIOL CHEM, V271, P9215, DOI 10.1074/jbc.271.16.9215; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; Johnson-Pais T, 2001, P NATL ACAD SCI USA, V98, P2211, DOI 10.1073/pnas.051415898; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Kumar AP, 1999, CANCER LETT, V137, P159, DOI 10.1016/S0304-3835(98)00351-6; LABELLA F, 1991, MOL CELL BIOL, V11, P5825, DOI 10.1128/MCB.11.12.5825; Lenferink AEG, 2000, P NATL ACAD SCI USA, V97, P9609, DOI 10.1073/pnas.160564197; Lipson KE, 1998, J PHARMACOL EXP THER, V285, P844; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Opitz OG, 2000, CANCER RES, V60, P2825; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Petersohn D, 1996, EUR J BIOCHEM, V239, P827, DOI 10.1111/j.1432-1033.1996.0827u.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Su KH, 2000, BIOCHEM J, V348, P281, DOI 10.1042/0264-6021:3480281; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; Wu XP, 1996, ONCOGENE, V12, P1397; XU J, 1993, J BIOL CHEM, V268, P16065; Yan GZ, 1997, J NEUROSCI, V17, P6122; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O	49	91	97	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1485	1492		10.1038/sj.onc.1205211	http://dx.doi.org/10.1038/sj.onc.1205211			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896576				2022-12-25	WOS:000173956800003
J	Karsunky, H; Mende, I; Schmidt, T; Moroy, T				Karsunky, H; Mende, I; Schmidt, T; Moroy, T			High levels of the onco-protein Gfi-1 accelerate T-cell proliferation and inhibit activation induced T-cell death in Jurkat T-cells	ONCOGENE			English	Article						Gfi-1; T-cell activation; p21(WAF1); Rb; G1 checkpoint	ZINC-FINGER PROTEIN; TRANSCRIPTIONAL REPRESSOR; TRANSGENIC MICE; MYC; LYMPHOMAGENESIS; LYMPHOCYTES; APOPTOSIS; CYCLE; ELIMINATION; SELECTION	Gfi-1 is a nuclear zinc finger protein with the activity of a transcriptional repressor and the ability to predispose for the development of T-cell lymphoma when expressed constitutively at high levels. Whereas thymic T-cell precursors express endogenous Gfi-1, mature peripheral T-cells lack Gfi-1 but upregulate its expression transiently after antigenic stimulation and activation of Erk1/2 demonstrating a role of Gfi-1 in T-cell activation. Here we show that constitutive expression of Gfi-1 accelerates S phase entry of primary, resting T-cells upon antigenic stimulation. In addition, high level Gfi-1 expression inhibits phorbol ester induced G1 arrest and activation induced cell death in Jurkat T-cells. We demonstrate that these effects of Gfi-1 concur with lower absolute levels and hyperphosphorylation of the pocket protein pRb. Moreover, phorbol ester induced expression of the negative cell cycle regulator p21(WAF1) is blocked in the presence of Gfi-1. These findings suggest that Gfi-1 contributes to T-cell lymphomagenesis by overriding a late G1 cell cycle checkpoint which controls activation induced death and S phase entry of T-cells.	Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany	University of Duisburg Essen	Moroy, T (corresponding author), Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, Virchowstr 173, D-45122 Essen, Germany.		Moroy, Tarik/D-9923-2011					Brehm A, 1999, BRIT J CANCER, V80, P38; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; KABELITZ D, 1993, IMMUNOL TODAY, V14, P338, DOI 10.1016/0167-5699(93)90231-9; Karas M, 1999, MOL BIOL CELL, V10, P4441, DOI 10.1091/mbc.10.12.4441; Karsunky H, 1999, ONCOGENE, V18, P7816, DOI 10.1038/sj.onc.1203205; Lenardo M J, 1995, Int Rev Immunol, V13, P115, DOI 10.3109/08830189509061742; Li QS, 2000, EUR J IMMUNOL, V30, P3329, DOI 10.1002/1521-4141(200011)30:11<3329::AID-IMMU3329>3.0.CO;2-#; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; Liu S, 2000, ANN HUM GENET, V64, P83, DOI 10.1017/S0003480000007971; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; Schmidt T, 1996, NUCLEIC ACIDS RES, V24, P2528, DOI 10.1093/nar/24.13.2528; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; Stankunas K, 1999, COLD SPRING HARB SYM, V64, P505, DOI 10.1101/sqb.1999.64.505; Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873; ZIEGLER SF, 1994, STEM CELLS, V12, P456, DOI 10.1002/stem.5530120502; Zornig M, 1996, ONCOGENE, V12, P1789; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	27	63	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2002	21	10					1571	1579		10.1038/sj/onc/1205216	http://dx.doi.org/10.1038/sj/onc/1205216			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896586				2022-12-25	WOS:000173956800013
J	De Giorgi, F; Lartigue, L; Bauer, MKA; Schubert, A; Grimm, S; Hanson, GT; Remington, SJ; Youle, RJ; Ichas, F				De Giorgi, F; Lartigue, L; Bauer, MKA; Schubert, A; Grimm, S; Hanson, GT; Remington, SJ; Youle, RJ; Ichas, F			The permeability transition pore signals apoptosis by directing Bax translocation and multimerization	FASEB JOURNAL			English	Article						apoptosis; bax; cytochrome c; FRET; permeability transition pore	CYTOCHROME-C RELEASE; ADENINE-NUCLEOTIDE TRANSLOCATOR; MITOCHONDRIAL INNER MEMBRANE; DEPENDENT ANION CHANNEL; CELL-DEATH; CASPASE ACTIVATION; CA2+; BCL-2; OLIGOMERIZATION; CYCLOPHILIN	Mitochondria are key players of apoptosis and can irreversibly commit the cell to death by releasing cytochrome c (Cyt.c) to the cytosol, where caspases 9 and 3 subsequently get activated. Under conditions of oxidative stress, opening of the mitochondrial permeability transition pore (PTP) represents an early trigger and is crucial in causing Cyt.c release. To account for the latter, current models propose that PTP gating would result, as is the case in vitro, in the rupture of the outer mitochondrial membrane caused by mitochondrial matrix swelling. Using live cell imaging and recombinant fluorescent probes based on the green fluorescent protein (GFP) and its mutants, we report that directed repetitive gating of the PTP triggers a delayed Cyt.c efflux, which is not associated with mitochondrial swelling. Instead, subcellular imaging shows that PTP opening signals the redistribution of the cytosolic protein Bax to the mitochondria, where it secondarily forms clusters that appear to be a prerequisite for Cyt.c release. Fluorescence resonance energy transfer imaging further reveals that Bax clustering coincides with the formation of Bax multimers. We conclude that the PTP is not itself a component of the Cyt.c release machinery, but that it acts indirectly by signaling Bax translocation and multimerization.	Univ Bordeaux 2, European Inst Chem & Biol, INSERM, E9929, F-33076 Bordeaux, France; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Oregon, Dept Chem, Eugene, OR 97403 USA; Univ Oregon, Dept Phys, Eugene, OR 97403 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; NINCDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Max Planck Society; University of Oregon; University of Oregon; University of Oregon; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Ichas, F (corresponding author), Univ Bordeaux 2, European Inst Chem & Biol, INSERM, E9929, F-33076 Bordeaux, France.	ichas@u-bordeaux2.fr	lartigue, lydia/I-9548-2014; Ichas, François/ABD-8277-2020	Ichas, François/0000-0001-8184-5248; De Giorgi, Francesca/0000-0003-4850-3582	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002859, ZIANS002859] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Elsliger MA, 1999, BIOCHEMISTRY-US, V38, P5296, DOI 10.1021/bi9902182; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Evtodienko YV, 1996, FEBS LETT, V393, P86, DOI 10.1016/0014-5793(96)00875-7; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; GUNTER TE, 1990, AM J PHYSIOL, V258, P755; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Johnson N, 1999, EUR J BIOCHEM, V263, P353, DOI 10.1046/j.1432-1327.1999.00490.x; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOEW LM, 1994, P NATL ACAD SCI USA, V91, P12579, DOI 10.1073/pnas.91.26.12579; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rolls MM, 1999, J CELL BIOL, V146, P29, DOI 10.1083/jcb.146.1.29; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YU WH, 1995, J BIOL CHEM, V270, P13998, DOI 10.1074/jbc.270.23.13998	37	215	221	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					607	+		10.1096/fj.01-0269fje	http://dx.doi.org/10.1096/fj.01-0269fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919169				2022-12-25	WOS:000174203700007
J	Lim, JH; Bustin, M; Ogryzko, VV; Postnikov, YV				Lim, JH; Bustin, M; Ogryzko, VV; Postnikov, YV			Metastable macromolecular complexes containing high mobility group nucleosome-binding chromosomal proteins in HeLa nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLASE COMPLEX; SELF-ORGANIZATION; CHROMATIN; HMG-14; DOMAIN; PHOSPHORYLATION; ARCHITECTURE; COMPONENTS; ACTIVATION; DISTINCT	High mobility group nucleosome-binding (HMGN) proteins belong to a family of nuclear proteins that bind to nucleosomes and enhance transcription from chromatin templates by altering the structure of the chromatin fiber. The intranuclear organization of these proteins is dynamic and related to the metabolic state of the cell. Here we report that similar to50% of the HMGN proteins are organized into macromolecular complexes in a fashion that is similar to that of other nuclear activities that modify the structure of the chromatin fiber. We identify several distinct HMGN-containing complexes that are relatively unstable and find that the inclusion of HMGN in the complexes varies according to the metabolic state of the cell. The nucleosome binding ability of HMGN in the complex is stronger than that of the free HMGN. We suggest that the inclusion of HMGN proteins into metastable multiprotein complexes serves to target the HMGN proteins to specific sites in chromatin and enhances their interaction with nucleosomes.	NCI, CCR, Prot Sect, NIH, Bethesda, MD 20892 USA; CNRS, UPR 9079, Inst Andre Lwoff, Lab Oncogenese, F-94801 Villejuif, France	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Centre National de la Recherche Scientifique (CNRS)	Postnikov, YV (corresponding author), NCI, CCR, Prot Sect, NIH, Bldg 37 Rm 3E-24, Bethesda, MD 20892 USA.		Ogryzko, Vasily/M-6665-2015; Bustin, Michael/G-6155-2015	Ogryzko, Vasily/0000-0002-8548-1389; Bustin, Michael/0000-0002-5147-7242				Aalfs JD, 2000, TRENDS BIOCHEM SCI, V25, P548, DOI 10.1016/S0968-0004(00)01689-3; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; Bianchi ME, 2000, EMBO REP, V1, P109, DOI 10.1093/embo-reports/kvd030; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P431, DOI 10.1016/S0968-0004(01)01855-2; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; CRIPPA MP, 1992, J MOL BIOL, V228, P442, DOI 10.1016/0022-2836(92)90833-6; Davie JR, 2000, CRIT REV EUKAR GENE, V10, P303; Ding HF, 1997, MOL CELL BIOL, V17, P5843, DOI 10.1128/MCB.17.10.5843; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Guschin D, 2000, J BIOL CHEM, V275, P35248, DOI 10.1074/jbc.M006041200; Hassan AH, 2001, FRONT BIOSCI, V6, pD1054, DOI 10.2741/Hassan; HESS B, 1995, J THEOR BIOL, V176, P181, DOI 10.1006/jtbi.1995.0187; Hock R, 1998, EMBO J, V17, P6992, DOI 10.1093/emboj/17.23.6992; Hock R, 1998, J CELL BIOL, V143, P1427, DOI 10.1083/jcb.143.6.1427; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Imbalzano AN, 1998, CRIT REV EUKAR GENE, V8, P225, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.10; JOHNS EW, 1982, HMG CHROMOSAL PROTEI; Khochbin S, 2001, FEBS LETT, V494, P141, DOI 10.1016/S0014-5793(01)02327-4; Kornberg RD, 1999, CURR OPIN GENET DEV, V9, P148, DOI 10.1016/S0959-437X(99)80022-7; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kuzmichev A, 2001, CURR TOP MICROBIOL, V254, P35; Langst G, 2001, J CELL SCI, V114, P2561; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; MARDIAN JKW, 1980, SCIENCE, V209, P1534, DOI 10.1126/science.7433974; Misteli T, 2001, J CELL BIOL, V155, P181, DOI 10.1083/jcb.200108110; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Pederson T, 2001, CELL, V104, P635, DOI 10.1016/S0092-8674(02)01455-1; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; POSTNIKOV YV, 1994, NUCLEIC ACIDS RES, V22, P4520, DOI 10.1093/nar/22.21.4520; Prymakowska-Bosak M, 2001, MOL CELL BIOL, V21, P5169, DOI 10.1128/MCB.21.15.5169-5178.2001; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rothhut B, 1997, CELL MOL LIFE SCI, V53, P522, DOI 10.1007/s000180050066; SANDEEN G, 1980, NUCLEIC ACIDS RES, V8, P3757, DOI 10.1093/nar/8.17.3757; Shirakawa H, 2000, J BIOL CHEM, V275, P37937, DOI 10.1074/jbc.M000989200; Trieschmann L, 1998, P NATL ACAD SCI USA, V95, P5468, DOI 10.1073/pnas.95.10.5468; TRIESCHMANN L, 1995, MOL CELL BIOL, V15, P6663; Vedeler A, 2000, BIOCHEM J, V348, P565, DOI 10.1042/0264-6021:3480565; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711	43	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20774	20782		10.1074/jbc.M200404200	http://dx.doi.org/10.1074/jbc.M200404200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11909857	hybrid			2022-12-25	WOS:000176204500087
J	Lonergan, PE; Martin, DSD; Horrobin, DF; Lynch, MA				Lonergan, PE; Martin, DSD; Horrobin, DF; Lynch, MA			Neuroprotective effect of eicosapentaenoic acid in hippocampus of rats exposed to gamma-irradiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; ACTIVATED PROTEIN-KINASES; POLYUNSATURATED FATTY-ACIDS; AGE-RELATED-CHANGES; CYTOCHROME-C; DIETARY SUPPLEMENTATION; CELL-DEATH; SIGNAL-TRANSDUCTION; CASPASE ACTIVATION; OXIDATIVE STRESS	Exposure to irradiation leads to detrimental changes in several cell types. In this study we assessed the changes induced in hippocampus by exposure of rats to whole body irradiation; the findings reveal that irradiation leads to apoptotic cell death in hippocampus, and as a consequence, long term potentiation in perforant path-granule cell synapses is markedly impaired. The evidence is consistent with the view that irradiation induced an increase in reactive oxygen species and that this leads to stimulation of the stress-activated protein kinase, JNK, and activation of the transcription factor, c-Jun. Consequent upon activation of JNK, a cascade of cell signaling events was stimulated that ultimately resulted in apoptosis, as suggested by parallel increases in cytochrome c translocation, caspase-3 activation, poly(ADP-ribose) polymerase cleavage, and terminal dUTP nick-end labeling staining. Treatment of rats with eicosapentaenoic acid inhibited the irradiation-induced increase in reactive oxygen species production and the subsequent cellular signaling events, suggesting that oxidative stress triggered apoptotic cell death in the hippocampus of rats exposed to irradiation. Significantly, when the compromise in cell viability induced by irradiation was prevented by eicosapentaenoic acid, long term potentiation was sustained in a manner similar to that in the sham-treated control group.	Trinity Coll Dublin, Dept Phys, Trinity Coll Inst Neurosci, Dublin 2, Ireland; Laxdale Ltd, Stirling, Scotland	Trinity College Dublin	Lynch, MA (corresponding author), Trinity Coll Dublin, Dept Phys, Trinity Coll Inst Neurosci, Dublin 2, Ireland.	lynchma@tcd.ie	Lonergan, Peter E/B-4544-2008	Lonergan, Peter E/0000-0001-7233-8156; Lynch, Marina/0000-0002-4631-0499				Babcock T, 2000, NUTRITION, V16, P1116, DOI 10.1016/S0899-9007(00)00392-0; BENKOVIC SA, 1993, J COMP NEUROL, V338, P97, DOI 10.1002/cne.903380108; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.0.CO;2-E; Cortopassi GA, 1999, BBA-BIOENERGETICS, V1410, P183, DOI 10.1016/S0005-2728(98)00166-2; Czeh B, 1998, HIPPOCAMPUS, V8, P548; Delgado M, 2000, J NEUROIMMUNOL, V110, P97, DOI 10.1016/S0165-5728(00)00359-3; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501; FINNEN MJ, 1991, BIOCHEM SOC T, V19, pS91, DOI 10.1042/bst019091s; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Gahtan E, 1998, EUR J NEUROSCI, V10, P538, DOI 10.1046/j.1460-9568.1998.00058.x; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hallan E, 1997, SCAND J IMMUNOL, V46, P601, DOI 10.1046/j.1365-3083.1997.d01-173.x; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; Hayashi H, 1999, CURR MED RES OPIN, V15, P177, DOI 10.1185/03007999909114089; HORROBIN DF, 1991, MED HYPOTHESES, V35, P23, DOI 10.1016/0306-9877(91)90078-D; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kannan, 2000, Pathophysiology, V7, P153, DOI 10.1016/S0928-4680(00)00053-5; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Korystov YN, 1996, FEBS LETT, V388, P238, DOI 10.1016/0014-5793(96)00538-8; Kumagae Y, 1999, MOL BRAIN RES, V67, P10, DOI 10.1016/S0169-328X(99)00013-3; LEBEL CP, 1990, NEUROCHEM INT, V17, P435, DOI 10.1016/0197-0186(90)90025-O; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Lynch MA, 2002, VITAM HORM, V64, P185, DOI 10.1016/S0083-6729(02)64006-3; Lynch MA, 1998, PROG NEUROBIOL, V56, P571, DOI 10.1016/S0301-0082(98)00054-9; MacManus A, 2000, J BIOL CHEM, V275, P4713, DOI 10.1074/jbc.275.7.4713; MARTIN DSD, 2000, SOC NEUROSCI, V26, P889; Martinou JC, 1996, CURR OPIN NEUROBIOL, V6, P609, DOI 10.1016/S0959-4388(96)80092-4; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; McGahon BM, 1999, NEUROBIOL AGING, V20, P643, DOI 10.1016/S0197-4580(99)00027-5; McGahon BM, 1999, NEUROSCIENCE, V94, P305, DOI 10.1016/S0306-4522(99)00219-5; MICHALOWSKI AS, 1994, ACTA ONCOL, V33, P139, DOI 10.3109/02841869409098397; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Murray CA, 1998, J BIOL CHEM, V273, P12161, DOI 10.1074/jbc.273.20.12161; Murray CA, 1998, J NEUROSCI, V18, P2974; Neary JT, 1997, NEWS PHYSIOL SCI, V12, P286; NEEDLEMAN P, 1979, P NATL ACAD SCI USA, V76, P944, DOI 10.1073/pnas.76.2.944; O'Brien MA, 2001, BIOTECHNIQUES, V30, P886, DOI 10.2144/01304pf01; O'Donnell E, 2000, EUR J NEUROSCI, V12, P345, DOI 10.1046/j.1460-9568.2000.00900.x; Obukowicz MG, 1998, J PHARMACOL EXP THER, V287, P157; Palakurthi SS, 2000, CANCER RES, V60, P2919; Park J, 1997, J BIOL CHEM, V272, P16725, DOI 10.1074/jbc.272.27.16725; PELLMAR TC, 1993, RADIAT RES, V136, P255, DOI 10.2307/3578619; PELLMAR TC, 1991, NEUROSCIENCE, V44, P353, DOI 10.1016/0306-4522(91)90060-2; PELLMAR TC, 1990, RADIAT RES, V122, P209, DOI 10.2307/3577608; PETTEL JB, 2000, EUR J NEUROSCI, V12, P621; PURASIRI P, 1994, CLIN SCI, V87, P711, DOI 10.1042/cs0870711; RICEEVANS C, 1993, PROG LIPID RES, V32, P71, DOI 10.1016/0163-7827(93)90006-I; RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Smith MA, 1998, J HISTOCHEM CYTOCHEM, V46, P731, DOI 10.1177/002215549804600605; Spencer JPE, 1998, J NEUROCHEM, V71, P2112; Steinauer KK, 2000, INT J RADIAT ONCOL, V48, P325, DOI 10.1016/S0360-3016(00)00671-4; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; TOLLIVER JM, 1987, RADIAT RES, V112, P555, DOI 10.2307/3577107; Tournier C, 1997, EUR J BIOCHEM, V244, P587, DOI 10.1111/j.1432-1033.1997.00587.x; Vereker E, 2001, EUR J NEUROSCI, V14, P1809, DOI 10.1046/j.0953-816x.2001.01809.x; Vereker E, 2000, J NEUROSCI, V20, P6811, DOI 10.1523/JNEUROSCI.20-18-06811.2000; Vereker E, 2000, J BIOL CHEM, V275, P26252, DOI 10.1074/jbc.M002226200; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yuen KS, 1997, PHOTOCHEM PHOTOBIOL, V65, P587, DOI 10.1111/j.1751-1097.1997.tb08610.x; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhivotovsky B, 1998, CELL DEATH DIFFER, V5, P459, DOI 10.1038/sj.cdd.4400386	73	107	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20804	20811		10.1074/jbc.M202387200	http://dx.doi.org/10.1074/jbc.M202387200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11912218	hybrid			2022-12-25	WOS:000176204500090
J	Ramakrishnan, B; Qasba, PK				Ramakrishnan, B; Qasba, PK			Structure-based design of beta 1,4-galactosyltransferase I (beta 4GaI-T1) with equally efficient N-acetylgalactosaminyltransferase activity - Point mutation broadens beta 4GaI-T1 donor specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LACTALBUMIN; CRYSTAL-STRUCTURE; BOVINE; ACCEPTOR; EXPRESSION	beta1,4-Galactosyltransferase I (Gal-T1) normally transfers Gal from LTDP-Gal to GlcNAc in the presence of Mn2+ ion. In the presence of alpha-lactalbumin (LA), the Gal acceptor specificity is altered from GlcNAc to Glc. Gal-T1 also transfers GaINAc from UDP-Ga1NAc to Glc-NAc, but with only similar to0.1% of Gal-T activity. To understand this low GaINAc-transferase activity, we have carried out the crystal structure analysis of the Gal-T1(.)LA complex with UDP-GalNAc at 2.1-Angstrom resolution. The crystal structure reveals that the LTDP-GalNAc binding to Gal-T1 is similar to the binding of LTDP-Gal to Gal-T1, except for an additional hydrogen bond formed between the N-acetyl group of GaINAc moiety with the Tyr-289 side chain hydroxyl group. Elimination of this additional hydrogen bond by mutating Tyr-289 residue to Leu, Ile, or Asn enhances the GaINAc-transferase activity. Although all three mutants exhibit enhanced GalNAc-transferase activity, the mutant Y289L exhibits GalNAc-transferase activity that is nearly 100% of its Gal-T activity, even while completely retaining its Gal-T activity. The steady state kinetic analyses on the Leu-289 mutant indicate that the K-m for GlcNAc has increased compared to the wild type. On the other hand, the catalytic constant (k(cat)) in the Gal-T reaction is comparable with the wild type, whereas it is 3-5-fold higher in the GaINAc-T reaction. Interestingly, in the presence of LA, these mutants also transfer GaINAc to Glc instead of to GlcNAc. The present study demonstrates that, in the Gal-T family, the Tyr-289/Phe-289 residue largely determines the sugar donor specificity.	NCI, Struct Glycobiol Sect, LECB, CCR,NIH, Frederick, MD 21702 USA; NCI, Intramural Res Support Program SAIC, LECB, CCR,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Qasba, PK (corresponding author), NCI, Struct Glycobiol Sect, LECB, CCR,NIH, Bldg 469,Rm 221, Frederick, MD 21702 USA.				NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREE PJ, 1978, BIOCHIM BIOPHYS ACTA, V544, P489; AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; BERLINER LJ, 1984, MOL CELL BIOCHEM, V62, P37, DOI 10.1007/BF00230075; BERLINER LJ, 1982, BIOCHEMISTRY-US, V21, P6340, DOI 10.1021/bi00268a003; BOEGGEMAN EE, 1993, PROTEIN ENG, V6, P779, DOI 10.1093/protein/6.7.779; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chung SJ, 1998, BIOORG MED CHEM LETT, V8, P3359, DOI 10.1016/S0960-894X(98)00618-0; DO KY, 1995, J BIOL CHEM, V270, P18447, DOI 10.1074/jbc.270.31.18447; HILL R, 1979, UCLA FORUM MED SCI, V21, P63; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; KARULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; KIM SC, 1988, ARCH BIOCHEM BIOPHYS, V267, P54, DOI 10.1016/0003-9861(88)90007-0; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; Navaza J, 1994, ACTA CRYSTALLOGR D, V50, P760; Nomura T, 1998, J BIOL CHEM, V273, P13570, DOI 10.1074/jbc.273.22.13570; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALCIC M M, 1991, Glycobiology, V1, P205, DOI 10.1093/glycob/1.2.205; Qasba PK, 1997, CRIT REV BIOCHEM MOL, V32, P255, DOI 10.3109/10409239709082574; Ramakrishnan B, 2002, BIOCHEM BIOPH RES CO, V291, P1113, DOI 10.1006/bbrc.2002.6506; Ramakrishnan B, 2002, J MOL BIOL, V318, P491, DOI 10.1016/S0022-2836(02)00020-7; Ramakrishnan B, 2001, J BIOL CHEM, V276, P37665, DOI 10.1074/jbc.M102458200; Ramakrishnan B, 2001, J MOL BIOL, V310, P205, DOI 10.1006/jmbi.2001.4757; Rao V. S. R., 1998, CONFORMATION CARBOHY; Van den Nieuwenhof IM, 1999, GLYCOBIOLOGY, V9, P115, DOI 10.1093/glycob/9.2.115; Van den Nieuwenhof IM, 1999, FEBS LETT, V459, P377, DOI 10.1016/S0014-5793(99)01284-3; Van den Nieuwenhof IM, 2000, EUR J BIOCHEM, V267, P4753, DOI 10.1046/j.1432-1327.2000.01528.x; Zhang YN, 1999, GLYCOBIOLOGY, V9, P815, DOI 10.1093/glycob/9.8.815	27	176	203	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20833	20839		10.1074/jbc.M111183200	http://dx.doi.org/10.1074/jbc.M111183200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11916963	hybrid			2022-12-25	WOS:000176204500094
J	Ulrich, H; Magdesian, MH; Alves, MJM; Colli, W				Ulrich, H; Magdesian, MH; Alves, MJM; Colli, W			In vitro selection of RNA aptamers that bind to cell adhesion receptors of Trypanosoma cruzi and inhibit cell invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; EXPONENTIAL ENRICHMENT; SYSTEMATIC EVOLUTION; MAMMALIAN-CELLS; TRANS-SIALIDASE; LIGANDS; SURFACE; INFECTION; ACTIVATION; MOLECULES	Trypanosoma cruzi causing Chagas' disease needs to invade host cells to complete its life cycle. Macromolecules on host cell surfaces such as laminin, thrombospondin, heparan sulfate, and fibronectin are believed to be important in mediating parasite-host cell adhesions and in the invasion process of the host cell by the parasite. The SELEX technique (systematic evolution of ligands bygxponential enrichment) was used to evolve nuclease-resistant RNA ligands (aptamer = to fit) that bind with affinities of 40-400 nm to parasite receptors for the host cell matrix molecules laminin, fibronectin, thrombospondin, and heparan sulfate. After eight consecutive rounds of in vitro selection four classes of RNA aptamers based on structural similarities were isolated and sequenced. All members of each class shared a common sequence motif and competed with the respective host cell matrix molecule that was used for displacement during the selection procedure. RNA pools following seven and eight selection rounds as well as individual aptamers sharing consensus motifs were active in inhibiting invasion of LLC-MK2 monkey kidney cells by T. cruzi in vitro.	Univ Fed Sao Paulo, Inst Quim, Dept Bioquim, BR-05513970 Sao Paulo, Brazil	Universidade Federal de Sao Paulo (UNIFESP)	Colli, W (corresponding author), Univ Fed Sao Paulo, Inst Quim, Dept Bioquim, Caixa Postal 26077, BR-05513970 Sao Paulo, Brazil.	walcolli@usp.br	Colli, Walter/ABA-5440-2021; Alves, Maria Julia/K-8976-2012; Ulrich, Henning/AAX-8586-2021; Colli, Walter/AAW-7649-2021; Ulrich, Henning/C-5245-2013; Colli, Walter/G-1188-2012	Alves, Maria Julia/0000-0001-7211-9631; Ulrich, Henning/0000-0002-2114-3815; Colli, Walter/0000-0001-7305-4673; Ulrich, Henning/0000-0002-2114-3815; 				Almeida-de-Faria M, 1999, EXP PARASITOL, V92, P263, DOI 10.1006/expr.1999.4423; ANDREWS NW, 1982, J PROTOZOOL, V29, P264, DOI 10.1111/j.1550-7408.1982.tb04024.x; ARMSTRONG PB, 2000, BIOCHIM BIOPHYS ACTA, V1470, P9; BRENER Z, 1973, ANNU REV MICROBIOL, V27, P347, DOI 10.1146/annurev.mi.27.100173.002023; Brody E N, 2000, J Biotechnol, V74, P5, DOI 10.1016/S1389-0352(99)00004-5; COLLI W, 1993, FASEB J, V7, P1257, DOI 10.1096/fasebj.7.13.8405811; CROSS GAM, 1993, ANNU REV MICROBIOL, V47, P385, DOI 10.1146/annurev.mi.47.100193.002125; Davis KA, 1998, NUCLEIC ACIDS RES, V26, P3915, DOI 10.1093/nar/26.17.3915; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Floege J, 1999, AM J PATHOL, V154, P169, DOI 10.1016/S0002-9440(10)65263-7; Ghosh AK, 2001, P NATL ACAD SCI USA, V98, P13278, DOI 10.1073/pnas.241491198; Giannelli G, 2001, CLIN EXP METASTAS, V18, P439; GIORDANO R, 1994, MOL BIOCHEM PARASIT, V65, P85, DOI 10.1016/0166-6851(94)90117-1; Giordano R, 1999, J BIOL CHEM, V274, P3461, DOI 10.1074/jbc.274.6.3461; GONCALVES MF, 1991, EXP PARASITOL, V72, P43, DOI 10.1016/0014-4894(91)90119-H; Grellier P, 2001, J BIOL CHEM, V276, P47078, DOI 10.1074/jbc.M106017200; HERRERA EM, 1994, MOL BIOCHEM PARASIT, V65, P73, DOI 10.1016/0166-6851(94)90116-3; Hess GP, 2000, P NATL ACAD SCI USA, V97, P13895, DOI 10.1073/pnas.240459497; Homann M, 1999, NUCLEIC ACIDS RES, V27, P2006, DOI 10.1093/nar/27.9.2006; Ito Y, 1998, J BIOACT COMPAT POL, V13, P114, DOI 10.1177/088391159801300203; Jayasena SD, 1999, CLIN CHEM, V45, P1628; Jenison RD, 1998, ANTISENSE NUCLEIC A, V8, P265, DOI 10.1089/oli.1.1998.8.265; Jeong S, 2001, BIOCHEM BIOPH RES CO, V281, P237, DOI 10.1006/bbrc.2001.4327; Kusser W, 2000, J Biotechnol, V74, P27; Leppanen O, 2000, ARTERIOSCL THROM VAS, V20, pE89, DOI 10.1161/01.ATV.20.11.e89; Lima APCA, 2002, J BIOL CHEM, V277, P5875, DOI 10.1074/jbc.M108518200; Magdesian MH, 2001, J BIOL CHEM, V276, P19382, DOI 10.1074/jbc.M011474200; MING M, 1995, CELL, V82, P287, DOI 10.1016/0092-8674(95)90316-X; Morris KN, 1998, P NATL ACAD SCI USA, V95, P2902, DOI 10.1073/pnas.95.6.2902; OConnell D, 1996, P NATL ACAD SCI USA, V93, P5883, DOI 10.1073/pnas.93.12.5883; Ostendorf T, 1999, J CLIN INVEST, V104, P913, DOI 10.1172/JCI6740; OUAISSI MA, 1986, SCIENCE, V234, P603, DOI 10.1126/science.3094145; PAN WH, 1995, P NATL ACAD SCI USA, V92, P11509, DOI 10.1073/pnas.92.25.11509; Pereira M. E. A., 1990, Modern parasite biology: cellular, immunological, and molecular aspects., P64; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Sargiannidou I, 2001, EXP BIOL MED, V226, P726, DOI 10.1177/153537020222600803; Scharfstein J, 2000, J EXP MED, V192, P1289, DOI 10.1084/jem.192.9.1289; Soeiro MD, 1999, CELL STRUCT FUNCT, V24, P139, DOI 10.1247/csf.24.139; Sultan A A, 1999, Int Microbiol, V2, P155; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Ulrich H, 1998, P NATL ACAD SCI USA, V95, P14051, DOI 10.1073/pnas.95.24.14051; Ulrich H, 2001, BRAZ J MED BIOL RES, V34, P295, DOI 10.1590/S0100-879X2001000300002; Wang J, 2000, RNA, V6, P571, DOI 10.1017/S1355838200992215; Willis MC, 1998, BIOCONJUGATE CHEM, V9, P573, DOI 10.1021/bc980002x; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	45	124	147	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20756	20762		10.1074/jbc.M111859200	http://dx.doi.org/10.1074/jbc.M111859200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11919187	hybrid			2022-12-25	WOS:000176204500085
J	Vargason, JM; Ho, PS				Vargason, JM; Ho, PS			The effect of cytosine methylation on the structure and geometry of the Holliday junction - The structure of d(CCGGTACm(5)CGG) at 1.5 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-WAY DNA JUNCTION; CRYSTAL-STRUCTURES; NUCLEIC-ACIDS; MACROMOLECULAR STRUCTURES; B-DNA; SEQUENCE; CRYSTALLOGRAPHY; RECOMBINATION; TRANSITION; REFINEMENT	The single crystal structure of the methylated sequence d(CCGGTACm(5)CGG) has been solved as an antiparallel stacked X Holliday junction to 1.5 Angstrom resolution. When compared with the parent nonmethylated d(CCGGTACCGG) structure, the duplexes are translated by 3.4 A along the helix axis and rotated by 10.8degrees relative to each other, rendering the major grooves more accessible overall. A Ca2+ complex is seen in the minor groove opposite the junction but is related to the B conformation of the stacked arms. At the junction itself, the hydrogen bond from the N4 nitrogen of cytosine C8 to the C7 phosphate at the crossover in the parent structure has been replaced by a water bridge. Thus, this direct interaction is not absolutely required to stabilize the junction at the previously defined ACC trinucleotide core. The more compact methylated junction forces the Na+ of the protected central cavity of the nonmethylated junction into a solvent cluster that spans the space between the junction crossover and the stacked arms. A series of void volumes within the methylated and the nonmethylated structures suggests that small monovalent cations can fill and vacate this central cavity without the need to unfold the four-stranded Holliday junction completely.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Ho, PS (corresponding author), Oregon State Univ, Dept Biochem & Biophys, ALS 2011, Corvallis, OR 97331 USA.		Ho, Pui/AAF-8838-2020; Ho, Pui S/F-6186-2014	Ho, Pui/0000-0002-8082-4311; Ho, Pui S/0000-0002-8082-4311	NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [R01 GM062957, R01 GM062957-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062957] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEHE M, 1981, P NATL ACAD SCI-BIOL, V78, P1619, DOI 10.1073/pnas.78.3.1619; BERMAN HM, 1992, BIOPHYS J, V63, P751, DOI 10.1016/S0006-3495(92)81649-1; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CLEGG RM, 1992, BIOCHEMISTRY-US, V31, P4846, DOI 10.1021/bi00135a016; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; COOPER JP, 1987, J MOL BIOL, V198, P711, DOI 10.1016/0022-2836(87)90212-9; Cox MM, 2001, ANNU REV GENET, V35, P53, DOI 10.1146/annurev.genet.35.102401.090016; DICKERSON RE, 1987, J BIOMOL STRUCT DYN, V5, P557, DOI 10.1080/07391102.1987.10506413; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Eichman BF, 2000, P NATL ACAD SCI USA, V97, P3971, DOI 10.1073/pnas.97.8.3971; Eichman BF, 2001, J MOL BIOL, V308, P15, DOI 10.1006/jmbi.2001.4567; ElHassan MA, 1996, J MOL BIOL, V259, P95, DOI 10.1006/jmbi.1996.0304; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FREDERICK CA, 1987, BIOPOLYMERS, V181, pS145; Hanseh C., 1979, SUBSTITUENT CONSTANT; HARDIN CC, 1993, BIOCHEMISTRY-US, V32, P5870, DOI 10.1021/bi00073a021; HO PS, 1988, J PHYS CHEM-US, V92, P939, DOI 10.1021/j100315a017; Ho PS, 2001, CURR OPIN STRUC BIOL, V11, P302, DOI 10.1016/S0959-440X(00)00219-0; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; Huheey J.E., 1978, INORGANIC CHEM PRINC; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Kielkopf CL, 2000, J MOL BIOL, V296, P787, DOI 10.1006/jmbi.1999.3478; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Leitner D, 2000, BIOCHEMISTRY-US, V39, P5886, DOI 10.1021/bi992630n; Lilley DMJ, 2000, Q REV BIOPHYS, V33, P109, DOI 10.1017/S0033583500003590; Lu XJ, 2000, J MOL BIOL, V300, P819, DOI 10.1006/jmbi.2000.3690; Mao CD, 1999, J AM CHEM SOC, V121, P5437, DOI 10.1021/ja9900398; Mayer-Jung C, 1998, EMBO J, V17, P2709, DOI 10.1093/emboj/17.9.2709; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Nowakowski J, 2000, J MOL BIOL, V300, P93, DOI 10.1006/jmbi.2000.3826; Nowakowski J, 1999, NAT STRUCT BIOL, V6, P151; Ortiz-Lombardia M, 1999, NAT STRUCT BIOL, V6, P913; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sha RJ, 2000, CHEM BIOL, V7, P743, DOI 10.1016/S1074-5521(00)00024-7; Smith GR, 2001, ANNU REV GENET, V35, P243, DOI 10.1146/annurev.genet.35.102401.090509; Tolstorukov MY, 2001, BIOPHYS J, V81, P3409, DOI 10.1016/S0006-3495(01)75973-5; Vargason JM, 2000, NAT STRUCT BIOL, V7, P758; Whitehurst CE, 2000, IMMUNITY, V13, P703, DOI 10.1016/S1074-7613(00)00069-8; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498	44	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					21041	21049		10.1074/jbc.M201357200	http://dx.doi.org/10.1074/jbc.M201357200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11919197	hybrid			2022-12-25	WOS:000176204500119
J	Palmblad, M; Westlind-Danielsson, A; Bergquist, J				Palmblad, M; Westlind-Danielsson, A; Bergquist, J			Oxidation of methionine 35 attenuates formation of amyloid beta-peptide 1-40 oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; IN-VITRO; PROTEIN FIBRILLOGENESIS; CEREBROSPINAL-FLUID; MASS-SPECTROMETER; FIBRIL FORMATION; AGGREGATION; NEUROTOXICITY; DISSOCIATION; MORPHOLOGY	Amyloid plaques formed by aggregation of the amyloid beta-peptide (Abeta) are an intrinsic component of Alzheimer disease pathogenesis. It has been suggested that oxidation of methionine 35 in Abeta has implications for Alzheimer disease, and it has been shown that oxidation of Met-35 significantly inhibits aggregation in vitro. In this study, the aggregational properties of Abeta-(1-40) before and after Met-35 oxidation were investigated using electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. The results show that Abeta-(1-40)Met-35(0) trimer and tetramer formation is significantly attenuated as compared with Abeta-(1-40). This suggests that oxidation of Met-35 inhibits a conformational switch in Abeta-(1-40) necessary for trimer but not dimer formation. Random incorporation of Abeta-(1-40) and Abeta-(1-40)Met-35(0) in homo- and heterooligomers could also be observed. This is the first report of an early rate-limiting step in Abeta-(1-40) aggregation. Slowing of the fibrillization process at this early step is likely to support prolonged solubility and clearance of Abeta from brain and may reduce disease progression.	Uppsala Univ, Angstrom Lab, Div Ion Phys, SE-75121 Uppsala, Sweden; Karolinska Inst, NEUROTEC, Novum, KFC, SE-14186 Huddinge, Sweden; Sahlgrens Univ Hosp, Univ Gothenburg, Dept Psychiat & Neurochem, Inst Clin Neurosci, SE-43180 Molndal, Sweden; Uppsala Univ, Inst Chem, Dept Analyt Chem, SE-75121 Uppsala, Sweden	Uppsala University; Karolinska Institutet; Sahlgrenska University Hospital; University of Gothenburg; Uppsala University	Bergquist, J (corresponding author), Uppsala Univ, Angstrom Lab, Div Ion Phys, Box 534, SE-75121 Uppsala, Sweden.		Bergquist, Jonas/C-5894-2015; Palmblad, Magnus/N-8203-2015	Palmblad, Magnus/0000-0002-5865-8994; Bergquist, Jonas/0000-0002-4597-041X				BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; Bitan G, 2001, J BIOL CHEM, V276, P35176, DOI 10.1074/jbc.M102223200; Butterfield DA, 1999, ANN NY ACAD SCI, V893, P265, DOI 10.1111/j.1749-6632.1999.tb07833.x; Chaney MO, 1998, PROTEIN ENG, V11, P761, DOI 10.1093/protein/11.9.761; Chen XG, 1997, FASEB J, V11, P817, DOI 10.1096/fasebj.11.10.9271367; Coles M, 1998, BIOCHEMISTRY-US, V37, P11064, DOI 10.1021/bi972979f; Golde TE, 2000, BBA-MOL BASIS DIS, V1502, P172, DOI 10.1016/S0925-4439(00)00043-0; Hakansson K, 2000, J AM SOC MASS SPECTR, V11, P210, DOI 10.1016/S1044-0305(99)00144-0; Harkany T, 2000, REV NEUROSCIENCE, V11, P329; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hasegawa K, 1999, BIOCHEMISTRY-US, V38, P15514, DOI 10.1021/bi991161m; HAYES RN, 1990, METHOD ENZYMOL, V193, P237, DOI 10.1016/0076-6879(90)93418-K; Huang THJ, 2000, J BIOL CHEM, V275, P36436, DOI 10.1074/jbc.M005698200; IVERSEN LL, 1995, BIOCHEM J, V311, P1; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kallberg Y, 2001, J BIOL CHEM, V276, P12945, DOI 10.1074/jbc.M010402200; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; Kisilevsky R, 1997, CRIT REV BIOCHEM MOL, V32, P361, DOI 10.3109/10409239709082674; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Kuo YM, 2001, J BIOL CHEM, V276, P12991, DOI 10.1074/jbc.M007859200; LANSBURY PT, 1995, NAT STRUCT BIOL, V2, P990, DOI 10.1038/nsb1195-990; Lomakin A, 1997, P NATL ACAD SCI USA, V94, P7942, DOI 10.1073/pnas.94.15.7942; Mehta PD, 2000, ARCH NEUROL-CHICAGO, V57, P100, DOI 10.1001/archneur.57.1.100; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Nilsson S, 2001, RAPID COMMUN MASS SP, V15, P1997, DOI 10.1002/rcm.466.abs; Palmblad M, 2000, RAPID COMMUN MASS SP, V14, P1029, DOI 10.1002/1097-0231(20000630)14:12<1029::AID-RCM984>3.0.CO;2-#; Palmblad M, 2000, EUR J MASS SPECTROM, V6, P267, DOI 10.1255/ejms.348; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Seilheimer B, 1997, J STRUCT BIOL, V119, P59, DOI 10.1006/jsbi.1997.3859; Sennvik K, 2000, NEUROSCI LETT, V278, P169, DOI 10.1016/S0304-3940(99)00929-5; Shao HY, 1999, J MOL BIOL, V285, P755, DOI 10.1006/jmbi.1998.2348; SHEN CL, 1995, BIOPHYS J, V69, P640, DOI 10.1016/S0006-3495(95)79940-4; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; Teplow DB, 1998, AMYLOID, V5, P121, DOI 10.3109/13506129808995290; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Watson AA, 1998, BIOCHEMISTRY-US, V37, P12700, DOI 10.1021/bi9810757; Westlind-Danielsson A, 2001, BIOCHEMISTRY-US, V40, P14736, DOI 10.1021/bi010375c; Yong W, 2002, P NATL ACAD SCI USA, V99, P150, DOI 10.1073/pnas.012584899	43	106	110	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19506	19510		10.1074/jbc.M112218200	http://dx.doi.org/10.1074/jbc.M112218200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11912198	hybrid			2022-12-25	WOS:000175894800037
J	Vanni, C; Mancini, P; Gao, Y; Ottaviano, C; Guo, F; Salani, B; Torrisi, MR; Zheng, Y; Eva, A				Vanni, C; Mancini, P; Gao, Y; Ottaviano, C; Guo, F; Salani, B; Torrisi, MR; Zheng, Y; Eva, A			Regulation of proto-Dbl by intracellular membrane targeting and protein stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; KAPPA-B; TRANSFORMING ACTIVITY; EXCHANGE FACTOR; ONCOGENIC DBL; RHO-GTPASES; C-JUN; ACTIVATION; BINDING; RAC	The pleckstrin homology (PH) domain of onco-Dbl, a guanine nucleotide exchange factor (GEF) for Cdc42 and RhoA GTPases, interacts with phosphoinositides (PIPs). This interaction modulates both the GEF activity and the targeting to the plasma membrane of onco-Dbl. Conversely, we have previously shown that in proto-Dbl an intramolecular interaction between the N-terminal domain and the PH domain imposes a negative regulation on both the DH and PH functions, suppressing its transforming activity. Here we have further investigated the mode of regulation of proto-Dbl by generating proto-Dbl mutants deleted of the last C-terminal 50 amino acids, which contain a PEST motif, and/or unable to bind to PIPs due to substitutions of the positively charged residues of the PH domain. The PH mutants of proto-Dbl retained a relative weak GEF activity toward Cdc42 and RhoA in vitro, but their RhoA activating potential was impaired in vivo. Further, these mutants lost both the plasma membrane targeting and the transforming activities, contrary to the PH mutants of onco-Dbl that retained the exchange activity both in vitro and in vivo and showed significant, but partially, reduced transforming activity. Deletion of the C-terminal sequences from onco-Dbl did not affect its function, whereas similar deletion of proto-Dbl led to an increase of transforming activity. Analysis of the half-life of the proto-Dbl mutants revealed that deletion of the C-terminal sequences increases the stability of the protein. Overall, the transformation potential of proto-Dbl mutants was associated with an augmented localization of the protein to the plasma membrane and a strong activation of Jun N-terminal kinase activity and transcription of cyclin D1. Together with previous observations, these data suggest that the biological activity of proto-Dbl is tightly regulated by a combination of mechanisms that involve intramolecular interaction, PH binding to PIPs, and the N- and C-terminal domain-dependent turnover of the protein.	Ist Giannina Gaslini, Mol Biol Lab, I-16147 Genoa, Italy; Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy; Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA	University of Genoa; IRCCS Istituto Giannina Gaslini; Sapienza University Rome; University of Tennessee System; University of Tennessee Health Science Center	Eva, A (corresponding author), Ist Giannina Gaslini, Mol Biol Lab, Largo Gaslini 5, I-16147 Genoa, Italy.		Eva, Alessandra/J-8268-2016; Zheng, Yi/J-7235-2015	Eva, Alessandra/0000-0003-2949-078X; Zheng, Yi/0000-0001-7089-6074; mancini, patrizia/0000-0003-0556-2056	NIGMS NIH HHS [GM53943] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Fenwick C, 2000, SCIENCE, V287, P869, DOI 10.1126/science.287.5454.869; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAZIANI G, 1989, ONCOGENE, V4, P823; Gulli MP, 2001, GENE DEV, V15, P365, DOI 10.1101/gad.876901; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; Jefferson AB, 1998, ONCOGENE, V16, P2303, DOI 10.1038/sj.onc.1201891; Jin SH, 2000, BIOCHEM BIOPH RES CO, V277, P718, DOI 10.1006/bbrc.2000.3744; Katan M, 1999, FEBS LETT, V452, P36, DOI 10.1016/S0014-5793(99)00531-1; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Nern A, 1999, J CELL BIOL, V144, P1187, DOI 10.1083/jcb.144.6.1187; Nishida K, 1999, FEBS LETT, V459, P186, DOI 10.1016/S0014-5793(99)01244-2; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Razzini G, 2000, J BIOL CHEM, V275, P14873, DOI 10.1074/jbc.275.20.14873; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RON D, 1991, NEW BIOL, V3, P372; RON D, 1989, ONCOGENE, V4, P1067; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; Zhu KJ, 2001, MOL CELL BIOL, V21, P425, DOI 10.1128/MCB.21.2.425-437.2001	43	29	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19745	19753		10.1074/jbc.M111025200	http://dx.doi.org/10.1074/jbc.M111025200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11907027	hybrid			2022-12-25	WOS:000175894800067
J	Wong, LH; Sim, H; Chatterjee-Kishore, M; Hatzinisiriou, I; Devenish, RJ; Stark, G; Ralph, SJ				Wong, LH; Sim, H; Chatterjee-Kishore, M; Hatzinisiriou, I; Devenish, RJ; Stark, G; Ralph, SJ			Isolation and characterization of a human STAT1 gene regulatory element - Inducibility by interferon (IFN) types I and II and role of IFN regulatory factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED RESPONSE ELEMENT; TRANSCRIPTIONAL ACTIVATOR; GAMMA-INTERFERONS; PROMOTER ELEMENT; ISGF3 COMPONENTS; MELANOMA-CELLS; KAPPA-B; ALPHA; EXPRESSION; DNA	The transcription factor STAT1 plays a pivotal role in signal transduction of type I and II interferons (IFNs). STAT1 activation leads to changes in expression of key regulatory genes encoding caspases and cell cycle inhibitors. Deficient STAT1 expression in human cancer cells and virally mediated inhibition of STAT1 function have been associated with cellular resistance to IFNs and mycobacterial infection in humans. Thus, given the relative importance of STAT1, we isolated and characterized a human STAT1 intronic enhancer region displaying IFN-regulated activity. Functional analyses by transient expression identified a repressor region and type I and II IFN-inducible elements within the STAT1 enhancer sequence. A candidate IRF-E/GAS/IRF-E (IGI) sequence containing GAAANN nucleotide repeats was shown by gel shift assay to bind to IFN regulatory factor-1 (IRF-1), but not to IFN-stimulated gene factor-3 (ISGF-3) or STAT1-3. An additional larger IGI-binding complex containing IRF-1 was identified. Mutation of the GAAANN repeats within the IGI DNA element eliminated IRF-1 binding and the IFN-regulated activity of the STAT1 intronic enhancer region. Transfection of the IFN-resistant MM96 cell line to express increased levels of IRF-1 protein also elevated STAT1, STAT2, and p48/ IRF-9 expression and enhanced cellular responsiveness to IFN-beta. Reciprocating regulation between IRF-1 and STAT1 genes and encoded proteins indicates that an intracellular amplifier circuit exists controlling cellular responsiveness to the IFNs.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia; Cleveland Clin Fdn, Dept Mol Biol, Cleveland, OH 44195 USA	Monash University; Cleveland Clinic Foundation	Ralph, SJ (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia.		Wong, Lee H/H-9757-2012; Ralph, Stephen J./AAE-4888-2019	Wong, Lee H/0000-0002-4005-7330; Ralph, Stephen J./0000-0002-4335-092X				Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; Au WC, 2001, J BIOL CHEM, V276, P41629, DOI 10.1074/jbc.M105121200; Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Burysek L, 1999, J VIROL, V73, P7334; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHUMAKOV IM, 1995, NATURE, V377, P175; de Veer MJ, 1998, GENOMICS, V54, P267, DOI 10.1006/geno.1998.5555; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; Grotzinger T, 1996, J BIOL CHEM, V271, P25253, DOI 10.1074/jbc.271.41.25253; Haddad B, 1998, CYTOGENET CELL GENET, V83, P58, DOI 10.1159/000015126; Haque SJ, 1998, SEMIN ONCOL, V25, P14; Hatina J, 1996, EXP CLIN IMMUNOGENET, V13, P55; Henderson YC, 1997, BRIT J HAEMATOL, V96, P566, DOI 10.1046/j.1365-2141.1997.d01-2057.x; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kirchhoff S, 1998, BIOCHIMIE, V80, P659, DOI 10.1016/S0300-9084(99)80019-4; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Kusumoto M, 1998, J STRUCT BIOL, V121, P363, DOI 10.1006/jsbi.1998.3970; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LEWIN AR, 1991, EUR J BIOCHEM, V199, P417, DOI 10.1111/j.1432-1033.1991.tb16139.x; Li XX, 1998, BIOCHIMIE, V80, P703, DOI 10.1016/S0300-9084(99)80023-6; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; Look DC, 1998, IMMUNITY, V9, P871, DOI 10.1016/S1074-7613(00)80652-4; MARKIE D, 1996, METHODS MOL BIOL YAC, P65; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MUNROE DJ, 1994, GENOMICS, V19, P506, DOI 10.1006/geno.1994.1100; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Pine R, 1997, NUCLEIC ACIDS RES, V25, P4346, DOI 10.1093/nar/25.21.4346; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VISVADER JE, 1992, EMBO J, V11, P4557, DOI 10.1002/j.1460-2075.1992.tb05557.x; White LC, 1996, IMMUNITY, V5, P365, DOI 10.1016/S1074-7613(00)80262-9; Wong LH, 1998, J IMMUNOL, V160, P5475; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Xie RL, 2001, J BIOL CHEM, V276, P18624, DOI 10.1074/jbc.M010391200; Yamamoto K, 1997, CYTOGENET CELL GENET, V77, P207, DOI 10.1159/000134578; YAN RQ, 1995, NUCLEIC ACIDS RES, V23, P459, DOI 10.1093/nar/23.3.459	55	82	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19408	19417		10.1074/jbc.M111302200	http://dx.doi.org/10.1074/jbc.M111302200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11909852	hybrid			2022-12-25	WOS:000175894800024
J	Kanuri, M; Minko, IG; Nechev, LV; Harris, TM; Harris, CM; Lloyd, RS				Kanuri, M; Minko, IG; Nechev, LV; Harris, TM; Harris, CM; Lloyd, RS			Error prone translesion synthesis past gamma-hydroxypropano deoxyguanosine, the primary acrolein-derived adduct in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-DELTA; IN-VIVO; ESCHERICHIA-COLI; MUTAGENESIS; PROPANODEOXYGUANOSINE; REPLICATION; LESIONS; REPAIR; VITRO	8-Hydroxy-5,6,7,8-tetrahydropyrimido[1,2-a]purin-10(3H)-one,3-(2'-deoxyriboside) (1,N-2-gamma-hydroxypropano deoxyguanosine, gamma-HOPdG) is a major DNA adduct that forms as a result of exposure to acrolein, an environmental pollutant and a product of endogenous lipid peroxidation. gamma-HOPdG has been shown previously not to be a miscoding lesion when replicated in Escherichia coli. In contrast to those prokaryotic studies, in vivo replication and mutagenesis assays in COS-7 cells using single stranded DNA containing a specific gamma-HOPdG adduct, revealed that the gamma-HOPdG adduct was significantly mutagenic. Analyses revealed both transversion and transition types of mutations at an overall mutagenic frequency of 7.4 x 10(-2)/translesion synthesis. In vitro gamma-HOPdG strongly blocks DNA synthesis by two major polymerases, pol delta and pol epsilon. Replicative blockage of pol delta by gamma-HOPdG could be diminished by the addition of proliferating cell nuclear antigen, leading to highly mutagenic translesion bypass across this adduct. The differential functioning and processing capacities of the mammalian polymerases may be responsible for the higher mutation frequencies observed in this study when compared with the accurate and efficient nonmutagenic bypass observed in the bacterial system.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Vanderbilt Univ, Dept Chem, Nashville, TN 37235 USA; Vanderbilt Univ, Ctr Mol Toxicol, Nashville, TN 37235 USA	University of Texas System; University of Texas Medical Branch Galveston; Vanderbilt University; Vanderbilt University	Lloyd, RS (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA.	rslloyd@utmb.edu		Lloyd, R. Stephen/0000-0001-7273-372X	NIEHS NIH HHS [ES00267, ES05355, ES06676] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, P01ES005355, P30ES000267] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BENAMIRA M, 1992, J BIOL CHEM, V267, P22392; BROCK N, 1979, ARZNEIMITTEL-FORSCH, V29-1, P659; BURCHAM PC, 1994, J BIOL CHEM, V269, P28844; Burcham PC, 1998, MUTAGENESIS, V13, P287, DOI 10.1093/mutage/13.3.287; Carmical JR, 2000, CHEM RES TOXICOL, V13, P18, DOI 10.1021/tx9901332; CHARY P, 1995, J BIOL CHEM, V270, P4990, DOI 10.1074/jbc.270.10.4990; CHAUDHARY AK, 1994, SCIENCE, V265, P1580, DOI 10.1126/science.8079172; Chen XL, 2000, J BIOL CHEM, V275, P17677, DOI 10.1074/jbc.M910278199; CHUI G, 1995, J BIOL CHEM, V270, P7799, DOI 10.1074/jbc.270.14.7799; CHUNG FL, 1984, CANCER RES, V44, P990; COHEN SM, 1992, CANCER RES, V52, P3577; CURREN RD, 1988, MUTAT RES, V209, P17, DOI 10.1016/0165-7992(88)90104-2; de los Santos C, 2001, J BIOL CHEM, V276, P9077, DOI 10.1074/jbc.M009028200; DOWNEY KM, 1988, CANCER CELLS EUKARYO, V6, P403; Fink SP, 1997, P NATL ACAD SCI USA, V94, P8652, DOI 10.1073/pnas.94.16.8652; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Johnson KA, 1997, J BIOL CHEM, V272, P11434; Kawanishi M, 1998, MUTAT RES-GEN TOX EN, V417, P65, DOI 10.1016/S1383-5718(98)00093-X; Khullar S, 1999, J MED CHEM, V42, P947, DOI 10.1021/jm980605u; Kozekov ID, 2001, CHEM RES TOXICOL, V14, P1482, DOI 10.1021/tx010127h; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; Lee Y, 1998, J BIOL CHEM, V273, P19490, DOI 10.1074/jbc.273.31.19490; Levine RL, 2001, J BIOL CHEM, V276, P18717, DOI 10.1074/jbc.M102158200; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; MARNETT LJ, 1985, MUTAT RES, V148, P25; MARNETT LJ, 1994, DNA ADDUCTS IDENTIFI, P151; MCDIARMID MA, 1991, MUTAT RES, V248, P93, DOI 10.1016/0027-5107(91)90091-2; McNees AG, 1997, J BIOL CHEM, V272, P33211, DOI 10.1074/jbc.272.52.33211; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1994, P NATL ACAD SCI USA, V91, P11899, DOI 10.1073/pnas.91.25.11899; Mozzherin DJ, 1997, P NATL ACAD SCI USA, V94, P6126, DOI 10.1073/pnas.94.12.6126; Mozzherin DJ, 1996, J BIOL CHEM, V271, P31711, DOI 10.1074/jbc.271.49.31711; NATH RG, 1994, P NATL ACAD SCI USA, V91, P7491, DOI 10.1073/pnas.91.16.7491; Nechev LV, 2000, CHEM RES TOXICOL, V13, P421, DOI 10.1021/tx990167+; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; Penn A, 2001, ENVIRON HEALTH PERSP, V109, P219, DOI 10.2307/3434688; PERKINS EG, 1992, ACS SYM SER, P310; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINGER B, 1999, IARC SCI PUBLICATION, V150; Stucki M, 2001, PROG NUCLEIC ACID RE, V65, P261; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TAN CK, 1986, J BIOL CHEM, V261, P2310; VanderVeen LA, 2001, J BIOL CHEM, V276, P9066, DOI 10.1074/jbc.M008900200; Yang IY, 2001, J BIOL CHEM, V276, P9071, DOI 10.1074/jbc.M008918200	45	69	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18257	18265		10.1074/jbc.M112419200	http://dx.doi.org/10.1074/jbc.M112419200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889127	hybrid			2022-12-25	WOS:000175975800004
J	Laroche-Joubert, N; Marsy, S; Michelet, S; Imbert-Teboul, M; Doucet, A				Laroche-Joubert, N; Marsy, S; Michelet, S; Imbert-Teboul, M; Doucet, A			Protein kinase A-independent activation of ERK and H,K-ATPase by cAMP in native kidney cells - Role of Epac I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-GATED CHANNEL; SIGNAL-REGULATED KINASE; CALCITONIN RECEPTOR; GRANULE EXOCYTOSIS; COLLECTING DUCT; STREPTOLYSIN-O; RAT-KIDNEY; CYCLIC-AMP; EXPRESSION; BINDING	This study aimed at determining the signaling pathways underlying calcitonin- and isoproterenol-induced stimulation of H,K-ATPase in rat renal collecting duct. H,K-ATPase activity was determined in microdissected collecting ducts preincubated with or without either specific inhibitors or antibodies directed against intracellular signaling proteins. Transient cell membrane permeabilization with streptolysin-O allowed intracellular access of antibodies. The stimulation of H,K-ATPase by calcitonin and isoproterenol was mimicked by cAMP analogues and was abolished by adenylyl cyclase inhibition. Protein kinase A inhibition abolished isoproterenol but not calcitonin effect on H,K-ATPase. Calcitonin increased the phosphorylation of extracellular signal-regulated kinase (ERK) in a protein kinase A-independent manner, and the inhibition of the ERK phosphorylation prevented the stimulation of H,K-ATPase by calcitonin. Antibodies directed against either the cAMP-activated guanine-nucleotide exchange factor Epac I, the monomeric G protein Rap-1 or the kinase Raf-B, curtailed the stimulation of H,K-ATPase by calcitonin, whereas antibodies against the related monomeric G protein Ras or kinase Raf-1 had no effect. In conclusion, calcitonin stimulates H,K-ATPase through a cAMP/Epac I/Rap-1/Raf-B/ERK cascade.	CEA Saclay, Serv Biol Cellulaire, Lab Biol Integree Cellules Renales, CNRS,Unite Rech Associee 1859, F-91191 Gif Sur Yvette, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Doucet, A (corresponding author), Ctr Etud Saclay, URA 1859, Batiment 520, F-91191 Gif Sur Yvette, France.							AnkorinaStark I, 1997, CELL CALCIUM, V21, P163, DOI 10.1016/S0143-4160(97)90040-3; Bailey MA, 2000, KIDNEY INT, V58, P1893, DOI 10.1111/j.1523-1755.2000.00361.x; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BASTANI B, 1995, J AM SOC NEPHROL, V5, P1476; BIEL M, 1994, P NATL ACAD SCI USA, V91, P3505, DOI 10.1073/pnas.91.9.3505; BuffinMeyer B, 1997, AM J PHYSIOL-RENAL, V272, pF124, DOI 10.1152/ajprenal.1997.272.1.F124; Chen Y, 1998, J BIOL CHEM, V273, P19809, DOI 10.1074/jbc.273.31.19809; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; ELALOUF JM, 1993, J CLIN INVEST, V91, P264, DOI 10.1172/JCI116180; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ghani EA, 1999, BIOCHEMISTRY-US, V38, P15204, DOI 10.1021/bi991678y; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; HERSEY SJ, 1995, PHYSIOL REV, V75, P155, DOI 10.1152/physrev.1995.75.1.155; HOHMAN RJ, 1985, P NATL ACAD SCI USA, V82, P4578, DOI 10.1073/pnas.82.14.4578; HORN VJ, 1988, J BIOL CHEM, V263, P12454; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; HOUSSAMI S, 1994, ENDOCRINOLOGY, V135, P183, DOI 10.1210/en.135.1.183; IMBERT M, 1975, PFLUG ARCH EUR J PHY, V354, P213, DOI 10.1007/BF00584645; Kampen GT, 2000, BLOOD, V95, P1911, DOI 10.1182/blood.V95.6.1911; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; Laroche-Joubert N, 2000, AM J PHYSIOL-RENAL, V279, pF1053, DOI 10.1152/ajprenal.2000.279.6.F1053; Leino L, 1999, BIOCHEM BIOPH RES CO, V265, P29, DOI 10.1006/bbrc.1999.1631; LEROSEY I, 1991, BIOCHEM BIOPH RES CO, V175, P430, DOI 10.1016/0006-291X(91)91582-W; MANDON B, 1995, AM J PHYSIOL-RENAL, V268, pF1070, DOI 10.1152/ajprenal.1995.268.6.F1070; Milella M, 1997, J IMMUNOL, V158, P3148; MOREL F, 1986, PHYSIOL REV, V66, P377, DOI 10.1152/physrev.1986.66.2.377; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; SCHWARTZ GJ, 1985, J CLIN INVEST, V75, P1638, DOI 10.1172/JCI111871; SIGA E, 1994, AM J PHYSIOL, V267, pF354, DOI 10.1152/ajprenal.1994.267.3.F354; SIGA E, 1993, AM J PHYSIOL, V264, pF221, DOI 10.1152/ajprenal.1993.264.2.F221; Siga E, 1996, AM J PHYSIOL-RENAL, V271, pF1217, DOI 10.1152/ajprenal.1996.271.6.F1217; SIGNAL IS, 1986, P NATL ACAD SCI USA, V83, P4725; Trotta R, 1998, J IMMUNOL, V161, P6648; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1	38	104	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18598	18604		10.1074/jbc.M201868200	http://dx.doi.org/10.1074/jbc.M201868200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11897793	hybrid			2022-12-25	WOS:000175975800048
J	Price, MO; Atkinson, SJ; Knaus, UG; Dinauer, MC				Price, MO; Atkinson, SJ; Knaus, UG; Dinauer, MC			Rac activation induces NADPH oxidase activity in transgenic COSphox cells, and the level of superoxide production is exchange factor-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; HUMAN NEUTROPHILS; SH3 DOMAIN; FLAVOCYTOCHROME B(558); COMPONENTS P47(PHOX); STRUCTURAL BASIS; EFFECTOR REGION; INSERT REGION; GTPASE RAC2; RHO-GTPASES	Transient expression of constitutively active Rac1 derivatives, (G12V) or Q61L), was sufficient to induce phagocyte NADPH oxidase activity in a COS-7 cell model in which human cDNAs for essential oxidase components, gp91(phox)) p22(phox), p47(phox), and p67(phox), were expressed as stable transgenes. Expression of constitutively active Rac1 in "COSphox,, cells induced translocation of p47(phox) and p67(phox) to the membrane. Furthermore, translocation of p47(phox) was induced in the absence of p67(phox) expression, even though Rac does not directly bind p47(phox). Rac effector domain point substitutions (A27K, G30S, D38A, Y40C), which can selectively eliminate interaction with different effector proteins, impaired Rac1V12-induced superoxide production. Activation of endogenous Rac1 by expression of constitutively active Rac-guanine nucleotide exchange factor (GEF) derivatives was sufficient to induce high level NADPH oxidase activity in COSphox cells. The constitutively active form of the hematopoietic-specific GEF, Vav1, was the most effective at activating superoxide production, despite detection of higher levels of Rac1-GTP upon expression of constitutively active Vav2 or Tiam1 derivatives. These data suggest that Rac can play a dual role in NADPH oxidase activation, both by directly participating in the oxidase complex and by activating signaling events leading to oxidase assembly, and that Vav1 may be the physiologically relevant GEF responsible for activating this Rac-regulated complex.	James Whitcomb Riley Hosp Children, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; James Whitcomb Riley Hosp Children, Dept Pediat Hematol Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Med Ctr, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Indiana Univ, Med Ctr, Dept Med Nephrol, Indianapolis, IN 46202 USA; Scripps Res Inst, Res Inst, Dept Immunol, La Jolla, CA 92037 USA	James Whitcomb Riley Hospital Children; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Scripps Research Institute	Dinauer, MC (corresponding author), Wells Ctr Pediat Res, 1044 W Walnut St,R4,Rm 402A, Indianapolis, IN 46202 USA.	mdinauer@iupui.edu		Price, Marianne/0000-0002-6652-534X	NCI NIH HHS [P30CA82709] Funding Source: Medline; NHLBI NIH HHS [R01HL45635] Funding Source: Medline; NIAID NIH HHS [AI35947] Funding Source: Medline; NIDDK NIH HHS [P50DK49218] Funding Source: Medline; NIGMS NIH HHS [GM37696] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA082709] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Adams ER, 1997, BIOCHEM J, V325, P249, DOI 10.1042/bj3250249; Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Ambruso DR, 2000, P NATL ACAD SCI USA, V97, P4654, DOI 10.1073/pnas.080074897; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Billadeau DD, 2000, J EXP MED, V192, P381, DOI 10.1084/jem.192.3.381; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; Crompton AM, 2000, J BIOL CHEM, V275, P25751, DOI 10.1074/jbc.M002050200; Cross AR, 2000, BIOCHEM J, V349, P113, DOI 10.1042/0264-6021:3490113; Cross AR, 1999, J BIOL CHEM, V274, P15519, DOI 10.1074/jbc.274.22.15519; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DEMENDEZ I, 1995, BLOOD, V85, P1104, DOI 10.1182/blood.V85.4.1104.bloodjournal8541104; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DINAUER M, 1998, HEMATOLOGY INFANCY C, V1, P889; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; Dusi S, 1996, BIOCHEM J, V314, P409, DOI 10.1042/bj3140409; El Benna J, 1999, J LEUKOCYTE BIOL, V66, P1014; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; HEYWORTH P, 1998, MOL CELLULAR BASIS I, P165; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; JACKSON JH, 1988, HEMATOL ONCOL CLIN N, V2, P317, DOI 10.1016/S0889-8588(18)30624-5; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kim C, 2001, J IMMUNOL, V166, P1223, DOI 10.4049/jimmunol.166.2.1223; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Lavigne MC, 1999, BLOOD, V94, p207A; Li Q, 1999, J BIOL CHEM, V274, P3764, DOI 10.1074/jbc.274.6.3764; McPhail LC, 1999, BBA-MOL CELL BIOL L, V1439, P277, DOI 10.1016/S1388-1981(99)00100-6; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; Park HS, 1999, BIOCHEM BIOPH RES CO, V259, P38, DOI 10.1006/bbrc.1999.0721; Price MO, 2002, BLOOD, V99, P2653, DOI 10.1182/blood.V99.8.2653; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; QUINN MT, 1993, J BIOL CHEM, V268, P20983; Rinckel LA, 1999, BIOCHEM BIOPH RES CO, V263, P118, DOI 10.1006/bbrc.1999.1334; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; Sathyamoorthy M, 1997, J BIOL CHEM, V272, P9141; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; Toporik A, 1998, BIOCHEMISTRY-US, V37, P7147, DOI 10.1021/bi9800404; UHLINGER DJ, 1994, J BIOL CHEM, V269, P22095; VAN AL, 1997, GENE DEV, V11, P2295; Vergnaud S, 2000, EUR J BIOCHEM, V267, P1059, DOI 10.1046/j.1432-1327.2000.01097.x; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wientjes FB, 2001, BIOCHEM BIOPH RES CO, V289, P382, DOI 10.1006/bbrc.2001.5982; Williams DA, 2000, BLOOD, V96, P1646; Xu XM, 1997, BIOCHEMISTRY-US, V36, P626, DOI 10.1021/bi962059h; XU XM, 1994, J BIOL CHEM, V269, P23569; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782	78	98	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19220	19228		10.1074/jbc.M200061200	http://dx.doi.org/10.1074/jbc.M200061200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11896053	hybrid			2022-12-25	WOS:000175975800126
J	Sakwe, AM; Engstrom, A; Larsson, M; Rask, L				Sakwe, AM; Engstrom, A; Larsson, M; Rask, L			Biosynthesis and secretion of parathyroid hormone are sensitive to proteasome inhibitors in dispersed bovine parathyroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; ENDOPLASMIC-RETICULUM CHAPERONES; DIBUTYRYL CYCLIC-AMP; POSTTRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; VITAMIN-D; PREPROPARATHYROID HORMONE; EXTRACELLULAR CALCIUM; MOLECULAR CHAPERONES; SIGNAL PEPTIDASES	Preproparathyroid hormone (prepro-PTH) is one of the proteins abundantly synthesized by parathyroid chief cells; yet under normal growth conditions, little or no prepro-PTH can be detected in these cells. Although this may be attributed to effective cotranslational translocation and proteolytic processing, proteasome-mediated degradation of PTH precursors may be important in the regulation of the levels of these precursors and hence PTH secretion. The effects of N-acetyl-Leu-Leu-norleucinal, N-acetyl-Leu-Leu-methional, carbobenzoxy-Leu-Leu-leucinal (MG132), benzyloxycarbonyl-Ile-Glu(t-butyl)-Ala-leucinal (proteasome inhibitor I), and lactacystin on the biosynthesis and secretion of PTH were examined in dispersed bovine parathyroid cells. We demonstrate that treatment of these cells with proteasome inhibitors caused the accumulation of prepro-PTH and pro-PTH. Compared with mock-treated cells, the processing of pro-PTH to PTH was delayed, and the secretion of intact PTH decreased in proteasome inhibitor-treated cells. Relieving the inhibition of the proteasome by chasing MG132-treated cells in medium without the inhibitor led to the rapid disappearance of the accumulated prepro-PTH, and the rate of PTH secretion was restored to levels comparable to those in mock-treated cells. Furthermore, overexpression of the Hsp70 family of molecular chaperones was observed in proteasome inhibitor-treated cells, and we show that PTH/PTH precursors interact with these molecular chaperones. These data suggest the involvement of parathyroid cell proteasomes in the quality control of PTH biosynthesis.	Uppsala Univ, Uppsala Biomed Ctr, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden	Uppsala University	Sakwe, AM (corresponding author), Uppsala Univ, Uppsala Biomed Ctr, Dept Med Biochem & Microbiol, POB 582, SE-75123 Uppsala, Sweden.	Amos.Sakwe@imbim.uu.se	Larsson, Marten/A-5992-2012; Rask, Lars B/L-4177-2013; Sakwe, Amos/AAU-7639-2020	Sakwe, Amos/0000-0002-2283-794X				Andersson M, 1999, EXP EYE RES, V69, P129, DOI 10.1006/exer.1999.0688; Bauskin AR, 2000, EMBO J, V19, P2212, DOI 10.1093/emboj/19.10.2212; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Black MT, 1998, CURR PHARM DESIGN, V4, P133; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; Brewer JW, 1997, EMBO J, V16, P7207, DOI 10.1093/emboj/16.23.7207; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Brown E M, 1993, Curr Opin Nephrol Hypertens, V2, P541, DOI 10.1097/00041552-199307000-00004; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1983, METABOLISM, V32, P1038, DOI 10.1016/0026-0495(83)90074-4; Bush KT, 1997, J BIOL CHEM, V272, P9086; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHU LLH, 1973, J CLIN INVEST, V52, P3089, DOI 10.1172/JCI107508; CHU LLH, 1983, MOL CELL ENDOCRINOL, V33, P157, DOI 10.1016/0303-7207(83)90164-8; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; COHN DV, 1986, VITAM HORM, V43, P283; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Glickman MH, 2000, SEMIN CELL DEV BIOL, V11, P149, DOI 10.1006/scdb.2000.0161; HABENER JF, 1979, ENDOCRINOLOGY, V104, P265, DOI 10.1210/endo-104-1-265; HAMILTON JW, 1986, MOL CELL ENDOCRINOL, V44, P179, DOI 10.1016/0303-7207(86)90061-4; HAMILTON JW, 1983, ENDOCRINOLOGY, V113, P285, DOI 10.1210/endo-113-1-285; HENDY GN, 1995, J BIOL CHEM, V270, P9517, DOI 10.1074/jbc.270.16.9517; Hurwitz S, 1996, CRIT REV BIOCHEM MOL, V31, P41, DOI 10.3109/10409239609110575; Kawazoe Y, 1998, EUR J BIOCHEM, V255, P356, DOI 10.1046/j.1432-1327.1998.2550356.x; Kim D, 1999, BIOCHEM BIOPH RES CO, V254, P264, DOI 10.1006/bbrc.1998.9840; Kopp F, 1997, P NATL ACAD SCI USA, V94, P2939, DOI 10.1073/pnas.94.7.2939; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lightcap ES, 2000, CLIN CHEM, V46, P673; MACGREGOR RR, 1975, ENDOCRINOLOGY, V97, P178, DOI 10.1210/endo-97-1-178; MACGREGOR RR, 1989, BIOCHEM BIOPH RES CO, V160, P1339, DOI 10.1016/S0006-291X(89)80150-0; MACGREGOR RR, 1978, CLIN ORTHOP RELAT R, P244; MACGREGOR RR, 1979, J BIOL CHEM, V254, P4428; Marambaud P, 1997, J NEUROCHEM, V68, P698; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Meerovitch K, 1997, J BIOL CHEM, V272, P6706, DOI 10.1074/jbc.272.10.6706; Moallem E, 1998, J BIOL CHEM, V273, P5253, DOI 10.1074/jbc.273.9.5253; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; MORRISSEY JJ, 1979, J CELL BIOL, V82, P93, DOI 10.1083/jcb.82.1.93; MORRISSEY JJ, 1979, J CELL BIOL, V83, P521, DOI 10.1083/jcb.83.3.521; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Muresan Z, 1998, MOL ENDOCRINOL, V12, P458, DOI 10.1210/me.12.3.458; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Naveh-Many T, 1999, CURR OPIN NEPHROL HY, V8, P415, DOI 10.1097/00041552-199907000-00004; NAVEHMANY T, 1990, J CLIN INVEST, V86, P1313, DOI 10.1172/JCI114840; Onyango I, 1999, EXP CELL RES, V247, P9, DOI 10.1006/excr.1998.4324; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; Ostrowska H, 1997, BIOCHEM BIOPH RES CO, V234, P729, DOI 10.1006/bbrc.1997.6434; RIDEFELT P, 1992, BIOCHEM BIOPH RES CO, V186, P556, DOI 10.1016/S0006-291X(05)80844-7; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; RUSSELL J, 1993, ENDOCRINOLOGY, V132, P2639, DOI 10.1210/en.132.6.2639; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sela-Brown A, 1999, MINER ELECTROL METAB, V25, P342, DOI 10.1159/000057471; Sherman M Y, 1996, EXS, V77, P57; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; WASSLER M, 1987, BIOCHEM J, V247, P407, DOI 10.1042/bj2470407; WATSON PH, 1995, J MOL ENDOCRINOL, V15, P61, DOI 10.1677/jme.0.0150061; WATSON PH, 1993, CLIN INVEST MED, V16, P58; YAMAMOTO M, 1989, J CLIN INVEST, V83, P1053, DOI 10.1172/JCI113946; ZULL JE, 1985, J BIOL CHEM, V260, P1608	64	9	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17687	17695		10.1074/jbc.M108576200	http://dx.doi.org/10.1074/jbc.M108576200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884387	hybrid			2022-12-25	WOS:000175685100039
J	Shenton, D; Perrone, G; Quinn, KA; Dawes, IW; Grant, CM				Shenton, D; Perrone, G; Quinn, KA; Dawes, IW; Grant, CM			Regulation of protein S-thiolation by glutaredoxin 5 in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE GENES; HUMAN ENDOTHELIAL-CELLS; OXIDATIVE STRESS; MIXED-DISULFIDES; THIOLTRANSFERASE GLUTAREDOXIN; ESCHERICHIA-COLI; REDOX REGULATION; GLUTATHIONE; THIOREDOXIN; REDUCTION	The irreversible oxidation of cysteine residues can be prevented by protein S-thiolation, a process by which protein -SH groups form mixed disulfides with low molecular weight thiols such as glutathione. We report here that this protein modification is not a simple response to the cellular redox state, since different oxidants lead to different patterns of protein S-thiolation. SDS-polyacrylamide gel electrophoresis shows that glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is the major target for modification following treatment with hydroperoxides (hydrogen peroxide or tert-butylhydroperoxide), whereas this enzyme is unaffected following cellular exposure to the thiol oxidant diamide. Further evidence that protein S-thiolation is tightly regulated in response to oxidative stress is provided by the finding that the Tdh3 GAPDH isoenzyme, and not the Tdh2 isoenzyme, is S-thiolated following exposure to H2O2 in vivo, whereas both GAPDH isoenzymes are S-thiolated when H2O2 is added to cell-free extracts. This indicates that cellular factors are likely to be responsible for the difference in GAPDH S-thiolation observed in vivo rather than intrinsic structural differences between the GAPDH isoenzymes. To begin to search for factors that can regulate the S-thiolation process, we investigated the role of the glutaredoxin family of oxidoreductases. We provide the first evidence that protein dethiolation in vivo is regulated by a monothiol-glutaredoxin rather than the classical glutaredoxins, which contain two active site cysteine residues. In particular, glutaredoxin 5 is required for efficient dethiolation of the Tdh3 GAPDH isoenzyme.	UMIST, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia	University of Manchester; University of New South Wales Sydney	Grant, CM (corresponding author), UMIST, Dept Biomol Sci, POB 88, Manchester M60 1QD, Lancs, England.			Grant, Chris/0000-0002-0616-6576				BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; COAN C, 1992, ARCH BIOCHEM BIOPHYS, V295, P369, DOI 10.1016/0003-9861(92)90530-A; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Davis DA, 1997, J BIOL CHEM, V272, P25935, DOI 10.1074/jbc.272.41.25935; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; Grant CM, 1999, MOL CELL BIOL, V19, P2650; Grant CM, 1998, BIOCHEM BIOPH RES CO, V253, P893, DOI 10.1006/bbrc.1998.9864; Grant CM, 1996, MOL MICROBIOL, V22, P739, DOI 10.1046/j.1365-2958.1996.d01-1727.x; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; MCALISTER L, 1985, J BIOL CHEM, V260, P5013; MCALISTER L, 1985, J BIOL CHEM, V260, P5019; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MILLER RM, 1991, ARCH BIOCHEM BIOPHYS, V287, P112, DOI 10.1016/0003-9861(91)90395-Y; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Ruoppolo M, 1997, BIOCHEMISTRY-US, V36, P12259, DOI 10.1021/bi970851s; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; SCHUPPEKOISTINEN I, 1994, ARCH BIOCHEM BIOPHYS, V315, P226, DOI 10.1006/abbi.1994.1494; Seres T, 1996, J IMMUNOL, V156, P1973; THOMAS JA, 1994, METHOD ENZYMOL, V233, P385; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; YOSHITAKE S, 1994, J BIOCHEM-TOKYO, V116, P42, DOI 10.1093/oxfordjournals.jbchem.a124500	30	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16853	16859		10.1074/jbc.M200559200	http://dx.doi.org/10.1074/jbc.M200559200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11882660	hybrid			2022-12-25	WOS:000175564500068
J	Ho, WZ; Lai, JP; Li, Y; Douglas, SD				Ho, WZ; Lai, JP; Li, Y; Douglas, SD			HIV enhances substance P expression in human immune cells	FASEB JOURNAL			English	Article						lymphocytes; gp120; tachykinin; neuroimmunoregulation; monocyte-derived macrophages	HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN BLOOD MONOCYTES; FACTOR-ALPHA RELEASE; NF-KAPPA-B; SYSTEM INTERACTIONS; ENDOTHELIAL-CELLS; GENE-EXPRESSION; MACROPHAGES; INFECTION; NEUROPEPTIDE	Substance P (SP), a potent modulator of neuroimmunoregulation, is expressed in human immune cells. We observed elevated plasma SP levels in HIV-infected men compared with uninfected subjects. In the present study, we investigated the possible cellular source of the increased SP level caused by HIV infection. Using real-time reverse transcriptase-polymerase chain reaction, we demonstrated that monocyte-derived macrophages (MDM) and lymphocytes from both placental cord blood and adult peripheral blood expressed SP mRNA, which was significantly increased by HIV infection. HIV-induced SP expression was positively related to virus replication in the infected MDM. Purified recombinant HIV envelope glycoprotein 120 (gp120) derived from both the macrophage-tropic strain (MN) and the T lymphocyte-tropic strain (IIIB), when added to MDM cultures, enhanced SP mRNA expression. The gp120-induced SP expression was abrogated by pretreating the cells with soluble CD4. Furthermore, the activation of HIV in the latently infected promonocytic cell line (U1) and T-cell line (ACH-2) up-regulated SP mRNA expression. These data support the hypothesis that interaction of HIV and SP may have significant in vivo relevance to the immunopathogenesis of HIV infection and AIDS.	Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat,Div Immunol & Infect Dis, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Douglas, SD (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat,Div Immunol & Infect Dis, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	douglas@email.chop.edu	Lai, Jianping/E-3583-2015	Lai, Jianping/0000-0002-3217-692X				ALIAKBARI J, 1987, BIOCHEM BIOPH RES CO, V148, P1440, DOI 10.1016/S0006-291X(87)80293-0; Annunziata P, 1998, AIDS, V12, P2377, DOI 10.1097/00002030-199818000-00006; Azzari C, 1992, Pediatr Med Chir, V14, P577; BLACK PH, 1994, ANTIMICROB AGENTS CH, V38, P7, DOI 10.1128/AAC.38.1.7; BLACK PH, 1994, ANTIMICROB AGENTS CH, V38, P1; BOST K L, 1992, Regional Immunology, V4, P105; CHIWAKATA C, 1991, ENDOCRINOLOGY, V128, P2441, DOI 10.1210/endo-128-5-2441; CLOUSE KA, 1989, J IMMUNOL, V142, P431; COVAS MJ, 1994, CLIN EXP IMMUNOL, V96, P384, DOI 10.1111/j.1365-2249.1994.tb06039.x; Douglas SD, 2001, AIDS, V15, P2043, DOI 10.1097/00002030-200110190-00019; Fehder WP, 1998, CLIN DIAGN LAB IMMUN, V5, P303, DOI 10.1128/CDLI.5.3.303-307.1998; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FOLKS TM, 1988, J IMMUNOL, V140, P1117; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; GILBERT MS, 1991, FRONT NEUROENDOCRIN, V12, P299; HASSAN NF, 1986, J IMMUNOL METHODS, V95, P273, DOI 10.1016/0022-1759(86)90415-1; HASSAN NF, 1990, J IMMUNOL METHODS, V130, P283, DOI 10.1016/0022-1759(90)90058-4; Ho WZ, 1996, J NEUROIMMUNOL, V71, P73, DOI 10.1016/S0165-5728(96)00132-4; Ho WZ, 1998, J NEUROIMMUNOL, V82, P126, DOI 10.1016/S0165-5728(97)00175-6; Ho WZ, 1997, J IMMUNOL, V159, P5654; Ho WZ, 1996, AIDS RES HUM RETROV, V12, P195, DOI 10.1089/aid.1996.12.195; Lai JP, 1998, J NEUROIMMUNOL, V86, P80, DOI 10.1016/S0165-5728(98)00025-3; Lai JP, 2001, P NATL ACAD SCI USA, V98, P3970, DOI 10.1073/pnas.071052298; Lai JP, 1999, J IMMUNOL METHODS, V230, P149, DOI 10.1016/S0022-1759(99)00120-9; Lai JP, 2000, NEUROSCIENCE, V101, P1137, DOI 10.1016/S0306-4522(00)00398-5; LAURENZI MA, 1990, SCAND J IMMUNOL, V31, P529, DOI 10.1111/j.1365-3083.1990.tb02801.x; LEE HR, 1994, CLIN DIAGN LAB IMMUN, V1, P419, DOI 10.1128/CDLI.1.4.419-423.1994; Li Y, 2001, J NEUROIMMUNOL, V121, P67, DOI 10.1016/S0165-5728(01)00439-8; Lieb K, 1997, J IMMUNOL, V159, P4952; LINNIK MD, 1989, PEPTIDES, V10, P957, DOI 10.1016/0196-9781(89)90175-7; Liu R, 1998, AIDS RES HUM RETROV, V14, P1509, DOI 10.1089/aid.1998.14.1509; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; Marriott I, 2000, J NEUROIMMUNOL, V102, P163, DOI 10.1016/S0165-5728(99)00182-4; MCGILLIS JP, 1990, ANN NY ACAD SCI, V594, P85; MILNER P, 1990, P ROY SOC B-BIOL SCI, V241, P245, DOI 10.1098/rspb.1990.0092; NAKANISHI S, 1987, PHYSIOL REV, V67, P1117, DOI 10.1152/physrev.1987.67.4.1117; PASCUAL DW, 1990, IMMUNOLOGY, V71, P52; PAYAN DG, 1984, J CLIN INVEST, V74, P1532, DOI 10.1172/JCI111567; PERNOW B, 1983, PHARMACOL REV, V35, P85; ROSENBERG ZF, 1990, IMMUNOL TODAY, V11, P176, DOI 10.1016/0167-5699(90)90070-P; ROSENBERG ZF, 1991, FASEB J, V5, P2382, DOI 10.1096/fasebj.5.10.1676689; SHARKEY KA, 1992, GASTROENTEROLOGY, V103, P18, DOI 10.1016/0016-5085(92)91090-Q; Toneatto S, 1999, AIDS, V13, P2343, DOI 10.1097/00002030-199912030-00005; WEINSTOCK JV, 1990, CELL IMMUNOL, V125, P380, DOI 10.1016/0008-8749(90)90092-6; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988	45	46	46	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					616	+		10.1096/fj.01-0655fje	http://dx.doi.org/10.1096/fj.01-0655fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919172				2022-12-25	WOS:000174203700010
J	Kim, HJ; Song, EJ; Lee, KJ				Kim, HJ; Song, EJ; Lee, KJ			Proteomic analysis of protein phosphorylations in heat shock response and thermotolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; FLIGHT-MASS-SPECTROMETRY; FACTOR-RECEPTOR KINASE; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE-C; DNA-BINDING; VIMENTIN FILAMENTS; MAMMALIAN-CELLS; MAPKAP KINASE-2; ACTIVATION	Heat shock (HS) induces a wide variety of biological processes, including inhibition of protein synthesis, elevated expression of heat shock proteins, induction of thermotolerance, and apoptotic cell death in a dose-dependent manner. We compared phosphorylated proteins in heat-shocked and thermotolerant cells using proteome analysis. After HS treatment of control RIF-1 and their thermotolerant derivatives, TR-RIF-1 cells, cellular proteins were separated by two-dimensional gel electrophoresis and the phosphorylated proteins were detected with the anti-phosphotyrosine antibodies. We found that 93 proteins showed significant changes in phosphorylation between control and thermotolerant cells as a function of recovery time after HS; we identified 81 of these proteins with peptide mass fingerprinting using MALDI-TOF MS after in-gel trypsin digestion. These phosphorylated proteins exhibit various cellular functions, including chaperones, ion channels, signaling molecules, in transcription and translation processes, amino acid biosynthesis, oxidoreduction, energy metabolism, and cell motility or structure, suggesting that HS turns on the various signaling pathways by activating protein-tyrosine kinases (PTKs). Of these, 20 proteins were previously identified phosphorylated proteins and 64 were newly identified. These proteins can be grouped into three families: 1) proteins highly phosphorylated in TR-RIF-1 cells at basal level and phosphorylated more significantly by HS in RIF-1 than TR-RIF-1; 2) proteins highly phosphorylated in control RIF-1 cells at basal level and phosphorylated more easily by HS in TR-RIF-1 than in RIF-1 cells; and 3) proteins with a similar basal phosphorylation level in both RIF-1 and TR-RIF-1 cells and responding to HS similarly in both cells. Most of the phosphorylated proteins are presumably involved in HS signaling in different ways, with the first and second families of proteins influencing thermotolerance. The possible tyrosine phosphorylation sites, the possible PTKs phosphorylating these proteins, and the proteins binding to these phosphorylated sites were predicted by the Netphos, ScanProsite, and Scansite programs. These results suggest that HS can activate various PTKs and HS responses can be regulated by phosphorylations of proteins having various functions.	Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Coll Pharm, Seoul 120750, South Korea; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea	Ewha Womans University; Ewha Womans University; Ewha Womans University	Lee, KJ (corresponding author), Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea.	kjl@mm.ewha.ac.kr		Song, Eun Joo/0000-0002-2420-6666; Lee, Kong-Joo/0000-0001-7972-6020				ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Bellagamba C, 1997, J BIOL CHEM, V272, P3195, DOI 10.1074/jbc.272.6.3195; BENDINELLI P, 1995, BIOCHEM BIOPH RES CO, V216, P54, DOI 10.1006/bbrc.1995.2591; CALDERWOOD SK, 1993, J CELL PHYSIOL, V155, P248, DOI 10.1002/jcp.1041550205; CALDERWOOD SK, 1993, J CELL PHYSIOL, V156, P153, DOI 10.1002/jcp.1041560121; CHEN F, 1995, BIOCHEM J, V312, P341, DOI 10.1042/bj3120341; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DUBOIS MF, 1991, CR ACAD SCI III-VIE, V313, P165; DUBOIS MF, 1993, FEBS LETT, V324, P191, DOI 10.1016/0014-5793(93)81391-C; DUNCAN RF, 1989, J CELL BIOL, V109, P467; ERDOS G, 1995, J CELL PHYSIOL, V164, P404, DOI 10.1002/jcp.1041640221; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GLOVER CVC, 1981, CELL, V23, P73, DOI 10.1016/0092-8674(81)90271-3; GRIMA DT, 1994, BIOCHEMISTRY-US, V33, P2921, DOI 10.1021/bi00176a023; HAHN GM, 1988, CANCER RES, V48, P1803; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KARASIK A, 1988, J BIOL CHEM, V263, P11862; KIANG JG, 1993, AM J PHYSIOL, V264, pC1561, DOI 10.1152/ajpcell.1993.264.6.C1561; Kim HJ, 2002, MOL CELL BIOCHEM, V229, P139, DOI 10.1023/A:1017941131744; Knowlton AA, 2000, AM J PHYSIOL-HEART C, V278, pH2143, DOI 10.1152/ajpheart.2000.278.6.H2143; KRISHNAN HB, 1987, BIOCHEM BIOPH RES CO, V148, P762, DOI 10.1016/0006-291X(87)90941-7; LANDER HM, 1992, CELL IMMUNOL, V145, P146, DOI 10.1016/0008-8749(92)90319-K; LANDRY J, 1988, RADIAT RES, V113, P426, DOI 10.2307/3577240; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; Lee SY, 2001, CELL DEATH DIFFER, V8, P1093, DOI 10.1038/sj.cdd.4400923; LEGAGNEUX V, 1990, EUR J BIOCHEM, V193, P121, DOI 10.1111/j.1432-1033.1990.tb19312.x; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIS JT, 1992, TRANSCRIPTIONAL REGU, V2, P907; LUTZ Y, 1988, EXP CELL RES, V175, P109, DOI 10.1016/0014-4827(88)90259-5; MAHER PA, 1989, J CELL BIOL, V108, P2029, DOI 10.1083/jcb.108.6.2029; Marcus K, 2000, ELECTROPHORESIS, V21, P2622, DOI 10.1002/1522-2683(20000701)21:13<2622::AID-ELPS2622>3.0.CO;2-3; Otto H, 2001, EUR J BIOCHEM, V268, P420, DOI 10.1046/j.1432-1033.2001.01901.x; PEPINSKY RB, 1991, METHOD ENZYMOL, V198, P260; PYPE S, 1994, J BIOL CHEM, V269, P31457; Quadroni M, 1999, ELECTROPHORESIS, V20, P664, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<664::AID-ELPS664>3.0.CO;2-A; REISS N, 1986, BIOCHEM J, V239, P691, DOI 10.1042/bj2390691; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Sechi S, 1998, ANAL CHEM, V70, P5150, DOI 10.1021/ac9806005; Sheffield LG, 1998, J ENDOCRINOL, V159, P111, DOI 10.1677/joe.0.1590111; Skouteris GG, 1996, J BIOL CHEM, V271, P27266, DOI 10.1074/jbc.271.44.27266; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; Soskic V, 1999, BIOCHEMISTRY-US, V38, P1757, DOI 10.1021/bi982093r; Steen H, 2002, J BIOL CHEM, V277, P1031, DOI 10.1074/jbc.M109992200; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; SUBJECK JR, 1986, AM J PHYSIOL, V250, pC1, DOI 10.1152/ajpcell.1986.250.1.C1; SYGUSCH J, 1990, ARCH BIOCHEM BIOPHYS, V283, P227, DOI 10.1016/0003-9861(90)90636-D; Valgeirsdottir S, 1998, J CELL SCI, V111, P1973; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Welch W J, 1987, Adv Exp Med Biol, V225, P287; Yanagida M, 2000, ELECTROPHORESIS, V21, P1890; YANG JM, 1995, BIOCHEM BIOPH RES CO, V210, P21, DOI 10.1006/bbrc.1995.1622	54	49	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23193	23207		10.1074/jbc.M201007200	http://dx.doi.org/10.1074/jbc.M201007200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11886868	hybrid			2022-12-25	WOS:000176475700015
J	Accola, MA; Huang, B; Al Masri, A; McNiven, MA				Accola, MA; Huang, B; Al Masri, A; McNiven, MA			The antiviral dynamin family member, MxA, tubulates lipids and localizes to the smooth endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CONFORMATIONAL CHANGE; CLATHRIN-MEDIATED ENDOCYTOSIS; PLECKSTRIN HOMOLOGY DOMAINS; MOTILITY FACTOR-RECEPTOR; COATED VESICLE FORMATION; GTP HYDROLYSIS; THOGOTO-VIRUS; PROTEIN; OLIGOMERIZATION; CAVEOLAE	Mx proteins are induced by type I interferon and inhibit a broad range of viruses by undefined mechanisms. They are included within the dynamin family of large GTPases, which are involved in vesicle trafficking and share common biophysical features. These properties include the propensity to self-assemble, an affinity for lipids, and the ability to tubulate membranes. In this report we establish that human MxA, despite sharing only 30% homology with conventional dynamin, possesses many of these properties. We demonstrate for the first time that MxA self-assembles into rings that tubulate lipids in vitro, and associates with a specific membrane compartment in cells, the smooth endoplasmic reticulum.	Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	McNiven, MA (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.							BENLIMAME N, 1995, J CELL BIOL, V129, P459, DOI 10.1083/jcb.129.2.459; Benlimame N, 1998, MOL BIOL CELL, V9, P1773, DOI 10.1091/mbc.9.7.1773; Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; Cole CN, 2001, FIELDS VIROLOGY, P2141; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; Di Paolo C, 1999, J BIOL CHEM, V274, P32071, DOI 10.1074/jbc.274.45.32071; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; FRESE M, 1995, J VIROL, V69, P3904, DOI 10.1128/JVI.69.6.3904-3909.1995; Gordien E, 2001, J VIROL, V75, P2684, DOI 10.1128/JVI.75.6.2684-2691.2001; Haller O, 1998, REV SCI TECH OIE, V17, P220, DOI 10.20506/rst.17.1.1084; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Henley JR, 1998, MOL BIOL CELL, V9, p195A; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hinshaw JE, 1999, CURR OPIN STRUC BIOL, V9, P260, DOI 10.1016/S0959-440X(99)80036-0; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; HORISBERGER MA, 1992, J VIROL, V66, P4705, DOI 10.1128/JVI.66.8.4705-4709.1992; Janzen C, 2000, J VIROL, V74, P8202, DOI 10.1128/JVI.74.17.8202-8206.2000; KARTENBECK J, 1989, J CELL BIOL, V109, P2721, DOI 10.1083/jcb.109.6.2721; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; Kochs G, 2002, J BIOL CHEM, V277, P14172, DOI 10.1074/jbc.M200244200; Kochs G, 1999, P NATL ACAD SCI USA, V96, P2082, DOI 10.1073/pnas.96.5.2082; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Maier O, 1996, BIOCHEM BIOPH RES CO, V223, P229, DOI 10.1006/bbrc.1996.0876; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; MELEN K, 1992, J BIOL CHEM, V267, P25898; MELEN K, 1994, J BIOL CHEM, V269, P2009; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; PITOSSI F, 1993, J VIROL, V67, P6726, DOI 10.1128/JVI.67.11.6726-6732.1993; Ponten A, 1997, J VIROL, V71, P2591, DOI 10.1128/JVI.71.4.2591-2599.1997; RICHTER MF, 1995, J BIOL CHEM, V270, P13512, DOI 10.1074/jbc.270.22.13512; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SANDVIG K, 1994, J CELL BIOL, V126, P53, DOI 10.1083/jcb.126.1.53; Sandvig Kirsten, 1994, Trends in Cell Biology, V4, P275, DOI 10.1016/0962-8924(94)90211-9; SCHNEIDERSCHAULIES S, 1994, J VIROL, V68, P6910, DOI 10.1128/JVI.68.11.6910-6917.1994; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; Schumacher B, 1998, J BIOL CHEM, V273, P28365, DOI 10.1074/jbc.273.43.28365; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Wang HJ, 1997, J CELL SCI, V110, P3043; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; WEITZ G, 1989, J INTERFERON RES, V9, P679, DOI 10.1089/jir.1989.9.679; Yoon Y, 2001, MOL BIOL CELL, V12, P2894, DOI 10.1091/mbc.12.9.2894	54	110	117	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21829	21835		10.1074/jbc.M201641200	http://dx.doi.org/10.1074/jbc.M201641200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11916975	hybrid			2022-12-25	WOS:000176286000092
J	Sandal, T; Stapnes, C; Kleivdal, H; Hedin, L; Doskeland, SO				Sandal, T; Stapnes, C; Kleivdal, H; Hedin, L; Doskeland, SO			A novel, extraneuronal role for cyclin-dependent protein kinase 5 (CDK5) - Modulation of cAMP-induced apoptosis in rat leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CDC2-LIKE KINASE; RETINOBLASTOMA PROTEIN; SELECTIVE INHIBITOR; NEURITE OUTGROWTH; DEATH; EXPRESSION; ACTIVATION; P35; CLEAVAGE; DIFFERENTIATION	A number of cyclin-dependent protein kinase (CDK) inhibitors were tested for the ability to protect IPC-81 rat leukemic cells against cAMP-induced apoptosis. A near perfect proportionality was observed between inhibitor potency to protect against cAMP-induced apoptosis and to antagonize CDK5, and to a lesser extent, CDK2 and CDK1. Enforced expression of dominant negative CDK5 (but not CDK1-dn or CDK2-dn) protected against death, indicating that CDK5 activity was necessary for cAMP-induced apoptosis. The CDK inhibitors failed to protect the cells against daunorubicine-, staurosporine-, or okadaic acid-induced apoptosis. The inhibition of CDK5 prevented the cleavage of pro-caspase-3 in cAMP-treated cells. The cells could be saved closer to the moment of their onset of death by inhibitors of caspases than by inhibitors of CDK5. This suggested that the action of CDK5 was upstream of caspase activation. The cAMP treatment resulted in a moderate increase of the level of CDK5 mRNA and protein in IPC-81 wild-type cells. Such cAMP induction of CDK5 was not observed in cells expressing the inducible cAMP early repressor. The cAMP-induced increase of CDK5 contributed to apoptosis since cells overexpressing CDK5-wt were more sensitive for cAMP-induced death. These results demonstrate the first example of a proapoptotic CDK action upstream of caspase activation and of an extra-neuronal effect of CDK5.	Univ Bergen, Dept Anat & Cell Biol, N-5009 Bergen, Norway	University of Bergen	Doskeland, SO (corresponding author), Univ Bergen, Dept Anat & Cell Biol, N-5009 Bergen, Norway.	stein.doskeland@iac.uib.no		Doskeland, Stein Ove/0000-0002-4009-4756				Ahuja HS, 1997, DEV GENET, V21, P258, DOI 10.1002/(SICI)1520-6408(1997)21:4<258::AID-DVG3>3.0.CO;2-6; Alvarez A, 1999, FEBS LETT, V459, P421, DOI 10.1016/S0014-5793(99)01279-X; Arellano M, 1997, INT J BIOCHEM CELL B, V29, P559, DOI 10.1016/S1357-2725(96)00178-1; Bajaj NPS, 2000, AMYOTROPH LATERAL SC, V1, P319, DOI 10.1080/146608200300079563; BRONSTEIN I, 1992, BIOTECHNIQUES, V12, P748; BRUNO S, 1992, CANCER RES, V52, P470; Catania A, 2001, NEURO-ONCOLOGY, V3, P89, DOI 10.1093/neuonc/3.2.89; Chadebech P, 2000, INT J CANCER, V87, P779, DOI 10.1002/1097-0215(20000915)87:6<779::AID-IJC3>3.3.CO;2-W; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARZYNKIEWICZ Z, 1995, J CELL BIOCHEM, V58, P151, DOI 10.1002/jcb.240580204; Davis ST, 2001, SCIENCE, V291, P134, DOI 10.1126/science.291.5501.134; DUPREZ E, 1993, J BIOL CHEM, V268, P8332; Fladmark KE, 2002, J BIOL CHEM, V277, P2804, DOI 10.1074/jbc.M109049200; Gao C, 2001, J CELL SCI, V114, P1145; Gao CY, 1997, DEV GENET, V20, P267; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; GJERTSEN BT, 1995, J BIOL CHEM, V270, P20599, DOI 10.1074/jbc.270.35.20599; GJERTSEN BT, 1994, J CELL SCI, V107, P3363; Gray N, 1999, CURR MED CHEM, V6, P859; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; Henchcliffe C, 1997, NEUROSCI LETT, V230, P41, DOI 10.1016/S0304-3940(97)00472-2; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Humbert S, 2000, J CELL SCI, V113, P975; Ishizuka T, 1995, GENE, V166, P267, DOI 10.1016/0378-1119(95)00650-8; Jin YH, 2000, J BIOL CHEM, V275, P30256, DOI 10.1074/jbc.M001902200; Kim SG, 2001, ONCOGENE, V20, P1254, DOI 10.1038/sj.onc.1204203; KITAGAWA M, 1993, ONCOGENE, V8, P2425; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Li BS, 2000, J NEUROSCI, V20, P6055, DOI 10.1523/JNEUROSCI.20-16-06055.2000; Li WW, 2001, CANCER RES, V61, P2579; Lorens JB, 2000, MOL THER, V1, P438, DOI 10.1006/mthe.2000.0063; Lu YJ, 2000, MOL CARCINOGEN, V29, P1; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1517, DOI 10.1046/j.1432-1327.2001.02022.x; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1518, DOI 10.1046/j.1432-1327.2001.02024.x; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 1995, Prog Cell Cycle Res, V1, P351; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; Motyl T, 1999, REPROD NUTR DEV, V39, P49, DOI 10.1051/rnd:19990103; Munoz JP, 2000, NEUROREPORT, V11, P2733, DOI 10.1097/00001756-200008210-00025; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Ruchaud S, 1997, BIOCHEM SOC T, V25, P410, DOI 10.1042/bst0250410; Ruchaud S, 1997, ONCOGENE, V15, P827, DOI 10.1038/sj.onc.1201248; Sandal T, 2001, CELL DEATH DIFFER, V8, P754, DOI 10.1038/sj.cdd.4400873; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Tang DM, 1996, BIOCHEM CELL BIOL, V74, P419, DOI 10.1139/o96-046; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; UCKER DS, 1991, NEW BIOL, V3, P103; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; VINTERMYR OK, 1993, EXP CELL RES, V206, P157, DOI 10.1006/excr.1993.1132; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yao SL, 1996, CANCER RES, V56, P4551; Yin MB, 1999, INT J CANCER, V83, P341, DOI 10.1002/(SICI)1097-0215(19991029)83:3<341::AID-IJC9>3.0.CO;2-3; Zhang JW, 2000, J NEUROCHEM, V75, P2346, DOI 10.1046/j.1471-4159.2000.0752346.x; Zhang Q, 1997, DEV BIOL, V183, P222, DOI 10.1006/dbio.1996.8494	73	54	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20783	20793		10.1074/jbc.M112248200	http://dx.doi.org/10.1074/jbc.M112248200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11909854	hybrid			2022-12-25	WOS:000176204500088
J	Shin, HS; Chin, MR; Kim, JS; Chung, JH; Ryu, CK; Jung, SY; Kim, DK				Shin, HS; Chin, MR; Kim, JS; Chung, JH; Ryu, CK; Jung, SY; Kim, DK			Purification and characterization of a cytosolic, 42-kDa and Ca2+-dependent phospholipase A(2) from bovine red blood cells - Its involvement in Ca2+-dependent release of arachidonic acid from mammalian red blood cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTES; EXTRACELLULAR PHOSPHOLIPASE-A2; ERYTHROPOIETIN RECEPTOR; SIGNAL TRANSDUCTION; PLATELET ACTIVATION; MEMBRANES; COLLAGEN; DEFORMABILITY; HEMATOPOIESIS; LIPOXYGENASE	It has become evident that a Ca2+-dependent release of arachidonic acid (AA) and subsequent formation of bioactive lipid mediators such as prostaglandins and leukotrienes in red blood cells (RBCs) can modify physiological functions of neighboring RECs and platelets. Here we identified a novel type of cytosolic PLA(2) in bovine and human RBCs and purified it to apparent homogeneity with a 14,000-fold purification. The purified enzyme, termed rPLA(2), has a molecular mass of 42 kDa and reveals biochemical properties similar to group IV cPLA(2), but shows different profiles from cPLA, in several column chromatographies. Moreover, rPLA2 did not react with any of anti-cPLA(2) and anti-cPLA(2) antibodies and was identified as an unknown protein in matrix-assisted laser desorption/ ionization time-of-flight mass spectrometric analysis. Divalent metal ions tested exhibited similar effects between rPLA(2) and cPLA(2), whereas mercurials inhibited cPLA(2) but had no effect on rPLA(2). Antibody against the 42-kDa protein not only precipitated the rPLA(2) activity, but also reacted with the 42-kDa protein from bovine and human IRBCs in immunoblot analysis. The 42-kDa protein band was selectively detected in murine fetal liver cells known as a type of progenitor cells of IRBCs. It was found that EA4, a derivative of quinone newly developed as an inhibitor for rPLA2, inhibited a Ca2+ ionophore-induced AA release from human and bovine RBCs, indicating that this enzyme is responsible for the Ca-dependent AA release from mammalian RBCs. Finally, erythroid progenitor cell assay utilizing diaminobenzidine staining of hemoglobinized fetal liver cells showed that rPLA2 detectable in erythroid cells was down-regulated when differentiated to non-erythroid cells. Together, our results suggest that the 42-kDa rPLA, identified as a novel form of Ca-dependent PLA(2) may play an important role in hemostasis, thrombosis, and/or erythropoiesis through the Ca2+-dependent release of AA.	Chung Ang Univ, Coll Pharm, Dept Environm & Hlth Chem, Dongjak Ku, Seoul 156756, South Korea; Seoul Natl Univ, Coll Pharm, Kwanak Ku, Seoul 151742, South Korea; Ewha Womans Univ, Coll Pharm, Dept Pharmaceut Anal, Seoul 120750, South Korea	Chung Ang University; Seoul National University (SNU); Ewha Womans University	Kim, DK (corresponding author), Chung Ang Univ, Coll Pharm, Dept Environm & Hlth Chem, Dongjak Ku, 221 Huksuk Dong, Seoul 156756, South Korea.			Jung, Sung Yun/0000-0003-1521-7977				ADACHI I, 1983, ARCH BIOCHEM BIOPHYS, V226, P118, DOI 10.1016/0003-9861(83)90276-X; ALLEN JE, 1971, SCIENCE, V174, P512, DOI 10.1126/science.174.4008.512; Andrews D A, 1999, Curr Opin Hematol, V6, P76, DOI 10.1097/00062752-199903000-00004; BECKMAN BS, 1991, ADV PROSTAG THROMB L, V21, P831; BECKMAN BS, 1989, EXP HEMATOL, V17, P309; CHANG HW, 1987, J BIOCHEM, V102, P147, DOI 10.1093/oxfordjournals.jbchem.a122026; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; Jensen ON, 1997, ANAL CHEM, V69, P4741, DOI 10.1021/ac970896z; JOHNSON GR, 1985, EXP HEMATOL, V13, P200; Jung KM, 2000, PLANT PHYSIOL, V123, P1057, DOI 10.1104/pp.123.3.1057; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; KIM DK, 1993, BIOCHEM J, V294, P261, DOI 10.1042/bj2940261; KIM DK, 1991, BIOCHEM BIOPH RES CO, V174, P189, DOI 10.1016/0006-291X(91)90504-Z; KIM DK, 1991, BIOCHIM BIOPHYS ACTA, V1083, P80; KOBAYASHI T, 1983, J BIOL CHEM, V258, P9116; KRAMER RM, 1978, BIOCHIM BIOPHYS ACTA, V507, P381, DOI 10.1016/0005-2736(78)90348-6; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; KUHN H, 1990, J BIOL CHEM, V265, P1454; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN FL, 1981, NATURE, V294, P667, DOI 10.1038/294667a0; LEVINE L, 1981, P NATL ACAD SCI-BIOL, V78, P7692, DOI 10.1073/pnas.78.12.7692; Li Q, 1996, J BIOL CHEM, V271, P18651, DOI 10.1074/jbc.271.31.18651; Light DB, 1997, J MEMBRANE BIOL, V158, P229, DOI 10.1007/s002329900260; MASONGARCIA M, 1992, AM J PHYSIOL, V262, pC1197; MASONGARCIA M, 1991, FASEB J, V5, P2958, DOI 10.1096/fasebj.5.14.1752362; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OGAWA M, 1976, BLOOD, V48, P407; Oonishi T, 1998, PROSTAG OTH LIPID M, V56, P89, DOI 10.1016/S0090-6980(98)00045-8; Oonishi T, 1997, AM J PHYSIOL-CELL PH, V273, pC1828, DOI 10.1152/ajpcell.1997.273.6.C1828; Park JB, 2000, J BIOL CHEM, V275, P21295, DOI 10.1074/jbc.M002463200; PAYSANT M, 1967, B SOC CHIM BIOL, V49, P169; PAYSANT M, 1970, B SOC CHIM BIOL, V52, P1257; PRATT YT, 1960, J AM CHEM SOC, V82, P1155, DOI 10.1021/ja01490a035; REIMERS RC, 1984, BLOOD, V64, P1200; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SANTOS MT, 1986, THROMB HAEMOSTASIS, V56, P376; SANTOS MT, 1991, J CLIN INVEST, V87, P571, DOI 10.1172/JCI115032; SHIGA T, 1985, BIOCHIM BIOPHYS ACTA, V814, P289, DOI 10.1016/0005-2736(85)90447-X; SNYDER DS, 1986, BLOOD, V67, P1675; ULEVITCH RJ, 1988, J BIOL CHEM, V263, P3079; VALLES J, 1991, BLOOD, V78, P154; Valles J, 1997, DIABETES, V46, P1047, DOI 10.2337/diabetes.46.6.1047; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; WURM G, 1991, ARCH PHARM, V324, P491; Yang L, 2000, BLOOD, V95, P2420, DOI 10.1182/blood.V95.7.2420.007k12_2420_2425	47	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					21086	21094		10.1074/jbc.M200203200	http://dx.doi.org/10.1074/jbc.M200203200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11909855	hybrid			2022-12-25	WOS:000176204500124
J	Thoden, JB; Holden, HM				Thoden, JB; Holden, HM			High resolution x-ray structure of galactose mutarotase from Lactococcus lactis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; CLONING; PROGRAM; GENES	Galactose mutarotase plays a key role in normal galactose metabolism by catalyzing the interconversion of Beta-D-galactose and alpha-D-galactose. Here we describe the three-dimensional architecture of galactose mutarotase from Lactococcus lactis determined to 1.9-Angstrom resolution. Each subunit of the dimeric enzyme displays a distinctive beta-sandwich motif. This tertiary structural element was first identified in beta-galactosidase and subsequently observed in copper amine oxidase, hyaluronate lyase, chondroitinase, and maltose phosphorylase. Two cis-peptides are found in each subunit, namely Pro(67) and Lys(136). The active site is positioned in a rather open cleft, and the electron density corresponding to the bound galactose unequivocally demonstrates that both anomers of the substrate are present in the crystalline enzyme. Those residues responsible for anchoring the Arg(71), sugar to the protein include Arg(71), His(96), His(170), As and Glu(304). Both His(96) and His(170) are strictly conserved among mutarotase amino acid sequences determined thus far. The imidazole nitrogens of these residues are located within hydrogen bonding distance to the C-5 oxygen of galactose. Strikingly, the carboxylate group of Glu(304) is situated at similar to2.7 Angstrom from the 1'-hydroxyl group of galactose, thereby suggesting its possible role as a general acid/base group.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Thoden, JB (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK047814, R01DK047814] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47814] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beebe JA, 1998, BIOCHEMISTRY-US, V37, P14989, DOI 10.1021/bi9816047; BOUFFARD GG, 1994, J MOL BIOL, V244, P269, DOI 10.1006/jmbi.1994.1728; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Egloff MP, 2001, STRUCTURE, V9, P689, DOI 10.1016/S0969-2126(01)00626-8; Erlandson KA, 2001, APPL ENVIRON MICROB, V67, P1445, DOI 10.1128/AEM.67.4.1445-1452.2001; Fethiere J, 1999, J MOL BIOL, V288, P635, DOI 10.1006/jmbi.1999.2698; GATZ C, 1986, J BACTERIOL, V168, P31, DOI 10.1128/jb.168.1.31-39.1986; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUCHO F, 1971, EUR J BIOCHEM, V23, P489, DOI 10.1111/j.1432-1033.1971.tb01645.x; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; JONES TA, 1992, MOL REPLACEMENT, P91; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; LOUDON GM, 1998, ORGANIC CHEM, P1209; MASKELL DJ, 1992, MOL MICROBIOL, V6, P3051, DOI 10.1111/j.1365-2958.1992.tb01763.x; MOLLET B, 1991, J BACTERIOL, V173, P4464, DOI 10.1128/JB.173.14.4464-4473.1991; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PARSONS MR, 1995, STRUCTURE, V3, P1171, DOI 10.1016/S0969-2126(01)00253-2; POOLMAN B, 1990, J BACTERIOL, V172, P4037, DOI 10.1128/jb.172.7.4037-4047.1990; Prade RA, 1996, BIOTECHNOL GENET ENG, V13, P101, DOI 10.1080/02648725.1996.10647925; ROUSSEL A, 1991, SILICON GRAPHICS GEO; RYPNIEWSKI WR, 1991, BIOCHEMISTRY-US, V30, P4126, DOI 10.1021/bi00231a003; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WALLENFELS K, 1965, BIOCHEM Z, V343, P307; ZHANG XJ, 1995, J APPL CRYSTALLOGR, V28, P624, DOI 10.1107/S0021889895001063	27	38	39	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20854	20861		10.1074/jbc.M201415200	http://dx.doi.org/10.1074/jbc.M201415200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11907040	hybrid			2022-12-25	WOS:000176204500097
J	Jaffe, EK; Kervinen, J; Martins, J; Stauffer, F; Neier, R; Wlodawer, A; Zdanov, A				Jaffe, EK; Kervinen, J; Martins, J; Stauffer, F; Neier, R; Wlodawer, A; Zdanov, A			Species-specific inhibition of porphobilinogen synthase by 4-oxosebacic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; ARTIFICIAL GENE; DEHYDRATASE; RESOLUTION; MECHANISM; MG(II); IONS	Porphobilinogen synthase (PBGS) catalyzes the condensation of two molecules of 5-aminolevulinic acid (ALA), an essential step in tetrapyrrole biosynthesis. 4-Oxosebacic acid (4-OSA) and 4,7-dioxosebacic acid (4,7-DOSA) are bisubstrate reaction intermediate analogs for PBGS. We show that 4-OSA is an active site-directed irreversible inhibitor for Escherichia coli PBGS, whereas human, pea, Pseudomonas aeruginosa, and Bradyrhizobium japonicum PBGS are insensitive to inhibition by 4-OSA. Some variants of human PBGS (engineered to resemble E. coli PBGS) have increased sensitivity to inactivation by 4-OSA, suggesting a structural basis for the specificity. The specificity of 4-OSA as a PBGS inhibitor is significantly narrower than that of 4,7-DOSA. Comparison of the crystal structures for E. coli PBGS inactivated by 4-OSA versus 4,7-DOSA shows significant variation in the half of the inhibitor that mimics the second substrate molecule (A-side ALA). Compensatory changes occur in the structure of the active site lid, which suggests that similar changes normally occur to accommodate numerous hybridization changes that must occur at C3 of A-side ALA during the PBGS-catalyzed reaction. A comparison of these with other PBGS structures identifies highly conserved active site water molecules, which are isolated from bulk solvent and implicated as proton acceptors in the PBGS-catalyzed reaction.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA; Univ Neuchatel, Dept Chem, CH-2007 Neuchatel, Switzerland; NCI, Macromol Crystallog Lab, NIH, Frederick, MD 21702 USA	Fox Chase Cancer Center; University of Neuchatel; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Jaffe, EK (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003654] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927] Funding Source: Medline; NIEHS NIH HHS [ES03654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARNARD GF, 1977, J BIOL CHEM, V252, P8965; Bock CW, 1999, J AM CHEM SOC, V121, P7360, DOI 10.1021/ja9906960; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COPELAND RA, 1995, BIOORG MED CHEM LETT, V5, P1947, DOI 10.1016/0960-894X(95)00330-V; Erskine PT, 1999, BIOCHEMISTRY-US, V38, P4266, DOI 10.1021/bi982137w; Erskine PT, 2001, FEBS LETT, V503, P196, DOI 10.1016/S0014-5793(01)02721-1; Erskine PT, 2001, J MOL BIOL, V312, P133, DOI 10.1006/jmbi.2001.4947; Frankenberg N, 1999, J MOL BIOL, V289, P591, DOI 10.1006/jmbi.1999.2808; Frankenberg N, 1999, BIOCHEMISTRY-US, V38, P13976, DOI 10.1021/bi9906470; Frankenberg N, 1999, BIOCHEMISTRY-US, V38, P13968, DOI 10.1021/bi9906468; Heine A, 2001, SCIENCE, V294, P369, DOI 10.1126/science.1063601; JAFFE EK, 1990, BIOCHEMISTRY-US, V29, P8345, DOI 10.1021/bi00488a021; JAFFE EK, 1986, J BIOL CHEM, V261, P9348; Jaffe EK, 2000, ACTA CRYSTALLOGR D, V56, P115, DOI 10.1107/S0907444999014894; JAFFE EK, 1995, J BIOENERG BIOMEMBR, V27, P169, DOI 10.1007/BF02110032; Jaffe EK, 2000, J BIOL CHEM, V275, P2619, DOI 10.1074/jbc.275.4.2619; Jaffe EK, 2001, J BIOL CHEM, V276, P1531, DOI 10.1074/jbc.M007663200; Jarret C, 2000, CHEM BIOL, V7, P185, DOI 10.1016/S1074-5521(00)00089-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORDAN PM, 1980, J CHEM SOC CHEM COMM, P240, DOI 10.1039/c39800000240; Kervinen J, 2001, BIOCHEMISTRY-US, V40, P8227, DOI 10.1021/bi010656k; Kervinen J, 2000, BIOCHEMISTRY-US, V39, P9018, DOI 10.1021/bi000620c; MITCHELL LW, 1993, ARCH BIOCHEM BIOPHYS, V300, P169, DOI 10.1006/abbi.1993.1024; NANDI DL, 1968, J BIOL CHEM, V243, P1236; NEIER R, 1996, ADV NITROG HETERCYC, V2, P35; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petrovich RM, 1996, J BIOL CHEM, V271, P8692, DOI 10.1074/jbc.271.15.8692; SPENCER P, 1995, BIOCHEM J, V305, P151, DOI 10.1042/bj3050151; Stauffer F, 2001, CHIMIA, V55, P314; Wynn R, 1996, PROTEIN SCI, V5, P1026	30	24	26	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19792	19799		10.1074/jbc.M201486200	http://dx.doi.org/10.1074/jbc.M201486200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11909869	hybrid			2022-12-25	WOS:000175894800072
J	Karpichev, IV; Cornivelli, L; Small, GM				Karpichev, IV; Cornivelli, L; Small, GM			Multiple regulatory roles of a novel Saccharomyces cerevisiae protein, encoded by YOL002c, in lipid and phosphate metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; TRANSCRIPTION FACTORS; PEROXISOME PROLIFERATION; HISTONE DEACETYLASE; GENE; EXPRESSION; SYSTEM; IDENTIFICATION; CONSTRUCTION; ACCUMULATION	The yeast open reading frame YOL002c encodes a putative membrane protein. This protein is evolutionarily conserved across species, including humans, although the function of each of these proteins remains unknown. YOL002c is highly expressed in yeast cells that are grown in the presence of saturated fatty acids such as myristate. Furthermore, cells in which the YOL002c gene is disrupted grow poorly on this carbon source. These mutant cells are also resistant to the polyene antibiotic, nystatin. Gene chip analysis on yol002cDelta cells revealed that a variety of genes encoding proteins involved in fatty acid metabolism and in the phosphate signaling pathway are induced in this mutant strain. In addition, our studies demonstrated that in the disruption strain acid phosphatase activity is expressed constitutively, and the cells accumulate polyphosphate to much higher levels than wild-type cells. A homologous human protein is able to partially rescue these defects in phosphate metabolism. We propose that YOL002c encodes a Saccharomyces cerevisiae protein that plays a key role in metabolic pathways that regulate lipid and phosphate metabolism.	CUNY City Coll, Dept Biol, New York, NY 10031 USA	City University of New York (CUNY) System; City College of New York (CUNY)	Small, GM (corresponding author), CUNY City Coll, Dept Biol, New York, NY 10031 USA.	gmsbh@cunyvm.cuny.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054976] Funding Source: NIH RePORTER; NCRR NIH HHS [G12 RR03060] Funding Source: Medline; NIDDK NIH HHS [R01DK54976] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS BG, 1972, J BACTERIOL, V111, P308, DOI 10.1128/JB.111.2.308-315.1972; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BARD M, 1972, Journal of Bacteriology, V111, P649; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; DENIS CL, 1981, J MOL BIOL, V148, P355, DOI 10.1016/0022-2836(81)90181-9; DMOCHOWSKA A, 1990, GENE, V88, P247, DOI 10.1016/0378-1119(90)90038-S; Dorland S, 2000, GENETICS, V154, P573; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Johnston M., 1992, MOL CELLULAR BIOL YE, P193; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KANEKO Y, 1982, MOL CELL BIOL, V2, P127, DOI 10.1128/MCB.2.2.127; Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69; Karpichev IV, 1998, MOL CELL BIOL, V18, P6560, DOI 10.1128/MCB.18.11.6560; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; Loewith R, 2001, J BIOL CHEM, V276, P24068, DOI 10.1074/jbc.M102176200; Luo Y, 1996, J BIOL CHEM, V271, P12068, DOI 10.1074/jbc.271.20.12068; MARINI F, 1961, J GEN MICROBIOL, V24, P51, DOI 10.1099/00221287-24-1-51; MCDONOUGH VM, 1992, J BIOL CHEM, V267, P5931; Measday V, 1997, MOL CELL BIOL, V17, P1212, DOI 10.1128/MCB.17.3.1212; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; Rottensteiner H, 1996, EMBO J, V15, P2924, DOI 10.1002/j.1460-2075.1996.tb00655.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1977, J BACTERIOL, V129, P1335, DOI 10.1128/JB.129.3.1335-1342.1977; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WANG TW, 1994, J BIOL CHEM, V269, P24480; WANG TW, 1992, NUCLEIC ACIDS RES, V20, P3495, DOI 10.1093/nar/20.13.3495; WURST H, 1995, J BACTERIOL, V177, P898, DOI 10.1128/jb.177.4.898-906.1995; Zhang SR, 1999, GENETICS, V151, P473	39	59	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19609	19617		10.1074/jbc.M202045200	http://dx.doi.org/10.1074/jbc.M202045200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11916977	hybrid			2022-12-25	WOS:000175894800050
J	Mattjus, P; Malewicz, B; Valiyaveettil, JT; Baumann, WJ; Bittman, R; Brown, RE				Mattjus, P; Malewicz, B; Valiyaveettil, JT; Baumann, WJ; Bittman, R; Brown, RE			Sphingomyelin modulates the transbilayer distribution of galactosylceramide in phospholipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; PHOSPHATIDYLCHOLINE VESICLES; UNILAMELLAR VESICLES; CHOLESTEROL EFFLUX; BILAYER-MEMBRANES; MODEL MEMBRANES; ASYMMETRY; SPHINGOLIPIDS; DOMAINS; RAFTS	The interrelationships among sphingolipid structure, membrane curvature, and glycosphingolipid transmembrane distribution remain poorly defined despite the emerging importance of sphingolipids in curved regions and vesicle buds of biomembranes. Here, we describe a novel approach to investigate the transmembrane distribution of galactosylceramide in phospholipid small unilamellar vesicles by C-13 NMR spectroscopy. Quantitation of the transbilayer distribution of [6-C-13]galactosylceramide (99.8% isotopic enrichment) was achieved by exposure of vesicles to the paramagnetic ion, Mn2+. The data show that [6-13C]galactosylceramide prefers (70%) the inner leaflet of phosphatidylcholine vesicles. Increasing the sphingomyelin content of the 1-palmitoyl-2-oleoyl-phosphatidylcholine vesicles shifted galactosylceramide from the inner to the outer leaflet. The amount of galactosylceramide localized in the inner leaflet decreased from 70% in pure 1-palmitoyl-2-oleoyl-phosphatidylcholine vesicles to only 40% in 1-palmitoyl-2-oleoyl-phosphatidylcholine/sphingomyelin (1:2) vesicles. The present study demonstrates that sphingomyelin can dramatically alter the transbilayer distribution of a monohexosylceramide, such as galactosylceramide, in 1-palmitoyl-2-oleoyl-phosphatidylcholine/sphingomyelin vesicles. The results suggest that sphingolipid-sphingolipid interactions that occur even in the absence of cholesterol play a role in controlling the transmembrane distributions of cerebrosides.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; CUNY Queens Coll, Dept Chem & Biochem, Flushing, NY 11367 USA	University of Minnesota System; City University of New York (CUNY) System; Queens College NY (CUNY)	Brown, RE (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	rebrown@hi.umn.edu	Mattjus, Peter/ABE-3596-2021; Mattjus, Peter/AAQ-7531-2021	Mattjus, Peter/0000-0001-8991-5933; Brown, Rhoderick/0000-0002-7337-3604	NIGMS NIH HHS [R01 GM045928, R01 GM045928-09, R01 GM045928-07, R01 GM045928-08, R01 GM045928-10] Funding Source: Medline; PHS HHS [16660] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045928] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BERDEN JA, 1975, BIOCHIM BIOPHYS ACTA, V375, P186, DOI 10.1016/0005-2736(75)90188-1; Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; BITTMAN R, 1984, BIOCHIM BIOPHYS ACTA, V772, P117, DOI 10.1016/0005-2736(84)90034-8; Bratton DL, 1997, J BIOL CHEM, V272, P26159, DOI 10.1074/jbc.272.42.26159; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown RE, 1998, J CELL SCI, V111, P1; BRUZIK KS, 1988, BIOCHIM BIOPHYS ACTA, V939, P315, DOI 10.1016/0005-2736(88)90076-4; Bruzik KS, 1997, BIOCHEMISTRY-US, V36, P566, DOI 10.1021/bi962204r; BRUZIK KS, 1990, BIOCHEMISTRY-US, V29, P4017, DOI 10.1021/bi00468a032; CASTELLINO FJ, 1978, ARCH BIOCHEM BIOPHYS, V189, P465, DOI 10.1016/0003-9861(78)90235-7; Closse C, 1999, BRIT J HAEMATOL, V107, P300, DOI 10.1046/j.1365-2141.1999.01718.x; Denzer K, 2000, J CELL SCI, V113, P3365; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; EVANS E, 1994, CHEM PHYS LIPIDS, V73, P39, DOI 10.1016/0009-3084(94)90173-2; EVANS E, 1987, J PHYS CHEM-US, V91, P4219, DOI 10.1021/j100300a003; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; FIANDOR J, 1985, SYNTHESIS-STUTTGART, P1121; GOLOLOBOV YG, 1981, TETRAHEDRON, V37, P437, DOI 10.1016/S0040-4020(01)92417-2; HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693, DOI 10.1515/znc-1973-11-1209; Holopainen JM, 2000, BIOPHYS J, V78, P830, DOI 10.1016/S0006-3495(00)76640-9; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; Huang C, 1974, Methods Enzymol, V32, P485; Hug P, 2000, J VIROL, V74, P6377, DOI 10.1128/JVI.74.14.6377-6385.2000; Huttner WB, 2001, CURR OPIN CELL BIOL, V13, P478, DOI 10.1016/S0955-0674(00)00239-8; ISRAELACHVILI JN, 1977, BIOCHIM BIOPHYS ACTA, V470, P185, DOI 10.1016/0005-2736(77)90099-2; KUMAR VV, 1986, BIOCHEM BIOPH RES CO, V139, P25, DOI 10.1016/S0006-291X(86)80074-2; KUMAR VV, 1989, BIOPHYS J, V55, P789, DOI 10.1016/S0006-3495(89)82877-2; KUMAR VV, 1988, BIOCHEMISTRY-US, V27, P393, DOI 10.1021/bi00401a059; LENTZ BR, 1978, BIOCHEMISTRY-US, V17, P5537, DOI 10.1021/bi00618a032; LENTZ BR, 1980, BIOCHEMISTRY-US, V19, P2555, DOI 10.1021/bi00553a003; Li XM, 2001, BIOCHEMISTRY-US, V40, P5954, DOI 10.1021/bi002791n; Lingwood CA, 2000, METHOD ENZYMOL, V312, P459; LITMAN BJ, 1974, BIOCHEMISTRY-US, V13, P2844, DOI 10.1021/bi00711a010; MAGGIO B, 1994, PROG BIOPHYS MOL BIO, V62, P55, DOI 10.1016/0079-6107(94)90006-X; Masserini M, 2001, BBA-MOL CELL BIOL L, V1532, P149, DOI 10.1016/S1388-1981(01)00128-7; Maulik PR, 1996, BIOPHYS J, V70, P2256, DOI 10.1016/S0006-3495(96)79791-6; Maulik PR, 1996, BIOCHEMISTRY-US, V35, P8025, DOI 10.1021/bi9528356; MURARI R, 1982, J ORG CHEM, V47, P2158, DOI 10.1021/jo00132a034; Ohvo H, 1997, BBA-LIPID LIPID MET, V1349, P131, DOI 10.1016/S0005-2760(97)00126-4; Raphael RM, 1996, BIOPHYS J, V71, P1374, DOI 10.1016/S0006-3495(96)79340-2; Rothblat GH, 1999, J LIPID RES, V40, P781; RUI YJ, 1994, J ORG CHEM, V59, P5758, DOI 10.1021/jo00098a040; RUOCCO MJ, 1983, BIOCHIM BIOPHYS ACTA, V735, P305, DOI 10.1016/0005-2736(83)90307-3; SACKMANN E, 1995, STRUCTURE DYNAMICS M, V1, P213; SCHMIDT CF, 1977, BIOCHEMISTRY-US, V16, P2649, DOI 10.1021/bi00631a011; Sillence DJ, 2000, METHOD ENZYMOL, V312, P562; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Svetina S, 1998, EUR BIOPHYS J BIOPHY, V27, P197, DOI 10.1007/s002490050126; Talbott CM, 2000, BBA-BIOMEMBRANES, V1467, P326, DOI 10.1016/S0005-2736(00)00229-7; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; TKACZUK P, 1979, BIOCHEM BIOPH RES CO, V91, P1415, DOI 10.1016/0006-291X(79)91224-5; van der Goot FG, 2001, SEMIN IMMUNOL, V13, P89, DOI 10.1006/smim.2000.0300; VASELLA A, 1991, HELV CHIM ACTA, V74, P2073, DOI 10.1002/hlca.19910740842; WEGMANN B, 1987, J CARBOHYD CHEM, V6, P357, DOI 10.1080/07328308708057926; YEAGLE PL, 1976, J BIOL CHEM, V251, P2110; Zha XH, 1998, J CELL BIOL, V140, P39, DOI 10.1083/jcb.140.1.39; [No title captured]	60	29	29	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19476	19481		10.1074/jbc.M201305200	http://dx.doi.org/10.1074/jbc.M201305200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11909867	hybrid, Green Accepted			2022-12-25	WOS:000175894800033
J	Misra, P; Qi, C; Yu, ST; Shah, SH; Cao, WQ; Rao, MS; Thimmapaya, B; Zhu, YJ; Reddy, JK				Misra, P; Qi, C; Yu, ST; Shah, SH; Cao, WQ; Rao, MS; Thimmapaya, B; Zhu, YJ; Reddy, JK			Interaction of PIMT with transcriptional coactivators CBP, p300, and PBP differential role in transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; CREB-BINDING-PROTEIN; NUCLEAR-RECEPTOR; HISTONE ACETYLTRANSFERASE; EMBRYONIC-DEVELOPMENT; TRAP220 COMPONENT; GENE; CLONING; COMPLEX; CBP/P300	PIMT (PRIP-interacting protein with methyltransferase domain), an RNA-binding protein with a methyltransferase domain capable of binding S-adenosylmethionine, has been shown previously to interact with nuclear receptor coactivator PRIP (peroxisome proliferator-activated receptor (PPAR)-interacting protein) and enhance its coactivator function. We now report that PIMT strongly interacts with transcriptional coactivators, CBP, p300, and P BP but not with SRC-1 and PGC-1alpha under in vitro and in vivo conditions. The PIMT binding sites on CBP and p300 are located in the cysteine-histidine-rich C/H1 and C/H3 domains, and the PIMT binding site on PBP is in the region encompassing amino acids 1101-1560. The N-terminal of PIMT (residues 1-369) containing the RNA binding domain interacts with both C/H1 and C/H3 domains of CBP and p300 and with the C-terminal portion of PBP that encompasses amino acids 1371-1560. The C-terminal of PIMT (residues 611-852), which binds S-adenosyl-L-methionine, interacts respectively with the C/H3 domain of CBP/p300 and with a region encompassing amino acids 1101-1370 of PBP. Immunoprecipitation data showed that PIMT forms a complex in vivo with CBP, p300, PBP, and PRIP. PIMT appeared to be co-localized in the nucleus with CBP, p300, and PBP. PIMT enhanced PBP-mediated transcriptional activity of the PPARgamma, as it did for PRIP, indicating synergism between PIMT and PBP. In contrast, PIMT functioned as a repressor of CBP/p300-mediated transactivation of PPARgamma. Based on these observations, we suggest that PIMT bridges the CBP/p300-anchored coactivator complex with the PBP-anchored coactivator complex but differentially modulates coactivator function such that inhibition of the CBP/p300 effect may be designed to enhance the activity of PBP and PRIP.	Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Microbiol & Immunol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Reddy, JK (corresponding author), Northwestern Univ, Dept Pathol, Feinberg Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.				NATIONAL CANCER INSTITUTE [R01CA088898, R01CA074403, R01CA084472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K08ES000356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023750, R37GM023750] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA74403, CA88898, CA84472] Funding Source: Medline; NIEHS NIH HHS [K08 ES00356] Funding Source: Medline; NIGMS NIH HHS [GM23750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; BOSSIE MA, 1992, MOL BIOL CELL, V3, P875, DOI 10.1091/mbc.3.8.875; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Crawford SE, 2002, J BIOL CHEM, V277, P3585, DOI 10.1074/jbc.M107995200; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Goodman RH, 2000, GENE DEV, V14, P1553; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Jung DJ, 2002, J BIOL CHEM, V277, P1229, DOI 10.1074/jbc.M110417200; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KAMIE Y, 1996, CELL, V85, P403; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Kung AL, 2000, GENE DEV, V14, P272; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Lei EP, 2001, GENE DEV, V15, P1771, DOI 10.1101/gad.892401; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; LIN J, 1998, CELL, V92, P829; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McCulloch V, 2002, MOL CELL BIOL, V22, P1116, DOI 10.1128/MCB.22.4.1116-1125.2002; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oike Y, 1999, BLOOD, V93, P2771; ONATE SA, 1995, SCIENCE, V270, P1354; Qi C, 1999, P NATL ACAD SCI USA, V96, P1585, DOI 10.1073/pnas.96.4.1585; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yu ST, 2001, J BIOL CHEM, V276, P42485, DOI 10.1074/jbc.M106480200; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510; Zhu YJ, 2000, J BIOL CHEM, V275, P14779, DOI 10.1074/jbc.C000121200; Zhu YJ, 1996, GENE EXPRESSION, V6, P185; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500; Zhu YJ, 2001, P NATL ACAD SCI USA, V98, P10380, DOI 10.1073/pnas.181347498	53	62	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					20011	20019		10.1074/jbc.M201739200	http://dx.doi.org/10.1074/jbc.M201739200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11912212	hybrid			2022-12-25	WOS:000175894800101
J	Wang, ZQ; Wang, MF; Lazo, JS; Carr, BI				Wang, ZQ; Wang, MF; Lazo, JS; Carr, BI			Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; VITAMIN-K ANALOGS; TYROSINE PHOSPHATASES; G(1)/S TRANSITION; MITOTIC INDUCER; FISSION YEAST; S-PHASE; INHIBITION; ACTIVATION; PHOSPHORYLATION	Cdc25A, a dual-specificity protein phosphatase, plays a critical role in cell cycle progression. Although cyclin-dependent kinases are established substrates, Cdc25A may also affect other proteins. We have shown here that Cdc25A interacts with epidermal growth factor receptor (EGFR) both physically and functionally in Hep3B human hepatoma cells. Cdc25A inhibitor Cpd 5, a vitamin K analog, inhibited Cdc25A activity in the Cdc25A-EGFR immunocomplex and consequently caused prolonged EGFR tyrosine phosphorylation. Both purified GST-Cdc25A protein and endogenous Hep3B cellular Cdc25A dephosphorylated tyrosine-phosphorylated EGFR, and Cpd 5 antagonized the phosphatase activity of Cdc25A. A functional Cdc25A-EGFR interaction was seen in NR-6 fibroblasts expressing ectopic EGFR but not with a receptor lacking the C terminus or a mutated kinase domain. These data link the cell cycle control Cdc25A phosphatase to an EGFR-linked mitogenic signaling pathway specifically involving EGFR dephosphorylation.	Univ Pittsburgh, Sch Med, Dept Surg, Thomas E Starzl Transplantat Inst, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Thomas E Starzl Transplantat Inst, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Carr, BI (corresponding author), Univ Pittsburgh, Sch Med, Dept Surg, Thomas E Starzl Transplantat Inst, E1552 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.			Carr, Brian/0000-0002-6111-5077	NCI NIH HHS [CA52995, CA82723, CA8039] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA052995, U01CA052995, R01CA082723] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blomberg I, 1999, MOL CELL BIOL, V19, P6183; BOHMER FD, 1993, FEBS LETT, V331, P276, DOI 10.1016/0014-5793(93)80352-U; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; Eckstein J., 1997, BIOCHIM BIOPHYS ACTA, V1332, P53; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Giebler HA, 2000, MOL CELL BIOL, V20, P4849, DOI 10.1128/MCB.20.13.4849-4858.2000; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Iavarone A, 1997, NATURE, V387, P417; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Ni RZ, 1998, J BIOL CHEM, V273, P9906, DOI 10.1074/jbc.273.16.9906; Nishikawa Y, 1999, J BIOL CHEM, V274, P34803, DOI 10.1074/jbc.274.49.34803; Rice RL, 1997, BIOCHEMISTRY-US, V36, P15965, DOI 10.1021/bi971338h; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; Tamura K, 2000, CANCER RES, V60, P1317; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; VANOBBERGHEN E, 1994, DIABETOLOGIA, V37, pS125, DOI 10.1007/BF00400836; Vogt A, 2001, J BIOL CHEM, V276, P20544, DOI 10.1074/jbc.M100078200; Wang ZQ, 2000, J CELL PHYSIOL, V183, P338, DOI 10.1002/(SICI)1097-4652(200006)183:3<338::AID-JCP6>3.0.CO;2-X; Wang ZQ, 2001, CANCER RES, V61, P7211; Wu FYH, 1999, EUR J CANCER, V35, P1388, DOI 10.1016/S0959-8049(99)00156-2; Xia K, 1999, MOL CELL BIOL, V19, P4819; Xu X, 1996, J BIOL CHEM, V271, P5118; ZHOU GC, 1994, J BIOL CHEM, V269, P28084; Zou XH, 2001, MOL CELL BIOL, V21, P4818, DOI 10.1128/MCB.21.14.4818-4828.2001	41	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19470	19475		10.1074/jbc.M201097200	http://dx.doi.org/10.1074/jbc.M201097200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11912208	hybrid			2022-12-25	WOS:000175894800032
J	Brin, E; Leis, J				Brin, E; Leis, J			HIV-1 integrase interaction with U3 and U5 terminal sequences in vitro defined using substrates with random sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL-DNA; IN-VITRO; REVERSE TRANSCRIPTION; RETROVIRAL DNA; PROTEIN; COMPLEXES; ENDS; RECOGNITION; INITIATION	Successful integration of viral genome into a host chromosome depends on interaction between viral integrase and its recognition sequences. We have used a reconstituted concerted human immunodeficiency virus, type 1 (HIV-1), integration system to analyze the role of integrase (IN) recognition sequences in formation of the IN-viral DNA complex capable of concerted integration. HIV-1 integrase was presented with substrates that contained all 4 bases at 8 mismatched positions that define the inverted repeat relationship between U3 and U5 long terminal repeats (LTR) termini and at positions 17-19, which are conserved in the termini. Evidence presented indicates that positions 17-20 of the IN recognition sequences are needed for a concerted DNA integration mechanism. All 4 bases were found at each randomized position in sequenced concerted DNA integrants, although in some instances there were preferences for specific bases. These results indicate that integrase tolerates a significant amount of plasticity as to what constitutes an IN recognition sequence. By having several positions randomized, the concerted integrants were examined for statistically significant relationships between selections of bases at different positions. The results of this analysis show not only relationships between different positions within the same LTR end but also between different positions belonging to opposite DNA termini.	Northwestern Univ, Sch Med, Dept Microbiol & Immunol, Chicago, IL 60611 USA	Northwestern University	Leis, J (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol & Immunol, 303 E Chicago Ave, Chicago, IL 60611 USA.				NATIONAL CANCER INSTITUTE [R01CA038046, R01CA052047] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA038046-16, CA38046, R01 CA052047-12, CA52047, R01 CA052047] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIYAR A, 1994, J VIROL, V68, P611, DOI 10.1128/JVI.68.2.611-618.1994; Aiyar A, 1996, J VIROL, V70, P3571, DOI 10.1128/JVI.70.6.3571-3580.1996; Brin E, 2002, J BIOL CHEM, V277, P10938, DOI 10.1074/jbc.M108116200; Carteau S, 1999, J VIROL, V73, P6670, DOI 10.1128/JVI.73.8.6670-6679.1999; COBRINIK D, 1991, J VIROL, V65, P3864, DOI 10.1128/JVI.65.7.3864-3872.1991; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Gao K, 2001, EMBO J, V20, P3565, DOI 10.1093/emboj/20.13.3565; Hindmarsh P, 1999, J VIROL, V73, P2994, DOI 10.1128/JVI.73.4.2994-3003.1999; Hindmarsh P, 1999, MICROBIOL MOL BIOL R, V63, P836, DOI 10.1128/MMBR.63.4.836-843.1999; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; McCord M, 1999, VIROLOGY, V259, P392, DOI 10.1006/viro.1999.9782; Miller JT, 1997, J VIROL, V71, P7648, DOI 10.1128/JVI.71.10.7648-7656.1997; Morgan AL, 2000, J GEN VIROL, V81, P839, DOI 10.1099/0022-1317-81-3-839; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; MURPHY JE, 1992, J VIROL, V66, P5092, DOI 10.1128/JVI.66.8.5092-5095.1992; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; Rice PA, 2001, NAT STRUCT BIOL, V8, P302, DOI 10.1038/86166; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; Wei SQ, 1998, P NATL ACAD SCI USA, V95, P10535, DOI 10.1073/pnas.95.18.10535; Yi JZ, 1999, BIOCHEMISTRY-US, V38, P8458, DOI 10.1021/bi982870n; Zhou HB, 2001, J VIROL, V75, P1359, DOI 10.1128/JVI.75.3.1359-1370.2001	23	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18357	18364		10.1074/jbc.M201354200	http://dx.doi.org/10.1074/jbc.M201354200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11897790	Green Accepted, hybrid			2022-12-25	WOS:000175975800015
J	Garcia-Ortega, L; Masip, M; Mancheno, JM; Onaderra, M; Lizarbe, MA; Garcia-Mayoral, MF; Bruix, M; del Pozo, AM; Gavilanes, JG				Garcia-Ortega, L; Masip, M; Mancheno, JM; Onaderra, M; Lizarbe, MA; Garcia-Mayoral, MF; Bruix, M; del Pozo, AM; Gavilanes, JG			Deletion of the NH2-terminal beta-hairpin of the ribotoxin alpha-sarcin produces a nontoxic but active ribonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME-INACTIVATING PROTEIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; FUNGAL RIBOTOXINS; CYTOTOXIN; PURIFICATION; RECOGNITION; MITOGILLIN; MECHANISM; SEQUENCE	Ribotoxins are a family of highly specific fungal ribonucleases that inactivate the ribosomes by hydrolysis of a single phosphodiester bond of the 28 S rRNA. alpha-Sarcin, the best characterized member of this family, is a potent cytotoxin that promotes apoptosis of human tumor cells after internalization via endocytosis. This latter ability is related to its interaction with phospholipid bilayers. These proteins share a common structural core with nontoxic ribonucleases of the RNase T1 family. However, significant structural differences between these two groups of proteins are related to the presence of a long amino-terminal beta-hairpin in ribotoxins and to the different length of their unstructured loops. The amino-terminal deletion mutant Delta(7-22) of alpha-sarcin has been produced in Escherichia coli and purified to homogeneity. It retains the same conformation as the wild-type protein as ascertained by complete spectroscopic characterization based on circular dichroism, fluorescence, and NMR techniques. This mutant exhibits ribonuclease activity against naked rRNA and synthetic substrates but lacks the specific ability of the wild-type protein to degrade rRNA in intact ribosomes. The results indicate that alpha-sarcin interacts with the ribosome at two regions, i.e. the well known sarcin-ricin loop of the rRNA and a different region recognized by the beta-hairpin of the protein. In addition, this latter protein portion is involved in interaction with cell membranes. The mutant displays decreased interaction with lipid vesicles and shows behavior compatible with the absence of one vesicle-interacting region. In agreement with this conclusion, the deletion mutant exhibits a very low cytotoxicity on human rhabdomyosarcoma cells.	Univ Complutense, Fac Quim, Dept Bioquim & Biol Mol 1, E-28040 Madrid, Spain; CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)	del Pozo, AM (corresponding author), Univ Complutense, Fac Quim, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain.	alvaro@bbm1.ucm.es; ppgf@bbm1.ucm.es	OÑADERRA, Mercedes/H-2527-2015; Mancheno, Jose/K-4984-2014; Lizarbe, M Antonia/K-5219-2014; Gavilanes, Jose G./K-5307-2014; Bruix, Marta/H-4161-2011; Garcia-Ortega, Lucia/J-3278-2016; Martinez-del-Pozo, Alvaro/L-8556-2014	OÑADERRA, Mercedes/0000-0003-2564-5609; Mancheno, Jose/0000-0001-6943-3291; Lizarbe, M Antonia/0000-0003-1722-1240; Gavilanes, Jose G./0000-0002-6852-341X; Bruix, Marta/0000-0002-0096-3558; Garcia-Ortega, Lucia/0000-0003-3479-2213; Martinez-del-Pozo, Alvaro/0000-0003-0043-5939				Barlett G.R., 1959, J BIOL CHEM, V234, P466; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BETTER M, 1992, J BIOL CHEM, V267, P16712; BLANK A, 1982, ANAL BIOCHEM, V120, P267, DOI 10.1016/0003-2697(82)90347-5; CamposOlivas R, 1996, PROTEIN SCI, V5, P969; Correll CC, 1999, J MOL BIOL, V292, P275, DOI 10.1006/jmbi.1999.3072; Correll CC, 1998, P NATL ACAD SCI USA, V95, P13436, DOI 10.1073/pnas.95.23.13436; de Antonio C, 2000, PROTEINS, V41, P350, DOI 10.1002/1097-0134(20001115)41:3<350::AID-PROT70>3.0.CO;2-V; EFTINK MR, 1983, BIOCHEMISTRY-US, V22, P5134, DOI 10.1021/bi00291a012; EGAMI F, 1980, MOL BIOL BIOCH BIOPH, P250; ENDO Y, 1990, J BIOL CHEM, V265, P2216; ENDO Y, 1982, J BIOL CHEM, V257, P9054; Garcia-Ortega L, 2000, LETT APPL MICROBIOL, V30, P298, DOI 10.1046/j.1472-765x.2000.00714.x; Garcia-Ortega L, 2001, PROTEIN SCI, V10, P1658, DOI 10.1110/ps.9601; GASSET M, 1989, BIOCHEM J, V258, P569, DOI 10.1042/bj2580569; GASSET M, 1990, BIOCHEM J, V265, P815, DOI 10.1042/bj2650815; HERTLER AA, 1989, J CLIN ONCOL, V7, P1932, DOI 10.1200/JCO.1989.7.12.1932; KANAYA S, 1995, J BIOCHEM-TOKYO, V118, P681, DOI 10.1093/oxfordjournals.jbchem.a124964; Kao R, 1999, J BIOL CHEM, V274, P12576, DOI 10.1074/jbc.274.18.12576; Kao R, 1995, BIOCHEM CELL BIOL, V73, P1151, DOI 10.1139/o95-124; Kao R, 2001, METHOD ENZYMOL, V341, P324, DOI 10.1016/S0076-6879(01)41161-X; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURUP VP, 1991, CLIN MICROBIOL REV, V4, P439, DOI 10.1128/CMR.4.4.439-456.1991; Lacadena J, 1999, PROTEINS, V37, P474, DOI 10.1002/(SICI)1097-0134(19991115)37:3<474::AID-PROT14>3.0.CO;2-N; LACADENA J, 1994, GENE, V142, P147, DOI 10.1016/0378-1119(94)90370-0; LACADENA J, 1995, BIOCHEM J, V309, P581, DOI 10.1042/bj3090581; Lacadena J, 1998, FEBS LETT, V424, P46, DOI 10.1016/S0014-5793(98)00137-9; Lamy B., 1992, GENETICALLY ENG TOXI, P237; Loverix S, 1998, EUR J BIOCHEM, V257, P286, DOI 10.1046/j.1432-1327.1998.2570286.x; MANCHENO JM, 1994, BIOPHYS J, V67, P1117, DOI 10.1016/S0006-3495(94)80578-8; MANCHENO JM, 1995, BIOPHYS J, V68, P2387, DOI 10.1016/S0006-3495(95)80421-2; MANCHENO JM, 1995, J THEOR BIOL, V172, P259, DOI 10.1006/jtbi.1995.0022; Mancheno JM, 1998, J PEPT RES, V51, P142; Martinez-Ruiz A, 2000, FEMS MICROBIOL LETT, V189, P165, DOI 10.1111/j.1574-6968.2000.tb09224.x; Martinez-Ruiz A, 2001, METHODS ENZYMOL, V341, P335, DOI 10.1016/S0076-6879(01)41162-1; Masip M, 2001, EUR J BIOCHEM, V268, P6190, DOI 10.1046/j.0014-2956.2001.02566.x; MOSER M, 1992, J IMMUNOL, V149, P454; Moussaoui M, 1998, J BIOL CHEM, V273, P25565, DOI 10.1074/jbc.273.40.25565; NOGUCHI S, 1995, BIOCHEMISTRY-US, V34, P15583, DOI 10.1021/bi00047a025; Olmo N, 2001, EUR J BIOCHEM, V268, P2113, DOI 10.1046/j.1432-1327.2001.02086.x; OLSON BH, 1965, APPL MICROBIOL, V13, P314, DOI 10.1128/AEM.13.3.314-321.1965; ONADERRA M, 1993, BIOCHEM J, V295, P221, DOI 10.1042/bj2950221; Onaderra M, 1998, MOL MEMBR BIOL, V15, P141, DOI 10.3109/09687689809074525; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; Perez-Canadillas JM, 1998, BIOCHEMISTRY-US, V37, P15865, DOI 10.1021/bi981672t; Perez-Canadillas JM, 2000, J MOL BIOL, V299, P1061, DOI 10.1006/jmbi.2000.3813; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RUSHIZKY GW, 1970, BIOCHEMISTRY-US, V9, P4966, DOI 10.1021/bi00827a021; SACCO G, 1983, J BIOL CHEM, V258, P5811; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO S, 1975, BIOCHEM J, V145, P353, DOI 10.1042/bj1450353; SCHINDLER DG, 1977, NUCLEIC ACIDS RES, V4, P1097, DOI 10.1093/nar/4.4.1097; Steyaert J, 1997, EUR J BIOCHEM, V247, P1, DOI 10.1111/j.1432-1033.1997.t01-1-00001.x; TURNAY J, 1993, MOL CELL BIOCHEM, V122, P39, DOI 10.1007/BF00925735; Uchida T., 1971, ENZYMES, V4, P205; WAWRZYNCZAK EJ, 1991, EUR J BIOCHEM, V196, P203, DOI 10.1111/j.1432-1033.1991.tb15805.x; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yang XJ, 1996, STRUCTURE, V4, P837, DOI 10.1016/S0969-2126(96)00090-1; Yang XJ, 2001, NAT STRUCT BIOL, V8, P968, DOI 10.1038/nsb1101-968; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Yoshida H, 2001, METHOD ENZYMOL, V341, P28, DOI 10.1016/S0076-6879(01)41143-8	65	44	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18632	18639		10.1074/jbc.M200922200	http://dx.doi.org/10.1074/jbc.M200922200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11897788	Green Published, hybrid			2022-12-25	WOS:000175975800053
J	Chaboute, ME; Clement, B; Philipps, G				Chaboute, ME; Clement, B; Philipps, G			S phase and weristem-specific expression of the tobacco RNR1b gene is mediated by an E2F element located in the 5 ' leader sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE RIBONUCLEOTIDE REDUCTASE; CYCLE-REGULATED TRANSCRIPTION; SYNCHRONIZED PLANT-CELLS; DNA-DAMAGE; ARABIDOPSIS-THALIANA; NUCLEAR ANTIGEN; ROOT-MERISTEMS; PROMOTER; BINDING; PROTEIN	The RB/E2F pathway is involved in the control of the G(1)/S transition of the eukaryotic cell cycle where various S phase genes are activated by specific E2F factors. Ribonucleotide reductase (RN-R) plays an essential role in the DNA synthesis pathway. Earlier studies showed that there are at least two RNR1 genes (RNR1a and RNR1b) and one RNR2 gene in tobacco. In synchronized tobacco BY2 cells, RNR1b gene expression is at its highest level in S phase. To investigate transcriptional regulation of the RNR1b gene, its promoter region was cloned and sequenced. Unlike its animal counterparts, the tobacco RNR1b promoter contains a consensus E2F-binding site. Surprisingly, this site is found in the leader sequence of the gene. We show here by gel shift analysis and antibody competition that one nuclear complex specifically binds this motif, and an E2F factor is part of this complex. Using reporter gene analysis, tobacco RNR1b promoter activity was detected during S phase in synchronized cells and in plant meristematic tissues. Mutation of the E2F element substantially reduced both activities. For the first time in plants, a single E2F motif found in the leader sequence plays an important role in the meristem and S phase-specific expression of the tobacco RNR1b gene.	Univ Strasbourg 1, CNRS, Inst Biol Mol Plantes, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chaboute, ME (corresponding author), Univ Strasbourg 1, CNRS, Inst Biol Mol Plantes, 12 Rue Gen Zimmer, F-67084 Strasbourg, France.			Chaboute, Marie-Edith/0000-0001-8688-721X				Afroze T, 2000, J BIOL CHEM, V275, P9062, DOI 10.1074/jbc.275.12.9062; Albani D, 2000, J BIOL CHEM, V275, P19258, DOI 10.1074/jbc.M909390199; AN G, 1987, METHOD ENZYMOL, V153, P292; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bartley PA, 2001, BLOOD CELL MOL DIS, V27, P409, DOI 10.1006/bcmd.2001.0398; Black AR, 1999, GENE, V237, P281, DOI 10.1016/S0378-1119(99)00305-4; Brown SC, 1991, LAB GUIDE CELLULAR M, P326; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chaboute ME, 1998, PLANT MOL BIOL, V38, P797, DOI 10.1023/A:1006083318906; Chaboute ME, 2000, PLANT CELL, V12, P1987, DOI 10.1105/tpc.12.10.1987; Chaubet N, 1996, PLANT J, V10, P425, DOI 10.1046/j.1365-313X.1996.10030425.x; Darbinian N, 1999, ONCOGENE, V18, P6398, DOI 10.1038/sj.onc.1203011; de Jager SM, 2001, PLANT MOL BIOL, V47, P555, DOI 10.1023/A:1011848528377; Di Fiore B, 1999, J BIOL CHEM, V274, P10339, DOI 10.1074/jbc.274.15.10339; Durfee T, 2000, PLANT MOL BIOL, V43, P635, DOI 10.1023/A:1006426808185; Egelkrout EM, 2001, PLANT CELL, V13, P1437, DOI 10.1105/tpc.13.6.1437; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; Filatov D, 1995, BIOCHEM SOC T, V23, P903, DOI 10.1042/bst0230903; FILATOV D, 1995, J BIOL CHEM, V270, P25239, DOI 10.1074/jbc.270.42.25239; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; JEFFERSON RA, 1987, EMBO J, V6, P3901; JOHANSSON E, 1995, J BIOL CHEM, V270, P30162, DOI 10.1074/jbc.270.50.30162; KOSUGI S, 1995, PLANT J, V7, P877, DOI 10.1046/j.1365-313X.1995.07060877.x; Koziczak M, 2000, MOL CELL BIOL, V20, P2014, DOI 10.1128/MCB.20.6.2014-2022.2000; KRAKOFF IH, 1968, CANCER RES, V28, P1559; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Magyar Z, 2000, FEBS LETT, V486, P79, DOI 10.1016/S0014-5793(00)02238-9; Manevski A, 2000, FEBS LETT, V483, P43, DOI 10.1016/S0014-5793(00)02056-1; Mankin SL, 1997, PLANT MOL BIOL REP, V15, P186, DOI 10.1007/BF02812270; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NAGATA T, 1992, INT REV CYTOL, V132, P1, DOI 10.1016/S0074-7696(08)62452-3; Oswald F, 1996, MOL CELL BIOL, V16, P1889; Ramirez-Parra E, 1999, NUCLEIC ACIDS RES, V27, P3527, DOI 10.1093/nar/27.17.3527; Ramirez-Parra E, 2000, FEBS LETT, V486, P73, DOI 10.1016/S0014-5793(00)02239-0; REGAD F, 1995, MOL GEN GENET, V248, P703, DOI 10.1007/BF02191710; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHHELD JP, 1995, PLANT J, V7, P245, DOI 10.1046/j.1365-313X.1995.7020245.x; Romero I, 1998, PLANT J, V14, P273, DOI 10.1046/j.1365-313X.1998.00113.x; Sekine M, 1999, FEBS LETT, V460, P117, DOI 10.1016/S0014-5793(99)01296-X; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tremousaygue D, 1999, PLANT J, V20, P553, DOI 10.1046/j.1365-313X.1999.00627.x; Wang PJ, 1997, MOL CELL BIOL, V17, P6114, DOI 10.1128/MCB.17.10.6114	50	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17845	17851		10.1074/jbc.M200959200	http://dx.doi.org/10.1074/jbc.M200959200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884409	hybrid			2022-12-25	WOS:000175685100059
J	Kuloglu, ES; McCaslin, DR; Markley, JL; Volkman, BF				Kuloglu, ES; McCaslin, DR; Markley, JL; Volkman, BF			Structural rearrangement of human lymphotactin, a C chemokine, under physiological solution conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CHEMICAL-SHIFT INDEX; NMR-SPECTROSCOPY; NOESY-HSQC; T-CELLS; 3-DIMENSIONAL STRUCTURE; BINDING SURFACE; XCR1 RECEPTOR; SH3 DOMAIN; IDENTIFICATION	NMR spectra of human lymphotactin (hLtn), obtained under various solution conditions, have revealed that the protein undergoes a major conformational rearrangement dependent on temperature and salt concentration. At high salt (200 mm NaCl) and low temperature (10degreesC), hLtn adopts a chemokine-like fold, which consists of a three-stranded antiparallel beta-sheet and a C-terminal alpha-helix (Kuloglu, E. S., McCaslin, D. R., Kitabwalla, M., Pauza, C. D., Markley, J. L., and Volkman, B. F. (2001) Biochemistry 40,12486-12496). We have used NMR spectroscopy, sedimentation equilibrium, and intrinsic fluorescence to monitor the reversible conformational change undergone by hLtn as a function of temperature and ionic strength. We have used two-, three- and four-dimensional NMR spectroscopy of isotopically enriched protein samples to determine structural properties of the conformational state stabilized at 45 degreesC and 0 ram NaCl. Patterns of NOEs and H-1(alpha) and C-13 chemical shifts show that hLtn rearranges under these conditions to form a four-stranded, antiparallel beta-sheet with a pattern of hydrogen bonding that is completely different from that of the chemokine fold stabilized at 10 degreesC and 200 ram NaCl. The C-terminal alpha-helix observed at 10degreesC and 200 mm NaCl, which is conserved in other chemokines, is absent at 45 degreesC and no salt, and the last 38 residues of the protein are completely disordered, as indicated by heteronuclear N-15-H-1 NOEs. Temperature dependence of the tryptophan fluorescence of hLtn in low and high salt confirmed that the chemokine conformation is stabilized by increased ionic strength. Sedimentation equilibrium analytical ultracentrifugation showed that hLtn at 40 degreesC in the presence of 100 mm NaCl exists mainly as a dimer. Under near physiological conditions of temperature, pH, and ionic strength, both the chemokine-like and non-chemokine-like conformations of hLtn are significantly populated. The functional relevance of this structural interconversion remains to be elucidated.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Biophys Instrumentat Facil, Madison, WI 53706 USA; Univ Wisconsin, Natl Magnet Resonance Facil Madison, Madison, WI 53706 USA	Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Volkman, BF (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.		Volkman, Brian F./ABE-7312-2020; Volkman, Brian F./ABE-7306-2020	Volkman, Brian F./0000-0002-6681-5179; Volkman, Brian F./0000-0002-6681-5179	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002301, S10RR013790, S10RR002781, S10RR008438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI045843, R01AI045843] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR002301, S10 RR002781, S10 RR013790, S10 RR008438] Funding Source: Medline; NIAID NIH HHS [R01 AI045843-02, R01 AI045843, AI45843, R01 AI045843-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Billeter M, 1995, J BIOMOL NMR, V5, P1; Boismenu R, 1996, J IMMUNOL, V157, P985; Cairns CM, 2001, J IMMUNOL, V167, P57, DOI 10.4049/jimmunol.167.1.57; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9307, DOI 10.1021/bi00029a005; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Gale LM, 1999, BIOESSAYS, V21, P17, DOI 10.1002/(SICI)1521-1878(199901)21:1<17::AID-BIES3>3.0.CO;2-4; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; Guan E, 2001, J BIOL CHEM, V276, P12404, DOI 10.1074/jbc.M006327200; Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270; Hedrick JA, 1997, J IMMUNOL, V158, P1533; Hedrick JA, 1997, METHOD ENZYMOL, V287, P206; Hoover DM, 2000, J BIOL CHEM, V275, P23187, DOI 10.1074/jbc.M002584200; Huang H, 2001, BIOCHEM BIOPH RES CO, V281, P378, DOI 10.1006/bbrc.2001.4363; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KENNEDY J, 1995, J IMMUNOL, V155, P203; Kuloglu ES, 2001, BIOCHEMISTRY-US, V40, P12486, DOI 10.1021/bi011106p; Laurence JS, 1998, BIOCHEMISTRY-US, V37, P9346, DOI 10.1021/bi980329l; Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196; Leong SR, 1997, PROTEIN SCI, V6, P609; Liwang AC, 1999, PROTEIN SCI, V8, P2270; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; Lubkowski J, 1997, NAT STRUCT BIOL, V4, P64, DOI 10.1038/nsb0197-64; Luther SA, 2001, NAT IMMUNOL, V2, P102, DOI 10.1038/84205; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; Marcaurelle LA, 2001, CHEM-EUR J, V7, P1129, DOI 10.1002/1521-3765(20010302)7:5<1129::AID-CHEM1129>3.0.CO;2-W; Markley JL, 1998, EUR J BIOCHEM, V256, P1, DOI 10.1046/j.1432-1327.1998.2560001.x; Mayer KL, 2000, BIOCHEMISTRY-US, V39, P8382, DOI 10.1021/bi000523j; Meunier S, 1997, BIOCHEMISTRY-US, V36, P4412, DOI 10.1021/bi9627929; Middel P, 2001, AM J PATHOL, V159, P1751, DOI 10.1016/S0002-9440(10)63022-2; Mizoue LS, 1999, BIOCHEMISTRY-US, V38, P1402, DOI 10.1021/bi9820614; Morshauser RC, 1999, J MAGN RESON, V139, P232, DOI 10.1006/jmre.1999.1802; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; MUHANDIRAM DR, 1993, J MAGN RESON SER B, V102, P317, DOI 10.1006/jmrb.1993.1102; Paavola CD, 1998, J BIOL CHEM, V273, P33157, DOI 10.1074/jbc.273.50.33157; Pace N., 1997, PROTEIN STRUCTURE PR, P253; PATEL SR, 1993, BIOCHEMISTRY-US, V32, P5466, DOI 10.1021/bi00071a024; Proudfoot AEI, 1998, EUR J DERMATOL, V8, P147; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Royer C A, 1995, Methods Mol Biol, V40, P65; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Shan LX, 2000, BIOCHEM BIOPH RES CO, V268, P938, DOI 10.1006/bbrc.2000.2235; Shao WP, 1998, BIOCHEMISTRY-US, V37, P8303, DOI 10.1021/bi980112r; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; Sticht H, 1999, BIOCHEMISTRY-US, V38, P5995, DOI 10.1021/bi990065i; Talluri S, 1996, J MAGN RESON SER B, V112, P200, DOI 10.1006/jmrb.1996.0132; Varley PG, 1997, EUR BIOPHYS J BIOPHY, V25, P437, DOI 10.1007/s002490050058; Wang JD, 1998, IMMUNOLOGY, V95, P56; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2; Yoshida T, 1998, J BIOL CHEM, V273, P16551, DOI 10.1074/jbc.273.26.16551; Young H, 1999, BIOCHEM J, V338, P591, DOI 10.1042/0264-6021:3380591; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; ZHANG YJ, 1995, MOL CELL BIOL, V15, P4851	70	59	60	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17863	17870		10.1074/jbc.M200402200	http://dx.doi.org/10.1074/jbc.M200402200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11889129	Green Accepted, hybrid			2022-12-25	WOS:000175685100061
J	Sindice, A; Basoglu, C; Cerci, A; Hirsch, JR; Potthast, R; Kuhn, M; Ghanekar, Y; Visweswariah, SS; Schlatter, E				Sindice, A; Basoglu, C; Cerci, A; Hirsch, JR; Potthast, R; Kuhn, M; Ghanekar, Y; Visweswariah, SS; Schlatter, E			Guanylin, uroguanylin, and heat-stable euterotoxin activate guanylate cyclase C and/or a pertussis toxin-sensitive G protein in human proximal tubule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY EPITHELIAL-CELLS; HCO3-SECRETION; MICE LACKING; K+ CHANNELS; KINASE-II; RECEPTOR; ENTEROTOXIN; TRANSPORT; PEPTIDE; PLASMA	Membrane guanylate cyclase C (GC-C) is the receptor for guanylin, uroguanylin, and heat-stable enterotoxin (STa) in the intestine. GC-C-deficient mice show resistance to STa in intestine but saluretic and diuretic effects of uroguanylin and STa are not disturbed. Here we describe the cellular effects of these peptides using immortalized human kidney epithelial (IHKE-1) cells with properties of the proximal tubule, analyzed with the slow-whole-cell patch clamp technique. Uroguanylin (10 or 100 nM) either hyperpolarized or depolarized membrane voltages (V-m). Guanylin and STa (both 10 or 100 nM), as well as 8-Br-cGMP (100 muM), depolarized V-m. All peptide effects were absent in the presence of 1 mm Ba2+. Uroguanylin and guanylin changed V-m pH dependently. Pertussis toxin (1 mug/ml, 24 h) inhibited hyperpolarizations caused by uroguanylin. Depolarizations caused by guanylin and uroguanylin were blocked by the tyrosine kinase inhibitor, genistein (10 muM). All three peptides increased cellular cGMP. mRNA for GC-C was detected in IHKE-1 cells and in isolated human proximal tubules. In IHKE-1 cells GC-C was also detected by immunostaining. These findings suggest that GC-C is probably the receptor for guanylin and STa. For uroguanylin two distinct signaling pathways exist in IHKE-1 cells, one involves GC-C and cGMP as second messenger, the other is cGMP-independent and connected to a pertussis toxin-sensitive G protein.	Univ Klinikum Munster, Med Klin & Poliklin D, D-48149 Munster, Germany; Univ Klinikum Munster, Inst Pharmakol & Toxikol, D-48149 Munster, Germany; Indian Inst Sci, Dept Mol Reprod Dev & Genet, Bangalore 560012, Karnataka, India	University of Munster; University of Munster; Indian Institute of Science (IISC) - Bangalore	Schlatter, E (corresponding author), Univ Klinikum Munster, Med Klin & Poliklin D, Domagkstr 3A, D-48149 Munster, Germany.	eberhard.schlatter@uni-muenster.de	Visweswariah, Sandhya/Q-7500-2019	Visweswariah, Sandhya/0000-0003-2786-7344				Bhandari R, 2001, BIOCHEMISTRY-US, V40, P9196, DOI 10.1021/bi002595g; Bhandari R, 2000, J BIOSCIENCES, V25, P339, DOI 10.1007/BF02703787; BROWN AM, 1991, J BIOENERG BIOMEMBR, V23, P499, DOI 10.1007/BF00785808; Carrithers SL, 2000, REGUL PEPTIDES, V95, P65, DOI 10.1016/S0167-0115(00)00139-7; Carrithers SL, 1999, BRAZ J MED BIOL RES, V32, P1337, DOI 10.1590/S0100-879X1999001100003; Charney AN, 2001, AM J PHYSIOL-GASTR L, V280, pG216, DOI 10.1152/ajpgi.2001.280.2.G216; CRANE JK, 1989, INFECT IMMUN, V57, P1186, DOI 10.1128/IAI.57.4.1186-1191.1989; CRANE MR, 1992, MOL PHARMACOL, V41, P1073; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; Derst C, 2001, KIDNEY INT, V59, P2197; Fonteles MC, 1998, AM J PHYSIOL-RENAL, V275, pF191, DOI 10.1152/ajprenal.1998.275.2.F191; FROMTER E, 1982, PFLUG ARCH EUR J PHY, V393, P179, DOI 10.1007/BF00582942; Fujimoto S, 2000, NEPHRON, V84, P88, DOI 10.1159/000045548; Furuya S, 1997, ANAT EMBRYOL, V196, P185, DOI 10.1007/s004290050090; Greenberg RN, 1997, J INVEST MED, V45, P276; GREGER R, 1991, PFLUG ARCH EUR J PHY, V419, P209, DOI 10.1007/BF00373009; Guba M, 1996, GASTROENTEROLOGY, V111, P1558, DOI 10.1016/S0016-5085(96)70018-5; GUDERMANN T, 1995, J MOL MED, V73, P51, DOI 10.1007/BF00270578; Hamra FK, 1997, P NATL ACAD SCI USA, V94, P2705, DOI 10.1073/pnas.94.6.2705; Hamra FK, 1996, ENDOCRINOLOGY, V137, P257, DOI 10.1210/en.137.1.257; HAMRA FK, 1993, P NATL ACAD SCI USA, V90, P10464, DOI 10.1073/pnas.90.22.10464; HAUGEN A, 1994, ENVIRON HEALTH PERSP, V102, P117, DOI 10.2307/3431773; Hirsch JR, 1999, J PHYSIOL-LONDON, V519, P645, DOI 10.1111/j.1469-7793.1999.0645n.x; Hirsch JR, 1999, J AM SOC NEPHROL, V10, P472; Joo NS, 1998, AM J PHYSIOL-GASTR L, V274, pG633, DOI 10.1152/ajpgi.1998.274.4.G633; Kinoshita H, 1999, NEPHRON, V81, P160, DOI 10.1159/000045272; Kinoshita H, 1997, KIDNEY INT, V52, P1028, DOI 10.1038/ki.1997.424; Kinoshita H, 1997, CLIN NEPHROL, V47, P28; KUHN M, 1993, FEBS LETT, V318, P205, DOI 10.1016/0014-5793(93)80022-M; LIMA AAM, 1992, PHARMACOL TOXICOL, V70, P163, DOI 10.1111/j.1600-0773.1992.tb00449.x; London RM, 1999, AM J PHYSIOL-RENAL, V276, pF882, DOI 10.1152/ajprenal.1999.276.6.F882; Lucas KA, 2000, PHARMACOL REV, V52, P375; Mann EA, 1997, BIOCHEM BIOPH RES CO, V239, P463, DOI 10.1006/bbrc.1997.7487; MEROT J, 1989, BIOCHIM BIOPHYS ACTA, V978, P134, DOI 10.1016/0005-2736(89)90508-7; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PAULMICHL M, 1988, FEBS LETT, V234, P263, DOI 10.1016/0014-5793(88)80094-2; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Potthast R, 2001, ENDOCRINOLOGY, V142, P3087, DOI 10.1210/en.142.7.3087; Schafer JA, 1997, AM J PHYSIOL-RENAL, V273, pF650, DOI 10.1152/ajprenal.1997.273.4.F650; SCHLATTER E, 1992, PFLUG ARCH EUR J PHY, V421, P381, DOI 10.1007/BF00374227; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; Selvaraj NG, 2000, BBA-MOL CELL RES, V1498, P32, DOI 10.1016/S0167-4889(00)00075-6; TVEITO G, 1989, CANCER RES, V49, P1829; Vaandrager AB, 2000, GASTROENTEROLOGY, V118, P108, DOI 10.1016/S0016-5085(00)70419-7; Vijayachandra K, 2000, BIOCHEMISTRY-US, V39, P16075, DOI 10.1021/bi0013849	45	51	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17758	17764		10.1074/jbc.M110627200	http://dx.doi.org/10.1074/jbc.M110627200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11889121	hybrid			2022-12-25	WOS:000175685100048
J	Clayton, DA; Grosshans, DR; Browning, MD				Clayton, DA; Grosshans, DR; Browning, MD			Aging and surface expression of hippocampal NMDA receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; LONG-TERM POTENTIATION; AGE; SUBUNIT; DEFICITS; NR1; DECLINES; MEMORY; LTP	Aging is known to alter many physiological processes within the brain including synaptic responses, long-term potentiation, learning, and memory. Aging has also been shown to alter the expression and distribution of N-methyl-D-aspartate (NMDA) receptors in many different brain regions, including the hippocampus. Additionally, we have recently reported that young adult rats show an activity-dependent increase in the surface expression of NMDA receptors. We have extended these observations in the present study in aged animals and have found that aged Fischer 344 rats fail to show activity-dependent changes in the surface distribution of NMDA receptors. In conjunction with this observation we have also noted that aged rats show an expression deficit in the C2 splice variant of the NR1 subunit. This subunit is preferentially shifted to the surface following stimulation in young adult animals. As the NMDA receptor is thought to play an important role in neuronal signaling, these observations suggest possible new areas of dysfunction in this receptor that might underlie age-related deficits in neuronal physiology.	Univ Colorado, Hlth Sci Ctr, Program Neurosci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Med Scientist Training Program, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Browning, MD (corresponding author), Univ Colorado, Hlth Sci Ctr, Program Neurosci, Box C236,4200 E 9th Ave, Denver, CO 80262 USA.	Michael.Browning@uchsc.edu						Bach ME, 1999, P NATL ACAD SCI USA, V96, P5280, DOI 10.1073/pnas.96.9.5280; Barnes CA, 1997, NEUROBIOL AGING, V18, P445, DOI 10.1016/S0197-4580(97)00044-4; Clayton DA, 2001, NEUROBIOL AGING, V22, P165, DOI 10.1016/S0197-4580(00)00196-2; CLAYTON DAM, 2002, IN PRESS J NEUROSCI; Desjardins S, 1997, NEUROBIOL AGING, V18, P37, DOI 10.1016/S0197-4580(96)00206-0; DETOLEDOMORRELL L, 1988, NEUROBIOL AGING, V9, P581, DOI 10.1016/S0197-4580(88)80117-9; Eckles-Smith K, 2000, MOL BRAIN RES, V78, P154, DOI 10.1016/S0169-328X(00)00088-7; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; Herman JP, 1998, NEUROBIOL AGING, V19, P581, DOI 10.1016/S0197-4580(98)00099-2; Huh KH, 1999, J BIOL CHEM, V274, P151, DOI 10.1074/jbc.274.1.151; Joseph JA, 1999, J NEUROSCI, V19, P8114; Kuehl-Kovarik MC, 2000, MECH AGEING DEV, V115, P39, DOI 10.1016/S0047-6374(00)00104-4; Lynch MA, 1998, PROG NEUROBIOL, V56, P571, DOI 10.1016/S0301-0082(98)00054-9; Magnusson KR, 2000, J NEUROSCI, V20, P1666; McGahon BM, 1999, NEUROBIOL AGING, V20, P655, DOI 10.1016/S0197-4580(99)00050-0; Okabe S, 1999, J NEUROSCI, V19, P7781; Sonntag WE, 2000, BRAIN RES BULL, V51, P331, DOI 10.1016/S0361-9230(99)00259-2; Wenk GL, 2000, BRAIN RES, V885, P1, DOI 10.1016/S0006-8993(00)02792-X; Winkler A, 1999, MOL BRAIN RES, V72, P166, DOI 10.1016/S0169-328X(99)00218-1	19	52	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14367	14369		10.1074/jbc.C200074200	http://dx.doi.org/10.1074/jbc.C200074200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11891215	hybrid			2022-12-25	WOS:000175203000005
J	Pierrel, F; Bjork, GR; Fontecave, M; Atta, M				Pierrel, F; Bjork, GR; Fontecave, M; Atta, M			Enzymatic modification of tRNAs - MiaB is an iron-sulfur protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO SYNTHESIS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; RADICAL MECHANISMS; BIOTIN; DIMETHYLALLYLTRANSFERASE; QUANTITATION; RECOGNITION; ANTICODON; SYNTHASE	The product of the miaB gene, MiaB, from Escherichia coli participates in the methylthiolation of the adenosine 37 residue during modification of tRNAs that read codons beginning with uridine. A His-tagged version of MiaB has been overproduced and purified to homogeneity. Gel electrophoresis and size exclusion chromatography revealed that MiaB protein is a monomer. As isolated MiaB contains both iron and sulfide and an apoprotein form can chelate as much as 2.5-3 iron and 3-3.5 sulfur atoms per polypeptide chain. UV-visible and EPR spectroscopy of MiaB indicate the presence of a [4Fe-4S] cluster under reducing and anaerobic conditions, whereas [2Fe-2S] and [3Fe-4S] forms are generated under aerobic conditions. Preliminary site-directed mutagenesis studies suggest that Cys(157), Cys(161), and Cys(164) are involved in iron chelation and that the cluster is essential for activity. Together with the previously shown requirement of S-adenosylmethionine (AdoMet) for the methylthiolation reaction, the finding that MiaB is an iron-sulfur protein suggests that it belongs to a superfamily of enzymes that uses [Fe-S] centers and AdoMet to initiate radical catalysis. MiaB is the first and only tRNA modification enzyme known to contain an Fe-S cluster.	Univ Grenoble 1, Lab Chim & Biochim, Ctr Redox Biol,CEA, Dept Biol Mol & Struct Chim Biol,CNRS,UMR 5047, F-38054 Grenoble 09, France; Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Umea University	Fontecave, M (corresponding author), Univ Grenoble 1, Lab Chim & Biochim, Ctr Redox Biol,CEA, Dept Biol Mol & Struct Chim Biol,CNRS,UMR 5047, 17 Ave Martyrs, F-38054 Grenoble 09, France.	mfontecave@cea.fr; mohamed.atta@cea.fr	Björk, Glenn/AAE-8219-2022; PIERREL, Fabien/M-6016-2014	PIERREL, Fabien/0000-0003-2083-3002				AGRIS PF, 1975, NUCLEIC ACIDS RES, V2, P691, DOI 10.1093/nar/2.5.691; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BALDWIN JE, 1990, CHEM REV, V90, P1079, DOI 10.1021/cr00105a001; Begley TP, 1999, CURR OPIN CHEM BIOL, V3, P623, DOI 10.1016/S1367-5931(99)00018-6; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BJORK GR, 1995, TRNA STRUCTURE BIOSY, P95; BJORK GR, 1996, CELLULAR MOL BIOL, P861; Bjork GR, 1992, TRANSFER RNA PROTEIN, P23; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCK M, 1983, ANAL BIOCHEM, V129, P1, DOI 10.1016/0003-2697(83)90044-1; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CONNOLLY DM, 1991, J BACTERIOL, V173, P1711, DOI 10.1128/jb.173.5.1711-1721.1991; CONNOLLY DM, 1989, J BACTERIOL, V171, P3233, DOI 10.1128/jb.171.6.3233-3246.1989; Esberg B, 1999, J BACTERIOL, V181, P7256, DOI 10.1128/JB.181.23.7256-7265.1999; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Fontecave M, 2001, CURR OPIN CHEM BIOL, V5, P506, DOI 10.1016/S1367-5931(00)00237-4; Frey PA, 2001, ANNU REV BIOCHEM, V70, P121, DOI 10.1146/annurev.biochem.70.1.121; GEFTER ML, 1969, BIOCHEM BIOPH RES CO, V36, P435, DOI 10.1016/0006-291X(69)90583-X; Gehrke CW, 1990, J CHROMATOGRAPHY LIB, pA3; GROSJEAN H, 1985, NUCLEIC ACIDS RES, V13, P5697, DOI 10.1093/nar/13.15.5697; Hewitson KS, 2002, J BIOL INORG CHEM, V7, P83, DOI 10.1007/s007750100268; JOHNSON MK, 1994, ENCY INORGANIC CHEM, V4, P1896; Kulzer R, 1998, J BIOL CHEM, V273, P4897, DOI 10.1074/jbc.273.9.4897; Leimkuhler S, 2001, J BIOL CHEM, V276, P22024, DOI 10.1074/jbc.M102072200; Leung HCE, 1997, J BIOL CHEM, V272, P13073, DOI 10.1074/jbc.272.20.13073; Marquet A, 2001, VITAM HORM, V61, P51; Moore JA, 1997, BIOCHEMISTRY-US, V36, P604, DOI 10.1021/bi962225l; Mueller EG, 2001, J BIOL CHEM, V276, P33588, DOI 10.1074/jbc.M104067200; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; ROSENBERG AH, 1969, J MOL BIOL, V46, P581, DOI 10.1016/0022-2836(69)90197-1; Soderberg T, 2000, BIOCHEMISTRY-US, V39, P6546, DOI 10.1021/bi992775u; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Tamarit J, 1999, J BIOL CHEM, V274, P31291, DOI 10.1074/jbc.274.44.31291	33	87	88	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13367	13370		10.1074/jbc.C100609200	http://dx.doi.org/10.1074/jbc.C100609200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11882645	hybrid			2022-12-25	WOS:000175096000003
J	Lottin, S; Vercoutter-Edouart, AS; Adriaenssens, E; Czeszak, X; Lemoine, J; Roudbaraki, M; Coll, J; Hondermarck, H; Dugimont, T; Curgy, JJ				Lottin, S; Vercoutter-Edouart, AS; Adriaenssens, E; Czeszak, X; Lemoine, J; Roudbaraki, M; Coll, J; Hondermarck, H; Dugimont, T; Curgy, JJ			Thioredoxin post-transcriptional regulation by H19 provides a new function to mRNA-like non-coding RNA	ONCOGENE			English	Article						H19 gene; non-coding RNA; riboregulator; proteomic; thioredoxin; oncogene	REDOX REGULATION; POSSIBLE ASSOCIATION; GENE-EXPRESSION; IMPRINTED H19; TRANSCRIPT; CARCINOMA; ANTISENSE; RECEPTOR; PRODUCT; OVEREXPRESSION	Classically, the functional product of coding genes is a protein whose synthesis is directed by an mRNA-template. However, in the last few years several genes yielding an mRNA-like non-coding RNA as a functional product have been identified. In most cases these transcripts are synthesized by the RNA polymerase II, capped, spliced and polyadenylated, like classical mRNA. These latter have non-conserved open reading frames and seem to be untranslated. Consequently, it has been proposed and admitted that these genes act at the RNA level, and are so-called 'riboregulators'. H19 belongs to this class of gene and its role remains a matter of debate: for some authors it is an oncogene, for others a tumour suppressor. Here, we demonstrate, using a proteomic approach, that an H19 overexpression in human cancerous mammary epithelial cells stably transfected with genomic DNA containing the entire H19 gene is responsible for positively regulating at the post-transcriptional level the thioredoxin, a key protein of the cellular redox metabolism. Interestingly, this protein accumulates in many cancerous tissues, such as breast carcinomas in which we have also demonstrated an overexpression of the H19 gene.	USTL, UPRES EA 1033, Dev Biol Lab, F-59655 Villeneuve Dascq, France; Lab Immunopathol Cellulaire Malad Infect, UMR 8527, F-59021 Lille, France; USTL, CNRS, UMR 8576, Chim Biol Lab, F-59655 Villeneuve Dascq, France; USTL, INSERM 9938, Lab Physiol & Physiopathol Prostate Humaine, F-59655 Villeneuve Dascq, France	Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Curgy, JJ (corresponding author), USTL, UPRES EA 1033, Dev Biol Lab, SN3, F-59655 Villeneuve Dascq, France.	curgy@univ-lille1.fr	lemoine, jerome/C-4272-2014	lemoine, jerome/0000-0002-5497-6880; Vercoutter-Edouart, Anne-Sophie/0000-0002-3243-7122; Morad, Roudbaraki/0000-0001-5751-3323				Adriaenssens E, 1998, AM J PATHOL, V153, P1597, DOI 10.1016/S0002-9440(10)65748-3; Adriaenssens E, 1999, ONCOGENE, V18, P4460, DOI 10.1038/sj.onc.1202819; Ariel I, 1997, J CLIN PATHOL-MOL PA, V50, P34, DOI 10.1136/mp.50.1.34; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DOUCRASY S, 1993, INT J ONCOL, V2, P753; Dugimont T, 1995, BIOL CELL, V85, P117, DOI 10.1016/0248-4900(96)85272-5; ELKIN M, 1995, FEBS LETT, V374, P57, DOI 10.1016/0014-5793(95)01074-O; Erdmann VA, 2000, NUCLEIC ACIDS RES, V28, P197, DOI 10.1093/nar/28.1.197; Erdmann VA, 2001, NUCLEIC ACIDS RES, V29, P189, DOI 10.1093/nar/29.1.189; Ferret PJ, 2000, BIOCHEM J, V346, P759, DOI 10.1042/0264-6021:3460759; FUJII S, 1991, CANCER, V68, P1583, DOI 10.1002/1097-0142(19911001)68:7<1583::AID-CNCR2820680720>3.0.CO;2-N; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; Grogan TM, 2000, HUM PATHOL, V31, P475, DOI 10.1053/hp.2000.6546; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; Joubel A, 1996, CELL MOL BIOL, V42, P1159; Juan V, 2000, NUCLEIC ACIDS RES, V28, P1221, DOI 10.1093/nar/28.5.1221; Kawahara N, 1996, CANCER RES, V56, P5330; Kelley RL, 2000, CELL, V103, P9, DOI 10.1016/S0092-8674(00)00099-4; KONDO M, 1995, ONCOGENE, V10, P1193; Lease RA, 1998, P NATL ACAD SCI USA, V95, P12456, DOI 10.1073/pnas.95.21.12456; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Lee MP, 1997, NAT GENET, V15, P181, DOI 10.1038/ng0297-181; Li YM, 1998, J BIOL CHEM, V273, P28247, DOI 10.1074/jbc.273.43.28247; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; Milligan L, 2000, ONCOGENE, V19, P5810, DOI 10.1038/sj.onc.1203965; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; POIRIER F, 1991, DEVELOPMENT, V113, P1105; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Ueno M, 2000, IMMUNOL LETT, V75, P15, DOI 10.1016/S0165-2478(00)00284-4; Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76; Vercoutter-Edouart AS, 2001, EXP CELL RES, V262, P59, DOI 10.1006/excr.2000.5066; Wevrick R, 1997, HUM MOL GENET, V6, P325, DOI 10.1093/hmg/6.2.325; Wilkin F, 2000, EUR J BIOCHEM, V267, P4020, DOI 10.1046/j.1432-1327.2000.01438.x; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	49	41	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1625	1631		10.1038/sj.onc.1205233	http://dx.doi.org/10.1038/sj.onc.1205233			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896592				2022-12-25	WOS:000173956800019
J	Wiest, T; Schwarz, E; Enders, C; Flechtenmacher, C; Bosch, FX				Wiest, T; Schwarz, E; Enders, C; Flechtenmacher, C; Bosch, FX			Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control	ONCOGENE			English	Article						human papillomavirus; head and neck cancer; p53; pRb; E6; E7 oncogenes	HUMAN-PAPILLOMAVIRUS TYPE-16; CERVICAL-CANCER; MEDIATED PCR; DNA; CARCINOMA; INFECTION; SEQUENCES; AMPLIFICATION; MUTATIONS; OVEREXPRESSION	We have identified parameters which define a causal role of HPV16 in head and neck cancer. Twenty-eight tumours which were typed positive for HPV16 DNA, were comprehensively analysed for expression of the viral oncogenes E6 and E7, the status of the p53 gene, and the protein status of pRb and p16(INK4a). In a subset of cases, we have searched for integrated viral DNA, and have determined the genomic status of the E6 gene. Expression of E6/E7 was found in 12 tumours most of which were derived from the oropharynx, whereas p53 mutations were present in 13 tumours from various sites. The tumours either carried p53 mutations but did not express E6/E7, or they did express E6/E7 but were p53-wild-type. Coexistence of E6/E7 expression with a mutated p53 was found in only one case. Strikingly, in most p53-mutated tumours without E6/E7 expression, we found the E6 gene to be disrupted. E6/E7 expression was associated with reduced pRb and overexpressed p16(INK4a). Viral-cellular fusion transcripts were found in two cases. Our data demonstrate that HPV16 DNA-positivity in head and neck cancers is not indicative of a causal role. A causal role of HPV16 in head and neck cancer is defined by: E6/E7 expression, viral integration with an intact E6 gene, and perturbation of pRb cell cycle control. Mostly, the p53 gene is wild-type.	Univ Hals Nasen Ohrenklin, Mol Biol Lab, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Angew Tumorvirol, D-69120 Heidelberg, Germany; Heidelberg Univ, Inst Pathol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Bosch, FX (corresponding author), Univ Hals Nasen Ohrenklin, Mol Biol Lab, Im Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	Franz_Bosch@med.uni-heidelberg.de						Andl T, 1998, CANCER RES, V58, P5; BARTEN M, 1995, VIRCHOWS ARCH, V427, P153; BERUMEN J, 1994, INT J CANCER, V56, P640, DOI 10.1002/ijc.2910560506; Chiba I, 1996, ONCOGENE, V12, P1663; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; DEVILLIERS EM, 1985, INT J CANCER, V36, P575, DOI 10.1002/ijc.2910360510; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELAWADY MK, 1987, VIROLOGY, V159, P389, DOI 10.1016/0042-6822(87)90478-8; Erber R, 1998, ONCOGENE, V16, P1671, DOI 10.1038/sj.onc.1201690; FUJITA M, 1992, CANCER RES, V52, P5323; Gardiol D, 1998, J GEN VIROL, V79, P1963, DOI 10.1099/0022-1317-79-8-1963; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Gruttgen A, 2001, J PATHOL, V194, P311, DOI 10.1002/path.906; Harrington JJ, 2001, NAT BIOTECHNOL, V19, P440, DOI 10.1038/88107; He D, 1997, INT J CANCER, V72, P959; HOPPESEYLER F, 1994, MOL CARCINOGEN, V10, P134, DOI 10.1002/mc.2940100304; JACOBS MV, 1995, J CLIN MICROBIOL, V33, P901, DOI 10.1128/JCM.33.4.901-905.1995; KAHN T, 1994, CANCER RES, V54, P1305; Klaes R, 2001, INT J CANCER, V92, P276, DOI 10.1002/ijc.1174; Klaes R, 1999, CANCER RES, V59, P6132; Luft F, 2001, INT J CANCER, V92, P9, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1144>3.0.CO;2-L; MAITLAND NJ, 1987, BRIT J CANCER, V56, P245, DOI 10.1038/bjc.1987.185; MATSUKURA T, 1989, VIROLOGY, V172, P63, DOI 10.1016/0042-6822(89)90107-4; MILDELANGOSCH K, 1995, INT J CANCER, V63, P639, DOI 10.1002/ijc.2910630507; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; Rassekh CH, 1998, LARYNGOSCOPE, V108, P362, DOI 10.1097/00005537-199803000-00010; RESNICK RM, 1990, JNCI-J NATL CANCER I, V82, P1477, DOI 10.1093/jnci/82.18.1477; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Scholes AGM, 1997, INT J CANCER, V71, P796, DOI 10.1002/(SICI)1097-0215(19970529)71:5<796::AID-IJC17>3.0.CO;2-6; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SNIJDERS PJF, 1992, INT J CANCER, V51, P845, DOI 10.1002/ijc.2910510602; STEENBERGEN RDM, 1995, CANCER RES, V55, P5465; van Houten VMM, 2001, INT J CANCER, V93, P232, DOI 10.1002/ijc.1313; VANDENBRULE AJC, 1989, J MED VIROL, V29, P20, DOI 10.1002/jmv.1890290105; Wilczynski SP, 1998, AM J PATHOL, V152, P145; YEUDALL WA, 1991, J GEN VIROL, V72, P173, DOI 10.1099/0022-1317-72-1-173; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	40	285	297	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1510	1517		10.1038/sj.onc.1205214	http://dx.doi.org/10.1038/sj.onc.1205214			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896579				2022-12-25	WOS:000173956800006
J	Kainulainen, T; Pender, A; D'Addario, M; Feng, YY; Lekic, P; McCulloch, CA				Kainulainen, T; Pender, A; D'Addario, M; Feng, YY; Lekic, P; McCulloch, CA			Cell death and mechanoprotection by filamin A in connective tissues after challenge by applied tensile forces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; PERIODONTAL-LIGAMENT; MECHANICAL FORCES; PLASMA-MEMBRANE; STRETCH; EXPRESSION; INTEGRINS; APOPTOSIS; IDENTIFICATION; COMMUNICATION	Cells in mechanically challenged environments must cope with high amplitude forces to maintain cell viability and tissue homeostasis. Currently, force-induced cell death and the identity of mechanoprotective factors are not defined. We examined death in cultured periodontal fibroblasts, connective tissue cells that are exposed to heavy applied forces in vivo. Static tensile forces (0.48 piconewtons/mum(2) cell area) were applied through magnetite beads coated with collagen or bovine serum albumin. There was a time-dependent increase of the percentage of propidium iodide-permeable cells in force-loaded cultures incubated with collagen but not bovine serum albumin beads, indicating a role for integrins. Cells exhibited reduced mitochondrial membrane potential, increased caspase-3 activation, nuclear condensation, terminal deoxy-nucleotidyl transferase nick end labeling staining, and detachment from the culture dish. The caspase-3 inhibitor acetyl-Asp-Glu-Val-Asp-aldehyde reduced detachment 3-fold. There was a rapid (<10-s) decrease in plasma membrane potential after force application, which, in filamin A-deficient melanoma cells, contributed to irreversible cell depolarization. In fibroblast cultures, cells with increased permeability to propidium iodide exhibited similar to 2-fold less filamin A content than impermeable cells. Fibroblasts transfected with antisense filamin A constructs or with filamin A constructs without an actin-binding domain exhibited 2-3-fold increased proportions of dead cells relative to controls. We conclude that high amplitude forces delivered through integrins can promote apoptosis in a proportion of cells and that filamin A confers mechanoprotection by preventing membrane depolarization.	Univ Toronto, Canadian Inst Hlth Res, Grp Matrix Dynam, Toronto, ON M5S 3E2, Canada; Univ Oulu, Dept Prosthet Dent & Stomatognath Physiol, Oulu, Finland; Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02115 USA; Univ Manitoba, Fac Dent, Dept Prevent Dent Sci, Winnipeg, MB R3E 0W2, Canada	Institute for Work & Health; University of Toronto; University of Oulu; Harvard University; Beth Israel Deaconess Medical Center; University of Manitoba	McCulloch, CA (corresponding author), Univ Toronto, Canadian Inst Hlth Res, Grp Matrix Dynam, Rm 244,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	christopher.mcculloch@utoronto.ca		Pender, Alexandra/0000-0001-5912-2457				Affar EB, 2001, J BIOL CHEM, V276, P2935, DOI 10.1074/jbc.M007269200; Berkovitz BKB, 1982, PERIODONTAL LIGAMENT; Bortner CD, 2001, J BIOL CHEM, V276, P4304, DOI 10.1074/jbc.M005171200; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; Browne KA, 2000, J BIOL CHEM, V275, P39262, DOI 10.1074/jbc.C000622200; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; Clements KM, 2001, OSTEOARTHR CARTILAGE, V9, P499, DOI 10.1053/joca.2000.0417; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; D'Addario M, 2001, J BIOL CHEM, V276, P31969, DOI 10.1074/jbc.M102715200; Edwards YS, 2000, AM J PHYSIOL-LUNG C, V279, pL1236, DOI 10.1152/ajplung.2000.279.6.L1236; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Glogauer M, 1997, J CELL SCI, V110, P11; Glogauer M, 1998, J BIOL CHEM, V273, P1689, DOI 10.1074/jbc.273.3.1689; Goldspink G, 1999, J ANAT, V194, P323, DOI 10.1046/j.1469-7580.1999.19430323.x; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; HOLEVINSKY KO, 1994, J MEMBRANE BIOL, V137, P59; Hui MZ, 1997, J CELL PHYSIOL, V172, P323, DOI 10.1002/(SICI)1097-4652(199709)172:3<323::AID-JCP6>3.0.CO;2-Q; Jankowski M, 1998, P NATL ACAD SCI USA, V95, P14558, DOI 10.1073/pnas.95.24.14558; Kimoto S, 1999, J PERIODONTAL RES, V34, P235, DOI 10.1111/j.1600-0765.1999.tb02249.x; Ko KS, 2000, J MEMBRANE BIOL, V174, P85, DOI 10.1007/s002320001034; Kobayashi ET, 1999, J DENT RES, V78, P1495, DOI 10.1177/00220345990780090301; Kobayashi Y, 2000, J BONE MINER RES, V15, P1924, DOI 10.1359/jbmr.2000.15.10.1924; Lew AM, 1999, BIOCHEM J, V341, P647, DOI 10.1042/0264-6021:3410647; Loening AM, 2000, ARCH BIOCHEM BIOPHYS, V381, P205, DOI 10.1006/abbi.2000.1988; Matsusaka T, 1999, J CLIN INVEST, V103, P1451, DOI 10.1172/JCI5056; Nguyen L, 1997, J PERIODONTAL RES, V32, P419, DOI 10.1111/j.1600-0765.1997.tb00554.x; PENDER N, 1991, J CELL SCI, V100, P187; ROBERTS WE, 1974, ARCH ORAL BIOL, V19, P17, DOI 10.1016/0003-9969(74)90219-2; RUBIN CT, 1985, CALCIFIED TISSUE INT, V37, P411, DOI 10.1007/BF02553711; Sachs F, 1998, REV PHYSIOL BIOCH P, V132, P1, DOI 10.1007/BFb0004985; SACKIN H, 1995, ANNU REV PHYSIOL, V57, P333, DOI 10.1146/annurev.ph.57.030195.002001; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Wang J, 2000, AM J PHYSIOL-HEART C, V279, pH2776, DOI 10.1152/ajpheart.2000.279.6.H2776; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; Wu Z, 1999, BIOCHEM BIOPH RES CO, V261, P419, DOI 10.1006/bbrc.1999.1057	39	78	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21998	22009		10.1074/jbc.M200715200	http://dx.doi.org/10.1074/jbc.M200715200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11909861	hybrid			2022-12-25	WOS:000176286000112
J	McManaman, JL; Bain, DL				McManaman, JL; Bain, DL			Structural and conformational analysis of the oxidase to dehydrogenase conversion of xanthine oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMITED PROTEOLYSIS; O-2-DEPENDENT TYPES; DEPENDENT TYPE; FREE-RADICALS; PURIFICATION; PROTEIN; CLONING; NAD; MECHANISM; CLEAVAGE	Xanthine oxidoreductase (XOR) is a 300-kDa homodimer that can exist as an NAD(+)-dependent dehydrogenase (XD) or as an O-2-dependent oxidase (XO) depending on the oxidation state of its cysteine thiols. Both XD and XO undergo limited cleavage by chymotrypsin and trypsin. Trypsin selectively cleaved both enzyme forms at Lys(184), while chymotrypsin cleaved XD primarily at Met(181) but cleaved XO at Met(181) and at Phe(560). Chymotrypsin, but not trypsin, cleavage also prevented the reductive conversion of XO to XD; thus the region surrounding Phe(560) appears to be important in the interconversion of the two forms. Size exclusion chromatography showed that disulfide bond formation reduced the hydrodynamic volume of the enzyme, and two-dimensional gel electrophoresis of chymotrypsin-digested XO showed significant, disulfide bond-mediated, conformational heterogeneity in the N-terminal third of the enzyme but no evidence of disulfide bonds between the N-terminal and C-terminal regions or between XOR subunits. These results indicate that intrasubunit disulfide bond formation leads to a global conformational change in XOR that results in the exposure of the region surrounding Phe(560). Conformational changes within this region in turn appear to play a critical role in the interconversion between the XD and XO forms of the enzyme.	Univ Colorado, Hlth Sci Ctr, Dept Physiol & Biophys, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	McManaman, JL (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Physiol & Biophys, 4200 E 9th Ave, Denver, CO 80262 USA.	jim.mcmanaman@uchsc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD038129] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045582] Funding Source: NIH RePORTER; NCI NIH HHS [CA46934] Funding Source: Medline; NHLBI NIH HHS [HL 45582-05AZ] Funding Source: Medline; NICHD NIH HHS [P01CHD38129] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMAYA Y, 1990, J BIOL CHEM, V265, P14170; APPEL RD, 1996, TRENDS BIOCHEM SCI, V19, P258; BECKER BF, 1993, FREE RADICAL BIO MED, V14, P615, DOI 10.1016/0891-5849(93)90143-I; Berglund L, 1996, J DAIRY SCI, V79, P198, DOI 10.3168/jds.S0022-0302(96)76351-8; Bray RC., 1975, ENZYMES, V12, P299, DOI DOI 10.1016/S1874-6047(08)60229-2; BUCHHEIM W, 1982, NATURWISSENSCHAFTEN, V69, P505, DOI 10.1007/BF00365826; CLARE DA, 1981, ARCH BIOCHEM BIOPHYS, V211, P44, DOI 10.1016/0003-9861(81)90427-6; COUGHLAN MP, 1979, J BIOL CHEM, V254, P694; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; FREDERIKS WM, 1993, J HISTOCHEM CYTOCHEM, V41, P667, DOI 10.1177/41.5.8468447; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; GLATIGNY A, 1995, J BIOL CHEM, V270, P3534, DOI 10.1074/jbc.270.8.3534; HILLE R, 1995, FASEB J, V9, P995, DOI 10.1096/fasebj.9.11.7649415; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; HUNT J, 1992, J BIOL CHEM, V267, P21479; ICHIDA K, 1993, GENE, V133, P279; JARASCH ED, 1981, CELL, V25, P67, DOI 10.1016/0092-8674(81)90232-4; LEE CS, 1987, GENETICS, V116, P55; MASSEY V, 1989, J BIOL CHEM, V264, P10567; Mather IH, 1998, J MAMMARY GLAND BIOL, V3, P259, DOI 10.1023/A:1018711410270; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; McManaman JL, 1996, ARCH BIOCHEM BIOPHYS, V332, P135, DOI 10.1006/abbi.1996.0325; McManaman JL, 1999, ARCH BIOCHEM BIOPHYS, V371, P308, DOI 10.1006/abbi.1999.1432; NAGLER LG, 1976, BIOCHIM BIOPHYS ACTA, V427, P78, DOI 10.1016/0005-2795(76)90287-7; NAKAMURA M, 1982, J BIOCHEM-TOKYO, V92, P1279, DOI 10.1093/oxfordjournals.jbchem.a134046; Nishino T, 1997, J BIOL CHEM, V272, P29859, DOI 10.1074/jbc.272.47.29859; Romao MJ, 1998, STRUCT BOND, V90, P69; SAITO T, 1989, J BIOL CHEM, V264, P10015; SAITO T, 1989, J BIOL CHEM, V264, P15930; SATO A, 1995, J BIOL CHEM, V270, P2818, DOI 10.1074/jbc.270.6.2818; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P390, DOI 10.1016/S0025-6196(12)64862-9; STIRPE F, 1969, J BIOL CHEM, V244, P3855; Stryer L., 1988, BIOCHEMISTRY-US; TERAO M, 1992, BIOCHEM J, V283, P863, DOI 10.1042/bj2830863; WAUD WR, 1975, ARCH BIOCHEM BIOPHYS, V169, P695, DOI 10.1016/0003-9861(75)90214-3; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P365, DOI 10.1016/0003-9861(76)90088-6; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P354, DOI 10.1016/0003-9861(76)90087-4; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	42	37	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21261	21268		10.1074/jbc.M200828200	http://dx.doi.org/10.1074/jbc.M200828200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11914370	hybrid			2022-12-25	WOS:000176286000020
J	Wong, W; Newell, EW; Jugloff, DGM; Jones, OT; Schlichter, LC				Wong, W; Newell, EW; Jugloff, DGM; Jones, OT; Schlichter, LC			Cell surface targeting and clustering interactions between heterologously expressed PSD-95 and the Shal voltage-gated potassium channel, Kv4.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; NMDA RECEPTOR SUBUNITS; K+ CHANNEL; OUTWARD CURRENTS; LOCALIZATION; MEMBRANE; BINDING; FAMILY; DENDRITES; NEURONS	Kv4.2 is a voltage-gated potassium channel that is critical in controlling the excitability of myocytes and neurons. Processes that influence trafficking and surface distribution patterns of Kv4.2 will affect its ability to contribute to cellular functions. The scaffolding/clustering protein PSD-95 regulates trafficking and distribution of several receptors and Shaker family Kv channels. We therefore investigated whether the C-terminal valine-serine-alanine-leucine (VSAL) of Kv4.2 is a novel binding motif for PSD-95. By using co-immunoprecipitation assays, we determined that full-length Kv4.2 and PSD-95 interact when co-expressed in mammalian cell lines. Mutation analysis in this heterologous expression system showed that the VSAL motif of Kv4.2 is necessary for PSD-95 binding. PSD-95 increased the surface expression of Kv4.2 protein and caused it to cluster, as shown by deconvolution microscopy and biotinylation assays. Deleting the C-terminal VSAL motif of Kv4.2 eliminated these effects, as did substituting a palmitoylation-deficient PSD-95 mutant. In addition to these effects of PSD-95 on Kv4.2 distribution, the channel itself promoted redistribution of PSD-95 to the cell surface in the heterologous expression system. This work represents the first evidence that a member of the Shal subfamily of Kv channels can bind to PSD-95, with functional consequences.	Univ Toronto, Hlth Network, Toronto Western Res Inst, Div Cellular & Mol Biol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Schlichter, LC (corresponding author), Toronto Western Hosp, MC9-415,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	schlicht@uhnres.utoronto.ca	Newell, Evan W/F-9711-2012	Newell, Evan W/0000-0002-2889-243X				Adams JP, 2000, J NEUROCHEM, V75, P2277, DOI 10.1046/j.1471-4159.2000.0752277.x; Alonso G, 1997, NEUROSCIENCE, V77, P617; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Anderson AE, 2000, J BIOL CHEM, V275, P5337, DOI 10.1074/jbc.275.8.5337; Aoki C, 2001, SYNAPSE, V40, P239, DOI 10.1002/syn.1047; Arnold DB, 1999, NEURON, V23, P149, DOI 10.1016/S0896-6273(00)80761-8; Bahring R, 2001, J PHYSIOL-LONDON, V535, P65, DOI 10.1111/j.1469-7793.2001.00065.x; BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; Burke NA, 1999, J GEN PHYSIOL, V113, P71, DOI 10.1085/jgp.113.1.71; CARR DW, 1992, J BIOL CHEM, V267, P16816; CHANDY KG, 1995, LIGAND VOLTAGE GATED, P1; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Cooper EC, 1998, J NEUROSCI, V18, P965; Debanne D, 1997, NATURE, V389, P286, DOI 10.1038/38502; El-Husseini AE, 2000, J CELL BIOL, V148, P159, DOI 10.1083/jcb.148.1.159; Fujita A, 2000, BIOCHEM BIOPH RES CO, V269, P1, DOI 10.1006/bbrc.1999.1893; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; Hoffman DA, 1998, J NEUROSCI, V18, P3521; Hsueh YP, 1999, J BIOL CHEM, V274, P532, DOI 10.1074/jbc.274.1.532; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Inagaki S, 2001, J BIOL CHEM, V276, P9174, DOI 10.1074/jbc.M009051200; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; JACKSON MB, 1991, P NATL ACAD SCI USA, V88, P380, DOI 10.1073/pnas.88.2.380; Jerng HH, 1997, BIOPHYS J, V72, P163, DOI 10.1016/S0006-3495(97)78655-7; Johns DC, 1997, J BIOL CHEM, V272, P31598, DOI 10.1074/jbc.272.50.31598; Jones OT, 1997, J NEUROSCI, V17, P6152; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; Khanna R, 2001, J BIOL CHEM, V276, P34028, DOI 10.1074/jbc.M105248200; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KINGSTON RE, 2001, CURRENT PROTOCOLS MO, V2; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kuryshev YA, 2001, AM J PHYSIOL-CELL PH, V281, pC290, DOI 10.1152/ajpcell.2001.281.1.C290; Li DQ, 2000, J BIOL CHEM, V275, P11597, DOI 10.1074/jbc.275.16.11597; Magee J, 1998, ANNU REV PHYSIOL, V60, P327, DOI 10.1146/annurev.physiol.60.1.327; MALETICSAVATIC M, 1995, J NEUROSCI, V15, P3840; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Nakamura TY, 2001, P NATL ACAD SCI USA, V98, P12808, DOI 10.1073/pnas.221168498; Nakamura TY, 2001, FEBS LETT, V499, P205, DOI 10.1016/S0014-5793(01)02560-1; Nehring RB, 2000, J NEUROSCI, V20, P156, DOI 10.1523/JNEUROSCI.20-01-00156.2000; Niethammer M, 1996, J NEUROSCI, V16, P2157; Nishiyama A, 2001, AM J PHYSIOL-HEART C, V281, pH1800, DOI 10.1152/ajpheart.2001.281.4.H1800; Petersen KR, 1999, PFLUG ARCH EUR J PHY, V437, P381, DOI 10.1007/s004240050792; Petrecca K, 2000, J NEUROSCI, V20, P8736; Roquemore EP, 1998, MOL BIOL CELL, V9, P2125, DOI 10.1091/mbc.9.8.2125; Serodio P, 1998, J NEUROPHYSIOL, V79, P1081, DOI 10.1152/jn.1998.79.2.1081; SERODIO P, 1994, J NEUROPHYSIOL, V72, P1516, DOI 10.1152/jn.1994.72.4.1516; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Takeuchi S, 2000, J MOL CELL CARDIOL, V32, P1361, DOI 10.1006/jmcc.2000.1172; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; VARGA AW, 2000, P 30 ANN M SOC NEUR; Wickenden AD, 1999, AM J PHYSIOL-HEART C, V276, pH1599, DOI 10.1152/ajpheart.1999.276.5.H1599; Wong W, 2000, MOL BIOL CELL, V11, p222A; Wong W, 2002, BIOPHYS J, V82, p253A; Xu HD, 1999, J PHYSIOL-LONDON, V519, P11, DOI 10.1111/j.1469-7793.1999.0011o.x; Yeola SW, 1997, CARDIOVASC RES, V33, P540, DOI 10.1016/S0008-6363(96)00221-0; Zhu GY, 1998, J NEUROSCI METH, V81, P73, DOI 10.1016/S0165-0270(98)00019-3; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1; [No title captured]	62	62	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20423	20430		10.1074/jbc.M109412200	http://dx.doi.org/10.1074/jbc.M109412200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923279	hybrid			2022-12-25	WOS:000176204500042
J	Cho, HJ; Jeong, HG; Lee, JS; Woo, ER; Hyun, JW; Chung, MH; You, HJ				Cho, HJ; Jeong, HG; Lee, JS; Woo, ER; Hyun, JW; Chung, MH; You, HJ			Oncogenic H-Ras enhances DNA repair through the Ras/phosphatidylinositol 3-kinase/Rac1 pathway in NIH3T3 cells - Evidence for association with reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CISPLATIN RESISTANCE; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; MESSENGER-RNA; CROSS-LINKS; N-RAS; P53; EXPRESSION; TRANSFORMATION	This study investigated the role of oncogenic H-Ras in DNA repair capacity in NIH3T3 cells. Expression of dominant-positive H-Ras (V12-H-Ras) enhanced the host cell reactivation of luciferase activity from UV-irradiated and cisplatin-treated plasmids and also increased the unscheduled DNA synthesis following cisplatin or UV treatment of cells. This observed enhancement of DNA repair capacity was inhibited by transient transfection with dominant-negative H-Ras (N17-H-Ras) or Rac1 (N17-Rac1) plasmids. Moreover, stable transfection of dominant-positive Rac1 (V12-Rac1) further enhanced DNA repair capacity. Because reactive oxygen species (ROS) are known to be a downstream effector of oncogenic Ras, we examined the role of ROS in DNA repair capacity. We found that ROS production by V12-H-Ras expression was mediated by the Ras/phosphatidylinositol 3-kinase (PI3K)/Rac1/NADPH oxidase-dependent pathway and that pretreatment of V12-H-Ras-transformed cells with an antioxidant (N-acetylcysteine) and an NADPH oxidase inhibitor (diphenyleneiodonium) decreased DNA repair capacity. Similarly, treatment with PI3K inhibitors (wortmannin and LY294002) inhibited the ability of oncogenic H-Ras to enhance DNA repair capacity. Furthermore, inhibition of the Ras/PI3K/Rac1/NADPH oxidase pathway resulted in increased sensitivity to cisplatin and UV in V12-H-Ras-expressing NIH3T3 cells. Taken together, these results provide evidence that oncogenic H-Ras activates DNA repair capacity through the RaS/PI3K/Rac1/NADPH oxidase-dependent pathway and that increased ROS production via this signaling pathway is required for enhancement of the DNA repair capacity induced by oncogenic H-Ras.	Chosun Univ, Dept Pharmacol, Sch Med, Kwangju 501759, South Korea; Chosun Univ, Res Ctr Proteineous Mat, Kwangju 501759, South Korea; Chosun Univ, Dept Pharm, Kwangju 501759, South Korea; Chosun Univ, Dept Biol Sci, Kwangju 501759, South Korea; Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea	Chosun University; Chosun University; Chosun University; Chosun University; Seoul National University (SNU)	You, HJ (corresponding author), Chosun Univ, Dept Pharmacol, Sch Med, 375 Seosuk Dong, Kwangju 501759, South Korea.	hjyou@mail.chosun.ac.kr		Jeong, Hye Gwang/0000-0002-8020-8914; You, Ho Jin/0000-0002-0530-4017				Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; AUCHSCHWELK W, 1992, J CARDIOVASC PHARM S, V9, P62; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; BASNAK'YAN A G, 1989, Molekulyarnaya Biologiya (Moscow), V23, P750; Bernhard EJ, 2000, CANCER RES, V60, P6597; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; Bouziane M, 2000, MUTAT RES-DNA REPAIR, V461, P15, DOI 10.1016/S0921-8777(00)00036-7; Burdon RH, 1996, FREE RADICAL RES, V24, P81, DOI 10.3109/10715769609088004; CHILAKAMARTI VR, 1998, P NATL ACAD SCI USA, V95, P5061; Costa M, 1999, NUCLEIC ACIDS RES, V27, P817, DOI 10.1093/nar/27.3.817; Crul M, 1997, CANCER TREAT REV, V23, P341, DOI 10.1016/S0305-7372(97)90032-3; Dempke W, 2000, ANTI-CANCER DRUG, V11, P225, DOI 10.1097/00001813-200004000-00001; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dhenaut A, 2000, MUTAT RES-DNA REPAIR, V461, P109, DOI 10.1016/S0921-8777(00)00042-2; Fan JG, 1997, BIOCHEM PHARMACOL, V53, P1203, DOI 10.1016/S0006-2952(97)00101-9; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; FITZGERALD TJ, 1985, AM J CLIN ONCOL-CANC, V8, P517, DOI 10.1097/00000421-198512000-00012; Gupta A, 1999, CARCINOGENESIS, V20, P2063, DOI 10.1093/carcin/20.11.2063; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HERMENS AF, 1992, CANCER RES, V52, P3073; Holford J, 1998, INT J CANCER, V77, P94, DOI 10.1002/(SICI)1097-0215(19980703)77:1<94::AID-IJC15>3.3.CO;2-Y; HURTA RAR, 1995, J CELL BIOCHEM, V57, P543, DOI 10.1002/jcb.240570319; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Imai K, 1998, GENE, V222, P287, DOI 10.1016/S0378-1119(98)00485-5; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; ISONISHI S, 1991, CANCER RES, V51, P5903; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; Korzets A, 1999, J LAB CLIN MED, V133, P362, DOI 10.1016/S0022-2143(99)90067-7; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; Lee-Kwon W, 1998, BIOCHEM J, V331, P591, DOI 10.1042/bj3310591; LEVY E, 1994, CARCINOGENESIS, V15, P845, DOI 10.1093/carcin/15.5.845; Liu RG, 2001, ONCOGENE, V20, P1486, DOI 10.1038/sj.onc.1204214; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Masumoto N, 1999, INT J CANCER, V80, P731, DOI 10.1002/(SICI)1097-0215(19990301)80:5<731::AID-IJC17>3.0.CO;2-H; McKay BC, 1999, CARCINOGENESIS, V20, P1389, DOI 10.1093/carcin/20.8.1389; NIE ZR, 1995, CANCER RES, V55, P4760; NIIMI S, 1991, BRIT J CANCER, V63, P237, DOI 10.1038/bjc.1991.56; PEREZ RP, 1993, CANCER RES, V53, P3771; PETERS GJ, 1993, INT J CANCER, V54, P450, DOI 10.1002/ijc.2910540316; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Scherer SJ, 2000, J BIOL CHEM, V275, P37469, DOI 10.1074/jbc.M006990200; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SKLER MD, 1908, CANCER RES, V48, P793; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Ward RA, 2000, J BIOL CHEM, V275, P36713, DOI 10.1074/jbc.M003017200; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WUKI, 1998, AM J PHYSIOL, V275, pL780; Yang JQ, 1999, MOL CARCINOGEN, V26, P180; Yen L, 1997, ONCOGENE, V14, P1827, DOI 10.1038/sj.onc.1201019; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zeng L, 1999, METH MOL B, V113, P87; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914; Zhu QZ, 2000, J BIOL CHEM, V275, P11492, DOI 10.1074/jbc.275.15.11492; Ziemann C, 1999, CARCINOGENESIS, V20, P407, DOI 10.1093/carcin/20.3.407	66	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19358	19366		10.1074/jbc.M200933200	http://dx.doi.org/10.1074/jbc.M200933200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11884408	hybrid			2022-12-25	WOS:000175894800017
J	Geum, D; Son, GH; Kim, K				Geum, D; Son, GH; Kim, K			Phosphorylation-dependent cellular localization and thermoprotective role of heat shock protein 25 in hippocampal progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; HUMAN HSP27; ACTIN POLYMERIZATION; MOLECULAR CHAPERONES; OXIDATIVE STRESS; BINDING PROTEINS; MAPKAP KINASE-2; RESISTANCE; EXPRESSION; APOPTOSIS	The present study examined phosphorylation-dependent cellular localization and the thermoprotective role of heat shock protein (HSP) 25 in hippocampal HiB5 cells. HSP25 was induced and phosphorylated by heat shock (at 43 degreesC for 3 h). HSP25, which was located in the cytoplasm in the normal condition, translocated into the nucleus after the heat shock. Transfection experiments with hsp27 mutants in which specific serine phosphorylation residues (Ser(78) and Ser(82)) were substituted with alanines or aspartic acids showed that phosphorylation of HSP27 is accompanied by its nuclear translocation. Phosphorylation of mitogen-activated protein kinases (MAPKs) such as p38 MAPK and ERK was markedly increased by the heat shock, and SB203580 (a p38 MAPK kinase inhibitor) and/or PD098059 (a MEK inhibitor) inhibited the phosphorylation of HSP25, indicating that p38 MAPK and ERK are upstream regulators of HSP25 phosphorylation in the heat shock condition. In the absence of heat shock, actin filament stability was not affected by SB203580 and/or PD098059. Heat shock caused disruption of the actin filament and cell death when phosphorylation of HSP25 was inhibited by SB203580 and/or PD098059. In addition, actin filament was more stable in Asp(78,82)-hsp27 (mimics the phosphorylated form) transfected HiB5 cells than in the normal and Ala(78,82)-hsp27 (nonphosphorylative form) transfected cells. In accordance with actin filament stability, the survival rate against the heat shock increased markedly in Asp(15,78,82)-hsp27 expressing HiB5 cells but decreased in Ala(15,78,82)-hsp27 expressing cells. These results support the idea that phosphorylation of HSP25 is critical for the maintenance of actin filament and enhancement of thermoresistance. Interestingly, HSP25 was dephosphorylated and returned to cytoplasm in a recovery time-dependent manner. This phenomenon was accompanied by an increment of apoptotic cell death as determined by nuclear and DNA fragmentation and fluorescence-activated cell sorter analysis. These results suggest that nuclear-translocated HSP25 might function to protect nuclear structure, thereby preventing apoptotic cell death.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea	Seoul National University (SNU)	Kim, K (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.	kyungjin@snu.ac.kr						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARRIGO AP, 1991, FEBS LETT, V282, P152, DOI 10.1016/0014-5793(91)80466-G; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clerk A, 1998, BIOCHEM J, V333, P581, DOI 10.1042/bj3330581; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; FROHLI E, 1993, GENE, V128, P273, DOI 10.1016/0378-1119(93)90574-M; Guay J, 1997, J CELL SCI, V110, P357; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUOT J, 1991, CANCER RES, V51, P5245; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Huot J, 1996, CANCER RES, V56, P273; Ishikawa Y, 1999, BRAIN RES, V824, P71, DOI 10.1016/S0006-8993(99)01108-7; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KIM YJ, 1984, MOL CELL BIOL, V4, P468, DOI 10.1128/MCB.4.3.468; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; Korber P, 1999, J BIOL CHEM, V274, P249, DOI 10.1074/jbc.274.1.249; Kwon YK, 1997, MOL CELLS, V7, P320; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Loktionova SA, 1996, FEBS LETT, V392, P100, DOI 10.1016/0014-5793(96)00792-2; McEwen BS, 1999, FRONT NEUROENDOCRIN, V20, P49, DOI 10.1006/frne.1998.0173; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PLESOFSKYVIG N, 1992, J MOL EVOL, V35, P537, DOI 10.1007/BF00160214; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; Schwarz E, 1996, BIOL CHEM, V377, P411; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Tan SL, 1998, J NEUROCHEM, V71, P95; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van de Klundert FAJM, 1998, EUR J CELL BIOL, V75, P38, DOI 10.1016/S0171-9335(98)80044-7; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	42	111	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19913	19921		10.1074/jbc.M104396200	http://dx.doi.org/10.1074/jbc.M104396200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11912188	hybrid			2022-12-25	WOS:000175894800089
J	Janssen, U; Stoffel, W				Janssen, U; Stoffel, W			Disruption of mitochondrial beta-oxidation of unsaturated fatty acids in the 3,2-trans-enoyl-CoA isomerase-deficient mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE BIFUNCTIONAL ENZYME; RAT-LIVER MITOCHONDRIA; ENOYL-COA; 3-CIS-2-TRANS-ENOYL-COA ISOMERASE; MOLECULAR-CLONING; GENE-EXPRESSION; PURIFICATION; IDENTIFICATION; ORGANIZATION; SEQUENCE	Cellular energy metabolism is largely sustained by mitochondrial beta-oxidation of saturated and unsaturated fatty acids. To study the role of unsaturated fatty acids in cellular lipid and energy metabolism we generated a null allelic mouse, deficient in 3,2-trans-enoyl-CoA isomerase (ECI) (eci(-/-) mouse). ECI is the link in mitochondrial beta-oxidation of unsaturated and saturated fatty acids and essential for the complete degradation and for maximal energy yield. Mitochondrial beta-oxidation of unsaturated fatty acids is interrupted in eci(-/-) mice at the level of their respective 3-cis- or 3-trans-enoyl-CoA intermediates. Fasting eci(-/-) mice accumulate unsaturated fatty acyl groups in ester lipids and deposit large amounts of triglycerides in hepatocytes (steatosis). Gene expression studies revealed the induction of peroxisome proliferator-activated receptor activation in eci(-/-) mice together with peroxisomal beta- and microsomal omega-oxidation enzymes. Combined peroxisomal beta- and microsomal omega-oxidation of the 3-enoyl-CoA intermediates leads to a specific pattern of medium chain unsaturated dicarboxylic acids excreted in the urine in high concentration (dicarboxylic aciduria). The urinary dicarboxylate pattern is a reliable diagnostic marker of the ECI genetic defect. The eci(-/-) mouse might be a model of a yet undefined inborn mitochondrial beta-oxidation disorder lacking the enzyme link that channels the intermediates of unsaturated fatty acids into the beta-oxidation spiral of saturated fatty acids.	Univ Cologne, Fac Med, Inst Biochem, Lab Mol Neurosci, D-59031 Cologne, Germany	University of Cologne	Stoffel, W (corresponding author), Univ Cologne, Fac Med, Inst Biochem, Lab Mol Neurosci, Joseph Stelzmannstr 52, D-59031 Cologne, Germany.							AMENDT BA, 1987, J CLIN INVEST, V79, P1303, DOI 10.1172/JCI112953; BENNETT MJ, 1990, ANN CLIN BIOCHEM, V27, P519, DOI 10.1177/000456329002700602; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADLEY A, 1987, PRODUCTION ANAL CHIM, P113; CHONCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; DIMAURO S, 1973, SCIENCE, V182, P929, DOI 10.1126/science.182.4115.929; EULERBERTRAM S, 1990, BIOL CHEM H-S, V371, P603, DOI 10.1515/bchm3.1990.371.2.603; HARDWICK JP, 1987, J BIOL CHEM, V262, P801; HOGAN B, 1986, MANIPULATING MOUSE E; ISHII N, 1987, J BIOL CHEM, V262, P8144; JANSSEN U, 1994, GENOMICS, V23, P223, DOI 10.1006/geno.1994.1480; KOIVURANTA KT, 1994, BIOCHEM J, V304, P787, DOI 10.1042/bj3040787; KRAHLING JB, 1978, BIOCHEM BIOPH RES CO, V82, P136, DOI 10.1016/0006-291X(78)90587-9; KUNAU WH, 1978, EUR J BIOCHEM, V91, P533, DOI 10.1111/j.1432-1033.1978.tb12707.x; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LUO MJ, 1994, J BIOL CHEM, V269, P2384; MULLERNEWEN G, 1991, BIOL CHEM H-S, V372, P613, DOI 10.1515/bchm3.1991.372.2.613; MULLERNEWEN G, 1995, EUR J BIOCHEM, V228, P68, DOI 10.1111/j.1432-1033.1995.tb20230.x; MULLERNEWEN G, 1993, BIOCHEMISTRY-US, V32, P11405; Novikov DK, 1999, ADV EXP MED BIOL, V466, P301; OSUMI T, 1985, J BIOL CHEM, V260, P8905; RACLOT T, 1995, J LIPID RES, V36, P2164; Sambrook J., 2002, MOL CLONING LAB MANU; STOFFEL W, 1978, H-S Z PHYSIOL CHEM, V359, P1777, DOI 10.1515/bchm2.1978.359.2.1777; Stoffel W, 1964, Hoppe Seylers Z Physiol Chem, V339, P167, DOI 10.1515/bchm2.1964.339.1.167; STOFFEL W, 1993, FEBS LETT, V333, P119, DOI 10.1016/0014-5793(93)80387-A; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; TSERNG KY, 1991, J BIOL CHEM, V266, P11614; VAMECQ J, 1985, BIOCHEM J, V230, P683, DOI 10.1042/bj2300683; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; WANDERS RJA, 1992, BIOCHEM BIOPH RES CO, V188, P1139, DOI 10.1016/0006-291X(92)91350-Y; WOOD PA, 1989, PEDIATR RES, V25, P38, DOI 10.1203/00006450-198901000-00010	32	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19579	19584		10.1074/jbc.M110993200	http://dx.doi.org/10.1074/jbc.M110993200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11916962	hybrid			2022-12-25	WOS:000175894800046
J	Sano, H; Liu, SCH; Lane, WS; Piletz, JE; Lienhard, GE				Sano, H; Liu, SCH; Lane, WS; Piletz, JE; Lienhard, GE			Insulin receptor substrate 4 associates with the protein IRAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; BINDING-SITES; KINASE; ADIPOCYTES; INTERACTS; ANTISERA; SUBUNIT; CLONING	The insulin receptor substrates (IRSs) are key components in signaling from the insulin receptor, and consequently any proteins that interact with them are expected to participate in insulin signaling. In this study we have searched for proteins that interact with IRS-4 by identifying the proteins that coimmunoprecipitated with IRS-4 from human embryonic kidney 293 cells by microsequencing through mass spectrometry. A group of proteins was found. These included phosphatidylinositol 3-kinase, a protein previously identified as an IRS-4 interactor, and several proteins for which there was no previous evidence of IRS-4 association. One of these proteins, named IRAS, that had been found earlier in another context was examined in detail. The results from the overexpression of IRAS, where its amount was about the same as that of IRS-4, indicated that IRAS associated directly with IRS-4 and showed that the increased complexation of IRS-4 with IRAS did not alter the insulin-stimulated tyrosine phosphorylation of IRS-4 or the association of IRS-4 with phosphatidylinositol 3-kinase or Grb2. On the other hand, overexpression of IRAS enhanced IRS-4-dependent insulin stimulation of the extracellularly regulated kinase. The domains of IRAS and IRS-4 responsible for the association of these two proteins were identified, and it was shown that IRAS also associates with IRS-1, IRS-2, and IRS-3.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Harvard Univ, Dept Mol & Cellular Biol, Microchem & proteom Anal Facil, Cambridge, MA 02138 USA; Univ Mississippi, Med Ctr, Dept Psychiat, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Pharmacol, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Physiol, Jackson, MS 39216 USA	Dartmouth College; Harvard University; University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center	Lienhard, GE (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Vail Bldg, Hanover, NH 03755 USA.			Piletz, John/0000-0002-0053-1587	NIMH NIH HHS [R01 MH049248, MH49248] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH049248] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alahari SK, 2000, J CELL BIOL, V151, P1141, DOI 10.1083/jcb.151.6.1141; Algenstaedt PM, 1997, J BIOL CHEM, V272, P23696, DOI 10.1074/jbc.272.38.23696; Bogdan S, 2001, CURR BIOL, V11, pR292, DOI 10.1016/S0960-9822(01)00167-1; Burks DJ, 1998, J BIOL CHEM, V273, P31061, DOI 10.1074/jbc.273.47.31061; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Craparo A, 1997, J BIOL CHEM, V272, P11663; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; Farah S, 1998, J BIOL CHEM, V273, P4740, DOI 10.1074/jbc.273.8.4740; Ivanov TR, 1998, J AUTONOM NERV SYST, V72, P98, DOI 10.1016/S0165-1838(98)00094-0; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; Kosaki A, 1998, J BIOL CHEM, V273, P940, DOI 10.1074/jbc.273.2.940; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; Munshi HG, 1996, BIOCHEMISTRY-US, V35, P15883, DOI 10.1021/bi962107y; Numan S, 1999, MOL BRAIN RES, V72, P97, DOI 10.1016/S0169-328X(99)00160-6; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Piletz JE, 2000, DNA CELL BIOL, V19, P319, DOI 10.1089/10445490050043290; PILETZ JE, 1993, J PHARMACOL EXP THER, V267, P1493; Qu BH, 1999, J BIOL CHEM, V274, P31179, DOI 10.1074/jbc.274.44.31179; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; Ueno H, 2000, MOL BIOL CELL, V11, P735, DOI 10.1091/mbc.11.2.735; VanRenterghem B, 1998, J BIOL CHEM, V273, P29942, DOI 10.1074/jbc.273.45.29942; White MF, 1998, RECENT PROG HORM RES, V53, P119; Xu GG, 1999, J BIOL CHEM, V274, P18067, DOI 10.1074/jbc.274.25.18067; Yamauchi T, 1998, J BIOL CHEM, V273, P15719, DOI 10.1074/jbc.273.25.15719	30	44	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19439	19447		10.1074/jbc.M111838200	http://dx.doi.org/10.1074/jbc.M111838200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11912194	hybrid			2022-12-25	WOS:000175894800028
J	Teneberg, S; Leonardsson, I; Karlsson, H; Jovall, PA; Angstrom, J; Danielsson, D; Naslund, I; Ljungh, A; Wadstrom, T; Karlsson, KA				Teneberg, S; Leonardsson, I; Karlsson, H; Jovall, PA; Angstrom, J; Danielsson, D; Naslund, I; Ljungh, A; Wadstrom, T; Karlsson, KA			Lactotetraosylceramide, a novel glycosphingolipid receptor for Helicobacter pylori, present in human gastric epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP ANTIGENS; CHROMATOGRAPHY-MASS-SPECTROMETRY; STRUCTURAL CHARACTERIZATION; GLYCOLIPID RECEPTORS; BINDING-SPECIFICITY; GAS-CHROMATOGRAPHY; DUODENAL MUCOSA; SMALL-INTESTINE; GROUP-A; EXPRESSION	The binding of Helicobacterpylori to glycosphingolipids was examined by binding of S-35-labeled bacteria to glycosphingolipids on thin-layer chromatograms. In addition to previously reported binding specificities, a selective binding to a non-acid tetraglycosylceramide of human meconium was found. This H. pylori binding glycosphingolipid was isolated and, on the basis of mass spectrometry, proton NMR spectroscopy, and degradation studies, were identified as Galbeta3GlcNAcbeta3Galbeta4Glcbeta1Cer (lactotetraosylceramide). When using non-acid glycosphingolipid preparations from human gastric epithelial cells, an identical binding of H. pylori to the tetraglycosylceramide interval was obtained in one of seven samples. Evidence for the presence of lactotetraosylceramide in the binding-active interval was obtained by proton NAIR spectroscopy of intact glycosphingolipids and by gas chromatography-electron ionization mass spectrometry of permethylated tetrasaccharides obtained by ceramide glycanase hydrolysis. The lactotetraosylceramide binding property was detected in 65 of 74 H. pylori isolates (88%). Binding of H. pylori to lactotetraosylceramide on thin-layer chromatograms was inhibited by preincubation with lactotetraose but not with lactose. Removal of the terminal galactose of lactotetraosylceramide by galactosidase hydrolysis abolished the binding as did hydrazinolysis of the acetamido group of the N-acetylglucosamine. Therefore, Galbeta3GlcNAc is an essential part of the binding epitope.	Univ Gothenburg, Inst Med Biochem, SE-40530 Gothenburg, Sweden; Orebro Med Ctr Hosp, Dept Gen Surg, SE-70185 Orebro, Sweden; Orebro Med Ctr Hosp, Dept Clin Microbiol & Immunol, SE-70185 Orebro, Sweden; Lund Univ, Dept Med Microbiol Dermatol & Infect, SE-22362 Lund, Sweden	University of Gothenburg; Lund University	Teneberg, S (corresponding author), Univ Gothenburg, Inst Med Biochem, POB 440, SE-40530 Gothenburg, Sweden.							Angstrom J, 1998, GLYCOBIOLOGY, V8, P297, DOI 10.1093/glycob/8.4.297; ASCENCIO F, 1993, J MED MICROBIOL, V38, P240, DOI 10.1099/00222615-38-4-240; BEACHEY EH, 1981, J INFECT DIS, V143, P325, DOI 10.1093/infdis/143.3.325; BJORK S, 1987, J BIOL CHEM, V262, P6758; BLASCO E, 1991, EUR J CANCER, V27, P501, DOI 10.1016/0277-5379(91)90396-U; BODE G, 1988, SCAND J GASTROENTERO, V23, P25, DOI 10.3109/00365528809091710; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; BREIMER ME, 1980, FEBS LETT, V118, P209, DOI 10.1016/0014-5793(80)80220-1; BREIMER ME, 1980, ADV MASS SPECTROM, V8, P1097; CLARKE CA, 1956, BRIT MED J, V2, P725, DOI 10.1136/bmj.2.4995.725; CLAUSEN H, 1986, J BIOL CHEM, V261, P1380; Cover T. L., 2001, PRINCIPLES BACTERIAL, P509; DICKEY W, 1993, GUT, V34, P351, DOI 10.1136/gut.34.3.351; DOHI T, 1991, J BIOL CHEM, V266, P24038; DOHI T, 1990, J BIOL CHEM, V265, P7880; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; Feldman RA, 2001, HELICOBACTER PYLORI: MOLECULAR AND CELLULAR BIOLOGY, P29; GASA S, 1983, J LIPID RES, V24, P174; HAKOMORI S, 1983, HDB LIPID RES, V3, P1; HANSSON GC, 1985, ANAL BIOCHEM, V146, P158, DOI 10.1016/0003-2697(85)90410-5; HANSSON GC, 1989, BIOCHEMISTRY-US, V28, P6672, DOI 10.1021/bi00442a021; HATTORI H, 1981, BIOCHIM BIOPHYS ACTA, V666, P361, DOI 10.1016/0005-2760(81)90295-2; HENRY S, 1995, VOX SANG, V69, P166, DOI 10.1111/j.1423-0410.1995.tb02591.x; HENRY SM, 1994, GLYCOCONJUGATE J, V11, P600, DOI 10.1007/BF00731312; HOLGERSSON J, 1991, J BIOCHEM-TOKYO, V110, P120, DOI 10.1093/oxfordjournals.jbchem.a123530; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V274, P14, DOI 10.1016/0003-9861(89)90410-4; Huesca M, 1996, INFECT IMMUN, V64, P2643, DOI 10.1128/IAI.64.7.2643-2648.1996; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Kamisago S, 1996, INFECT IMMUN, V64, P624, DOI 10.1128/IAI.64.2.624-628.1996; Karlsson Hasse, 1994, Molecular Biotechnology, V1, P165, DOI 10.1007/BF02921557; Karlsson K A, 1978, Prog Chem Fats Other Lipids, V16, P207, DOI 10.1016/0079-6832(78)90045-9; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P212; KARLSSON KA, 1979, J BIOL CHEM, V254, P9311; KARLSSON KA, 1976, GLYCOLIPID METHODOLO, P97; KOERNER TAW, 1983, BIOCHEMISTRY-US, V22, P2676, DOI 10.1021/bi00280a014; LARSON G, 1987, CARBOHYD RES, V161, P281, DOI 10.1016/S0008-6215(00)90085-5; LEDEEN RW, 1978, RES METHOD NEUROCHEM, V4, P371; LINGWOOD CA, 1992, INFECT IMMUN, V60, P2470, DOI 10.1128/IAI.60.6.2470-2474.1992; MARCUS DM, 1976, P NATL ACAD SCI USA, V73, P3263, DOI 10.1073/pnas.73.9.3263; MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010; MENTIS A, 1991, EPIDEMIOL INFECT, V106, P221, DOI 10.1017/S0950268800048366; MillerPodraza H, 1996, GLYCOCONJUGATE J, V13, P453, DOI 10.1007/BF00731478; NATOMI H, 1993, LIPIDS, V28, P737, DOI 10.1007/BF02535996; QUIGLEY EMM, 1987, GASTROENTEROLOGY, V92, P1876, DOI 10.1016/0016-5085(87)90619-6; RAPPE AK, 1991, J PHYS CHEM-US, V95, P3358, DOI 10.1021/j100161a070; ROTTER JI, 1983, PRINCIPLES PRACTICE, P863; SAITOH T, 1991, FEBS LETT, V282, P385, DOI 10.1016/0014-5793(91)80519-9; SAMUELSSON BE, 1990, METHOD ENZYMOL, V193, P623, DOI 10.1016/0076-6879(90)93442-N; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; THOMSEN LL, 1990, GUT, V31, P1230, DOI 10.1136/gut.31.11.1230; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Waldi D., 1962, DUNNSCHICHT CHROMATO, P496; YANG HJ, 1971, J BIOL CHEM, V246, P1192	53	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19709	19719		10.1074/jbc.M201113200	http://dx.doi.org/10.1074/jbc.M201113200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11914375	Green Published, hybrid			2022-12-25	WOS:000175894800063
J	Hotokezaka, Y; Tobben, U; Hotokezaka, H; van Leyen, K; Beatrix, B; Smith, DH; Nakamura, T; Wiedmann, M				Hotokezaka, Y; Tobben, U; Hotokezaka, H; van Leyen, K; Beatrix, B; Smith, DH; Nakamura, T; Wiedmann, M			Interaction of the eukaryotic elongation factor 1A with newly synthesized polypeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; FACTOR EF-TU; ENDOPLASMIC-RETICULUM; FACTOR 1-ALPHA; MESSENGER-RNA; SECRETORY PROTEIN; CROSS-LINKING; IN-VIVO; COMPLEX; TRANSLOCATION	eEF1A, the eukaryotic homologue of bacterial elongation factor Tu, is a well characterized translation elongation factor responsible for delivering aminoacyl-tRNAs to the A-site at the ribosome. Here we show for the first time that eEF1A also associates with the nascent chain distal to the peptidyltransferase center. This is demonstrated for a variety of nascent chains of different lengths and sequences. Interestingly, unlike other ribosome-associated factors, eEF1A also interacts with polypeptides after their release from the ribosome. We demonstrate that eEF1A does not bind to correctly folded full-length proteins but interacts specifically with proteins that are unable to fold correctly in a cytosolic environment. This association was demonstrated both by photo-cross-linking and by a functional refolding assay.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Nagasaki Univ, Sch Dent, Dept Orthodont, Nagasaki 8528588, Japan; Free Univ Berlin, Inst Kristallog, D-14195 Berlin, Germany	Memorial Sloan Kettering Cancer Center; Nagasaki University; Free University of Berlin	Wiedmann, M (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	m-wiedmann@ski.mskcc.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050920] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50920-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beatrix B, 2000, J BIOL CHEM, V275, P37838, DOI 10.1074/jbc.M006368200; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Caldas TD, 1998, J BIOL CHEM, V273, P11478, DOI 10.1074/jbc.273.19.11478; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; DESHAIES RJ, 1988, TRENDS BIOCHEM SCI, V13, P384, DOI 10.1016/0968-0004(88)90180-6; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Funfschilling U, 1999, MOL BIOL CELL, V10, P3289, DOI 10.1091/mbc.10.10.3289; George R, 1998, P NATL ACAD SCI USA, V95, P2296, DOI 10.1073/pnas.95.5.2296; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; GONEN H, 1994, P NATL ACAD SCI USA, V91, P7648, DOI 10.1073/pnas.91.16.7648; GORLICH D, 1991, METHOD CELL BIOL, V34, P241; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Kudlicki W, 1997, J BIOL CHEM, V272, P32206, DOI 10.1074/jbc.272.51.32206; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURING B, 1995, P NATL ACAD SCI USA, V92, P9435, DOI 10.1073/pnas.92.21.9435; Liu G, 1996, J CELL BIOL, V135, P953, DOI 10.1083/jcb.135.4.953; Moller I, 1998, P NATL ACAD SCI USA, V95, P13425, DOI 10.1073/pnas.95.23.13425; Moller I, 1998, FEBS LETT, V441, P1, DOI 10.1016/S0014-5793(98)01440-9; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; Naylor DJ, 2001, BIOCHEM SOC SYMP, V68, P45, DOI 10.1042/bss0680045; Paschen SA, 2001, IUBMB LIFE, V52, P101, DOI 10.1080/15216540152845894; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Plath K, 2000, J CELL BIOL, V151, P167, DOI 10.1083/jcb.151.1.167; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; SHIINA N, 1994, SCIENCE, V266, P282, DOI 10.1126/science.7939665; STRYER L, 1995, BIOCHEMISTRY-US, P898; Turner GC, 2000, SCIENCE, V289, P2117, DOI 10.1126/science.289.5487.2117; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0	40	67	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18545	18551		10.1074/jbc.M201022200	http://dx.doi.org/10.1074/jbc.M201022200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893745	hybrid			2022-12-25	WOS:000175975800040
J	Shibata, M; Katoh, H; Sonoda, M; Ohkawa, H; Shimoyama, M; Fukuzawa, H; Kaplan, A; Ogawa, T				Shibata, M; Katoh, H; Sonoda, M; Ohkawa, H; Shimoyama, M; Fukuzawa, H; Kaplan, A; Ogawa, T			Genes essential to sodium-dependent bicarbonate transport in cyanobacteria - Function and phylogenetic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; SP STRAIN PCC-6803; HCO3(-) TRANSPORT; NA+ UPTAKE; PCC 7942; PCC6803; IDENTIFICATION; COTRANSPORTER; INHIBITION; SYMPORT	The cyanobacterium. Synechocystis sp. strain PCC 6803 possesses two CO2 uptake systems and two HCO3- transporters. We transformed a mutant impaired in CO2 uptake and in cmpA-D encoding a HCO3- transporter with a transposon inactivation library, and we recovered mutants unable to take up HCO3- and grow in low CO2 at pH 9.0. They are all tagged within slr1512 (designated sbtA). We show that SbtA-mediated transport is induced by low CO2, requires Na+, and plays the major role in HCO3- uptake in Synechocystis. Inactivation of slr1509 (homologous to ntpJ encoding a Na+/K+-translocating protein) abolished the ability of cells to grow at [Na+] higher than 100 m-m and severely depressed the activity of the SbtA-mediated HCO3- transport. We propose that the SbtA-mediated HCO3- transport is driven by DeltamuNa(+) across the plasma membrane, which is disrupted by inactivating ntpJ. Phylogenetic analyses indicated that two types of sbtA exist in various cyanobacterial strains, all of which possess ntpJ. The sbtA gene is the first one identified as essential to Na+-dependent HCO3- transport in photosynthetic organisms and may play a crucial role in carbon acquisition when CO2 supply is limited, or in Prochlorococcus strains that do not possess CO2 uptake systems or Cmp-dependent HCO3- transport.	Nagoya Univ, Biosci Ctr, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan; Hebrew Univ Jerusalem, Dept Plant Sci, IL-91904 Jerusalem, Israel	Nagoya University; Kyoto University; Hebrew University of Jerusalem	Ogawa, T (corresponding author), Nagoya Univ, Biosci Ctr, Chikusa Ku, Nagoya, Aichi 4648601, Japan.	ogawater@agr.nagoya-u.ac.jp	Fukuzawa, Hideya/I-5906-2018; Kaplan, Aaron/GLN-5655-2022	Fukuzawa, Hideya/0000-0003-0963-5662; Kaplan, Aaron/0000-0002-0815-5731				AGUSTIN V, 1992, NUCLEIC ACIDS RES, V20, P6331; ALBA H, 1981, J BIOL CHEM, V256, P1905; BLUMWALD E, 1984, BIOCHEM BIOPH RES CO, V122, P452, DOI 10.1016/0006-291X(84)90497-2; Bonfil DJ, 1998, FEBS LETT, V430, P236, DOI 10.1016/S0014-5793(98)00662-0; BROWN II, 1990, FEBS LETT, V270, P203, DOI 10.1016/0014-5793(90)81268-S; Chelly Jamel, 1994, P97; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; ESPIE GS, 1994, PLANT PHYSIOL, V104, P1419, DOI 10.1104/pp.104.4.1419; Hagemann M, 1997, J BACTERIOL, V179, P1727, DOI 10.1128/jb.179.5.1727-1733.1997; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Kaneko T, 1996, DNA Res, V3, P109; Kaplan A, 1999, ANNU REV PLANT PHYS, V50, P539, DOI 10.1146/annurev.arplant.50.1.539; KAPLAN A, 1989, PLANT PHYSIOL, V89, P1220, DOI 10.1104/pp.89.4.1220; Katoh A, 1996, J BACTERIOL, V178, P5452, DOI 10.1128/jb.178.18.5452-5455.1996; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MILLER AG, 1984, J BACTERIOL, V159, P100, DOI 10.1128/JB.159.1.100-106.1984; Nierman WC, 2001, P NATL ACAD SCI USA, V98, P4136, DOI 10.1073/pnas.061029298; OGAWA T, 1991, P NATL ACAD SCI USA, V88, P4275, DOI 10.1073/pnas.88.10.4275; Ohkawa H, 2000, J BIOL CHEM, V275, P31630, DOI 10.1074/jbc.M003706200; Ohkawa H, 2000, J BACTERIOL, V182, P2591, DOI 10.1128/JB.182.9.2591-2596.2000; Omata T, 1999, P NATL ACAD SCI USA, V96, P13571, DOI 10.1073/pnas.96.23.13571; Partensky F, 1999, MICROBIOL MOL BIOL R, V63, P106, DOI 10.1128/MMBR.63.1.106-127.1999; REINHOLD L, 1984, PLANT PHYSIOL, V76, P1090, DOI 10.1104/pp.76.4.1090; Ritchie RJ, 1996, PLANT PHYSIOL, V112, P1573, DOI 10.1104/pp.112.4.1573; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; SCHERER S, 1988, PLANT PHYSIOL, V86, P769, DOI 10.1104/pp.86.3.769; Shibata M, 2001, P NATL ACAD SCI USA, V98, P11789, DOI 10.1073/pnas.191258298; So AKC, 1998, CAN J BOT, V76, P1084, DOI 10.1139/b98-071; Soleimani M, 2000, KIDNEY INT, V57, P371, DOI 10.1046/j.1523-1755.2000.00857.x; SoltesRak E, 1997, J BACTERIOL, V179, P769, DOI 10.1128/jb.179.3.769-774.1997; STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971; Takami H, 2000, NUCLEIC ACIDS RES, V28, P4317, DOI 10.1093/nar/28.21.4317; Uozumi N, 2000, PLANT PHYSIOL, V122, P1249, DOI 10.1104/pp.122.4.1249; von Caemmerer S, 2000, ADV PHOTOSYNTHESIS, V9, P399	35	204	211	2	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18658	18664		10.1074/jbc.M112468200	http://dx.doi.org/10.1074/jbc.M112468200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11904298	hybrid			2022-12-25	WOS:000175975800056
J	Strano, S; Fontemaggi, G; Costanzo, A; Rizzo, MG; Monti, O; Baccarini, A; Del Sal, G; Levrero, M; Sacchi, A; Oren, M; Blandino, G				Strano, S; Fontemaggi, G; Costanzo, A; Rizzo, MG; Monti, O; Baccarini, A; Del Sal, G; Levrero, M; Sacchi, A; Oren, M; Blandino, G			Physical interaction with human tumor-derived p53 mutants inhibits p63 activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAIN-OF-FUNCTION; KINASE C-ABL; P73 GENE; DNA-DAMAGE; CELL-LINES; WILD-TYPE; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTIONAL ACTIVITY; APOPTOTIC RESPONSE; FUNCTION MUTATIONS	The p53 tumor suppressor gene is the most frequent target for genetic alterations in human cancers, whereas the recently discovered homologues p73 and p63 are rarely mutated. We and others have previously reported that human tumor-derived p53 mutants can engage in a physical association with different isoforms of p73, inhibiting their transcriptional activity. Here, we report that human tumor-derived p53 mutants can associate in vitro and in vivo with p63 through their respective core domains. We show that the interaction with mutant p53 impairs in vitro and in vivo sequence-specific DNA binding of p63 and consequently affects its transcriptional activity. We also report that in cells carrying endogenous mutant p53, such as T47D cells, p63 is unable to recruit some of its target gene promoters. Unlike wild-type p53, the binding to specific p53 mutants markedly counteracts p63-induced growth inhibition. This effect is, at least partially, mediated by the core domain of mutant p53. Thus, inactivation of p53 family members may contribute to the biological properties of specific p53 mutants in promoting tumorigenesis and in conferring selective survival advantage to cancer cells.	Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy; Univ Roma La Sapienza, Fdn Andrea Cesalpino, Lab Gene Express, I-00161 Rome, Italy; Dipartimento Biochim Biofis & Chim Macromol, Lab Nazl CIB, I-34012 Trieste, Italy; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Sapienza University Rome; Weizmann Institute of Science	Blandino, G (corresponding author), Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Via Messi Doro 156, I-00158 Rome, Italy.	blandino@ifo.it	strano, sabrina/B-6743-2013; Costanzo, Antonio/D-3896-2012; Blandino, Giovanni/B-1137-2013; Rizzo, Maria Giulia/B-2107-2018; Strano, Sabrina/K-9654-2016; Costanzo, Antonio/GZG-2433-2022; Fontemaggi, Giulia/K-9702-2016; Levrero, Massimo/G-5680-2016	strano, sabrina/0000-0002-6341-4230; Blandino, Giovanni/0000-0002-6970-2241; Rizzo, Maria Giulia/0000-0002-5009-2412; Costanzo, Antonio/0000-0001-9697-2557; Fontemaggi, Giulia/0000-0001-8332-8842; Oren, Moshe/0000-0003-4311-7172; Levrero, Massimo/0000-0002-4978-0875				Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Agami R, 1999, NATURE, V399, P809; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gong JG, 1999, NATURE, V399, P806; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; HSIAO M, 1994, AM J PATHOL, V145, P702; Hussain SP, 1998, CANCER RES, V58, P4023; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Lee YI, 2000, ONCOGENE, V19, P3717, DOI 10.1038/sj.onc.1203694; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1995, ONCOGENE, V10, P2387; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MIYASHITA T, 1995, CELL, V80, P293; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Nylander K, 2000, INT J CANCER, V87, P368, DOI 10.1002/1097-0215(20000801)87:3<368::AID-IJC9>3.3.CO;2-A; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Park BJ, 2000, CANCER RES, V60, P3370; Prives C, 1999, J PATHOL, V187, P112; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; SHAULSKY G, 1991, CANCER RES, V51, P5232; Sigal A, 2000, CANCER RES, V60, P6788; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Strano S, 2001, FEBS LETT, V490, P163, DOI 10.1016/S0014-5793(01)02119-6; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; SUDOL M, 1994, ONCOGENE, V9, P2145; Sunahara M, 1998, INT J ONCOL, V13, P319; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yamaguchi K, 2000, INT J CANCER, V86, P684, DOI 10.1002/(SICI)1097-0215(20000601)86:5<684::AID-IJC13>3.0.CO;2-M; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	67	175	175	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18817	18826		10.1074/jbc.M201405200	http://dx.doi.org/10.1074/jbc.M201405200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893750	hybrid			2022-12-25	WOS:000175975800076
J	Cellai, C; Laurenzana, A; Vannucchi, AM; Della Malva, N; Bianchi, L; Paoletti, F				Cellai, C; Laurenzana, A; Vannucchi, AM; Della Malva, N; Bianchi, L; Paoletti, F			Specific PAF antagonist WEB-2086 induces terminal differentiation of murine and human leukemia cells	FASEB JOURNAL			English	Article						inducer; PAF receptor; maturation; neoplasia; differentiation therapy	PLATELET-ACTIVATING-FACTOR; HYBRID POLAR COMPOUNDS; TRANSFORMED-CELLS; IN-VITRO; MYELOGENOUS LEUKEMIA; HISTONE DEACETYLASE; POTENT INDUCERS; ACID; STIMULATION; EXPRESSION	A pharmacological approach to neoplasia by differentiation therapy relies on the availability of cytodifferentiating agents whose antitumor efficacy is usually assayed first on malignant cells in vitro. Using murine erythroleukemia cells (MELCs) as the model, we found that WEB-2086, a triazolobenzodiazepine-derived PAF antagonist originally developed as an anti-inflammatory drug, induces a dose-dependent inhibition of MELC growth and hemoglobin accumulation as a result of a true commitment to differentiation. MELCs treated for 5 days with 1 mM WEB-2086 show greater than or equal to85% benzidine-positive cells, increased expression of alpha- and beta-globin genes, and down-regulation of c-Myb. This differentiation pattern, which does not involve histone H4 acetylation and is abrogated by the action of phorbol 12-myristate 13-acetate, recalls the pattern induced by hexamethylene bisacetamide (HMBA). In addition to MELCs, human erythroleukemia K562 and HEL and myeloid HL60 cells are massively committed to maturation by WEB-2086 and, with some differences, by its analog, WEB-2170. This suggests that WEB-2086, structurally distant from other known inducers, might be a member of a new class of cytodifferentiation agents active on a broad range of transformed cells in vitro and useful, prospectively, for anticancer therapy due to their high tolerability in vivo.	Univ Florence, Dept Expt Path & Oncol, I-50134 Florence, Italy; Careggi Hosp, Dept Hematol, I-50139 Florence, Italy	University of Florence; University of Florence; Azienda Ospedaliero Universitaria Careggi	Paoletti, F (corresponding author), Univ Florence, Dept Expt Path & Oncol, Viale GB Morgagni 50, I-50134 Florence, Italy.	fcplt@unifi.it	Vannucchi, Alessandro M./K-7499-2016	Vannucchi, Alessandro M./0000-0001-5755-0730				ADAMUS WS, 1989, CLIN PHARMACOL THER, V45, P270, DOI 10.1038/clpt.1989.27; ANDREEFF M, 1992, BLOOD, V80, P2604; BIRKE FW, 1988, CLIN EXP PHARM PHY S, V13, P2; Boccellino M, 2000, J CELL PHYSIOL, V183, P254, DOI 10.1002/(SICI)1097-4652(200005)183:2<254::AID-JCP12>3.0.CO;2-U; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bussolati B, 2000, AM J PATHOL, V157, P1713, DOI 10.1016/S0002-9440(10)64808-0; CASALSSTENZEL J, 1987, J PHARMACOL EXP THER, V241, P974; CASALSSTENZEL J, 1990, METHOD ENZYMOL, V187, P455; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; Denizot Y, 1996, J LIPID MEDIAT CELL, V15, P1, DOI 10.1016/S0929-7855(96)00447-6; Dupuis F, 1997, BBA-MOL CELL RES, V1359, P241, DOI 10.1016/S0167-4889(97)00106-7; Dupuis F, 1998, MEDIAT INFLAMM, V7, P99, DOI 10.1080/09629359891243; FALETTO DL, 1985, CELL, V43, P315, DOI 10.1016/0092-8674(85)90037-6; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; FRIEND C, 1976, HARVEY LECT, V72, P253; GIERS G, 1990, BLUT, V61, P21, DOI 10.1007/BF01739429; GUSELLA JF, 1980, BLOOD, V56, P481; HARRISON PR, 1976, NATURE, V262, P353, DOI 10.1038/262353a0; HEUER HO, 1990, HDB PAF PAF ANTAGONI, P171; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Im SY, 1996, CANCER RES, V56, P2662; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; KOSTRABA NC, 1975, J BIOL CHEM, V250, P1548; LOHMANN HF, 1988, LANCET, V2, P1147; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Lukashova V, 2001, J BIOL CHEM, V276, P24113, DOI 10.1074/jbc.M100720200; Marks P A, 1984, Cancer, V54, P2766, DOI 10.1002/1097-0142(19841201)54:2+<2766::AID-CNCR2820541424>3.0.CO;2-N; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MARKS PA, 1987, CANCER RES, V47, P659; MARKS PA, 1994, P NATL ACAD SCI USA, V91, P10251, DOI 10.1073/pnas.91.22.10251; Marks PA, 1996, INT J HEMATOL, V63, P1; MELLONI E, 1987, P NATL ACAD SCI USA, V84, P5282, DOI 10.1073/pnas.84.15.5282; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; PAPAYANNOPOULOU MP, 1982, SCIENCE, V216, P1233; REUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862, DOI 10.1073/pnas.73.3.862; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; Stojanov T, 1999, BIOL REPROD, V60, P674, DOI 10.1095/biolreprod60.3.674; TAHRAOUI L, 1988, MOL PHARMACOL, V34, P145; TESSNER TG, 1989, J BIOL CHEM, V264, P4794; UKENA D, 1988, FEBS LETT, V228, P285, DOI 10.1016/0014-5793(88)80017-6; Vannucchi AM, 1997, BRIT J HAEMATOL, V99, P500, DOI 10.1046/j.1365-2141.1997.4273230.x; VENABLE ME, 1993, J LIPID RES, V34, P691; WAXMAN S, 1986, CANCER DETECT PREV, V9, P395; YAMASAKI H, 1977, P NATL ACAD SCI USA, V74, P3451, DOI 10.1073/pnas.74.8.3451; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	53	18	33	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3					733	+		10.1096/fj.01-0602fje	http://dx.doi.org/10.1096/fj.01-0602fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923217				2022-12-25	WOS:000174755900006
J	von Kobbe, C; Karmakar, P; Dawut, L; Opresko, P; Zeng, XM; Brosh, RM; Hickson, ID; Bohr, VA				von Kobbe, C; Karmakar, P; Dawut, L; Opresko, P; Zeng, XM; Brosh, RM; Hickson, ID; Bohr, VA			Colocalization, physical, and functional interaction between Werner and Bloom syndrome proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; DNA HELICASE; CELL-CYCLE; FLAP ENDONUCLEASE-1; HOLLIDAY JUNCTIONS; WRN HELICASE; TELOMERASE; BINDING; COMPLEX; 3'->5'-EXONUCLEASE	The RecQ helicase family comprises a conserved group of proteins implicated in several aspects of DNA metabolism. Three of the family members are defective in heritable diseases characterized by abnormal growth, premature aging, and predisposition to malignancies. These include the WRN and BLM gene products that are defective in Werner and Bloom syndromes, disorders which share many phenotypic and cellular characteristics including spontaneous genomic instability. Here, we report a physical and functional interaction between BLM and WRN. These proteins were coimmunoprecipitated from a nuclear matrix-solubilized fraction, and the purified recombinant proteins were shown to interact directly. Moreover, BLM and WRN colocalized to nuclear foci in three human cell lines. Two regions of WRN that mediate interaction with BLM were identified, and one of these was localized to the exonuclease domain of WRN. Functionally, BLM inhibited the exonuclease activity of WRN. This is the first demonstration of a physical and functional interaction between RecQ helicases. Our observation that RecQ family members interact provides new insights into the complex phenotypic manifestations resulting from the loss of these proteins.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Univ Oxford, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Cancer Research UK; University of Oxford	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Schock Dr, Baltimore, MD 21224 USA.	vbohr@nih.gov	Hickson, Ian/AAJ-7548-2020; Bohr, Vilhelm/AAP-5931-2020	von Kobbe, Cayetano/0000-0003-3895-3790; Opresko, Patricia/0000-0002-6470-2189; Hickson, Ian/0000-0002-0583-566X	NATIONAL INSTITUTE ON AGING [Z01AG000741, ZIAAG000741, Z01AG000726, ZIAAG000726] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Bohr VA, 2000, EXP GERONTOL, V35, P695, DOI 10.1016/S0531-5565(00)00145-5; Brosh RM, 2000, NUCLEIC ACIDS RES, V28, P2420, DOI 10.1093/nar/28.12.2420; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dutertre S, 2000, ONCOGENE, V19, P2731, DOI 10.1038/sj.onc.1203595; Fontoura BMA, 1999, J CELL BIOL, V144, P1097, DOI 10.1083/jcb.144.6.1097; Frei C, 2000, J CELL SCI, V113, P2641; Gharibyan V, 1999, MOL CARCINOGEN, V26, P261, DOI 10.1002/(SICI)1098-2744(199912)26:4<261::AID-MC5>3.0.CO;2-A; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Grobelny JV, 2000, J CELL SCI, V113, P4577; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; Hisama FM, 2000, CANCER RES, V60, P2372; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; Imamura O, 2002, ONCOGENE, V21, P954, DOI 10.1038/sj.onc.1205143; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kusano K, 2001, SCIENCE, V291, P2600, DOI 10.1126/science.291.5513.2600; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Li BM, 2000, J BIOL CHEM, V275, P39800; Lindor NM, 2000, AM J MED GENET, V90, P223, DOI 10.1002/(SICI)1096-8628(20000131)90:3<223::AID-AJMG7>3.0.CO;2-Z; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Machwe A, 2000, NUCLEIC ACIDS RES, V28, P2762, DOI 10.1093/nar/28.14.2762; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; Moser MJ, 2000, NUCLEIC ACIDS RES, V28, P648, DOI 10.1093/nar/28.2.648; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Oshima J, 2000, BIOESSAYS, V22, P894, DOI 10.1002/1521-1878(200010)22:10<894::AID-BIES4>3.0.CO;2-B; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; van Brabant AJ, 2000, BIOCHEMISTRY-US, V39, P14617, DOI 10.1021/bi0018640; von Kobbe C, 2000, MOL CELL, V6, P1243, DOI 10.1016/S1097-2765(00)00120-9; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Yankiwski V, 2000, P NATL ACAD SCI USA, V97, P5214, DOI 10.1073/pnas.090525897; Yeager TR, 1999, CANCER RES, V59, P4175	45	107	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					22035	22044		10.1074/jbc.M200914200	http://dx.doi.org/10.1074/jbc.M200914200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11919194	hybrid			2022-12-25	WOS:000176286000116
J	Fournier, HN; Dupe-Manet, S; Bouvard, D; Lacombe, ML; Marie, C; Block, MR; Albiges-Rizo, C				Fournier, HN; Dupe-Manet, S; Bouvard, D; Lacombe, ML; Marie, C; Block, MR; Albiges-Rizo, C			Integrin cytoplasmic domain-associated protein 1 alpha (ICAP-1 alpha) interacts directly with the metastasis suppressor nm23-H2, and both proteins are targeted to newly formed cell adhesion sites upon integrin engagement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; X-RAY STRUCTURE; TUMOR-METASTASIS; MELANOMA-CELLS; CATALYTIC MECHANISM; BIOLOGICAL FUNCTION; DEPENDENT PROTEIN; BINDING; GTPASE; LINE	Cell adhesion-dependent signaling implicates cytoplasmic proteins interacting with the intracellular tails of integrins. Among those, the integrin cytoplasmic domain-associated protein 1alpha (ICAP-1alpha) has been shown to interact specifically with the beta(1), integrin cytoplasmic domain. Although it is likely that this protein plays an important role in controlling cell adhesion and migration, little is known about its actual function. To search for potential ICAP-1alpha-binding proteins, we used a yeast two-hybrid screen and identified the human metastatic suppressor protein nm23-H2 as a new partner of ICAP-1alpha. This direct interaction was confirmed in vitro, using purified recombinant ICA-P1alpha and nm23-H2, and by coimmunoprecipitation from CHO cell lysates over-expressing ICAP-1alpha. The physiological relevance of this interaction is provided by confocal fluorescence microscopy, which shows that ICAP-1alpha and nm23-H2 are colocalized in lamellipodia during the early stages of cell spreading. These adhesion sites are enriched in occupied 13, integrins and precede the formation of focal adhesions devoid of ICAP-1alpha and nm23-H2, indicating the dynamic segregation of components of matrix adhesions. This peripheral staining of ICAP-1alpha and nm23-1-12 is only observed in cells spreading on fibronectin and collagen and is absent in cells spreading on poly-L-lysine, vitronectin, or laminin. This is consistent with the fact that targeting of both ICAP-1alpha and nm23-H2 to the cell periphery is dependent on 13, integrin engagement rather than being a consequence of cell adhesion. This finding represents the first evidence that the tumor suppressor nm23-H2 could act on beta(1) integrin-mediated cell adhesion by interacting with one of the integrin partners, ICAP-1alpha.	UJF, Fac Med Grenoble,UMR CNRS 5538, Inst Albert Bonniot, Lab Etud Differenciat & Adherence Cellulaires, F-38706 La Tronche, France; Max Planck Inst Biochem, Dept Mol Med, D-82152 Martinsried, Germany; Univ Paris 06, INSERM U402, F-75012 Paris, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Max Planck Society; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Block, MR (corresponding author), UJF, Fac Med Grenoble,UMR CNRS 5538, Inst Albert Bonniot, Lab Etud Differenciat & Adherence Cellulaires, Domaine Merci, F-38706 La Tronche, France.		Bouvard, Daniel/M-2727-2013; Block, Marc R/M-2740-2013; Albiges-Rizo, Corinne/M-2568-2013; Bouvard, Daniel/B-1260-2017	Block, Marc R/0000-0003-2214-9706; Bouvard, Daniel/0000-0002-0845-6681; ALBIGES-RIZO, Corinne/0000-0002-6333-4150				BABA H, 1995, CANCER RES, V55, P1977; Bouvard D, 1998, BIOCHEM BIOPH RES CO, V252, P46, DOI 10.1006/bbrc.1998.9592; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; Chang DD, 2002, J BIOL CHEM, V277, P8140, DOI 10.1074/jbc.M109031200; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; Gonin P, 1999, BIOCHEMISTRY-US, V38, P7265, DOI 10.1021/bi982990v; Hamby C V, 1995, Biochem Biophys Res Commun, V211, P579; Hamby CV, 2000, INT J CANCER, V88, P547, DOI 10.1002/1097-0215(20001115)88:4<547::AID-IJC5>3.0.CO;2-L; Hartsough MT, 2000, J BIOENERG BIOMEMBR, V32, P301, DOI 10.1023/A:1005597231776; KANTOR JD, 1993, CANCER RES, V53, P1971; Kashiwagi H, 1997, J CELL BIOL, V137, P1433, DOI 10.1083/jcb.137.6.1433; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; Lascu I, 2000, J BIOENERG BIOMEMBR, V32, P237, DOI 10.1023/A:1005532912212; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Lochter A, 1999, MOL BIOL CELL, V10, P271, DOI 10.1091/mbc.10.2.271; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; Ma DQ, 2002, J BIOL CHEM, V277, P1560, DOI 10.1074/jbc.M108359200; Miyazaki H, 1999, CLIN CANCER RES, V5, P4301; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; Otero AD, 2000, J BIOENERG BIOMEMBR, V32, P269, DOI 10.1023/A:1005589029959; Otsuki Y, 2001, P NATL ACAD SCI USA, V98, P4385, DOI 10.1073/pnas.071411598; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Pozzi M, 1998, J CELL BIOL, V142, P587; Reddy KB, 2001, J BIOL CHEM, V276, P28300, DOI 10.1074/jbc.M102794200; Ridley A, 2000, J CELL BIOL, V150, pF107, DOI 10.1083/jcb.150.4.F107; Sastry SK, 1999, J CELL BIOL, V144, P1295, DOI 10.1083/jcb.144.6.1295; Schaertl S, 1999, J BIOL CHEM, V274, P20159, DOI 10.1074/jbc.274.29.20159; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Stroeken PJM, 2000, ONCOGENE, V19, P1232, DOI 10.1038/sj.onc.1203423; Tang SQ, 1999, J CELL BIOL, V147, P1073, DOI 10.1083/jcb.147.5.1073; TAWIL N, 1993, J CELL BIOL, V120, P261, DOI 10.1083/jcb.120.1.261; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457; Xu J, 1996, DEV BIOL, V177, P544, DOI 10.1006/dbio.1996.0184; Zamir E, 2001, J CELL SCI, V114, P3583; Zhang XA, 1999, J BIOL CHEM, V274, P11, DOI 10.1074/jbc.274.1.11; Zhu JH, 1999, P NATL ACAD SCI USA, V96, P14911, DOI 10.1073/pnas.96.26.14911	47	88	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20895	20902		10.1074/jbc.M200200200	http://dx.doi.org/10.1074/jbc.M200200200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11919189	hybrid			2022-12-25	WOS:000176204500102
J	Gowher, H; Jeltsch, A				Gowher, H; Jeltsch, A			Molecular enzymology of the catalytic domains of the Dnmt3a and Dnmt3b DNA methyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ICF SYNDROME; CYTOSINE-5 METHYLTRANSFERASE; MAINTENANCE METHYLATION; CHROMOSOME INSTABILITY; ENZYMATIC-PROPERTIES; CPG ISLANDS; MOUSE; GENE; REPLICATION; COMPLEX	The C-terminal domains of the mammalian DNA methyltransferases Dnmt1, Dnmt3a, and Dnmt3b harbor all the conserved motifs characteristic for cytosine-C5 methyltransferases. Whereas the isolated catalytic domain of Dnmt1 is inactive, we show here that the C-terminal domains of Dnmt3a and Dnmt3b are catalytically active. Neither Dnmt3a nor Dnmt3b shows a significant preference for the satellite 2 sequence, although Dnmt3b is required for methylation of these regions in vivo. However, the catalytic domain of Dnmt3a methylates DNA in a distributive reaction, whereas Dnmt3b is processive, which accelerates methylation of macromolecular DNA in vitro. This property could make Dnmt3b a preferred enzyme for methylation at satellite 2 repeats, since they are highly CG-rich. We have also analyzed the catalytic activities of six different mutations found in ICF (immunodeficiency, centromeric instability, and facial abnormalities) patients in the catalytic domain of Dnmt3b. Five of them display catalytic activities reduced by 10-50-fold; one mutant was inactive in our assay (residual activity <1%). These results confirm that a reduced catalytic activity of Dnm3b causes ICF. However, the mutations in general do not completely abrogate catalytic activity. This finding may explain why ICF patients are viable, whereas nmt3b knock-out mice die during embryogenesis.	Univ Giessen, FB 8, Inst Biochem, D-35392 Giessen, Germany	Justus Liebig University Giessen	Jeltsch, A (corresponding author), Univ Giessen, FB 8, Inst Biochem, Heinrich Buff Ring 58, D-35392 Giessen, Germany.	Albert.Jeltsch@chemie.bio.uni-giessen.de	Jeltsch, Albert/O-7404-2014; Gowher, Humaira/AAG-7112-2019	Jeltsch, Albert/0000-0001-6113-9290; 				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Bacolla A, 2001, J BIOL CHEM, V276, P18605, DOI 10.1074/jbc.M100404200; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; CHAPMAN V, 1984, NATURE, V307, P284, DOI 10.1038/307284a0; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; DRYDEN DTF, 1998, S ADENOSYLMETHIONINE, P283; Ehrlich M, 2001, HUM MOL GENET, V10, P2917, DOI 10.1093/hmg/10.25.2917; Fatemi M, 2001, J MOL BIOL, V309, P1189, DOI 10.1006/jmbi.2001.4709; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gowher H, 2001, J MOL BIOL, V309, P1201, DOI 10.1006/jmbi.2001.4710; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hansen RS, 2000, HUM MOL GENET, V9, P2575, DOI 10.1093/hmg/9.18.2575; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hassan KMA, 2001, HUM GENET, V109, P452; Hsieh CL, 1999, MOL CELL BIOL, V19, P8211; Jeltsch Albert, 2002, Methods Mol Biol, V182, P85; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; LIUB Y, 1998, NUCLEIC ACIDS RES, V26, P1038; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; Margot JB, 2000, J MOL BIOL, V297, P293, DOI 10.1006/jmbi.2000.3588; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pfeifer GP, 2000, CURR TOP MICROBIOL, V249, P1; Pradhan S, 2000, EMBO J, V19, P2103, DOI 10.1093/emboj/19.9.2103; Qiu C, 2002, NAT STRUCT BIOL, V9, P217, DOI 10.1038/nsb759; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Roth M, 1998, J BIOL CHEM, V273, P17333, DOI 10.1074/jbc.273.28.17333; Roth M, 2000, BIOL CHEM, V381, P269, DOI 10.1515/BC.2000.035; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; SANFORD J, 1984, NUCLEIC ACIDS RES, V12, P2823, DOI 10.1093/nar/12.6.2823; Tuck-Muller CM, 2000, CYTOGENET CELL GENET, V89, P121, DOI 10.1159/000015590; Warnecke PM, 2000, CURR OPIN ONCOL, V12, P68, DOI 10.1097/00001622-200001000-00012; Wijmenga C, 2000, HUM MUTAT, V16, P509, DOI 10.1002/1098-1004(200012)16:6<509::AID-HUMU8>3.3.CO;2-M; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Zimmermann C, 1997, BIOL CHEM, V378, P393, DOI 10.1515/bchm.1997.378.5.393	53	148	158	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20409	20414		10.1074/jbc.M202148200	http://dx.doi.org/10.1074/jbc.M202148200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11919202	hybrid			2022-12-25	WOS:000176204500040
J	Cai, ZW; Sheppard, DN				Cai, ZW; Sheppard, DN			Phloxine B interacts with the cystic fibrosis transmembrane conductance regulator at multiple sites to modulate channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE CELL-LINE; CL CHANNELS; FLUORESCEIN DERIVATIVES; CHLORIDE CHANNEL; BINDING-SITES; CFTR; INHIBITION; GENISTEIN; BLOCK; ACTIVATION	The fluorescein derivative phloxine B is a potent modulator of the cystic fibrosis transmembrane conductance regulator (CFTR). Low micromolar concentrations of phloxine B stimulate CFTR Cl- currents, whereas higher concentrations of the drug inhibit CFTR. In this study, we investigated the mechanism of action of phloxine B. Phloxine B (1 muM) stimulated wild-type CFTR and the most common cystic fibrosis mutation, DeltaF508, by increasing the open probability of phosphorylated CFTR Cl- channels. At each concentration of ATP tested, the drug slowed the rate of channel closure without altering the opening rate. Based on the effects of fluorescein derivatives on transport ATPases, these data suggest that phloxine B might stimulate CFTR by binding to the ATP-binding site of the second nucleotide-binding domain (NBD2) to slow the dissociation of ATP from NBD1. Channel block by phloxine B (40 muM) was voltage-dependent, enhanced when external Cl- concentration was reduced and unaffected by ATP (5 mM), suggesting that phloxine B inhibits CFTR by occluding the pore. We conclude that phloxine B interacts directly with CFTR at multiple sites to modulate channel activity. It or related agents might be of value in the development of new treatments for diseases caused by the malfunction of CFTR.	Univ Bristol, Sch Med Sci, Dept Physiol, Bristol BS8 1TD, Avon, England; Univ Edinburgh, Western Gen Hosp, Med Genet Sect, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland	University of Bristol; University of Edinburgh	Sheppard, DN (corresponding author), Univ Bristol, Sch Med Sci, Dept Physiol, Univ Walk, Bristol BS8 1TD, Avon, England.		Sheppard, David N/AAV-4187-2021	Sheppard, David N/0000-0001-5533-9130				Al-Nakkash L, 2001, J PHARMACOL EXP THER, V296, P464; Bachmann A, 2000, BRIT J PHARMACOL, V131, P433, DOI 10.1038/sj.bjp.0703600; Cai Z, 1999, BRIT J PHARMACOL, V128, P108, DOI 10.1038/sj.bjp.0702748; CAI Z, 2000, PEDIAT PULMONAL S, V20, P180; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Csanady L, 1999, J GEN PHYSIOL, V114, P49, DOI 10.1085/jgp.114.1.49; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DEWEILLE JR, 1992, J BIOL CHEM, V267, P4557; Elferink RPJO, 2000, SEMIN LIVER DIS, V20, P293, DOI 10.1055/s-2000-9385; French PJ, 1997, AM J PHYSIOL-CELL PH, V273, pC747, DOI 10.1152/ajpcell.1997.273.2.C747; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; Guerrant R. L., 1990, REV INFECT DIS, V12, P41; Gupta J, 2002, PFLUG ARCH EUR J PHY, V443, P739, DOI 10.1007/s00424-001-0762-0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hwang TC, 1999, TRENDS PHARMACOL SCI, V20, P448, DOI 10.1016/S0165-6147(99)01386-3; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; Hwang TC, 1997, AM J PHYSIOL-CELL PH, V273, pC988, DOI 10.1152/ajpcell.1997.273.3.C988; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Ishihara H, 1997, AM J PHYSIOL-CELL PH, V273, pC1278, DOI 10.1152/ajpcell.1997.273.4.C1278; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; Lansdell KA, 2000, J PHYSIOL-LONDON, V524, P317, DOI 10.1111/j.1469-7793.2000.t01-1-00317.x; Lansdell KA, 1998, J PHYSIOL-LONDON, V508, P379, DOI 10.1111/j.1469-7793.1998.379bq.x; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Linsdell P, 1996, AM J PHYSIOL-CELL PH, V271, pC628, DOI 10.1152/ajpcell.1996.271.2.C628; Linsdell P, 1999, BRIT J PHARMACOL, V126, P1471, DOI 10.1038/sj.bjp.0702458; Linsdell P, 1996, J PHYSIOL-LONDON, V496, P687, DOI 10.1113/jphysiol.1996.sp021719; Luo JX, 2000, AM J PHYSIOL-CELL PH, V279, pC108, DOI 10.1152/ajpcell.2000.279.1.C108; MARSHALL J, 1994, J BIOL CHEM, V269, P2987; MCDONOUGH S, 1994, NEURON, V13, P623, DOI 10.1016/0896-6273(94)90030-2; NESLUND GG, 1984, CURR TOP CELL REGUL, V24, P447; Randak C, 1999, BIOCHEM J, V340, P227, DOI 10.1042/0264-6021:3400227; RIORDAN JR, 1989, SCIENCE, V245, P1066; Schultz B. D., 1999, Physiological Reviews, V79, pS109; SCHWANSTECHER M, 1995, PHARMACOLOGY, V50, P182, DOI 10.1159/000139281; Sheppard DN, 1997, J PHYSIOL-LONDON, V503, P333, DOI 10.1111/j.1469-7793.1997.333bh.x; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Sullivan LP, 1998, PHYSIOL REV, V78, P1165, DOI 10.1152/physrev.1998.78.4.1165; Venglarik CJ, 1996, BIOPHYS J, V70, P2696, DOI 10.1016/S0006-3495(96)79839-9; Walsh KB, 1999, BRIT J PHARMACOL, V127, P369, DOI 10.1038/sj.bjp.0702562; Wang F, 1998, J GEN PHYSIOL, V111, P477, DOI 10.1085/jgp.111.3.477; Weinreich F, 1997, PFLUG ARCH EUR J PHY, V434, P484, DOI 10.1007/s004240050424; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; Xie JX, 2000, BIOPHYS J, V78, P1293, DOI 10.1016/S0006-3495(00)76685-9; Yang ICH, 1997, AM J PHYSIOL-CELL PH, V272, pC142, DOI 10.1152/ajpcell.1997.272.1.C142; Zeltwanger S, 1999, J GEN PHYSIOL, V113, P541, DOI 10.1085/jgp.113.4.541	50	52	53	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19546	19553		10.1074/jbc.M108023200	http://dx.doi.org/10.1074/jbc.M108023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11904291	hybrid			2022-12-25	WOS:000175894800042
J	Gravel, A; Gosselin, J; Flamand, L				Gravel, A; Gosselin, J; Flamand, L			Human herpesvirus 6 immediate-early 1 protein is a sumoylated nuclear phosphoprotein colocalizing with promyelocytic leukemia protein-associated nuclear bodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX VIRUS TYPE-1; UBIQUITIN-LIKE MODIFIERS; HUMAN CYTOMEGALOVIRUS; MULTIPLE-SCLEROSIS; VARIANT-B; COVALENT MODIFICATION; SUMO-1 MODIFICATION; DOMAIN-10 ND10; CODING CONTENT; DNA-SEQUENCES	Immediate-early (IE) proteins are the first proteins expressed following viral entry and play a crucial role in the initiation of infection. We report the cloning and characterization of a full-length IE1 transcript and protein (IE1B) from human herpesvirus 6 (HHV-6) variant B. The IE1B transcript consists of five exons (3720 nucleotides), three of which are coding for the IE1 protein. The 1078-amino acid-long IE1B protein is 62% identical and 75% similar to the 941-amino acid IE1 from HHV-6 variant A. IE1B protein can be detected at 4 h post-infection (P.I.), and it is distributed as small intranuclear structures. The maximal number of IE1 bodies (similar to10-12/nucleus) is detected at 12 h P.I. after which the IE1 bodies condense into 1-3 larger entities by 24-48 h P.I. During infection the IE1B protein is phosphorylated on serine and threonine residues. IE1B undergoes further post-translational modification with its conjugation to the small ubiquitin-like modifier (SUMO-1) peptide. IE1B colocalizes with SUMO-1 and promyelocytic leukemia nuclear bodies during infection as well as in transfection experiments. Finally, IE1 from variant B is a weaker transactivator than IE1 from variant A, when assayed using heterologous promoters. Overall, the characterization of the HHV-6 IE1B protein presented highlights the similarity and divergence between IE1 from both variants and provides useful information pertaining to the early phase of infection.	CHU Laval, Res Ctr, Rheumatol & Immunol Res Ctr, Virol Lab, Quebec City, PQ G1V 4G2, Canada; CHU Laval, Res Ctr, Rheumatol & Immunol Res Ctr, Lab Viral Immunol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University; Laval University	Flamand, L (corresponding author), CHU Laval, Res Ctr, Rheumatol & Immunol Res Ctr, Virol Lab, Room T1-49,2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.			Gravel, Annie/0000-0001-5229-5750; Flamand, Louis/0000-0001-5010-4586				ABLASHI D, 1993, ARCH VIROL, V129, P363, DOI 10.1007/BF01316913; Ablashi DV, 1998, MULT SCLER, V4, P490, DOI 10.1177/135245859800400606; Adamson AL, 2001, J VIROL, V75, P2388, DOI 10.1128/JVI.75.5.2388-2399.2001; Ahn JH, 1997, J VIROL, V71, P4599, DOI 10.1128/JVI.71.6.4599-4613.1997; Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; Ahn JH, 2001, J VIROL, V75, P3859, DOI 10.1128/JVI.75.8.3859-3872.2001; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASANO Y, 1990, LANCET, V335, P862, DOI 10.1016/0140-6736(90)90983-C; BIEGALKE BJ, 1991, VIROLOGY, V183, P381, DOI 10.1016/0042-6822(91)90151-Z; Bonura F, 1999, MICROBIOLOGICA, V22, P161; Burkham J, 2001, J VIROL, V75, P2353, DOI 10.1128/JVI.75.5.2353-2367.2001; CARRIGAN DR, 1990, J INFECT DIS, V162, P844, DOI 10.1093/infdis/162.4.844; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; Coates ARM, 1998, NAT MED, V4, P537, DOI 10.1038/nm0598-537b; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; DEWHURST S, 1993, J CLIN MICROBIOL, V31, P416, DOI 10.1128/JCM.31.2.416-418.1993; Dominguez G, 1999, J VIROL, V73, P8040, DOI 10.1128/JVI.73.10.8040-8052.1999; DOWNING RG, 1987, LANCET, V2, P390; ENSOLI B, 1989, EMBO J, V8, P3019, DOI 10.1002/j.1460-2075.1989.tb08452.x; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Fillet AM, 1998, NAT MED, V4, P537, DOI 10.1038/nm0598-537a; Flamand L, 1998, J VIROL, V72, P8797, DOI 10.1128/JVI.72.11.8797-8805.1998; FLAMAND L, 1991, J VIROL, V65, P5105, DOI 10.1128/JVI.65.9.5105-5110.1991; GHAZAL P, 1991, J VIROL, V65, P6735, DOI 10.1128/JVI.65.12.6735-6742.1991; GOMPELS UA, 1995, VIROLOGY, V209, P29, DOI 10.1006/viro.1995.1228; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Grivel JC, 1999, NAT MED, V5, P344, DOI 10.1038/6565; HALL CB, 1994, NEW ENGL J MED, V331, P432, DOI 10.1056/NEJM199408183310703; Hofmann H, 2000, J VIROL, V74, P2510, DOI 10.1128/JVI.74.6.2510-2524.2000; HORVAT RT, 1991, J VIROL, V65, P2895, DOI 10.1128/JVI.65.6.2895-2902.1991; HUANG LM, 1991, ARCH DIS CHILD, V66, P1443, DOI 10.1136/adc.66.12.1443; HUANG LM, 1990, LANCET, V336, P60, DOI 10.1016/0140-6736(90)91580-4; Isegawa Y, 1999, J VIROL, V73, P8053, DOI 10.1128/JVI.73.10.8053-8063.1999; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; Ishov AM, 1997, J CELL BIOL, V138, P5, DOI 10.1083/jcb.138.1.5; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1998, J BIOL CHEM, V273, P11349, DOI 10.1074/jbc.273.18.11349; Kasolo FC, 1997, J GEN VIROL, V78, P847, DOI 10.1099/0022-1317-78-4-847; KELLY C, 1995, J GEN VIROL, V76, P2887, DOI 10.1099/0022-1317-76-11-2887; Korioth F, 1996, EXP CELL RES, V229, P155, DOI 10.1006/excr.1996.0353; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lapenta V, 1997, GENOMICS, V40, P362, DOI 10.1006/geno.1996.4556; LAVAU C, 1995, ONCOGENE, V11, P871; LIU B, 1992, J VIROL, V66, P4434, DOI 10.1128/JVI.66.7.4434-4444.1992; LOPEZ C, 1988, J INFECT DIS, V157, P1271, DOI 10.1093/infdis/157.6.1271; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; MARTIN MED, 1991, J VIROL, V65, P5381, DOI 10.1128/JVI.65.10.5381-5390.1991; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; Maul GG, 1996, VIROLOGY, V217, P67, DOI 10.1006/viro.1996.0094; Muller S, 1999, J VIROL, V73, P5137; NICHOLAS J, 1994, VIROLOGY, V204, P738, DOI 10.1006/viro.1994.1589; PREZIOSO PJ, 1992, J PEDIATR-US, V120, P921, DOI 10.1016/S0022-3476(05)81962-6; Regad T, 2001, EMBO J, V20, P3495, DOI 10.1093/emboj/20.13.3495; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; Santoro F, 1999, CELL, V99, P817, DOI 10.1016/S0092-8674(00)81678-5; SCHIEWE U, 1994, J VIROL, V68, P2978, DOI 10.1128/JVI.68.5.2978-2985.1994; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Soldan SS, 1997, NAT MED, V3, P1394, DOI 10.1038/nm1297-1394; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Takeda K, 1996, VIRUS RES, V41, P193, DOI 10.1016/0168-1702(96)01287-7; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Xu YX, 2001, J VIROL, V75, P10683, DOI 10.1128/JVI.75.22.10683-10695.2001; YAMANISHI K, 1988, LANCET, V1, P1065; YEUNG KC, 1993, VIROLOGY, V195, P786, DOI 10.1006/viro.1993.1431; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	77	46	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19679	19687		10.1074/jbc.M200836200	http://dx.doi.org/10.1074/jbc.M200836200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11901159	hybrid			2022-12-25	WOS:000175894800059
J	Richard, E; Alam, SM; Arredondo-Vega, FX; Patel, DD; Hershfield, MS				Richard, E; Alam, SM; Arredondo-Vega, FX; Patel, DD; Hershfield, MS			Clustered charged amino acids of human adenosine deaminase comprise a functional epitope for binding the adenosine deaminase complexing protein CD26/dipeptidyl peptidase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; T-CELL ACTIVATION; HUMAN CD26; COMBINED IMMUNODEFICIENCY; ENZYMATIC-ACTIVITY; IMMUNE-RESPONSE; HOT-SPOTS; DEFICIENCY; INTERFACES; ANTIGEN	Human adenosine deaminase (ADA) occurs as a 41-kDa soluble monomer in all cells. On epithelia and lymphoid cells of humans, but not mice, ADA also occurs bound to the membrane glycoprotein CD26/dipeptidyl peptidase IV. This "ecto-ADA" has been postulated to regulate extracellular Ado levels, and also the function of CD26 as a co-stimulator of activated T cells. The CD26-binding site of human ADA has been localized by homolog scanning to the peripheral alpha2-helix (amino acids 126-143). Among the 5 non-conserved residues within this segment, Arg-142 in human and Gln-142 in mouse ADA largely determined the capacity for stable binding to CD26 (Richard, E., Arredondo-Vega, F. X., Santisteban, I., Kelly, S. J., Patel, D. D., and Hershfield, M. S. (2000) J. Exp. Med. 192, 1223-1235). We have now mutagenized conserved alpha2-helix residues in human and mouse ADA and used surface plasmon resonance to evaluate binding kinetics to immobilized rabbit CD26. In addition to Arg-142, we found that Glu-139 and Asp-143 of human ADA are also important for CD26 binding. Mutating these residues to alanine increased dissociation rates 6-11-fold and the apparent dissociation constant K-D for wild type human ADA from 17 to 112-160 nM, changing binding free energy by 1.1-1.3 kcal/mol. This cluster of 3 charged residues appears to be a "functional epitope" that accounts for about half of the difference between human and mouse ADA in free energy of binding to CD26.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Hershfield, MS (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 3049, Durham, NC 27710 USA.	msh@biochem.duke.edu	Alam, S. Munir/AAC-6711-2019	Richard Rodriguez, Eva Maria/0000-0001-9711-1417	NIAID NIH HHS [R01 AI47604] Funding Source: Medline; NIDDK NIH HHS [R01 DK20902] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047604] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020902] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott CA, 1999, EUR J BIOCHEM, V266, P798, DOI 10.1046/j.1432-1327.1999.00902.x; ANDY RJ, 1982, J BIOL CHEM, V257, P7922; Arredondo-Vega FX, 1998, AM J HUM GENET, V63, P1049, DOI 10.1086/302054; ARREDONDOVEGA FX, 1990, J CLIN INVEST, V86, P444, DOI 10.1172/JCI114730; Blanco J, 1996, EXP CELL RES, V225, P102, DOI 10.1006/excr.1996.0161; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BRIGHAMBURKE M, 1992, ANAL BIOCHEM, V205, P125, DOI 10.1016/0003-2697(92)90588-X; BRISTOL LA, 1992, J IMMUNOL, V149, P367; CHANG Z, 1991, BIOCHEMISTRY-US, V30, P2273, DOI 10.1021/bi00222a033; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DADDONA PE, 1978, J BIOL CHEM, V253, P4617; DeMeester I, 1996, J IMMUNOL METHODS, V189, P99, DOI 10.1016/0022-1759(95)00239-1; DINJENS WNM, 1989, J BIOL CHEM, V264, P19215; Dong RP, 1997, J IMMUNOL, V159, P6070; Dong RP, 1996, J IMMUNOL, V156, P1349; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; Franco R, 1998, IMMUNOL REV, V161, P27, DOI 10.1111/j.1600-065X.1998.tb01569.x; GIBLETT ER, 1972, LANCET, V2, P1067; Hershfield MS., 2001, METABOLIC MOL BASES, V8th, P2585; Hu ZJ, 2000, PROTEINS, V39, P331, DOI 10.1002/(SICI)1097-0134(20000601)39:4<331::AID-PROT60>3.0.CO;2-A; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; Lackmann M, 1998, GROWTH FACTORS, V16, P39, DOI 10.3109/08977199809017490; LEE KH, 1994, PROTEINS, V20, P68, DOI 10.1002/prot.340200108; Li YL, 2000, BIOCHEMISTRY-US, V39, P6296, DOI 10.1021/bi000054l; Marguet D, 2000, P NATL ACAD SCI USA, V97, P6874, DOI 10.1073/pnas.120069197; MARTIN M, 1995, J IMMUNOL, V155, P4630; Morimoto C, 1998, IMMUNOL REV, V161, P55, DOI 10.1111/j.1600-065X.1998.tb01571.x; MORRISON ME, 1993, J EXP MED, V177, P1135, DOI 10.1084/jem.177.4.1135; NISHIHARA H, 1973, BIOCHIM BIOPHYS ACTA, V302, P429, DOI 10.1016/0005-2744(73)90172-1; Rich RL, 2000, J MOL RECOGNIT, V13, P388, DOI 10.1002/1099-1352(200011/12)13:6<388::AID-JMR516>3.0.CO;2-#; Richard E, 2000, J EXP MED, V192, P1223, DOI 10.1084/jem.192.9.1223; SANTISTEBAN I, 1995, HUM MOL GENET, V4, P2081, DOI 10.1093/hmg/4.11.2081; SANTISTEBAN I, 1993, J CLIN INVEST, V92, P2291, DOI 10.1172/JCI116833; SCHRADER WP, 1990, J BIOL CHEM, V265, P19312; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; STEEG C, 1995, CELL IMMUNOL, V164, P311, DOI 10.1006/cimm.1995.1175; TANAKA T, 1993, P NATL ACAD SCI USA, V90, P4586, DOI 10.1073/pnas.90.10.4586; TIRUPPATHI C, 1990, J BIOL CHEM, V265, P1476; TIRUPPATHI C, 1993, AM J PHYSIOL, V265, pG81, DOI 10.1152/ajpgi.1993.265.1.G81; TROTTA PP, 1978, MOL PHARMACOL, V14, P199; Tsai CJ, 1997, PROTEIN SCI, V6, P53; VIVIER I, 1991, J IMMUNOL, V147, P447; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; YOUNG L, 1994, PROTEIN SCI, V3, P717	49	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19720	19726		10.1074/jbc.M111901200	http://dx.doi.org/10.1074/jbc.M111901200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11901152	hybrid			2022-12-25	WOS:000175894800064
J	Hanzelmann, P; Schwarz, G; Mendel, RR				Hanzelmann, P; Schwarz, G; Mendel, RR			Functionality of alternative splice forms of the first enzymes involved in human molybdenum cofactor biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLYBDOPTERIN SYNTHASE; ARTHROBACTER NICOTINOVORANS; UBIQUITIN ACTIVATION; RADICAL MECHANISMS; CONVERTING FACTOR; CRYSTAL-STRUCTURE; READING FRAMES; EARLY STEPS; PRECURSOR-Z	In humans, genetic deficiencies of enzymes involved in molybdenum cofactor biosynthesis trigger an autosomal recessive and usually fatal disease with severe mostly neurological symptoms. In each of the three biosynthesis steps, at least two proteins or domains are linked for catalysis. For steps 1 and 2, bicistronic mocs (molybdenum cofactor synthesis) mRNAs were found (mocs1 and mocs2) that have been proposed to encode two separate proteins (A and B). In both cases, the A proteins share a highly conserved ubiquitin-like double glycine motif, which is functionally important at least for the small subunit of molybdopterin (MPT) synthase (MOCS2A). Besides the bicistronic form of mocs1, two alternative splice transcripts were found, resulting in the expression of multidomain proteins embodying both MOCS1A, but without the double glycine motif, and the entire MOCS1B. Here we describe the first functional characterization of the human proteins MOCS1A and MOCS1B as well as the MOCS1A-MOCS1B fusion proteins that catalyze the formation of precursor Z, a 6-alkyl pterin with a cyclic phosphate, the immediate precursor of MPT in molybdenum cofactor biosynthesis. High level expression of MOCS1A and MOCS1B in Escherichia coli resulted in the formation and accumulation of precursor Z that was subsequently converted to MPT. We showed that for catalytic activity MOCS1A needs an accessible C-terminal double glycine motif. In the MOCS1A-MOCS1B fusion proteins lacking the MOCS1A double glycines, only MOCS1B activity could be detected. No evidence was found for an expression of MOCS1B from the bicistronic mocs1A-mocs1B splice type I cDNA, indicating that MOCS1B is only expressed as a fusion to an inactive MOCS1A. Comparative mutational studies of MOCS1A and the small subunit of the E. coli MPT synthase (MoaD) indicate a different function of the double glycine motifs in both proteins.	Tech Univ Carolo Wilhelmina Braunschweig, Inst Plant Biol, D-38023 Braunschweig, Germany	Braunschweig University of Technology	Mendel, RR (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Plant Biol, D-38023 Braunschweig, Germany.		Schwarz, Guenter/ABE-9643-2021	Schwarz, Guenter/0000-0002-2118-9338				Bacher A., 1991, CHEM BIOCH FLAVOPROT, P215; BAKER KP, 1991, MOL MICROBIOL, V5, P901, DOI 10.1111/j.1365-2958.1991.tb00764.x; Begley TP, 1999, CURR OPIN CHEM BIOL, V3, P623, DOI 10.1016/S1367-5931(99)00018-6; BROWN GM, 1985, FOLATES PTERINS, V2, P299; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Cheek J, 2001, J BIOL INORG CHEM, V6, P209, DOI 10.1007/s007750100210; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; Frey PA, 2001, ANNU REV BIOCHEM, V70, P121, DOI 10.1146/annurev.biochem.70.1.121; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gray TA, 2000, RNA, V6, P928, DOI 10.1017/S1355838200000182; Gutzke G, 2001, J BIOL CHEM, V276, P36268, DOI 10.1074/jbc.M105321200; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFF T, 1995, J BIOL CHEM, V270, P6100, DOI 10.1074/jbc.270.11.6100; JOHNSON JL, 1993, ADV EXP MED BIOL, V338, P373; JOHNSON JL, 1989, J CLIN INVEST, V83, P897, DOI 10.1172/JCI113974; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; Kisker C, 1998, FEMS MICROBIOL REV, V22, P503, DOI 10.1016/S0168-6445(98)00040-0; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; Leimkuhler S, 2001, J BIOL CHEM, V276, P34695, DOI 10.1074/jbc.M102787200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACGREGOR CH, 1974, J BIOL CHEM, V249, P5321; Menendez C, 1996, FEBS LETT, V391, P101, DOI 10.1016/0014-5793(96)00712-0; MENENDEZ C, 1995, ARCH MICROBIOL, V164, P142, DOI 10.1007/s002030050246; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; RAJAGOPALAN KV, 1996, ESCHERICHIA COLI SAL, P674; REISS J, 1987, MOL GEN GENET, V206, P352, DOI 10.1007/BF00333594; Reiss J, 2000, HUM GENET, V106, P157, DOI 10.1007/s004390051023; Reiss J, 1998, NAT GENET, V20, P51, DOI 10.1038/1706; Reiss J, 1998, HUM GENET, V103, P639, DOI 10.1007/s004390050884; Reiss J, 2001, AM J HUM GENET, V68, P208, DOI 10.1086/316941; Rieder C, 1998, EUR J BIOCHEM, V255, P24, DOI 10.1046/j.1432-1327.1998.2550024.x; RIVERS SL, 1993, MOL MICROBIOL, V8, P1071, DOI 10.1111/j.1365-2958.1993.tb01652.x; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Solomon PS, 1999, MICROBIOL-UK, V145, P1421, DOI 10.1099/13500872-145-6-1421; Stallmeyer B, 1999, AM J HUM GENET, V64, P698, DOI 10.1086/302295; Stallmeyer B, 1999, P NATL ACAD SCI USA, V96, P1333, DOI 10.1073/pnas.96.4.1333; Unkles SE, 1997, J BIOL CHEM, V272, P28381, DOI 10.1074/jbc.272.45.28381; WUEBBENS MM, 1993, J BIOL CHEM, V268, P13493; Wuebbens MM, 2000, STRUCTURE, V8, P709, DOI 10.1016/S0969-2126(00)00157-X; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082	45	55	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18303	18312		10.1074/jbc.M200947200	http://dx.doi.org/10.1074/jbc.M200947200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11891227	hybrid			2022-12-25	WOS:000175975800009
J	Panopoulos, AD; Bartos, D; Zhang, L; Watowich, SS				Panopoulos, AD; Bartos, D; Zhang, L; Watowich, SS			Control of myeloid-specific integrin alpha(M)beta(2) (CD11b/CD18) expression by cytokines is regulated by Stat3-dependent activation of PU.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; G-CSF RECEPTOR; HEMATOPOIETIC PROGENITOR CELLS; GRANULOCYTIC DIFFERENTIATION; DEPENDENT PROLIFERATION; TRANSCRIPTION FACTORS; TARGETED DISRUPTION; GENE-EXPRESSION; BONE-MARROW; IN-VIVO	Granulocyte colony-stimulating factor (G-CSF) plays an essential role in regulating multiple aspects of hematopoiesis. To elucidate the role of G-CSF in controlling hematopoietic cell migration capabilities, we studied inducible expression of the myeloid-specific marker, integrin alpha(M)beta(2) (CD11b/CD18, Mac-1), in the myeloid cell line, 32D. We found that G-CSF stimulates the synthesis and cell surface expression of alpha(M) and beta(2) integrin subunits. Induction of both alpha(M) and beta(2) is dependent on Stat3, a major G-CSF-responsive signaling protein. However, the kinetics of expression suggested the involvement of an intermediate protein regulated by Stat3. Our results demonstrate that Stat3 signaling stimulates the expression of PU.1, a critical regulator of myelopoiesis. Furthermore, we show that PU.1 is an essential intermediate for the inducible expression of alpha(M)beta(2) integrin. Thus, Stat3 promotes alpha(M)beta(2) integrin expression through its activation of PU.1. These findings indicate that G-CSF-dependent Stat3 signals stimulate the changes in cell adhesion and migration capabilities that occur during myeloid cell development. These data also demonstrate a link between Stat3 and PU.1, suggesting that Stat3 may play an instructive role in hematopoiesis.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Watowich, SS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Box 178,1515 Holcombe Blvd, Houston, TX 77030 USA.			Panopoulos, Athanasia/0000-0002-9610-2604; Watowich, Stephanie/0000-0003-1969-659X	NCI NIH HHS [CA 77447, R01 CA077447-03, R01 CA077447-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077447] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KL, 1999, BLOOD, V94, P2310, DOI 10.1182/blood.V94.7.2310.419k34_2310_2318; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Betsuyaku T, 1999, J CLIN INVEST, V103, P825, DOI 10.1172/JCI5191; CHEN HM, 1995, ONCOGENE, V11, P1549; Cheng T, 1996, P NATL ACAD SCI USA, V93, P13158, DOI 10.1073/pnas.93.23.13158; de Koning JP, 1998, BLOOD, V91, P1924, DOI 10.1182/blood.V91.6.1924.1924_1924_1933; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; DUHRSEN U, 1988, BLOOD, V72, P2074; Etzioni A, 1999, BLOOD, V94, P3281, DOI 10.1182/blood.V94.10.3281.422k37_3281_3288; Faust N, 2000, BLOOD, V96, P719; Fisher RC, 1999, BLOOD, V94, P1283, DOI 10.1182/blood.V94.4.1283.416k16_1283_1290; Goldsmith MA, 1998, P NATL ACAD SCI USA, V95, P7006, DOI 10.1073/pnas.95.12.7006; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Klemsz MJ, 1996, MOL CELL BIOL, V16, P390; Levesque JP, 2001, BLOOD, V98, P1289, DOI 10.1182/blood.V98.5.1289; Li YL, 2001, BLOOD, V98, P2958, DOI 10.1182/blood.V98.10.2958; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Liu FL, 2000, BLOOD, V95, P3025, DOI 10.1182/blood.V95.10.3025.010k32_3025_3031; Liu FL, 1996, IMMUNITY, V5, P491, DOI 10.1016/S1074-7613(00)80504-X; Longmore GD, 1998, BLOOD, V91, P870, DOI 10.1182/blood.V91.3.870.870_870_878; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; McLemore ML, 1998, J CLIN INVEST, V102, P483, DOI 10.1172/JCI3216; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; Nakajima H, 2001, BLOOD, V98, P897, DOI 10.1182/blood.V98.4.897; Nicholson SE, 1996, J BIOL CHEM, V271, P26947, DOI 10.1074/jbc.271.43.26947; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Semerad CL, 1999, IMMUNITY, V11, P153, DOI 10.1016/S1074-7613(00)80090-4; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Welte K, 1996, BLOOD, V88, P1907, DOI 10.1182/blood.V88.6.1907.bloodjournal8861907; Wooten DK, 2000, J BIOL CHEM, V275, P26566, DOI 10.1074/jbc.M003495200	41	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19001	19007		10.1074/jbc.M112271200	http://dx.doi.org/10.1074/jbc.M112271200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889125	Green Accepted, hybrid			2022-12-25	WOS:000175975800099
J	Roepstorff, K; Thomsen, P; Sandvig, K; van Deurs, B				Roepstorff, K; Thomsen, P; Sandvig, K; van Deurs, B			Sequestration of epidermal growth factor receptors in non-caveolar lipid rafts inhibits ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL DEPLETION; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; DOMAINS; KINASE; GANGLIOSIDE; ACTIVATION; TYROSINE	Cholesterol depletion has been shown to increase mitogen-activated protein kinase activation in response to stimulation with epidermal growth factor (EGF) (Furuchi, T., and Anderson, R. G. W. (1998) J. Biol. Chem. 273,21099-21104). However, the underlying mechanisms are unknown. We show that cholesterol depletion increases EGF binding, whereas cholesterol loading lowers EGF binding. Based on binding analyses, we demonstrate that the observed changes in EGF binding are caused by alterations in the number of EGF receptors available for ligand binding, whereas the affinity of the receptor for EGF remains unaltered. We also show by immunofluorescence that in unstimulated cells the EGF receptor is localized in non-caveolar lipid rafts containing the ganglioside GM1 and that patching of these rafts by cholera toxin B-chain causes co-patching of EGF receptors. Experiments with solubilization in different detergents at 4 degreesC show that the association of the EGF receptor with these rafts is sensitive to Triton X-100 extraction but insensitive to extraction with another non-ionic detergent, Brij 58. Furthermore, experiments with cholesterol-depleted cells show that the association is cholesterol-dependent. We propose that non-caveolar lipid rafts function as negative regulators of EGF receptor signaling by sequestering a fraction of the EGF receptors in a state inaccessible for ligand binding.	Univ Copenhagen, Panum Inst, Dept Med Anat, Struct Cell Biol Unit, DK-2200 Copenhagen N, Denmark; Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway	University of Copenhagen; University of Oslo	van Deurs, B (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Anat, Struct Cell Biol Unit, DK-2200 Copenhagen N, Denmark.							Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; Grimmer S, 2000, MOL BIOL CELL, V11, P4205, DOI 10.1091/mbc.11.12.4205; Hailstones D, 1998, J LIPID RES, V39, P369; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Jang IH, 2001, FEBS LETT, V491, P4, DOI 10.1016/S0014-5793(01)02165-2; Lang DM, 1998, J NEUROBIOL, V37, P502, DOI 10.1002/(SICI)1097-4695(199812)37:4<502::AID-NEU2>3.0.CO;2-S; Miljan EA, 2002, J BIOL CHEM, V277, P10108, DOI 10.1074/jbc.M111669200; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Mobius W, 1999, J HISTOCHEM CYTOCHEM, V47, P1005; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Pang L, 1999, BIOCHEMISTRY-US, V38, P12003, DOI 10.1021/bi990227a; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Schlegel A, 2001, CYTOKINE GROWTH F R, V12, P41, DOI 10.1016/S1359-6101(00)00022-8; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Wang XQ, 2001, J INVEST DERMATOL, V116, P69, DOI 10.1046/j.1523-1747.2001.00222.x; Waugh MG, 1999, BIOCHEM J, V337, P591, DOI 10.1042/0264-6021:3370591	23	153	157	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18954	18960		10.1074/jbc.M201422200	http://dx.doi.org/10.1074/jbc.M201422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886870	hybrid			2022-12-25	WOS:000175975800092
J	Vlasie, M; Chowdhury, S; Banerjee, R				Vlasie, M; Chowdhury, S; Banerjee, R			Importance of the histidine ligand to coenzyme B-12 in the reaction catalyzed by methylmalonyl-CoA mutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COBALT-CARBON BOND; X-RAY STRUCTURE; GLUTAMATE MUTASE; C-BOND; CLOSTRIDIUM-TETANOMORPHUM; B-12-BINDING SUBUNIT; METHIONINE SYNTHASE; DIOL DEHYDRATASE; LONG COBALT; A MUTASE	Methylmalonyl-CoA mutase is an adenosylcobalamin (AdoCbl)-dependent enzyme that catalyzes the rearrangement of methylmalonyl-CoA to succinyl-CoA. The crystal structure of this protein revealed that binding of the cofactor is accompanied by a significant conformational change in which dimethylbenzimidazole, the lower axial ligand to the cobalt in solution, is replaced by His-610 donated by the active site. The contribution of the lower axial base to the similar to10(12)-fold rate acceleration of the homolytic cleavage of the upper axial cobalt-carbon bond has been the subject of intense scrutiny in the model inorganic literature. In contrast, trans ligand effects in methylmalonyl-CoA mutase and indeed the significance of the ligand replacement are poorly understood. In this study, we have used site-directed mutagenesis to create the H610A and H610N variants of methylmalonyl-CoA mutase and report that both mutations exhibit both diminished activity (5,000- and 40,000-fold, respectively) and profoundly weakened affinity for the native cofactor, AdoCbl. In contrast, binding of the truncated cofactor analog, adenosylcobinamide, lacking the nucleotide tail, is less impaired. The catalytic failure of the His-610 mutants is in marked contrast to the phenotype of the adenosylcobinamide-GDP reconstituted wild type enzyme that exhibits only a 4-fold decrease in activity, although His-610 fails to coordinate when this cofactor analog is bound. Together, these studies suggest that His-610 may: (i) play a structural role in organizing a high affinity cofactor binding site possibly via electrostatic interactions with Asp-608 and Lys-604, as suggested by the crystal structure and (ii) play a role in catalyzing the displacement of dimethylbenzimidazole thereby facilitating the conformational change that must precede cofactor docking to the mutase active site.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045776, R29DK045776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abend A, 1999, ARCH BIOCHEM BIOPHYS, V370, P138, DOI 10.1006/abbi.1999.1382; Banerjee R, 2001, BIOCHEMISTRY-US, V40, P6191, DOI 10.1021/bi0104423; BROWN KL, 1984, J AM CHEM SOC, V106, P7894, DOI 10.1021/ja00337a043; BROWN KL, 1991, INORG CHEM, V30, P3420, DOI 10.1021/ic00018a011; CHEMALY SM, 1980, J CHEM SOC DALTON, P2274, DOI 10.1039/dt9800002274; Chen HP, 1997, BIOCHEMISTRY-US, V36, P7884, DOI 10.1021/bi970169y; Chowdhury S, 2000, BIOCHEMISTRY-US, V39, P7998, DOI 10.1021/bi992535e; Chowdhury S, 1999, BIOCHEMISTRY-US, V38, P15287, DOI 10.1021/bi9914762; Chowdhury S, 2001, J BIOL CHEM, V276, P1015, DOI 10.1074/jbc.M006842200; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; Garr CD, 1996, INORG CHEM, V35, P5912, DOI 10.1021/ic951272j; GENO MK, 1987, J AM CHEM SOC, V109, P1238, DOI 10.1021/ja00238a039; GRATE JH, 1979, J AM CHEM SOC, V101, P4601, DOI 10.1021/ja00510a027; HAY BP, 1987, J AM CHEM SOC, V109, P8012, DOI 10.1021/ja00260a011; HAY BP, 1988, POLYHEDRON, V7, P1469, DOI 10.1016/S0277-5387(00)81775-1; ISHIDA A, 1993, BIOCHEMISTRY-US, V32, P1535, DOI 10.1021/bi00057a018; Jarrett JT, 1996, BIOCHEMISTRY-US, V35, P2464, DOI 10.1021/bi952389m; Lawrence CC, 1999, J BIOL CHEM, V274, P7039, DOI 10.1074/jbc.274.11.7039; LENHERT PG, 1961, NATURE, V192, P937, DOI 10.1038/192937a0; Maiti N, 1999, J BIOL CHEM, V274, P32733, DOI 10.1074/jbc.274.46.32733; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; MARZILLI LG, 1979, J AM CHEM SOC, V101, P6754, DOI 10.1021/ja00516a049; MCKIE N, 1990, BIOCHEM J, V269, P293, DOI 10.1042/bj2690293; NG FTT, 1982, J AM CHEM SOC, V104, P621, DOI 10.1021/ja00366a045; PADMAKUMAR R, 1995, J BIOL CHEM, V270, P9295, DOI 10.1074/jbc.270.16.9295; Padmakumar R, 1997, BIOCHEMISTRY-US, V36, P3713, DOI 10.1021/bi962503g; RANDACCIO L, 1980, J AM CHEM SOC, V102, P7373; Reitzer R, 1999, STRUCTURE, V7, P891, DOI 10.1016/S0969-2126(99)80116-6; Shibata N, 1999, STRUCTURE, V7, P997, DOI 10.1016/S0969-2126(99)80126-9; Sirovatka JM, 1997, J AM CHEM SOC, V119, P3057, DOI 10.1021/ja963380q; STUPPERICH E, 1990, EUR J BIOCHEM, V193, P105, DOI 10.1111/j.1432-1033.1990.tb19310.x; SUMMERS MF, 1983, J AM CHEM SOC, V105, P6259, DOI 10.1021/ja00358a012; TAOKA S, 1994, J BIOL CHEM, V269, P31630; Tollinger M, 1998, STRUCTURE, V6, P1021, DOI 10.1016/S0969-2126(98)00103-8; Tollinger M, 2001, J MOL BIOL, V309, P777, DOI 10.1006/jmbi.2001.4696; WADDINGTON MD, 1993, J AM CHEM SOC, V115, P4629, DOI 10.1021/ja00064a026; Yamanishi M, 1998, BIOCHEMISTRY-US, V37, P4799, DOI 10.1021/bi972572a; [No title captured]	38	21	21	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18523	18527		10.1074/jbc.M111809200	http://dx.doi.org/10.1074/jbc.M111809200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893736	hybrid			2022-12-25	WOS:000175975800037
J	Wang, J; Vock, VM; Li, SL; Olivas, OR; Wilkinson, MF				Wang, J; Vock, VM; Li, SL; Olivas, OR; Wilkinson, MF			A quality control pathway that down-regulates aberrant T-cell receptor (TCR) transcripts by a mechanism requiring UPF2 and translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DECAY; NONSENSE CODONS; GENE-EXPRESSION; MEDIATED DECAY; IN-VIVO; SURVEILLANCE; SEQUENCES; NUCLEAR; TERMINATION; INITIATION	Nonsense-mediated decay (NMD) is an RNA surveillance pathway that degrades mRNAs containing premature termination codons (PTC). T-cell receptor (TCR) and immunoglobulin (Ig) transcripts, which are encoded by genes that very frequently acquire PTCs during lymphoid ontogeny, are down-regulated much more dramatically in response to PTCs than are other known transcripts. Another feature unique to TCR, Ig, and a subset of other mRNAs is that they are down-regulated in response to nonsense codons in the nuclear fraction of cells. This is paradoxical, as the only well recognized entity that recognizes nonsense codons is the cytoplasmic translation apparatus. Therefore, we investigated whether translation is responsible for this nuclear-associated mechanism. We found that the down-regulation of TCR-beta transcripts in response to nonsense codons requires several features of translation, including an initiator ATG and the ability to scan. We also found that optimal down-regulation depends on a Kozak consensus sequence surrounding the initiator ATG and that it can be initiated by an internal ribosome entry site, neither of which has been demonstrated before for any other PTC-bearing mRNA. At least a portion of this down-regulatory response is mediated by the NMD pathway as antisense hUPF2 transcripts increased the levels of PTC-bearing TCR-beta transcripts in the nuclear fraction of cells. We conclude that a hUPF2-dependent RNA surveillance pathway with translation-like features operating in the nuclear fraction of cells prevents the expression of potentially deleterious truncated proteins encoded by non-productively rearranged TCR genes.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Wilkinson, MF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Box 180,1515 Holcombe Blvd, Houston, TX 77030 USA.	mwilkins@mail.mdanderson.org	Li, Shulin/D-6478-2011		NIGMS NIH HHS [GM 58595] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058595] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARKER GF, 1994, MOL CELL BIOL, V14, P1986, DOI 10.1128/MCB.14.3.1986; BELGRADER P, 1993, P NATL ACAD SCI USA, V90, P482, DOI 10.1073/pnas.90.2.482; Buzina A, 1999, MOL BIOL CELL, V10, P515, DOI 10.1091/mbc.10.3.515; Carter MS, 2000, COLD SPRING HARBOR M, V39, P615; Carter MS, 1996, EMBO J, V15, P5965, DOI 10.1002/j.1460-2075.1996.tb00983.x; CARTER MS, 1995, J BIOL CHEM, V270, P28995, DOI 10.1074/jbc.270.48.28995; CONNOR A, 1994, J BIOL CHEM, V269, P25178; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; DIRKS W, 1993, GENE, V128, P247, DOI 10.1016/0378-1119(93)90569-O; Dostie J, 2000, J CELL BIOL, V148, P239, DOI 10.1083/jcb.148.2.239; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; Gonzalez CI, 2001, GENE, V274, P15, DOI 10.1016/S0378-1119(01)00552-2; Gudikote JP, 2002, EMBO J, V21, P125, DOI 10.1093/emboj/21.1.125; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Hennecke M, 2001, NUCLEIC ACIDS RES, V29, P3327, DOI 10.1093/nar/29.16.3327; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hilleren P, 1999, RNA, V5, P711, DOI 10.1017/S1355838299990519; Iborra FJ, 2001, SCIENCE, V293, P1139, DOI 10.1126/science.1061216; Jacobson A, 2000, COLD SPRING HARBOR M, V39, P827; Kessler O, 1996, MOL CELL BIOL, V16, P4426; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Li SL, 1997, J EXP MED, V185, P985, DOI 10.1084/jem.185.6.985; Li SL, 1998, IMMUNITY, V8, P135, DOI 10.1016/S1074-7613(00)80466-5; LOZANO F, 1994, EMBO J, V13, P4617, DOI 10.1002/j.1460-2075.1994.tb06783.x; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; Maquat LE, 2000, COLD SPRING HARBOR M, V39, P849; MEEROVITCH K, 1991, J VIROL, V65, P5895, DOI 10.1128/JVI.65.11.5895-5901.1991; Mendell JT, 2000, MOL CELL BIOL, V20, P8944, DOI 10.1128/MCB.20.23.8944-8957.2000; Moriarty PM, 1998, MOL CELL BIOL, V18, P2932, DOI 10.1128/MCB.18.5.2932; Muhlemann O, 2001, MOL CELL, V8, P33, DOI 10.1016/S1097-2765(01)00288-X; Noensie EN, 2001, NAT BIOTECHNOL, V19, P434, DOI 10.1038/88099; PELLETIER J, 1988, MOL CELL BIOL, V8, P1103, DOI 10.1128/MCB.8.3.1103; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; QIAN L, 1993, J IMMUNOL, V151, P6801; SARNOW P, 1989, J VIROL, V63, P467, DOI 10.1128/JVI.63.1.467-470.1989; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; Thermann R, 1998, EMBO J, V17, P3484, DOI 10.1093/emboj/17.12.3484; TRONO D, 1988, SCIENCE, V241, P445, DOI 10.1126/science.2839901; Wang J, 2000, BIOTECHNIQUES, V29, P976, DOI 10.2144/00295bm09; Wang J, 2002, EMBO REP, V3, P274, DOI 10.1093/embo-reports/kvf036; WHITFIELD TT, 1994, DEV BIOL, V165, P731, DOI 10.1006/dbio.1994.1289; Wilkinson MF, 2001, BIOESSAYS, V23, P775, DOI 10.1002/bies.1113	42	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18489	18493		10.1074/jbc.M111781200	http://dx.doi.org/10.1074/jbc.M111781200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889124	hybrid			2022-12-25	WOS:000175975800032
J	Penheiter, AR; Caride, AJ; Enyedi, A; Penniston, JT				Penheiter, AR; Caride, AJ; Enyedi, A; Penniston, JT			Tryptophan 1093 is largely responsible for the slow off rate of calmodulin from plasma membrane Ca2+ pump 4b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; CALCIUM-PUMP; CA-2+ PUMP; COMPLEX; RECOGNITION; ACTIVATION; PEPTIDE; CELLS; 2B	Tryptophan 1093 resides in the 28-residue calmodulin-binding/autoinhibitory domain of the plasma membrane Ca2+ pump (PMCA). Previous studies with the isolated calmodulin-binding/autoinhibitory peptide from PMCA have shown that mutations of the tryptophan residue decrease the affinity of the peptide for calmodulin and its affinity as an inhibitor of proteolytically activated pump. In this study, the PMCA mutation in which tryptophan 1093 is converted to alanine (W1093A) was constructed in the full-length PMCA isoform 4b. The mutant pump was expressed in COS cells, and its steady state and pre-steady state kinetic properties were examined. The W1093A pump exhibited an increased basal activity in the absence of calmodulin, so the activation was similar to2-fold (it is 10-fold in the wild type). The W1093A mutation also lowered the steady state affinity for calmodulin from K-0.5 of 9 nM for wild type to 144 nM (assayed at 700 nM free Ca2+). Pre-steady state measurements of the rate of activation by Ca2+-calmodulin revealed that the W1093A mutant responded 2.5-fold faster to calmodulin. In contrast to these relatively modest effects, the half-time of inactivation of the mutant was reduced by more than 2 orders of magnitude from 41 min to 7 s. We conclude that tryptophan 1093 does not play a substantial role in Ca2+-calmodulin recognition; rather it functions primarily to slow the inactivation of the calmodulin-activated pump.	Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Natl Inst Haematol & Immunol, H-1113 Budapest, Hungary	Mayo Clinic	Penniston, JT (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.		Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376	NIDCD NIH HHS [DC04200] Funding Source: Medline; NIGMS NIH HHS [GM28835] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004200] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; Caride AJ, 1999, J BIOL CHEM, V274, P35227, DOI 10.1074/jbc.274.49.35227; Caride AJ, 2001, J BIOL CHEM, V276, P39797, DOI 10.1074/jbc.M104380200; Caride AJ, 2001, CELL CALCIUM, V30, P49, DOI 10.1054/ceca.2001.0212; Elshorst B, 1999, BIOCHEMISTRY-US, V38, P12320, DOI 10.1021/bi9908235; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; ENYEDI A, 1993, J BIOL CHEM, V268, P17120; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; ENYEDI A, 1994, J BIOL CHEM, V269, P41; Filoteo AG, 2000, J BIOL CHEM, V275, P4323, DOI 10.1074/jbc.275.6.4323; IKURA M, 1992, CELL CALCIUM, V13, P391, DOI 10.1016/0143-4160(92)90052-T; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P6247, DOI 10.1021/bi00239a024; LINSE S, 1991, J BIOL CHEM, V266, P8050; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Verma AK, 1996, J BIOL CHEM, V271, P3714; VERMA AK, 1994, J BIOL CHEM, V269, P1687; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008	19	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17728	17732		10.1074/jbc.M111608200	http://dx.doi.org/10.1074/jbc.M111608200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11886854	hybrid			2022-12-25	WOS:000175685100044
J	Shakarian, AM; Joshi, MB; Ghedin, E; Dwyer, DM				Shakarian, AM; Joshi, MB; Ghedin, E; Dwyer, DM			Molecular dissection of the functional domains of a unique, tartrate-resistant, surface membrane acid phosphatase in the primitive human pathogen Leishmania donovani	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMASTIGOTES; AMASTIGOTES; MEXICANA; CLONING; PROTEIN; GENES	The primitive trypanosomatid pathogen of humans, Leishmania donovani, constitutively expresses a unique externally oriented, tartrate-resistant, acid phosphatase on its surface membrane. This is of interest because these organisms are obligate intracellular protozoan parasites that reside and multiply within the hydrolytic milieu of mammalian macrophage phago-lysosomes. Here we report the identification of the gene encoding this novel L. donovani enzyme. In addition, we characterized its structure, demonstrated its constitutive expression in both parasite developmental forms, and determined the cell surface membrane localization of its translated protein product. Further, we used a variety of green fluorescent protein chimeric constructs as reporters in a homologous leishmanial expression system to dissect the functional domains of this unique, tartrate-resistant, surface membrane enzyme.	NIAID, Cell Biol Sect, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; Salva Regina Univ, Dept Biol & Biomed Sci, Newport, RI 02840 USA; Inst Genom Res, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); J. Craig Venter Institute	Dwyer, DM (corresponding author), NIAID, Cell Biol Sect, Parasit Dis Lab, NIH, Bldg 4,Rm 126,4 Ctr Dr,MSC-0425, Bethesda, MD 20892 USA.		Ghedin, Elodie/Y-5654-2019	Ghedin, Elodie/0000-0002-1515-725X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000745, Z01AI000745, Z01AI000162] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATES PA, 1987, MOL BIOCHEM PARASIT, V26, P289, DOI 10.1016/0166-6851(87)90081-8; Clayton C, 1998, MOL BIOCHEM PARASIT, V97, P221, DOI 10.1016/S0166-6851(98)00115-7; DAS S, 1986, MOL BIOCHEM PARASIT, V20, P143, DOI 10.1016/0166-6851(86)90026-5; Debrabant A, 2000, J BIOL CHEM, V275, P16366, DOI 10.1074/jbc.M908725199; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DWYER DM, 1974, Z PARASITENKD, V43, P227, DOI 10.1007/BF00328879; Ellis SL, 1998, EXP PARASITOL, V89, P161, DOI 10.1006/expr.1998.4298; GBENLE GO, 1992, BIOCHEM J, V285, P41, DOI 10.1042/bj2850041; GOTTLIEB M, 1981, SCIENCE, V212, P939, DOI 10.1126/science.7233189; GOTTLIEB M, 1982, MOL CELL BIOL, V2, P76, DOI 10.1128/MCB.2.1.76; GOTTLIEB M, 1981, EXP PARASITOL, V52, P117, DOI 10.1016/0014-4894(81)90067-9; JOSHI M, 1993, MOL BIOCHEM PARASIT, V58, P345, DOI 10.1016/0166-6851(93)90057-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LaCount MW, 1998, J BIOL CHEM, V273, P30406, DOI 10.1074/jbc.273.46.30406; Lamp EC, 2000, LEUKEMIA LYMPHOMA, V39, P477, DOI 10.3109/10428190009113378; MCCARTHYBURKE C, 1991, EXP PARASITOL, V73, P385, DOI 10.1016/0014-4894(91)90112-A; McCombie W R, 1992, DNA Seq, V2, P289, DOI 10.3109/10425179209030961; Oddie GW, 2000, BONE, V27, P575, DOI 10.1016/S8756-3282(00)00368-9; REMALEY AT, 1985, J BIOL CHEM, V260, P880; SCHNEIDER G, 1993, EMBO J, V12, P2609, DOI 10.1002/j.1460-2075.1993.tb05921.x; Shakarian AM, 1997, GENE, V196, P127, DOI 10.1016/S0378-1119(97)00218-7; Shakarian AM, 1998, GENE, V208, P315, DOI 10.1016/S0378-1119(98)00011-0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; *UNDP WORLD BANK W, 1999, TROP DIS RES PROGR 1; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Wiese M, 1996, MOL BIOCHEM PARASIT, V82, P153, DOI 10.1016/0166-6851(96)02729-6; WIESE M, 1995, EMBO J, V14, P1067, DOI 10.1002/j.1460-2075.1995.tb07089.x; ZANG WW, 1996, MOL BIOCHEM PARASIT, V78, P79	28	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17994	18001		10.1074/jbc.M200114200	http://dx.doi.org/10.1074/jbc.M200114200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882658	hybrid			2022-12-25	WOS:000175685100077
J	Nomoto, M; Yamaguchi, R; Kohno, K; Kasai, H				Nomoto, M; Yamaguchi, R; Kohno, K; Kasai, H			Relations between clusters of oxidatively damaged nucleotides and active or open nucleosomes in the rat Nth 1 gene	ONCOGENE			English	Article						nucleotide damage; 8-hydroxyguanine; micrococcal nuclease; active or open nucleosomes; Nth 1 gene	POLYCYSTIC KIDNEY-DISEASE; SITE-SPECIFIC MUTAGENESIS; DNA-DAMAGE; FERRIC NITRILOTRIACETATE; TRANSCRIPTION FACTORS; IONIZING-RADIATION; RENAL CARCINOGEN; HUMAN HOMOLOG; 8-HYDROXYGUANINE; REPAIR	The distribution of oxidative damage to bases such as 8-hydroxyguanine (8-OH-Gua), was determined at the nucleotide level of resolution using the ligation-mediated PCR technique. Administration of a renal carcinogen, ferric nitrilotriacetate (Fe-NTA), is known to induce oxidative stress and subsequent formation of 8-OH-Gua in the kidney. Whole genomic DNA was isolated from the rat kidney with or without Fe-NTA treatment and then digested with formamidopyrimidine-DNA glycosylase (Fpg). As a target, we focused on the gene of a DNA repair enzyme for thymine glycol, Nth 1. Cleaved signals were found in exon 1 and exon 3, but not exon 5. Nucleosomes in these regions, enriched in damaged nucleotides, were highly accessible to micrococcal nuclease, especially in the kidney. Taking into account the function of the protein segment encoded by these regions, we discussed the molecular mechanism of the restricted formation of the damaged nucleotides.	Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahata Nishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Urol, Yahata Nishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Inst Ind Ecol Sci, Dept Environm Oncol, Yahata Nishi Ku, Kitakyushu, Fukuoka 8078555, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan	Nomoto, M (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahata Nishi Ku, Kitakyushu, Fukuoka 8078555, Japan.	m-nomoto@med.uoeh-u.ac.jp						AKMAN SA, 1991, MUTAT RES, V261, P123, DOI 10.1016/0165-1218(91)90058-T; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; AWAI M, 1979, AM J PATHOL, V95, P663; BASU AK, 1989, P NATL ACAD SCI USA, V86, P7677, DOI 10.1073/pnas.86.20.7677; Burn TC, 1996, GENOME RES, V6, P525, DOI 10.1101/gr.6.6.525; CHEN RH, 1992, P NATL ACAD SCI USA, V89, P5413, DOI 10.1073/pnas.89.12.5413; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHUNG MH, 1992, BIOCHEM BIOPH RES CO, V188, P1, DOI 10.1016/0006-291X(92)92341-T; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; DIZDAROGLU M, 1992, MUTAT RES, V275, P331, DOI 10.1016/0921-8734(92)90036-O; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; EBINA Y, 1986, J NATL CANCER I, V76, P107; FEIG DI, 1994, P NATL ACAD SCI USA, V91, P6609, DOI 10.1073/pnas.91.14.6609; Floyd R A, 1986, Free Radic Res Commun, V1, P163, DOI 10.3109/10715768609083148; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5; KASAI H, 1993, ADV MUT RES, V4, P31; Kato K, 2000, BBA-GENE STRUCT EXPR, V1493, P91, DOI 10.1016/S0167-4781(00)00168-8; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Kobayashi T, 1999, CANCER RES, V59, P1206; KONISHI T, 1995, J BIOCHEM-TOKYO, V118, P1021, DOI 10.1093/jb/118.5.1021; LOEB LA, 1988, P NATL ACAD SCI USA, V85, P3918, DOI 10.1073/pnas.85.11.3918; MACCABEE M, 1994, J MOL BIOL, V236, P514, DOI 10.1006/jmbi.1994.1162; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCBRIDE TJ, 1991, BIOCHEMISTRY-US, V30, P207, DOI 10.1021/bi00215a030; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUELLER PR, 1991, CURRENT PROTOCOLS S, V14; NAKAE D, 1995, CANCER LETT, V97, P233, DOI 10.1016/0304-3835(95)03980-B; NELLIST M, 1993, CELL, V75, P1305; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOMOTO M, 1995, BBA-GENE STRUCT EXPR, V1264, P35, DOI 10.1016/0167-4781(95)00158-D; Nomoto M, 1999, CARCINOGENESIS, V20, P837, DOI 10.1093/carcin/20.5.837; OKADA S, 1987, BIOCHIM BIOPHYS ACTA, V922, P28, DOI 10.1016/0005-2760(87)90241-4; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; TATA JR, 1978, J MOL BIOL, V118, P249, DOI 10.1016/0022-2836(78)90227-9; TCHOU J, 1994, J BIOL CHEM, V269, P15318; TKESHELASHVILI LK, 1991, J BIOL CHEM, V266, P6401; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Tu YQ, 1997, J BIOL CHEM, V272, P20747, DOI 10.1074/jbc.272.33.20747; UMEMURA T, 1990, CARCINOGENESIS, V11, P345, DOI 10.1093/carcin/11.2.345; WEITZMAN SA, 1990, BLOOD, V76, P655; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Yamaguchi R, 1996, CARCINOGENESIS, V17, P2419, DOI 10.1093/carcin/17.11.2419	52	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1649	1657		10.1038/sj.onc.1205237	http://dx.doi.org/10.1038/sj.onc.1205237			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896596				2022-12-25	WOS:000174214200003
J	Chekenya, M; Hjelstuen, M; Enger, PO; Thorsen, F; Jacob, AL; Probst, B; Haraldseth, O; Pilkington, G; Butt, A; Levine, JM; Bjerkvig, R				Chekenya, M; Hjelstuen, M; Enger, PO; Thorsen, F; Jacob, AL; Probst, B; Haraldseth, O; Pilkington, G; Butt, A; Levine, JM; Bjerkvig, R			NG2 proteoglycan promotes angiogenesis-dependent tumor growth in the central nervous system by sequestering angiostatin	FASEB JOURNAL			English	Article						angiogenesis; glioblastoma; pericytes	CHONDROITIN-SULFATE PROTEOGLYCAN; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; PROGENITOR CELLS; MELANOMA-CELLS; EXPRESSION; PERICYTES; BINDING; PERMEABILITY; INHIBITION	During embryogenesis, the NG2 proteoglycan is expressed on immature capillary vessels, but as the vessels mature they lose this expression. NG2 is up-regulated in high-grade gliomas, but it is not clear to what extent it contributes to malignant progression. Using a combination of high spatial and temporal resolution functional magnetic resonance imaging and histopathological analyses, we show here that overexpression of NG2 increases tumor initiation and growth rates, neovascularization, and cellular proliferation, which predisposes to a poorer survival outcome. By confocal microscopy and cDNA gene array expression profiles, we also show that NG2 tumors express lower levels of hypoxia inducible factor-1alpha, vascular endothelial growth factor, and endogenous angiostatin in vivo compared with wild-type tumors. Moreover, we demonstrate that NG2-positive cells bind, internalize, and coimmunoprecipitate with angiostatin. These results indicate a unique role for NG2 in regulating the transition from small, poorly vascularized tumors to large, highly vascular gliomas in situ by sequestering angiostatin.	Univ Bergen, Dept Anat & Cell Biol, N-5009 Bergen, Norway; SINTEF, Unimed MR Ctr, N-7465 Trondheim, Norway; Norwegian Univ Sci & Technol, Dept Anesthesia & Med Imaging, N-7034 Trondheim, Norway; Kings Coll London, Inst Psychiat, Dept Neuropathol, London SE5 8AF, England; Kings Coll London, Guys Kings & St Thomas Sch Biomed Sci, Ctr Neurosci, London SE1 1UL, England; SUNY Stony Brook, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA	University of Bergen; SINTEF; Norwegian University of Science & Technology (NTNU); University of London; King's College London; University of London; King's College London; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bjerkvig, R (corresponding author), Univ Bergen, Dept Anat & Cell Biol, Arstadveien 19, N-5009 Bergen, Norway.	Rolf.Bjerkvig@pki.uib.no		Butt, Arthur/0000-0001-7579-0746; Chekenya, PhD, Dr Philos, Dr. Martha/0000-0001-7241-3451; Thorsen, Frits/0000-0002-7762-3703				Behm FG, 1996, BLOOD, V87, P1134, DOI 10.1182/blood.V87.3.1134.bloodjournal8731134; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; BIGNER DD, 1995, J NEURO-ONCOL, V24, P109, DOI 10.1007/BF01052668; BUMOL TF, 1983, P NATL ACAD SCI-BIOL, V80, P529, DOI 10.1073/pnas.80.2.529; Burg MA, 1997, EXP CELL RES, V235, P254, DOI 10.1006/excr.1997.3674; Burg MA, 1998, J CELL PHYSIOL, V177, P299, DOI 10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3.3.CO;2-0; Burg MA, 1999, CANCER RES, V59, P2869; D'Amore P A, 1992, Semin Cancer Biol, V3, P49; Fang XX, 1999, MOL BIOL CELL, V10, P3373, DOI 10.1091/mbc.10.10.3373; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gillies RJ, 2000, NEOPLASIA, V2, P139, DOI 10.1038/sj.neo.7900076; Goretzki L, 1999, J BIOL CHEM, V274, P16831, DOI 10.1074/jbc.274.24.16831; Goretzki L, 2000, J BIOL CHEM, V275, P28625, DOI 10.1074/jbc.M002290200; GRAKO KA, 1995, EXP CELL RES, V221, P231, DOI 10.1006/excr.1995.1371; HARPER JR, 1983, J NATL CANCER I, V71, P259; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Horner PJ, 2000, J NEUROSCI, V20, P2218; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Mahesparan R, 1999, ACTA NEUROPATHOL, V97, P231, DOI 10.1007/s004010050979; MANTEL N, 1959, J NATL CANCER I, V22, P719; NISHIYAMA A, 1993, MOL BIOL CELL, V4, P1097, DOI 10.1091/mbc.4.11.1097; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; Noble M, 2001, CONT NEUROS, P123; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; Ozerdem U, 2002, MICROVASC RES, V63, P129, DOI 10.1006/mvre.2001.2376; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; Pouly S, 2001, ACTA NEUROPATHOL, V102, P313; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; REAL FX, 1985, CANCER RES, V45, P4401; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SCHLINGEMANN RO, 1990, AM J PATHOL, V136, P1393; SCHLINGEMANN RO, 1991, AM J PATHOL, V138, P1335; SCHRAPPE M, 1991, CANCER RES, V51, P4986; Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050-1738(96)00039-4; Shoshan Y, 1999, P NATL ACAD SCI USA, V96, P10361, DOI 10.1073/pnas.96.18.10361; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; SU MY, 1994, MAGN RESON MED, V32, P714, DOI 10.1002/mrm.1910320606; TOFTS PS, 1991, MAGNET RESON MED, V17, P357, DOI 10.1002/mrm.1910170208; YUHAS JM, 1977, CANCER RES, V37, P3639	45	77	81	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					586	+		10.1096/fj.01-0632fje	http://dx.doi.org/10.1096/fj.01-0632fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919162				2022-12-25	WOS:000174203700015
J	Prest, SJ; May, FEB; Westley, BR				Prest, SJ; May, FEB; Westley, BR			The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells	FASEB JOURNAL			English	Article						pS2; estrogen; metastasis; trefoil peptide; migration	INTESTINAL TREFOIL FACTOR; INDUCED PS2 PROTEIN; NORMAL STOMACH; MESSENGER-RNA; TAMOXIFEN; DOMAIN; EXPRESSION; PNR-2/PS2; PEPTIDE; RECEPTOR	The human trefoil protein TFF1 is a small cysteine-rich secreted protein that is frequently expressed in breast tumors under the control of estrogen. The function of TFF1 in breast cancer is unknown. To test the hypothesis that it promotes tumor dissemination, we produced recombinant TFF1 and assessed its ability to stimulate the movement of breast cancer cells by using in vitro wounding and migration assays. Recombinant TFF1 stimulated migration at concentrations of TFF1 found in culture medium. Migration of MCF-7 breast cancer cells, which secrete TFF1, was stimulated by lower concentrations of TFF1 than MDA MB231 cells that do not produce TFF1. Dimeric TFF1, linked by a disulfide bond, and monomeric TFF1 are produced by estrogen-responsive breast cancer cell lines. Recombinant TFF1 dimer was eightfold more potent than TFF1 monomer, implying that the interaction of TFF1 with its receptor is facilitated by dimerization. The majority of TFF1-stimulated migration resulted from chemotaxis, but dimeric TFF1 stimulated some chemokinesis. These results show that estrogens can stimulate the motility of breast cancer cells via the induction of TFF1 and suggest that one reason for the efficacy of hormonal therapies is their ability to reduce expression of TFF1 and, hence, the migration of breast tumor cells.	Univ Newcastle Upon Tyne, Royal Victoria Infirm, Sch Clin & Lab Sci, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK	Westley, BR (corresponding author), Univ Newcastle Upon Tyne, Royal Victoria Infirm, Sch Clin & Lab Sci, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	B.R.Westley@ncl.ac.uk			Breast Cancer Now [1999:88] Funding Source: Medline	Breast Cancer Now		BAKER ME, 1988, BIOCHEM J, V253, P307, DOI 10.1042/bj2530307; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; CARR M, 1995, BRIT J CANCER, V72, P1427, DOI 10.1038/bjc.1995.525; Chadwick MP, 1997, BIOCHEM J, V327, P117, DOI 10.1042/bj3270117; CHADWICK MP, 1995, BIOCHEM J, V308, P1001, DOI 10.1042/bj3081001; Crosier M, 2001, AM J PATHOL, V159, P215, DOI 10.1016/S0002-9440(10)61687-2; FOEKENS JA, 1994, BRIT J CANCER, V70, P1217, DOI 10.1038/bjc.1994.476; HARRIS M, 1984, BRIT J CANCER, V50, P23, DOI 10.1038/bjc.1984.135; HAUSER F, 1993, P NATL ACAD SCI USA, V90, P6961, DOI 10.1073/pnas.90.15.6961; HENRY JA, 1991, BRIT J CANCER, V63, P615, DOI 10.1038/bjc.1991.141; HENRY JA, 1991, BRIT J CANCER, V64, P677, DOI 10.1038/bjc.1991.380; HENRY JA, 1989, BRIT J CANCER, V61, P32; JOHNSON ME, 1989, CLIN SUPERV, V7, P59; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Marchbank T, 1998, J PATHOL, V185, P153; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MAY FEB, 1988, J BIOL CHEM, V263, P12901; May FEB, 1997, J PATHOL, V183, P4; MAY FEB, 1986, CANCER RES, V46, P6034; MAY FEB, 1987, J BIOL CHEM, V262, P15894; McClelland RA, 1996, BREAST CANCER RES TR, V41, P31, DOI 10.1007/BF01807034; Newton JL, 2000, GUT, V46, P312, DOI 10.1136/gut.46.3.312; NUNEZ AM, 1987, ENDOCRINOLOGY, V121, P1759, DOI 10.1210/endo-121-5-1759; PIGGOTT NH, 1991, J PATHOL, V163, P95, DOI 10.1002/path.1711630204; POLSHAKOV VI, 1995, EUR J BIOCHEM, V233, P847, DOI 10.1111/j.1432-1033.1995.847_3.x; Polshakov VI, 1997, J MOL BIOL, V267, P418, DOI 10.1006/jmbi.1997.0896; POULSOM R, 1993, AM J PHYSIOL, V265, P205; PRUDHOMME JF, 1995, DNA CELL BIOL, V4, P11; Ribieras S, 1998, BBA-REV CANCER, V1378, pF61, DOI 10.1016/S0304-419X(98)00016-X; RIO MC, 1987, P NATL ACAD SCI USA, V84, P9243, DOI 10.1073/pnas.84.24.9243; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; RIO MC, 1988, CR ACAD SCI III-VIE, V307, P825; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHWARTZ LH, 1991, CANCER RES, V51, P624; Soubeyran I, 1996, BRIT J CANCER, V74, P1120, DOI 10.1038/bjc.1996.500; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; WESTLEY B, 1978, CELL, V15, P367, DOI 10.1016/0092-8674(78)90005-3; WESTLEY B, 1984, J BIOL CHEM, V259, P30; Wiede A, 1999, AM J RESP CRIT CARE, V159, P1330, DOI 10.1164/ajrccm.159.4.9804149; Williams MA, 2001, FEBS LETT, V493, P70, DOI 10.1016/S0014-5793(01)02276-1; WILSON YG, 1994, BRIT J SURG, V81, P1155, DOI 10.1002/bjs.1800810824; WISEMAN LR, 1989, J STEROID BIOCHEM, V33, P1, DOI 10.1016/0022-4731(89)90349-X	45	147	149	2	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					592	+		10.1096/fj.01-0498fje	http://dx.doi.org/10.1096/fj.01-0498fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919164				2022-12-25	WOS:000174203700013
J	Field, SJ; Prior, L; Roldan, MD; Cheesman, MR; Thomson, AJ; Spiro, S; Butt, JN; Watmought, NJ; Richardson, DJ				Field, SJ; Prior, L; Roldan, MD; Cheesman, MR; Thomson, AJ; Spiro, S; Butt, JN; Watmought, NJ; Richardson, DJ			Spectral properties of bacterial nitric-oxide reductase - Resolution of pH-dependent forms of the active site heme b(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; PARACOCCUS-DENITRIFICANS; HORSERADISH-PEROXIDASE; SOYBEAN LEGHEMOGLOBIN; DINUCLEAR CENTER; COPPER OXIDASES; LIGATION; PURIFICATION; TEMPERATURE; MYOGLOBIN	Bacterial nitric-oxide reductase catalyzes the two electron reduction of nitric oxide to nitrous oxide. In the oxidized form the active site non-heme Fe-B and high spin heme b(3) are mu-oxo bridged. The heme b(3) has a ligand-to-metal charge transfer band centered at 595 nm, which is insensitive to pH over the range of 6.0-8.5. Partial reduction of nitric-oxide reductase yields a three electron-reduced state where only the heme b(3) remains oxidized. This results in a shift of the heme b(3) charge transfer band lambda(max) to longer wavelengths. At pH 6.0 the charge transfer band lambda(max) is 605 nm, whereas at pH 8.5 it is 635 nm. At pH 6.5 and 7.5 the nitric-oxide reductase ferric heme b(3) population is a mixture of both 605- and 635-nm forms. Magnetic circular dichroism spectroscopy suggests that at all pH values examined the proximal ligand to the ferric heme b(3) in the three electron-reduced form is histidine. At pH 8.5 the distal ligand is hydroxide, whereas at pH 6.0, when the enzyme is most active, it is water.	Univ E Anglia, Sch Biol Sci, Ctr Met Proc Spect, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Chem Sci, Ctr Met Proc Spect, Norwich NR4 7TJ, Norfolk, England	University of East Anglia; University of East Anglia	Richardson, DJ (corresponding author), Univ E Anglia, Sch Biol Sci, Ctr Met Proc Spect, Norwich NR4 7TJ, Norfolk, England.	d.richardson@uea.ac.uk	Watmough, Nicholas J/A-6643-2010; Butt, Julea/E-2133-2011; Roldán Ruiz, María Dolores/K-4370-2014; Spiro, Stephen/B-1838-2009; Richardson, David J/E-2275-2011	Watmough, Nicholas J/0000-0001-5901-6750; Butt, Julea/0000-0002-9624-5226; Roldán Ruiz, María Dolores/0000-0001-7173-8641; Spiro, Stephen/0000-0001-5975-9984; 				BRACETE AM, 1991, BIOCHIM BIOPHYS ACTA, V1080, P264, DOI 10.1016/0167-4838(91)90012-O; BRILL AS, 1961, BIOCHEM J, V78, P246, DOI 10.1042/bj0780246; Butland G, 2001, J BACTERIOL, V183, P189, DOI 10.1128/JB.183.1.189-199.2001; Cheesman MR, 1998, BIOCHEMISTRY-US, V37, P3994, DOI 10.1021/bi972437y; CHENG JC, 1973, NATURE, V241, P193, DOI 10.1038/241193a0; Cramm R, 1999, FEBS LETT, V460, P6, DOI 10.1016/S0014-5793(99)01315-0; DAWSON JH, 1976, J AM CHEM SOC, V98, P3707, DOI 10.1021/ja00428a054; DAWSON JH, 1989, PHYSICAL BIOINORGANI; DEGIER JWL, 1994, MOL MICROBIOL, V13, P183, DOI 10.1111/j.1365-2958.1994.tb00414.x; DERMASTIA M, 1991, J BIOL CHEM, V266, P10899; Dutton P L, 1978, Methods Enzymol, V54, P411; EGLINTON DG, 1983, BIOCHIM BIOPHYS ACTA, V742, P648, DOI 10.1016/0167-4838(83)90284-4; Girsch P, 1997, BBA-BIOENERGETICS, V1318, P202, DOI 10.1016/S0005-2728(96)00138-7; Gronberg KLC, 1999, BIOCHEMISTRY-US, V38, P13780, DOI 10.1021/bi9916426; HEISS B, 1989, J BACTERIOL, V171, P3288, DOI 10.1128/jb.171.6.3288-3297.1989; Hendriks J, 1998, J BIOENERG BIOMEMBR, V30, P15, DOI 10.1023/A:1020547225398; Hendriks J, 1998, BIOCHEMISTRY-US, V37, P13102, DOI 10.1021/bi980943x; Hendriks JHM, 2001, BIOCHEMISTRY-US, V40, P13361, DOI 10.1021/bi011428t; Jones DK, 1998, BIOCHEM J, V330, P983; KOBAYASHI N, 1977, BIOCHIM BIOPHYS ACTA, V493, P340, DOI 10.1016/0005-2795(77)90190-8; Moenne-Loccoz P, 2000, J AM CHEM SOC, V122, P9344, DOI 10.1021/ja0016295; MONKARA F, 1992, BIOCHIM BIOPHYS ACTA, V1100, P184; NOZAWA T, 1976, BIOCHIM BIOPHYS ACTA, V427, P652, DOI 10.1016/0005-2795(76)90209-9; Sakurai N, 1997, BIOCHEMISTRY-US, V36, P13809, DOI 10.1021/bi971070u; SEWARD HE, 1999, THESIS U E ANGLIA; SHINIJI K, 2001, J INORG BIOCHEM, V83, P281; SIEVERS G, 1983, BIOCHIM BIOPHYS ACTA, V742, P637, DOI 10.1016/0167-4838(83)90283-2; SPRINGALL J, 1976, BIOCHIM BIOPHYS ACTA, V453, P494, DOI 10.1016/0005-2795(76)90145-8; Suharti, 2001, BIOCHEMISTRY-US, V40, P2632, DOI 10.1021/bi0020067; VICKERY L, 1976, J AM CHEM SOC, V98, P343, DOI 10.1021/ja00418a005; Watmough NJ, 1998, J BIOENERG BIOMEMBR, V30, P55, DOI 10.1023/A:1020507511285; Watmough NJ, 1999, BBA-BIOENERGETICS, V1411, P456, DOI 10.1016/S0005-2728(99)00032-8; YOSHIDA S, 1975, BIOCHIM BIOPHYS ACTA, V405, P122, DOI 10.1016/0005-2795(75)90322-0	33	40	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20146	20150		10.1074/jbc.M112202200	http://dx.doi.org/10.1074/jbc.M112202200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11901154	hybrid			2022-12-25	WOS:000176204500009
J	Yang, YK; Chen, M; Lai, YM; Gantz, I; Georgeson, KE; Harmon, CM				Yang, YK; Chen, M; Lai, YM; Gantz, I; Georgeson, KE; Harmon, CM			Molecular determinants of human melanocortin-4 receptor responsible for antagonist SHU9119 selective activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGOUTI-RELATED PROTEIN; ALPHA-MELANOTROPIN; FRAMESHIFT MUTATION; BIOLOGICAL-ACTIVITY; IN-VITRO; OBESITY; ANALOGS; AGONIST; HORMONE; RATS	The hypothalamic melanocortin-4 receptor (MC4R), a seven transmembrane G-protein-coupled receptor, plays an important role in the regulation of body weight. The synthetic melanocortin analog SHU9119 has been widely used to characterize the physiological role of MC4R in feeding behavior and energy homeostasis. Previous studies indicated that SHU9119 is an agonist at the melanocortin-1 receptor (MC1R) but an antagonist at the MC4R. However, the molecular basis of the interaction between hMC4R and SHU9119 has not been clearly defined. To gain insight into the molecular determinants of hMC4R in the selectivity of SHU9119 chimeras and mutants hMC1R and hMC4R were expressed in cell lines and pharmacologically analyzed. A region of receptor containing the third transmembrane of hMC4R was found to be required for selective SHU9119 antagonism. Further mutagenesis studies of this region of hMC4R demonstrated that the amino acid residue leucine 133 in the third transmembrane was critical for the selective antagonist activity of SHU9119. The single substitution of leucine 133 to methionine did not affect SHU9119 binding to hMC4R. However, this substitution did convert SHU9119 from an antagonist to an agonist. Conversely, exchange of Met(128) in hMC1R to Leu, the homologous residue 133 of hMC4R, displayed a reduction in SHU9119 binding affinity and potency. This report provides the details of the molecular recognition of SHU9119 antagonism at hMC4R and shows that amino acid Leu(133) of hMC4R plays a key role in melanocortin receptor subtype specificity.	Univ Alabama, Div Pediat Surg, Dept Surg, Birmingham, AL 35233 USA; Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA	University of Alabama System; University of Alabama Birmingham; University of Michigan System; University of Michigan	Harmon, CM (corresponding author), Univ Alabama, Div Pediat Surg, Dept Surg, 300 ACC,1600 7th Ave S, Birmingham, AL 35233 USA.							Bednarek MA, 2000, BIOCHEM BIOPH RES CO, V272, P23, DOI 10.1006/bbrc.2000.2589; Benoit SC, 2000, J NEUROSCI, V20, P3442, DOI 10.1523/JNEUROSCI.20-09-03442.2000; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Gu W, 1999, DIABETES, V48, P635, DOI 10.2337/diabetes.48.3.635; Haskell-Luevano C, 2000, PEPTIDES, V21, P49, DOI 10.1016/S0196-9781(99)00167-9; Haskell-Luevano C, 2001, BIOCHEMISTRY-US, V40, P6164, DOI 10.1021/bi010025q; HaskellLuevano C, 1997, J MED CHEM, V40, P1738, DOI 10.1021/jm960845e; Hinney A, 1999, J CLIN ENDOCR METAB, V84, P1483, DOI 10.1210/jc.84.4.1483; HRUBY VJ, 1995, J MED CHEM, V38, P3454, DOI 10.1021/jm00018a005; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Jonsson L, 2001, NEUROREPORT, V12, P3703, DOI 10.1097/00001756-200112040-00020; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Raposinho PD, 2000, ENDOCRINOLOGY, V141, P4419, DOI 10.1210/en.141.12.4419; SADAFFAROOGI I, 2000, J CLIN INVEST, V106, P271; SAWYER TK, 1982, P NATL ACAD SCI-BIOL, V79, P1751, DOI 10.1073/pnas.79.6.1751; SAWYER TK, 1980, P NATL ACAD SCI-BIOL, V77, P5754, DOI 10.1073/pnas.77.10.5754; Schioth HB, 1996, LIFE SCI, V59, P797, DOI 10.1016/0024-3205(96)00370-0; Schioth HB, 1997, PEPTIDES, V18, P1009, DOI 10.1016/S0196-9781(97)00079-X; Schioth HB, 1999, NEUROPEPTIDES, V33, P191, DOI 10.1054/npep.1999.0760; Thiele TE, 1998, AM J PHYSIOL-REG I, V274, pR248, DOI 10.1152/ajpregu.1998.274.1.R248; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; Vrinten DH, 2001, ANESTH ANALG, V93, P1572, DOI 10.1097/00000539-200112000-00052; Yang Y, 2000, BIOCHEMISTRY-US, V39, P14900, DOI 10.1021/bi001684q; Yang YK, 1997, J BIOL CHEM, V272, P23000, DOI 10.1074/jbc.272.37.23000; Yang YK, 1999, J BIOL CHEM, V274, P14100, DOI 10.1074/jbc.274.20.14100; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404	27	65	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20328	20335		10.1074/jbc.M201343200	http://dx.doi.org/10.1074/jbc.M201343200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11912210	hybrid			2022-12-25	WOS:000176204500031
J	Hartman, HB; Hu, X; Tyler, KX; Dalal, CK; Lazar, MA				Hartman, HB; Hu, X; Tyler, KX; Dalal, CK; Lazar, MA			Mechanisms regulating adipocyte expression of resistin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-RECEPTOR-GAMMA; BINDING-PROTEIN-ALPHA; OB GENE-EXPRESSION; PPAR-GAMMA; ADIPOSE-TISSUE; TRANSCRIPTIONAL ACTIVATION; HISTONE H3; ANTIDIABETIC THIAZOLIDINEDIONE; INSULIN-RESISTANCE; 3T3-L1 ADIPOCYTES	Resistin, also known as Adipocyte Secreted Factor (ADSF) and Found in Inflammatory Zone 3 (FIZZ3), is a mouse protein with potential roles in insulin resistance and adipocyte differentiation. The resistin gene is expressed almost exclusively in adipocytes. Here we show that a proximal 264-base pair fragment of the mouse resistin promoter is sufficient for expression in adipocytes. Ectopic expression of the adipogenic transcription factor CCAAT/enhancer-binding protein (C/EBPalpha) was sufficient for expression in non-adipogenic cells. C/EBPalpha binds specifically to a site that is essential for expression of the resistin promoter. Chromatin immunoprecipitation studies of the endogenous gene demonstrated adipocyte-specific association of C/EBPalpha with the proximal resistin promoter in adipocytes but not preadipocytes. C/EBPalpha binding was associated with the recruitment of coactivators p300 and CREB-binding protein and a dramatic increase in histone acetylation in the vicinity of the resistin promoter. The antidiabetic thiazolidinedione (TZD) drug rosiglitazone reduced resistin expression with an ED50 similar to its K-d for binding to peroxisome proliferator activated receptor gamma (PPARgamma). Other TZD- and non-TZD PPARgamma ligands also down-regulated resistin expression. However, no functional PPARgamma binding site was found within 6.2 kb of the transcriptional start site, suggesting that if PPARgamma is involved, it is either acting at a long distance from the start site, in an intron, or indirectly. Nevertheless, rosiglitazone treatment selectively decreased histone acetylation at the resistin promoter without a change in occupation by C/EBPalpha, CREB-binding protein, or p300. Thus, adipocyte specificity of resistin gene expression is because of C/EBPalpha binding, leading to the recruitment of transcriptional coactivators and histone acetylation that is characteristic of an active chromatin environment. TZD reduces resistin gene expression at least in part by reducing histone acetylation associated with the binding of C/EBPalpha in mature adipocytes.	Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Diabet Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Lazar, MA (corresponding author), Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, 611 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	lazar@mail.med.upenn.edu	Lazar, Mitchell A/AAF-3738-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049780, P01DK049210] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49210, DK49780] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Berger SL, 2001, SCIENCE, V292, P64; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brunmair B, 2001, DIABETES, V50, P2309, DOI 10.2337/diabetes.50.10.2309; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Davies GF, 2001, BIOCHEM PHARMACOL, V62, P1071, DOI 10.1016/S0006-2952(01)00764-X; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; Guardiola AR, 2002, J BIOL CHEM, V277, P3350, DOI 10.1074/jbc.M109861200; Hamm JK, 1999, ANN NY ACAD SCI, V892, P134, DOI 10.1111/j.1749-6632.1999.tb07792.x; Haugen F, 2001, FEBS LETT, V507, P105, DOI 10.1016/S0014-5793(01)02968-4; HE YF, 1995, J BIOL CHEM, V270, P28887, DOI 10.1074/jbc.270.48.28887; Holcomb IN, 2000, EMBO J, V19, P4046, DOI 10.1093/emboj/19.15.4046; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; Hwang CS, 1996, P NATL ACAD SCI USA, V93, P873, DOI 10.1073/pnas.93.2.873; Jonke J, 2002, OBES RES, V10, P1; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Kim JH, 2001, J BIOL CHEM, V276, P24667, DOI 10.1074/jbc.M010793200; Kim KM, 2001, J BIOL CHEM, V276, P37409, DOI 10.1074/jbc.M106728200; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; LI Y, 2002, IN PRESS MOL ENDOCRI, V16; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; McTernan CL, 2002, LANCET, V359, P46, DOI 10.1016/S0140-6736(02)07281-1; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Nagaev I, 2001, BIOCHEM BIOPH RES CO, V285, P561, DOI 10.1006/bbrc.2001.5173; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; Reitman ML, 2000, TRENDS ENDOCRIN MET, V11, P410, DOI 10.1016/S1043-2760(00)00309-X; Rocchi S, 2001, MOL CELL, V8, P737, DOI 10.1016/S1097-2765(01)00353-7; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; ROY DY, 1995, MOL CELL BIOL, V15, P6481; Savage DB, 2001, DIABETES, V50, P2199, DOI 10.2337/diabetes.50.10.2199; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Shao DL, 1997, J BIOL CHEM, V272, P21473, DOI 10.1074/jbc.272.34.21473; SPIEGELMAN BM, 1988, TRENDS GENET, V4, P203, DOI 10.1016/0168-9525(88)90077-7; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Steppan CM, 2001, P NATL ACAD SCI USA, V98, P502, DOI 10.1073/pnas.98.2.502; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Takata Y, 2001, J BIOL CHEM, V276, P12893, DOI 10.1074/jbc.M011655200; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; Umemiya H, 1997, BIOCHEM BIOPH RES CO, V233, P121, DOI 10.1006/bbrc.1997.6414; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhang B, 1996, J BIOL CHEM, V271, P9455, DOI 10.1074/jbc.271.16.9455; Zhang JS, 1997, MOL CELL BIOL, V17, P6887, DOI 10.1128/MCB.17.12.6887	70	125	136	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19754	19761		10.1074/jbc.M201451200	http://dx.doi.org/10.1074/jbc.M201451200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11901161	hybrid			2022-12-25	WOS:000175894800068
J	Jiang, FL; Yi, L; Moore, M; Chen, MY; Rohl, T; van Wijk, KJ; de Gier, JWL; Henry, R; Dalbey, RE				Jiang, FL; Yi, L; Moore, M; Chen, MY; Rohl, T; van Wijk, KJ; de Gier, JWL; Henry, R; Dalbey, RE			Chloroplast YidC homolog Albino3 can functionally complement the bacterial YidC depletion strain and promote membrane insertion of both bacterial and chloroplast thylakoid proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; CHLOROPHYLL-BINDING PROTEIN; COLI INNER MEMBRANE; ESCHERICHIA-COLI; CYTOPLASMIC MEMBRANE; TARGETING PATHWAY; SEC-TRANSLOCASE; PLASMA-MEMBRANE; COAT PROTEIN; OXA1P	A new component of the bacterial translocation machinery, YidC, has been identified that specializes in the integration of membrane proteins. YidC is homologous to the mitochondrial Oxa1p and the chloroplast Alb3, which functions in a novel pathway for the insertion of membrane proteins from the mitochondrial matrix and chloroplast stroma, respectively. We find that Alb3 can functionally complement the Escherichia coli YidC depletion strain and promote the membrane insertion of the M13 procoat and leader peptidase that were previously shown to depend on the bacterial YidC for membrane translocation. In addition, the chloroplast Alb3 that is expressed in bacteria is essential for the insertion of chloroplast cpSecE protein into the bacterial inner membrane. Surprisingly, Alb3 is not required for the insertion of cpSecE into the thylakoid membrane. These results underscore the importance of Oxa1p homologs for membrane protein insertion in bacteria and demonstrate that the requirement for Oxa1p homologs is different in the bacterial and thylakoid membrane systems.	Ohio State Univ, Dept Chem, Mol Cellular Dev Biol Program, Columbus, OH 43210 USA; Ohio State Univ, Prot Res Grp, Columbus, OH 43210 USA; Univ Arkansas, Dept Biol Sci, Fayetteville, AR 72701 USA; Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA; Stockholm Univ, Dept Biochem & Biophys, Arrhenius Labs, S-106 Stockholm, Sweden	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Arkansas System; University of Arkansas Fayetteville; Cornell University; Stockholm University	Dalbey, RE (corresponding author), Ohio State Univ, Dept Chem, Mol Cellular Dev Biol Program, 120 W 18Th Ave, Columbus, OH 43210 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063862] Funding Source: NIH RePORTER; NCRR NIH HHS [1P20 RR15569-02] Funding Source: Medline; NIGMS NIH HHS [GM63862] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Chen MY, 2002, J BIOL CHEM, V277, P7670, DOI 10.1074/jbc.M110644200; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1989, J BIOL CHEM, V264, P14225; Cristobal S, 1999, J BIOL CHEM, V274, P20068, DOI 10.1074/jbc.274.29.20068; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; Dalbey RE, 2000, CURR OPIN CELL BIOL, V12, P435, DOI 10.1016/S0955-0674(00)00113-7; de Gier JW, 2001, MOL MICROBIOL, V40, P314, DOI 10.1046/j.1365-2958.2001.02392.x; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Froderberg L, 2001, FEBS LETT, V498, P52, DOI 10.1016/S0014-5793(01)02494-2; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; HENRY R, 1994, J BIOL CHEM, V269, P10189; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; HULFORD A, 1994, J BIOL CHEM, V269, P3251; ITO K, 1980, J BIOL CHEM, V255, P2123; Kiefer D, 1999, EMBO J, V18, P6299, DOI 10.1093/emboj/18.22.6299; Kim SJ, 1999, J BIOL CHEM, V274, P4715, DOI 10.1074/jbc.274.8.4715; Kim SJ, 1998, FEBS LETT, V424, P105, DOI 10.1016/S0014-5793(98)00148-3; KOHORN BD, 1991, J BIOL CHEM, V266, P12048; KUHN A, 1988, EUR J BIOCHEM, V177, P267, DOI 10.1111/j.1432-1033.1988.tb14372.x; Luirink J, 2001, FEBS LETT, V501, P1, DOI 10.1016/S0014-5793(01)02616-3; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; Mant A, 2001, J BIOL CHEM, V276, P36200, DOI 10.1074/jbc.M102914200; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; Mori H, 2001, BBA-MOL CELL RES, V1541, P80, DOI 10.1016/S0167-4889(01)00150-1; Neumann-Haefelin C, 2000, EMBO J, V19, P6419, DOI 10.1093/emboj/19.23.6419; Qi HY, 1999, J BIOL CHEM, V274, P8993, DOI 10.1074/jbc.274.13.8993; Ridder ANJA, 2000, BIOCHEMISTRY-US, V39, P6521, DOI 10.1021/bi000073v; Saaf A, 1998, J BIOL CHEM, V273, P30415, DOI 10.1074/jbc.273.46.30415; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; SAMUELSON JC, 2001, J BIOL CHEM, V16, P16; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Settles AM, 1998, TRENDS CELL BIOL, V8, P494, DOI 10.1016/S0962-8924(98)01387-7; Stuart RA, 2000, NATURE, V406, P575, DOI 10.1038/35020668; Sundberg E, 1997, PLANT CELL, V9, P717, DOI 10.1105/tpc.9.5.717; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; WICKNER WT, 1994, SCIENCE, V266, P1197, DOI 10.1126/science.7973701; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; Woolhead CA, 2001, J BIOL CHEM, V276, P40841, DOI 10.1074/jbc.M106523200	53	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19281	19288		10.1074/jbc.M110857200	http://dx.doi.org/10.1074/jbc.M110857200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11891220	hybrid			2022-12-25	WOS:000175894800007
J	Kokoska, RJ; Bebenek, K; Boudsocq, F; Woodgate, R; Kunkel, TA				Kokoska, RJ; Bebenek, K; Boudsocq, F; Woodgate, R; Kunkel, TA			Low fidelity DNA synthesis by a Y family DNA polymerase due to misalignment in the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DINB1 GENE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; POL-ETA; SULFOLOBUS-SOLFATARICUS; XERODERMA-PIGMENTOSUM; REVERSE-TRANSCRIPTASE; INDUCED MUTAGENESIS; ADAPTIVE MUTATION; ERROR-PRONE	Sulfolobus solfataricus DNA polymerase IV (Dpo4) is a member of the Y family of DNA polymerases whose crystal structure has recently been solved. As a model for other evolutionarily conserved Y family members that perform translesion DNA synthesis and have low fidelity, we describe here the base substitution and frameshift fidelity of DNA synthesis by Dpo4. Dpo4 generates all 12 base-base mismatches at high rates, 11 of which are similar to those of its human homolog, DNA polymerase kappa This result is consistent with the Dpo4 structure, implying lower geometric selection for correct base pairs. Surprisingly, Dpo4 generates C-dCMP mismatches at an unusually high average rate and preferentially at cytosine Ranked by 5'-template guanine. Dpo4 also has very low frameshift fidelity and frequently generates deletions of even noniterated nucleotides, especially cytosine flanked by a W-template guanine. Both unusual features of error specificity suggest that Dpo4 can incorporate dNTP precursors when two template nucleotides are present in the active site binding pocket. These results have implications for mutagenesis resulting from DNA synthesis by Y family polymerases.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; NICHHD, Sect DNA Replicat Repair & Mutagenesis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Kunkel, TA (corresponding author), NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA.		Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788; Woodgate, Roger/0000-0001-5581-4616	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001500] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001500] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 2000, COLD SPRING HARB SYM, V65, P81, DOI 10.1101/sqb.2000.65.81; Boudsocq F, 2001, NUCLEIC ACIDS RES, V29, P4607, DOI 10.1093/nar/29.22.4607; Chiapperino D, 2002, J BIOL CHEM, V277, P11765, DOI 10.1074/jbc.M112139200; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; Efrati E, 1997, J BIOL CHEM, V272, P2559; Foster PL, 2000, COLD SPRING HARB SYM, V65, P21, DOI 10.1101/sqb.2000.65.21; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Hashim MF, 1997, J BIOL CHEM, V272, P20205, DOI 10.1074/jbc.272.32.20205; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; Kool ET, 1998, BIOPOLYMERS, V48, P3, DOI 10.1002/(SICI)1097-0282(1998)48:1<3::AID-BIP2>3.0.CO;2-7; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; Kuraoka I, 2001, J BIOL CHEM, V276, P49283, DOI 10.1074/jbc.M107779200; Levine RL, 2001, J BIOL CHEM, V276, P18717, DOI 10.1074/jbc.M102158200; Lewis DA, 1999, J BIOL CHEM, V274, P32924, DOI 10.1074/jbc.274.46.32924; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Matsuda T, 2001, J MOL BIOL, V312, P335, DOI 10.1006/jmbi.2001.4937; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McKenzie GJ, 2001, MOL CELL, V7, P571, DOI 10.1016/S1097-2765(01)00204-0; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Roberts J.D., 1996, DNA REPLICATION EUKA, P217; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; Silvian LF, 2001, NAT STRUCT BIOL, V8, P984, DOI 10.1038/nsb1101-984; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	43	97	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19633	19638		10.1074/jbc.M202021200	http://dx.doi.org/10.1074/jbc.M202021200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11919199	hybrid			2022-12-25	WOS:000175894800053
J	Saitoh, M; Pullen, N; Brennan, P; Cantrell, D; Dennis, PB; Thomas, G				Saitoh, M; Pullen, N; Brennan, P; Cantrell, D; Dennis, PB; Thomas, G			Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; IN-VIVO; LATE-PHASE; PROTEIN; P70(S6K); INSULIN; PDK1; AKT; IDENTIFICATION; GROWTH	A critical step in S6 kinase 1 (S6K1) activation is Thr(229) phosphorylation in the activation loop by the phosphoinositide-dependent protein kinase (PDK1). Thr(229) phosphorylation requires prior phosphorylation of the Ser/Thr-Pro sites in the autoinhibitory domain and Thr(389) in the linker domain, consistent with PDK1 more effectively catalyzing Thr(229) phosphorylation in a variant harboring acidic residues in these positions (S6K1-E389D(3)E). S6K1-E389D(3)E has high basal activity and exhibits partial resistance to rapamycin and wortmannin, and its activity can be further augmented by mitogens, effects presumably mediated by Thr(229) phosphorylation. However, PDK1-induced Thr(229) phosphorylation is reported to be constitutive rather than phosphatidylinositide 3,4,5-trisphosphate-dependent, suggesting that S6K1-E389D(3)E activity is mediated through a distinct site. Here we use phosphospecific antibodies to show that Thr(229) is fully phosphorylated in S6K1-E389D(3)E in the absence of mitogens and that regulation of S6K1-E389D(3)E activity by mitogens, rapamycin, or wortmannin parallels Ser(371) phosphorylation. Consistent with this observation, a dominant interfering allele of the mammalian target of rapamycin, mTOR, inhibits mitogen-induced Ser(371) phosphorylation and activation of S6K1-E389D(3)E, whereas wild type mTOR stimulates both responses. Moreover, in vitro mTOR directly phosphorylates Ser(371), and this event modulates Thr(389) phosphorylation by mTOR, compatible with earlier in vivo findings.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland; Imperial Canc Res Fund, London WC2A 3PX, England	Friedrich Miescher Institute for Biomedical Research; Cancer Research UK	Thomas, G (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.	gthomas@fmi.ch	Brennan, Paul/B-9210-2009; Thomas, George/K-9235-2014; Brennan, Paul/ABB-9196-2021	Brennan, Paul/0000-0001-8792-0499; Thomas, George/0000-0003-3518-8149; Brennan, Paul/0000-0001-8792-0499; Cantrell, Doreen/0000-0001-7525-3350; Pullen, Nicholas/0000-0002-4014-9278				Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Fadden P, 1997, J BIOL CHEM, V272, P10240; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HARA K, 1995, BIOCHEM BIOPH RES CO, V208, P735, DOI 10.1006/bbrc.1995.1399; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hentges KE, 2001, P NATL ACAD SCI USA, V98, P13796, DOI 10.1073/pnas.241184198; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Somwar R, 1998, AM J PHYSIOL-ENDOC M, V275, pE618, DOI 10.1152/ajpendo.1998.275.4.E618; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; SUSA M, 1992, J BIOL CHEM, V267, P6905; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Welch H, 1998, J BIOL CHEM, V273, P11248, DOI 10.1074/jbc.273.18.11248; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3	58	135	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					20104	20112		10.1074/jbc.M201745200	http://dx.doi.org/10.1074/jbc.M201745200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11914378	hybrid			2022-12-25	WOS:000175894800112
J	Skurat, AV; Dietrich, AD; Zhai, LM; Roach, PJ				Skurat, AV; Dietrich, AD; Zhai, LM; Roach, PJ			GNIP, a novel protein that binds and activates glycogenin, the self-glucosylating initiator of glycogen biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE GLYCOGENIN; CLASS-I REGION; MOLECULAR-CLONING; MULTIGENIC FAMILIES; STRUCTURAL-ANALYSIS; FINGER; GENE; BIOGENESIS; MECHANISM; LINKAGE	Glycogenin is a self-glucosylating protein involved in the initiation of glycogen biosynthesis. Self-glucosylation leads to the formation of an oligosaccharide chain, which, when long enough, supports the action of glycogen synthase to elongate it and form a mature glycogen molecule. To identify possible regulators of glycogenin, the yeast two-hybrid strategy was employed. By using rabbit skeletal muscle glycogenin as a bait, cDNAs encoding three different proteins were isolated from the human skeletal muscle cDNA library. Two of the cDNAs encoded glycogenin and glycogen synthase, respectively, proteins known to be interactors. The third cDNA encoded a polypeptide of unknown function and was designated GNIP (glycogenin interacting protein). Northern blot analysis revealed that GNIP mRNA is highly expressed in skeletal muscle. The gene for GNIP generates at least four isoforms by alternative splicing. The largest isoform GNIP1 contains, from NH2- to COOH-terminal, a RING finger, a B box, a putative coiled-coil region, and a B30.2-like motif. The previously identified protein TRIM? (tripartite motif containing protein 7) is also derived from the GNIP gene and is composed of the RING finger, B box, and coiled-coil regions. The GNIP2 and GNIP3 isoforms consist of the coiled-coil region and B30.2-like domain. Physical interaction between GNIP2 and glycogenin was confirmed by co-immunoprecipitation, and in addition GNIP2 was shown to stimulate glycogenin self-glucosylation 3-4-fold. GNIPs may represent a novel participant in the initiation of glycogen synthesis.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Ctr Diabet Res, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Roach, PJ (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	proach@iupui.edu						Aksentijevich I, 1997, CELL, V90, P797; ALONSO MD, 1995, FASEB J, V9, P1126, DOI 10.1096/fasebj.9.12.7672505; ALONSO MD, 1995, J BIOL CHEM, V270, P15315, DOI 10.1074/jbc.270.25.15315; Baque S, 1997, FEBS LETT, V417, P355, DOI 10.1016/S0014-5793(97)01299-4; Bernot A, 1997, NAT GENET, V17, P25; CAO YJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P293, DOI 10.1006/abbi.1995.1295; CAO YJ, 1993, J BIOL CHEM, V268, P14687; CAO YJ, 1993, J BIOL CHEM, V268, P21717; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; CHENG C, 1995, MOL CELL BIOL, V15, P6632; CHU TW, 1995, GENOMICS, V29, P229, DOI 10.1006/geno.1995.1236; Gassama-Diagne A, 2001, J BIOL CHEM, V276, P18352, DOI 10.1074/jbc.M009784200; Henry J, 1997, IMMUNOGENETICS, V46, P383, DOI 10.1007/s002510050292; Henry J, 1998, MOL BIOL EVOL, V15, P1696, DOI 10.1093/oxfordjournals.molbev.a025896; INOUE S, 1993, P NATL ACAD SCI USA, V90, P11117, DOI 10.1073/pnas.90.23.11117; James P, 1996, GENETICS, V144, P1425; Lin A, 1999, ARCH BIOCHEM BIOPHYS, V363, P163, DOI 10.1006/abbi.1998.1073; Miozzo MC, 1996, BIOCHEM MOL BIOL INT, V40, P173; Mu J, 1997, J BIOL CHEM, V272, P27589, DOI 10.1074/jbc.272.44.27589; OGAVA S, 1998, BIOCHEM BIOPH RES CO, V251, P515; Orimo A, 2000, GENOMICS, V69, P143, DOI 10.1006/geno.2000.6318; Orimo A, 2000, BIOCHEM BIOPH RES CO, V276, P45, DOI 10.1006/bbrc.2000.3380; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; PLATT T, 1972, EXPT MOL GENETICS, P352; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; REDDY BA, 1991, NUCLEIC ACIDS RES, V19, P6330, DOI 10.1093/nar/19.22.6330; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Roach PJ, 1997, PROG NUCLEIC ACID RE, V57, P289, DOI 10.1016/S0079-6603(08)60284-6; RODRIGUEZ IR, 1985, BIOCHEM BIOPH RES CO, V132, P829, DOI 10.1016/0006-291X(85)91206-9; RODRIGUEZ IR, 1988, ARCH BIOCHEM BIOPHYS, V260, P628, DOI 10.1016/0003-9861(88)90491-2; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Seto MH, 1999, PROTEINS, V35, P235, DOI 10.1002/(SICI)1097-0134(19990501)35:2<235::AID-PROT9>3.3.CO;2-O; SKURAT AV, 1993, J BIOL CHEM, V268, P14701; Skurat AV, 1997, EUR J BIOCHEM, V245, P147, DOI 10.1111/j.1432-1033.1997.t01-1-00147.x; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; SMYTHE C, 1990, EUR J BIOCHEM, V189, P199, DOI 10.1111/j.1432-1033.1990.tb15477.x; SMYTHE C, 1988, EMBO J, V7, P2681, DOI 10.1002/j.1460-2075.1988.tb03121.x; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TISSOT C, 1995, J BIOL CHEM, V270, P14891, DOI 10.1074/jbc.270.25.14891; VERNET C, 1993, J MOL EVOL, V37, P600; VISKUPIC E, 1992, J BIOL CHEM, V267, P25759	45	56	58	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19331	19338		10.1074/jbc.M201190200	http://dx.doi.org/10.1074/jbc.M201190200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11916970	hybrid			2022-12-25	WOS:000175894800013
J	Kambe, T; Narita, H; Yamaguchi-Iwai, Y; Hirose, J; Amano, T; Sugiura, N; Sasaki, R; Mori, K; Iwanaga, T; Nagao, M				Kambe, T; Narita, H; Yamaguchi-Iwai, Y; Hirose, J; Amano, T; Sugiura, N; Sasaki, R; Mori, K; Iwanaga, T; Nagao, M			Cloning and characterization of a novel mammalian zinc transporter, zinc transporter 5, abundantly expressed in pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFERS RESISTANCE; SYNAPTIC VESICLES; ION-TRANSPORT; GENE; FAMILY; PROTEIN; RECEPTOR; BIOLOGY; MOUSE	Intracellular homeostasis for zinc is achieved through the coordinate regulation of specific transporters engaged in zinc influx, efflux, and intracellular compartmentalization. We have identified a novel mammalian zinc transporter, zinc transporter 5 (ZnT-5), by virtue of its similarity to ZRC1, a zinc transporter of Saccharomyces cerevisiae, a member of the cation diffusion facilitator family. Human ZnT-5 (hZnT-5) cDNA encodes a 765-amino acid protein with 15 predicted membrane-spanning domains. hZnT-5 was ubiquitously expressed in all tested human tissues and abundantly expressed in the pancreas. In the human pancreas, hZnT-5 was expressed abundantly in insulin-containing beta cells that contain zinc at the highest level in the body. The hZnT-5 immunoreactivity was found to be associated with secretory granules by electron microscopy. The hZnT-5-derived zinc transport activity was detected using the Golgi-enriched vesicles prepared from hZnT-5-induced HeLa/hZnT-5 cells in which exogenous hZnT-5 expression is inducible by the Tet-on gene regulation system. This activity was dependent on time, temperature, and concentration and was saturable. Moreover, zinc at a high concentration (10 mm) inhibited the growth of yeast expressing hZnT-5. These results suggest that ZnT-5 plays an important role for transporting zinc into secretory granules in pancreatic beta cells.	Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Kyoto 6068502, Japan; Kyoto Womens Univ, Dept Food Sci, Kyoto 6058501, Japan; Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Kyoto 6068502, Japan; Univ Shiga Prefecture, Sch Human Cultures, Dept Life Style Studies, Shiga 5228533, Japan; Hokkaido Univ, Grad Sch Vet Med, Dept Biomed Sci, Sapporo, Hokkaido 0600818, Japan	Kyoto University; Kyoto Womens University; Kyoto University; University Shiga Prefecture; Hokkaido University	Kambe, T (corresponding author), Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Kyoto 6068502, Japan.							Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; ASLAM N, 1992, J CELL PHYSIOL, V151, P533, DOI 10.1002/jcp.1041510312; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Clifford KS, 2000, DIABETES RES CLIN PR, V49, P77, DOI 10.1016/S0168-8227(00)00141-8; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; Costello LC, 1999, J BIOL CHEM, V274, P17499, DOI 10.1074/jbc.274.25.17499; Cousins RJ, 2000, J NUTR, V130, p1384S, DOI 10.1093/jn/130.5.1384S; Dodson G, 1998, CURR OPIN STRUC BIOL, V8, P189, DOI 10.1016/S0959-440X(98)80037-7; Eide D, 1997, CURR OPIN CELL BIOL, V9, P573, DOI 10.1016/S0955-0674(97)80036-1; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Guerinot ML, 2000, BBA-BIOMEMBRANES, V1465, P190, DOI 10.1016/S0005-2736(00)00138-3; Hershfinkel M, 2001, P NATL ACAD SCI USA, V98, P11749, DOI 10.1073/pnas.201193398; Huang EP, 1997, P NATL ACAD SCI USA, V94, P13386, DOI 10.1073/pnas.94.25.13386; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; HUANG XF, 1995, J BIOL CHEM, V270, P20417, DOI 10.1074/jbc.270.35.20417; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Li LT, 2001, J BIOL CHEM, V276, P5036, DOI 10.1074/jbc.M008969200; McMahon RJ, 1998, P NATL ACAD SCI USA, V95, P4841, DOI 10.1073/pnas.95.9.4841; Morishita E, 1996, BLOOD, V88, P465, DOI 10.1182/blood.V88.2.465.bloodjournal882465; Murgia C, 1999, AM J PHYSIOL-GASTR L, V277, pG1231, DOI 10.1152/ajpgi.1999.277.6.G1231; Nagao M, 1999, BIOCHEM BIOPH RES CO, V257, P289, DOI 10.1006/bbrc.1999.0446; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; Persans MW, 2001, P NATL ACAD SCI USA, V98, P9995, DOI 10.1073/pnas.171039798; Reyes JG, 1996, AM J PHYSIOL-CELL PH, V270, pC401, DOI 10.1152/ajpcell.1996.270.2.C401; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; van der Zaal BJ, 1999, PLANT PHYSIOL, V119, P1047, DOI 10.1104/pp.119.3.1047; Williams R. J. P., 1989, ZINC HUMAN BIOL; ZALEWSKI PD, 1994, J HISTOCHEM CYTOCHEM, V42, P877, DOI 10.1177/42.7.8014471	37	219	227	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19049	19055		10.1074/jbc.M200910200	http://dx.doi.org/10.1074/jbc.M200910200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11904301	hybrid			2022-12-25	WOS:000175975800105
J	Karlson, L; Pejler, G; Froman, G; Hellman, L				Karlson, L; Pejler, G; Froman, G; Hellman, L			Rat mast cell protease 4 is a beta-chymase with unusually stringent substrate recognition profile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEASES; SPECIFICITY; TRYPTASE; LIBRARIES; MECHANISM; HEPARIN	Activated mast cells release a variety of potent inflammatory mediators including histamine, cytokines, proteoglycans, and serine proteases. The serine proteases belong to either the chymase (chymotrypsin-like substrate specificity) or tryptase (trypsin-like specificity) family. In this report we have investigated the substrate specificity of a recently identified mast cell protease, rat mast cell protease-4 (rMCP-4). Based on structural homology, rMCP-4 is predicted to belong to the chymase family, although rMCP-4 has previously not been characterized at the protein level. rMCP-4 was expressed with an N-terminal His tag followed by an enterokinase site substituting for the native activation peptide. The enterokinase-cleaved fusion protein was labeled by diisopropyl fluorophosphate, demonstrating that it is an active serine protease. Moreover, rMCP-4 hydrolyzed MeO-Suc-Arg-Ala-Tyr-pNA, thus verifying that this protease belongs to the chymase family. rMCP-4 bound to heparin, and the enzymatic activity toward MeO-Suc-Arg-Ala-Tyr-pNA was strongly enhanced in the presence of heparin. Detailed analysis of the substrate specificity was performed using peptide phage display technique. After six rounds of amplification a consensus sequence, Leu-Val-Trp-Phe-Arg-Gly, was obtained. The corresponding peptide was synthesized, and rMCP-4 was shown to cleave only the Phe-Arg bond in this peptide. This demonstrates that rMCP-4 displays a striking preference for bulky/aromatic amino acid residues in both the P1 and P2 positions.	Uppsala Univ, Dept Cell & Mol Biol, Biomed Ctr, SE-75124 Uppsala, Sweden; Swedish Univ Agr Sci, Dept Vet Med Chem, Biomed Ctr, SE-75123 Uppsala, Sweden; Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden	Uppsala University; Swedish University of Agricultural Sciences; Uppsala University	Hellman, L (corresponding author), Uppsala Univ, Dept Cell & Mol Biol, Biomed Ctr, Box 596, SE-75124 Uppsala, Sweden.							Backes BJ, 2000, NAT BIOTECHNOL, V18, P187, DOI 10.1038/72642; Caughey GH, 2000, BBA-PROTEIN STRUCT M, V1480, P245, DOI 10.1016/S0167-4838(00)00076-5; Chandrasekharan UM, 1996, SCIENCE, V271, P502, DOI 10.1126/science.271.5248.502; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; Hallgren J, 2000, BIOCHEMISTRY-US, V39, P13068, DOI 10.1021/bi000973b; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Huang CF, 2001, J BIOL CHEM, V276, P26276, DOI 10.1074/jbc.M102356200; Hudaky P, 1999, EUR J BIOCHEM, V259, P528, DOI 10.1046/j.1432-1327.1999.00075.x; Hunt JE, 1997, J BIOL CHEM, V272, P29158, DOI 10.1074/jbc.272.46.29158; Knight PA, 2000, J EXP MED, V192, P1849, DOI 10.1084/jem.192.12.1849; Lutzelschwab C, 1997, J EXP MED, V185, P13, DOI 10.1084/jem.185.1.13; Lutzelschwab C, 1998, EUR J IMMUNOL, V28, P3730, DOI 10.1002/(SICI)1521-4141(199811)28:11&lt;3730::AID-IMMU3730&gt;3.0.CO;2-0; Mekori YA, 2000, IMMUNOL REV, V173, P131, DOI 10.1034/j.1600-065X.2000.917305.x; Miller HRP, 1996, VET IMMUNOL IMMUNOP, V54, P331, DOI 10.1016/S0165-2427(96)05696-6; Pejler G, 1999, BIOCHEMISTRY-US, V38, P12187, DOI 10.1021/bi991046b; Pemberton AD, 1998, BBA-GEN SUBJECTS, V1379, P29, DOI 10.1016/S0304-4165(97)00078-0; POWERS JC, 1985, BIOCHEMISTRY-US, V24, P2048, DOI 10.1021/bi00329a037; REMINGTON SJ, 1988, BIOCHEMISTRY-US, V27, P8097, DOI 10.1021/bi00421a019; SALI A, 1993, J BIOL CHEM, V268, P9023; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Scudamore CL, 1998, EUR J CELL BIOL, V75, P321, DOI 10.1016/S0171-9335(98)80065-4; TRONG HL, 1989, BIOCHEMISTRY-US, V28, P391; Welle M, 1997, J LEUKOCYTE BIOL, V61, P233, DOI 10.1002/jlb.61.3.233	23	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18579	18585		10.1074/jbc.M110356200	http://dx.doi.org/10.1074/jbc.M110356200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11896050	hybrid			2022-12-25	WOS:000175975800045
J	May, P; Reddy, YK; Herz, J				May, P; Reddy, YK; Herz, J			Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE; ALZHEIMERS-DISEASE; CYTOSOLIC ADAPTER; BINDING DOMAIN; APOE RECEPTOR; FE65 PROTEIN; GENE FAMILY; IN-VIVO; NOTCH	The low density lipoprotein (LDL) receptor-related protein (LRP) is a multifunctional cell surface receptor that interacts through its cytoplasmic tail with adaptor and scaffold proteins that participate in cellular signaling. Its extracellular domain, like that of the signaling receptor Notch and of amyloid precursor protein (APP), is proteolytically processed at multiple positions. This similarity led us to investigate whether LRP, like APP and Notch, might also be cleaved at a third, intramembranous or cytoplasmic site, resulting in the release of its intracellular domain. Using independent experimental approaches we demonstrate that the cytoplasmic domain is released by a gamma-secretase-like activity and that this event is modulated by protein kinase C. Furthermore, cytoplasmic adaptor proteins that bind to the LRP tail affect the subcellular localization of the free intracellular domain and may regulate putative signaling functions. Finally, we show that the degradation of the free tail fragment is mediated by the proteasome. These findings suggest a novel role for the intracellular domain of LRP that may involve the subcellular translocation of preassembled signaling complexes from the plasma membrane.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Herz, J (corresponding author), Univ Texas SW, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063762, P01HL020948, R37HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043408] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL063762, HL20948, HL63762] Funding Source: Medline; NINDS NIH HHS [NS43408] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; DUILIO A, 1991, NUCLEIC ACIDS RES, V19, P5269, DOI 10.1093/nar/19.19.5269; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Liu CX, 2001, J BIOL CHEM, V276, P28889, DOI 10.1074/jbc.M102727200; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; NI CY, 2001, SCIENCE, V25, P25; Quinn KA, 1997, J BIOL CHEM, V272, P23946, DOI 10.1074/jbc.272.38.23946; Quinn KA, 1999, EXP CELL RES, V251, P433, DOI 10.1006/excr.1999.4590; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Van Uden E, 1999, MOL CELL NEUROSCI, V14, P129, DOI 10.1006/mcne.1999.0772; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Willnow TE, 1999, NAT CELL BIOL, V1, pE157, DOI 10.1038/14109; WILLNOW TE, 1994, J CELL SCI, V107, P719	47	252	260	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18736	18743		10.1074/jbc.M201979200	http://dx.doi.org/10.1074/jbc.M201979200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11907044	hybrid			2022-12-25	WOS:000175975800066
J	Xie, WS; Han, SY; Khan, M; DeJong, J				Xie, WS; Han, SY; Khan, M; DeJong, J			Regulation of ALF gene expression in somatic and male germ line tissues involves partial and site-specific patterns of methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONVERTING ENZYME ACE; BINDING PROTEIN GENE; CPG-RICH PROMOTER; DNA METHYLATION; TRANSCRIPTION FACTORS; MOUSE PROTAMINE-1; TRANSGENIC MICE; TESTIS; SPERMATOGENESIS; DEMETHYLATION	ALF (TFIIAalpha/beta-like factor) is a germ cell-specific counterpart of the large (alpha/beta) subunit of general transcription factor TFIIA. Here we isolated homologous GC-rich promoters from the mouse and human ALF genes and used promoter deletion analysis to identify sequences active in COS-7 and 293 cells. Further, bisulfite sequence analysis of the mouse ALF promoter showed that all 21 CpG dinucleotides between -179 and +207 were partially methylated in five somatic tissues, brain, heart, liver, lung, and muscle, and in epididymal spermatozoa from adult mice. In contrast, DNA from prepubertal mouse testis and from purified spermatocytes were unmethylated except at C(+19)G and C(+170)G. We also found that ALF expression correlates with a strong promoter-proximal DNase I-hypersensitive site present in nuclei from testis but not from liver. Finally we show that in vitro methylation of the ALF promoter inhibits activity and that 5-aza-2'-deoxycytidine treatment reactivates the endogenous ALF gene in a panel of seven different mouse and human somatic cell lines. Overall the results show that silencing in somatic cells is methylation-dependent and reversible and that a unique CpG-specific methylation pattern at the ALF promoter precedes expression in pachytene spermatocytes. This pattern is transient as remethylation of the ALF promoter in haploid germ cell DNA has occurred by the time spermatozoa are present in the epididymis.	Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75080 USA	University of Texas System; University of Texas Dallas	DeJong, J (corresponding author), Univ Texas, Dept Mol & Cell Biol, 2601 N Floyd Rd, Richardson, TX 75080 USA.							Aoyagi N, 2001, MOL CELL BIOL, V21, P6808, DOI 10.1128/MCB.21.20.6808-6819.2001; ARIEL M, 1991, P NATL ACAD SCI USA, V88, P2317, DOI 10.1073/pnas.88.6.2317; ARIEL M, 1994, NAT GENET, V7, P59, DOI 10.1038/ng0594-59; Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BONNY C, 1995, DEV GENET, V16, P210, DOI 10.1002/dvg.1020160213; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Choi YC, 1997, MAMM GENOME, V8, P317, DOI 10.1007/s003359900431; CHOI YC, 1991, J BIOL CHEM, V266, P20504; De Smet C, 1999, MOL CELL BIOL, V19, P7327; FREIMAN RN, 2001, NATURE, V293, P2084; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191; Han SY, 2001, BIOL REPROD, V64, P507, DOI 10.1095/biolreprod64.2.507; Hiller MA, 2001, GENE DEV, V15, P1021, DOI 10.1101/gad.869101; HOWARD T, 1993, MOL CELL BIOL, V13, P18, DOI 10.1128/MCB.13.1.18; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; Hsieh CL, 1999, MOL CELL BIOL, V19, P46; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; Iannello RC, 2000, J BIOL CHEM, V275, P19603, DOI 10.1074/jbc.M001867200; Iannello RC, 1997, MOL CELL BIOL, V17, P612, DOI 10.1128/MCB.17.2.612; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KEENE KC, 2001, MECH DEVELOP, V106, P3; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; Kumari M, 1996, J BIOL CHEM, V271, P14390, DOI 10.1074/jbc.271.24.14390; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Li SM, 1998, J BIOL CHEM, V273, P31191, DOI 10.1074/jbc.273.47.31191; Liu F, 1997, J BIOL CHEM, V272, P5056, DOI 10.1074/jbc.272.8.5056; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Martianov I, 2001, MOL CELL, V7, P509, DOI 10.1016/S1097-2765(01)00198-8; Matsuo K, 1998, EMBO J, V17, P1446, DOI 10.1093/emboj/17.5.1446; McCarrey J, 1993, CELL MOL BIOL TESTIS, P58; McCarrey JR, 1998, SEMIN CELL DEV BIOL, V9, P459, DOI 10.1006/scdb.1998.0199; Meistrich M L, 1977, Methods Cell Biol, V15, P15, DOI 10.1016/S0091-679X(08)60207-1; MONK M, 1987, DEVELOPMENT, V99, P371; Muller C, 2000, MOL CELL BIOL, V20, P3316, DOI 10.1128/MCB.20.9.3316-3329.2000; Ozer J, 2000, J BIOL CHEM, V275, P122, DOI 10.1074/jbc.275.1.122; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Persengiev SP, 1996, MOL ENDOCRINOL, V10, P742, DOI 10.1210/me.10.6.742; Schmidt EE, 1997, J BIOL CHEM, V272, P5326, DOI 10.1074/jbc.272.8.5326; SCHMIDT EE, 1995, DEVELOPMENT, V121, P2373; SIERRA F, 1993, GENE TRANSCRIPTION P, P129; Singer T, 2001, GENE DEV, V15, P591, DOI 10.1101/gad.193701; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; Teichmann M, 1999, P NATL ACAD SCI USA, V96, P13720, DOI 10.1073/pnas.96.24.13720; TRASLER JM, 1990, MOL CELL BIOL, V10, P1828, DOI 10.1128/MCB.10.4.1828; Trasler JM, 1998, SEMIN CELL DEV BIOL, V9, P467, DOI 10.1006/scdb.1998.0225; Upadhyaya AB, 1999, J BIOL CHEM, V274, P18040, DOI 10.1074/jbc.274.25.18040; Veenstra GJC, 2001, TRENDS BIOCHEM SCI, V26, P665, DOI 10.1016/S0968-0004(01)01970-3; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; ZAMBROWICZ BP, 1993, P NATL ACAD SCI USA, V90, P5071, DOI 10.1073/pnas.90.11.5071; Zhang D, 2001, SCIENCE, V292, P1153, DOI 10.1126/science.1059188	57	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17765	17774		10.1074/jbc.M200954200	http://dx.doi.org/10.1074/jbc.M200954200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11889132	hybrid			2022-12-25	WOS:000175685100049
J	Mann, J; Oakley, F; Johnson, PWM; Mann, DA				Mann, J; Oakley, F; Johnson, PWM; Mann, DA			CD40 induces interleukin-6 gene transcription in dendritic cells - Regulation by TRAF2, AP-1, NF-kappa B, and CBF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL KINASE; T-CELLS; IN-VIVO; ACTIVATION; INDUCTION; EXPRESSION; IL-6; ALPHA; PHOSPHORYLATION; DETERMINANTS	CD40-induced activation of cytokine gene expression in dendritic cells (DC) is an important process in the initiation of primary immune responses. We have determined the intracellular signaling events that lead to CD40 ligation-induced activation of interleukin-6 (IL-6) gene transcription in a murine DC line, FSDC, that is phenotypically representative of bone marrow-derived DC. IL-6 reverse transcriptase-PCR and promoter assays established the responsiveness of FSDC to anti-CD40 ligation. Further promoter assays showed that the transcription factors NF-kappaB and AP-1 are downstream transcriptional mediators of CD40-induced IL-6 gene expression. Anti-CD40 treatment of FSDC stimulated increased expression of specific NF-kappaB (p50:p65) and AP-1 (c-Jun, JunB, JunD, and c-Fos) DNA-protein complexes. Overexpression of an IkappaB-alpha super-repressor or a dominant negative JunD resulted in a strong inhibition of CD40-inducible IL-6 promoter activity supporting a role for both transcription factors. Upstream signal transduction events were studied by transfection of wild type and mutant human CD40 expression constructs into FSDC followed by stimulation with an anti-human CD40 antibody. These experiments revealed that anti-CD40 stimulation of NF-kappaB and IL-6 gene transcription requires specific amino acid residues in the cytoplasmic region of CD40 involved in the recruitment of TRAF2. Induction of IL-6 mRNA by anti-CD40 treatment was found to be a transient event (24 h) and was followed by a diminution of IL-6 transcript to levels below those found in unstimulated cells. This loss of IL-6 expression was associated with reduced p50:p65 NF-kappaB DNA binding and elevated binding of CBF1 to a site overlapping the NF-kappaB site. Overexpression of CBF1 resulted in a profound inhibition of basal and anti-CD40-induced IL-6 promoter activities indicating that prolonged induction of CBF1 may contribute to the transient nature of the IL-6 response. The physiological relevance of these molecular events to DC function is discussed.	Univ Southampton, Southampton Gen Hosp, Div Infect Inflammat & Repair, Liver Grp, Southampton SO16 6YD, Hants, England; Univ Southampton, Southampton Gen Hosp, Div Canc Sci, Southampton SO16 6YD, Hants, England	University of Southampton; University of Southampton	Mann, DA (corresponding author), Univ Southampton, Southampton Gen Hosp, Div Infect Inflammat & Repair, Liver Grp, Level D, Southampton SO16 6YD, Hants, England.	dam2@soton.ac.uk	Johnson, Peter/O-3529-2019; Johnson, Peter/L-2403-2018	Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Mann, Derek/0000-0003-0950-243X				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Baccam M, 1999, EUR J IMMUNOL, V29, P3855, DOI 10.1002/(SICI)1521-4141(199912)29:12<3855::AID-IMMU3855>3.0.CO;2-S; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Demoulin JB, 1999, EUR CYTOKINE NETW, V10, P49; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drakesmith H, 1998, P NATL ACAD SCI USA, V95, P14903, DOI 10.1073/pnas.95.25.14903; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Elsharkawy AM, 1999, HEPATOLOGY, V30, P761, DOI 10.1002/hep.510300327; Franchimont N, 1999, J BIOL CHEM, V274, P6783, DOI 10.1074/jbc.274.10.6783; Franchimont N, 1997, J CLIN INVEST, V100, P1797, DOI 10.1172/JCI119707; GAJEWSKI TF, 1995, J IMMUNOL, V154, P5637; GIROLOMONI G, 1995, EUR J IMMUNOL, V25, P2163, DOI 10.1002/eji.1830250807; Grammer AC, 2001, ADV IMMUNOL, V76, P61, DOI 10.1016/S0065-2776(01)76019-1; Grassl C, 1999, J AM SOC NEPHROL, V10, P1466; Grohmann U, 2001, J IMMUNOL, V167, P708, DOI 10.4049/jimmunol.167.2.708; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; HASBOLD J, 1994, EUR J IMMUNOL, V24, P1835, DOI 10.1002/eji.1830240817; Hsing Y, 1997, J IMMUNOL, V159, P4898; HUO L, 1995, J IMMUNOL, V154, P3300; Huo L, 1996, J IMMUNOL, V157, P3812; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Jalukar SV, 2000, J IMMUNOL, V164, P623, DOI 10.4049/jimmunol.164.2.623; Jefferies C, 2001, MOL CELL BIOL, V21, P4544, DOI 10.1128/MCB.21.14.4544-4552.2001; Jobin C, 1999, J IMMUNOL, V162, P4447; Kannan R, 1997, RANDOM STRUCT ALGOR, V11, P1, DOI 10.1002/(SICI)1098-2418(199708)11:1<1::AID-RSA1>3.0.CO;2-X; La Flamme AC, 1999, J IMMUNOL, V162, P5829; Leal IS, 1999, INFECT IMMUN, V67, P5747, DOI 10.1128/IAI.67.11.5747-5754.1999; Lee HH, 1999, P NATL ACAD SCI USA, V96, P1421, DOI 10.1073/pnas.96.4.1421; Leo E, 1999, J BIOL CHEM, V274, P22414, DOI 10.1074/jbc.274.32.22414; Palmieri M, 1999, NUCLEIC ACIDS RES, V27, P2785, DOI 10.1093/nar/27.13.2785; Pullen SS, 1999, J BIOL CHEM, V274, P14246, DOI 10.1074/jbc.274.20.14246; Revy P, 1999, J IMMUNOL, V163, P787; Shen CH, 2001, J IMMUNOL, V166, P411, DOI 10.4049/jimmunol.166.1.411; Shen ZH, 1997, J IMMUNOL, V158, P2723; Smart DE, 2001, J BIOL CHEM, V276, P24414, DOI 10.1074/jbc.M101840200; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; Sutherland CL, 1999, J IMMUNOL, V162, P4720; Suzuki Y, 1997, INFECT IMMUN, V65, P2339, DOI 10.1128/IAI.65.6.2339-2345.1997; Teague TK, 1997, J IMMUNOL, V158, P5791; Teague TK, 2000, J EXP MED, V191, P915, DOI 10.1084/jem.191.6.915; Thomson AW, 1995, TRANSPLANTATION, V60, P1555, DOI 10.1097/00007890-199560120-00030; Tsukamoto N, 1999, P NATL ACAD SCI USA, V96, P1234, DOI 10.1073/pnas.96.4.1234; VAN SJ, 1990, ANNU REV IMMUNOL, V8, P253	44	74	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17125	17138		10.1074/jbc.M109250200	http://dx.doi.org/10.1074/jbc.M109250200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11886848	hybrid			2022-12-25	WOS:000175564500105
J	Hidaka, S; Yoshimatsu, H; Kondou, S; Tsuruta, Y; Oka, K; Noguchi, H; Okamoto, K; Sakino, H; Teshima, Y; Okeda, T; Sakata, T				Hidaka, S; Yoshimatsu, H; Kondou, S; Tsuruta, Y; Oka, K; Noguchi, H; Okamoto, K; Sakino, H; Teshima, Y; Okeda, T; Sakata, T			Chronic central leptin infusion restores hyperglycemia independent of food intake and insulin level in streptozotocin-induced diabetic rats	FASEB JOURNAL			English	Article						STZ-induced insulin-deficient diabetes; glucose transporters; uncoupling proteins; anti-diabetic drugs	PERIPHERAL GLUCOSE-UPTAKE; BROWN ADIPOSE-TISSUE; SKELETAL-MUSCLE; UNCOUPLING PROTEIN; MESSENGER-RNA; BODY-WEIGHT; EXPRESSION; MICE; RESISTANCE; STIMULATION	We examined the effects of chronic centrally administered leptin on the glucose metabolism of streptozotocin-induced diabetic (STZ-D) rats, a model for insulin-dependent diabetes mellitus. When 3 mug . rat(-1) . day(-1) of leptin was infused into the third ventricle for 6 consecutive days (STZ-LEP), STZ-D rats became completely euglycemic. The effect was not seen when the same dosage was administered s.c. Centrally administered leptin did not affect peripheral insulin levels. The feeding volume of STZ-LEP rats was suppressed to the level of non-STZ-D control rats. No improvement of hyperglycemia was noted when STZ-D rats were pair-fed to match the feeding volume of STZ-LEP rats. Thus, the euglycemia of STZ-LEP rats cannot be due to the decreased feeding volume. In the STZ-D rat, glucokinase mRNA, a marker of glycolysis, is down-regulated whereas glucose-6-phosphatase mRNA, a marker of gluconeogenesis, and glucose transporter (GLUT) 2, which is implicated in the release of glucose from liver, are up-regulated. GLUT4, uncoupling protein (UCP) 1, and UCP3 were down-regulated in brown adipose tissue. These parameters returned to normal upon central infusion of leptin. GLUT4 was not down-regulated in the skeletal muscle of STZ-D rats; however, fatty acid binding protein and carnitine palmitoyltransferase I, markers for utilization and beta-oxidation of fatty acids, were up-regulated and restored when the rats were treated with leptin. The increase and subsequent decrease of fatty acid utilization suggests a decrease of glucose uptake in the skeletal muscle of STZ-D rats, which was restored upon central leptin administration. We conclude that centrally infused leptin does not control serum glucose by regulating feeding volume or elevating peripheral insulin, but by regulating hepatic glucose production, peripheral glucose uptake, and energy expenditure. The present study indicates the possibility of future development of a new class of anti-diabetic agents that act centrally and independent of insulin action.	Oita Med Univ, Sch Med, Dept Internal Med 1, Oita 8795593, Japan	Oita University	Sakata, T (corresponding author), Oita Med Univ, Sch Med, Dept Internal Med 1, Oita 8795593, Japan.	SAKATA@oita-med.ac.jp						Auwerx J, 1998, LANCET, V351, P737, DOI 10.1016/S0140-6736(97)06348-4; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; Berti L, 1997, DIABETOLOGIA, V40, P606, DOI 10.1007/s001250050722; BURCELIN R, 1993, BIOCHEM J, V291, P109, DOI 10.1042/bj2910109; Chinookoswong N, 1999, DIABETES, V48, P1487, DOI 10.2337/diabetes.48.7.1487; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Dunbar JC, 1997, DIABETES, V46, P2040, DOI 10.2337/diabetes.46.12.2040; Ebihara K, 2001, DIABETES, V50, P1440, DOI 10.2337/diabetes.50.6.1440; Emilsson V, 1997, DIABETES, V46, P313, DOI 10.2337/diabetes.46.2.313; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fruhbeck G, 2000, DIABETOLOGIA, V43, P3, DOI 10.1007/s001250050002; FUJIMOTO K, 1986, AM J PHYSIOL, V251, pR481, DOI 10.1152/ajpregu.1986.251.3.R481; Haque MS, 1999, DIABETES, V48, P1706, DOI 10.2337/diabetes.48.9.1706; Havel PJ, 1998, AM J PHYSIOL-REG I, V274, pR1482, DOI 10.1152/ajpregu.1998.274.5.R1482; Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532; Hidaka S, 2000, P SOC EXP BIOL MED, V224, P172, DOI 10.1046/j.1525-1373.2000.22417.x; Hidaka S, 1998, BBA-LIPID LIPID MET, V1389, P178, DOI 10.1016/S0005-2760(97)00188-4; Hidaka S, 1999, DIABETES, V48, P430, DOI 10.2337/diabetes.48.2.430; Hidaka S, 2001, J NEUROCHEM, V77, P993, DOI 10.1046/j.1471-4159.2001.00317.x; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; Kahn BB, 1996, DIABETES, V45, P1644, DOI 10.2337/diabetes.45.11.1644; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; Kim EM, 1999, AM J PHYSIOL-REG I, V276, pR1320, DOI 10.1152/ajpregu.1999.276.5.R1320; LANG CH, 1995, AM J PHYSIOL-REG I, V268, pR492, DOI 10.1152/ajpregu.1995.268.2.R492; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; Minokoshi Y, 1999, DIABETES, V48, P287, DOI 10.2337/diabetes.48.2.287; Muller G, 1997, J BIOL CHEM, V272, P10585, DOI 10.1074/jbc.272.16.10585; NEUFER PD, 1993, J BIOL CHEM, V268, P13824; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OKA Y, 1990, DIABETES, V39, P441, DOI 10.2337/diabetes.39.4.441; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PENICAUD L, 1985, AM J PHYSIOL, V249, pE514, DOI 10.1152/ajpendo.1985.249.5.E514; RENOLD AE, 1953, J BIOL CHEM, V204, P533; RICHARDSON JM, 1991, J BIOL CHEM, V266, P12690; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; Rossetti L, 1997, J BIOL CHEM, V272, P27758, DOI 10.1074/jbc.272.44.27758; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; Shi ZQ, 1998, METABOLISM, V47, P1274, DOI 10.1016/S0026-0495(98)90336-5; SHIBATA H, 1989, AM J PHYSIOL, V257, pR96, DOI 10.1152/ajpregu.1989.257.1.R96; SHIMADA M, 2000, GEOMECH RES SER, V2, P1; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; SUDO M, 1991, AM J PHYSIOL, V261, pE298, DOI 10.1152/ajpendo.1991.261.3.E298; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; TSAKIRIDIS T, 1995, BIOCHEM J, V309, P1; WILLIAMS G, 1989, DIABETES, V38, P321, DOI 10.2337/diabetes.38.3.321	48	83	84	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					509	518		10.1096/fj.01-0164com	http://dx.doi.org/10.1096/fj.01-0164com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11919153				2022-12-25	WOS:000175425900004
J	Sounni, NE; Devy, L; Hajitou, A; Frankenne, F; Munaut, C; Gilles, C; Deroanne, C; Thompson, EW; Foidart, JM; Noel, A				Sounni, NE; Devy, L; Hajitou, A; Frankenne, F; Munaut, C; Gilles, C; Deroanne, C; Thompson, EW; Foidart, JM; Noel, A			MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression	FASEB JOURNAL			English	Article						matrix metalloproteinases; MCF7 cells; MT1-MMP overexpression; VEGF	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; BREAST-CARCINOMA CELLS; IN-SITU HYBRIDIZATION; MT-MMP EXPRESSION; INTEGRIN ALPHA-V-BETA-3; TISSUE INHIBITOR; STROMAL CELLS; ACTIVATION; PROGRESSION; CANCER	Membrane type 1 metalloprotease (MT1-MMP) is a transmembrane metalloprotease that plays a major role in the extracellular matrix remodeling, directly by degrading several of its components and indirectly by activating pro-MMP2. We investigated the effects of MT1-MMP overexpression on in vitro and in vivo properties of human breast adenocarcinoma MCF7 cells, which do not express MT1-MMP or MMP-2. MT1-MMP and MMP-2 cDNAs were either transfected alone or cotransfected. All clones overexpressing MT1-MMP 1) were able to activate endogenous or exogenous pro-MMP-2, 2) displayed an enhanced in vitro invasiveness through matrigel-coated filters independent of MMP-2 transfection, 3) induced the rapid development of highly vascularized tumors when injected subcutanously in nude mice, and 4) promoted blood vessels sprouting in the rat aortic ring assay. These effects were observed in all clones overexpressing MT1-MMP regardless of MMP-2 expression levels, suggesting that the production of MMP-2 by tumor cells themselves does not play a critical role in these events. The angiogenic phenotype of MT1-MMP producing cells was associated with an up-regulation of VEGF expression. These results emphasize the importance of MT1-MMP during tumor angiogenesis and open new opportunities for the development of antiangiogenic strategies combining inhibitors of MT1-MMP and VEGF antagonists.	Univ Liege, Lab Biol Tumor & Dev, B-4000 Sart Tilman Par Liege, Belgium; Univ Liege, Lab Connect Tissues Biol, B-4000 Sart Tilman Par Liege, Belgium; St Vincents Inst Med Res, Victorian Breast Canc Res Consortium, Invas & Metastasis Unit, Fitzroy, Vic 3065, Australia	University of Liege; University of Liege; St. Vincent's Institute of Medical Research	Noel, A (corresponding author), Univ Liege, Lab Biol Tumor & Dev, B-4000 Sart Tilman Par Liege, Belgium.	agnes.noel@ulg.ac.be	Thompson, Erik W/A-1425-2009; Sounni, Nor Eddine/AAY-8766-2021; Thompson, Erik/GPK-2067-2022; Munaut, Carine/K-8138-2019	Thompson, Erik W/0000-0002-9723-4924; Sounni, Nor Eddine/0000-0001-9962-9236; Thompson, Erik/0000-0002-9723-4924; Noel, Agnes/0000-0002-7670-6179				Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Belien ATJ, 1999, J CELL BIOL, V144, P373, DOI 10.1083/jcb.144.2.373; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Blacher Silvia, 2001, Angiogenesis, V4, P133, DOI 10.1023/A:1012251229631; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; Gilles C, 1996, INT J CANCER, V65, P209; Gingras D, 2001, FEBS LETT, V507, P231, DOI 10.1016/S0014-5793(01)02985-4; Hajitou A, 2001, CANCER RES, V61, P3450; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hofmann UB, 2000, J PATHOL, V191, P245; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Itoh T, 1998, CANCER RES, V58, P1048; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; MILLER DL, 1994, CELL GROWTH DIFFER, V5, P1263; Mori M, 1997, INT J CANCER, V74, P316, DOI 10.1002/(SICI)1097-0215(19970620)74:3<316::AID-IJC14>3.0.CO;2-9; Nawrocki B, 1997, INT J CANCER, V72, P556, DOI 10.1002/(SICI)1097-0215(19970807)72:4<556::AID-IJC2>3.3.CO;2-#; NICOSIA RF, 1990, LAB INVEST, V63, P115; NOEL A, 1993, BRIT J CANCER, V68, P909, DOI 10.1038/bjc.1993.453; Noel A, 1997, INVAS METAST, V17, P221; NOEL A, 1994, PATHOL RES PRACT, V190, P934; NOMURA H, 1995, CANCER RES, V55, P3263; Ohtani H, 1996, INT J CANCER, V68, P565, DOI 10.1002/(SICI)1097-0215(19961127)68:5<565::AID-IJC2>3.0.CO;2-X; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Polette M, 1996, VIRCHOWS ARCH, V428, P29; POLETTE M, 1994, VIRCHOWS ARCH, V424, P641, DOI 10.1007/BF01069745; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; SOUNNI NE, 2001, IN PRESS INT J CANC; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TOKURAKU M, 1995, INT J CANCER, V64, P355, DOI 10.1002/ijc.2910640513; Ueno H, 1997, CANCER RES, V57, P2055; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	44	220	245	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					555	564		10.1096/fj.01-0790com	http://dx.doi.org/10.1096/fj.01-0790com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11919158				2022-12-25	WOS:000175425900009
J	Monti, P; Campomenosi, P; Ciribilli, Y; Iannone, R; Inga, A; Abbondandolo, A; Resnick, MA; Fronza, G				Monti, P; Campomenosi, P; Ciribilli, Y; Iannone, R; Inga, A; Abbondandolo, A; Resnick, MA; Fronza, G			Tumour p53 mutations exhibit promoter selective dominance over wild type p53	ONCOGENE			English	Article						dominance; p53; mutation; yeast functional assay; p53 responsive element	CELL-CYCLE; MUTANTS; YEAST; INHIBITION; PROTEIN; DNA; IDENTIFICATION; TRANSCRIPTION; CANCERS; ARREST	The tumour suppressor gene p53 is frequently mutated in human cancer. Tumour derived p53 mutants are usually transcriptionally inactive, but some mutants retain the ability to transactivate a subset of p53 target genes. In addition to simple loss of function, some p53 mutants may be carcinogenic through a dominant negative mechanism. Aiming at a more general classification of p53 mutants into predictive functional categories it is important to determine (i) which p53 mutants are dominant, (ii) what features characterize dominant mutants and (iii) whether dominance is target gene specific. The ability of 71 p53 mutants to inhibit wild type p53 was determined using a simple yeast transcriptional assay. Approximately 30% of the mutants were dominant. They preferentially affect highly conserved amino acids (P < 0.005), which are frequently mutated in turnours (P < 0.005), and usually located near the DNA binding surface of the protein (P < 0.001). Different tumour-derived amino acid substitutions at the same codon usually have the same dominance phenotype. To determine whether the ability of p53 mutants to inhibit wild type p53 is target gene specific, the dominance towards p21, bax, and PIG3 binding sites was examined. Approximately 40% of the 45 mutants examined were dominant for the p21 (17/45) or PIG3 (20/45) responsive elements and 71% (32/45) were dominant for the bax responsive element. These differences are statistically significant (p21 vs bax, P < 0.003; bax vs PIG3, P < 0.02, Fisher's exact test) and defined a hierarchy of dominance. Finally, we extended the analysis to a group of mutants isolated in BRCA-associated tumours, some of which retained wild type level of transcription in yeast as well as in human cells, but show gain of function in transformation assays. Since transformation assays require transdominant inhibition of the endogenous wild type allele, one possible explanation for the behaviour of the BRCA-associated mutants is that they adopt conformations able to bind DNA alone but not in mixed tetramers with wild type p53. The yeast data do not support this explanation, because all BRCA-associated mutants that behaved as wild type in transcription assay were recessive in dominance assays.	Natl Canc Res Inst, IST, Mutagenesis Lab, I-16132 Genoa, Italy; Univ Insubria, DBSF, Human Genet Lab, Varese, Italy; NIEHS, Chromosome Stabil Grp, Res Triangle Pk, NC 27709 USA; Univ Genoa, Dept Oncol Biol & Genet, Genoa, Italy	University of Insubria; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Genoa	Fronza, G (corresponding author), Natl Canc Res Inst, IST, Mutagenesis Lab, Largo R Benzi 10, I-16132 Genoa, Italy.	gilberto.fronza@istge.it	resnick, Michael/F-1668-2019; Inga, Alberto/AAC-3815-2022; Monti, Paola/Y-1118-2019; Ciribilli, Yari/K-2751-2018; Campomenosi, Paola/C-9729-2011; Fronza, Gilberto/AAG-8735-2019	resnick, Michael/0000-0002-8473-7506; Inga, Alberto/0000-0002-8767-1637; Monti, Paola/0000-0002-1978-4998; Ciribilli, Yari/0000-0001-9231-379X; Campomenosi, Paola/0000-0002-8853-1134; Fronza, Gilberto/0000-0003-3722-553X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065079, Z01ES065079] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Blagosklonny MV, 2001, CARCINOGENESIS, V22, P861, DOI 10.1093/carcin/22.6.861; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Di Como CJ, 1998, ONCOGENE, V16, P2527; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FREBOURG T, 1994, CANCER RES, V54, P878; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Inga A, 1997, CARCINOGENESIS, V18, P2019, DOI 10.1093/carcin/18.10.2019; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; Inga A, 1999, CANCER RES, V59, P689; Inga A, 1998, CARCINOGENESIS, V19, P741, DOI 10.1093/carcin/19.5.741; Joers A, 1998, ONCOGENE, V17, P2351, DOI 10.1038/sj.onc.1202146; Kelly JD, 1999, J BIOL CHEM, V274, P18327, DOI 10.1074/jbc.274.26.18327; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Marutani M, 1999, CANCER RES, V59, P4765; Monti P, 2000, MUTAGENESIS, V15, P127, DOI 10.1093/mutage/15.2.127; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Robert V, 2000, CARCINOGENESIS, V21, P563, DOI 10.1093/carcin/21.4.563; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; Waterman MJF, 1996, CANCER RES, V56, P158	27	57	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1641	1648		10.1038/sj.onc.1205250	http://dx.doi.org/10.1038/sj.onc.1205250			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896595				2022-12-25	WOS:000174214200002
J	Idzko, M; Panther, E; Corinti, S; Morelli, A; Ferrari, D; Herouy, Y; Dichmann, S; Mockenhaupt, M; Gebicke-Haerter, P; Di Virgilio, F; Girolomoni, G; Norgauer, J				Idzko, M; Panther, E; Corinti, S; Morelli, A; Ferrari, D; Herouy, Y; Dichmann, S; Mockenhaupt, M; Gebicke-Haerter, P; Di Virgilio, F; Girolomoni, G; Norgauer, J			Sphingosine 1-phosphate induces chemotaxis of immature dendritic cells and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses	FASEB JOURNAL			English	Article						Ca2+; actin polymerization; IL-12; IL-10	MULTIPLE SIGNALING PATHWAYS; G-PROTEINS; SPHINGOSINE-1-PHOSPHATE; RECEPTOR; ACTIVATION; ANGIOGENESIS; INHIBITION; PLATELETS; PHOSPHATE; SUBTYPES	Sphingosine 1-phosphate (S1P) is a potent extracellular lysolipid phosphoric acid mediator that is released after IgE-stimulation of mast cells. Here we investigated the biological activity and intracellular signaling of S1P on human dendritic cells (DC), which are specialized antigen presenting cells with the ability to migrate into peripheral tissues and lymph nodes, as well as control the activation of naive T cells. We show that immature and mature DC express the mRNA for different S1P receptors, such as endothelial differentiation gene (EDG)-1, EDG-3, EDG-5, and EDG-6. In immature DC, S1P stimulated pertussis toxin-sensitive Ca2+ increase actin-polymerization and chemotaxis. These responses were lost by DC matured with lipopolysaccharide. In maturing DC, however, S1P inhibited the secretion of tumor necrosis factor and interleukin (IL)-12, whereas it enhanced secretion of IL-10. As a consequence, mature DC exposed to S1P showed a reduced and increased capacity to generate allogeneic Th1 and Th2 responses, respectively. In summary, our study implicates that S1P might regulate the trafficking of DC and ultimately favor Th2 lymphocyte-dominated immunity.	Dept Expt Dermatol, D-79104 Freiburg, Germany; Ist Dermopatico Immacolata, Immunol Lab, Rome, Italy; Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Ferrara	Norgauer, J (corresponding author), Dept Expt Dermatol, Hauptstr 7, D-79104 Freiburg, Germany.	Norgauer@haut.ukl.uni-freiburg.de	GIROLOMONI, Giampiero/AAC-3405-2022; Ferrari, Davide/F-5644-2015; Eckhardt, Erik/G-1567-2010; Di Virgilio, Francesco/J-3754-2018; DI VIRGILIO, Francesco/O-4634-2019	Ferrari, Davide/0000-0002-5727-9204; Di Virgilio, Francesco/0000-0003-3566-1362; DI VIRGILIO, Francesco/0000-0003-3566-1362				Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Berger A, 1996, MOL PHARMACOL, V50, P451; BROCKLYN JR, 2000, BLOOD, V95, P2624; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dichmann S, 2000, J CELL PHYSIOL, V185, P394, DOI 10.1002/1097-4652(200012)185:3<394::AID-JCP9>3.3.CO;2-Q; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; English D, 1999, J HEMATOTH STEM CELL, V8, P627, DOI 10.1089/152581699319795; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Kleuss C, 1997, P NATL ACAD SCI USA, V94, P6116, DOI 10.1073/pnas.94.12.6116; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; la Sala A, 2001, J IMMUNOL, V166, P1611, DOI 10.4049/jimmunol.166.3.1611; Lanzavecchia A, 2000, SCIENCE, V290, P92, DOI 10.1126/science.290.5489.92; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Panther E, 2001, FASEB J, V15, P1963, DOI 10.1096/fj.01-0169com; Pastore S, 1997, J CLIN INVEST, V99, P3009, DOI 10.1172/JCI119496; Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1; Siffert W, 1998, NAT GENET, V18, P45, DOI 10.1038/ng0198-45; Sozzani S, 2000, J CLIN IMMUNOL, V20, P151, DOI 10.1023/A:1006659211340; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Wollenberg A, 2000, CLIN EXP DERMATOL, V25, P530, DOI 10.1046/j.1365-2230.2000.00699.x; Yatomi Y, 2000, BLOOD, V96, P3431; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	37	155	158	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					625	+		10.1096/fj.01-0625fje	http://dx.doi.org/10.1096/fj.01-0625fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919175				2022-12-25	WOS:000174203700011
J	Pance, A; Chantome, A; Reveneau, S; Bentrari, F; Jeannin, JF				Pance, A; Chantome, A; Reveneau, S; Bentrari, F; Jeannin, JF			A repressor in the proximal human inducible nitric oxide synthase promoter modulates transcriptional activation	FASEB JOURNAL			English	Article						AP-1; repressor; transcriptional regulation; NOSII	CYTOKINE INDUCTION; MOLECULAR-CLONING; AP-1 REPRESSOR; DLD-1 CELLS; L-ARGININE; GENE; EXPRESSION; INHIBITION; REQUIRES; NITRATE	The human inducible nitric oxide synthase (iNOS or NOSII) gene is regulated through an extended and complex promoter. In this study, the transcriptional regulation of human NOSII is investigated in the human colon cell line HCT-8R. Stimulation with a cytokine mix (interferon-gamma, interleukin 1-beta, and tumor necrosis factor alpha) induces NOSII mRNA accumulation, as well as promoter activity in these cells. Several random deletions were performed within the proximal 7 kb of the promoter, which led to the identification of a region, whose deletion provokes a marked increase in transcriptional activity upon cytokine stimulation. Furthermore, this region is shown to repress a viral-driven luciferase construct, mainly at basal levels. An AP-1-like sequence present in this region that is specifically recognized by nuclear proteins is shown to be involved in the repressive effect. This element is capable of repressing a viral promoter, and its deletion augments cytokine-stimulated transcription. These findings are confirmed in various cell lines and suggest a general mechanism for the control of basal levels of NOSII expression, to avoid unnecessary toxicity under normal conditions.	Univ Bourgogne, Fac Med, Ecole Prat Hautes Etud, Canc Immunotherapy Lab, F-21000 Dijon, France; Univ Bourgogne, Fac Med, INSERM, U517, F-21000 Dijon, France	Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Pance, A (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.	apance@reacciun.ve	Pance, Alena/AAH-2878-2021	Pance, Alena/0000-0002-9017-2644				Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; BUNE AJ, 1995, FEBS LETT, V366, P127, DOI 10.1016/0014-5793(95)00495-U; CHU SC, 1995, J BIOL CHEM, V270, P10625, DOI 10.1074/jbc.270.18.10625; Chu SC, 1998, BIOCHEM BIOPH RES CO, V248, P871, DOI 10.1006/bbrc.1998.9062; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Eissa NT, 1998, P NATL ACAD SCI USA, V95, P7625, DOI 10.1073/pnas.95.13.7625; Eissa NT, 1996, J BIOL CHEM, V271, P27184, DOI 10.1074/jbc.271.43.27184; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Goldring CEP, 2000, FASEB J, V14, P2393; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; Kleinert H, 1996, J BIOL CHEM, V271, P6039, DOI 10.1074/jbc.271.11.6039; Laubach VE, 1997, BBA-GENE STRUCT EXPR, V1351, P287, DOI 10.1016/S0167-4781(96)06909-6; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; Patterson T, 2001, ONCOGENE, V20, P634, DOI 10.1038/sj.onc.1204134; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; Prabhakar SS, 2001, AM J PHYSIOL-RENAL, V281, pF179, DOI 10.1152/ajprenal.2001.281.1.F179; Ratovitski EA, 1999, J BIOL CHEM, V274, P30250, DOI 10.1074/jbc.274.42.30250; Ravi R, 1998, CANCER RES, V58, P4531; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Spitsin SV, 1996, MOL MED, V2, P226, DOI 10.1007/BF03401619; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316	30	25	26	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					631	+		10.1096/fj.01-0450fje	http://dx.doi.org/10.1096/fj.01-0450fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919177				2022-12-25	WOS:000174203700005
J	Toko, H; Zhu, WD; Takimoto, E; Shiojima, I; Hiroi, Y; Zou, YZ; Oka, T; Akazawa, H; Mizukami, M; Sakamoto, M; Terasaki, F; Kitaura, Y; Takano, H; Nagai, T; Nagai, R; Komuro, I				Toko, H; Zhu, WD; Takimoto, E; Shiojima, I; Hiroi, Y; Zou, YZ; Oka, T; Akazawa, H; Mizukami, M; Sakamoto, M; Terasaki, F; Kitaura, Y; Takano, H; Nagai, T; Nagai, R; Komuro, I			Csx/Nkx2-5 is required for homeostasis and survival of cardiac myocytes in the adult heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TINMAN-RELATED GENES; FACTOR NKX2-5; TRANSCRIPTION; DOXORUBICIN; EXPRESSION; DIFFERENTIATION; MUTATIONS; DISEASE; APOPTOSIS; PROTEIN	Csx/Nkx2-5, which is essential for cardiac development of the embryo, is abundantly expressed in the adult heart. We here examined the role of Csx/Nkx2-5 in the adult heart using two kinds of transgenic mice. Transgenic mice that overexpress a dominant negative mutant of Csx/Nkx2-5 (DN-TG mice) showed degeneration of cardiac myocytes and impairment of cardiac function. Doxorubicin induced more marked cardiac dysfunction in DN-TG mice and less in transgenic mice that overexpress wild type Csx/Nkx2-5 (WT-TG mice) compared with non-transgenic mice. Doxorubicin induced cardiomyocyte apoptosis, and the number of apoptotic cardiomyocytes was high in the order of DN-TG mice, non-transgenic mice, and WT-TG mice. Overexpression of the dominant negative mutant of Csx/Nkx2-5 induced apoptosis in cultured cardiomyocytes, while expression of wild type Csx/Nkx2-5 protected cardiomyocytes from doxorubicin-induced apoptotic death. These results suggest that Csx/Nkx2-5 plays a critical role in maintaining highly differentiated cardiac phenotype and in protecting the heart from stresses including doxorubicin.	Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, Chiba 2608670, Japan; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan; Shinshu Univ, Sch Med, Dept Internal Med, Matsumoto, Nagano 3908621, Japan; Osaka Med Coll, Dept Internal Med 3, Takatsuki, Osaka 5698686, Japan	Chiba University; University of Tokyo; Shinshu University; Osaka Medical College	Komuro, I (corresponding author), Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.			Akazawa, Hiroshi/0000-0002-3574-9607				Benson DW, 1999, J CLIN INVEST, V104, P1567, DOI 10.1172/JCI8154; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; Chen JN, 1996, DEVELOPMENT, V122, P3809; Chen SC, 1999, HYPERTENSION, V34, P1223, DOI 10.1161/01.HYP.34.6.1223; Cleaver OB, 1996, DEVELOPMENT, V122, P3549; Grow MW, 1998, DEV BIOL, V204, P187, DOI 10.1006/dbio.1998.9080; GULICK J, 1991, J BIOL CHEM, V266, P9180; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; ITO H, 1990, P NATL ACAD SCI USA, V87, P4275, DOI 10.1073/pnas.87.11.4275; Kasahara H, 2001, J BIOL CHEM, V276, P4570, DOI 10.1074/jbc.M004995200; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; KURABAYASHI M, 1994, J BIOL CHEM, V269, P6031; LEWIS W, 1987, LAB INVEST, V56, P295; LINTS TJ, 1993, DEVELOPMENT, V119, P1654; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Poizat C, 2000, MOL CELL BIOL, V20, P8643, DOI 10.1128/MCB.20.23.8643-8654.2000; RAHMAN A, 1982, CANCER RES, V42, P1817; Saadane N, 1999, BRIT J PHARMACOL, V127, P1165, DOI 10.1038/sj.bjp.0702676; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; SOMEYA A, 1978, BIOCHEM BIOPH RES CO, V85, P1542, DOI 10.1016/0006-291X(78)91178-6; Takimoto E, 2000, BIOCHEM BIOPH RES CO, V270, P1074, DOI 10.1006/bbrc.2000.2561; Tanaka M, 1999, DEVELOPMENT, V126, P1269; Thompson JT, 1998, AM J PHYSIOL-HEART C, V274, pH1569, DOI 10.1152/ajpheart.1998.274.5.H1569; Zhu WD, 2000, J BIOL CHEM, V275, P35291, DOI 10.1074/jbc.M000525200; Zhu WD, 1999, CIRCULATION, V100, P2100, DOI 10.1161/01.CIR.100.20.2100; Zou YM, 1997, DEVELOPMENT, V124, P793	27	60	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24735	24743		10.1074/jbc.M107669200	http://dx.doi.org/10.1074/jbc.M107669200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11889119	hybrid			2022-12-25	WOS:000176611800100
J	Jezewska, MJ; Galletto, R; Bujalowskii, W				Jezewska, MJ; Galletto, R; Bujalowskii, W			Dynamics of gapped DNA recognition by human polymerase beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; DIFFERENT BINDING MODES; TRANSFER RNA-PHE; KINETIC MECHANISM; TEMPLATE-PRIMER; REPAIR SYNTHESIS; PROTEIN HEXAMER; ANTICODON LOOP; ABASIC SITE; HELICASE	Kinetics of human polymerase 13 binding to gapped DNA substrates having single stranded (ss) DNA gaps with five or two nucleotide residues in the ssDNA gap has been examined, using the fluorescence stopped-flow technique. The mechanism of the recognition does not depend on the length of the ssDNA gap. Formation of the enzyme complex with both DNA substrates occurs by a minimum three-step reaction, with the bimolecular step followed by two isomerization steps. The results indicate that the polymerase initiates the association with gapped DNA substrates through the DNA-binding subsite located on the 8-kDa domain of the enzyme. This first association step is independent of the length of the ssDNA gap and is characterized by similar rate constants for both examined DNA substrates. The subsequent, first-order transition occurs at the rate of -600-1200 s(-1). This is the major docking step accompanied by favorable free energy changes in which the 31-kDa domain engages in interactions with the DNA. The 5'-terminal PO4- group downstream from the primer is not a specific recognition element of the gap. However, the phosphate group affects the enzyme orientation in the complex with the DNA, particularly, for the substrate with a longer gap.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy ctr struct Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Bujalowskii, W (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, 301 Univ BLvd, Galveston, TX 77555 USA.			Galletto, Roberto/0000-0001-6435-122X	NIGMS NIH HHS [GM-58565] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058565] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bandwar RP, 2001, J BIOL CHEM, V276, P14075, DOI 10.1074/jbc.M011289200; Bernasconi C. F., 1976, RELAXATION KINETICS; Budd ME, 1997, MUTAT RES-DNA REPAIR, V384, P157, DOI 10.1016/S0921-8777(97)00024-4; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P6372, DOI 10.1021/bi00369a005; Bujalowski W, 2000, BIOCHEMISTRY-US, V39, P2106, DOI 10.1021/bi992413m; Bujalowski W, 2000, J MOL BIOL, V295, P831, DOI 10.1006/jmbi.1999.3378; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P6365, DOI 10.1021/bi00369a004; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; Bujalowski W., 2000, SPECTROPHOTOMETRY SP, P141; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P1; CONNORS KW, 1990, CHEM KINETICS STUDY, P133; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HAMMOND RA, 1990, BIOCHEMISTRY-US, V29, P286, DOI 10.1021/bi00453a039; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; Jezewska MJ, 1996, J BIOL CHEM, V271, P4261; Jezewska MJ, 1998, J BIOL CHEM, V273, P9058, DOI 10.1074/jbc.273.15.9058; Jezewska MJ, 1998, BIOCHEMISTRY-US, V37, P3116, DOI 10.1021/bi972564u; Jezewska MJ, 1998, J BIOL CHEM, V273, P10515, DOI 10.1074/jbc.273.17.10515; Jezewska MJ, 2001, J BIOL CHEM, V276, P16123, DOI 10.1074/jbc.M010434200; Jezewska MJ, 2001, J MOL BIOL, V313, P977, DOI 10.1006/jmbi.2001.5042; Jezewska MJ, 2001, BIOCHEMISTRY-US, V40, P3295, DOI 10.1021/bi002749s; Jezewska MJ, 1998, J MOL BIOL, V284, P1113, DOI 10.1006/jmbi.1998.2252; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; MATSUMOTO Y, 1991, MOL CELL BIOL, V11, P4441, DOI 10.1128/MCB.11.9.4441; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PILAR RL, 1968, ELEMENTARY QUANTUM C; PORSCHKE D, 1978, BIOPOLYMERS, V17, P315; PORSCHKE D, 1976, BIOCHEMISTRY-US, V15, P1495; PRASAD R, 1994, J BIOL CHEM, V269, P18096; Rajendran S, 2000, J MOL BIOL, V303, P773, DOI 10.1006/jmbi.2000.4124; Rajendran S, 2001, BIOCHEMISTRY-US, V40, P11794, DOI 10.1021/bi011173j; Rajendran S, 2001, J MOL BIOL, V308, P477, DOI 10.1006/jmbi.2001.4571; Rajendran S, 1998, J BIOL CHEM, V273, P31021, DOI 10.1074/jbc.273.47.31021; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; Zhong XJ, 1997, BIOCHEMISTRY-US, V36, P11891, DOI 10.1021/bi963181j	43	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20316	20327		10.1074/jbc.M200918200	http://dx.doi.org/10.1074/jbc.M200918200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11912205	hybrid			2022-12-25	WOS:000176204500030
J	Milanini-Mongiat, J; Pouyssegur, J; Pages, G				Milanini-Mongiat, J; Pouyssegur, J; Pages, G			Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases - Their implication in vascular endothelial growth factor gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; INTERNAL RIBOSOME ENTRY; DNA-BINDING ACTIVITY; NIH 3T3 CELLS; MAP KINASE; FACTOR EXPRESSION; SP1-MEDIATED TRANSCRIPTION; SIGNAL-TRANSDUCTION; PROMOTER ACTIVITY; CYCLE REGULATION	Sp1 regulates activation of many genes implicated in tumor growth and cell cycle progression. We have previously demonstrated its implication in the up-regulation of vascular endothelial growth factor (VEGF) gene transcription following growth factor stimulation of quiescent cells, a situation where p42/p44 mitogen-activate protein kinase (MAPK) activity is dramatically increased. Here we show that p42/p44 MAPK directly phosphorylates Sp1 on threonines 453 and 739 both in vitro and in vivo. Mutation of these sites to alanines decreases by half the MAPK-dependent transcriptional activity of Sp1, in the context of the VEGF promoter, in SL2 Drosophila cells devoid of the endogenous Sp1 protein. Moreover, inducible overexpression of the (T453A,T739A) Sp1 double mutant compromises MAPK-driven VEGF mRNA transcription in fibroblasts. These results highlight Sp1 as a key molecular link between elevated activation of the Ras much greater than p42/p44MAPK signaling pathway and increased VEGF expression, two major steps deregulated in tumor cells.	Ctr Antoine Lacassagne, Inst Signalling Dev Biol & Canc Res, F-06189 Nice 2, France	UNICANCER; Centre Antoine Lacassagne	Pages, G (corresponding author), Ctr Antoine Lacassagne, Inst Signalling Dev Biol & Canc Res, 33 Ave Valombrose, F-06189 Nice 2, France.		Pages, Gilles/N-7135-2017	Milanini, Julie/0000-0002-5861-2830				Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; de Borja PF, 2001, EMBO J, V20, P5737; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gartel AL, 2000, ONCOGENE, V19, P5182, DOI 10.1038/sj.onc.1203900; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Gioeli D, 1999, CANCER RES, V59, P279; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JANKNECHT R, 1994, ONCOGENE, V9, P1273; Jensen DE, 1997, J CELL BIOCHEM, V67, P24, DOI 10.1002/(SICI)1097-4644(19971001)67:1<24::AID-JCB3>3.0.CO;2-Y; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Miyata Y, 1999, BBA-MOL CELL RES, V1451, P334, DOI 10.1016/S0167-4889(99)00107-X; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; Pal S, 2001, J BIOL CHEM, V276, P2395, DOI 10.1074/jbc.M007818200; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Rak J, 2000, CANCER RES, V60, P490; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Salh B, 1999, ANTICANCER RES, V19, P731; Salimath B, 2000, ONCOGENE, V19, P3470, DOI 10.1038/sj.onc.1203672; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schmidt CM, 1997, BIOCHEM BIOPH RES CO, V236, P54, DOI 10.1006/bbrc.1997.6840; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; SETH A, 1992, J BIOL CHEM, V267, P24796; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; Song XD, 1999, J BIOL CHEM, V274, P1677, DOI 10.1074/jbc.274.3.1677; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; Zhang LL, 2000, CANCER RES, V60, P3655	83	260	270	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20631	20639		10.1074/jbc.M201753200	http://dx.doi.org/10.1074/jbc.M201753200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11904305	hybrid			2022-12-25	WOS:000176204500070
J	Nutt, LK; Chandra, J; Pataer, A; Fang, BL; Roth, JA; Swisher, SG; O'Neil, RG; McConkey, DJ				Nutt, LK; Chandra, J; Pataer, A; Fang, BL; Roth, JA; Swisher, SG; O'Neil, RG; McConkey, DJ			Bax-mediated Ca2+ mobilization promotes cytochrome c release during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY PROTEINS; ENDOPLASMIC-RETICULUM; INTRACELLULAR CALCIUM; MITOCHONDRIAL CONTROL; PROAPOPTOTIC BAX; ION-CHANNEL; DEATH; PHOSPHORYLATION; HOMEOSTASIS; EXPRESSION	Previous studies have demonstrated that Ca2+ is released from the endoplasmic reticulum (ER) in some models of apoptosis, but the mechanisms involved and the functional significance remain obscure. We confirmed that apoptosis induced by some (but not all) proapoptotic stimuli was associated with caspase-independent, BCL-2-sensitive emptying of the ER Ca2+ pool in human PC-3 prostate cancer cells. This mobilization of ER Ca2+ was associated with a concomitant increase in mitochondrial Ca2+ levels, and neither ER Ca2+ mobilization nor mitochondrial Ca2+ uptake occurred in Bax-null DU-145 cells. Importantly, restoration of DU145 Bax expression via adenoviral gene transfer restored ER Ca2+ release and mitochondrial Ca2+ uptake and dramatically accelerated the kinetics of staurosporine-induced cytochrome c release, demonstrating a requirement for Bax expression in this model system. In addition, an inhibitor of the mitochondrial Ca2+ uniporter (RU-360) attenuated mitochondrial Ca2+ uptake, cytochrome c release, and DNA fragmentation, directly implicating the mitochondrial Ca2+ changes in cell death. Together, our data demonstrate that Bax-mediated alterations in ER and mitochondrial Ca2+ levels serve as important upstream signals for cytochrome c release in some examples of apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol 173, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Sect Thorac & Mol Oncol, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Texas, Houston Med Sch, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	McConkey, DJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol 173, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dmcconke@mdanderson.org			NATIONAL CANCER INSTITUTE [R29CA069676, P01CA078778, T32CA009598] Funding Source: NIH RePORTER; NCI NIH HHS [2P50-CA70970-04, CA09598, P01-CA78778-O1A1, CA69676] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Chandra J, 1998, BLOOD, V92, P4220, DOI 10.1182/blood.V92.11.4220.423k49_4220_4229; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; FURUYA Y, 1994, CANCER RES, V54, P6167; Gogvadze V, 2001, J BIOL CHEM, V276, P19066, DOI 10.1074/jbc.M100614200; Haldar S, 1996, CANCER RES, V56, P1253; HALDAR S, 1995, P NATL ACAD SCI USA, V342, P195; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; McConkey DJ, 1996, CANCER RES, V56, P5594; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Nutt LK, 2000, J AM SOC NEPHROL, V11, P1225, DOI 10.1681/ASN.V1171225; Pacher P, 2001, EMBO J, V20, P4107, DOI 10.1093/emboj/20.15.4107; Pataer A, 2000, CANCER RES, V60, P788; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Shinoura N, 1999, CANCER RES, V59, P4119; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	52	165	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20301	20308		10.1074/jbc.M201604200	http://dx.doi.org/10.1074/jbc.M201604200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11909872	hybrid			2022-12-25	WOS:000176204500028
J	Chen, YF; Randlett, MD; Findell, JL; Schaller, GE				Chen, YF; Randlett, MD; Findell, JL; Schaller, GE			Localization of the ethylene receptor ETR1 to the endoplasmic reticulum of Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUXIN-BINDING PROTEIN; PLASMA-MEMBRANE; TRANSMEMBRANE PROTEINS; VACUOLAR MEMBRANE; GENE FAMILY; H+-ATPASE; RESPONSES; RETENTION; MUTANT; PLANTS	The ethylene receptor ETR1 of Arabidopsis contains transmembrane domains responsible for ethylene binding and membrane localization. Sequence analysis does not provide information as to which membrane system of the plant cell ETR1 is localized. Examination by aqueous two-phase partitioning, sucrose density-gradient centrifugation, and immunoelectron microscopy indicates that ETR1 is predominantly localized to the endoplasmic reticulum. Localization of ETR1 showed no change following a cycloheximide chase. Ethylene binding by ETR1 did not affect localization to the endoplasmic reticulum, based upon analysis of plants treated with the ethylene precursor 1-aminocyclopropane-1-carboxylic acid and by examination of a mutant receptor that does not bind ethylene. Determinants within the amino-terminal half of ETR1 are sufficient for targeting to and retention at the endoplasmic reticulum. These data support a central role of the plant endoplasmic reticulum. in hormone perception and signal transduction.	Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA	University System Of New Hampshire; University of New Hampshire	Schaller, GE (corresponding author), Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA.							Abeles F, 1992, ETHYLENE PLANT BIOL; Alonso JM, 1999, SCIENCE, V284, P2148, DOI 10.1126/science.284.5423.2148; [Anonymous], FUNDAMENTALS MED C A; Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; Bauly JM, 2000, PLANT PHYSIOL, V124, P1229, DOI 10.1104/pp.124.3.1229; Benghezal M, 2000, PLANT CELL, V12, P1179, DOI 10.1105/tpc.12.7.1179; Bleecker AB, 1999, TRENDS PLANT SCI, V4, P269, DOI 10.1016/S1360-1385(99)01427-2; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; Chen JG, 2001, GENE DEV, V15, P902, DOI 10.1101/gad.866201; DENECKE J, 1992, EMBO J, V11, P2345, DOI 10.1002/j.1460-2075.1992.tb05294.x; DENECKE J, 1991, PLANT CELL, V3, P1025, DOI 10.1105/tpc.3.9.1025; DeWitt ND, 1996, PLANT PHYSIOL, V112, P833, DOI 10.1104/pp.112.2.833; EVANS DE, 1982, PLANT CELL ENVIRON, V5, P101; EVANS DE, 1982, PLANTA, V154, P48, DOI 10.1007/BF00385495; Gamble RL, 1998, P NATL ACAD SCI USA, V95, P7825, DOI 10.1073/pnas.95.13.7825; GARCIA PD, 1987, J BIOL CHEM, V262, P9463; GAUBLE RL, 2002, PLANT PHYSIOL, V128, P1428; Hall AE, 1999, PLANT PHYSIOL, V121, P291, DOI 10.1104/pp.121.1.291; Henderson J, 1997, PLANTA, V202, P313, DOI 10.1007/s004250050133; Hirayama T, 1999, CELL, V97, P383, DOI 10.1016/S0092-8674(00)80747-3; HOFTE H, 1992, PLANT CELL, V4, P995, DOI 10.1105/tpc.4.8.995; Hong BM, 1999, PLANT PHYSIOL, V119, P1165, DOI 10.1104/pp.119.4.1165; Hua J, 1998, PLANT CELL, V10, P1321, DOI 10.1105/tpc.10.8.1321; Hua J, 1998, CELL, V94, P261, DOI 10.1016/S0092-8674(00)81425-7; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Koizumi N, 2001, PLANT PHYSIOL, V127, P949, DOI 10.1104/pp.010636; Kwak SH, 1997, PLANT CELL PHYSIOL, V38, P1142, DOI 10.1093/oxfordjournals.pcp.a029099; Larsen PB, 2001, PLANT PHYSIOL, V125, P1061, DOI 10.1104/pp.125.2.1061; LARSSON C, 1987, METHOD ENZYMOL, V148, P558; LORD JM, 1987, METHOD ENZYMOL, V148, P542; MAESHIMA M, 1992, PLANT PHYSIOL, V98, P1248, DOI 10.1104/pp.98.4.1248; Martin W, 1998, PLANT PHYSIOL, V118, P9, DOI 10.1104/pp.118.1.9; NAPIER RM, 1992, J CELL SCI, V102, P261; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Pedrazzini E, 1996, P NATL ACAD SCI USA, V93, P4207, DOI 10.1073/pnas.93.9.4207; PIMENTEL E, 1994, HDB GROWTH FACTORS, V3; RAZ V, 1992, PLANT CELL, V4, P1123, DOI 10.1105/tpc.4.9.1123; Rodriguez FI, 1999, SCIENCE, V283, P996, DOI 10.1126/science.283.5404.996; Sandhu P, 2000, J NEUROL NEUROSUR PS, V68, P97, DOI 10.1136/jnnp.68.1.97; SCHALLER GE, 1995, J BIOL CHEM, V270, P12526, DOI 10.1074/jbc.270.21.12526; Schaller GE, 1995, METHOD CELL BIOL, V50, P129, DOI 10.1016/S0091-679X(08)61027-4; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; Schaller GE, 2000, ADV BOT RES, V32, P109, DOI 10.1016/S0065-2296(00)32023-7; Taylor RS, 1997, MOL BIOL CELL, V8, P1911, DOI 10.1091/mbc.8.10.1911; Timpte C, 2001, TRENDS PLANT SCI, V6, P586, DOI 10.1016/S1360-1385(01)02150-1; VONHEIJNE G, 1986, J MOL BIOL, V189, P239, DOI 10.1016/0022-2836(86)90394-3; Weatherman RV, 1999, ANNU REV BIOCHEM, V68, P559, DOI 10.1146/annurev.biochem.68.1.559; Woeste KE, 2000, PLANT CELL, V12, P443, DOI 10.1105/tpc.12.3.443; Yang TB, 2000, J BIOL CHEM, V275, P38467, DOI 10.1074/jbc.M003566200	50	234	267	5	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19861	19866		10.1074/jbc.M201286200	http://dx.doi.org/10.1074/jbc.M201286200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11916973	hybrid			2022-12-25	WOS:000175894800082
J	French, CA; Masson, JY; Griffin, CS; O'Regan, P; West, SC; Thacker, J				French, CA; Masson, JY; Griffin, CS; O'Regan, P; West, SC; Thacker, J			Role of mammalian RAD51L2 (RAD51C) in recombination and genetic stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; DNA-REPAIR GENE; HOMOLOGOUS RECOMBINATION; VERTEBRATE CELLS; NUCLEAR FOCI; REPLICATION FORKS; SOMATIC-CELLS; RECA HOMOLOGS; HAMSTER-CELLS; MOUSE GENES	The highly conserved RAD51 protein has a central role in homologous recombination. Five novel RAD51-like genes have been identified in mammalian cells, but little is known about their functions. A DNA damage-sensitive hamster cell line, irs3, was found to have a mutation in the RAD51L2 gene and an undetectable level of RAD51L2 protein. Resistance of irs3 to DNA-damaging agents was significantly increased by expression of the human RAD51L2 gene, but not by other RAD51-like genes or RAD51 itself. Consistent with a role for RAD51L2 in homologous recombination, irs3 cells show a reduction in sister chromatid exchange, an increase in isochromatid breaks, and a decrease in damage-dependent RAD51 focus formation compared with wild type cells. As recently demonstrated for human cells, we show that RAD51L2 forms part of two separate complexes of hamster RAD51-like proteins. Strikingly, neither complex of RAD51-like proteins is formed in irs3 cells. Our results demonstrate that RAD51L2 has a key role in mammalian RAD51-dependent processes, contingent on the formation of protein complexes involved in homologous recombination repair.	MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Oxon, England; Canc Res UK, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	Thacker, J (corresponding author), MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Oxon, England.	j.thacker@har.mrc.ac.uk		French, Catherine/0000-0003-2072-8413; West, Stephen/0000-0001-8848-9418; Masson, Jean Yves/0000-0002-4403-7169				Albala JS, 1997, GENOMICS, V46, P476, DOI 10.1006/geno.1997.5062; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Braybrooke JP, 2000, J BIOL CHEM, V275, P29100, DOI 10.1074/jbc.M002075200; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P1653, DOI 10.1093/nar/26.7.1653; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; JONES NJ, 1993, CARCINOGENESIS, V14, P2487, DOI 10.1093/carcin/14.12.2487; JONES NJ, 1988, MUTAT RES, V193, P139, DOI 10.1016/0167-8817(88)90044-2; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; Justice MJ, 1999, HUM MOL GENET, V8, P1955, DOI 10.1093/hmg/8.10.1955; Kurumizaka H, 2001, P NATL ACAD SCI USA, V98, P5538, DOI 10.1073/pnas.091603098; Leasure CS, 2001, GENE, V271, P59, DOI 10.1016/S0378-1119(01)00498-X; Liu N, 2002, NUCLEIC ACIDS RES, V30, P1009, DOI 10.1093/nar/30.4.1009; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Masson JY, 2001, P NATL ACAD SCI USA, V98, P8440, DOI 10.1073/pnas.111005698; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8235, DOI 10.1073/pnas.121007798; Miller KA, 2002, J BIOL CHEM, V277, P8406, DOI 10.1074/jbc.M108306200; O'Regan P, 2001, J BIOL CHEM, V276, P22148, DOI 10.1074/jbc.M102396200; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PERRY P, 1974, NATURE, V251, P156, DOI 10.1038/251156a0; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; Pittman DL, 1998, GENOMICS, V49, P103, DOI 10.1006/geno.1998.5226; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Rice MC, 1997, P NATL ACAD SCI USA, V94, P7417, DOI 10.1073/pnas.94.14.7417; SAVAGE JRK, 1976, J MED GENET, V13, P103, DOI 10.1136/jmg.13.2.103; Schild D, 2000, J BIOL CHEM, V275, P16443, DOI 10.1074/jbc.M001473200; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHIBUYA T, 1993, MUTAT RES, V297, P3, DOI 10.1016/0165-1110(93)90005-8; Sigurdsson S, 2001, GENE DEV, V15, P3308, DOI 10.1101/gad.935501; SIMINOVITCH L, 1976, CELL, V7, P1, DOI 10.1016/0092-8674(76)90249-X; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Sonoda E, 2001, P NATL ACAD SCI USA, V98, P8388, DOI 10.1073/pnas.111006398; STEINGRIMSDOTTIR H, 1992, NUCLEIC ACIDS RES, V20, P1201, DOI 10.1093/nar/20.6.1201; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Takata M, 2000, MOL CELL BIOL, V20, P6476, DOI 10.1128/MCB.20.17.6476-6482.2000; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Tambini CE, 1997, GENOMICS, V41, P84, DOI 10.1006/geno.1997.4636; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tashiro S, 1996, ONCOGENE, V12, P2165; Thacker J, 1999, BIOCHIMIE, V81, P77, DOI 10.1016/S0300-9084(99)80041-8; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; THACKER J, 1994, MUTAGENESIS, V9, P163, DOI 10.1093/mutage/9.2.163; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; TUCKER JD, 1991, MUTAT RES, V254, P143, DOI 10.1016/0921-8777(91)90005-A; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; Wiese C, 2002, NUCLEIC ACIDS RES, V30, P1001, DOI 10.1093/nar/30.4.1001; Yuan SSF, 1999, CANCER RES, V59, P3547	61	87	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19322	19330		10.1074/jbc.M201402200	http://dx.doi.org/10.1074/jbc.M201402200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11912211	hybrid			2022-12-25	WOS:000175894800012
J	Pei, Y; Shuman, S				Pei, Y; Shuman, S			Interactions between fission yeast mRNA capping enzymes and elongation factor Spt5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; POLYMERASE-II ELONGATION; SACCHAROMYCES-CEREVISIAE; P-TEFB; TRANSCRIPTION; TRIPHOSPHATASE; GUANYLYLTRANSFERASE; PHOSPHORYLATION; COMPLEX; DSIF	Elongating RNA polymerase 11 is targeted by macromolecular assemblies that regulate mRNA synthesis and processing. The capping apparatus is the first of the assemblies to act on the nascent pre-mRNA. Although recruitment of the capping enzymes to the transcription complex is dependent on phosphorylation of the C-terminal domain of the Rpb1 subunit of polymerase 11 (Pol-II), there may be additional levels of control that coordinate capping with elongation. Here we show that the triphosphatase (Pct1) and guanylyltransferase (Peel) enzymes of the fission yeast capping apparatus bind independently to the elongation factor Spt5. The C-terminal domain of the 990-amino acid Schizosaccharomyces pombe Spt5 protein, composed of repeats of a nonapeptide motif (consensus sequence TPAWNSGSK), is necessary and sufficient for binding to the capping enzymes in vivo (in a two-hybrid assay) and in vitro. As few as four nonamer repeats suffice for Spt5 binding to Pct1 in vitro, whereas six repeats are required for Spt5 binding to Peel. A 116-amino acid fragment of the guanylyltransferase Peel suffices for binding to the Spt5 C-terminal domain (CTD) but not for binding to the Pol-II CTD. Pct1 and Peel can bind simultaneously to the Spt5 CTD in vitro. We find that Spt5 is essential for viability of S. pombe and that it interacts in vivo with S. pombe Spt4 via a central domain distinct from the Spt5 CTD. We suggest that Spt5-induced arrest of elongation at promoter proximal positions ensures a temporal window for recruitment of the capping enzymes.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Pei, Yi/D-8998-2011	Pei, Yi/0000-0002-3466-760X	NIGMS NIH HHS [GM52470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrulis ED, 2000, GENE DEV, V14, P2635, DOI 10.1101/gad.844200; Changela A, 2001, EMBO J, V20, P2575, DOI 10.1093/emboj/20.10.2575; Chiu YL, 2001, J BIOL CHEM, V276, P12959, DOI 10.1074/jbc.M007901200; Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Guo S, 2000, NATURE, V408, P366, DOI 10.1038/35042590; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Ho CK, 1999, NUCLEIC ACIDS RES, V27, P4671, DOI 10.1093/nar/27.24.4671; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; INOUE K, 1989, GENE DEV, V3, P1472, DOI 10.1101/gad.3.9.1472; Ivanov D, 2000, MOL CELL BIOL, V20, P2970, DOI 10.1128/MCB.20.9.2970-2983.2000; Kaplan CD, 2000, GENE DEV, V14, P2623, DOI 10.1101/gad.831900; Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200; Lehman K, 1999, J BIOL CHEM, V274, P22668, DOI 10.1074/jbc.274.32.22668; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; OHNO M, 1987, P NATL ACAD SCI USA, V84, P5187, DOI 10.1073/pnas.84.15.5187; Pei Y, 2001, J BIOL CHEM, V276, P28075, DOI 10.1074/jbc.M102170200; Pei Y, 2001, NUCLEIC ACIDS RES, V29, P387, DOI 10.1093/nar/29.2.387; Ping YH, 2001, J BIOL CHEM, V276, P12951, DOI 10.1074/jbc.M006130200; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Renner DB, 2001, J BIOL CHEM, V276, P42601, DOI 10.1074/jbc.M104967200; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Schwer B, 1998, NUCLEIC ACIDS RES, V26, P2050, DOI 10.1093/nar/26.9.2050; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; SWANSON MS, 1991, MOL CELL BIOL, V11, P3009, DOI 10.1128/MCB.11.6.3009; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	37	101	103	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19639	19648		10.1074/jbc.M200015200	http://dx.doi.org/10.1074/jbc.M200015200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11893740	hybrid			2022-12-25	WOS:000175894800054
J	Sitailo, LA; Tibudan, SS; Denning, MF				Sitailo, LA; Tibudan, SS; Denning, MF			Activation of caspase-9 is required for UV-induced apoptosis of human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; KINASE-C-DELTA; NF-KAPPA-B; CYTOCHROME-C; SKIN-CANCER; CELL-DEATH; ULTRAVIOLET-IRRADIATION; EXPRESSION; P53	UV radiation from the sun activates both the membrane death receptor and the intrinsic or mitochondrial apoptotic signaling pathways in epidermal keratinocytes, triggering apoptosis and affording protection against skin cancer formation. We have investigated the involvement of caspase-9 in the UV death effector pathway in human keratinocytes, since this is the initiating caspase in the mitochondrial pathway required for UV-induced apoptosis in some, but not all, cell types. UV radiation triggered activation of caspase-3, caspase-9, and caspase-8 with similar kinetics, although the rank order of activation was caspase-3 > caspase-9 > caspase-8. Inhibition of caspase-9 with either the peptide inhibitor benzyloxycarbonyl-Leu-Glu(OCH3)-His-Asp(OCH3)-fluoromethyl ketone, or expression of a catalytically inactive caspase-9 by retroviral transduction, protected normal keratinocytes from UV-induced apoptosis. HaCaT keratinocytes harboring mutant p53 alleles were also protected from UV-induced apoptosis by the dominant negative caspase-9. The dominant negative caspase-9 blocked UV-induced activation of caspase-3, caspase-9, and caspase-8, and also protected cells from the loss of mitochondrial membrane potential. In contrast, the dominant negative caspase-9 did not protect from anti-Fas-induced apoptosis or caspase activation. These results identify caspase-9 as the critical upstream caspase initiating apoptosis by UV radiation in human keratinocytes, the relevant cell type for this important environmental carcinogen.	Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Skin Canc Res Program, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago	Denning, MF (corresponding author), Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Skin Canc Res Program, 2160 S 1st Ave,Rm 304, Maywood, IL 60153 USA.				NCI NIH HHS [CA83784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bacon P. E., 2000, Journal of Investigative Dermatology, V114, P763; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gillardon F, 1999, CELL DEATH DIFFER, V6, P55, DOI 10.1038/sj.cdd.4400455; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grenet J, 1999, GENE, V226, P225, DOI 10.1016/S0378-1119(98)00565-4; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Leverkus M, 1998, J INVEST DERMATOL, V110, P353, DOI 10.1046/j.1523-1747.1998.00154.x; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; Li G, 1998, J INVEST DERMATOL, V110, P72, DOI 10.1046/j.1523-1747.1998.00090.x; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; MITRA R, 1994, KERATINOCYTE METHODS, P17; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; Qin JZ, 1999, J BIOL CHEM, V274, P37957, DOI 10.1074/jbc.274.53.37957; Qin JZ, 2001, J INVEST DERMATOL, V117, P898, DOI 10.1046/j.0022-202x.2001.01477.x; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610; Rossiter H, 2001, CANCER RES, V61, P3619; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; Shapiro HM, 2000, METHODS, V21, P271, DOI 10.1006/meth.2000.1007; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Taylor JK, 1999, ONCOGENE, V18, P4495, DOI 10.1038/sj.onc.1202836; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	47	132	144	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19346	19352		10.1074/jbc.M200401200	http://dx.doi.org/10.1074/jbc.M200401200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11919192	hybrid			2022-12-25	WOS:000175894800015
J	Constantinescu, A; Gordon, AS; Diamond, I				Constantinescu, A; Gordon, AS; Diamond, I			CAMP-dependent protein kinase types I and II differentially regulate cAMP response element-mediated gene expression - Implications for neuronal responses to ethanol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING-PROTEIN; CATALYTIC SUBUNIT; CYCLIC-AMP; ANCHORING PROTEIN; CELL-LINE; RII-BETA; NUCLEAR; ADENOSINE; LOCALIZATION; MECHANISM	We have shown that ethanol induces translocation of cAMP-dependent protein kinase (PKA) to the nucleus, cAMP response element-binding protein (CREB) phosphorylation, and cAMP response element-mediated gene transcription in NG108-15 cells. However, little is known about which PKA types regulate this process. We show here that under basal conditions NG108-15 cells contain type I PKA (CbetaRIbeta) primarily in cytosol and type H PKA (CalphaRIIbeta) in the particulate and nuclear fractions. Antagonists of both type I and type H PKA inhibit forskolin- and ethanol-induced cAMP response element-mediated gene transcription. However, only the typeII PKA antagonist inhibits forskolin-induced Cot and ethanol-induced Calpha and RIIbeta translocation to the nucleus and CREB phosphorylation; the type I antagonist is without effect. Our data suggest that forskolin- and ethanol-induced CREB phosphorylation and gene activation are differentially mediated by the two types of PKA. We propose that type II PKA is translocated and activated in the nucleus and induces CREB phosphorylation that is necessary but not sufficient for gene transcription. By contrast, type I PKA is activated in the cytoplasm, turning on a downstream pathway that activates other transcription cofactors that interact with phosphorylated CREB to induce gene transcription.	Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, Emeryville, CA 94608 USA; Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Mol & Cellular Pharmacol, Emeryville, CA 94608 USA; Univ Calif San Francisco, Grad Program Neurosci, Emeryville, CA 94608 USA; Univ Calif San Francisco, Ctr Neurobiol Addict, Emeryville, CA 94608 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Constantinescu, A (corresponding author), Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, 5858 Horton St,Suite 200, Emeryville, CA 94608 USA.	anconst@itsa.ucsf.edu			NIAAA NIH HHS [R37 AA10030] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA010030] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Adams MR, 1997, P NATL ACAD SCI USA, V94, P12157, DOI 10.1073/pnas.94.22.12157; Akileswaran L, 2001, J BIOL CHEM, V276, P17448, DOI 10.1074/jbc.M101171200; Asher O, 2002, J PHARMACOL EXP THER, V301, P66, DOI 10.1124/jpet.301.1.66; Brandon EP, 1998, J NEUROSCI, V18, P3639; Brandon EP, 1997, CURR OPIN NEUROBIOL, V7, P397, DOI 10.1016/S0959-4388(97)80069-4; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; BUDILLON A, 1995, P NATL ACAD SCI USA, V92, P10634, DOI 10.1073/pnas.92.23.10634; CADD GG, 1990, J BIOL CHEM, V265, P19502; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; Constantinescu A, 1999, J BIOL CHEM, V274, P26985, DOI 10.1074/jbc.274.38.26985; CORBIN JD, 1975, J BIOL CHEM, V250, P218; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; DIAMOND I, 1987, P NATL ACAD SCI USA, V84, P1413, DOI 10.1073/pnas.84.5.1413; Dohrman DP, 2002, ALCOHOL CLIN EXP RES, V26, P407, DOI 10.1111/j.1530-0277.2002.tb02553.x; Dohrman DP, 1996, P NATL ACAD SCI USA, V93, P10217, DOI 10.1073/pnas.93.19.10217; Eide T, 1998, EXP CELL RES, V238, P305, DOI 10.1006/excr.1997.3855; Gamm DM, 1996, J BIOL CHEM, V271, P15736, DOI 10.1074/jbc.271.26.15736; GJERTSEN BT, 1995, J BIOL CHEM, V270, P20599, DOI 10.1074/jbc.270.35.20599; Goodman RH, 2000, GENE DEV, V14, P1553; GORDON AS, 1986, P NATL ACAD SCI USA, V83, P2105, DOI 10.1073/pnas.83.7.2105; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; KEMP BE, 1980, J BIOL CHEM, V255, P2914; Mayford M, 1999, TRENDS GENET, V15, P463, DOI 10.1016/S0168-9525(99)01846-6; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; Michael LF, 2000, MOL CELL BIOL, V20, P1596, DOI 10.1128/MCB.20.5.1596-1603.2000; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; NAGY LE, 1989, MOL PHARMACOL, V36, P744; Nestler EJ, 2001, AM J ADDICTION, V10, P201, DOI 10.1080/105504901750532094; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Newlon MG, 2001, EMBO J, V20, P1651, DOI 10.1093/emboj/20.7.1651; Paolillo M, 1999, J BIOL CHEM, V274, P6546, DOI 10.1074/jbc.274.10.6546; Park SK, 2000, J BIOL CHEM, V275, P20588, DOI 10.1074/jbc.M002460200; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; SAPRU MK, 1994, J PHARMACOL EXP THER, V271, P542; Schwede F, 2000, PHARMACOL THERAPEUT, V87, P199, DOI 10.1016/S0163-7258(00)00051-6; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; SOLBERG R, 1994, EXP CELL RES, V214, P595, DOI 10.1006/excr.1994.1297; TABAKOFF B, 1988, NEW ENGL J MED, V318, P134, DOI 10.1056/NEJM198801213180302; Thiele TE, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-10-j0003.2000; Tibbs VC, 1998, J BIOL CHEM, V273, P25783, DOI 10.1074/jbc.273.40.25783; TORTORA G, 1990, J BIOL CHEM, V265, P18067; TRINCZEK B, 1993, EUR J CELL BIOL, V60, P196; Ventra C, 1996, J NEUROCHEM, V66, P1752; Wand G, 2001, J NEUROSCI, V21, P5297, DOI 10.1523/JNEUROSCI.21-14-05297.2001; Wiley JC, 1999, J BIOL CHEM, V274, P6381, DOI 10.1074/jbc.274.10.6381; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Zanger K, 1999, MOL ENDOCRINOL, V13, P268, DOI 10.1210/me.13.2.268	52	35	35	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18810	18816		10.1074/jbc.M112107200	http://dx.doi.org/10.1074/jbc.M112107200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886856	hybrid			2022-12-25	WOS:000175975800075
J	Funakoshi, Y; Ichiki, T; Takeda, H; Tokuno, T; Iino, N; Takeshita, A				Funakoshi, Y; Ichiki, T; Takeda, H; Tokuno, T; Iino, N; Takeshita, A			Critical role of cAMP-response element-binding protein for angiotensin II-induced hypertrophy of vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR CREB; C-FOS GENE; TRANSCRIPTION FACTOR; SIGNALING PATHWAYS; KINASE ACTIVATION; ADENYLATE-CYCLASE; CROSS-TALK; PHOSPHORYLATION; RECEPTOR; EXPRESSION	We reported previously an important role of cyclic AMP-response element (CRE) for the induction of interleukin-6 gene expression by angiotensin H (AngII). We examined signaling pathways that are responsible for AngII-induced phosphorylation of CRE-binding protein (CREB) at serine 133 that is a critical marker for the activation in rat vascular smooth muscle cells (VSMC). AngII time dependently induced phosphorylation of CREB with a peak at 5 min. The AngII-induced phosphorylation of CREB was blocked by CV11974, an AngII type I receptor antagonist, suggesting that AngII type I receptor may mediate the phosphorylation of CREB. Inhibition of extracellular signal-regulated protein kinase (ERK) by PD98059 or inhibition of p38 mitogen-activated protein kinase (MAPK) by SB203580 partially inhibited AngII-induced CREB phosphorylation. A protein kinase A inhibitor, HS9, also partially suppressed AngII-induced CREB phosphorylation. Inhibition of epidermal growth factor-receptor by AG1478 suppressed the AngII-induced CREB phosphorylation as well as activation of ERK and p38MAPK. Overexpression of the dominant negative form of CREB by an adenovirus vector suppressed AngII-induced c-fos expression and incorporation of [H-3]leucine to VSMC. These findings suggest that AngII may activate multiple signaling pathways involving two MAPK pathways and protein kinase A, all of which contribute to the activation of CREB. Transactivation of epidermal growth factor-receptor is also critical for AngII-induced CREB phosphorylation. Activation of CREB may be important for the regulation of gene expression and hypertrophy of VSMC induced by AngII.	Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Ichiki, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							Abraham ST, 1997, CIRC RES, V81, P575, DOI 10.1161/01.RES.81.4.575; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Blair AS, 1999, J BIOL CHEM, V274, P36293, DOI 10.1074/jbc.274.51.36293; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; Funakoshi Y, 1999, HYPERTENSION, V34, P118, DOI 10.1161/01.HYP.34.1.118; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HARTIG E, 1991, NUCLEIC ACIDS RES, V19, P4153, DOI 10.1093/nar/19.15.4153; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; JARD S, 1981, J BIOL CHEM, V256, P2603; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; Lin RZ, 1998, J BIOL CHEM, V273, P30033, DOI 10.1074/jbc.273.45.30033; Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098; MISSALE C, 1989, REGUL PEPTIDES, V24, P167, DOI 10.1016/0167-0115(89)90235-8; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; POBINER BF, 1985, J BIOL CHEM, V260, P6200; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Somers JP, 1999, MOL ENDOCRINOL, V13, P1364, DOI 10.1210/me.13.8.1364; Takahashi E, 1997, CIRC RES, V81, P268, DOI 10.1161/01.RES.81.2.268; Takahashi T, 1999, AM J PHYSIOL-HEART C, V276, pH1927, DOI 10.1152/ajpheart.1999.276.6.H1927; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; WANG WW, 1994, GENE, V143, P261, DOI 10.1016/0378-1119(94)90107-4; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	40	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18710	18717		10.1074/jbc.M110430200	http://dx.doi.org/10.1074/jbc.M110430200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11907026	hybrid			2022-12-25	WOS:000175975800063
J	Graness, A; Chwieralski, CE; Reinhold, D; Thim, L; Hoffmann, W				Graness, A; Chwieralski, CE; Reinhold, D; Thim, L; Hoffmann, W			Protein kinase C and ERK activation are required for TFF-peptide-stimulated bronchial epithelial cell migration and tumor necrosis factor-alpha-induced interleukin-6 (IL-6) and IL-8 secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTESTINAL TREFOIL FACTOR; HUMAN SPASMOLYTIC POLYPEPTIDE; SIGNAL-TRANSDUCTION PATHWAYS; GENE-EXPRESSION; TRANSCRIPTION FACTORS; INFLAMMATORY CYTOKINES; FACTOR RECEPTOR; GROWTH-FACTOR; CANCER CELLS	TFF-peptides (formerly P-domain peptides, trefoil factors) are typical secretory products of many mucous epithelia and are aberrantly secreted during chronic inflammatory diseases. They are known to enhance the migration of intestinal, corneal, and bronchial epithelial cells. Using the human bronchial epithelial cell line BEAS-2B as a model, it is shown here for the first time that TFF-peptides are capable of modulating the inflammatory response in vitro by regulating tumor necrosis factor-alpha-induced secretion of interleukin (IL)-6 and IL-8. In contrast, TFF2 itself does not change IL-6 and IL-8 secretion but triggers sustained activation of the extracellular signal-regulated kinases (ERK1/2) as well as phosphorylation of c-Jun N-terminal kinase (JN-K). A complex differential regulation of tumor necrosis factor-a-induced IL-6 and IL-8 secretion by TFF2 is observed that involves signaling via protein kinase C and ERK1/2. Furthermore, the motogenic effect of TFF2 on BEAS-2B cells is analyzed using a modified Boyden chamber assay. This migratory effect is shown to be dependent not only on protein kinase C and ERK1/2 but also on the activation of the Src family of tyrosine kinases. Taken together, the data presented indicate an important physiological role of TFF-peptides during inflammatory conditions of mucous epithelia.	Otto von Guericke Univ, Inst Mol Biol & Med Chem, D-39120 Magdeburg, Germany; Otto von Guericke Univ, Inst Immunol, D-39120 Magdeburg, Germany; Novo Nordisk AS, Dept Prot Chem, DK-2880 Bagsvaerd, Denmark	Otto von Guericke University; Otto von Guericke University; Novo Nordisk	Hoffmann, W (corresponding author), Univ Klinikum, Inst Mol Biol & Med Chem, Leipziger Str 44, D-39120 Magdeburg, Germany.		Hoffmann, Werner/AAY-9182-2020					Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; Basu A, 2001, BIOCHEM BIOPH RES CO, V280, P883, DOI 10.1006/bbrc.2000.4209; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bin W, 2001, AM J PHYSIOL-LUNG C, V280, pL675, DOI 10.1152/ajplung.2001.280.4.L675; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Boxberger Hans-Juergen, 1998, European Journal of Cell Biology, V75, P56; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; Carter AB, 1999, AM J RESP CELL MOL, V20, P751, DOI 10.1165/ajrcmb.20.4.3420; Chen D, 1999, J IMMUNOL, V163, P5796; Chen YH, 2000, BIOCHEM BIOPH RES CO, V274, P576, DOI 10.1006/bbrc.2000.3176; De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919; DEVLIN RB, 1994, AM J PHYSIOL, V266, P612; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Graness A, 1997, BIOCHEM J, V327, P147, DOI 10.1042/bj3270147; Graness A, 1998, J BIOL CHEM, V273, P32016, DOI 10.1074/jbc.273.48.32016; Hall CL, 1996, ONCOGENE, V13, P2213; HANBY AM, 1993, GASTROENTEROLOGY, V105, P1110, DOI 10.1016/0016-5085(93)90956-D; HAUSER F, 1993, P NATL ACAD SCI USA, V90, P6961, DOI 10.1073/pnas.90.15.6961; Hoffmann W, 2002, INT REV CYTOL, V213, P147; Hoffmann W, 2001, HISTOL HISTOPATHOL, V16, P319, DOI 10.14670/HH-16.319; Hollande F, 2001, J BIOL CHEM, V276, P40402, DOI 10.1074/jbc.M105090200; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Jin YJ, 2001, J BIOL CHEM, V276, P30342, DOI 10.1074/jbc.M102404200; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kilpatrick LE, 2000, AM J PHYSIOL-CELL PH, V279, pC2011, DOI 10.1152/ajpcell.2000.279.6.C2011; Kinoshita K, 2000, MOL CELL BIOL, V20, P4680, DOI 10.1128/MCB.20.13.4680-4690.2000; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Krause A, 1998, J BIOL CHEM, V273, P23681, DOI 10.1074/jbc.273.37.23681; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; Lakshminarayanan V, 1997, J BIOL CHEM, V272, P32910, DOI 10.1074/jbc.272.52.32910; Lalani EN, 1999, LAB INVEST, V79, P537; Leong KG, 2000, HISTOL HISTOPATHOL, V15, P1303, DOI 10.14670/HH-15.1303; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Monton C, 1998, Monaldi Arch Chest Dis, V53, P56; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Oertel M, 2001, AM J RESP CELL MOL, V25, P418, DOI 10.1165/ajrcmb.25.4.4429; Pitman RS, 2000, J GASTROENTEROL, V35, P805, DOI 10.1007/s005350070017; Quay JL, 1998, AM J RESP CELL MOL, V19, P98, DOI 10.1165/ajrcmb.19.1.3132; REDDEL RR, 1988, CANCER RES, V48, P1904; Reibman J, 2000, J IMMUNOL, V165, P1618, DOI 10.4049/jimmunol.165.3.1618; Remacle-Bonnet MM, 2000, CANCER RES, V60, P2007; Richards CD, 1998, CYTOKINES, P87, DOI 10.1016/B978-012498340-3/50007-5; Roebuck KA, 1999, J INTERF CYTOK RES, V19, P429, DOI 10.1089/107999099313866; Taupin D, 1999, J CLIN INVEST, V103, pR31, DOI 10.1172/JCI3304; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; Thim L, 1997, CELL MOL LIFE SCI, V53, P888, DOI 10.1007/s000180050108; THIM L, 1993, FEBS LETT, V318, P345, DOI 10.1016/0014-5793(93)80543-4; THIM L, 1995, BIOCHEMISTRY-US, V34, P4757, DOI 10.1021/bi00014a033; Thim L, 2000, REGUL PEPTIDES, V90, P61, DOI 10.1016/S0167-0115(00)00110-5; TOMASETTO C, 1990, EMBO J, V9, P407, DOI 10.1002/j.1460-2075.1990.tb08125.x; Tomasetto C, 2000, GASTROENTEROLOGY, V118, P70, DOI 10.1016/S0016-5085(00)70415-X; Van Linden AA, 2000, J BIOL CHEM, V275, P6996, DOI 10.1074/jbc.275.10.6996; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VASALLI P, 1992, ANNU REV IMMUNOL, V10, P411; Wiede A, 1999, AM J RESP CRIT CARE, V159, P1330, DOI 10.1164/ajrccm.159.4.9804149; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Williams R, 1996, J CELL SCI, V109, P63; Wright NA, 1998, PHILOS T R SOC B, V353, P925, DOI 10.1098/rstb.1998.0257; Wright NA, 1997, FEBS LETT, V408, P121, DOI 10.1016/S0014-5793(97)00424-9; Wyatt TA, 1997, AM J PHYSIOL-LUNG C, V273, pL1007, DOI 10.1152/ajplung.1997.273.5.L1007; Xing Z, 1999, HISTOL HISTOPATHOL, V14, P185, DOI 10.14670/HH-14.185; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhao DZ, 2001, J BIOL CHEM, V276, P44464, DOI 10.1074/jbc.M104942200	75	80	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18440	18446		10.1074/jbc.M200468200	http://dx.doi.org/10.1074/jbc.M200468200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11884401	hybrid			2022-12-25	WOS:000175975800025
J	Santos, M; Paramio, JM; Bravo, A; Ramirez, A; Jorcano, JL				Santos, M; Paramio, JM; Bravo, A; Ramirez, A; Jorcano, JL			The expression of keratin K10 in the basal layer of the epidermis inhibits cell proliferation and prevents skin tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; TRANSGENIC MOUSE SKIN; TUMOR-SUPPRESSOR PTEN; GROWTH-FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; INTERMEDIATE FILAMENTS; EPIDERMOLYTIC HYPERKERATOSIS; GENE-EXPRESSION; MICE; DIFFERENTIATION	Forced expression of K10, a keratin normally expressed in postmitotic, terminally differentiating epidermal keratinocytes, inhibits the progression of the cell cycle in cultured cells (Paramio, J. M., Casanova, M. Ll., Segrelles, C., Mittnacht, S., Lane, E. B., and Jorcano, J. L. (1999) Mol CelL Biol. 19, 3086-3094). This process requires a functional retinoblastoma (pRb) gene product and is mediated by K10-induced inhibition of Akt and PKCzeta, two signaling intermediates belonging to the phosphoinositide (PI) 3-kinase signal transduction pathway (Paramio, J. M., Segrelles, C., Ruiz, S., and Jorcano, J. L. (2001) Mol. Cell Biol. 21, 7449-7459). Extending earlier in vitro studies to the in vivo situation, this work analyzes the alterations found in transgemic mice that ectopically express K10 in the proliferative basal cells of the epidermis. Increased expression of K10 led to a hypoplasic and hyperkeratotic epidermis due to a dramatic decrease in skin keratinocyte proliferation in association with the inhibition of Akt and PKCzeta activities. The inhibition of cell proliferation and Akt and PKCzeta activities was also observed although to a minor extent in low hK10-expressing mice. These animals displayed no overt epidermal phenotype nor overexpression of K10. In these non-phenotypic mice, ectopic K10 expression also resulted in decreased skin tumorigenesis. Collectively, these data demonstrate that keratin K10 in vivo functions include the control of epithelial proliferation in skin epidermis.	CIEMAT, Project Cell & Mol Biol & Gene Therapy, E-28040 Madrid, Spain; Univ Santiago Compostela, Sch Vet, Dept Anim Pathol, E-27002 Lugo, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Universidade de Santiago de Compostela	Paramio, JM (corresponding author), CIEMAT, Project Cell & Mol Biol & Gene Therapy, Av Complutense 22, E-28040 Madrid, Spain.		Santos, Mirentxu/AAA-1727-2020; Paramio, Jesus M/M-8482-2014; Ramirez, Angel/A-4800-2018; Moral, Ana María Bravo/AAD-3339-2021	Paramio, Jesus M/0000-0001-7520-3177; Ramirez, Angel/0000-0001-7745-5108; Moral, Ana María Bravo/0000-0002-5282-8921				ALBERS KM, 1995, J CELL BIOL, V128, P157, DOI 10.1083/jcb.128.1.157; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bang OS, 2001, J CELL SCI, V114, P81; BLESSING M, 1993, J CELL BIOL, V120, P743, DOI 10.1083/jcb.120.3.743; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Casanova ML, 1999, J CLIN INVEST, V103, P1587, DOI 10.1172/JCI5343; Caulin C, 2000, J CELL BIOL, V149, P17, DOI 10.1083/jcb.149.1.17; CHENG J, 1992, CELL, V70, P811, DOI 10.1016/0092-8674(92)90314-3; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DiGiovanni J, 2000, CANCER RES, V60, P1561; EICHNER R, 1986, J CELL BIOL, V102, P1767, DOI 10.1083/jcb.102.5.1767; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUCHS E, 1992, P NATL ACAD SCI USA, V89, P6906, DOI 10.1073/pnas.89.15.6906; FUCHS EV, 1997, MOL BIOL CELL, V69, P899; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Gilbert S, 2001, J CELL BIOL, V154, P763, DOI 10.1083/jcb.200102130; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Inada H, 2001, J CELL BIOL, V155, P415, DOI 10.1083/jcb.200103078; Irvine AD, 1999, BRIT J DERMATOL, V140, P815, DOI 10.1046/j.1365-2133.1999.02810.x; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LLOYD C, 1995, J CELL BIOL, V129, P1329, DOI 10.1083/jcb.129.5.1329; MCLEAN WHI, 1995, CURR OPIN CELL BIOL, V7, P118; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; OMARY MB, 1992, J CELL BIOL, V117, P583, DOI 10.1083/jcb.117.3.583; Paladini RD, 1999, J CELL BIOL, V146, P1185, DOI 10.1083/jcb.146.5.1185; Paladini RD, 1998, J CELL BIOL, V142, P1035, DOI 10.1083/jcb.142.4.1035; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Paramio JM, 1999, ONCOGENE, V18, P7462, DOI 10.1038/sj.onc.1203151; PARAMIO JM, 1994, EXP CELL RES, V215, P319, DOI 10.1006/excr.1994.1348; Paramio JM, 2001, J BIOL CHEM, V276, P44203, DOI 10.1074/jbc.M105650200; Paramio JM, 2001, MOL CELL BIOL, V21, P7449, DOI 10.1128/MCB.21.21.7449-7459.2001; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; RAMIREZ A, 1995, P NATL ACAD SCI USA, V92, P4783, DOI 10.1073/pnas.92.11.4783; Ramirez A, 2001, GENETICS, V158, P341; Reichelt J, 2001, MOL BIOL CELL, V12, P1557, DOI 10.1091/mbc.12.6.1557; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; ROOP DR, 1988, CANCER RES, V48, P3245; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Santos M, 1997, MOL CARCINOGEN, V20, P3, DOI 10.1002/(SICI)1098-2744(199709)20:1<3::AID-MC2>3.0.CO;2-R; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; TAKAHASHI K, 1994, J CELL BIOL, V127, P505, DOI 10.1083/jcb.127.2.505; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, CANCER RES, V59, P442; Vandromme M, 2001, J BIOL CHEM, V276, P8173, DOI 10.1074/jbc.M005587200; Wan YS, 2001, INT J ONCOL, V18, P461; Wawersik M, 2000, MOL BIOL CELL, V11, P3315, DOI 10.1091/mbc.11.10.3315; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397	59	86	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19122	19130		10.1074/jbc.M201001200	http://dx.doi.org/10.1074/jbc.M201001200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889133	hybrid			2022-12-25	WOS:000175975800114
J	Smirnov, SP; McDearmon, EL; Li, SH; Ervasti, JM; Tryggvason, K; Yurchenco, PD				Smirnov, SP; McDearmon, EL; Li, SH; Ervasti, JM; Tryggvason, K; Yurchenco, PD			Contributions of the LG modules and furin processing to laminin-2 functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL MUSCULAR-DYSTROPHY; EXTRAEMBRYONIC ENDODERMAL CELLS; ALPHA-DYSTROGLYCAN BINDING; BASEMENT-MEMBRANES; ALPHA-7-BETA-1 INTEGRIN; HEPARIN-BINDING; SHORT-ARM; MEROSIN; RECEPTOR; CHAIN	The alpha2-laminin subunit contributes to basement membrane functions in muscle, nerve, and other tissues, and mutations in its gene are causes of congenital muscular dystrophy. The alpha2 G-domain modules, mutated in several of these disorders, are thought to mediate different cellular interactions. To analyze these contributions, we expressed recombinant laminin-2 (alpha(2)beta(1)gamma(1)) with LG4-5, LG1-3, and LG1-5 modular deletions. Wild-type and LG4-5 deleted-laminins were isolated from medium intact and cleaved within LG3 by a furin-like convertase. Myoblasts adhered predominantly through LG1-3 while alpha-dystroglycan bound to both LG1-3 and LG4-5. Recombinant laminin stimulated acetylcholine receptor (AChR) clustering; however, clustering was induced only by the proteolytic processed form, even in the absence of LG4-5. Furthermore, clustering required alpha(6)beta(1) integrin and alpha-dystroglycan binding activities available on LG1-3, acting in concert with laminin polymerization. The ability of the modified laminins to mediate basement membrane assembly was also evaluated in embryoid bodies where it was found that both LG1-3 and LG4-5, but not processing, were required. In conclusion, there is a division of labor among LG-modules in which (i) LG4-5 is required for basement membrane assembly but not for AChR clustering, and (ii) laminin-induced AChR clustering requires furin cleavage of LG3 as well as alpha-dystroglycan and alpha(6)beta(1) integrin binding.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, Piscataway, NJ 08854 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Wisconsin System; University of Wisconsin Madison; Karolinska Institutet	Yurchenco, PD (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, Piscataway, NJ 08854 USA.		Ervasti, James/AAZ-4786-2020	Yurchenco, Peter/0000-0003-0387-2317	NIAMS NIH HHS [ARO1985] Funding Source: Medline; NIDDK NIH HHS [DK36425] Funding Source: Medline; NINDS NIH HHS [NS38469] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR001985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK036425, R01DK036425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038469] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Burkin DJ, 2001, J CELL BIOL, V152, P1207, DOI 10.1083/jcb.152.6.1207; Burkin DJ, 1998, J CELL BIOL, V143, P1067, DOI 10.1083/jcb.143.4.1067; Burkin DJ, 2000, J CELL SCI, V113, P2877; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; Cohen MW, 1997, J CELL BIOL, V136, P1047, DOI 10.1083/jcb.136.5.1047; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; Cote PD, 2002, J BIOL CHEM, V277, P4672, DOI 10.1074/jbc.M106879200; Cote PD, 1999, NAT GENET, V23, P338, DOI 10.1038/15519; Edwards JP, 1998, BRAIN RES, V788, P262, DOI 10.1016/S0006-8993(98)00010-9; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; Feltri ML, 2002, J CELL BIOL, V156, P199, DOI 10.1083/jcb.200109021; Guicheney P, 1997, NEUROMUSCULAR DISORD, V7, P180, DOI 10.1016/S0960-8966(97)00460-4; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; Kuang W, 1998, J CLIN INVEST, V102, P844, DOI 10.1172/JCI3705; Kuang W, 1999, LAB INVEST, V79, P1601; LAW PK, 1983, EXP NEUROL, V80, P361, DOI 10.1016/0014-4886(83)90289-3; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; Mallet WG, 1999, J CELL BIOL, V146, P345, DOI 10.1083/jcb.146.2.345; Matsumura K, 1997, NEUROMUSCULAR DISORD, V7, P7, DOI 10.1016/S0960-8966(96)00402-6; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; Montanaro F, 1998, J NEUROSCI, V18, P1250; Montanaro F, 1999, J CELL BIOL, V145, P1325, DOI 10.1083/jcb.145.6.1325; Murray P, 2000, J CELL BIOL, V150, P1215, DOI 10.1083/jcb.150.5.1215; Murray P, 2001, J CELL SCI, V114, P931; Murray P, 2001, MECH DEVELOP, V101, P213, DOI 10.1016/S0925-4773(00)00554-2; Pall EA, 1996, J BIOL CHEM, V271, P3817; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PIKKARAINEN T, 1992, EUR J BIOCHEM, V209, P571, DOI 10.1111/j.1432-1033.1992.tb17322.x; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; Rambukkana A, 1998, SCIENCE, V282, P2076, DOI 10.1126/science.282.5396.2076; Sewry CA, 1997, NEUROPEDIATRICS, V28, P217, DOI 10.1055/s-2007-973703; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; Sugiyama JE, 1997, J CELL BIOL, V139, P181, DOI 10.1083/jcb.139.1.181; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Talts JF, 1999, FEBS LETT, V458, P319, DOI 10.1016/S0014-5793(99)01180-1; Talts JF, 1998, FEBS LETT, V426, P71, DOI 10.1016/S0014-5793(98)00312-3; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; TREMBLAY JP, 1988, SYNAPSE, V2, P148, DOI 10.1002/syn.890020206; Tsiper MV, 2002, J CELL SCI, V115, P1005; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; Yurchenco PD, 1997, P NATL ACAD SCI USA, V94, P10189, DOI 10.1073/pnas.94.19.10189; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286	45	77	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18928	18937		10.1074/jbc.M201880200	http://dx.doi.org/10.1074/jbc.M201880200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886875	hybrid			2022-12-25	WOS:000175975800089
J	Tarumi, T; Kravtsov, DV; Zhao, MM; Williams, SM; Gailani, D				Tarumi, T; Kravtsov, DV; Zhao, MM; Williams, SM; Gailani, D			Cloning and characterization of the human factor XI gene promoter - Transcription factor hepatocyte nuclear factor 4 alpha (HNF-4 alpha) is required for hepatocyte-specific expression of factor XI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; HUMAN-PLASMA PREKALLIKREIN; HEMOPHILIA-B LEYDEN; ACYL-COA THIOESTERS; BINDING-SITE; RECEPTOR SUPERFAMILY; FACTOR HNF-4; DEFICIENCY; IDENTIFICATION; FAMILY	Factor XI is the zymogen of a plasma protease produced primarily in liver that is required for normal blood coagulation. We cloned similar to2600 base pairs of the human factor XI gene upstream of exon one, identified transcription start sites, and conducted a functional analysis. Luciferase reporter assays demonstrate that the 381 base pairs upstream of exon one are sufficient for maximum promoter activity in HepG2 hepatocellular carcinoma cells. The removal of 19 base pairs between -381 and -363 results in a nearly complete loss of promoter activity. This region contains the sequence ACTTTG, a motif required for binding of the transcription factor hepatocyte nuclear factor 4alpha (HNF-4alpha) to the promoters of several genes. Gel mobility shift assays using HepG2 or rat hepatocyte nuclear extract confirm HNF-4alpha binds between bp -375 and -360. Scrambling the ACTTTG motif completely abolishes promoter activity in luciferase assays. The factor XI promoter functions poorly when transfected into HeLa carcinoma cells, and gel mobility shift experiments with HeLa nuclear extracts demonstrate no HNF-4alpha binding to the ACTTTG sequence. When a rat HNF-4alpha expression construct is co-transfected into HeLa cells, factor XI promoter activity is enhanced similar to10-fold. We conclude that HNF-4alpha is required for hepatocyte-specific expression of factor XI.	Vanderbilt Univ, Div Hematol Oncol, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; Meharry Med Coll, Dept Microbiol, Nashville, TN 37208 USA	Vanderbilt University; Vanderbilt University; Meharry Medical College	Gailani, D (corresponding author), Vanderbilt Univ, Div Hematol Oncol, Dept Pathol, 777 Preston Res Bldg,2220 Pierce Ave, Nashville, TN 37232 USA.	dave.gailani@mcmail.vanderbilt.edu	Williams, Scott/B-9491-2012; Williams, Scott/Q-4812-2019	Williams, Scott/0000-0002-4835-9544	NHLBI NIH HHS [HL58837] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058837] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arbini AA, 1997, BLOOD, V89, P176, DOI 10.1182/blood.V89.1.176.176_176_182; ASAKAI R, 1987, BIOCHEMISTRY-US, V26, P7221, DOI 10.1021/bi00397a004; ASAKAI R, 1991, NEW ENGL J MED, V325, P153, DOI 10.1056/NEJM199107183250303; BANCROFT JD, 1992, BIOCHEMISTRY-US, V31, P12469, DOI 10.1021/bi00164a025; BEAUBIEN G, 1991, BIOCHEMISTRY-US, V30, P1628, DOI 10.1021/bi00220a027; Carew JA, 2000, BLOOD, V96, P4370; Chan JCY, 2001, AM J PATHOL, V158, P469, DOI 10.1016/S0002-9440(10)63989-2; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; Colman R. W., 2001, HEMOSTASIS THROMBOSI, P103; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; de Visser MCH, 2001, THROMB HAEMOSTASIS, V85, P1011; Degen JL, 2001, THROMB HAEMOSTASIS, V86, P130; Degen SJF, 1998, CRIT REV EUKAR GENE, V8, P203, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.60; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duncan SA, 1997, DEVELOPMENT, V124, P279; DZIK WH, 1987, NEW ENGL J MED, V316, P1217; ERDMANN D, 1995, J BIOL CHEM, V270, P22988, DOI 10.1074/jbc.270.39.22988; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; FURIE B, 1992, NEW ENGL J MED, V326, P800; Gailani D, 1997, BLOOD, V90, P1055, DOI 10.1182/blood.V90.3.1055.1055_1055_1064; GAILANI D, 2001, METABOLIC MOL BASIS, V3, P4433; Greenberg D, 1995, P NATL ACAD SCI USA, V92, P12347, DOI 10.1073/pnas.92.26.12347; Greenberg D L, 2001, HEMOSTASIS THROMBOSI, P21; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hertz R, 2001, BIOCHEM PHARMACOL, V61, P1057, DOI 10.1016/S0006-2952(01)00578-0; HUANG MN, 1992, J BIOL CHEM, V267, P15440; Hung HL, 1996, J BIOL CHEM, V271, P2323, DOI 10.1074/jbc.271.4.2323; Iacoviello L, 1998, NEW ENGL J MED, V338, P79, DOI 10.1056/NEJM199801083380202; KATO A, 1989, CYTOGENET CELL GENET, V52, P77, DOI 10.1159/000132844; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Li JX, 2000, GENE DEV, V14, P464; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Martincic D, 1998, BLOOD, V92, P3309, DOI 10.1182/blood.V92.9.3309.421k36_3309_3317; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; Meijers JCM, 2000, NEW ENGL J MED, V342, P696, DOI 10.1056/NEJM200003093421004; MILLS KA, 1995, MAMM GENOME, V6, P278, DOI 10.1007/BF00352416; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; Neth P, 2001, THROMB HAEMOSTASIS, V85, P1043, DOI 10.1055/s-0037-1615961; OHKUBO Y, 1990, THROMB HAEMOSTASIS, V63, P417; PATTHY L, 1990, SEMIN THROMB HEMOST, V16, P245, DOI 10.1055/s-2007-1002677; Pollak ES, 1996, J BIOL CHEM, V271, P1738, DOI 10.1074/jbc.271.3.1738; REIJNEN MJ, 1992, P NATL ACAD SCI USA, V89, P6300, DOI 10.1073/pnas.89.14.6300; REIJNEN MJ, 1993, BLOOD, V82, P151, DOI 10.1182/blood.V82.1.151.bloodjournal821151; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P207; Sladek R, 2000, ADV PHARMACOL, V47, P23; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; Tarumi T, 2000, GENOMICS, V70, P269, DOI 10.1006/geno.2000.6393; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; Tordai H, 1999, FEBS LETT, V461, P63, DOI 10.1016/S0014-5793(99)01416-7; Vlieg AV, 2000, BLOOD, V95, P3678; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; Yu HR, 2000, GENOMICS, V69, P225, DOI 10.1006/geno.2000.6330	58	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18510	18516		10.1074/jbc.M201886200	http://dx.doi.org/10.1074/jbc.M201886200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11891231	hybrid			2022-12-25	WOS:000175975800035
J	Zhang, Y; Qiu, WJ; Chan, SC; Han, JH; He, X; Lin, SC				Zhang, Y; Qiu, WJ; Chan, SC; Han, JH; He, X; Lin, SC			Casein kinase I and casein kinase II differentially regulate Axin function in Wnt and JNK pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS POLYPOSIS-COLI; ACTIVATED PROTEIN-KINASE; BETA-CATENIN; SIGNALING PATHWAY; HEPATOCELLULAR CARCINOMAS; NEGATIVE REGULATOR; PHOSPHATASE 2A; EPSILON; PHOSPHORYLATION; TRANSCRIPTION	Axin uses different combinations of functional domains in down-regulation of the Wnt pathway and activation of the MEKK1/JNK pathway. We are interested in the elucidation of the functional switch of Axin. In the present study, we show that the Wnt activator CKIepsilon, but not CKIIalpha, Frat1, LRP5, or LRP6, inhibited Axin-mediated JNK activation. We also found that both CKIalpha and CKIepsilon interacted with Axin, whereas CKIIalpha did not bind to Axin and had no effect on Axin-mediated JNK activity even though CKIIalpha has also been suggested to be an activator for the Wnt pathway. The COOH-terminal region and the MEKK1-interacting domain of Axin are important for CKIalpha-Axin and CKIepsilon-Axin interaction. We further demonstrated that CKIepsilon and CKIalpha binding to Axin excluded MEKK1 binding, indicating that a competitive physical occupancy may underlie the inhibitory effect. Moreover, our data indicated that CKIepsilon kinase activity plays an additive role in this effect. Taken together, we have demonstrated that CKI and CKII exhibit differential effects on Axin-MEKK1 interaction and Axin-mediated JNK activation. Furthermore, our data suggest that CKI may provide a possible switch mechanism for Axin function in the regulation of Wnt and JNK pathways.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Inst Mol & Cell Biol, Singapore 117609, Singapore; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Harvard Univ, Sch Med, Childrens Hosp, Div Neurosci, Boston, MA 02115 USA	Hong Kong University of Science & Technology; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Scripps Research Institute; Harvard University; Boston Children's Hospital; Harvard Medical School	Lin, SC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China.	linsc@ust.hk	Lin, SC/G-4666-2010; QIU, WENJING/GZL-9992-2022; Han, J/G-4671-2010	Zhang, Yi/0000-0003-2785-1780				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Clevers H, 2000, NAT GENET, V24, P206, DOI 10.1038/73396; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Grietzen KF, 1999, J BIOL CHEM, V274, P32063, DOI 10.1074/jbc.274.45.32063; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; Kadoya T, 2000, J BIOL CHEM, V275, P37030, DOI 10.1074/jbc.M005984200; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; McKay RM, 2001, DEV BIOL, V235, P378, DOI 10.1006/dbio.2001.0307; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Neo SY, 2000, BIOCHEM BIOPH RES CO, V272, P144, DOI 10.1006/bbrc.2000.2751; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Rivers A, 1998, J BIOL CHEM, V273, P15980, DOI 10.1074/jbc.273.26.15980; Rubinfeld B, 2001, J BIOL CHEM, V276, P39037, DOI 10.1074/jbc.M105148200; Sakanaka C, 2000, RECENT PROG HORM RES, V55, P225; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Spink KE, 2000, EMBO J, V19, P2270, DOI 10.1093/emboj/19.10.2270; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zhang Y, 2001, J BIOL CHEM, V276, P32152, DOI 10.1074/jbc.M104451200; Zhang Y, 2000, J BIOL CHEM, V275, P25008, DOI 10.1074/jbc.M002491200	48	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17706	17712		10.1074/jbc.M111982200	http://dx.doi.org/10.1074/jbc.M111982200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884395	hybrid			2022-12-25	WOS:000175685100041
J	Zhou, NM; Luo, ZW; Luo, JS; Fan, XJ; Cayabyab, M; Hiraoka, M; Liu, DX; Han, XB; Pesavento, J; Dong, CZ; Wang, YL; An, J; Kaji, H; Sodroski, JG; Huang, ZW				Zhou, NM; Luo, ZW; Luo, JS; Fan, XJ; Cayabyab, M; Hiraoka, M; Liu, DX; Han, XB; Pesavento, J; Dong, CZ; Wang, YL; An, J; Kaji, H; Sodroski, JG; Huang, ZW			Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RECEPTOR CXCR4; SMALL-MOLECULE; CORECEPTOR ACTIVITY; BIOLOGICAL FUNCTION; MEMBRANE-FUSION; CELL-ADHESION; TROPIC HIV-1; FACTOR-I; VMIP-II	Chemokine receptor CXCR4 plays an important role in the immune system and the cellular entry of human immunodeficiency virus type 1 (HIV-1). To probe the stereospecificity of the CXCR4-ligand interface, D-amino acid peptides derived from natural chemokines, viral macrophage inflammatory protein II (vMIP-II) and stromal cell-derived factor-1alpha (SDF-1alpha), were synthesized and found to compete with I-125-SDF-1alpha and monoclonal antibody 12G5 binding to CXCR4 with potency and selectivity comparable with or higher than their L-peptide counterparts. This was surprising because of the profoundly different side chain topologies between D- and L-enantiomers, which circular dichroism spectroscopy showed adopt mirror image conformations. Further direct binding experiments using D-peptide labeled with fluorescein (designated as FAM-DV1) demonstrated that D- and L-peptides shared similar or at least overlapping binding site(s) on the CXCR4 receptor. Structure-activity analyses of related peptide analogs of mixed chiralities or containing alanine replacements revealed specific residues at the N-terminal half of the peptides as key binding determinants. Acting as CXCR4 antagonists and with much higher biological stability than L-counterparts, the D-peptides showed significant activity in inhibiting the replication of CXCR4-dependent HIV-1 strains. These results show the remarkable stereochemical flexibility of the CXCR4-peptide interface. Further studies to understand the mechanism of this unusual feature of the CXCR4 binding surface might aid the development of novel CXCR4-binding molecules like the D-peptides that have high affinity and stability.	Univ Illinois, Dept Biochem, Sch Mol & Cellular Biol, Urbana, IL 61801 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	University of Illinois System; University of Illinois Urbana-Champaign; Jefferson University; Jefferson University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Huang, ZW (corresponding author), Univ Illinois, Dept Biochem, Sch Mol & Cellular Biol, 302 Burrill Hall,MC-119,407 S Goodwin Ave, Urbana, IL 61801 USA.			Pesavento, James/0000-0001-6107-3666; Dong, Changzhi/0000-0001-7927-6306	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI042848, R21AI045414, R01AI041851, R01AI024755, R37AI024755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057761] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45414, AI41851, AI24755, AI42848] Funding Source: Medline; NIGMS NIH HHS [GM57761] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Blondelle SE, 2000, J PEPT RES, V55, P148, DOI 10.1034/j.1399-3011.2000.00162.x; Boshoff C, 1997, SCIENCE, V278, P290, DOI 10.1126/science.278.5336.290; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; Butcher DJ, 1997, FEBS LETT, V409, P183, DOI 10.1016/S0014-5793(97)00504-8; Chabot DJ, 2000, J BIOL CHEM, V275, P23774, DOI 10.1074/jbc.M003438200; Chabot DJ, 1999, J VIROL, V73, P6598, DOI 10.1128/JVI.73.8.6598-6609.1999; Chabot DJ, 2000, J VIROL, V74, P4404, DOI 10.1128/JVI.74.9.4404-4413.2000; Choe H, 1998, J VIROL, V72, P6113, DOI 10.1128/JVI.72.7.6113-6118.1998; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Dealwis C, 1998, P NATL ACAD SCI USA, V95, P6941, DOI 10.1073/pnas.95.12.6941; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Feifel B, 1998, J BIOL CHEM, V273, P11999, DOI 10.1074/jbc.273.20.11999; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FISHER PJ, 1994, NATURE, V368, P651, DOI 10.1038/368651a0; FUJIHASHI T, 1995, AIDS RES HUM RETROV, V11, P461, DOI 10.1089/aid.1995.11.461; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; Heveker N, 1998, CURR BIOL, V8, P369, DOI 10.1016/S0960-9822(98)70155-1; Kajumo F, 2000, VIROLOGY, V271, P240, DOI 10.1006/viro.2000.0308; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Li CF, 1997, BIOCHEMISTRY-US, V36, P15404, DOI 10.1021/bi971817g; Li S, 1998, J BIOL CHEM, V273, P16442, DOI 10.1074/jbc.273.26.16442; Loetscher P, 1998, J BIOL CHEM, V273, P22279, DOI 10.1074/jbc.273.35.22279; Lu ZH, 1997, P NATL ACAD SCI USA, V94, P6426, DOI 10.1073/pnas.94.12.6426; Luo JS, 1999, BIOCHEM BIOPH RES CO, V264, P42, DOI 10.1006/bbrc.1999.1476; Luo ZW, 1997, PROTEIN ENG, V10, P1039, DOI 10.1093/protein/10.9.1039; Luo ZW, 2000, BIOCHEMISTRY-US, V39, P13545, DOI 10.1021/bi000633q; Luo ZW, 1999, BIOCHEM BIOPH RES CO, V263, P691, DOI 10.1006/bbrc.1999.1441; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; MILES AJ, 1994, J BIOL CHEM, V269, P30939; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; Murakami T, 1997, J EXP MED, V186, P1389, DOI 10.1084/jem.186.8.1389; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Picard L, 1997, VIROLOGY, V231, P105, DOI 10.1006/viro.1997.8506; Satoh T, 1997, J BIOL CHEM, V272, P12175, DOI 10.1074/jbc.272.18.12175; Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383; Sodroski JG, 1999, CELL, V99, P243, DOI 10.1016/S0092-8674(00)81655-4; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; THALI M, 1992, J VIROL, V66, P5635, DOI 10.1128/JVI.66.9.5635-5641.1992; Wang ZX, 1998, J BIOL CHEM, V273, P15007, DOI 10.1074/jbc.273.24.15007; Zhou NM, 2001, J BIOL CHEM, V276, P42826, DOI 10.1074/jbc.M106582200; Zhou NM, 2000, EUR J IMMUNOL, V30, P164, DOI 10.1002/1521-4141(200001)30:1<164::AID-IMMU164>3.0.CO;2-X; Zhou NM, 2000, BIOCHEMISTRY-US, V39, P3782, DOI 10.1021/bi992750v; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	56	112	116	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17476	17485		10.1074/jbc.M202063200	http://dx.doi.org/10.1074/jbc.M202063200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11880384	hybrid			2022-12-25	WOS:000175685100013
J	Takahashi, N; Kawada, T; Yamamoto, T; Goto, T; Taimatsu, A; Aoki, N; Kawasaki, H; Taira, K; Yokoyama, KK; Kamei, Y; Fushiki, T				Takahashi, N; Kawada, T; Yamamoto, T; Goto, T; Taimatsu, A; Aoki, N; Kawasaki, H; Taira, K; Yokoyama, KK; Kamei, Y; Fushiki, T			Overexpression and ribozyme-mediated targeting of transcriptional coactivators CREB-binding protein and p300 revealed their indispensable roles in adipocyte differentiation through the regulation of peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; INSULIN-RESISTANCE; C/EBP-BETA; RETINOIC-ACID; MICE LACKING; ADIPOGENESIS; ADIPONECTIN; EXPRESSION; OBESITY; CBP	The cAMP-response element-binding protein-binding protein (CBP) and p300 are common coactivators for several transcriptional factors. It has been reported that both CDP and p300 are significant for the activation of peroxisome proliferator-activated receptor gamma (PPAR-gamma), which is a crucial nuclear receptor in adipogenesis. However, it remains unclear whether CDP and/or p300 is physiologically essential to the activation of PPARgamma in adipocytes and adipocyte differentiation. In this study, we investigated the physiological significance of CBP/p300 in NIH3T3 cells transiently expressing PPARgamma and CDP and in 3T3-L1 preadipocytes stably expressing CDP- or p300-specific ribozymes. In PPARgamma-transfected NIH3T3 cells, induction of expression of PPARgamma target genes such as adipocyte fatty acid-binding protein (aP2) and lipoprotein lipase (LPL) by adding thiazolidinedione was enhanced, depending on the amount of a CDP expression plasmid transfected. Expression of aP2 and LPL genes, as well as glycerol-3-phosphate dehydrogenase activity and triacylglyceride accumulation after adipogenic induction, was largely suppressed in 3T3-L1 adipocytes expressing either the CDP- or p300-specific active ribozyme, but not in inactive ribozyme-expressing cells. These data suggest that both CDP and p300 are indispensable for the full activation of PPARgamma and adipocyte differentiation and that CDP and p300 do not mutually complement in the process.	Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Nutr Chem Lab,Sakyo Ku, Kyoto 6068502, Japan; Biooriented Res Advancement Inst, Project Obes & Lipid Metab Regulat, Tokyo 1050001, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan; Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Tokyo 1138656, Japan; Natl Inst Adv Ind Sci & Technol, Gene Discovery Res Ctr, Tsukuba, Ibaraki 3058562, Japan; Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 3050074, Japan; Japan Sci & Technol Corp, Precursory Res Embryon Sci & Technol, Tokyo 1628636, Japan	Kyoto University; National Agriculture & Food Research Organization - Japan; Nagoya University; University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST); RIKEN; Japan Science & Technology Agency (JST)	Kawada, T (corresponding author), Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Nutr Chem Lab,Sakyo Ku, Kyoto 6068502, Japan.	fat@kais.kyoto-u.ac.jp	Goto, Tsuyoshi/AAY-2344-2020; Takahashi, Nobuyuki/AAX-8671-2021	Goto, Tsuyoshi/0000-0003-1283-147X; Takahashi, Nobuyuki/0000-0002-9705-662X; Takahashi, Nobuyuki/0000-0003-0126-6292				Adachi M, 2000, NEW ENGL J MED, V343, P856, DOI 10.1056/NEJM200009213431205; Bradley RL, 2001, RECENT PROG HORM RES, V56, P329, DOI 10.1210/rp.56.1.329; Castillo G, 1999, EMBO J, V18, P3676, DOI 10.1093/emboj/18.13.3676; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Elberg G, 2000, J BIOL CHEM, V275, P27815; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Goodman RH, 2000, GENE DEV, V14, P1553; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Hotta K, 2001, DIABETES, V50, P1126, DOI 10.2337/diabetes.50.5.1126; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; KAMEI Y, 1993, BIOCHEM J, V293, P807, DOI 10.1042/bj2930807; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawada T, 1996, INT J OBESITY, V20, pS52; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kodera Y, 2000, J BIOL CHEM, V275, P33201, DOI 10.1074/jbc.C000517200; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Misawa K, 2000, P NATL ACAD SCI USA, V97, P3062, DOI 10.1073/pnas.060489597; Mizukami J, 1997, BIOCHEM BIOPH RES CO, V240, P61, DOI 10.1006/bbrc.1997.7602; ONATE SA, 1995, SCIENCE, V270, P1354; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rasmussen R, 2001, RAPID CYCLE REAL TIM, P21, DOI [10.1007/978-3-642-59524-0_3, DOI 10.1007/978-3-642-59524-0_3]; Reginato MJ, 1998, J BIOL CHEM, V273, P32679, DOI 10.1074/jbc.273.49.32679; Robinson CE, 1998, BIOCHEM BIOPH RES CO, V244, P671, DOI 10.1006/bbrc.1998.8305; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tanaka Y, 2000, MECH DEVELOP, V95, P133, DOI 10.1016/S0925-4773(00)00360-9; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Trayhurn P, 2001, P NUTR SOC, V60, P329, DOI 10.1079/PNS200194; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan ZM, 1999, ONCOGENE, V18, P5714, DOI 10.1038/sj.onc.1202930	46	128	132	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16906	16912		10.1074/jbc.M200585200	http://dx.doi.org/10.1074/jbc.M200585200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11884404	hybrid			2022-12-25	WOS:000175564500076
J	Wu, F; Yan, W; Pan, JL; Morser, J; Wu, QY				Wu, F; Yan, W; Pan, JL; Morser, J; Wu, QY			Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGESTIVE-HEART-FAILURE; SERINE-PROTEASE; RAT-HEART; CELLS; RECEPTOR; FAMILY; ENZYME; MOUSE; GENES; LOCALIZATION	Corin is a type II transmembrane serine protease abundantly expressed in the heart. In a previous study using transfected 293 cells, we showed that corin converted pro-atrial natriuretic peptide (pro-ANP) to atrial natriuretic peptide (ANP), suggesting that corin is likely the pro-ANP convertase. Because other serine proteases such as thrombin and kallikrein had previously also been shown to cleave pro-ANP in vitro, it remained to demonstrate that corin is indeed the endogenous pro-ANP convertase in cardiomyocytes. In this study, we examined pro-ANP processing in a murine cardiac muscle cell line, HL-5. Northern analysis showed that corin mRNA was present in HL-5 cells. In HL-5 cells transfected with a plasmid expressing pro-ANP, recombinant pro-ANP was converted to mature ANP as determined by Western analysis, indicating the presence of the endogenous pro-ANP convertase in these cells. The processed recombinant ANP was shown to be active in an enzyme-linked immunosorbent assay-based cGMP assay in baby hamster kidney cells. The processing of recombinant pro-ANP in HL-5 cells was highly sequence-specific, because mutation R98A, but not mutations R101A and R102A, in pro-ANP prevented the conversion of pro-ANP to ANP. Expression of recombinant wild-type corin enhanced the processing of pro-ANP in HL-5 cells. In contrast, overexpression of active site mutant corm S985A or transfection of oligonucleotide small interfering RNA duplexes directed against the mouse corin gene completely inhibited the processing of recombinant pro-ANP in HL-5 cells. These results indicate that corin is the physiological pro-ANP convertase in cardiac myocytes.	Berlex Biosci, Dept Cardiovasc Res, Richmond, CA 94804 USA		Wu, QY (corresponding author), Berlex Biosci, Dept Cardiovasc Res, 15049 San Pablo Ave, Richmond, CA 94804 USA.			Wu, Qingyu/0000-0003-0561-9315				Allgren RL, 1997, NEW ENGL J MED, V336, P828, DOI 10.1056/NEJM199703203361203; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BORISOV AB, 1995, ANN NY ACAD SCI, V752, P80, DOI 10.1111/j.1749-6632.1995.tb17408.x; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; BURNETT JC, 1986, SCIENCE, V231, P1145, DOI 10.1126/science.2935937; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Colucci WS, 2000, NEW ENGL J MED, V343, P246, DOI 10.1056/NEJM200007273430403; CORTHORN J, 1991, MOL CELL BIOCHEM, V103, P31; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; GOTTLIEB SS, 1989, J AM COLL CARDIOL, V13, P1534, DOI 10.1016/0735-1097(89)90344-6; Hayashi M, 2001, J AM COLL CARDIOL, V37, P1820, DOI 10.1016/S0735-1097(01)01233-5; Hooper JD, 2000, EUR J BIOCHEM, V267, P6931, DOI 10.1046/j.1432-1327.2000.01806.x; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; IMADA T, 1988, J BIOL CHEM, V263, P9515; ITO T, 1988, P NATL ACAD SCI USA, V85, P8365, DOI 10.1073/pnas.85.21.8365; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; Levin ER, 1998, NEW ENGL J MED, V339, P321; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; LOPEZ MJ, 1995, NATURE, V378, P65, DOI 10.1038/378065a0; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MOREAU T, 1995, BBA-PROTEIN STRUCT M, V1249, P168, DOI 10.1016/0167-4838(95)00038-V; PANDEY KN, 1991, BIOCHEM BIOPH RES CO, V180, P437, DOI 10.1016/S0006-291X(05)81312-9; ROBBINS J, 1990, J BIOL CHEM, V265, P11905; SCHWARTZ D, 1985, SCIENCE, V229, P397, DOI 10.1126/science.3160114; SEI CA, 1992, MOL ENDOCRINOL, V6, P309, DOI 10.1210/me.6.3.309; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; SEIDAH NG, 1986, BIOSCIENCE REP, V6, P835, DOI 10.1007/BF01117107; SEIDMAN CE, 1984, SCIENCE, V226, P1206, DOI 10.1126/science.6542248; SHIELDS PP, 1988, J BIOL CHEM, V263, P8091; SHIONO S, 1986, BIOCHEM BIOPH RES CO, V135, P728, DOI 10.1016/0006-291X(86)90989-7; THIBAULT G, 1987, BIOCHEM J, V241, P265, DOI 10.1042/bj2410265; Tomita Y, 1998, J BIOCHEM-TOKYO, V124, P784, DOI 10.1093/oxfordjournals.jbchem.a022180; Wilkins MR, 1997, LANCET, V349, P1307, DOI 10.1016/S0140-6736(96)07424-7; Wu QY, 2001, FRONT BIOSCI-LANDMRK, V6, pD192; Yan W, 1999, J BIOL CHEM, V274, P14926, DOI 10.1074/jbc.274.21.14926; Yan W, 2000, P NATL ACAD SCI USA, V97, P8525, DOI 10.1073/pnas.150149097	41	122	131	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16900	16905		10.1074/jbc.M201503200	http://dx.doi.org/10.1074/jbc.M201503200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11884416	hybrid			2022-12-25	WOS:000175564500075
J	Charron, G; Laforest, S; Gagnon, C; Drolet, G; Mouginot, D				Charron, G; Laforest, S; Gagnon, C; Drolet, G; Mouginot, D			Acute sodium deficit triggers plasticity of the brain angiotensin type 1 receptors	FASEB JOURNAL			English	Article						hydromineral hemeostasis; salt appetite; furosemide; renin-angiotensin system; hypothalamus	MEDIAN PREOPTIC NUCLEUS; C-FOS EXPRESSION; SUBFORNICAL ORGAN; SALT APPETITE; LAMINA TERMINALIS; PARAVENTRICULAR NUCLEUS; PERIPHERAL ANGIOTENSIN; AT(1) RECEPTOR; II RECEPTORS; RAT-BRAIN	The brain renin-angiotensin system (bRAS) is involved in the control of hydromineral balance. However, little information is available on the functional regulation of the bRAS as a consequence of sodium deficit in the extracellular fluid compartments. We used a pharmacological model of acute Na+ depletion (furosemide injections) to investigate changes of a major component of the bRAS, the hypothalamic angiotensin type 1A (AT(1A)) receptors. Furosemide induced a rapid and long-lasting expression of the AT(1A) mRNA in the subfornical organ, the median preoptic nucleus (MnPO), and the parvocellular division of the paraventricular nucleus (pPVN). Na+ depletion increased the number of cells expressing AT(1A) mRNA in the pPVN, but not in the MnPO. The enhancement of AT(1A) mRNA expression was associated with an increase in AT(1) binding sites in all the regions studied. It is of interest that in the paraventricular nucleus, the majority of the neurons expressing AT(1A) mRNA also showed an increase in metabolic activity (Fos-related antigen immunoreactivity [FRA-ir]). By contrast, in the MnPO, we observe two distinct cell populations. Our data demonstrated that an acute Na+ deficit induced a functional regulation of the hypothalamic AT(1A) receptors, indicating that these receptors are subject to plasticity in response to hydromineral perturbations.	Univ Laval, CHUL, Ctr Rech, Unite Neurosci, Quebec City, PQ G1V 4G2, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada	Laval University; Universite de Montreal	Mouginot, D (corresponding author), Univ Laval, CHUL, Ctr Rech, Unite Neurosci, Local RC9800,2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	didier.mouginot@crchul.ulaval.ca						AGUILERA G, 1981, CIRC RES, V49, P751, DOI 10.1161/01.RES.49.3.751; AGUILERA G, 1995, J NEUROENDOCRINOL, V7, P775, DOI 10.1111/j.1365-2826.1995.tb00714.x; BADOER E, 1993, BRAIN RES, V610, P216, DOI 10.1016/0006-8993(93)91403-F; Bai D, 1998, AM J PHYSIOL-REG I, V275, pR632, DOI 10.1152/ajpregu.1998.275.2.R632; BELLUCCI A, 1984, J CLIN INVEST, V74, P1593, DOI 10.1172/JCI111575; CHENG HF, 1995, J CLIN INVEST, V95, P2012, DOI 10.1172/JCI117886; Denton DA, 1996, P NATL ACAD SCI USA, V93, P7397, DOI 10.1073/pnas.93.14.7397; Dumont EC, 1999, NEUROSCIENCE, V93, P877, DOI 10.1016/S0306-4522(99)00206-7; Ferguson AV, 2001, EXP BIOL MED, V226, P85, DOI 10.1177/153537020122600205; Ferguson AV, 1998, PROG NEUROBIOL, V54, P169, DOI 10.1016/S0301-0082(97)00065-8; Fitch GK, 2000, BRAIN RES, V861, P363, DOI 10.1016/S0006-8993(00)02048-5; Fitch GK, 2000, BRAIN RES, V861, P377, DOI 10.1016/S0006-8993(00)02049-7; Fitts DA, 1996, AM J PHYSIOL-REG I, V270, pR1092, DOI 10.1152/ajpregu.1996.270.5.R1092; FITTS DA, 1990, BEHAV NEUROSCI, V104, P818, DOI 10.1037/0735-7044.104.5.818; Fitzsimons JT, 1998, PHYSIOL REV, V78, P583, DOI 10.1152/physrev.1998.78.3.583; FLUHARTY SJ, 1983, BEHAV NEUROSCI, V97, P746, DOI 10.1037/0735-7044.97.5.746; GALAVERNA O, 1992, BRAIN RES BULL, V28, P89, DOI 10.1016/0361-9230(92)90234-O; GENOVESI S, 1993, CIRC RES, V73, P906, DOI 10.1161/01.RES.73.5.906; Giles ME, 1999, J HISTOCHEM CYTOCHEM, V47, P507, DOI 10.1177/002215549904700409; HAN L, 1995, NEUROSCI LETT, V193, P173, DOI 10.1016/0304-3940(95)11693-Q; HERBERT J, 1992, NEUROSCIENCE, V51, P867, DOI 10.1016/0306-4522(92)90526-8; JALOWIEC JE, 1974, BEHAV BIOL, V10, P313, DOI 10.1016/S0091-6773(74)91914-2; JARVIS MF, 1994, PEPTIDES, V15, P1037, DOI 10.1016/0196-9781(94)90068-X; Johnson AK, 1997, FRONT NEUROENDOCRIN, V18, P292, DOI 10.1006/frne.1997.0153; Lane JM, 1997, NEUROSCIENCE, V78, P1167, DOI 10.1016/S0306-4522(96)00604-5; LEBRUN CJ, 1995, NEUROSCIENCE, V65, P93, DOI 10.1016/0306-4522(94)00482-K; Lenkei Z, 1998, NEUROSCIENCE, V82, P827; LI Z, 1993, NEUROSCIENCE, V55, P197, DOI 10.1016/0306-4522(93)90466-S; LI ZH, 1993, AM J PHYSIOL, V265, pR302, DOI 10.1152/ajpregu.1993.265.2.R302; LIND RW, 1984, BRAIN RES, V321, P209, DOI 10.1016/0006-8993(84)90174-4; Mansi JA, 1997, AM J PHYSIOL-REG I, V272, pR813, DOI 10.1152/ajpregu.1997.272.3.R813; McKinley MJ, 1999, J CLIN NEUROSCI, V6, P289, DOI 10.1016/S0967-5868(99)90050-4; MCKINLEY MJ, 1995, BRAIN RES BULL, V37, P131, DOI 10.1016/0361-9230(94)00266-4; Nickenig G, 1998, HYPERTENSION, V31, P1272, DOI 10.1161/01.HYP.31.6.1272; NISSEN R, 1994, J PHYSIOL-LONDON, V479, P207, DOI 10.1113/jphysiol.1994.sp020289; Oldfield BJ, 2001, J NEUROENDOCRINOL, V13, P139, DOI 10.1046/j.1365-2826.2001.00597.x; OLDFIELD BJ, 1994, NEUROSCIENCE, V60, P255, DOI 10.1016/0306-4522(94)90219-4; Potts PD, 2000, NEUROSCIENCE, V95, P499; ROWLAND NE, 1994, BRAIN RES BULL, V33, P427, DOI 10.1016/0361-9230(94)90286-0; Rowland NE, 1996, BRAIN RES, V728, P90; SAKAI RR, 1989, BEHAV NEUROSCI, V103, P186, DOI 10.1037/0735-7044.103.1.186; SAKAI RR, 1987, BEHAV NEUROSCI, V101, P724, DOI 10.1037/0735-7044.101.5.724; SAKAI RR, 1990, APPETITE, V15, P161, DOI 10.1016/0195-6663(90)90017-3; SANDBERG K, 1994, HYPERTENSION S1, V23, P137; Schmid C, 1997, HYPERTENSION, V29, P923, DOI 10.1161/01.HYP.29.4.923; SHEN E, 1992, J AUTONOM NERV SYST, V37, P227, DOI 10.1016/0165-1838(92)90045-I; SPINEDI E, 1983, NEUROENDOCRINOLOGY, V37, P446, DOI 10.1159/000123591; Starbuck EM, 1998, APPETITE, V31, P309, DOI 10.1006/appe.1998.0169; Strehlow K, 1999, AM J PHYSIOL-HEART C, V277, pH1701, DOI 10.1152/ajpheart.1999.277.5.H1701; Swanson L. W., 1992, BRAIN MAPS STRUCTURE; THUNHORST RL, 1994, AM J PHYSIOL, V267, pR171, DOI 10.1152/ajpregu.1994.267.1.R171; THUNHORST RL, 1990, BEHAV NEUROSCI, V104, P637, DOI 10.1037/0735-7044.104.4.637; Thunhorst RL, 1998, AM J PHYSIOL-REG I, V274, pR1807; THUNHORST RL, 1987, AM J PHYSIOL, V252, pR409, DOI 10.1152/ajpregu.1987.252.2.R409; Thunhorst RL, 1996, NEUROSCI BIOBEHAV R, V20, P101, DOI 10.1016/0149-7634(95)00050-O; TRAVIS KA, 1993, AM J PHYSIOL, V264, pR1200, DOI 10.1152/ajpregu.1993.264.6.R1200; Wang DH, 1998, J HYPERTENS, V16, P467, DOI 10.1097/00004872-199816040-00008; WEISINGER RS, 1990, BRAIN RES, V526, P23, DOI 10.1016/0006-8993(90)90245-7; WEISS ML, 1986, AM J PHYSIOL, V250, pR250, DOI 10.1152/ajpregu.1986.250.2.R250; ZHANG DM, 1984, PHYSIOL BEHAV, V32, P677, DOI 10.1016/0031-9384(84)90325-1	60	26	26	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					610	+		10.1096/fj.01-0531fje	http://dx.doi.org/10.1096/fj.01-0531fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919170				2022-12-25	WOS:000174203700004
J	Nielsen, TH; Baunsgaard, L; Blennow, A				Nielsen, TH; Baunsgaard, L; Blennow, A			Intermediary glucan structures formed during starch granule biosynthesis are enriched in short side chains, a dynamic pulse labeling approach.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT; DEFICIENT; ENZYME; PHOSPHORYLATION; ISOAMYLASE; LACKING	The formation of intermediary glucans, mature starch, and phytoglycogen was studied using leaves of Arabidopsis thaliana wild type and dbe mutant, which lacks plastidic isoamylase (Zeeman, S. C., Umemoto, T., Lue, W. L., Au-Yeung, P., Martin, C., Smith, A. M., and Chen, J. (1998) Plant Cell 10, 1699-1711). A new approach to the study of starch biosynthesis was developed based on "very short pulse" labeling of leaf starch through photosynthetic fixation of (CO2)-C-14. This allowed selective analysis of the structure of starch formed within a 30-s period. This time frame is shorter than the period required for the formation of a single crystalline amylopectin lamella and consequently permits a direct analysis of intermediary structures during granule formation. Analysis of chain length distribution showed that the most recently formed outer layer of the granules has a structure different from the mature starch. The outer layer is enriched in short chains that are 6-11 glucose residues long. Side chains with 6 glucose residues are the shortest abundant chains formed, and they are formed exclusively by transfer from donor chains of 12 glucose residues or longer. The labeling pattern shows that chain transfer resulting in branching is a rapid and efficient process, and the preferential labeling of shorter chains in the intermediary granule bound glucan is suggested to be a direct consequence of efficient branching. Although similar, the short chain intermediary structure is not identical to phytoglycogen, which is an even more highly branched molecule with very few longer chains (more than 40 glucose residues). Pulse and chase labeling profiles for the dbe mutant showed that the final structure is more highly branched than the intermediary structures, which implies that branching of phytoglycogen occurs over a longer time period than branching of starch.	Royal Vet & Agr Univ, Plant Biochem Lab, DK-1871 Frederiksberg C, Denmark; Royal Vet & Agr Univ, Ctr Mol Plant Physiol, Dept Plant Biol, DK-1871 Frederiksberg C, Denmark	University of Copenhagen; University of Copenhagen	Nielsen, TH (corresponding author), Royal Vet & Agr Univ, Plant Biochem Lab, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.	thni@kvl.dk	Nielsen, Tom Hamborg H/F-7539-2014; Blennow, Andreas/F-7451-2014	Nielsen, Tom Hamborg H/0000-0002-8469-7145; Blennow, Andreas/0000-0001-6476-9546				Blennow A, 1998, CARBOHYD RES, V307, P45, DOI 10.1016/S0008-6215(98)00015-9; Blennow A, 2000, CARBOHYD POLYM, V41, P163, DOI 10.1016/S0144-8617(99)00082-X; BLENNOW A, 1998, EUR J BIOCHEM, V252, P148; Buleon A, 1998, INT J BIOL MACROMOL, V23, P85, DOI 10.1016/S0141-8130(98)00040-3; Buleon A, 1997, PLANT PHYSIOL, V115, P949, DOI 10.1104/pp.115.3.949; CASPAR T, 1985, PLANT PHYSIOL, V79, P11, DOI 10.1104/pp.79.1.11; GUAN HP, 1995, P NATL ACAD SCI USA, V92, P964, DOI 10.1073/pnas.92.4.964; GUAN HP, 1993, PLANT PHYSIOL, V102, P1269, DOI 10.1104/pp.102.4.1269; JAMES MG, 1995, PLANT CELL, V7, P417, DOI 10.1105/tpc.7.4.417; JENKINS JPJ, 1993, STARCH-STARKE, V45, P417; Kossmann J, 2000, CRIT REV PLANT SCI, V19, P171, DOI 10.1016/S0735-2689(00)80002-7; Kubo A, 1999, PLANT PHYSIOL, V121, P399, DOI 10.1104/pp.121.2.399; LIN TP, 1988, PLANT PHYSIOL, V86, P1131, DOI 10.1104/pp.86.4.1131; MANNERS DJ, 1989, CARBOHYD POLYM, V11, P87, DOI 10.1016/0144-8617(89)90018-0; Mouille G, 1996, PLANT CELL, V8, P1353; Myers AM, 2000, PLANT PHYSIOL, V122, P989, DOI 10.1104/pp.122.4.989; Nakamura Y, 1997, PLANT J, V12, P143, DOI 10.1046/j.1365-313X.1997.12010143.x; Preiss J., 1988, BIOCH PLANTS, V14., P181; Rydberg U, 2001, EUR J BIOCHEM, V268, P6140, DOI 10.1046/j.0014-2956.2001.02568.x; Smith AM, 1997, ANNU REV PLANT PHYS, V48, P65, DOI 10.1146/annurev.arplant.48.1.67; Smith AM, 2001, BIOMACROMOLECULES, V2, P335, DOI 10.1021/bm000133c; Tomlinson KL, 1997, PLANT J, V11, P31, DOI 10.1046/j.1365-313X.1997.11010031.x; Zeeman SC, 1998, PLANT J, V15, P357, DOI 10.1046/j.1365-313X.1998.00213.x; Zeeman SC, 1998, PLANT CELL, V10, P1699, DOI 10.1105/tpc.10.10.1699	24	38	41	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20249	20255		10.1074/jbc.M201866200	http://dx.doi.org/10.1074/jbc.M201866200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11919198	hybrid			2022-12-25	WOS:000176204500021
J	He, YC; Crouch, E				He, YC; Crouch, E			Surfactant protein D gene regulation - Interactions among the conserved CCAAT/enhancer-binding protein elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; COLLAGEN-LIKE DOMAIN; C-REACTIVE PROTEIN; ACUTE LUNG INJURY; C/EBP-DELTA; TRANSCRIPTIONAL REGULATION; DIFFERENTIAL EXPRESSION; CELL-PROLIFERATION; MAMMALIAN LECTIN; INNATE IMMUNITY	Surfactant protein D (SP-D) plays roles in pulmonary host defense and surfactant homeostasis and is increased following acute lung injury. Given the importance of CCAAT/enhancer-binding protein (C/EBP)binding elements in the systemic acute-phase response and lung development and the expression of C/EBP isoforms by lung epithelial cells, we hypothesized that conserved C/EBP motifs in the near-distal and proximal promoters contribute to the regulation of SP-D expression by C/EBPs. Five SP-D motifs (-432, -340, -319, -140, and -90) homologous to the C/EBP consensus sequence specifically bound to C/EBPs in gel shift assays, and four of the five sites (-432, -340, -319, and -90) efficiently competed for the binding of C/EBPalpha, C/EBPbeta, or C/EBPdelta to consensus oligomers. Cotransfection of C/EBPalpha, C/EBPbeta, or C/EBPdelta cDNA in H441 lung adenocarcinoma cells significantly increased the luciferase activity of a wild-type SP-D promoter construct containing 698 by of upstream sequence (SS698). Transfection of C/EBP also increased the level of endogenous SP-D mRNA in H441 cells. Transactivation of the reporter construct was abrogated by deletion of sequences upstream of -205. Independent site-directed mutagenesis of the sites at -432, -340, and -319 reduced C/EBP-mediated activation by similar to50%, and mutagenesis of the site at -432 in combination with either of the tandem sites at -340 and -319 blocked activation. The conserved AP-1 element at -109 was required for maximal promoter activity, but not for the transactivation of SS698 by C/EBPs. Thus, interactions among C/EBP elements in the near-distal promoter can modulate the promoter activity of SP-D.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL)	Crouch, E (corresponding author), Barnes Jewish Hosp, Dept Pathol & Immunol, Rm 2457,N Campus,Surg Pathol Mailstop 90-31-649,2, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594, R01HL044015] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29594, HL44015] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aderibigbe AO, 1999, AM J RESP CELL MOL, V20, P219, DOI 10.1165/ajrcmb.20.2.3348; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Breed DR, 1997, ENDOCRINOLOGY, V138, P5527, DOI 10.1210/en.138.12.5527; Burgess-Beusse BL, 1998, MOL CELL BIOL, V18, P7269, DOI 10.1128/MCB.18.12.7269; Cassel TN, 2000, AM J RESP CELL MOL, V22, P469, DOI 10.1165/ajrcmb.22.4.3916; Charles A, 2001, J CELL BIOCHEM, V83, P414, DOI 10.1002/jcb.1239; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CHOI AMK, 1995, AM J RESP CELL MOL, V13, P74, DOI 10.1165/ajrcmb.13.1.7598940; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; DArmiento J, 1997, GENE, V195, P19, DOI 10.1016/S0378-1119(97)00123-6; Dentener MA, 2000, AM J RESP CELL MOL, V23, P146, DOI 10.1165/ajrcmb.23.2.3855; FEY GH, 1987, MOL BIOL MED, V4, P323; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; HANSEN S, 2002, IN PRESS MOL IMMUNOL; He YC, 2000, J BIOL CHEM, V275, P31051, DOI 10.1074/jbc.M003499200; Heuertz RM, 1997, MOL MED TODAY, V3, P539, DOI 10.1016/S1357-4310(97)01145-3; Ikegami M, 2000, AM J PHYSIOL-LUNG C, V279, pL468, DOI 10.1152/ajplung.2000.279.3.L468; Jain-Vora S, 1998, INFECT IMMUN, V66, P4229; KAWASAKI N, 1994, BIOCHEM BIOPH RES CO, V198, P597, DOI 10.1006/bbrc.1994.1087; Kawasaki N, 1998, J BIOCHEM, V124, P1188, DOI 10.1093/oxfordjournals.jbchem.a022237; KLAMPFER L, 1995, J BIOL CHEM, V270, P3677, DOI 10.1074/jbc.270.8.3677; Lag M, 2000, EXP LUNG RES, V26, P383, DOI 10.1080/019021400408326; Lawson PR, 2000, IMMUNOL REV, V173, P66, DOI 10.1034/j.1600-065X.2000.917308.x; Lawson PR, 1999, AM J RESP CELL MOL, V20, P953, DOI 10.1165/ajrcmb.20.5.3343; Lee PT, 2000, AM J RESP CELL MOL, V23, P652, DOI 10.1165/ajrcmb.23.5.4016; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LeVine AM, 2000, J IMMUNOL, V165, P3934, DOI 10.4049/jimmunol.165.7.3934; LI F, 1995, AM J PHYSIOL-LUNG C, V269, pL241, DOI 10.1152/ajplung.1995.269.2.L241; Madsen J, 2000, J IMMUNOL, V164, P5866, DOI 10.4049/jimmunol.164.11.5866; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; McIntosh JC, 1996, AM J RESP CELL MOL, V15, P509, DOI 10.1165/ajrcmb.15.4.8879185; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Reading PC, 1997, J VIROL, V71, P8204, DOI 10.1128/JVI.71.11.8204-8212.1997; Rust K, 1996, AM J RESP CELL MOL, V14, P121, DOI 10.1165/ajrcmb.14.2.8630261; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sugahara K, 1999, CELL TISSUE RES, V297, P261, DOI 10.1007/s004410051354; Toonen RFG, 1996, BIOCHEM J, V316, P467, DOI 10.1042/bj3160467; White MR, 2000, J IMMUNOL, V165, P2108, DOI 10.4049/jimmunol.165.4.2108; Yamada T, 1997, J BIOCHEM-TOKYO, V121, P731; YANG FM, 1995, LAB INVEST, V73, P433	42	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19530	19537		10.1074/jbc.M201126200	http://dx.doi.org/10.1074/jbc.M201126200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11912209	hybrid			2022-12-25	WOS:000175894800040
J	Reid, J; Kelly, SM; Watt, K; Price, NC; McEwan, IJ				Reid, J; Kelly, SM; Watt, K; Price, NC; McEwan, IJ			Conformational analysis of the androgen receptor amino-terminal domain involved in transactivation - Influence of structure-stabilizing solutes and protein-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION DOMAIN; HUMAN GLUCOCORTICOID RECEPTOR; LIGAND-BINDING DOMAIN; NUCLEAR RECEPTOR; SECONDARY STRUCTURE; ALPHA-HELIX; IN-VITRO; COACTIVATOR; REGIONS; VP16	The androgen receptor (AR) is a member of the nuclear receptor superfamily. Sequences within the large amino-terminal domain of the receptor have been shown to be important for transactivation and protein-protein interactions; however, little is known about the structure and folding of this region. In the present study we show that a 344-amino acid polypeptide representing the main determinants for transactivation has the propensity to form a-helical structure and that mutations which disrupt putative helical regions alter conformation. Folding of the AR was observed in the presence of the helix-stabilizing solvent trifluoroethanol and the natural osmolyte trimethylamine N-oxide (TMAO). TMAO resulted in the movement of two tryptophan residues to a less solvent-exposed environment and the formation of secondary/tertiary structure resistant to protease cleavage. Critically, binding to the RAP74 subunit of the general transcription factor TFIIF resulted in extensive protease resistance, consistent with induced folding of the receptor transactivation domain. These data indicate that this region of the AR is structurally flexible and folds into a stable conformation upon interactions with a component of the general transcription machinery.	Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland; Univ Glasgow, IBLS, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Aberdeen; University of Glasgow	McEwan, IJ (corresponding author), Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Foresterhill, Aberdeen AB25 2ZD, Scotland.		Kelly, Sharon/K-4611-2013	Kelly, Sharon/0000-0002-3516-1387				Alen P, 1999, MOL CELL BIOL, V19, P6085; Bain DL, 2000, J BIOL CHEM, V275, P7313, DOI 10.1074/jbc.275.10.7313; Baskakov I, 1998, J BIOL CHEM, V273, P4831, DOI 10.1074/jbc.273.9.4831; Baskakov IV, 1999, J BIOL CHEM, V274, P10693, DOI 10.1074/jbc.274.16.10693; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CammersGoodwin A, 1996, J AM CHEM SOC, V118, P3082, DOI 10.1021/ja952900z; Cato ACB, 1998, TRENDS ENDOCRIN MET, V9, P150, DOI 10.1016/S1043-2760(98)00039-3; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; Choong CS, 1998, J MOL ENDOCRINOL, V21, P235, DOI 10.1677/jme.0.0210235; DahlmanWright K, 1996, BIOCHEMISTRY-US, V35, P1323, DOI 10.1021/bi952409k; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Gao TS, 1996, J STEROID BIOCHEM, V59, P9, DOI 10.1016/S0960-0760(96)00097-0; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Hi R, 1999, J BIOL CHEM, V274, P35152, DOI 10.1074/jbc.274.49.35152; Hiipakka RA, 1998, TRENDS ENDOCRIN MET, V9, P317, DOI 10.1016/S1043-2760(98)00081-2; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Hua QX, 1998, BIOCHEMISTRY-US, V37, P5858, DOI 10.1021/bi9800808; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1994, BIOCHEMISTRY-US, V33, P14064, DOI 10.1021/bi00251a015; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; Kumar R, 1999, J BIOL CHEM, V274, P24737, DOI 10.1074/jbc.274.35.24737; Kumar R, 2001, J BIOL CHEM, V276, P18146, DOI 10.1074/jbc.M100825200; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Lee DK, 2000, J BIOL CHEM, V275, P9308, DOI 10.1074/jbc.275.13.9308; Lee H, 2000, J BIOL CHEM, V275, P29426, DOI 10.1074/jbc.M003107200; Ma H, 1999, MOL CELL BIOL, V19, P6164; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; McEwan IJ, 2001, BIOCHEM SOC T, V29, P222; McEwan IJ, 1996, BIOCHEMISTRY-US, V35, P9584, DOI 10.1021/bi960793v; Nagadoi A, 1999, J MOL BIOL, V287, P593, DOI 10.1006/jmbi.1999.2620; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; Parker D, 1999, MOL CELL BIOL, V19, P5601; Poujol N, 2000, J BIOL CHEM, V275, P24022, DOI 10.1074/jbc.M001999200; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; RAJUN R, 1996, INT J PEPT PROT RES, V48, P328; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; Shen F, 1996, J BIOL CHEM, V271, P4819; Shen F, 1996, J BIOL CHEM, V271, P4827; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Tan JA, 2000, ENDOCRINOLOGY, V141, P3440, DOI 10.1210/en.141.9.3440; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; WANG BQ, 1995, J BIOL CHEM, V270, P27035, DOI 10.1074/jbc.270.45.27035; Warnmark A, 2001, J BIOL CHEM, V276, P45939, DOI 10.1074/jbc.M107875200; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Yamamoto A, 2000, J CELL BIOL, V150, P873, DOI 10.1083/jcb.150.4.873	56	108	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					20079	20086		10.1074/jbc.M201003200	http://dx.doi.org/10.1074/jbc.M201003200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11896058	hybrid			2022-12-25	WOS:000175894800109
J	Schouten, A; Rossien, J; Bakker, J; Schots, A				Schouten, A; Rossien, J; Bakker, J; Schots, A			Formation of disulfide bridges by a single-chain Fv antibody in the reducing ectopic environment of the plant cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENDOPLASMIC-RETICULUM; INTRACELLULAR EXPRESSION; SECRETORY PATHWAY; REDOX STATE; REVERSE-TRANSCRIPTASE; VARIABLE FRAGMENTS; TRANSGENIC TOBACCO; ESCHERICHIA-COLI; PROTEIN	Disulfide bridge formation in the reducing environment of the cytosol is considered a rare event and is mostly linked to inactivation of protein activity. In this report the in vivo redox state of a single-chain Fv (scFv) antibody fragment in the plant cytosol was investigated. The scFv antibody fragment consists of the variable light and heavy chain domains from a mouse IgG antibody, which are connected by a flexible linker peptide. In each domain one disulfide bridge is present. The functionality of antibodies, which are normally secreted via the oxidizing environment of the endoplasmic reticulum, depends on the formation of intramolecular disulfide bridges. We demonstrate that a scFv can form intramolecular disulfide bridges and is functionally expressed in the cytosol of stably transformed plants. In addition, the formation of intermolecular disulfide bridges through a cysteine present in the linker peptide was observed. In contrast, transient expression in tobacco protoplasts resulted in a cytosolic scFv lacking disulfide bridges, which had a substantially reduced affinity for the antigen. This indicates that functionality rather than stability is determined by the presence of disulfide bridges in the in planta-expressed scFv antibody. The controversial observation of disulfide bond formation in the cytosol is discussed.	Univ Wageningen & Res Ctr, Nematol Lab, Lab Mol Recognit & Antibody Technol, Dept Plant Sci, NL-6700 ES Wageningen, Netherlands	Wageningen University & Research	Schouten, A (corresponding author), Univ Wageningen & Res Ctr, Phytopathol Lab, Dept Plant Sci, POB 8025, NL-6700 EE Wageningen, Netherlands.	sander.schouten@fyto.dpw.wau.nl	Schots, Arjen/U-1839-2017; Schots, Arjen/ABF-8014-2020	Schots, Arjen/0000-0002-6036-7088; Schots, Arjen/0000-0002-6036-7088				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; ALOSI MC, 1988, PLANT PHYSIOL, V86, P1089, DOI 10.1104/pp.86.4.1089; ALSCHER RG, 1989, PHYSIOL PLANTARUM, V77, P457, DOI 10.1111/j.1399-3054.1989.tb05667.x; ANDERSON LE, 1995, PLANTA, V196, P118, DOI 10.1007/BF00193225; BIOCCA S, 1993, BIOCHEM BIOPH RES CO, V197, P422, DOI 10.1006/bbrc.1993.2496; BIOCCA S, 1995, BIO-TECHNOL, V13, P1110, DOI 10.1038/nbt1095-1110; BIOCCA S, 1994, BIO-TECHNOL, V12, P396, DOI 10.1038/nbt0494-396; BIOCCA S, 1995, TRENDS CELL BIOL, V5, P248, DOI 10.1016/S0962-8924(00)89019-4; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; CHOUDHARY AD, 1990, PLANT PHYSIOL, V94, P1802, DOI 10.1104/pp.94.4.1802; CSEKE C, 1986, BIOCHIM BIOPHYS ACTA, V853, P43, DOI 10.1016/0304-4173(86)90004-2; De Jaeger G, 1999, EUR J BIOCHEM, V259, P426, DOI 10.1046/j.1432-1327.1999.00060.x; DENECKE J, 1989, Methods in Molecular and Cellular Biology, V1, P19; DEVRIES AAF, 1995, J VIROL, V69, P3441, DOI 10.1128/JVI.69.6.3441-3448.1995; DUAN LX, 1994, P NATL ACAD SCI USA, V91, P5075, DOI 10.1073/pnas.91.11.5075; Fecker LF, 1997, ARCH VIROL, V142, P1857, DOI 10.1007/s007050050203; Freund C, 1996, BIOCHEMISTRY-US, V35, P8457, DOI 10.1021/bi952764a; Garaci E, 1997, J LEUKOCYTE BIOL, V62, P54, DOI 10.1002/jlb.62.1.54; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GLOCKSHUBER R, 1992, BIOCHEMISTRY-US, V31, P1270, DOI 10.1021/bi00120a002; GOTO Y, 1979, J BIOCHEM-TOKYO, V86, P1433, DOI 10.1093/oxfordjournals.jbchem.a132661; HEROUART D, 1993, P NATL ACAD SCI USA, V90, P3108, DOI 10.1073/pnas.90.7.3108; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JAMSA E, 1994, YEAST, V10, P355, DOI 10.1002/yea.320100308; JIANG WR, 1995, J VIROL, V69, P1044, DOI 10.1128/JVI.69.2.1044-1049.1995; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MACIEJEWSKI JP, 1995, NAT MED, V1, P667, DOI 10.1038/nm0795-667; MHASHILKAR AM, 1995, EMBO J, V14, P1542, DOI 10.1002/j.1460-2075.1995.tb07140.x; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OWEN M, 1992, BIO-TECHNOL, V10, P790, DOI 10.1038/nbt0792-790; Parks D, 1997, NUCLEIC ACIDS RES, V25, P1289, DOI 10.1093/nar/25.6.1289; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; PINEIRO M, 1994, P NATL ACAD SCI USA, V91, P3867, DOI 10.1073/pnas.91.9.3867; RENNENBERG H, 1982, PLANT PHYSIOL, V69, P766, DOI 10.1104/pp.69.4.766; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; Ryabova LA, 1997, NAT BIOTECHNOL, V15, P79, DOI 10.1038/nbt0197-79; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schouten A, 1997, FEBS LETT, V415, P235, DOI 10.1016/S0014-5793(97)01129-0; Schouten A, 1996, PLANT MOL BIOL, V30, P781, DOI 10.1007/BF00019011; Sengupta S, 2001, J BIOL CHEM, V276, P30111, DOI 10.1074/jbc.M104324200; Sengupta S, 2001, J BIOL CHEM, V276, P46896, DOI 10.1074/jbc.M108451200; Shaheen F, 1996, J VIROL, V70, P3392, DOI 10.1128/JVI.70.6.3392-3400.1996; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; Szederkenyi J, 1997, PLANTA, V202, P349, DOI 10.1007/s004250050137; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; Tavladoraki P, 1999, EUR J BIOCHEM, V262, P617, DOI 10.1046/j.1432-1327.1999.00443.x; TAVLADORAKI P, 1993, NATURE, V366, P469, DOI 10.1038/366469a0; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; VANENGELEN FA, 1995, TRANSGENIC RES, V4, P288, DOI 10.1007/BF01969123; WERGE TM, 1994, FEBS LETT, V351, P393, DOI 10.1016/0014-5793(94)00892-2; WINGATE VPM, 1988, PLANT PHYSIOL, V87, P206, DOI 10.1104/pp.87.1.206; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	57	30	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19339	19345		10.1074/jbc.M201245200	http://dx.doi.org/10.1074/jbc.M201245200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11916972	hybrid			2022-12-25	WOS:000175894800014
J	Kamemura, K; Hayes, BK; Comer, FI; Hart, GW				Kamemura, K; Hayes, BK; Comer, FI; Hart, GW			Dynamic interplay between O-glycosylation and O-phosphorylation of nucleocytoplasmic proteins - Alternative glycosylation/phosphorylation of Thr-58, a known mutational hot spot of c-Myc in lymphomas, is regulated by mitogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; CYTOSOLIC PROTEINS; GLCNAC TRANSFERASE; TERMINAL DOMAIN; IN-VIVO; NUCLEAR; TRANSACTIVATION; PROTEASOME; EXPRESSION; LITHIUM	Previously, we reported that c-Myc is glycosylated by O-linked N-acetylglucosamine at Thr-58, a known phosphorylation site and a mutational hot spot in lymphomas. In this paper, we describe the production and characterization of two Thr-58 site-specific antibodies and use them to examine the modification of Thr-58 in living cells. One antibody specifically reacts with the Thr-58-glycosylated form of c-Myc, and the other reacts only with unmodified Thr-58 in c-Myc. Using these antibodies together with a commercial anti-Thr-58-phosphorylated c-Myc antibody, we simultaneously detected three forms of c-Myc (Thr-58-unmodified, -phosphorylated, and -glycosylated). It has been reported that Thr-58 phosphorylation is dependent on a prior phosphorylation of Ser-62. Mutagenesis of Ser-62 to Ala showed a marked decrease of Thr-58 phosphorylation and a marked increase of Thr-58 glycosylation. Growth inhibition of HL60 cells by serum starvation increases Thr-58 glycosylation and correspondingly decreases its phosphorylation. Serum stimulation has the opposite effect upon the modification status of Thr-58. A candidate kinase responsible for Thr-58 phosphorylation is the glycogen synthase kinase 3 (GSK3). Lithium, a competitive inhibitor of GSK3, decreased Thr-58 phosphorylation and increased its glycosylation. Finally, we show that the Thr-58-phosphorylated form of c-Myc predominantly accumulates in the cytoplasm rather than the nucleus upon inhibition of proteasome activity. These data suggest that hierarchical phosphorylation of Ser-62 and Thr-58 and alternative glycosylation/phosphorylation of Thr-58 together regulate the myriad functions of c-Myc in cells.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Hart, GW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	gwhart@jhmi.edu		Hart, Gerald/0000-0001-7812-4351	NCI NIH HHS [CA42486] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042486] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; Amati B, 2001, BBA-REV CANCER, V1471, pM135, DOI 10.1016/S0304-419X(01)00020-8; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Cheng XG, 2000, BIOCHEMISTRY-US, V39, P11609, DOI 10.1021/bi000755i; Cheng XG, 2001, J BIOL CHEM, V276, P10570, DOI 10.1074/jbc.M010411200; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Dang CV, 1999, MOL CELL BIOL, V19, P1; Du XL, 2001, J CLIN INVEST, V108, P1341, DOI 10.1172/JCI11235; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Ferrer I, 2001, NEUROPATH APPL NEURO, V27, P343, DOI 10.1046/j.1365-2990.2001.00348.x; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Griffith LS, 1999, EUR J BIOCHEM, V262, P824, DOI 10.1046/j.1432-1327.1999.00439.x; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Izumi H, 2001, J CELL SCI, V114, P1533; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Lubas WA, 1997, J BIOL CHEM, V272, P9316; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Medina L, 1998, GLYCOBIOLOGY, V8, P383, DOI 10.1093/glycob/8.4.383; Mora A, 2001, J NEUROCHEM, V78, P199, DOI 10.1046/j.1471-4159.2001.00410.x; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; Noguchi K, 2001, BIOCHEM BIOPH RES CO, V281, P1313, DOI 10.1006/bbrc.2001.4498; PULVERER BJ, 1994, ONCOGENE, V9, P59; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490	56	165	192	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19229	19235		10.1074/jbc.M201729200	http://dx.doi.org/10.1074/jbc.M201729200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11904304	hybrid			2022-12-25	WOS:000175975800127
J	Sweet, CR; Preston, A; Toland, E; Ramirez, SM; Cotter, RJ; Maskell, DJ; Raetz, CRH				Sweet, CR; Preston, A; Toland, E; Ramirez, SM; Cotter, RJ; Maskell, DJ; Raetz, CRH			Relaxed acyl chain specificity of Bordetella UDP-N-acetylglucosamine acyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-A BIOSYNTHESIS; ESCHERICHIA-COLI ENCODES; LIPOPOLYSACCHARIDE BIOSYNTHESIS; BRONCHISEPTICA INFECTION; ENDOTOXIN BIOSYNTHESIS; CARRIER PROTEIN; KENNEL COUGH; GENE; PERTUSSIS; IDENTIFICATION	Lipid A (endotoxin) is a major structural component of Gram-negative outer membranes. It also serves as the hydrophobic anchor of lipopolysaccharide and is a potent activator of the innate immune response. Lipid A molecules from the genus Bordetella are reported to exhibit unusual structural asymmetry with respect to the acyl chains at the 3- and 3'-positions. These acyl chains are attached by LTDP-N-acetylglucosamine acyltransferase (LpxA). To determine the origin of the acyl variability, the single lpxA ortholog present in each of the genomes of Bordetella bronchiseptica (lpxA(Br)), Bordetella parapertussis (lpxA(Pa)), and Bordetella pertussis (lpxA(Pe)) was cloned and expressed in Escherichia coli. In contrast to all LpxA proteins studied to date, LpxA]3, and LpxA(Pe) display relaxed acyl chain length specificity in vitro, utilizing C10OH-ACP, C12OH-ACP, and C14OH-ACP at similar rates. Furthermore, hybrid lipid A molecules synthesized at 42 degreesC by an E. coli lpxA mutant complemented with lpxA(Pe) contain C10OH, C12OH, and C14OH at both the 3- and 3'-positions, as determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. In contrast, LpxA from B. parapertussis did not display relaxed specificity but was selective for C10OH-ACP. This study provides an enzymatic explanation for some of the unusual acyl chain variations found in Bordetella lipid A.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Cambridge, Dept Clin Vet Med, Ctr Vet Sci, Cambridge CB3 0ES, England; Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spectrometry Facil, Baltimore, MD 21205 USA	Duke University; University of Cambridge; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu		Preston, Andrew/0000-0002-1489-280X; Kalb, Suzanne/0000-0002-8067-136X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008558, R01GM054882, R01GM051310] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54882, GM51310, GM08558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen A, 1996, MOL MICROBIOL, V19, P37, DOI 10.1046/j.1365-2958.1996.354877.x; AMANO K, 1990, J GEN MICROBIOL, V136, P481, DOI 10.1099/00221287-136-3-481; ANDERSON MS, 1985, J BIOL CHEM, V260, P5536; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; Aussel L, 2000, RAPID COMMUN MASS SP, V14, P595, DOI 10.1002/(SICI)1097-0231(20000415)14:7<595::AID-RCM919>3.0.CO;2-4; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Babinski KJ, 1998, FASEB J, V12, pA1288; BURNS EH, 1993, J CLIN MICROBIOL, V31, P1838, DOI 10.1128/JCM.31.7.1838-1844.1993; Caroff M, 2001, J ENDOTOXIN RES, V7, P63, DOI 10.1177/09680519010070011101; CAROFF M, 1990, J BACTERIOL, V172, P1121, DOI 10.1128/jb.172.2.1121-1128.1990; Caroff M, 2000, FEBS LETT, V477, P8, DOI 10.1016/S0014-5793(00)01720-8; CAROFF M, 1994, 17 INT CARB S; Chaby R, 1988, PATHOGENESIS IMMUNIT, P247; Cherry JD, 1996, J INFECT DIS, V174, pS259, DOI 10.1093/infdis/174.Supplement_3.S259; CHERRY JD, 1992, VACCINE, V10, P1033, DOI 10.1016/0264-410X(92)90113-X; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; COLEMAN J, 1988, J BACTERIOL, V170, P1268, DOI 10.1128/jb.170.3.1268-1274.1988; COSTELLO CE, 1990, METHOD ENZYMOL, V193, P738, DOI 10.1016/0076-6879(90)93448-T; COTTER PA, 1994, INFECT IMMUN, V62, P3381, DOI 10.1128/IAI.62.8.3381-3390.1994; Cotter PA, 2001, PRINCIPLES BACTERIAL, P619; CROWELL DN, 1986, J BACTERIOL, V168, P152, DOI 10.1128/jb.168.1.152-159.1986; GALANOS C, 1985, EUR J BIOCHEM, V148, P1, DOI 10.1111/j.1432-1033.1985.tb08798.x; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; GUEIRARD P, 1995, J CLIN MICROBIOL, V33, P2002, DOI 10.1128/JCM.33.8.2002-2006.1995; HEININGER U, 1994, PEDIATR INFECT DIS J, V13, P306, DOI 10.1097/00006454-199404000-00011; KELLY TM, 1993, J BIOL CHEM, V268, P19866; Khan SA, 1998, MOL MICROBIOL, V29, P571, DOI 10.1046/j.1365-2958.1998.00952.x; LEBBAR S, 1994, CARBOHYD RES, V259, P257, DOI 10.1016/0008-6215(94)84061-X; LUDERITZ O, 1966, ANN NY ACAD SCI, V133, P349, DOI 10.1111/j.1749-6632.1966.tb52376.x; MOHAN S, 1994, J BIOL CHEM, V269, P32896; Nennig ME, 1996, JAMA-J AM MED ASSOC, V275, P1672, DOI 10.1001/jama.275.21.1672; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; Pichichero ME, 1997, ARCH PEDIAT ADOL MED, V151, P35, DOI 10.1001/archpedi.1997.02170380039006; PORTER JF, 1995, FEMS MICROBIOL LETT, V132, P195, DOI 10.1111/j.1574-6968.1995.tb07833.x; Porter JF, 1996, FEMS MICROBIOL LETT, V135, P131, DOI 10.1111/j.1574-6968.1996.tb07977.x; PORTER JF, 1994, MICROBIOL-SGM, V140, P255, DOI 10.1099/13500872-140-2-255; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; RAY A, 1991, FEMS MICROBIOL LETT, V79, P211, DOI 10.1016/0378-1097(91)90088-R; REINA J, 1991, INFECTION, V19, P46, DOI 10.1007/BF01643760; Rick PD, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P283; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RUTTER JM, 1981, VET REC, V108, P451, DOI 10.1136/vr.108.21.451; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STIBITZ S, 1989, NATURE, V338, P266, DOI 10.1038/338266a0; Sweet CR, 2001, J BIOL CHEM, V276, P19565, DOI 10.1074/jbc.M101868200; Tamion F, 1996, SCAND J INFECT DIS, V28, P197, DOI 10.3109/00365549609049077; THRUSFIELD MV, 1991, J SMALL ANIM PRACT, V32, P215, DOI 10.1111/j.1748-5827.1991.tb00550.x; THRUSFIELD MV, 1991, J SMALL ANIM PRACT, V32, P455, DOI 10.1111/j.1748-5827.1991.tb00987.x; TOMASIEWICZ HG, 1987, J BACTERIOL, V169, P5735, DOI 10.1128/jb.169.12.5735-5744.1987; VanderZee A, 1997, J BACTERIOL, V179, P6609, DOI 10.1128/jb.179.21.6609-6617.1997; WATANABE M, 1990, J GEN MICROBIOL, V136, P489, DOI 10.1099/00221287-136-3-489; WESTPHAL O, 1983, PROG ALLERGY, V33, P9; Wyckoff TJO, 1998, TRENDS MICROBIOL, V6, P154, DOI 10.1016/S0966-842X(98)01230-X; Wyckoff TJO, 1998, J BIOL CHEM, V273, P32369, DOI 10.1074/jbc.273.49.32369; Wyckoff TJO, 1999, J BIOL CHEM, V274, P27047, DOI 10.1074/jbc.274.38.27047; Young K, 1995, J BIOL CHEM, V270, P30384, DOI 10.1074/jbc.270.51.30384; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93; Zarrouk H, 1997, J BACTERIOL, V179, P3756, DOI 10.1128/jb.179.11.3756-3760.1997	64	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18281	18290		10.1074/jbc.M201057200	http://dx.doi.org/10.1074/jbc.M201057200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889134	hybrid			2022-12-25	WOS:000175975800007
J	Weng, ZG; Xin, M; Pablo, L; Grueneberg, D; Hagel, M; Bain, G; Muller, T; Papkoff, J				Weng, ZG; Xin, M; Pablo, L; Grueneberg, D; Hagel, M; Bain, G; Muller, T; Papkoff, J			Protection against anoikis and down-regulation of cadherin expression by a regulatable beta-catenin protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							WNT SIGNALING PATHWAY; TRANSCRIPTION FACTOR LEF-1; CELL-ADHESION MOLECULES; APC TUMOR-SUPPRESSOR; MAP KINASE; COLORECTAL-CANCER; XENOPUS EMBRYOS; AXIS FORMATION; C-MYC; NEOPLASTIC TRANSFORMATION	beta-Catenin signaling plays a key role in a variety of cellular contexts during embryonic development and tissue differentiation. Aberrant beta-catenin signaling has also been implicated in promoting human colorectal carcinomas as well as a variety of other cancers. To study the molecular and cellular biological functions of beta-catenin in a controlled fashion, we created a regulatable form of activated beta-catenin by fusion to a modified estrogen receptor (ER) ligand binding domain (G525R). Transfection of tissue culture cells with expression vectors encoding this hybrid protein allows the signal transduction function of beta-catenin to be induced by the synthetic estrogen, 4-hydroxytamoxifen, leading to regulated activation of a beta-catenin-lymphocyte enhancer-binding factor-dependent reporter gene as well as induction of endogenous cyclin D1 expression. The activation of ER-beta-catenin signaling rescues RK3E cells from anoikis and correlates with an increased phosphorylation of mitogen-activated protein kinase. The inhibition of anoikis by ER-beta-catenin can be abolished by a mitogen-activated protein kinase pathway inhibitor, PD98059. Evidence is also provided to show that ER-beta-catenin down-regulates cadherin protein levels. These findings support a key role for activated beta-catenin signaling in processes that contribute to tumor formation and progression.	Aventis Pharmaceut, Canbridge Genom Ctr, Cambridge, MA 02139 USA	Sanofi-Aventis	Weng, ZG (corresponding author), Infin Pharmaceut Inc, 650 Albany St, Boston, MA 02118 USA.			Weng, Zhigang/0000-0003-1885-5501				ABERLE H, 1994, J CELL SCI, V107, P3655; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Aziz N, 1999, MOL CELL BIOL, V19, P1101; BAE SN, 1993, BREAST CANCER RES TR, V24, P241, DOI 10.1007/BF01833264; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Briegel K, 1996, DEVELOPMENT, V122, P3839; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; DEBENEDETTI L, 1994, CANCER RES, V54, P3553; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fearon ER, 2000, JNCI-J NATL CANCER I, V92, P515, DOI 10.1093/jnci/92.7.515; Ferkey DM, 2000, DEV BIOL, V225, P471, DOI 10.1006/dbio.2000.9816; Finlay D, 2000, CELL DEATH DIFFER, V7, P302, DOI 10.1038/sj.cdd.4400652; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Giannini AL, 2000, EXP CELL RES, V255, P207, DOI 10.1006/excr.1999.4785; Gonzalez-Amaro R, 1999, CRIT REV IMMUNOL, V19, P389; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Hakimelahi S, 2000, J BIOL CHEM, V275, P10905, DOI 10.1074/jbc.275.15.10905; Handschuh G, 1999, ONCOGENE, V18, P4301, DOI 10.1038/sj.onc.1202790; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Ingham PW, 1996, TRENDS GENET, V12, P382, DOI 10.1016/0168-9525(96)30096-6; ISHIBASHI T, 1994, J BIOL CHEM, V269, P7645; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Malik HS, 1997, P NATL ACAD SCI USA, V94, P13738, DOI 10.1073/pnas.94.25.13738; MAREEL M, 1995, CANCER DETECT PREV, V19, P451; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATTIONI T, 1994, METHOD CELL BIOL, V43, P335; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEIFER M, 1994, DEVELOPMENT, V120, P369; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Polakis P, 2000, GENE DEV, V14, P1837; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Rehberger S, 1997, EXP CELL RES, V233, P363, DOI 10.1006/excr.1997.3562; Reichert M, 2000, J BIOL CHEM, V275, P9492, DOI 10.1074/jbc.275.13.9492; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; Sokol SY, 1999, CURR OPIN GENET DEV, V9, P405, DOI 10.1016/S0959-437X(99)80061-6; SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1988, CELL DIFFER DEV, V25, P91, DOI 10.1016/0922-3371(88)90104-9; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tepass U, 1999, CURR OPIN CELL BIOL, V11, P540, DOI 10.1016/S0955-0674(99)00025-3; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tomlinson A, 1997, DEVELOPMENT, V124, P4515; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Xu LF, 2000, GENE DEV, V14, P585; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	123	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18677	18686		10.1074/jbc.M105331200	http://dx.doi.org/10.1074/jbc.M105331200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11904289	hybrid			2022-12-25	WOS:000175975800059
J	Ponamarev, MV; Longley, MJ; Nguyen, D; Kunkel, TA; Copeland, WC				Ponamarev, MV; Longley, MJ; Nguyen, D; Kunkel, TA; Copeland, WC			Active site mutation in DNA polymerase gamma associated with progressive external ophthalmoplegia causes error-prone DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P55 ACCESSORY SUBUNIT; MITOCHONDRIAL-DNA; MULTIPLE DELETIONS; ESCHERICHIA-COLI; KLENOW FRAGMENT; FIDELITY; REPLICATION; MTDNA; IDENTIFICATION; DISORDER	Progressive external ophthalmoplegia (PEO) is a heritable mitochondrial disorder characterized by the accumulation of multiple point mutations and large deletions in mtDNA. Autosomal dominant PEO was recently shown to co-segregate with a heterozygous Y955C mutation in the human gene encoding the sole mitochondrial DNA polymerase, DNA polymerase gamma (pol gamma). Since Tyr-955 is a highly conserved residue critical for nucleotide recognition among family A DNA polymerases, we analyzed the effects of the Y955C mutation on the kinetics and fidelity of DNA synthesis by the purified human mutant polymerase in complex with its accessory subunit. The Y955C enzyme retains a wild-type catalytic rate (k(cat)) but suffers a 45-fold decrease in apparent binding affinity for the incoming nucleoside triphosphate (K-m). The Y955C derivative is 2-fold less accurate for base pair substitutions than wild-type pol gamma despite the action of intrinsic exonucleolytic proofreading. The fall mutator effect of the Y955C substitution was revealed by genetic inactivation of the exonuclease, and error rates for certain mismatches were elevated by 10-100-fold. The error-prone DNA synthesis observed for the Y955C pol gamma is consistent with the accumulation of mtDNA mutations in patients with PEO.	NIEHS, Genet Mol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Copeland, WC (corresponding author), NIEHS, Genet Mol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Copeland, William/C-4242-2019; Kunkel, Thomas A./D-5088-2019	Copeland, William/0000-0002-0359-0953; Kunkel, Thomas A./0000-0002-9900-1788	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065070, ZIAES065070, Z01ES065078, ZIAES065078] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820; Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279; JOHNS DR, 1989, P NATL ACAD SCI USA, V86, P8059, DOI 10.1073/pnas.86.20.8059; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; Kaukonen JA, 1996, AM J HUM GENET, V58, P763; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200; Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197; Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w; Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; Saveson CJ, 1997, GENETICS, V146, P457; SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034; Van Goethem G, 2000, J MED GENET, V37, P547, DOI 10.1136/jmg.37.7.547; VanGoethem G, 1997, EUR J NEUROL, V4, P476; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WERNETTE CM, 1988, BIOCHEMISTRY-US, V27, P6046, DOI 10.1021/bi00416a033; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0; Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333	29	103	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15225	15228		10.1074/jbc.C200100200	http://dx.doi.org/10.1074/jbc.C200100200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11897778	hybrid			2022-12-25	WOS:000175510400002
J	Numazaki, M; Tominaga, T; Toyooka, H; Tominaga, M				Numazaki, M; Tominaga, T; Toyooka, H; Tominaga, M			Direct phosphorylation of capsaicin receptor VR1 by protein Kinase C epsilon and identification of two target serine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; PAIN; SENSITIZATION; PATHWAY; CHANNEL	The capsaicin receptor, VR1, is a sensory neuron-specific ion channel that serves as a polymodal detector of pain-producing chemical and physical stimuli. It has been reported that ATP, one of the inflammatory mediators, potentiates the VR1 currents evoked by capsaicin or protons and reduces the temperature threshold for activation of VR1 through metabotropic P2Y(1) receptors in a protein Kinase C (PKC)-dependent pathway, suggesting the phosphorylation of VR1 by PKC. In this study, direct phosphorylation of VR1 upon application of phorbol 12-myristate 13-acetate (PMA) was proven biochemically in cells expressing VR1. An in vitro kinase assay using glutathione S-transferase fusion proteins with cytoplasmic segments of VR1 showed that both the first intracellular loop and carboxyl terminus of VR1 were phosphorylated by PKCepsilon. Patch clamp analysis of the point mutants where Ser or Thr residues were replaced with Ala in the total 16 putative phosphorylation sites showed that two Ser residues, Ser(502) and Ser(800) were involved in the potentiation of the capsaicin-evoked currents by either PMA or ATP. In the cells expressing S502A/S800A double mutant, the temperature threshold for activation was not reduced upon PMA treatment. The two sites would be promising targets for the development of substance modulating VR1 function, thereby reducing pain.	Mie Univ, Sch Med, Dept Physiol, Tsu, Mie 5148507, Japan; Univ Tsukuba, Sch Med, Dept Anesthesiol, Tsukuba, Ibaraki 3050006, Japan; Fdn Advancement Int Sci, Tsukuba, Ibaraki 3050062, Japan	Mie University; University of Tsukuba	Tominaga, M (corresponding author), Mie Univ, Sch Med, Dept Physiol, Edobashi 2-174, Tsu, Mie 5148507, Japan.	tominaga@doc.medic.mie-u.ac.jp						Aley KO, 2000, J NEUROSCI, V20, P4680, DOI 10.1523/JNEUROSCI.20-12-04680.2000; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, CURR OPIN NEUROBIOL, V9, P525, DOI 10.1016/S0959-4388(99)00009-4; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Cesare P, 1999, P NATL ACAD SCI USA, V96, P7658, DOI 10.1073/pnas.96.14.7658; Cesare P, 1996, P NATL ACAD SCI USA, V93, P15435, DOI 10.1073/pnas.93.26.15435; Cesare P, 1999, NEURON, V23, P617, DOI 10.1016/S0896-6273(00)80813-2; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Fields H. L., 1987, PAIN; Francesconi A, 2000, P NATL ACAD SCI USA, V97, P6185, DOI 10.1073/pnas.97.11.6185; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Khasar SG, 1999, NEURON, V24, P253, DOI 10.1016/S0896-6273(00)80837-5; Malmberg AB, 1997, SCIENCE, V278, P279, DOI 10.1126/science.278.5336.279; Martin WJ, 2001, J NEUROSCI, V21, P5321, DOI 10.1523/JNEUROSCI.21-14-05321.2001; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Szallasi A, 1999, PHARMACOL REV, V51, P159; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Tominaga M, 2000, PAIN REV, V7, P97, DOI 10.1191/096813000678809447; Tominaga M, 2001, P NATL ACAD SCI USA, V98, P6951, DOI 10.1073/pnas.111025298; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Wood JN, 1999, CURR OPIN GENET DEV, V9, P328, DOI 10.1016/S0959-437X(99)80049-5; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765	25	377	401	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13375	13378		10.1074/jbc.C200104200	http://dx.doi.org/10.1074/jbc.C200104200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11884385	hybrid			2022-12-25	WOS:000175096000005
J	Chen, J; Kremer, CS; Bender, TP				Chen, J; Kremer, CS; Bender, TP			A Myb dependent pathway maintains Friend murine erythroleukemia cells in an immature and proliferating state	ONCOGENE			English	Article						c-Myb; A-Myb; B-Myb; erythroleukemia; transcription factor; differentiation	HUMAN HEMATOPOIETIC-CELLS; UP-REGULATES BCL-2; C-MYB; B-MYB; A-MYB; ERYTHROID-DIFFERENTIATION; TERMINAL DIFFERENTIATION; DOWN-REGULATION; TRANSCRIPTION FACTOR; MESSENGER-RNA	Friend murine erythroleukemia (MEL) cells are transformed erythroid precursors that are held in an immature and proliferating state but can be induced to differentiate in vivo by treatment with a variety of chemical agents such as N, N-hexamethylene bisacetamide (HMBA). To investigate the role of Myb proteins in maintaining MEL cells in an immature and proliferating state we have produced stable transfectants in the C19 MEL cell line that contain a dominant interfering Myb allele (MEnT) under the control of an inducible mouse metallothionein I promoter. When expression of MEnT protein was induced with ZnCl2, the stable transfectants differentiated with kinetics that were similar to wild type C19 MEL cells treated with HMBA, including induction of alpha-globin mRNA expression, assembly of hemoglobin and growth arrest. Expression of endogenous c-myb and c-myc was also decreased in response to MEnT. Expression of mad-1 mRNA was rapidly increased in response to expression of MEnT resulting in a shift from predominantly c-Myc/Max complexes to predominantly Mad/Max containing complexes. These results strongly suggest that C19 MEL cells are held in an immature and proliferating state by a pathway that is dependent on Myb activity.	Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Mol Physiol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Biol Phys, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Bender, TP (corresponding author), Univ Virginia Hlth Syst, Dept Microbiol, POB 800734, Charlottesville, VA 22908 USA.				NIGMS NIH HHS [GM55985] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; Bies J, 1996, ONCOGENE, V12, P355; CASADEVALL N, 1991, J BIOL CHEM, V266, P16015; CHERN YJ, 1991, BLOOD, V78, P991, DOI 10.1182/blood.V78.4.991.bloodjournal784991; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; CRAIG RW, 1984, CANCER RES, V44, P442; Cultraro CM, 1997, MOL CELL BIOL, V17, P2353, DOI 10.1128/MCB.17.5.2353; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; Ess KC, 1999, ONCOGENE, V18, P1103, DOI 10.1038/sj.onc.1202387; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOLAY J, 1991, BLOOD, V77, P149; Golay J, 1996, BLOOD, V87, P1900; Golay J, 1998, J IMMUNOL, V160, P2786; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; Lipsick JS, 1996, ONCOGENE, V13, P223; Lyon JJ, 1996, GENE, V182, P123, DOI 10.1016/S0378-1119(96)00531-8; LYON JJ, 1995, DIFFERENTIATION, V59, P171, DOI 10.1046/j.1432-0436.1995.5930171.x; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; Marks PA, 1996, INT J HEMATOL, V63, P1; Matushansky I, 2000, FRONT BIOSCI, V5, pD488, DOI 10.2741/Matushan; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; RICHON VM, 1989, ONCOGENE, V4, P165; Saville MK, 1998, ADV CANCER RES, V72, P109; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Spadaccini A, 1998, J BIOL CHEM, V273, P23793, DOI 10.1074/jbc.273.37.23793; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; YEN A, 1992, J CELL PHYSIOL, V153, P147, DOI 10.1002/jcp.1041530119; ZHUO SQ, 1995, P NATL ACAD SCI USA, V92, P4234, DOI 10.1073/pnas.92.10.4234; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	58	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1859	1869		10.1038/sj.onc.1205003	http://dx.doi.org/10.1038/sj.onc.1205003			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896618				2022-12-25	WOS:000174284500008
J	Foletti, A; Ackermann, J; Schmidt, A; Hummler, E; Beermann, F				Foletti, A; Ackermann, J; Schmidt, A; Hummler, E; Beermann, F			Absence of fibroblast growth factor 2 does not prevent tumor formation originating from the RPE	ONCOGENE			English	Article						eye; FGF; transgenic; gene targeting; pigment; RPE	RETINAL-PIGMENT EPITHELIUM; TRANSGENIC MICE; CELL-LINE; INDUCED TRANSDIFFERENTIATION; TRANSFORMED PHENOTYPE; TARGETED DISRUPTION; MELANOCYTIC LESIONS; T-ANTIGEN; EXPRESSION; GENE	We have analysed the importance of fibroblast growth factor 2 (FGF2) in tumor development. In a transgenic mouse model (Tyrpl-Tag) tumors form in the retinal pigment epithelium (RPE), invade surrounding tissues, and metastasize to lymph node and spleen. To address whether RPE tumor formation is dependent on FGF2, we generated FGF2-deficient mice. Such mice appeared healthy and exhibited no impairment of growth or development. Tyrpl-Tag transgenic mice, which are lacking FGF2 (FGF2-/-) developed RPE tumors that metastasize to spleen and lymph nodes. Tumor growth and survival rate are identical to Typpl-Tag transgenic littermates expressing FGF2. Cell lines were isolated from RPE tumors of wild-type and FGF2-deficient mice. They grow in culture, are pigmented and form vascularized tumors, when injected subcutaneously into nude mice of either FGF2-/- or FGF2+/+ genetic background. Kinetics of tumor growth was identical and independent of presence of FGF2. Together, these results demonstrate that FGF2 is not essential for tumor formation of the RPE thus suggesting that tumor growth in general may not be dependent on FGF2.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	Swiss Institute Experimental Cancer Research; University of Lausanne	Beermann, F (corresponding author), Swiss Inst Expt Canc Res, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.							ANAND R, 1994, INVEST OPHTH VIS SCI, V35, P3533; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Beermann F, 1999, PIGM CELL RES, V12, P71, DOI 10.1111/j.1600-0749.1999.tb00746.x; Berking C, 2001, AM J PATHOL, V158, P943, DOI 10.1016/S0002-9440(10)64041-2; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BRADL M, 1991, P NATL ACAD SCI USA, V88, P164, DOI 10.1073/pnas.88.1.164; Bryckaert M, 1999, ONCOGENE, V18, P7584, DOI 10.1038/sj.onc.1203200; CRICKARD K, 1994, GYNECOL ONCOL, V55, P277, DOI 10.1006/gyno.1994.1290; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; ELYAZIDI I, 1995, ANTICANCER RES, V15, P783; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; Fiore F, 1997, INT J DEV BIOL, V41, P639; Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Hackett SF, 1997, EXP EYE RES, V64, P865, DOI 10.1006/exer.1996.0256; HALABAN R, 1988, ONCOGENE RES, V3, P177; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Jordan S, 2000, PIGM CELL RES, V13, P70, DOI 10.1034/j.1600-0749.2000.130204.x; KAESTNER KH, 1994, GENE, V148, P67, DOI 10.1016/0378-1119(94)90234-8; Kato T, 1999, BRAIN DEV-JPN, V21, P138; LOEFFLER KU, 1996, GRAEFES ARCH CLIN EX, V234, P70; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MARET A, 1995, CANCER RES, V55, P5075; Menzel T, 1996, BLOOD, V87, P1056, DOI 10.1182/blood.V87.3.1056.bloodjournal8731056; Miller DL, 2000, MOL CELL BIOL, V20, P2260, DOI 10.1128/MCB.20.6.2260-2268.2000; MINTZ B, 1992, P NATL ACAD SCI USA, V89, P11421, DOI 10.1073/pnas.89.23.11421; Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641; Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.3.CO;2-R; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; Nguyen MTT, 2000, DEVELOPMENT, V127, P3581; OBrien T, 1997, CANCER RES, V57, P136; Ogata N, 1996, CURR EYE RES, V15, P1008, DOI 10.3109/02713689609017649; OPAS M, 1994, DEV BIOL, V161, P440, DOI 10.1006/dbio.1994.1043; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; Ozaki H, 1998, AM J PATHOL, V153, P757, DOI 10.1016/S0002-9440(10)65619-2; PELLIEUX C, 2001, IN PRESS J CLIN INVE; Penna D, 1998, ONCOGENE, V17, P2601, DOI 10.1038/sj.onc.1202196; RAKOCZY PE, 1993, INVEST OPHTH VIS SCI, V34, P1845; REED JA, 1994, AM J PATHOL, V144, P329; Sakaguchi DS, 1997, DEV DYNAM, V209, P387, DOI 10.1002/(SICI)1097-0177(199708)209:4<387::AID-AJA6>3.0.CO;2-E; Schmidt A, 1998, BRAIN RES PROTOC, V3, P54, DOI 10.1016/S1385-299X(98)00021-X; Schultz JE, 1999, J CLIN INVEST, V104, P709, DOI 10.1172/JCI7315; SCOTT G, 1991, J INVEST DERMATOL, V96, P318, DOI 10.1111/1523-1747.ep12465203; Sliutz G, 1995, ANTICANCER RES, V15, P2675; TAKAHASHI JA, 1992, J NEUROSURG, V76, P792, DOI 10.3171/jns.1992.76.5.0792; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; Vaccarino FM, 1999, NAT NEUROSCI, V2, P246, DOI 10.1038/6350; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201; ZUNIGA MBA, 1996, DEV BIOL, V180, P680	57	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1841	1847		10.1038/sj.onc.1205030	http://dx.doi.org/10.1038/sj.onc.1205030			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896616				2022-12-25	WOS:000174284500006
J	Gafni, RI; McCarthy, EF; Hatcher, T; Meyers, JL; Inoue, N; Reddy, C; Weise, M; Barnes, KM; Abad, V; Baron, J				Gafni, RI; McCarthy, EF; Hatcher, T; Meyers, JL; Inoue, N; Reddy, C; Weise, M; Barnes, KM; Abad, V; Baron, J			Recovery from osteoporosis through skeletal growth: early bone mass acquisition has little effect on adult bone density	FASEB JOURNAL			English	Article						child; glucocorticoids; dexamethasone; adolescence; bone density	ACUTE LYMPHOBLASTIC-LEUKEMIA; MINERAL DENSITY; DIETARY CALCIUM; CHILDREN; MECHANISMS; CHILDHOOD; RABBIT; GLUCOCORTICOIDS; DETERMINANTS; DEFICIENCY	It is often assumed that bone mineral accretion should be optimized throughout childhood to maximize peak bone mass. In contrast, we hypothesized that bone mineral acquisition early in life would have little or no effect on adult bone mass because many areas of the juvenile skeleton are replaced in toto through skeletal growth. To test this hypothesis, we induced osteoporosis by administering dexamethasone to 5-week-old rabbits for 5 weeks and then allowed them to recover for 16 weeks. Tibial bone mineral density (ash weight/volume) was decreased in the dexamethasone-treated animals at the end of treatment but recovered completely. Bone structure in the femur was assessed by histomorphometry. Trabecular and cortical bone in the distal metaphysis was made osteoporotic by dexamethasone, but was then replaced through endochondral bone formation and recovered. Periosteal bone formation rate in the diaphysis was decreased during dexamethasone treatment but afterwards rebounded above controls and normalized cortical width. Our data suggest that bone mineral acquisition early in life has little effect on adult bone density because the juvenile bone is largely replaced through growth. If this concept generalizes, then interventions to maximize peak bone mass should be directed at adolescents rather than young children.	NICHHD, Unit Growth & Dev, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Bone Histomorphometry Lab, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Orthopaed Biomech Lab, Dept Orthopaed Surg, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Johns Hopkins University; Johns Hopkins University	Gafni, RI (corresponding author), NICHHD, Unit Growth & Dev, Dev Endocrinol Branch, NIH, Bldg 10,Room 10N262,10 Ctr Dr MSC 1862, Bethesda, MD 20892 USA.	gafnir@mail.nih.gov		Gafni, Rachel/0000-0002-7970-3491	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000640] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000640] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abad Veronica, 1997, Hormone Research (Basel), V48, P173; An YHH, 1996, AM J VET RES, V57, P1786; Bachrach LK, 2001, TRENDS ENDOCRIN MET, V12, P22, DOI 10.1016/S1043-2760(00)00336-2; Bass S, 1998, J BONE MINER RES, V13, P500, DOI 10.1359/jbmr.1998.13.3.500; BERGER M, 1982, ACTA ENDOCRINOL-COP, V99, P459, DOI 10.1530/acta.0.0990459; COOPER C, 1995, J BONE MINER RES, V10, P940; FRISANCHO AR, 1970, HUM BIOL, V42, P639; Gafni RI, 2001, PEDIATR RES, V50, P618, DOI 10.1203/00006450-200111000-00014; Gafni RI, 2000, PEDIATR NEPHROL, V14, P616, DOI 10.1007/s004670000338; GILSANZ V, 1990, J PEDIATR-US, V117, P238, DOI 10.1016/S0022-3476(05)80536-0; GILSANZ V, 1988, RADIOLOGY, V166, P847, DOI 10.1148/radiology.166.3.3340782; GILSANZ V, 1991, AM J PHYSIOL, V260, pE471, DOI 10.1152/ajpendo.1991.260.3.E471; GRARDEL B, 1994, OSTEOPOROSIS INT, V4, P204, DOI 10.1007/BF01623240; Haapasalo H, 2000, BONE, V27, P351, DOI 10.1016/S8756-3282(00)00331-8; Haugen M, 2000, ARTHRITIS RHEUM-US, V43, P1504, DOI 10.1002/1529-0131(200007)43:7<1504::AID-ANR13>3.3.CO;2-S; Hui S L, 1990, Osteoporos Int, V1, P30, DOI 10.1007/BF01880413; JOHNSTON CC, 1992, NEW ENGL J MED, V327, P82, DOI 10.1056/NEJM199207093270204; Lee WTK, 1997, ACTA PAEDIATR, V86, P570, DOI 10.1111/j.1651-2227.1997.tb08936.x; Li M, 1996, BONE, V19, P81, DOI 10.1016/8756-3282(96)00170-6; Loro ML, 2000, J CLIN ENDOCR METAB, V85, P3908; Lucidarme N, 2000, J PEDIATR-US, V137, P56, DOI 10.1067/mpd.2000.106219; MASOUD I, 1986, J ORTHOP RES, V4, P221, DOI 10.1002/jor.1100040211; *NAT RES COUNC, 1996, GUID CAR US LAB; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; PETERSON CA, 1995, J BONE MINER RES, V10, P81; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; Rizzoli R, 1999, OSTEOPOROSIS INT, V9, P17, DOI 10.1007/PL00004155; SANDLER RB, 1985, AM J CLIN NUTR, V42, P270, DOI 10.1093/ajcn/42.2.270; Shen V, 1997, BONE, V21, P345, DOI 10.1016/S8756-3282(97)00153-1; Slemenda CW, 1997, J BONE MINER RES, V12, P676, DOI 10.1359/jbmr.1997.12.4.676; Soyka LA, 2000, J CLIN ENDOCR METAB, V85, P3951, DOI 10.1210/jc.85.11.3951; Thearle M, 2000, J CLIN ENDOCR METAB, V85, P2122, DOI 10.1210/jc.85.6.2122; Warner JT, 1999, PEDIATR RES, V45, P544, DOI 10.1203/00006450-199904010-00014; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799	34	47	50	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					736	+		10.1096/fj.01-0640fje	http://dx.doi.org/10.1096/fj.01-0640fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923218				2022-12-25	WOS:000174755900003
J	Pawlowski, JE; Ertel, JR; Allen, MP; Xu, M; Butler, C; Wilson, EM; Wierman, ME				Pawlowski, JE; Ertel, JR; Allen, MP; Xu, M; Butler, C; Wilson, EM; Wierman, ME			Liganded androgen receptor interaction with beta-catenin - Nuclear co-localization and modulation of transcriptional activity in neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; AR SUPPRESSES TRANSCRIPTION; PROSTATE-CANCER CELLS; MAMMARY-TUMOR VIRUS; COLORECTAL CARCINOMAS; OVARIAN CARCINOMAS; GENE ACTIVATION; XENOPUS EMBRYOS; BINDING DOMAIN; FACTOR LEF-1	A yeast two-hybrid assay was employed to identify androgen receptor (AR) protein partners in gonadotropin-releasing hormone neuronal cells. By using an AR deletion construct (AR-(Delta371-485)) as a bait beta-catenin was identified as an AR-interacting protein from a gonadotropin-releasing hormone neuronal cell library. Immunolocalization of co-transfected AR and FLAG-beta-catenin demonstrated that FLAG-beta-catenin was predominantly cytoplasmic in the absence of androgen. In the presence of 5alpha-dihydrotestosterone, FLAG-beta-catenin completely co-localized to the nucleus with AR. This effect was specific to AR because liganded progesterone, glucocorticoid, or estrogen a receptors did not translocate FLAG-beta-catenin to the nucleus. Agonist-bound AR was required because the AR antagonists casodex and hydroxyflutamide failed to translocate beta-catenin. Time course experiments demonstrated that co-translocation occurred with similar kinetics. Nuclear co-localization was independent of the glycogen synthase kinase-3beta, p42/44 ERK mitogen-activated protein kinase, and phosphatidylinositol 3-kinase pathways because inhibitors of these pathways had no effect. Transcription assays demonstrated that liganded AR repressed beta-catenin/T cell factor-responsive reporter gene activity. Conversely, co-expression of beta-catenin/T cell factor repressed AR stimulation of AR-responsive reporter gene activity. Our data suggest that liganded AR shuttles beta-catenin to the nucleus and that nuclear interaction of AR with beta-catenin may modulate transcriptional activity in androgen target tissues.	Vet Affairs Med Ctr, Res Serv, Denver, CO 80220 USA; Univ Colorado, Dept Med, Ctr Hlth Sci, Denver, CO 80220 USA; Univ N Carolina, Lab Reprod Biol, Chapel Hill, NC 27599 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of North Carolina; University of North Carolina Chapel Hill	Wierman, ME (corresponding author), Vet Affairs Med Ctr, Res Serv, 111H,1055 Clermont St, Denver, CO 80220 USA.							Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ADLER AJ, 1993, MOL CELL BIOL, V13, P6326, DOI 10.1128/MCB.13.10.6326; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Curtin D, 2001, MOL ENDOCRINOL, V15, P1906, DOI 10.1210/me.15.11.1906; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; El-Tanani M, 2001, J BIOL CHEM, V276, P41675, DOI 10.1074/jbc.M103966200; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Fukuchi T, 1998, CANCER RES, V58, P3526; Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002-9440(10)65148-6; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Issack PS, 1998, CELL GROWTH DIFFER, V9, P837; Jorgensen JS, 2001, MOL ENDOCRINOL, V15, P1496, DOI 10.1210/me.15.9.1496; Jorgensen JS, 2001, MOL ENDOCRINOL, V15, P1505, DOI 10.1210/me.15.9.1505; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Kemppainen JA, 1999, MOL ENDOCRINOL, V13, P440, DOI 10.1210/me.13.3.440; KEPA JK, 1992, NUCLEIC ACIDS RES, V20, P1393, DOI 10.1093/nar/20.6.1393; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Lamb DJ, 2001, VITAM HORM, V62, P199, DOI 10.1016/S0083-6729(01)62005-3; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Palacios J, 1998, CANCER RES, V58, P1344; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; Prefontaine GG, 1999, J BIOL CHEM, V274, P26713, DOI 10.1074/jbc.274.38.26713; RADOVICK S, 1991, P NATL ACAD SCI USA, V88, P3402, DOI 10.1073/pnas.88.8.3402; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; SCARLETT CO, 1995, MOL ENDOCRINOL, V9, P413, DOI 10.1210/me.9.4.413; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Sun W, 2001, J NEUROENDOCRINOL, V13, P249, DOI 10.1046/j.1365-2826.2001.00620.x; Tan JA, 2000, ENDOCRINOLOGY, V141, P3440, DOI 10.1210/en.141.9.3440; TAN JA, 1988, MOL ENDOCRINOL, V2, P1276, DOI 10.1210/mend-2-12-1276; Truica CI, 2000, CANCER RES, V60, P4709; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Voeller HJ, 1998, CANCER RES, V58, P2520; Wang X, 2001, J BIOL CHEM, V276, P40417, DOI 10.1074/jbc.M104765200; Wright K, 1999, INT J CANCER, V82, P625, DOI 10.1002/(SICI)1097-0215(19990827)82:5<625::AID-IJC1>3.0.CO;2-2; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115; Zhurinsky J, 2000, J CELL SCI, V113, P3127	66	144	149	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20702	20710		10.1074/jbc.M200545200	http://dx.doi.org/10.1074/jbc.M200545200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11916967	hybrid			2022-12-25	WOS:000176204500078
J	Shen, GZ; Zhao, JD; Reimer, SK; Antonkine, ML; Cai, Q; Weiland, SM; Golbeck, JH; Bryant, DA				Shen, GZ; Zhao, JD; Reimer, SK; Antonkine, ML; Cai, Q; Weiland, SM; Golbeck, JH; Bryant, DA			Assembly of photosystem II. Inactivation of the rubA gene encoding a membrane-associated rubredoxin in the cyanobacterium Synechococcus sp PCC 7002 causes a loss of photosystem I activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS PROTECTION; AMINO-ACID-SEQUENCE; DESULFOVIBRIO-VULGARIS; NUCLEOTIDE-SEQUENCE; ELECTRON-TRANSFER; ESCHERICHIA-COLI; EXPRESSION; PROTEINS; RUBRERYTHRIN; CLONING	A 4.4-kb HindIII fragment, encoding an unusual rubredoxin (denoted RubA), a homolog of the Synechocystis sp. PCC 6803 gene slr2034 and Arabidopsis thaliana HCF136, and the psbEFLJ operon, was cloned from the cyanobacterium Synechococcus sp. PCC 7002. Inactivation of the slr2034 homolog produced a mutant with no detectable phenotype and wild-type photosystem (PS) II levels. Inactivation of the rubA gene of Synechococcus sp. PCC 7002 produced a mutant unable to grow photoautotrophically. RubA and PS I electron transport activity were completely absent in the mutant, although PS 11 activity was similar to80% of the wild-type level. RubA contains a domain of similar to50 amino acids with very high similarity to the rubredoxins of anaerobic bacteria and archaea, but it also contains a region of about 50 amino acids that is predicted to form a flexible hinge and a transmembrane a-helix at its C terminus. Overproduction of the water-soluble rubredoxin domain in Escherichia coli led to a product with the absorption and EPR spectra of typical rubredoxins. RubA was present in thylakoid but not plasma membranes of cyanobacteria and in chloroplast thylakoids isolated from spinach and Chlamydomonas reinhardtii. Fractionation studies suggest that RubA might transiently associate with PS I monomers, but no evidence for an association with PS I trimers or PS II was observed. PS I levels were significantly lower than in the wild type (similar to40%), but trimeric PS I complexes could be isolated from the rubA mutant. These PS I complexes completely lacked the stromal subunits PsaC, PsaD), and PsaE but contained all membrane-intrinsic subunits. The three missing proteins could be detected immunologically in whole cells, but their levels were greatly reduced, and degradation products were also detected. Our results indicate that RubA plays a specific role in the biogenesis of PS I.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Peking Univ, Coll Life Sci, Dept Plant Mol Biol, Beijing 100871, Peoples R China; St Francis Univ, Dept Biol, Loretto, PA 15940 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Peking University	Bryant, DA (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, S-234 Frear Bldg, University Pk, PA 16802 USA.	dab14@psu.edu						Bartsevich VV, 1997, J BIOL CHEM, V272, P6382, DOI 10.1074/jbc.272.10.6382; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Boudreau E, 1997, EMBO J, V16, P6095, DOI 10.1093/emboj/16.20.6095; BROSIUS J, 1989, DNA-J MOLEC CELL BIO, V8, P759, DOI 10.1089/dna.1989.8.759; BUZBY JS, 1985, SCIENCE, V230, P805, DOI 10.1126/science.2997920; CANTRELL A, 1987, PLANT MOL BIOL, V9, P453, DOI 10.1007/BF00015877; Chitnis PR, 2001, ANNU REV PLANT PHYS, V52, P593, DOI 10.1146/annurev.arplant.52.1.593; Coulter ED, 2001, ARCH BIOCHEM BIOPHYS, V394, P76, DOI 10.1006/abbi.2001.2531; da Costa PN, 2001, MOL MICROBIOL, V41, P217, DOI 10.1046/j.1365-2958.2001.02509.x; Das A, 2001, J BACTERIOL, V183, P1560, DOI 10.1128/JB.183.5.1560-1567.2001; DINER BA, 1996, OXYGENIC PHOTOSYNTHE, P213; Douglas S, 2001, NATURE, V410, P1091, DOI 10.1038/35074092; Eidsness MK, 1999, BIOCHEMISTRY-US, V38, P14803, DOI 10.1021/bi991661f; EISEN JA, 2002, IN PRESS P NATL ACAD; Funk C, 1999, BIOCHEMISTRY-US, V38, P9397, DOI 10.1021/bi990545+; GEISSDORFER W, 1995, MICROBIOL-UK, V141, P1425, DOI 10.1099/13500872-141-6-1425; Golbeck J. H., 1995, CRC HDB ORGANIC PHOT, P1407; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; Gomes CM, 1997, J BIOL CHEM, V272, P22502, DOI 10.1074/jbc.272.36.22502; Guedon E, 2001, BIOCHEM BIOPH RES CO, V285, P496, DOI 10.1006/bbrc.2001.5196; Harlow E., 1988, ANTIBODIES LAB MANUA; He QF, 2001, J BIOL CHEM, V276, P306, DOI 10.1074/jbc.M008686200; Jenney FE, 1999, SCIENCE, V286, P306, DOI 10.1126/science.286.5438.306; Johnson TW, 2000, J BIOL CHEM, V275, P8523, DOI 10.1074/jbc.275.12.8523; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Jung YS, 1995, PHOTOSYNTH RES, V46, P249, DOI 10.1007/BF00020437; Kaneko T, 2001, DNA RES, V8, P205, DOI 10.1093/dnares/8.5.205; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; KOK M, 1989, J BIOL CHEM, V264, P5442; LeGall J, 1998, FEBS LETT, V429, P295, DOI 10.1016/S0014-5793(98)00610-3; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; Lojero CG, 1996, PHOTOSYNTH RES, V47, P293, DOI 10.1007/BF02184290; Lumppio HL, 2001, J BACTERIOL, V183, P101, DOI 10.1128/JB.183.1.101-108.2001; MATHIEU I, 1992, BIOCHEM J, V285, P255, DOI 10.1042/bj2850255; Meurer J, 1998, EMBO J, V17, P5286, DOI 10.1093/emboj/17.18.5286; MEYER J, 1990, BIOCHEM J, V271, P839, DOI 10.1042/bj2710839; Naver H, 2001, PLANT CELL, V13, P2731, DOI 10.1105/tpc.010253; Norling B, 1998, FEBS LETT, V436, P189, DOI 10.1016/S0014-5793(98)01123-5; Pakrasi HB, 1995, ANNU REV GENET, V29, P755; REY L, 1992, J MOL BIOL, V228, P998, DOI 10.1016/0022-2836(92)90886-O; Sakamoto T, 1997, PHYSIOLOGY, BIOCHEMISTRY AND MOLECULAR BIOLOGY OF PLANT LIPIDS, P380; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schluchter WM, 1996, PHOTOCHEM PHOTOBIOL, V64, P53, DOI 10.1111/j.1751-1097.1996.tb02421.x; Schweimer K, 2000, PROTEIN SCI, V9, P1474, DOI 10.1110/ps.9.8.1474; SEKI Y, 1989, J BIOCHEM-TOKYO, V106, P336, DOI 10.1093/oxfordjournals.jbchem.a122854; SHEN GZ, 1994, J BIOL CHEM, V269, P13904; SHEN GZ, 1995, PHOTOSYNTH RES, V44, P41, DOI 10.1007/BF00018295; Shen GZ, 2002, J BIOL CHEM, V277, P20355, DOI 10.1074/jbc.M201104200; Shen GZ, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P3147; STEVENS SE, 1980, P NATL ACAD SCI-BIOL, V77, P6052, DOI 10.1073/pnas.77.10.6052; STUDIER FW, 1918, METHOD ENZYMOL, P60; Theologis A, 2000, NATURE, V408, P816, DOI 10.1038/35048500; Togasaki Robert K., 1998, Advances in Photosynthesis, V7, P13; Vassiliev IR, 2001, BBA-BIOENERGETICS, V1507, P139, DOI 10.1016/S0005-2728(01)00197-9; VERMAAS W, 1993, ANNU REV PLANT PHYS, V44, P457, DOI 10.1146/annurev.pp.44.060193.002325; Wastl J, 2000, J BIOL CHEM, V275, P30058, DOI 10.1074/jbc.M004629200; Wastl J, 2000, FEBS LETT, V471, P191, DOI 10.1016/S0014-5793(00)01399-5; Yang F, 1998, J PHYS CHEM B, V102, P8288, DOI 10.1021/jp981952i; Yoon KS, 1999, J BIOL CHEM, V274, P29772, DOI 10.1074/jbc.274.42.29772; Zhao JD, 1998, ANAL BIOCHEM, V264, P263, DOI 10.1006/abio.1998.2845; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	61	99	115	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20343	20354		10.1074/jbc.M201103200	http://dx.doi.org/10.1074/jbc.M201103200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11914373	hybrid			2022-12-25	WOS:000176204500033
J	Spencer, ML; Shao, HP; Andres, DA				Spencer, ML; Shao, HP; Andres, DA			Induction of neurite extension and survival in pheochromocytoma cells by the Rit GTPase.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; RAS-RELATED GTPASES; PC12 CELLS; NEURONAL SURVIVAL; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; B-RAF; SYMPATHETIC NEURONS; BINDING PROTEIN	The Rit, Rin, and Ric proteins comprise a distinct and evolutionarily conserved subfamily of the Ras-like small G-proteins. Although these proteins share the majority of core effector domain residues with Ras, recent studies suggest that Rit uses novel effector pathways to regulate NIH3T3 cell proliferation and transformation, while the functions of Rin and Ric remain largely unknown. Since we demonstrate that Rit is expressed in neurons, we investigated the role of Rit signaling in promoting the differentiation and survival of pheochromocytoma cells. In this study, we show that expression of constitutively active Rit (RitL79) in PC6 cells results in neuronal differentiation, characterized by the elaboration of an extensive network of neurite-like processes that are morphologically distinct from those mediated by the expression of oncogenic Ras. Although activated Rit fails to stimulate mitogen-activated protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) signaling pathways in COS cells, RitL79 induced the phosphorylation of ERK1/2 in PC6 cells. We also find that Rit-mediated effects on neurite outgrowth can be blocked by co-expression of dominant-negative mutants of C-Raf1 or mitogen-activated protein kinase kinase I (MEK1). Moreover, expression of dominant-negative Rit is sufficient to inhibit NGF-induced neurite outgrowth. Expression of active Rit inhibits growth factor-withdrawal mediated apoptosis of PC6 cells, but does not induce phosphorylation of Akt/protein kinase B, suggesting that survival does not utilize the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Instead, pharmacological inhibitors of MEK block Rit-stimulated cell survival. Taken together, these studies suggest that Rit represents a distinct regulatory protein, capable of mediating differentiation and cell survival in PC6 cells using a MEK-dependent signaling pathway to achieve its effects.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	University of Kentucky	Andres, DA (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, 800 Rose St, Lexington, KY 40536 USA.	dandres@pop.uky.edu						Atwal JK, 2000, NEURON, V27, P265, DOI 10.1016/S0896-6273(00)00035-0; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOUME HR, 1991, NATURE, V349, P117; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Estus S, 1997, J NEUROSCI, V17, P7736; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Finlin BS, 2000, BIOCHEM J, V347, P223, DOI 10.1042/0264-6021:3470223; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hetman M, 2000, ACTA NEUROBIOL EXP, V60, P531; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Klesse LJ, 1998, J NEUROSCI, V18, P10420; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Lee CHJ, 1996, J NEUROSCI, V16, P6784; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mazzoni IE, 1999, J NEUROSCI, V19, P9716; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Owada K, 1999, J NEUROCHEM, V73, P2084; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Rusyn EV, 2000, ONCOGENE, V19, P4685, DOI 10.1038/sj.onc.1203836; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; Shao HP, 2000, J BIOL CHEM, V275, P26914; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; Spencer ML, 2002, J BIOL CHEM, V277, P17605, DOI 10.1074/jbc.M111400200; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Vaillant AR, 1999, J CELL BIOL, V146, P955, DOI 10.1083/jcb.146.5.955; Villalba M, 1997, J NEUROSCI, V17, P83, DOI 10.1523/JNEUROSCI.17-01-00083.1997; Virdee K, 1996, J NEUROCHEM, V67, P1801; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	59	42	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20160	20168		10.1074/jbc.M201092200	http://dx.doi.org/10.1074/jbc.M201092200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11914372	hybrid			2022-12-25	WOS:000176204500011
J	Thuerauf, DJ; Morrison, LE; Hoover, H; Glembotski, CC				Thuerauf, DJ; Morrison, LE; Hoover, H; Glembotski, CC			Coordination of ATF6-mediated transcription and ATF6 degradation by a domain that is shared with the viral transcription factor, VP16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; GLUCOSE-REGULATED PROTEINS; RNA-POLYMERASE-II; DNA-BINDING; IN-VIVO; ELEMENT; ACTIVATION; GENE; INDUCTION	ATF6 is a 670-amino acid endoplasmic reticulum (ER) transmembrane protein that is cleaved in response to ER stress. The resulting N-terminal fragment of similar to400 amino acids translocates to the nucleus and activates selected ER stress-inducible genes, such as GRP-78 and sarco/endoplasmic reticulum ATPase, which are required for cell survival. In studying the mechanism of ATF6-activated transcription, we found that when HeLa cells were transfected with a plasmid encoding ATF6-(1-373), ER stress-inducible reporter gene activation was high, but ATF6-(1-373) expression was low, unless a proteasome inhibitor was added. In contrast, transfection with a plasmid encoding ATF6494-373) resulted in low reporter activation and high expression of ATF6-(94-373), which was independent of the proteasome inhibitor. Thus, the information responsible for transcriptional activation and proteasomal degradation must lie within the N-terminal 93 amino acids of ATF6. This portion of ATF6 was found to be homologous to the herpes simplex viral protein, VP16. One 8-amino acid domain of particular interest in this region of ATF6 is 75% identical to the VN8 region in VP16. VN8 is required for VP16-mediated transcription, as well as rapid degradation of VP16 by proteasomes. Point mutations in the VNS-Iike region of ATF6 caused a loss of transcription, increased expression levels, and an increase in half-life. Thus, the potent transcriptional activities and rapid degradation of ATF6 and VP16 require the VN8 domains in each protein. Homology searches indicate that ATF6 is the only eukaryotic protein known that possesses an active VN8 domain, raising questions about how this domain evolved and the functional importance underlying its appearance in only these two transcription factors.	San Diego State Univ, Heart Inst, San Diego, CA 92182 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University; California State University System; San Diego State University	Glembotski, CC (corresponding author), San Diego State Univ, Heart Inst, San Diego, CA 92182 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056861] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-56861] Funding Source: Medline; NINDS NIH HHS [NS/HL-25073] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Desterro JMP, 2000, CELL MOL LIFE SCI, V57, P1207, DOI 10.1007/PL00000760; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Haze K, 2001, BIOCHEM J, V355, P19, DOI 10.1042/0264-6021:3550019; Hoppe T, 2001, CURR OPIN CELL BIOL, V13, P344, DOI 10.1016/S0955-0674(00)00218-0; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MIN J, 1995, GENOMICS, V30, P149, DOI 10.1006/geno.1995.9891; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; SETH A, 1992, J BIOL CHEM, V267, P24796; Spear E, 2001, TRAFFIC, V2, P515, DOI 10.1034/j.1600-0854.2001.20801.x; Tanaka M, 1996, P NATL ACAD SCI USA, V93, P4311, DOI 10.1073/pnas.93.9.4311; Thomas D, 2000, CURR BIOL, V10, pR341, DOI 10.1016/S0960-9822(00)00462-0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; Thuerauf DJ, 2001, J BIOL CHEM, V276, P48309, DOI 10.1074/jbc.M107146200; Wang Y, 2000, J BIOL CHEM, V275, P27013; Wu M, 2000, GENE DEV, V14, P301; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	31	54	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20734	20739		10.1074/jbc.M201749200	http://dx.doi.org/10.1074/jbc.M201749200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11909875	hybrid			2022-12-25	WOS:000176204500082
J	Chang, JS; Seok, H; Kwon, TK; Min, DS; Ahn, BH; Lee, YH; Suh, JW; Kim, JW; Iwashita, S; Omori, A; Ichinose, S; Numata, O; Seo, JK; Oh, YS; Suh, PG				Chang, JS; Seok, H; Kwon, TK; Min, DS; Ahn, BH; Lee, YH; Suh, JW; Kim, JW; Iwashita, S; Omori, A; Ichinose, S; Numata, O; Seo, JK; Oh, YS; Suh, PG			Interaction of elongation factor-1 alpha and pleckstrin homology domain of phospholipase C-gamma 1 with activating its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4-KINASE; TYROSINE KINASE; SIGNALING MOLECULES; FACTOR 1-ALPHA; COMMON FOLD; C ISOZYMES; PH DOMAINS; MEMBRANE; BINDING; CELLS	The pleckstrin homology (PH) domain is a small motif for membrane targeting in the signaling molecules. Phospholipase C (PLC)-gamma1 has two putative PH domains, an NH2-terminal and a split PH domain. Here we report studies on the interaction of the PH domain of PLC-gamma1 with translational elongation factor (Ef)-1alpha, which has been shown to be a phosphatidylinositol 4-kinase activator. By pull-down of cell extract with the glutathione S-transferase (GST) fusion proteins with various domains of PLC-gamma1 followed by peptide sequence analysis, we identified EF-1alpha as a binding partner of a split PH domain of PLC-gamma1. Analysis by site-directed mutagenesis of the PH domain revealed that the beta2-sheet of a split PH domain is critical for the interaction with EF-1alpha. Moreover, Dot-blot assay shows that a split PH domain specifically binds to phosphoinositides including phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate (PIP2). So the PH domain of PLC-gamma1 binds to both EF-1alpha and PIP2. The binding affinity of EF-1alpha to the GST-PH domain fusion protein increased in the presence of PIP2. although PIP2 does not bind to EF-1alpha directly. This suggests that EF-1alpha may control the binding affinity between the PH domain and PIP2. PLC-gamma1 is substantially activated in the presence of EF-1alpha with a bell-shaped curve in relation to the molar ratio between them, whereas a double point mutant PLC-gamma1 (Y509A/F510A) that lost its binding affinity to EF-1a shows basal level activity. Taken together, our data show that EF-1alpha plays a direct role in phosphoinositide metabolism of cellular signaling by regulating PLC-gamma1 activity via a split PH domain.	Daejin Univ, Coll Nat Sci, Dept Life Sci, Kyonggi Do 487711, South Korea; Keimyung Univ, Coll Med, Dept Immunol, Taegu 700712, South Korea; Catholic Univ Korea, Coll Med, Dept Physiol, Seoul 137701, South Korea; Yeungnam Univ, Coll Med, Dept Biochem, Taegu 705717, South Korea; Myongji Univ, Coll Nat Sci, Dept Biol Sci, Kyonggi Do 449728, South Korea; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 194, Japan; Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan; Seoul Natl Univ, Coll Med, Inst Canc Res, In2Gen, Seoul 110799, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Kyungbuk 790784, South Korea	Daejin University; Keimyung University; Catholic University of Korea; Yeungnam University; Myongji University; University of Tsukuba; Seoul National University (SNU); Pohang University of Science & Technology (POSTECH)	Chang, JS (corresponding author), Daejin Univ, Coll Nat Sci, Dept Life Sci, Kyonggi Do 487711, South Korea.		Seo, Jeong Kon/H-4770-2016; Suh, Pann-Ghill/F-3610-2010	Oh, Yong-Seok/0000-0002-9039-2014				Bae SS, 2000, FASEB J, V14, P1083, DOI 10.1096/fasebj.14.9.1083; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CARVALHO MDD, 1984, ARCH BIOCHEM BIOPHYS, V234, P603, DOI 10.1016/0003-9861(84)90310-2; Chang JS, 1997, CANCER RES, V57, P5465; COCKCROFT S, 1992, BIOCHEM J, V288, P1; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; Edmonds BT, 1998, J BIOL CHEM, V273, P10288, DOI 10.1074/jbc.273.17.10288; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; KAUR KJ, 1994, J BIOL CHEM, V269, P23045; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Negrutskii BS, 1998, PROG NUCLEIC ACID RE, V60, P47, DOI 10.1016/S0079-6603(08)60889-2; NISHIKI T, 1994, J BIOL CHEM, V269, P10498; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Numata O, 2000, J BIOCHEM, V127, P51, DOI 10.1093/oxfordjournals.jbchem.a022583; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Razzini G, 2000, J BIOL CHEM, V275, P14873, DOI 10.1074/jbc.275.20.14873; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; SHIRASAWA T, 1992, NUCLEIC ACIDS RES, V20, P909, DOI 10.1093/nar/20.4.909; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAKEDA T, 1995, J BIOCHEM-TOKYO, V117, P869, DOI 10.1093/oxfordjournals.jbchem.a124789; TANIGUCHI S, 1991, NUCLEIC ACIDS RES, V19, P6949, DOI 10.1093/nar/19.24.6949; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417; YANG W, 1994, J BIOL CHEM, V269, P3852; YANG WN, 1993, J BIOL CHEM, V268, P392; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0	45	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19697	19702		10.1074/jbc.M111206200	http://dx.doi.org/10.1074/jbc.M111206200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11886851	hybrid, Green Published			2022-12-25	WOS:000175894800061
J	Hao, JJ; Narayanan, K; Ramachandran, A; He, G; Almushayt, A; Evans, C; George, A				Hao, JJ; Narayanan, K; Ramachandran, A; He, G; Almushayt, A; Evans, C; George, A			Odontoblast cells immortalized by telomerase produce mineralized dentin-like tissue both in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR IMMORTALIZATION; MATRIX PROTEIN-1; IN-VITRO; DIFFERENTIATION; EXPRESSION; GENE; PULP; LINE; BIOMINERALIZATION; ESTABLISHMENT	The formation of dentin provides one well accepted paradigm for studying mineralized tissue formation. For the assembly of dentin, several cellular signaling pathways cooperate to provide neural crest-derived mesenchymal cells with positional information. Further, "cross-talk" between signaling pathways from the mesenchymal derived odontoblast cells and the epithelially derived ameloblasts during development is responsible for the formation of functional odontoblasts. These intercellular signals are tightly regulated, both temporally and spatially. When isolated from the developing tooth germ, odontoblasts quickly lose their potential to maintain the odontoblast-specific phenotype. Therefore, generation of an odontoblast cell line would be a valuable reproducible tool for studying the modulatory effects involved in odontoblast differentiation as well as the molecular events involved in mineralized dentin formation. In this study an immortalized odontoblast cell line, which has the required biochemical machinery to produce mineralized tissue in vitro, has been generated. These cells were implanted into animal models to determine their in vivo effects on dentin formation. After implantation, we observed a multistep, programmed cascade of gene expression in the exogenous odontoblasts as the dentin formed de novo. Some of the genes expressed include the dentin matrix proteins 1, 2, and 3, which are extracellular matrix molecules responsible for the ultimate formation of mineralized dentin. The biological response was also examined by histology and radiography and confirmed for mineral deposition by von Kossa staining. Thus, a transformed odontoblast cell line was created with high proliferative capacity that might ultimately be used for the regeneration and repair of dentin in vivo.	Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA; Univ Illinois, Dept Orthodont, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	George, A (corresponding author), Univ Illinois, Dept Oral Biol, MC 690, Chicago, IL 60612 USA.		Hu, Ruogu/B-2203-2008; Narayanan, Karthikeyan/D-1957-2010; Almushayt, Abdullah/GQH-3275-2022	Narayanan, Karthikeyan/0000-0001-5136-2296; GEORGE, ANNE/0000-0002-9008-7642	NIDCR NIH HHS [DE11657] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE011657] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Beck GR, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; D'Errico JA, 1999, BONE, V25, P39, DOI 10.1016/S8756-3282(99)00096-4; D'Souza RN, 1999, DEVELOPMENT, V126, P2911; Den Besten PK, 1998, CONNECT TISSUE RES, V38, P3; DUCY P, 1997, CELL, V89, P677; GEORGE A, 1993, J BIOL CHEM, V268, P12624; George A, 1996, J BIOL CHEM, V271, P32869, DOI 10.1074/jbc.271.51.32869; GOLDBERG M, 1998, P 6 INT C CHEM BIOL, P297; Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797; Hahn WC, 2001, ANN MED, V33, P123, DOI 10.3109/07853890109002067; KASUGAI S, 1993, ARCH ORAL BIOL, V38, P769, DOI 10.1016/0003-9969(93)90073-U; KASUGAI S, 1988, ARCH ORAL BIOL, V33, P887, DOI 10.1016/0003-9969(88)90018-0; Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014; MacDougall M, 1989, Connect Tissue Res, V22, P71; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Migliaccio M, 2000, J IMMUNOL, V165, P4978, DOI 10.4049/jimmunol.165.9.4978; Narayanan K, 2001, P NATL ACAD SCI USA, V98, P4516, DOI 10.1073/pnas.081075198; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; RUCH JV, 1995, INT J DEV BIOL, V39, P51; SAKAMOTO S, 1985, BIOCHEM BIOPH RES CO, V133, P709, DOI 10.1016/0006-291X(85)90962-3; Sambrook J., 2002, MOL CLONING LAB MANU; Srinivasan R, 1999, CONNECT TISSUE RES, V40, P251, DOI 10.3109/03008209909000703; TAKAGI Y, 1983, CLIN ORTHOP RELAT R, P282; TAKAGI Y, 1981, CHEM BIOL MINERALIZE, P233; THESLEFF I, 1995, INT J DEV BIOL, V39, P35; Thonemann B, 2000, ARCH ORAL BIOL, V45, P857, DOI 10.1016/S0003-9969(00)00056-X; Winn SR, 1999, J BONE MINER RES, V14, P1721, DOI 10.1359/jbmr.1999.14.10.1721; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765	31	44	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19976	19981		10.1074/jbc.M112223200	http://dx.doi.org/10.1074/jbc.M112223200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11904297	hybrid			2022-12-25	WOS:000175894800097
J	Lin, DCH; Bullock, CM; Ehlert, FJ; Chen, JL; Tian, H; Zhou, QY				Lin, DCH; Bullock, CM; Ehlert, FJ; Chen, JL; Tian, H; Zhou, QY			Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins/endocrine gland vascular endothelial growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANAGEMENT; MOTILITY	We previously described two mammalian secreted proteins, prokineticin 1 and prokineticin 2, that potently contract gastrointestinal smooth muscle. Prokineticin 1 has also been shown to promote angiogenesis by stimulating proliferation, migration, and fenestration of endocrine organ-derived endothelial cells. Here we report the cloning and characterization of two closely related G protein-coupled receptors as receptors for prokineticins. Expression of prokineticin receptors in heterologous systems shows that these receptors bind to and are activated by nanomolar concentrations of recombinant prokineticins. Activation of prokineticin receptors leads to mobilization of calcium, stimulation of phosphoinositide turnover, and activation of p44/p42 MAPK signaling pathways that are consistent with the effects of prokineticins on smooth muscle contraction and angiogenesis. mRNA expression analysis reveals that prokineticin receptors are expressed in gastrointestinal organs, endocrine glands, and other tissues.	Tularik Inc, San Francisco, CA 94080 USA; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Tian, H (corresponding author), Tularik Inc, 2 Corp Dr, San Francisco, CA 94080 USA.		Ehlert, Frederick J/T-4220-2019					An SZ, 2001, P NATL ACAD SCI USA, V98, P7576, DOI 10.1073/pnas.131200698; Baldi P, 1994, J Comput Biol, V1, P311, DOI 10.1089/cmb.1994.1.311; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Camilleri M, 2001, GASTROENTEROLOGY, V120, P652, DOI 10.1053/gast.2001.21908; De Ponti F, 1998, PHARMACOL THERAPEUT, V80, P49, DOI 10.1016/S0163-7258(98)00021-7; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fujimiya M, 2000, PEPTIDES, V21, P1565, DOI 10.1016/S0196-9781(00)00313-2; LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000; Li M, 2001, MOL PHARMACOL, V59, P692, DOI 10.1124/mol.59.4.692; PAGES G, 2000, ANN NY ACAD SCI, V902, P182; Pandolfino JE, 2000, GASTROENTEROLOGY, V118, pS32, DOI 10.1016/S0016-5085(00)70005-9; Parker R, 2000, BBA-GENE STRUCT EXPR, V1491, P369, DOI 10.1016/S0167-4781(00)00023-3; RUBANYI GM, 2000, ANGIOGENESIS HLTH DI; Sawyer GW, 1999, J PHARMACOL EXP THER, V289, P464	14	257	283	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19276	19280		10.1074/jbc.M202139200	http://dx.doi.org/10.1074/jbc.M202139200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11886876	hybrid			2022-12-25	WOS:000175894800006
J	Rolny, C; Spillmann, D; Lindahl, U; Claesson-Welsh, L				Rolny, C; Spillmann, D; Lindahl, U; Claesson-Welsh, L			Heparin amplifies platelet-derived growth factor (PDGF)-BB-induced PDGF alpha-receptor but not PDGF beta-receptor tyrosine phosphorylation in heparan sulfate-deficient cells - Effects on signal transduction and biological responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PROTEASE-ACTIVATED LIGAND; DIFFERENT DIMERIC FORMS; FACTOR-A CHAIN; FIBROBLAST-GROWTH; KINASE ACTIVATION; B-CHAIN; BINDING; FGF; DIMERIZATION	Platelet-derived growth factor (PDGF) induces mitogenic and migratory responses in a wide variety of cells, by activating specific receptor tyrosine kinases denoted the PDGF alpha- and beta-receptors. Different PDGF isoforms bind in a distinct manner to glycosaminoglycans, particularly heparan sulfate. In the present study, we show potentiation by exogenous heparin of PDGF-BB-induced PDGF alpha-receptor tyrosine phosphorylation in heparan sulfate-deficient Chinese hamster ovary (CHO) 677 cells. This effect was not seen for PDGF-AA treatment, and heparin lacked a potentiating effect on PDGF-BB stimulation of the PDGF beta-receptor. Heparin did not affect the affinity of PDGF-BB binding for the PDGF receptors on CHO 677 cells. The PDGF-BB-stimulated PDGF alpha-receptor phosphorylation was enhanced in a dose-dependent fashion by heparin at low concentration. The effect was modulated by 2-O- and 6-O-desulfation of the polysaccharide. Maximal induction of PDGF alpha-receptor tyrosine phosphorylation (6-fold) in CHO 677 cells was achieved by treatment with a heparin decasaccharide, but shorter oligosaccharides consisting of four or more monosaccharide units were also able to augment PDGF alpha-receptor phosphorylation, albeit at higher concentrations. Heparin potentiated PDGF-BB-induced activation of mitogen-activated protein kinase and protein kinase B (Akt) and allowed increased chemotaxis of the CHO 677 cells toward PDGF-BB. In conclusion, heparin modulates PDGF-BB-induced PDGF a-receptor phosphorylation and downstream signaling, with consequences for cellular responsiveness to the growth factor.	Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, S-75185 Uppsala, Sweden; Biomed Ctr, Dept Biochem & Microbiol, S-75123 Uppsala, Sweden	Uppsala University	Claesson-Welsh, L (corresponding author), Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, Dag Hammarskjolds V20, S-75185 Uppsala, Sweden.		Rolny, Charlotte/AET-0493-2022	Rolny, Charlotte/0000-0003-4979-9266				Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; BLUMENKRANTZ N, 1973, ANAL BIOCHEM, V56, P10, DOI 10.1016/0003-2697(73)90163-2; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; Chon JH, 2001, AM J PHYSIOL-CELL PH, V280, pC1394, DOI 10.1152/ajpcell.2001.280.6.C1394; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1989, ACTA ONCOL, V28, P331, DOI 10.3109/02841868909111202; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FAGER G, 1995, J CELL PHYSIOL, V163, P380, DOI 10.1002/jcp.1041630218; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HAMMACHER A, 1988, EUR J BIOCHEM, V176, P179, DOI 10.1111/j.1432-1033.1988.tb14266.x; Heldin Carl-Henrik, 1996, Cytokine and Growth Factor Reviews, V7, P3, DOI 10.1016/1359-6101(96)00002-0; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KELLY JL, 1993, J CELL BIOL, V121, P1153, DOI 10.1083/jcb.121.5.1153; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDAHL U, 1966, J BIOL CHEM, V241, P2113; Loo BM, 2001, J BIOL CHEM, V276, P16868, DOI 10.1074/jbc.M011226200; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MAHADEVAN D, 1995, J BIOL CHEM, V270, P27595, DOI 10.1074/jbc.270.46.27595; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Pukac LA, 1997, J CELL PHYSIOL, V172, P69, DOI 10.1002/(SICI)1097-4652(199707)172:1<69::AID-JCP8>3.0.CO;2-B; RAINES EW, 1993, BRIT HEART J, V69, pS30; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Schilling D, 1998, BIOCHEM J, V333, P637, DOI 10.1042/bj3330637; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; Sundberg C, 1997, AM J PATHOL, V151, P479; Swertfeger DK, 2001, J BIOL CHEM, V276, P25043, DOI 10.1074/jbc.M102357200	42	48	49	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19315	19321		10.1074/jbc.M111805200	http://dx.doi.org/10.1074/jbc.M111805200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11912193	hybrid			2022-12-25	WOS:000175894800011
J	Wong, I; Lundquist, AJ; Bernards, AS; Mosbaugh, DW				Wong, I; Lundquist, AJ; Bernards, AS; Mosbaugh, DW			Presteady-state analysis of a single catalytic turnover by Escherichia coli uracil-DNA glycosylase reveals a "pinch-pull-push" mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFUSION-DRIVEN MECHANISMS; BASE-EXCISION-REPAIR; INHIBITOR PROTEIN; CRYSTAL-STRUCTURE; NUCLEIC-ACIDS; KINETIC-ANALYSIS; ABASIC SITES; TARGET BASE; COMPLEX; METHYLTRANSFERASE	Uracil-DNA glycosylase catalyzes the excision of uracils from DNA via a mechanism where the uracil is extrahelically flipped out of the DNA helix into the enzyme active site. A conserved leucine is inserted into the DNA duplex space vacated by the uracil leading to the paradigmatic "push-pull" mechanism of nucleotide flipping. However, the order of these two steps during catalysis has not been conclusively established. We report a complete kinetic analysis of a single catalytic turnover using a hydrolyzable duplex oligodeoxyribonucleotide substrate containing a uracil:2-aminopurine base pair. Rapid chemical-quenched-flow methods defined the kinetics of excision at the active site during catalysis. Stopped-flow fluorometry monitoring the 2-aminopurine fluorescence defined the kinetics of uracil flipping. Parallel experiments detecting the protein fluorescence showed a slower Leu(191) insertion step occurring after nucleotide flipping but before excision. The inserted Leu(191) acts as a doorstop to prevent the return of the flipped-out uracil residue, thereby facilitating the capture of the uracil in the active site and does not play a direct role in "pushing" the uracil out of the DNA helix. The results define for the first time the proper sequence of events during a catalytic cycle and establish a "pull-push", as opposed to a "push-pull", mechanism for nucleotide flipping.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA; Oregon State Univ, Environm Hlth Sci Ctr, Corvallis, OR 97331 USA	Oregon State University; Oregon State University; Oregon State University	Wong, I (corresponding author), Oregon State Univ, Dept Biochem & Biophys, 2011 Agr & Life Sci Bldg, Corvallis, OR 97331 USA.		Hu, Ruogu/B-2203-2008		NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM32823, GM58771] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058771, R01GM032823] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BENNETT SE, 1993, J BIOL CHEM, V268, P26879; BENNETT SE, 1992, J BIOL CHEM, V267, P22512; BENNETT SE, 1995, BIOCHEMISTRY-US, V34, P6109, DOI 10.1021/bi00018a014; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; Cheng XD, 1996, STRUCTURE, V4, P639, DOI 10.1016/S0969-2126(96)00068-8; Drohat AC, 1999, BIOCHEMISTRY-US, V38, P11876, DOI 10.1021/bi9910880; Drohat AC, 1999, BIOCHEMISTRY-US, V38, P11866, DOI 10.1021/bi9910878; Handa P, 2001, J BIOL CHEM, V276, P17324, DOI 10.1074/jbc.M011166200; HIGLEY M, 1993, MUTAT RES, V294, P109, DOI 10.1016/0921-8777(93)90019-D; Hornby DP, 1998, CURR OPIN BIOTECH, V9, P354, DOI 10.1016/S0958-1669(98)80007-4; Jiang YL, 2001, BIOCHEMISTRY-US, V40, P7710, DOI 10.1021/bi010622c; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; Lloyd RS, 1997, BIOPOLYMERS, V44, P139; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; O'Gara M, 1998, NAT STRUCT BIOL, V5, P872, DOI 10.1038/2312; Parikh SS, 2000, P NATL ACAD SCI USA, V97, P5083, DOI 10.1073/pnas.97.10.5083; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Parikh SS, 2000, MUTAT RES-DNA REPAIR, V460, P183, DOI 10.1016/S0921-8777(00)00026-4; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Putnam CD, 1999, J MOL BIOL, V287, P331, DOI 10.1006/jmbi.1999.2605; Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P957, DOI 10.1021/bi001665g; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; Ravishankar R, 1998, NUCLEIC ACIDS RES, V26, P4880, DOI 10.1093/nar/26.21.4880; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Sanderson RJ, 1996, J BIOL CHEM, V271, P29170, DOI 10.1074/jbc.271.46.29170; SAVVA R, 1995, NAT STRUCT BIOL, V2, P752, DOI 10.1038/nsb0995-752; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Stivers JT, 1998, NUCLEIC ACIDS RES, V26, P3837, DOI 10.1093/nar/26.16.3837; Stivers JT, 1999, BIOCHEMISTRY-US, V38, P952, DOI 10.1021/bi9818669; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2209, DOI 10.1021/bi951884f; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; Werner RM, 2000, BIOCHEMISTRY-US, V39, P14054, DOI 10.1021/bi0018178; Werner RM, 2000, BIOCHEMISTRY-US, V39, P12585, DOI 10.1021/bi001532v; WHITSON PA, 1986, BIOCHEMISTRY-US, V25, P3845, DOI 10.1021/bi00361a016; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030; Wong I, 1997, BIOCHEMISTRY-US, V36, P3115, DOI 10.1021/bi9621977; Xiao GY, 1999, PROTEINS, V35, P13; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	45	60	62	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19424	19432		10.1074/jbc.M201198200	http://dx.doi.org/10.1074/jbc.M201198200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11907039	hybrid			2022-12-25	WOS:000175894800026
J	Dumermuth, E; Beuret, N; Spiess, M; Crottet, P				Dumermuth, E; Beuret, N; Spiess, M; Crottet, P			Ubiquitous 9-O-acetylation of sialoglycoproteins restricted to the Golgi complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-C-VIRUS; N-LINKED OLIGOSACCHARIDES; ACID O-ACETYLTRANSFERASE; HAMSTER OVARY CELLS; SIALIC ACIDS; N-ACETYL-9-O-ACETYLNEURAMINIC ACID; RECEPTOR DETERMINANT; BOVINE CORONAVIRUS; GLYCOSYLATION; MEMBRANE	9-O-Acetylation of sialic acid is known as a cell type-specific modification of secretory and plasma membrane glycoconjugates of higher vertebrates with important functions in modulating cell-cell recognition. Using a recombinant probe derived from influenza C virus hemagglutinin, we discovered 9-O-acetylated protein in the Golgi complex of various cell lines, most of which did not display 9-O-acetylated sialic acid on the cell surface. All cell lines expressed a sulfated glycoprotein of 50 kDa (sgp50) carrying 9-O-acetylated sialic acids, which was used as a model substrate. Like gp40, the major receptor for influenza C virus of Madin-Darby canine kidney I cells, sgp50 is 9-O-acetylated on O-linked glycans. However, gp40 was not 9-O-acetylated when expressed in Madin-Darby canine kidney II or COS-7 cells. The results demonstrate the existence of two 9-O-acetylation machineries for O-glycosylated proteins with distinct substrate specificities. The widespread occurrence of 9-O-acetylated protein in the Golgi furthermore suggests an additional intracellular role for this modification.	Univ Basel, Bioctr, CH-4056 Basel, Switzerland	University of Basel	Spiess, M (corresponding author), Univ Basel, Bioctr, Klingelbergstr 70, CH-4056 Basel, Switzerland.	Martin.Spiess@unibas.ch		Spiess, Martin/0000-0001-7139-0550				BUTOR C, 1993, J BIOL CHEM, V268, P10197; Chammas R, 1996, MOL BIOL CELL, V7, P1691, DOI 10.1091/mbc.7.11.1691; DIAZ S, 1989, J BIOL CHEM, V264, P19416; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; Harms G, 1996, GLYCOCONJUGATE J, V13, P621, DOI 10.1007/BF00731450; HERRLER G, 1987, VIROLOGY, V159, P102, DOI 10.1016/0042-6822(87)90352-7; HERRLER G, 1988, J GEN VIROL, V69, P839, DOI 10.1099/0022-1317-69-4-839; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; Itin C, 1997, J BIOL CHEM, V272, P27737, DOI 10.1074/jbc.272.44.27737; KLEIN A, 1994, P NATL ACAD SCI USA, V91, P7782, DOI 10.1073/pnas.91.16.7782; KONAMI Y, 1994, FEBS LETT, V342, P334, DOI 10.1016/0014-5793(94)80527-X; Krishna M, 1997, J EXP MED, V185, P1997, DOI 10.1084/jem.185.11.1997; LEE EU, 1989, J BIOL CHEM, V264, P13848; LEITINGER B, 1994, J BIOL CHEM, V269, P8115; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; LOHMANDER LS, 1979, J BIOL CHEM, V254, P551; MUCHMORE EA, 1987, FASEB J, V1, P229, DOI 10.1096/fasebj.1.3.3623000; Puthalakath H, 1996, J BIOL CHEM, V271, P27818, DOI 10.1074/jbc.271.44.27818; ROBERTSON MA, 1978, CELL, V13, P515, DOI 10.1016/0092-8674(78)90325-2; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; SCHAUER R, 1991, Glycobiology, V1, P449, DOI 10.1093/glycob/1.5.449; SCHULTZE B, 1992, J GEN VIROL, V73, P901, DOI 10.1099/0022-1317-73-4-901; SCHULTZE B, 1993, ADV EXP MED BIOL, V342, P299; Schwarz A, 1997, J HISTOCHEM CYTOCHEM, V45, P611, DOI 10.1177/002215549704500413; Shi WX, 1996, J BIOL CHEM, V271, P15130, DOI 10.1074/jbc.271.25.15130; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Varki A, 1998, TRENDS CELL BIOL, V8, P34, DOI 10.1016/S0962-8924(97)01198-7; WESSELS HP, 1991, METHOD CELL BIOL, V34, P287; Yim M, 2001, P NATL ACAD SCI USA, V98, P2222, DOI 10.1073/pnas.041621998; ZIMMER G, 1992, EUR J BIOCHEM, V204, P209, DOI 10.1111/j.1432-1033.1992.tb16626.x; ZIMMER G, 1994, GLYCOBIOLOGY, V4, P343, DOI 10.1093/glycob/4.3.343; ZIMMER G, 1995, J BIOL CHEM, V270, P17815, DOI 10.1074/jbc.270.30.17815; Zimmer G, 1997, BIOCHEM J, V326, P99, DOI 10.1042/bj3260099	39	11	11	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18687	18693		10.1074/jbc.M109408200	http://dx.doi.org/10.1074/jbc.M109408200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11904293	hybrid			2022-12-25	WOS:000175975800060
J	Katz, YS; Danon, A				Katz, YS; Danon, A			The 3 '-untranslated region of chloroplast psbA mRNA stabilizes binding of regulatory proteins to the leader of the message	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CHLAMYDOMONAS-REINHARDTII; 5'-UNTRANSLATED REGION; TRANSLATION INITIATION; TOBACCO CHLOROPLASTS; SECONDARY STRUCTURE; GENE-EXPRESSION; LIGHT; REQUIRES; DETERMINANTS	The 5'-leader and 3'-tail of chloroplast mRNAs have been suggested to play a role in posttranscriptional regulation of expression of the message. The regulation is thought to be mediated, at least in part, by regulatory proteins that are encoded by the nuclear genome and targeted to the chloroplast where they interact with chloroplast mRNAs. Previous studies identified high affinity binding of the 5'-untranslated region (UTR) of the chloroplast psbA mRNA by Chlamydomonas reinhardtit proteins. Here we tested whether the 3'-UTR of psbA mRNA alone or linked in cis with the 5'-UTR of the mRNA affects the high affinity binding of the message in vitro. We did not detect high affinity binding that is unique to the 3'-UTR. However, we show that the cis-linked 3'-UTR increases the stability of the 5'-UTR binding complex. This effect could provide a means for translational discrimination against mRNAs that are incorrectly processed.	Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Danon, A (corresponding author), Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel.							Alexander C, 1998, NUCLEIC ACIDS RES, V26, P2265, DOI 10.1093/nar/26.10.2265; Boudreau E, 2000, EMBO J, V19, P3366, DOI 10.1093/emboj/19.13.3366; Bruick RK, 1999, TRENDS PLANT SCI, V4, P190, DOI 10.1016/S1360-1385(99)01402-8; Bruick RK, 1998, J CELL BIOL, V143, P1145, DOI 10.1083/jcb.143.5.1145; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; Drager RG, 1999, PLANT J, V19, P521, DOI 10.1046/j.1365-313X.1999.00546.x; Eibl C, 1999, PLANT J, V19, P333, DOI 10.1046/j.1365-313X.1999.00543.x; Fargo DC, 2001, PLANT CELL, V13, P207, DOI 10.1105/tpc.13.1.207; Franch T, 1996, MOL MICROBIOL, V21, P1049, DOI 10.1046/j.1365-2958.1996.771431.x; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; GIRARDBASCOU J, 1992, CURR GENET, V22, P47, DOI 10.1007/BF00351741; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; Hirose T, 1996, EMBO J, V15, P1687, DOI 10.1002/j.1460-2075.1996.tb00514.x; Kim JM, 1997, SCIENCE, V278, P1954, DOI 10.1126/science.278.5345.1954; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lindahl L, 1992, CURR OPIN GENET DEV, V2, P720, DOI 10.1016/S0959-437X(05)80132-7; Lisitsky I, 1996, P NATL ACAD SCI USA, V93, P13398, DOI 10.1073/pnas.93.23.13398; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; MAYFIELD SP, 1994, J CELL BIOL, V127, P1537, DOI 10.1083/jcb.127.6.1537; MAYFIELD SP, 1995, ANNU REV PLANT PHYS, V46, P147, DOI 10.1146/annurev.pp.46.060195.001051; McCormac DJ, 2001, J BIOL CHEM, V276, P3476, DOI 10.1074/jbc.M009236200; Memon AR, 1996, PLANT MOL BIOL, V30, P1195, DOI 10.1007/BF00019552; Monde RA, 2000, BIOCHIMIE, V82, P573, DOI 10.1016/S0300-9084(00)00606-4; Monde RA, 2000, PLANT MOL BIOL, V44, P529, DOI 10.1023/A:1026540310934; Ossenbuhl F, 2000, MOL CELL BIOL, V20, P8134, DOI 10.1128/MCB.20.21.8134-8142.2000; Rott R, 1998, MOL CELL BIOL, V18, P4605, DOI 10.1128/MCB.18.8.4605; SCHUSTER G, 1991, EMBO J, V10, P1493, DOI 10.1002/j.1460-2075.1991.tb07669.x; STAUB JM, 1994, PLANT J, V6, P547, DOI 10.1046/j.1365-313X.1994.6040547.x; Trebitsh T, 2000, MOL CELL BIOL, V20, P1116, DOI 10.1128/MCB.20.4.1116-1123.2000; Vaistij FE, 2000, PLANT J, V21, P469, DOI 10.1046/j.1365-313x.2000.00700.x; Voorma H. O., 1996, TRANSLATIONAL CONTRO, p[759, 759]; Yohn CB, 1998, J CELL BIOL, V142, P435, DOI 10.1083/jcb.142.2.435; Yohn CB, 1996, MOL CELL BIOL, V16, P3560; Yohn CB, 1998, P NATL ACAD SCI USA, V95, P2238, DOI 10.1073/pnas.95.5.2238	37	11	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18665	18669		10.1074/jbc.M201033200	http://dx.doi.org/10.1074/jbc.M201033200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11904302	hybrid			2022-12-25	WOS:000175975800057
J	Konieczny, I; Liberek, K				Konieczny, I; Liberek, K			Cooperative action of Escherichia coli ClpB protein and DnaK chaperone in the activation of a replication initiation protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RANGE PLASMID RK2; HEAT-SHOCK PROTEINS; DISTANTLY RELATED BACTERIA; MOLECULAR CHAPERONES; CLP/HSP100 FAMILY; ENCODED PROTEINS; IN-VIVO; TRFA; ORIGIN; GRPE	The Escherichia coli molecular chaperone protein ClpB is a member of the highly conserved Hsp100/Clp protein family. Previous studies have shown that the ClpB protein is needed for bacterial thermotolerance. Purified ClpB protein has been shown to reactivate chemically and heat-denatured proteins. In this work we demonstrate that the combined action of ClpB and the DnaK, DnaJ, and GrpE chaperones leads to the activation of DNA replication of the broad-host-range plasmid RK2. In contrast, ClpB is not needed for the activation of the oriC-dependent replication of E. coli. Using purified protein components we show that the ClpB/DnaK/DnaJ/GrpE synergistic action activates the plasmid RK2 replication initiation protein TrfA by converting inactive dimers to an active monomer form. In contrast, Hsp78/Ssc1/Mdj1/Mge1, the corresponding protein system from yeast mitochondria, cannot activate the TrfA replication protein. Our results demonstrate for the first time that the CIpB/DnaK/DnaJ/GrpE system is involved in protein monomerization and in the activation of a DNA replication factor.	Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, PL-80822 Gdansk, Poland	Fahrenheit Universities; University of Gdansk	Konieczny, I (corresponding author), Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, 24 Kladki, PL-80822 Gdansk, Poland.		Liberek, Krzysztof/F-5812-2011	Konieczny, Igor/0000-0002-1588-5601; Liberek, Krzysztof/0000-0002-7532-9279				Banecki B, 1998, BBA-GENE STRUCT EXPR, V1442, P39, DOI 10.1016/S0167-4781(98)00118-3; Blasina A, 1996, P NATL ACAD SCI USA, V93, P3559, DOI 10.1073/pnas.93.8.3559; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; Caspi R, 2000, J BIOL CHEM, V275, P18454, DOI 10.1074/jbc.M000552200; CEREGHINO JL, 1993, J BIOL CHEM, V268, P24926; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Doran KS, 1998, J BIOL CHEM, V273, P8447, DOI 10.1074/jbc.273.14.8447; Doran KS, 1999, MOL MICROBIOL, V33, P490, DOI 10.1046/j.1365-2958.1999.01491.x; Doran KS, 1999, J BIOL CHEM, V274, P17918, DOI 10.1074/jbc.274.25.17918; DURLAND RH, 1990, J BACTERIOL, V172, P3859, DOI 10.1128/jb.172.7.3859-3867.1990; DURLAND RH, 1987, PLASMID, V18, P164, DOI 10.1016/0147-619X(87)90044-8; FANG FC, 1991, J BACTERIOL, V173, P5861, DOI 10.1128/jb.173.18.5861-5868.1991; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; HEINEMANN JA, 1989, NATURE, V340, P205, DOI 10.1038/340205a0; HWANG DS, 1990, J BIOL CHEM, V265, P19244; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; KITAGAWA M, 1991, J BACTERIOL, V173, P4247, DOI 10.1128/JB.173.14.4247-4253.1991; KITTELL BL, 1991, P NATL ACAD SCI USA, V88, P1389, DOI 10.1073/pnas.88.4.1389; Konieczny I, 1997, J BIOL CHEM, V272, P20173, DOI 10.1074/jbc.272.32.20173; Konieczny I, 1997, J BIOL CHEM, V272, P33312, DOI 10.1074/jbc.272.52.33312; Konieczny I, 1997, P NATL ACAD SCI USA, V94, P14378, DOI 10.1073/pnas.94.26.14378; KONIECZNY I, 1999, GENETICS ENG, P95; KORNACKI JA, 1984, PLASMID, V11, P48, DOI 10.1016/0147-619X(84)90006-4; Krzewska J, 2001, FEBS LETT, V489, P92, DOI 10.1016/S0014-5793(00)02423-6; Laskowska E, 1996, MOL MICROBIOL, V22, P555, DOI 10.1046/j.1365-2958.1996.1231493.x; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; LIN J, 1992, J BACTERIOL, V174, P4110, DOI 10.1128/jb.174.12.4110-4119.1992; LINDQUIST S, 1999, MOL CHAPERONES FOLDI, P347; Liu JJ, 1999, MOL MICROBIOL, V33, P415, DOI 10.1046/j.1365-2958.1999.01489.x; Makovets S, 1998, MOL MICROBIOL, V28, P25, DOI 10.1046/j.1365-2958.1998.00767.x; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; PERRI S, 1991, J BIOL CHEM, V266, P12536; PINKNEY M, 1988, J MOL BIOL, V203, P927, DOI 10.1016/0022-2836(88)90118-0; SCHMIDHAUSER TJ, 1983, PLASMID, V9, P325, DOI 10.1016/0147-619X(83)90010-0; SHINGLER V, 1984, J MOL BIOL, V175, P229, DOI 10.1016/0022-2836(84)90346-2; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; STALKER DM, 1981, MOL GEN GENET, V181, P8, DOI 10.1007/BF00338997; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1; TILLY K, 1990, New Biologist, V2, P812; TILLY K, 1989, J BACTERIOL, V171, P6025, DOI 10.1128/jb.171.11.6025-6029.1989; Toukdarian AE, 1998, GENE, V223, P205, DOI 10.1016/S0378-1119(98)00370-9; Toukdarian AE, 1996, J BIOL CHEM, V271, P7072, DOI 10.1074/jbc.271.12.7072; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WOO KM, 1992, J BIOL CHEM, V267, P20429; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	55	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18483	18488		10.1074/jbc.M107580200	http://dx.doi.org/10.1074/jbc.M107580200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889118	hybrid			2022-12-25	WOS:000175975800031
J	Spagnoli, A; Torello, M; Nagalla, SR; Horton, WA; Pattee, P; Hwa, V; Chiarelli, F; Roberts, CT; Rosenfeld, RG				Spagnoli, A; Torello, M; Nagalla, SR; Horton, WA; Pattee, P; Hwa, V; Chiarelli, F; Roberts, CT; Rosenfeld, RG			Identification of STAT-1 as a molecular target of IGFBP-3 in the process of chondrogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-3; BREAST-CANCER CELLS; CHONDROCYTE PROLIFERATION; GROWTH-HORMONE; RECEPTOR; BETA; APOPTOSIS; DIFFERENTIATION; EXPRESSION; MICE	The chondrogenesis process requires the ordered proliferation and differentiation of chondrocytes. Insulinlike growth factor-binding protein (IGFBP)-3, well characterized as the carrier of insulin-like growth factor (IGF), has been reported to have intrinsic bioactivity that is independent of IGF binding. The mechanisms involved in this IGF-independent action are still unclear. Using the RCJ3.1C5.18 chondrogenic cells, which in culture progresses from undifferentiated to terminally differentiated chondrocytes, we have shown previously that IGFBP-3 has an IGF-independent, antiproliferative effect in undifferentiated and early differentiated but not in terminally differentiated chondrocytes. In the present study, cDNA microarray analysis was used to screen for genes: 1) that were regulated by IGFBP-3 in early but not in terminally differentiated chondrocytes; 2) that were regulated specifically by IGFBP-3, but not by IGF-I; and 3) whose regulation was abolished by coincubation of IGFBP-3 with IGF-I. Signal transducer and activator of transcription (STAT)-1 was the gene that, fulfilling the screening criteria, exhibited the greatest up-regulation by IGFBP-3 (>40-fold). STAT-1 gene up-regulation was confirmed by Northern analysis of cells treated with IGFBP-3 or transfected with an IGFBP-3 expression vector. Remarkably, similar results were obtained when cells were transfected with an IGFBP-3 mutant unable to bind IGFs, definitively demonstrating the IGF-independent action of IGFBP-3. Consistent with the up-regulation of STAT-1 mRNA, IGFBP-3 also increased STAT-1 protein expression. Furthermore, both IGFBP-3 and the IGFBP-3 mutant induced STAT-1 phosphorylation and its nuclear localization. An antisense STAT-1 oligonucleotide abolished the IGF-independent cell apoptosis induced by IGFBP-3. We have demonstrated that STAT-1 is a major intracellular signaling and transcriptional target of the IGF-independent apoptotic effect of IGFBP-3 in chondrogenesis.	Vanderbilt Univ, Med Ctr, Dept Pediat, Med Ctr N T0107, Nashville, TN 37232 USA; Shriners Hosp Children, Res Ctr, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA; Univ G dAnnunzio, Dept Pediat, I-66013 Chieti, Italy	Vanderbilt University; Oregon Health & Science University; G d'Annunzio University of Chieti-Pescara	Spagnoli, A (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pediat, Med Ctr N T0107, Nashville, TN 37232 USA.	anna.spagnoli@mcmail.vanderbilt.edu	Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772				BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967, DOI 10.1152/ajpendo.2000.278.6.E967; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; Booth BA, 1996, GROWTH REGULAT, V6, P206; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Buckway CK, 2001, J CLIN ENDOCR METAB, V86, P4943, DOI 10.1210/jc.86.10.4943; Butt AJ, 2000, J BIOL CHEM, V275, P39174, DOI 10.1074/jbc.M908888199; Conover CA, 2000, ENDOCRINOLOGY, V141, P3098, DOI 10.1210/en.141.9.3098; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fanayan S, 2000, J BIOL CHEM, V275, P39146, DOI 10.1074/jbc.M006964200; Fernihough JK, 1996, ARTHRITIS RHEUM, V39, P1556, DOI 10.1002/art.1780390916; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; GRIGORIADIS AE, 1990, DEV BIOL, V142, P313, DOI 10.1016/0012-1606(90)90352-J; Grigoriadis AE, 1996, DIFFERENTIATION, V60, P299, DOI 10.1046/j.1432-0436.1996.6050299.x; Horton William A., 1997, Current Opinion in Pediatrics, V9, P437, DOI 10.1097/00008480-199708000-00021; Johnson GA, 2001, BIOL REPROD, V64, P1392, DOI 10.1095/biolreprod64.5.1392; Knudtson KL, 2001, ENDOCRINOLOGY, V142, P3749, DOI 10.1210/en.142.9.3749; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Legeai-Mallet L, 1998, J BIOL CHEM, V273, P13007, DOI 10.1074/jbc.273.21.13007; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Lunstrum GP, 1999, J HISTOCHEM CYTOCHEM, V47, P1, DOI 10.1177/002215549904700101; Martel-Pelletier J, 1998, INFLAMM RES, V47, P90, DOI 10.1007/s000110050288; Matsumoto T, 1996, J ENDOCRINOL, V148, P355, DOI 10.1677/joe.0.1480355; Modric T, 2001, ENDOCRINOLOGY, V142, P1958, DOI 10.1210/en.142.5.1958; OH Y, 1993, J BIOL CHEM, V268, P26045; OH YM, 1993, J BIOL CHEM, V268, P14964; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Sahni M, 2001, DEVELOPMENT, V128, P2119; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; SPAGNOLI A, 1995, J CLIN ENDOCR METAB, V80, P3668, DOI 10.1210/jc.80.12.3668; Spagnoli A, 1996, ENDOCRIN METAB CLIN, V25, P615, DOI 10.1016/S0889-8529(05)70343-1; Spagnoli A, 2001, J BIOL CHEM, V276, P5533, DOI 10.1074/jbc.M005088200; SPAGNOLI A, 1997, CURR OPIN ENDOCRINOL, V4, P1; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stewart DM, 2001, ENDOCRINOLOGY, V142, P98, DOI 10.1210/en.142.1.98; Stewart MD, 2001, ENDOCRINOLOGY, V142, P1786, DOI 10.1210/en.142.5.1786; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Wu HB, 2000, J CELL BIOCHEM, V77, P288, DOI 10.1002/(SICI)1097-4644(20000501)77:2<288::AID-JCB11>3.0.CO;2-J; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324	45	42	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18860	18867		10.1074/jbc.M200218200	http://dx.doi.org/10.1074/jbc.M200218200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886859	hybrid			2022-12-25	WOS:000175975800080
J	Bodelon, G; Labrada, L; Martinez-Costas, J; Benavente, J				Bodelon, G; Labrada, L; Martinez-Costas, J; Benavente, J			Modification of late membrane permeability in avian reovirus-infected cells - Viroporin activity of the S1-encoded nonstructural p10 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-CELLS; ADENOVIRUS DEATH PROTEIN; TYPE-1 VPU PROTEIN; ANIMAL VIRUSES; INDUCIBLE EXPRESSION; ATTACHMENT PROTEIN; CYSTEINE RESIDUES; BREFELDIN-A; M2 PROTEIN; HELA-CELLS	Infection of chicken embryo fibroblasts by avian reovirus induces an increase in the permeability of the host plasma membrane at late, but not early, infection times. The absence of permeability changes at early infection times, as well as the dependence of late membrane modification on both viral protein synthesis and an active exocytic route, suggest that a virus-encoded membrane protein is required for avian reovirus to permeabilize cells. Further studies revealed that expression of nonstructural p10 protein in bacterial cells arrested cell growth and enhanced membrane permeability. Membrane leakiness was also observed following transient expression of p10 in BSC-40 monkey cells. Both its permeabilizing effect and the fact that p10 shares several structural and physical characteristics with other membrane-active viral proteins indicate that p10 is an avian reovirus viroporin. Furthermore, the fusogenic extracellular NH2-terminal domain of p10 appears to be dispensable for permeabilizing activity, because its deletion entirely abolished the fusogenic activity of p10, without affecting its ability to associate with cell membranes and to enhance membrane permeability. Similar properties have reported previously for immunodeficiency virus type I transmembrane glycoprotein gp41. Thus, like gp41, p10 appears to be a multifunctional protein that plays key roles in virus-host interaction.	Univ Santiago de Compostela, Fac Farm, Dept Bioquim & Biol Mol, Santiago De Compostela 15782, Spain	Universidade de Santiago de Compostela	Benavente, J (corresponding author), Univ Santiago de Compostela, Fac Farm, Dept Bioquim & Biol Mol, Santiago De Compostela 15782, Spain.	bnjbena@usc.es	Martinez-Costas, Jose/E-9005-2011; Benavente, Javier/N-6475-2016; Bodelon, Gustavo/H-2870-2013	Martinez-Costas, Jose/0000-0002-8877-7775; Benavente, Javier/0000-0003-4857-0312; Bodelon, Gustavo/0000-0003-2815-7635				Aldabe R, 1996, J BIOL CHEM, V271, P23134, DOI 10.1074/jbc.271.38.23134; ARROYO J, 1995, J VIROL, V69, P4095, DOI 10.1128/JVI.69.7.4095-4102.1995; BENEDETTO A, 1980, VIROLOGY, V106, P123, DOI 10.1016/0042-6822(80)90227-5; Bodelon G, 2001, VIROLOGY, V290, P181, DOI 10.1006/viro.2001.1159; Browne EP, 2000, J GEN VIROL, V81, P1955, DOI 10.1099/0022-1317-81-8-1955; Caballero M, 1998, J VIROL, V72, P8198, DOI 10.1128/JVI.72.10.8198-8204.1998; CARRASCO L, 1993, NATO ADV SCI INST SE, V240, P283; CARRASCO L, 1978, NATURE, V272, P694, DOI 10.1038/272694a0; CARRASCO L, 1995, ADV VIRUS RES, V45, P61, DOI 10.1016/S0065-3527(08)60058-5; CARRASCO L, 1976, NATURE, V264, P807, DOI 10.1038/264807a0; CARRASCO L, 1989, PHARMACOL THERAPEUT, V40, P171, DOI 10.1016/0163-7258(89)90096-X; CASTRILLO JL, 1987, J GEN VIROL, V68, P325, DOI 10.1099/0022-1317-68-2-325; Castrucci MR, 1997, VIROLOGY, V238, P128, DOI 10.1006/viro.1997.8809; Chang YS, 1999, J VIROL, V73, P6257, DOI 10.1128/JVI.73.8.6257-6264.1999; Ciccaglione AR, 1998, VIROLOGY, V250, P1, DOI 10.1006/viro.1998.9380; CONTRERAS A, 1979, J VIROL, V29, P114, DOI 10.1128/JVI.29.1.114-122.1979; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; DOMES R, 1989, J CELL BIOL, V109, P61; Duncan R, 1998, VIROLOGY, V250, P263, DOI 10.1006/viro.1998.9371; Duncan R, 1996, VIROLOGY, V224, P453, DOI 10.1006/viro.1996.0552; DUNCAN R, 1995, VIROLOGY, V212, P752, DOI 10.1006/viro.1995.1536; FUCHS P, 1983, CURR TOP MICROBIOL, V102, P57; GAEDIGKNITSCHKO K, 1990, VIROLOGY, V175, P282, DOI 10.1016/0042-6822(90)90210-I; GARD G, 1970, J VIROL, V6, P100, DOI 10.1128/JVI.6.1.100-106.1970; Gonzalez ME, 1998, BIOCHEMISTRY-US, V37, P13710, DOI 10.1021/bi981527f; Grande A, 2000, VIROLOGY, V274, P367, DOI 10.1006/viro.2000.0473; Grande A, 2000, J VIROL METHODS, V85, P43, DOI 10.1016/S0166-0934(99)00155-X; GUINEA R, 1994, FEBS LETT, V343, P242, DOI 10.1016/0014-5793(94)80564-4; Hausmann J, 1998, VIROLOGY, V244, P343, DOI 10.1006/viro.1998.9135; Jecht M, 1998, VIROLOGY, V252, P218, DOI 10.1006/viro.1998.9451; KNIPE DM, 1996, VIROLOGY, P273; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LACAL JC, 1980, J ANTIBIOT, V33, P441, DOI 10.7164/antibiotics.33.441; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMA J, 1995, FEBS LETT, V367, P5, DOI 10.1016/0014-5793(95)00523-C; LAMA J, 1992, BIOCHEM BIOPH RES CO, V188, P972, DOI 10.1016/0006-291X(92)91327-M; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MartinezCostas J, 1997, J VIROL, V71, P59; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; MUNOZ A, 1984, VIROLOGY, V137, P150, DOI 10.1016/0042-6822(84)90018-7; NAIR CN, 1984, J GEN VIROL, V65, P1135, DOI 10.1099/0022-1317-65-6-1135; Nibert ML, 1996, J VIROL, V70, P7295, DOI 10.1128/JVI.70.10.7295-7300.1996; NUSS DL, 1975, P NATL ACAD SCI USA, V72, P1258, DOI 10.1073/pnas.72.4.1258; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; Perez M, 1997, VIROLOGY, V235, P342, DOI 10.1006/viro.1997.8696; PISANI G, 1995, BIOCHEM BIOPH RES CO, V211, P627, DOI 10.1006/bbrc.1995.1859; RANKIN JT, 1989, VIROLOGY, V168, P147, DOI 10.1016/0042-6822(89)90413-3; ROBERTSON MD, 1986, VET B, V56, P759; SANZ MA, 1994, J BIOL CHEM, V269, P12106; Shmulevitz M, 2002, J VIROL, V76, P609, DOI 10.1128/JVI.76.2.609-618.2002; Shmulevitz M, 2000, EMBO J, V19, P902, DOI 10.1093/emboj/19.5.902; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tiganos E, 1998, VIROLOGY, V251, P96, DOI 10.1006/viro.1998.9368; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; van Niekerk M, 2001, VIROLOGY, V279, P499, DOI 10.1006/viro.2000.0709; VanKuppeveld FJM, 1997, VIROLOGY, V227, P111, DOI 10.1006/viro.1996.8320; YANG CL, 1995, P NATL ACAD SCI USA, V92, P9871, DOI 10.1073/pnas.92.21.9871	57	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17789	17796		10.1074/jbc.M202018200	http://dx.doi.org/10.1074/jbc.M202018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11893756	hybrid			2022-12-25	WOS:000175685100052
J	Reynolds, TH; Bodine, SC; Lawrence, JC				Reynolds, TH; Bodine, SC; Lawrence, JC			Control of Ser(2448) phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; P70 S6 KINASE; SIGNALING PATHWAY; RAT PLANTARIS; PHAS-I; ACTIVATION; MECHANISM; SITES; HYPERTROPHY; TRANSLATION	We have investigated the effects of insulin, amino acids, and the degree of muscle loading on the phosphorylation of Ser(2448), a site in the mammalian target of rapamycin (mTOR) phosphorylated by protein kinase B (PKB) in vitro. Phosphorylation was assessed by immunoblotting with a phosphospecific antibody (antiSer(P)(2448)) and with mTAb1, an activating antibody whose binding is inhibited by phosphorylation in the region of mTOR that contains Ser(2448). Incubating rat diaphragm muscles with insulin increased Ser(2448) phosphorylation but did not change the total amount of mTOR. Insulin, but not amino acids, activated PKB, as evidenced by increased phosphorylation of both Ser(308). and Thr(473) in the kinase. Ser(2448) phosphorylation was also modulated by muscle-loading. Overloading the rat plantaris muscle by synergist muscle ablation, which promotes hypertrophy of the plantaris muscle, increased Ser(2448) phosphorylation. In contrast, unloading the gastrocnemius muscle by hindlimb suspension, which promotes atrophy of the muscle, decreased Ser(2448) phosphorylation, an effect that was fully reversible. Neither overloading nor hindlimb suspension significantly changed the total amount of mTOR. In summary, our results demonstrate that atrophy and hypertrophy of skeletal muscle are associated with decreases and increases in Ser(2448) phosphorylation, suggesting that modulation of this site may have an important role in the control of protein synthesis.	Univ Virginia Hlth Syst, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Med, Charlottesville, VA 22908 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	University of Virginia; University of Virginia; Regeneron	Lawrence, JC (corresponding author), Univ Virginia Hlth Syst, Dept Pharmacol, POB 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	jc13p@virginia.edu		Bodine, Sue/0000-0002-5742-9145; Reynolds, Thomas/0000-0002-0290-528X	NIAMS NIH HHS [AR-41180] Funding Source: Medline; NIDDK NIH HHS [DK-52753] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052753] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; [Anonymous], 1980, PRINCIPLES PROCEDURE; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; Baar K, 1999, AM J PHYSIOL-CELL PH, V276, pC120, DOI 10.1152/ajpcell.1999.276.1.C120; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Charlton M, 1998, J NUTR, V128, p323S, DOI 10.1093/jn/128.2.323S; FLAIM KE, 1980, AM J PHYSIOL, V239, pE88, DOI 10.1152/ajpendo.1980.239.1.E88; Grzelkowska K, 1999, J ENDOCRINOL, V160, P137, DOI 10.1677/joe.0.1600137; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hornberger TA, 2001, AM J PHYSIOL-CELL PH, V281, pC179, DOI 10.1152/ajpcell.2001.281.1.C179; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; MUNOZ KA, 1994, METABOLISM, V43, P994, DOI 10.1016/0026-0495(94)90179-1; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; NOBLE EG, 1984, CAN J PHYSIOL PHARM, V62, P1178, DOI 10.1139/y84-197; PAIN VM, 1974, J BIOL CHEM, V249, P4510; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; Price SR, 1996, J CLIN INVEST, V98, P1703, DOI 10.1172/JCI118968; Roy RR, 1997, J APPL PHYSIOL, V83, P280, DOI 10.1152/jappl.1997.83.1.280; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE715, DOI 10.1152/ajpendo.2000.279.4.E715; THOMASON DB, 1987, J APPL PHYSIOL, V63, P130, DOI 10.1152/jappl.1987.63.1.130	29	217	226	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17657	17662		10.1074/jbc.M201142200	http://dx.doi.org/10.1074/jbc.M201142200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884412	hybrid			2022-12-25	WOS:000175685100035
J	Yu, DN; Thomas-Tikhonenko, A				Yu, DN; Thomas-Tikhonenko, A			A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis	ONCOGENE			English	Article						Myc; p53; B-lymphoma; immunoglobulins; gene rearrangement	EPSTEIN-BARR-VIRUS; C-MYC; BURKITT-LYMPHOMA; TRANSGENIC MICE; APOPTOSIS; GENE; REARRANGEMENTS; TRANSLOCATION; EXPRESSION; PROTEIN	The c-Myc oncoprotein is strongly implicated in B-cell neoplasms such as human Burkitt lymphomas and mouse plasmocytomas. Transgenic mice in which the myc gene is juxtaposed to an immunoglobulin enhancer (Emu-myc) also develop B-cell lymphomas, but relatively late in life. In addition, these neoplasms are invariably clonal, suggesting the involvement of additional mutations. Such mutations frequently affect the p53 tumour suppressor gene or its positive regulator Arf, hinting that inactivation of the p53 pathway might be the second hit required for the progression towards malignancy. However, even tumours arising in Emu-myc/Arf-null animals are thought to be clonal. This observation raised doubts whether overexpression of Myc in p53-null B-cell precursors is sufficient for tumorigenesis. To address this question, we have established a new, non-transgenic mouse model of B-lymphoma. This model is based on isolation of primary bone marrow (BM) cells, admixing them with packaging cells producing a Myc-encoding retrovirus (LMycSN), and subcutaneous injection into a host with which BM cells are syngeneic. Predictably, wild type BM cells infected in vivo by LMycSN were not tumorigenic. However, LMycSN-infected p53-null BM cells readily gave rise to B-cell lymphomas composed predominantly of late pro-B/small pre-B-cells. In these tumours, heavy chain gene rearrangements were analysed using two independent PCR-based assays. All neoplasms with DJ-rearrangements were found to be polyclonal. This result suggests that inactivation of p53 and overexpression of Myc is all that is necessary for the development of full-fledged B-lymphomas. Our model would also be instrumental in assessing the transforming potential of Myc mutants and in studying cooperation between Myc and other oncogenes.	Univ Penn, Dept Pathobiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Thomas-Tikhonenko, A (corresponding author), Univ Penn, Dept Pathobiol, 3800 Spruce St, Philadelphia, PA 19104 USA.	andreit@mail.vet.upenn.edu	Thomas-Tikhonenko, Andrei/E-5329-2011	Thomas-Tikhonenko, Andrei/0000-0002-2739-2206	NCI NIH HHS [CA 71881] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA071881, R29CA071881] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BLACKWOOD EM, 1994, MOL BIOL CELL, V5, P597, DOI 10.1091/mbc.5.5.597; Bower M, 2001, BRIT J HAEMATOL, V112, P863, DOI 10.1046/j.1365-2141.2001.02654.x; Brandvold KA, 2000, ONCOGENE, V19, P2780, DOI 10.1038/sj.onc.1203589; Cory S, 1999, CANCER RES, V59, p1685S; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HSU B, 1995, ONCOGENE, V11, P175; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; KLEIN G, 1993, GENE, V135, P189, DOI 10.1016/0378-1119(93)90065-B; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; NEWCOMB EW, 1995, LEUKEMIA LYMPHOMA, V17, P211, DOI 10.3109/10428199509056825; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PELICCI PG, 1986, J EXP MED, V164, P2049, DOI 10.1084/jem.164.6.2049; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Rolink AG, 1999, NATURE, V401, P603, DOI 10.1038/44164; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TENBOEKEL E, 1995, INT IMMUNOL, V7, P1013; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; Yu DN, 2001, CANCER LETT, V173, P145, DOI 10.1016/S0304-3835(01)00612-7; Zimber-Strobl U, 1999, CURR TOP MICROBIOL, V246, P315; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	49	41	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1922	1927		10.1038/sj.onc.1205244	http://dx.doi.org/10.1038/sj.onc.1205244			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896625				2022-12-25	WOS:000174284500015
J	Heim, M; Johnson, J; Boess, F; Bendik, I; Weber, P; Hunziker, W; Fluhmann, B				Heim, M; Johnson, J; Boess, F; Bendik, I; Weber, P; Hunziker, W; Fluhmann, B			Phytanic acid, a natural peroxisome proliferator-activated receptor agonist, regulates glucose metabolism in rat primary hepatocytes	FASEB JOURNAL			English	Article						phytol; glucose transporter; glucokinase; insulin resistance; adipocyte	RETINOID-X-RECEPTOR; LIPID-METABOLISM; TISSUE DISTRIBUTION; SIGNALING PATHWAYS; PRISTANIC ACID; FATTY-ACIDS; PPAR-ALPHA; INSULIN; LIVER; EXPRESSION	Phytanic acid, a metabolite of the chlorophyll molecule, is part of the human diet and is present in normal human serum at low micromolar concentrations. It was previously shown to be a ligand of the 9-cis-retinoic acid receptor and peroxisome proliferator-activated receptor (PPAR)alpha. PPAR agonists are widely used in the treatment of type 2 diabetes. Here, we report that phytanic acid is not only a transactivator of PPARalpha, but it also acts via PPARbeta and PPARgamma in CV-1 cells that have been cotransfected with the respective full-length receptor and an acyl-CoA oxidase-PPAR-responsive element-luciferase construct. We observed that, in contrast to other fatty acids, phytanic acid at physiological concentrations enhances uptake of 2-deoxy-D-glucose in rat primary hepatocytes. This result could be explained by the increase in mRNA expression of glucose transporters-1 and -2 and glucokinase, as determined by quantitative real-time reverse transcriptase-polymerase chain reaction. Compared with the PPARgamma-specific agonist ciglitazone, phytanic acid exerts only minor effects on the differentiation of C3H10T1/2 cells into mature adipocytes. These results clearly demonstrate that phytanic acid acts via different PPAR isoforms to modulate expression of genes involved in glucose metabolism, thus suggesting a potential role of phytanic acid in the management of insulin resistance.	Roche Vitamins Ltd, Dept Human Nutr & Hlth, Res & Dev, CH-4070 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Pharma Res, CH-4070 Basel, Switzerland; Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany	Roche Holding; Roche Holding; University of Freiburg	Fluhmann, B (corresponding author), Roche Vitamins Ltd, Dept Human Nutr & Hlth, Res & Dev, Bldg 93-8-56, CH-4070 Basel, Switzerland.	beat.fluehmann@roche.com	Johnson, James R/D-9721-2014; Johnson, James R/A-8174-2012	Johnson, James R/0000-0002-8849-0993; 				AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; AVIGAN J, 1966, BIOCHIM BIOPHYS ACTA, V116, P391, DOI 10.1016/0005-2760(66)90022-1; Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Ellinghaus P, 1999, J BIOL CHEM, V274, P2766, DOI 10.1074/jbc.274.5.2766; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GOLDLIN CR, 1991, TOXICOLOGY, V69, P79, DOI 10.1016/0300-483X(91)90155-T; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kim H, 2000, DIABETES, V49, P1517, DOI 10.2337/diabetes.49.9.1517; Kitareewan S, 1996, MOL BIOL CELL, V7, P1153, DOI 10.1091/mbc.7.8.1153; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lemberger T, 1996, ANN NY ACAD SCI, V804, P231, DOI 10.1111/j.1749-6632.1996.tb18619.x; Lemotte PK, 1996, EUR J BIOCHEM, V236, P328, DOI 10.1111/j.1432-1033.1996.00328.x; Lenhard JM, 1997, BIOCHEM PHARMACOL, V54, P801, DOI 10.1016/S0006-2952(97)00229-3; Lohray BB, 2001, J MED CHEM, V44, P2675, DOI 10.1021/jm010143b; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; McCarty MF, 2001, MED HYPOTHESES, V56, P217, DOI 10.1054/mehy.2000.1153; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Murakami K, 1998, DIABETES, V47, P1841, DOI 10.2337/diabetes.47.12.1841; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; Palmer CNA, 1998, MOL PHARMACOL, V53, P14, DOI 10.1124/mol.53.1.14; Radziuk J, 2001, DIABETES-METAB RES, V17, P250, DOI 10.1002/dmrr.217; RATNAYAKE WMN, 1989, LIPIDS, V24, P630, DOI 10.1007/BF02535080; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; VANDENBRANDEN C, 1986, PEDIATR RES, V20, P411, DOI 10.1203/00006450-198605000-00007; Verhoeven NM, 1998, J INHERIT METAB DIS, V21, P697, DOI 10.1023/A:1005476631419; VidalPuig AJ, 1997, J CLIN INVEST, V99, P2416, DOI 10.1172/JCI119424; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Wolfrum C, 1999, J LIPID RES, V40, P708; Zimmermann U, 1997, J ENDOCRINOL, V155, P423, DOI 10.1677/joe.0.1550423; Zomer AWM, 2000, J LIPID RES, V41, P1801	36	91	97	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					718	+		10.1096/fj.01-0816fje	http://dx.doi.org/10.1096/fj.01-0816fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923221				2022-12-25	WOS:000174755900004
J	Grimm, D; Bauer, J; Kossmehl, P; Shakibaei, M; Schonberger, J; Pickenhahn, H; Schulze-Tanzil, G; Vetter, R; Eilles, C; Paul, M; Cogoli, A				Grimm, D; Bauer, J; Kossmehl, P; Shakibaei, M; Schonberger, J; Pickenhahn, H; Schulze-Tanzil, G; Vetter, R; Eilles, C; Paul, M; Cogoli, A			Simulated microgravity alters differentiation and increases apoptosis in human follicular thyroid carcinoma cells	FASEB JOURNAL			English	Article						extracellular matrix proteins; hormones; clinorotation; thyroid tumor; programmed cell death	EXTRACELLULAR-MATRIX PROTEINS; MULTICELLULAR SPHEROIDS; POLY(ADP-RIBOSE) POLYMERASE; PRESSURE-OVERLOAD; GENE-EXPRESSION; TUMOR-CELL; GROWTH; CULTURE; SPACE; DEATH	This study focuses on the effects of simulated microgravity (0g) on the human follicular thyroid carcinoma cell line ML-1. Cultured on a three-dimensional clinostat, ML-1 cells formed three-dimensional MCTSs (MCTS diameter: 0.3+/-0.01 mm). After 24 and 48 h of clinorotation, the cells significantly decreased fT3 and fT4 secretion but up-regulated the thyroid-stimulating hormone-receptor expression as well as the production of vimentin, vinculin, and extracellular matrix proteins (collagen I and III, laminin, fibronectin, chondroitin sulfate) compared with controls. Furthermore, ML-1 cells grown on the clinostat showed elevated amounts of the apoptosis-associated Fas protein, of p53, and of bax but showed reduced quantities of bcl-2. In addition, signs of apoptosis became detectable, as assessed by terminal deoxynucleotidyl transferase-mediated dUTP digoxigenin nick end labeling, 4', 6-diamidino-2-phenylindole staining, DNA laddering, and 85-kDa apoptosis-related cleavage fragments. These fragments resulted from enhanced 116-kDa poly(ADP-ribose)polymerase (PARP) activity and apoptosis. These observations suggest that clinorotation elevates intermediate filaments, cell adhesion molecules, and extracellular matrix proteins and simultaneously induces apoptosis in follicular thyroid cancer cells. In conclusion, our experiments could provide a regulatory basis for the finding that astronauts show low thyroid hormone levels after space flight, which may be explained by the increase of apoptosis in thyrocytes as a result of simulated 0g.	Free Univ Berlin, Benjamin Franklin Med Ctr, Inst Clin Pharmacol & Toxicol, D-14195 Berlin, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Free Univ Berlin, Inst Anat, D-14195 Berlin, Germany; Univ Regensburg, Dept Nucl Med, D-8400 Regensburg, Germany; Swiss Fed Inst Technol, Space Biol Grp, Zurich, Switzerland	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; Free University of Berlin; University of Regensburg; Swiss Federal Institutes of Technology Domain; ETH Zurich	Grimm, D (corresponding author), Free Univ Berlin, Benjamin Franklin Med Ctr, Inst Clin Pharmacol & Toxicol, Garystr 5, D-14195 Berlin, Germany.	dgrimm@zedat.fu-berlin.de	Paul, Martin/K-5425-2015; Prof. Dr. Shakibaei, Mehdi/AAA-7004-2020	Prof. Dr. Shakibaei, Mehdi/0000-0002-6304-7506; Grimm, Daniela/0000-0002-4991-3105				Arscott PL, 1999, J CLIN ENDOCR METAB, V84, P4246, DOI 10.1210/jc.84.11.4246; Buechner SA, 1997, J CLIN INVEST, V100, P2691, DOI 10.1172/JCI119814; CARLSSON J, 1984, RECENT RESULTS CANC, V95, P1; Chappell DB, 1998, CANCER IMMUNOL IMMUN, V47, P65, DOI 10.1007/s002620050505; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; Cogoli M, 1992, ASGSB Bull, V5, P59; Davies CD, 1997, ANTICANCER RES, V17, P4317; Grimm D, 1998, J HYPERTENS, V16, P1345, DOI 10.1097/00004872-199816090-00016; Grimm D, 1997, THYROID, V7, P859, DOI 10.1089/thy.1997.7.859; GRIMM D, 1995, THYROID, V5, P155, DOI 10.1089/thy.1995.5.155; Grimm D, 2001, J MOL CELL CARDIOL, V33, P487, DOI 10.1006/jmcc.2000.1321; GRIMM D, 1999, APOPTOSIS CARDIAC BI, P317; GRINDELAND RE, 1990, FASEB J, V4, P105, DOI 10.1096/fasebj.4.1.2295371; GUNGA HC, 1994, SCI RESULTS GERMAN S, P732; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hammond TG, 2000, PHYSIOL GENOMICS, V3, P163, DOI 10.1152/physiolgenomics.2000.3.3.163; Hammond TG, 1999, NAT MED, V5, P359, DOI 10.1038/7331; Hashemi BB, 1999, FASEB J, V13, P2071, DOI 10.1096/fasebj.13.14.2071; Hermann S, 2001, INT J CANCER, V92, P805, DOI 10.1002/ijc.1284; HOSEN T, 1992, BOT MAG, V105, P53; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; Ingram M, 1997, IN VITRO CELL DEV-AN, V33, P459; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Khaoustov VI, 1999, IN VITRO CELL DEV-AN, V35, P501; Kim M, 1997, EXP CELL RES, V231, P235, DOI 10.1006/excr.1996.3462; Kohrle J, 2000, CELL MOL LIFE SCI, V57, P1853, DOI 10.1007/PL00000667; Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007; LEWIS ML, 1996, FUNDAMENTALS SPACE L, P21; LEWIS ML, 2001, FASEB J; Margolis L, 1999, J UROLOGY, V161, P290, DOI 10.1016/S0022-5347(01)62134-7; Martin A, 2000, THYROID, V10, P481, DOI 10.1089/thy.2000.10.481; Mizutani Y, 1997, CANCER, V79, P1180, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1180::AID-CNCR17>3.0.CO;2-W; Mountz JD, 1999, RECENT PROG HORM RES, V54, P235; NEDERMAN T, 1984, CANCER RES, V44, P3090; Ohnishi T, 1999, MUTAT RES-FUND MOL M, V430, P271, DOI 10.1016/S0027-5107(99)00138-4; PAULUS W, 1994, INT J CANCER, V58, P841, DOI 10.1002/ijc.2910580616; SAKAR D, 2000, J BONE MINER RES, V15, P489; Schatten H, 2001, ACTA ASTRONAUT, V49, P399, DOI 10.1016/S0094-5765(01)00116-3; Schonberger J, 2000, J MOL MED, V78, P102, DOI 10.1007/s001090000085; Schwarzenberg M, 1999, ADV SPACE RES, V24, P793, DOI 10.1016/S0273-1177(99)00075-7; SHAKIBAEI M, 1995, J HISTOCHEM CYTOCHEM, V43, P1061, DOI 10.1177/43.10.7560884; SOLDATENKOV VA, 1995, CANCER RES, V55, P4240; Soldatenkov VA, 2000, INT J CANCER, V90, P59, DOI 10.1002/(SICI)1097-0215(20000420)90:2<59::AID-IJC1>3.0.CO;2-4; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Strollo F, 1999, ADV SPACE B, V7, P99, DOI 10.1016/S1569-2574(08)60008-8; SUTHERLAND R, 1981, CANCER RES, V41, P2980; SUTHERLAND RM, 1986, CANCER RES, V46, P5320; TANIMOTO C, 1995, ENDOCR J, V42, P193, DOI 10.1507/endocrj.42.193; WALTENBERGER J, 1998, ANGIOGENESIS, V2, P115; White RJ, 2001, NATURE, V409, P1115, DOI 10.1038/35059243; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YUHAS JM, 1977, CANCER RES, V37, P3639; Zhau HE, 1997, IN VITRO CELL DEV-AN, V33, P375	53	149	159	0	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					604	+		10.1096/fj.01-0673fje	http://dx.doi.org/10.1096/fj.01-0673fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919168				2022-12-25	WOS:000174203700003
J	Conway, C; McCulloch, R; Ginger, ML; Robinson, NP; Browitt, A; Barry, JD				Conway, C; McCulloch, R; Ginger, ML; Robinson, NP; Browitt, A; Barry, JD			Ku is important for telomere maintenance, but not for differential expression of telomeric VSG genes, in African trypanosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; BINDING PROTEIN KU; ANTIGENIC VARIATION; SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; HOMOLOGOUS RECOMBINATION; LENGTH MAINTENANCE; FISSION YEAST; BRUCEI; END	Trypanosome antigenic variation, involving differential expression of variant surface glycoprotein (VSG) genes, has a strong association with telomeres and with DNA recombination. All expressed VSGs are telomeric, and differential activation involves recombination into the telomeric environment or silencing/activation of subtelomeric promoters. A number of pathogen contingency gene systems associated with immune evasion involve telomeric loci, which has prompted speculation that chromosome ends provide conditions conducive for the operation of rapid gene switching mechanisms. Ku is a protein associated with eukaryotic telomeres that is directly involved in DNA recombination and in gene silencing. We have tested the hypothesis that Ku in trypanosomes is centrally involved in differential VSG expression. We show, via the generation of null mutants, that trypanosome Ku is closely involved in telomere length maintenance, more so for a transcriptionally active than an inactive telomere, but exhibits no detectable influence on DNA double strand break repair. The absence of Ku and the consequent great shortening of telomeres had no detectable influence either on the rate of VSG switching or on the silencing of the telomeric promoters of the VSG subset that is expressed in the tsetse fly.	Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, Glasgow G11 6NU, Lanark, Scotland	University of Glasgow	Barry, JD (corresponding author), Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, 56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.	j.d.barry@biol.gla.ac.uk		Ginger, Michael/0000-0002-9643-8482; Robinson, Nick/0000-0002-6094-1924				Aravind L, 2001, GENOME RES, V11, P1365, DOI 10.1101/gr.181001; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Barry JD, 1998, MOL BIOCHEM PARASIT, V91, P93, DOI 10.1016/S0166-6851(97)00193-X; Barry JD, 2001, ADV PARASIT, V49, P1, DOI 10.1016/S0065-308X(01)49037-3; Baumann P, 2000, MOL BIOL CELL, V11, P3265, DOI 10.1091/mbc.11.10.3265; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; Blundell PA, 1996, MOL BIOCHEM PARASIT, V76, P215, DOI 10.1016/0166-6851(95)02560-X; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; BRUN R, 1979, ACTA TROP, V36, P289; Chaves I, 1999, EMBO J, V18, P4846, DOI 10.1093/emboj/18.17.4846; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; Deitsch KW, 1997, MICROBIOL MOL BIOL R, V61, P281, DOI 10.1128/.61.3.281-293.1997; del Portillo HA, 2001, NATURE, V410, P839, DOI 10.1038/35071118; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Doherty AJ, 2001, FEBS LETT, V500, P186, DOI 10.1016/S0014-5793(01)02589-3; Donelson JE, 1998, MOL BIOCHEM PARASIT, V91, P51, DOI 10.1016/S0166-6851(97)00209-0; Downs JA, 1999, MOL CELL BIOL, V19, P6260; Dubrana K, 2001, CURR OPIN CELL BIOL, V13, P281, DOI 10.1016/S0955-0674(00)00210-6; Featherstone C, 1999, CURR BIOL, V9, pR759, DOI 10.1016/S0960-9822(00)80005-6; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Ferreira MG, 2001, MOL CELL, V7, P55, DOI 10.1016/S1097-2765(01)00154-X; Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GRAHAM SV, 1990, PARASITOLOGY, V101, P361, DOI 10.1017/S0031182000060558; Grandin N, 2000, MOL CELL BIOL, V20, P8397, DOI 10.1128/MCB.20.22.8397-8408.2000; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Horn D, 2000, EMBO J, V19, P2332, DOI 10.1093/emboj/19.10.2332; Horn D, 1997, EMBO J, V16, P7422, DOI 10.1093/emboj/16.24.7422; HORN D, 1995, CELL, V83, P555, DOI 10.1016/0092-8674(95)90095-0; Kass-Eisler A, 2000, TRENDS BIOCHEM SCI, V25, P200, DOI 10.1016/S0968-0004(00)01557-7; KITTEN T, 1990, P NATL ACAD SCI USA, V87, P6077, DOI 10.1073/pnas.87.16.6077; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Mages GJ, 1996, J BIOL CHEM, V271, P7910, DOI 10.1074/jbc.271.14.7910; Manolis KG, 2001, EMBO J, V20, P210, DOI 10.1093/emboj/20.1.210; McCulloch R, 1997, MOL CELL BIOL, V17, P833, DOI 10.1128/MCB.17.2.833; McCulloch R, 1999, GENE DEV, V13, P2875, DOI 10.1101/gad.13.21.2875; Milne GT, 1996, MOL CELL BIOL, V16, P4189; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; Munoz-Jordan JL, 2001, EMBO J, V20, P579, DOI 10.1093/emboj/20.3.579; Murti KG, 1999, P NATL ACAD SCI USA, V96, P14436, DOI 10.1073/pnas.96.25.14436; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PAYS E, 1983, NUCLEIC ACIDS RES, V11, P8137, DOI 10.1093/nar/11.23.8137; Pays E, 2001, MOL BIOCHEM PARASIT, V114, P1, DOI 10.1016/S0166-6851(01)00242-0; Peterson SE, 2001, NAT GENET, V27, P64, DOI 10.1038/83778; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; Robinson NP, 1999, MOL CELL BIOL, V19, P5839; Rudenko G, 1998, TRENDS MICROBIOL, V6, P113, DOI 10.1016/S0966-842X(97)01200-6; RUDENKO G, 1995, CELL, V83, P547, DOI 10.1016/0092-8674(95)90094-2; Scherf A, 2001, CURR OPIN MICROBIOL, V4, P409, DOI 10.1016/S1369-5274(00)00227-7; SCHWARTZ JL, 1989, MUTAT RES, V216, P111, DOI 10.1016/0165-1161(89)90011-3; Shore D, 2001, CURR OPIN GENET DEV, V11, P189, DOI 10.1016/S0959-437X(00)00178-7; Siede W, 1996, GENETICS, V142, P91; Stringer JR, 2001, INFECT IMMUN, V69, P627, DOI 10.1128/IAI.69.2.627-639.2001; Vanhamme L, 2001, TRENDS PARASITOL, V17, P338, DOI 10.1016/S1471-4922(01)01922-5; VegaPalas MA, 1997, NAT GENET, V15, P232, DOI 10.1038/ng0397-232; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Woodard RL, 2001, J BIOL CHEM, V276, P15423, DOI 10.1074/jbc.M010752200	61	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21269	21277		10.1074/jbc.M200550200	http://dx.doi.org/10.1074/jbc.M200550200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11919193	hybrid			2022-12-25	WOS:000176286000021
J	Ji, ZS; Miranda, RD; Newhouse, YM; Weisgraber, KH; Huang, YD; Mahley, RW				Ji, ZS; Miranda, RD; Newhouse, YM; Weisgraber, KH; Huang, YD; Mahley, RW			Apolipoprotein E4 potentiates amyloid beta peptide-induced lysosomal leakage and apoptosis in neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; CENTRAL-NERVOUS-SYSTEM; RADICAL OXIDATIVE STRESS; ALZHEIMERS-DISEASE; NEURITE OUTGROWTH; FIBRIL FORMATION; TERMINAL DOMAIN; TRANSGENIC MICE; CYTOCHROME-C	We assessed the isoform-specific effects of apolipoprotein (apo) E on the response of Neuro-2a cells to the amyloid beta peptide (Abeta1-42). As determined by the intracellular staining pattern and the release of beta-hexosaminidase into the cytosol, apoE4-transfected cells treated with aggregated Abeta1-42 showed a greater tendency toward lysosomal leakage than neo- or apoE3-transfected cells. Abeta1-42 caused significantly greater cell death and more than 2-fold greater DNA fragmentation in apoE4-secreting than in apoE3-secreting or control cells. H2O2 or staurosporine enhanced cell death and apoptosis in apoE4-transfected cells but not in apoE3-transfected cells. A caspase-9 inhibitor abolished the potentiation of Abeta1-42-induced apoptosis by apoE4. Similar results were obtained with conditioned medium from cells secreting apoE3 or apoE4. Cells preincubated for 4 h with a source of apoE3 or apoE4, followed by removal of apoE from the medium and from the cell surface, still exhibited the isoform-specific response to Abeta1-42, indicating that the potentiation of apoptosis required intracellular apoE, presumably in the endosomes or lysosomes. Studies of phospholipid (dimyristoylphosphatidylcholine) bilayer vesicles encapsulating 5-(and-6)-carboxyfluoreseein dye showed that apoE4 remodeled and disrupted the phospholipid vesicles to a greater extent than apoE3 or apoE2. In response to Abeta1-42, vesicles containing apoE4 were disrupted to a greater extent than those containing apoE3. These findings are consistent with apoE4 forming a reactive molecular intermediate that avidly binds phospholipid and may insert into the lysosomal membrane, destabilizing it and causing lysosomal leakage and apoptosis in response to Abeta1-42.	Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Mahley, RW (corresponding author), Univ Calif San Francisco, Gladstone Inst Neurol Dis, POB 419100, San Francisco, CA 94141 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47660] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aleshkov SB, 1999, BIOCHEMISTRY-US, V38, P8918, DOI 10.1021/bi982002q; Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Boland K, 1996, J BIOL CHEM, V271, P18032, DOI 10.1074/jbc.271.30.18032; Burdick D, 1997, BRAIN RES, V746, P275, DOI 10.1016/S0006-8993(96)01262-0; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Butterfield DA, 1997, CHEM RES TOXICOL, V10, P495, DOI 10.1021/tx960130e; Buttini M, 2000, NEUROSCIENCE, V97, P207, DOI 10.1016/S0306-4522(00)00069-5; Carter DB, 2001, ANN NEUROL, V50, P468, DOI 10.1002/ana.1134; CASTANO EM, 1995, BIOCHEM J, V306, P599, DOI 10.1042/bj3060599; Cataldo AM, 1996, J NEUROSCI, V16, P186; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; DONG LM, 1994, J BIOL CHEM, V269, P22358; Drouet B, 2001, J NEUROCHEM, V76, P117, DOI 10.1046/j.1471-4159.2001.00047.x; Du YS, 1997, J NEUROCHEM, V69, P299; Estus S, 1997, J NEUROSCI, V17, P7736; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HERZ J, 1994, ANN NY ACAD SCI, V737, P14, DOI 10.1111/j.1749-6632.1994.tb44298.x; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; HOWLETT DR, 1995, NEURODEGENERATION, V4, P23, DOI 10.1006/neur.1995.0003; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; Hughes SR, 1998, P NATL ACAD SCI USA, V95, P3275, DOI 10.1073/pnas.95.6.3275; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; Isahara K, 1999, NEUROSCIENCE, V91, P233, DOI 10.1016/S0306-4522(98)00566-1; JI ZS, 1993, J BIOL CHEM, V268, P10160; Jolivalt C, 2000, FREE RADICAL BIO MED, V28, P129, DOI 10.1016/S0891-5849(99)00232-4; Jordan J, 1998, J NEUROSCI, V18, P195; Kaback M M, 1977, Prog Clin Biol Res, V18, P267; Kagedal K, 2001, BIOCHEM J, V359, P335, DOI 10.1042/0264-6021:3590335; Kalman J, 2000, NEUROBIOL AGING, V21, P555, DOI 10.1016/S0197-4580(00)00150-0; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; KLAUSNER RD, 1985, J BIOL CHEM, V260, P3719; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Kruger R, 1999, ANN NEUROL, V45, P611, DOI 10.1002/1531-8249(199905)45:5<611::AID-ANA9>3.0.CO;2-X; Kuida K, 2000, INT J BIOCHEM CELL B, V32, P121, DOI 10.1016/S1357-2725(99)00024-2; LaDu MJ, 1997, J NEUROSCI RES, V49, P9, DOI 10.1002/(SICI)1097-4547(19970701)49:1<9::AID-JNR2>3.0.CO;2-H; LaFerla FM, 1996, J CLIN INVEST, V98, P1626, DOI 10.1172/JCI118957; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Lendon CL, 2000, EUR J NEUROSCI, V12, P2235, DOI 10.1046/j.1460-9568.2000.00113.x; Li YP, 1996, BRAIN RES, V738, P196, DOI 10.1016/S0006-8993(96)00733-0; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Mazziotti M, 1998, BIOCHEM J, V332, P517, DOI 10.1042/bj3320517; McLaurin J, 2000, J STRUCT BIOL, V130, P259, DOI 10.1006/jsbi.2000.4289; Michikawa M, 2001, J NEUROSCI, V21, P7226, DOI 10.1523/JNEUROSCI.21-18-07226.2001; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; MORROW J, 2000, PROTEIN SCI S1, V9, P101; Morrow JA, 2000, BIOCHEMISTRY-US, V39, P11657, DOI 10.1021/bi000099m; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Narita M, 1997, J NEUROCHEM, V69, P1904; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; Pedersen WA, 2000, J NEUROCHEM, V74, P1426, DOI 10.1046/j.1471-4159.2000.0741426.x; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Pillot T, 1999, J NEUROCHEM, V72, P230, DOI 10.1046/j.1471-4159.1999.0720230.x; Pillot T, 1999, J NEUROCHEM, V73, P1626, DOI 10.1046/j.1471-4159.1999.0731626.x; Pillot T, 1997, EUR J BIOCHEM, V243, P650, DOI 10.1111/j.1432-1033.1997.00650.x; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Qiu ZH, 1999, J NEUROCHEM, V73, P1393, DOI 10.1046/j.1471-4159.1999.0731393.x; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Ramassamy C, 1999, FREE RADICAL BIO MED, V27, P544, DOI 10.1016/S0891-5849(99)00102-1; Roberg K, 2001, LAB INVEST, V81, P149, DOI 10.1038/labinvest.3780222; Roberg K, 1999, FREE RADICAL BIO MED, V27, P1228, DOI 10.1016/S0891-5849(99)00146-X; Rodrigues CMP, 2000, MOL MED, V6, P936, DOI 10.1007/BF03401828; Roth KA, 2001, J NEUROPATH EXP NEUR, V60, P829, DOI 10.1093/jnen/60.9.829; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SWANSON J, 1987, J CELL BIOL, V104, P1217, DOI 10.1083/jcb.104.5.1217; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.00218.x; Troy CM, 2000, J NEUROSCI, V20, P1386; UEDA K, 1994, BRAIN RES, V639, P240, DOI 10.1016/0006-8993(94)91736-1; Uetsuki T, 1999, J NEUROSCI, V19, P6955, DOI 10.1523/JNEUROSCI.19-16-06955.1999; Ulery PG, 2000, J CLIN INVEST, V106, P1077, DOI 10.1172/JCI11455; Varadarajan S, 2000, J STRUCT BIOL, V130, P184, DOI 10.1006/jsbi.2000.4274; WEINSTEIN JN, 1981, BIOCHIM BIOPHYS ACTA, V647, P270, DOI 10.1016/0005-2736(81)90255-8; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; Xu J, 2001, J CEREBR BLOOD F MET, V21, P702, DOI 10.1097/00004647-200106000-00008; Yang AJ, 1998, J NEUROSCI RES, V52, P691, DOI 10.1002/(SICI)1097-4547(19980615)52:6<691::AID-JNR8>3.0.CO;2-3; Yang DS, 1999, NEUROSCIENCE, V90, P1217, DOI 10.1016/S0306-4522(98)00561-2; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	113	140	146	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21821	21828		10.1074/jbc.M112109200	http://dx.doi.org/10.1074/jbc.M112109200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11912196	hybrid			2022-12-25	WOS:000176286000091
J	Vabulas, RM; Braedel, S; Hilf, N; Singh-Jasuja, H; Herter, S; Ahmad-Nejad, P; Kirschning, CJ; da Costa, C; Rammensee, HG; Wagner, H; Schild, H				Vabulas, RM; Braedel, S; Hilf, N; Singh-Jasuja, H; Herter, S; Ahmad-Nejad, P; Kirschning, CJ; da Costa, C; Rammensee, HG; Wagner, H; Schild, H			The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the toll-like receptor 2/4 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ENDOCYTOSIS; CUTTING EDGE; MATURATION; ANTIGEN; CHAPERONE; IMMUNITY; SIGNAL; HSP90; HSP70; CD91	The heat shock protein Gp96 has been shown to induce specific immune responses. On one hand, this phenomenon is based on the specific interaction with CD91 that mediates endocytosis and results in major histocompatibility complex class I-restricted representation of the Gp96-associated peptides. On the other hand, Gp96 induces activation of professional antigen-presenting cells, resulting in the production of pro-inflammatory cytokines and up-regulation of costimulatory molecules by unknown mechanisms. In this study, we have analyzed the consequences of Gp96 interaction with cells expressing different Toll-like receptors (TLRs) and with bone marrow-derived dendritic cells from mice lacking functional TLR2 and/or TLR4 molecules. We find that the Gp96-TLR2/4 interaction results in activation of nuclear factor kappaB-driven reporter genes and mitogen- and stress-activated protein kinases and induces IkappaBalpha degradation. Bone marrow-derived dendritic cells of C3H/HeJ and more pronounced C3H/HeJ/ TLR2(-/-) mice fail to respond to Gp96. Interestingly, activation of bone marrow-derived dendritic cells depends on endocytosis of Gp96 molecules. Our results provide, for the first time, the molecular basis for understanding the Gp96-mediated activation of antigen-presenting cells by describing the simultaneous stimulation of the innate and adaptive immune system. This feature explains the remarkable ability of Gp96 to induce specific immune responses against tumors and pathogens.	Univ Tubingen, Inst Cell Biol, Dept Immunol, D-72076 Tubingen, Germany; Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany	Eberhard Karls University of Tubingen; Technical University of Munich	Schild, H (corresponding author), Univ Tubingen, Inst Cell Biol, Dept Immunol, Morgenstelle 15, D-72076 Tubingen, Germany.	hansjoerg.schild@uni-tuebingen.de	Vabulas, R. Martin/D-3506-2011					Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; ARNOLD D, 1995, J EXP MED, V182, P885, DOI 10.1084/jem.182.3.885; Arnold-Schild D, 1999, J IMMUNOL, V162, P3757; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Berwin B, 2001, J BIOL CHEM, V276, P21083, DOI 10.1074/jbc.M101836200; BEVAN MJ, 1976, J IMMUNOL, V117, P2233; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; BLACHERE NE, 1993, J IMMUNOTHER, V14, P352, DOI 10.1097/00002371-199311000-00016; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Chen W, 1999, J IMMUNOL, V162, P3212; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; Golenbock DT, 2001, NAT IMMUNOL, V2, P286, DOI 10.1038/86289; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Kaisho T, 2001, TRENDS IMMUNOL, V22, P78, DOI 10.1016/S1471-4906(00)01811-1; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Randow F, 2001, NAT CELL BIOL, V3, P891, DOI 10.1038/ncb1001-891; ROCK KL, 1990, SCIENCE, V249, P918, DOI 10.1126/science.2392683; Schild H, 1999, CURR OPIN IMMUNOL, V11, P109, DOI 10.1016/S0952-7915(99)80019-3; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Singh-Jasuja H, 2000, J EXP MED, V191, P1965, DOI 10.1084/jem.191.11.1965; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; SRIVASTAVA PK, 1991, CURR OPIN IMMUNOL, V3, P654; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; UDONO H, 1994, J IMMUNOL, V152, P5398; UDONO H, 1994, P NATL ACAD SCI USA, V301, P919; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Wagner H, 2001, IMMUNITY, V14, P499, DOI 10.1016/S1074-7613(01)00144-3; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; Zheng H, 2001, J IMMUNOL, V167, P6731, DOI 10.4049/jimmunol.167.12.6731	35	377	399	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20847	20853		10.1074/jbc.M200425200	http://dx.doi.org/10.1074/jbc.M200425200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11912201	hybrid			2022-12-25	WOS:000176204500096
J	Feng, JW; Wehbi, H; Roberts, MF				Feng, JW; Wehbi, H; Roberts, MF			Role of tryptophan residues in interfacial binding of phosphatidylinositol-specific phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM SPECTRA; ANGLE NEUTRON-SCATTERING; BACILLUS-CEREUS; CRYSTAL-STRUCTURE; ACTIVE-SITE; ACTIVATION; PROTEINS; DOMAIN; INHIBITION	The phosphatidylinositol-specific phospholipase C (PI-PLC) from Bacillus thuringiensis exhibits several types of interfacial activation. In the crystal structure of the closely related Bacillus cereus PI-PLC, the rim of the active site is flanked by a short helix B and a loop that show an unusual clustering of hydrophobic amino acids. Two of the seven tryptophans in PI-PLC are among the exposed residues. To test the importance of these residues in substrate and activator binding, we prepared several mutants of Trp-47 (in helix B) and Trp-242 (in the loop). Two other tryptophans, Trp-178 and Trp-280, which are not near the rim, were mutated as controls. Kinetic (both phosphotransferase and cyclic phosphodiesterase activities), fluorescence, and vesicle binding analyses showed that both Trp-47 and Trp-242 residues are important for the enzyme to bind to interfaces, both activating zwitterionic and substrate anionic surfaces. Partitioning of the enzyme to vesicles is decreased more than 10-fold for either W47A or W242A, and removal of both tryptophans (W47A/W242A) yields enzyme with virtually no affinity for phospholipid surfaces. Replacement of either tryptophan with phenylalanine or isoleucine has moderate effects on enzyme affinity for surfaces but yields a fully active enzyme. These results are used to describe how the enzyme is activated by interfaces.	Boston Coll, Merkert Chem Ctr, Boston, MA 02167 USA	Boston College	Roberts, MF (corresponding author), Boston Coll, Merkert Chem Ctr, 2609 Beacon St, Boston, MA 02167 USA.	mary.roberts@bc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060418] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60418] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Braman J, 1996, Methods Mol Biol, V57, P31; Ellis MV, 1998, J BIOL CHEM, V273, P11650, DOI 10.1074/jbc.273.19.11650; GARIGAPATI VR, 1995, J COLLOID INTERF SCI, V169, P486, DOI 10.1006/jcis.1995.1059; Gassler CS, 1997, BIOCHEMISTRY-US, V36, P12802, DOI 10.1021/bi971102d; Gelb MH, 1999, CURR OPIN STRUC BIOL, V9, P428, DOI 10.1016/S0959-440X(99)80059-1; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; HENDRICKSON HS, 1992, BIOCHEMISTRY-US, V31, P12169, DOI 10.1021/bi00163a028; LEWIS KA, 1993, BIOCHEMISTRY-US, V32, P8836, DOI 10.1021/bi00085a014; LIN TL, 1986, J AM CHEM SOC, V108, P3499, DOI 10.1021/ja00272a055; LIN TL, 1987, J PHYS CHEM-US, V91, P406, DOI 10.1021/j100286a031; Lookene A, 1997, J BIOL CHEM, V272, P766, DOI 10.1074/jbc.272.2.766; Malenbaum SE, 1998, BIOCHEMISTRY-US, V37, P17915, DOI 10.1021/bi981230h; MARQUES MB, 1989, J CLIN MICROBIOL, V27, P2451, DOI 10.1128/JCM.27.11.2451-2454.1989; MENGAUD J, 1991, MOL MICROBIOL, V5, P367, DOI 10.1111/j.1365-2958.1991.tb02118.x; Moser J, 1997, J MOL BIOL, V273, P269, DOI 10.1006/jmbi.1997.1290; Nakamura M, 1998, J BIOCHEM, V123, P1145; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Pigault C, 1999, BIOCHEM BIOPH RES CO, V254, P484, DOI 10.1006/bbrc.1998.9965; Qian XQ, 1998, BIOCHEMISTRY-US, V37, P6513, DOI 10.1021/bi972650u; SHASHIDHAR MS, 1990, BIOCHIM BIOPHYS ACTA, V1042, P410, DOI 10.1016/0005-2760(90)90172-T; Stieglitz K, 1999, J BIOL CHEM, V274, P35367, DOI 10.1074/jbc.274.50.35367; Sumandea M, 1999, BIOCHEMISTRY-US, V38, P16290, DOI 10.1021/bi9921384; Verza G, 2000, BBA-BIOMEMBRANES, V1464, P27, DOI 10.1016/S0005-2736(99)00244-8; VOLWERK JJ, 1994, BIOCHEMISTRY-US, V33, P3464, DOI 10.1021/bi00178a002; Wallace BA, 1999, ADV EXP MED BIOL, V467, P789; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Williams RL, 1999, BBA-MOL CELL BIOL L, V1441, P255, DOI 10.1016/S1388-1981(99)00150-X; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Wu YQ, 1997, BIOCHEMISTRY-US, V36, P8514, DOI 10.1021/bi970560j; ZHONG L, 1994, BIOCHEMISTRY-US, V33, P2121; Zhou C, 1997, BIOCHEMISTRY-US, V36, P347, DOI 10.1021/bi960601w; Zhou C, 1997, BIOCHEMISTRY-US, V36, P10089, DOI 10.1021/bi970846o; Zhou C, 1998, BIOCHEMISTRY-US, V37, P16430, DOI 10.1021/bi980601r	37	50	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19867	19875		10.1074/jbc.M200938200	http://dx.doi.org/10.1074/jbc.M200938200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11912206	hybrid			2022-12-25	WOS:000175894800083
J	Li, JM; Shah, AM				Li, JM; Shah, AM			Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED SUPEROXIDE FORMATION; PLASMA-MEMBRANE; NAD(P)H OXIDASE; EXPRESSION; ACTIN; GP91(PHOX); FLAVOCYTOCHROME; BIOSYNTHESIS; COMPONENTS; MATURATION	The phagocyte-type NADPH oxidase expressed in endothelial cells differs from the neutrophil enzyme in that it exhibits low level activity even in the absence of agonist stimulation, and it generates intracellular reactive oxygen species. The mechanisms underlying these differences are unknown. We studied the subcellular location of (a) oxidase subunits and (b) functionally active enzyme in unstimulated endothelial cells. Confocal microscopy revealed co-localization of the major oxidase subunits, i.e. gp91(phox), p22(phox), p47(phox), and p67(phox), in a mainly perinuclear distribution. Plasma membrane biotinylation experiments confirmed the predominantly (>90%) intracellular distribution of gp91(phox) and p22(phox). After subcellular protein fractionation, similar to50% of the gp91(phox) (91-kDa band), p22(phox), p67(phox), and p40(phox) pools and similar to30% of the p47(phox) were present in the 1475 X g ("nucleus-rich") fraction. Likewise, similar to50% of total NADPH-dependent O-2(.-) production (assessed by lucigenin (5 muM) chemiluminescence) was found in the 1475 x g fraction. Co-immunoprecipitation studies and measurement of NADPH-dependent reactive oxygen species production (cytochrome c reduction assay) demonstrated that p22(phox), gp91(phox), p47(phox), p67(phox), and p40(phox) existed as a functional complex in the cytoskeletal fraction. These results indicate that, in contrast to the neutrophil enzyme, a substantial proportion of the NADPH oxidase in unstimulated endothelial cells exists as a preassembled intracellular complex associated with the cytoskeleton.	Kings Coll London, GKT Sch Med, Dept Cardiol, London SE5 9PJ, England	University of London; King's College London	Shah, AM (corresponding author), Kings Coll London, GKT Sch Med, Dept Cardiol, Bessemer Rd, London SE5 9PJ, England.	ajay.shah@kcl.ac.uk		Shah, Ajay/0000-0002-6547-0631				Al-Mehdi AB, 1998, CIRC RES, V83, P730, DOI 10.1161/01.RES.83.7.730; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bayraktutan U, 1998, CARDIOVASC RES, V38, P256, DOI 10.1016/S0008-6363(98)00003-0; BAYRAKTUTAN U, 2000, ARTERIOSCLER THROMB, V20, P1093; Crawford LE, 1996, J BIOL CHEM, V271, P26863, DOI 10.1074/jbc.271.43.26863; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; El Benna J, 1999, J LEUKOCYTE BIOL, V66, P1014; Gorlach A, 2000, CIRC RES, V87, P26, DOI 10.1161/01.RES.87.1.26; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; Hinton R. H., 1997, SUBCELLULAR FRACTION, P31; Hua J, 2000, J LEUKOCYTE BIOL, V68, P216; Inoue I, 2000, LIFE SCI, V67, P863, DOI 10.1016/S0024-3205(00)00680-9; JESAITIS AJ, 1990, J CLIN INVEST, V85, P821, DOI 10.1172/JCI114509; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; Kunsch C, 1999, CIRC RES, V85, P753, DOI 10.1161/01.RES.85.8.753; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Li AE, 1999, CIRC RES, V85, P304, DOI 10.1161/01.RES.85.4.304; Li JM, 1998, AM J PHYSIOL-HEART C, V275, pH814, DOI 10.1152/ajpheart.1998.275.3.H814; Li JM, 2001, J MOL CELL CARDIOL, V33, P1119, DOI 10.1006/jmcc.2001.1372; Li JM, 1997, J MOL CELL CARDIOL, V29, P2213, DOI 10.1006/jmcc.1997.0457; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; Mohazzab HKM, 1994, AM J PHYSIOL, V266, P2568; MOHAZZABH KM, 1994, AM J PHYSIOL-LUNG C, V267, pL815, DOI 10.1152/ajplung.1994.267.6.L815; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; PIPER HM, 1990, CELL CULTURE TECHNIQ, P178; Smith KR, 2001, AM J PHYSIOL-LUNG C, V280, pL442, DOI 10.1152/ajplung.2001.280.3.L442; Sohn HY, 2000, J BIOL CHEM, V275, P18745, DOI 10.1074/jbc.M000026200; Stitt M., 1984, METHOD ENZYMAT AN, P359; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Tamura M, 2000, BIOCHEM BIOPH RES CO, V276, P1186, DOI 10.1006/bbrc.2000.3598; Tamura M, 2000, BIOCHEM J, V349, P369, DOI 10.1042/0264-6021:3490369; Tanaka K, 1999, J BIOL CHEM, V274, P33979, DOI 10.1074/jbc.274.48.33979; Vassault A, 1983, METHOD ENZYMAT AN, P119; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; Wallach TM, 1997, BIOCHEM J, V321, P583, DOI 10.1042/bj3210583; Wientjes FB, 1997, J LEUKOCYTE BIOL, V61, P303, DOI 10.1002/jlb.61.3.303; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; Yu LX, 1999, J BIOL CHEM, V274, P4364, DOI 10.1074/jbc.274.7.4364; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; Yun S, 1998, TRANSPLANTATION, V66, P103, DOI 10.1097/00007890-199807150-00016; ZULUETA JJ, 1995, AM J RESP CELL MOL, V12, P41, DOI 10.1165/ajrcmb.12.1.7529030	43	325	337	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19952	19960		10.1074/jbc.M110073200	http://dx.doi.org/10.1074/jbc.M110073200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11893732	hybrid			2022-12-25	WOS:000175894800094
J	Butler, GS; Sim, D; Tam, E; Devine, D; Overall, CM				Butler, GS; Sim, D; Tam, E; Devine, D; Overall, CM			Mannose-binding lectin (MBL) mutants are susceptible to matrix metalloproteinase proteolysis - Potential role in human MBL deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-LIKE DOMAIN; GELATINASE-A; COMPLEMENT ACTIVATION; EXTRACELLULAR-MATRIX; SEVERE INFECTIONS; SERINE PROTEASES; VARIANT ALLELES; IV COLLAGENASE; PROTEIN; ASSOCIATION	Mannose-binding lectin (MBL) plays a critical role in innate immunity. Point mutations in the collagen-like domain (R32C, G34D, or G37E) of MBL cause a serum deficiency, predisposing patients to infections and diseases such as rheumatoid arthritis. We examined whether MBL mutants show enhanced susceptibility to proteolysis by matrix metalloproteinases (MMPs), which are important mediators in inflammatory tissue destruction. Human and rat MBL were resistant to proteolysis in the native state but were cleaved selectively within the collagen-like domain by multiple MMPs after heat denaturation. In contrast, rat MBL with mutations homologous to those of the human variants (R23C, G25D, or G28E) was cleaved efficiently without denaturation in the collagen-like domain by MMP-2 and MMP-9 (gelatinases A and B) and MMP-14 (membrane type-1 MMP), as well as by MMP-1 (collagenase-1), MMP-8 (neutrophil collagenase), MMP-3 (stromelysin-1), neutrophil elastase, and bacterial collagenase. Sites and order of cleavage of the rat MBL mutants for MMP-2 and MMP-9 were: Gly(45)-Lys(46)-->Gly(51)-Ser(52)-->Gly(63)-Gln(64)-->Asn(80)-Met(81) which differed from that of MMP-14, Gly(39)-Leu(40)-->Asn(80)-Mets(81), revealing that the MMPs were not functionally interchangeable. These sites were homologous to those cleaved in denatured human MBL. Hence, perturbation of the collagen-like structure of MBL by natural mutations or by denaturation renders MBL susceptible to MMP cleavage. MMPs are likely to contribute to MBL deficiency in individuals with variant alleles and may also be involved in clearance of MBL and modulation of the host response in normal individuals.	Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Pathol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Butler, GS (corresponding author), Univ British Columbia, Dept Oral Biol & Med Sci, JB Macdonald Bldg,2199 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	gsbutler@interchange.ubc.ca; chris.overall@ubc.ca	Butler, Georgina/GQP-7553-2022	Butler, Georgina/0000-0003-1172-1578				Arora M, 2001, J BIOL CHEM, V276, P43087, DOI 10.1074/jbc.M105455200; Bigg HF, 2001, CANCER RES, V61, P3610; Cawson T, 1998, MOL MED TODAY, V4, P130, DOI 10.1016/S1357-4310(97)01192-1; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; Colombatti A, 2000, MATRIX BIOL, V19, P289, DOI 10.1016/S0945-053X(00)00074-3; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; DAVIES EJ, 1995, ARTHRITIS RHEUM, V38, P110, DOI 10.1002/art.1780380117; DOLO V, 1994, J SUBMICR CYTOL PATH, V26, P173; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; EZEKOWITZ RAB, 1988, J EXP MED, V167, P1034, DOI 10.1084/jem.167.3.1034; FUJITA T, 1995, JPN J CANCER RES, V86, P187, DOI 10.1111/j.1349-7006.1995.tb03038.x; Gabolde M, 1999, BRIT MED J, V319, P1166, DOI 10.1136/bmj.319.7218.1166; Garred P, 1997, LANCET, V349, P236, DOI 10.1016/S0140-6736(96)08440-1; Garred P, 1999, ARTHRITIS RHEUM, V42, P2145, DOI 10.1002/1529-0131(199910)42:10<2145::AID-ANR15>3.0.CO;2-#; Garred P, 1999, J CLIN INVEST, V104, P431, DOI 10.1172/JCI6861; Garred P, 2000, J RHEUMATOL, V27, P26; Graudal NA, 2000, ARTHRITIS RHEUM, V43, P515, DOI 10.1002/1529-0131(200003)43:3<515::AID-ANR6>3.0.CO;2-T; Harrington DJ, 1996, INFECT IMMUN, V64, P1885, DOI 10.1128/IAI.64.6.1885-1891.1996; Heise CT, 2000, J IMMUNOL, V165, P1403, DOI 10.4049/jimmunol.165.3.1403; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; Kishore U, 2000, IMMUNOPHARMACOLOGY, V49, P159, DOI 10.1016/S0162-3109(00)80301-X; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; KURATA H, 1993, BIOCHEM BIOPH RES CO, V191, P1204, DOI 10.1006/bbrc.1993.1345; LIPSCOMBE RJ, 1995, IMMUNOLOGY, V85, P660; Ma Y, 1999, P NATL ACAD SCI USA, V96, P371, DOI 10.1073/pnas.96.2.371; Madsen HO, 1998, J IMMUNOL, V161, P3169; MADSEN HO, 1995, J IMMUNOL, V155, P3013; Marshall DCL, 1998, NEUROSCI LETT, V254, P97, DOI 10.1016/S0304-3940(98)00674-0; Matsushita M, 2001, IMMUNOL REV, V180, P78, DOI 10.1034/j.1600-065X.2001.1800107.x; MATSUSHITA M, 1995, BIOCHEM J, V311, P1021, DOI 10.1042/bj3111021; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Neth O, 2001, LANCET, V358, P614, DOI 10.1016/S0140-6736(01)05776-2; Ohtani K, 1999, J BIOL CHEM, V274, P13681, DOI 10.1074/jbc.274.19.13681; Okamoto T, 1997, J BIOL CHEM, V272, P6059, DOI 10.1074/jbc.272.9.6059; Overall CM, 2000, METH MOL B, V151, P79, DOI 10.1385/1-59259-046-2:079; Overall CM, 2000, J BIOL CHEM, V275, P39497, DOI 10.1074/jbc.M005932200; Parks WC, 2001, RESP RES, V2, P10, DOI 10.1186/rr33; Perides G, 1999, J NEUROSCI RES, V58, P779, DOI 10.1002/(SICI)1097-4547(19991215)58:6&lt;779::AID-JNR5&gt;3.0.CO;2-L; Peterslund NA, 2001, LANCET, V358, P637, DOI 10.1016/S0140-6736(01)05785-3; Ruiz S, 1999, J LEUKOCYTE BIOL, V66, P416, DOI 10.1002/jlb.66.3.416; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; SUPER M, 1989, LANCET, V2, P1236; Tan SM, 1996, BIOCHEM J, V319, P329, DOI 10.1042/bj3190329; Tenner AJ, 1999, CURR OPIN IMMUNOL, V11, P34, DOI 10.1016/S0952-7915(99)80007-7; THIEL S, 1989, FEBS LETT, V250, P78, DOI 10.1016/0014-5793(89)80689-1; Trinder PKE, 1996, IMMUNOLOGY, V87, P355, DOI 10.1046/j.1365-2567.1996.495559.x; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Wallis R, 1999, J BIOL CHEM, V274, P3580, DOI 10.1074/jbc.274.6.3580; Wallis R, 1999, J IMMUNOL, V163, P4953; Wallis R, 2000, J BIOL CHEM, V275, P30962, DOI 10.1074/jbc.M004030200; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Watford WT, 2001, J IMMUNOL, V167, P6593, DOI 10.4049/jimmunol.167.11.6593; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Wong NKH, 1999, MOL IMMUNOL, V36, P853, DOI 10.1016/S0161-5890(99)00106-6; Yeo SJ, 1999, ARCH VIROL, V144, P1361, DOI 10.1007/s007050050592; Yokota T, 2000, BLOOD, V96, P1723, DOI 10.1182/blood.V96.5.1723; YOKOTA Y, 1995, J BIOCHEM-TOKYO, V117, P414, DOI 10.1093/jb/117.2.414; ZUCKER S, 1987, BIOCHIM BIOPHYS ACTA, V924, P225, DOI 10.1016/0304-4165(87)90091-2	62	42	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17511	17519		10.1074/jbc.M201461200	http://dx.doi.org/10.1074/jbc.M201461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11891230	hybrid			2022-12-25	WOS:000175685100017
J	Lin, X; Taube, R; Fujinaga, K; Peterlin, BM				Lin, X; Taube, R; Fujinaga, K; Peterlin, BM			P-TEFb containing cyclin K and Cdk9 can activate transcription via RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; POLYMERASE-II; HIV-1 TAT; ELONGATION-FACTOR; IN-VITRO; HIGH-AFFINITY; KINASE; DSIF; T1; IDENTIFICATION	Different positive transcription elongation factor b (P-TEFb) complexes isolated from mammalian cells contain a common catalytic subunit (Cdk9) and the unique regulatory cyclins CycT1, CycT2a, CycT2b, or CycK. The role of CycK as a transcriptional cyclin was demonstrated in this study. First, CycK activated transcription when tethered heterologously to RNA, which required the kinase activity of Cdk9. Although this P-TEFb could phosphorylate the C-terminal domain (CTD) of RNA polymerase II (RNAPII) in vitro, in contrast to CycT1 and CycT2, CycK did not activate transcription when tethered to DNA. Interestingly, when the C termini of CycT1 and CycT2 or only the histidine-rich stretch from positions 481 to 551 in CycT1 were added to CycK, the extended chimeras activated transcription equivalently via DNA. Moreover, these transcriptional effects required the CTD of RNAPII in cells. Thus, CycK functions as P-TEFb only via RNA, which suggests the presence of cellular RNA-bound activators that require CycK for their transcriptional activity.	Univ Calif San Francisco, Mt Zion Canc Ctr, Dept Med, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Microbiol, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Immunol, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Peterlin, BM (corresponding author), Univ Calif San Francisco, Mt Zion Canc Ctr, Dept Med, Rm N215 ,2340 Sutter St, San Francisco, CA 94115 USA.	matija@itsa.ucsf.edu	TAUBE, RAN/F-2029-2012	TAUBE, RAN/0000-0002-2062-4537	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049104] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI49104-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Chen D, 1999, P NATL ACAD SCI USA, V96, P13468, DOI 10.1073/pnas.96.23.13468; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Garber ME, 1999, CURR OPIN IMMUNOL, V11, P460, DOI 10.1016/S0952-7915(99)80077-6; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; Kiernan RE, 2001, MOL CELL BIOL, V21, P7956, DOI 10.1128/MCB.21.23.7956-7970.2001; Kwak YT, 1999, J MOL BIOL, V288, P57, DOI 10.1006/jmbi.1999.2664; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MATERA AG, 1993, J CELL BIOL, V121, P715, DOI 10.1083/jcb.121.4.715; Meininghaus M, 2000, J BIOL CHEM, V275, P24375, DOI 10.1074/jbc.M001883200; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Ping YH, 2001, J BIOL CHEM, V276, P12951, DOI 10.1074/jbc.M006130200; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Reines D, 1999, CURR OPIN CELL BIOL, V11, P342, DOI 10.1016/S0955-0674(99)80047-7; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Sengupta DJ, 1999, RNA, V5, P596, DOI 10.1017/S1355838299002113; Taube R, 2002, MOL CELL BIOL, V22, P321, DOI 10.1128/MCB.22.1.321-331.2002; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	42	49	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16873	16878		10.1074/jbc.M200117200	http://dx.doi.org/10.1074/jbc.M200117200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11884399	hybrid			2022-12-25	WOS:000175564500071
J	Vermes, C; Jacobs, JJ; Zhang, J; Firneisz, G; Roebuck, KA; Glant, TT				Vermes, C; Jacobs, JJ; Zhang, J; Firneisz, G; Roebuck, KA; Glant, TT			Shedding of the interleukin-6 (IL-6) receptor (gp80) determines the ability of IL-6 to induce gp130 phosphorylation in human osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MARROW STROMAL CELLS; PROTEIN-KINASE-C; BONE-MARROW; SIGNAL-TRANSDUCTION; MYELOMA CELLS; MESSENGER-RNA; OSTEOCLAST DIFFERENTIATION; GROWTH-FACTORS; CYTOKINES; EXPRESSION	Human osteoblasts produce interleukin-6 (IL-6) and respond to IL-6 in the presence of soluble IL-6 receptor (sIL-6R), but the cell surface expression of IL-6R and the mechanism of sIL-6R production are largely unknown. Three different human osteoblast-like cell lines (MG-63, HOS, and SaOS-2) and bone marrow-derived primary human osteoblasts expressed both IL-6R and gp130 as determined by flow cytometry and immunoprecipitation. However, the membrane-bound IL-6R was nonfunctional, as significant tyrosine phosphorylation of gp130 did not occur in the presence of IL-6. Phorbol myristate acetate induced a dramatic increase of both IL-6R shedding (i.e. the production of sIL-6R) and IL-6 release in osteoblast cultures, but the cell surface expression of gp130 remained unchanged. IL-6 complexed with sIL-6R, either exogenously introduced or derived from the nonfunctional cell surface form by shedding, induced rapid tyrosine phosphorylation of gp130. This effect was inhibited by neutralizing antibodies to either sIL-6R or gp130, indicating that the gp130 activation was induced by IL-6/sIL-6R/gp130 interaction. Protein kinase C inhibitors blocked phorbol myristate acetate-induced and spontaneous shedding of IL-6R resulting in the absence of sIL-6R in the culture medium, which in turn also prevented the activation of gp130. In conclusion, human osteoblasts express cell surface IL-6R, which is unable to transmit IL-6-induced signals until it is shed into its soluble form. This unique mechanism provides the flexibility for osteoblasts to control their own responsiveness to IL-6 via the activation of an IL-6R sheddase, resulting in an immediate production of functionally active osteoblast-derived sIL-6R.	Rush Univ, Rush Presbyterian St Lukes Med Ctr, Dept Orthoped Surg, Chicago, IL 60612 USA; Rush Univ, Rush Presbyterian St Lukes Med Ctr, Dept Biochem, Chicago, IL 60612 USA; Rush Univ, Rush Presbyterian St Lukes Med Ctr, Dept Immunol Microbiol, Chicago, IL 60612 USA	Rush University; Rush University; Rush University	Glant, TT (corresponding author), Rush Univ, Rush Presbyterian St Lukes Med Ctr, Dept Orthoped Surg, 1653 W Congress Pkwy, Chicago, IL 60612 USA.		Firneisz, Gabor/AAC-9654-2021; Jacobs, Joshua/AGG-8284-2022; Zhang, Jian/A-2564-2008	Firneisz, Gabor/0000-0002-9123-8131; Zhang, Jian/0000-0002-9523-5296; Jacobs, Joshua/0000-0003-3902-7334				Adebanjo OA, 1998, J CELL BIOL, V142, P1347, DOI 10.1083/jcb.142.5.1347; Althoff K, 2001, BIOCHEM J, V353, P663, DOI 10.1042/0264-6021:3530663; Bellido T, 1996, J CLIN INVEST, V97, P431, DOI 10.1172/JCI118432; Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; Franchimont N, 1997, ENDOCRINOLOGY, V138, P5248, DOI 10.1210/en.138.12.5248; Gao Y, 1998, BONE, V22, P487, DOI 10.1016/S8756-3282(98)00040-4; Girasole G, 1999, CLIN ENDOCRINOL, V51, P801, DOI 10.1046/j.1365-2265.1999.00896.x; Glant Tibor T., 1996, Am J Ther, V3, P27, DOI 10.1097/00045391-199601000-00006; GLANT TT, 1993, J BONE MINER RES, V8, P1071; GLITZ D, 1992, TXB BIOCH CLIN CORRE, P746; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Heymann D, 2000, CYTOKINE, V12, P1455, DOI 10.1006/cyto.2000.0747; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HORIUCHI S, 1994, EUR J IMMUNOL, V24, P1945, DOI 10.1002/eji.1830240837; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Jones SA, 1998, EUR J IMMUNOL, V28, P3514, DOI 10.1002/(SICI)1521-4141(199811)28:11<3514::AID-IMMU3514>3.3.CO;2-K; Jones SA, 2001, FASEB J, V15, P43, DOI 10.1096/fj.99-1003rev; Kim CH, 1997, ENDOCR RES, V23, P181, DOI 10.3109/07435809709031852; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KISHIMOTO T, 1992, INT J IMMUNOPHARMACO, V14, P431; Lin SC, 1997, J CLIN INVEST, V100, P1980, DOI 10.1172/JCI119729; LITTLEWOOD AJ, 1991, ENDOCRINOLOGY, V129, P1513, DOI 10.1210/endo-129-3-1513; LUST JA, 1992, CYTOKINE, V4, P96, DOI 10.1016/1043-4666(92)90043-Q; Majors AK, 1997, J ORTHOPAED RES, V15, P546, DOI 10.1002/jor.1100150410; Manolagas SC, 1998, ANN NY ACAD SCI, V840, P194, DOI 10.1111/j.1749-6632.1998.tb09563.x; Modur V, 1997, J CLIN INVEST, V100, P2752, DOI 10.1172/JCI119821; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; Mullberg J, 1999, BIOCHEM SOC T, V27, P211; MULLBERG J, 1995, J IMMUNOL, V155, P5198; MullerNewen G, 1996, EUR J BIOCHEM, V236, P837, DOI 10.1111/j.1432-1033.1996.00837.x; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Muschler GF, 1997, J BONE JOINT SURG AM, V79A, P1699, DOI 10.2106/00004623-199711000-00012; Nishimura R, 1998, J BONE MINER RES, V13, P777, DOI 10.1359/jbmr.1998.13.5.777; O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301; O'Brien CA, 2000, J CELL BIOCHEM, V79, P532, DOI 10.1002/1097-4644(20001215)79:4<532::AID-JCB20>3.0.CO;2-U; Oh JW, 1996, CYTOKINE, V8, P401, DOI 10.1006/cyto.1996.0055; Romas E, 1996, J EXP MED, V183, P2581, DOI 10.1084/jem.183.6.2581; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Taga T, 1997, ANN MED, V29, P63, DOI 10.3109/07853899708998744; Thabard W, 1999, CLIN CANCER RES, V5, P2693; Thabard W, 2001, BIOCHEM J, V358, P193, DOI 10.1042/0264-6021:3580193; UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461; Vermes C, 2000, J BONE MINER RES, V15, P1756, DOI 10.1359/jbmr.2000.15.9.1756; WANG Y, 1995, J CELL BIOCHEM, V57, P610, DOI 10.1002/jcb.240570405; YAO JL, 1995, J BONE MINER RES, V10, P1417	51	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16879	16887		10.1074/jbc.M200546200	http://dx.doi.org/10.1074/jbc.M200546200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11884403	hybrid			2022-12-25	WOS:000175564500072
J	Hirbec, H; Perestenko, O; Nishimune, A; Meyer, G; Nakanishi, S; Henley, JM; Dev, KK				Hirbec, H; Perestenko, O; Nishimune, A; Meyer, G; Nakanishi, S; Henley, JM; Dev, KK			The PDZ proteins PICK1, GRIP, and syntenin bind multiple glutamate receptor subtypes - Analysis of PDZ binding motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; KINASE-C-ALPHA; AMPA RECEPTOR; INTERACTS; SURFACE; GLUR2; PHOSPHORYLATION; ORGANIZATION; RECOGNITION; SYNAPSES	Using sequence homology searches, yeast two-hybrid assays and glutathione S-transferase (GST)-pull-down approaches we have identified a series of glutamate receptor subunits that interact differentially with the PDZ proteins GRIP, PICK1, and syntenin. GST-pull-down experiments identified more interactions than detected by yeast two-hybrid assays. We report several receptor-protein interactions, strong ones include: W GRIP and syntenin with mGluR7a, mGluR4a, and mGluR6; (ii) PICK1 and GRIP with mGluR3; and (iii) syntenin with all forms of GluR1-4 and mGluR7b. We further characterized the novel mGluR7a-GRIP interaction found both in yeast two-hybrid and GST-pull-down assays and observed that mGluR7a localization overlapped with GRIP with in hippocampal neurons. The wide range of targets for PICK1, GRIP, and syntenin suggests they may represent a molecular mechanism that can concentrate and/or regulate a number of different receptors at a common site on a synapse. These data also suggest that the structural determinants involved in PDZ interactions are more complex than originally envisaged.	Univ Bristol, Sch Med, Dept Anat, MRC,Ctr Synapt Plast, Bristol BS8 1TD, Avon, England; Kyoto Univ, Dept Biol Sci, Fac Med, Kyoto 6068501, Japan	University of Bristol; Kyoto University	Dev, KK (corresponding author), Novartis Pharma AG, Nervous Syst Res, CH-4002 Basel, Switzerland.		Hirbec, Helene/ABE-4188-2021; Henley, Jeremy M/A-2776-2009	Hirbec, Helene/0000-0002-5593-5255; Dev, Kumlesh/0000-0003-4274-9119; Henley, Jeremy/0000-0003-3589-8335	Medical Research Council [G9629038] Funding Source: Medline; MRC [G9629038] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bezprozvanny I, 2001, FEBS LETT, V509, P457, DOI 10.1016/S0014-5793(01)03214-8; Boudin H, 2000, NEURON, V28, P485, DOI 10.1016/S0896-6273(00)00127-6; Chung HJ, 2000, J NEUROSCI, V20, P7258; Daw MI, 2000, NEURON, V28, P873, DOI 10.1016/S0896-6273(00)00160-4; Dev KK, 1999, NEUROPHARMACOLOGY, V38, P635, DOI 10.1016/S0028-3908(98)00230-5; Dev KK, 2001, TRENDS PHARMACOL SCI, V22, P355, DOI 10.1016/S0165-6147(00)01684-9; Dev KK, 2000, J NEUROSCI, V20, P7252; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Dong HL, 1999, J NEUROSCI, V19, P6930, DOI 10.1523/JNEUROSCI.19-16-06930.1999; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Hsueh YP, 1998, NEURON, V21, P1227, DOI 10.1016/S0896-6273(00)80641-8; KOHLER M, 1994, J BIOL CHEM, V269, P17367; Koroll M, 2001, J BIOL CHEM, V276, P10646, DOI 10.1074/jbc.M010647200; Lin WJ, 2001, BIOCHEM J, V354, P635, DOI 10.1042/0264-6021:3540635; Matsuda S, 2000, EMBO J, V19, P2765, DOI 10.1093/emboj/19.12.2765; Osten P, 2000, NEURON, V27, P313, DOI 10.1016/S0896-6273(00)00039-8; Perez JL, 2001, J NEUROSCI, V21, P5417, DOI 10.1523/JNEUROSCI.21-15-05417.2001; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wyszynski M, 1999, J NEUROSCI, V19, P6528; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; Ye B, 2000, NEURON, V26, P603, DOI 10.1016/S0896-6273(00)81198-8	29	114	118	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15221	15224		10.1074/jbc.C200112200	http://dx.doi.org/10.1074/jbc.C200112200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11891216	Green Published, hybrid			2022-12-25	WOS:000175510400001
J	Steinert, JR; Wyatt, AW; Poston, L; Jacob, R; Mann, GE				Steinert, JR; Wyatt, AW; Poston, L; Jacob, R; Mann, GE			Preeclampsia is associated with altered Ca2+ regulation and nitric oxide production in human fetal venous endothelial cells	FASEB JOURNAL			English	Article						intracellular calcium; human umbilical vein; histamine; cGMP; Gd3+	NORMAL-PREGNANCY; DEPENDENT RELAXATION; RESISTANCE ARTERIES; LIPID-PEROXIDATION; HEME OXYGENASE; PLACENTAL BED; SYNTHASE; WOMEN; ENTRY; HISTAMINE	Preeclampsia (PE) is a leading cause of maternal hypertension in pregnancy, fetal growth restriction, premature birth, and fetal and maternal mortality (1). Activation and dysfunction of the maternal and fetal endothelium in PE may be the consequence of increased oxidative stress associated with circulating lipid peroxides (2-4), and in cases of severe maternal hypertension, uterine and umbilical artery waveforms are abnormal (5). We have investigated PE-associated abnormalities in the regulation of intracellular Ca2+ ([Ca2+](i)) and cyclic guanosine monophosphate (cGMP) production (index of nitric oxide [NO]) in human fetal umbilical vein endothelial cells. Basal [Ca2+](i) was slightly elevated in PE cells, whereas agonist-stimulated Ca2+ entry was reduced in cells from PE compared with normal term or age-matched preterm pregnancies. Furthermore, PE cells exhibited a decreased permeability to Ba2+ but an increased permeability to Mn2+ and Gd3+, suggesting that PE is associated with phenotypic alterations in fetal endothelial cation channel(s). Basal and histamine-stimulated cGMP levels were elevated in PE compared with preterm or normal cells, implying an increased NO production in PE. However, immunoblots for endothelial NO synthase (eNOS) and soluble guanylyl cyclase (sGC) revealed reduced eNOS expression in PE and preterm cells, with negligible changes in sGC levels. This study provides important and novel insights into abnormalities of fetal endothelial cells isolated from women with PE, revealing an altered cation membrane permeability and activity of eNOS-sGC pathway. As these changes are sustained in culture in vitro, this may reflect long-term "programming" of the fetal cardiovascular system.	Kings Coll London, GKT Sch Biomed Sci, Ctr Cardiovasc Biol & Med, London SE1 1UL, England	University of London; King's College London	Mann, GE (corresponding author), Kings Coll London, GKT Sch Biomed Sci, Ctr Cardiovasc Biol & Med, New Hunts House,Rm 2-34B,Guys Campus, London SE1 1UL, England.	giovanni.mann@kcl.ac.uk	Steinert, Joern/ABB-4561-2020; Steinert, Joern/A-6678-2008; Steinert, Joern R/AAI-2742-2020	Steinert, Joern/0000-0003-1640-0845; Steinert, Joern R/0000-0003-1640-0845; Mann, Giovanni/0000-0001-7311-2044				AbdAlla S, 2001, NAT MED, V7, P1003, DOI 10.1038/nm0901-1003; Ashworth JR, 1997, BRIT J OBSTET GYNAEC, V104, P1152, DOI 10.1111/j.1471-0528.1997.tb10939.x; Barber A, 2001, FASEB J, V15, P1158, DOI 10.1096/fj.00-0376com; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; Bertrand C, 1999, AM J OBSTET GYNECOL, V180, P650, DOI 10.1016/S0002-9378(99)70268-1; BOGLE RG, 1992, BRIT J PHARMACOL, V105, P768, DOI 10.1111/j.1476-5381.1992.tb09053.x; Brennecke SP, 1997, CLIN SCI, V93, P51, DOI 10.1042/cs0930051; Broad LM, 1996, BIOCHEM J, V316, P759, DOI 10.1042/bj3160759; BROWN MA, 1995, CLIN EXP PHARMACOL P, V22, P781, DOI 10.1111/j.1440-1681.1995.tb01937.x; Chappell LC, 1999, LANCET, V354, P810, DOI 10.1016/S0140-6736(99)80010-5; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Cockell AP, 1997, HYPERTENSION, V30, P247, DOI 10.1161/01.HYP.30.2.247; Di Iorio R, 1998, EUR J OBSTET GYN R B, V76, P65, DOI 10.1016/S0301-2115(97)00159-0; Esplin MS, 2001, NEW ENGL J MED, V344, P867, DOI 10.1056/NEJM200103223441201; Faxen M., 2001, Archives of Gynecology and Obstetrics, V265, P45, DOI 10.1007/s004040000152; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Green J, 2000, J AM SOC NEPHROL, V11, P1188, DOI 10.1681/ASN.V1171188; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; HUBEL CA, 1989, AM J OBSTET GYNECOL, V161, P1025, DOI 10.1016/0002-9378(89)90778-3; Hyrc KB, 2000, CELL CALCIUM, V27, P75, DOI 10.1054/ceca.1999.0092; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; Kohler R, 1998, J HYPERTENS, V16, P1149, DOI 10.1097/00004872-199816080-00011; Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933; Kwan HY, 2000, J BIOL CHEM, V275, P6758, DOI 10.1074/jbc.275.10.6758; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; LYALL F, 1995, AM J OBSTET GYNECOL, V173, P714, DOI 10.1016/0002-9378(95)90328-3; LYALL F, 1994, J HYPERTENS, V12, P1339; Mahdy Z, 1998, J PHYSIOL-LONDON, V508, P609, DOI 10.1111/j.1469-7793.1998.00609.x; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Matteo R, 1998, AM J OBSTET GYNECOL, V178, P402, DOI 10.1016/S0002-9378(98)80033-1; MCCARTHY AL, 1993, AM J OBSTET GYNECOL, V168, P1323, DOI 10.1016/0002-9378(93)90389-Z; Morgan AJ, 1998, J PHYSIOL-LONDON, V513, P83, DOI 10.1111/j.1469-7793.1998.083by.x; Morgan AJ, 1996, BIOCHEM J, V320, P505; Nanno H, 1998, PRENAT NEONAT MED, V3, P222; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Oguogho A, 1996, CLIN AUTON RES, V6, P153, DOI 10.1007/BF02281902; OHTA A, 1989, BIOCHIM BIOPHYS ACTA, V984, P151, DOI 10.1016/0005-2736(89)90210-1; Orpana AK, 1996, AM J OBSTET GYNECOL, V174, P1056, DOI 10.1016/S0002-9378(96)70350-2; Paltauf-Doburzynska J, 1998, J PHYSIOL-LONDON, V513, P369, DOI 10.1111/j.1469-7793.1998.369bb.x; Parra MC, 2001, AM J OBSTET GYNECOL, V184, P497, DOI 10.1067/mob.2001.110311; Pascoal IF, 1998, J CLIN INVEST, V101, P464, DOI 10.1172/JCI557; Poston L, 1996, J HUM HYPERTENS, V10, P391; Ranta VH, 1998, HYPERTENS PREGNANCY, V17, P307, DOI 10.3109/10641959809009604; ROBERTSON WB, 1967, J PATHOL BACTERIOL, V93, P581, DOI 10.1002/path.1700930219; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; Shaamash AH, 2001, INT J GYNECOL OBSTET, V72, P127, DOI 10.1016/S0020-7292(00)00314-3; Silver RK, 1996, AM J OBSTET GYNECOL, V175, P1013, DOI 10.1016/S0002-9378(96)80044-5; SOBREVIA L, 1995, J PHYSIOL-LONDON, V489, P183, DOI 10.1113/jphysiol.1995.sp021040; SOWERS JR, 1989, AM J OBSTET GYNECOL, V161, P441, DOI 10.1016/0002-9378(89)90539-5; Suzuki Y, 2000, BRIT J PHARMACOL, V131, P37, DOI 10.1038/sj.bjp.0703529; Takacs P, 2001, FASEB J, V15, P279; TRUDINGER BJ, 1985, AM J OBSTET GYNECOL, V152, P155, DOI 10.1016/S0002-9378(85)80016-8; Walsh SW, 2000, FASEB J, V14, P1289, DOI 10.1096/fj.14.10.1289; Wang J, 1998, J NEPHROL, V11, P53; WANG YI, 1994, HYPERTENS PREGNANCY, V13, P171, DOI 10.3109/10641959409009570	56	58	63	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3					721	+		10.1096/fj.01-0916fje	http://dx.doi.org/10.1096/fj.01-0916fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923225				2022-12-25	WOS:000174755900005
J	Piccinini, G; Bacchiocchi, R; Serresi, M; Vivani, C; Rossetti, S; Gennaretti, C; Cabonari, D; Fazioli, F				Piccinini, G; Bacchiocchi, R; Serresi, M; Vivani, C; Rossetti, S; Gennaretti, C; Cabonari, D; Fazioli, F			A ligand-inducible epidermal growth factor receptor/anaplastic lymphoma kinase chimera promotes mitogenesis and transforming properties in 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; ACTIVATED PROTEIN-KINASE; PHOSPHOLIPASE-C-GAMMA; ANAPLASTIC LYMPHOMA; MOLECULAR CHARACTERIZATION; KI-1 LYMPHOMA; ALK; GENE; SPECIFICITY; SHC	Oncogenic rearrangements of the anaplastic lymphoma kinase (ALK) gene, encoding a receptor type tyrosine kinase, are frequently associated with anaplastic large cell lymphomas. Such rearrangements juxtapose the intracellular domain of ALK to 5'-end sequences belonging to different genes and create transforming fusion proteins. To understand how the oncogenic versions of ALK contribute to lymphomagenesis, it is important to analyze the biological effects and the biochemical properties of this receptor under controlled conditions of activation. To this aim, we constructed chimeric receptor molecules in which the extracellular domain of the ALK kinase is replaced by the extracellular, ligand-binding domain of the epidermal growth factor receptor (EGFR). Upon transfection in NIH 3T3 fibroblasts, the EGFR/ALK chimera was correctly synthesized and transported to the cell surface, where it was fully functional in forming high versus low affinity EGF-binding sites and transducing an EGF-dependent signal intracellularly. Overexpression of the EGFR/ALK chimera in NIH 3T3 was sufficient to induce the malignant phenotype; the appearance of the transformed phenotype was, however, conditionally dependent on the administration of EGF. Moreover, the EGFR/ALK chimera was significantly more active in inducing transformation and DNA synthesis than the wild type EGFR when either was expressed at similar levels in NIH 3T3 cells. Comparative analysis of the biochemical pathways implicated in the transduction of mitogenic signals did not show any increased ability of the EGFR/ALK to phosphorylate PLC-gamma and MAPK compared with the EGFR. On the contrary, EGFR/ALK showed to have a consistently greater effect on phosphatidylinositol 3-kinase activity compared with the EGFR, indicating that this enzyme plays a major role in mediating the mitogenic effects of ALK in NIH 3T3 cells.	Univ Ancona, Inst Internal Med, Cellular & Mol Biol Lab, I-60020 Ancona, Italy; Univ Ancona, Inst Urol, I-60020 Ancona, Italy	Marche Polytechnic University; Marche Polytechnic University	Fazioli, F (corresponding author), Univ Ancona, Inst Internal Med, Cellular & Mol Biol Lab, Via Tronto 10-A, I-60020 Ancona, Italy.	fazioli@popcsi.unian.it						AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Falini B, 1998, AM J PATHOL, V153, P875, DOI 10.1016/S0002-9440(10)65629-5; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Harlow E., 1988, ANTIBODIES LABORATOR, P341; HERBST R, 1991, J BIOL CHEM, V266, P19908; Hernandez L, 1999, BLOOD, V94, P3265; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; KADIN ME, 1994, J CLIN ONCOL, V12, P884, DOI 10.1200/JCO.1994.12.5.884; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lamant L, 1999, BLOOD, V93, P3088; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LONARDO F, 1990, New Biologist, V2, P992; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MASON DY, 1990, BRIT J HAEMATOL, V74, P161; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SALCINI AE, 1994, ONCOGENE, V9, P2827; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SEEDORF K, 1992, MOL CELL BIOL, V12, P4347, DOI 10.1128/MCB.12.10.4347; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SHIOTA M, 1994, ONCOGENE, V9, P1567; Slupianek A, 2001, CANCER RES, V61, P2194; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; Souttou B, 2001, J BIOL CHEM, V276, P9526, DOI 10.1074/jbc.M007333200; STEIN H, 1991, ANN ONCOL, V2, P33, DOI 10.1093/annonc/2.suppl_2.33; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Tort F, 2001, LAB INVEST, V81, P419, DOI 10.1038/labinvest.3780249; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Trinei M, 2000, CANCER RES, V60, P793; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Weber D, 2000, CANCER RES, V60, P5284; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551	61	23	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22231	22239		10.1074/jbc.M111145200	http://dx.doi.org/10.1074/jbc.M111145200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11919185	hybrid			2022-12-25	WOS:000176313600018
J	Maxwell, RA; Welch, WH; Horodyski, FM; Schegg, KM; Schooley, DA				Maxwell, RA; Welch, WH; Horodyski, FM; Schegg, KM; Schooley, DA			Juvenile hormone diol kinase - II. Sequencing, cloning, and molecular modeling of juvenile hormone-selective diol kinase from Manduca sexta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; P-LOOP; CRYSTAL-STRUCTURE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; FAMILY; MOTIF; GTP; MECHANISM; CLEAVAGE; IDENTIFICATION	The gene sequence of Manduca sexta juvenile hormone diol kinase (JHDK) codes for an enzyme that has 59% sequence identity to Drosophila melanogaster sarcoplasmic calcium-binding protein-2 (dSCP2). JHDK and dSCP2 are similar to G-proteins with three conserved sequence elements involved in purine nucleotide binding. Both proteins contain two pairs of EF-hand motifs. Characterization and partial purification of the D. melanogaster homolog of M. sexta JHDK from adult D. melanogaster gave material with JHDK activity. This activity has an experimental pI and molecular mass that are nearly identical to those of dSCP2. Moreover, D. melanogaster phosphotransferase activity has very similar chromatographic retention in three systems compared with M. sexta JHDK. Substrate docking to three-dimensional models of JHDK has shown that the three conserved nucleotide-binding elements surround the putative substrate-binding site and align with conserved sequence elements of p21(Ras) and adenylate kinase. D. melanogaster dSCP2 is a homolog of M. sexta JHDK, and these proteins constitute a novel kinase family that binds nucleotides using the scaffold of an SCP (Protein Data Bank code 2SCP).	Univ Nevada, Dept Biochem, Reno, NV 89557 USA; Ohio Univ, Dept Biomed Sci, Athens, OH 45701 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; University System of Ohio; Ohio University	Schooley, DA (corresponding author), Univ Nevada, Dept Biochem, 1664 N Virginia St, Reno, NV 89557 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; COX JA, 1981, BIOCHEMISTRY-US, V20, P5430, DOI 10.1021/bi00522a012; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; de Rinaldis M, 1998, J MOL BIOL, V284, P1211, DOI 10.1006/jmbi.1998.2248; deKort CAD, 1996, ARCH INSECT BIOCHEM, V33, P1, DOI 10.1002/(SICI)1520-6327(1996)33:1&lt;1::AID-ARCH1&gt;3.0.CO;2-2; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DURUSSEL I, 1993, BIOCHEMISTRY-US, V32, P2394, DOI 10.1021/bi00060a034; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Feyereisen R., 1985, P391; Gombos Z, 2001, J BIOL CHEM, V276, P22529, DOI 10.1074/jbc.M010508200; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L; INGLIS AS, 1983, METHOD ENZYMOL, V91, P324; Izard T, 2000, EMBO J, V19, P2690, DOI 10.1093/emboj/19.11.2690; Kelly LE, 1997, INSECT BIOCHEM MOLEC, V27, P783, DOI 10.1016/S0965-1748(97)00062-3; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; Llorca O, 1997, J STRUCT BIOL, V118, P31, DOI 10.1006/jsbi.1996.3832; Lo Conte L, 2000, NUCLEIC ACIDS RES, V28, P257, DOI 10.1093/nar/28.1.257; Matte A, 1996, J MOL BIOL, V256, P126, DOI 10.1006/jmbi.1996.0072; Matte A, 1997, J BIOL CHEM, V272, P8105, DOI 10.1074/jbc.272.13.8105; Maxwell RA, 2002, J BIOL CHEM, V277, P21874, DOI 10.1074/jbc.M201510200; Maxwell RA, 2002, ANAL BIOCHEM, V305, P40, DOI 10.1006/abio.2002.5660; MILNERWHITE EJ, 1991, J MOL BIOL, V221, P751; Nelson TJ, 1996, P NATL ACAD SCI USA, V93, P13808, DOI 10.1073/pnas.93.24.13808; Orengo CA, 1999, CURR OPIN STRUC BIOL, V9, P374, DOI 10.1016/S0959-440X(99)80051-7; PISZKIEW.D, 1970, BIOCHEM BIOPH RES CO, V40, P1173, DOI 10.1016/0006-291X(70)90918-6; Rety S, 1999, NAT STRUCT BIOL, V6, P89; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schlauderer GJ, 1996, J MOL BIOL, V256, P223, DOI 10.1006/jmbi.1996.0080; SEGALAS I, 1995, FEBS LETT, V371, P171, DOI 10.1016/0014-5793(95)00844-Y; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Thompson PR, 1998, J BIOL CHEM, V273, P14788, DOI 10.1074/jbc.273.24.14788; Truman JW, 1999, NATURE, V401, P447, DOI 10.1038/46737; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; Vetter IR, 1999, Q REV BIOPHYS, V32, P1, DOI 10.1017/S0033583599003480; Via A, 2000, J MOL BIOL, V303, P455, DOI 10.1006/jmbi.2000.4151; VIJAYKUMAR S, 1992, J MOL BIOL, V224, P413, DOI 10.1016/0022-2836(92)91004-9; Zarembinski TI, 1998, P NATL ACAD SCI USA, V95, P15189, DOI 10.1073/pnas.95.26.15189; [No title captured]	43	27	34	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21882	21890		10.1074/jbc.M201509200	http://dx.doi.org/10.1074/jbc.M201509200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11909870	hybrid			2022-12-25	WOS:000176286000099
J	Li, HC; Lee, TH; Avraham, H				Li, HC; Lee, TH; Avraham, H			A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; PROTEIN; ACTIVATION; CTIP; LOCALIZATION; ASSOCIATION; EXPRESSION; COMPLEX	Germ-line mutations in BRCA1 predispose individuals to breast and ovarian cancers. We observed a novel endogenous association of BRCA1 with Nmi (N-Mye-interacting protein) in breast cancer cells. Nmi was found to interact specifically with BRCA1, both in vitro and in vivo, by binding to two major domains in BRCA1, amino acid residues 298-683 and 1301-1863. Homodimerization of Nmi enhanced its association with BRCA1 Nmi functioned as an adaptor molecule to recruit c-Mye to a complex containing Nmi-c-Myc-BRCAL Because c-Myc can activate transcription of the human telomerase reverse transcriptase gene (hTERT), we addressed the role of BRCA1 and Nmi in modulating c-Myc-induced hTERT promoter activity. Although Nmi or BRCA1 alone had no effect on c-Myc induced hTERT promoter activity, BRCA1 together with Nmi significantly inhibited this c-Myc induced hTERT promoter activity (similar to75% inhibition). Two mutated forms of BRCA1, a missense (A1708E) and a nonsense (Y1853X) that have been identified in familial breast cancers, associated with Nmi and c-Myc but failed to suppress c-Myc-induced hTERT promoter activity. These results demonstrate a novel pathogenic mechanism whereby mutations in BRCA1, via a novel transcription factor complex containing BRCA1, c-Myc, and Nmi, impair inhibition of c-Mye-induced hTERT promoter activity, which allows sustained activation of telomerase, a key enzyme in carcinogenesis.	Harvard Univ, Inst Med, Div Expt Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center	Avraham, H (corresponding author), Harvard Univ, Inst Med, Div Expt Med, Beth Israel Deaconess Med Ctr, 4 Blackfan Circle, Boston, MA 02115 USA.	havraham@caregroup.harvard.edu		Avraham, Hava/0000-0002-7545-3640	NATIONAL CANCER INSTITUTE [R21CA087290, R01CA076226] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051456] Funding Source: NIH RePORTER; NCI NIH HHS [CA76226, R21CA87290] Funding Source: Medline; NHLBI NIH HHS [HL51456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; BANGE FC, 1994, J BIOL CHEM, V269, P1091; Bao JX, 1996, ONCOGENE, V12, P2171; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Falchetti ML, 1999, ONCOGENE, V18, P1515, DOI 10.1038/sj.onc.1202438; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Lee ND, 1999, J INTERF CYTOK RES, V19, P1245, DOI 10.1089/107999099312902; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Oh S, 1999, BIOCHEM BIOPH RES CO, V263, P361, DOI 10.1006/bbrc.1999.1366; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; Takakura M, 1999, CANCER RES, V59, P551; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang Q, 2000, ONCOGENE, V19, P6152, DOI 10.1038/sj.onc.1203974; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199; Zhou XJ, 2000, J BIOL CHEM, V275, P21364, DOI 10.1074/jbc.M003177200; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	40	104	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20965	20973		10.1074/jbc.M112231200	http://dx.doi.org/10.1074/jbc.M112231200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11916966	hybrid			2022-12-25	WOS:000176204500111
J	Murakami, M; Horowitz, A; Tang, SQ; Ware, JA; Simons, M				Murakami, M; Horowitz, A; Tang, SQ; Ware, JA; Simons, M			Protein kinase C (PKC) delta regulates PKC alpha activity in a syndecan-4-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY ENDOTHELIAL-CELLS; CYTOPLASMIC DOMAIN; PROLIFERATION; GROWTH; PHOSPHORYLATION; MIGRATION; INHIBITION; EXPRESSION; ACTIVATION; MORPHOLOGY	The phosphorylation state of Ser(183) in the cytoplasmic tail of syndecan-4 determines the binding affinity of the cytoplasmic tail to phosphatidylinositol 4,5-bisphosphate (PIP2), the capacity of the tail to multimerize, and its ability to activate protein kinase C (PKC) alpha. We sought to identify the kinase responsible for this phosphorylation and to determine its downstream effects on PKCalpha activity and on endothelial cell function. Among several PKC isoenzymes tested, only PKCalpha and -delta were able to specifically phosphorylate Ser(183) in vitro. However, studies in cultured endothelial cells showed that the phosphorylation level of syndecan-4 was significantly reduced in endothelial cells expressing a dominant negative (DN) PKCS but not a DN PKCalpha mutant. Syndecan-4/plp(2)-dependent PKCa activity was significantly increased in PKCdelta DN cells, while PKCdelta overexpression was accompanied by decreased PKCa activity. PKCdelta-overexpressing cells exhibited a significantly lower proliferation rate and an impaired tube formation in response to FGF2, which were mirrored by similar observations in PKCa DN endothelial cells. These findings suggest that PKCdelta is the kinase responsible for syndecan-4 phosphorylation, which, in turn, attenuates the cellular response to FGF2 by reducing PKCalpha activity. The reduced PKCa activity then leads to impaired endothelial cell function. We conclude that PKCdelta regulates PKCalpha activity in a syndecan-4-dependent manner.	Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Cardiol Sect, Lebanon, NH 03756 USA; Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Angiogenesis Res Ctr, Lebanon, NH 03756 USA; Eli Lilly & Co, Indianapolis, IN 46285 USA	Dartmouth College; Dartmouth College; Eli Lilly	Simons, M (corresponding author), Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Cardiol Sect, 1 Med Ctr Dr, Lebanon, NH 03756 USA.		Simons, Michael/G-8553-2014; Horowitz, Arie/AAT-9482-2021; Horowitz, Arie/F-4628-2015	Simons, Michael/0000-0003-0348-7734; Horowitz, Arie/0000-0001-6239-1287	NHLBI NIH HHS [HL63609, HL62289, HL51043] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062289, P50HL063609, R01HL051043] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashton AW, 1999, J BIOL CHEM, V274, P20805, DOI 10.1074/jbc.274.30.20805; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; Garcia-Paramio P, 1998, BIOCHEM J, V333, P631, DOI 10.1042/bj3330631; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; Horowitz A, 1999, BIOCHEMISTRY-US, V38, P15871, DOI 10.1021/bi991363i; Horowitz A, 1998, J BIOL CHEM, V273, P25548, DOI 10.1074/jbc.273.40.25548; Horowitz A, 1998, J BIOL CHEM, V273, P10914, DOI 10.1074/jbc.273.18.10914; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; KENT KC, 1995, CIRC RES, V77, P231, DOI 10.1161/01.RES.77.2.231; Longley RL, 1999, J CELL SCI, V112, P3421; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; Rosson D, 1997, J BIOL CHEM, V272, P14950, DOI 10.1074/jbc.272.23.14950; Shizukuda Y, 1999, CIRC RES, V85, P247, DOI 10.1161/01.RES.85.3.247; Simons M, 2001, CELL SIGNAL, V13, P855, DOI 10.1016/S0898-6568(01)00190-5; Volk R, 1999, J BIOL CHEM, V274, P24417, DOI 10.1074/jbc.274.34.24417; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4	23	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20367	20371		10.1074/jbc.M202501200	http://dx.doi.org/10.1074/jbc.M202501200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11916978	hybrid			2022-12-25	WOS:000176204500035
J	Siligardi, G; Panaretou, B; Meyer, P; Singh, S; Woolfson, DN; Piper, PW; Pearl, LH; Prodromou, C				Siligardi, G; Panaretou, B; Meyer, P; Singh, S; Woolfson, DN; Piper, PW; Pearl, LH; Prodromou, C			Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50(cdc97)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; BINDING-SITE; DOMAIN; CDC37; P50(CDC37); CYCLE; RAF; HOP; IDENTIFICATION; INVOLVEMENT	In vivo activation of client proteins by Hsp90 depends on its ATPase-coupled conformational cycle and on interaction with a variety of co-chaperone proteins. For some client proteins the co-chaperone Sti1/Hop/p60 acts as a "scaffold," recruiting Hsp70 and the bound client to Hsp90 early in the cycle and suppressing ATP turnover by Hsp90 during the loading phase. Recruitment of protein kinase clients to the Hsp90 complex appears to involve a specialized co-chaperone, Cdc37p/p50(cdc37), whose binding to Hsp90 is mutually exclusive of Sti1/Hop/p60. We now show that Cdc37p/p50(cdc37), like Sti1/Hop/p60, also suppresses ATP turnover by Hsp90 supporting the idea that client protein loading to Hsp90 requires a "relaxed" ADP-bound conformation. Like Sti1/Hop/p60, Cdc37p/p50(cdc37) binds to Hsp90 as a dimer, and the suppressed ATPase activity of Hsp90 is restored when Cde37p/p50(cdc37) is displaced by the immunophilin co-chaperone Cpr6/Cyp40. However, unlike Sti1/Hop/p60, which can displace geldanamycin upon binding to Hsp90, Cdc37p/p50(cdc37) forms a stable complex with geldanamycin-bound Hsp90 and may be sequestered in geldanamycin-inhibited Hsp90 complexes in vivo.	Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, London SW3 6JB, England; Kings Coll London, Pharmaceut Opt Spect Ctr, Dept Pharm, London SE1 9NN, England; Kings Coll London, Div Life Sci, London SE1 9NN, England; Univ Sussex, Sch Biol Sci, Ctr Biolmol Design & Drug Dev, Brighton BN1 9QG, E Sussex, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; King's College London; University of London; King's College London; University of Sussex; University of London; University College London	Prodromou, C (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, 237 Fulham Rd, London SW3 6JB, England.	prodromu@icr.ac.uk	Woolfson, Dek Neil/ABC-4338-2021; Prodromou, Chrisostomos/ABA-9133-2021; Meyer, Philippe/AAC-6038-2019; Siligardi, Giuliano/AAO-7024-2020	Prodromou, Chrisostomos/0000-0003-4320-1147; Meyer, Philippe/0000-0002-6220-0679; Pearl, Laurence/0000-0002-6910-1809				Abbas-Terki T, 2000, FEBS LETT, V467, P111, DOI 10.1016/S0014-5793(00)01134-0; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Farrell A, 2000, MOL CELL BIOL, V20, P749, DOI 10.1128/MCB.20.3.749-754.2000; Freeman DJ, 1998, J CHEM SOC PERK T 2, P129, DOI 10.1039/a703530f; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; KURZ LC, 1992, BIOCHEMISTRY-US, V31, P7908, DOI 10.1021/bi00149a023; Morishima Y, 2000, J BIOL CHEM, V275, P6894, DOI 10.1074/jbc.275.10.6894; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Ramsey AJ, 2000, J BIOL CHEM, V275, P17857, DOI 10.1074/jbc.M001625200; Renzoni DA, 1996, BIOCHEMISTRY-US, V35, P15646, DOI 10.1021/bi9620969; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Setalo G, 2002, J NEUROBIOL, V50, P1, DOI 10.1002/neu.10000; Shao J, 2001, J BIOL CHEM, V276, P206, DOI 10.1074/jbc.M007583200; Siligardi G, 1998, ENANTIOMER, V3, P77; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; Smith DF, 2000, SEMIN CELL DEV BIOL, V11, P45, DOI 10.1006/scdb.1999.0350; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007	39	211	220	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20151	20159		10.1074/jbc.M201287200	http://dx.doi.org/10.1074/jbc.M201287200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11916974	hybrid			2022-12-25	WOS:000176204500010
J	Kanazawa, H; Ohsawa, K; Sasaki, Y; Kohsaka, S; Imai, Y				Kanazawa, H; Ohsawa, K; Sasaki, Y; Kohsaka, S; Imai, Y			Macrophage/microglia-specific protein Iba1 enhances membrane ruffling and Rac activation via phospholipase C-gamma-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; ACTIN STRESS FIBERS; GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; HUMAN NEUTROPHILS; BINDING PROTEIN; CHEMOTAXIS; INVOLVEMENT; RHO; KINASE	Iba1 is a macrophage/microglia-specific calcium-binding protein that is involved in RacGTPase-dependent membrane ruffling and phagocytosis. In this study, we introduced Iba1 into Swiss 3T3 fibroblasts and demonstrated the enhancement of platelet-derived growth factor (PDGF)-induced membrane ruffling and chemotaxis. Wortmannin treatment did not completely suppressed this enhanced membrane ruffling in Iba1-expressing cells, whereas it did in Iba1-nonexpressing cells, suggesting that the enhancement is mediated through a phosphatidylinositol 3-kinase (PI3K)-independent signaling pathway. Porcine aorta endothelial cells transfected with expression constructs of Iba1 and PDGF receptor add-back mutants were used to analyze the signaling pathway responsible for the Iba1-induced enhancement of membrane ruffling. In the absence of Iba1 expression, PDGF did not induced membrane ruffling in cells expressing the Tyr-1021 receptor mutant, which is capable of activating phospholipase C-gamma (PLC-gamma) but not PI3K. In contrast, in the presence of Iba1 expression, membrane ruffling was formed in cells expressing the Tyr-1021 mutant. In addition, Rac was shown to be activated during membrane ruffling in cells expressing Iba1 and the Tyr-1021 mutant. Furthermore, dominant negative forms of PLC-gamma completely suppressed PDGF-induced Iba1-dependent membrane ruffling and Rac activation. These results indicate the existence of a novel signaling pathway where PLC-gamma activates Rac in a manner dependent on Iba1.	Natl Inst Neurosci, Dept Neurochem, Kodaira, Tokyo 1878502, Japan	National Center for Neurology & Psychiatry - Japan	Kohsaka, S (corresponding author), Natl Inst Neurosci, Dept Neurochem, 4-1-1 Ogawahigashi, Kodaira, Tokyo 1878502, Japan.							Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Allen WE, 1997, J CELL SCI, V110, P707; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Arrieumerlou C, 1998, EUR J IMMUNOL, V28, P1877, DOI 10.1002/(SICI)1521-4141(199806)28:06<1877::AID-IMMU1877>3.3.CO;2-9; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; DOWNEY GP, 1994, CURR OPIN IMMUNOL, V6, P113, DOI 10.1016/0952-7915(94)90042-6; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Geijsen N, 1999, BLOOD, V94, P1121, DOI 10.1182/blood.V94.3.1121.415k04_1121_1130; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTWIG JH, 1988, CELL MOTIL CYTOSKEL, V10, P117, DOI 10.1002/cm.970100116; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HOMMA Y, 1992, J BIOL CHEM, V267, P21844; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; MA YH, 1994, J BIOL CHEM, V269, P30734; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKAJIMA K, 1993, NEUROSCI RES, V17, P187, DOI 10.1016/0168-0102(93)90047-T; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; Ohsawa K, 2000, J CELL SCI, V113, P3073; Ohsawa K, 1997, GLIA, V21, P285; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ronnstrand L, 1999, J BIOL CHEM, V274, P22089, DOI 10.1074/jbc.274.31.22089; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WENNSTROM S, 1994, ONCOGENE, V9, P651; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; Yokote K, 1996, J BIOL CHEM, V271, P5101	41	139	142	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					20026	20032		10.1074/jbc.M109218200	http://dx.doi.org/10.1074/jbc.M109218200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11916959	hybrid			2022-12-25	WOS:000175894800103
J	Ozawa, M				Ozawa, M			Lateral dimerization of the E-cadherin extracellular domain is necessary but not sufficient for adhesive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROXIMAL REGION; CELL-ADHESION; CYTOPLASMIC DOMAIN; CALCIUM-BINDING; PROTEIN INTERACTIONS; MOLECULE UVOMORULIN; COMPLEX-FORMATION; STRUCTURAL BASIS; N-CADHERIN; P120(CTN)	Cadherins are transmembrane glycoproteins involved in Ca2+-dependent cell-cell adhesion. Using L cells coexpressing E-cadherin constructs with different epitope tags, we examined the lateral dimerization of E-cadherin and its adhesive activity by co-immunoprecipitation and aggregation assays, respectively. Although the transmembrane domain is required for dimerization, tail-less constructs possessing the transmembrane domain of either N-cadherin or CD45 show dimerization and are active in aggregation assays. Two mutant constructs having either of two amino acid substitutions, W2A or substitutions that disrupt the recognition sequence for endoproteolytic enzymes involved in removal of the precursor segment, cannot form dimers and are inactive in aggregation. These monomeric proteins, like their wild-type dimerizing counterparts, retain their Ca2+-dependent resistance to trypsin digestion, suggesting that dimerization per se does not induce a large conformational change. Two other constructs, having either an amino acid substitution, D134A, or a C-terminal deletion of 70 amino acid residues, retain the ability to associate laterally but are inactive in aggregation assays. Staurosporine treatment of cells expressing the latter construct increases aggregation but does not increase the extent of lateral dimerization. Thus, lateral dimerization is necessary, but not sufficient for adhesive activity.	Kagoshima Univ, Fac Med, Dept Biochem, Kagoshima 8908520, Japan	Kagoshima University	Ozawa, M (corresponding author), Kagoshima Univ, Fac Med, Dept Biochem, Kagoshima 8908520, Japan.			Ozawa, Masayuki/0000-0002-7887-8441				Alattia JR, 1997, FEBS LETT, V417, P405, DOI 10.1016/S0014-5793(97)01333-1; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Baumgartner W, 2000, P NATL ACAD SCI USA, V97, P4005, DOI 10.1073/pnas.070052697; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Chappuis-Flament S, 2001, J CELL BIOL, V154, P231, DOI 10.1083/jcb.200103143; Chitaev NA, 1998, J CELL BIOL, V142, P837, DOI 10.1083/jcb.142.3.837; Corps E, 2001, J BIOL CHEM, V276, P30862, DOI 10.1074/jbc.M101712200; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Huber O, 1999, J CELL SCI, V112, P4415; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Koch AW, 1997, BIOCHEMISTRY-US, V36, P7697, DOI 10.1021/bi9705624; LEMMON MA, 1994, FEBS LETT, V346, P17, DOI 10.1016/0014-5793(94)00467-6; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Nieman MT, 1999, J CELL SCI, V112, P1621; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Ozawa M, 2001, J CELL SCI, V114, P503; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; REID RA, 1990, NUCLEIC ACIDS RES, V18, P5896, DOI 10.1093/nar/18.19.5896; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; Shan WS, 2000, J CELL BIOL, V148, P579, DOI 10.1083/jcb.148.3.579; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sivasankar S, 1999, P NATL ACAD SCI USA, V96, P11820, DOI 10.1073/pnas.96.21.11820; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; Takeda H, 1999, NAT STRUCT BIOL, V6, P310, DOI 10.1038/7542; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; Troxell ML, 1999, AM J PHYSIOL-CELL PH, V276, pC404, DOI 10.1152/ajpcell.1999.276.2.C404; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0	44	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19600	19608		10.1074/jbc.M202029200	http://dx.doi.org/10.1074/jbc.M202029200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11916976	hybrid			2022-12-25	WOS:000175894800049
J	Joubert, F; Mazet, JL; Mateo, P; Hoerter, JA				Joubert, F; Mazet, JL; Mateo, P; Hoerter, JA			(31)P NMR detection of subcellular creatine kinase fluxes in the perfused rat heart - Contractility modifies energy transfer pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-NUCLEOTIDE TRANSLOCASE; IN-VIVO REGULATION; OXIDATIVE-PHOSPHORYLATION; OXYGEN-CONSUMPTION; MITOCHONDRIAL RESPIRATION; SATURATION TRANSFER; METABOLIC-CONTROL; LEAST 2ND-ORDER; CARDIAC-MUSCLE; ATP	The subeellular fluxes of exchange of ATP and phosphocreatine (PCr) between mitochondria, cytosol, and ATPases were assessed by (31)P NMR spectroscopy to investigate the pathways of energy transfer in a steady state beating heart. Using a combined analysis of four protocols of inversion magnetization transfer associated with biochemical data, three different creatine kinase (CK) activities were resolved in the rat heart perfused in isovolumic control conditions: (i) a cytosolic CK functioning at equilibrium (forward, F(f) = PCr --> ATP, and reverse flux, F(r) = ATP --> PCr = 3.3 mM.s(-1)), (ii) a CK localized in the vicinity of ATPases (MM-CK bound isoform) favoring ATP synthesis (F(f) = 1.7 x F(r)), and (iii) a mitochondrial CK displaced toward PCr synthesis (Ff = 0.3 and F(r) = 2.6 mM,s(-1)). This study thus provides the first experimental evidence that the energy is carried from mitochondria to ATPases by PCr (i.e. CK shuttle) in the whole heart. In contrast, a single CK functioning at equilibrium was sufficient to describe the data when ATP synthesis was partly inhibited by cyanide (0.15 mM). In this case, ATP was directly transferred from mitochondria to cytosol suggesting that cardiac activity modified energy transfer pathways. Bioenergetic implications of the localization and activity of enzymes within myocardial cells are discussed.	Univ Paris Sud, Fac Pharm, INSERM, U446, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Hoerter, JA (corresponding author), Univ Paris Sud, Fac Pharm, INSERM, U446, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.	jacqueline.hoerter@cep.u-psud.fr		Joubert, Frederic/0000-0003-0239-1052				Aliev MK, 1997, BIOPHYS J, V73, P428, DOI 10.1016/S0006-3495(97)78082-2; ARRIODUPONT M, 1992, EUR J BIOCHEM, V207, P951, DOI 10.1111/j.1432-1033.1992.tb17129.x; Balschi JA, 1997, J MOL CELL CARDIOL, V29, P3123, DOI 10.1006/jmcc.1997.0539; BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; CHANCE B, 1955, J BIOL CHEM, V217, P385; Chung YR, 1999, AM J PHYSIOL-HEART C, V277, pH1410, DOI 10.1152/ajpheart.1999.277.4.H1410; Cieslar JH, 2000, J BIOL CHEM, V275, P6129, DOI 10.1074/jbc.275.9.6129; Crawford RM, 2001, FASEB J, V15, P102, DOI 10.1096/fj.01-0446fje; De Sousa E, 1999, CIRC RES, V85, P68; HEADRICK JP, 1994, AM J PHYSIOL, V267, pH1074, DOI 10.1152/ajpheart.1994.267.3.H1074; HOERTER JA, 1988, AM J PHYSIOL, V255, pC192, DOI 10.1152/ajpcell.1988.255.2.C192; JACOBUS WE, 1982, ARCH BIOCHEM BIOPHYS, V219, P167, DOI 10.1016/0003-9861(82)90146-1; JACOBUS WE, 1985, ANNU REV PHYSIOL, V47, P707; Jeneson JAL, 2000, AM J PHYSIOL-CELL PH, V279, pC813, DOI 10.1152/ajpcell.2000.279.3.C813; Jeneson JAL, 1996, J BIOL CHEM, V271, P27995, DOI 10.1074/jbc.271.45.27995; Joubert F, 2000, BIOPHYS J, V79, P1, DOI 10.1016/S0006-3495(00)76269-2; Joubert F, 2001, BIOPHYS J, V81, P2995, DOI 10.1016/S0006-3495(01)75940-1; Joubert F, 2001, BIOCHEMISTRY-US, V40, P2129, DOI 10.1021/bi001695j; KATZ LA, 1989, AM J PHYSIOL, V256, pH265, DOI 10.1152/ajpheart.1989.256.1.H265; Kay L, 2000, J BIOL CHEM, V275, P6937, DOI 10.1074/jbc.275.10.6937; Kemp GJ, 1998, MOL CELL BIOCHEM, V184, P249, DOI 10.1023/A:1006848726795; KORETSKY AP, 1986, BIOCHEMISTRY-US, V25, P77, DOI 10.1021/bi00349a012; Kowaltowski AJ, 2001, AM J PHYSIOL-HEART C, V280, pH649, DOI 10.1152/ajpheart.2001.280.2.H649; KUSHMERICK MJ, 1992, AM J PHYSIOL, V263, pC598, DOI 10.1152/ajpcell.1992.263.3.C598; Laclau MN, 2001, J MOL CELL CARDIOL, V33, P947, DOI 10.1006/jmcc.2001.1357; MATEO P, 1999, AM J PHYSIOL, V46, pH308; MCFARLAND EW, 1994, BIOPHYS J, V67, P1912, DOI 10.1016/S0006-3495(94)80674-5; Mekhfi H, 1996, CIRC RES, V78, P1016, DOI 10.1161/01.RES.78.6.1016; Minajeva A, 1996, PFLUG ARCH EUR J PHY, V432, P904, DOI 10.1007/s004240050214; MOREADITH RW, 1982, J BIOL CHEM, V257, P899; Nascimben L, 1996, CIRCULATION, V94, P1894, DOI 10.1161/01.CIR.94.8.1894; Saks VA, 1996, BBA-BIOENERGETICS, V1274, P81, DOI 10.1016/0005-2728(96)00011-4; SAKS VA, 1976, BIOCHEMISTRY-MOSCOW+, V41, P1701; SAKS VA, 1985, J BIOL CHEM, V260, P7757; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; Sata M, 1996, CIRCULATION, V93, P310, DOI 10.1161/01.CIR.93.2.310; Soboll S, 1999, J MOL CELL CARDIOL, V31, P857, DOI 10.1006/jmcc.1998.0925; STEPANOV V, 1997, AM J PHYSIOL, V42, pC1397; UGURBIL K, 1986, BIOCHEMISTRY-US, V25, P100, DOI 10.1021/bi00349a015; Vendelin M, 2000, AM J PHYSIOL-CELL PH, V278, pC747, DOI 10.1152/ajpcell.2000.278.4.C747; VENTURACLAPIER R, 1987, J GEN PHYSIOL, V89, P815, DOI 10.1085/jgp.89.5.815; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Wallimann T, 1996, J MUSCLE RES CELL M, V17, P177, DOI 10.1007/BF00124240; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; Ye Y, 2001, AM J PHYSIOL-HEART C, V281, pH376, DOI 10.1152/ajpheart.2001.281.1.H376; ZAHLER R, 1987, BIOPHYS J, V51, P883, DOI 10.1016/S0006-3495(87)83416-1	46	51	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18469	18476		10.1074/jbc.M200792200	http://dx.doi.org/10.1074/jbc.M200792200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886866	hybrid			2022-12-25	WOS:000175975800029
J	Potamitou, A; Neubauer, P; Holmgren, A; Vlamis-Gardikas, A				Potamitou, A; Neubauer, P; Holmgren, A; Vlamis-Gardikas, A			Expression of Escherichia coli glutaredoxin 2 is mainly regulated by ppGpp and sigma(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; DOPAMINE-INDUCED APOPTOSIS; OXYR TRANSCRIPTION FACTOR; GENE-EXPRESSION; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; RNA-POLYMERASE; GLUTATHIONE; RPOS; THIOREDOXIN	Escherichia coli glutaredoxin 2 (Grx2, encoded by grxB) differs greatly from the other two glutaredoxins in structure and catalytic properties. In a wild type strain, levels of Grx2 increased 3-fold in the stationary phase (up to 8 mug/mg). Guanosine-3',5'-tetraphoshate (ppGpp) and sigma(S), which regulate the transcription of genes in the stationary phase, dramatically affected the expression of Grx2. spoTrelA null mutants, lacking ppGpp, had very low levels of Grx2, while overproduction of full-length RelA or valine-induced starvation of isoleucine, both conditions elevating ppGpp levels, resulted in elevation of Grx2. Null mutants for the sigma(S)-specific protease ClpP, which have higher levels of sigma(S), exhibited a 3-fold Grx2 increase. sigma(S) in trans also increased the levels of Grx2. Therefore the stationary phase expression of Grx2 is determined by the sigma(S)-bound form of RNA polymerase in connection with ppGpp, while basal levels should be attributed to sigma(70)-RNA polymerase holoenzyme. Osmotic pressure and cAMP also affected the expression of Grx2, presumably via sigma(S). Furthermore, Grx2 levels were elevated in an oxyR(-) strain. In accordance with the role of Grx2 as a stationary phase protein, null mutants for grxB were shown to lyse under starvation conditions and exhibited a distorted morphology.	Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden; Univ Oulu, Dept Proc Environm Engn, Bioproc Engn Lab, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr Oulu, FIN-90014 Oulu, Finland	Karolinska Institutet; University of Oulu; University of Oulu	Holmgren, A (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden.		Fernandes, Aristi/D-2507-2015; Neubauer, Peter/N-8146-2013; Neubauer, Peter/W-4518-2019; Vlamis, Alexios/AAF-5152-2020	Neubauer, Peter/0000-0002-1214-9713; Vlamis, Alexios/0000-0001-5068-6459				Arnold CN, 2001, J BACTERIOL, V183, P2178, DOI 10.1128/JB.183.7.2178-2186.2001; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; BECKERHAPAK M, 1995, FEMS MICROBIOL LETT, V134, P39, DOI 10.1111/j.1574-6968.1995.tb07911.x; Bianchi AA, 1999, MOL MICROBIOL, V34, P1029, DOI 10.1046/j.1365-2958.1999.01664.x; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; CASHEL M, 1996, ESCHERICHIA COLI SAL, V1, P1458; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; Colland F, 2000, EMBO J, V19, P3028, DOI 10.1093/emboj/19.12.3028; Daily D, 2001, J BIOL CHEM, V276, P21618, DOI 10.1074/jbc.M101400200; Daily D, 2001, J BIOL CHEM, V276, P1335, DOI 10.1074/jbc.M008121200; Davis R., 1980, ADV BACTERIAL GENETI; Dukan S, 1998, GENE DEV, V12, P3431, DOI 10.1101/gad.12.21.3431; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; Farewell A, 1998, MOL MICROBIOL, V29, P1039, DOI 10.1046/j.1365-2958.1998.00990.x; GENTRY DR, 1993, J BACTERIOL, V175, P7982, DOI 10.1128/JB.175.24.7982-7989.1993; HENGGEARONIS R, 1993, J BACTERIOL, V175, P259, DOI 10.1128/JB.175.1.259-265.1993; HenggeAronis R, 1996, MOL MICROBIOL, V21, P887, DOI 10.1046/j.1365-2958.1996.511405.x; HENGGEARONIS R, 1996, ESCHERICHIA COLI SAL, V1, P1497; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; Kodym R, 1999, J BIOL CHEM, V274, P5131, DOI 10.1074/jbc.274.8.5131; Kvint K, 2000, J BIOL CHEM, V275, P14795, DOI 10.1074/jbc.C000128200; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; LANGE R, 1991, MOL MICROBIOL, V5, P49, DOI 10.1111/j.1365-2958.1991.tb01825.x; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Lim CJ, 2000, BBA-GENE STRUCT EXPR, V1491, P1, DOI 10.1016/S0167-4781(00)00026-9; LOEWEN PC, 1993, J BACTERIOL, V175, P2150, DOI 10.1128/JB.175.7.2150-2153.1993; LOEWEN PC, 1979, CAN J BIOCHEM CELL B, V57, P107, DOI 10.1139/o79-013; Loewen PC, 1998, CAN J MICROBIOL, V44, P707, DOI 10.1139/cjm-44-8-707; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Monje-Casas F, 2001, J BIOL CHEM, V276, P18031, DOI 10.1074/jbc.M011728200; POTAMITOU A, 2002, IN PRESS J BIOL CHEM, V277; Ritz D, 2000, J BIOL CHEM, V275, P2505, DOI 10.1074/jbc.275.4.2505; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; SARUBBI E, 1988, MOL GEN GENET, V213, P214, DOI 10.1007/BF00339584; SCHREIBER G, 1991, J BIOL CHEM, V266, P3760; Schweder T, 1996, J BACTERIOL, V178, P470, DOI 10.1128/jb.178.2.470-476.1996; Shi J, 1999, J BIOL CHEM, V274, P36039, DOI 10.1074/jbc.274.51.36039; Tao K, 1997, J BACTERIOL, V179, P5967, DOI 10.1128/jb.179.18.5967-5970.1997; Teich A, 1999, BIOTECHNOL PROGR, V15, P123, DOI 10.1021/bp980102h; Vlamis-Gardikas A, 2002, J BIOL CHEM, V277, P10861, DOI 10.1074/jbc.M111024200; VlamisGardikas A, 1997, J BIOL CHEM, V272, P11236; Xia B, 2001, J MOL BIOL, V310, P907, DOI 10.1006/jmbi.2001.4721; YIM HH, 1994, J BACTERIOL, V176, P100, DOI 10.1128/JB.176.1.100-107.1994; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	50	21	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17775	17780		10.1074/jbc.M201306200	http://dx.doi.org/10.1074/jbc.M201306200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11889138	hybrid			2022-12-25	WOS:000175685100050
J	Shin, CY; Mellon, I; Turker, MS				Shin, CY; Mellon, I; Turker, MS			Multiple mutations are common at mouse Aprt in genotoxin-exposed mismatch repair deficient cells	ONCOGENE			English	Article						multiple mutations; genetic instability; DNA mismatch repair; genotoxin exposure	TRANSCRIPTION-COUPLED REPAIR; NUCLEOTIDE-EXCISION-REPAIR; SILENT MUTATIONS; APC MUTATIONS; P53 MUTATIONS; SKIN TUMORS; MICE; HYPERMUTABILITY; UV; SPECIFICITY	Mismatch repair deficiency is known to contribute to elevated rates of mutations, particularly at mono- and dinucleotide repeat sequences. However, such repeats are often missing from the coding regions of endogenous genes. To determine the types of mutations that can occur within an endogenous gene lacking highly susceptible repeat sequences, we examined mutagenic events at the 2.3 kb mouse Aprt gene in kidney cell lines derived from mice deficient for the PMS2 and MLH1 mismatch repair proteins. The Aprt mutation rate was increased 33-fold and 3.6-20-fold for Mlh1 and Pms2 null cell lines. respectively, when compared with a wildtype kidney cell line. For the Pms2 null cells this increase resulted from both intragenic events, which were predominantly base-pairs substitutions, and loss of heterozygosity events. Almost all mutations in the,Mlh1 null cells were due to base-pair substitutions. A:T-->G:C transitions (54% of small events) were predominant in the Pms2 null cells whereas G:C-A:T transitions (36%) were the most common base-pair change in the Mlh1 null cells. Interestingly, 4-9% of the spontaneous mutant alleles in the mismatch repair deficient cells exhibited two well-separated base-pair substitution events. The percentage of mutant alleles with two and occasionally three base-pair substitutions increased when the Pms2 and Mlh1 null cells were treated with ultraviolet radiation (15-21%) and when the Mlh1 null cells were treated with hydrogen peroxide (35%). In most cases the distance separating the multiple base-pair substitutions on a given allele was in excess of 100 base-pairs, suggesting that the two mutational events were not linked directly to a single DNA lesion. The significance of these results is discussed with regards to the roles for the PMS2 and MLH1 proteins in preventing spontaneous and genotoxin-related mutations.	Oregon Hlth & Sci Univ, CROET, Portland, OR 97201 USA; Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA; Univ Kentucky, Dept Pathol & Lab Med, Lexington, KY USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Oregon Health & Science University; Oregon State University; University of Kentucky; Oregon Health & Science University	Turker, MS (corresponding author), Oregon Hlth & Sci Univ, CROET, L606,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	turkerm@ohsu.edu			NATIONAL CANCER INSTITUTE [R01CA076528, R01CA056383] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045535, R29GM045535] Funding Source: NIH RePORTER; NCI NIH HHS [CA56383, CA76528] Funding Source: Medline; NIEHS NIH HHS [1P42 ES10338] Funding Source: Medline; NIGMS NIH HHS [GM45535] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrew SE, 2000, CARCINOGENESIS, V21, P1291, DOI 10.1093/carcin/21.7.1291; Andrew SE, 1997, ONCOGENE, V15, P123, DOI 10.1038/sj.onc.1201180; Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Baross-Francis A, 1998, P NATL ACAD SCI USA, V95, P8739, DOI 10.1073/pnas.95.15.8739; Baross-Francis A, 2001, ONCOGENE, V20, P619, DOI 10.1038/sj.onc.1204138; BHATTACHARYYA NP, 1995, HUM MOL GENET, V4, P2057, DOI 10.1093/hmg/4.11.2057; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Buettner VL, 2000, MUTAT RES-FUND MOL M, V452, P219, DOI 10.1016/S0027-5107(00)00090-7; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; Glaab WE, 2000, CANCER RES, V60, P4921; Glaab WE, 1998, MUTAT RES-FUND MOL M, V398, P197, DOI 10.1016/S0027-5107(98)00004-9; Hardman RA, 2001, CANCER RES, V61, P1392; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; HARWOOD J, 1991, MOL CELL BIOL, V11, P3163, DOI 10.1128/MCB.11.6.3163; HORN PL, 1984, J CELL PHYSIOL, V121, P309, DOI 10.1002/jcp.1041210207; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KANJILAL S, 1993, CANCER RES, V53, P2961; Kato T, 1998, MUTAT RES-FUND MOL M, V422, P279, DOI 10.1016/S0027-5107(98)00208-5; Khattar NH, 1997, SOMAT CELL MOLEC GEN, V23, P51, DOI 10.1007/BF02679955; KOZAK C, 1975, SOMAT CELL GENET, V1, P371, DOI 10.1007/BF01538668; Kuraguchi M, 2000, ONCOGENE, V19, P5755, DOI 10.1038/sj.onc.1203962; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; Li GM, 1999, ONCOL RES, V11, P393; Liu HB, 2000, GENETICS, V154, P503; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; LOEB LA, 1991, CANCER RES, V51, P3075; Luria SE, 1943, GENETICS, V28, P491; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; O'Driscoll M, 1999, CARCINOGENESIS, V20, P799, DOI 10.1093/carcin/20.5.799; Ohzeki S, 1997, CARCINOGENESIS, V18, P1127, DOI 10.1093/carcin/18.6.1127; PARSONS R, 1995, CANCER RES, V55, P5548; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Phear G, 1996, MOL CELL BIOL, V16, P6516; Rose JA, 2000, CANCER RES, V60, P3404; Schmutte C, 1998, BIOL CHEM, V379, P377; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Strauss BS, 2000, MUTAT RES-FUND MOL M, V457, P93, DOI 10.1016/S0027-5107(00)00135-4; Strauss BS, 1998, GENETICS, V148, P1619; Strauss BS, 1997, CARCINOGENESIS, V18, P1445, DOI 10.1093/carcin/18.8.1445; Strauss BS, 1998, SEMIN CANCER BIOL, V8, P431, DOI 10.1006/scbi.1998.0092; Takeuchi S, 1998, CANCER RES, V58, P641; Tobi SE, 1999, CARCINOGENESIS, V20, P1293, DOI 10.1093/carcin/20.7.1293; Tomita-Mitchell A, 2000, MUTAT RES-FUND MOL M, V450, P125, DOI 10.1016/S0027-5107(00)00020-8; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; TURKER M, 1995, MUTAT RES-FUND MOL M, V329, P97, DOI 10.1016/0027-5107(95)00046-L; Turker MS, 1998, SEMIN CANCER BIOL, V8, P407, DOI 10.1006/scbi.1998.0112; Turker MS, 1999, CANCER RES, V59, P1837; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; Wang HX, 1999, J BIOL CHEM, V274, P16894, DOI 10.1074/jbc.274.24.16894; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850	57	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1768	1776		10.1038/sj.onc.1205241	http://dx.doi.org/10.1038/sj.onc.1205241			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896608				2022-12-25	WOS:000174214200015
J	Liberto, M; Cobrinik, D; Minden, A				Liberto, M; Cobrinik, D; Minden, A			Rho regulates p21(CIP1) cyclin D1, and checkpoint control in mammary epithelial cells	ONCOGENE			English	Article						Rho; p21(CIP1); cyclin D1; MCF10A; epithelial cells	ADP-RIBOSYLATION; CDC42 GTPASES; DBL FAMILY; EXPRESSION; KINASE; RAC; TRANSFORMATION; ACTIVATION; OVEREXPRESSION; GROWTH	The small GTPase Rho is important for cell cycle progression and Ras transformation in fibroblasts. However, it is unclear whether Rho is needed for proliferation in other cell types, and its targets in promoting normal cell cycle progression are unknown. Here, we demonstrate that Rho is required for G1 to S progression in MCF10A mammary epithelial cells, both in response to EGF and in response to oncogenic Ras. We describe two effects of Rho, the repression of p21(CIP1) and the induction of cyclin D1, that may underlie its role in promoting S phase entry. The Rho inhibitor, C3 exotransferase, induced p21(CIP1) both in EGF-stimulated and V12Ras-expressing cells. In addition, C3 blocked EGF-stimulated cyclin D1 promoter activity whereas V14RhoA induced the cyclin D1 promoter and cooperated with V12Ras in cyclin D1 induction. Finally, a high proportion of cells co-expressing V14RhoA and V12Ras displayed lobulated, polyploid nuclei that were actively synthesizing DNA. Our results demonstrate that Rho plays a fundamental role in promoting Ras-dependent S phase entry in mammary epithelial cells, whether in response to normal or oncogenic signaling, and indicate that in cells expressing oncogenic Ras, the activation of Rho diminishes p21(CIP1) expression, increases cyclin D1 promoter activity, and uncouples DNA synthesis from mitosis.	Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA; Columbia Univ, Sherman Fairchild Ctr, New York, NY 10027 USA	Columbia University; Columbia University	Cobrinik, D (corresponding author), Columbia Univ, Coll Phys & Surg, 650 W 168th St,BB20-09, New York, NY 10032 USA.	dc197@columbia.edu; agm24@columbia.edu			NATIONAL CANCER INSTITUTE [R01CA076342] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA76342] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKTORIES K, 1995, METHOD ENZYMOL, V256, P184; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; GILLETT C, 1994, CANCER RES, V54, P1812; GUDAS J, 1995, ONCOGENE, V11, P253; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kerkhoff E, 1998, CANCER RES, V58, P1636; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KHOSRAVIFAR R, 1997, ADV CANCER RES, V72, P72; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; LI Y, 1994, ONCOGENE, V9, P2261; Liberto M, 2000, CANCER LETT, V154, P151, DOI 10.1016/S0304-3835(00)00378-5; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MICHIELI P, 1994, CANCER RES, V54, P3391; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Sicinski P, 1997, J MAMMARY GLAND BIOL, V2, P335, DOI 10.1023/A:1026391128117; SOULE HD, 1990, CANCER RES, V50, P6075; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Tombes RM, 1998, BIOCHEM J, V330, P1451; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VAN AL, 1997, GENE DEV, V11, P2295; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhou P, 1996, CANCER RES, V56, P36	48	53	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1590	1599		10.1038/sj.onc.1205242	http://dx.doi.org/10.1038/sj.onc.1205242			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896588				2022-12-25	WOS:000173956800015
J	Mahmud, DL; G-Amlak, M; Deb, DK; Platanias, LC; Uddin, S; Wickrema, A				Mahmud, DL; G-Amlak, M; Deb, DK; Platanias, LC; Uddin, S; Wickrema, A			Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells	ONCOGENE			English	Article						forkhead transcription factors; erythropoietin; stem cell factor; acetylation; p300	CREB-BINDING PROTEIN; FACTOR GATA-1; KINASE; ACTIVATION; AKT; SIGNALS; DEATH; SURVIVAL; PATHWAY; FKHRL1	The mammalian forkhead transcription factors, FOXO3a (FKHRL1), FOXO1a (FKHR) and FOXO4 (AFX) are negatively regulated by PKB/Akt kinase. In the present study we examined the engagement of forkhead family of transcription factors in erythropoietin (Epo)- and stem cell factor (SCF)-mediated signal transduction. Our data show that all three forkhead family members, FOXO3a, FOXO1a and FOXO4 are phosphorylated in human primary erythroid progenitors. Experiments performed to determine various upstream signaling pathways contributing to phosphorylation of forkhead family members show that only PI-3-kinase pathway is required for inactivation of FOXO3a. Our data also demonstrate that during Epo deprivation FOXO3a interacts with the transcriptional coactivator p300 and such interaction is disrupted by stimulation of cells with Epo. To determine the domains in FOXO3a, mediating its interaction with p300, we performed GST pull-down assays and found that the N-terminus region containing the first 52 amino acids was sufficient for binding p300. Finally, our data demonstrate that FOXO3a and FOXO1a are acetylated during growth factor deprivation and such acetylation is reversed by stimulation with Epo. Thus mammalian forkhead transcription factors are involved in Epo and SCF signaling in primary erythroid progenitors and may play a role in the induction of apoptotic and mitogenic signals.	Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA; Univ Illinois, Med Ctr, Chicago, IL USA	University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Wickrema, A (corresponding author), Univ Chicago, Hematol Oncol Sect, MC 2115,5841 S Maryland Ave, Chicago, IL 60637 USA.	Awickrem@medicine.bsd.uchicago.edu		Uddin, Shahab/0000-0003-1886-6710				Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Huang SM, 1999, ONCOGENE, V18, P4958, DOI 10.1038/sj.onc.1202889; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Kaestner KH, 2000, GENE DEV, V14, P142; Kashii Y, 2000, BLOOD, V96, P941, DOI 10.1182/blood.V96.3.941.015k14_941_949; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRANTZ SB, 1991, BLOOD, V77, P419; Lee A, 1996, INT J OPER PROD MAN, V16, P12, DOI 10.1108/01443579610119063; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MUTA K, 1994, J CLIN INVEST, V94, P34, DOI 10.1172/JCI117327; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Tanaka M, 2001, J BIOL CHEM, V276, P15082, DOI 10.1074/jbc.M007958200; Uddin S, 2000, BIOCHEM BIOPH RES CO, V275, P16, DOI 10.1006/bbrc.2000.3266; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000	33	89	91	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1556	1562		10.1038/sj.onc.1205230	http://dx.doi.org/10.1038/sj.onc.1205230			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896584				2022-12-25	WOS:000173956800011
J	Suarez, T; Biswas, SB; Biswas, EE				Suarez, T; Biswas, SB; Biswas, EE			Biochemical defects in retina-specific human ATP binding cassette transporter nucleotide binding domain 1 mutants associated with macular degeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE GENE ABCR; ARCHAEON THERMOCOCCUS-LITORALIS; STARGARDT-DISEASE; FLUORESCENCE ANISOTROPY; MUTATIONAL ANALYSIS; MOLECULAR-GENETICS; NUMERICAL-ANALYSIS; ESTROGEN-RECEPTOR; CRYSTAL-STRUCTURE; PIGMENTOSA	The retina-specific human ABC transporter (ABCR) functions in the retinal transport system and has been implicated in several inherited visual diseases, including Stargardt disease, fundus flavimaculatus, cone-rod dystrophy, and age-related macular degeneration. We have previously described a general ribonucleotidase activity of the first nucleotide binding domain (NBD1) of human ABCR (Biswas, E. E. (2001) Biochemistry 40, 8181-8187). In this communication, we present a quantitative study analyzing the effects of certain disease-associated mutations, Gly-863 --> Ala, Pro-940 --> Arg, and Arg-943 --> Gln on the nucleotide binding, and general ribonucleotidase activities of this domain. NBD1 proteins, harboring these mutations, were created through in vitro site-specific mutagenesis and expressed in Escherichia coli. Results of the enzyme-kinetic studies indicated that these mutations altered the ATPase and CTPase activities of NBD1. The G863A and P940R mutations were found to have significant attenuation of the rates of nucleotide hydrolysis and binding affinities. On the other hand, the R943Q mutation had small, but detectable reduction in its nucleotidase activity and nucleotide binding affinity. We have measured the nucleotide binding affinities of NB protein and its mutants quantitatively by fluorescence anisotropy changes during protein binding to ethenoadenosine ATP (epsilonATP), a fluorescent ATP analogue. We have correlated the dissociation constant (K-D) and the rates of nucleotide hydrolysis (V-max) of NBD1 and its mutants with the available genetic data for these mutations.	Thomas Jefferson Univ, Dept Lab Sci, Program Biotechnol, Philadelphia, PA 19107 USA; Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Mol Biol, Stratford, NJ 08043 USA; Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Stratford, NJ 08043 USA	Jefferson University; Rowan University; Rowan University School of Osteopathic Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Biswas, EE (corresponding author), Thomas Jefferson Univ, Dept Lab Sci, Program Biotechnol, Philadelphia, PA 19107 USA.				NATIONAL EYE INSTITUTE [R15EY013113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036002] Funding Source: NIH RePORTER; NEI NIH HHS [EY13113-01] Funding Source: Medline; NIGMS NIH HHS [GM36002-13] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; Bessant DAR, 2001, CURR OPIN GENET DEV, V11, P307, DOI 10.1016/S0959-437X(00)00195-7; Biswas EE, 1999, BIOCHEMISTRY-US, V38, P10919, DOI 10.1021/bi990048t; Biswas EE, 1995, PROTEIN EXPRES PURIF, V6, P763, DOI 10.1006/prep.1995.0007; Biswas EE, 2001, BIOCHEMISTRY-US, V40, P8181, DOI 10.1021/bi0106686; Biswas EE, 2000, BIOCHEMISTRY-US, V39, P15879, DOI 10.1021/bi0015966; Booth CL, 2000, BIOCHEMISTRY-US, V39, P5518, DOI 10.1021/bi992931x; Boyer M, 2000, NUCLEIC ACIDS RES, V28, P2494, DOI 10.1093/nar/28.13.2494; BRADFORD M, 1906, ANAL BIOCHEM, V72, P248; Briggs CE, 2001, INVEST OPHTH VIS SCI, V42, P2229; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Drobnik W, 2001, GASTROENTEROLOGY, V120, P1203, DOI 10.1053/gast.2001.23250; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; EWART GD, 1994, J BIOL CHEM, V269, P10370; Greller G, 1999, J BIOL CHEM, V274, P20259, DOI 10.1074/jbc.274.29.20259; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Imasheva ES, 2001, BIOCHEMISTRY-US, V40, P13320, DOI 10.1021/bi0110138; Jacobson SG, 2000, INVEST OPHTH VIS SCI, V41, P1898; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251; Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11; Maugeri A, 1999, AM J HUM GENET, V64, P1024, DOI 10.1086/302323; Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004; MORBACH S, 1993, J BIOL CHEM, V268, P18617; Nasonkin I, 1998, HUM GENET, V102, P21, DOI 10.1007/s004390050649; Neitz M, 2000, ARCH OPHTHALMOL-CHIC, V118, P691; Ozers MS, 1997, J BIOL CHEM, V272, P30405, DOI 10.1074/jbc.272.48.30405; Papaioannou M, 2000, INVEST OPHTH VIS SCI, V41, P16; PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415; ROYER CA, 1993, ANAL BIOCHEM, V210, P91, DOI 10.1006/abio.1993.1155; ROYER CA, 1992, METHOD ENZYMOL, V210, P481; ROYER CA, 1990, ANAL BIOCHEM, V191, P287, DOI 10.1016/0003-2697(90)90221-T; Rozet JM, 1999, J MED GENET, V36, P447; Shroyer NF, 2001, INVEST OPHTH VIS SCI, V42, P2757; Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244; Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179; Zhang K, 1999, AM J OPHTHALMOL, V128, P720, DOI 10.1016/S0002-9394(99)00236-6	47	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21759	21767		10.1074/jbc.M202053200	http://dx.doi.org/10.1074/jbc.M202053200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11919200	hybrid			2022-12-25	WOS:000176286000084
J	Chuang, JZ; Zhou, H; Zhu, M; Li, SH; Li, XJ; Sung, CH				Chuang, JZ; Zhou, H; Zhu, M; Li, SH; Li, XJ; Sung, CH			Characterization of a brain-enriched chaperone, MRJ, that inhibits huntingtin aggregation and toxicity independently	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAJ; NEURONAL INTRANUCLEAR INCLUSIONS; N-TERMINAL HUNTINGTIN; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; NEGATIVE REGULATION; CULTURED NEURONS; STRIATAL NEURONS; ATPASE ACTIVITY; HUMAN HOMOLOG	Molecular chaperones are involved in a wide range of cellular events, such as protein folding and oligomeric protein complex assembly. DnaK- and DnaJ-Iike proteins are the two major classes of molecular chaperones in mammals. Recent studies have shown that DnaJ-Iike family proteins can inhibit polyglutamine aggregation, a hallmark of many neurodegenerative diseases, including Huntington's disease (HD). Although most DnaJ-Iike proteins studied are ubiquitously expressed, some have restricted expression, so it is possible that some specific chaperones may affect polyglutamine aggregation in specific neurons. In this report, we describe the isolation of a DnaJ-Iike protein MRJ and the characterization of its chaperone activity. Tissue distribution studies showed that MRJ is highly enriched in the central nervous system. In an in vitro cell model of HD, over-expressed MRJ effectively suppressed polyglutamine-dependent protein aggregation, caspase activity, and cellular toxicity. Collectively, these results suggest that MRJ has a relevant functional role in neurons.	Cornell Univ, Weill Med Coll, Margaret M Dyson Vis Res Inst, Dept Ophthalmol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Cell Biol & Anat, New York, NY 10021 USA; Emory Univ, Dept Human Genet, Atlanta, GA 30322 USA	Cornell University; Cornell University; Emory University	Sung, CH (corresponding author), Cornell Univ, Weill Med Coll, Margaret M Dyson Vis Res Inst, Dept Ophthalmol, 1300 York Ave,LC313, New York, NY 10021 USA.	chsung@mail.med.cornell.edu			NEI NIH HHS [R01 EY011307, EY11307] Funding Source: Medline; NIA NIH HHS [AG19206] Funding Source: Medline; NINDS NIH HHS [NS41449] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019206] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARBE MF, 1988, SCIENCE, V241, P1817, DOI 10.1126/science.3175623; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Berruti G, 1998, EXP CELL RES, V239, P430, DOI 10.1006/excr.1997.3879; BRIGHTMAN SE, 1995, GENE, V153, P249, DOI 10.1016/0378-1119(94)00741-A; Chai YH, 1999, J NEUROSCI, V19, P10338; CHEETHAM ME, 1992, BIOCHEM J, V284, P469, DOI 10.1042/bj2840469; CHUANG JZ, 1995, J CELL BIOL, V128, P1095, DOI 10.1083/jcb.128.6.1095; Chuang JZ, 1999, J NEUROSCI, V19, P2919; Cooper JK, 1998, HUM MOL GENET, V7, P783, DOI 10.1093/hmg/7.5.783; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Davis AR, 1998, INT J BIOCHEM CELL B, V30, P1203, DOI 10.1016/S1357-2725(98)00091-0; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; FERRANTE RJ, 1985, SCIENCE, V230, P561, DOI 10.1126/science.2931802; GAESTEL M, 1993, GENE, V128, P279, DOI 10.1016/0378-1119(93)90575-N; Genevaux P, 2001, J BIOL CHEM, V276, P7906, DOI 10.1074/jbc.M003855200; GRAVELAND GA, 1985, SCIENCE, V227, P770, DOI 10.1126/science.3155875; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; Holmberg M, 1998, HUM MOL GENET, V7, P913, DOI 10.1093/hmg/7.5.913; Hunter PJ, 1999, DEVELOPMENT, V126, P1247; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; Izawa I, 2000, J BIOL CHEM, V275, P34521, DOI 10.1074/jbc.M003492200; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; KAJIWARA K, 1993, NAT GENET, V3, P208, DOI 10.1038/ng0393-208; KATO K, 1994, J BIOL CHEM, V269, P15302; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; Lee DH, 1996, MOL CELL BIOL, V16, P4773; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Li H, 2000, NAT GENET, V25, P385, DOI 10.1038/78054; Li M, 1998, ANN NEUROL, V44, P249, DOI 10.1002/ana.410440216; Li SH, 1999, J NEUROSCI, V19, P5159; Li SH, 1998, HUM MOL GENET, V7, P777, DOI 10.1093/hmg/7.5.777; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; OH S, 1993, BIOCHIM BIOPHYS ACTA, V1174, P114, DOI 10.1016/0167-4781(93)90104-L; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; RAABE T, 1991, NUCLEIC ACIDS RES, V19, P6645, DOI 10.1093/nar/19.23.6645; RORDORF G, 1991, NEURON, V7, P1043, DOI 10.1016/0896-6273(91)90348-4; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; Seki N, 1999, J HUM GENET, V44, P185, DOI 10.1007/s100380050139; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; Tavaria M, 1996, CELL STRESS CHAPERON, V1, P23, DOI 10.1379/1466-1268(1996)001<0023:AHSGTT>2.3.CO;2; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WALL D, 1994, J BIOL CHEM, V269, P5446; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898; Yaglom JA, 1996, MOL CELL BIOL, V16, P3679; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zhou H, 2001, J BIOL CHEM, V276, P48417, DOI 10.1074/jbc.M104140200	66	86	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19831	19838		10.1074/jbc.M109613200	http://dx.doi.org/10.1074/jbc.M109613200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11896048	hybrid			2022-12-25	WOS:000175894800078
J	Shainoff, JR; Smejkal, GB; DiBello, PM; Sung, SS; Bush, LA; Di Cera, E				Shainoff, JR; Smejkal, GB; DiBello, PM; Sung, SS; Bush, LA; Di Cera, E			Allosteric effects potentiating the release of the second fibrinopeptide a from fibrinogen by thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLOW->FAST TRANSITION; POLYMERIZATION SITE; BINDING-SITES; IDENTIFICATION; INTERMEDIATE; MOLECULES; CLEAVAGE; CHAIN; FORMS	Fibrin formation depends on the release of the two N-terminal fibrinopeptides A (FPA) from fibrinogen, and its formation is accompanied by an intermediate, alpha-profibrin, which lacks only one of the FPA. In this study, we confirm that the maximal levels of alpha-profibrin found over the course of thrombin reactions with human fibrinogen are only half of what would be expected if the first and second FPA were being released independently with equal rate constants. The rapidity of release of the fibrinopeptides by thrombin had been shown to depend on an allosteric transformation that is induced when Na+ binds to a site defined by the 215-227 residues of thrombin, a transformation that results in the exposure of its fibrinogen-binding exosites transforming the thrombin from a slow to a fast acting form toward fibrinogen. When choline was substituted for sodium to transform thrombin to its slow form, the maximal levels of alpha-profibrin rose to those expected for independent release of the two FPA. Thus, it is only the fast thrombin that releases the second FPA fast, and that fast release only occurs when both FPA are present because of a partial coupling of its release with that of the first FPA. The release of the FPA from purified alpha-profibrin with the first FPA already missing is no faster than the release of any FPA. Surprisingly, we also found that slow thrombin became increasingly transformed to a fast form in the absence of sodium when the fibrinogen was elevated to high concentrations. This potentiation by concentrated fibrinogen also occurs with the recombinant mutant thrombin (Y225P), which is otherwise slow in both the presence and absence of Na+. The potentiation of thrombin by fibrinogen must be short-lived so that the thrombin reverts to its slow acting form in the interim among encounters with other fibrinogen molecules in dilute fibrinogen solutions lacking Na+, whereas at high fibrinogen concentrations the thrombin encounters other molecules before it reverts back to the slow form.	Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Cleveland State University; Washington University (WUSTL)	Shainoff, JR (corresponding author), Cleveland State Univ, Dept Chem, 2351 Euclid Ave, Cleveland, OH 44115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049413, R01HL060896, R01HL049413, R01HL016361, R01HL058141] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60896, HL58141, HL16361, HL49413] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYALA YH, 1994, J MOL BIOL, V235, P733, DOI 10.1006/jmbi.1994.1024; BAILEY K, 1951, NATURE, V167, P233, DOI 10.1038/167233a0; BLOMBACK B, 1972, J BIOL CHEM, V247, P1496; BUCALA R, 1984, P NATL ACAD SCI-BIOL, V81, P105, DOI 10.1073/pnas.81.1.105; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; DEMPFLE CE, 1993, BLOOD COAGUL FIBRIN, V4, P79, DOI 10.1097/00001721-199304010-00013; GLADNER JA, 1959, J BIOL CHEM, V234, P62; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; HURLETJENSEN A, 1982, THROMB RES, V27, P419, DOI 10.1016/0049-3848(82)90059-7; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; LORAND L, 1951, NATURE, V167, P992, DOI 10.1038/167992a0; MARSHALL AG, 1978, BIOPHYSICAL CHEM PRI, P281; MATHUR A, 1993, BIOCHEMISTRY-US, V32, P7568, DOI 10.1021/bi00080a031; Meh DA, 1996, J BIOL CHEM, V271, P23121, DOI 10.1074/jbc.271.38.23121; MEH DA, 1995, J LAB CLIN MED, V125, P384; MIYATA T, 1987, J BIOCHEM-TOKYO, V102, P93, DOI 10.1093/oxfordjournals.jbchem.a122046; NASKI MC, 1990, J BIOL CHEM, V265, P1401; OLEXA SA, 1981, J BIOL CHEM, V256, P3544; Shainoff JR, 1996, J BIOL CHEM, V271, P24129, DOI 10.1074/jbc.271.39.24129; SHAINOFF JR, 1983, ANN NY ACAD SCI, V408, P254, DOI 10.1111/j.1749-6632.1983.tb23249.x; SHAINOFF JR, 1962, J EXP MED, V116, P687, DOI 10.1084/jem.116.5.687; Shainoff JR, 2001, ANN NY ACAD SCI, V936, P147; Shainoff JR, 2001, THROMB RES, V101, P91, DOI 10.1016/S0049-3848(00)00383-2; SHAINOFF JR, 1993, AD ELECTROP, V6, P61; Spraggon G, 1997, NATURE, V389, P455, DOI 10.1038/38947; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; WEISEL JW, 1986, BIOPHYS J, V50, P1079, DOI 10.1016/S0006-3495(86)83552-4; Yang Z, 2001, BIOCHEMISTRY-US, V40, P12515, DOI 10.1021/bi011394p	29	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19367	19373		10.1074/jbc.M108804200	http://dx.doi.org/10.1074/jbc.M108804200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11891217	hybrid			2022-12-25	WOS:000175894800018
J	Yu, CF; Liu, ZX; Cantley, LG				Yu, CF; Liu, ZX; Cantley, LG			ERK negatively regulates the epidermal growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RECEPTOR TYROSINE KINASE; EPITHELIAL MORPHOGENESIS; PHOSPHOINOSITIDE 3-KINASE; NEURITE OUTGROWTH; DOCKING PROTEIN; PC12 CELLS; C-MET; BINDING; SHP2	We have examined the ability of epidermal growth factor (EGF)-stimulated ERK activation to regulate Grb2-associated binder-1 (Gab1)/phosphatidylinositol 3-kinase (PI3K) interactions. Inhibiting ERK activation with the MEK inhibitor U0126 increased the EGF-stimulated association of Gab1 with either full-length glutathione S-transferase-p85 or the p85 C-terminal Src homology 2 (SH2) domain, a result reproduced by co-immunoprecipitation of the native proteins from intact cells. This increased association of Gab1 and the PI3K correlates with an increase in PI3K activity and greater phosphorylation of Akt. This result is in direct contrast to what we have previously reported following HGF stimulation where MEK inhibition decreased the HGF-stimulated association of Gab1 and p85. In support of this divergent effect of ERK on Gab1/PI3K association following HGF and EGF stimulation, U0126 decreased the HGF-stimulated association of p85 and the Gab1 c-Met binding domain but did not alter the EGF-stimulated association of p85 and the c-Met binding domain. An examination of the mechanism of this effect revealed that the treatment of cells with EGF + U0126 increased the tyrosine phosphorylation of Gab1 as well as its association with another SH2-containing protein, SHP2. Furthermore, overexpression of a catalytically inactive form of SHP2 or pretreatment with pervanadate markedly increased EGF-stimulated Gab1 tyrosine phosphorylation. These experiments demonstrate that EGF and HGF-mediated ERK activation result in divergent effects on Gab1/PI3K signaling. HGF-stimulated ERK activation increases the Gab1/PI3K association, whereas EGF-stimulated ERK activation results in a decrease in the tyrosine phosphorylation of Gab1 and a decreased association with the PI3K. SHP2 is shown to associate with and dephosphorylate Gab1, suggesting that EGF-stimulated ERK might act through the regulation of SHP2.	Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, New Haven, CT 06520 USA	Yale University	Yu, CF (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, 333 Cedar St,LMP 2093, New Haven, CT 06520 USA.	chengfang.yu@yale.edu			NIDDK NIH HHS [DK54911] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054911] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BARROS EJG, 1995, P NATL ACAD SCI USA, V92, P4412, DOI 10.1073/pnas.92.10.4412; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Frevert EU, 1998, J BIOL CHEM, V273, P25480, DOI 10.1074/jbc.273.39.25480; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Kameda H, 2001, MOL CELL BIOL, V21, P6895, DOI 10.1128/MCB.21.20.6895-6905.2001; Karihaloo A, 2001, J BIOL CHEM, V276, P9166, DOI 10.1074/jbc.M009963200; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Korhonen JM, 1999, J BIOL CHEM, V274, P37307, DOI 10.1074/jbc.274.52.37307; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; Roshan B, 1999, J BIOL CHEM, V274, P36362, DOI 10.1074/jbc.274.51.36362; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Yu CF, 2001, J BIOL CHEM, V276, P32552, DOI 10.1074/jbc.M104493200	24	113	116	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19382	19388		10.1074/jbc.M200732200	http://dx.doi.org/10.1074/jbc.M200732200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11896055	hybrid			2022-12-25	WOS:000175894800020
J	Alliegro, MC; Alliegro, MA				Alliegro, MC; Alliegro, MA			Nuclear injection of anti-pigpen antibodies inhibits endothelial cell division	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOGENESIS; AMILORIDE; PHENOTYPE	Endothelial cell proliferation is required for angiogenesis in both embryonic and adult tissues. In rat brain tumors, it has recently been shown that the nuclear protein pigpen is expressed selectively in endothelial cells of developing microvasculature but not in the established peritumoral vessels (Blank, M., Weinschenk, T., Priemer, M., and Schluesener, H. (2001) J. Biol. Chem. 276,16464-16468). This finding suggests that pigpen may be important for promoting the undifferentiated, or "angiogenic" endothelial cell phenotype. Our studies show that pigpen protein and mRNA are expressed in actively dividing endothelial cells and down-regulated as they become confluent. Protein distribution is regulated in a cell cycle-dependent manner. We conclude that this expression pattern is important for and not simply ancillary to proliferation because nuclear microinjection of anti-pigpen Fab fragments inhibited endothelial cell division. Moreover, expression of the proliferating cell marker Ki67 was inhibited in antibody-injected cells. The absence of Ki67 suggests exit from rather than arrest within (for example, at the G(1)/S interface) the cell cycle. Together with earlier observations on the structure and expression of this molecule, our data support the hypothesis that pigpen helps regulate endothelial cell differentiation state.	Louisiana State Univ, Hlth Sci Ctr, Dept Cell Biol & Anat, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Alliegro, MC (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Cell Biol & Anat, 1901 Perdido St, New Orleans, LA 70112 USA.							Alliegro MC, 1996, DEV BIOL, V174, P288, DOI 10.1006/dbio.1996.0074; Alliegro MC, 2001, CELL BIOL INT, V25, P577, DOI 10.1006/cbir.2000.0735; ALLIEGRO MC, 1993, J EXP ZOOL, V267, P245, DOI 10.1002/jez.1402670302; Blank M, 2001, J BIOL CHEM, V276, P16464, DOI 10.1074/jbc.M100347200; Boudreau N, 1997, J CELL BIOL, V139, P257, DOI 10.1083/jcb.139.1.257; FENSELAU A, 1976, CANCER RES, V36, P3269; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Goding J., 1986, MONOCLONAL ANTIBODIE, P108; HLA T, 1995, BIOCHIM BIOPHYS ACTA, V260, P227; Kohler A, 1999, ANAT EMBRYOL, V200, P313, DOI 10.1007/s004290050282; OKEEFE RT, 1994, J CELL BIOL, V124, P249, DOI 10.1083/jcb.124.3.249; PANET R, 1986, BIOCHEM J, V239, P745, DOI 10.1042/bj2390745; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9	14	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19037	19041		10.1074/jbc.M200737200	http://dx.doi.org/10.1074/jbc.M200737200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886863	hybrid			2022-12-25	WOS:000175975800103
J	Anterola, AM; Jeon, JH; Davin, LB; Lewis, NG				Anterola, AM; Jeon, JH; Davin, LB; Lewis, NG			Transcriptional control of monolignol biosynthesis in Pinus taeda - Factors affecting monolignol ratios and carbon allocation in phenylpropanoid metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CINNAMYL ALCOHOL-DEHYDROGENASE; PHENYLALANINE AMMONIA-LYASE; ALTERED LIGNIN COMPOSITION; COA REDUCTASE CCR; LOBLOLLY-PINE; METHYLATION PATHWAY; ARABIDOPSIS-THALIANA; MOLECULAR-CLONING; DOWN-REGULATION; ENZYME	Transcriptional profiling of the phenylpropanoid pathway in Pinus taeda cell suspension cultures was carried out using quantitative real time PCR analyses of all known genes involved in the biosynthesis of the two monolignols, p-coumaryl and coniferyl alcohols (lignin/ lignan precursors). When the cells were transferred to a medium containing 8% sucrose and 20 mm potassium iodide, the monolignol/phenylpropanoid pathway was induced, and transcript levels for phenylalanine ammonia lyase, cinnamate 4-hydroxylase, p-coumarate 3-hydroxylase, 4-coumarate:CoA ligase, caffeoyl-CoA O-methyltransferase, cinnamoyl-CoA reductase, and cinnamyl alcohol dehydrogenase were coordinately up-regulated. Provision of increasing levels of exogenously supplied Phe to saturating levels (40 mM) to the induction medium resulted in further up-regulation of their transcript levels in the P. taeda cell cultures; this in turn was accompanied by considerable increases in both p-coumaryl and coniferyl alcohol formation and excretion. By contrast, transcript levels for both cinnamate 4-hydroxylase and p-coumarate 3-hydroxylase were only slightly up-regulated. These data, when considered together with metabolic profiling results and genetic manipulation of various plant species, reveal that carbon allocation to the pathway and its differential distribution into the two monolignols is controlled by Phe supply and differential modulation of cinnamate 4-hydroxylase and p-coumarate 3-hydroxylase activities, respectively. The coordinated up-regulation of phenylalanine ammonia lyase, 4-coumarate:CoA ligase, caffeoyl-CoA O-methyltransferase, cinnnamoyl-CoA reductase and cinnamyl alcohol dehydrogenase in the presence of increasing concentrations of Phe also indicates that these steps are not truly rate-limiting, because they are modulated according to metabolic demand. Finally, the transcript profile of a putative acid/ester O-methyltransferase, proposed as an alternative catalyst for O-methylation leading to coniferyl alcohol, was not up-regulated under any of the conditions employed, suggesting that it is not, in fact, involved in monolignol biosynthesis.	Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA	Washington State University	Lewis, NG (corresponding author), Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA.	lewisn@wsu.edu		Davin, Laurence/0000-0002-3248-6485; Lewis, Norman/0000-0001-5742-032X				Anterola AM, 1999, BIOCHEM BIOPH RES CO, V261, P652, DOI 10.1006/bbrc.1999.1097; ANTEROLA AM, 2002, PHYTOCHEMISTRY; ATANASSOVA R, 1995, PLANT J, V8, P465, DOI 10.1046/j.1365-313X.1995.8040465.x; Baucher M, 1999, PLANT MOL BIOL, V39, P437, DOI 10.1023/A:1006182925584; Baucher M, 1998, CRIT REV PLANT SCI, V17, P125, DOI 10.1016/S0735-2689(98)00360-8; Chabannes M, 2001, PLANT J, V28, P257, DOI 10.1046/j.1365-313X.2001.01140.x; Coruzzi GM, 2001, CURR OPIN PLANT BIOL, V4, P247, DOI 10.1016/S1369-5266(00)00168-0; Croteau R., 2000, BIOCH MOL BIOL PLANT, P1250, DOI DOI 10.1201/B11003-3; DESTEVENS G, 1953, P NATL ACAD SCI USA, V39, P80; Douglas CJ, 1996, TRENDS PLANT SCI, V1, P171, DOI 10.1016/1360-1385(96)10019-4; EBERHARDT TL, 1993, J BIOL CHEM, V268, P21088; Franke R, 2002, PLANT J, V30, P47, DOI 10.1046/j.1365-313X.2002.01267.x; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOFFNER D, 1994, PLANT PHYSIOL, V106, P625, DOI 10.1104/pp.106.2.625; GOWRI G, 1991, PLANT PHYSIOL, V97, P7, DOI 10.1104/pp.97.1.7; GRIMAPETTENATI J, 1994, PHYTOCHEMISTRY, V37, P941, DOI 10.1016/S0031-9422(00)89508-4; GROSS GG, 1973, FEBS LETT, V31, P283, DOI 10.1016/0014-5793(73)80123-1; GROSS GG, 1975, FEBS LETT, V54, P259, DOI 10.1016/0014-5793(75)80087-1; Guo DG, 2001, TRANSGENIC RES, V10, P457, DOI 10.1023/A:1012278106147; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Holton TA, 1996, METHOD ENZYMOL, V272, P275, DOI 10.1016/S0076-6879(96)72033-5; Hu WJ, 1999, NAT BIOTECHNOL, V17, P808, DOI 10.1038/11758; Jin HL, 2000, EMBO J, V19, P6150, DOI 10.1093/emboj/19.22.6150; JUNG HG, 1986, J ANIM SCI, V62, P1703, DOI 10.2527/jas1986.6261703x; Kajita S, 1996, PLANT CELL PHYSIOL, V37, P957, DOI 10.1093/oxfordjournals.pcp.a029045; KUTSUKI H, 1982, PHYTOCHEMISTRY, V21, P19, DOI 10.1016/0031-9422(82)80006-X; Lacombe E, 1997, PLANT J, V11, P429, DOI 10.1046/j.1365-313X.1997.11030429.x; Lauvergeat V, 2001, PHYTOCHEMISTRY, V57, P1187, DOI 10.1016/S0031-9422(01)00053-X; Lee D, 1997, PLANT CELL, V9, P1985, DOI 10.1105/tpc.9.11.1985; Lewis N.G., 1999, COMPR NAT PROD CHEM, V3, P617, DOI [10.1016/B978-0-08-091283-7.00085-0, DOI 10.1016/B978-0-08-091283-7.00085-0]; LEWIS NG, 1990, ANNU REV PLANT PHYS, V41, P455, DOI 10.1146/annurev.pp.41.060190.002323; Li LG, 1997, P NATL ACAD SCI USA, V94, P5461, DOI 10.1073/pnas.94.10.5461; Li LG, 1999, PLANT MOL BIOL, V40, P555, DOI 10.1023/A:1006244325250; Moller SG, 1999, J MOL BIOL, V293, P219, DOI 10.1006/jmbi.1999.2992; NOSE M, 1995, PHYTOCHEMISTRY, V39, P71, DOI 10.1016/0031-9422(95)95268-Y; OMALLEY DM, 1992, PLANT PHYSIOL, V98, P1364, DOI 10.1104/pp.98.4.1364; ROBERTS JC, 1996, CHEM PAPER, P161; RUSSELL DW, 1967, ARCH BIOCHEM BIOPHYS, V122, P257, DOI 10.1016/0003-9861(67)90150-6; Schoch G, 2001, J BIOL CHEM, V276, P36566, DOI 10.1074/jbc.M104047200; SCURFIELD G, 1973, SCIENCE, V179, P647, DOI 10.1126/science.179.4074.647; Sewalt VJH, 1997, PLANT PHYSIOL, V115, P41, DOI 10.1104/pp.115.1.41; Tamagnone L, 1998, PLANT CELL, V10, P135, DOI 10.1105/tpc.10.2.135; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; van Rensburg H, 2000, ACS SYM SER, V742, P118; vanHeerden PS, 1996, J BIOL CHEM, V271, P12350, DOI 10.1074/jbc.271.21.12350; VOO KS, 1995, PLANT PHYSIOL, V108, P85, DOI 10.1104/pp.108.1.85; WARSHAW MM, 1970, BIOPOLYMERS, V9, P1079, DOI 10.1002/bip.1970.360090910; WESTING ARTHUR H., 1965, BOT REV, V31, P381, DOI 10.1007/BF02859131; WHETTEN RW, 1992, PLANT PHYSIOL, V98, P380, DOI 10.1104/pp.98.1.380; Whitbred JM, 2000, PLANT PHYSIOL, V124, P47, DOI 10.1104/pp.124.1.47; YE ZH, 1994, PLANT CELL, V6, P1427, DOI 10.1105/tpc.6.10.1427; Zhang XH, 1997, PLANT PHYSIOL, V113, P65, DOI 10.1104/pp.113.1.65; ZUCKER M, 1965, PLANT PHYSIOL, V40, P779, DOI 10.1104/pp.40.5.779	53	115	133	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18272	18280		10.1074/jbc.M112051200	http://dx.doi.org/10.1074/jbc.M112051200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11891223	hybrid			2022-12-25	WOS:000175975800006
J	Dodon, MD; Hamaia, S; Martin, J; Gazzolo, L				Dodon, MD; Hamaia, S; Martin, J; Gazzolo, L			Heterogeneous nuclear ribonucleoprotein A1 interferes with the binding of the human T cell leukemia virus type 1 Rex regulatory protein to its response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXON SPLICING SILENCER; HTLV-I REX; MESSENGER-RNA; HNRNP A1; MAMMALIAN-CELLS; EXPORT SIGNAL; TRANSCRIPTION; VIVO; TRANSFORMATION; REQUIREMENTS	The human T cell leukemia virus, type 1 (HTLV-1), Rex protein mediates the nuclear export of unspliced and incompletely spliced viral mRNAs. This post-transcriptional activity is dependent in part on the binding of this protein to cis-regulatory sequences termed the Rex-response element (XRE). We have proposed previously that the decreased functionality exhibited by Rex in human lymphoblastoid Jurkat T cells may be linked to alterations in the Rex/XRE interactions. The analysis of the ribonucleoprotein complexes formed between Jurkat nuclear proteins and XRE-RNA led to the identification of a 36-kDa protein as heterogeneous nuclear ribonucleoprotein (hnRNP) A1. In vitro binding assays revealed that hnRNP A1 proteins were found to interfere with the binding of Rex to XRE, whereas nuclear extracts depleted of these proteins were unable to disrupt Rex-XRE complexes. Furthermore, A1 proteins from Jurkat cells were acting in a concentration-dependent manner, suggesting that the amount of these RNA-binding proteins is a critical parameter in controlling Rex activity. We indeed observed a lower level of hnRNP A1 in in vitro HTLV-1-transformed virus-producing T cells than that detected in Jurkat cells. Likewise, overexpression of hnRNP A1 proteins in 293T cells and in Jurkat cells led to a decrease in the expression of a reporter gene dependent on Rex/XRE interactions. Such a decrease was not observed when the expression of the same reporter gene by cells overexpressing hnRNP A1 was dependent on the interactions of human immunodeficiency virus Rev protein with the Rev-response element. These findings indicate that hnRNP A1 by competing with Rex for the formation of REX-XRE complexes is specifically involved in the modulation of the post-transcriptional activity of Rex.	Univ Lyon 1, Fac Med RTH Laennec, CNRS, UMR 5537, F-69372 Lyon 8, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Dodon, MD (corresponding author), INSERM, U412, 46 Allee Italie, F-69364 Lyon 07, France.		Martin, Juliette/N-5545-2016; Duc-Dodon, Madeleine/I-6580-2016; Martin, Juliette/T-9457-2019	Martin, Juliette/0000-0002-4787-0885; Martin, Juliette/0000-0002-4787-0885				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BALLAUN C, 1991, J VIROL, V65, P4408, DOI 10.1128/JVI.65.8.4408-4413.1991; BLACK AC, 1994, VIROLOGY, V200, P29, DOI 10.1006/viro.1994.1159; BLACK AC, 1995, J VIROL, V69, P6852, DOI 10.1128/JVI.69.11.6852-6858.1995; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; BOGERD HP, 1991, P NATL ACAD SCI USA, V88, P5704, DOI 10.1073/pnas.88.13.5704; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CACERES JF, 1997, EUKARYOTIC MRNA PROC, P174; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; Diaz JJ, 1996, NATURE, V379, P273, DOI 10.1038/379273a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; GAZDAR AF, 1980, BLOOD, V55, P409; GRASSMANN R, 1991, J VIROL, V65, P3721, DOI 10.1128/JVI.65.7.3721-3727.1991; GREEN PL, 1994, RETROVIRIDAE, V3, P277; GRONE M, 1994, VIROLOGY, V204, P144, DOI 10.1006/viro.1994.1518; Hamaia S, 1997, J VIROL, V71, P8514, DOI 10.1128/JVI.71.11.8514-8521.1997; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; KILEDJIAN M, 1996, RNA PROTEIN INTERACT, P127; Li HP, 1997, P NATL ACAD SCI USA, V94, P9544, DOI 10.1073/pnas.94.18.9544; MICHAEL WM, 1995, CELL, V83, P415; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; Najera I, 1999, J MOL BIOL, V285, P1951, DOI 10.1006/jmbi.1998.2473; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Parslow Tristram G., 1993, P101; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; POPOVIC M, 1983, P NATL ACAD SCI-BIOL, V80, P5402, DOI 10.1073/pnas.80.17.5402; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; Shi ST, 2000, EMBO J, V19, P4701, DOI 10.1093/emboj/19.17.4701; SHUKLA RR, 1994, J VIROL, V68, P2224, DOI 10.1128/JVI.68.4.2224-2229.1994; Si ZH, 1997, NUCLEIC ACIDS RES, V25, P861, DOI 10.1093/nar/25.4.861; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; UNGE T, 1991, P NATL ACAD SCI USA, V88, P7145, DOI 10.1073/pnas.88.16.7145; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764	41	16	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18744	18752		10.1074/jbc.M109087200	http://dx.doi.org/10.1074/jbc.M109087200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893730	hybrid			2022-12-25	WOS:000175975800067
J	Dohke, Y; Turner, RJ				Dohke, Y; Turner, RJ			Evidence that the transmembrane biogenesis of aquaporin 1 is cotranslational in intact mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO TRANSLATION; ENDOPLASMIC-RETICULUM MEMBRANE; WATER CHANNELS; TOPOLOGY; PROTEIN; TRANSLOCATION; INSERTION; CHIP28; DETERMINANTS; INTEGRATION	Most polytopic membrane proteins are believed to integrate into the membrane of the endoplasmic reticulum (ER) cotranslationally. However, recent studies with Xenopus oocytes and dog pancreatic microsomes have suggested that this is not the case for human aquaporin 1 (AQP1). These experiments indicate that membrane-spanning segments (MSSs) 2 and 4 of AQP1 do not integrate into the membrane cotranslationally so that this protein initially adopts a four MSS topology. A later maturation event involving a 180-degree rotation of MSS 3 from an N-lum/C-cyt to an N-cyt/C-lum orientation and the concomitant integration of MSSs 2 and 4 into the membrane results in the final six MSS topology. Here we examine the biogenesis of AQP1 in the human embryonic kidney cell line HEK-293T. To do this, we constructed an expression vector for a fusion protein consisting of the enhanced green fluorescent protein followed by an insertion site for AQP1 sequences and a C-terminal glycosylation tag. We then transiently transfected HEK-293T cells with this vector containing the AQP1 sequence truncated after each MSS. Glycosylation of the C-terminal tag was used to monitor its location relative to the ER lumen and consequently the membrane integration and orientation of successive MSSs. In contrast to previous studies our results indicate that AQP1 integrates into the ER membrane cotranslationally in intact HEK-293T cells.	NIDCR, Membrane Biol Sect, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Turner, RJ (corresponding author), NIDCR, Membrane Biol Sect, Gene Therapy & Therapeut Branch, NIH, Bldg 10,Rm 1A01,10 Ctr Dr MSC 1190, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000415, Z01DE000415] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; Bayle D, 1997, J BIOL CHEM, V272, P19697, DOI 10.1074/jbc.272.32.19697; Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; Gerelsaikhan T, 2000, J BIOL CHEM, V275, P40471, DOI 10.1074/jbc.M007751200; GRAHAM JM, 1992, CELL BIOL LABFAX, P7; Hermansson M, 2001, J MOL BIOL, V313, P1171, DOI 10.1006/jmbi.2001.5108; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; Lu Y, 2000, MOL BIOL CELL, V11, P2973, DOI 10.1091/mbc.11.9.2973; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Nilsson I, 2000, J BIOL CHEM, V275, P6207, DOI 10.1074/jbc.275.9.6207; Ota K, 1998, MOL CELL, V2, P495, DOI 10.1016/S1097-2765(00)80149-5; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; Ren G, 2001, P NATL ACAD SCI USA, V98, P1398, DOI 10.1073/pnas.041489198; SHI LB, 1995, BIOCHEMISTRY-US, V34, P8250, DOI 10.1021/bi00026a006; SKACH WR, 1994, J CELL BIOL, V125, P803, DOI 10.1083/jcb.125.4.803; SKACH WR, 1993, J BIOL CHEM, V268, P23552; von Heijne G, 1999, Q REV BIOPHYS, V32, P285, DOI 10.1017/S0033583500003541; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590	23	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15215	15219		10.1074/jbc.C100646200	http://dx.doi.org/10.1074/jbc.C100646200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11884383	hybrid			2022-12-25	WOS:000175203000108
J	Horiguchi, N; Takayama, H; Toyoda, M; Otsuka, T; Fukusato, T; Merlino, G; Takagi, H; Mori, M				Horiguchi, N; Takayama, H; Toyoda, M; Otsuka, T; Fukusato, T; Merlino, G; Takagi, H; Mori, M			Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine	ONCOGENE			English	Article						HGF transgenic; hepatocellular carcinoma; c-Met; diethylnitrosamine; VEGF	FACTOR SCATTER FACTOR; FULMINANT HEPATIC-FAILURE; FACTOR-ALPHA; HEPATOCELLULAR CARCINOMAS; ABNORMAL-DEVELOPMENT; LIVER-REGENERATION; MOLECULAR-CLONING; SOMATIC MUTATIONS; EPITHELIAL-CELLS; GENE-EXPRESSION	Hepatocyte growth factor (HGF) is a mitogen for hepatocytes, but it is not clear whether HGF stimulates or inhibits hepatocarcinogenesis. We previously reported that HGF transgenic mice under the metallothionein gene promoter developed benign and malignant liver tumors spontaneously after 17 months of age. To elucidate the role of HGF in hepatocarcinogenesis, diethylnitrosamine (DEN) was administered to HGF transgenic mice. HGF overexpression accelerated DEN-induced hepatocarcinogenesis, often accompanied by abnormal blood vessel formation. In this study, 59% of transgenic mates (versus 20% of wild-type males) and 39% of transgenic females (versus 2% of wild-type females) developed either benign or malignant liver tumors by 48 weeks (P<0.005, P<0.001, respectively). Moreover, 33% of males and 23% of female transgenic mice developed hepatocellular carcinoma (HCC), while none of the wild-type mice developed HCC (P<0.001, P<0.005, respectively). Enhanced kinase activity of the HGF receptor, Met, was detected in most of these tumors. Expression of vascular endothelial growth factor (VEGF) was up-regulated in parallel with HGF transgene expression. Taken together, our results suggest that HGF promotes hepatocarcinogenesis through the autocrine activation of the HGF-Met signaling pathway in association with stimulation of angiogenesis by HGF itself and/or indirectly through VEGF.	Gunma Univ, Sch Med, Dept Internal Med 1, Gunma 3718511, Japan; Gunma Univ, Sch Med, Div Diagnost Pathol, Gunma 3718511, Japan; NCI, Mol Biol Lab, Bethesda, MD 20892 USA	Gunma University; Gunma University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Takagi, H (corresponding author), Gunma Univ, Sch Med, Dept Internal Med 1, Showa Machi 3-39-15, Gunma 3718511, Japan.							Bell A, 1999, ONCOGENE, V18, P887, DOI 10.1038/sj.onc.1202379; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; CRAIG JR, 1989, ATLAS TUMOR PATHOLOG; DErrico A, 1996, HEPATOLOGY, V24, P60, DOI 10.1002/hep.510240112; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; FARBER E, 1987, LAB INVEST, V56, P4; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FUJIWARA K, 1993, HEPATOLOGY, V18, P1443, DOI 10.1016/0270-9139(93)90237-H; Gille J, 1998, J INVEST DERMATOL, V111, P1160, DOI 10.1046/j.1523-1747.1998.00418.x; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HSIA CC, 1992, CANCER, V70, P1049, DOI 10.1002/1097-0142(19920901)70:5&lt;1049::AID-CNCR2820700507&gt;3.0.CO;2-C; ISHIKI Y, 1992, HEPATOLOGY, V16, P1227, DOI 10.1016/0270-9139(92)90019-6; Jeffers M, 1996, ONCOGENE, V13, P853; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Kosai K, 1998, BIOCHEM BIOPH RES CO, V244, P683, DOI 10.1006/bbrc.1998.8293; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; LIU ML, 1995, CARCINOGENESIS, V16, P841, DOI 10.1093/carcin/16.4.841; LIU YH, 1993, BIOCHIM BIOPHYS ACTA, V1216, P299, DOI 10.1016/0167-4781(93)90159-B; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; Mise M, 1996, HEPATOLOGY, V23, P455; MIYAZAKI M, 1992, CELL BIOL INT REP, V16, P145, DOI 10.1016/S0309-1651(06)80108-6; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Morishita R, 2000, ANN NY ACAD SCI, V902, P369; Moriyama T, 1998, BIOCHEM BIOPH RES CO, V249, P73, DOI 10.1006/bbrc.1998.9078; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Ogasawara H, 1998, GASTROENTEROLOGY, V114, P775, DOI 10.1016/S0016-5085(98)70591-8; Otsuka T, 1998, CANCER RES, V58, P5157; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Park WS, 1999, CANCER RES, V59, P307; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PRESUMANN R, 1988, BIOCH CHEM CARCINOGE, P25; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Rosen EM, 1997, CIBA F SYMP, V212, P215; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SHIOTA G, 1994, HEPATOLOGY, V19, P962, DOI 10.1016/0270-9139(94)90297-6; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SHIOTA G, 1995, RES COMMUN MOL PATH, V90, P17; Suzuki K, 1996, CANCER RES, V56, P3004; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; TAKAGI H, 1992, CANCER RES, V52, P5171; TAKAGI H, 1993, CANCER RES, V53, P4329; Takayama H, 1997, LAB INVEST, V77, P131; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 2001, LAB INVEST, V81, P297, DOI 10.1038/labinvest.3780238; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Tuck AB, 1996, AM J PATHOL, V148, P225; Ueki T, 1999, NAT MED, V5, P226, DOI 10.1038/5593; Van Belle E, 1998, CIRCULATION, V97, P381; WU JC, 1994, CANCER RES, V54, P5964; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; YAONO M, 1995, JPN J CANCER RES, V86, P718, DOI 10.1111/j.1349-7006.1995.tb02459.x; YEH YC, 1987, CANCER RES, V47, P896; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	65	102	120	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1791	1799		10.1038/sj.onc.1205248	http://dx.doi.org/10.1038/sj.onc.1205248			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896611				2022-12-25	WOS:000174284500001
J	Pintucci, G; Moscatelli, D; Saponara, F; Biernacki, PR; Baumann, FG; Bizekis, C; Galloway, AC; Basilico, C; Mignatti, P				Pintucci, G; Moscatelli, D; Saponara, F; Biernacki, PR; Baumann, FG; Bizekis, C; Galloway, AC; Basilico, C; Mignatti, P			Lack of ERK activation and cell migration in FGF-2-deficient endothelial cells	FASEB JOURNAL			English	Article						MAPK; wound healing	FIBROBLAST GROWTH-FACTOR; SEX MYOBLAST MIGRATION; PROTEIN-KINASES; SIGNAL; ELEGANS; ROLES	The formation of blood capillaries from preexisting vessels (angiogenesis) and vascular remodeling secondary to atherosclerosis or vessel injury are characterized by endothelial cell migration and proliferation. Numerous growth factors control these cell functions. Basic fibroblast growth factor (FGF-2), a potent angiogenesis inducer, stimulates endothelial cell proliferation, migration, and proteinase production in vitro and in vivo. However, mice genetically deficient in FGF-2 have no apparent vascular defects. We have observed that endothelial cell migration in response to mechanical damage in vitro is accompanied by activation of the extracellular signal-regulated kinase (ERK) pathway, which can be blocked by neutralizing anti-FGF-2 antibodies. Endothelial cells from mice that are genetically deficient in FGF-2 neither migrate nor activate ERK in response to mechanical wounding. Addition of exogenous FGF-2 restores a normal cell response, which shows that impaired migration results from the genetic deficiency of this growth factor. Injury-induced ERK activation in endothelial cells occurs only at the edge of the wound. In addition, FGF-2-induced ERK activation mediates endothelial cell migration in response to wounding without a significant effect on proliferation. These data show that FGF-2 is a key regulator of endothelial cell migration during wound repair.	NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Dept Surg, John HC Ranson Basic Sci Res Lab, New York, NY 10016 USA; NYU, Sch Med, Seymour Cohn Cardiovasc Surg Res Lab, Div Cardiothorac Surg, New York, NY 10016 USA	New York University; New York University; New York University; New York University	Mignatti, P (corresponding author), NYU, Sch Med, Dept Cell Biol, 550 1st Ave, New York, NY 10016 USA.	mignap01@med.nyu.edu		Bizekis, Costas/0000-0001-5763-2306; Galoway, Aubrey/0000-0001-5461-3820; Mignatti, Paolo/0000-0002-8157-457X				Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Bogoyevitch MA, 2000, CARDIOVASC RES, V45, P826, DOI 10.1016/S0008-6363(99)00386-7; Burdine RD, 1997, P NATL ACAD SCI USA, V94, P2433, DOI 10.1073/pnas.94.6.2433; Chen EB, 1998, TRENDS GENET, V14, P322, DOI 10.1016/S0168-9525(98)01507-8; Cines DB, 1998, BLOOD, V91, P3527; Cospedal R, 1999, CARDIOVASC RES, V41, P708, DOI 10.1016/S0008-6363(98)00232-6; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; ETTENSON DS, 1995, ARTERIOSCL THROM VAS, V15, P515, DOI 10.1161/01.ATV.15.4.515; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; KLINT P, 1999, FRONT BIOSCI, V4, P165; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meurice T, 1996, CIRCULATION, V93, P18, DOI 10.1161/01.CIR.93.1.18; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; Pintucci G, 1999, SURGERY, V126, P422, DOI 10.1067/msy.1999.99169; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SCHWARTZ SM, 1995, THROMB HAEMOSTASIS, V74, P541; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; TSUBOI R, 1990, J CELL BIOL, V110, P511, DOI 10.1083/jcb.110.2.511; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; Zieske JD, 2000, PROG RETIN EYE RES, V19, P257, DOI 10.1016/S1350-9462(99)00018-X; Zubilewicz A, 2001, ONCOGENE, V20, P1403, DOI 10.1038/sj.onc.1204231	29	92	102	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					598	+		10.1096/fj.01-0815fje	http://dx.doi.org/10.1096/fj.01-0815fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919166				2022-12-25	WOS:000174203700008
J	Matoba, Y; Katsube, Y; Sugiyama, M				Matoba, Y; Katsube, Y; Sugiyama, M			The crystal structure of prokaryotic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; PANCREATIC PHOSPHOLIPASE-A2; VENOM PHOSPHOLIPASE-A2; MOLECULAR-DYNAMICS; PROTEIN STRUCTURES; FACTOR REFINEMENT; RESOLUTION; BOVINE; COMPLEX; PROGRAM	In this study, the x-ray crystal structures of the calcium-free and calcium-bound forms of phospholipase A(2) (PLA(2)), produced extracellularly by Streptomyces violaceoruber, were determined by using the multiple isomorphous replacement and molecular replacement methods, respectively. The former and latter structures were refined to an R-factor of 18.8% at a 1.4-Angstrom resolution and an R-factor of 15.0% at a 1.6-Angstrom resolution, respectively. The overall structure of the prokaryotic PLA(2) exhibits a novel folding topology that demonstrates that it is completely distinct from those of eukaryotic PLA(2)s, which have been already determined by x-ray and NMR analyses. Furthermore, the coordination geometry of the calcium(II) ion apparently deviated from that of eukaryotic PLA(2)s. Regardless of the evolutionary divergence, the catalytic mechanism including the calcium(II) ion on secreted PLA(2) seems to be conserved between prokaryotic and eukaryotic cells. Demonstrating that the overall structure determined by x-ray analysis is almost the same as that determined by NMR analysis is useful to discuss the catalytic mechanism at the molecular level of the bacterial PLA(2).	Hiroshima Univ, Fac Med, Inst Pharmaceut Sci, Fac Med Minami Ku, Hiroshima 7348551, Japan; Rigaku Co, Inst Xray Res, Akishima, Tokyo 1960003, Japan	Hiroshima University; Rigaku Corporation	Sugiyama, M (corresponding author), Hiroshima Univ, Fac Med, Inst Pharmaceut Sci, Fac Med Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.		Hu, Ruogu/B-2203-2008					BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNIE S, 1985, J BIOL CHEM, V260, P9742; BRUNNETT B, 1993, SURVEYS MATH IND, V3, P1; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIJKSTRA BW, 1984, BIOCHEMISTRY-US, V23, P2759, DOI 10.1021/bi00307a035; DIJKSTRA BW, 1981, J MOL BIOL, V147, P97, DOI 10.1016/0022-2836(81)90081-4; DIJKSTRA BW, 1982, ACTA CRYSTALLOGR B, V38, P793, DOI 10.1107/S0567740882004099; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FUREY W, 1990, METHOD ENZYMOL, V276, P472; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; HIGASHI T, 1990, J APPL CRYSTALLOGR, V23, P253, DOI 10.1107/S0021889890002461; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; KONNERT JH, 1980, ACTA CRYSTALLOGR A, V36, P344, DOI 10.1107/S0567739480000794; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Matoba Y, 2000, J INORG BIOCHEM, V82, P221, DOI 10.1016/S0162-0134(00)00147-1; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1982, PREPARATION ANAL PRO, P96; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NOEL JP, 1991, BIOCHEMISTRY-US, V30, P11801, DOI 10.1021/bi00115a010; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Snitko Y, 1999, BIOCHEMISTRY-US, V38, P7803, DOI 10.1021/bi990600e; Sugiyama M, 2002, J BIOL CHEM, V277, P20051, DOI 10.1074/jbc.M200264200; Sumandea M, 1999, BIOCHEMISTRY-US, V38, P16290, DOI 10.1021/bi9921384; THUNNISSEN MMG, 1990, NATURE, V374, P689; TOMOO K, 1994, PROTEINS, V19, P330, DOI 10.1002/prot.340190408; VANDENBERG B, 1995, J BIOMOL NMR, V5, P110, DOI 10.1007/BF00208802; VANDENBERG B, 1995, NAT STRUCT BIOL, V2, P402, DOI 10.1038/nsb0595-402; VANDENBERG B, 1995, EMBO J, V14, P4123, DOI 10.1002/j.1460-2075.1995.tb00086.x; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158; ZHU HX, 1995, BIOCHEMISTRY-US, V34, P15307, DOI 10.1021/bi00046a040	41	34	36	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					20059	20069		10.1074/jbc.M200263200	http://dx.doi.org/10.1074/jbc.M200263200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11897785	hybrid			2022-12-25	WOS:000175894800107
J	Caccuri, AM; Antonini, G; Allocati, N; Di Ilio, C; De Maria, F; Innocenti, F; Parker, MW; Masulli, M; Lo Bello, M; Turella, P; Federici, G; Ricci, G				Caccuri, AM; Antonini, G; Allocati, N; Di Ilio, C; De Maria, F; Innocenti, F; Parker, MW; Masulli, M; Lo Bello, M; Turella, P; Federici, G; Ricci, G			GSTB1-1 from Proteus mirabilis - A snapshot of an enzyme in the evolutionary pathway from a redox enzyme to a conjugating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; ACTIVE-SITE; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; DISULFIDE OXIDOREDUCTASE; 3-DIMENSIONAL STRUCTURE; PROTON RELEASE; BLOOD-CELLS; ALPHA-CLASS; THIOLTRANSFERASE	The native form of the bacterial glutathione transferase B1-1 (EC 2.5.1.18) is characterized by one glutathione (GSH) molecule covalently linked to Cys-10. This peculiar disulfide, only found in the Beta and Omega class glutathione S-transferases (GSTs) but absent in all other GSTs, prompts questions about its role and how GSH can be activated and utilized in the reaction normally performed by GSTs. Stopped-flow and spectroscopic experiments suggest that, in the native enzyme (GSTB1-1ox), a second GSH molecule is present, albeit transiently, in the active site. This second GSH binds to the enzyme through a bimolecular interaction followed by a fast thiol-disulfide exchange with the covalently bound GSH. The apparent pK(a) of the non-covalently bound GSH is lowered from 9.0 to 6.4 +/- 0.2 in similar fashion to other GSTs. The reduced form of GSTB1-1 (GSTB1-1red) binds GSH 100-fold faster and also induces a more active deprotonation of the substrate with an apparent pK(a) of 5.2 +/- 0.1. Apparently, the absence of the mixed disulfide does not affect k(cat), and K-m values in the GST conjugation activity, which is rate-limited by the chemical step both in GSTB1-1red and in GSTB1-1ox. However, GSTB1-1ox follows a steady-state random sequential mechanism whereas a rapid-equilibrium random sequential mechanism is adopted by GSTB1-1red. Remarkably, GSTB1-lox and GSTB1-1red are equally able to catalyze a glutaredoxin-like catalysis using cysteine S-sulfate and hydroxyethyl disulfide as substrates. Cys-10 is an essential residue in this redox activity, and its replacement by alanine abolishes this enzymatic activity completely. It appears that GSTB1-1 behaves like an "intermediate enzyme" between the thiol-disulfide oxidoreductase and the GST superfamilies.	Univ Roma Tor Vergata, Dept Biol, RM-00133 Rome, Italy; Univ Aquila, Dept Basic & Appl Biol, I-67010 Coppito, Italy; Univ Rome 3, Dept Biol, I-00145 Rome, Italy; Univ Chieti, Dept Biomed Sci, I-66013 Chieti, Italy; St Vincents Inst Med Res, Biota Struct Biol Lab, Fitzroy, Vic 3065, Australia; Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Childrens Hosp, Ist Ric & Cura Carattere Sci, I-00165 Rome, Italy	University of Rome Tor Vergata; University of L'Aquila; Roma Tre University; G d'Annunzio University of Chieti-Pescara; St. Vincent's Institute of Medical Research; Sapienza University Rome	Ricci, G (corresponding author), Univ Roma Tor Vergata, Dept Biol, Viale Ric Sci, RM-00133 Rome, Italy.		Parker, Michael W/F-9069-2013; CACCURI, ANNA MARIA/AFU-2643-2022	Parker, Michael W/0000-0002-3101-1138; MASULLI, Michele/0000-0003-0235-709X; CACCURI, ANNA MARIA/0000-0002-3756-4163; Antonini, Giovanni/0000-0002-2115-8961; ALLOCATI, Nerino/0000-0003-2670-8085				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; ALLOCATI N, 1994, FEBS LETT, V354, P191, DOI 10.1016/0014-5793(94)01115-X; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; AXELSSON K, 1978, BIOCHEMISTRY-US, V17, P2978, DOI 10.1021/bi00608a006; Board PG, 1997, BIOCHEM J, V328, P929; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BUETLER TM, 1992, J ENVIRON SCI HEAL C, V10, P181; Caccuri AM, 2002, BIOCHEMISTRY-US, V41, P4686, DOI 10.1021/bi0158425; Caccuri AM, 2001, J BIOL CHEM, V276, P5427, DOI 10.1074/jbc.M002819200; Caccuri AM, 1998, BIOCHEMISTRY-US, V37, P3028, DOI 10.1021/bi971903g; Caccuri AM, 1999, BIOCHEM J, V344, P419, DOI 10.1042/0264-6021:3440419; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; Casalone E, 1998, FEBS LETT, V423, P122, DOI 10.1016/S0014-5793(98)00080-5; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P15810, DOI 10.1021/bi971504l; DIILIO C, 1988, BIOCHEM J, V255, P971, DOI 10.1042/bj2550971; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P3562, DOI 10.1021/bi00434a062; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P63; Kampranis SC, 2000, J BIOL CHEM, V275, P29207, DOI 10.1074/jbc.M002359200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LITWACK G, 1971, NATURE, V234, P466, DOI 10.1038/234466a0; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1986, CHEM SCRIPTA, V26B, P281; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088, DOI 10.1021/bi00239a002; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P8883, DOI 10.1021/bi00100a023; Nishida M, 1998, J MOL BIOL, V281, P135, DOI 10.1006/jmbi.1998.1927; Nordstrand K, 1999, J MOL BIOL, V286, P541, DOI 10.1006/jmbi.1998.2444; Oakley AJ, 1997, J MOL BIOL, V274, P84, DOI 10.1006/jmbi.1997.1364; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; Perito B, 1996, BIOCHEM J, V318, P157, DOI 10.1042/bj3180157; Piredda L, 1999, FASEB J, V13, P355, DOI 10.1096/fasebj.13.2.355; RAGHUNATHAN S, 1994, J MOL BIOL, V238, P815, DOI 10.1006/jmbi.1994.1336; Reinemer P, 1996, J MOL BIOL, V255, P289, DOI 10.1006/jmbi.1996.0024; Ricci G, 1996, J BIOL CHEM, V271, P16187, DOI 10.1074/jbc.271.27.16187; Rossjohn J, 1998, STRUCT FOLD DES, V6, P721, DOI 10.1016/S0969-2126(98)00074-4; Rossjohn J, 1998, STRUCTURE, V6, P309, DOI 10.1016/S0969-2126(98)00034-3; Schmidt DMZ, 2001, BIOCHEMISTRY-US, V40, P15707, DOI 10.1021/bi011640x; Segel IH, 1975, ENZYME KINETICS, P460; Srinivasan U, 1997, BIOCHEMISTRY-US, V36, P3199, DOI 10.1021/bi962017t; TOUNG YPS, 1993, J BIOL CHEM, V268, P9737; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; Wilce MCJ, 1994, BIOCHIM BIOPHYS ACTA, V205, P1	49	37	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18777	18784		10.1074/jbc.M201137200	http://dx.doi.org/10.1074/jbc.M201137200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889135	hybrid			2022-12-25	WOS:000175975800071
J	Repa, JJ; Berge, KE; Pomajzl, C; Richardson, JA; Hobbs, H; Mangelsdorf, DJ				Repa, JJ; Berge, KE; Pomajzl, C; Richardson, JA; Hobbs, H; Mangelsdorf, DJ			Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTORS; BILE-ACID SYNTHESIS; RAT HEPATOMA-CELLS; LXR-ALPHA; DIETARY-CHOLESTEROL; MESSENGER-RNA; MICE; IDENTIFICATION; GENE; METABOLISM	Mutations in the ATP-binding cassette (ABC) transporters ABCG5 and ABCG8 have recently been shown to cause the autosomal recessive disorder sitosterolemia. Here we demonstrate that the ABCG5 and ABCG8 genes are direct targets of the oxysterol receptors liver X receptor (LXR) alpha and LXRbeta. Diets containing high cholesterol markedly increased the expression of ABCG5/G8 mRNA in mouse liver and intestine. This increase was also observed using synthetic ligands of LXR and its heterodimeric partner, the retinoid X receptor. In situ hybridization analyses of tissues from LXR agonist-treated mice revealed that ABCG5/G8 mRNA is located in hepatocytes and enterocytes and is increased upon LXR activation. In addition, expression of the LXR target gene ABCA1, previously implicated in the control of cholesterol absorption, was also dramatically up-regulated in jejunal enterocytes upon exposure to LXR agonists. These changes in ABC transporter gene expression were not observed in mice lacking LXRs. Furthermore, in the rat hepatoma cell line FTO2B, LXR-dependent transcription of the ABCG5/G8 genes was cycloheximide-resistant, indicating that these genes are directly regulated by LXRs. The addition of ABCG5 and AECG8 to the growing list of LXR target genes further supports the notion that LXRs serve as sterol sensors to coordinately regulate sterol catabolism, storage, efflux, and elimination.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Div Cardiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mangelsdorf, DJ (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Eckhardt, Erik/G-1567-2010	Repa, Joyce/0000-0001-5740-1954; Mangelsdorf, David/0000-0002-4355-0796	NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberti S, 2001, J CLIN INVEST, V107, P565, DOI 10.1172/JCI9794; BEHER WT, 1963, J NUTR, V79, P523, DOI 10.1093/jn/79.4.523; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bjorkhem I., 1995, METABOLIC MOL BASES, P2073; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BROWN MS, 1978, J BIOL CHEM, V253, P1121; Claudel T, 2001, P NATL ACAD SCI USA, V98, P2610, DOI 10.1073/pnas.041609298; Costet P, 2000, J BIOL CHEM, V275, P28240; DeBose-Boyd RA, 2001, P NATL ACAD SCI USA, V98, P1477, DOI 10.1073/pnas.98.4.1477; Drobnik W, 2001, GASTROENTEROLOGY, V120, P1203, DOI 10.1053/gast.2001.23250; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Ikeda S, 2000, BIOCHEM BIOPH RES CO, V273, P1063, DOI 10.1006/bbrc.2000.3071; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lawn RM, 2001, ARTERIOSCL THROM VAS, V21, P378, DOI 10.1161/01.ATV.21.3.378; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Mukherjee R, 1998, ARTERIOSCL THROM VAS, V18, P272, DOI 10.1161/01.ATV.18.2.272; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Pollner R, 1997, FEBS LETT, V405, P31, DOI 10.1016/S0014-5793(97)00152-X; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; SALEN G, 1989, J LIPID RES, V30, P1319; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schwarz M, 1998, J LIPID RES, V39, P1833; Shelton JM, 2000, J LIPID RES, V41, P532; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Trappe R, 1999, BBA-GENE STRUCT EXPR, V1446, P341, DOI 10.1016/S0167-4781(99)00107-4; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; WIEBEL FJ, 1984, EUR J BIOCHEM, V145, P455, DOI 10.1111/j.1432-1033.1984.tb08577.x; Willy PJ, 1997, GENE DEV, V11, P289, DOI 10.1101/gad.11.3.289; WYNSHAWBORIS A, 1984, J BIOL CHEM, V259, P2161; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; Zhang Z, 2001, J LIPID RES, V42, P649	42	639	668	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18793	18800		10.1074/jbc.M109927200	http://dx.doi.org/10.1074/jbc.M109927200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11901146	hybrid			2022-12-25	WOS:000175975800073
J	Wang, CG; Risteli, M; Heikkinen, J; Hussa, AK; Uitto, L; Myllyla, R				Wang, CG; Risteli, M; Heikkinen, J; Hussa, AK; Uitto, L; Myllyla, R			Identification of amino acids important for the catalytic activity of the collagen glucosyltransferase associated with the multifunctional lysyl hydroxylase 3 (LH3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKS; GLYCOSYLTRANSFERASES; CLONING; ISOFORM; MOUSE; RESIDUES	Collagen glucosyltransferase (GGT) activity has recently been shown to be associated with human lysyl hydroxylase (LH) isoform. 3 (LH3) (Heikkinen, J., Risteli, M., Wang, C., Latvala, J., Rossi, M., Valtavaara, M., Myllyla, R. (2000) J. Biol. Chem. 275, 36158-36163). The LH and GGT activities of the multifunctional LH3 protein modify lysyl residues in collagens posttranslationally to form hydroxylysyl and glucosylgalactosyl hydroxylysyl residues respectively. We now report that in the nematode, Caenorhabditis elegans, where only one ortholog is found for lysyl hydroxylase, the LH and GGT activities are also associated with the same gene product. The aim of the present studies is the identification of amino acids important for the catalytic activity of GGT. Our data indicate that the GGT active site is separate from the carboxyl-terminal LH active site of human LH3, the amino acids important for the GGT activity being located at the amino-terminal part of the molecule. Site-directed mutagenesis of a conserved cysteine at position 144 to isoleucine and a leucine at position 208 to isoleucine caused a marked reduction in GGT activity. These amino acids were conserved in C elegans LH and mammalian LH3, but not in LH1 or LH2, which lack GGT activity. The data also reveal a DXD-like motif in LH3 characteristic of many glycosyltransferases and the mutagenesis of aspartates of this motif eliminated the GGT activity. Reduction in GGT activity was not accompanied by a change in the LH activity of the molecule. Thus GGT activity can be manipulated independently of LH activity in LH3. These data provide the information needed to design knock-out studies for investigation of the function of glucosylgalactosyl hydroxylysyl residues of collagens in vivo.	Univ Oulu, Bioctr Oulu, Dept Biochem, FIN-90014 Oulu, Finland	Finland National Institute for Health & Welfare; University of Oulu	Myllyla, R (corresponding author), Univ Oulu, Bioctr Oulu, Dept Biochem, POB 3000, FIN-90014 Oulu, Finland.	raili.myllyla@oulu.fi	Wang, Chunguang/AAE-6997-2020; Wang, Chunguang/AAE-7054-2020	Wang, Chunguang/0000-0001-5569-321X				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; AYAD S, 1998, EXTRACELLULAR MATRIX, P43; BATEMAN JF, 1996, EXTRACELLULAR MATRIX, V2, P22; Blaxter M, 2000, YEAST, V17, P37, DOI 10.1002/(SICI)1097-0061(200004)17:1<37::AID-YEA11>3.0.CO;2-P; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Brinckmann J, 1999, J INVEST DERMATOL, V113, P617, DOI 10.1046/j.1523-1747.1999.00735.x; Dennis JW, 1999, BIOESSAYS, V21, P412, DOI 10.1002/(SICI)1521-1878(199905)21:5<412::AID-BIES8>3.0.CO;2-5; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; HAUTALA T, 1992, GENOMICS, V13, P62, DOI 10.1016/0888-7543(92)90202-4; Heikkinen J, 2000, J BIOL CHEM, V275, P36158, DOI 10.1074/jbc.M006203200; KADLER K, 1994, PROTEIN PROFILE, V1, P519; Kielty Cay M., 1993, P103; Kivirikko K I, 1979, Int Rev Connect Tissue Res, V8, P23; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Knott L, 1998, BONE, V22, P181, DOI 10.1016/S8756-3282(97)00279-2; Moro L, 2000, CALCIFIED TISSUE INT, V66, P151, DOI 10.1007/s002230010030; MYLLYLA R, 1975, EUR J BIOCHEM, V52, P401, DOI 10.1111/j.1432-1033.1975.tb04008.x; Norman KR, 2000, DEV BIOL, V227, P690, DOI 10.1006/dbio.2000.9897; Notbohm H, 1999, J BIOL CHEM, V274, P8988, DOI 10.1074/jbc.274.13.8988; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; Passoja K, 1998, FEBS LETT, V434, P145, DOI 10.1016/S0014-5793(98)00966-1; Pirskanen A, 1996, J BIOL CHEM, V271, P9398, DOI 10.1074/jbc.271.16.9398; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Ruotsalainen H, 1999, MATRIX BIOL, V18, P325, DOI 10.1016/S0945-053X(99)00016-5; Sipila L, 2000, MAMM GENOME, V11, P1132, DOI 10.1007/s003350010214; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Valtavaara M, 1997, J BIOL CHEM, V272, P6831, DOI 10.1074/jbc.272.11.6831; Valtavaara M, 1998, J BIOL CHEM, V273, P12881, DOI 10.1074/jbc.273.21.12881; Vollrath B, 2001, MOL CELL BIOL, V21, P5688, DOI 10.1128/MCB.21.16.5688-5697.2001; Wassen MHM, 2000, J BONE MINER RES, V15, P1776, DOI 10.1359/jbmr.2000.15.9.1776	30	43	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18568	18573		10.1074/jbc.M201389200	http://dx.doi.org/10.1074/jbc.M201389200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11896059	hybrid			2022-12-25	WOS:000175975800043
J	Johnson, BA; Stehn, JR; Yaffe, MB; Blackwell, TK				Johnson, BA; Stehn, JR; Yaffe, MB; Blackwell, TK			Cytoplasmic localization of tristetraprolin involves 14-3-3-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENTS; ACTIVATED PROTEIN-KINASE; ALPHA MESSENGER-RNA; FINGER TRANSCRIPTION FACTOR; EARLY RESPONSE GENES; TNF-ALPHA; C-ELEGANS; NUCLEOCYTOPLASMIC TRANSPORT; DEFICIENCY SYNDROME; P38 MAPK	The immediate early gene tristetraprolin (TTP) is induced transiently in many cell types by numerous extracellular stimuli TTP encodes a zinc finger protein that can bind and destabilize mRNAs that encode tumor necrosis factor-alpha (TNFalpha) and other cytokines. We hypothesize that TTP also has a broader role in growth factor-responsive pathways. In support of this model, we have previously determined that TTP induces apoptosis through the mitochondrial pathway, analogously to certain oncogenes and other immediate-early genes, and that TTP sensitizes cells to the pro-apoptotic signals of TNFa. In this study, we show that TTP and the related proteins TIS11b and TIS11d bind specifically to 14-3-3 proteins and that individual 14-3-3 isoforms preferentially bind to different phosphorylated TTP species. 14-3-3 binding does not appear to inhibit or promote induction of apoptosis by TTP but is one of multiple mechanisms that localize TTP to the cytoplasm. Our results provide the first example of 14-3-3 interacting functionally with an RNA binding protein and binding in vivo to a Type 11 14-3-3 binding site. They also suggest that 14-3-3 binding is part of a complex network of stimuli and interactions that regulate TTP function.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Blackwell, TK (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.	blackwell@cbr.med.harvard.edu	Stehn, Justine/G-5115-2013	Stehn, Justine/0000-0002-2136-5450	NCI NIH HHS [CA84418] Funding Source: Medline; NIGMS NIH HHS [GM60594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bustin SA, 1999, DNA CELL BIOL, V18, P653, DOI 10.1089/104454999315060; Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; Carballo E, 2001, BLOOD, V98, P2389, DOI 10.1182/blood.V98.8.2389; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; DUBOIS RN, 1995, CELL GROWTH DIFFER, V6, P523; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Guedes S, 1997, DEVELOPMENT, V124, P731; HAAS CA, 1993, NEUROSCIENCE, V53, P91, DOI 10.1016/0306-4522(93)90287-P; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HEXIMER SP, 1993, DNA CELL BIOL, V12, P73, DOI 10.1089/dna.1993.12.73; Johnson BA, 2000, ONCOGENE, V19, P1657, DOI 10.1038/sj.onc.1203474; JOHNSON BA, 2002, IN PRESS ONCOGENE; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kontoyiannis D, 2001, EMBO J, V20, P3760, DOI 10.1093/emboj/20.14.3760; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kronnie GT, 2001, DEV GENES EVOL, V211, P261, DOI 10.1007/s004270100145; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; MESNER PW, 1995, J NEUROSCI, V15, P7357; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; MITTELSTADT PR, 1993, J IMMUNOL, V150, P4822; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Phillips RS, 2002, J BIOL CHEM, V277, P11606, DOI 10.1074/jbc.M111457200; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Rutault K, 2001, J BIOL CHEM, V276, P6666, DOI 10.1074/jbc.M005486200; Schubert CM, 2000, MOL CELL, V5, P671, DOI 10.1016/S1097-2765(00)80246-4; Tabara H, 1999, DEVELOPMENT, V126, P1; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1995, J BIOL CHEM, V270, P13341, DOI 10.1074/jbc.270.22.13341; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; Tenenhaus C, 2001, GENE DEV, V15, P1031, DOI 10.1101/gad.876201; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; VARNUM BC, 1989, ONCOGENE, V4, P119; Vasudevan S, 2001, MOL CELL, V7, P1191, DOI 10.1016/S1097-2765(01)00279-9; VIDAL M, 1997, YEAST 2 HYBRID SYSTE, P109; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Zeng Y, 1999, MOL CELL BIOL, V19, P7410	49	102	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18029	18036		10.1074/jbc.M110465200	http://dx.doi.org/10.1074/jbc.M110465200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11886850	hybrid			2022-12-25	WOS:000175685100081
J	Sargsyan, E; Baryshev, M; Szekely, L; Sharipo, A; Mkrtchian, S				Sargsyan, E; Baryshev, M; Szekely, L; Sharipo, A; Mkrtchian, S			Identification of ERp29, an endoplasmic reticulum lumenal protein, as a new member of the thyroglobulin folding complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMINAL ER PROTEINS; MOLECULAR CHAPERONES; SECRETORY PATHWAY; GENE-EXPRESSION; RAT-LIVER; CELLS; THYROCYTES; WINDBEUTEL; DROSOPHILA; RESIDENT	Folding and post-translational modification of the thyroid hormone precursor, thyroglobulin (Tg), in the endoplasmic reticulum (ER) of the thyroid epithelial cells is facilitated by several molecular chaperones and folding enzymes, such as BiP, GRP94, calnexin, protein disulfide isomerase, ERp72, and others. They have been shown to associate simultaneously and/or sequentially with Tg in the course of its maturation, thus forming large heterocomplexes in the ER of thyrocytes. Here we present evidence that such complexes include a novel member, an Ell-resident lumenal protein, ERp29, which is present in all mammalian tissues with exceptionally high levels of expression in the secretory cells. ERp29 was induced upon treatment of FRTL-5 rat thyrocytes with the thyroid-stimulating hormone, which is essential for the maintenance of thyroid cells and Tg biosynthesis. Chemical cross-linking followed by the cell lysis and immunoprecipitation of ERp29 or Tg revealed association of these proteins and additionally, immunocomplexes that also included major ER chaperones, BiP and GRP94. Sucrose density gradient analysis indicated co-localization of ERp29 with Tg and BiP in the fractions containing large macromolecular complexes. This was supported by immunofluorescent microscopy showing co-localization of ERp29 with Tg in the putative transport vesicular structures. Affinity chromatography using Tg as an affinity ligand demonstrated that ERp29 might be selectively isolated from the FRTL-5 cell lysate or purified lumenal fraction of rat liver microsomes along with the other ER chaperones. Preferential association with the urea-denatured Tg-Sepharose was indicative of either direct or circuitous ERp29/Tg interactions in a chaperone-like manner. Despite the presence of the C-terminal ER-retrieval signal, significant amounts of ERp29 were also recovered from the culture medium of stimulated thyrocytes, indicating ERp29 secretion. Based on these data, we suggest that the function of ERp29 in thyroid cells is connected with folding and/or secretion of Tg.	Karolinska Inst, Div Mol Toxicol, Inst Environm Med, S-17177 Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Univ Latvia, Biomed Res & Study Ctr, LV-1067 Riga, Latvia	Karolinska Institutet; Karolinska Institutet; Latvian Biomedical Research & Study Centre; University of Latvia	Mkrtchian, S (corresponding author), Karolinska Inst, Div Mol Toxicol, Inst Environm Med, S-17177 Stockholm, Sweden.	souren.mkrtchian@imm.ki.se	Szekely, Laszlo/B-1268-2009	Szekely, Laszlo/0000-0001-6144-6573; Mkrtchian, Souren/0000-0001-9801-2736				Argon Y, 1999, SEMIN CELL DEV BIOL, V10, P495, DOI 10.1006/scdb.1999.0320; Arvan P, 1997, THYROID, V7, P89, DOI 10.1089/thy.1997.7.89; Bruneau N, 2000, MICROSC RES TECHNIQ, V49, P329, DOI 10.1002/(SICI)1097-0029(20000515)49:4<329::AID-JEMT2>3.0.CO;2-H; Demmer J, 1997, FEBS LETT, V402, P145, DOI 10.1016/S0014-5793(96)01513-X; DORNER AJ, 1990, J BIOL CHEM, V265, P22029; EKHOLM R, 1990, INT REV CYTOL, V120, P243; ENDO T, 1991, MOL ENDOCRINOL, V5, P905, DOI 10.1210/mend-5-7-905; Fang C, 1997, BIOTECHNIQUES, V23, P52, DOI 10.2144/97231bm09; Ferrari DM, 1998, EUR J BIOCHEM, V255, P570, DOI 10.1046/j.1432-1327.1998.2550570.x; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Helenius A, 2001, PHILOS T ROY SOC B, V356, P147, DOI 10.1098/rstb.2000.0759; Herrmann JM, 1999, TRENDS CELL BIOL, V9, P5, DOI 10.1016/S0962-8924(98)01414-7; HERZOG V, 1992, J CELL BIOL, V118, P1071, DOI 10.1083/jcb.118.5.1071; Hubbard MJ, 2000, EUR J BIOCHEM, V267, P1945, DOI 10.1046/j.1432-1327.2000.01193.x; JOHANSSON I, 1988, BIOCHEMISTRY-US, V27, P1925, DOI 10.1021/bi00406a019; Johnson S, 2001, TRENDS CELL BIOL, V11, P122, DOI 10.1016/S0962-8924(01)01926-2; KIM PS, 1993, J BIOL CHEM, V268, P4873; Kim PS, 1996, J CELL BIOL, V133, P517, DOI 10.1083/jcb.133.3.517; Konsolaki M, 1998, GENE DEV, V12, P120, DOI 10.1101/gad.12.1.120; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; Kwon OY, 2000, FEBS LETT, V475, P27, DOI 10.1016/S0014-5793(00)01617-3; Liepinsh E, 2001, STRUCTURE, V9, P457, DOI 10.1016/S0969-2126(01)00607-4; Marino M, 2001, MOL ENDOCRINOL, V15, P1829, DOI 10.1210/me.15.10.1829; Mezghrani A, 2000, J BIOL CHEM, V275, P1920, DOI 10.1074/jbc.275.3.1920; Mkrtchian S, 1998, EUR J BIOCHEM, V251, P304, DOI 10.1046/j.1432-1327.1998.2510304.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; Sargsyan E, 2002, GENE, V285, P127, DOI 10.1016/S0378-1119(02)00417-1; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; Sen J, 2000, DEVELOPMENT, V127, P5541; Stevens FJ, 1999, SEMIN CELL DEV BIOL, V10, P443, DOI 10.1006/scdb.1999.0315; Szekely L, 1999, J GEN VIROL, V80, P2889, DOI 10.1099/0022-1317-80-11-2889; Wiest DL, 1997, P NATL ACAD SCI USA, V94, P1884, DOI 10.1073/pnas.94.5.1884; Willnow TE, 1999, NAT CELL BIOL, V1, pE157, DOI 10.1038/14109; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; Xiao GQ, 1999, MOL BRAIN RES, V72, P121, DOI 10.1016/S0169-328X(99)00188-6	36	86	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17009	17015		10.1074/jbc.M200539200	http://dx.doi.org/10.1074/jbc.M200539200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11884402	hybrid			2022-12-25	WOS:000175564500089
J	Doherty, TM; Uzui, H; Fitzpatrick, LA; Tripathi, PV; Dunstan, CR; Asotra, K; Rajavashisth, TB				Doherty, TM; Uzui, H; Fitzpatrick, LA; Tripathi, PV; Dunstan, CR; Asotra, K; Rajavashisth, TB			Rationale for the role of osteoclast-like cells in arterial calcification	FASEB JOURNAL			English	Article						atherosclerosis; mineral resorption; mononuclear phagocytes; OLCs	COLONY-STIMULATING FACTOR; CARBONIC-ANHYDRASE-II; KAPPA-B LIGAND; FMS PROTOONCOGENE PRODUCT; BEAM COMPUTED-TOMOGRAPHY; MATRIX GLA PROTEIN; RECEPTOR ACTIVATOR; IN-VITRO; VASCULAR CALCIFICATION; BONE-RESORPTION	Atherosclerotic arteries frequently become calcified, and these calcium deposits are associated with a high risk of adverse clinical events. Descriptive studies suggest calcification is an organized and regulated process with many similarities to osteogenesis, yet the mechanism and its relationship to atherosclerosis remain largely unknown. In bone development and homeostasis, mineral deposition by osteoblasts and mineral resorption by osteoclasts are delicately balanced such that there is no overall gain or loss in bone mass. We hypothesize that there exists in arteries a mechanism that similarly balances mineral deposition with resorption. We propose that the cellular mediators of arterial mineral resorption are osteoclast-like cells (OLCs) derived from hematopoietic precursors of the mononuclear phagocytic lineage. In arterial microenvironments, mononuclear precursors are induced to differentiate toward OLCs by macrophage-colony stimulating factor and receptor activator of NF-kappaB ligand, both of which are necessary and sufficient for osteoclastogenesis and mineral resorption in bone. OLCs may participate in normal mineral homeostasis within the arterial wall or, alternatively, may be recruited to specific sites within developing plaque. Net calcium deposition occurs as a result of focal perturbation of the balance between the activity of osteoblast-like cells and OLCs. Our proposed mechanism thus views arterial mineral deposition not so much as an active pathological process, but as a localized failure of protective mechanisms that actively oppose mineral deposition within the disordered metabolic milieu of developing atherosclerotic plaque.	Cedars Sinai Med Ctr, Div Cardiol, Atherosclerosis Res Ctr, Dept Med, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Burns & Allen Res Inst, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Div Endocrinol, Rochester, MN 55905 USA; Amgen Inc, Dept Dev, Thousand Oaks, CA 91320 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Mayo Clinic; Amgen	Rajavashisth, TB (corresponding author), Cedars Sinai Med Ctr, Div Cardiol, Atherosclerosis Res Ctr, Dept Med, Davis Res Bldg,Room 1062,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	rajavashisth@cshs.org	Dunstan, Colin/G-6214-2013; Rajavashisth, Tripathi/ABB-6379-2020	Dunstan, Colin/0000-0001-7586-4071; 	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013717] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058555, R29HL051980, R01HL051980] Funding Source: NIH RePORTER; NCRR NIH HHS [1S10RR13717] Funding Source: Medline; NHLBI NIH HHS [HL 58555, HL 51980] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOSTROM K, 1993, J CLIN INVEST, V91, P1800, DOI 10.1172/JCI116391; Bostrom K, 2001, AM J CARDIOL, V88, p20E; Bostrom K, 2000, CRIT REV EUKAR GENE, V10, P151; Boyce BF, 1999, LAB INVEST, V79, P83; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Canfield AE, 2000, FEBS LETT, V487, P267, DOI 10.1016/S0014-5793(00)02363-2; Canfield AE, 2000, Z KARDIOL, V89, P20; CLINTON SK, 1992, AM J PATHOL, V140, P301; Collin-Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200; Detrano RC, 2000, CURR PROB CARDIOLOGY, V25, P374, DOI 10.1067/mcd.2000.104848; DOHERTY TM, 1994, CALCIFIED TISSUE INT, V54, P224, DOI 10.1007/BF00301683; Doherty TM, 1999, AM HEART J, V137, P806, DOI 10.1016/S0002-8703(99)70403-5; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; Han CL, 2001, J VASC RES, V38, P113, DOI 10.1159/000051038; Heinemann DEH, 2000, IMMUNOBIOLOGY, V202, P68, DOI 10.1016/S0171-2985(00)80054-6; Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Itoh K, 2001, ENDOCRINOLOGY, V142, P3656, DOI 10.1210/en.142.8.3656; Jono S, 1998, CIRCULATION, V98, P1302, DOI 10.1161/01.CIR.98.13.1302; Jono S, 1997, ARTERIOSCL THROM VAS, V17, P1135, DOI 10.1161/01.ATV.17.6.1135; Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10; Kartsogiannis V, 1999, BONE, V25, P525, DOI 10.1016/S8756-3282(99)00214-8; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LAITALA T, 1994, J CLIN INVEST, V93, P2311, DOI 10.1172/JCI117235; Lehenkari P, 1998, EXP CELL RES, V242, P128, DOI 10.1006/excr.1998.4071; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; McGowan NWA, 2001, ENDOCRINOLOGY, V142, P1678, DOI 10.1210/en.142.4.1678; Min H, 2000, J EXP MED, V192, P463, DOI 10.1084/jem.192.4.463; Miyamoto N, 2000, J ORTHOP RES, V18, P647, DOI 10.1002/jor.1100180418; Mori K, 1998, FEBS LETT, V433, P19, DOI 10.1016/S0014-5793(98)00870-9; Mori K, 1999, ARTERIOSCL THROM VAS, V19, P2112, DOI 10.1161/01.ATV.19.9.2112; Neale SD, 2000, BONE, V27, P409, DOI 10.1016/S8756-3282(00)00345-8; O'Malley PG, 2000, AM J CARDIOL, V85, P945, DOI 10.1016/S0002-9149(99)00906-6; O'Rourke RA, 2000, J AM COLL CARDIOL, V36, P326, DOI 10.1016/S0735-1097(00)00831-7; Price PA, 2001, ARTERIOSCL THROM VAS, V21, P1610, DOI 10.1161/hq1001.097102; Proudfoot D, 1998, ARTERIOSCL THROM VAS, V18, P379, DOI 10.1161/01.ATV.18.3.379; Qiao JH, 1997, AM J PATHOL, V150, P1687; Quinn JMW, 2000, J BONE MINER RES, V15, P1459, DOI 10.1359/jbmr.2000.15.8.1459; Rajavashisth T, 1998, J CLIN INVEST, V101, P2702, DOI 10.1172/JCI119891; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; RETTENMIER CW, 1986, J CLIN INVEST, V77, P1740, DOI 10.1172/JCI112496; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; ROSENFELD ME, 1992, AM J PATHOL, V140, P291; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Shalhoub V, 2000, BRIT J HAEMATOL, V111, P501, DOI 10.1046/j.1365-2141.2000.02379.x; SHERR CJ, 1988, COLD SPRING HARB SYM, V53, P521, DOI 10.1101/SQB.1988.053.01.060; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIOI A, 1995, ARTERIOSCL THROM VAS, V15, P2003, DOI 10.1161/01.ATV.15.11.2003; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SPICER SS, 1989, AM J PATHOL, V134, P947; Stary HC, 2000, Z KARDIOL, V89, P28; Stary HC, 1999, ATLAS ATHEROSCLEROSI; Suda T, 2001, Novartis Found Symp, V232, P235; Suda Tatsuo, 1996, P87; Sundquist KT, 1999, HISTOCHEM CELL BIOL, V111, P55, DOI 10.1007/s004180050333; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tintut Y, 2001, CURR OPIN LIPIDOL, V12, P555, DOI 10.1097/00041433-200110000-00012; Tsurukai T, 2000, J BONE MINER METAB, V18, P177, DOI 10.1007/s007740070018; Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478; WATSON KE, 1994, J CLIN INVEST, V93, P2106, DOI 10.1172/JCI117205; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	66	83	87	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6							UNSP 0892-6638/02/0016-0577	10.1096/fj.01-0898hyp	http://dx.doi.org/10.1096/fj.01-0898hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11919160				2022-12-25	WOS:000175425900011
J	Chew, LJ; Pan, HG; Yu, JY; Tian, S; Huang, WQ; Zhang, JY; Pang, S; Li, LY				Chew, LJ; Pan, HG; Yu, JY; Tian, S; Huang, WQ; Zhang, JY; Pang, S; Li, LY			A novel secreted splice variant of vascular endothelial cell growth inhibitor	FASEB JOURNAL			English	Article						angiogenesis; autocrine; endothelium; secretion; VEGI	TUMOR-NECROSIS-FACTOR; ALPHA IN-VITRO; MESSENGER-RNA; PROTEIN-KINASE; TNF-ALPHA; LENTIVIRAL VECTOR; PREMESSENGER RNA; DOWN-REGULATION; SOLUBLE FORM; FACTOR-BETA	Vascular endothelial cell growth inhibitor (VEGI), a member of the tumor necrosis factor (TNF) family, is an endothelial cell-specific inhibitor of angiogenesis. Overexpression by cancer cells of a secretable VEGI fusion protein resulted in abrogation of xenograft tumor progression, but overexpression of full-length VEGI was completely without effect. This finding indicates that secretion is essential for VEGI action. Here we report the identification of two new VEGI isoforms consisting of 251 and 192 amino acid residues. Both isoforms show endothelial cell-specific expression and share a C-terminal 151-residue segment with the previously described VEGI, which comprises 174 residues. The isoforms are generated from a 17 kb human gene by alternative splicing. Their expression is regulated in parallel by inflammatory cytokines TNF-alpha and interferon-gamma. VEGI-251, the most abundant isoform, contains a putative secretion signal. VEGI protein is detected in conditioned media of endothelial cells and VEGI-251-transfected mammalian cells. Overexpression of VEGI-251 in endothelial cells causes dose-dependent cell death. VEGI-251-transfected cancer cells form xenograft tumors of reduced growth rate and microvessel density compared with tumors of empty vector transfectants. These findings support the view that endothelial cell-secreted VEGI may function as an autocrine inhibitor of angiogenesis and a naturally existing modulator of vascular homeostasis.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20007 USA; Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA; Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA	Georgetown University; Medical University of South Carolina; University of California System; University of California Los Angeles	Li, LY (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Oncol, 3970 Reservoir Rd NW,RB-E301, Washington, DC 20007 USA.	lilu@georgetown.edu	Li, Luyuan/E-8951-2012					BALDWIN HS, 1996, CARDIOVASC RES, V31, P34; Boldrini L, 2000, BRIT J CANCER, V83, P480, DOI 10.1054/bjoc.2000.1345; CHALFANT CE, 1995, J BIOL CHEM, V270, P13326, DOI 10.1074/jbc.270.22.13326; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Derrigo M, 2000, INT J MOL MED, V5, P111; DOUKAS J, 1990, J IMMUNOL, V145, P1727; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Eissa NT, 1996, J BIOL CHEM, V271, P27184, DOI 10.1074/jbc.271.43.27184; ENGERMAN RL, 1967, LAB INVEST, V17, P738; FAJARDO LF, 1992, AM J PATHOL, V140, P539; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Haridas V, 1999, ONCOGENE, V18, P6496, DOI 10.1038/sj.onc.1203059; He YL, 1999, MOL ENDOCRINOL, V13, P537, DOI 10.1210/me.13.4.537; Hohlbaum AM, 2000, J EXP MED, V191, P1209, DOI 10.1084/jem.191.7.1209; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; Horrevoets AJG, 1999, BLOOD, V93, P3418, DOI 10.1182/blood.V93.10.3418.410k23_3418_3431; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; LEEK RD, 1994, J LEUKOCYTE BIOL, V56, P423, DOI 10.1002/jlb.56.4.423; Lou H, 2001, ENDOCR REV, V22, P205, DOI 10.1210/er.22.2.205; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MCKAY NG, 1994, BIOCHEM BIOPH RES CO, V199, P1005, DOI 10.1006/bbrc.1994.1329; Metheny LJ, 1996, EXP CELL RES, V228, P44, DOI 10.1006/excr.1996.0297; Molostvov G, 2001, BRIT J HAEMATOL, V113, P891, DOI 10.1046/j.1365-2141.2001.02835.x; Mueller C, 1999, J BIOL CHEM, V274, P38112, DOI 10.1074/jbc.274.53.38112; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Ono Y, 1999, HYPERTENSION, V34, P609, DOI 10.1161/01.HYP.34.4.609; Patterson C, 1996, J CLIN INVEST, V98, P490, DOI 10.1172/JCI118816; Pollman MJ, 1999, J CELL PHYSIOL, V178, P359, DOI 10.1002/(SICI)1097-4652(199903)178:3<359::AID-JCP10>3.3.CO;2-F; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; RIO DC, 1993, CURR OPIN GENET DEV, V3, P574, DOI 10.1016/0959-437X(93)90093-5; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; SHIFRIN VI, 1993, J BIOL CHEM, V268, P25376; Shudo K, 2001, EUR J IMMUNOL, V31, P2504, DOI 10.1002/1521-4141(200108)31:8<2504::AID-IMMU2504>3.0.CO;2-C; Stewart SA, 1999, P NATL ACAD SCI USA, V96, P12039, DOI 10.1073/pnas.96.21.12039; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; WANG A, 1991, J BIOL CHEM, V266, P15598; Wang JH, 1999, SHOCK, V11, P311, DOI 10.1097/00024382-199905000-00002; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Wright P, 1999, CANCER BIOTHER RADIO, V14, P49, DOI 10.1089/cbr.1999.14.49; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yu JY, 2001, CIRC RES, V89, P1161, DOI 10.1161/hh2401.101909; Yue TL, 1999, J BIOL CHEM, V274, P1479, DOI 10.1074/jbc.274.3.1479; Zhai YF, 1999, INT J CANCER, V82, P131, DOI 10.1002/(SICI)1097-0215(19990702)82:1<131::AID-IJC22>3.3.CO;2-F; Zhai YF, 1999, FASEB J, V13, P181, DOI 10.1096/fasebj.13.1.181	48	86	109	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3					742	+		10.1096/fj.01-0757fje	http://dx.doi.org/10.1096/fj.01-0757fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923219				2022-12-25	WOS:000174755900009
J	Moritz, W; Meier, F; Stroka, D; Giuliani, M; Kugelmeier, P; Nett, PC; Lehmann, R; Candinas, D; Gassmann, M; Weber, M				Moritz, W; Meier, F; Stroka, D; Giuliani, M; Kugelmeier, P; Nett, PC; Lehmann, R; Candinas, D; Gassmann, M; Weber, M			Apoptosis in hypoxic human pancreatic islets correlates with HIF-1 alpha expression	FASEB JOURNAL			English	Article						caspase-3; hypoxia; islet transplantation	INDUCIBLE FACTOR 1-ALPHA; FACTOR-I HIF-1; NUCLEAR TRANSLOCATION; INSULIN-SECRETION; FACTOR-1-ALPHA; TRANSPLANTATION; INDUCTION; PROTEIN; GENE; RAT	To become insulin independent, patients with type 1 diabetes mellitus require transplantation of at least two donor pancreata because of massive beta-cell loss in the early post-transplantation period. Many studies describing the introduction of new immunosuppressive protocols have shown that this loss is due to not only immunological events but also nonimmunological factors. To test to what extent hypoxia may contribute to early graft loss, we analyzed the occurrence of apoptotic events and the expression of hypoxia-inducible factor 1 (HIF-1), a heterodimeric transcription factor consisting of an oxygen-dependent alpha subunit and a constitutive beta subunit. Histological analysis of human and rat islets revealed nuclear pyknosis as early as 6 h after hypoxic exposure (1% O-2). Moreover, immunoreactivity to activated caspase-3 was observed in the core region of isolated human islets. Of note, both of these markers of apoptosis topographically overlap with HIF-1alpha immunoreactivity. HIF-1alpha mRNA was detected in islets from human and rat as well as in several murine beta-cell lines. When exposed to hypoxia, mouse insulinoma cells (MIN6) had an increased HIF-1alpha protein level, whereas its mRNA level did not alter. In conclusion, our data provide convincing evidence that reduced oxygenation is an important cause of beta-cell loss and suggest that HIF-1alpha protein level is an indicator for hypoxic regions undergoing apoptotic cell death. These observations suggest that gene expression under the control of HIF-1 represents a potential therapeutic tool for improving engraftment of transplanted islets.	Univ Zurich Hosp, Clin Visceral & Transplant Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Div Endocrinol & Diabetol, CH-8091 Zurich, Switzerland; Univ Birmingham, Liver Labs, Birmingham B15 2TH, W Midlands, England; Univ Zurich, Inst Physiol & Vet Physiol, CH-8057 Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Birmingham; University of Zurich	Weber, M (corresponding author), Univ Zurich Hosp, Clin Visceral & Transplant Surg, Ramistr 100, CH-8091 Zurich, Switzerland.	markus.weber@chi.usz.ch	Stroka, Deborah M/F-1806-2013; Lehmann, Roger/B-9120-2015	Lehmann, Roger/0000-0002-3681-4431; Stroka, Deborah/0000-0002-3517-3871; Gassmann, Max/0000-0003-2750-8878				ALEJANDRO R, 1988, TRANSPLANTATION, V45, P1036, DOI 10.1097/00007890-198806000-00008; Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; BONNERWEIR S, 1982, DIABETES, V31, P883, DOI 10.2337/diabetes.31.10.883; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Camenisch G, 2001, PFLUG ARCH EUR J PHY, V443, P240, DOI 10.1007/s004240100679; Carlsson PO, 2001, DIABETES, V50, P489, DOI 10.2337/diabetes.50.3.489; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chilov D, 1999, J CELL SCI, V112, P1203; DAVALLI AM, 1995, TRANSPLANTATION, V59, P817, DOI 10.1097/00007890-199503270-00003; DECOURTEN M, 1997, EPIDEMIOLOGY NIDDM N; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; Hanke J, 2001, CELLS TISSUES ORGANS, V169, P113, DOI 10.1159/000047869; Hofer T, 2001, FASEB J, V15, P2715, DOI 10.1096/fj.01-0546fje; HOFER T, 2002, IN PRESS EUR J PHYSL; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Ilieva A, 1999, J ENDOCRINOL, V161, P357, DOI 10.1677/joe.0.1610357; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Joseph B, 2001, ONCOGENE, V20, P2877, DOI 10.1038/sj.onc.1204402; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; KENDALL DM, 1990, NEW ENGL J MED, V322, P898, DOI 10.1056/NEJM199003293221305; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Linetsky E, 1997, DIABETES, V46, P1120, DOI 10.2337/diabetes.46.7.1120; Mandal M, 1999, BIOCHEM BIOPH RES CO, V260, P775, DOI 10.1006/bbrc.1999.0966; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; MENGER MD, 1989, DIABETES, V38, P199, DOI 10.2337/diab.38.1.S199; MENGER MD, 1992, J CLIN INVEST, V90, P1361, DOI 10.1172/JCI116002; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Moede T, 1999, FEBS LETT, V461, P229, DOI 10.1016/S0014-5793(99)01446-5; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Palmer LA, 1998, AM J PHYSIOL-LUNG C, V274, pL212, DOI 10.1152/ajplung.1998.274.2.L212; Paraskevas S, 1997, TRANSPL P, V29, P750, DOI 10.1016/S0041-1345(96)00452-6; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Rosenberg L, 1999, SURGERY, V126, P393, DOI 10.1067/msy.1999.98783; Ryan EA, 2001, DIABETES, V50, P710, DOI 10.2337/diabetes.50.4.710; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Stratta RJ, 1998, SURGERY, V124, P823, DOI 10.1067/msy.1998.91366; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Thomas FT, 1999, SURGERY, V126, P299, DOI 10.1067/msy.1999.99164; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang RN, 1999, J ENDOCRINOL, V163, P181, DOI 10.1677/joe.0.1630181; Wenger RH, 1997, KIDNEY INT, V51, P560, DOI 10.1038/ki.1997.79; Wenger RH, 1996, BLOOD, V87, P756, DOI 10.1182/blood.V87.2.756.bloodjournal872756; Wenger RH, 1997, BIOL CHEM, V378, P609; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zhong H, 1998, CANCER RES, V58, P5280; Zhong H, 1999, CANCER RES, V59, P5830	54	148	161	2	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					745	+		10.1096/fj.01-0403fje	http://dx.doi.org/10.1096/fj.01-0403fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923216				2022-12-25	WOS:000174755900008
J	Ye, LW; Maloney, PC				Ye, LW; Maloney, PC			Structure/function relationships in OxlT, the oxalate/formate antiporter of Oxalobacter formigenes - Assignment of transmembrane helix 2 to the translocation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELIBIOSE CARRIER; ESCHERICHIA-COLI; OXALATE; TRANSPORTER; IDENTIFICATION; EXCHANGE; PROTEIN; UHPT	We constructed a single cysteine panel encompassing transmembrane helix two (TM2) of OxlT, the oxalate/formate antiporter of Oxalobacter formigenes. Among the 21 positions targeted, cysteine substitution identified one (phenylalanine 59) as essential to OxlT expression and three (glutamine 56, glutamine 66, and serine 69) as potentially critical to OxlT function. By probing membranes with a bulky hydrophilic probe (Oregon Green maleimide) we also located a central inaccessible core of at least eight residues in length, extending from leucine 61 to glycine 68. Functional assays based on reconstitution of crude detergent extracts showed that of single cysteine mutants within the TAU core only the Q63C variant was substantially (greater than or equal to95%) inhibited by thiol-specific agents (carboxyethyl methanethiosulfonate and ethylsulfonate methanethiosulfonate). Subsequent analytical work using the purified Q63C protein showed that inhibition by ethylsulfonate methanethiosulfonate was blocked by substrate and that the concentration dependence of such substrate protection occurred with a binding constant of 0.16 mm oxalate, comparable with the Michaelis constant observed for oxalate transport (0.23 mm). These findings lead us to conclude that position 63 ties on the OxlT translocation pathway. Our conclusion is strengthened by the finding that position 63, along with most other positions relevant to TM2 function, is found on a helical face that can be cross-linked to the pathway-facing surface of TM11.	Johns Hopkins Med Sch, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Maloney, PC (corresponding author), Johns Hopkins Med Sch, Dept Physiol, Baltimore, MD 21205 USA.	pmaloney@jhmi.edu						Abe K, 1996, J BIOL CHEM, V271, P6789, DOI 10.1074/jbc.271.12.6789; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; Fann MC, 1998, J BIOL CHEM, V273, P33735, DOI 10.1074/jbc.273.50.33735; Franco PJ, 2001, BBA-BIOMEMBRANES, V1510, P231, DOI 10.1016/S0005-2736(00)00353-9; Fu DX, 1998, J BIOL CHEM, V273, P17962, DOI 10.1074/jbc.273.28.17962; Fu DX, 2001, J BIOL CHEM, V276, P8753, DOI 10.1074/jbc.M008417200; Fu DX, 1997, J BIOL CHEM, V272, P2129; Hall JA, 1999, J BIOL CHEM, V274, P6148, DOI 10.1074/jbc.274.10.6148; Hall JA, 2001, J BIOL CHEM, V276, P25107, DOI 10.1074/jbc.M102017200; HAMA H, 1994, J BIOL CHEM, V269, P1063; Heymann JAW, 2001, EMBO J, V20, P4408, DOI 10.1093/emboj/20.16.4408; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Kim YM, 2001, J BIOL CHEM, V276, P36681, DOI 10.1074/jbc.M106079200; MALONEY PC, 1994, CURR OPIN CELL BIOL, V6, P571, DOI 10.1016/0955-0674(94)90079-5; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Paulsen IT, 2000, J MOL BIOL, V301, P75, DOI 10.1006/jmbi.2000.3961; RUAN ZS, 1992, J BIOL CHEM, V267, P10537; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; Ye LW, 2001, J BACTERIOL, V183, P2490, DOI 10.1128/JB.183.8.2490-2496.2001	20	17	19	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20372	20378		10.1074/jbc.M111140200	http://dx.doi.org/10.1074/jbc.M111140200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11919184	hybrid			2022-12-25	WOS:000176204500036
J	Beullens, M; Bollen, M				Beullens, M; Bollen, M			The protein phosphatase-1 regulator NIPP1 is also a splicing factor involved in a late step of spliceosome assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-ORGANIZATION; RNA-BINDING; PHOSPHORYLATION; SUBUNIT; SITE; INHIBITOR; COMPLEX	NIPP1 is a ubiquitous regulator of protein phosphatase-1 (PP1) and is targeted to the splicing factor storage sites (speckles) in the nucleus by its forkhead-associated domain. We show here that NIPP1 is also a component of the spliceosomes in HeLa cell-splicing extracts and that the interaction with the spliceosomes requires a functional forkhead-associated domain. The in vitro splicing of beta-globin pre-mRNA was not affected by exogenous wild type NIPP1 but was blocked by mutants that lacked residues 225-329. The inhibition by these dominant negative mutants resulted from a block in a late phase of spliceosome assembly, i.e. at the transition between the B-complex and the C-complex. Site-directed mutagenesis furthermore showed that this spliceosomal function of NIPP1 was unrelated to its ability to bind PP1 or RNA. Our data suggest that NIPP1 can function independently as a splicing factor and a phosphatase regulator.	Katholieke Univ Leuven, Afdeling Biocheim, Fac Geneeskunde, B-3000 Louvain, Belgium	KU Leuven	Bollen, M (corresponding author), Katholieke Univ Leuven, Afdeling Biocheim, Fac Geneeskunde, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.							Beullens M, 2000, BIOCHEM J, V352, P651, DOI 10.1042/0264-6021:3520651; BEULLENS M, 1997, METHOD MOL BIOL, V93, P145; Bollen M, 2002, TRENDS CELL BIOL, V12, P138, DOI 10.1016/S0962-8924(01)02247-4; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; CARDINALI B, 1994, FEBS LETT, V352, P276, DOI 10.1016/0014-5793(94)00973-2; Ceulemans H, 2002, BIOESSAYS, V24, P371, DOI 10.1002/bies.10069; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; Das R, 2000, MOL CELL, V5, P779, DOI 10.1016/S1097-2765(00)80318-4; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Jagiello I, 2000, J CELL SCI, V113, P3761; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Jin QM, 1999, BIOCHEM J, V342, P13, DOI 10.1042/0264-6021:3420013; Mayeda A, 1999, METH MOL B, V118, P315; MERMOUD JE, 1992, NUCLEIC ACIDS RES, V20, P5263, DOI 10.1093/nar/20.20.5263; Misteli T, 1997, TRENDS CELL BIOL, V7, P135, DOI 10.1016/S0962-8924(96)20043-1; Murray MV, 1999, GENE DEV, V13, P87, DOI 10.1101/gad.13.1.87; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; PARK IK, 1994, J BIOL CHEM, V269, P944; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; Trinkle-Mulcahy L, 1999, J CELL SCI, V112, P157; Vulsteke V, 1997, J BIOL CHEM, V272, P32972, DOI 10.1074/jbc.272.52.32972; Wang CY, 1998, GENE DEV, V12, P1409, DOI 10.1101/gad.12.10.1409; Wang X, 1999, EMBO J, V18, P4549, DOI 10.1093/emboj/18.16.4549; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Xiao SH, 1998, EMBO J, V17, P6359, DOI 10.1093/emboj/17.21.6359	25	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19855	19860		10.1074/jbc.M200847200	http://dx.doi.org/10.1074/jbc.M200847200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11909864	hybrid			2022-12-25	WOS:000175894800081
J	Myre, MA; O'Day, DH				Myre, MA; O'Day, DH			Nucleomorphin - A novel, acidic, nuclear calmodulin-binding protein from Dictyostelium that regulates nuclear number	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTAL REGULATION; CHAIN KINASE; CELL; FUSION; DISCOIDEUM; MYOSIN; DOMAIN; PHOSPHORYLATION; NUCLEOPLASMIN; CALCINEURIN	Probing of Dictyostelium discoideum cell extracts after SDS-PAGE using S-35-recombinant calmodulin (CaM) as a probe has revealed approximately three-dozen Ca2+. dependent calmodulin binding proteins. Here, we report the molecular cloning, expression, and subcellular localization of a gene encoding a novel calmodulin-binding protein (CaMBP); we have called nucleomorphin, from D. discoideum. A lambdaZAP cDNA expression library of cells from multicellular development was screened using a recombinant calmodulin probe (S-35-VU1-CaM). The open reading frame of 1119 nucleotides encodes a polypeptide of 340 amino acids with a calculated molecular mass of 38.7 kDa and is constitutively expressed throughout the Dictyostelium life cycle. Nucleomorphin contains a highly acidic glutamic/aspartic acid inverted repeat (DEED) with significant similarity to the conserved nucleoplasmin domain and a putative transmembrane domain in the carboxyl-terminal region. Southern blotting reveals that nucleomorphin exists as a single copy gene. Using gel overlay assays and CaM-agarose we show that bacterially expressed nucleomorphin binds to bovine CaM in a Ca2+-dependent manner. Amino-terminal fusion to the green fluorescence protein (GFP) showed that GFP-NumA localized to the nucleus as distinct arc-like patterns similar to heterochromatin regions. GFP-NumA lacking the acidic DEED repeat still showed are-like accumulations at the nuclear periphery, but the number of nuclei in these cells was increased markedly compared with control cells. Cells expressing GFP-NumA lacking the transmembrane domain localized to the nuclear periphery but did not affect nuclear number or gross morphology. Nucleomorphin is the first nuclear CaMBP to be identified in Dictyostelium. Furthermore, these data present the first identification of a member of the nucleoplasmin family as a calmodulin-binding protein and suggest nucleomorphin has a role in nuclear structure in Dictyostelium.	Univ Toronto, Dept Zool, Mississauga, ON L5L 1C6, Canada	University of Toronto; University Toronto Mississauga	O'Day, DH (corresponding author), Univ Toronto, Dept Zool, 3359 Mississauga Rd,Rm 3030, Mississauga, ON L5L 1C6, Canada.	doday@credit.erin.utoronto.ca		O'Day, Danton/0000-0003-0163-9044				Adachi H, 1997, J CELL BIOL, V137, P891, DOI 10.1083/jcb.137.4.891; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anderson JT, 1996, J BIOL CHEM, V271, P6605, DOI 10.1074/jbc.271.12.6605; Andrade R, 2001, CHROMOSOMA, V109, P545, DOI 10.1007/s004120000121; Arazi T, 1999, PLANT J, V20, P171, DOI 10.1046/j.1365-313x.1999.00588.x; BROCKERHOFF SE, 1994, J CELL BIOL, V124, P315, DOI 10.1083/jcb.124.3.315; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Clancy CE, 1997, J BIOL CHEM, V272, P11812, DOI 10.1074/jbc.272.18.11812; COTTEN M, 1986, BIOCHEMISTRY-US, V25, P5063, DOI 10.1021/bi00366a014; Crevel G, 1997, J STRUCT BIOL, V118, P9, DOI 10.1006/jsbi.1996.3836; Dammann H, 1996, EUR J BIOCHEM, V238, P391, DOI 10.1111/j.1432-1033.1996.0391z.x; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; DINGERMANN T, 1990, DEV GENET, V11, P410, DOI 10.1002/dvg.1020110514; DINGWALL C, 1989, J CELL SCI, P243; DINGWALL C, 1988, J CELL BIOL, V107, P841, DOI 10.1083/jcb.107.3.841; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; FRIEDBERG F, 1991, PROT SEQ DATA ANAL, V3, P335; Gauthier ML, 2001, CELL SIGNAL, V13, P575, DOI 10.1016/S0898-6568(01)00187-5; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; Harlow E., 1988, ANTIBODIES LAB MANUA; Hellstern S, 1997, RES MICROBIOL, V148, P335, DOI 10.1016/S0923-2508(97)81589-6; Horn F, 1996, DIFFERENTIATION, V60, P269, DOI 10.1046/j.1432-0436.1996.6050269.x; Howe L, 1998, J BIOL CHEM, V273, P20693, DOI 10.1074/jbc.273.33.20693; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KELLER CH, 1982, BIOCHEMISTRY-US, V21, P156, DOI 10.1021/bi00530a027; Kessen U, 1999, J BIOL CHEM, V274, P37821, DOI 10.1074/jbc.274.53.37821; KINCAID R, 1993, ADV SEC MESS PHOSPH, V27, P1; Kolman MF, 1997, J BIOL CHEM, V272, P16904, DOI 10.1074/jbc.272.27.16904; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LADANT D, 1989, J BIOL CHEM, V264, P4015; LEITING B, 1991, BIOCHEM BIOPH RES CO, V180, P1403, DOI 10.1016/S0006-291X(05)81352-X; Levi S, 2000, PLASMID, V44, P231, DOI 10.1006/plas.2000.1487; Loomis W., 2012, DEV DICTYOSTELIUM DI; Ludbrook SB, 1997, J BIOL CHEM, V272, P15682, DOI 10.1074/jbc.272.25.15682; Lydan M A, 1994, Methods Mol Biol, V31, P389; LYDAN MA, 1988, EXP CELL RES, V178, P51, DOI 10.1016/0014-4827(88)90377-1; LYDAN MA, 1994, FEMS MICROBIOL LETT, V115, P137, DOI 10.1111/j.1574-6968.1994.tb06628.x; LYDAN MA, 1993, EXP CELL RES, V205, P134, DOI 10.1006/excr.1993.1067; LYDAN MA, 1994, BIOCHEM BIOPH RES CO, V201, P430, DOI 10.1006/bbrc.1994.1719; MANLAN A, 1984, ADV CYCLIC NUCLEOTID, V201, P227; MARIDOR G, 1990, NUCLEIC ACIDS RES, V18, P1286, DOI 10.1093/nar/18.5.1286; MARSHAK DR, 1984, BIOCHEMISTRY-US, V23, P2891, DOI 10.1021/bi00308a007; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Neuhaus EM, 1998, J STRUCT BIOL, V121, P326, DOI 10.1006/jsbi.1998.3971; ODAY DH, 1995, MEM MUS NATL HIST NA, V165, P121; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Pang KM, 1998, CURR BIOL, V8, P405, DOI 10.1016/S0960-9822(98)70159-9; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PHILPOTT A, 1991, CELL, V65, P569, DOI 10.1016/0092-8674(91)90089-H; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; RATAJCZAK T, 1995, BIOCHEM BIOPH RES CO, V209, P117, DOI 10.1006/bbrc.1995.1478; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rivero F, 1996, J CELL SCI, V109, P2679; Safadi F, 2000, J BIOL CHEM, V275, P35457, DOI 10.1074/jbc.M002720200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shackleford Gregory M., 2001, BMC Genomics, V2, P1; SHARP PM, 1989, NUCLEIC ACIDS RES, V17, P5029, DOI 10.1093/nar/17.13.5029; Tsvetkov PO, 1999, J BIOL CHEM, V274, P18161, DOI 10.1074/jbc.274.26.18161; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; Westphal M, 1997, CURR BIOL, V7, P176, DOI 10.1016/S0960-9822(97)70088-5; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4; Ye XJ, 1997, J BIOL CHEM, V272, P3606, DOI 10.1074/jbc.272.6.3606; [No title captured]	65	32	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19735	19744		10.1074/jbc.M109717200	http://dx.doi.org/10.1074/jbc.M109717200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11919178	hybrid			2022-12-25	WOS:000175894800066
J	Sugiyama, M; Ohtani, K; Izuhara, M; Koike, T; Suzuki, K; Imamura, S; Misaki, H				Sugiyama, M; Ohtani, K; Izuhara, M; Koike, T; Suzuki, K; Imamura, S; Misaki, H			A novel prokaryotic phospholipase A(2) - Characterization, gene cloning, and solution structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; CANCER CELL-LINE; CRYSTAL-STRUCTURE; VENOM PHOSPHOLIPASES-A2; SNAKE-VENOM; RESOLUTION; EXPRESSION; MECHANISM; COMPLEX; GROWTH	Until now, phospholipase A(2) (PLA(2); EC 3.1.14) has been found only from eukaryotic sources. In the present study, we found a secreted PIA, which is produced by a soil bacterium, Streptomyces violaceoruber A-2688, demonstrating that the enzyme is the first phospholipase A(2) identified in prokaryote. After characterization of the novel PLA(2), a gene encoding the enzyme was cloned, sequenced, and overexpressed using a Streptomyces host-vector system. The amino acid sequence showed that the prokaryotic PLA(2) has only four cysteines and less homology to the eukaryotic ones, which have 12-16 cysteines. The solution structures of the prokaryotic PLA(2), bound and unbound with calcium(II) ion, were determined by using the NMR technique and structure calculation. The overall structure of the S. violaceoruber PLA(2), which is composed of only five a-helices, is completely different from those of eukaryotic PLA(2)s, which consist of beta-sheets and alpha-helices. The structure of the calcium-binding domain is obviously distinct from that without the ion; the ligands for the calcium(II) ion are the two carboxylates of Asp(43) (monodentate) and Asp(65) (bidentate), the carbonyl oxygen of Leu(44), and three water molecules. A calcium-binding experiment showed that the calcium dissociation constant (similar to5 mm) for the prokaryotic PLA(2) is much larger than those of eukaryotic ones.	Hiroshima Univ, Fac Med, Inst Pharmaceut Sci, Minami Ku, Hiroshima 7348551, Japan; Asahi Kasei Corp, Fine Chem & Diagnost Div, Diagnost Res & Dev, Shizuoka 4102321, Japan	Hiroshima University; Asahi Kasei Corporation	Sugiyama, M (corresponding author), Hiroshima Univ, Fac Med, Inst Pharmaceut Sci, Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.							BRUNIE S, 1985, J BIOL CHEM, V260, P9742; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P118, DOI 10.1016/0005-2744(68)90249-0; DENNIS EA, 1987, BIO-TECHNOL, V5, P1294, DOI 10.1038/nbt1287-1294; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DENNIS EA, 1987, DRUG DEVELOP RES, V10, P205, DOI 10.1002/ddr.430100404; DIJKSTRA BW, 1981, J MOL BIOL, V147, P97, DOI 10.1016/0022-2836(81)90081-4; DIJKSTRA BW, 1982, ACTA CRYSTALLOGR B, V38, P793, DOI 10.1107/S0567740882004099; DRANKENBERG T, 1984, BIOCHEMISTRY-US, V23, P2387; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; HANADA K, 1995, FEBS LETT, V373, P85, DOI 10.1016/0014-5793(95)01005-Y; Hawgood B., 1991, HDB NATURAL TOXINS R, V5, P3; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hopwood D. A., 1985, GENETIC MANIPULATION; HRARA S, 1989, J BIOCHEM-TOKYO, V105, P395; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KARMER RM, 1989, J BIOL CHEM, V264, P5768; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; Kinoshita E, 1997, FEBS LETT, V407, P343, DOI 10.1016/S0014-5793(97)00373-6; Kinoshita E, 1996, INT J ONCOL, V9, P1219; LECHEVALIER MP, 1977, BIOCHEM SYST ECOL, V5, P249, DOI 10.1016/0305-1978(77)90021-7; Matoba Y, 2002, J BIOL CHEM, V277, P20059, DOI 10.1074/jbc.M200263200; MCINTOSH JM, 1995, J BIOL CHEM, V270, P3518, DOI 10.1074/jbc.270.8.3518; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; POWERS R, 1993, BIOCHEMISTRY-US, V32, P6744, DOI 10.1021/bi00077a030; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; SOLAGNI E, 2001, EMBO J, V20, P5079; SUZUKI K, 1992, BIOSCI BIOTECH BIOCH, V56, P432, DOI 10.1271/bbb.56.432; TESHIMA K, 1981, J BIOCHEM, V89, P13, DOI 10.1093/oxfordjournals.jbchem.a133173; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; VANDENBERG B, 1995, EMBO J, V14, P4123, DOI 10.1002/j.1460-2075.1995.tb00086.x; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787	38	46	56	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					20051	20058		10.1074/jbc.M200264200	http://dx.doi.org/10.1074/jbc.M200264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11897786	hybrid			2022-12-25	WOS:000175894800106
J	Tao, GZ; Rott, LS; Lowe, AW; Omary, MB				Tao, GZ; Rott, LS; Lowe, AW; Omary, MB			Hyposmotic stress induces cell growth arrest via proteasome activation and cyclin/cyclin-dependent kinase degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSMOTIC-STRESS; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; INDUCED APOPTOSIS; VOLUME REGULATION; ESCHERICHIA-COLI; PROTEIN-KINASE; CYCLIN-E; PHOSPHORYLATION; PATHWAYS	Ordered cell cycle progression requires the expression and activation of several cyclins and cyclin-dependent kinases (Cdks). Hyperosmotic stress causes growth arrest possibly via proteasome-mediated degradation of cyclin D1. We studied the effect of hyposmotic conditions on three colonic (Caco2, HRT18, HT29) and two pancreatic (AsPC-1 and PaCa-2) cell lines. Hyposmosis caused reversible cell growth arrest of the five cell lines in a cell cycle-independent fashion, although some cell lines accumulated at the G(1)/S interface. Growth arrest was followed by apoptosis or by formation of multinucleated giant cells, which is consistent with cell cycle catastrophe. Hyposmosis dramatically decreased Cdc2, Cdk2, Cdk4, cyclin B1, and cyclin D3 expression in a time-dependent fashion, in association with an overall decrease in cellular protein synthesis. However, some protein levels remained unaltered, including cyclin E and keratin 8. Selective proteasome inhibition prevented Cdk and cyclin degradation and reversed hyposmotic stress-induced growth arrest, whereas calpain and lysosome enzyme inhibitors had no measurable effect on cell cycle protein degradation. Therefore, hyposmotic stress inhibits cell growth and, depending on the cell type, causes cell cycle catastrophe with or without apoptosis. The growth arrest is due to decreased protein synthesis and proteasome activation, with subsequent degradation of several cyclins and Cdks.	Palo Alto Vet Affairs Med Ctr, Dept Med, Palo Alto, CA 94034 USA; Stanford Univ, Ctr Digest Dis, Stanford, CA 94305 USA	Stanford University	Omary, MB (corresponding author), Palo Alto Vet Affairs Med Ctr, Dept Med, Palo Alto, CA 94034 USA.			Omary, Bishr/0000-0002-8624-2347	NIDDK NIH HHS [DK56339, DK47918] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056339, R01DK047918] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad N, 2001, CLIN CANCER RES, V7, P1466; Alepuz PM, 2001, MOL CELL, V7, P767, DOI 10.1016/S1097-2765(01)00221-0; Alexander MR, 2001, MOL BIOL CELL, V12, P53, DOI 10.1091/mbc.12.1.53; Ashrafian H, 2001, EUR J NEUROL, V8, P103, DOI 10.1046/j.1468-1331.2001.00176.x; Blount P, 1999, TRENDS MICROBIOL, V7, P420, DOI 10.1016/S0966-842X(99)01594-2; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; BREWSTER JL, 1994, YEAST, V10, P425, DOI 10.1002/yea.320100402; Burg MB, 1996, FASEB J, V10, P1598, DOI 10.1096/fasebj.10.14.9002551; Calamita G, 2000, MOL MICROBIOL, V37, P254, DOI 10.1046/j.1365-2958.2000.02016.x; Canman CE, 2001, CURR BIOL, V11, pR121, DOI 10.1016/S0960-9822(01)00057-4; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chinni SR, 2001, ONCOGENE, V20, P2927, DOI 10.1038/sj.onc.1204365; CHOU CF, 1993, J BIOL CHEM, V268, P4465; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Du LT, 2001, INT J ONCOL, V19, P811; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fan XM, 2001, INT J CANCER, V93, P481, DOI 10.1002/ijc.1373; Gatsios P, 1998, J BIOL CHEM, V273, P22962, DOI 10.1074/jbc.273.36.22962; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hohmann S, 2000, TRENDS MICROBIOL, V8, P33, DOI 10.1016/S0966-842X(99)01645-5; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jackle T, 2001, AM J PHYSIOL-CELL PH, V281, pC1716, DOI 10.1152/ajpcell.2001.281.5.C1716; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Kim RD, 2000, J SURG RES, V90, P58, DOI 10.1006/jsre.2000.5866; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; Koyama T, 2001, J PHYSIOL-LONDON, V532, P759, DOI 10.1111/j.1469-7793.2001.0759e.x; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Ku NO, 2001, J BIOL CHEM, V276, P26792, DOI 10.1074/jbc.M103315200; Kultz D, 1998, J EXP BIOL, V201, P3015; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; Kuwayama H, 1996, SCIENCE, V271, P207, DOI 10.1126/science.271.5246.207; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; Leitch V, 2001, P NATL ACAD SCI USA, V98, P2894, DOI 10.1073/pnas.041616498; Liu F, 1999, MOL CELL BIOL, V19, P5113; Malek AM, 1998, STROKE, V29, P2631, DOI 10.1161/01.STR.29.12.2631; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mountian I, 1998, EUR J CELL BIOL, V77, P196, DOI 10.1016/S0171-9335(98)80107-6; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; NYSTROM T, 1994, MOL MICROBIOL, V11, P537, DOI 10.1111/j.1365-2958.1994.tb00334.x; Okada Y, 2001, J PHYSIOL-LONDON, V532, P3, DOI 10.1111/j.1469-7793.2001.0003g.x; OKADA Y, 1997, AM J PHYSIOL, V273, P775; Rizoli SB, 2000, AM J PHYSIOL-CELL PH, V279, pC619, DOI 10.1152/ajpcell.2000.279.3.C619; Rizoli SB, 1999, J BIOL CHEM, V274, P22072, DOI 10.1074/jbc.274.31.22072; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; Toivola DM, 2000, EXP CELL RES, V255, P156, DOI 10.1006/excr.1999.4787; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van der Wijk T, 2000, CELL PHYSIOL BIOCHEM, V10, P289, DOI 10.1159/000016359; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Yamada Y, 2000, EUR J HAEMATOL, V64, P315, DOI 10.1034/j.1600-0609.2000.90110.x; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yoshikawa R, 2001, CANCER RES, V61, P1029; Zhang Z., 1998, AM J PHYSIOL, V275, P1104; Zischka H, 1999, EMBO J, V18, P4241, DOI 10.1093/emboj/18.15.4241	66	23	34	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19295	19303		10.1074/jbc.M109654200	http://dx.doi.org/10.1074/jbc.M109654200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11897780	hybrid			2022-12-25	WOS:000175894800009
J	Wang, Y; Xu, AM; Knight, C; Xu, LY; Cooper, GJS				Wang, Y; Xu, AM; Knight, C; Xu, LY; Cooper, GJS			Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin - Potential role in the modulation of its insulin-sensitizing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-SPECIFIC PROTEIN; PLASMA-CONCENTRATIONS; ADIPOCYTE; GENE; EXPRESSION; OBESITY; RESISTANCE; ACRP30; PHOSPHORYLATION; IDENTIFICATION	It has recently been shown that the fat-derived hormone adiponectin has the ability to decrease hyperglycemia and to reverse insulin resistance. However, bacterially produced full-length adiponectin is functionally inactive. Here, we show that endogenous adiponectin secreted by adipocytes is post-translationally modified into eight different isoforms, as shown by two-dimensional gel electrophoresis. Carbohydrate detection revealed that six of the adiponectin isoforms are glycosylated. The glycosylation sites were mapped to several lysines (residues 68, 71, 80, and 104) located in the collagenous domain of adiponectin, each having the surrounding motif of GXKGE(D). These four lysines were found to be hydroxylated and subsequently glycosylated. The glycosides attached to each of these four hydroxylated lysines are possibly glucosylgalactosyl groups. Functional analysis revealed that full-length adiponectin produced by mammalian cells is much more potent than bacterially generated adiponectin in enhancing the ability of subphysiological concentrations of insulin to inhibit gluconeogenesis in primary rat hepatocytes, whereas this insulin-sensitizing ability was significantly attenuated when the four glycosylated lysines were substituted with arginines. These results indicate that full-length adiponectin produced by mammalian cells is functionally active as an insulin sensitizer and that hydroxylation and glycosylation of the four lysines in the collagenous domain might contribute to this activity.	Univ Auckland, Sch Biol Sci, Auckland 1001, New Zealand	University of Auckland	Xu, AM (corresponding author), Univ Auckland, Sch Biol Sci, Level 4,Thomas Bldg,Private Bag 92019, Auckland 1001, New Zealand.		Cooper, Garth JS/I-3201-2015; Wang, Yu/B-4534-2009; Xu, Aimin/D-3291-2013	Cooper, Garth JS/0000-0001-5241-3163; Xu, Aimin/0000-0002-0668-033X; wang, yu/0000-0001-8697-2940				Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Bradley RL, 2001, RECENT PROG HORM RES, V56, P329, DOI 10.1210/rp.56.1.329; COLLEY KJ, 1987, J BIOL CHEM, V262, P10290; Combatsiaris TP, 2001, DIABETES, V50, pA271; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Das K, 2001, BIOCHEM BIOPH RES CO, V280, P1120, DOI 10.1006/bbrc.2001.4217; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Fruhbeck G, 2001, AM J PHYSIOL-ENDOC M, V280, pE827, DOI 10.1152/ajpendo.2001.280.6.E827; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; Hotta K, 2001, DIABETES, V50, P1126, DOI 10.2337/diabetes.50.5.1126; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; JOHNSON RG, 1980, CLIN ORTHOP RELAT R, P282; Kim S, 2000, J NUTR, V130, p3110S; Leffert H L, 1979, Methods Enzymol, V58, P536; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P803; Saito K, 1999, GENE, V229, P67, DOI 10.1016/S0378-1119(99)00041-4; Sato C, 2001, J BIOL CHEM, V276, P28849, DOI 10.1074/jbc.M104148200; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; SHINKAI H, 1979, BIOCHEM J, V177, P847, DOI 10.1042/bj1770847; Statnick M A, 2000, Int J Exp Diabetes Res, V1, P81, DOI 10.1155/EDR.2000.81; Steppan CM, 2002, TRENDS ENDOCRIN MET, V13, P18, DOI 10.1016/S1043-2760(01)00522-7; Takahashi M, 2000, INT J OBESITY, V24, P861, DOI 10.1038/sj.ijo.0801244; Wang Y, 2001, DIABETES, V50, P1821, DOI 10.2337/diabetes.50.8.1821; Wang Y, 1999, FEBS LETT, V462, P25, DOI 10.1016/S0014-5793(99)01496-9; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Wu GC, 2001, J BIOL CHEM, V276, P35450, DOI 10.1074/jbc.M009704200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yang WS, 2001, J CLIN ENDOCR METAB, V86, P3815, DOI 10.1210/jc.86.8.3815	33	283	323	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19521	19529		10.1074/jbc.M200601200	http://dx.doi.org/10.1074/jbc.M200601200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11912203	hybrid			2022-12-25	WOS:000175894800039
J	Frank, S; Schulthess, T; Landwehr, R; Lustig, A; Mini, T; Jeno, P; Engel, J; Kammerer, RA				Frank, S; Schulthess, T; Landwehr, R; Lustig, A; Mini, T; Jeno, P; Engel, J; Kammerer, RA			Characterization of the matrilin coiled-coil domains reveals seven novel isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; ALPHA-HELICAL PROTEIN; C-TERMINAL DOMAIN; EXTRACELLULAR-MATRIX; A-DOMAIN; FILAMENTOUS NETWORK; MOLECULAR-STRUCTURE; TISSUE DISTRIBUTION; AMINO-ACID; CARTILAGE	Matrilins constitute a family of four oligomeric extracellular proteins that are involved in the development and homeostasis of cartilage and bone. To reveal their homo- and heterotypic oligomerization propensities, we analyzed the four human matrilin coiled-coil domains by biochemical and biophysical methods. These studies not only confirmed the homo- and heterotypic oligomerization states reported for the full-length proteins but revealed seven novel matrilin isoforms. Specific heterotrimeric interactions of variable chain stoichiometries were observed between matrilin-1 and matrilin-2, matrilin-1 and matrilin-4, and matrilin-2 and matrilin-4. In addition, matrilin-1 formed two different specific heterotetramers with matrilin-3. Interestingly, a distinct heterotrimer consisting of three different chains was formed between matrilin-1, matrilin-2, and matrilin-4. No interactions, however, were observed between matrilin-2 and matrilin-3 or between matrilin-3 and matrilin-4. Both homo- and heterotypic oligomers folded into parallel disulfide-linked structures, although coiled-coil formation was not dependent on disulfide bridge formation. Our results indicate that the heterotypic preferences seen for the matrilin coiled-coil domains are the result of the packing of the hydrophobic core rather than ionic interactions. Mass spectrometry revealed that the concentrations of the individual chains statistically determined the stoichiometry of the heteromers, suggesting that formation of the different matrillin chain combinations is controlled by expression levels.	Univ Basel, Bioctr, Dept Biophys Chem, CH-4056 Basel, Switzerland; Univ Basel, Bioctr, Dept Biochem, CH-4056 Basel, Switzerland; Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Basel; University of Basel; University of Manchester	Engel, J (corresponding author), Univ Basel, Bioctr, Dept Biophys Chem, Klingelbergstr 70, CH-4056 Basel, Switzerland.	juergen.engel@unibas.ch		Kammerer, Richard/0000-0003-4570-5197				Aszodi A, 1996, EUR J BIOCHEM, V236, P970, DOI 10.1111/j.1432-1033.1996.00970.x; Beck K, 1996, J MOL BIOL, V256, P909, DOI 10.1006/jmbi.1996.0137; Beck K, 1997, EMBO J, V16, P3767, DOI 10.1093/emboj/16.13.3767; Belluoccio D, 1998, GENOMICS, V53, P391, DOI 10.1006/geno.1998.5519; Belluoccio D, 1997, FEBS LETT, V415, P212, DOI 10.1016/S0014-5793(97)01126-5; Chanut-Delalande H, 2001, J BIOL CHEM, V276, P24352, DOI 10.1074/jbc.M101182200; Chapman KL, 2001, NAT GENET, V28, P393, DOI 10.1038/ng573; CHEN Q, 1995, MOL BIOL CELL, V6, P1743, DOI 10.1091/mbc.6.12.1743; Chen Q, 1999, MOL BIOL CELL, V10, P2149, DOI 10.1091/mbc.10.7.2149; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; COLOMBATTI A, 1991, BLOOD, V77, P2305; Dames SA, 1998, NAT STRUCT BIOL, V5, P687, DOI 10.1038/1382; DAVIS MT, 1995, ANAL CHEM, V67, P4549, DOI 10.1021/ac00120a019; Deak F, 1999, MATRIX BIOL, V18, P55, DOI 10.1016/S0945-053X(98)00006-7; Deak F, 1997, J BIOL CHEM, V272, P9268; Dong HJ, 1996, J MOL BIOL, V260, P649, DOI 10.1006/jmbi.1996.0428; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Efimov VP, 1996, PROTEINS, V24, P259, DOI 10.1002/(SICI)1097-0134(199602)24:2<259::AID-PROT13>3.0.CO;2-M; Guo Y, 2000, BIOPHYS CHEM, V85, P179, DOI 10.1016/S0301-4622(00)00119-8; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hauser N, 1996, J BIOL CHEM, V271, P32247, DOI 10.1074/jbc.271.50.32247; HAUSER N, 1994, J BIOL CHEM, V269, P25747; Hodges RS, 1996, BIOCHEM CELL BIOL, V74, P133, DOI 10.1139/o96-015; Huang XM, 1999, DEV DYNAM, V216, P434, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<434::AID-DVDY11>3.3.CO;2-O; Kammerer RA, 1999, EMBO J, V18, P6762, DOI 10.1093/emboj/18.23.6762; Kammerer RA, 1997, MATRIX BIOL, V15, P555, DOI 10.1016/S0945-053X(97)90031-7; Keating AE, 2001, P NATL ACAD SCI USA, V98, P14825, DOI 10.1073/pnas.261563398; Klatt AR, 2000, J BIOL CHEM, V275, P3999, DOI 10.1074/jbc.275.6.3999; Klatt AR, 2001, J BIOL CHEM, V276, P17267, DOI 10.1074/jbc.M100587200; Kleemann-Fischer D, 2001, ARCH BIOCHEM BIOPHYS, V387, P209, DOI 10.1006/abbi.2000.2256; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Makihira S, 1999, J BIOL CHEM, V274, P11417, DOI 10.1074/jbc.274.16.11417; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; Pace C N, 1986, Methods Enzymol, V131, P266; Pan OH, 1998, J BIOL CHEM, V273, P14205, DOI 10.1074/jbc.273.23.14205; PAULSSON M, 1979, BIOCHEM J, V183, P539, DOI 10.1042/bj1830539; PAULSSON M, 1982, BIOCHEM J, V207, P207, DOI 10.1042/bj2070207; Paulsson M, 1999, BIOCHEM SOC T, V27, P824, DOI 10.1042/bst0270824; PETERS J, 1995, J MOL BIOL, V245, P385, DOI 10.1006/jmbi.1994.0032; Peters J, 1996, J MOL BIOL, V257, P1031, DOI 10.1006/jmbi.1996.0221; Piecha D, 1999, J BIOL CHEM, V274, P13353, DOI 10.1074/jbc.274.19.13353; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Segat D, 2000, MATRIX BIOL, V19, P649, DOI 10.1016/S0945-053X(00)00112-8; SODEK J, 1972, P NATL ACAD SCI USA, V69, P3800, DOI 10.1073/pnas.69.12.3800; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; Van Holde K. E., 1985, PHYSICAL BIOCH, P93; Wagener R, 1998, FEBS LETT, V438, P165, DOI 10.1016/S0014-5793(98)01293-9; Wagener R, 1997, FEBS LETT, V413, P129, DOI 10.1016/S0014-5793(97)00895-8; Wagener R, 1998, FEBS LETT, V436, P123, DOI 10.1016/S0014-5793(98)01111-9; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307; WOOLFSON DN, 1995, PROTEIN SCI, V4, P1596, DOI 10.1002/pro.5560040818; Wu JJ, 1998, J BIOL CHEM, V273, P17433, DOI 10.1074/jbc.273.28.17433; Zhang Y, 2000, J BIOL CHEM, V275, P32628, DOI 10.1074/jbc.M002594200	59	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19071	19079		10.1074/jbc.M202146200	http://dx.doi.org/10.1074/jbc.M202146200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11896063	hybrid			2022-12-25	WOS:000175975800108
J	Fukuda, T; Kiuchi, K; Takahashi, M				Fukuda, T; Kiuchi, K; Takahashi, M			Novel mechanism of regulation of Rac activity and lamellipodia formation by RET tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; PHOSPHATIDYLINOSITOL 3-KINASE; DOCKING SITE; RHO GTPASES; PROTEIN; RECEPTOR; SHC; ACTIVATION; NEURONS; BINDING	Rac activation in neuronal cells plays an important role in lamellipodia formation that is a critical event for neuritogenesis. It is well known that the Rac activity is regulated via activation of phosphatidylinositol 3-kinase (PI3K) by a variety of receptor tyrosine kinases. Here we show that increased serine phosphorylation on RET receptor tyrosine kinase following cAMP elevation promotes lamellipodia formation of neuronal cells induced by glial cell line-derived neurotrophic factor (GDNF). We identified serine 696 in RET as a putative phosphorylation site by protein kinase A and found that mutation of this serine almost completely inhibited lamellipodia formation by GDNF without affecting activation of the PI3K/ AKT signaling pathway. Mutation of tyrosine 1062 in RET, whose phosphorylation is crucial for activation of PI3K, also inhibited lamellipodia formation by GDNF. Inhibition of lamellipodia formation by mutation of either serine 696 or tyrosine 1062 was associated with decrease of the Rac1-guanine nucleotide exchange factor (GEF) activity, suggesting that this activity is regulated by two different signaling pathways via serine 696 and tyrosine 1062 in RET. Moreover, in the presence of serine 696 mutation, lamellipodia formation was rescued by replacing tyrosine 687 with phenylalanine. These findings propose a novel mechanism that receptor tyrosine kinase modulates actin dynamics in neuronal cells via its cAMP-dependent phosphorylation.	Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; RIKEN, Inst Phys & Chem Res, Biomomet Control Res Ctr, Lab Genes Motor Syst,Moriyama Ku, Nagoya, Aichi 4630003, Japan	Nagoya University; RIKEN	Takahashi, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	mtakaha@med.nagoya-u.ac.jp	TAKAHASHI, Masahide/I-7244-2014; Takahashi, Masahide/AAN-4770-2020	Takahashi, Masahide/0000-0002-2803-2683				Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Barone MV, 2001, ONCOGENE, V20, P6973, DOI 10.1038/sj.onc.1204886; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bohm SK, 1997, BIOCHEM J, V322, P1; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Chern YJ, 2000, CELL SIGNAL, V12, P195, DOI 10.1016/S0898-6568(99)00084-4; Chiariello M, 1998, ONCOGENE, V16, P2435, DOI 10.1038/sj.onc.1201778; Dell'Acqua ML, 1998, EMBO J, V17, P2246, DOI 10.1093/emboj/17.8.2246; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Engele J, 1996, CELL TISSUE RES, V286, P235, DOI 10.1007/s004410050692; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; Hanson MG, 1998, J NEUROSCI, V18, P7361; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Hayashi Y, 2001, BIOCHEM BIOPH RES CO, V281, P682, DOI 10.1006/bbrc.2001.4338; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; Murakami H, 1999, ONCOGENE, V18, P1975, DOI 10.1038/sj.onc.1202514; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Qiao S, 2001, J BIOL CHEM, V276, P9460, DOI 10.1074/jbc.M008744200; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249	44	110	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19114	19121		10.1074/jbc.M200643200	http://dx.doi.org/10.1074/jbc.M200643200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886862	hybrid			2022-12-25	WOS:000175975800113
J	Jackson, AD; Denu, JM				Jackson, AD; Denu, JM			Structural identification of 2 '- and 3 '-O-acetyl-ADP-ribose as novel metabolites derived from the Sir2 family of beta-NAD(+)-dependent histone/protein deacetylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SILENCING PROTEIN SIR2; SACCHAROMYCES-CEREVISIAE; ACYL MIGRATION; LIFE-SPAN; YEAST; NAD; GLUCURONIDE; EXPRESSION; STABILITY; LONGEVITY	The Sir2 (silent information regulator 2) family of histone/protein deacetylases has been implicated in a wide range of biological activities, including gene silencing, life-span extension, and chromosomal stability. Their dependence on beta-NAD(+) for activity is unique among the known classes of histone/protein deacetylase. Sir2 enzymes have been shown to couple substrate deacetylation and beta-NAD(+) cleavage to the formation of O-acetyl-ADP-ribose, a newly described metabolite. To gain a better understanding of the catalytic mechanism and of the biological implications of producing this molecule, we have performed a detailed enzymatic and structural characterization of O-acetyl-ADP-ribose. Through the use of mass spectrometry, rapid quenching techniques, and NMR structural analyses, 2'-O-acetyl-ADP-ribose and 3'-O-acetyl-ADP-ribose were found to be the solution products produced by the Sir2 family of enzymes. Rapid quenching approaches under single-turnover conditions identified 2'-O-acetyl-ADP-ribose as the enzymatic product, whereas 3'-O-acetyl-ADP-ribose was formed by intramolecular transesterification after enzymatic release into bulk solvent, where 2'- and 3'-O-acetyl-ADP-ribose exist in equilibrium (48:52). In addition to H-1 and C-13 chemical shift assignments for each regioisomer, heteronuclear multiple-bond correlation spectroscopy was used to assign unambiguously the position of the acetyl group. These findings are highly significant, because they differ from the previous conclusion, which suggested that 1'-O-acetyl-ADP-ribose was the solution product of the reaction. Possible mechanisms for the generation of 2'-O-acetyl-ADP-ribose are discussed.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Denu, JM (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	denuj@ohsu.edu			NIDDK NIH HHS [DK07680-12] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BARKER R, 1961, J ORG CHEM, V26, P4605, DOI 10.1021/jo01069a095; BORRA MT, 2002, J BIOL CHEM     0125; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; Corcoran O, 2001, CHEM RES TOXICOL, V14, P1363, DOI 10.1021/tx010015q; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Hasegawa H, 2001, BIOL PHARM BULL, V24, P852, DOI 10.1248/bpb.24.852; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jemnitz K, 2000, EUR J DRUG METAB PH, V25, P153, DOI 10.1007/BF03192307; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kim Y, 2000, ANAL BIOCHEM, V280, P308, DOI 10.1006/abio.2000.4546; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; Mortensen RW, 2001, DRUG METAB DISPOS, V29, P375; RINE J, 1987, GENETICS, V116, P9; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288	30	175	178	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18535	18544		10.1074/jbc.M200671200	http://dx.doi.org/10.1074/jbc.M200671200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893743	hybrid			2022-12-25	WOS:000175975800039
J	Jin, SB; Zhao, J; Bjork, P; Schmekel, K; Ljungdahl, PO; Wieslander, L				Jin, SB; Zhao, J; Bjork, P; Schmekel, K; Ljungdahl, PO; Wieslander, L			Mrd1p is required for processing of pre-rRNA and for maintenance of steady-state levels of 40 S ribosomal subunits in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEOLAR RIBONUCLEOPROTEIN; EXTERNAL TRANSCRIBED SPACER; RNA RECOGNITION MOTIFS; TRANS-ACTING FACTORS; SMALL NUCLEAR-RNA; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; SNORNP PROTEIN; U3 SNORNP; IN-VIVO	Ribosome biogenesis is a conserved process in eukaryotes that requires a large number of small nucleolar RNAs and trans-acting proteins. The Saccharomyces cerevisiae MRD1 (Multiple RNA-binding domain) gene encodes a novel protein that contains five consensus RNA-binding domains. Mrd1p is essential for viability. Mrd1p partially co-localizes with the nucleolar protein Nop1p. Depletion of Mrd1p leads to a selective reduction of 18 S rRNA and 40 S ribosomal subunits. Mrd1p associates with the 35 S precursor rRNA (pre-rRNA) and U3 small nucleolar RNAs and is necessary for the initial processing at the A(0)-A(2) cleavage sites in pre-rRNA. The presence of five RNA-binding domains in Mrd1p suggests that Mrd1p may function to correctly fold pre-rRNA, a requisite for proper cleavage. Sequence comparisons suggest that Mrd1p homologues exist in all eukaryotes.	Stockholm Univ, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden; Karolinska Inst, Ludwig Inst Canc Res, SE-17177 Stockholm, Sweden	Stockholm University; Karolinska Institutet; Ludwig Institute for Cancer Research	Wieslander, L (corresponding author), Stockholm Univ, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden.		Wieslander, Lars/B-4670-2016; Ljungdahl, Per O/M-5258-2013; Zhao, Jian/F-9991-2019	Wieslander, Lars/0000-0003-3271-6946; Ljungdahl, Per O/0000-0002-6625-3540; Zhao, Jian/0000-0001-5659-730X				Allain FHT, 2000, EMBO J, V19, P6870, DOI 10.1093/emboj/19.24.6870; ALLEN JB, 1994, YEAST, V10, P1267, DOI 10.1002/yea.320101003; Allmang C, 1996, RNA, V2, P63; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BELTRAME M, 1994, NUCLEIC ACIDS RES, V22, P4057, DOI 10.1093/nar/22.20.4057; Billy E, 2000, EMBO J, V19, P2115, DOI 10.1093/emboj/19.9.2115; Brachmann CB, 1998, YEAST, V14, P115; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Colley A, 2000, MOL CELL BIOL, V20, P7238, DOI 10.1128/MCB.20.19.7238-7246.2000; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Dunbar DA, 1997, MOL CELL BIOL, V17, P5803, DOI 10.1128/MCB.17.10.5803; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; Enright CA, 1996, RNA, V2, P1094; Filipowicz W, 1999, ACTA BIOCHIM POL, V46, P377, DOI 10.18388/abp.1999_4171; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Ginisty H, 1999, J CELL SCI, V112, P761; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; Guthrie C, 1991, METHODS ENZYMOLOGY, V194; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hong B, 1997, MOL CELL BIOL, V17, P378, DOI 10.1128/MCB.17.1.378; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; Hurt E, 1999, J CELL BIOL, V144, P389, DOI 10.1083/jcb.144.3.389; JANSEN R, 1993, EMBO J, V12, P2549, DOI 10.1002/j.1460-2075.1993.tb05910.x; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Kressler D, 1997, MOL CELL BIOL, V17, P7283, DOI 10.1128/MCB.17.12.7283; LAFONTAINE D, 1995, GENE DEV, V9, P2470, DOI 10.1101/gad.9.20.2470; Lafontaine DLJ, 1999, RNA, V5, P455, DOI 10.1017/S135583829998192X; Lalev AI, 2000, J MOL BIOL, V302, P65, DOI 10.1006/jmbi.2000.4015; Leary DJ, 2001, FEBS LETT, V509, P145, DOI 10.1016/S0014-5793(01)03143-X; Lee SJ, 1999, MOL CELL BIOL, V19, P5441; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; MORRISSEY JP, 1995, TRENDS BIOCHEM SCI, V20, P78, DOI 10.1016/S0968-0004(00)88962-8; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; MOUGEY EB, 1993, MOL CELL BIOL, V13, P5990, DOI 10.1128/MCB.13.10.5990; Moy TI, 1999, GENE DEV, V13, P2118, DOI 10.1101/gad.13.16.2118; ODay CL, 1996, NUCLEIC ACIDS RES, V24, P3201, DOI 10.1093/nar/24.16.3201; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; ORRICK LR, 1973, P NATL ACAD SCI USA, V70, P1316, DOI 10.1073/pnas.70.5.1316; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Pintard L, 2000, MOL CELL BIOL, V20, P1370, DOI 10.1128/MCB.20.4.1370-1381.2000; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith J.A., 2000, CURRENT PROTOCOLS MO; Stage-Zimmermann T, 2000, MOL BIOL CELL, V11, P3777, DOI 10.1091/mbc.11.11.3777; Sun C, 1997, J BIOL CHEM, V272, P25345, DOI 10.1074/jbc.272.40.25345; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; Tollervey D, 1996, EXP CELL RES, V229, P226, DOI 10.1006/excr.1996.0364; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; TRAPMAN J, 1975, EXP CELL RES, V90, P95, DOI 10.1016/0014-4827(75)90361-4; UDEM SA, 1973, J BIOL CHEM, V248, P1412; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; Venema J, 2000, RNA, V6, P1660, DOI 10.1017/S1355838200001369; Venema J, 1997, MOL CELL BIOL, V17, P3398, DOI 10.1128/MCB.17.6.3398; VENEMA J, 1995, EMBO J, V14, P4883, DOI 10.1002/j.1460-2075.1995.tb00169.x; Venema J, 1996, EMBO J, V15, P5701, DOI 10.1002/j.1460-2075.1996.tb00954.x; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Watkins NJ, 2000, CELL, V103, P457, DOI 10.1016/S0092-8674(00)00137-9; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Wiederkehr T, 1998, RNA, V4, P1357, DOI 10.1017/S1355838298980955; Wu P, 1998, J BIOL CHEM, V273, P16453, DOI 10.1074/jbc.273.26.16453; Yelin R, 2001, BBA-BIOMEMBRANES, V1510, P426, DOI 10.1016/S0005-2736(00)00374-6	68	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18431	18439		10.1074/jbc.M112395200	http://dx.doi.org/10.1074/jbc.M112395200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11884397	hybrid			2022-12-25	WOS:000175975800024
J	Miake, H; Mizusawa, H; Iwatsubo, T; Hasegawa, M				Miake, H; Mizusawa, H; Iwatsubo, T; Hasegawa, M			Biochemical characterization of the core structure of alpha-synuclein filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; PAIRED HELICAL FILAMENTS; GLIAL CYTOPLASMIC INCLUSIONS; PARKINSONS-DISEASE; LEWY BODIES; ALZHEIMERS-DISEASE; FIBRIL FORMATION; PROTEIN-TAU; IN-VITRO; MUTATIONS	Intracellular filamentous aggregates comprised of alpha-synuclein such as Lewy bodies and glial cytoplasmic inclusions are the defining hallmarks of a subset of neurodegenerative diseases including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. We have analyzed biochemical and structural properties of alpha-synuclein filaments assembled in vitro or extracted from brains of patients with multiple system atrophy and found that both types of filaments are insoluble to detergents and partially resistant to proteinase K digestion. Immunoelectron microscopy and immunoblot analysis showed that both amino and carboxyl termini of alpha-synuclein in in vitro assembled filaments were degraded by proteinase K treatment, whereas the central portion of alpha-synuclein is resistant to proteinase K and retains filamentous structures. Protein sequencing and mass spectrometric analyses of the proteinase K-resistant, minimal fragment of 7 kDa revealed that amino acid residues 31-109 of alpha-synuclein constitute the core unit of the filaments. These observations suggest that the central half of the alpha-synuclein polypeptide, containing five tandem repeats as well as a part of the carboxyl-terminal acidic region, forms the core structure of alpha-synuclein filaments, which is coated by the amino- and carboxyl-terminaI portions at the periphery.	Tokyo Metropolitan Org Med Res, Tokyo Inst Psychiat, Dept Mol Neurobiol, Setagaya Ku, Tokyo 1568585, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Med & Dent Univ, Grad Sch Med, Dept Neurol & Neurol Sci, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Institute of Psychiatry; Tokyo Metropolitan Institute of Medical Science; University of Tokyo; Tokyo Medical & Dental University (TMDU)	Hasegawa, M (corresponding author), Tokyo Metropolitan Org Med Res, Tokyo Inst Psychiat, Dept Mol Neurobiol, Setagaya Ku, 2-1-8 Kamikitazawa, Tokyo 1568585, Japan.							Baba M, 1998, AM J PATHOL, V152, P879; Biere AL, 2000, J BIOL CHEM, V275, P34574, DOI 10.1074/jbc.M005514200; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; CROWTHER RA, 1992, FEBS LETT, V309, P199, DOI 10.1016/0014-5793(92)81094-3; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Crowther RA, 2000, NEUROSCI LETT, V292, P128, DOI 10.1016/S0304-3940(00)01440-3; Culvenor JG, 1999, AM J PATHOL, V155, P1173, DOI 10.1016/S0002-9440(10)65220-0; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goedert M, 2001, CURR OPIN GENET DEV, V11, P343, DOI 10.1016/S0959-437X(00)00200-8; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; HASEGAWA M, 1993, J NEUROCHEM, V60, P2068, DOI 10.1111/j.1471-4159.1993.tb03491.x; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jakes R, 1999, NEUROSCI LETT, V269, P13, DOI 10.1016/S0304-3940(99)00411-5; Jo EJ, 2000, J BIOL CHEM, V275, P34328, DOI 10.1074/jbc.M004345200; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KSIEZAKREDING H, 1991, NEURON, V6, P717, DOI 10.1016/0896-6273(91)90169-Z; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; NOVAK M, 1993, EMBO J, V12, P365, DOI 10.1002/j.1460-2075.1993.tb05665.x; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Wakabayashi K, 1998, NEUROSCI LETT, V249, P180, DOI 10.1016/S0304-3940(98)00407-8; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573	35	205	212	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19213	19219		10.1074/jbc.M110551200	http://dx.doi.org/10.1074/jbc.M110551200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893734	hybrid			2022-12-25	WOS:000175975800125
J	Van Hooser, JP; Liang, Y; Maeda, T; Kuksa, V; Jang, GF; He, YG; Rieke, F; Fong, HKW; Detwiler, PB; Palczewski, K				Van Hooser, JP; Liang, Y; Maeda, T; Kuksa, V; Jang, GF; He, YG; Rieke, F; Fong, HKW; Detwiler, PB; Palczewski, K			Recovery of visual functions in a mouse model of Leber congenital amaurosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL-PIGMENT EPITHELIUM; VERTEBRATE RETINA; RPE65 MUTATIONS; OUTER SEGMENTS; BLOOD-PLASMA; GENE; PROTEIN; RHODOPSIN; BINDING; CYCLE	The visual process is initiated by the photoisomerization of 11-cis-retinal to all-trans-retinal. For sustained vision the 11-cis-chromophore must be regenerated from all-trans-retinal. This requires RPE65, a dominant retinal pigment epithelium protein. Disruption of the RPE65 gene results in massive accumulation of all-trans-retinyl esters in the retinal pigment epithelium, lack of 11-cis-retinal and therefore rhodopsin, and ultimately blindness. We reported previously (Van Hooser, J. P., Aleman, T. S., He, Y. G., Cideciyan, A. V., Kuksa, V., Pittler, S. J., Stone, E. M., Jacobson, S. G., and Palczewski, K. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 8623-8628) that in Rpe65-/- mice, oral administration of 9-cis-retinal generated isorhodopsin, a rod photopigment, and restored light sensitivity to the electroretinogram. Here, we provide evidence that early intervention by 9-cis-retinal administration significantly attenuated retinal ester accumulation and supported rod retinal function for more than 6 months post-treatment. In single cell recordings rod light sensitivity was shown to be a function of the amount of regenerated isorhodopsin; high doses restored rod responses with normal sensitivity and kinetics. Highly attenuated residual rod function was observed in untreated Rpe65-/- mice. This rod function is likely a consequence of low efficiency production of 11-cis-retinal by photo-conversion of all-trans-retinal in the retina as demonstrated by retinoid analysis. These studies show that pharmacological intervention produces long lasting preservation of visual function in dark-reared Rpe65-/- mice and may be a useful therapeutic strategy in recovering vision in humans diagnosed with Leber congenital amaurosis caused by mutations in the RPE65 gene, an inherited group of early onset blinding and retinal degenerations.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Univ So Calif, Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Microbiol, Los Angeles, CA 90033 USA; Doheny Eye Inst, Los Angeles, CA 90033 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Southern California; University of Southern California; Doheny Eye Institute	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.			Detwiler, Peter/0000-0003-3910-2023	NEI NIH HHS [EY66388, R01 EY008061, P30 EY001730, EY01730, R01 EY011850, EY11850, R01 EY002048, EY08061, EY02048, EY07031] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY001730, R01EY002048, R01EY008061, R29EY008061, R01EY011850] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alloway PG, 2000, NEURON, V28, P129, DOI 10.1016/S0896-6273(00)00091-X; BAYLOR DA, 1984, J PHYSIOL-LONDON, V354, P203, DOI 10.1113/jphysiol.1984.sp015372; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAEKEVELT CR, 1990, ANAT ANZEIGER, V171, P351; Chen P, 2001, NAT GENET, V28, P256, DOI 10.1038/90089; CORNWALL MC, 1994, J PHYSIOL-LONDON, V480, P261, DOI 10.1113/jphysiol.1994.sp020358; Denke MA, 2002, JAMA-J AM MED ASSOC, V287, P102, DOI 10.1001/jama.287.1.102; Dryja TP, 2001, AM J HUM GENET, V68, P1295, DOI 10.1086/320113; Gerber S, 2001, EUR J HUM GENET, V9, P561, DOI 10.1038/sj.ejhg.5200689; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; Jang GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/jbc.M104949200; Jang GF, 2000, J BIOL CHEM, V275, P28128; Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023; KROLL AJ, 1964, ARCH OPHTHALMOL-CHIC, V71, P683; LAMB TD, 1981, J PHYSIOL-LONDON, V319, P463, DOI 10.1113/jphysiol.1981.sp013921; LAVAIL MM, 1987, EXP EYE RES, V44, P877, DOI 10.1016/S0014-4835(87)80050-7; LEBER T, 1869, A VONGRAEFES ARCH OP, V15, P1, DOI DOI 10.1007/BF02721213; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; Lorenz B, 2000, INVEST OPHTH VIS SCI, V41, P2735; McBee JK, 2000, BIOCHEMISTRY-US, V39, P11370, DOI 10.1021/bi001061c; McBee JK, 2001, J BIOL CHEM, V276, P48483, DOI 10.1074/jbc.M105840200; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Melia TJ, 1997, BIOPHYS J, V73, P3182, DOI 10.1016/S0006-3495(97)78344-9; NAPOLI JL, 1984, BIOCHEM J, V223, P267, DOI 10.1042/bj2230267; PAGHROEHL K, 1992, CELL MOTIL CYTOSKEL, V21, P235, DOI 10.1002/cm.970210307; Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d; Perrault I, 1996, NAT GENET, V14, P461, DOI 10.1038/ng1296-461; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2000, METHOD ENZYMOL, V316, P705; SANYAL S, 1988, EXP EYE RES, V46, P731, DOI 10.1016/S0014-4835(88)80059-9; Schweigert FJ, 1998, INT J VITAM NUTR RES, V68, P237; Schweigert FJ, 2000, INT J VITAM NUTR RES, V70, P84, DOI 10.1024/0300-9831.70.3.84; Seeliger MW, 2001, NAT GENET, V29, P70, DOI 10.1038/ng712; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Sohocki MM, 2000, NAT GENET, V24, P79, DOI 10.1038/71732; Stiles WS, 1933, P R SOC LOND B-CONTA, V112, P428, DOI 10.1098/rspb.1933.0020; Swaroop A, 1999, HUM MOL GENET, V8, P299, DOI 10.1093/hmg/8.2.299; Thompson DA, 2000, INVEST OPHTH VIS SCI, V41, P4293; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297	39	126	137	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19173	19182		10.1074/jbc.M112384200	http://dx.doi.org/10.1074/jbc.M112384200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11897783	Green Accepted, hybrid			2022-12-25	WOS:000175975800120
J	Sachdev, P; Zeng, L; Wang, LH				Sachdev, P; Zeng, L; Wang, LH			Distinct role of phosphatidylinositol 3-kinase and Rho family GTPases in Vav3-induced cell transformation, cell motility, and morphological changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VAV PROTOONCOGENE PRODUCT; TUMOR-SUPPRESSOR GENE; MAP KINASE KINASE; EXTRACELLULAR-MATRIX; MAST-CELLS; ACTIVATION; RAC; BINDING; GROWTH; CDC42	Vav3 is a member of the Vav family of guanine nucleotide exchange factors (GEFs) for the Rho family GTPases. Deleting the N-terminal calponin homology (CH) domain to generate Vav3-(5-10) or deleting both the CH and the acidic domain to generate Vav3-(6-10) results in activating the transforming potential of Vav3. Expression of either the full-length Vav3 or its truncation mutants led to activation of phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), focal adhesion kinase (FAK), and Stat3. We investigated the requirement of these signaling molecules for Vav3-induced focus formation and found that PI3K and its downstream signaling molecules, Akt and p70 S6 kinase, are required, albeit to varying degrees. Inhibition of PI3K had a more dramatic effect than inhibition of MAPK on Vav3-(6-10)-induced focus formation. Activated PI3K enhanced the focus-forming activity of Vav3-(6-10). Wild type FAK but not Y397F mutant FAK enhanced Vav3-(6-10) -induced focus formation. Dominant negative(dn) mutant of Stat3 resulted in a 60% inhibition of the focus-forming activity of Vav3-(6-10). Moreover, Rac1, RhoA, and to a lesser extent, Cdc42, are important for Vav3-(6-10) -induced focus formation. Constitutively activated (ca) Rac synergizes with Vav3-(6-10) in focus formation. This synergy requires signaling via Rho-associated kinase (ROK) and p21-activated kinase (PAK), downstream effectors of Rac. Consistently, a ca PAK mutant enhanced, whereas a dn PAK mutant inhibited the focus-forming ability of Vav3-(6-10). Despite having potent focus-forming ability, Vav3-(6-10) has very weak colony-forming ability. This colony-forming ability of Vav3-(6-10) can be enhanced dramatically by co-expressing an activated PI3K and to some extent by co-expressing an activated PAK mutant or c-Myc. Interestingly, inhibition of PI3K and MAPK had no effect on the ability of either wild type or Vav3-(6-10) to induce cytoskeletal changes including formation of lamellipodia and filopodia in NIH 3T3 cells. Over expression of Vav3 or Vav3-(6-10) resulted in an enhancement of cell motility. This enhancement was dependent on PI3K, Rac1, and Cdc42 but not on Rho. Overall, our results show that signaling pathways of PI3K, MAPK, and Rho family GTPases are differentially required for Vav3-induced focus formation, colony formation, morphological changes, and cell motility.	CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Wang, LH (corresponding author), CUNY Mt Sinai Sch Med, Dept Microbiol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	lu-hai.wang@mssm.edu	Wang, Lu-Hai/E-3986-2010		NATIONAL CANCER INSTITUTE [R01CA029339] Funding Source: NIH RePORTER; NCI NIH HHS [CA55054, CA29339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Collins TL, 1997, IMMUNOL TODAY, V18, P221; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; DeFranco AL, 2001, NAT IMMUNOL, V2, P482, DOI 10.1038/88669; Dekel I, 2000, FEBS LETT, V472, P99, DOI 10.1016/S0014-5793(00)01413-7; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Djouder N, 2001, J IMMUNOL, V166, P1627, DOI 10.4049/jimmunol.166.3.1627; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Karnoub AE, 2001, MOL CELL BIOL, V21, P2847, DOI 10.1128/MCB.21.8.2847-2857.2001; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Manetz TS, 2001, MOL CELL BIOL, V21, P3763, DOI 10.1128/MCB.21.11.3763-3774.2001; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Nishida M, 2001, EMBO J, V20, P2995, DOI 10.1093/emboj/20.12.2995; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RAMOSMORALES F, 1995, ONCOGENE, V11, P1665; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sachdev P, 2001, J BIOL CHEM, V276, P26461, DOI 10.1074/jbc.M010995200; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Shigematsu H, 1997, J BIOL CHEM, V272, P14334, DOI 10.1074/jbc.272.22.14334; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Trenkle T, 2000, GENE, V245, P139, DOI 10.1016/S0378-1119(00)00026-3; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VAN AL, 1997, GENE DEV, V11, P2295; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	65	67	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17638	17648		10.1074/jbc.M111575200	http://dx.doi.org/10.1074/jbc.M111575200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884391	Green Published, hybrid			2022-12-25	WOS:000175685100033
J	Rozhkova, EA; Fujimoto, N; Sagami, I; Daff, SN; Shimizu, T				Rozhkova, EA; Fujimoto, N; Sagami, I; Daff, SN; Shimizu, T			Interactions between the isolated oxygenase and reductase domains of neuronal nitric-oxide synthase - Assessing the role of calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON FLOW-THROUGH; FLAVIN; EXPRESSION; ACTIVATION; BINDING; SITE; IDENTIFICATION; RECONSTITUTION; COMPLEX	Nitric-oxide synthase (NOS) is a fusion protein composed of an oxygenase domain with a heme-active site and a reductase domain with an NADPH binding site and requires Ca2+/calmodulin (CaM) for NO formation activity. We studied NO formation activity in reconstituted systems consisting of the isolated oxygenase and reductase domains of neuronal NOS with and without the CaM binding site. Reductase domains with 33-amino acid C-terminal truncations were also examined. These were shown to have faster cytochrome c reduction rates in the absence of CaM. N-G-hydroxy-L-Arg, an intermediate in the physiological NO synthesis reaction, was found to be a viable substrate. Turnover rates for N-G-hydroxy-L-Arg in the absence of Ca2+/CaM in most of the reconstituted systems were 2.3-3.1 min(-1). Surprisingly, the NO formation activities with CaM binding sites on either reductase or oxygenase domains were decreased dramatically on addition of Ca2+/CaM. However, NADPH oxidation and cytochrome c reduction rates were increased by the same procedure. Activation of the reductase domains by CaM addition or by C-terminal deletion failed to increase the rate of NO synthesis. Therefore, both mechanisms appear to be less important than the domain-domain interaction, which is controlled by CaM binding in wild-type neuronal NOS, but not in the reconstituted systems.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan; Univ Edinburgh, Dept Chem, Edinburgh EH9 3JJ, Midlothian, Scotland	Tohoku University; University of Edinburgh	Shimizu, T (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.	shimizu@tagen.tohoku.ac.jp		Shimizu, Toru/0000-0002-3950-5554				Adak S, 2002, P NATL ACAD SCI USA, V99, P107, DOI 10.1073/pnas.012470099; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Chen PF, 2000, J BIOL CHEM, V275, P13155, DOI 10.1074/jbc.275.17.13155; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P11316, DOI 10.1021/bi00036a003; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; IYANAGI T, 1981, BIOCHEMISTRY-US, V20, P1722, DOI 10.1021/bi00510a004; Lee SJ, 2000, J BIOL CHEM, V275, P36067, DOI 10.1074/jbc.M003935200; Ludwig ML, 1999, STRUCTURE, V7, pR73, DOI 10.1016/S0969-2126(99)80047-1; Masters B.S., 2000, NITRIC OXIDE BIOL PA, P91; Matsuda H, 1999, BBA-GEN SUBJECTS, V1473, P345, DOI 10.1016/S0304-4165(99)00193-2; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; Mayer B, 2000, NITRIC OXIDE; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Montgomery HJ, 2000, J BIOL CHEM, V275, P5052, DOI 10.1074/jbc.275.7.5052; Nakano R, 1996, J BIOL CHEM, V271, P8570, DOI 10.1074/jbc.271.15.8570; Newton DC, 1998, ARCH BIOCHEM BIOPHYS, V359, P249, DOI 10.1006/abbi.1998.0917; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishida CR, 2001, J BIOL CHEM, V276, P20116, DOI 10.1074/jbc.M101548200; Panda K, 2001, J BIOL CHEM, V276, P23349, DOI 10.1074/jbc.M100687200; Pfeiffer S, 1999, ANGEW CHEM INT EDIT, V38, P1715, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1714::AID-ANIE1714>3.0.CO;2-3; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RAMAN CS, 2000, PORPHYRIN HDB, V4, P293; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Sagami I, 1998, J BIOL CHEM, V273, P2105, DOI 10.1074/jbc.273.4.2105; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Sagami I, 2000, J BIOL CHEM, V275, P26150, DOI 10.1074/jbc.M000534200; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Shimanuki T, 1999, J BIOL CHEM, V274, P26956, DOI 10.1074/jbc.274.38.26956; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Stuehr DJ, 2000, HANDB EXP PHARMACOL, V143, P33; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337	37	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16888	16894		10.1074/jbc.M200642200	http://dx.doi.org/10.1074/jbc.M200642200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11884406	hybrid			2022-12-25	WOS:000175564500073
J	Morcinek, JC; Weisser, C; Geissinger, E; Schartl, M; Wellbrock, C				Morcinek, JC; Weisser, C; Geissinger, E; Schartl, M; Wellbrock, C			Activation of STAT5 triggers proliferation and contributes to anti-apoptotic signalling mediated by the oncogenic Xmrk kinase	ONCOGENE			English	Article						STAT5; Xmrk; melanoma; bcl-x; apoptosis; proliferation	RECEPTOR TYROSINE KINASE; EPIDERMAL-GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CELLULAR-RESPONSE; FAMILY-MEMBER; CELLS; EGF; TRANSFORMATION; PHOSPHORYLATION; SUPPRESSION	Extensive studies of primary tumors and tumor derived cell lines revealed that inappropriate activation of specific STATs (particularly of STAT3 and STAT5) occurs with high frequency in a wide variety of human cancers. We reported recently that the melanoma inducing EGFR-related receptor Xmrk specifically induces constitutive activation of STAT5 in fish melanoma cells. However. little is known about the role of STAT5 in solid tumours in general and its function in melanoma in particular. Recent examinations suggest that activated STAT signalling participates in oncogenesis by stimulating cell proliferation and preventing apoptosis. As an initial approach to understanding the consequences of Xmrk-induced STAT5 signalling we used the well characterized pro B-cell line Ba/F3 as a sensitive system to analyse mitogenic as well as anti-apoptotic signalling. We identified STAT5 activation as being involved in both growth and survival signalling triggered by the Xmrk kinase possibly due to STAT5 induced expression of phnI and bcl-x. We also found a new mechanism of activation of STAT5 by receptor tyrosine kinases, whereby direct interaction of the receptor kinase domain with the STAT protein in a phosphotyrosine independent way led to activation of STAT5 in terms of DNA binding and target gene expression.	Univ Wurzburg, Theodor Boveri Inst, Bioctr, Dept Physiol Chem 1, D-97074 Wurzburg, Germany	University of Wurzburg	Wellbrock, C (corresponding author), Univ Wurzburg, Theodor Boveri Inst, Bioctr, Dept Physiol Chem 1, Hubland, D-97074 Wurzburg, Germany.	wellbrock@biozentrum.uni-wuerzburg.de		Schartl, Manfred/0000-0001-9882-5948; Wellbrock, Claudia/0000-0002-3825-6381				Baudler M, 1999, EXP CELL RES, V249, P212, DOI 10.1006/excr.1999.4470; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DiGiovanna MP, 1998, ONCOGENE, V17, P1877, DOI 10.1038/sj.onc.1202091; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; FENDLY BM, 1990, CANCER RES, V50, P1550; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; Jaster R, 1999, CELL SIGNAL, V11, P769, DOI 10.1016/S0898-6568(99)00050-9; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Lischke A, 1996, ANAL BIOCHEM, V236, P322, DOI 10.1006/abio.1996.0173; Mayr S, 1998, EUR J BIOCHEM, V258, P784, DOI 10.1046/j.1432-1327.1998.2580784.x; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; Paukku K, 2000, BIOCHEM J, V345, P759, DOI 10.1042/0264-6021:3450759; PERIS K, 1991, ARCH DERMATOL RES, V283, P500, DOI 10.1007/BF00371922; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wellbrock C, 1999, EUR J BIOCHEM, V260, P275, DOI 10.1046/j.1432-1327.1999.00180.x; Wellbrock C, 1998, ONCOGENE, V16, P3047, DOI 10.1038/sj.onc.1201844; Wellbrock C, 2000, EUR J BIOCHEM, V267, P3513, DOI 10.1046/j.1432-1327.2000.01378.x; WINKLER C, 1994, ONCOGENE, V9, P1517; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; Zhang K, 1996, J BIOL CHEM, V271, P3884; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	42	46	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1668	1678		10.1038/sj.onc.1205148	http://dx.doi.org/10.1038/sj.onc.1205148			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896598				2022-12-25	WOS:000174214200005
J	Dajee, M; Tarutani, M; Deng, H; Cai, T; Khavari, PA				Dajee, M; Tarutani, M; Deng, H; Cai, T; Khavari, PA			Epidermal Ras blockade demonstrates spatially localized Ras promotion of proliferation and inhibition of differentiation	ONCOGENE			English	Article						epithelium; growth control; Ras; differentiation; skin	CELL-CYCLE ARREST; H-RAS; ONCOGENIC RAS; N-RAS; MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; GENE-TRANSFER; STEM-CELLS; EXPRESSION; SKIN	While important in carcinogenesis, the role of Ras in normal self-renewing tissues such as epidermis is unclear. To address this, we altered Ras function in undifferentiated and differentiating epidermal layers. Ras blockade within undifferentiated basal epidermal cells leads to decreased integrin expression, diminished growth capacity and induction of differentiation. Ras blockade in post-mitotic suprabasal epidermis exerts no effect. In contrast, regulated Ras and Raf activation inhibits differentiation. These findings indicate that spatially restricted Ras/Raf signaling divides epidermis into an undifferentiated proliferative compartment and a differentiating post-mitotic compartment and suggest a new role for Ras in tissue homeostasis.	VA Palo Alto Healthcare Syst, Menlo Pk, CA 94025 USA; Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Khavari, PA (corresponding author), 269 Campus Dr,Room 2145, Stanford, CA 94305 USA.	khavari@CMGM.stanford.edu			NIAMS NIH HHS [AR43799, AR45192] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043799, R01AR045192, R29AR043799] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; Brown K, 1998, CURR BIOL, V8, P516, DOI 10.1016/S0960-9822(98)70203-9; Choate KA, 1996, HUM GENE THER, V7, P2247, DOI 10.1089/hum.1996.7.18-2247; Choate KA, 1996, NAT MED, V2, P1263, DOI 10.1038/nm1196-1263; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; DALE BA, 1987, J INVEST DERMATOL, V88, P306, DOI 10.1111/1523-1747.ep12466185; Deng H, 1998, BIOTECHNIQUES, V25, P274, DOI 10.2144/98252gt02; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DLUGOSZ AA, 1994, CANCER RES, V54, P6413; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Ewen M E, 2000, Prog Cell Cycle Res, V4, P1; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Ferbeyre G, 2000, GENE DEV, V14, P2015; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GREENHALGH DA, 1993, CANCER RES, V53, P5071; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; Haase I, 2001, J CLIN INVEST, V108, P527, DOI 10.1172/JCI200112153; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Halfar K, 2001, DEVELOPMENT, V128, P1687; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; IVANYI D, 1989, J PATHOL, V159, P7, DOI 10.1002/path.1711590105; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; Li A, 1998, P NATL ACAD SCI USA, V95, P3902, DOI 10.1073/pnas.95.7.3902; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Marshall CJ, 1999, BIOCHEM SOC T, V27, P363, DOI 10.1042/bst0270363; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Robbins PB, 2001, P NATL ACAD SCI USA, V98, P5193, DOI 10.1073/pnas.091484998; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; Ruiz-Hidalgo MJ, 1999, INT J ONCOL, V14, P777; Schmidt M, 2000, J BIOL CHEM, V275, P41011, DOI 10.1074/jbc.M003716200; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shi B, 2000, BIOCHEM CELL BIOL, V78, P469, DOI 10.1139/bcb-78-4-469; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; STOCKSCHLADER MAR, 1994, GENE THER, V1, P317; Takahashi H, 2001, J BIOL CHEM, V276, P36632, DOI 10.1074/jbc.M102021200; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; Watt FM, 1998, PHILOS T R SOC B, V353, P831, DOI 10.1098/rstb.1998.0247; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YUSPA SH, 1983, CANCER RES, V43, P6021; YUSPA SH, 1994, CANCER RES, V54, P1178; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728	59	84	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1527	1538		10.1038/sj.onc.1205287	http://dx.doi.org/10.1038/sj.onc.1205287			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896581				2022-12-25	WOS:000173956800008
J	Wang, DM; Lipsick, JS				Wang, DM; Lipsick, JS			Mutational analysis of the transcriptional activation domains of v-Myb	ONCOGENE			English	Article						v-Myb; transcriptional activation; transformation; leukemia; oncogene	TRANSFORMATION; TRANSACTIVATION; COACTIVATOR; ONCOGENE; CBP	A minimal transcription activation domain of the v-Myb oncoprotein was initially mapped to a central cluster of charged residues using GAL4-Myb fusion proteins. This region has been proposed to interact directly with the CBP co-activator in animal cells. Regions flanking this central domain of v-Myb are required for transcriptional activation by the native, unfused protein in both mammalian cells and in budding yeast. To identify the critical residues for transcriptional activation, we have now subjected the minimal activation domain and flanking regions including the heptad leucine repeat to random PCR-mediated mutagenesis. We found that the entire region examined can endure extensive substitutions without affecting transcriptional activation by v-Myb in budding yeast. The few mutations that did affect transcriptional activation altered acidic residues within the minimal activation domain or the heptad leucine repeat region, rather than leucine residues. Remarkably, there was a strong concordance between transcriptional activation in animal cells and in budding yeast, even though budding yeast have no known homologue of CBP or related co-activators. In contrast, there was not a strong correlation between transcriptional activation and oncogenic transformation.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University	Lipsick, JS (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.	lipsick@stanford.edu			NATIONAL CANCER INSTITUTE [T32CA009151, R01CA043592] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09151, R01 CA43592] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartunek P, 1997, ONCOGENE, V15, P2939, DOI 10.1038/sj.onc.1201457; CHEN RH, 1995, ONCOGENE, V11, P1771; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Fu SL, 1996, J VIROL, V70, P5600, DOI 10.1128/JVI.70.8.5600-5610.1996; Ganter B, 1999, ADV CANCER RES, V76, P21, DOI 10.1016/S0065-230X(08)60773-3; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Leung DW, 1989, TECHNIQUE, V1, P11; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	14	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1611	1615		10.1038/sj.onc.1205236	http://dx.doi.org/10.1038/sj.onc.1205236			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896590				2022-12-25	WOS:000173956800017
J	Dwir, O; Steeber, DA; Schwarz, US; Camphausen, RT; Kansas, GS; Tedder, TF; Alon, R				Dwir, O; Steeber, DA; Schwarz, US; Camphausen, RT; Kansas, GS; Tedder, TF; Alon, R			L-selectin dimerization enhances tether formation to properly spaced ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; P-SELECTIN; GLYCOPROTEIN LIGAND-1; LEUKOCYTE ADHESION; CELL-ADHESION; SHEAR THRESHOLD; HIGH-AFFINITY; BINDING-PROPERTIES; HUMAN NEUTROPHILS; FLOW	Selectin counterreceptors are glycoprotein scaffolds bearing multiple carbohydrate ligands with exceptional ability to tether flowing cells under disruptive shear forces. Bond clusters may facilitate formation and stabilization of selectin tethers. L-selectin ligation has been shown to enhance L-selectin rolling on endothelial surfaces. We now report that monoclonal antibodies-induced L-selectin dimerization enhances L-selectin leukocyte tethering to purified physiological L-selectin ligands and glycopeptides. Microkinetic analysis of individual tethers suggests that leukocyte rolling is enhanced through the dimerization-induced increase in tether formation, rather than by tether stabilization. Notably, L-selectin dimerization failed to augment L-selectin-mediated adhesion below a threshold ligand density, suggesting that L-selectin dimerization enhanced adhesiveness only to properly clustered ligand. In contrast, an epidermal growth factor domain substitution of L-selectin enhanced tether formation to L-selectin ligands irrespective of ligand density, suggesting that this domain controls intrinsic ligand binding properties of L-selectin without inducing L-selectin dimerization. Strikingly, at low ligand densities, where L-selectin tethering was not responsive to dimerization, elevated shear stress restored sensitivity of tethering to selectin dimerization. This is the first indication that shear stress augments effective selectin ligand density at local contact sites by promoting L-selectin encounter of immobilized ligand.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA; Max Planck Inst Colloids & Interfaces, D-14424 Potsdam, Germany; Wyeth Genet Inst, Cambridge, MA 02140 USA; Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	Weizmann Institute of Science; Duke University; Max Planck Society; Pfizer; Northwestern University	Alon, R (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.		Schwarz, Ulrich/ABB-5642-2020; Schwarz, Ulrich S/K-4111-2014; ALON, RONEN/GRX-6987-2022	Schwarz, Ulrich/0000-0003-1483-640X; Schwarz, Ulrich S/0000-0003-1483-640X; Alon, Ronen/0000-0001-9161-6369	NHLBI NIH HHS [1R24HL64381] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alon R, 1998, P NATL ACAD SCI USA, V95, P11631, DOI 10.1073/pnas.95.20.11631; Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; Chang KC, 2000, BIOPHYS J, V79, P1891, DOI 10.1016/S0006-3495(00)76439-3; Chang KC, 2000, P NATL ACAD SCI USA, V97, P11262, DOI 10.1073/pnas.200240897; Chang KC, 1999, BIOPHYS J, V76, P1280, DOI 10.1016/S0006-3495(99)77291-7; Chen SQ, 1997, P NATL ACAD SCI USA, V94, P3172, DOI 10.1073/pnas.94.7.3172; Chen SQ, 1999, J CELL BIOL, V144, P185, DOI 10.1083/jcb.144.1.185; Chen SQ, 2001, P NATL ACAD SCI USA, V98, P950, DOI 10.1073/pnas.98.3.950; Dwir O, 1998, CELL ADHES COMMUN, V6, P349, DOI 10.3109/15419069809010793; Dwir O, 2000, J BIOL CHEM, V275, P18682, DOI 10.1074/jbc.M001103200; Dwir O, 2001, J CELL BIOL, V155, P145, DOI 10.1083/jcb.200103042; Evans E, 2001, P NATL ACAD SCI USA, V98, P3784, DOI 10.1073/pnas.061324998; Evans SS, 1999, J IMMUNOL, V162, P3615; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; Goetz DJ, 1997, J CELL BIOL, V137, P509, DOI 10.1083/jcb.137.2.509; Greenberg AW, 2000, BIOPHYS J, V79, P2391, DOI 10.1016/S0006-3495(00)76484-8; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KANSAS GS, 1994, J CELL BIOL, V124, P609, DOI 10.1083/jcb.124.4.609; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LASKY LA, 1992, COLD SPRING HARB SYM, V57, P259, DOI 10.1101/SQB.1992.057.01.031; Lawrence MB, 1997, J CELL BIOL, V136, P717, DOI 10.1083/jcb.136.3.717; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Li X, 1998, J EXP MED, V188, P1385, DOI 10.1084/jem.188.7.1385; Marttila AT, 2000, FEBS LETT, V467, P31, DOI 10.1016/S0014-5793(00)01119-4; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; MCEVER RP, 1997, J CLIN INVEST, V100, P97; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; Puri KD, 1998, NATURE, V392, P930, DOI 10.1038/31954; Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771; Ramachandran V, 2001, P NATL ACAD SCI USA, V98, P10166, DOI 10.1073/pnas.171248098; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; Seppo A, 1996, GLYCOBIOLOGY, V6, P65, DOI 10.1093/glycob/6.1.65; Setiadi H, 1998, J CELL BIOL, V142, P859, DOI 10.1083/jcb.142.3.859; Snapp KR, 1998, J CELL BIOL, V142, P263, DOI 10.1083/jcb.142.1.263; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; Steeber DA, 1997, J IMMUNOL, V159, P952; Stockton BM, 1998, IMMUNITY, V8, P373, DOI 10.1016/S1074-7613(00)80542-7; Toppila S, 1997, EUR J IMMUNOL, V27, P1360, DOI 10.1002/eji.1830270610; Tu LL, 1996, J IMMUNOL, V157, P3995; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4	49	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21130	21139		10.1074/jbc.M201999200	http://dx.doi.org/10.1074/jbc.M201999200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11907045	hybrid			2022-12-25	WOS:000176286000005
J	Chiba, H; Pattanajitvilai, S; Evans, AJ; Harbeck, RJ; Voelker, DR				Chiba, H; Pattanajitvilai, S; Evans, AJ; Harbeck, RJ; Voelker, DR			Human surfactant protein D (SP-D) binds Mycoplasma pneumoniae by high affinity interactions with lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-FUMIGATUS CONIDIA; BRONCHOALVEOLAR LAVAGE; ENHANCES PHAGOCYTOSIS; ALVEOLAR MACROPHAGES; RAT; PHOSPHATIDYLINOSITOL; LIPOPOLYSACCHARIDES; GLUCOSYLCERAMIDE; SPECIFICITY; MECHANISMS	Increasing evidence now identifies surfactant protein D (SP-D) as an important element of the innate immune system of the lung. In this study, we examined the interactions of rat and human SP-D with the human pathogen, Mycoplasma pneumoniae. Rat and human SP-D bound the organism with high affinity in a reaction that required Ca2+ and was inhibited by EGTA. Membranes derived from the organism bound the proteins in a similar manner, except the rat SP-D also exhibited a significant level of Ca2+-independent binding. Pretreatment of membranes with proteases did not alter the Ca2+-dependent SP-D binding of membranes by either protein. Mannose, glucose, maltose, and inositol, at millimolar concentrations, competed for human SP-D binding to the bacterial membrane. Lipids extracted from membranes and separated by two-dimensional thin layer chromatography bound human SP-D with high affinity in a Ca2+-dependent reaction. A tandem mutant of SP-D with E321Q and N323D substitutions, failed to bind M. pneumoniae lipids, directly implicating the carbohydrate recognition domain in the interaction. The interaction of rat and human SP-D with M. pneumoniae was unaffected by the presence of surfactant lipids and the hydrophobic surfactant proteins. These findings demonstrate that M. pneumoniae is likely to be recognized by SP-D in the alveolar environment and that primary determinants recognized on the organism are lipid components of the cell membrane.	Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, Denver, CO 80206 USA	National Jewish Health	Voelker, DR (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045286] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45286] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen MJ, 1999, INFECT IMMUN, V67, P4563, DOI 10.1128/IAI.67.9.4563-4569.1999; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CROUCH E, 1994, J BIOL CHEM, V269, P17311; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; DAY AJ, 1994, BIOCHEM SOC T, V22, P83, DOI 10.1042/bst0220083; Eda S, 1997, BIOCHEM J, V323, P393, DOI 10.1042/bj3230393; GIL JC, 1993, ANN ALLERGY, V70, P23; Hartshorn KL, 1998, AM J PHYSIOL-LUNG C, V274, pL958, DOI 10.1152/ajplung.1998.274.6.L958; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; Hickman-Davis JM, 1998, AM J PHYSIOL-LUNG C, V274, pL270, DOI 10.1152/ajplung.1998.274.2.L270; HONDA Y, 1995, AM J RESP CRIT CARE, V152, P1860, DOI 10.1164/ajrccm.152.6.8520747; KING RJ, 1973, AM J PHYSIOL, V224, P788, DOI 10.1152/ajplegacy.1973.224.4.788; Kraft M, 1998, AM J RESP CRIT CARE, V158, P998, DOI 10.1164/ajrccm.158.3.9711092; Krause Duncan C., 1992, P417; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; KUROKI Y, 1992, BIOCHEM BIOPH RES CO, V187, P963, DOI 10.1016/0006-291X(92)91291-W; LAINE RA, 1974, METHODS MEMBRANE BIO, P205; Madan T, 1997, INFECT IMMUN, V65, P3171, DOI 10.1128/IAI.65.8.3171-3179.1997; McIntosh JC, 1996, AM J PHYSIOL-LUNG C, V271, pL310, DOI 10.1152/ajplung.1996.271.2.L310; MELBYE H, 1994, EUR RESPIR J, V7, P1239, DOI 10.1183/09031936.94.07071239; Ofek I, 2001, INFECT IMMUN, V69, P24, DOI 10.1128/IAI.69.1.24-33.2001; OGASAWARA Y, 1995, J BIOL CHEM, V270, P14725, DOI 10.1074/jbc.270.24.14725; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; OGASAWARA Y, 1995, J BIOL CHEM, V270, P19052, DOI 10.1074/jbc.270.32.19052; ORIORDAN DM, 1995, J CLIN INVEST, V95, P2699, DOI 10.1172/JCI117972; PERSSON A, 1990, J BIOL CHEM, V265, P5755; PERSSON AV, 1992, BIOCHEMISTRY-US, V31, P12183, DOI 10.1021/bi00163a030; PLACKETT P, 1969, AUST J EXP BIOL MED, V47, P171, DOI 10.1038/icb.1969.19; POLLACK J D, 1973, Journal of Infectious Diseases, V127, pS32; Restrepo CI, 1999, AM J RESP CELL MOL, V21, P576, DOI 10.1165/ajrcmb.21.5.3334; ROTTEM S, 1980, BIOCHIM BIOPHYS ACTA, V604, P65, DOI 10.1016/0005-2736(80)90585-4; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Sano H, 1999, J IMMUNOL, V163, P387; Sano H, 2000, J BIOL CHEM, V275, P22442, DOI 10.1074/jbc.M001107200; SCHELENZ S, 1995, INFECT IMMUN, V63, P3360, DOI 10.1128/IAI.63.9.3360-3366.1995; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; van Rozendaal BAWM, 2000, J INFECT DIS, V182, P917, DOI 10.1086/315799	40	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20379	20385		10.1074/jbc.M201089200	http://dx.doi.org/10.1074/jbc.M201089200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11916969	hybrid			2022-12-25	WOS:000176204500037
J	Nisole, S; Said, EA; Mische, C; Prevost, MC; Krust, B; Bouvet, P; Bianco, A; Briand, JP; Hovanessian, AG				Nisole, S; Said, EA; Mische, C; Prevost, MC; Krust, B; Bouvet, P; Bianco, A; Briand, JP; Hovanessian, AG			The Anti-HIV pentameric pseudopeptide HB-19 binds the C-terminal end of nucleolin and prevents anchorage of virus particles in the plasma membrane of target cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-PI INTERACTIONS; SURFACE-EXPRESSED NUCLEOLIN; V3 LOOP; GLYCINE-RICH; PROTEIN; INHIBITION; DOMAIN; ENTRY; GP120; ATTACHMENT	The multivalent pseudopeptide HB-19 that binds the cell-surface-expressed nucleolin is a potent inhibitor of human immunodeficiency virus (HIV) infection by blocking virus particle attachment and thus anchorage in the plasma membrane. We show that cross-linking of surface-bound HB-19A (like HB-19 but with a modified template) results in aggregation of HB-19A with surface nucleolin. Consistent with its specific action, HB-19A binding to different types of cells reaches saturation at concentrations that have been reported to result in inhibition of HrV infection. By using Chinese hamster ovary mutant cell lines, we confirm that the binding of IFM-19A to surface nucleolin is independent of heparan and chondroitin sulfate proteoglyeans. In vitro generated full-length nucleolin was found to bind HB-19A, whereas the N-terminal part containing the acidic amino acid stretches of nucleolin did not. The use of various deletion constructs of the C-terminal part of nucleolin then permitted the identification of the extreme C-terminal end of nucleolin, containing repeats of the amino acid motif, RGG, as the domain that binds HB-19A. Finally, a synthetic peptide corresponding to the last C-terminal 63 amino acids was able to inhibit HIV infection at the stage of HIV attachment to cells, thus suggesting that this domain could be functional in the HIV anchorage process.	Inst Pasteur, URA 1930 CNRS, Unite Virol & Immunol Cellulaire, F-75724 Paris 15, France; Ecole Normale Super Lyon, CNRS UMR 5665, F-69007 Lyon, France; Inst Biol Mol & Cellulaire, UPR 9021 CNRS, F-67084 Strasbourg, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS)	Hovanessian, AG (corresponding author), Inst Pasteur, URA 1930 CNRS, Unite Virol & Immunol Cellulaire, 28 Rue Dr Roux, F-75724 Paris 15, France.	arahovan@pasteur.fr	, Bouvet/AAC-8779-2020; Nisole, Sébastien/ABA-2367-2021; Said, Elias/AAY-5557-2020	Nisole, Sébastien/0000-0001-9793-419X; Said, Elias/0000-0003-4224-6351; Bouvet, Philippe/0000-0003-4524-2233				Bouvet P, 1998, J BIOL CHEM, V273, P19025, DOI 10.1074/jbc.273.30.19025; Callebaut C, 1996, VIROLOGY, V218, P181, DOI 10.1006/viro.1996.0178; Callebaut C, 1998, J BIOL CHEM, V273, P21988, DOI 10.1074/jbc.273.34.21988; Callebaut C, 2001, VIROLOGY, V281, P248, DOI 10.1006/viro.2000.0767; Callebaut C, 1997, J BIOL CHEM, V272, P7159, DOI 10.1074/jbc.272.11.7159; CALLEBAUT C, 2001, J BIOL CHEM, V281, P248; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; DEJONG JJ, 1992, J VIROL, V66, P6777, DOI 10.1128/JVI.66.11.6777-6780.1992; Deng JS, 1996, MOL BIOL REP, V23, P191, DOI 10.1007/BF00351168; DEVERDUGO UR, 1995, J VIROL, V69, P6751, DOI 10.1128/JVI.69.11.6751-6757.1995; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Dumler I, 1999, CURR BIOL, V9, P1468, DOI 10.1016/S0960-9822(00)80116-5; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; FANG SH, 1993, EXP CELL RES, V208, P48, DOI 10.1006/excr.1993.1221; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; Ginisty H, 1999, J CELL SCI, V112, P761; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; Hanakahi LA, 2000, BIOCHEMISTRY-US, V39, P15493, DOI 10.1021/bi001683y; Hanakahi LA, 1999, J BIOL CHEM, V274, P15908, DOI 10.1074/jbc.274.22.15908; Hovanessian AG, 2000, EXP CELL RES, V261, P312, DOI 10.1006/excr.2000.5071; KLEINMAN HK, 1991, ARCH BIOCHEM BIOPHYS, V290, P320, DOI 10.1016/0003-9861(91)90547-V; KRANTZ S, 1995, BBA-MOL CELL RES, V1266, P109, DOI 10.1016/0167-4889(95)00028-Q; Krust B, 2001, P NATL ACAD SCI USA, V98, P14090, DOI 10.1073/pnas.221467298; KRUST B, 1993, AIDS RES HUM RETROV, V9, P1087, DOI 10.1089/aid.1993.9.1087; LAPEYRE B, 1986, J BIOL CHEM, V261, P9167; Larrucea S, 1999, BIOCHEM BIOPH RES CO, V266, P51, DOI 10.1006/bbrc.1999.1766; Limal D, 1998, J PEPT RES, V52, P121; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; Marechal V, 1998, J VIROL, V72, P2208; Mecozzi S, 1996, P NATL ACAD SCI USA, V93, P10566, DOI 10.1073/pnas.93.20.10566; Mondor I, 1998, J VIROL, V72, P3623, DOI 10.1128/JVI.72.5.3623-3634.1998; Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000; Murakami T, 1997, J EXP MED, V186, P1389, DOI 10.1084/jem.186.8.1389; Nisole S, 1999, J BIOL CHEM, V274, P27875, DOI 10.1074/jbc.274.39.27875; Nisole S, 2000, AIDS RES HUM RETROV, V16, P237, DOI 10.1089/088922200309331; NISOLE S, 2002, IN PRESS EXP CELL RE; Pletneva EV, 2001, J AM CHEM SOC, V123, P6232, DOI 10.1021/ja010401u; RODERIQUEZ G, 1995, J VIROL, V69, P2233, DOI 10.1128/JVI.69.4.2233-2239.1995; Saphire ACS, 1999, EMBO J, V18, P6771, DOI 10.1093/emboj/18.23.6771; SCHNEIDER J, 1986, J GEN VIROL, V67, P2533, DOI 10.1099/0022-1317-67-11-2533; Seddiki N, 1999, AIDS RES HUM RETROV, V15, P381, DOI 10.1089/088922299311358; SEMENKOVICH CF, 1990, BIOCHEMISTRY-US, V29, P9708, DOI 10.1021/bi00493a028; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; SRIVASTAVA M, 1989, FEBS LETT, V250, P99, DOI 10.1016/0014-5793(89)80692-1; Stauber RH, 1999, BIOCHEM BIOPH RES CO, V258, P695, DOI 10.1006/bbrc.1999.0511; Tamamura H, 1998, BIOORGAN MED CHEM, V6, P473, DOI 10.1016/S0968-0896(97)10055-4; Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2; Valenzuela A, 1997, J VIROL, V71, P8289, DOI 10.1128/JVI.71.11.8289-8298.1997; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088	53	74	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20877	20886		10.1074/jbc.M110024200	http://dx.doi.org/10.1074/jbc.M110024200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11919179	hybrid, Green Published			2022-12-25	WOS:000176204500100
J	Abrescia, C; De Gregorio, E; Frontini, M; Mantovani, R; Di Nocera, P				Abrescia, C; De Gregorio, E; Frontini, M; Mantovani, R; Di Nocera, P			A novel intragenic sequence enhances initiator-dependent transcription in human embryonic kidney 293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CORE PROMOTER ELEMENT; DROSOPHILA-MELANOGASTER; TATA-BOX; DOC-ELEMENTS; DNA-BINDING; F-ELEMENTS; DOWNSTREAM; COMPLEX; ACTIVATION	In a variety of Drosophila TATA-less promoters, transcription is directed by initiator (Inr) sequences, which are faithfully and efficiently recognized only when Ranked 3' by the downstream promoter element (DPE). This motif, which is conserved at similar to30 bp from the RNA start site, is viewed as a downstream counterpart to the TATA box, and is recognized by the general transcription factor (TF) IID. By transient expression assays in human embryonic kidney 293 cells, we show that DE1 (distal element 1), a DNA motif located at residues +23 to +29, sustains faithful Inr-dependent transcription as efficiently as the DPE. Transcription significantly increased when DE1 and DPE sequences were adjacently placed on the same template. Results emerging from in vivo RNA analyses matched electrophoretic mobility shift assay data. In agarose-electrophoretic mobility shift assays, retarded DNA-protein complexes resulting from the interaction of human holo-TFIID with either Inr(+)/DPE+ or Inr(+)/DE1(+) promoters were formed at comparable levels, whereas binding of TFIID to both DE1 and DPE motifs was 2-fold increased. The strict requirement for spacing between the Inr and DPE was not observed for DE1, as locating the motif 4 bp away from the +1 site did not impair transcriptional enhancement. DE1 sequences may be common to many promoters and be overlooked because of their poor sequence homology.	Univ Studi Napoli Federico 2, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Modena & Reggio, Dipartimento Biol Anim, I-41100 Modena, Italy	Universita di Modena e Reggio Emilia	Di Nocera, P (corresponding author), Univ Studi Napoli Federico 2, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.		De Gregorio, Eliana/AAK-2086-2020	De Gregorio, Eliana/0000-0002-2529-8611				BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; Butler JEF, 2001, GENE DEV, V15, P2515, DOI 10.1101/gad.924301; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLGAN J, 1995, P NATL ACAD SCI USA, V92, P1955, DOI 10.1073/pnas.92.6.1955; CONTURSI C, 1995, J BIOL CHEM, V270, P26570, DOI 10.1074/jbc.270.44.26570; Croager EJ, 2000, AM J PATHOL, V156, P1723, DOI 10.1016/S0002-9440(10)65043-2; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; Frontini M, 2002, J BIOL CHEM, V277, P5841, DOI 10.1074/jbc.M103651200; GRIMALDI G, 1988, P NATL ACAD SCI USA, V85, P5502, DOI 10.1073/pnas.85.15.5502; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Knutson A, 2000, J BIOL CHEM, V275, P14190, DOI 10.1074/jbc.275.19.14190; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; Kraus RJ, 1996, NUCLEIC ACIDS RES, V24, P1531, DOI 10.1093/nar/24.8.1531; Kutach AK, 2000, MOL CELL BIOL, V20, P4754, DOI 10.1128/MCB.20.13.4754-4764.2000; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Lewis BA, 2000, P NATL ACAD SCI USA, V97, P7172, DOI 10.1073/pnas.120181197; Liberati C, 1999, J MOL BIOL, V285, P1441, DOI 10.1006/jmbi.1998.2384; Minchiotti G, 1997, J MOL BIOL, V267, P37, DOI 10.1006/jmbi.1996.0860; Minchiotti G, 1997, FEBS LETT, V411, P189, DOI 10.1016/S0014-5793(97)00689-3; MINCHIOTTI G, 1991, MOL CELL BIOL, V11, P5171, DOI 10.1128/MCB.11.10.5171; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; Perier RC, 1999, NUCLEIC ACIDS RES, V27, P307, DOI 10.1093/nar/27.1.307; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Willy PJ, 2000, SCIENCE, V290, P982, DOI 10.1126/science.290.5493.982; Wu CH, 2001, MOL CELL BIOL, V21, P1593, DOI 10.1128/MCB.21.5.1593-1602.2001; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	34	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19594	19599		10.1074/jbc.M201193200	http://dx.doi.org/10.1074/jbc.M201193200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11916971	Green Published, hybrid			2022-12-25	WOS:000175894800048
J	Warner, RG; Hundt, C; Weiss, S; Turnbull, JE				Warner, RG; Hundt, C; Weiss, S; Turnbull, JE			Identification of the heparan sulfate binding sites in the cellular prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYRIAN GOLDEN-HAMSTER; S-TRANSFERASE FUSION; INCUBATION PERIOD; ESCHERICHIA-COLI; AMYLOID PLAQUES; COPPER-BINDING; REPEAT REGION; CONGO RED; PRP; SCRAPIE	Data from cell culture and animal models of prion disease support the separate involvement of both heparan sulfate proteoglycans and copper (II) ions in prion (PrP) metabolism. Though direct interactions between prion protein and heparin have been recorded, little is known of the structural features implicit in this interaction or of the involvement of copper (II) ions. Using biosensor and enzyme-linked immunosorbent assay methodology we report direct heparin and heparan sulfate-binding activity in recombinant cellular prion protein (PrPc). We also demonstrate that the interaction of recombinant PrPc with heparin is weakened in the presence of Cu(II) ions and is particularly sensitive to competition with dextran sulfate. Competitive inhibition experiments with chemically modified heparins also indicate that 2-O-sulfate groups (but not 6-O-sulfate groups) are essential for heparin recognition. We have also identified three regions of the prion protein capable of independent binding to heparin and heparan sulfate: residues 23-52, 53-93, and 110-128. Interestingly, the interaction of an octapeptide-spanning peptide motif amino acids 53-93 with heparin is enhanced by Cu(II) ions. Significantly, a peptide of this sequence is able to inhibit the binding of full-length prion molecule to heparin, suggesting a direct role in heparin recognition within the intact protein. The collective data suggest a complex interaction between prion protein and heparin/ heparan sulfate and has implications for the cellular and pathological functions of prion proteins.	Univ Birmingham, Sch Biosci, Mol Cell Biol Labs, Birmingham B15 2TT, W Midlands, England; LMU, Inst Biochem, Genzentrum, Mol Biol Lab, D-81377 Munich, Germany	University of Birmingham; University of Munich	Turnbull, JE (corresponding author), Univ Birmingham, Sch Biosci, Mol Cell Biol Labs, Birmingham B15 2TT, W Midlands, England.	j.e.turnbull@bham.ac.uk	Warner, Richard/C-8910-2011					Appel TR, 1999, BIOL CHEM, V380, P1295, DOI 10.1515/BC.1999.165; Beringue V, 2000, J VIROL, V74, P5432, DOI 10.1128/JVI.74.12.5432-5440.2000; Brimacombe DB, 1999, BIOCHEM J, V342, P605, DOI 10.1042/0264-6021:3420605; Brown DR, 2000, EMBO J, V19, P1180, DOI 10.1093/emboj/19.6.1180; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Caspi S, 1998, J BIOL CHEM, V273, P3484, DOI 10.1074/jbc.273.6.3484; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; DEGIOIA L, 1994, J BIOL CHEM, V269, P7859; Edenhofer F, 1996, J VIROL, V70, P4724, DOI 10.1128/JVI.70.7.4724-4728.1996; FARQUHAR CF, 1986, J GEN VIROL, V67, P463, DOI 10.1099/0022-1317-67-3-463; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GABIZON R, 1993, J CELL PHYSIOL, V157, P319, DOI 10.1002/jcp.1041570215; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; GUIROY DC, 1991, ACTA NEUROPATHOL, V82, P87, DOI 10.1007/BF00293949; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; Jobling MF, 1999, J NEUROCHEM, V73, P1557, DOI 10.1046/j.1471-4159.1999.0731557.x; Jobling MF, 2001, BIOCHEMISTRY-US, V40, P8073, DOI 10.1021/bi0029088; LADOGANA A, 1992, J GEN VIROL, V73, P661, DOI 10.1099/0022-1317-73-3-661; LEE WT, 1984, J EXP MED, V159, P1790, DOI 10.1084/jem.159.6.1790; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; McBride PA, 1998, EXP NEUROL, V149, P447, DOI 10.1006/exnr.1997.6740; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; MULTHAUP G, 1995, J MOL RECOGNIT, V8, P247; Nadkarni VD, 1997, BIOTECHNIQUES, V23, P382, DOI 10.2144/97233bm07; Ono K, 1999, GLYCOBIOLOGY, V9, P705, DOI 10.1093/glycob/9.7.705; Perez M, 1998, BIOCHEM J, V335, P369, DOI 10.1042/bj3350369; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; Shaked GM, 2001, J BIOL CHEM, V276, P14324, DOI 10.1074/jbc.M007815200; Shaked Y, 2001, J VIROL, V75, P7872, DOI 10.1128/JVI.75.17.7872-7874.2001; SHYNG SL, 1995, J BIOL CHEM, V270, P30221; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; SNOW AD, 1990, LAB INVEST, V63, P601; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Supattapone S, 2001, J VIROL, V75, P1408, DOI 10.1128/JVI.75.3.1408-1413.2001; Supattapone S, 1999, P NATL ACAD SCI USA, V96, P14529, DOI 10.1073/pnas.96.25.14529; Telling GC, 1997, PROTEIN SCI, V6, P825; Toida T, 1997, J CHROMATOGR A, V787, P266, DOI 10.1016/S0021-9673(97)00658-4; Volkel D, 1998, EUR J BIOCHEM, V251, P462, DOI 10.1046/j.1432-1327.1998.2510462.x; WEISS S, 1995, J VIROL, V69, P4776, DOI 10.1128/JVI.69.8.4776-4783.1995; Weiss S, 1997, J VIROL, V71, P8790, DOI 10.1128/JVI.71.11.8790-8797.1997; Weiss S, 1996, BIOCHEM BIOPH RES CO, V219, P173, DOI 10.1006/bbrc.1996.0201; Wong BS, 2000, BIOCHEM BIOPH RES CO, V269, P726, DOI 10.1006/bbrc.2000.2355; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Wrenshall LE, 1999, J IMMUNOL, V163, P3793; Yates EA, 1996, CARBOHYD RES, V294, P15; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6	57	178	188	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18421	18430		10.1074/jbc.M110406200	http://dx.doi.org/10.1074/jbc.M110406200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11882649	hybrid			2022-12-25	WOS:000175975800023
J	Desmots, F; Rissel, M; Gilot, D; Lagadic-Gossmann, D; Morel, F; Guguen-Guillouzo, C; Guillouzo, A; Loyer, P				Desmots, F; Rissel, M; Gilot, D; Lagadic-Gossmann, D; Morel, F; Guguen-Guillouzo, C; Guillouzo, A; Loyer, P			Pro-inflammatory cytokines tumor necrosis factor alpha and interleukin-6 and survival factor epidermal growth factor positively regulate the murine GSTA4 enzyme in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE S-TRANSFERASES; MITOGEN-ACTIVATED PROTEIN; ANTIOXIDANT RESPONSE ELEMENT; REGENERATING RAT-LIVER; FACTOR KAPPA-B; LIPID-PEROXIDATION; OXIDATIVE STRESS; RAPID ACTIVATION; SUPERGENE FAMILY; PRIMARY CULTURE	We hypothesized that glutathione transferases could be induced and may participate to cellular defenses against the oxidative stress occurring during liver regeneration. Here, we evidenced that murine GSTA1 (mGSTA1), A4, Pi, and Mu are up-regulated during mouse liver regeneration, exhibiting a biphasic pattern of induction correlating early G(1) phase and G(1)/S transition of the cell cycle. Using confocal microscopy Immunolocalization and subcellular fractionation, mGSTA4 was demonstrated in both mitochondria and cytosol and found preferentially increased in cytosol during liver regeneration. In addition, mGSTA4 was induced in vivo and in cultured hepatocytes by tumor necrosis factor a (TNFalpha), interleukin-6 (IL-6), and epidermal growth factor (EGF), factors that play crucial roles in hepatocyte survival and proliferation during liver regeneration. However, the mitogenic effect of EGF was not responsible for the induction of mGSTA4. In transient transfections, IL-6 and EGF, but not TNFalpha, transactivated the human GSTA4 (hGSTA4) promoter cloned upstream of the luciferase reporter gene suggesting that IL-6 and EGF up-regulated hGSTA4 at a transcriptional level, whereas TNFalpha could rather act at a post-transcriptional level. The inhibition of phosphoinositide 3-kinase, p38 MAPK, and MEK/ERK signaling pathways, using specific inhibitors, prevented EGF-dependent induction of mGSTA4 and transactivation of hGSTA4 promoter. Altogether, these data favor the conclusion that, in regenerating hepatocytes, several GST isoforms are induced and that cytokines TNFalpha and IL-6 and survival factor EGF positively regulate mGSTA4 via survival signaling pathways.	Univ Rennes 1, Fac Pharm, INSERM, U456, F-35043 Rennes, France; Hop Pontchaillou, INSERM, U522, F-35033 Rennes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm)	Guillouzo, A (corresponding author), Univ Rennes 1, Fac Pharm, INSERM, U456, 2 Ave Pr Leon Bernard, F-35043 Rennes, France.		LOYER, Pascal/K-1838-2019; GUILLOUZO, Andre/Z-2373-2019; LAGADIC-GOSSMANN, Dominique/I-5079-2015	LAGADIC-GOSSMANN, Dominique/0000-0002-4888-236X; LOYER, PASCAL/0000-0002-5656-2673				Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; ALBRECHT JH, 1993, AM J PHYSIOL, V265, P857; AWASTHI YC, 1994, INT J BIOCHEM, V26, P295, DOI 10.1016/0020-711X(94)90050-7; Bhagwat SV, 1998, BIOCHEM PHARMACOL, V56, P831, DOI 10.1016/S0006-2952(98)00228-7; BOITIER E, 1995, CANCER RES, V55, P3028; Carnovale CE, 2000, J HEPATOL, V32, P798, DOI 10.1016/S0168-8278(00)80249-4; Chandel NS, 2001, J BIOL CHEM, V276, P42728, DOI 10.1074/jbc.M103074200; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Cheng JZ, 1999, ARCH BIOCHEM BIOPHYS, V372, P29, DOI 10.1006/abbi.1999.1479; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; Desmots F, 2002, FREE RADICAL BIO MED, V32, P93, DOI 10.1016/S0891-5849(01)00767-5; Desmots F, 2001, J HISTOCHEM CYTOCHEM, V49, P1573, DOI 10.1177/002215540104901211; Desmots F, 1998, BIOCHEM J, V336, P437, DOI 10.1042/bj3360437; DiazGuerra MJM, 1997, BIOCHEM J, V326, P791, DOI 10.1042/bj3260791; FARDEL O, 1992, BIOCHEM PHARMACOL, V44, P2259, DOI 10.1016/0006-2952(92)90355-M; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; Gardner JL, 2001, ARCH BIOCHEM BIOPHYS, V390, P19, DOI 10.1006/abbi.2001.2352; GILOT D, 2002, IN PRESS J GENE MED; GOON D, 1993, TOXICOL APPL PHARM, V119, P175, DOI 10.1006/taap.1993.1058; GUGUEN C, 1975, BIOL GASTRO-ENTEROL, V8, P223; Habig W H, 1981, Methods Enzymol, V77, P398; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HAYES JD, 1995, FREE RADICAL RES, V22, P193, DOI 10.3109/10715769509147539; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hong F, 2000, BIOCHEM BIOPH RES CO, V279, P974, DOI 10.1006/bbrc.2000.4044; JENSSON H, 1986, FEBS LETT, V203, P207, DOI 10.1016/0014-5793(86)80743-8; Kang KW, 2000, MOL PHARMACOL, V58, P1017, DOI 10.1124/mol.58.5.1017; LANGOUET S, 1995, BIOCHEM BIOPH RES CO, V216, P793, DOI 10.1006/bbrc.1995.2691; Lee FYJ, 1999, HEPATOLOGY, V29, P677, DOI 10.1002/hep.510290320; LEE SJ, 1993, BIOCHEM J, V293, P137, DOI 10.1042/bj2930137; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; Maheo K, 1997, J BIOL CHEM, V272, P16125, DOI 10.1074/jbc.272.26.16125; Mori M, 1995, Nihon Ika Daigaku Zasshi, V62, P447; Plumpe J, 2000, AM J PHYSIOL-GASTR L, V278, pG173, DOI 10.1152/ajpgi.2000.278.1.G173; Rai RM, 1998, P NATL ACAD SCI USA, V95, P13829, DOI 10.1073/pnas.95.23.13829; SATOH K, 1995, CARCINOGENESIS, V16, P869, DOI 10.1093/carcin/16.4.869; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Singh SP, 2002, J BIOL CHEM, V277, P4232, DOI 10.1074/jbc.M109678200; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; TESHIGAWARA M, 1995, RES EXP MED, V195, P55, DOI 10.1007/BF02576774; Tjalkens RB, 1998, ARCH BIOCHEM BIOPHYS, V359, P42, DOI 10.1006/abbi.1998.0895; Tzung SP, 1997, AM J PATHOL, V150, P1985; Webber EM, 1998, HEPATOLOGY, V28, P1226, DOI 10.1002/hep.510280509; Yamada Y, 1998, HEPATOLOGY, V28, P959, DOI 10.1002/hep.510280410; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yang Y, 2001, J BIOL CHEM, V276, P19220, DOI 10.1074/jbc.M100551200; Yin ZM, 2000, CANCER RES, V60, P4053	51	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17892	17900		10.1074/jbc.M112351200	http://dx.doi.org/10.1074/jbc.M112351200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884396	hybrid			2022-12-25	WOS:000175685100065
J	Martin, A; Schneider, S; Schwer, B				Martin, A; Schneider, S; Schwer, B			Prp43 is an essential RNA-dependent ATPase required for release of lariat-intron from the spliceosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; BOX SPLICING FACTOR; SACCHAROMYCES-CEREVISIAE; NUCLEOSIDE TRIPHOSPHATASE; MUTATIONAL ANALYSIS; HELICASE; PROTEIN; PRP16; MUTANTS; HOMOLOG	The essential Saccharomyces cerevisiae PRP43 gene encodes a 767-amino acid protein of the DEXH-box family. Prp43 has been implicated in spliceosome disassembly (Arenas, J. E., and Abelson, J. N. (1997) Proc. Natl. Acatl. Sci. U. S. A 94, 11798-11802). Here we show that purified recombinant Prp43 is an RNA-dependent ATPase. Alanine mutations at conserved residues within motifs I ((119)GSGKT(123)), II ((215)DEAH(218)) and VI ((423)QRAGRAGR(430)) that diminished ATPase activity in vitro were lethal in vivo, indicating that ATP hydrolysis is necessary for the biological function of Prp43. Overexpression of lethal, ATPase-defective mutants in a wild-type strain resulted in dominant-negative growth inhibition. The ATPase-defective mutant T123A interfered in trans with the in vitro splicing function of wild-type Prp43. T123A did not affect the chemical steps of splicing or the release of mature mRNA from the spliceosome, but it blocked the release of the excised lariat-intron from the spliceosome. We show that the lariat-intron is not accessible to debranching by purified Dbr1 when it is held in the T123A-arrested splicing complex. Our results define a new ATP-dependent step of splicing that is catalyzed by Prp43.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Cornell University	Schwer, B (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.				NIGMS NIH HHS [GM50288] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050288] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI A, 1995, EMBO J, V14, P4001, DOI 10.1002/j.1460-2075.1995.tb00071.x; ARENAS J, 1987, J BIOL CHEM, V262, P4274; Arenas JE, 1997, P NATL ACAD SCI USA, V94, P11798, DOI 10.1073/pnas.94.22.11798; BINDEREIF A, 1986, MOL CELL BIOL, V6, P2582, DOI 10.1128/MCB.6.7.2582; Burge CB, 1999, RNA WORLD, P525; Campodonico E, 2002, GENETICS, V160, P407; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; Chen JYF, 2001, MOL CELL, V7, P227, DOI 10.1016/S1097-2765(01)00170-8; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; Edwalds-Gilbert G, 2000, RNA, V6, P1106, DOI 10.1017/S1355838200992483; Gee S, 1997, P NATL ACAD SCI USA, V94, P11803, DOI 10.1073/pnas.94.22.11803; Gross CH, 1998, J VIROL, V72, P4729, DOI 10.1128/JVI.72.6.4729-4736.1998; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Heilek GM, 1997, J VIROL, V71, P6264, DOI 10.1128/JVI.71.8.6264-6266.1997; Hotz HR, 1998, GENETICS, V149, P807; Jankowsky E, 2000, NUCLEIC ACIDS RES, V28, P333, DOI 10.1093/nar/28.1.333; Jankowsky E, 2001, SCIENCE, V291, P121, DOI 10.1126/science.291.5501.121; KIM SH, 1993, P NATL ACAD SCI USA, V90, P888, DOI 10.1073/pnas.90.3.888; Kim SH, 1996, MOL CELL BIOL, V16, P6810; Kistler AL, 2001, GENE DEV, V15, P42, DOI 10.1101/gad.851301; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; Linder P, 2000, YEAST, V16, P507, DOI 10.1002/(SICI)1097-0061(200004)16:6<507::AID-YEA549>3.0.CO;2-N; MADHANI HD, 1994, ANNU REV GENET, V28, P1; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Raghunathan PL, 1998, SCIENCE, V279, P857, DOI 10.1126/science.279.5352.857; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; Schneider S, 2001, J BIOL CHEM, V276, P21184, DOI 10.1074/jbc.M101964200; SCHNEIDER S, 2002, J BIOL CHEM     0220; Schwer B, 1998, EMBO J, V17, P2086, DOI 10.1093/emboj/17.7.2086; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; Schwer B, 2001, NAT STRUCT BIOL, V8, P113, DOI 10.1038/84091; Schwer B, 2000, EMBO J, V19, P6582, DOI 10.1093/emboj/19.23.6582; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stevens SW, 2002, MOL CELL, V9, P31, DOI 10.1016/S1097-2765(02)00436-7; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; Wang Y, 1998, RNA, V4, P1216, DOI 10.1017/S1355838298980992	39	142	144	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17743	17750		10.1074/jbc.M200762200	http://dx.doi.org/10.1074/jbc.M200762200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11886864	hybrid			2022-12-25	WOS:000175685100046
J	Montplaisir, V; Lan, NC; Guimond, J; Savineau, C; Bhat, PV; Mader, S				Montplaisir, V; Lan, NC; Guimond, J; Savineau, C; Bhat, PV; Mader, S			Recombinant class I aldehyde dehydrogenases specific for all-trans- or 9-cis-retinal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDIZING ENZYME-ACTIVITY; RETINOIC ACID; ESCHERICHIA-COLI; RAT-KIDNEY; GENE-EXPRESSION; OXIDATION; CDNA; CLONING; PURIFICATION; STOMACH	The molecular basis for the specificity of aldehyde dehydrogenases (ALDHs) for retinal, the precursor of the morphogen retinoic acid, is still poorly understood. We have expressed in Escherichia coli both retinal dehydrogenase (RALDH), a cytosolic aldehyde dehydrogenase originally isolated from rat kidney, and the highly homologous phenobarbital-induced aldehyde dehydrogenase (PB-ALDH). Oxidation of propanal was observed with both enzymes. On the other hand, recombinant RALDH efficiently catalyzed oxidation of 9-cis- and all-trans-retinal, whereas PB-ALDH was inactive with all-trans-retinal and poorly active with 9-cis-retinal. A striking difference between PB-ALDH and all other class I ALDHs is the identity of the amino acid immediately preceding the active nucleophile Cys(302) (Ile(301) instead of Cys(301)). Nevertheless, these amino acids could be exchanged in either RALDH or PB-ALDH without affecting substrate specificity. Characterization of chimeric enzymes demonstrates that distinct groups of amino acids control the differential activity of RALDH and PB-ALDH with all-trans- and 9-cis-retinal. Of 52 divergent amino acids, the first 17 are crucial for activity with all-trans-retinal, whereas the next 25 are important for catalysis of 9-cis-retinal oxidation. Recombinant enzymes with specificity for all-trans- or 9-cis-retinal were obtained, which should provide useful tools to study the relative importance of local production of all-trans- versus 9-cis-retinoic acid in development and tissue differentiation.	Univ Montreal, Fac Med, Dept Biochem, Montreal, PQ H3R 3N2, Canada; Univ Montreal, Dept Med, Montreal, PQ H3R 3N2, Canada; CHUM Res Ctr, Lab Nutr & Canc, Montreal, PQ H2W 1T8, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Bhat, PV (corresponding author), Univ Montreal, Fac Med, Dept Biochem, CP6128 Succursale Ctr Ville, Montreal, PQ H3R 3N2, Canada.	bhatp@medclin.umontreal.ca; sylvie.mader@umontreal.ca						Bhat PV, 1998, BIOCHEM CELL BIOL, V76, P59, DOI 10.1139/bcb-76-1-59; Bhat PV, 1998, FEBS LETT, V426, P260, DOI 10.1016/S0014-5793(98)00355-X; Bhat PV, 1995, GENE, V166, P303, DOI 10.1016/0378-1119(96)81752-5; Bhat PV, 1998, J HISTOCHEM CYTOCHEM, V46, P1025, DOI 10.1177/002215549804600906; Bhat PV, 1996, BIOCHEM CELL BIOL, V74, P695, DOI 10.1139/o96-076; BHAT PV, 1988, BIOCHIM BIOPHYS ACTA, V967, P211, DOI 10.1016/0304-4165(88)90011-6; Bhat PV, 1998, FASEB J, V12, pA841; BHAT PV, 1988, BIOCHEM CELL BIOL, V66, P735, DOI 10.1139/o88-084; BHAT PV, 1998, BIOCHEM PHARMACOL, V57, P195; Blaner William S., 1994, P229; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; DE LUCA LM, 1991, FASEB J, V5, P2924; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; DUNN TJ, 1989, J BIOL CHEM, V264, P13057; ELAKAWI Z, 1994, BIOCHEMISTRY-US, V33, P1938, DOI 10.1021/bi00173a042; Hsu LC, 1999, BIOCHEM J, V339, P387, DOI 10.1042/0264-6021:3390387; HSU LC, 1992, J BIOL CHEM, V267, P3030; Kathmann EC, 2000, BIOCHEMISTRY-US, V39, P11170, DOI 10.1021/bi001120m; LABRECQUE J, 1995, BIOCHEM J, V305, P681, DOI 10.1042/bj3050681; LABRECQUE J, 1993, BIOCHEM CELL BIOL, V71, P85, DOI 10.1139/o93-013; Lamb AL, 1999, BIOCHEMISTRY-US, V38, P6003, DOI 10.1021/bi9900471; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; Li HX, 2000, MECH DEVELOP, V95, P283, DOI 10.1016/S0925-4773(00)00352-X; LINDAHL R, 1984, J BIOL CHEM, V259, P1991; LINDAHL R, 1992, CRIT REV BIOCHEM MOL, V27, P283, DOI 10.3109/10409239209082565; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; Mangelsdorf David J., 1994, P319; Moore SA, 1998, STRUCTURE, V6, P1541, DOI 10.1016/S0969-2126(98)00152-X; Penzes P, 1997, BBA-PROTEIN STRUCT M, V1342, P175, DOI 10.1016/S0167-4838(97)00102-7; Perozich J, 1999, PROTEIN SCI, V8, P137, DOI 10.1110/ps.8.1.137; ROBERTS AB, 1984, RETINOIDS, V2, P209; SAARI JC, 1995, VISUAL NEUROSCI, V12, P263, DOI 10.1017/S095252380000794X; SMITH SM, 1989, DEVELOPMENT, V107, P121; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; YOSHIDA A, 1992, ENZYME, V46, P239, DOI 10.1159/000468794; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x	37	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17486	17492		10.1074/jbc.M112445200	http://dx.doi.org/10.1074/jbc.M112445200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882655	hybrid			2022-12-25	WOS:000175685100014
J	Watanabe, Y; Shiratsuchi, A; Shimizu, K; Takizawa, T; Nakanishi, Y				Watanabe, Y; Shiratsuchi, A; Shimizu, K; Takizawa, T; Nakanishi, Y			Role of phosphatidylserine exposure and sugar chain desialylation at the surface of influenza virus-infected cells in efficient phagocytosis by macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-A/UDORN/72 H3N2 VIRUS; TEMPERATURE-SENSITIVE MUTANTS; APOPTOTIC CELLS; ENCODING GENE; DEATH KNELL; RECOGNITION; LYMPHOCYTES; CLEARANCE; RECEPTOR; PROTEIN	HeLa cells infected with influenza A virus undergo typical caspase-dependent apoptosis and are efficiently phagocytosed by mouse peritoneal macrophages in a manner mediated by the membrane phospholipid phosphatidylserine, which is translocated to the surface of virus-infected cells during apoptosis. However, the extent of phagocytosis is not always parallel with the level of phosphatidylserine externalization. Here we examined the involvement of influenza virus neuraminidase (NA) in efficient phagocytosis of virus-infected cells. HeLa cells infected with an influenza virus strain expressing temperature-sensitive NA underwent apoptosis and produced viral proteins, including the defective NA, at a non-permissive temperature to almost the same extent as cells infected with the wild-type virus. The cells were, however, phagocytosed by macrophages with reduced efficiency. In addition, phagocytosis of cells infected with the wild-type virus was severely inhibited when the cells had been maintained in the presence of the NA inhibitor zanamivir. On the other hand, the binding of sialic acid-recognizing lectins to the cell surface declined after infection with the wild-type virus. The decrease in the extent of lectin binding was greatly attenuated when cells were infected with the mutant virus or when wild-type virus-infected cells were maintained in the presence of zanamivir. These results indicate that sugar chains are desialylated by NA at the surface of virus-infected cells. We conclude that the presence of both phosphatidylserine and asialoglycomoieties on the cell surface is required for efficient phagocytosis of influenza virus-infected cells by macrophages.	Kanazawa Univ, Grad Sch Med Sci, Kanazawa, Ishikawa 9200934, Japan; Nihon Univ, Sch Med, Itabashi Ku, Tokyo 1738610, Japan; Aichi Human Serv Ctr, Inst Dev Res, Aichi 4800392, Japan	Kanazawa University; Nihon University	Nakanishi, Y (corresponding author), Kanazawa Univ, Grad Sch Med Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.		Nakanishi, Yoshinobu/D-4602-2014; Shiratsuchi, Akiko/D-8391-2015	Nakanishi, Yoshinobu/0000-0002-8767-3587; Shiratsuchi, Akiko/0000-0002-7811-4409				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; Chen WS, 2001, NAT MED, V7, P1306, DOI 10.1038/nm1201-1306; Chimini G, 2001, CELL DEATH DIFFER, V8, P545, DOI 10.1038/sj.cdd.4400833; DINI L, 1992, FEBS LETT, V296, P174, DOI 10.1016/0014-5793(92)80373-O; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Fadok VA, 2001, CELL DEATH DIFFER, V8, P582, DOI 10.1038/sj.cdd.4400856; Falasca L, 1996, EXP CELL RES, V224, P152, DOI 10.1006/excr.1996.0123; Fujii C, 2001, CELL DEATH DIFFER, V8, P1113, DOI 10.1038/sj.cdd.4400920; Fujimoto I, 1998, CELL DEATH DIFFER, V5, P426, DOI 10.1038/sj.cdd.4400362; Fujimoto I, 2000, J VIROL, V74, P3399, DOI 10.1128/JVI.74.7.3399-3403.2000; Granville DJ, 1998, CELL DEATH DIFFER, V5, P653, DOI 10.1038/sj.cdd.4400388; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Martin Seamus J., 1996, P107; Morris SJ, 1999, J GEN VIROL, V80, P137, DOI 10.1099/0022-1317-80-1-137; Pradhan D, 1997, MOL BIOL CELL, V8, P767, DOI 10.1091/mbc.8.5.767; Ren Y, 1998, CELL DEATH DIFFER, V5, P563, DOI 10.1038/sj.cdd.4400407; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Savill J, 1997, BRIT MED BULL, V53, P491; Schagat TL, 2001, J IMMUNOL, V166, P2727, DOI 10.4049/jimmunol.166.4.2727; Schlegel RA, 1999, CELL DEATH DIFFER, V6, P583, DOI 10.1038/sj.cdd.4400529; Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817; Schultz-Cherry S, 2001, J VIROL, V75, P7875, DOI 10.1128/JVI.75.17.7875-7881.2001; Scott CB, 1996, J IMMUNOL, V157, P351; SHIMIZU K, 1974, VIROLOGY, V62, P90, DOI 10.1016/0042-6822(74)90305-5; SHIMIZU K, 1985, VACCINE, V3, P207, DOI 10.1016/0264-410X(85)90107-0; SHIMIZU K, 1982, VIROLOGY, V117, P45, DOI 10.1016/0042-6822(82)90506-2; SHIMIZU K, 1982, VIROLOGY, V117, P38, DOI 10.1016/0042-6822(82)90505-0; SHIMIZU K, 1984, SEGMENTED NEGATIVE S, P387; SHIMIZU K, 1981, REPLICATION NEGATIVE, P369; Shiratsuchi A, 2000, J VIROL, V74, P9240, DOI 10.1128/JVI.74.19.9240-9244.2000; Shiratsuchi A, 1998, BIOCHEM BIOPH RES CO, V246, P549, DOI 10.1006/bbrc.1998.8663; Shiratsuchi A, 1997, J BIOL CHEM, V272, P2354, DOI 10.1074/jbc.272.4.2354; TAKIZAWA T, 1995, VIROLOGY, V209, P288, DOI 10.1006/viro.1995.1260; TAKIZAWA T, 1993, J GEN VIROL, V74, P2347, DOI 10.1099/0022-1317-74-11-2347; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; WADA N, 1995, J BIOL CHEM, V270, P18007, DOI 10.1074/jbc.270.30.18007; WILLIAMSON P, 1994, MOL MEMBR BIOL, V11, P199, DOI 10.3109/09687689409160430; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; Zhirnov OP, 2002, J VIROL, V76, P1617, DOI 10.1128/JVI.76.4.1617-1625.2002	49	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18222	18228		10.1074/jbc.M201074200	http://dx.doi.org/10.1074/jbc.M201074200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884410	hybrid, Green Submitted			2022-12-25	WOS:000175685100105
J	Huang, JM; Kirk, B; Favis, R; Soussi, T; Paty, P; Cao, WG; Barany, F				Huang, JM; Kirk, B; Favis, R; Soussi, T; Paty, P; Cao, WG; Barany, F			An endonuclease/ligase based mutation scanning method especially suited for analysis of neoplastic tissue	ONCOGENE			English	Article						mutation detection; endonuclease V; thermostable ligase; mismatch recognition	SINGLE-NUCLEOTIDE POLYMORPHISMS; DEOXYINOSINE-SPECIFIC ENDONUCLEASE; ENZYME MISMATCH CLEAVAGE; HIPPEL-LINDAU-DISEASE; RAS POINT MUTATIONS; K-RAS; GERMLINE MUTATIONS; CARRIER FREQUENCY; CHEMICAL CLEAVAGE; SENSITIVE METHOD	Knowledge of inherited and sporadic mutations in known and candidate cancer genes may influence clinical decisions. We have developed a mutation scanning method that combines thermostable EndonucleaseV (Endo V) and DNA ligase. Variant and wild-type PCR amplicons are generated using fluorescently labeled primers, and heteroduplexed. Thermotoga maritima (Tma) EndoV recognizes and primarily cleaves heteroduplex DNA one base 3' to the mismatch, as well as nicking matched DNA at low levels. Thermus species (Tsp.) AK16D DNA ligase reseals the background nicks to create a highly sensitive and specific assay. The fragment mobility on a DNA sequencing gel reveals the approximate position of the mutation. This method identified 31/35 and 8/8 unique point mutations and insertions/deletions, respectively, in the p53, VHL, K-ras, APC, BRCA1, and BRCA2 genes. The method has the sensitivity to detect K-ras mutations diluted 1 :20 with wildtype DNA, a p53 mutation in a 1.7 kb amplicon, and unknown p53 mutations in pooled DNA samples. EndoV/Ligase mutation scanning combined with PCR/LDR/Universal array proved superior to automated DNA sequencing for detecting p53 mutations in colon tumors. This technique is well suited for scanning low-frequency mutations in pooled samples and for analysing tumor DNA containing a minority of the unknown mutation.	Cornell Univ, Joan & Sanford I Weill Med Coll, Strang Canc Prevent Ctr, Hearst Microbiol Res Ctr,Dept Microbiol, New York, NY 10021 USA; Inst Curie, Lab Genotoxicol Tumeurs, F-75248 Paris, France; Mem Sloan Kettering Canc Ctr, Dept Surg, Colorectal Serv, New York, NY 10021 USA	Cornell University; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Memorial Sloan Kettering Cancer Center	Barany, F (corresponding author), Cornell Univ, Joan & Sanford I Weill Med Coll, Strang Canc Prevent Ctr, Hearst Microbiol Res Ctr,Dept Microbiol, Box 62,Room B-406,1300 York Ave, New York, NY 10021 USA.	barany@med.cornell.edu		soussi, thierry/0000-0001-8184-3293	NATIONAL CANCER INSTITUTE [R01CA081467, P01CA065930] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA81467, P01-CA65930] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abeliovich D, 1997, AM J HUM GENET, V60, P505; Ahrendt SA, 1999, P NATL ACAD SCI USA, V96, P7382, DOI 10.1073/pnas.96.13.7382; Aurelio ON, 1998, CANCER RES, V58, P2190; Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Beller U, 1997, GYNECOL ONCOL, V67, P123, DOI 10.1006/gyno.1997.4844; Berman DB, 1996, CANCER RES, V56, P3409; Broll R, 1999, EUR J CANCER, V35, P1083, DOI 10.1016/S0959-8049(99)00058-1; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Chen F, 1996, J MED GENET, V33, P716, DOI 10.1136/jmg.33.8.716; CHEN J, 1994, ENV HLTH PERSPECT, V3, P227; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Fahy E, 1997, NUCLEIC ACIDS RES, V25, P3102, DOI 10.1093/nar/25.15.3102; Favis R, 2000, NAT BIOTECHNOL, V18, P561, DOI 10.1038/75452; FODDE R, 1994, HUM MUTAT, V3, P83, DOI 10.1002/humu.1380030202; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Gerry NP, 1999, J MOL BIOL, V292, P251, DOI 10.1006/jmbi.1999.3063; Giunta C, 1996, DIAGN MOL PATHOL, V5, P265, DOI 10.1097/00019606-199612000-00007; GULDBERG P, 1994, NUCLEIC ACIDS RES, V22, P880, DOI 10.1093/nar/22.5.880; Hacia JG, 1999, NAT GENET, V21, P42, DOI 10.1038/4469; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Hansen Lise Lotte, 1995, P275; HARIS II, 1994, PCR METH APPL, V3, P268; Hayashi K, 1991, PCR Methods Appl, V1, P34; Heide I, 1997, EUR J CANCER, V33, P1314, DOI 10.1016/S0959-8049(97)00118-4; Henke W, 1997, NUCLEIC ACIDS RES, V25, P3957, DOI 10.1093/nar/25.19.3957; Huang JM, 2001, BIOCHEMISTRY-US, V40, P8738, DOI 10.1021/bi010183h; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; Khanna M, 1999, ONCOGENE, V18, P27, DOI 10.1038/sj.onc.1202291; KHRAPKO K, 1994, NUCLEIC ACIDS RES, V22, P364, DOI 10.1093/nar/22.3.364; KORN SH, 1993, J CLIN PATHOL, V46, P621, DOI 10.1136/jcp.46.7.621; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Libutti SK, 2000, SURGERY, V128, P1022, DOI 10.1067/msy.2000.110239; Liu J, 2000, MUTAT RES-DNA REPAIR, V461, P169, DOI 10.1016/S0921-8777(00)00054-9; LIU Q, 1995, BIOTECHNIQUES, V18, P470; Makino R, 1992, PCR Methods Appl, V2, P10; Mohr VH, 2000, AM J PATHOL, V157, P1615, DOI 10.1016/S0002-9440(10)64799-2; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; Oleykowski CA, 1998, NUCLEIC ACIDS RES, V26, P4597, DOI 10.1093/nar/26.20.4597; PERUCHO M, 1989, CANCER CEL, V7, P137; POMP D, 1991, BIOTECHNIQUES, V10, P58; Prives C, 1999, J PATHOL, V187, P112; REES WA, 1993, BIOCHEMISTRY-US, V32, P137, DOI 10.1021/bi00052a019; RIDANPAA M, 1993, HUM MOL GENET, V2, P639, DOI 10.1093/hmg/2.6.639; RIDANPAA M, 1995, MUTAT RES-ENVIR MUTA, V334, P357, DOI 10.1016/0165-1161(95)90073-X; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; Sgambati MT, 2000, AM J HUM GENET, V66, P84, DOI 10.1086/302726; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Stephens JC, 2001, SCIENCE, V293, P489, DOI 10.1126/science.1059431; Stolle C, 1998, HUM MUTAT, V12, P417, DOI 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; Taylor GR, 1999, ELECTROPHORESIS, V20, P1125, DOI 10.1002/(SICI)1522-2683(19990101)20:6<1125::AID-ELPS1125>3.0.CO;2-O; Thiagalingam S, 2001, P NATL ACAD SCI USA, V98, P2698, DOI 10.1073/pnas.051625398; Tong J, 1999, NUCLEIC ACIDS RES, V27, P788, DOI 10.1093/nar/27.3.788; Tortola S, 1999, J CLIN ONCOL, V17, P1375, DOI 10.1200/JCO.1999.17.5.1375; Underhill PA, 1996, P NATL ACAD SCI USA, V93, P196, DOI 10.1073/pnas.93.1.196; Walther MM, 1999, J UROLOGY, V162, P659, DOI 10.1097/00005392-199909010-00004; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Webley KM, 2000, J PATHOL, V191, P361; WINTER E, 1985, P NATL ACAD SCI USA, V82, P7575, DOI 10.1073/pnas.82.22.7575; Xu JF, 1996, CARCINOGENESIS, V17, P321; Yan H, 2000, NATURE, V403, P723, DOI 10.1038/35001659; YAO M, 1994, ANN NY ACAD SCI, V726, P315, DOI 10.1111/j.1749-6632.1994.tb52837.x; YAO M, 1994, J BIOL CHEM, V269, P31390; Yen H, 2000, SCIENCE, V289, P1890; YOUIL R, 1995, P NATL ACAD SCI USA, V92, P87, DOI 10.1073/pnas.92.1.87; Zirvi M, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.24.e40; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	77	32	39	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1909	1921		10.1038/sj.onc.1205109	http://dx.doi.org/10.1038/sj.onc.1205109			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896624				2022-12-25	WOS:000174284500014
